PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Heiss, G; Wallace, R; Anderson, GL; Aragaki, A; Beresford, SAA; Brzyski, R; Chlebowski, RT; Gass, M; LaCroix, A; Manson, JE; Prentice, RL; Rossouw, J; Stefanick, ML				Heiss, Gerardo; Wallace, Robert; Anderson, Garnet L.; Aragaki, Aaron; Beresford, Shirley A. A.; Brzyski, Robert; Chlebowski, Rowan T.; Gass, Margery; LaCroix, Andrea; Manson, Joann E.; Prentice, Ross L.; Rossouw, Jacques; Stefanick, Marcia L.		WHI Investigators	Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL HORMONE-THERAPY; PLUS PROGESTIN; CANCER; WOMEN; SURVIVAL; BREAST; MAMMOGRAPHY; REPLACEMENT; DISEASE; TRIAL	Context The Women's Health Initiative ( WHI) trial of estrogen plus progestin vs placebo was stopped early, after a mean 5.6 years of follow- up, because the overall health risks of hormone therapy exceeded its benefits. Objective To report health outcomes at 3 years ( mean 2.4 years of follow- up) after the intervention was stopped. Design, Setting, and Participants The intervention phase was a double- blind, placebo- controlled, randomized trial of conjugated equine estrogens ( CEE) 0.625 mg daily plus medroxyprogesterone acetate ( MPA) 2.5 mg daily, in 16 608 women aged 50 through 79 years, recruited by 40 centers from 1993 to 1998. The postintervention phase commenced July 8, 2002, and included 15 730 women. Main Outcome Measures Semi- annual monitoring and outcomes ascertainment continued per trial protocol. The primary end points were coronary heart disease and invasive breast cancer. A global index summarizing the balance of risks and benefits included the 2 primary end points plus stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, and death due to other causes. Results The risk of cardiovascular events after the intervention was comparable by initial randomized assignments, 1.97% ( annualized rate) in the CEE plus MPA ( 343 events) and 1.91% in the placebo group ( 323 events). A greater risk of malignancies occurred in the CEE plus MPA than in the placebo group ( 1.56% [ n= 281] vs 1.26% [ n= 218]; hazard ratio [ HR], 1.24; 95% confidence interval [ CI], 1.04- 1.48). More breast cancers were diagnosed in women who had been randomly assigned to receive CEE plus MPA vs placebo ( 0.42% [ n= 79] vs 0.33% [ n= 60]; HR, 1.27; 95% CI, 0.91- 1.78) with a modest trend toward a lower HR during the follow- up after the intervention. All- cause mortality was somewhat higher in the CEE plus MPA than in the placebo group ( 1.20% [ n= 233] vs 1.06% [ n= 196]; HR, 1.15; 95% CI, 0.95- 1.39). The global index of risks and benefits was unchanged from randomization through March 31, 2005 ( HR, 1.12; 95% CI, 1.03- 1.21), indicating that the risks of CEE plus MPA exceed the benefits for chronic disease prevention. Conclusions The increased cardiovascular risks in the women assigned to CEE plus MPA during the intervention period were not observed after the intervention. A greater risk of fatal and nonfatal malignancies occurred after the intervention in the CEE plus MPA group and the global risk index was 12% higher in women randomly assigned to receive CEE plus MPA compared with placebo. Trial Registration clinicaltrials. gov Identifier: NCT00000611.	[Heiss, Gerardo] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27514 USA; [Wallace, Robert] Univ Iowa, Iowa City, IA USA; [Anderson, Garnet L.; Aragaki, Aaron; Beresford, Shirley A. A.; LaCroix, Andrea; Prentice, Ross L.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; [Brzyski, Robert] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA; [Chlebowski, Rowan T.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA; [Gass, Margery] Univ Cincinnati, Cincinnati, OH USA; [Manson, Joann E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; [Rossouw, Jacques] NHLBI, Bethesda, MD 20892 USA; [Stefanick, Marcia L.] Stanford Prevent Res Ctr, Stanford, CA USA	University of North Carolina; University of North Carolina Chapel Hill; University of Iowa; Fred Hutchinson Cancer Center; University of Texas System; University of Texas Health San Antonio; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; University System of Ohio; University of Cincinnati; Harvard University; Brigham & Women's Hospital; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Stanford University	Heiss, G (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, 137 E Franklin St,Ste 306, Chapel Hill, NC 27514 USA.	gerardo_heiss@unc.edu		Anderson, Garnet/0000-0001-5087-7837				*AM COLL OBST GYN, 2004, OBSTET GYNECOL S, V104, pS1; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2006, MATURITAS, V55, P103, DOI 10.1016/j.maturitas.2006.05.004; Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739; Breen N, 2007, CANCER-AM CANCER SOC, V109, P2405, DOI 10.1002/cncr.22723; Cauley JA, 2003, JAMA-J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729; Chlebowski RT, 2004, NEW ENGL J MED, V350, P991, DOI 10.1056/NEJMoa032071; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Cushman M, 2004, JAMA-J AM MED ASSOC, V292, P1573, DOI 10.1001/jama.292.13.1573; Ettinger B, 1996, OBSTET GYNECOL, V87, P6, DOI 10.1016/0029-7844(95)00358-4; Ganti AK, 2006, J CLIN ONCOL, V24, P59, DOI 10.1200/JCO.2005.02.9827; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Johnson MS, 2005, ANN INTERN MED, V142, P855, DOI 10.7326/0003-4819-142-10-200505170-00011; LaCroix Andrea Z, 2005, Am J Med, V118 Suppl 12B, P79, DOI 10.1016/j.amjmed.2005.09.039; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Marquez-Garban DC, 2007, STEROIDS, V72, P135, DOI 10.1016/j.steroids.2006.11.019; Ockene JK, 2005, JAMA-J AM MED ASSOC, V294, P183, DOI 10.1001/jama.294.2.183; Palomares MR, 1996, CANCER, V78, P2119, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2119::AID-CNCR12>3.0.CO;2-1; Ravdin PM, 2007, NEW ENGL J MED, V356, P1670, DOI 10.1056/NEJMsr070105; Robins JM, 2000, BIOMETRICS, V56, P779, DOI 10.1111/j.0006-341X.2000.00779.x; ROSS H, 2007, J CLIN ONCOL S, V24, P7039; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Wisnivesky JP, 2007, J CLIN ONCOL, V25, P1705, DOI 10.1200/JCO.2006.08.1455	26	272	284	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	2008	299	9					1036	1045		10.1001/jama.299.9.1036	http://dx.doi.org/10.1001/jama.299.9.1036			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	269JH	18319414	Green Published, Bronze			2023-01-03	WOS:000253644800021
J	[Anonymous]				[Anonymous]			Music in stroke rehabilitation	LANCET			English	Editorial Material																			0	4	4	2	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 1	2008	371	9614					698	698						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	268RI	18313483				2023-01-03	WOS:000253596700003
J	Ramakrishna, BS; Subramanian, V; Mohan, V; Sebastian, BK; Young, GP; Farthing, MJ; Binder, HJ				Ramakrishna, Balakrishnan S.; Subramanian, Venkataraman; Mohan, Vivek; Sebastian, Bendon K.; Young, Graeme P.; Farthing, Michael J.; Binder, Henry J.			A Randomized Controlled Trial of Glucose versus Amylase Resistant Starch Hypo-Osmolar Oral Rehydration Solution for Adult Acute Dehydrating Diarrhea	PLOS ONE			English	Article							EFFICACY; THERAPY; CHOLERA; ADJUNCT	Background: Reduction of gross diarrhea rate in excess of that seen over time with intravenous therapy and appropriate antibiotics is not usually achieved by oral glucose-electrolyte rehydration therapy for cholera and cholera-like diarrheas. Methodology and Principal Findings: This prospective randomized clinical trial at a tertiary referral hospital in southern India was undertaken to determine whether amylase resistant starch, substituting for glucose in hypo-osmolar oral rehydration solution, would reduce diarrhea duration and weight in adults with acute severe dehydrating diarrhea. 50 adult males with severe watery diarrhea of less than three days' duration and moderate to severe dehydration were randomized to receive hypo-osmolar ORS (HO-ORS) or HO-ORS in which amylase resistant high amylose maize starch 50g/L substituted for glucose (HAMS-ORS). All remaining therapy followed standard protocol. Duration of diarrhea (ORS commencement to first formed stool) in hours was significantly shorter with HAMS-ORS (median 19, IQR 10-28) compared to HO-ORS (median 42, IQR 24-50) (Bonferroni adjusted P, P-adj < 0.001). Survival analysis (Kaplan-Meier) showed faster recovery from diarrhea in the HAMS-ORS group (P < 0.001, log rank test). Total diarrhea fecal weight in grams (median, IQR) was not significantly lower in the HAMS-ORS group (2190, 1160-5635) compared to HO-ORS (5210, 2095-12190) (P-adj = 0.08). However, stool weight at 13-24 hours (280, 0-965 vs. 1360, 405-2985) and 25-48 hours (0, 0-360 vs. 1080, 55-3485) were significantly lower in HAMS-ORS compared to HO-ORS group (Padj = 0.048 and P = 0.012, respectively). ORS intake after first 24 hours was lower in the HAMS-ORS group. Subgroup analysis of patients with culture isolates of Vibrio cholerae indicated similar significant differences between the treatment groups. Conclusions: Compared to HO-ORS, HAMS-ORS reduced diarrhea duration by 55% and significantly reduced fecal weight after the first 12 hours of ORS therapy in adults with cholera-like diarrhea.	[Ramakrishna, Balakrishnan S.; Subramanian, Venkataraman; Mohan, Vivek; Sebastian, Bendon K.] Christian Med Coll & Hosp, Wellcome Trust Res Lab, Vellore, Tamil Nadu, India; [Young, Graeme P.] Flinders Univ S Australia, Dept Med, Adelaide, SA, Australia; [Farthing, Michael J.] Univ London, St Georges, London, England; [Binder, Henry J.] Yale Univ, Sch Med, Dept Intern Med, New Haven, CT USA	Christian Medical College & Hospital (CMCH) Vellore; Flinders University South Australia; University of London; Yale University	Ramakrishna, BS (corresponding author), Christian Med Coll & Hosp, Wellcome Trust Res Lab, Vellore, Tamil Nadu, India.	rama@cmcvellore.ac.in	Subramanian, Venkataraman/B-8274-2011; Ramakrishna, Balakrishnan/D-6808-2015	Subramanian, Venkataraman/0000-0003-3603-0861; Ramakrishna, Balakrishnan/0000-0001-5090-9501; Young, Graeme/0000-0001-9458-8383	International Trilateral Collaborative Research [063150/A/00/Z]; Wellcome Trust, London, UK	International Trilateral Collaborative Research; Wellcome Trust, London, UK(Wellcome Trust)	The study was funded by International Trilateral Collaborative Research Grant No. 063150/A/00/Z from the Wellcome Trust, London, UK. The funding source had no involvement in the authors' work.	Alam NH, 2000, J PEDIATR GASTR NUTR, V31, P503, DOI 10.1097/00005176-200011000-00010; Alam NH, 1999, LANCET, V354, P296, DOI 10.1016/S0140-6736(98)09332-5; Alam Seema, 2006, Indian Journal of Pediatrics, V73, P693, DOI 10.1007/BF02898447; Binder HJ, 1998, GASTROENTEROLOGY, V115, P512, DOI 10.1016/S0016-5085(98)70237-9; BINDER HJ, 1991, LARGE INTESTINE PHYS, P1164; Brown IL, 2004, J AOAC INT, V87, P727; Desjeux JF, 1997, BAILLIERE CLIN GASTR, V11, P509, DOI 10.1016/S0950-3528(97)90029-4; Duggan C, 2004, JAMA-J AM MED ASSOC, V291, P2628, DOI 10.1001/jama.291.21.2628; Dupont WD, 1997, CONTROL CLIN TRIALS, V18, P274, DOI 10.1016/S0197-2456(97)00074-3; GREENOUGH WB, 1993, J DIARRHOEAL DIS RES, V11, P1; Guerrant RL, 2003, CLIN INFECT DIS, V37, P398, DOI 10.1086/376619; Hahn S., 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002847; HEIMDAHL A, 1983, SCAND J INFECT DIS, V15, P293, DOI 10.3109/inf.1983.15.issue-3.10; Hoekstra JH, 2004, J PEDIATR GASTR NUTR, V39, P239, DOI 10.1097/00005176-200409000-00003; HUNT JB, 1992, GUT, V33, P1652, DOI 10.1136/gut.33.12.1652; Le Leu RK, 2003, CARCINOGENESIS, V24, P1347, DOI 10.1093/carcin/bgg098; Lewis SJ, 1997, SCAND J GASTROENTERO, V32, P920, DOI 10.3109/00365529709011203; LINDENBA.J, 1965, LANCET, V1, P1081; Murphy C, 2004, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003754.PUB2; NALIN DR, 2004, JAMA-J AM MED ASSOC, V21, P2632; NATH SK, 1989, AM J PHYSIOL, V256, pG335, DOI 10.1152/ajpgi.1989.256.2.G335; PHILLIPS J, 1995, AM J CLIN NUTR, V62, P121; Raghupathy P, 2006, J PEDIATR GASTR NUTR, V42, P362, DOI 10.1097/01.mpg.0000214163.83316.41; RAMAKRISHNA BS, 1993, GUT, V34, P1215, DOI 10.1136/gut.34.9.1215; Ramakrishna BS, 2000, NEW ENGL J MED, V342, P308, DOI 10.1056/NEJM200002033420502; Sanchez JL, 1997, LANCET, V349, P1825, DOI 10.1016/S0140-6736(97)04486-3; Thillainayagam AV, 1998, GASTROENTEROLOGY, V114, P197, DOI 10.1016/S0016-5085(98)70647-X; UNICEF, 2006, OR REH SALTS PROD NE; WHO, 1995, WHOCDR953	29	34	35	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1587	10.1371/journal.pone.0001587	http://dx.doi.org/10.1371/journal.pone.0001587			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270575	Green Accepted, gold, Green Submitted, Green Published			2023-01-03	WOS:000260535900021
J	Hazir, T; Fox, LM; Bin Nisar, Y; Fox, MP; Ashraf, YP; MacLeod, WB; Ramzan, A; Maqbool, S; Masood, T; Hussain, W; Murtaza, A; Khawar, N; Tariq, P; Asghar, R; Simon, JL; Thea, DM; Qazi, SA				Hazir, Tabish; Fox, LeAnne M.; Bin Nisar, Yasir; Fox, Matthew P.; Ashraf, Yusra Pervaiz; MacLeod, William B.; Ramzan, Afroze; Maqbool, Sajid; Masood, Tahir; Hussain, Waqar; Murtaza, Asifa; Khawar, Nadeem; Tariq, Parveen; Asghar, Rai; Simon, Jonathon L.; Thea, Donald M.; Qazi, Shamim A.		NO SHOTS Study Grp	Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency trial	LANCET			English	Article							ACUTE RESPIRATORY-INFECTIONS; ANTIMICROBIAL RESISTANCE; MULTICENTER; COMMUNITY; BACTERIAL; ETIOLOGY; PAKISTAN; IMPACT; DEATH; RISK	Background WHO case management guidelines for severe pneumonia involve referral to hospital for treatment with parenteral antibiotics. If equally as effective as parenteral treatment, home-based oral antibiotic treatment could reduce referral, admission, and treatment costs. Our aim was to determine whether home treatment with high-dose oral amoxicillin and inpatient treatment with parenteral ampicillin were equivalent for the treatment of severe pneumonia in children. Methods This randomised, open-label equivalency trial was done at seven study sites in Pakistan. 2037 children aged 3-59 months with severe pneumonia were randomly allocated to either initial hospitalisation and parenteral ampicillin (100 mg/kg per day in four doses) for 48 h, followed by 3 days of oral amoxicillin (80-90 mg/kg per day; n=1012) or to home-based treatment for 5 days with oral amoxicillin (80-90 mg/kg per day in two doses; n=1025). Follow-up assessments were done at 1, 3, 6, and 14 days after enrolment. The primary outcome was treatment failure (clinical deterioration) by day 6. Analyses were done per protocol and by intention to treat. This trial is registered, ISRCTN95821329. Findings In the per-protocol population, 36 individuals were excluded from the hospitalised group and 37 from the ambulatory group, mainly because of protocol violations or loss to follow-up. There were 87 (8.6%) treatment failures in the hospitalised group and 77 (7.5%) in the ambulatory group (risk difference 1 . 1%; 95% CI -1.3 to 3.5) by day 6. Five (0 . 2%) children died within 14 days of enrolment, one in the ambulatory group and four in the hospitalised group. In each case, treatment failure was declared before death and the antibiotic had been changed. None of the deaths were considered to be associated with treatment allocation; there were no serious adverse events reported in the trial. Interpretation Home treatment with high-dose oral amoxicillin is equivalent to currently recommended hospitalisation and parenteral ampicillin for treatment of severe pneumonia without underlying complications, suggesting that WHO recommendations for treatment of severe pneumonia need to be revised.	[Fox, LeAnne M.; Fox, Matthew P.; MacLeod, William B.; Simon, Jonathon L.; Thea, Donald M.] Boston Univ, Sch Publ Hlth, Ctr Int Hlth & Dev, Boston, MA 02118 USA; [Ramzan, Afroze] Natl Inst Child Hlth, Karachi, Pakistan; [Hazir, Tabish; Bin Nisar, Yasir; Ashraf, Yusra Pervaiz] Pakistan Inst Med Sci, Childrens Hosp, Islamabad, Pakistan; [Maqbool, Sajid; Masood, Tahir] Childrens Hosp, Lahore, Pakistan; [Hussain, Waqar] Sheikh Zayed Hosp, Lahore, Pakistan; [Murtaza, Asifa] Fed Govt Serv Hosp, Islamabad, Pakistan; [Khawar, Nadeem] Univ Peshawar, Khyber Med Coll, Pashawar, Pakistan; [Tariq, Parveen] Rawalpindi Med Coll, Rawalpindi, Pakistan; [Asghar, Rai] Rawalpindi Gen Hosp, Rawalpindi, Pakistan; [Qazi, Shamim A.] WHO, CH-1211 Geneva, Switzerland	Boston University; Pakistan Institute of Medical Sciences; University of Peshawar; National University of Sciences & Technology - Pakistan; Rawalpindi Medical College; Rawalpindi Medical College; World Health Organization	Thea, DM (corresponding author), Boston Univ, Sch Publ Hlth, Ctr Int Hlth & Dev, 85 E Concord St, Boston, MA 02118 USA.	dthea@bu.edu	Fox, Matthew/K-2004-2019; Nisar, Yasir Bin/AFO-2407-2022	MacLeod, William/0000-0001-8003-8874; Simon, Jonathon/0000-0001-6740-549X; Thea, Donald/0000-0002-6933-1030; Fox, Matthew/0000-0001-9887-0634				Addo-Yobo E, 2004, LANCET, V364, P1141, DOI 10.1016/S0140-6736(04)17100-6; Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8; Cesar JA, 1999, BRIT MED J, V318, P1316, DOI 10.1136/bmj.318.7194.1316; Chantry CJ, 2007, BREASTFEED MED, V2, P63, DOI 10.1089/bfm.2007.0002; Chow SC, 2002, CONTROL CLIN TRIALS, V23, P515, DOI 10.1016/S0197-2456(02)00222-2; Craig WA, 1998, CLIN INFECT DIS, V26, P1, DOI 10.1086/516284; Fonseca W, 2003, ANTIMICROB AGENTS CH, V47, P997, DOI 10.1128/AAC.47.3.997-1001.2003; FORGIE IM, 1992, PEDIATR INFECT DIS J, V11, P466, DOI 10.1097/00006454-199206000-00009; GHAFOOR A, 1990, REV INFECT DIS, V12, pS907; HIETALA J, 1989, PEDIATR INFECT DIS J, V8, P683, DOI 10.1097/00006454-198910000-00004; Juven T, 2000, PEDIATR INFECT DIS J, V19, P293, DOI 10.1097/00006454-200004000-00006; KORPPI M, 1989, PEDIATR INFECT DIS J, V8, P687, DOI 10.1097/00006454-198910000-00005; Lieberthal AS, 2004, PEDIATRICS, V113, P1451, DOI 10.1542/peds.113.5.1451; MASTRO TD, 1991, LANCET, V337, P156, DOI 10.1016/0140-6736(91)90813-5; McCormick AW, 2003, NAT MED, V9, P424, DOI 10.1038/nm839; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Peterson S, 2004, LANCET, V363, P1955, DOI 10.1016/S0140-6736(04)16411-8; Qazi SA, 2002, ARCH DIS CHILD, V86, P113, DOI 10.1136/adc.86.2.113; Qazi SA, 1996, B WORLD HEALTH ORGAN, V74, P501; Renaud B, 2007, CLIN INFECT DIS, V44, P41, DOI 10.1086/509331; RODEWALD LE, 1993, J PEDIATR-US, V123, P143, DOI 10.1016/S0022-3476(05)81560-4; Sehgal V, 1997, Indian Pediatr, V34, P213; SHAH N, 1994, J TROP PEDIATRICS, V40, P201, DOI 10.1093/tropej/40.4.201; SHANN F, 1989, PEDIATR INFECT DIS J, V8, P852, DOI 10.1097/00006454-198912000-00005; Straus WL, 1998, LANCET, V352, P270, DOI 10.1016/S0140-6736(97)10294-X; TUPASI TE, 1988, J INFECT DIS, V157, P615, DOI 10.1093/infdis/157.4.615; *UNAIDS, 2001, AIDS EP UPD; *WHO, 1991, PROGR CONTR AC RESP; *WHO, 1993, BRONCH OTH MED TREAT; Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0	31	115	126	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 5	2008	371	9606					49	56		10.1016/S0140-6736(08)60071-9	http://dx.doi.org/10.1016/S0140-6736(08)60071-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248YH	18177775				2023-01-03	WOS:000252192600030
J	Qiao, J; Kottke, T; Willmon, C; Galivo, F; Wongthida, P; Diaz, RM; Thompson, J; Ryno, P; Barber, GN; Chester, J; Selby, P; Harrington, K; Melcher, A; Vile, RG				Qiao, Jian; Kottke, Timothy; Willmon, Candice; Galivo, Feorillo; Wongthida, Phonphimon; Diaz, Rosa Maria; Thompson, Jill; Ryno, Pamela; Barber, Glen N.; Chester, John; Selby, Peter; Harrington, Kevin; Melcher, Alan; Vile, Richard G.			Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy	NATURE MEDICINE			English	Article							VESICULAR STOMATITIS-VIRUS; BREAST-CANCER; MALIGNANT-MELANOMA; GENE-THERAPY; DELIVERY; VECTORS; INDUCTION; RESPONSES; EFFICACY; IMMUNITY	In many common cancers, dissemination of secondary tumors via the lymph nodes poses the most significant threat to the affected individual. Metastatic cells often reach the lymph nodes by mimicking the molecular mechanisms used by hematopoietic cells to traffic to peripheral lymphoid organs. Therefore, we exploited naive T cell trafficking in order to chaperone an oncolytic virus to lymphoid organs harboring metastatic cells. Metastatic burden was initially reduced by viral oncolysis and was then eradicated, as tumor cell killing in the lymph node and spleen generated protective antitumor immunity. Lymph node purging of tumor cells was possible even in virus-immune mice. Adoptive transfer of normal T cells loaded with oncolytic virus into individuals with cancer would be technically easy to implement both to reduce the distribution of metastases and to vaccinate the affected individual in situ against micrometastatic disease. As such, this adoptive transfer could have a great therapeutic impact, in the adjuvant setting, on many different cancer types.	[Qiao, Jian; Kottke, Timothy; Willmon, Candice; Galivo, Feorillo; Wongthida, Phonphimon; Diaz, Rosa Maria; Thompson, Jill; Ryno, Pamela; Vile, Richard G.] Mayo Clin, Program Mol Med, Rochester, MN 55905 USA; [Barber, Glen N.] Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Dept Microbiol & Immunol, Miami, FL 33136 USA; [Chester, John; Selby, Peter; Melcher, Alan; Vile, Richard G.] Univ Leeds, Leeds Teaching Hosp UK Natl Hlth Serv Trust, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England; [Chester, John; Selby, Peter; Melcher, Alan; Vile, Richard G.] Univ Leeds, Leeds Inst Mol Med, Leeds LS9 7TF, W Yorkshire, England; [Vile, Richard G.] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA; [Harrington, Kevin] Inst Canc Res, London SW7 3RP, England	Mayo Clinic; University of Miami; Cancer Research UK; University of Leeds; University of Leeds; Mayo Clinic; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Vile, RG (corresponding author), Mayo Clin, Program Mol Med, Rochester, MN 55905 USA.	vile.richard@mayo.edu		Melcher, Alan/0000-0002-2042-3380; Harrington, Kevin/0000-0002-6014-348X; Galivo, Feorillo/0000-0002-0553-922X; Willmon, Candice/0000-0002-9103-7364	NCI NIH HHS [CA RO1107082-02] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altman DG, 1991, PRACTICAL STAT MED R, P365; Arnould L, 2006, BRIT J CANCER, V94, P259, DOI 10.1038/sj.bjc.6602930; Balachandran S, 2001, J VIROL, V75, P3474, DOI 10.1128/JVI.75.7.3474-3479.2001; Balachandran S, 2000, IUBMB LIFE, V50, P135, DOI 10.1080/15216540050212169; Benson JR, 2007, LANCET ONCOL, V8, P331, DOI 10.1016/S1470-2045(07)70103-1; Beri A, 2006, NAT CLIN PRACT UROL, V3, P602, DOI 10.1038/ncpuro0625; Chang GJ, 2007, J NATL CANCER I, V99, P433, DOI 10.1093/jnci/djk092; Chester J, 2002, NAT BIOTECHNOL, V20, P256, DOI 10.1038/nbt0302-256; Cole C, 2005, NAT MED, V11, P1073, DOI 10.1038/nm1297; Crittenden M, 2003, CANCER RES, V63, P3173; Diaz RM, 2007, CANCER RES, V67, P2840, DOI 10.1158/0008-5472.CAN-06-3974; Dyall R, 1998, J EXP MED, V188, P1553, DOI 10.1084/jem.188.9.1553; Ebert O, 2005, CANCER GENE THER, V12, P350, DOI 10.1038/sj.cgt.7700794; Engelhorn ME, 2006, NAT MED, V12, P198, DOI 10.1038/nm1363; Fernandez M, 2002, J VIROL, V76, P895, DOI 10.1128/JVI.76.2.895-904.2002; Harrington K, 2002, HUM GENE THER, V13, P1263, DOI 10.1089/104303402760128504; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Kelly PF, 2007, MOL THER, V15, P211, DOI 10.1038/sj.mt.6300033; Kottke T, 2006, GENE THER, V13, P1166, DOI 10.1038/sj.gt.3302722; Lichty BD, 2004, HUM GENE THER, V15, P821, DOI 10.1089/1043034041839208; Linardakis E, 2002, CANCER RES, V62, P5495; Lun X, 2006, JNCI-J NATL CANCER I, V98, P1546, DOI 10.1093/jnci/djj413; Markovic SN, 2007, MAYO CLIN PROC, V82, P490, DOI 10.4065/82.4.490; Matsuura K, 2006, CANCER-AM CANCER SOC, V106, P1227, DOI 10.1002/cncr.21729; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Murta EFC, 2000, TUMORI J, V86, P403, DOI 10.1177/030089160008600507; Ong HT, 2007, GENE THER, V14, P324, DOI 10.1038/sj.gt.3302880; Peters AM, 1998, BRIT J RADIOL, V71, P252, DOI 10.1259/bjr.71.843.9616233; Power AT, 2007, MOL THER, V15, P123, DOI 10.1038/sj.mt.6300039; Shields JD, 2007, ONCOGENE, V26, P2997, DOI 10.1038/sj.onc.1210114; Shinozaki K, 2005, HEPATOLOGY, V41, P196, DOI 10.1002/hep.20536; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Takeuchi H, 2004, CLIN CANCER RES, V10, P2351, DOI 10.1158/1078-0432.CCR-03-0195; Thanarajasingam U, 2007, CANCER RES, V67, P300, DOI 10.1158/0008-5472.CAN-06-1017; Thirukkumaran CM, 2007, BONE MARROW TRANSPL, V40, P1, DOI 10.1038/sj.bmt.1705668; Thomas DA, 2005, CANCER CELL, V8, P369, DOI 10.1016/j.ccr.2005.10.012; Thorne SH, 2005, CURR GENE THER, V5, P429, DOI 10.2174/1566523054546215; Walker LSK, 2002, NAT REV IMMUNOL, V2, P11, DOI 10.1038/nri701; Weninger W, 2003, SEMIN IMMUNOL, V15, P257, DOI 10.1016/j.smim.2003.08.007; Wiley HE, 2001, J NATL CANCER I, V93, P1638, DOI 10.1093/jnci/93.21.1638; Yokoyama WM, 2006, IMMUNOL REV, V214, P143, DOI 10.1111/j.1600-065X.2006.00458.x; Yotnda P, 2004, BLOOD, V104, P2272, DOI 10.1182/blood-2003-11-3803	43	118	130	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2008	14	1					37	44		10.1038/nm1681	http://dx.doi.org/10.1038/nm1681			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	249IV	18066076				2023-01-03	WOS:000252222400020
J	Hancock, MJ; Maher, CG; Latimer, J; McLachlan, AJ; Cooper, CW; Day, RO; Spindler, MF; McAuley, JH				Hancock, Mark J.; Maher, Chris G.; Latimer, Jane; McLachlan, Andrew J.; Cooper, Chris W.; Day, Richard O.; Spindler, Megan F.; McAuley, James H.			Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial	LANCET			English	Article							GUIDELINES; MANAGEMENT; DISABILITY; RISK	Background We aimed to investigate whether the addition of non-steroidal anti-inflammatory drugs or spinal manipulative therapy, or both, would result in faster recovery for patients with acute low back pain receiving recommended first-line care. Methods 240 patients with acute low back pain who had seen theirgeneral practitioner and had been given advice and paracetamol were randomly allocated to one of four groups in our community-based study: diclofenac 50 mg twice daily and placebo manipulative therapy (n=60); spinal manipulative therapy and placebo drug (n=60); didofenac 50 mg twice daily and spinal manipulative therapy (n=60); or double placebo (n=60). The primary outcome was days to recovery from pain assessed by survival curves (log-rank test) in an intention-to-treat analysis. This trial was registered with the Australian Clinical Trials Registry, ACTRN012605000036617. Findings Neither diclofenac nor spinal manipulative therapy appreciably reduced the number of days until recovery compared with placebo drug or placebo manipulative therapy (diclofenac hazard ratio 1.09, 95% CI 0.84-1-42, p=0.516; spinal manipulative therapy hazard ratio 1.01, 95% Cl 0.77-1-31, p=0.955). 237 patients (99%) either recovered or were censored 12 weeks after randomisation. 22 patients had possible adverse reactions including gastrointestinal disturbances, dizziness, and heart palpitations. Half of these patients were in the active diclofenac group, the other half were taking placebo. One patient taking active diclofenac had a suspected hypersensitivity reaction and ceased treatment. Interpretation Patients with acute low back pain receiving recommended first-line care do not recover more quickly with the addition of diclofenac or spinal manipulative therapy.	Univ Sydney, Back Pain Res Grp, Lidcombe, NSW 1825, Australia; Univ Sydney, Fac Pharm, Ctr Educ & Res Aging, Lidcombe, NSW 1825, Australia; Univ Sydney, Discipline Gen Practice, Lidcombe, NSW 1825, Australia; Univ Sydney, Dept Clin Pharmacol, Lidcombe, NSW 1825, Australia; Australia & St Vincents Hosp, Sydney, NSW, Australia	University of Sydney; University of Sydney; University of Sydney; University of Sydney; St Vincents Hospital Sydney	Hancock, MJ (corresponding author), Univ Sydney, Back Pain Res Grp, POB 170, Lidcombe, NSW 1825, Australia.	M.Hancock@usyd.edu.au	Maher, Christopher/AAC-6267-2019; Hancock, Mark J/B-6999-2013; Day, Richard/D-8699-2011; McAuley, James Henry/HHC-3949-2022	Maher, Christopher/0000-0002-1628-7857; Hancock, Mark J/0000-0002-9277-5377; Day, Richard/0000-0002-6045-6937; McAuley, James Henry/0000-0002-0550-828X; McLachlan, Andrew/0000-0003-4674-0242				Assendelft WJJ, 2003, ANN INTERN MED, V138, P871, DOI 10.7326/0003-4819-138-11-200306030-00008; BORKOVEC TD, 1972, J BEHAV THER EXP PSY, V3, P257, DOI 10.1016/0005-7916(72)90045-6; Cannon CP, 2006, LANCET, V368, P1771, DOI 10.1016/S0140-6736(06)69666-9; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; GRIEVE G, 1984, MOBILISATION SPINE N; Hancock MJ, 2006, AUST J PHYSIOTHER, V52, P135, DOI 10.1016/S0004-9514(06)70049-6; Hancock MJ, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-57; Jull G, 1994, GRIEVES MODERN MANUA; Koes BW, 2001, SPINE, V26, P2504, DOI 10.1097/00007632-200111150-00022; Maitland GD., 1986, VERTEBRAL MANIPULATI; *MED OUTC TRUST, 1994, SF 36 HLTH SURV SCOR; Ngandu NH, 1997, STAT MED, V16, P611, DOI 10.1002/(SICI)1097-0258(19970330)16:6<611::AID-SIM437>3.0.CO;2-T; Pengel LHM, 2004, SPINE, V29, P879, DOI 10.1097/00007632-200404150-00011; Richy F, 2004, ANN RHEUM DIS, V63, P759, DOI 10.1136/ard.2003.015925; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Schaffer D, 2006, MED J AUSTRALIA, V185, P501, DOI 10.5694/j.1326-5377.2006.tb00665.x; Stratford P., 1995, PHYSIOTHER CAN, V47, P258, DOI [10.3138/ptc.47.4.258, DOI 10.3138/PTC.47.4.258]; TERRETT AGJ, 1992, CHIROPR J AUST, V22, P129; van Tulder M, 2006, EUR SPINE J, V15, pS169, DOI 10.1007/s00586-006-1071-2; van Tulder MW, 2000, SPINE, V25, P2501, DOI 10.1097/00007632-200010010-00013	20	148	150	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 10	2007	370	9599					1638	1643		10.1016/S0140-6736(07)61686-9	http://dx.doi.org/10.1016/S0140-6736(07)61686-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230NO	17993364				2023-01-03	WOS:000250883400023
J	Parmet, WE				Parmet, Wendy E.			Legal power and legal rights - Isolation and quarantine in the case of drug-resistant tuberculosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Northeastern Univ, Sch Law, Boston, MA 02115 USA	Northeastern University	Parmet, WE (corresponding author), Northeastern Univ, Sch Law, Boston, MA 02115 USA.							DiGiovanni C, 2004, BIOSECUR BIOTERROR, V2, P265, DOI 10.1089/bsp.2004.2.265; Gasner MR, 1999, NEW ENGL J MED, V340, P359, DOI 10.1056/NEJM199902043400506; NEUMANN J, 2007, LOS ANGELES TIM 0607, pA12; 2005, FED REG         1130, V70, P71892	4	29	29	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 2	2007	357	5					433	435		10.1056/NEJMp078133	http://dx.doi.org/10.1056/NEJMp078133			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	195UB	17671251				2023-01-03	WOS:000248436300001
J	Menter, A; Griffiths, CEM				Menter, Alan; Griffiths, Christopher E. M.			Psoriasis 2 - Current and future management of psoriasis	LANCET			English	Review							CHRONIC PLAQUE PSORIASIS; LONG-TERM SAFETY; LOW-DOSE CYCLOSPORINE; FUMARIC-ACID ESTERS; ULTRAVIOLET-B PHOTOTHERAPY; SHORT-CONTACT DITHRANOL; TO-SEVERE PSORIASIS; G G(-1) OINTMENT; DOUBLE-BLIND; BETAMETHASONE DIPROPIONATE	Management of psoriasis begins with identification of the extent of cutaneous disease. However, a holistic, contractual approach to treatment is encouraged, with particular reference to psychosocial disability and quality-of-life issues. of The presence of psoriasis on palms, soles, body folds, genitals, face, or nails, and concomitant joint disease, are also important when considering treatment options. An evidence-based approach is essential in delineating differences between the many available treatments. However, archaic approaches, especially combinational ones, are routinely used by some clinicians, with inadequate prospective or comparative evidence. Treatments currently available are: topical agents used predominantly for mild disease and for recalcitrant lesions in more severe disease; phototherapy for moderate disease; and systemic agents including photochemotherapy, oral agents, and newer injectable biological of agents, which have revolutionised the management of severe psoriasis. Other innovative treatments are undergoing clinical studies, with the aim of maintaining safe, long-term control of the condition.	Univ Manchester, Hope Hosp, Dermatol Ctr, Salford M6 8HD, Lancs, England; Baylor Res Inst, Dallas, TX 75246 USA; SW Med Sch, Dallas, TX 75246 USA	University of Manchester; Baylor Scott & White Health; Baylor University Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas	Griffiths, CEM (corresponding author), Univ Manchester, Hope Hosp, Dermatol Ctr, Salford M6 8HD, Lancs, England.	christopher.griffiths@manchester.ac.uk	menter md, alan/A-8250-2009; Griffiths, Christopher E.M./P-5448-2014	Griffiths, Christopher E.M./0000-0001-5371-4427				Agarwal R, 2002, J DERMATOL, V29, P529, DOI 10.1111/j.1346-8138.2002.tb00321.x; [Anonymous], 2005, Prescrire Int, V14, P123; Antoni C, 2005, ANN RHEUM DIS, V64, P1150, DOI 10.1136/ard.2004.032268; Ashcroft DM, 2000, BMJ-BRIT MED J, V320, P963, DOI 10.1136/bmj.320.7240.963; Bawle EV, 1998, TERATOLOGY, V57, P51, DOI 10.1002/(SICI)1096-9926(199802)57:2<51::AID-TERA2>3.3.CO;2-O; Bissonnette R, 2006, J AM ACAD DERMATOL, V54, P472, DOI 10.1016/j.jaad.2005.10.061; Bongartz T, 2006, JAMA-J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275; Bowman PH, 2002, J AM ACAD DERMATOL, V46, P907, DOI 10.1067/mjd.2002.120453; Bruner Christine R, 2003, Dermatol Online J, V9, P2; Cameron H, 2002, BRIT J DERMATOL, V147, P973, DOI 10.1046/j.1365-2133.2002.04996.x; Campalani E, 2007, J INVEST DERMATOL, V127, P1860, DOI 10.1038/sj.jid.5700808; Carroll CL, 2005, ARCH DERMATOL, V141, P43, DOI 10.1001/archderm.141.1.43; Chalmers RJG, 2005, BRIT J DERMATOL, V152, P444, DOI 10.1111/J.1365-2133.2005.06422.X; Chamian F, 2005, P NATL ACAD SCI USA, V102, P2075, DOI 10.1073/pnas.0409569102; Chaudhari U, 2001, LANCET, V357, P1842, DOI 10.1016/S0140-6736(00)04954-0; Clark CM, 1999, BRIT J DERMATOL, V141, P279; Cooper EJ, 2000, CLIN EXP DERMATOL, V25, P111; CORNELL RC, 1985, ARCH DERMATOL, V121, P63, DOI 10.1001/archderm.121.1.63; Coven TR, 1997, ARCH DERMATOL, V133, P1514, DOI 10.1001/archderm.133.12.1514; DIGIOVANNA JJ, 1995, ARCH DERMATOL, V131, P1263, DOI 10.1001/archderm.131.11.1263; Douglas WS, 2002, ACTA DERM-VENEREOL, V82, P131, DOI 10.1080/00015550252948194; DUHRA P, 1993, J AM ACAD DERMATOL, V28, P466, DOI 10.1016/0190-9622(93)70069-6; Duweb G, 2005, INT J TISSUE REACT, V27, P155; Ellis CN, 2001, NEW ENGL J MED, V345, P248, DOI 10.1056/NEJM200107263450403; Fiala Z, 2006, ARCH DERMATOL RES, V298, P243, DOI 10.1007/s00403-006-0691-z; FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869; Fortune DG, 2003, ARCH DERMATOL, V139, P752, DOI 10.1001/archderm.139.6.752; Fortune DG, 2002, BRIT J DERMATOL, V146, P458, DOI 10.1046/j.1365-2133.2002.04622.x; Gerritsen MJP, 2001, BRIT J DERMATOL, V144, P17, DOI 10.1046/j.1365-2133.2001.00035.x; Giannetti A, 1999, J EUR ACAD DERMATOL, V13, P91, DOI 10.1016/S0926-9959(99)00056-2; Goeckerman W., 1925, NW MED, V24, P229; Gordon KB, 2006, J AM ACAD DERMATOL, V55, P598, DOI 10.1016/j.jaad.2006.05.027; Gottlieb AB, 2004, J AM ACAD DERMATOL, V51, P534, DOI 10.1016/j.jaad.2004.02.021; Gottlieb AB, 2005, BRIT J DERMATOL, V152, P1219, DOI 10.1111/j.1365-2133.2005.06661.x; Gottlieb AB, 2003, ARCH DERMATOL, V139, P1627, DOI 10.1001/archderm.139.12.1627; Gottlieb Alice B, 2004, J Drugs Dermatol, V3, P614; Gribetz C, 2004, J AM ACAD DERMATOL, V51, P731, DOI 10.1016/j.jaad.2004.06.010; Griffiths C E, 2000, Health Technol Assess, V4, P1; Griffiths CEM, 2004, BRIT J DERMATOL, V150, P11, DOI 10.1111/j.0366-077X.2004.05949.x; GROSSMAN RM, 1994, J AM ACAD DERMATOL, V31, P68, DOI 10.1016/S0190-9622(94)70138-5; Grundmann-Kollmann M, 2004, J AM ACAD DERMATOL, V50, P734, DOI 10.1016/S0190-9622(03)00792-8; GUPTA AK, 1995, J RHEUMATOL, V22, P894; Harries MJ, 2005, BRIT J DERMATOL, V153, P549, DOI 10.1111/j.1365-2133.2005.06728.x; Heydendael VMR, 2003, NEW ENGL J MED, V349, P658, DOI 10.1056/NEJMoa021359; Hoefnagel JJ, 2003, BRIT J DERMATOL, V149, P363, DOI 10.1046/j.1365-2133.2003.05433.x; Hutchinson PE, 2000, DERMATOLOGY, V201, P139, DOI 10.1159/000018457; IEST J, 1989, BRIT J DERMATOL, V120, P665, DOI 10.1111/j.1365-2133.1989.tb01354.x; INGRAM JT, 1953, BRIT MED J, V2, P591, DOI 10.1136/bmj.2.4836.591; JONES EL, 1975, J INVEST DERMATOL, V65, P537, DOI 10.1111/1523-1747.ep12610346; KATZ HI, 1991, DERMATOLOGICA, V183, P269, DOI 10.1159/000247698; Kaur I, 2001, J DERMATOL, V28, P448, DOI 10.1111/j.1346-8138.2001.tb00008.x; Kokelj F, 1998, J EUR ACAD DERMATOL, V10, P143, DOI 10.1111/j.1468-3083.1998.tb00714.x; Kragballe K, 2006, BRIT J DERMATOL, V154, P1155, DOI 10.1111/j.1365-2133.2006.07236.x; KRAGBALLE K, 1991, LANCET, V337, P1229, DOI 10.1016/0140-6736(91)92906-I; KRAGBALLE K, 1991, ACTA DERM-VENEREOL, V71, P475; Kremer JM, 1997, ARTHRITIS RHEUM, V40, P1829, DOI 10.1002/art.1780401016; Krueger GG, 2007, NEW ENGL J MED, V356, P580, DOI 10.1056/NEJMoa062382; Krueger GG, 2004, DERMATOL CLIN, V22, P407, DOI 10.1016/j.det.2004.03.014; Lahfa M, 2003, EUR J DERMATOL, V13, P261; LARSEN FG, 1993, J INVEST DERMATOL, V100, P623; LEAVELL UW, 1970, ARCH DERMATOL, V102, P144, DOI 10.1001/archderm.102.2.144; Lebwohl M, 2004, J AM ACAD DERMATOL, V51, P723, DOI 10.1016/j.jaad.2004.07.011; Lebwohl M, 2003, ARCH DERMATOL, V139, P719, DOI 10.1001/archderm.139.6.719; Lebwohl M, 1998, J AM ACAD DERMATOL, V39, P447, DOI 10.1016/S0190-9622(98)70323-8; Lebwohl M, 2001, J AM ACAD DERMATOL, V45, P544, DOI 10.1067/mjd.2001.116347; LEBWOHL M, 2004, NEW ENGL J MED, V349, P13; Lebwohl MG, 1998, J AM ACAD DERMATOL, V39, P590, DOI 10.1016/S0190-9622(98)70008-8; Leonardi CL, 2005, J AM ACAD DERMATOL, V52, P425, DOI 10.1016/j.jaad.2004.09.029; Leonardi CL, 2004, DERMATOL CLIN, V22, P427, DOI 10.1016/j.det.2004.03.015; Leonardi CL, 2003, NEW ENGL J MED, V349, P2014, DOI 10.1056/NEJMoa030409; LEVINE MJ, 1979, J INVEST DERMATOL, V73, P170, DOI 10.1111/1523-1747.ep12581626; Lowe NJ, 1996, J AM ACAD DERMATOL, V35, P710, DOI 10.1016/S0190-9622(96)90726-4; Mason J, 2002, BRIT J DERMATOL, V146, P351, DOI 10.1046/j.1365-2133.2000.04713.x; McGill A, 2005, FASEB J, V19, P1012, DOI 10.1096/fj.04-2664fje; Mease PJ, 2004, ARTHRITIS RHEUM-US, V50, P2264, DOI 10.1002/art.20335; Mease PJ, 2005, ARTHRITIS RHEUM-US, V52, P3279, DOI 10.1002/art.21306; Mease PJ, 2000, LANCET, V356, P385, DOI 10.1016/S0140-6736(00)02530-7; Menter A, 2005, ARCH DERMATOL, V141, P31, DOI 10.1001/archderm.141.1.31; Menter A, 2007, J AM ACAD DERMATOL, V56, P31, DOI 10.1016/j.jaad.2006.07.017; Miyachi Y, 2002, EUR J DERMATOL, V12, P463; Monastirli A, 2002, SKIN PHARMACOL APPL, V15, P246, DOI 10.1159/000065971; MOY RL, 1985, ARCH DERMATOL, V121, P1297, DOI 10.1001/archderm.121.10.1297; Mrowietz U, 1998, BRIT J DERMATOL, V138, P456; MUELLER W, 1979, NEW ENGL J MED, V301, P555; Naldi L, 2005, BRIT J DERMATOL, V152, P597, DOI 10.1111/j.1365-2133.2005.06563.x; Nast Alexander, 2006, J Dtsch Dermatol Ges, V4 Suppl 2, pS1, DOI 10.1111/j.1610-0387.2006.06172.x; *NIH CLIN EXC, ET EF TREATM AD PSOR; Ortonne JP, 2003, BRIT J DERMATOL, V148, P326, DOI 10.1046/j.1365-2133.2003.05228.x; Papp KA, 2003, J AM ACAD DERMATOL, V48, P48, DOI 10.1067/mjd.2003.130; PARRISH JA, 1981, J INVEST DERMATOL, V76, P359, DOI 10.1111/1523-1747.ep12520022; Paul CF, 2003, J INVEST DERMATOL, V120, P211, DOI 10.1046/j.1523-1747.2003.12040.x; PITTELKOW MR, 1981, ARCH DERMATOL, V117, P465, DOI 10.1001/archderm.117.8.465; Queille-Roussel C, 2001, BRIT J DERMATOL, V144, P507, DOI 10.1046/j.1365-2133.2001.04076.x; Raddadi AA, 1999, BRIT J DERMATOL, V140, P1197; Raman GV, 1998, J HYPERTENS, V16, pS39; RAMSAY B, 1990, J AM ACAD DERMATOL, V23, P73, DOI 10.1016/0190-9622(90)70189-O; Ramsay CA, 2000, DERMATOLOGY, V200, P17, DOI 10.1159/000018309; RAMSAY CA, 1994, DERMATOLOGY, V189, P260, DOI 10.1159/000246851; Reich K, 2005, LANCET, V366, P1367, DOI 10.1016/S0140-6736(05)67566-6; Reitamo S, 1998, J INVEST DERMATOL, V111, P396, DOI 10.1046/j.1523-1747.1998.00323.x; Richards HL, 2006, J EUR ACAD DERMATOL, V20, P370, DOI 10.1111/j.1468-3083.2006.01565.x; Ring J, 2001, BRIT J DERMATOL, V144, P495, DOI 10.1046/j.1365-2133.2001.04074.x; Roenigk HH, 1998, J AM ACAD DERMATOL, V38, P478, DOI 10.1016/S0190-9622(98)70508-0; Ruderisch HS, 2004, SKIN PHARMACOL PHYS, V17, P129, DOI 10.1159/000077239; Salim A, 2006, BRIT J DERMATOL, V154, P1169, DOI 10.1111/j.1365-2133.2006.07289.x; Sandhu K, 2003, J DERMATOL, V30, P458, DOI 10.1111/j.1346-8138.2003.tb00416.x; Santini MP, 2001, P NATL ACAD SCI USA, V98, P9575, DOI 10.1073/pnas.161299698; Sarzi-Puttini P, 2002, RHEUMATOL INT, V21, P234, DOI 10.1007/s00296-001-0166-7; Scerri L, 1999, ADV EXP MED BIOL, V455, P343; Schrader P, 2002, Z RHEUMATOL, V61, P545, DOI 10.1007/s00393-002-0369-7; SCHWECKENDIEK W, 1959, Med Monatsschr, V13, P103; Smith CH, 2005, BRIT J DERMATOL, V153, P486, DOI 10.1111/j.1365-2133.2005.06893.x; SPEIGHT EL, 1994, BRIT J DERMATOL, V130, P79, DOI 10.1111/j.1365-2133.1994.tb06887.x; STERN RS, 1990, NEW ENGL J MED, V322, P1093, DOI 10.1056/NEJM199004193221601; Stern RS, 2001, J AM ACAD DERMATOL, V44, P755, DOI 10.1067/mjd.2001.114576; STERN RS, 1988, J INVEST DERMATOL, V91, P120, DOI 10.1111/1523-1747.ep12464137; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; Stucker M, 2002, SKIN RES TECHNOL, V8, P133, DOI 10.1034/j.1600-0846.2002.00330.x; Swinkels OQJ, 2003, SKIN PHARMACOL APPL, V16, P12, DOI 10.1159/000068285; Swinkels OQJ, 2002, BRIT J DERMATOL, V146, P621, DOI 10.1046/j.1365-2133.2002.04698.x; Taibjee SM, 2005, BRIT J DERMATOL, V153, P960, DOI 10.1111/j.1365-2133.2005.06827.x; TANEW A, 1991, J AM ACAD DERMATOL, V25, P682, DOI 10.1016/0190-9622(91)70253-X; Tanghetti E A, 2000, Cutis, V66, P4; Torras H, 2004, J Dermatolog Treat, V15, P98, DOI 10.1080/09546630410023322; Treumer F, 2003, J INVEST DERMATOL, V121, P1383, DOI 10.1111/j.1523-1747.2003.12605.x; Turner RJ, 2000, BRIT J DERMATOL, V143, P957, DOI 10.1046/j.1365-2133.2000.03827.x; Tyring S, 2006, LANCET, V367, P29, DOI 10.1016/S0140-6736(05)67763-X; Tzung TY, 2005, ACTA DERM-VENEREOL, V85, P236, DOI 10.1080/00015550510027405; Van de Kerkhof PCM, 1998, BRIT J DERMATOL, V138, P84; van de Kerkhof PCM, 2002, BRIT J DERMATOL, V146, P414, DOI 10.1046/j.1365-2133.2002.04567.x; Van Zander JoEllen, 2005, Expert Opin Drug Saf, V4, P129, DOI 10.1517/14740338.4.1.129; Volden G, 2001, J DERMATOL TREAT, V12, P141; Warren RB, 2005, BRIT J DERMATOL, V153, P869, DOI 10.1111/j.1365-2133.2005.06880.x; Weinstein GD, 1997, J AM ACAD DERMATOL, V37, P85, DOI 10.1016/S0190-9622(97)70216-0; Weinstein GD, 2003, J AM ACAD DERMATOL, V48, P760, DOI 10.1067/mjd.2003.103; WILSON DJ, 1988, BRIT J DERMATOL, V119, P597, DOI 10.1111/j.1365-2133.1988.tb03470.x; Winterfield L, 2004, DERMATOL CLIN, V22, P437, DOI 10.1016/j.det.2004.03.011; Woo WK, 2003, BRIT J DERMATOL, V149, P146, DOI 10.1046/j.1365-2133.2003.05380.x; Yamauchi PS, 2004, DERMATOL CLIN, V22, P449, DOI 10.1016/j.det.2003.12.002; Young HS, 2006, J INVEST DERMATOL, V126, P453, DOI 10.1038/sj.jid.5700096; Zachariae H, 1997, BRIT J DERMATOL, V136, P531, DOI 10.1046/j.1365-2133.1997.6101586.x; ZACKHEIM HS, 1994, J AM ACAD DERMATOL, V30, P452, DOI 10.1016/S0190-9622(94)70055-9; Zhou YW, 2003, J CUTAN MED SURG, V7, P193, DOI 10.1007/s10227-002-0113-6; Zonneveld IM, 1998, ARCH DERMATOL, V134, P1101, DOI 10.1001/archderm.134.9.1101	144	245	254	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 21	2007	370	9583					272	284		10.1016/S0140-6736(07)61129-5	http://dx.doi.org/10.1016/S0140-6736(07)61129-5			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	194MG	17658398				2023-01-03	WOS:000248347900032
J	Dansinger, ML; Tatsioni, A; Wong, JB; Chung, M; Balk, EM				Dansinger, Michael L.; Tatsioni, Athina; Wong, John B.; Chung, Mei; Balk, Ethan M.			Meta-analysis: The effect of dietary counseling for weight loss	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; CARDIOVASCULAR RISK-FACTORS; LIFE-STYLE INTERVENTION; ANTIHYPERTENSIVE MEDICATION REQUIREMENTS; INSULIN SENSITIVITY; REDUCTION PROGRAM; OVERWEIGHT MEN; EXERCISE; OBESE; HYPERTENSION	Background: Dietary and lifestyle modification efforts are the primary treatments for people who are obese or overweight. The effect of dietary counseling on long-term weight change is unclear. Purpose: To perform a meta-analysis of the effect of dietary counseling compared with usual care on body mass index (BMI) over time in adults. Data Sources: Early studies (1980 through 1997) from a previously published systematic review; MEDLINE and the Cochrane Central Register of Controlled Trials from 1997 through July 2006. Study Selection: English-language randomized, controlled trials ( 16 weeks in duration) in overweight adults that reported the effect of dietary counseling on weight. The authors included only weight loss studies with a dietaty component. Data Extraction: Single reviewers.; performed full data extraction; at least 1 additional reviewer reviewed the data. Data Synthesis: Random-effects, model meta-analyses of 46 trials of dietary counseling revealed a maximum net treatment effect of -1.9 (95% Cl, -2.3 to -1.5) BMI units (approximately -6%) at 12 months. Meta-analysis of changes in weight over time (slopes) and meta-regression suggest a change of approximately -0.1 BMI unit per month from 3 to 12 months of active programs and a regain of approximately 0.02 to 0.03 BMI unit per month during subsequent maintenance phases. Different analyses suggested that calorie recommendations, frequency of support meetings, inclusion of exercise, and diabetes may be independent predictors of weight change. Limitations: The interventions, study samples, and weight changes were heterogeneous. Studies were generally of moderate to poor methodological quality. They had high rates of missing data and failed to explain these losses. The meta-analytic techniques could not fully account for these limitations. Conclusions: Compared with usual care, dietary counseling interventions produce modest weight losses that diminish over time. In future studies, minimizing loss to follow-up and determining which factors result in more effective weight loss should be emphasized.	Tufts Univ, New England Med Ctr, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Dansinger, ML (corresponding author), Tufts Univ, New England Med Ctr, 750 Washington St,NEMC 216, Boston, MA 02111 USA.	mdansinger@tufts-nemc.org	Balk, Ethan/AAJ-2547-2020; Tatsioni, Athina/AAQ-5413-2020	Wong, John/0000-0003-4203-9010	NCRR NIH HHS [K23RR020709] Funding Source: Medline; PHS HHS [290-02-0022] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams KF, 2006, NEW ENGL J MED, V355, P763, DOI 10.1056/NEJMoa055643; AgursCollins TD, 1997, DIABETES CARE, V20, P1503, DOI 10.2337/diacare.20.10.1503; Anderson JW, 2001, AM J CLIN NUTR, V74, P579; Anderssen Sigmund, 1995, Blood Pressure, V4, P343, DOI 10.3109/08037059509077619; [Anonymous], 1990, Arch Intern Med, V150, P153, DOI 10.1001/archinte.150.1.153; Appel LJ, 2003, JAMA-J AM MED ASSOC, V289, P2083, DOI 10.1001/jama.289.16.2083; Avenell A, 2004, J HUM NUTR DIET, V17, P293, DOI 10.1111/j.1365-277X.2004.00530.x; Avenell A, 2004, HEALTH TECHNOL ASSES, V8, P1; Ayyad C, 2000, Obes Rev, V1, P113, DOI 10.1046/j.1467-789x.2000.00019.x; Balk EM, 2002, JAMA-J AM MED ASSOC, V287, P2973, DOI 10.1001/jama.287.22.2973; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406; Clark M, 2004, BRIT J HEALTH PSYCH, V9, P365, DOI 10.1348/1359107041557066; CROFT PR, 1986, J ROY COLL GEN PRACT, V36, P445; Dalle Grave R, 2004, Eat Weight Disord, V9, P69; DAVIS BR, 1993, ARCH INTERN MED, V153, P1773, DOI 10.1001/archinte.153.15.1773; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DICKSON R, 1997, EFFECTIVE HLTH CARE, V3, P1; Djuric Z, 2002, OBES RES, V10, P657, DOI 10.1038/oby.2002.89; Douketis JD, 1999, THROMB HAEMOSTASIS, V82, P1028; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Escalante-Pulido M, 2003, DIABETES NUTR METAB, V16, P277; Esposito K, 2004, JAMA-J AM MED ASSOC, V291, P2978, DOI 10.1001/jama.291.24.2978; Field AE, 2001, ARCH INTERN MED, V161, P1581, DOI 10.1001/archinte.161.13.1581; *FINN DIAB PREV ST, 2003, DIABETES CARE, V26, P3230; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861; Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187; Fontaine KR, 2000, INT J EAT DISORDER, V27, P101, DOI 10.1002/(SICI)1098-108X(200001)27:1&lt;101::AID-EAT12&gt;3.0.CO;2-D; Glasgow RE, 2003, AM J PUBLIC HEALTH, V93, P1261, DOI 10.2105/AJPH.93.8.1261; Glenny AM, 1997, INT J OBESITY, V21, P715, DOI 10.1038/sj.ijo.0800495; GUARE JC, 1995, OBES RES, V3, P329, DOI 10.1002/j.1550-8528.1995.tb00158.x; HAKALA P, 1989, EUR J CLIN NUTR, V43, P421; Hankey CR, 2002, J HUM NUTR DIET, V15, P439, DOI 10.1046/j.1365-277X.2002.00397.x; Haynes R B, 1984, J Hypertens, V2, P535, DOI 10.1097/00004872-198410000-00014; HELLENIUS ML, 1993, ATHEROSCLEROSIS, V103, P81, DOI 10.1016/0021-9150(93)90042-S; Heshka S, 2003, JAMA-J AM MED ASSOC, V289, P1792, DOI 10.1001/jama.289.14.1792; Hinderliter A, 2002, ARCH INTERN MED, V162, P1333, DOI 10.1001/archinte.162.12.1333; Hoeger KM, 2004, FERTIL STERIL, V82, P421, DOI 10.1016/j.fertnstert.2004.02.104; *ICAN STUD, 2004, DIABETES CARE, V27, P1570; JALKANEN L, 1991, SCAND J SOC MED, V19, P66, DOI 10.1177/140349489101900112; Jones DW, 1999, AM J HYPERTENS, V12, P1175, DOI 10.1016/S0895-7061(99)00123-5; KARVETTI RL, 1992, EUR J CLIN NUTR, V46, P743; Kastarinen MJ, 2002, J HYPERTENS, V20, P2505, DOI 10.1097/00004872-200212000-00031; KATZEL LI, 1995, JAMA-J AM MED ASSOC, V274, P1915, DOI 10.1001/jama.274.24.1915; Khan MA, 2000, OBES RES, V8, P43, DOI 10.1038/oby.2000.7; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; LANGFORD HG, 1985, JAMA-J AM MED ASSOC, V253, P657, DOI 10.1001/jama.253.5.657; Leermakers EA, 1998, INT J OBESITY, V22, P1103, DOI 10.1038/sj.ijo.0800734; MACMAHON SW, 1985, CLIN EXP PHARMACOL P, V12, P267, DOI 10.1111/j.1440-1681.1985.tb02645.x; MARKS BL, 1995, MED SCI SPORT EXER, V27, P1243; Mayer-Davis EJ, 2004, AM J PUBLIC HEALTH, V94, P1736, DOI 10.2105/AJPH.94.10.1736; McAuley KA, 2002, DIABETES CARE, V25, P445, DOI 10.2337/diacare.25.3.445; McTigue KM, 2003, ANN INTERN MED, V139, P933, DOI 10.7326/0003-4819-139-11-200312020-00013; Mensink M, 2003, OBES RES, V11, P1588, DOI 10.1038/oby.2003.211; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; MORRIS CN, 1983, J AM STAT ASSOC, V78, P47, DOI 10.2307/2287098; Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523; *NEDCOM, 2003, ANN INTERN MED, V138, P24; Nicklas BJ, 2004, AM J CLIN NUTR, V79, P544; Nordmann AJ, 2006, ARCH INTERN MED, V166, P285, DOI 10.1001/archinte.166.3.285; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Oldroyd JC, 2001, DIABETES RES CLIN PR, V52, P29, DOI 10.1016/S0168-8227(00)00244-8; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Simkin-Silverman LR, 2003, ANN BEHAV MED, V26, P212, DOI 10.1207/S15324796ABM2603_06; Southard Barbara H, 2003, J Cardiopulm Rehabil, V23, P341, DOI 10.1097/00008483-200309000-00003; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; Swinburn BA, 2001, DIABETES CARE, V24, P619, DOI 10.2337/diacare.24.4.619; Tate DF, 2006, ARCH INTERN MED, V166, P1620, DOI 10.1001/archinte.166.15.1620; Tate DF, 2001, JAMA-J AM MED ASSOC, V285, P1172, DOI 10.1001/jama.285.9.1172; Toobert DJ, 2005, ANN BEHAV MED, V29, P128, DOI 10.1207/s15324796abm2902_7; Toobert DJ, 2000, ANN BEHAV MED, V22, P1, DOI 10.1007/BF02895162; U.S. Department of Health and Human Services, 2001, SURG GEN CALL ACT PR; Ware JH, 2003, NEW ENGL J MED, V348, P2136, DOI 10.1056/NEJMe030054; Whelton PK, 1998, JAMA-J AM MED ASSOC, V279, P839, DOI 10.1001/jama.279.11.839; Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657; Wing RR, 1998, DIABETES CARE, V21, P350, DOI 10.2337/diacare.21.3.350; WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801; WOOD PD, 1991, NEW ENGL J MED, V325, P461, DOI 10.1056/NEJM199108153250703	80	328	332	0	53	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2007	147	1					41	50		10.7326/0003-4819-147-1-200707030-00007	http://dx.doi.org/10.7326/0003-4819-147-1-200707030-00007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	186MN	17606960				2023-01-03	WOS:000247782900006
J	Shepard, JAO; Wright, CD; Hasserjian, RP; Fidias, P; Choi, NCH				Shepard, Jo-Anne O.; Wright, Cameron D.; Hasserjian, Robert P.; Fidias, Panos; Choi, Noah C. H.			Case 16-2007: A 61-year-old man with a mediastinal mass - Thymoma, WHO type B1, with individual changes after preoperative chemoradiation.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STAGE-III THYMOMA; THYMIC EPITHELIAL TUMORS; RADIATION-THERAPY; MALIGNANT THYMOMA; SURGICAL RESECTION; INVASIVE THYMOMA; MULTIDISCIPLINARY APPROACH; ADJUVANT RADIATION; INTERGROUP TRIAL; LUNG-CANCER		Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Hematol & Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Surg, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiat Oncol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University; Harvard University; Harvard University; Harvard University; Massachusetts General Hospital	Shepard, JAO (corresponding author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.							BERNATZ PE, 1961, J THORAC CARDIOV SUR, V42, P424; Bretti S, 2004, LUNG CANCER, V44, P69, DOI 10.1016/j.lungcan.2003.09.022; CIERNIK IF, 1994, J CLIN ONCOL, V12, P1484, DOI 10.1200/JCO.1994.12.7.1484; COWEN D, 1995, RADIOTHER ONCOL, V34, P9, DOI 10.1016/0167-8140(94)01493-M; CURRAN WJ, 1988, J CLIN ONCOL, V6, P1722, DOI 10.1200/JCO.1988.6.11.1722; Detterbeck FC, 2004, ANN THORAC SURG, V77, P1860, DOI 10.1016/j.athoracsur.2003.10.001; Engels EA, 2003, INT J CANCER, V105, P546, DOI 10.1002/ijc.11099; FORNASIERO A, 1991, CANCER, V68, P30, DOI 10.1002/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4; Giaccone G, 1996, J CLIN ONCOL, V14, P814, DOI 10.1200/JCO.1996.14.3.814; HANIUDA M, 1992, ANN THORAC SURG, V54, P311, DOI 10.1016/0003-4975(92)91391-L; HU E, 1986, CANCER, V57, P1101, DOI 10.1002/1097-0142(19860315)57:6<1101::AID-CNCR2820570606>3.0.CO;2-A; Jeong YJ, 2004, AM J ROENTGENOL, V183, P283, DOI 10.2214/ajr.183.2.1830283; Kim ES, 2004, LUNG CANCER, V44, P369, DOI 10.1016/j.lungcan.2003.12.010; Kondo K, 2003, ANN THORAC SURG, V76, P878, DOI 10.1016/S0003-4975(03)00555-1; KRUEGER JB, 1988, RADIOLOGY, V168, P855, DOI 10.1148/radiology.168.3.3136511; Kuo T, 2000, HISTOPATHOLOGY, V36, P403; Loehrer PJ, 2004, J CLIN ONCOL, V22, p629S; Loehrer PJ, 1997, J CLIN ONCOL, V15, P3093, DOI 10.1200/JCO.1997.15.9.3093; Loehrer PJ, 2001, CANCER-AM CANCER SOC, V91, P2010, DOI 10.1002/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2; Mangi AA, 2005, ANN THORAC SURG, V79, P1834, DOI 10.1016/j.athoracsur.2004.12.051; Mangi AA, 2002, ANN THORAC SURG, V74, P1033, DOI 10.1016/S0003-4975(02)03828-6; MARINO M, 1985, VIRCHOWS ARCH A, V407, P119, DOI 10.1007/BF00737071; MARX A, 2004, TUMORS LUNG PLEURA T, P145; MASAOKA A, 1981, CANCER, V48, P2485, DOI 10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R; MORNEX F, 1995, INT J RADIAT ONCOL, V32, P651, DOI 10.1016/0360-3016(95)00079-E; Myojin M, 2000, INT J RADIAT ONCOL, V46, P927, DOI 10.1016/S0360-3016(99)00514-3; Okumura M, 2002, CANCER-AM CANCER SOC, V94, P624, DOI 10.1002/cncr.10226; Palmieri G, 2002, CANCER-AM CANCER SOC, V94, P1414, DOI 10.1002/cncr.10374; Pottgen C, 2006, CLIN CANCER RES, V12, P97, DOI 10.1158/1078-0432.CCR-05-0510; QUINTANILLAMARTINEZ L, 1993, HUM PATHOL, V24, P958, DOI 10.1016/0046-8177(93)90109-T; QUINTANILLAMARTINEZ L, 1994, CANCER-AM CANCER SOC, V74, P606, DOI 10.1002/1097-0142(19940715)74:2<606::AID-CNCR2820740212>3.0.CO;2-T; Rosai J, 1976, ATLAS TUMOR PATHOLOG, P34; Rusch VW, 2001, J THORAC CARDIOV SUR, V121, P472, DOI 10.1067/mtc.2001.112465; Shimosato Y, 1997, ATLAS TUMOR PATHOL, P93; Shin DM, 1998, ANN INTERN MED, V129, P100, DOI 10.7326/0003-4819-129-2-199807150-00006; Tiseo M, 2005, J CLIN ONCOL, V23, P1578, DOI 10.1200/JCO.2005.03.115; URGESI A, 1990, RADIOTHER ONCOL, V19, P273, DOI 10.1016/0167-8140(90)90154-O; Venuta F, 2003, ANN THORAC SURG, V76, P1866, DOI 10.1016/S0003-4975(03)01020-8; Welsh JS, 2000, JAMA-J AM MED ASSOC, V283, P1142, DOI 10.1001/jama.283.9.1142; Wright CD, 2005, J THORAC CARDIOV SUR, V130, P1413, DOI 10.1016/j.jtcvs.2005.07.026	40	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 24	2007	356	21					2185	2193		10.1056/NEJMcpc079010	http://dx.doi.org/10.1056/NEJMcpc079010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170ON	17522403				2023-01-03	WOS:000246673100011
J	O'Keane, V; Marsh, MS				O'Keane, Veronica; Marsh, Michael S.			Pregnancy plus - Depression during pregnancy	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Kings Coll London, Inst Psychiat, London SE5 8AF, England	University of London; King's College London	O'Keane, V (corresponding author), Kings Coll London, Inst Psychiat, London SE5 8AF, England.	v.o'keane@iop.kcl.ac.uk		o'keane, veronica/0000-0002-1519-099X				Cohen LS, 2006, JAMA-J AM MED ASSOC, V295, P499, DOI 10.1001/jama.295.5.499; Copper RL, 1996, AM J OBSTET GYNECOL, V175, P1286, DOI 10.1016/S0002-9378(96)70042-X; Dayan J, 2002, AM J EPIDEMIOL, V155, P293, DOI 10.1093/aje/155.4.293; Evans J, 2001, BRIT MED J, V323, P257, DOI 10.1136/bmj.323.7307.257; Oates M, 2003, BRIT J PSYCHIAT, V183, P279, DOI 10.1192/bjp.183.4.279; Oberlander TF, 2006, ARCH GEN PSYCHIAT, V63, P898, DOI 10.1001/archpsyc.63.8.898; Rahman A, 2003, PSYCHOL MED, V33, P1161, DOI 10.1017/S0033291703008286; Spinelli MG, 2003, AM J PSYCHIAT, V160, P555, DOI 10.1176/appi.ajp.160.3.555; Wadhwa PD, 2002, REGUL PEPTIDES, V108, P149, DOI 10.1016/S0167-0115(02)00102-7; Wogelius P, 2006, EPIDEMIOLOGY, V17, P701, DOI 10.1097/01.ede.0000239581.76793.ae	10	85	87	1	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 12	2007	334	7601					1003	1005		10.1136/bmj.39189.662581.55	http://dx.doi.org/10.1136/bmj.39189.662581.55			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170AI	17494021	Green Published			2023-01-03	WOS:000246632800034
J	de Cerio, ALD; Zabalegui, N; Rodriguez-Calvillo, M; Inoges, S; Bendandi, M				de Cerio, A. Lopez-Diaz; Zabalegui, N.; Rodriguez-Calvillo, M.; Inoges, S.; Bendandi, M.			Anti-idiotype antibodies in cancer treatment	ONCOGENE			English	Review						idiotype; lymphoma; solid tumors; immunotherapy	B-CELL LYMPHOMA; HUMORAL IMMUNE-RESPONSE; NON-HODGKINS-LYMPHOMA; COLONY-STIMULATING FACTOR; IDIOTYPE VACCINATION; DNA VACCINES; T-CELL; CLINICAL BENEFIT; DENDRITIC CELLS; HIGH-RISK	As a cancer immunotherapy tool, idiotypes (Ids) have been used in different ways over the last three decades, depending on the actual human tumor cell target. It all started with passive, monoclonal, anti-Id antibody treatment of B-cell lymphoma, a setting in which results were tantalizing, but logistics unsustainable. It then moved toward the development of anti-Id vaccines for the treatment of the same tumors, a setting in which we have recently provided the first formal proof of principle of clinical benefit associated with the use of a human cancer vaccine. Meanwhile, it also expanded in the direction of exploiting the antigenic mimicry of some Ids with Id-unrelated, tumor-associated antigens for the immunotherapy of a number of solid tumors, a setting in which clinical results are still far from being consolidated. All in all, over the years Id-based immunotherapy has paved the way for a number of seminal therapeutic improvements for cancer patients, including the development of most if not all Id-unrelated monoclonal antibodies that have recently revolutionized the field.	Univ Navarra, Unic Clin, Ctr Appl Med Res, Oncol Div,Lab Immunotherapy, Pamplona 31008, Spain; Univ Navarra, Unic Clin, Cell Therapy Area, Oncol Div,Lab Immunotherapy, Pamplona 31008, Spain	University of Navarra; University of Navarra	Bendandi, M (corresponding author), Univ Navarra, Unic Clin, Ctr Appl Med Res, Oncol Div,Lab Immunotherapy, Avda Pio XII,55 & 36, Pamplona 31008, Spain.	mbendandi@unav.es	Inogés, Susana/AAW-6785-2021					Alfonso M, 2002, J IMMUNOL, V168, P2523, DOI 10.4049/jimmunol.168.5.2523; ALLEBES W, 1991, LEUKEMIA RES, V15, P215, DOI 10.1016/0145-2126(91)90123-B; ALLEBES WA, 1990, SCAND J IMMUNOL, V32, P441, DOI 10.1111/j.1365-3083.1990.tb03184.x; Baral R, 2001, INT J CANCER, V92, P88, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1148>3.0.CO;2-9; Barrios Y, 2002, HAEMATOLOGICA, V87, P400; Bendandi M, 2006, LEUKEMIA LYMPHOMA, V47, P29, DOI 10.1080/10428190500272473; Bendandi M, 2001, Expert Rev Anticancer Ther, V1, P65, DOI 10.1586/14737140.1.1.65; Bendandi M, 1999, NAT MED, V5, P1171, DOI 10.1038/13928; Bendandi M, 2006, REV RECENT CLIN TRIA, V1, P67, DOI 10.2174/157488706775246120; Bendandi Maurizio, 2004, Expert Rev Vaccines, V3, P163, DOI 10.1586/14760584.3.2.163; Benvenuti F, 2000, GENE THER, V7, P605, DOI 10.1038/sj.gt.3301133; Bertinetti C, 2006, CANCER RES, V66, P4496, DOI 10.1158/0008-5472.CAN-05-4233; Bertinetti C, 2006, EUR J HAEMATOL, V77, P395, DOI 10.1111/j.1600-0609.2006.00740.x; Bhattacharya-Chatterjee M, 2002, EXPERT OPIN BIOL TH, V2, P869, DOI 10.1517/14712598.2.8.869; Birebent B, 2001, CRIT REV ONCOL HEMAT, V39, P107, DOI 10.1016/S1040-8428(01)00125-1; BIREBENT B, 2001, J CANCER RES CLIN, V2, P27; Caspar CB, 1997, BLOOD, V90, P3699, DOI 10.1182/blood.V90.9.3699; Chang CC, 2005, J BIOL CHEM, V280, P10164, DOI 10.1074/jbc.M409161200; Coscia M, 2004, LEUKEMIA, V18, P139, DOI 10.1038/sj.leu.2403181; Cull G, 1999, BRIT J HAEMATOL, V107, P648; Davis TA, 1998, BLOOD, V92, P1184, DOI 10.1182/blood.V92.4.1184.416k05_1184_1190; Diaz A, 2003, CLIN IMMUNOL, V107, P80, DOI 10.1016/S1521-6616(03)00036-6; Foon KA, 1997, CLIN CANCER RES, V3, P1267; Foon KA, 1999, J CLIN ONCOL, V17, P2889, DOI 10.1200/JCO.1999.17.9.2889; Guthmann MD, 2006, J IMMUNOTHER, V29, P215, DOI 10.1097/01.cji.0000188502.11348.34; Hawkins RE, 1997, HUM GENE THER, V8, P1287, DOI 10.1089/hum.1997.8.10-1287; Herlyn D, 1989, Viral Immunol, V2, P271, DOI 10.1089/vim.1989.2.271; Hsu FJ, 1997, BLOOD, V89, P3129, DOI 10.1182/blood.V89.9.3129; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Hurvitz SA, 2005, EXPERT OPIN BIOL TH, V5, P841, DOI 10.1517/14712598.5.6.841; Inoges S, 2003, HAEMATOLOGICA, V88, P1438; Inoges S, 2006, J NATL CANCER I, V98, P1292, DOI 10.1093/jnci/djj358; King CA, 1998, NAT MED, V4, P1281, DOI 10.1038/3266; Kwak LW, 1996, P NATL ACAD SCI USA, V93, P10972, DOI 10.1073/pnas.93.20.10972; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; Longo DL, 2006, JNCI-J NATL CANCER I, V98, P1263, DOI 10.1093/jnci/djj371; Lutzky J, 2002, SEMIN ONCOL, V29, P462, DOI 10.1053/sonc.2002.35241; MALONEY DG, 1992, BLOOD, V80, P1502; Massaia M, 1999, BLOOD, V94, P673, DOI 10.1182/blood.V94.2.673.414k30_673_683; MEEKER T, 1985, NEW ENGL J MED, V312, P1658, DOI 10.1056/NEJM198506273122602; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; MITTELMAN A, 1994, CANCER RES, V54, P415; Mittelman A, 1995, CLIN CANCER RES, V1, P705; MOHANTY K, 2006, BREAST CANC RES TREA; Mosolits S, 2004, CLIN CANCER RES, V10, P5391, DOI 10.1158/1078-0432.CCR-04-0425; Murray JL, 2004, CANCER RES, V64, P5481, DOI 10.1158/0008-5472.CAN-04-0517; Neelapu S, 2005, BONE MARROW TRANSPL, V36, P315, DOI 10.1038/sj.bmt.1705057; Neelapu Sattva S, 2005, Clin Lymphoma, V6, P61, DOI 10.3816/CLM.2005.n.031; Neelapu SS, 2005, NAT MED, V11, P986, DOI 10.1038/nm1290; Osterborg A, 1998, BLOOD, V91, P2459, DOI 10.1182/blood.V91.7.2459.2459_2459_2466; Pfisterer J, 2006, ANN ONCOL, V17, P1568, DOI 10.1093/annonc/mdl357; PIGNATARI GC, 2006, J BIOTECHNOL; RAFFELD M, 1985, NEW ENGL J MED, V312, P1653, DOI 10.1056/NEJM198506273122601; Rasmussen T, 2003, BLOOD, V101, P4607, DOI 10.1182/blood-2002-06-1925; Redfern CH, 2006, J CLIN ONCOL, V24, P3107, DOI 10.1200/JCO.2005.04.4289; Reece DE, 2000, BONE MARROW TRANSPL, V26, P729, DOI 10.1038/sj.bmt.1702607; REECE DE, 2001, CLIN BREAST CANCER, V1, P52; Reichardt VL, 1999, BLOOD, V93, P2411, DOI 10.1182/blood.V93.7.2411.407a24_2411_2419; Reichardt VL, 2003, HAEMATOLOGICA, V88, P1139; Reinartz S, 2004, CLIN CANCER RES, V10, P1580, DOI 10.1158/1078-0432.CCR-03-0056; Reinartz S, 2003, CANCER RES, V63, P3234; Sabbatini P, 2006, CLIN CANCER RES, V12, P5503, DOI 10.1158/1078-0432.CCR-05-2670; SAHA A, 2006, CANC IMMUNOL IMMUNOT; Saleh MN, 1998, J IMMUNOTHER, V21, P379, DOI 10.1097/00002371-199809000-00006; Savelyeva N, 2001, NAT BIOTECHNOL, V19, P760, DOI 10.1038/90816; SOMASUNDARAM R, 1995, J IMMUNOL, V155, P3253; STEVENSON FK, 1995, IMMUNOL REV, V145, P211, DOI 10.1111/j.1600-065X.1995.tb00083.x; STEVENSON FK, 1995, ANN NY ACAD SCI, V27, P212; SUGIYAMA T, 1991, J IMMUNOL, V146, P3097; Timmerman JM, 2002, BLOOD, V99, P1517, DOI 10.1182/blood.V99.5.1517; Timmerman John M, 2002, Curr Treat Options Oncol, V3, P307, DOI 10.1007/s11864-002-0030-3; Titzer S, 2000, BRIT J HAEMATOL, V108, P805, DOI 10.1046/j.1365-2141.2000.01958.x; ULLENHAG GJ, 2006, CLIN CANC RES; Weng WK, 2004, J CLIN ONCOL, V22, P4717, DOI 10.1200/JCO.2004.06.003; WENG WK, 2006, BLOOD; Zhu DL, 2001, TRENDS MOL MED, V7, P566, DOI 10.1016/S1471-4914(01)02126-8	76	44	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3594	3602		10.1038/sj.onc.1210371	http://dx.doi.org/10.1038/sj.onc.1210371			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530013				2023-01-03	WOS:000246816100002
J	Pfeiffer, P; Qvortrup, C; Eriksen, JG				Pfeiffer, P.; Qvortrup, C.; Eriksen, J. G.			Current role of antibody therapy in patients with metastatic colorectal cancer	ONCOGENE			English	Review						metastatic colorectal cancer; antibodies; bevacizumab; cetuximab; panitumumab	GROWTH-FACTOR RECEPTOR; MULTICENTER PHASE-II; BEVACIZUMAB PLUS FLUOROURACIL; 1ST-LINE TREATMENT; RANDOMIZED-TRIAL; MONOCLONAL-ANTIBODY; BOLUS FLUOROURACIL; MOLECULAR DETERMINANTS; 3RD-LINE CHEMOTHERAPY; CONTINUOUS-INFUSION	In less than 10 years, the number and importance of nonsurgical treatment modalities in patients with colorectal cancer (CRC) have increased dramatically, both in the adjuvant and the advanced settings. However, despite the improvement of cytotoxic therapy in CRC, many patients still develop progressive disease and unfortunately in patients with disease resistant to 5-fluorouracil/folinic acid, irinotecan and oxaliplatin, no effective cytotoxic therapy is known. The rapidly expanding knowledge in tumor biology has encouraged optimism for the possibility to find and target tumor-specific mechanisms and thereby increase both efficacy and tolerance. A great number of 'targeted drugs' are being tested in clinical trials and some of these new drugs, like bevacizumab, cetuximab and panitumumab, are available for routine use in health care. These new targeted drugs will expand the therapeutic arsenal in CRC to a great extent, but they will also add to the complexity of treatment of CRC. In this review, we summarize the current status of antibody therapy in patients with CRC.	Odense Univ Hosp, Dept Oncol, DK-5000 Odense C, Denmark	University of Southern Denmark; Odense University Hospital	Pfeiffer, P (corresponding author), Odense Univ Hosp, Dept Oncol, Sdr Blvd 29, DK-5000 Odense C, Denmark.	per.pfeiffer@ouh.regionsyddanmark.dk	Qvortrup, Camilla/AAD-3366-2019	Pfeiffer, Per/0000-0002-2925-0586; Qvortrup, Camilla/0000-0001-9338-9841				Abubakr Y, 2006, J CLIN ONCOL, V24, p160S; Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16; Adams GP, 2001, CANCER RES, V61, P4750; Agero ALC, 2006, J AM ACAD DERMATOL, V55, P657, DOI 10.1016/j.jaad.2005.10.010; ANDRE T, 2007, P ASCO GI; Arnold D, 2006, ANN ONCOL, V17, pX122, DOI 10.1093/annonc/mdl249; Azuma M, 2006, CLIN COLORECTAL CANC, V6, P214, DOI 10.3816/CCC.2006.n.038; Barber TD, 2004, NEW ENGL J MED, V351, P2883, DOI 10.1056/NEJM200412303512724; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; BERRY SR, 2006, P ASCO GI; Borner M, 2006, J CLIN ONCOL, V24, p158S; Bouche O, 2005, ANN ONCOL, V16, P1711, DOI 10.1093/annonc/mdi300; Busam KJ, 2001, BRIT J DERMATOL, V144, P1169, DOI 10.1046/j.1365-2133.2001.04226.x; Carmichael J, 2002, J CLIN ONCOL, V20, P3617, DOI 10.1200/JCO.2002.10.129; Carson EJ, 2005, J CLIN ONCOL, V23, p284S; Cassidy J, 2006, ANN ONCOL, V17; Chen HX, 2006, J CLIN ONCOL, V24, P3354, DOI 10.1200/JCO.2005.05.1573; Chong G, 2006, ANN ONCOL, V17, P437, DOI 10.1093/annonc/mdj090; Chung KY, 2005, J CLIN ONCOL, V23, P1803, DOI 10.1200/JCO.2005.08.037; Ciardiello F, 2003, EUR J CANCER, V39, P1348, DOI 10.1016/S0959-8049(03)00235-1; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; Cunningham MP, 2006, CANCER RES, V66, P7708, DOI 10.1158/0008-5472.CAN-06-1000; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; deGramont A, 1997, J CLIN ONCOL, V15, P808, DOI 10.1200/JCO.1997.15.2.808; Dittrich C, 2006, ANN ONCOL, V17, P24; Douillard JY, 2002, J CLIN ONCOL, V20, P3605, DOI 10.1200/JCO.2002.04.123; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Ellis LM, 2005, J CLIN ONCOL, V23, P4853, DOI 10.1200/JCO.2005.23.754; Fakih MG, 2006, CLIN COLORECTAL CANC, V6, P152, DOI 10.3816/CCC.2006.n.033; Falcone A, 2006, J CLIN ONCOL, V24, p149S; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Folprecht G, 2005, ANN ONCOL, V16, P1311, DOI 10.1093/annonc/mdi246; Folprecht G, 2006, ANN ONCOL, V17, P450, DOI 10.1093/annonc/mdj084; Fuchs C, 2006, J CLIN ONCOL, V24, p147S; Fyfe GA, 2004, J CLIN ONCOL, V22, p274S; Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136; Giantonio BJ, 2006, ANN ONCOL, V17, P1399, DOI 10.1093/annonc/mdl161; Giantonio BJ, 2005, J CLIN ONCOL, V23, p1S; GIANTONIO BJ, 2006, J CLIN ONCOL, V24; Gibson TB, 2006, CLIN COLORECTAL CANC, V6, P29, DOI 10.3816/CCC.2006.n.01; GLIMELIUS B, 2005, EUR J CANC S, V3; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; Grabau DA, 1998, APPL IMMUNOHISTOCHEM, V6, P209, DOI 10.1097/00022744-199812000-00006; Grothey A, 2004, J CLIN ONCOL, V22, P1209, DOI 10.1200/JCO.2004.11.037; Grothey A, 2005, J CLIN ONCOL, V23, P9441, DOI 10.1200/JCO.2005.04.4792; Grothey A, 2002, P AM SOC CLIN ONCOL, V21; GROTHEY A, 2003, EUR J CANC, V90; Gruenberger T, 2006, J CLIN ONCOL, V24, P2592, DOI 10.1200/JCO.2005.05.2910; HAMBLETON J, 2005, J CLIN ONCOL, V23; HAMBLETON J, 2004, J CLIN ONCOL, V22; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARARI PM, 2003, P AM SOC CLIN ONCOL, V22; Hebbar M, 2006, ANTI-CANCER DRUG, V17, P855, DOI 10.1097/01.cad.0000217425.44584.9f; Hecht J, 2006, J CLIN ONCOL, V24, p157S; HECHT J, 2006, P ASCO GI; HEDRICK E, 2004, J CLIN ONCOL, V22; HEINEMANN V, 2006, J CLIN ONCOL, V24; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Hillner BE, 2005, CANCER-AM CANCER SOC, V104, P1871, DOI 10.1002/cncr.21411; Ho C, 2006, J CLIN ONCOL, V24, P3214, DOI 10.1200/JCO.2006.06.5128; HOLDEN SN, 2005, J CLIN ONCOL, V23; Howdieshell TR, 2001, J SURG RES, V96, P173, DOI 10.1006/jsre.2001.6089; Huang SM, 2004, CANCER RES, V64, P5355, DOI 10.1158/0008-5472.CAN-04-0562; HUMBLET Y, 2005, J CLIN ONCOL, V23; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Ince WL, 2005, JNCI-J NATL CANCER I, V97, P981, DOI 10.1093/jnci/dji174; JENNIS A, 2005, J CLIN ONCOL, V23; Jubb AM, 2006, J CLIN ONCOL, V24, P217, DOI 10.1200/JCO.2005.01.5388; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112; Kemeny N, 2004, J CLIN ONCOL, V22, P4753, DOI 10.1200/JCO.2004.03.119; Kohne CH, 2003, J CLIN ONCOL, V21, P3721, DOI 10.1200/JCO.2003.11.122; KOZLOFF M, 2006, J CLIN ONCOL, V24; KRETZSCHMAR A, 2006, ASCO GI; KUBICKA S, 2006, ASCO GI; LABIANCA R, 2006, J CLIN ONCOL, V24; Lenz HJ, 2006, J CLIN ONCOL, V24, P4914, DOI 10.1200/JCO.2006.06.7595; Leung RC, 2007, J CLIN ONCOL, V25; Lim DH, 2005, CANCER CHEMOTH PHARM, V56, P10, DOI 10.1007/s00280-004-0963-2; Luo FR, 2005, CLIN CANCER RES, V11, P5558, DOI 10.1158/1078-0432.CCR-05-0368; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Lyseng-Williamson KA, 2006, AM J CANC, V5, P43; Maindrault-Goebel F, 2007, J CLIN ONCOL, V25; Malik I, 2005, J CLIN ONCOL, V23, p251S; Matar P, 2004, CLIN CANCER RES, V10, P6487, DOI 10.1158/1078-0432.CCR-04-0870; Meropol NJ, 2005, J CLIN ONCOL, V23, P1791, DOI 10.1200/JCO.2005.10.951; Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958; MINERS AH, 2005, BMJ-BRIT MED J, V330, P365; MORELLI MP, 2006, J CLIN ONCOL, V24; Moroni M, 2005, LANCET ONCOL, V6, P279, DOI 10.1016/S1470-2045(05)70102-9; NOVOTNY WF, 2004, J CLIN ONCOL, V22; Nygren P, 2005, ACTA ONCOL, V44, P203, DOI 10.1080/02841860510029798; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Paramore LC, 2006, CLIN COLORECTAL CANC, V6, P52, DOI 10.3816/CCC.2006.n.021; PEETERS M, 2006, PHASE 3 MULTICENTER; Perez-Soler R, 2006, J CLIN ONCOL, V24, p129S; Personeni N, 2005, SEMIN ONCOL, V32, pS59, DOI 10.1053/j.seminoncol.2005.04.029; Pfeiffer P, 2006, ANN ONCOL, V17, P252, DOI 10.1093/annonc/mdj060; PFEIFFER P, 2007, P ASCO GI; PFEIFFER P, 2007, IN PRESS ACTA ONCOL; PITOT HC, 2005, J CLIN ONCOL, V23; Punt CJA, 2002, LANCET, V360, P671, DOI 10.1016/S0140-6736(02)09836-7; Ragnhammar P, 2001, ACTA ONCOL, V40, P282, DOI 10.1080/02841860151116367; Repertinger SK, 2004, J INVEST DERMATOL, V123, P982, DOI 10.1111/j.0022-202X.2004.23478.x; Robert C, 2005, LANCET ONCOL, V6, P491, DOI 10.1016/S1470-2045(05)70243-6; Rosati G, 2003, ANTICANCER RES, V23, P2981; Rothenberg ML, 2003, J CLIN ONCOL, V21, P2059, DOI 10.1200/JCO.2003.11.126; Rougier P, 1998, LANCET, V352, P1407, DOI 10.1016/S0140-6736(98)03085-2; ROUGIER P, 2004, J CLIN ONCOL, V23; Saif MW, 2006, CLIN COLORECTAL CANC, V6, P118, DOI 10.3816/CCC.2006.n.028; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Saltz L., 2001, P AM SOC CLIN ONCOL, V20, p3a; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; SALTZ LB, 2005, J CLIN ONCOL, V23; SALTZ LB, 2006, J CLIN ONCOL, V24; Saunders M, 2006, BRIT J CANCER, V95, P131, DOI 10.1038/sj.bjc.6603233; Scappaticci FA, 2005, J SURG ONCOL, V91, P173, DOI 10.1002/jso.20301; Scartozzi M, 2004, J CLIN ONCOL, V22, P4772, DOI 10.1200/JCO.2004.00.117; Schrag D, 2005, J NATL CANCER I, V97, P1221, DOI 10.1093/jnci/dji242; Schrag D, 2004, NEW ENGL J MED, V351, P317, DOI 10.1056/NEJMp048143; Shia J, 2005, MODERN PATHOL, V18, P1350, DOI 10.1038/modpathol.3800417; Skillings JR, 2005, J CLIN ONCOL, V23, p196S; Sorbye H, 2004, J CLIN ONCOL, V22, P31, DOI 10.1200/JCO.2004.05.188; Souglakos J, 2006, BRIT J CANCER, V94, P798, DOI 10.1038/sj.bjc.6603011; Starling Naureen, 2005, Curr Oncol Rep, V7, P173, DOI 10.1007/s11912-005-0070-5; Stern M, 2005, CRIT REV ONCOL HEMAT, V54, P11, DOI 10.1016/j.critrevonc.2004.10.011; Sugrue M, 2006, J CLIN ONCOL, V24, p154S; TABERNERO J, 2006, J CLIN ONCOL, V24; Tabernero JM, 2004, J CLIN ONCOL, V22, p248S; Tonra JR, 2006, CLIN CANCER RES, V12, P2197, DOI 10.1158/1078-0432.CCR-05-1682; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; Tsuchihashi Z, 2005, NEW ENGL J MED, V353, P208, DOI 10.1056/NEJM200507143530218; Vallbohmer D, 2005, J CLIN ONCOL, V23, P3536, DOI 10.1200/jco.2005.23.16_suppl.3536; Van Cutsem E, 2004, BRIT J CANCER, V90, P1190, DOI 10.1038/sj.bjc.6601676; Van Cutsem E, 2006, EUR J CANCER, V42, P2212, DOI 10.1016/j.ejca.2006.04.012; van Doorn R, 2002, BRIT J DERMATOL, V147, P598, DOI 10.1046/j.1365-2133.2002.04864.x; VANCUTSEM E, 2007, P ASCO GI; VANCUTSEM E, 2007, P ASCO GI 2007; Venook A, 2006, J CLIN ONCOL, V24, p148S; Veronese ML, 2004, EUR J CANCER, V40, P1292, DOI 10.1016/j.ejca.2004.02.014; Vincenzi B, 2006, BRIT J CANCER, V94, P792, DOI 10.1038/sj.bjc.6603018; Vincenzi B, 2006, Ann Oncol, V17, P527, DOI 10.1093/annonc/mdj014; Vincenzi B, 2006, ANN ONCOL, V17, P835, DOI 10.1093/annonc/mdl031; Wilke H, 2006, J CLIN ONCOL, V24, p158S; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; Yamamoto Deanna Sanchez, 2004, Clin J Oncol Nurs, V8, P654	148	41	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3661	3678		10.1038/sj.onc.1210377	http://dx.doi.org/10.1038/sj.onc.1210377			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530020				2023-01-03	WOS:000246816100009
J	Malmquist, NA; Baldwin, J; Phillips, MA				Malmquist, Nicholas A.; Baldwin, Jeffrey; Phillips, Margaret A.			Detergent-dependent kinetics of truncated Plasmodium falciparum dihydroorotate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDATE PHOSPHATASE-ACTIVITY; YEAST SACCHAROMYCES-CEREVISIAE; CRITICAL MICELLE CONCENTRATION; MALARIA PARASITE; TRITON X-100; PHOSPHATIDYLINOSITOL 4-KINASE; TITRATION CALORIMETRY; ESCHERICHIA-COLI; MIXED MICELLES; MEMBRANE	The survival of the malaria parasite Plasmodium falciparum is dependent upon the de novo biosynthesis of pyrimidines. P. falciparum dihydroorotate dehydrogenase ( PfDHODH) catalyzes the fourth step in this pathway in an FMN-dependent reaction. The full-length enzyme is associated with the inner mitochondrial membrane, where ubiquinone ( CoQ) serves as the terminal electron acceptor. The lipophilic nature of the co-substrate suggests that electron transfer to CoQ occurs at the two-dimensional lipid-solution interface. Here we show that PfDHODH associates with liposomes even in the absence of the N-terminal transmembrane-spanning domain. The association of a series of ubiquinone substrates with detergent micelles was studied by isothermal titration calorimetry, and the data reveal that CoQ analogs with long decyl ( CoQ(D)) or geranyl ( CoQ(2)) tails partition into detergent micelles, whereas that with a short prenyl tail ( CoQ(1)) remains in solution. PfDHODH-catalyzed reduction of CoQD and CoQ2, but not CoQ(1), is stimulated as detergent concentrations ( Tween 80 or Triton X-100) are increased up to their critical micelle concentrations, beyond which activity declines. Steady-state kinetic data acquired for the reaction with CoQ(D) and CoQ(2) in substrate-detergent mixed micelles fit well to a surface dilution kinetic model. In contrast, the data for CoQ(1) as a substrate were well described by solution steady-state kinetics. Our results suggest that the partitioning of lipophilic ubiquinone analogues into detergent micelles needs to be an important consideration in the kinetic analysis of enzymes that utilize these substrates.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Phillips, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 6001 Forest Pk Rd, Dallas, TX 75390 USA.	margaret.phillips@utsouthwestern.edu		Malmquist, Nicholas/0000-0003-2822-8245	NIAID NIH HHS [R01 AI053680, R01-AI053680] Funding Source: Medline; NIGMS NIH HHS [T32-GM008203] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053680] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008203] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldwin J, 2005, J BIOL CHEM, V280, P21847, DOI 10.1074/jbc.M501100200; Baldwin J, 2002, J BIOL CHEM, V277, P41827, DOI 10.1074/jbc.M206854200; Boa AN, 2005, BIOORGAN MED CHEM, V13, P1945, DOI 10.1016/j.bmc.2005.01.017; Breman JG, 2001, AM J TROP MED HYG, V64, P1; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CARMAN GM, 1979, J BIOL CHEM, V254, P8391; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CHATTOPADHYAY A, 1984, ANAL BIOCHEM, V139, P408, DOI 10.1016/0003-2697(84)90026-5; COPELAND RA, 1995, ARCH BIOCHEM BIOPHYS, V323, P79, DOI 10.1006/abbi.1995.0012; Davis JP, 1996, BIOCHEMISTRY-US, V35, P1270, DOI 10.1021/bi952168g; de Macedo CS, 2002, FEMS MICROBIOL LETT, V207, P13, DOI 10.1111/j.1574-6968.2002.tb11021.x; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; Deems RA, 2000, ANAL BIOCHEM, V287, P1, DOI 10.1006/abio.2000.4766; ENGEL WD, 1980, BIOCHIM BIOPHYS ACTA, V592, P211, DOI 10.1016/0005-2728(80)90182-6; Gelb MH, 2000, BBA-MOL CELL BIOL L, V1488, P20, DOI 10.1016/S1388-1981(00)00106-2; Hansen M, 2004, PROTEIN SCI, V13, P1031, DOI 10.1110/ps.03533004; Heerklotz H, 1996, J PHYS CHEM-US, V100, P6764, DOI 10.1021/jp9523534; Heerklotz H, 2000, BIOPHYS J, V78, P2435, DOI 10.1016/S0006-3495(00)76787-7; Heerklotz H, 2000, BBA-BIOMEMBRANES, V1508, P69, DOI 10.1016/S0304-4157(00)00009-5; Heikkila T, 2006, BIOORG MED CHEM LETT, V16, P88, DOI 10.1016/j.bmcl.2005.09.045; Hurt DE, 2006, BIOORG MED CHEM LETT, V16, P1610, DOI 10.1016/j.bmcl.2005.12.029; Hurt DE, 2006, ACTA CRYSTALLOGR D, V62, P312, DOI 10.1107/S0907444905042642; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; Karibian D, 1978, Methods Enzymol, V51, P58; KRUNGKRAI J, 1991, BIOCHEMISTRY-US, V30, P1934, DOI 10.1021/bi00221a029; KRUNGKRAI J, 1995, BBA-GEN SUBJECTS, V1243, P351, DOI 10.1016/0304-4165(94)00158-T; Liu SP, 2000, STRUCT FOLD DES, V8, P25, DOI 10.1016/S0969-2126(00)00077-0; NAGY M, 1992, P NATL ACAD SCI USA, V89, P8966, DOI 10.1073/pnas.89.19.8966; Nara T, 2000, GENE, V257, P209, DOI 10.1016/S0378-1119(00)00411-X; NICKELS JT, 1992, J BIOL CHEM, V267, P16297; Norager S, 2002, STRUCTURE, V10, P1211, DOI 10.1016/S0969-2126(02)00831-6; Qin CB, 2002, J BIOL CHEM, V277, P49685, DOI 10.1074/jbc.M209598200; Rawls J, 2000, EUR J BIOCHEM, V267, P2079, DOI 10.1046/j.1432-1327.2000.01213.x; Rowland P, 1997, STRUCTURE, V5, P239, DOI 10.1016/S0969-2126(97)00182-2; Rowland P, 2000, STRUCTURE, V8, P1227, DOI 10.1016/S0969-2126(00)00530-X; SEELIG J, 1991, BIOCHEMISTRY-US, V30, P9354, DOI 10.1021/bi00102a031; SHERMAN IW, 1979, MICROBIOL REV, V43, P453, DOI 10.1128/MMBR.43.4.453-495.1979; Srivastava IK, 1999, MOL MICROBIOL, V33, P704, DOI 10.1046/j.1365-2958.1999.01515.x; Triglia T, 1998, EMBO J, V17, P3807, DOI 10.1093/emboj/17.14.3807; Ullrich A, 2001, EUR J BIOCHEM, V268, P1861, DOI 10.1046/j.1432-1033.2001.02061.x; Vial HJ, 2003, MOL BIOCHEM PARASIT, V126, P143, DOI 10.1016/S0166-6851(02)00281-5; Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X; WU WI, 1994, J BIOL CHEM, V269, P29495; WU WI, 1993, J BIOL CHEM, V268, P13830; Wu WI, 1996, BIOCHEMISTRY-US, V35, P3790, DOI 10.1021/bi952808f; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130	48	18	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12678	12686		10.1074/jbc.M609893200	http://dx.doi.org/10.1074/jbc.M609893200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17329250	hybrid			2023-01-03	WOS:000245942800037
J	Sari, ABA; Sheldon, TA; Cracknell, A; Turnbull, A				Sari, Ali Baba-Akbari; Sheldon, Trevor A.; Cracknell, Alison; Turnbull, Alastair			Sensitivity of routine system for reporting patient safety incidents in an NHS hospital: retrospective patient case note review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ADVERSE EVENTS; BARRIERS; ERROR	Objective To evaluate the performance of a routine incident reporting system in identifying patient safety incidents. Design Two stage retrospective review of patients' case notes and analysis of data submitted to the routine incident reporting system on the same patients. Setting A large NHS hospital in England. Population 1006 hospital admissions between January and May 2004: surgery (n=311), general medicine (n=251), elderly care (n=184), orthopaedics (n=131), urology (n=61), and three other specialties (n=68). Main outcome measures Proportion of admissions with at least one patient safety incident; proportion and type of patient safety incidents missed by routine incident reporting and case note review methods. Results 324 patient safety incidents were identified in 230/1006 admissions (22.9%; 95% confidence interval 20.3% to 25.5%). 270 (83%) patient safety incidents were identified by case note review only, 21 (7%) by the routine reporting system only, and 33 (100%) by both methods. 110 admissions (10.9%; 9.0% to 12.8%) had at least one patient safety incident resulting in patient harm, all of which were detected by the case note review and six (5%) by the reporting system. Conclusion The routine incident reporting system may be poor at identifying patient safety incidents, particularly those resulting in harm. Structured case note review may have a useful role in surveillance of routine incident reporting and associated quality improvement programmes.	Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; Gen Infirm, Leeds LS1 3EX, W Yorkshire, England; York Hosp, York YO31 8HE, N Yorkshire, England	University of York - UK; Leeds General Infirmary	Sheldon, TA (corresponding author), Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England.	tas5@york.ac.uk	Sheldon, Trevor/AAK-7088-2021	Sheldon, Trevor/0000-0002-7479-5913				Baker GR, 2004, CAN MED ASSOC J, V170, P1678, DOI 10.1503/cmaj.1040498; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Campbell M.J., 1999, MED STAT SUMMARY APP, V3rd; Davis Peter, 2002, N Z Med J, V115, pU271; Evans SM, 2006, QUAL SAF HEALTH CARE, V15, P39, DOI 10.1136/qshc.2004.012559; Firth-Cozens J, 2002, QUAL SAF HEALTH CARE, V11, P7, DOI 10.1136/qhc.11.1.7; Kilbridge PM, 2006, QUAL SAF HEALTH CARE, V15, P148, DOI 10.1136/qshc.2006.018218; Kingston MJ, 2004, MED J AUSTRALIA, V181, P36, DOI 10.5694/j.1326-5377.2004.tb06158.x; National Patient Safety Agency, 2005, BUILD MEM PREV HARM; Thomas EJ, 2003, J GEN INTERN MED, V18, P61, DOI 10.1046/j.1525-1497.2003.20147.x; Uribe CL, 2002, J HEALTHC MANAG, V47, P263, DOI 10.1097/00115514-200207000-00009; Vincent C, 2001, BRIT MED J, V322, P517, DOI 10.1136/bmj.322.7285.517; VINCENT C, 2001, CLIN RISK MANAGEMENT; Vincent C., 2006, PATIENT SAFETY; Walsh T, 2002, PHYSIOL MEAS, V23, pR111, DOI 10.1088/0967-3334/23/3/201; Wilson RM, 1995, MED J AUSTRALIA, V163, P458, DOI 10.5694/j.1326-5377.1995.tb124691.x	16	252	255	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 13	2007	334	7584					79	81		10.1136/bmj.39031.507153.AE	http://dx.doi.org/10.1136/bmj.39031.507153.AE			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	127DZ	17175566	Green Published, Bronze			2023-01-03	WOS:000243566800030
J	Chen, IA				Chen, Irene A.			The emergence of cells during the origin of life	SCIENCE			English	Editorial Material							FATTY-ACID VESICLES; GROWTH; RNA		Harvard Univ, Sch Med, Div Hlth Sci & Technol, Boston, MA 02115 USA; MIT, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Chen, IA (corresponding author), Harvard Univ, Sch Med, Div Hlth Sci & Technol, Boston, MA 02115 USA.	ichen@post.harvard.edu		Chen, Irene/0000-0001-6040-7927				ALLEN WILLIAM V., 1967, CURR MOD BIOL, V1, P24; Chen IA, 2005, J AM CHEM SOC, V127, P13213, DOI 10.1021/ja051784p; Chen IA, 2004, BIOPHYS J, V87, P988, DOI 10.1529/biophysj.104.039875; Chen IA, 2004, SCIENCE, V305, P1474, DOI 10.1126/science.1100757; Chen IA, 2004, P NATL ACAD SCI USA, V101, P7965, DOI 10.1073/pnas.0308045101; Chen IA, 2006, COLD SPRING HARB MON, V43, P57; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; Hanczyc MM, 2003, SCIENCE, V302, P618, DOI 10.1126/science.1089904; Johnston WK, 2001, SCIENCE, V292, P1319, DOI 10.1126/science.1060786; Knoll AH, 2003, LIFE YOUNG PLANET 1; ORGEL LE, 1968, J MOL BIOL, V38, P381, DOI 10.1016/0022-2836(68)90393-8; Rushdi AI, 2001, ORIGINS LIFE EVOL B, V31, P103, DOI 10.1023/A:1006702503954; Steitz TA, 2003, TRENDS BIOCHEM SCI, V28, P411, DOI 10.1016/S0968-0004(03)00169-5; SZATHMARY E, 1987, J THEOR BIOL, V128, P463, DOI 10.1016/S0022-5193(87)80191-1; Szostak JW, 2001, NATURE, V409, P387, DOI 10.1038/35053176; YUEN GU, 1973, NATURE, V246, P301, DOI 10.1038/246303a0	16	31	32	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 8	2006	314	5805					1558	1559		10.1126/science.1137541	http://dx.doi.org/10.1126/science.1137541			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	113UX	17158315				2023-01-03	WOS:000242624600029
J	Curiel, TJ				Curiel, Tyler J.			Murder or mercy? Hurricane Katrina and the need for disaster training.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									San Antonio Canc Inst, San Antonio, TX USA; Canc Therapy & Res Ctr S Texas, San Antonio, TX 78229 USA	Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio	Curiel, TJ (corresponding author), San Antonio Canc Inst, San Antonio, TX USA.								0	16	16	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2006	355	20					2067	2069		10.1056/NEJMp068196	http://dx.doi.org/10.1056/NEJMp068196			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	104YU	17108341	Bronze			2023-01-03	WOS:000241997300003
J	Legg, L; Drummond, A; Leonardi-Bee, J; Gladman, JRF; Corr, S; Donkervoort, M; Edmans, J; Gilbertson, L; Jongboed, L; Logan, P; Sackley, C; Walker, M; Langhorne, P				Legg, Lynn; Drummond, Avril; Leonardi-Bee, Jo; Gladman, J. R. F.; Corr, Susan; Donkervoort, Mireille; Edmans, Judi; Gilbertson, Louise; Jongboed, Lyn; Logan, Pip; Sackley, Catherine; Walker, Marion; Langhorne, Peter			Occupational therapy for patients with problems in personal activities of daily living after stroke: systematic review of randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							REHABILITATION	Objective To determine whether occupational therapy focused specifically on personal activities of daily living improves recovery for patients after stroke. Design Systematic review and meta-analysis. Data sources The Cochrane stroke group trials register, the Cochrane central register of controlled trials, Medline, Embase, CINAHL, PsycLIT, AMED, Wilson Social Sciences Abstracts, Science Citation Index, Social Science Citation, Arts and Humanities Citation Index, Dissertations Abstracts register, Occupational Therapy Research Index, scanning reference lists, personal communication with authors, and hand searching. Review methods Trials were included if they evaluated the effect of occupational therapy focused on practice of personal activities of daily living or where performance in such activities was the target of the occupational therapy intervention in a stroke population. Original data were sought from trialists. Two reviewers independently reviewed each trial for methodological quality. Disagreements were resolved by consensus. Results Nine randomised controlled trials including 12 58 participants met the inclusion criteria. Occupational therapy delivered to patients after stroke and targeted towards personal activities of daily living increased performance scores (standardised mean difference 0. 18, 95% confidence interval 0.04 to 0.32, P=0.01) and reduced the risk of poor outcome (death, deterioration or dependency in personal activities of daily living) (odds ratio 0.67, 95% confidence interval 0.51 to 0.87, P=0.003). For every 100 people who received occupational therapy focused on personal activities of daily living, 11 (95% confidence interval 7 to 30) would be spared a poor outcome. Conclusions Occupational therapy focused on improving personal activities of daily living after stroke can improve performance and reduce the risk of deterioration in these abilities. Focused occupational therapy should be available to everyone who has had a stroke.	Glasgow Royal Infirm Univ NHS Trust, Acad Sect Geriatr Med, Glasgow G31 2ER, Lanark, Scotland; Queens Med Ctr, Sch Med, Div Rehabil & Ageing, Nottingham NG7 2UH, England; Univ Northampton, Sch Hlth, Div Occupat Therapy, Northampton NN2 7AL, England; Erasmus Univ, Med Ctr, NL-3000 CA Rotterdam, Netherlands; Royal Haslar Hosp, Occupat Therapy Serv, Gosport PO12 2AA, Hants, England; Univ British Columbia, Sch Rehabil Sci, Online Programs, Dept Occupat Sci & Occupat Therapy, Vancouver, BC V6T 2B5, Canada; Univ Birmingham, Sch Hlth Sci, Birmingham B15 2TT, W Midlands, England	University of Nottingham; University of Northampton; Erasmus University Rotterdam; Erasmus MC; University of British Columbia; University of Birmingham	Legg, L (corresponding author), Glasgow Royal Infirm Univ NHS Trust, Acad Sect Geriatr Med, Glasgow G31 2ER, Lanark, Scotland.	step@clinmed.ga.ac.uk	; Gladman, John/M-7429-2015	Walker, Marion/0000-0002-3534-591X; Leonardi-Bee, Jo/0000-0003-0893-6068; Corr, Susan/0000-0001-6018-5260; Logan, Philippa/0000-0002-6657-2381; sackley, catherine/0000-0002-8580-6622; Gladman, John/0000-0002-8506-7786; Drummond, Avril/0000-0003-1220-8354				*AM OCC THER ASS, 1994, AM J OCCUP THER, V48, P1072; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Collin C, 1988, Int Disabil Stud, V10, P61; De Wit L, 2006, STROKE, V37, P1483, DOI 10.1161/01.STR.0000221709.23293.c2; Granger CV, 1993, GUIDE UNIFORM DATA S; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HIGGINS JPT, 2005, COCHRANE LIB; HOPSON S, 1981, PRACTICE OCCUPATIONA, P31; Langhorne P, 2002, AGE AGEING, V31, P365, DOI 10.1093/ageing/31.5.365; Langhorne P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000197.pub3; Legg L, 2004, LANCET, V363, P352; Legg LA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003585.pub2; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Murray DM, 2001, STAT MED, V20, P1373, DOI 10.1002/sim.675; *NORD COCHR CTR CO, 2003, REV MAN REVMAN VERS; SANDERCOCK P, 2002, COCHRANE LIB; Steultjens EMJ, 2005, CLIN REHABIL, V19, P247, DOI 10.1191/0269215505cr870oa; Steultjens EMJ, 2003, STROKE, V34, P676, DOI 10.1161/01.STR.0000057576.77308.30; Sulter G, 1999, STROKE, V30, P1538, DOI 10.1161/01.STR.30.8.1538; WADE DT, 1987, J NEUROL NEUROSUR PS, V50, P177, DOI 10.1136/jnnp.50.2.177; Walker MF, 2004, STROKE, V35, P2226, DOI 10.1161/01.STR.0000137766.17092.fb; WHITING S, 1980, BR J OCCUP THER, V2, P44	22	91	95	0	30	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 3	2007	335	7626					922	925		10.1136/bmj.39343.466863.55	http://dx.doi.org/10.1136/bmj.39343.466863.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230AS	17901469	Green Published, Green Submitted, Green Accepted, Bronze			2023-01-03	WOS:000250848300032
J	Morel, CM				Morel, Carlos M.			The road to recovery	NATURE			English	Editorial Material							DEVELOPING-COUNTRIES; EXPERIENCE; BRAZIL		Fiocruz MS, Ctr Technol Dev Hlth, BR-21045900 Rio De Janeiro, Brazil; Fiocruz MS, Med & Drugs Technol Inst, BR-21045900 Rio De Janeiro, Brazil	Center for Technological Development in Health (CDTS); Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz	Morel, CM (corresponding author), Fiocruz MS, Ctr Technol Dev Hlth, BR-21045900 Rio De Janeiro, Brazil.		Morel, Carlos/AHD-9349-2022; Casas, Carmen Phang Romero/J-3465-2017; Morel, Carlos M/B-4079-2009; Morel, Carlos/Q-9657-2019	Casas, Carmen Phang Romero/0000-0002-2759-0544; Morel, Carlos M/0000-0003-2752-0009; Morel, Carlos/0000-0003-2752-0009				Almeida Celia, 2002, Cad. Saúde Pública, V18, P905, DOI 10.1590/S0102-311X2002000400002; Basu P, 2005, NAT BIOTECHNOL, V23, P13, DOI 10.1038/nbt0105-13; Bernardes AT, 2003, RES POLICY, V32, P865, DOI 10.1016/S0048-7333(02)00089-6; Borgatti S. P., 1999, UCINET 6 0 VERSION 1; BUSS PM, 2005, VACINAS SOROS IMUNIZ; Ferrer M, 2004, NAT BIOTECHNOL, V22, pDC8, DOI 10.1038/nbt1204supp-DC8; GADELHA C, 2003, SAUDE MANGUINHOS, V10, P697; Gama A. A. S., 2003, QUIM NOVA, V26, P618; Gadelha CAG, 2006, REV SAUDE PUBL, V40, P11, DOI 10.1590/S0034-89102006000400003; Levi GC, 2002, AIDS, V16, P2373, DOI 10.1097/00002030-200212060-00001; Mahoney RT, 2007, VACCINE, V25, P4003, DOI 10.1016/j.vaccine.2007.02.047; Morel C., 2005, INNOVATION STRATEGY, V1, P1; Morel CM, 2005, SCIENCE, V309, P401, DOI 10.1126/science.1115538; Olive JM, 1997, J INFECT DIS, V175, pS189, DOI 10.1093/infdis/175.Supplement_1.S189; Temporão José Gomes, 2003, Hist. cienc. saude-Manguinhos, V10, P601, DOI 10.1590/S0104-59702003000500008; Viotti EB, 2002, TECHNOL FORECAST SOC, V69, P653, DOI 10.1016/S0040-1625(01)00167-6	16	15	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 13	2007	449	7159					180	182		10.1038/449180a	http://dx.doi.org/10.1038/449180a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	209NF	17851516	Bronze, Green Published			2023-01-03	WOS:000249394500040
J	Armitage, M; Eddleston, J; Stokes, T				Armitage, Mary; Eddleston, Jane; Stokes, Tim		Guideline Dev Grp	Recognising and responding to acute illness in adults in hospital: summary of NICE guidance	BRITISH MEDICAL JOURNAL			English	Article									Royal Bournemouth Hosp, Bournemouth Diabet & Endocrine Ctr, Bournemouth BH18 8BT, Dorset, England; Manchester Royal Infirm, Manchester M13 9WL, Lancs, England; Natl Inst Hlth & Clin Excellence, Manchester M1 5AN, Lancs, England	University of Manchester; National Institute for Health & Care Excellence	Armitage, M (corresponding author), Royal Bournemouth Hosp, Bournemouth Diabet & Endocrine Ctr, Bournemouth BH18 8BT, Dorset, England.	mary.armitage@rbch.nhs.uk	Stokes, Tim/M-9420-2018	Stokes, Tim/0000-0002-1127-1952				*DEP HLTH, 2000, COMPR CRIT CAR REV A; *NAT I HLTH CLIN E, 2007, NICE CLIN GUID, V50	2	28	28	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 4	2007	335	7613					258	259		10.1136/bmj.39272.679688.47	http://dx.doi.org/10.1136/bmj.39272.679688.47			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	201QC	17673769	Green Published			2023-01-03	WOS:000248846700031
J	Conway, PH; Cnaan, A; Zaoutis, T; Henry, BV; Grundmeier, RW; Keren, R				Conway, Patrick H.; Cnaan, Avital; Zaoutis, Theoklis; Henry, Brandon V.; Grundmeier, Robert W.; Keren, Ron			Recurrent urinary tract infections in children - Risk factors and association with prophylactic antimicrobials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY VESICOURETERAL REFLUX; CONTROLLED-TRIAL; BACTERIURIA; MANAGEMENT; THERAPY	Context The evidence regarding risk factors for recurrent urinary tract infection ( UTI) and the risks and benefits of antimicrobial prophylaxis in children is scant. Objectives To identify risk factors for recurrent UTI in a pediatric primary care cohort, to determine the association between antimicrobial prophylaxis and recurrent UTI, and to identify the risk factors for resistance among recurrent UTIs. Design, Patients, and Setting From a network of 27 primary care pediatric practices in urban, suburban, and semirural areas spanning 3 states, a cohort of children aged 6 years or younger who were diagnosed with first UTI between July 1, 2001, and May 31, 2006, was assembled. Time-to-event analysis was used to determine risk factors for recurrent UTI and the association between antimicrobial prophylaxis and recurrent UTI, and a nested case-control study was performed among children with recurrent UTI to identify risk factors for resistant infections. Main Outcome Measures Time to recurrent UTI and antimicrobial resistance of recurrent UTI pathogens. Results Among 74 974 children in the network, 611 (0.007 per person-year) had a first UTI and 83 (0.12 per person-year after first UTI) had a recurrent UTI. In multivariable Cox time-to-event models, factors associated with increased risk of recurrent UTI included white race (0.17 per person-year; hazard ratio [HR], 1.97; 95% confidence interval [CI], 1.22-3.16), age 3 to 4 years (0.22 per person-year; HR, 2.75; 95% CI, 1.37-5.51), age 4 to 5 years (0.19 per person-year; HR, 2.47; 95% CI, 1.19-5.12), and grade 4 to 5 vesicoureteral reflux (0.60 per person-year; HR, 4.38; 95% CI, 1.26-15.29). Sex and grade 1 to 3 vesicoureteral reflux were not associated with risk of recurrence. Antimicrobial prophylaxis was not associated with decreased risk of recurrent UTI ( HR, 1.01; 95% CI, 0.50-2.02), even after adjusting for propensity to receive prophylaxis, but was a risk factor for antibimicrobial resistance among children with recurrent UTI ( HR, 7.50; 95% CI, 1.60-35.17). Conclusion Among the children in this study, antimicrobial prophylaxis was not associated with decreased risk of recurrent UTI, but was associated with increased risk of resistant infections.	Univ Penn, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA; Univ Penn, Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Biostat & Epidemiol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Ctr Biomed Informat, Philadelphia, PA 19104 USA; Cincinnati Childrens Hosp Med Ctr, Ctr Hlth Care Qual, Cincinnati, OH USA; Cincinnati Childrens Hosp Med Ctr, Div Gen Pediat, Cincinnati, OH USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Conway, PH (corresponding author), Univ Penn, Robert Wood Johnson Clin Scholars Program, 423 Guardian Dr,Bloddey Hall 1303A, Philadelphia, PA 19104 USA.	pconway2@mail.med.upenn.edu			NCRR NIH HHS [U54 RR023567-01] Funding Source: Medline; NICHD NIH HHS [K23 HD043179] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K23HD043179] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Austin PC, 2007, STAT MED, V26, P734, DOI 10.1002/sim.2580; Bergman DA, 1999, PEDIATRICS, V103, P843; BISSET GS, 1987, AM J ROENTGENOL, V148, P479, DOI 10.2214/ajr.148.3.479; Downs SH, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.4.e54; Elder JS, 1997, J UROLOGY, V157, P1846, DOI 10.1016/S0022-5347(01)64882-1; Garin EH, 2006, PEDIATRICS, V117, P626, DOI 10.1542/peds.2005-1362; GLEESON FV, 1991, ARCH DIS CHILD, V66, P1282, DOI 10.1136/adc.66.11.1282; Gorelick MH, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e54; Hellerstein S, 2002, PEDIATR NEPHROL, V17, P506, DOI 10.1007/s00467-002-0899-x; HELLSTROM A, 1991, ARCH DIS CHILD, V66, P232, DOI 10.1136/adc.66.2.232; HOBERMAN A, 1994, J PEDIATR-US, V124, P513, DOI 10.1016/S0022-3476(05)83127-0; Kwok Wing-Yee, 2006, BMC Pediatr, V6, P10, DOI 10.1186/1471-2431-6-10; LEBOWITZ RL, 1985, PEDIATR RADIOL, V15, P105, DOI 10.1007/BF02388714; LOHR JA, 1977, PEDIATRICS, V59, P562; Lutter SA, 2005, ARCH PEDIAT ADOL MED, V159, P924, DOI 10.1001/archpedi.159.10.924; Mahant S, 2002, ARCH DIS CHILD, V86, P419, DOI 10.1136/adc.86.6.419; Mazzola BL, 2003, J NEPHROL, V16, P133; MCKERROW W, 1984, BRIT MED J, V289, P299, DOI 10.1136/bmj.289.6440.299; Panaretto KS, 1999, J PAEDIATR CHILD H, V35, P454, DOI 10.1046/j.1440-1754.1999.355417.x; Reddy PP, 1997, PEDIATRICS, V100, P555; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; SAVAGE DCL, 1975, LANCET, V1, P358; Shaikh N, 2003, PEDIATRICS, V112, P1134, DOI 10.1542/peds.112.5.1134; SMELLIE JM, 1988, PEDIATR NEPHROL, V2, P12, DOI 10.1007/BF00870372; SMELLIE JM, 1978, LANCET, V2, P175; SNODGRASS W, 1991, UROLOGY, V38, P341, DOI 10.1016/0090-4295(91)80148-Z; UHARI M, 1988, BRIT MED J, V297, P450, DOI 10.1136/bmj.297.6646.450; WAN JL, 1995, J UROLOGY, V154, P797, DOI 10.1016/S0022-5347(01)67167-2; WILLIAMS GJ, 2006, COCHRANE DB SYST REV, V3; WINBERG J, 1974, Acta Paediatrica Scandinavica Supplement, P1; WINBERG J, 1975, KIDNEY INT, V8, pS101	31	244	257	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2007	298	2					179	186		10.1001/jama.298.2.179	http://dx.doi.org/10.1001/jama.298.2.179			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188HI	17622599	Bronze			2023-01-03	WOS:000247910600023
J	Beckstead, JA; Wong, K; Gupta, V; Wan, CPL; Cook, VR; Weinberg, RB; Weers, PMM; Ryan, RO				Beckstead, Jennifer A.; Wong, Kasuen; Gupta, Vinita; Wan, Chung-Ping L.; Cook, Victoria R.; Weinberg, Richard B.; Weers, Paul M. M.; Ryan, Robert O.			The C terminus of apolipoprotein A-V modulates lipid-binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; APOLIPOPHORIN-III; DOMAIN-STRUCTURE; HUMAN SERUM; MICE; HYPERTRIGLYCERIDEMIA; ASSOCIATION; LIPASE; HYDROLYSIS; DEFICIENCY	Human apolipoprotein A-V (apoA-V) is a potent modulator of plasma triacylglycerol (TG) levels. To probe different regions of this 343-amino-acid protein, four single Trp apoA-V variants were prepared. The variant with a Trp at position 325, distal to the tetraproline sequence at residues 293-296, displayed an 11-nm blue shift in wavelength of maximum fluorescence emission upon lipid association. To evaluate the structural and functional role of this C-terminal segment, a truncated apoA-V comprising amino acids 1-292 was generated. Far UV circular dichroism spectra of full-length apoA-V and apoA-V-(1-292) were similar, with similar to 50% alpha-helix content. In guanidine HCl denaturation experiments, both full-length and truncated apoA-V yielded biphasic profiles consistent with the presence of two structural domains. The denaturation profile of the lower stability component ( but not the higher stability component) was affected by truncation. Truncated apoA-V displayed an attenuated ability to solubilize L-alpha-dimyristoylphosphatidylcholine phospholipid vesicles compared with full-length apoA-V, whereas a peptide corresponding to the deleted C-terminal segment displayed markedly enhanced kinetics. The data support the concept that the C-terminal region is not required for apoA-V to adopt a folded protein structure, yet functions to modulate apoA-V lipid-binding activity; therefore, this concept may be relevant to the mechanism whereby apoA-V influences plasma TG levels.	CHORI, Ctr Prevent Obes Diabet & Cardiovasc Dis, Oakland, CA 94609 USA; Univ Calif Berkeley, Dept Nutrit Sci & Toxicol, Berkeley, CA 94720 USA; Calif State Univ Long Beach, Dept Chem & Biochem, Long Beach, CA 90840 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA	Children's Hospital Oakland Research Institute; University of California System; University of California Berkeley; California State University System; California State University Long Beach; Wake Forest University; Wake Forest University	Ryan, RO (corresponding author), CHORI, Ctr Prevent Obes Diabet & Cardiovasc Dis, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	rryan@chori.org		Mauldin, Kasuen/0000-0001-9220-8033	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030897, R01HL073061, R15HL077135, R23HL030897] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL030897-23, HL 73061, R01 HL030897, R01 HL073061, HL 077135, HL 30897] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ajees AA, 2006, P NATL ACAD SCI USA, V103, P2126, DOI 10.1073/pnas.0506877103; Alborn WE, 2006, CLIN CHEM, V52, P514, DOI 10.1373/clinchem.2005.061374; Beckstead JA, 2003, BIOCHEMISTRY-US, V42, P9416, DOI 10.1021/bi034509t; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; Fruchart-Najib J, 2004, BIOCHEM BIOPH RES CO, V319, P397, DOI 10.1016/j.bbrc.2004.05.003; Grosskopf I, 2005, ARTERIOSCL THROM VAS, V25, P2573, DOI 10.1161/01.ATV.0000186189.26141.12; Ishihara M, 2005, J LIPID RES, V46, P2015, DOI 10.1194/jlr.D500018-JLR200; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JI Y, 1995, J BIOL CHEM, V270, P11290, DOI 10.1074/jbc.270.19.11290; Ledford AS, 2006, J BIOL CHEM, V281, P8871, DOI 10.1074/jbc.M507657200; Lookene A, 2005, J BIOL CHEM, V280, P25383, DOI 10.1074/jbc.M501589200; MAEDA N, 1994, J BIOL CHEM, V269, P23610; Marcais C, 2005, J CLIN INVEST, V115, P2862, DOI 10.1172/JCI24471; Merkel M, 2005, J BIOL CHEM, V280, P21553, DOI 10.1074/jbc.M411412200; MONERA OD, 1994, PROTEIN SCI, V3, P1984, DOI 10.1002/pro.5560031110; Morrow JA, 2000, BIOCHEMISTRY-US, V39, P11657, DOI 10.1021/bi000099m; O'Brien PJ, 2005, CLIN CHEM, V51, P351, DOI 10.1373/clinchem.2004.040824; Oliva CP, 2005, ARTERIOSCL THROM VAS, V25, P411, DOI 10.1161/01.ATV.0000153087.36428.dd; Pearson K, 2005, J BIOL CHEM, V280, P38576, DOI 10.1074/jbc.M506802200; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; Saito H, 2004, PROG LIPID RES, V43, P350, DOI 10.1016/j.plipres.2004.05.002; Saito H, 2003, J BIOL CHEM, V278, P23227, DOI 10.1074/jbc.M303365200; Schaap FG, 2004, J BIOL CHEM, V279, P27941, DOI 10.1074/jbc.M403240200; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; van der Vliet HN, 2002, BIOCHEM BIOPH RES CO, V295, P1156, DOI 10.1016/S0006-291X(02)00808-2; van der Vliet HN, 2001, J BIOL CHEM, V276, P44512, DOI 10.1074/jbc.M106888200; Wang JJ, 2002, P NATL ACAD SCI USA, V99, P1188, DOI 10.1073/pnas.032565999; Weers PMM, 2000, J LIPID RES, V41, P416; Weers PMM, 2001, EUR J BIOCHEM, V268, P3728, DOI 10.1046/j.1432-1327.2001.02282.x; Weinberg RB, 2003, J BIOL CHEM, V278, P34438, DOI 10.1074/jbc.M303784200; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	34	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15484	15489		10.1074/jbc.M611797200	http://dx.doi.org/10.1074/jbc.M611797200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17401142	hybrid			2023-01-03	WOS:000246589600024
J	Elson-Schwab, L; Garner, OB; Schuksz, M; Crawford, BE; Esko, JD; Tor, Y				Elson-Schwab, Lev; Garner, Omai B.; Schuksz, Manuela; Crawford, Brett E.; Esko, Jeffrey D.; Tor, Yitzhak			Guanidinylated neomycin delivers large, bioactive cargo into cells through a heparan sulfate-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; CELLULAR-UPTAKE; FIBROBLAST-GROWTH; RICH PEPTIDES; TAT PEPTIDE; TRANSLOCATION; MOLECULES; PROTEIN; MEMBRANES; ARGININE	Facilitating the uptake of molecules into living cells is of substantial interest for basic research and drug delivery applications. Arginine-rich peptides have been shown to facilitate uptake of high molecular mass cargos into cells, but the mechanism of uptake is complex and may involve multiple receptors. In this report, we show that a derivative of the aminoglycoside antibiotic neomycin, in which all of the ammonium groups have been converted into guanidinium groups, can carry large (> 300 kDa) bioactive molecules across cell membranes. Delivery occurs at nanomolar transporter concentrations and under these conditions depends entirely on cell surface heparan sulfate proteoglycans. Conjugation of guanidinoneomycin to the plant toxin saporin, a ribosome-inactivating agent, results in proteoglycan-dependent cell toxicity. In contrast, an arginine-rich peptide shows both heparan sulfate-dependent and -independent cellular uptake. The high selectivity of guanidi-noneomycin for heparan sulfate suggests the possibility of exploiting differences in proteoglycan compositions to target delivery to different cell types.	Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Zacharon Pharmaceut Inc, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; BioMarin Pharmaceutical Inc.; Zacharon Pharmaceuticals Inc.	Esko, JD (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA.	jesko@ucsd.edu; ytor@ucsd.edu			NATIONAL CANCER INSTITUTE [T32CA067754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033063, R01GM077471, R37GM033063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS047101] Funding Source: NIH RePORTER; NCI NIH HHS [CA11227, CA67754] Funding Source: Medline; NIAID NIH HHS [AI47673, 5F31AI05891602] Funding Source: Medline; NIGMS NIH HHS [GM33063, GM77471] Funding Source: Medline; NINDS NIH HHS [NS047101] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; Caesar CEB, 2006, BIOCHEMISTRY-US, V45, P7682, DOI 10.1021/bi052095t; Chung HH, 2004, BIOPOLYMERS, V76, P83, DOI 10.1002/bip.10597; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fernandex-Carneado J, 2005, J AM CHEM SOC, V127, P869, DOI 10.1021/ja044006q; Fillon YA, 2005, J AM CHEM SOC, V127, P11798, DOI 10.1021/ja052377g; Flavell DJ, 1998, CURR TOP MICROBIOL, V234, P57; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Fuchs SM, 2004, BIOCHEMISTRY-US, V43, P2438, DOI 10.1021/bi035933x; Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009; Futaki S, 2006, BIOPOLYMERS, V84, P241, DOI 10.1002/bip.20421; Futaki S, 2002, BIOCHEMISTRY-US, V41, P7925, DOI 10.1021/bi0256173; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Hardman J, 2006, AMINOGLYCOSIDES GOOD, V11; Hitz T, 2006, BIOCHEMISTRY-US, V45, P5817, DOI 10.1021/bi060285d; Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Luedtke NW, 2003, J AM CHEM SOC, V125, P12374, DOI 10.1021/ja0360135; Luedtke NW, 2000, J AM CHEM SOC, V122, P12035, DOI 10.1021/ja002421m; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200; Rothbard JB, 2005, ADV DRUG DELIVER REV, V57, P495, DOI 10.1016/j.addr.2004.10.003; Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536; RYSER HJP, 1968, SCIENCE, V159, P390, DOI 10.1126/science.159.3813.390; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Umezawa N, 2002, J AM CHEM SOC, V124, P368, DOI 10.1021/ja017283v; Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005; Wei G, 1999, J BIOL CHEM, V274, P7857, DOI 10.1074/jbc.274.12.7857; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	35	61	71	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13585	13591		10.1074/jbc.M700463200	http://dx.doi.org/10.1074/jbc.M700463200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17311923	hybrid			2023-01-03	WOS:000246060300047
J	Klompas, M				Klompas, Michael			Does this patient have ventilator-associated pneumonia?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROTECTED SPECIMEN BRUSH; INTENSIVE-CARE UNITS; NOSOCOMIAL PNEUMONIA; BRONCHOALVEOLAR LAVAGE; CRITICALLY-ILL; DIAGNOSTIC-ACCURACY; RANDOMIZED-TRIAL; INFECTIONS; POSTMORTEM; VALIDATION	Context Ventilator-associated pneumonia (VAP) is a common and serious nosocomial infection. Accurate, timely diagnosis enables affected patients to receive appropriate therapy and avoids mistreatment of patients having other conditions. Objective To review the published medical literature describing the precision and accuracy of clinical, radiographic, and laboratory data to diagnose bacterial VAP relative to a histological gold standard. Data Sources English-language articles identified by a structured search strategy using MEDLINE ( January 1966-October 31, 2006) and Google Scholar. Additional articles were identified through the reference lists of studies and review papers identified by the search strategy. Study Selection Included studies described clinical findings associated with VAP in 25 or more patients receiving mechanical ventilation who subsequently underwent pulmonary biopsy or autopsy. Fourteen studies describing clinical findings in 655 patients met inclusion criteria. Data Extraction Data were abstracted onto a structured form, allowing calculation of the likelihood ratios (LRs) for each sign or combination of findings. Data Synthesis The presence or absence of fever, abnormal white blood cell count, or purulent pulmonary secretions do not substantively alter the probability of VAP. However, the combination of a new radiographic infiltrate with at least 2 of fever, leukocytosis, or purulent sputum increases the likelihood of VAP ( summary LR, 2.8; 95% confidence interval, 0.97-7.9). The absence of a new infiltrate on a plain chest radiograph lowers the likelihood of VAP ( summary LR, 0.35; 95% confidence interval, 0.14-0.87). Fewer than 50% neutrophils on cell count analysis of lower pulmonary secretions makes VAP unlikely ( LR range, 0.05-0.10). Conclusions Routine bedside evaluation coupled with radiographic information provides suggestive but not definitive evidence that VAP is present or absent. Given the severity of VAP and the frequency of serious conditions that can mimic VAP, clinicians should be ready to consider additional tests that provide further evidence for VAP or that establish another diagnosis.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Infect Dis,Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Pilgrim Hlth Care, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care	Klompas, M (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Infect Dis,Channing Lab, 15 Francis St,PBB-4, Boston, MA 02115 USA.	mklompas@partners.org	Klompas, Michael/Z-2415-2019					AlvarezLerma F, 1996, INTENS CARE MED, V22, P387, DOI 10.1007/BF01712153; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Balthazar AB, 2001, BRAZ J MED BIOL RES, V34, P993, DOI 10.1590/S0100-879X2001000800004; Bregeon F, 2000, EUR RESPIR J, V16, P969, DOI 10.1183/09031936.00.16596900; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; CHASTRE J, 1984, AM REV RESPIR DIS, V130, P924; Chastre J, 2006, CURR OPIN CRIT CARE, V12, P446, DOI 10.1097/01.ccx.0000244125.46871.44; Cook D, 1998, J CRIT CARE, V13, P159, DOI 10.1016/S0883-9441(98)90000-4; CROCE MA, 1994, J TRAUMA, V37, P721, DOI 10.1097/00005373-199411000-00005; Eddy DM., 1992, META ANAL CONFIDENCE; Fabregas N, 1996, ANESTHESIOLOGY, V84, P760, DOI 10.1097/00000542-199604000-00002; Fabregas N, 1999, THORAX, V54, P867, DOI 10.1136/thx.54.10.867; Fagon JY, 1996, JAMA-J AM MED ASSOC, V275, P866, DOI 10.1001/jama.275.11.866; FAGON JY, 1993, CHEST, V103, P547, DOI 10.1378/chest.103.2.547; Gibot S, 2004, NEW ENGL J MED, V350, P451, DOI 10.1056/NEJMoa031544; Heyland D, 2006, NEW ENGL J MED, V355, P2619, DOI 10.1056/NEJMoa052904; Heyland DK, 1999, AM J RESP CRIT CARE, V159, P1249, DOI 10.1164/ajrccm.159.4.9807050; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; HORAN TC, 2004, HOSP EPIDEMIOLOGY IN, P1659; JIMENEZ P, 1989, CRIT CARE MED, V17, P882, DOI 10.1097/00003246-198909000-00007; Johanson WG, 2003, INTENS CARE MED, V29, P23, DOI 10.1007/s00134-002-1589-7; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; Kirtland SH, 1997, CHEST, V112, P445, DOI 10.1378/chest.112.2.445; Legras A, 1998, INTENS CARE MED, V24, P1040, DOI 10.1007/s001340050713; Luna CM, 1997, CHEST, V111, P676, DOI 10.1378/chest.111.3.676; MARQUETTE CH, 1995, AM J RESP CRIT CARE, V151, P1878, DOI 10.1164/ajrccm.151.6.7767535; MARQUETTE CH, 1993, AM REV RESPIR DIS, V147, P211, DOI 10.1164/ajrccm/147.1.211; MEDURI GU, 1994, CHEST, V106, P221, DOI 10.1378/chest.106.1.221; Minei JP, 2000, SHOCK, V14, P331, DOI 10.1097/00024382-200014030-00016; MONTRAVERS P, 1993, AM REV RESPIR DIS, V147, P38, DOI 10.1164/ajrccm/147.1.38; OSLER W, 1907, PRINCIPLES PRACTICES, P183; Papazian L, 1996, AM J RESP CRIT CARE, V154, P91, DOI 10.1164/ajrccm.154.1.8680705; PAPAZIAN L, 1995, AM J RESP CRIT CARE, V152, P1982, DOI 10.1164/ajrccm.152.6.8520766; Papazian L, 1997, ANESTHESIOLOGY, V87, P268, DOI 10.1097/00000542-199708000-00013; Petersen IS, 1999, SCAND J INFECT DIS, V31, P299, DOI 10.1080/00365549950163617; PUGIN J, 1991, AM REV RESPIR DIS, V143, P1121, DOI 10.1164/ajrccm/143.5_Pt_1.1121; Rao VK, 1998, CHEST, V114, P549, DOI 10.1378/chest.114.2.549; Rello J, 2002, CHEST, V122, P2115, DOI 10.1378/chest.122.6.2115; RELLO J, 1993, CHEST, V104, P1230, DOI 10.1378/chest.104.4.1230; RELLO J, 1991, CHEST, V100, P439, DOI 10.1378/chest.100.2.439; ROUBY JJ, 1992, AM REV RESPIR DIS, V146, P1059, DOI 10.1164/ajrccm/146.4.1059; ROUBY JJ, 1989, ANESTHESIOLOGY, V71, P679, DOI 10.1097/00000542-198911000-00010; Safdar N, 2005, CRIT CARE MED, V33, P2184, DOI 10.1097/01.CCM.0000181731.53912.D9; Schurink CAM, 2004, INTENS CARE MED, V30, P217, DOI 10.1007/s00134-003-2018-2; TIMSIT JF, 1993, CHEST, V104, P104, DOI 10.1378/chest.104.1.104; Torres A, 2000, CRIT CARE MED, V28, P2799, DOI 10.1097/00003246-200008000-00020; TORRES A, 1994, AM J RESP CRIT CARE, V149, P324, DOI 10.1164/ajrccm.149.2.8306025; Torres A, 2001, EUR RESPIR J, V17, P1034, DOI 10.1183/09031936.01.17510340; Trouillet JL, 1998, AM J RESP CRIT CARE, V157, P531, DOI 10.1164/ajrccm.157.2.9705064; Urli T, 2002, J HOSP INFECT, V52, P130, DOI 10.1053/jhin.2002.1271; WUNDERINK RG, 1992, CHEST, V101, P458, DOI 10.1378/chest.101.2.458	51	217	226	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 11	2007	297	14					1583	1593		10.1001/jama.297.14.1583	http://dx.doi.org/10.1001/jama.297.14.1583			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155PG	17426278				2023-01-03	WOS:000245589800027
J	Colquhoun, D				Colquhoun, David			Science degrees without the science	NATURE			English	Editorial Material									UCL, Dept Pharmacol, London WC1E 6BT, England	University of London; University College London	Colquhoun, D (corresponding author), UCL, Dept Pharmacol, London WC1E 6BT, England.		Colquhoun, David/C-1664-2008	Colquhoun, David/0000-0002-4263-017X				Barry CA, 2006, SOC SCI MED, V62, P2646, DOI 10.1016/j.socscimed.2005.11.025; Desmond Adrian, 1992, POLITICS EVOLUTION M; GOLDACRE B, 2007, GUARDIAN        0217; HARRIS M, 2003, U NHS PARTNERS CARE; HOLMES OW, 1842, HOM ITS KINDR DEL; Lancet, 2005, LANCET, V336, P690; 2000, QAA OTHER SUBJECTS A	7	25	25	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 22	2007	446	7134					373	374		10.1038/446373a	http://dx.doi.org/10.1038/446373a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	148MO	17377563				2023-01-03	WOS:000245079500018
J	Finall, AI; McIntosh, SA; Thompson, WD				Finall, A. I.; McIntosh, S. A.; Thompson, W. D.			Subcutaneous inflammation mimicking metastatic malignancy induced by injection of mistletoe extract	BRITISH MEDICAL JOURNAL			English	Editorial Material							CLINICAL-TRIALS; PANNICULITIS; CANCER		Univ Wales Hosp, Cardiff & Vale NHS Trust, Dept Histopathol, Cardiff CF14 4XW, Wales; Aberdeen Royal Infirm, Unit Breast Surg, Aberdeen AB25 2ZD, Scotland	Cardiff University; University of Aberdeen	Finall, AI (corresponding author), Univ Wales Hosp, Cardiff & Vale NHS Trust, Dept Histopathol, Cardiff CF14 4XW, Wales.	Alison.Finall@CardiffandVale.wales.nhs.uk	McIntosh, Stuart/J-9512-2012	McIntosh, Stuart/0000-0002-4123-9611				Ernst E, 2003, INT J CANCER, V107, P262, DOI 10.1002/ijc.11386; Gorter R W, 1998, Am J Ther, V5, P181, DOI 10.1097/00045391-199805000-00009; HARRIS RB, 1999, ARCH DERMATOPATHOL, V21, P365; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Huber R, 2000, J ALTERN COMPLEM MED, V6, P305, DOI 10.1089/10755530050120664; JAFFE N, 1971, NEW ENGL J MED, V284, P366, DOI 10.1056/NEJM197102182840706; JANIS JF, 1968, ARCH DERMATOL, V97, P640, DOI 10.1001/archderm.97.6.640; Kaegi E, 1998, CAN MED ASSOC J, V158, P1157; Kienle GS, 2003, EUR J MED RES, V8, P109; Mabed M, 2004, BRIT J CANCER, V90, P65, DOI 10.1038/sj.bjc.6601463; *NAT CANC I, MISTL EXTR; PETERS MS, 1991, J CUTAN PATHOL, V18, P189, DOI 10.1111/j.1600-0560.1991.tb00151.x; PORTER R, 1997, MED HIST HUMANITY AN, P112; WINKELMANN RK, 1985, J AM ACAD DERMATOL, V13, P988, DOI 10.1016/S0190-9622(85)70250-2	14	5	5	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1293	1294		10.1136/bmj.39044.460023.BE	http://dx.doi.org/10.1136/bmj.39044.460023.BE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185712	Bronze, Green Submitted, Green Published			2023-01-03	WOS:000243160700010
J	Gilsdorf, JR				Gilsdorf, Janet R.			A long time ago	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												gilsdorf@umich.edu							0	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2006	296	23					2777	2778		10.1001/jama.296.23.2777	http://dx.doi.org/10.1001/jama.296.23.2777			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116TR	17179446				2023-01-03	WOS:000242826400001
J	Liben, S; Papadatou, D; Wolfe, J				Liben, Stephen; Papadatou, Danai; Wolfe, Joanne			Paediatric palliative care: challenges and emerging ideas	LANCET			English	Review							OF-LIFE CARE; FACULTY-DEVELOPMENT PROGRAM; PHYSICIAN-ASSISTED SUICIDE; SIOP WORKING COMMITTEE; MEDICAL-EDUCATION; DYING CHILDREN; HEALTH-PROFESSIONALS; INTERNATIONAL SURVEY; PSYCHOSOCIAL ISSUES; FAMILY PERSPECTIVES	Paediatric palliative care is an emerging subspecialty that focuses on achieving the best possible quality of life for children with life-threatening conditions and their families. To achieve this goal, the individuals working in this field need to: clearly define the population served; better understand the needs of children with fife-threatening conditions and their families; develop an approach that will be appropriate across different communities; provide care that responds adequately to suffering; advance strategies that support caregivers and health-care providers; and promote needed change by cultivating educational programmes. Despite these challenges, advances in paediatric palliative care have been achieved in a short period of time; we expect far greater progress as the field becomes more formalised and research networks are established.	[Wolfe, Joanne] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Wolfe, Joanne] Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Dept Populat Sci, Boston, MA 02115 USA; [Liben, Stephen] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Montreal, PQ, Canada; [Papadatou, Danai] Univ Athens, Fac Nursing, GR-10679 Athens, Greece	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; McGill University; National & Kapodistrian University of Athens	Wolfe, J (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.	joanne_wolfe@dfci.harvard.edu	Harding, Richard/G-9729-2012		NCI NIH HHS [5 K07 CA 096746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K07CA096746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM AC HOSP PALL M, FELL PROGR DIR; [Anonymous], 1993, Death Stud, V17, P277; ARMSTRONGDAILEY A, 2001, HOSP CARE CHILDREN; *ASS CHILDR LIF TH, 2003, GUID DEV CHILDR PALL; Ayers T, 2004, DEATH STUD, V28, P491, DOI 10.1080/07481180490461188; Bagatell R, 2002, PEDIATRICS, V110, P348, DOI 10.1542/peds.110.2.348; Barclay S, 2003, PALLIATIVE MED, V17, P27, DOI 10.1191/0269216303pm665oa; Barnard D, 1999, ACAD MED, V74, P499, DOI 10.1097/00001888-199905000-00014; Barnes LL, 2000, PEDIATRICS, V106, P899; BEHNKE M, 1987, DEATH STUD, V11, P169, DOI 10.1080/07481188708252189; BENOLIEL JQ, 1993, PERSONAL CARE IMPERS, P3; BERMAN S, 1983, CLIN PEDIATR, V22, P175, DOI 10.1177/000992288302200302; Block SD, 2005, NEW ENGL J MED, V353, P1313, DOI 10.1056/NEJMp048171; BLUEBLONDLANGNE.M, 1978, PRIVATE WORLDS DYING; Bostrom BA, 2002, ISSUES LAW MED, V18, P57; BOURI M, 2006, PEDIATRIKI, V69, P118; Bradshaw Glenna, 2005, J Palliat Med, V8, P86, DOI 10.1089/jpm.2005.8.86; British Medical Association, 2001, CONS RIGHTS CHOIC HL; BROWN SE, 1995, INFANT YOUNG CHILD, V7, P13, DOI 10.1097/00001163-199501000-00004; Browning DM, 2006, CHILD ADOL PSYCH CL, V15, P795, DOI 10.1016/j.chc.2006.03.002; Browning David M, 2005, J Pediatr Nurs, V20, P326, DOI 10.1016/j.pedn.2005.03.004; BURNE SR, 1984, BMJ-BRIT MED J, V289, P1665, DOI 10.1136/bmj.289.6459.1665; CARTER B, 2004, PALLIATIVE CARE INFA; Carter BS, 2004, PEDIATRICS, V114, pE361, DOI 10.1542/peds.2003-0654-F; Cassell E J, 1992, NLN Publ, P1; Cassell E.J., 2004, NATURE SUFFERING GOA; Charlton R, 1996, PALLIATIVE MED, V10, P240, DOI 10.1177/026921639601000308; *CHIPPS, CALL CHANG REC IMPR; Chochinov HM, 2002, JAMA-J AM MED ASSOC, V287, P2253, DOI 10.1001/jama.287.17.2253; Chochinov HM, 2006, CA-CANCER J CLIN, V56, P84, DOI 10.3322/canjclin.56.2.84; Clarkson RS, 1998, J PORTFOLIO MANAGE, V25, P33, DOI 10.3905/jpm.1998.409653; Cohen SR, 2001, PALLIATIVE MED, V15, P363, DOI 10.1191/026921601680419401; Contro N, 2002, ARCH PEDIAT ADOL MED, V156, P14, DOI 10.1001/archpedi.156.1.14; Contro NA, 2004, PEDIATRICS, V114, P1248, DOI 10.1542/peds.2003-0857-L; CORR CA, 1992, DEATH STUD, V16, P343, DOI 10.1080/07481189208252582; Corr CA, 2002, DEATH STUD, V26, P595, DOI 10.1080/074811802760191726; Dangel T, 2002, J PAIN SYMPTOM MANAG, V24, P222, DOI 10.1016/S0885-3924(02)00461-X; Davies B, 2005, J PALLIATIVE CARE, V21, P252, DOI 10.1177/082585970502100404; Davies B, 2004, J PALLIAT CARE, V20, P277, DOI 10.1177/082585970402000403; Davies B, 2002, J PALLIATIVE CARE, V18, P59, DOI 10.1177/082585970201800109; Davies B, 1996, Pediatr Nurs, V22, P500; De Graves S, 2005, EUR J CANCER CARE, V14, P132, DOI 10.1111/j.1365-2354.2005.00520.x; De Lima MHAL, 2001, HEALTH POLICY, V56, P99, DOI 10.1016/S0168-8510(00)00130-5; Denny CC, 2006, J CLIN ETHIC, V17, P39; Derish MT, 2000, J LAW MED ETHICS, V28, P109, DOI 10.1111/j.1748-720X.2000.tb00001.x; Dickinson George E, 2002, Am J Hosp Palliat Care, V19, P181, DOI 10.1177/104990910201900309; Doka K.J., 1989, DISENFRANCHISED GRIE; DowneWamboldt B, 1997, DEATH STUD, V21, P177; DOYAL L, 1994, PEDIATR NEPHROL, V8, P768, DOI 10.1007/BF00869118; Drake R, 2003, J PAIN SYMPTOM MANAG, V26, P594, DOI 10.1016/S0885-3924(03)00202-1; Eliott J, 2005, INTERDISCIPLINARY PERSPECTIVES ON HOPE, P3; ENG B, 1999, GRIEF HEALING ARTS C, P127; Faulkner KW, 1997, AM J NURS, V97, P64, DOI 10.2307/3465368; Feudtner C, 2006, PEDIATRICS, V117, pE932, DOI 10.1542/peds.2005-2078; Feudtner C, 2002, PEDIATRICS, V109, P887, DOI 10.1542/peds.109.5.887; Field M.J., 2003, CHILDREN DIE IMPROVI; Fins JJ, 2005, HASTINGS CENT REP, V35, P8, DOI 10.1353/hcr.2005.0038; Fleischman A, 2005, PEDIATRICS, V115, pE742, DOI 10.1542/peds.2004-2237; Fowler K, 2006, J CLIN ONCOL, V24, P1099, DOI 10.1200/JCO.2005.02.6591; Frager G, 1996, J PALLIATIVE CARE, V12, P9; Fraser H C, 2001, J Palliat Med, V4, P337, DOI 10.1089/109662101753123959; Friedrichsdorf SJ, 2005, J PAIN SYMPTOM MANAG, V29, P156, DOI 10.1016/j.jpainsymman.2004.05.004; Ganzini L, 2006, J CLIN ETHIC, V17, P27; Gatrad AR, 2003, BRIT MED J, V327, P176, DOI 10.1136/bmj.327.7408.176; Goldman A, 2006, PEDIATRICS, V117, pE1179, DOI 10.1542/peds.2005-0683; GOLDMAN A, 1998, CARE DYING CHILD; Goldman A, 2012, OXFORD TXB PALLIATIV, V2, P500; Goodenough B, 2004, PSYCHO-ONCOLOGY, V13, P779, DOI 10.1002/pon.795; Hain R, 2003, PALLIATIVE MED, V17, P229, DOI 10.1191/0269216303pm777ed; Harding R, 2005, LANCET, V365, P1971, DOI 10.1016/S0140-6736(05)66666-4; Hays RM, 2006, J PALLIAT MED, V9, P716, DOI 10.1089/jpm.2006.9.716; Heller Karen S, 2005, J Pediatr Nurs, V20, P335, DOI 10.1016/j.pedn.2005.03.005; Henley Lesley D, 2002, Dev World Bioeth, V2, P38, DOI 10.1111/1471-8847.00034; Hilden JM, 2001, J CLIN ONCOL, V19, P205, DOI 10.1200/JCO.2001.19.1.205; Himelstein BP, 2004, NEW ENGL J MED, V350, P1752, DOI 10.1056/NEJMra030334; Hinds P S, 1994, J Pediatr Nurs, V9, P388; Hinds Pamela S, 2005, J Palliat Med, V8 Suppl 1, pS70, DOI 10.1089/jpm.2005.8.s-70; Hinds PS, 2005, J CLIN ONCOL, V23, P9146, DOI 10.1200/JCO.2005.10.538; Hinds PS, 2004, QUAL LIFE RES, V13, P761, DOI 10.1023/B:QURE.0000021697.43165.87; Hurwitz CA, 2004, JAMA-J AM MED ASSOC, V292, P2141, DOI 10.1001/jama.292.17.2141; Hutchinson F, 2003, POSTGRAD MED J, V79, P566, DOI 10.1136/pmj.79.936.566; Jalmsell L, 2006, PEDIATRICS, V117, P1314, DOI 10.1542/peds.2005-1479; JANKOVIC M, 1994, PEDIATR HEMAT ONCOL, V11, P75, DOI 10.3109/08880019409141903; JELLINEK MS, 1993, CRIT CARE MED, V21, P775, DOI 10.1097/00003246-199305000-00023; Kaplan LJ, 2000, OMEGA-J DEATH DYING, V41, P187, DOI 10.2190/NGG6-YPAH-40AB-CNX0; Kato Y, 2004, PEDIATR INT, V46, P478, DOI 10.1111/j.1442-200x.2004.01913.x; Kaye J M, 1998, J Cancer Educ, V13, P52; Kearney M., 2000, PLACE HEALING WORKIN; Kennedy D, 1997, Crit Care Nurs Q, V20, P63; Khaneja S, 1998, ARCH PEDIAT ADOL MED, V152, P909; Kolarik RC, 2006, PEDIATRICS, V117, P1949, DOI 10.1542/peds.2005-1111; Koshy RC, 1998, SUPPORT CARE CANCER, V6, P430, DOI 10.1007/s005200050190; Kreicbergs U, 2004, NEW ENGL J MED, V351, P1175, DOI 10.1056/NEJMoa040366; KREICBERGS U, 2005, J CLIN ONCOL, P23; Kushnir T, 1997, CANCER NURS, V20, P414, DOI 10.1097/00002820-199712000-00005; KUTTNER L, 2004, MAKING EVERY MOMENT; Lauer M E, 1985, Cancer Nurs, V8, P21, DOI 10.1097/00002820-198508010-00002; LAUER ME, 1989, CANCER, V63, P988, DOI 10.1002/1097-0142(19890301)63:5<988::AID-CNCR2820630534>3.0.CO;2-Y; LAUER ME, 1983, PEDIATRICS, V71, P107; Li J, 2003, LANCET, V361, P363, DOI 10.1016/S0140-6736(03)12387-2; Lieberman L, 2006, MED EDUC, V40, P539, DOI 10.1111/j.1365-2929.2006.02479.x; Mack JW, 2005, J CLIN ONCOL, V23, P9155, DOI 10.1200/JCO.2005.04.010; Mack JW, 2004, J CLIN ONCOL, V22, P563, DOI 10.1200/JCO.2004.04.078; MacLeod RD, 2003, MED EDUC, V37, P51, DOI 10.1046/j.1365-2923.2003.01412.x; MARTINSON IM, 1994, CANCER NURS, V17, P72; Masera G, 1997, MED PEDIATR ONCOL, V28, P382, DOI 10.1002/(SICI)1096-911X(199705)28:5<382::AID-MPO12>3.0.CO;2-D; Maytum Jennifer C, 2004, J Pediatr Health Care, V18, P171, DOI 10.1016/S0891-5245(03)00309-2; McCallum DE, 2000, J PAIN SYMPTOM MANAG, V20, P417, DOI 10.1016/S0885-3924(00)00212-8; McKinley D, 2001, Int J Nurs Pract, V7, P251, DOI 10.1046/j.1440-172x.2001.00288.x; Meekin SA, 2000, ACAD MED, V75, P986, DOI 10.1097/00001888-200010000-00011; Meyer EC, 2006, PEDIATRICS, V117, P649, DOI 10.1542/peds.2005-0144; Meyer EC, 2002, CRIT CARE MED, V30, P226, DOI 10.1097/00003246-200201000-00032; *NAT HOSP PALL CAR, CHIPPS WORKGR DEC; National Hospice and Palliative Care Organization, 2000, COMP PED PALL CAR; Nelson RM, 2000, PEDIATRICS, V106, P351; NITSCHKE R, 1982, J PEDIATR-US, V101, P471; Nyambedha EO, 2003, SOC SCI MED, V57, P301, DOI 10.1016/S0277-9536(02)00359-3; Nyambedha EO, 2001, HEALTH POLICY, V58, P83, DOI 10.1016/S0168-8510(01)00145-2; Oehler J M, 1992, Am J Crit Care, V1, P81; OEHLER JM, 1991, HEART LUNG, V20, P500; Olson M S, 1998, J Pediatr Oncol Nurs, V15, P13, DOI 10.1177/104345429801500103; Olthuis G, 2003, MED EDUC, V37, P928, DOI 10.1046/j.1365-2923.2003.01635.x; Oneschuk D, 2000, J PAIN SYMPTOM MANAG, V20, P174, DOI 10.1016/S0885-3924(00)00172-X; Pagel I, 1986, Issues Compr Pediatr Nurs, V9, P131, DOI 10.3109/01460868609094402; Papadatou D, 1997, DEATH STUD, V21, P575, DOI 10.1080/074811897201787; Papadatou D, 2000, OMEGA-J DEATH DYING, V41, P59, DOI 10.2190/TV6M-8YNA-5DYW-3C1E; Papadatou D, 1996, DEATH STUD, V20, P215, DOI 10.1080/07481189608252778; Papadatou D, 2001, CANCER NURS, V24, P402, DOI 10.1097/00002820-200110000-00013; Papadatou D, 1999, ILLNESS CRISIS LOSS, V7, P37; Papadatou Danai, 2002, Pediatr Nurs, V28, P345; Pierucci RL, 2001, PEDIATRICS, V108, P653, DOI 10.1542/peds.108.3.653; Rashotte J, 1997, HEART LUNG, V26, P372, DOI 10.1016/S0147-9563(97)90024-8; Rawlinson F, 2002, PALLIATIVE MED, V16, P51, DOI 10.1191/0269216302pm508oa; Rebagliato M, 2000, JAMA-J AM MED ASSOC, V284, P2451, DOI 10.1001/jama.284.19.2451; Robinson MR, 2006, PEDIATRICS, V118, pE719, DOI 10.1542/peds.2005-2298; Rushton CH, 2006, J PALLIAT MED, V9, P922, DOI 10.1089/jpm.2006.9.922; Rushton Cynda Hylton, 2005, J Pediatr Nurs, V20, P311, DOI 10.1016/j.pedn.2005.03.003; Rutkow Lainie, 2005, J Contemp Health Law Policy, V22, P107; Sagara M, 1998, CANCER NURS, V21, P274, DOI 10.1097/00002820-199808000-00009; Sahler OJZ, 2000, PEDIATRICS, V105, P575, DOI 10.1542/peds.105.3.575; Sartain SA, 2000, J ADV NURS, V32, P913, DOI 10.1046/j.1365-2648.2000.01556.x; Seale C, 2000, SOC SCI MED, V51, P917, DOI 10.1016/S0277-9536(00)00071-X; Serwint JR, 2006, J PALLIAT MED, V9, P70, DOI 10.1089/jpm.2006.9.70; Serwint JR, 2002, ACAD MED, V77, P278, DOI 10.1097/00001888-200204000-00004; SHARP MC, 1992, J PEDIATR-US, V121, P539, DOI 10.1016/S0022-3476(05)81141-2; Solomon MZ, 2005, PEDIATRICS, V116, P872, DOI 10.1542/peds.2004-0905; SOURKES BM, 1999, GRIEF HEALING ARTS, P119; Sourkes BM, 1995, ARMFULS TIME PSYCHOL; Spinetta JJ, 2000, MED PEDIATR ONCOL, V35, P122; Steele R, 2005, J PALLIATIVE CARE, V21, P5, DOI 10.1177/082585970502100102; Sullivan AM, 2005, ACAD MED, V80, P657, DOI 10.1097/00001888-200507000-00008; Sullivan AM, 2003, J GEN INTERN MED, V18, P685, DOI 10.1046/j.1525-1497.2003.21215.x; Sullivan AM, 2006, J GEN INTERN MED, V21, P907, DOI 10.1007/BF02743136; Trill MD, 1997, ANN NY ACAD SCI, V809, P197, DOI 10.1111/j.1749-6632.1997.tb48083.x; Vazirani RM, 2000, CRIT CARE MED, V28, P3740, DOI 10.1097/00003246-200011000-00036; Verhagen AAE, 2005, PEDIATRICS, V116, P736, DOI 10.1542/peds.2005-0014; von Gunten Charles F, 2004, J Support Oncol, V2, P166; von Gunten Charles F, 2004, J Palliat Med, V7, P209, DOI 10.1089/109662104773709332; Wass H, 2004, DEATH STUD, V28, P289, DOI 10.1080/07481180490432315; Weissman DE, 2002, ACAD MED, V77, P299, DOI 10.1097/00001888-200204000-00008; Wilson Golder N., 1993, V384, P157; Wolfe J, 2000, NEW ENGL J MED, V342, P326, DOI 10.1056/NEJM200002033420506; Wolfe J, 2000, JAMA-J AM MED ASSOC, V284, P2469, DOI 10.1001/jama.284.19.2469; Wood EB, 2002, ACAD MED, V77, P285, DOI 10.1097/00001888-200204000-00005; WOOLLEY H, 1989, ARCH DIS CHILD, V64, P114, DOI 10.1136/adc.64.1.114; World Health Organization, WHO DEF PALL CAR CHI; Yam BMC, 2001, J CLIN NURS, V10, P651, DOI 10.1046/j.1365-2702.2001.00532.x; [No title captured]	168	192	195	1	32	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 8	2008	371	9615					852	864		10.1016/S0140-6736(07)61203-3	http://dx.doi.org/10.1016/S0140-6736(07)61203-3			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	272NQ	17707080				2023-01-03	WOS:000253866500032
J	Pannu, N; Klarenbach, S; Wiebe, N; Manns, B; Tonelli, M				Pannu, Neesh; Klarenbach, Scott; Wiebe, Natasha; Manns, Braden; Tonelli, Marcello		Alberta Kidney Dis Network	Renal replacement therapy in patients with acute renal failure - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CONTINUOUS VENOVENOUS HEMOFILTRATION; CRITICALLY-ILL PATIENTS; ACUTE KIDNEY INJURY; INTENSIVE-CARE UNITS; INTERMITTENT HEMODIALYSIS; GLOMERULAR-FILTRATION; METHODOLOGICAL QUALITY; CONTINUOUS DIALYSIS; HOSPITAL MORTALITY; PROGNOSTIC-FACTORS	Context Acute renal failure requiring dialytic support is associated with a high risk of mortality and substantial morbidity. Objectives To summarize current evidence guiding provision of dialysis for patients with acute renal failure, to make recommendations for management, and to identify areas in which additional research is needed. Data Sources Systematic searches of peer- reviewed publications in MEDLINE, EMBASE, and All EBM Reviews through October 2007. Study Selection Randomized controlled trials ( RCTs) and prospective cohort studies studying dialytic support in adults with acute renal failure that reported the incidence of clinical outcomes such as mortality, length of stay, need for chronic dialysis, or development of hypotension. Data Extraction Quality was independently assessed by 2 reviewers using the Jadad score ( RCTs) and the Downs and Black checklist ( cohort studies). A single reviewer extracted data, which were independently verified by a second reviewer. Results of RCTs were pooled using a random- effects model. Data Synthesis From 173 retrieved articles, 30 RCTs and 8 prospective cohort studies were eligible. No conclusions could be drawn about optimal indications for or timing of renal replacement. Available data comparing continuous renal replacement therapy ( CRRT) with intermittent hemodialysis demonstrated no clinically relevant difference between modalities, including for all- cause mortality ( relative risk [ RR], 1.10; 95% confidence interval [ CI], 0.99- 1.23; I-2= 0%) or for the requirement for chronic dialysis treatment in survivors ( RR, 0.91; 95% CI, 0.56- 1.49; I-2= 0%). For patients treated with CRRT, limited data suggest that bicarbonate may be preferable to other forms of dialysate alkali and that citrate infusion may be an alternative to systemic anticoagulation in patients at high risk of bleeding. Among patients treated with continuous venovenous hemofiltration ( CVVHF), the risk of death was lower at doses of 35 mL/ kg per hour ( RR of death compared with doses of 20 mL/ kg per hour, 0.74; 95% CI, 0.63- 0.88). The use of unsubstituted cellulosic membranes should be avoided in intermittent hemodialysis ( RR of death compared with biocompatible membranes, 1.23; 95% CI, 1.01- 1.50). Conclusions Based on current data, intermittent hemodialysis and CRRT appear to lead to similar clinical outcomes for patients with ARF. If CVVHF is used, a dose of 35 mL/ kg per hour should be provided. Given the paucity of good- quality evidence in this important area, additional large randomized trials are needed to evaluate clinically important outcomes.	[Pannu, Neesh; Klarenbach, Scott; Wiebe, Natasha; Tonelli, Marcello] Univ Alberta, Dept Med, Edmonton, AB T6B 2B7, Canada; [Pannu, Neesh; Tonelli, Marcello] Univ Alberta, Div Crit Care Med, Edmonton, AB T6B 2B7, Canada; [Manns, Braden] Univ Alberta, Dept Publ Hlth Sci, Edmonton, AB T6B 2B7, Canada; [Klarenbach, Scott; Manns, Braden; Tonelli, Marcello] Inst Hlth Econ, Edmonton, AB, Canada; [Manns, Braden] Univ Calgary, Dept Med, Div Nephrol, Calgary, AB, Canada; [Manns, Braden] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada	University of Alberta; University of Alberta; University of Alberta; University of Calgary; University of Calgary	Tonelli, M (corresponding author), Univ Alberta, Dept Med, 7-129 Clin Sci Bldg,8440 112, Edmonton, AB T6B 2B7, Canada.		Manns, Braden J/I-8942-2012; Wiebe, Natasha/V-7803-2019; Tonelli, Marcello/B-3028-2009	Wiebe, Natasha/0000-0002-5613-1582; Tonelli, Marcello/0000-0002-0846-3187				Albright RC, 2000, MAYO CLIN PROC, V75, P1141, DOI 10.4065/75.11.1141; Ali T, 2007, J AM SOC NEPHROL, V18, P1292, DOI 10.1681/ASN.2006070756; Andreev E, 1999, J INTERN MED, V246, P247, DOI 10.1046/j.1365-2796.1999.00515.x; *ANZICS CLIN TRIAL, RENAL STUD; Augustine JJ, 2004, AM J KIDNEY DIS, V44, P1000, DOI 10.1053/j.ajkd.2004.08.022; Bagshaw SM, 2005, CRIT CARE, V9, pR700, DOI 10.1186/cc3879; Barenbrock M, 2000, KIDNEY INT, V58, P1751, DOI 10.1046/j.1523-1755.2000.00336.x; Barletta JF, 2006, PEDIATR NEPHROL, V21, P842, DOI 10.1007/s00467-006-0049-y; Bouman CSC, 2002, CRIT CARE MED, V30, P2205, DOI 10.1097/00003246-200210000-00005; Brause M, 2003, CRIT CARE MED, V31, P841, DOI 10.1097/01.CCM.0000054866.45509.D0; Bret M, 1998, RENAL FAILURE, V20, P493, DOI 10.3109/08860229809045138; Brivet FG, 1996, CRIT CARE MED, V24, P192, DOI 10.1097/00003246-199602000-00003; Chertow GM, 2005, J AM SOC NEPHROL, V16, P3365, DOI 10.1681/ASN.2004090740; Cho MK, 1996, ANN INTERN MED, V124, P485, DOI 10.7326/0003-4819-124-5-199603010-00004; Clark WR, 2004, CONTRIB NEPHROL, V144, P264; CONGER JD, 1975, J TRAUMA, V15, P1056, DOI 10.1097/00005373-197512000-00003; DAVENPORT A, 1993, KIDNEY INT, V43, pS245; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Favre H, 1996, SEMIN DIALYSIS, V9, P112, DOI 10.1111/j.1525-139X.1996.tb00637.x; FEEST TG, 1993, BMJ-BRIT MED J, V306, P481, DOI 10.1136/bmj.306.6876.481; Gasparovic V, 2003, RENAL FAILURE, V25, P855, DOI 10.1081/JDI-120024300; Gastaldello K, 2000, NEPHROL DIAL TRANSPL, V15, P224, DOI 10.1093/ndt/15.2.224; Gettings LG, 1999, INTENS CARE MED, V25, P805, DOI 10.1007/s001340050956; GILLUM DM, 1986, CLIN NEPHROL, V25, P249; Guerin C, 2002, INTENS CARE MED, V28, P1411, DOI 10.1007/s00134-002-1433-0; HAKIM RM, 1994, NEW ENGL J MED, V331, P1338, DOI 10.1056/NEJM199411173312003; Hein OV, 2004, RENAL FAILURE, V26, P297, DOI 10.1081/JDI-120039529; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P153; Herget-Rosenthal S, 2005, CLIN NEPHROL, V64, P41; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Himmelfarb J, 1998, J AM SOC NEPHROL, V9, P257; Hoste EAJ, 2006, CURR OPIN CRIT CARE, V12, P531, DOI 10.1097/MCC.0b013e3280102af7; Hsu CY, 2007, KIDNEY INT, V72, P208, DOI 10.1038/sj.ki.5002297; Hsu CY, 2007, CURR OPIN NEPHROL HY, V16, P221, DOI 10.1097/MNH.0b013e3280895ad9; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; John S, 2001, NEPHROL DIAL TRANSPL, V16, P320, DOI 10.1093/ndt/16.2.320; Jones CH, 1998, ARTIF ORGANS, V22, P638, DOI 10.1046/j.1525-1594.1998.06165.x; Jorres A, 1999, LANCET, V354, P1337, DOI 10.1016/S0140-6736(99)01213-1; KAUFMAN J, 1991, AM J KIDNEY DIS, V17, P191, DOI 10.1016/S0272-6386(12)81128-0; Kielstein JT, 2004, AM J KIDNEY DIS, V43, P342, DOI 10.1053/j.ajkd.2003.10.021; KIHARA M, 1994, NEPHRON, V67, P36, DOI 10.1159/000187885; Kumar VA, 2004, INT J ARTIF ORGANS, V27, P371, DOI 10.1177/039139880402700505; Kunz R, 1998, BRIT MED J, V317, P1185, DOI 10.1136/bmj.317.7167.1185; KURTAL H, 1995, ARTIF ORGANS, V19, P391, DOI 10.1111/j.1525-1594.1995.tb02347.x; Kutsogiannis DJ, 2005, KIDNEY INT, V67, P2361, DOI 10.1111/j.1523-1755.2005.00342.x; Levraut J, 1997, CRIT CARE MED, V25, P58, DOI 10.1097/00003246-199701000-00013; Liano F, 1996, KIDNEY INT, V50, P811, DOI 10.1038/ki.1996.380; Liu KD, 2006, CLIN J AM SOC NEPHRO, V1, P915, DOI 10.2215/CJN.01430406; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Mehta RL, 2003, J AM SOC NEPHROL, V14, P2178, DOI 10.1097/01.ASN.0000079042.13465.1A; Mehta RL, 2001, KIDNEY INT, V60, P1154, DOI 10.1046/j.1523-1755.2001.0600031154.x; Metnitz PGH, 2002, CRIT CARE MED, V30, P2051, DOI 10.1097/00003246-200209000-00016; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Morgera S, 1997, RENAL FAILURE, V19, P155, DOI 10.3109/08860229709026270; Morgera S, 2006, CRIT CARE MED, V34, P2099, DOI 10.1097/01.CCM.0000229147.50592.F9; Neveu H, 1996, NEPHROL DIAL TRANSPL, V11, P293, DOI 10.1093/oxfordjournals.ndt.a027256; Noble JSC, 2006, RENAL FAILURE, V28, P323, DOI 10.1080/08860220600591487; Ostermann ME, 2005, INTENS CARE MED, V31, P250, DOI 10.1007/s00134-004-2523-y; Palevsky PM, 2005, CLIN TRIALS, V2, P423, DOI 10.1191/1740774505cn116oa; Pannu Neesh, 2005, Ther Clin Risk Manag, V1, P141, DOI 10.2147/tcrm.1.2.141.62908; Pettila V, 2001, CLIN NEPHROL, V56, P324; Ponikvar JB, 2001, ARTIF ORGANS, V25, P946, DOI 10.1046/j.1525-1594.2001.06753.x; Ronco C, 2000, LANCET, V356, P26, DOI 10.1016/S0140-6736(00)02430-2; Ronco C, 2006, CRIT CARE, V10, DOI 10.1186/cc4843; Saudan P, 2006, KIDNEY INT, V70, P1312, DOI 10.1038/sj.ki.5001705; Schiffl H, 2002, NEW ENGL J MED, V346, P305, DOI 10.1056/NEJMoa010877; SCHIFFL H, 1994, LANCET, V344, P570, DOI 10.1016/S0140-6736(94)91964-X; SCHRADER J, 1990, T AM SOC ART INT ORG, V36, P28; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Song, 2000, HEALTH TECHNOL ASSES, V4, P1, DOI DOI 10.3310/HTA4100; STEFANIDIS I, 1995, CONTRIB NEPHROL, V116, P140; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Sugahara Souichi, 2004, Hemodial Int, V8, P320, DOI 10.1111/j.1492-7535.2004.80404.x; Swartz RD, 2005, CLIN NEPHROL, V63, P335; Uchino S, 2007, INT J ARTIF ORGANS, V30, P281, DOI 10.1177/039139880703000402; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; Uehlinger DE, 2005, NEPHROL DIAL TRANSPL, V20, P1630, DOI 10.1093/ndt/gfh880; US Renal Data System, 2006, USRDS 2006 ANN DAT R; VANACKER BAC, 1992, LANCET, V340, P1326, DOI 10.1016/0140-6736(92)92502-7; Vinsonneau C, 2006, LANCET, V368, P379, DOI 10.1016/S0140-6736(06)69111-3; Waikar SS, 2006, J AM SOC NEPHROL, V17, P1143, DOI 10.1681/ASN.2005091017; WEBB AR, 1995, INTENS CARE MED, V21, P84, DOI 10.1007/BF02425162; Wells M, 1997, S AFR J SURG, V35, P20; Wiebe N, 2006, J CLIN EPIDEMIOL, V59, P342, DOI 10.1016/j.jclinepi.2005.08.017; Xue JL, 2006, J AM SOC NEPHROL, V17, P1135, DOI 10.1681/ASN.2005060668	87	206	235	2	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	2008	299	7					793	805		10.1001/jama.299.7.793	http://dx.doi.org/10.1001/jama.299.7.793			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263OR	18285591				2023-01-03	WOS:000253226900022
J	Goldstein, NE; Fischberg, D				Goldstein, Nathan E.; Fischberg, Daniel			Update in palliative medicine	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							OF-LIFE CARE; DOSE MORPHINE USE; HEART-FAILURE; RANDOMIZED-TRIAL; OPIOID USE; END; PNEUMONIA; SURVIVAL; GASTROENTEROSTOMY; MORTALITY		[Goldstein, Nathan E.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Goldstein, NE (corresponding author), Mt Sinai Sch Med, Dept Geriatr & Adult Dev, 1 Gustave Levy Pl,Box 1070, New York, NY 10029 USA.	nathan.goldstein@mssm.edu			NATIONAL INSTITUTE ON AGING [K23AG025933] Funding Source: NIH RePORTER; NIA NIH HHS [K23AG025933] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agar MH., 2004, CLIN PRACT GUID QUAL, DOI 10.4135/9781848608191; Bercovitch M, 2004, CANCER-AM CANCER SOC, V101, P1473, DOI 10.1002/cncr.20485; Bercovitch M, 1999, CANCER-AM CANCER SOC, V86, P871, DOI 10.1002/(SICI)1097-0142(19990901)86:5<871::AID-CNCR25>3.0.CO;2-L; BOAS RA, 1982, BRIT J ANAESTH, V54, P501, DOI 10.1093/bja/54.5.501; Campbell ML, 2006, CRIT CARE MED, V34, pS355, DOI 10.1097/01.CCM.0000237248.16818.E5; Campbell ML, 2003, CHEST, V123, P266, DOI 10.1378/chest.123.1.266; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; Ferrante FM, 1996, ANESTH ANALG, V82, P91, DOI 10.1097/00000539-199601000-00016; GUDJONSSON B, 1987, CANCER, V60, P2284, DOI 10.1002/1097-0142(19871101)60:9<2284::AID-CNCR2820600930>3.0.CO;2-V; Hosono S, 2007, J GASTROENTEROL, V42, P283, DOI 10.1007/s00535-006-2003-y; Huehnergarth KV, 2005, AM J CARDIOL, V95, P1492, DOI 10.1016/j.amjcard.2005.02.022; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Levy WC, 2006, CIRCULATION, V113, P1424, DOI 10.1161/CIRCULATIONAHA.105.584102; Loeb M, 2006, JAMA-J AM MED ASSOC, V295, P2503, DOI 10.1001/jama.295.21.2503; Lynn J, 1997, New Horiz, V5, P56; Maggioni AP, 2005, J CARD FAIL, V11, P91, DOI 10.1016/j.cardfail.2004.05.004; Mann DL, 2004, CIRCULATION, V109, P1594, DOI 10.1161/01.CIR.0000124490.27666.B2; Marrie TJ, 2002, INFECT CONT HOSP EP, V23, P159, DOI 10.1086/502030; Muder RR, 1996, ARCH INTERN MED, V156, P2365, DOI 10.1001/archinte.156.20.2365; Norton SA, 2007, CRIT CARE MED, V35, P1530, DOI 10.1097/01.CCM.0000266533.06543.0C; Packer M, 1996, NEW ENGL J MED, V335, P1107, DOI 10.1056/NEJM199610103351504; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; Portenoy RK, 2006, J PAIN SYMPTOM MANAG, V32, P532, DOI 10.1016/j.jpainsymman.2006.08.003; Teno JM, 2005, J AM GERIATR SOC, V53, P1905, DOI 10.1111/j.1532-5415.2005.53563.x; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Teno JM, 2001, J PAIN SYMPTOM MANAG, V22, P738, DOI 10.1016/S0885-3924(01)00335-9; Thorns A, 2000, LANCET, V356, P398, DOI 10.1016/S0140-6736(00)02534-4; Tremont-Lukats IW, 2005, ANESTH ANALG, V101, P1738, DOI 10.1213/01.ANE.0000186348.86792.38; Twaddle ML, 2007, J PALLIAT MED, V10, P86, DOI 10.1089/jpm.2006.0048; VANDERSCHELLING GP, 1993, WORLD J SURG, V17, P128, DOI 10.1007/BF01655726	30	4	5	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	2008	148	2					135	140		10.7326/0003-4819-148-2-200801150-00008	http://dx.doi.org/10.7326/0003-4819-148-2-200801150-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254NZ	18195337				2023-01-03	WOS:000252594600006
J	O'Farrell, N; Moodley, P; Sturm, AW				O'Farrell, Nigel; Moodley, Prashini; Sturm, A. Wim			Genital herpes in Africa: time to rethink treatment	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; SIMPLEX-VIRUS; WOMEN; ACYCLOVIR; INFECTION; REACTIVATION; PREVALENCE; THERAPY; IMPACT; SPREAD		[O'Farrell, Nigel] Ealing Gen Hosp, London UB1 3HW, England; [Moodley, Prashini; Sturm, A. Wim] Univ KwaZulu Natal, Nelson Mandela Sch Med, Dept Med Microbiol, Durban, South Africa	Imperial College London; University of Kwazulu Natal	O'Farrell, N (corresponding author), Ealing Gen Hosp, Pasteur Suite,Uxbridge Rd, London UB1 3HW, England.	nigel.ofarrell@lshtm.ac.uk						Aoki FY, 2006, CLIN INFECT DIS, V42, P8, DOI 10.1086/498521; Blower S, 2004, J INFECT DIS, V190, P1610, DOI 10.1086/424850; BROCK BV, 1990, JAMA-J AM MED ASSOC, V263, P418, DOI 10.1001/jama.263.3.418; Celum C, 2004, B WORLD HEALTH ORGAN, V82, P447; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7; KOELLE DM, 1992, ANN INTERN MED, V116, P433, DOI 10.7326/0003-4819-116-6-433; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; LANGENBERG A, 1989, ANN INTERN MED, V110, P882, DOI 10.7326/0003-4819-110-11-882; Levin MJ, 2004, CLIN INFECT DIS, V39, pS248, DOI 10.1086/422364; MAYAUD P, 2006, ANRS SAT S TOR 15 AU; Nagot N, 2007, NEW ENGL J MED, V356, P790, DOI 10.1056/NEJMoa062607; O'Farrell N, 1999, SEX TRANSM INFECT, V75, P377, DOI 10.1136/sti.75.6.377; O'Farrell N, 2006, SEX TRANSM DIS, V33, P558, DOI 10.1097/01.olq.0000216033.00860.1b; OFARRELL N, 2005, 16 BIENN M INT SOC S; Paz-Bailey G, 2005, CLIN INFECT DIS, V41, P1304, DOI 10.1086/496979; REICHMAN RC, 1984, JAMA-J AM MED ASSOC, V251, P2103, DOI 10.1001/jama.251.16.2103; Reyes M, 2003, ARCH INTERN MED, V163, P76, DOI 10.1001/archinte.163.1.76; Spruance SL, 1996, ARCH INTERN MED, V156, P1729, DOI 10.1001/archinte.156.15.1729; STIGMA, 2019, GUID MAN SEX TRANSM; Trollope-Kumar K, 2006, LANCET, V367, P1380, DOI 10.1016/S0140-6736(06)68593-0; Wald A, 2000, NEW ENGL J MED, V342, P844, DOI 10.1056/NEJM200003233421203; Wald A, 2006, J INFECT DIS, V194, P42, DOI 10.1086/504717; Wald A, 2002, CLIN INFECT DIS, V34, P944, DOI 10.1086/339325; Wald A, 2002, J INFECT DIS, V185, P45, DOI 10.1086/338231; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; White PJ, 1999, SEX TRANSM INFECT, V75, P49, DOI 10.1136/sti.75.1.49; Williams JR, 2007, SEX TRANSM DIS, V34, P123, DOI 10.1097/01.olq.0000258486.81492.a2	29	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC-JAN	2007	370	9605					2164	2166		10.1016/S0140-6736(07)61910-2	http://dx.doi.org/10.1016/S0140-6736(07)61910-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247DY	18156037				2023-01-03	WOS:000252058600038
J	Nelson, EC; Braun, PV				Nelson, Erik C.; Braun, Paul V.			Enhancing colloids through the surface	SCIENCE			English	Editorial Material							PARTICLES; NANOPARTICLES; BIDISPERSE; CRYSTALS		Univ Illinois, Beckman Inst, Dept Mat Sci & Engn, Urbana, IL 61801 USA; Univ Illinois, Frederick Seitz Mat Res Lab, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Nelson, EC (corresponding author), Univ Illinois, Beckman Inst, Dept Mat Sci & Engn, Urbana, IL 61801 USA.	pbraun@uiuc.edu						Biancaniello PL, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.058302; Cho YS, 2005, J AM CHEM SOC, V127, P15968, DOI 10.1021/ja0550632; DeVries GA, 2007, SCIENCE, V315, P358, DOI 10.1126/science.1133162; Dinsmore AD, 2002, SCIENCE, V298, P1006, DOI 10.1126/science.1074868; Glotzer SC, 2007, NAT MATER, V6, P557, DOI 10.1038/nmat1949; Hermanson KD, 2001, SCIENCE, V294, P1082, DOI 10.1126/science.1063821; Hong L, 2006, NANO LETT, V6, P2510, DOI 10.1021/nl061857i; Leunissen ME, 2005, NATURE, V437, P235, DOI 10.1038/nature03946; Maier SA, 2003, NAT MATER, V2, P229, DOI 10.1038/nmat852; Milam VT, 2003, LANGMUIR, V19, P10317, DOI 10.1021/la034376c; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; Piech M, 2006, LANGMUIR, V22, P1379, DOI 10.1021/la051636c; Plunkett KN, 2005, J AM CHEM SOC, V127, P14574, DOI 10.1021/ja054666a; Zhang G, 2005, NANO LETT, V5, P143, DOI 10.1012/nl048121a; Zhang ZL, 2005, LANGMUIR, V21, P11547, DOI 10.1021/la0513611	15	34	35	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 9	2007	318	5852					924	925		10.1126/science.1148009	http://dx.doi.org/10.1126/science.1148009			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	229FM	17991849				2023-01-03	WOS:000250788500027
J	Genton, B; Pluschke, G; Degen, L; Kammer, AR; Westerfeld, N; Okitsu, SL; Schroller, S; Vounatsou, P; Mueller, MM; Tanner, M; Zurbriggen, R				Genton, Blaise; Pluschke, Gerd; Degen, Lukas; Kammer, Andreas R.; Westerfeld, Nicole; Okitsu, Shinji L.; Schroller, Sandro; Vounatsou, Penelope; Mueller, Markus M.; Tanner, Marcel; Zurbriggen, Rinaldo			A Randomized Placebo-Controlled Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Synthetic Peptides in Healthy Adult Volunteers	PLOS ONE			English	Article								Background and Objectives. Influenza virosomes represent an innovative human-compatible antigen delivery system that has already proven its suitability for subunit vaccine design. The aim of the study was to proof the concept that virosomes can also be used to elicit high titers of antibodies against synthetic peptides. The specific objective was to demonstrate the safety and immunogenicity of two virosome-formulated P. falciparum protein derived synthetic peptide antigens given in two different doses alone or in combination. Methodology/Principal Findings. The design was a single blind, randomized, placebo controlled, dose-escalating study involving 46 healthy Caucasian volunteers aged 18-45 years. Five groups of 8 subjects received virosomal formulations containing 10 mu g or 50 mu g of AMA 49-CPE, an apical membrane antigen-1 (AMA-1) derived synthetic phospatidylethanolamine (PE)-peptide conjugate or 10 ug or 50 ug of UK39, a circumsporozoite protein (CSP) derived synthetic PE-peptide conjugate or 50 ug of both antigens each. A control group of 6 subjects received unmodified virosomes. Virosomal formulations of the antigens (designated PEV301 and PEV302 for the AMA-1 and the CSP virosomal vaccine, respectively) or unmodified virosomes were injected i. m. on days 0, 60 and 180. In terms of safety, no serious or severe adverse events (AEs) related to the vaccine were observed. 11/46 study participants reported 16 vaccine related local AEs. Of these 16 events, all being pain, 4 occurred after the 1(st), 7 after the 2(nd) and 5 after the 3(rd) vaccination. 6 systemic AEs probably related to the study vaccine were reported after the 1(st) injection, 10 after the 2(nd) and 6 after the 3(rd). Generally, no difference in the distribution of the systemic AEs between either the doses applied (10 respectively 50 mu g) or the synthetic antigen vaccines (PEV301 and PEV302) used for immunization was found. In terms of immunogenicity, both PEV301 and PEV302 elicited already after two injections a synthetic peptide-specific antibody response in all volunteers immunized with the appropriate dose. In the case of PEV301 the 50 mu g antigen dose was associated with a higher mean antibody titer and seroconversion rate than the 10 mu g dose. In contrast, for PEV302 mean titer and seroconversion rate were higher with the lower dose. Combined delivery of PEV301 and PEV302 did not interfere with the development of an antibody response to either of the two antigens. No relevant antibody responses against the two malaria antigens were observed in the control group receiving unmodified virosomes. Conclusions. The present study demonstrates that three immunizations with the virosomal malaria vaccine components PEV301 or/and PEV302 (containing 10 mu g or 50 mu g of antigen) are safe and well tolerated. At appropriate antigen doses seroconversion rates of 100% were achieved. Two injections may be sufficient for eliciting an appropriate immune response, at least in individuals with pre-existing anti-malarial immunity. These results justify further development of a final multi-stage virosomal vaccine formulation incorporating additional malaria antigens. Trial Registration. ClinicalTrials. gov NCT00400101	[Genton, Blaise; Pluschke, Gerd; Okitsu, Shinji L.; Vounatsou, Penelope; Mueller, Markus M.; Tanner, Marcel] Swiss Trop Inst, CH-4002 Basel, Switzerland; [Degen, Lukas; Schroller, Sandro] Univ Basel Hosp, Clin Res Ctr, CH-4031 Basel, Switzerland; [Kammer, Andreas R.; Westerfeld, Nicole; Zurbriggen, Rinaldo] Pev Biotech Ltd, Bern, Switzerland	University of Basel; Swiss Tropical & Public Health Institute; University of Basel	Genton, B (corresponding author), Swiss Trop Inst, CH-4002 Basel, Switzerland.	blaise.genton@unibas.ch	Degen, Lukas/D-2121-2010	Vounatsou, Penelope/0000-0002-4904-5352	Pevion Biotech	Pevion Biotech	Funding: The clinical trial was funded by Pevion Biotech. Three authors (RZ, ARK, NW) were employees of this company and were involved in study design (RZ), immunology experiments (ARK, NW), paper writing (RZ) and decision to submit (RZ). The first and second authors were not employed by the company, had access to all data and take responsibility for the accuracy of the analyses and the manuscript.	Aguado Teresa, 1999, Vaccine, V17, P2321; Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; Bisang C, 1998, J AM CHEM SOC, V120, P7439, DOI 10.1021/ja980444j; Bovier PA, 2005, VACCINE, V23, P2424, DOI 10.1016/j.vaccine.2004.11.024; Clarke Paul D, 2006, Travel Med Infect Dis, V4, P313, DOI 10.1016/j.tmaid.2006.01.001; Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342; Ghasparian A, 2006, CHEM COMMUN, P174, DOI 10.1039/b510812h; Good MF, 2005, TRENDS PARASITOL, V21, P29, DOI 10.1016/j.pt.2004.10.006; Kashala O, 2002, VACCINE, V20, P2263, DOI 10.1016/S0264-410X(02)00115-9; Kato K, 2005, P NATL ACAD SCI USA, V102, P5552, DOI 10.1073/pnas.0501594102; Luke TC, 2003, J EXP BIOL, V206, P3803, DOI 10.1242/jeb.00644; MAYORGA PO, 2003, J INFECT DIS, V188, P671; Moreno R, 2001, CHEMBIOCHEM, V2, P838, DOI 10.1002/1439-7633(20011105)2:11<838::AID-CBIC838>3.0.CO;2-4; Mueller MS, 2003, INFECT IMMUN, V71, P4749, DOI 10.1128/IAI.71.8.4749-4758.2003; OKITSU SL, 2007, CHEM BIOL IN PRESS; Pancharoen C, 2005, CLIN INFECT DIS, V41, P1537, DOI 10.1086/497266; Pfeiffer B, 2003, ANGEW CHEM INT EDIT, V42, P2368, DOI 10.1002/anie.200250348; Pfeiffer B, 2001, CHIMIA, V55, P334; Pink J Richard, 2004, Vaccine, V22, P2097, DOI 10.1016/j.vaccine.2004.01.021; Poltl-Frank F, 1999, CLIN EXP IMMUNOL, V117, P496; Zurbriggen R, 2003, VACCINE, V21, P921, DOI 10.1016/S0264-410X(02)00541-8	21	45	47	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2007	2	10							e1018	10.1371/journal.pone.0001018	http://dx.doi.org/10.1371/journal.pone.0001018			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HV	17925866	gold, Green Published			2023-01-03	WOS:000207456000017
J	Muller, K; Faeh, C; Diederich, F				Mueller, Klaus; Faeh, Christoph; Diederich, Francois			Fluorine in pharmaceuticals: Looking beyond intuition	SCIENCE			English	Review							THROMBIN ACTIVE-SITE; C-F; MEDICINAL CHEMISTRY; MULTIPOLAR INTERACTIONS; ORGANIC FLUORINE; INHIBITORS; DRUG; DISCOVERY; AFFINITY; POTENT	Fluorine substituents have become a widespread and important drug component, their introduction facilitated by the development of safe and selective fluorinating agents. Organofluorine affects nearly all physical and adsorption, distribution, metabolism, and excretion properties of a lead compound. Its inductive effects are relatively well understood, enhancing bioavailability, for example, by reducing the basicity of neighboring amines. In contrast, exploration of the specific influence of carbon-fluorine single bonds on docking interactions, whether through direct contact with the protein or through stereoelectronic effects on molecular conformation of the drug, has only recently begun. Here, we review experimental progress in this vein and add complementary analysis based on comprehensive searches in the Cambridge Structural Database and the Protein Data Bank.	F Hoffmann La Roche, Div Pharmaceut, Discovery Chem, CH-4070 Basel, Switzerland; ETH, Organ Chem Lab, CH-8093 Zurich, Switzerland	Roche Holding; Swiss Federal Institutes of Technology Domain; ETH Zurich	Muller, K (corresponding author), F Hoffmann La Roche, Div Pharmaceut, Discovery Chem, CH-4070 Basel, Switzerland.	klaus.mueller@roche.com; diederich@org.chem.ethz.ch						Alberati D, 2006, BIOORG MED CHEM LETT, V16, P4311, DOI 10.1016/j.bmcl.2006.05.058; Avdeef Alex, 2001, Current Topics in Medicinal Chemistry, V1, P277, DOI 10.2174/1568026013395100; Begue JP, 2006, J FLUORINE CHEM, V127, P992, DOI 10.1016/j.jfluchem.2006.05.006; Biffinger JC, 2004, CHEMBIOCHEM, V5, P622, DOI 10.1002/cbic.200300910; Black WC, 2005, BIOORG MED CHEM LETT, V15, P4741, DOI 10.1016/j.bmcl.2005.07.071; Bohm HJ, 2004, CHEMBIOCHEM, V5, P637, DOI 10.1002/cbic.200301023; *CAMBR CRYST DAT C, 2007, CSD VERS 5 28; *CAMBR CRYST DAT C, 2005, PDB SEARCH PERF US W; *DAYL CHEM INF SYS, MEDCHEM DAT VERS 06; DELANO WL, 2006, MACPYMOL V0 99; Dolbier WR, 2005, J FLUORINE CHEM, V126, P157, DOI 10.1016/j.jfluchem.2004.09.033; Drlica K, 2003, CURR TOP MED CHEM, V3, P249, DOI 10.2174/1568026033452537; Dunitz JD, 2006, CHEM-EUR J, V12, P6804, DOI 10.1002/chem.200600092; Dunitz JD, 1997, CHEM-EUR J, V3, P89, DOI 10.1002/chem.19970030115; Fermini B, 2003, NAT REV DRUG DISCOV, V2, P439, DOI 10.1038/nrd1108; Fischer H, 2000, CHIMIA, V54, P640; Harper DB, 2003, HANDB ENVIRON CHEM, V3, P141; Hayashi H, 2002, CHEM COMMUN, P1618, DOI 10.1039/b204471d; HernandezTrujillo J, 1996, J PHYS CHEM-US, V100, P6524, DOI 10.1021/jp953576x; Hof F, 2004, ANGEW CHEM INT EDIT, V43, P5056, DOI 10.1002/anie.200460781; Hoffmann-Roder A, 2006, CHEMMEDCHEM, V1, P1205, DOI 10.1002/cmdc.200600124; Isanbor C, 2006, J FLUORINE CHEM, V127, P303, DOI 10.1016/j.jfluchem.2006.01.011; Jamieson C, 2006, J MED CHEM, V49, P5029, DOI 10.1021/jm060379l; Jensen HH, 2002, CHEM-EUR J, V8, P1218, DOI 10.1002/1521-3765(20020301)8:5<1218::AID-CHEM1218>3.0.CO;2-X; Joubert J, 2003, ANGEW CHEM INT EDIT, V42, P3133, DOI 10.1002/anie.200351301; Kim CY, 2001, J AM CHEM SOC, V123, P9620, DOI 10.1021/ja011034p; Kim CY, 2000, J AM CHEM SOC, V122, P12125, DOI 10.1021/ja002627n; Kirk KL, 2006, J FLUORINE CHEM, V127, P1013, DOI 10.1016/j.jfluchem.2006.06.007; Kirsch P., 2013, MODERN FLUOROORGANIC; Krishnamurthy VM, 2007, CHEM-ASIAN J, V2, P94, DOI 10.1002/asia.200600360; Lal GS, 1999, J ORG CHEM, V64, P7048, DOI 10.1021/jo990566+; Leroux F, 2005, CHEM REV, V105, P827, DOI 10.1021/cr040075b; Leroux F, 2004, CHEMBIOCHEM, V5, P644, DOI 10.1002/cbic.200300906; Ma JA, 2004, CHEM REV, V104, P6119, DOI 10.1021/cr030143e; MAREN TH, 1993, J BIOL CHEM, V268, P26233; Martino R, 2006, CHEMOTHERAPY, V52, P215, DOI 10.1159/000094744; MATSUMOTO J, 1984, J MED CHEM, V27, P292, DOI 10.1021/jm00369a011; Matsushima A, 2000, J BIOCHEM-TOKYO, V128, P225, DOI 10.1093/oxfordjournals.jbchem.a022745; Meyer EA, 2003, ANGEW CHEM INT EDIT, V42, P1210, DOI 10.1002/anie.200390319; MIDDLETON WJ, 1975, J ORG CHEM, V40, P574, DOI 10.1021/jo00893a007; Morgenthaler M, 2007, CHEMMEDCHEM, V2, P1100, DOI 10.1002/cmdc.200700059; Obst U, 1997, CHEM BIOL, V4, P287, DOI 10.1016/S1074-5521(97)90072-7; Olsen J, 2004, ORG BIOMOL CHEM, V2, P1339, DOI 10.1039/b402515f; Olsen JA, 2003, ANGEW CHEM INT EDIT, V42, P2507, DOI 10.1002/anie.200351268; Olsen JA, 2004, CHEMBIOCHEM, V5, P666, DOI 10.1002/cbic.200300907; Park BK, 2001, ANNU REV PHARMACOL, V41, P443, DOI 10.1146/annurev.pharmtox.41.1.443; Patani GA, 1996, CHEM REV, V96, P3147, DOI 10.1021/cr950066q; Paulini R, 2005, ANGEW CHEM INT EDIT, V44, P1788, DOI 10.1002/anie.200462213; Perrin D. D., 1981, PKA PREDICTION ORGAN, V1; Roth BD, 2002, PROGR MED CHEM, V40, P1, DOI 10.1016/S0079-6468(08)70080-8; ROTH BD, 1990, J MED CHEM, V33, P21, DOI 10.1021/jm00163a005; Rowley M, 2001, J MED CHEM, V44, P1603, DOI 10.1021/jm0004998; Schlosser M, 2006, ANGEW CHEM INT EDIT, V45, P5432, DOI 10.1002/anie.200600449; Schweizer E, 2006, CHEMMEDCHEM, V1, P611, DOI 10.1002/cmdc.200600015; Schweizer E, 2006, ORG BIOMOL CHEM, V4, P2364, DOI 10.1039/b602585d; Smart B. E., 1994, ORGANOFLUORINE CHEM, P57, DOI DOI 10.1007/978-1-4899-1202-2_3; Smart BE, 2001, J FLUORINE CHEM, V109, P3, DOI 10.1016/S0022-1139(01)00375-X; Snyder JP, 2000, J AM CHEM SOC, V122, P544, DOI 10.1021/ja9934504; Sun AM, 2005, CHEM-EUR J, V11, P1579, DOI 10.1002/chem.200400835; van Niel MB, 1999, J MED CHEM, V42, P2087, DOI 10.1021/jm981133m; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; Wollin L, 2006, PULM PHARMACOL THER, V19, P343, DOI 10.1016/j.pupt.2005.09.002; WONG DT, 1995, LIFE SCI, V57, P411, DOI 10.1016/0024-3205(95)00209-O; Zhao K, 2003, BIOORGAN MED CHEM, V11, P207, DOI 10.1016/S0968-0896(02)00384-X; 2006, INTEGRITY PROUS SCI	65	4665	4710	25	901	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 28	2007	317	5846					1881	1886		10.1126/science.1131943	http://dx.doi.org/10.1126/science.1131943			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214US	17901324				2023-01-03	WOS:000249764300028
J	Foster, NE; Thomas, E; Barlas, P; Hil, JC; Young, J; Mason, E; Hay, EM				Foster, Nadine E.; Thomas, Elaine; Barlas, Panos; Hil, Jonathan C.; Young, Julie; Mason, Elizabeth; Hay, Elaine M.			Acupuncture as an adjunct to exercise based physiotherapy for osteoarthritis of the knee: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; PLACEBO NEEDLE; HOME EXERCISE; OLDER-ADULTS; PAIN; THERAPY; RECOMMENDATIONS; HIP; PREVALENCE; MANAGEMENT	Objective To investigate the benefit of adding acupuncture to a course of advice and exercise delivered by physiotherapists for pain reduction in patients with osteoarthritis of the knee. Design Multicentre, randomised controlled trial. Setting 37 physiotherapy centres accepting primary care patients referred from general practitioners in the Midlands, United Kingdom. Participants 352 adults aged 50 or more with a clinical diagnosis of knee osteoarthritis. Interventions Advice and exercise (n=116), advice and exercise plus true acupuncture (n=117), and advice and exercise plus non-penetrating acupuncture (n=119). Main outcome measures The primary outcome was change in scores on the Western Ontario and McMaster Universities osteoarthritis index pain subscale at six months. Secondary outcomes included function, pain intensity, and unpleasantness of pain at two weeks, six weeks, six months, and 12 months. Results Follow-up rate at six months was 94%. The mean (SD) baseline pain score was 9.2 (3.8). At six months mean reductions in pain were 2.28 (3.8) for advice and exercise, 2.32 (1 for advice and exercise plus true acupuncture, and 2.53 (4.2) for advice and exercise plus non-penetrating acupuncture. Mean differences in change scores between advice and exercise alone and each acupuncture group were 0.08 (95% confidence interval -1.0 to 0.9) for advice and exercise plus true acupuncture and 0.25 (-0.8 to 1.3) for advice and exercise plus non-penetrating acupuncture. Similar nonsignificant differences were seen at other follow-up points. Compared with advice and exercise atone there were small, statistically significant improvements in pain intensity and unpleasantness at two and six weeks for true acupuncture and at all follow-up points for non-penetrating acupuncture. Conclusion The addition of acupuncture to a course of advice and exercise for osteoarthritis of the knee delivered by physiotherapists provided no additional improvement in pain scores. Small benefits in pain intensity and unpleasantness were observed in both acupuncture groups, making it unlikely that this was due to acupuncture needling effects.	Univ Keele, Primary Care Musculoskeletal Res Ctr, Keele ST5 5BG, Staffs, England; Univ Keele, Sch Hlth & Rehabil, Keele ST5 5BG, Staffs, England	Keele University; Keele University	Foster, NE (corresponding author), Univ Keele, Primary Care Musculoskeletal Res Ctr, Keele ST5 5BG, Staffs, England.	n.foster@keele.ac.uk	Barlas, Panos/AAF-9892-2021	Barlas, Panos/0000-0002-4734-4236; Foster, Nadine/0000-0003-4429-9756	National Institute for Health Research [PC6/CSA04/03] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		*ARTHR CAR, 2004, OST NAT COMPR UK REP; Bausell RB, 2005, EVAL HEALTH PROF, V28, P9, DOI 10.1177/0163278704273081; Bellamy N, 1996, WOMAC OSTEOARTHRITIS; Berman BM, 1999, RHEUMATOLOGY, V38, P346, DOI 10.1093/rheumatology/38.4.346; Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Campbell Anthony, 2006, Acupunct Med, V24, P118; Cibere J, 2005, ARTHRITIS RHEUM-US, V52, pS509; Derry CJ, 2006, CLIN MED, V6, P381, DOI 10.7861/clinmedicine.6-4-381; Duncan RC, 2006, RHEUMATOLOGY, V45, P757, DOI 10.1093/rheumatology/kei270; Ezzo J, 2001, ARTHRITIS RHEUM, V44, P819, DOI 10.1002/1529-0131(200104)44:4<819::AID-ANR138>3.0.CO;2-P; FOSTER NE, 1999, P CHART SOC PHYS C O, P27; FOSTER NE, 2000, RHEUMATOLOGY S1, V39, P166; Hay E, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471-2474-5-31; Hay EM, 2006, BRIT MED J, V333, P995, DOI 10.1136/BMJ.38977.590752.0B; House of Lords' Science and Technology Committee, 2000, 6 HOUS LORDS SCI TEC; Jinks C, 2002, PAIN, V100, P55, DOI 10.1016/S0304-3959(02)00239-7; Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742; Kleinhenz J, 1999, PAIN, V83, P235, DOI 10.1016/S0304-3959(99)00107-4; Lund Irene, 2006, Acupunct Med, V24, P13; NORMAN GR, 1994, BIOSTATISTICS BARE E, P160; O'Reilly SC, 1999, ANN RHEUM DIS, V58, P15, DOI 10.1136/ard.58.1.15; *OFF NAT STAT, 2000, STAND OCC CLASS 2000, V2, P4; *OFF NAT STAT, 2002, NAT STAT SOC CLASS U, P4; Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016; Peat G, 2001, ANN RHEUM DIS, V60, P91, DOI 10.1136/ard.60.2.91; Pham T, 2003, J RHEUMATOL, V30, P1648; Pham T, 2004, OSTEOARTHR CARTILAGE, V12, P389, DOI 10.1016/j.joca.2004.02.001; Pound P, 2005, SOC SCI MED, V61, P133, DOI 10.1016/j.socscimed.2004.11.063; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Roddy E, 2005, RHEUMATOLOGY, V44, P67, DOI 10.1093/rheumatology/keh399; Scharf HP, 2006, ANN INTERN MED, V145, P12, DOI 10.7326/0003-4819-145-1-200607040-00005; Smidt N, 2005, AUST J PHYSIOTHER, V51, P71, DOI 10.1016/S0004-9514(05)70036-2; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; Thomas KJ, 2001, BRIT J GEN PRACT, V51, P25; Thomas KS, 2005, ARTHRIT RHEUM-ARTHR, V53, P388, DOI 10.1002/art.21173; Van Baar ME, 1999, ARTHRITIS RHEUM-US, V42, P1361, DOI 10.1002/1529-0131(199907)42:7<1361::AID-ANR9>3.0.CO;2-9; Vas J, 2004, BMJ-BRIT MED J, V329, P1216, DOI 10.1136/bmj.38238.601447.3A; Vickers A, 2000, BRIT MED J, V321, P683, DOI 10.1136/bmj.321.7262.683; VINCENT C, 1995, J ROY SOC MED, V88, P199; White A, 2007, RHEUMATOLOGY, V46, P384, DOI 10.1093/rheumatology/kel413; White AR, 2001, COMPLEMENT THER MED, V9, P237, DOI 10.1054/ctim.2001.0489; Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7; Witt CM, 2006, ARTHRITIS RHEUM-US, V54, P3485, DOI 10.1002/art.22154	44	125	137	2	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 1	2007	335	7617					436	440B		10.1136/bmj.39280.509803.BE	http://dx.doi.org/10.1136/bmj.39280.509803.BE			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208VF	17699546	Green Published, Green Accepted, Green Submitted, Bronze			2023-01-03	WOS:000249346600033
J	Montini, G; Toffolo, A; Zucchetta, P; Dall'Amico, R; Gobber, D; Calderan, A; Maschio, F; Pavanello, L; Molinari, PP; Scorrano, D; Zanchetta, S; Cassar, W; Brisotto, P; Corsini, A; Sartori, S; Da Dalt, L; Murer, L; Zacchello, G				Montini, Giovanni; Toffolo, Antonella; Zucchetta, Pietro; Dall'Amico, Roberto; Gobber, Daniela; Calderan, Alessandro; Maschio, Francesca; Pavanello, Luigi; Molinari, Pier Paolo; Scorrano, Dante; Zanchetta, Sergio; Cassar, Walburga; Brisotto, Paolo; Corsini, Andrea; Sartori, Stefano; Da Dalt, Liviana; Murer, Luisa; Zacchello, Graziella			Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							URINARY-TRACT-INFECTIONS; ATRIAL-FIBRILLATION; GENERAL-PRACTICE; PREVALENCE; MANAGEMENT	Objective To compare the efficacy of oral antibiotic treatment alone with treatment started parenterally and completed orally in children with a first episode of acute pyelonephritis. Design Multicentre, randomised controlled, open labelled, parallel group, non-inferiority trial. Setting 28 paediatric units in north east Italy. Participants 502 children aged 1 month to <7 years with clinical pyelonephritis. Intervention Oral co-amoxiclav (50 mg/kg/day in three doses for 10 days) or parenteral ceftriaxone (50 mg/kg/ day in a single parenteral dose) for three days, followed by oral co-amoxiclav (50 mg/kg/day in three divided doses for seven days). Main outcomes measures Primary outcome was the rate of renal scarring. Secondary measures of efficacy were time to defervescence ((37 C), reduction in inflammatory indices, and percentage with sterile urine after 72 hours. An exploratory subgroup analysis was conducted in the children in whom pyelonephritis was confirmed by dimercaptosuccinic acid (DMSA) scintigraphy within 10 days after study entry. Results Intention to treat analysis showed no significant differences between oral (n=244) and parenteral (n=258) treatment, both in the primary outcome (scarring scintigraphy at 12 months 27/197 (13.7%) v 36/203 (17.7%), difference in risk-4%, 95% confidence interval -11.1% to 3.1%) and secondary outcomes (time to defervescence 36.9 hours (SD 19.7) v34.3 hours (SD 20), mean difference 2.6 (-0.9 to 6.0); white cell count 9.8x10(9)/I (SD 3.5) v 9.5X10(9)/l(SD 3.1), mean difference 0.3 (-0.3 to 0.9); percentage with sterile urine 185/186 v 203/204, risk difference -0.05% (-1.5% to 1.4%)). Similar results were found in the subgroup of 278 children with confirmed acute pyelonephritis on scintigraphy at study entry. Conclusions Treatment with oral antibiotics is as effective as parenteral then oral treatment in the management of the first episode of clinical pyelonephritis in children.	Univ Padua, Azienda Osped, Dept Paediat, Nephrol Dialysis & Transplant Unit, I-35128 Padua, Italy; Univ Padua, Azienda Osped, Dept Nucl Med, I-35128 Padua, Italy; Univ Padua, Azienda Osped, Epidemiol Unit, I-35128 Padua, Italy; Bologna Hosp, Paediat Unit, Bologna, Italy; Belluno Hosp, Paediat Unit, Belluno, Italy; Soave Hosp, Paediat Unit, Verona, Italy; Bolzano Hosp, Paediat Unit, Bolzano, Italy; Montebelluna Hosp, Paediat Unit, Montebelluna, Italy; Paediat Unit, Bentivoglio, Italy; Univ Padua, Azienda Osped, Dept Paediat, Emergency Unit, I-35128 Padua, Italy	University of Padua; Azienda Ospedaliera - Universita di Padova; University of Padua; Azienda Ospedaliera - Universita di Padova; University of Padua; Azienda Ospedaliera - Universita di Padova; ULSS 1 Dolomiti; Ospedale di Belluno; Krankenhaus Bozen; ULSS 2 Marca TV; Ospedale Montebelluna; University of Padua; Azienda Ospedaliera - Universita di Padova	Montini, G (corresponding author), Univ Padua, Azienda Osped, Dept Paediat, Nephrol Dialysis & Transplant Unit, I-35128 Padua, Italy.	montini@pediatria.unipd.it	Montini, Giovanni/AAC-6612-2022; Sartori, Stefano/K-9498-2016; Zucchetta, Pietro/I-7102-2012; Murer, Luisa LM/I-8830-2018	Montini, Giovanni/0000-0002-7350-4475; Sartori, Stefano/0000-0002-0012-6848; Murer, Luisa LM/0000-0002-3010-2337				[Anonymous], 1991, J R Coll Physicians Lond, V25, P36; Benador D, 2001, ARCH DIS CHILD, V84, P241, DOI 10.1136/adc.84.3.241; Bloomfield P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003772.pub2; Craig JC, 2004, BMJ-BRIT MED J, V328, P179, DOI 10.1136/bmj.328.7433.179; D'Agostino RB, 2003, STAT MED, V22, P169, DOI 10.1002/sim.1425; Davis RC, 2002, BRIT MED J, V325, P1156, DOI 10.1136/bmj.325.7373.1156; DORLANDS, 2003, ILLUSTRATED MED DICT; Downs SH, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.4.e54; Ghiro L, 2002, NEPHRON, V90, P8, DOI 10.1159/000046308; Hoberman A, 1999, PEDIATRICS, V104, P79, DOI 10.1542/peds.104.1.79; Jahnukainen T, 2005, PEDIATR NEPHROL, V20, P1043, DOI 10.1007/s00467-005-1898-5; JAKOBSSON B, 1994, ARCH DIS CHILD, V70, P111, DOI 10.1136/adc.70.2.111; Jungner Gunnar, 1968, PRINCIPLES PRACTICE, P34; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lip GYH, 1997, BRIT J GEN PRACT, V47, P285; Majeed A, 2001, HEART, V86, P284, DOI 10.1136/heart.86.3.284; Marjoram J, 1996, BRIT J GEN PRACT, V46, P283; Morgan S, 2002, BRIT J GEN PRACT, V52, P373; NATHAN DG, 1998, PEDIAT HEMATOLOGY; Onyeka B A, 2003, J Obstet Gynaecol, V23, P174; RUSHTON HG, 1992, J UROLOGY, V147, P1327, DOI 10.1016/S0022-5347(17)37555-9; SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259; Somerville S, 2000, BRIT J GEN PRACT, V50, P727; Stewart S, 2001, HEART, V86, P516, DOI 10.1136/heart.86.5.516; Stokland E, 1996, J PEDIATR-US, V129, P815, DOI 10.1016/S0022-3476(96)70024-0; Sudlow M, 1998, BRIT MED J, V317, P327, DOI 10.1136/bmj.317.7154.327; TOLKOFFRUBIN NE, 2000, KIDNEY, P1449; Wald E, 2004, CURR OPIN PEDIATR, V16, P85, DOI 10.1097/00008480-200402000-00016; Wheeldon NM, 1998, HEART, V79, P50, DOI 10.1136/hrt.79.1.50; WINBERG J, 1974, Acta Paediatrica Scandinavica Supplement, P1; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; Zaki M, 2005, PEDIATR NEPHROL, V20, P1116, DOI 10.1007/s00467-005-1880-2	32	109	115	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 25	2007	335	7616					386	388A		10.1136/bmj.39244.692442.55	http://dx.doi.org/10.1136/bmj.39244.692442.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206VC	17611232	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000249210000028
J	Eavri, R; Lorberboum-Galski, H				Eavri, Ronen; Lorberboum-Galski, Haya			A novel approach for enzyme replacement therapy - The use of phenylalanine hydroxylase-based fusion proteins for the treatment of phenylketonuria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMMONIA-LYASE; TRANSDUCTION; ANTAGONIST; CELLS; PKU; MOTILITY; DELIVERY; DISEASE; CANCER; MOUSE	Metabolic diseases arise from mutations in key enzymes of major metabolic pathways. One promising approach for the treatment of such diseases is based on the administration of a wild-type enzyme to substitute the activity of the impaired enzyme by the use of enzyme replacement therapy, yet it is important to deliver this enzyme to the specific deficient tissue. We suggest a new concept for the treatment of metabolic diseases using fusion proteins. We examined the feasibility of this concept in the well characterized metabolic disease, phenylketonuria (PKU), which results from a mutation in the liver enzyme phenylalanine hydroxylase (PAH). PAH is a key enzyme in the metabolic pathway of phenylalanine. Deficiency in PAH leads to high and persistent levels of this amino acid in the plasma of PKU patients, causing permanent neurological damage. Currently a low protein diet is still considered the only effective treatment for most PKU patients. To restore PAH activity in the liver of PKU patients, we constructed PAH-based fusion proteins with delivery moieties based on the HIV-transactivator of transcription peptide, and fragments of human hepatocyte growth factor aiming to specifically target PAH to the liver. We show that these new fusion proteins can be delivered into a variety of human liver cell lines and retain PAH activity after being internalized. We also show that plasma phenylalanine levels were dramatically lowered in mice treated with PAH-based fusion proteins after intravenous administration. We therefore suggest an alternative concept for the treatment of PKU using targeted fusion proteins, which may also be applied to the treatment of other metabolic diseases.	Hebrew Univ Jerusalem, Fac Med, Dept Cellular Biochem & Human Genet, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Lorberboum-Galski, H (corresponding author), Hebrew Univ Jerusalem, Fac Med, Dept Cellular Biochem & Human Genet, IL-91120 Jerusalem, Israel.	hayalg@md.huji.ac.il	Lorberboum-Galski, Haya/K-8839-2019					ATHERTON ND, 1988, CLIN CHEM, V34, P2241; BERRY MN, 1991, ISOLATED HEPATOCYTES, P14; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Cai SR, 2006, EUR J PHARM SCI, V27, P311, DOI 10.1016/j.ejps.2005.10.011; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Chen L, 2005, P NATL ACAD SCI USA, V102, P15581, DOI 10.1073/pnas.0503877102; Ding Z, 2006, GENE THER, V13, P587, DOI 10.1038/sj.gt.3302684; Foss F, 2006, SEMIN ONCOL, V33, pS11, DOI 10.1053/j.seminoncol.2005.12.017; Gamez A, 2004, MOL THER, V9, P124, DOI 10.1016/j.ymthe.2003.11.002; Grabowski GA, 2005, CURR OPIN PEDIATR, V17, P519, DOI 10.1097/01.mop.0000172702.33128.19; Hufton SE, 1998, BBA-PROTEIN STRUCT M, V1382, P295, DOI 10.1016/S0167-4838(97)00171-4; Kaufman S, 1999, P NATL ACAD SCI USA, V96, P3160, DOI 10.1073/pnas.96.6.3160; Levy HL, 1999, P NATL ACAD SCI USA, V96, P1811, DOI 10.1073/pnas.96.5.1811; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; Nechushtan A, 1997, J BIOL CHEM, V272, P11597; Parr C, 2000, INT J CANCER, V85, P563, DOI 10.1002/(SICI)1097-0215(20000215)85:4<563::AID-IJC19>3.3.CO;2-4; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; Sarkissian CN, 2005, MOL GENET METAB, V86, pS22, DOI 10.1016/j.ymgme.2005.06.016; Sarkissian CN, 1999, P NATL ACAD SCI USA, V96, P2339, DOI 10.1073/pnas.96.5.2339; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SCRIVER CR, 1995, CLIN BIOCHEM, V28, P137, DOI 10.1016/0009-9120(94)00076-8; SHIMAN R, 1980, J BIOL CHEM, V255, P4793; Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005; Wang L, 2005, MOL GENET METAB, V86, P134, DOI 10.1016/j.ymgme.2005.05.012	24	26	27	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23402	23409		10.1074/jbc.M703367200	http://dx.doi.org/10.1074/jbc.M703367200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17565982	hybrid			2023-01-03	WOS:000248577500040
J	Vickers, MR; MacLennan, AH; Lawton, B; Ford, D; Martin, J; Meredith, SK; DeStavola, BL; Rose, S; Dowell, A; Wikes, HC; Darbyshire, JH; Meade, TW				Vickers, Madge R.; MacLennan, Alastair H.; Lawton, Beverley; Ford, Deborah; Martin, Jeannett; Meredith, Sarah K.; DeStavola, Bianca L.; Rose, Sally; Dowell, Anthony; Wikes, Helen C.; Darbyshire, Janet H.; Meade, Tom W.		WISDOM Team	Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; PLUS PROGESTIN; BREAST-CANCER; YOUNGER; OLDER; RISK; HRT	Objective To assess the long term risks and benefits of hormone replacement therapy (combined hormone therapy versus placebo, and oestrogen alone versus combined hormone therapy). Design Multicentre, randomised, placebo controlled, double blind trial. Setting General practices in UK (384), Australia (91), and New Zealand (24). Participants Postmenopausal women aged 50-69 years at randomisation. At early closure of the trial, 56 583 had been screened, 8980 entered run-in, and 5692 (26% of target of 22 300) started treatment. Interventions Oestrogen only therapy (conjugated equine oestrogens 0.625 ring orally daily) or combined hormone therapy (conjugated equine oestrogens plus medroxyprogesterone acetate 2.5/5-0 ring orally daily). Ten years of treatment planned. Main outcome measures Primary outcomes: major cardiovascular disease, osteoporotic fractures, and breast cancer. Secondary outcomes: other cancers, death from all causes, venous thromboembolism, cerebrovascular disease, dementia, and quality of life. Results The trial was prematurely closed during recruitment, after a median follow-up of 11.9 months (interquartile range 7.1-19.6, total 6498 women years) in those enrolled, after the publication of early results from the women's health initiative study. The mean age of randomised women was 62.8 (SID 4.8) years. When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)). There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)). Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences. Conclusions Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause. The results are consistent with the findings of the women's health initiative study and secondary prevention studies. Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.	Univ Adelaide, Womens & Childrens Hosp, Adelaide, SA 5006, Australia; MRC Gen Practice Res, London NW1 2ND, England; Wellington Sch Med & Hlth Sci, Dept Primary Hlth Care & Gen Practice, Wellington, New Zealand; MRC Clin Trials Unit, London NW1 2DA, England; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England	University of Adelaide; Womens & Childrens Hospital Australia; University of Otago; Medical Research Council Clinical Trials Unit; University of London; London School of Hygiene & Tropical Medicine	MacLennan, AH (corresponding author), Univ Adelaide, Womens & Childrens Hosp, Adelaide, SA 5006, Australia.	alastair.maclennan@adelaide.edu.au	Golmohamad, Ramez/E-4848-2014	Golmohamad, Ramez/0000-0002-9958-7037; Lawton, Beverley/0000-0003-2447-8386	Medical Research Council [MC_U122797165] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Bajekal M, HLTH SURVEY ENGLAND; Cherry N, 2002, LANCET, V360, P2001; Clarke SC, 2002, BJOG-INT J OBSTET GY, V109, P1056, DOI 10.1111/j.1471-0528.2002.01544.x; Clarkson TB, 2005, MATURITAS, V51, P64, DOI 10.1016/j.maturitas.2005.02.016; Collett D., 1994, MODELLING SURVIVAL D; Cushman M, 2004, JAMA-J AM MED ASSOC, V292, P1573, DOI 10.1001/jama.292.13.1573; Grodstein F, 2006, J WOMENS HEALTH, V15, P35, DOI 10.1089/jwh.2006.15.35; Hoibraaten E, 2000, THROMB HAEMOSTASIS, V84, P961; Holmberg L, 2004, LANCET, V363, P453, DOI 10.1016/S0140-6736(04)15493-7; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Lawton B, 2003, BRIT MED J, V327, P845, DOI 10.1136/bmj.327.7419.845; MacLennan A, 2002, CLIMACTERIC, V5, P313, DOI 10.1080/713605308; Maclennan A H, 2004, Cochrane Database Syst Rev, pCD002978, DOI 10.1002/14651858.CD002978.pub2; MacLennan AH, 2006, MENOPAUSE, V13, P28, DOI 10.1097/01.gme.0000191204.38664.61; MacLennan AH, 2004, CLIMACTERIC, V7, P138, DOI 10.1080/13697130410001713733; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Manson JE, 2007, NEW ENGL J MED, V356, P2591, DOI 10.1056/NEJMoa071513; MOEHRER B, 2003, COCHRANE DB SYST REV; Phillips LS, 2005, FERTIL STERIL, V83, P558, DOI 10.1016/j.fertnstert.2004.11.012; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Salpeter S, 2005, CLIMACTERIC, V8, P307, DOI 10.1080/13697130500345505; Salpeter SR, 2006, J GEN INTERN MED, V21, P363, DOI 10.1111/j.1525-1497.2006.00389.x; Salpeter SR, 2004, J GEN INTERN MED, V19, P791, DOI 10.1111/j.1525-1497.2004.30281.x; Stefanick ML, 2006, JAMA-J AM MED ASSOC, V295, P1647, DOI 10.1001/jama.295.14.1647; SUCKLING I, 2003, COCHRANE DB SYST REV; Tanko LB, 2006, CLIMACTERIC, V9, P169, DOI 10.1080/13697130600738765; VEENUS P, 2006, MATURITIAS, V55, P162; Vickers M, 2002, CLIMACTERIC, V5, P317, DOI 10.1080/713605309; VICKERS M, 1996, J BR MENOPAUSE SOC, V1, P9; Vickers Madge R, 2007, BMC Womens Health, V7, P2, DOI 10.1186/1472-6874-7-2; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432	33	166	170	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 4	2007	335	7613					239	+		10.1136/bmj.39266.425069.AD	http://dx.doi.org/10.1136/bmj.39266.425069.AD			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	201QC	17626056	Green Submitted, Green Published, Bronze, Green Accepted			2023-01-03	WOS:000248846700027
J	Fabre, C; Carvalho, G; Tasdemir, E; Braun, T; Ades, L; Grosjean, J; Boehrer, S; Metivier, D; Souquere, S; Pierron, G; Fenaux, P; Kroemer, G				Fabre, C.; Carvalho, G.; Tasdemir, E.; Braun, T.; Ades, L.; Grosjean, J.; Boehrer, S.; Metivier, D.; Souquere, S.; Pierron, G.; Fenaux, P.; Kroemer, G.			NF-kappa B inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia	ONCOGENE			English	Article						apoptosis; autophagy; caspases; chemotherapy; mitochondria	THERAPEUTIC TARGET; APOPTOSIS; AUTOPHAGY; CANCER; PATHWAY; LINE	CD34(+) bone marrow blasts from high-risk myelodysplastic syndrome (MDS) patients as well as MDS patient-derived cell lines (P39 and MOLM13) constitutively activate the nuclear factor-kappa B (NF-kappa B) pathway and undergo apoptosis when NF-kappa B is inhibited. Here, we show that the combination of conventional chemotherapeutic agents (daunorubicin, mitoxantrone, 5-azacytidine or camptothecin) with the NF-kappa B inhibitor BAY11-7082 did not yield a synergistic cytotoxicity. In contrast, BAY11-7082 (which targets the NF-kappa B-activating I-kappa B kinase (IKK) complex) or knockdown of essential components of the NF-kappa B system (such as the IKK1 and IKK2 subunits of the IKK complex and the p65 subunit of NF-kappa B), by small interfering RNAs sensitized MDS cell lines to starvation-induced apoptosis. The combination of BAY11-7082 and nutrient depletion synergistically killed the acute myeloid leukemia (AML) cell line U937 as well as primary CD34+ bone marrow blasts from AML and high-risk MDS patients. The synergistic killing by BAY11-7082, combined with nutrient depletion, led to cell death accompanied by all hallmarks of apoptosis, including an early loss of the mitochondrial transmembrane potential, the release of cytochrome c and apoptosis-inducing factor (AIF) from mitochondria, activation of caspase-3, phosphatidylserine exposure on the plasma membrane surface and nuclear chromatin condensation. Transmission electron microscopy revealed the presence of numerous autophagic vacuoles in the cytoplasm before cells underwent nuclear apoptosis. Nonetheless, cell death was neither inhibited by the pan-caspase inhibitor z-VAD-fmk nor by knockdown of AIF or of essential components of the autophagy pathway (ATG5, ATG6/ Beclin-1, ATG10, ATG12). In contrast, external supply of glucose, insulin or insulin-like growth factor-I could retard the cell death induced by BAY11-7082 combined with starvation. These results suggest that in MDS cells, NF-kappa B inhibition can precipitate a bioenergetic crisis that leads to an autophagic stress response followed by apoptotic cell death.	Inst Gustave Roussy, CNRS, FRE 2939, F-94805 Villejuif, France; INSERM, Unit Apoptosis Canc & Immun, F-94800 Villejuif, France; Univ Paris 11, Fac Paris Sud, F-94800 Villejuif, France; Univ Paris 11, Hop Paul Brousse, INSERM U542, F-94800 Villejuif, France; Univ Paris 13, AP HP, Hop Avicenne, Serv Hematol Clin, Bobigny, France; Inst Andre Lwoff, CNRS, Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Centre National de la Recherche Scientifique (CNRS)	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, FRE 2939, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Ades, lionel/T-6882-2019; KROEMER, Guido/B-4263-2013	KROEMER, Guido/0000-0002-9334-4405				Akdemir F, 2006, DEVELOPMENT, V133, P1457, DOI 10.1242/dev.02332; Birkenkamp KU, 2004, LEUKEMIA, V18, P103, DOI 10.1038/sj.leu.2403145; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Braun T, 2006, CELL DEATH DIFFER, V13, P748, DOI 10.1038/sj.cdd.4401874; Braun T, 2006, BLOOD, V107, P1156; CARVALHO G, 2006, ONCOGENE        1016; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Dombret H, 2002, SEMIN HEMATOL, V39, P8, DOI 10.1053/shem.2002.33608; Engedal N, 2003, J BIOL CHEM, V278, P10934, DOI 10.1074/jbc.M211556200; Fenaux P, 2005, SEMIN ONCOL, V32, pS11, DOI 10.1053/j.seminoncol.2005.06.016; Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hassan Z, 1999, EXP HEMATOL, V27, P1322, DOI 10.1016/S0301-472X(99)00066-1; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Israel A, 2006, CELL DEATH DIFFER, V13, P685, DOI 10.1038/sj.cdd.4401891; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; Martin DN, 2004, DEVELOPMENT, V131, P275, DOI 10.1242/dev.00933; Matsuo Y, 1997, LEUKEMIA, V11, P1469, DOI 10.1038/sj.leu.2400768; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Modjtahedi N, 2006, TRENDS CELL BIOL, V16, P264, DOI 10.1016/j.tcb.2006.03.008; NAGAI M, 1984, GANN, V75, P1100; Rajkumar SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030; Ribrag V, 2003, LEUKEMIA, V17, P319, DOI 10.1038/sj.leu.2402726; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Silverman Lewis R, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS12, DOI 10.1038/ncponc0347; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645	36	80	92	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4071	4083		10.1038/sj.onc.1210187	http://dx.doi.org/10.1038/sj.onc.1210187			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17213804				2023-01-03	WOS:000247252700003
J	Coombes, R				Coombes, Rebecca			Cold turkey	BRITISH MEDICAL JOURNAL			English	Article												rcoombes@bmjgroup.com						Advisory Council on the Misuse of Drugs, 2005, METH REV; Fulde GWO, 2007, MED J AUSTRALIA, V186, P334, DOI 10.5694/j.1326-5377.2007.tb00931.x; GLOSSOP M, 2006, BRIT MED J, V333, P272; Gray SD, 2007, MED J AUSTRALIA, V186, P336, DOI 10.5694/j.1326-5377.2007.tb00932.x; *HAMPSH CONST, 2007, NAT PROBL PROF METH; *PROPR ASS GREAT B, 2007, INF US COUNT PSEUD L	6	2	2	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 9	2007	334	7605					1190	1192		10.1136/bmj.39223.422824.AD	http://dx.doi.org/10.1136/bmj.39223.422824.AD			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	179GF	17556470	Green Published			2023-01-03	WOS:000247277000028
J	Wang, DS; Buckinx, R; Lecorronc, H; Mangin, JM; Rigo, JM; Legendre, P				Wang, Dian-Shi; Buckinx, Roeland; Lecorronc, Herve; Mangin, Jean-Marie; Rigo, Jean-Michel; Legendre, Pascal			Mechanisms for picrotoxinin and picrotin blocks of alpha(2) homomeric glycine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITORY GLYCINE RECEPTOR; GABA(A) RECEPTOR; CHLORIDE CHANNEL; CONFORMATIONAL-CHANGE; CRAYFISH MUSCLE; SUBUNIT; BINDING; ACETYLCHOLINE; ANTAGONIST; MEMBRANE	Contrary to its effect on the gamma-aminobutyric acid type A and C receptors, picrotoxin antagonism of the alpha(1) homomeric glycine receptors (GlyRs) has been shown to be non-use-dependent and nonselective between the picrotoxin components picrotoxinin and picrotin. Picrotoxin antagonism of the embryonic alpha(2) homomeric GlyR is known to be use-dependent and reflects a channel-blocking mechanism, but the selectivity of picrotoxin antagonism of the embryonic alpha(2) homomeric GlyRs between picrotoxinin and picrotin is unknown. Hence, we used the patch clamp recording technique in the outside-out configuration to investigate, at the single channel level, the mechanism of picrotin- and picrotoxinin-induced inhibition of currents, which were evoked by the activation of alpha(2) homomeric GlyRs stably transfected into Chinese hamster ovary cells. Although both picrotoxinin and picrotin inhibited glycine-evoked outside-out currents, picrotin had a 30 times higher IC50 than picrotoxinin. Picrotin-evoked inhibition displayed voltage dependence, whereas picrotoxinin did not. Picrotoxinin and picrotin decreased the mean open time of the channel in a concentration-dependent manner, indicating that these picrotoxin components can bind to the receptor in its open state. When picrotin and glycine were co-applied, a large rebound current was observed at the end of the application. This rebound current was considerably smaller when picrotoxinin and glycine were co-applied. Both picrotin and picrotoxinin were unable to bind to the unbound conformation of the receptor, but both could be trapped at their binding site when the channel closed during glycine dissociation. Our data indicate that picrotoxinin and picrotin are not equivalent in blocking alpha(2) homomeric GlyR.	Univ Paris 06, NPA, UKMR 7102, CNRS, F-75252 Paris 05, France; Childrens Natl Med Ctr, Ctr Neurosci Res, Washington, DC 20010 USA; Univ Hasselt, Biomed Res Ctr, B-3590 Diepenbeek, Belgium; Fourth Mil Med Univ, Dept Anat, Xian 710032, Peoples R China	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Children's National Health System; Hasselt University; Air Force Military Medical University	Legendre, P (corresponding author), Univ Paris 06, NPA, UKMR 7102, CNRS, Batiment B,6 Etage,Case 1,9 Quai St, F-75252 Paris 05, France.	pascal.legendre@snv.jussieu.fr	Buckinx, Roeland/G-9482-2011; Rigo, Jean-Michel/E-3456-2010	Buckinx, Roeland/0000-0001-9976-2889; Rigo, Jean-Michel/0000-0002-0031-526X; Mangin, Jean-Marie/0000-0002-7804-0251				Adelsberger H, 1998, EUR J NEUROSCI, V10, P179, DOI 10.1046/j.1460-9568.1998.00038.x; BORMANN J, 1993, EMBO J, V12, P3729, DOI 10.1002/j.1460-2075.1993.tb06050.x; Breitinger HG, 2001, J BIOL CHEM, V276, P29657, DOI 10.1074/jbc.M100446200; Burzomato V, 2004, J NEUROSCI, V24, P10924, DOI 10.1523/JNEUROSCI.3424-04.2004; Chen LG, 2006, P NATL ACAD SCI USA, V103, P5185, DOI 10.1073/pnas.0600370103; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; Colquhoun D, 2004, TRENDS NEUROSCI, V27, P337, DOI 10.1016/j.tins.2004.04.010; Colquhoun David, 1995, P397; CURTIS DR, 1974, ERG PHYSIOL BIOL CH, V69, P97; Das P, 2003, NEUROPHARMACOLOGY, V44, P431, DOI 10.1016/S0028-3908(03)00032-7; Dibas MI, 2002, J BIOL CHEM, V277, P9112, DOI 10.1074/jbc.M111356200; Erkkila BE, 2004, NEUROREPORT, V15, P1969, DOI 10.1097/00001756-200408260-00027; Etter A, 1999, J NEUROCHEM, V72, P318, DOI 10.1111/jnc.1999.72.1.318; FRANKE C, 1987, NEUROSCI LETT, V77, P199, DOI 10.1016/0304-3940(87)90586-6; Gentet LJ, 2002, J PHYSIOL-LONDON, V544, P97, DOI 10.1113/jphysiol.2001.015321; Grudzinska J, 2005, NEURON, V45, P727, DOI 10.1016/j.neuron.2005.01.028; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hawthorne R, 2005, J BIOL CHEM, V280, P35836, DOI 10.1074/jbc.M506645200; Hawthorne R, 2006, J NEUROCHEM, V98, P395, DOI 10.1111/j.1471-4159.2006.03875.x; KENAKIN TP, 1987, PHARM ANAL DRUG RECE, P163; KUHSE J, 1991, FEBS LETT, V283, P73, DOI 10.1016/0014-5793(91)80557-J; Legendre P, 1998, J NEUROSCI, V18, P2856; Legendre P, 2000, J NEUROSCI, V20, P140, DOI 10.1523/JNEUROSCI.20-01-00140.2000; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; Lynch JW, 1997, EMBO J, V16, P110, DOI 10.1093/emboj/16.1.110; LYNCH JW, 1995, J BIOL CHEM, V270, P13799, DOI 10.1074/jbc.270.23.13799; Lynch JW, 2004, PHYSIOL REV, V84, P1051, DOI 10.1152/physrev.00042.2003; MACONOCHIE DJ, 1995, J GEN PHYSIOL, V106, P113, DOI 10.1085/jgp.106.1.113; Mangin JA, 2003, J PHYSIOL-LONDON, V553, P369, DOI 10.1113/jphysiol.2003.052142; Muroi Y, 2006, BIOCHEMISTRY-US, V45, P7013, DOI 10.1021/bi060222v; Olsen RW, 2006, P NATL ACAD SCI USA, V103, P6081, DOI 10.1073/pnas.0601121103; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; Qian HH, 2005, MOL PHARMACOL, V67, P470, DOI 10.1124/mol.104.003996; Ramakrishnan L, 2005, BIOCHEMISTRY-US, V44, P8523, DOI 10.1021/bi0477283; Saul B, 1999, J NEUROSCI, V19, P869; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; Steinbach JH, 2000, MOL PHARMACOL, V58, P11, DOI 10.1124/mol.58.1.11; TRILLER A, 1990, New Biologist, V2, P637; Wang DS, 2006, J BIOL CHEM, V281, P3841, DOI 10.1074/jbc.M511022200; WEBB TI, 2007, IN PRESS CURR PHARM; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; ZHANG DX, 1995, P NATL ACAD SCI USA, V92, P11756, DOI 10.1073/pnas.92.25.11756; Zhorov BS, 2000, BIOPHYS J, V78, P1786, DOI 10.1016/S0006-3495(00)76729-4	44	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16016	16035		10.1074/jbc.M701502200	http://dx.doi.org/10.1074/jbc.M701502200			20	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17405877	hybrid			2023-01-03	WOS:000246794300010
J	Quill, TE				Quill, Timothy E.			Legal regulation of physician-assisted death - The latest report cards	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SUICIDE		Univ Rochester, Sch Med, Ctr Eth Humanities & Palliat Care, Rochester, NY 14627 USA	University of Rochester	Quill, TE (corresponding author), Univ Rochester, Sch Med, Ctr Eth Humanities & Palliat Care, Rochester, NY 14627 USA.							Ganzini L, 2004, PHYS ASSISTED DYING, P165; Morrison RS, 2004, NEW ENGL J MED, V350, P2582, DOI 10.1056/NEJMcp035232; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; Tolle SW, 2004, J CLIN ETHIC, V15, P111; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6	5	27	29	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 10	2007	356	19					1911	1913		10.1056/NEJMp078061	http://dx.doi.org/10.1056/NEJMp078061			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	165KX	17494924				2023-01-03	WOS:000246305500003
J	de Wildt, SN; Verzijden, R; van den Anker, JN; de Hoog, M				de Wildt, Saskia N.; Verzijden, Ron; van den Anker, John N.; de Hoog, Matthijs			Lesson of the week - Information technology cannot guarantee patient safety	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	16th Annual Meeting of the European-Society-of-Pediatric-and-Neonatal-Intensive-Care	SEP 15-17, 2005	Antwerp, BELGIUM	European Soc Pediat & Neonatal Intens Care			CALCULATOR	Human error and software inadequacy can combine to make drug doses calculated on handheld computers unreliable	Erasmus MC Sophia Childrens Hosp, Dept Paediat, NL-3015 GJ Rotterdam, Netherlands; Ron Verzijden Management Consultants, Toronto, ON M5J 2Y5, Canada; Childrens Hosp, Natl Med Ctr, Div Pediat Clin Pharmacol, Washington, DC 20010 USA	Erasmus University Rotterdam; Erasmus MC; Children's National Health System	de Wildt, SN (corresponding author), Hosp Sick Children, Div Clin Pharmacol & Toxicol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	s.dewildt@erasmusmc.nl	de Hoog, Matthijs/A-3882-2013; de Wildt, Saskia/A-9589-2008; de Wildt, Saskia/AFX-4656-2022	de Wildt, Saskia/0000-0002-0502-0647; de Wildt, Saskia/0000-0002-0502-0647				Bates DW, 2003, NEW ENGL J MED, V348, P2526, DOI 10.1056/NEJMsa020847; *EUR SPREADSH RISK, 2006, SPREADSH MIST NEWS S; LAUDON KC, 2000, MANAGEMENT INFORM SY, P377; LUTEN R C, 1986, Journal of Emergency Medicine, V4, P9, DOI 10.1016/0736-4679(86)90107-1; MELZERLANGE M, 1991, AM J DIS CHILD, V145, P264, DOI 10.1001/archpedi.1991.02160030032016; NEU J, 1982, CRIT CARE MED, V10, P610, DOI 10.1097/00003246-198209000-00012	6	11	11	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 21	2007	334	7598					851	852		10.1136/bmj.39104.625903.80	http://dx.doi.org/10.1136/bmj.39104.625903.80			2	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	162MD	17446618	Green Published			2023-01-03	WOS:000246090800037
J	Mehta, DK; Aronson, JK				Mehta, Dinesh K.; Aronson, Jeffrey K.			Give a drug a good name	LANCET			English	Editorial Material									Royal Pharmaceut Soc Great Britain, London SE1 7JN, England; Univ Oxford, Dept Clin Pharmacol, Oxford, England	University of Oxford	Mehta, DK (corresponding author), Royal Pharmaceut Soc Great Britain, London SE1 7JN, England.	dmehta@bnf.org						Aronson J, 2004, BRIT J GEN PRACT, V54, P559; Aronson Jeffrey K, 2004, Expert Opin Drug Saf, V3, P167; Aronson JK, 2000, BMJ-BRIT MED J, V320, P506, DOI 10.1136/bmj.320.7233.506; SASHKOVA G, 2004, WHO DRUG INFO, V18, P123; 2002, WHO DRUG INFO, V16, P194; 1965, WHO CHRONICLE, V19, P446	6	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 21	2007	369	9570					1326	1328		10.1016/S0140-6736(07)60612-6	http://dx.doi.org/10.1016/S0140-6736(07)60612-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	159HL	17448803				2023-01-03	WOS:000245856100008
J	Rossouw, JE; Prentice, RL; Manson, JE; Wu, LL; Barad, D; Barnabei, VM; Ko, M; LaCroix, AZ; Margolis, KL; Stefanick, ML				Rossouw, Jacques E.; Prentice, Ross L.; Manson, Joann E.; Wu, LieLing; Barad, David; Barnabei, Vanessa M.; Ko, Marcia; LaCroix, Andrea Z.; Margolis, Karen L.; Stefanick, Marcia L.			Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; ESTROGEN PLUS PROGESTIN; RANDOMIZED CONTROLLED-TRIAL; REPLACEMENT THERAPY; SECONDARY PREVENTION; MYOCARDIAL-INFARCTION; EQUINE ESTROGEN; WOMEN; HEALTH; ATHEROSCLEROSIS	Context The timing of initiation of hormone therapy may influence its effect on cardiovascular disease. Objective To explore whether the effects of hormone therapy on risk of cardiovascular disease vary by age or years since menopause began. Design, Setting, and Participants Secondary analysis of the Women's Health Initiative (WHI) randomized controlled trials of hormone therapy in which 10 739 postmenopausal women who had undergone a hysterectomy were randomized to conjugated equine estrogens (CEE) or placebo and 16 608 postmenopausal women who had not had a hysterectomy were randomized to CEE plus medroxyprogesterone acetate ( CEE + MPA) or placebo. Women aged 50 to 79 years were recruited to the study from 40 US clinical centers between September 1993 and October 1998. Main Outcome Measures Statistical test for trend of the effect of hormone therapy on coronary heart disease (CHD) and stroke across categories of age and years since menopause in the combined trials. Results In the combined trials, there were 396 cases of CHD and 327 cases of stroke in the hormone therapy group vs 379 cases of CHD and 239 cases of stroke in the placebo group. For women with less than 10 years since menopause began, the hazard ratio (HR) for CHD was 0.76 (95% confidence interval [CI], 0.50-1.16); 10 to 19 years, 1.10 ( 95% CI, 0.84-1.45); and 20 or more years, 1.28 ( 95% CI, 1.03-1.58) ( P for trend=. 02). The estimated absolute excess risk for CHD for women within 10 years of menopause was - 6 per 10 000 person-years; for women 10 to 19 years since menopause began, 4 per 10 000 person-years; and for women 20 or more years from menopause onset, 17 per 10 000 person-years. For the age group of 50 to 59 years, the HR for CHD was 0.93 ( 95% CI, 0.65-1.33) and the absolute excess risk was - 2 per 10 000 person-years; 60 to 69 years, 0.98 ( 95% CI, 0.79-1.21) and - 1 per 10 000 person-years; and 70 to 79 years, 1.26 ( 95% CI, 1.00-1.59) and 19 per 10 000 person-years (P for trend=. 16). Hormone therapy increased the risk of stroke ( HR, 1.32; 95% CI, 1.12-1.56). Risk did not vary significantly by age or time since menopause. There was a nonsignificant tendency for the effects of hormone therapy on total mortality to be more favorable in younger than older women ( HR of 0.70 for 50-59 years; 1.05 for 60-69 years, and 1.14 for 70-79 years; P for trend=. 06). Conclusions Women who initiated hormone therapy closer to menopause tended to have reduced CHD risk compared with the increase in CHD risk among women more distant from menopause, but this trend test did not meet our criterion for statistical significance. A similar nonsignificant trend was observed for total mortality but the risk of stroke was elevated regardless of years since menopause. These data should be considered in regard to the short-term treatment of menopausal symptoms.	NHLBI, Womens Hlth Initiat Branch, Bethesda, MD 20892 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med, Boston, MA 02115 USA; Albert Einstein Coll Med, Dept Obstet & Gynecol, New York, NY USA; Albert Einstein Coll Med, Dept Womens Hlth, New York, NY USA; Med Coll Wisconsin, Dept Obstet & Gynecol, Milwaukee, WI 53226 USA; Mayo Clin, Div Womens Hlth Internal Med, Scottsdale, AZ USA; Univ Minnesota, Berman Ctr Clin Res, Minneapolis, MN USA; Stanford Univ, Dept Med, Palo Alto, CA 94304 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Fred Hutchinson Cancer Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Yeshiva University; Yeshiva University; Medical College of Wisconsin; Mayo Clinic; Mayo Clinic Phoenix; University of Minnesota System; University of Minnesota Twin Cities; Stanford University	Rossouw, JE (corresponding author), NHLBI, Womens Hlth Initiat Branch, 6701 Rockledge Dr,Bldg 2,Suite 10018, Bethesda, MD 20892 USA.	rossouwj@nih.gov	Barad, David/AAF-4332-2021	Barnabei, Vanessa/0000-0002-9650-0143; Margolis, Karen/0000-0003-1862-7402				*ACOG TASK FORC HO, 2004, OBSTET GYNECOL S, V104, pS1; Alexander KP, 2001, J AM COLL CARDIOL, V38, P1, DOI 10.1016/S0735-1097(01)01329-8; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Barrett-Connor E, 1998, ANNU REV PUBL HEALTH, V19, P55, DOI 10.1146/annurev.publhealth.19.1.55; COX DR, 1972, J R STAT SOC B, V34, P187; Dwyer KM, 2002, AM J EPIDEMIOL, V156, P438, DOI 10.1093/aje/kwf051; Grodstein F, 2006, J WOMENS HEALTH, V15, P35, DOI 10.1089/jwh.2006.15.35; Grodstein F, 2003, NEW ENGL J MED, V348, P645, DOI 10.1056/NEJMsb022365; Grodstein F, 2001, ANN INTERN MED, V135, P1, DOI 10.7326/0003-4819-135-1-200107030-00003; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; Harman SM, 2005, CLIMACTERIC, V8, P3, DOI 10.1080/13697130500042417; Heckbert SR, 2001, ARCH INTERN MED, V161, P1709, DOI 10.1001/archinte.161.14.1709; Heckbert SR, 1997, ARCH INTERN MED, V157, P1330, DOI 10.1001/archinte.157.12.1330; Hendrix SL, 2006, CIRCULATION, V113, P2425, DOI 10.1161/CIRCULATIONAHA.105.594077; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hsia J, 2006, ARCH INTERN MED, V166, P357, DOI 10.1001/archinte.166.3.357; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Johnson MS, 2005, ANN INTERN MED, V142, P855, DOI 10.7326/0003-4819-142-10-200505170-00011; Mack WJ, 2004, FERTIL STERIL, V82, P391, DOI 10.1016/j.fertnstert.2004.01.034; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Mendelsohn ME, 2005, SCIENCE, V308, P1583, DOI 10.1126/science.1112062; Prentice RL, 2006, AM J EPIDEMIOL, V163, P589, DOI 10.1093/aje/kwj079; ROSSOUW JE, 1995, AM J CARDIOL, V76, pC86, DOI 10.1016/S0002-9149(99)80476-7; Rossouw JE, 2005, MATURITAS, V51, P51, DOI 10.1016/j.maturitas.2005.02.015; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432	28	1203	1264	3	56	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 4	2007	297	13					1465	1477		10.1001/jama.297.13.1465	http://dx.doi.org/10.1001/jama.297.13.1465			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153AM	17405972	Green Published			2023-01-03	WOS:000245404100023
J	Nathan, C				Nathan, Carl			Aligning pharmaceutical innovation with medical need	NATURE MEDICINE			English	Editorial Material							DRUG DISCOVERY; GLOBAL HEALTH; ANTIBIOTICS; FRAMEWORK; BUSINESS; ACCESS; CANCER		Cornell Univ, Weill Med Coll, New York, NY 10021 USA	Cornell University	Nathan, C (corresponding author), Cornell Univ, Weill Med Coll, 1300 York Ave, New York, NY 10021 USA.	cnathan@med.cornell.edu						Abramowicz M, 2003, VANDERBILT LAW REV, V56, P115; Barton JH, 2005, JAMA-J AM MED ASSOC, V294, P2075, DOI 10.1001/jama.294.16.2075; Check E, 2006, NATURE, V444, P412, DOI 10.1038/444412b; Chirac P, 2006, LANCET, V367, P1560, DOI 10.1016/S0140-6736(06)68672-8; Clardy J, 2006, NAT BIOTECHNOL, V24, P1541, DOI 10.1038/nbt1266; Cuatrecasas P, 2006, J CLIN INVEST, V116, P2837, DOI 10.1172/JCI29999; Danzon Patricia M, 2003, Int J Health Care Finance Econ, V3, P183, DOI 10.1023/A:1025384819575; DUGGER C, 2006, NY TIMES        1201, pA9; Fenical W, 2006, NAT CHEM BIOL, V2, P666, DOI 10.1038/nchembio841; Fisher ES, 2006, NEW ENGL J MED, V355, P1845, DOI 10.1056/NEJMp068221; Fox JL, 2006, NAT BIOTECHNOL, V24, P1521, DOI 10.1038/nbt1206-1521; Hubbard T, 2004, PLOS BIOL, V2, P147, DOI 10.1371/journal.pbio.0020052; Katz ML, 2006, NAT BIOTECHNOL, V24, P1529, DOI 10.1038/nbt1206-1529; Kremer M, 1998, Q J ECON, V113, P1137, DOI 10.1162/003355398555865; KREMER M, 2004, STRONG MED CREATING, P55; LANJOUW J, 2006, INNOVATIONS, V1, P108; Leaf C, 2004, FORTUNE, V149, P76; Lewis K, 2006, NAT BIOTECHNOL, V24, P1504, DOI 10.1038/nbt1206-1504; Lopez AD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P1, DOI 10.1596/978-0-8213-6262-4; Love JP, 2006, B WORLD HEALTH ORGAN, V84, P408; MacCoss M, 2004, SCIENCE, V303, P1810, DOI 10.1126/science.1096800; Nathan C, 2004, NATURE, V431, P899, DOI 10.1038/431899a; Nathan C, 2005, NAT REV DRUG DISCOV, V4, P887, DOI 10.1038/nrd1878; Nwaka S, 2006, NAT REV DRUG DISCOV, V5, P941, DOI 10.1038/nrd2144; Outterson Kevin, 2005, Yale J Health Policy Law Ethics, V5, P193; Payne DJ, 2007, NAT REV DRUG DISCOV, V6, P29, DOI 10.1038/nrd2201; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; Pisano GP, 2006, HARVARD BUS REV, V84, P114; Pogge TW, 2005, METAPHILOSOPHY, V36, P182, DOI 10.1111/j.1467-9973.2005.00362.x; Renslo AR, 2006, NAT CHEM BIOL, V2, P701, DOI 10.1038/nchembio837; Sporn MB, 2006, NAT CLIN PRACT ONCOL, V3, P364, DOI 10.1038/ncponc0536; Walsh C. T., 2005, TREATING INFECT DIS, P1	32	37	39	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2007	13	3					304	308		10.1038/nm0307-304	http://dx.doi.org/10.1038/nm0307-304			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	143JC	17342145				2023-01-03	WOS:000244715700042
J	Gutierrez, F; Padilla, S; Masia, M; Iribarren, JA; Moreno, S; Viciana, P; Munoz, L; Sirvent, JLG; Vidal, F; Lopez-Aldeguer, J; Blanco, JR; Leal, M; Rodriguez-Arenas, MA; Hoyos, SP				Gutierrez, Felix; Padilla, Sergio; Masia, Mar; Iribarren, Jose A.; Moreno, Santiago; Viciana, Pompeyo; Munoz, Leopoldo; Gomez Sirvent, Jose L.; Vidal, Francesc; Lopez-Aldeguer, Jose; Blanco, Jose R.; Leal, Manuel; Angeles Rodriguez-Arenas, Maria; Perez Hoyos, Santiago		CoRIS-MD	Clinical Outcome of HIV-Infected Patients with Sustained Virologic Response to Antiretroviral Therapy: Long-Term Follow-Up of a Multicenter Cohort	PLOS ONE			English	Article								Background. Limited information exists on long-term prognosis of patients with sustained virologic response to antiretroviral therapy. We aimed to assess predictors of unfavorable clinical outcome in patients who maintain viral suppression with HAART. Methods. Using data collected from ten clinic-based cohorts in Spain, we selected all antiretroviral-naive adults who initiated HAART and maintained plasma HIV-1 RNA levels,500 copies/mL throughout follow-up. Factors associated with disease progression were determined by Cox proportional-hazards models. Results. Of 2,613 patients who started HAART, 757 fulfilled the inclusion criteria. 61% of them initiated a protease inhibitor-based HAART regimen, 29.7% a nonnucleoside reverse-transcriptase inhibitor-based regimen, and 7.8% a triple-nucleoside regimen. During 2,556 person-years of follow-up, 22 (2.9%) patients died (mortality rate 0.86 per 100 person-years), and 40 (5.3%) died or developed a new AIDS-defining event. The most common causes of death were neoplasias and liver failure. Mortality was independently associated with a CD4-T cell response,50 cells/L after 12 months of HAART (adjusted hazard ratio [AHR], 4.26 [95% confidence interval {CI}, 1.68-10.83]; P = .002), and age at initiation of HAART (AHR, 1.06 per year; 95% CI, 1.02-1.09; P = .001). Initial antiretroviral regimen chosen was not associated with different risk of clinical progression. Conclusions. Patients with sustained virologic response on HAART have a low mortality rate over time. Long-term outcome of these patients is driven by immunologic response at the end of the first year of therapy and age at the time of HAART initiation, but not by the initial antiretroviral regimen selected.	[Gutierrez, Felix; Padilla, Sergio; Masia, Mar] Univ Miguel Hernandez, Univ Elche, Gen Hosp, Unidad Enfermedades Infecciosas, Alicante, Spain; [Iribarren, Jose A.] Hosp Donostia, Unidad Enfermedades Infecciosas, San Sebastian, Spain; [Moreno, Santiago] Hosp Ramon & Cajal, Serv Enfermedades Infecciosas, E-28034 Madrid, Spain; [Viciana, Pompeyo; Leal, Manuel] Hosp Univ Virgen Rodo, Serv Enfermedades Infecciosas, Seville, Spain; [Munoz, Leopoldo] Hosp Univ San Cecilio, Unidad Enfermedades Infecciosas, Granada, Spain; [Gomez Sirvent, Jose L.] Hosp Univ Canarias, Unidad Enfermedades Infecciosas, Santa Cruz de Tenerife, Spain; [Vidal, Francesc] Univ Rovira & Virgili, Hosp Univ Tarragona Joan XXIII, Unidad Enfermedades Infecciosas, Tarragona, Spain; [Lopez-Aldeguer, Jose] Hosp La Fe, Unidad Enfermedades Infecciosas, E-46009 Valencia, Spain; [Blanco, Jose R.] Hosp La Rioja, Area Enfermedades Infecciosas, Logrono, La Rioja, Spain; [Angeles Rodriguez-Arenas, Maria] Univ Miguel Hernandez, Dept Salud Publ, Alicante, Spain; [Perez Hoyos, Santiago] EVES, Valencia, Spain	General University Hospital of Alicante; Universidad Miguel Hernandez de Elche; University Hospital Donostia; Hospital Universitario Ramon y Cajal; Hospital Universitario San Cecilio; Universidad de la Laguna; Universitat Rovira i Virgili; Hospital Universitari De Tarragona Joan XXIII; Hospital Universitari i Politecnic La Fe; Universidad Miguel Hernandez de Elche	Gutierrez, F (corresponding author), Univ Miguel Hernandez, Univ Elche, Gen Hosp, Unidad Enfermedades Infecciosas, Alicante, Spain.	gutierrez_fel@gva.es	IBIS, VIH/O-8856-2015; DEL AMO VALERO, JULIA/M-7020-2015; Leal, Manuel/C-8458-2015; Oteo, Jose A./AAB-3134-2020; Blanco, Jose-Ramon/L-6768-2018; Perez Hoyos, Santiago/O-1075-2019; Iribarren, José/AAK-5528-2021; Rodriguez-Arenas, M. Angeles/AAE-2705-2021; Padilla, Sergio/U-7682-2017; Masia, Mar/U-7510-2017; Lopez.Cortes, Luis Fernando/S-5625-2018	DEL AMO VALERO, JULIA/0000-0002-3104-540X; Oteo, Jose A./0000-0001-7080-6542; Blanco, Jose-Ramon/0000-0002-4268-0150; Perez Hoyos, Santiago/0000-0001-9797-4917; Rodriguez-Arenas, M. Angeles/0000-0002-8115-054X; Padilla, Sergio/0000-0002-8420-7310; Vidal, Francesc/0000-0002-6692-6186; Masia, Mar/0000-0001-9878-2458; Lopez.Cortes, Luis Fernando/0000-0002-3804-3458; Perez Elias/0000-0001-5700-5257; Bernal, Enrique/0000-0002-4041-0579	Red Tematica Cooperativa de Investigacion en SIDA del Fondo de Investigacion Sanitaria (FISss) [PI051338]	Red Tematica Cooperativa de Investigacion en SIDA del Fondo de Investigacion Sanitaria (FISss)	Supported in part by the "Red Tematica Cooperativa de Investigacion en SIDA (Red de Grupos 173 y Expte: PI051338; RIS)'' del Fondo de Investigacion Sanitaria (FISss).	Bartlett JA, 2001, AIDS, V15, P1369, DOI 10.1097/00002030-200107270-00006; Binquet C, 2001, AM J EPIDEMIOL, V153, P386, DOI 10.1093/aje/153.4.386; Bonnet F, 2005, HIV MED, V6, P198, DOI 10.1111/j.1468-1293.2005.00290.x; Braitstein P, 2006, J INFECT DIS, V193, P259, DOI 10.1086/498908; DeGruttola V, 1997, J INFECT DIS, V175, P237, DOI 10.1093/infdis/175.2.237; Demeter LM, 2001, ANN INTERN MED, V135, P954, DOI 10.7326/0003-4819-135-11-200112040-00007; *DHHS PAN CLIN PRA, 2006, GUID US ANT AG HIV 1; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Gebhardt M, 1998, AIDS, V12, P1195, DOI 10.1097/00002030-199810000-00012; Grabar S, 2004, AIDS, V18, P2029, DOI 10.1097/00002030-200410210-00007; Grabar S, 2005, JAIDS-J ACQ IMM DEF, V39, P284, DOI 10.1097/01.qai.0000160925.33935.72; Grabar S, 2000, ANN INTERN MED, V133, P401, DOI 10.7326/0003-4819-133-6-200009190-00007; Hogg RS, 2002, AIDS, V16, P1051, DOI 10.1097/00002030-200205030-00012; Hortelano CME, 2004, MED CLIN-BARCELONA, V122, P1; Li QS, 2004, J INFECT DIS, V189, P572, DOI 10.1086/381396; Marimoutou C, 2001, J ACQ IMMUN DEF SYND, V27, P161, DOI 10.1097/00126334-200106010-00011; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0; Mocroft A, 2002, AIDS, V16, P1663, DOI 10.1097/00002030-200208160-00012; Moore DM, 2006, AIDS, V20, P371, DOI 10.1097/01.aids.0000196180.11293.9a; Moore DM, 2005, JAIDS-J ACQ IMM DEF, V40, P288, DOI 10.1097/01.qai.0000182847.38098.d1; Olsen CH, 2005, AIDS, V19, P319; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perez-Hoyos S, 2003, AIDS, V17, P353, DOI 10.1097/00002030-200302140-00009; Piketty C, 2001, J INFECT DIS, V183, P1328, DOI 10.1086/319861; Puoti M, 2000, J ACQ IMMUN DEF SYND, V24, P211; Rockstroh JK, 2005, J INFECT DIS, V192, P992, DOI 10.1086/432762; Rodriguez-Arenas MA, 2006, AIDS RES HUM RETROV, V22, P715, DOI 10.1089/aid.2006.22.715; Schechter M, 2006, J ANTIMICROB CHEMOTH, V58, P506, DOI 10.1093/jac/dkl263; Staszewski S, 1998, AIDS, V12, P1991, DOI 10.1097/00002030-199815000-00010; Sterne JAC, 2005, LANCET, V366, P378, DOI 10.1016/S0140-6736(05)67022-5; Valdez H, 2001, CLIN INFECT DIS, V32, P1487, DOI 10.1086/320164; Weber R, 2005, 12 C RETR OPP INF 22; Welch K, 2002, AIDS PATIENT CARE ST, V16, P75, DOI 10.1089/10872910252806126; Wood E, 2003, ANN INTERN MED, V139, P810, DOI 10.7326/0003-4819-139-10-200311180-00008	36	41	42	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e89	10.1371/journal.pone.0000089	http://dx.doi.org/10.1371/journal.pone.0000089			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183720	Green Published, gold, Green Submitted			2023-01-03	WOS:000207443600088
J	Abgrall, S				Abgrall, Sophie			Initial strategy for antiretroviral-naive patients	LANCET			English	Editorial Material							SEQUENTIAL 3-DRUG REGIMENS; RANDOMIZED-TRIAL; HIV-1 INFECTION; THERAPY; EFFICACY		Avicenne Hosp, Dept Infect & Trop Dis, F-93000 Bobigny, France; Univ Paris 13, Bobigny, France; Univ Paris 06, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; UDICE-French Research Universities; Sorbonne Universite	Abgrall, S (corresponding author), Avicenne Hosp, Dept Infect & Trop Dis, F-93000 Bobigny, France.	sophie.abgrall@avc.aphp.fr						Arasteh K, 2005, AIDS, V19, P943, DOI 10.1097/01.aids.0000171408.38490.01; Flandre P, 2002, AIDS, V16, P561, DOI 10.1097/00002030-200203080-00007; Kirk O, 1999, AIDS, V13, pF9, DOI 10.1097/00002030-199901140-00002; MacArthur RD, 2006, LANCET, V368, P2125, DOI 10.1016/S0140-6736(06)69861-9; Nelson M, 2005, JAIDS-J ACQ IMM DEF, V40, P404, DOI 10.1097/01.qai.0000185314.56556.c3; Phillips AN, 2004, AIDS, V18, P1795, DOI 10.1097/00002030-200409030-00008; Reijers MHE, 1998, LANCET, V352, P185, DOI 10.1016/S0140-6736(98)06193-5; Robbins GK, 2003, NEW ENGL J MED, V349, P2293, DOI 10.1056/NEJMoa030264; Shafer RW, 2003, NEW ENGL J MED, V349, P2304, DOI 10.1056/NEJMoa030265; WILLIAMS I, 2004, 11 C RETR OPP INF CR; Yeni P, 2006, LANCET, V368, P287, DOI 10.1016/S0140-6736(06)69074-0	11	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 16	2006	368	9553					2107	2109		10.1016/S0140-6736(06)69842-5	http://dx.doi.org/10.1016/S0140-6736(06)69842-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EZ	17174691				2023-01-03	WOS:000242856900004
J	King, MT; Fayers, PM				King, Madeleine T.; Fayers, Peter M.			Making quality-of-life results more meaningful for clinicians	LANCET			English	Editorial Material							TRIALS		[King, Madeleine T.] Univ Technol Sydney, Ctr Hlth Econ Res & Evaluat, Sydney, NSW 2043, Australia; [Fayers, Peter M.] Univ Aberdeen, Dept Publ Hlth, Aberdeen, Scotland; [Fayers, Peter M.] Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, N-7034 Trondheim, Norway	University of Technology Sydney; University of Aberdeen; Norwegian University of Science & Technology (NTNU)	King, MT (corresponding author), Univ Technol Sydney, Ctr Hlth Econ Res & Evaluat, Sydney, NSW 2043, Australia.	Madeleine.King@chere.uts.edu.au		Fayers, Peter/0000-0003-4778-1513				*CLIN TRIALS COOP, 1988, CANC THER EV PROGR G; Fayers P, 2002, EUR J CANCER, V38, pS125; Fayers P, 2001, EORTC QLQ C30 SCORIN, V3th; FAYERS PM, 2000, QUALITY LIFE ASSESSM, P325; Guyatt G, 2007, QUAL LIFE RES, V16, P1097, DOI 10.1007/s11136-007-9223-3; JOHNSON JR, 1985, CANCER TREAT REP, V69, P1155; Medical Research Council, 1998, GUID GOOD CLIN PRACT; *MRC, 1998, VIRT CYCL WORK TOG H; Osoba D, 2005, EUR J CANCER, V41, P280, DOI 10.1016/j.ejca.2004.10.017; Osoba D, 1992, Qual Life Res, V1, P211, DOI 10.1007/BF00635620; Schunemann HJ, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-62; Wisloff F, 1996, BRIT J HAEMATOL, V94, P324, DOI 10.1046/j.1365-2141.1996.d01-1802.x	12	21	21	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 1	2008	371	9614					709	710		10.1016/S0140-6736(08)60324-4	http://dx.doi.org/10.1016/S0140-6736(08)60324-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268RI	18313491				2023-01-03	WOS:000253596700011
J	Girard, TD; Kress, JP; Fuchs, BD; Thomason, JWW; Schweickert, WD; Pun, BT; Taichman, DB; Dunn, JG; Pohlman, AS; Kinniry, PA; Jackson, JC; Canonico, AE; Light, RW; Shintani, AK; Thompson, JL; Gordon, SM; Hall, JB; Dittus, RS; Bernard, GR; Ely, EW				Girard, Timothy D.; Kress, John P.; Fuchs, Barry D.; Thomason, Jason W. W.; Schweickert, William D.; Pun, Brenda T.; Taichman, Darren B.; Dunn, Jan G.; Pohlman, Anne S.; Kinniry, Paul A.; Jackson, James C.; Canonico, Angelo E.; Light, Richard W.; Shintani, Ayumi K.; Thompson, Jennifer L.; Gordon, Sharon M.; Hall, Jesse B.; Dittus, Robert S.; Bernard, Gordon R.; Ely, E. Wesley			Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial	LANCET			English	Article							CRITICALLY-ILL PATIENTS; CONFUSION ASSESSMENT METHOD; DAILY INTERRUPTION; RELIABILITY; ANALGESICS; INFUSIONS; VALIDITY; DELIRIUM; RISK; GUIDELINES	Background Approaches to removal of sedation and mechanical ventilation for critically ill patients vary widely. Our aim was to assess a protocol that paired spontaneous awakening trials (SATs)-ie, daily interruption of sedatives-with spontaneous breathing trials (SBTs). Methods In four tertiary-care hospitals, we randomly assigned 336 mechanically ventilated patients in intensive care to management with a daily SAT followed by an SBT (intervention group; n=168) or with sedation per usual care plus a daily SBT (control group; n=168). The primary endpoint was time breathing without assistance. Data were analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00097630. Findings One patient in the intervention group did not begin their assigned treatment protocol because of withdrawal of consent and thus was excluded from analyses and lost to follow-up. Seven patients in the control group discontinued their assigned protocol, and two of these patients were lost to follow-up. Patients in the intervention group spent more days breathing without assistance during the 28-day study period than did those in the control group (14.7 days vs 11 . 6 days; mean difference 3 . 1 days, 95% CI 0.7 to 5.6; p=0.02) and were discharged from intensive care (median time in intensive care 9.1 days vs 12.9 days; p=0.01) and the hospital earlier (median time in the hospital 14.9 days vs 19.2 days; p=0.04). More patients in the intervention group self-extubated than in the control group (16 patients vs six patients; 6.0% difference, 95% CI 0. 6% to 11.8%; p=0.03), but the number of patients who required reintubation after self-extubation was similar (five patients vs three patients; 1. 2% difference, 95% CI -5.2% to 2.5%; p=0.47), as were total reintubation rates (13.8% vs 12 . 5%; 1. 3% difference, 95% CI -8.6% to 6 . 1%; p=0. 73). At any instant during the year after enrolment, patients in the intervention group were less likely to die than were patients in the control group (HR 0.68, 95% CI 0 .50 to 0. 92; p=0.01). For every seven patients treated with the intervention, one life as saved (number needed to treat was 7.4, 95% CI 4 . 2 to 35. 5). Interpretation Our results suggest that a wake up and breathe protocol that pairs daily spontaneous awakening trials (ie, interruption of sedatives) with daily spontaneous breathing trials results in better outcomes for mechanically ventilated patients in intensive care than current standard approaches and should become routine practice.	[Girard, Timothy D.; Thomason, Jason W. W.; Pun, Brenda T.; Jackson, James C.; Light, Richard W.; Gordon, Sharon M.; Dittus, Robert S.; Bernard, Gordon R.; Ely, E. Wesley] Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Dept Med,Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; [Canonico, Angelo E.] St Thomas Hosp, Dept Med, Nashville, TN USA; [Dunn, Jan G.] St Thomas Hosp, St Thomas Res Inst, Nashville, TN USA; [Shintani, Ayumi K.; Thompson, Jennifer L.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA; [Gordon, Sharon M.; Dittus, Robert S.; Ely, E. Wesley] Tennessee Valley Healthcare Syst, Dept Vet Affairs Med Ctr, VA Serv, VA Tennessee Valley Geriatr Res Educ & Clin Ctr, Nashville, TN USA; [Kress, John P.; Schweickert, William D.; Pohlman, Anne S.; Hall, Jesse B.] Univ Chicago, Dept Med, Sect Pulm & Crit Care, Chicago, IL 60637 USA; [Fuchs, Barry D.; Taichman, Darren B.; Kinniry, Paul A.] Univ Penn, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA	Vanderbilt University; Saint Thomas Hospital; Saint Thomas Hospital; Vanderbilt University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; University of Chicago; University of Pennsylvania	Girard, TD (corresponding author), Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Dept Med,Div Allergy Pulm & Crit Care Med, 6th Floor MCE 6110, Nashville, TN 37232 USA.	timothy.girard@vanderbilt.edu	Ely, E. Wesley/Z-2018-2019; Girard, Timothy/I-3008-2019	Ely, E. Wesley/0000-0003-3957-2172; Girard, Timothy/0000-0002-9833-4871	NCRR NIH HHS [RR024975] Funding Source: Medline; NHLBI NIH HHS [HL007123] Funding Source: Medline; NIA NIH HHS [AG001023] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024975] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007123] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Carson SS, 2006, CRIT CARE MED, V34, P1326, DOI 10.1097/01.CCM.0000215513.63207.7F; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; Devlin JW, 2006, CRIT CARE MED, V34, P556, DOI 10.1097/01.CCM.0000199058.88904.D6; Dupont WD, 1997, CONTROL CLIN TRIALS, V18, P274, DOI 10.1016/S0197-2456(97)00074-3; Efron B., 1993, INTRO BOOTSTRAP; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; Ely EW, 2002, CONFUSION ASSESSMENT; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Esteban A, 1997, AM J RESP CRIT CARE, V156, P459, DOI 10.1164/ajrccm.156.2.9610109; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Heffner JE, 2000, NEW ENGL J MED, V342, P1520, DOI 10.1056/NEJM200005183422011; Hong JJ, 2000, NEW ENGL J MED, V343, P814; Ihaka R., 1996, J COMPUT GRAPH STAT, V5, P299, DOI [DOI 10.1080/10618600.1996.10474713, 10.2307/1390807]; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kollef MH, 1997, CRIT CARE MED, V25, P567, DOI 10.1097/00003246-199704000-00004; Kress JP, 2007, CRIT CARE MED, V35, P365, DOI 10.1097/01.CCM.0000254334.46406.B3; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kress JP, 2003, AM J RESP CRIT CARE, V168, P1457, DOI 10.1164/rccm.200303-455OC; Lellouche F, 2006, AM J RESP CRIT CARE, V174, P894, DOI 10.1164/rccm.200511-1780OC; MacIntyre NR, 2001, CHEST, V120, p375S, DOI 10.1378/chest.120.6_suppl.375S; Marelich GP, 2000, CHEST, V118, P459, DOI 10.1378/chest.118.2.459; Martin J, 2007, CRIT CARE, V11, DOI 10.1186/cc6189; Mehta S, 2006, CRIT CARE MED, V34, P374, DOI 10.1097/01.CCM.0000196830.61965.F1; Novaes MAFP, 1999, INTENS CARE MED, V25, P1421, DOI 10.1007/s001340051091; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da; Pinhu L, 2003, LANCET, V361, P332, DOI 10.1016/S0140-6736(03)12329-X; PUNTILLO KA, 1990, HEART LUNG, V19, P526; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Schweickert WD, 2004, CRIT CARE MED, V32, P1272, DOI 10.1097/01.CCM.0000127263.54807.79; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; TANIOS MA, 2005, P AM THORAC SOC, V2, pA793; Weinert CR, 2007, CRIT CARE MED, V35, P393, DOI 10.1097/01.CCM.0000254339.18639.1D; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949	40	1224	1295	0	76	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 12	2008	371	9607					126	134		10.1016/S0140-6736(08)60105-1	http://dx.doi.org/10.1016/S0140-6736(08)60105-1			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	252ND	18191684				2023-01-03	WOS:000252452300027
J	Li, J; Zeng, XH; Mo, HY; Rolen, U; Gao, YF; Zhang, XS; Chen, QY; Zhang, L; Zeng, MS; Li, MZ; Huang, WL; Wang, XN; Zeng, YX; Masucci, MG				Li, Jiang; Zeng, Xue-hui; Mo, Hao-yuan; Rolen, Ulrika; Gao, Yan-fang; Zhang, Xiao-shi; Chen, Qiu-yan; Zhang, Li; Zeng, Mu-sheng; Li, Man-zhi; Huang, Wen-lin; Wang, Xiao-ning; Zeng, Yi-xin; Masucci, Maria G.			Functional Inactivation of EBV-Specific T-Lymphocytes in Nasopharyngeal Carcinoma: Implications for Tumor Immunotherapy	PLOS ONE			English	Article							EPSTEIN-BARR-VIRUS; LATENT MEMBRANE-PROTEIN; ADOPTIVE TRANSFER; SOUTHERN CHINESE; CELL RESPONSES; BLOOD; INTERLEUKIN-10; INHIBITION; EXPRESSION; SUPPRESSION	Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV) associated malignancy with high prevalence in Southern Chinese. In order to assess whether defects of EBV-specific immunity may contribute to the tumor, the phenotype and function of circulating T-cells and tumor infiltrating lymphocytes (TILs) were investigated in untreated NPC patients. Circulating naive CD(3+)CD45RA(+) and CD4(+)CD25(-) cells were decreased, while activated CD4(+)CD25(+) T-cells and CD3(-)CD16(+) NK-cells were increased in patients compared to healthy donors. The frequency of T-cells recognizing seven HLA-A2 restricted epitopes in LMP1 and LMP2 was lower in the patients and remained low after stimulation with autologous EBV-carrying cells. TILs expanded in low doses of IL-2 exhibited an increase of CD3(+)CD4(+), CD3(+)CD45RO(+) and CD4(+)CD25(+) cells and 2 to 5 fold higher frequency of LMP1 and LMP2 tetramer positive cells compared to peripheral blood. EBV-specific cytotoxicity could be reactivated from the blood of most patients, whereas the TILs lacked cytotoxic activity and failed to produce IFN gamma upon specific stimulation. Thus, EBV-specific rejection responses appear to be functionally inactivated at the tumor site in NPC.	[Li, Jiang; Zeng, Mu-sheng; Li, Man-zhi; Huang, Wen-lin; Zeng, Yi-xin] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, Guangzhou 510275, Guangdong, Peoples R China; [Li, Jiang; Mo, Hao-yuan; Gao, Yan-fang; Zhang, Xiao-shi; Chen, Qiu-yan; Zhang, Li; Zeng, Mu-sheng; Li, Man-zhi; Huang, Wen-lin; Zeng, Yi-xin] Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou 510275, Guangdong, Peoples R China; [Li, Jiang; Mo, Hao-yuan; Gao, Yan-fang; Zhang, Xiao-shi; Chen, Qiu-yan; Zhang, Li; Zeng, Mu-sheng; Li, Man-zhi; Huang, Wen-lin; Zeng, Yi-xin] Sun Yat Sen Univ, Ctr Canc, Dept Biotherapy, Guangzhou 510275, Guangdong, Peoples R China; [Li, Jiang; Mo, Hao-yuan; Gao, Yan-fang; Zhang, Xiao-shi; Chen, Qiu-yan; Zhang, Li; Zeng, Mu-sheng; Li, Man-zhi; Huang, Wen-lin; Zeng, Yi-xin] Sun Yat Sen Univ, Ctr Canc, Dept Expt Res, Guangzhou 510275, Guangdong, Peoples R China; [Li, Jiang; Mo, Hao-yuan; Gao, Yan-fang; Zhang, Xiao-shi; Chen, Qiu-yan; Zhang, Li; Zeng, Mu-sheng; Li, Man-zhi; Huang, Wen-lin; Zeng, Yi-xin] Sun Yat Sen Univ, Ctr Canc, Dept Radiotherapy, Guangzhou 510275, Guangdong, Peoples R China; [Zeng, Xue-hui; Wang, Xiao-ning] Technol Univ So China, Sch Biotechnol, Inst Mol Immunol, Guangzhou, Guangdong, Peoples R China; [Rolen, Ulrika; Masucci, Maria G.] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Karolinska Institutet	Zeng, YX (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, Guangzhou 510275, Guangdong, Peoples R China.	zengyxi@mail.sysu.edu.cn; maria.masucci@ki.se	huang, wen/GXW-0661-2022; Masucci, Maria/AAC-6666-2019	Masucci, Maria/0000-0002-5541-2809; zeng, musheng/0000-0003-3509-5591	Guangdong Province Natural Fund [04300284]; International Joint Project grant [2005B50301007]; NSFC; Research Grant Council of Hong Kong joint research fund [30418003]; NSF of China [30170872]; Swedish Cancer Society; Swedish Foundation for International Scientific Cooperation (STINT)	Guangdong Province Natural Fund; International Joint Project grant; NSFC(National Natural Science Foundation of China (NSFC)); Research Grant Council of Hong Kong joint research fund; NSF of China(National Natural Science Foundation of China (NSFC)); Swedish Cancer Society(Swedish Cancer Society); Swedish Foundation for International Scientific Cooperation (STINT)	We wish to thank Zhan Pen for assistance with FACS analysis, and Dr. Lu-lu Xiao for HLA typing. This study was supported by grants from the Guangdong Province Natural Fund (04300284), International Joint Project grant (2005B50301007), NSFC and the Research Grant Council of Hong Kong joint research fund (30418003) and NSF of China (30170872); and by grants from the Swedish Cancer Society and the Swedish Foundation for International Scientific Cooperation (STINT) (to MGM).	Ansell SM, 2002, BLOOD, V99, P67, DOI 10.1182/blood.V99.1.67; Asselin-Paturel C, 1999, GENE THER, V6, P606, DOI 10.1038/sj.gt.3300841; Blake N, 1997, IMMUNITY, V7, P791, DOI 10.1016/S1074-7613(00)80397-0; Brooks JM, 2000, J VIROL, V74, P1801, DOI 10.1128/JVI.74.4.1801-1809.2000; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; Burgos JS, 2005, MED ONCOL, V22, P113, DOI 10.1385/MO:22:2:113; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Chen WH, 2004, CELL MOL IMMUNOL, V1, P328; Comoli P, 2004, ANN ONCOL, V15, P113, DOI 10.1093/annonc/mdh027; Dolcetti R, 2006, PROGRESS IN VIRUS RESEARCH, P191; Dukers DF, 2000, J IMMUNOL, V165, P663, DOI 10.4049/jimmunol.165.2.663; Fang CY, 2004, J IMMUNOL METHODS, V287, P21, DOI 10.1016/j.jim.2004.01.021; Favre N, 1997, J IMMUNOL METHODS, V204, P57, DOI 10.1016/S0022-1759(97)00033-1; Feldman AL, 2002, INT J CANCER, V99, P149, DOI 10.1002/ijc.10292; FRISAN T, 1995, BLOOD, V86, P1493, DOI 10.1182/blood.V86.4.1493.bloodjournal8641493; Goldsmith DB, 2002, CLIN OTOLARYNGOL, V27, P61, DOI 10.1046/j.0307-7772.2001.00529.x; GUSTAFSSON A, BLOOD IN PRESS; Herbst H, 1996, BLOOD, V87, P2918, DOI 10.1182/blood.V87.7.2918.bloodjournal8772918; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; Hislop AD, 2002, J EXP MED, V195, P893, DOI 10.1084/jem.20011692; HO JH, 1978, IARC SCI PUBL, P99; HU LF, 1991, J VIROL, V65, P1558, DOI 10.1128/JVI.65.3.1558-1567.1991; Jimenez R, 2005, CYTOKINE, V32, P45, DOI 10.1016/j.cyto.2005.07.009; Khanna R, 1998, CANCER RES, V58, P310; Kis LL, 2006, BLOOD, V107, P2928, DOI 10.1182/blood-2005-06-2569; LEE AG, 1993, LIPOSOME TECHNOLOGY, V2, P1; Lee TV, 2000, J INTERF CYTOK RES, V20, P391, DOI 10.1089/107999000312333; LEVINE AM, 1994, ANN ONCOL, V5, pS29, DOI 10.1093/annonc/5.suppl_2.S29; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Linehan DC, 2005, IMMUNOL RES, V32, P155, DOI 10.1385/IR:32:1-3:155; Mould RF, 2002, BRIT J RADIOL, V75, P307, DOI 10.1259/bjr.75.892.750307; NAKAGOMI H, 1994, INT J CANCER, V57, P240, DOI 10.1002/ijc.2910570218; Ogino T, 2007, INT J CANCER, V120, P2401, DOI 10.1002/ijc.22334; Rickinson AB, 1997, ANNU REV IMMUNOL, V15, P405, DOI 10.1146/annurev.immunol.15.1.405; Shao JY, 2004, CANCER, V100, P1162, DOI 10.1002/cncr.20099; Straathof KCM, 2005, BLOOD, V105, P1898, DOI 10.1182/blood-2004-07-2975; STRANG G, 1987, EUR J IMMUNOL, V17, P1007, DOI 10.1002/eji.1830170717; Tatsumi-Tamori A, 2000, ANN OTO RHINOL LARYN, V109, P1125, DOI 10.1177/000348940010901208; THORN RM, 1974, J IMMUNOL METHODS, V4, P301, DOI 10.1016/0022-1759(74)90073-8; Vockerodt M, 2001, VIROLOGY, V280, P183, DOI 10.1006/viro.2000.0768; WALLACE LE, 1982, EUR J IMMUNOL, V12, P1012, DOI 10.1002/eji.1830121206; Wang HY, 2007, CURR OPIN IMMUNOL, V19, P217, DOI 10.1016/j.coi.2007.02.004; Wang RF, 2006, SEMIN CANCER BIOL, V16, P106, DOI 10.1016/j.semcancer.2005.11.004; Wei WZ, 2004, CANCER IMMUNOL IMMUN, V53, P73, DOI 10.1007/s00262-003-0444-1; Whitney BM, 2002, J MED VIROL, V67, P359, DOI 10.1002/jmv.10073; Wolfl M, 2004, CYTOM PART A, V57A, P120, DOI 10.1002/cyto.a.10116; Yin Y, 2003, SCIENCE, V301, P1371, DOI 10.1126/science.1088902; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Zeng YX, 2002, SEMIN CANCER BIOL, V12, P443, DOI 10.1016/S1044579X02000871	49	78	79	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2007	2	11							e1122	10.1371/journal.pone.0001122	http://dx.doi.org/10.1371/journal.pone.0001122			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10IZ	17987110	Green Published, Green Submitted, gold			2023-01-03	WOS:000207459000006
J	Winer, EP; Harris, JR; Smith, BL; D'Alessandro, HA; Brachtel, EF; Barbie, DA; Harris, NL				Winer, Eric P.; Harris, Jay R.; Smith, Barbara L.; D'Alessandro, Helen Anne; Brachtel, Elena F.; Barbie, David A.; Harris, Nancy Lee			A 62-year-old woman with a second breast cancer - Invasive ductal carcinoma, and ductal carcinoma in situ, of the right breast, grade 3 of 3, estrogen-receptor-positive and HER2-positive.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRIAL COMPARING DOXORUBICIN; ADJUVANT THERAPY; CANCER; TRASTUZUMAB; WOMEN; MAMMOGRAPHY; SURVIVAL; RISK; CYCLOPHOSPHAMIDE; SURVEILLANCE		Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Surg Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Winer, EP (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.							Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Abe O, 2005, LANCET, V366, P2087; Adjuvant! Online, ADJUVANT ONLINE DECI; Albain K, 2005, BREAST CANC RES TREA, V90, P195; Berry DA, 2000, J CLIN ONCOL, V18, P3471, DOI 10.1200/JCO.2000.18.20.3471; Carlson Robert W, 2006, J Natl Compr Canc Netw, V4 Suppl 1, pS1; CHANG JC, 2004, DIS BREAST, P675; Chia SK, 2004, J CLIN ONCOL, V22, P1630, DOI 10.1200/JCO.2004.09.070; CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5; Degner LF, 1997, JAMA-J AM MED ASSOC, V277, P1485, DOI 10.1001/jama.277.18.1485; Ellis MJ, 2006, J CLIN ONCOL, V24, P3019, DOI 10.1200/JCO.2005.04.3034; HEALEY EA, 1993, J CLIN ONCOL, V11, P1545, DOI 10.1200/JCO.1993.11.8.1545; Hu JCC, 2001, EUR J SURG ONCOL, V27, P335, DOI 10.1053/ejso.2000.1078; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Joensuu H, 2006, NEW ENGL J MED, V354, P809, DOI 10.1056/NEJMoa053028; Jones, 2007, J CLIN ONCOL, V25, P1819, DOI 10.1200/JCO.2007.11.9602; Jones SE, 2006, J CLIN ONCOL, V24, P5381, DOI 10.1200/JCO.2006.06.5391; Kriege M, 2004, NEW ENGL J MED, V351, P427, DOI 10.1056/NEJMoa031759; Kuhl CK, 2005, J CLIN ONCOL, V23, P8469, DOI 10.1200/JCO.2004.00.4960; Olivotto IA, 2005, J CLIN ONCOL, V23, P2716, DOI 10.1200/JCO.2005.06.178; Partridge A H, 2001, J Natl Cancer Inst Monogr, P135; PARTRIDGE AH, 2003, J NATL CANC I MONOGR, V31, P131; PARTRIDGE AH, 2002, J NATL CANC I MONOGR, V94, P866; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Press MF, 2005, CLIN CANCER RES, V11, P6598, DOI 10.1158/1078-0432.CCR-05-0636; Preston DL, 2002, RADIAT RES, V158, P220, DOI 10.1667/0033-7587(2002)158[0220:REOBCR]2.0.CO;2; Pritchard KI, 2006, NEW ENGL J MED, V354, P2103, DOI 10.1056/NEJMoa054504; ROBBINS P, 1995, HUM PATHOL, V26, P873, DOI 10.1016/0046-8177(95)90010-1; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; ROSEN PP, 1989, J CLIN ONCOL, V7, P355, DOI 10.1200/JCO.1989.7.3.355; Saphner T, 1996, J CLIN ONCOL, V14, P2738, DOI 10.1200/JCO.1996.14.10.2738; Shen Y, 2005, JNCI-J NATL CANCER I, V97, P1195, DOI 10.1093/jnci/dji239; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; SLAMON D, 2005, 28 ANN SAN ANT BREAS; Tan-Chiu E, 2005, J CLIN ONCOL, V23, P7811, DOI 10.1200/JCO.2005.02.4091; Wang S, 2000, J CLIN PATHOL, V53, P374, DOI 10.1136/jcp.53.5.374; Warner E, 2004, JAMA-J AM MED ASSOC, V292, P1317, DOI 10.1001/jama.292.11.1317; Winer EP, 2005, J CLIN ONCOL, V23, P619, DOI 10.1200/JCO.2005.09.121; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775	39	2	2	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 18	2007	357	16					1640	1648		10.1056/NEJMcpc079026	http://dx.doi.org/10.1056/NEJMcpc079026			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221AY	17942877				2023-01-03	WOS:000250200500011
J	DeSmet, PAGM; Kramers, C; Britten, N				DeSmet, Peter A. G. M.; Kramers, Cees; Britten, Nicky			Can drug regimens be adapted to patients, or vice versa?	LANCET			English	Editorial Material							MUCOCUTANEOUS REACTIONS; LOW DOSAGE; SIMVASTATIN; HYPERCHOLESTEROLEMIA; CHOLESTEROL; ADHERENCE; GOLD		Radboud Univ Nijmegen Med Ctr, Dept Clin Pharm, NL-6525 GA Nijmegen, Netherlands; Radboud Univ Nijmegen, Dept Pharmacol & Toxicol, Nijmegen, Netherlands; Univ Plymouth, Peninsula Med Sch, Exeter, Devon, England; Univ Exeter, Exeter, Devon, England	Radboud University Nijmegen; Radboud University Nijmegen; University of Exeter; University of Plymouth; University of Exeter	DeSmet, PAGM (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Clin Pharm, NL-6525 GA Nijmegen, Netherlands.	pdesmet@winap.nl	Smet, P.A.G.M./L-4654-2015; Kramers, C./L-4458-2015					Cheatum DE, 1996, J RHEUMATOL, V23, P944; Hughes DA, 2003, CLIN PHARMACOL THER, V74, P1, DOI 10.1016/S0009-9236(03)00091-2; Jenkins DJA, 2005, AM J CLIN NUTR, V81, P380; KLINKHOFF AV, 1995, J RHEUMATOL, V22, P1657; Kripalani S, 2007, ARCH INTERN MED, V167, P540, DOI 10.1001/archinte.167.6.540; Mangin EFM, 2004, ANN PHARMACOTHER, V38, P1789, DOI 10.1345/aph.1E134; Moreyra AE, 2005, ARCH INTERN MED, V165, P1161, DOI 10.1001/archinte.165.10.1161; Pound P, 2005, SOC SCI MED, V61, P133, DOI 10.1016/j.socscimed.2004.11.063; Rindone JP, 1999, PHARMACOTHERAPY, V19, P399, DOI 10.1592/phco.19.6.399.31045; TUOMILEHTO J, 1994, J CARDIOVASC PHARM, V24, P941, DOI 10.1097/00005344-199424060-00012	10	2	2	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 8	2007	370	9590					813	814		10.1016/S0140-6736(07)61395-6	http://dx.doi.org/10.1016/S0140-6736(07)61395-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	214JH	17826156				2023-01-03	WOS:000249733300011
J	Brown, RL				Brown, Rachel L.			Epilepsy onscreen: getting it wrong	LANCET			English	Editorial Material									Univ Oxford Somerville Coll, Oxford OX2 6HD, England	University of Oxford	Brown, RL (corresponding author), Univ Oxford Somerville Coll, Oxford OX2 6HD, England.	r.l.brown@some.oxon.org						BAXENDALE S, 2007, EPILEPSY BEHAV  0628; *JOHN AMB, 2007, IFIRSTAID 1 AID ADV	2	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 4	2007	370	9585					371	371		10.1016/S0140-6736(07)61174-X	http://dx.doi.org/10.1016/S0140-6736(07)61174-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	197XL	17679001				2023-01-03	WOS:000248590200009
J	Shanafelt, TD; Kay, NE				Shanafelt, Tait D.; Kay, Neil E.			Combination therapies for previously untreated CLL	LANCET			English	Editorial Material							CHRONIC LYMPHOCYTIC-LEUKEMIA; FLUDARABINE PLUS CYCLOPHOSPHAMIDE		Mayo Clin, Coll Med, Rochester, MN 55905 USA	Mayo Clinic	Kay, NE (corresponding author), Mayo Clin, Coll Med, Rochester, MN 55905 USA.	kay.neil@mayo.edu						Bellosillo B, 1999, BLOOD, V94, P2836, DOI 10.1182/blood.V94.8.2836.420k35_2836_2843; Catovsky D, 2007, LANCET, V370, P230, DOI 10.1016/S0140-6736(07)61125-8; Eichhorst BF, 2006, BLOOD, V107, P885, DOI 10.1182/blood-2005-06-2395; Flinn IW, 2007, J CLIN ONCOL, V25, P793, DOI 10.1200/JCO.2006.08.0762; Flinn IW, 2000, BLOOD, V96, P71, DOI 10.1182/blood.V96.1.71.013k21_71_75; Levy V, 2001, J CLIN EPIDEMIOL, V54, P747, DOI 10.1016/S0895-4356(00)00359-0; O'Brien SM, 2001, J CLIN ONCOL, V19, P1414, DOI 10.1200/JCO.2001.19.5.1414; Rai KR, 2000, NEW ENGL J MED, V343, P1750, DOI 10.1056/NEJM200012143432402	8	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 21	2007	370	9583					197	198		10.1016/S0140-6736(07)61100-3	http://dx.doi.org/10.1016/S0140-6736(07)61100-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	194MG	17658375				2023-01-03	WOS:000248347900005
J	Stowell, CP; Gelfand, JA; Shepard, JO; Kratz, A; Nundy, S				Stowell, Christopher P.; Gelfand, Jeffrey A.; Shepard, Jo-Anne O.; Kratz, Alexander; Nundy, Surajit			A woman with relapsing fevers and recent onset of dyspnea - Recurrent, fulminant babesiosis in an asplenic patient	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BOVIS-INFECTED ERYTHROCYTES; EXCHANGE-TRANSFUSION; BLOOD-DONORS; MALARIA; CLINDAMYCIN; PARASITEMIA; MICROTI; QUININE		Massachusetts Gen Hosp, Blood Transfus Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University	Stowell, CP (corresponding author), Massachusetts Gen Hosp, Blood Transfus Serv, Boston, MA 02114 USA.		Gelfand, Jeffrey A/G-1885-2018	Gelfand, Jeffrey A/0000-0002-4118-5676				BOUSTANI MR, 1994, AM J RESP CRIT CARE, V149, P1689, DOI 10.1164/ajrccm.149.6.8004331; Chen QJ, 2000, CLIN MICROBIOL REV, V13, P439, DOI 10.1128/CMR.13.3.439-450.2000; Corpelet C, 2005, EUR J CLIN MICROBIOL, V24, P74, DOI 10.1007/s10096-004-1270-x; Dorman SE, 2000, TRANSFUSION, V40, P375, DOI 10.1046/j.1537-2995.2000.40030375.x; Dzikowski R, 2006, MOL MICROBIOL, V59, P364, DOI 10.1111/j.1365-2958.2005.05007.x; Falagas ME, 1996, CLIN INFECT DIS, V22, P809, DOI 10.1093/clinids/22.5.809; Fraser IP, 2006, NEW ENGL J MED, V355, P1715, DOI 10.1056/NEJMcpc069022; Gelfand JA, 1998, CURR CLIN TOPICS INF, V18, P201; Hatcher JC, 2001, CLIN INFECT DIS, V32, P1117, DOI 10.1086/319742; Hemmer RM, 2000, PARASITOL RES, V86, P121, DOI 10.1007/s004360050021; HUGHES WT, 1995, J INFECT DIS, V172, P1042, DOI 10.1093/infdis/172.4.1042; JACOBY GA, 1980, NEW ENGL J MED, V303, P1098, DOI 10.1056/NEJM198011063031906; Krause PJ, 1998, NEW ENGL J MED, V339, P160, DOI 10.1056/NEJM199807163390304; Kutter Dolphe, 2002, Clin Lab, V48, P163; Leiby DA, 2005, TRANSFUSION, V45, P1804, DOI 10.1111/j.1537-2995.2005.00609.x; Leiby DA, 2002, TRANSFUSION, V42, P1585, DOI 10.1046/j.1537-2995.2002.00251.x; O'Connor RM, 2000, J IMMUNOL, V164, P2037, DOI 10.4049/jimmunol.164.4.2037; O'Connor RM, 1999, INFECT IMMUN, V67, P3921; Pantanowitz L, 2002, TRANSFUS MED REV, V16, P131, DOI 10.1053/tmrv.2002.31462; Powell VI, 2002, TRANSFUS MED REV, V16, P239, DOI 10.1053/tmrv.2002.33437; RAOULT D, 1987, ANN INTERN MED, V107, P943, DOI 10.7326/0003-4819-107-6-944_2; ROSNER F, 1984, AM J MED, V76, P696, DOI 10.1016/0002-9343(84)90298-5; Setty S, 2003, AM J CLIN PATHOL, V120, P554, DOI 10.1309/N3DP9MFPNUJD4XJY; Shaio MF, 1998, AM J TROP MED HYG, V58, P335, DOI 10.4269/ajtmh.1998.58.335; Weiss LM, 2001, NEW ENGL J MED, V344, P773; White DJ, 1998, ARCH INTERN MED, V158, P2149, DOI 10.1001/archinte.158.19.2149	26	29	29	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 31	2007	356	22					2313	2319		10.1056/NEJMcpc079011	http://dx.doi.org/10.1056/NEJMcpc079011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172PO	17538091				2023-01-03	WOS:000246816500012
J	Alinari, L; Lapalombella, R; Andritsos, L; Baiocchi, RA; Lin, TS; Byrd, JC				Alinari, L.; Lapalombella, R.; Andritsos, L.; Baiocchi, R. A.; Lin, T. S.; Byrd, J. C.			Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia	ONCOGENE			English	Review						B-cell chronic lymphocytic leukemia; CD52 antigen; alemtuzumab; monoclonal antibody therapy; T-cell depletion; immunosuppression	MONOCLONAL-ANTIBODY THERAPY; STEM-CELL TRANSPLANTATION; INTENSITY ALLOGENEIC TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; PHASE-II TRIAL; RESIDUAL DISEASE; T-CELLS; LYMPHOPROLIFERATIVE DISORDERS; SUBCUTANEOUS ALEMTUZUMAB; PROLYMPHOCYTIC LEUKEMIA	Alemtuzumab (Campath-1H) is a humanized IgG1 monoclonal antibody that targets the human CD52 antigen. CD52 is expressed by a variety of lymphoid neoplasms and most human mononuclear cell subsets. In 2001, alemtuzumab was approved for marketing in the United States and Europe for use in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). In heavily pretreated patients with CLL, the overall response rate (ORR) is approximately 35%, and in previously untreated patients the ORR is greater than 80%, with a recent randomized study suggesting it is superior to alkylator-based therapy. Importantly, alemtuzumab is effective in patients with high-risk del(17p13.1) and del(11q22.3) CLL. Alemtuzumab combination studies with fludarabine and/or monoclonal antibodies such as rituximab have demonstrated promising results. Alemtuzumab is also being studied in CLL patients as consolidation therapy for treatment of minimal residual disease, in preparation for stem cell transplantation and to prevent acute and chronic graft versus host disease. Alemtuzumab is frequently associated with acute 'first-dose' reactions when administered intravenously, but is much better tolerated when administered subcutaneously without loss of therapeutic efficacy. Additional potential adverse events associated with alemtuzumab administration include myelosuppression as well as profound cellular immune dysfunction with the associated risk of viral reactivation and other opportunistic infections. Additional studies detailing the mechanism of action of alemtuzumab as well as new strategies for prevention of opportunistic infections will aid in the future therapeutic development of this agent.	Ohio State Univ, Dept Med, Div Hematol Oncol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Byrd, JC (corresponding author), Ohio State Univ, Dept Internal Med, Div Hematol Oncol, B301 Starling Loving Hall,320 W 10th Ave, Columbus, OH 43210 USA.	john.byrd@osumc.edu	Lapalombella, Rosa/C-2837-2014; Lapalombella, Rosa/AAG-1856-2021					Bowen AL, 1997, BRIT J HAEMATOL, V96, P617, DOI 10.1046/j.1365-2141.1997.d01-2061.x; Buggins AGS, 2002, BLOOD, V100, P1715, DOI 10.1182/blood.V100.5.1715.h81702001715_1715_1720; Byrd John C, 2004, Hematology Am Soc Hematol Educ Program, P163; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Cheson BD, 2006, CANCER IMMUNOL IMMUN, V55, P188, DOI 10.1007/s00262-005-0010-0; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; CROWE JS, 1992, CLIN EXP IMMUNOL, V87, P105; Deans JP, 2002, IMMUNOLOGY, V107, P176, DOI 10.1046/j.1365-2567.2002.01495.x; Delgado J, 2006, BLOOD, V107, P1724, DOI 10.1182/blood-2005-08-3372; Dyer MJS, 1997, BRIT J HAEMATOL, V97, P669, DOI 10.1046/j.1365-2141.1997.1062924.x; Elsner J, 1996, BLOOD, V88, P4684, DOI 10.1182/blood.V88.12.4684.bloodjournal88124684; Elter T, 2005, J CLIN ONCOL, V23, P7024, DOI 10.1200/JCO.2005.01.9950; Faderl S, 2003, BLOOD, V101, P3413, DOI 10.1182/blood-2002-07-1952; Faulkner RD, 2004, BLOOD, V103, P428, DOI 10.1182/blood-2003-05-1406; Ferrajoli A, 2003, CANCER, V98, P773, DOI 10.1002/cncr.11551; Flinn IW, 1998, SEMIN ONCOL, V25, P60; Flynn JM, 2000, CURR OPIN ONCOL, V12, P574, DOI 10.1097/00001622-200011000-00010; Frampton JE, 2003, DRUGS, V63, P1229, DOI 10.2165/00003495-200363120-00003; Garcia A, 2003, BIOCHIMIE, V85, P727, DOI 10.1016/j.biochi.2003.09.005; GILLEECE MH, 1993, BLOOD, V82, P807; Ginaldi L, 1998, LEUKEMIA RES, V22, P185, DOI 10.1016/S0145-2126(97)00158-6; Golay J, 2004, HAEMATOLOGICA, V89, P1476; Hale G, 2004, BLOOD, V104, P948, DOI 10.1182/blood-2004-02-0593; HALE G, 1985, J IMMUNOL, V134, P3056; HALE G, 1990, TISSUE ANTIGENS, V35, P118, DOI 10.1111/j.1399-0039.1990.tb01767.x; Hale G, 2001, CYTOTHERAPY, V3, P137, DOI 10.1080/146532401753174098; HALE G, 1993, J REPROD IMMUNOL, V23, P189, DOI 10.1016/0165-0378(93)90007-5; Hale G, 2002, BONE MARROW TRANSPL, V30, P797, DOI 10.1038/sj.bmt.1703733; HALE G, 1983, BLOOD, V62, P873; Hillmen P, 2006, J CLIN ONCOL, V24, p339S; ISAACS JD, 1992, LANCET, V340, P748, DOI 10.1016/0140-6736(92)92294-P; Juliusson G, 2006, BONE MARROW TRANSPL, V37, P503, DOI 10.1038/sj.bmt.1705263; Keating MJ, 2002, BLOOD, V99, P3554, DOI 10.1182/blood.V99.10.3554; Kennedy B, 2002, BLOOD, V99, P2245, DOI 10.1182/blood.V99.6.2245; Klangsinsirikul P, 2002, BLOOD, V99, P2586, DOI 10.1182/blood.V99.7.2586; Kottaridis PD, 2000, BLOOD, V96, P2419; Lenihan DJ, 2004, BLOOD, V104, P655, DOI 10.1182/blood-2003-07-2345; Lin TS, 2005, LEUKEMIA, V19, P1207, DOI 10.1038/sj.leu.2403782; Lin TS, 2005, BLOOD, V105, P289, DOI 10.1182/blood-2004-02-0651; Lozanski G, 2004, BLOOD, V103, P3278, DOI 10.1182/blood-2003-10-3729; Lundin J, 2004, LEUKEMIA, V18, P484, DOI 10.1038/sj.leu.2403258; Lundin J, 2002, BLOOD, V100, P768, DOI 10.1182/blood-2002-01-0159; Martino R, 2001, BRIT J HAEMATOL, V115, P653, DOI 10.1046/j.1365-2141.2001.03153.x; Michallet M, 1996, ANN INTERN MED, V124, P311, DOI 10.7326/0003-4819-124-3-199602010-00005; Mone AP, 2006, LEUKEMIA, V20, P272, DOI 10.1038/sj.leu.2404014; Montillo M, 2006, J CLIN ONCOL, V24, P2337, DOI 10.1200/JCO.2005.04.6037; Moreton P, 2005, J CLIN ONCOL, V23, P2971, DOI 10.1200/JCO.2005.04.021; Morris E, 2004, BLOOD, V104, P3865, DOI 10.1182/blood-2004-03-1105; Nguyen DD, 2002, CLIN LYMPHOMA, V3, P105, DOI 10.3816/CLM.2002.n.016; Nuckel H, 2005, EUR J PHARMACOL, V514, P217, DOI 10.1016/j.ejphar.2005.03.024; O'Brien S, 2005, BLOOD, V106, p830A; O'Brien SM, 2003, CANCER, V98, P2657, DOI 10.1002/cncr.11871; Osterborg A, 1996, BRIT J HAEMATOL, V93, P151, DOI 10.1046/j.1365-2141.1996.450989.x; Osterborg A, 1997, J CLIN ONCOL, V15, P1567, DOI 10.1200/JCO.1997.15.4.1567; Osterborg A, 2006, SEMIN ONCOL, V33, pS29, DOI 10.1053/j.seminoncol.2006.01.027; Perez-Simon JA, 2002, BLOOD, V100, P3121, DOI 10.1182/blood-2002-03-0701; Perkins JG, 2002, CANCER-AM CANCER SOC, V94, P2033, DOI 10.1002/cncr.0680; Rai KR, 2002, J CLIN ONCOL, V20, P3891, DOI 10.1200/JCO.2002.06.119; Ratzinger G, 2003, BLOOD, V101, P1422, DOI 10.1182/blood-2002-04-1093; Robak T, 2005, BIODRUGS, V19, P9, DOI 10.2165/00063030-200519010-00002; Rossmann E D, 2001, Hematol J, V2, P300, DOI 10.1038/sj.thj.6200119; Rowan W, 1998, IMMUNOLOGY, V95, P427; ROZMAN C, 1995, NEW ENGL J MED, V333, P1052, DOI 10.1056/NEJM199510193331606; Smolewski P, 2005, LEUKEMIA LYMPHOMA, V46, P87, DOI 10.1080/13693780400007151; Sorror ML, 2005, J CLIN ONCOL, V23, P3819, DOI 10.1200/JCO.2005.04.569; Stanglmaier M, 2004, ANN HEMATOL, V83, P634, DOI 10.1007/s00277-004-0917-0; Stilgenbauer S, 2002, NEW ENGL J MED, V347, P452, DOI 10.1056/NEJM200208083470619; Watanabe T, 2006, CLIN IMMUNOL, V120, P247, DOI 10.1016/j.clim.2006.05.006; Wendtner CM, 2004, LEUKEMIA, V18, P1093, DOI 10.1038/sj.leu.2403354; Wierda W, 2004, BLOOD, V104, p101A, DOI 10.1182/blood.V104.11.340.340; Wing MG, 1996, J CLIN INVEST, V98, P2819, DOI 10.1172/JCI119110; XIA MQ, 1993, MOL IMMUNOL, V30, P1089; XIA MQ, 1993, BIOCHEM J, V293, P633, DOI 10.1042/bj2930633; Zent CS, 2004, LEUKEMIA RES, V28, P495, DOI 10.1016/j.leukres.2003.09.011; Zhang ML, 2006, BLOOD, V108, P705, DOI 10.1182/blood-2005-11-4607	75	82	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3644	3653		10.1038/sj.onc.1210380	http://dx.doi.org/10.1038/sj.onc.1210380			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530018				2023-01-03	WOS:000246816100007
J	Berkowitz, SA; Gerstenblith, G; Anderson, GF				Berkowitz, Scott A.; Gerstenblith, Gary; Anderson, Gerard F.			Medicare prescription drug coverage gap - Navigating the "doughnut hole" with patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University	Anderson, GF (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Hampton House 302, Baltimore, MD 21205 USA.	ganderso@jhsph.edu						Berlowitz DR, 1998, NEW ENGL J MED, V339, P1957, DOI 10.1056/NEJM199812313392701; Centers for Medicare and Medicaid Services, MED YOU; CUBANSKI J, 2006, HLTH AFF MILLWO 1121, pW1; *DEST RX, PART D OPT; *KAIS FAM FDN, 2006, PRESCR DRUG COV MED; *KAIS FAM FDN, 2006, KAIS DAIL HLTH POL R; Mitka M, 2006, JAMA-J AM MED ASSOC, V296, P1720; *PRICEWATERHOUSECO, 2006, SIGN COV GAP MED PAR; SIMON S, 2006, NATL PUBLIC RAD 1007; Tseng CW, 2004, JAMA-J AM MED ASSOC, V292, P952, DOI 10.1001/jama.292.8.952; *US DEP HHS, 2006, MEDICARE        1013; *US FDA, 2005, INF IMP DRUGS; *US FDA, OR BOOK	13	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	2007	297	8					868	870		10.1001/jama.297.8.868	http://dx.doi.org/10.1001/jama.297.8.868			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140DS	17327528				2023-01-03	WOS:000244485000029
J	Markowitz, AJ; Pantilat, SZ				Markowitz, Amy J.; Pantilat, Steven Z.			Palliative care for frail older adults: "There are things I can't do anymore that I wish I could"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Boockvar KS, 2006, JAMA-J AM MED ASSOC, V296, P2245, DOI 10.1001/jama.296.18.2245	1	1	1	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2006	296	24					2967	2967		10.1001/jama.296.24.2967	http://dx.doi.org/10.1001/jama.296.24.2967			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120FD	17190898				2023-01-03	WOS:000243069000029
J	Arce, C; Perez-Plasencia, C; Gonzalez-Fierro, A; de la Cruz-Hernandez, E; Revilla-Vazquez, A; Chavez-Blanco, A; Trejo-Becerril, C; Perez-Cardenas, E; Taja-Chayeb, L; Bargallo, E; Villarreal, P; Ramirez, T; Vela, T; Candelaria, M; Camargo, MF; Robles, E; Duenas-Gonzalez, A				Arce, Claudia; Perez-Plasencia, Carlos; Gonzalez-Fierro, Aurora; de la Cruz-Hernandez, Erick; Revilla-Vazquez, Alma; Chavez-Blanco, Alma; Trejo-Becerril, Catalina; Perez-Cardenas, Enrique; Taja-Chayeb, Lucia; Bargallo, Enrique; Villarreal, Patricia; Ramirez, Teresa; Vela, Teresa; Candelaria, Myrna; Camargo, Maria F.; Robles, Elizabeth; Duenas-Gonzalez, Alfonso			A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer	PLOS ONE			English	Article								Background. Aberrant DNA methylation and histone deacetylation participate in cancer development and progression; hence, their reversal by inhibitors of DNA methylation and histone deacetylases (HDACs) is at present undergoing clinical testing in cancer therapy. As epigenetic alterations are common to breast cancer, in this proof-of-concept study demethylating hydralazine, plus the HDAC inhibitor magnesium valproate, were added to neoadjuvant doxorubicin and cyclophosphamide in locally advanced breast cancer to assess their safety and biological efficacy. Methodology. This was a single-arm interventional trial on breast cancer patients (ClinicalTrials.gov Identifier: NCT00395655). After signing informed consent, patients were typed for acetylator phenotype and then treated with hydralazine at 182 mg for rapid-, or 83 mg for slow-acetylators, and magnesium valproate at 30 mg/kg, starting from day -7 until chemotherapy ended, the latter consisting of four cycles of doxorubicin 60 mg/m(2) and cyclophosphamide 600 mg/m(2) every 21 days. Core-needle biopsies were taken from primary breast tumors at diagnosis and at day 8 of treatment with hydralazine and valproate. Main Findings. 16 patients were included and received treatment as planned. All were evaluated for clinical response and toxicity and 15 for pathological response. Treatment was well-tolerated. The most common toxicity was drowsiness grades 1-2. Five (31%) patients had clinical CR and eight (50%) PR for an ORR of 81%. No patient progressed. One of 15 operated patients (6.6%) had pathological CR and 70% had residual disease <3 cm. There was a statistically significant decrease in global 5(m)C content and HDAC activity. Hydralazine and magnesium valproate up- and down-regulated at least 3-fold, 1,091 and 89 genes, respectively. Conclusions. Hydralazine and magnesium valproate produce DNA demethylation, HDAC inhibition, and gene reactivation in primary tumors. Doxorubicin and cyclophosphamide treatment is safe, well-tolerated, and appears to increase the efficacy of chemotherapy. A randomized phase III study is ongoing to support the efficacy of so-called epigenetic or transcriptional cancer therapy.	[Perez-Plasencia, Carlos; Gonzalez-Fierro, Aurora; de la Cruz-Hernandez, Erick; Chavez-Blanco, Alma; Trejo-Becerril, Catalina; Perez-Cardenas, Enrique; Taja-Chayeb, Lucia; Camargo, Maria F.; Duenas-Gonzalez, Alfonso] Univ Nacl Autonoma Mexico, Inst Nacl Cancerol INCAN, Inst Invest Biomed, Unidad Invest Biomed Canc, Mexico City 04510, DF, Mexico; [Arce, Claudia; Candelaria, Myrna; Robles, Elizabeth] Inst Nacl Cancerol INCAN, Div Invest Clin, Mexico City, DF, Mexico; [Revilla-Vazquez, Alma] Univ Nacl Autonoma Mexico, Lab Desarrollo Metodos Analit, FES Cuautitlan, Cuautitlan, Estado Mexico, Mexico; [Bargallo, Enrique; Villarreal, Patricia; Ramirez, Teresa] Inst Nacl Cancerol INCAN, Dept Tumores Mamarios, Mexico City, DF, Mexico; [Vela, Teresa] Inst Nacl Cancerol INCAN, Dept Patol, Mexico City, DF, Mexico	Instituto Nacional de Cancerologia (INCAN); Universidad Nacional Autonoma de Mexico; Instituto Nacional de Cancerologia (INCAN); Universidad Nacional Autonoma de Mexico; Instituto Nacional de Cancerologia (INCAN); Instituto Nacional de Cancerologia (INCAN)	Duenas-Gonzalez, A (corresponding author), Univ Nacl Autonoma Mexico, Inst Nacl Cancerol INCAN, Inst Invest Biomed, Unidad Invest Biomed Canc, Mexico City 04510, DF, Mexico.	alfonso_duenasg@yahoo.com	De la Cruz-Hernandez, Erick/E-1487-2019; Perez-Plasencia, Carlos/P-2372-2019	De la Cruz-Hernandez, Erick/0000-0001-5236-7347; Perez-Plasencia, Carlos/0000-0002-8593-8211; Revilla Vazquez, Alma Luisa/0000-0002-4714-0866	CONACyT [SALUD-2002-C01-6579, AVANCE C01-294]; Psicofarma; S. A. de C. V., Mexico	CONACyT(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Psicofarma; S. A. de C. V., Mexico	This work was supported by CONACyT grants SALUD-2002-C01-6579 and AVANCE C01-294, and by Psicofarma, S. A. de C. V., Mexico. Sponsors did not participate in study design; collection, analysis, and interpretation of data; writing of the paper; nor decision to submit it for publication.	Acharya S, 2000, J PEDIAT HEMATOL ONC, V22, P62, DOI 10.1097/00043426-200001000-00012; Angeles E, 2005, LETT DRUG DES DISCOV, V2, P282, DOI 10.2174/1570180054038413; Blagosklonny MV, 2005, CANCER RES, V65, P7386, DOI 10.1158/0008-5472.CAN-04-3433; Bonadonna G, 1998, J CLIN ONCOL, V16, P93, DOI 10.1200/JCO.1998.16.1.93; Bourg V, 2001, ANN ONCOL, V12, P217, DOI 10.1023/A:1008331708395; Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294; Brain E, 1997, BRIT J CANCER, V75, P1360, DOI 10.1038/bjc.1997.230; Buchholz TA, 2002, CANCER J, V8, P461, DOI 10.1097/00130404-200211000-00010; Bug G, 2005, CANCER RES, V65, P2537, DOI 10.1158/0008-5472.CAN-04-3011; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Castaneda-Hernandez G., 1995, Am J Ther, V2, P57, DOI 10.1097/00045391-199501000-00011; Chavez-Blanco A, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-2; Chavez-Blanco A, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-22; Claus R, 2005, SEMIN ONCOL, V32, P511, DOI 10.1053/j.seminoncol.2005.07.024; Cristofanilli M, 2006, CANCER-AM CANCER SOC, V107, P935, DOI 10.1002/cncr.22080; FERNANDEZSANCHE.M, 1998, MED ONCOL, V23, P171; Fisher B, 1997, J CLIN ONCOL, V15, P2483, DOI 10.1200/JCO.1997.15.7.2483; Frank NY, 2005, CANCER RES, V65, P4320, DOI 10.1158/0008-5472.CAN-04-3327; Gagnon J, 2003, ANTI-CANCER DRUG, V14, P193, DOI 10.1097/00001813-200303000-00002; GARCIAMANERO G, 2006, BLOOD           0801; Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314; Gollob JA, 2006, CLIN CANCER RES, V12, P4619, DOI 10.1158/1078-0432.CCR-06-0883; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Guerrero KS, 2005, ELECTROPHORESIS, V26, P1057, DOI 10.1002/elps.200410040; Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008-5472.CAN-03-0799; Hartsough MT, 2001, CANCER RES, V61, P2320; Huang GC, 2004, MOL CELL BIOL, V24, P8447, DOI 10.1128/MCB.24.19.8447-8456.2004; Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459; Karagiannis TC, 2006, ONCOGENE, V25, P3885, DOI 10.1038/sj.onc.1209417; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Kaufmann M, 2006, J CLIN ONCOL, V24, P1940, DOI 10.1200/JCO.2005.02.6187; Kim MS, 2003, CANCER RES, V63, P7291; Kitazono M, 2002, CANCER BIOL THER, V1, P665, DOI 10.4161/cbt.317; Klisovic MI, 2003, LEUKEMIA, V17, P350, DOI 10.1038/sj.leu.2402776; Kuerer HM, 1999, J CLIN ONCOL, V17, P460, DOI 10.1200/JCO.1999.17.2.460; LESSER JM, 1974, DRUG METAB DISPOS, V2, P351; Li L, 2005, J COMPUT BIOL, V12, P370, DOI 10.1089/cmb.2005.12.370; Mai A, 2005, MED RES REV, V25, P261, DOI 10.1002/med.20024; Mamelak AJ, 2005, EXP DERMATOL, V14, P336, DOI 10.1111/j.0906-6705.2005.00278.x; Mauri D, 2005, JNCI-J NATL CANCER I, V97, P188, DOI 10.1093/jnci/dji021; Mielnicki LM, 2001, J MAMMARY GLAND BIOL, V6, P169, DOI 10.1023/A:1011356623442; Modlich O, 2004, CLIN CANCER RES, V10, P6418, DOI 10.1158/1078-0432.CCR-04-1031; Morrell LE, 1998, CANCER-AM CANCER SOC, V82, P503, DOI 10.1002/(SICI)1097-0142(19980201)82:3<503::AID-CNCR12>3.0.CO;2-5; Perez-Plasencia C, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-27; POWLES TJ, 1995, J CLIN ONCOL, V13, P547, DOI 10.1200/JCO.1995.13.3.547; Primeau M, 2003, INT J CANCER, V103, P177, DOI 10.1002/ijc.10789; REECE PA, 1980, J CHROMATOGR, V181, P427, DOI 10.1016/S0378-4347(00)81145-7; Rouzier R, 2005, J CLIN ONCOL, V23, P8331, DOI 10.1200/JCO.2005.01.2898; Rouzier R, 2002, J CLIN ONCOL, V20, P1304, DOI 10.1200/JCO.20.5.1304; Samlowski WE, 2005, J CLIN ONCOL, V23, P3897, DOI 10.1200/JCO.2005.06.118; Scholl SM, 1995, EUR J CANCER, V31A, P1969, DOI 10.1016/0959-8049(95)00454-8; Schover LR, 1994, J PSYCHOL HUMAN SEXU, V6, P5; SCHWARTZ GF, 1994, CANCER, V73, P362, DOI 10.1002/1097-0142(19940115)73:2<362::AID-CNCR2820730221>3.0.CO;2-L; Segura-Pacheco B, 2003, CLIN CANCER RES, V9, P1596; Selivanova G, 1998, SEMIN CANCER BIOL, V8, P369, DOI 10.1006/scbi.1998.0099; Shi HD, 2003, CANCER RES, V63, P2164; Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063; Sonnemann J, 2006, INT J ONCOL, V28, P755; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tang Bo, 2005, Zhonghua Bing Li Xue Za Zhi, V34, P283; Tomasi TB, 2006, CANCER IMMUNOL IMMUN, V55, P1159, DOI 10.1007/s00262-006-0164-4; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van der Hage JA, 2001, J CLIN ONCOL, V19, P4224, DOI 10.1200/JCO.2001.19.22.4224; Wong TWL, 2000, LIFE SCI, V67, pPL1111; Yan PS, 2001, CANCER RES, V61, P8375; Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115; Zambrano P, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-44; Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440; Zhu WG, 2001, CANCER RES, V61, P1327	70	113	123	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e98	10.1371/journal.pone.0000098	http://dx.doi.org/10.1371/journal.pone.0000098			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183730	Green Published, Green Submitted, gold			2023-01-03	WOS:000207443600097
J	Weigel, PH; Kyossev, Z; Torres, LC				Weigel, Paul H.; Kyossev, Zhetcho; Torres, Lindsey C.			Phospholipid dependence and liposome reconstitution of purified hyaluronan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							10-N-NONYL ACRIDINE-ORANGE; STREPTOCOCCUS-PYOGENES; MOLECULAR-CLONING; BACILLUS-SUBTILIS; CARDIOLIPIN; BIOSYNTHESIS; EQUISIMILIS; DOMAINS; GENE; DYE	Previous radiation inactivation and enzyme characterization studies demonstrated that the Streptococcus equisimilis hyaluronan synthase (seHAS) is phospholipid-dependent and that cardiolipin (CL) is the best phospholipid for enzyme activation. Here we investigated the ability of seHAS, purified in the absence of added lipid, to be activated by synthetic phosphatidic acid (PA), phosphatidylserine, or CL lipids containing fatty acyl chains of different length or different numbers of double bonds. The most effective lipid was tetraoleoyl CL (TO-CL), whereas tetramyristoyl CL (TMCL) was ineffective. None of the phosphatidylserine species tested gave significant activation. PAs containing C10 to C18 saturated acyl chains were not effective activators, and neither were oleoyl lyso PA, dilinoleoyl PA, or PA containing one oleoyl chain and either a palmitoyl or stearoyl chain. In contrast, dioleoyl PA stimulated seHAS similar to 10-fold, to similar to 20% of the activity observed with TO-CL. The tested acidic lipids such as PA and CL activated the enzyme most efficiently if they contained only oleic acid. Mixing experiments showed that the enzyme interacts preferentially with TO-CL in the presence of TM-CL. Similarly, seHAS incorporated into phosphotidylcholine-based liposomes showed increasing activity with increasing TO-CL, but not TM-CL, content. Inactivation of membrane-bound seHAS by solubilization with Nonidet P-40 was prevented by TO-CL, but not TM-CL. The pH dependence of seHAS in the presence of synthetic or naturally occurring CLs showed the same pattern of lipid preference between pH6 and 10.5. Unexpectedly, HAS showed lipid-independent activity at pH 11.5. The results suggest that Class I HAS enzymes are lipid-dependent and that assembly of active seHAS-lipid complexes has high specificity for the phospholipid head group and the nature of the fatty acyl chains.	Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.	paul-weigel@ouhsc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35978] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bodevin-Authelet S, 2005, J BIOL CHEM, V280, P8813, DOI 10.1074/jbc.M412803200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHANDRA NC, 1991, ARCH BIOCHEM BIOPHYS, V290, P345, DOI 10.1016/0003-9861(91)90550-3; DeAngelis PL, 1999, CELL MOL LIFE SCI, V56, P670, DOI 10.1007/s000180050461; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; Fernandez MIG, 2004, ANAL BIOCHEM, V328, P174, DOI 10.1016/j.ab.2004.01.020; Gomez B, 1999, BIOCHEMISTRY-US, V38, P9031, DOI 10.1021/bi990603r; Heldermon C, 2001, J BIOL CHEM, V276, P2037, DOI 10.1074/jbc.M002276200; Itano N, 2002, IUBMB LIFE, V54, P195, DOI 10.1080/15216540214929; Kawai F, 2004, J BACTERIOL, V186, P1475, DOI 10.1128/JB.186.5.1475-1483.2004; Kumari K, 1997, J BIOL CHEM, V272, P32539, DOI 10.1074/jbc.272.51.32539; Kumari K, 2006, J BIOL CHEM, V281, P11755, DOI 10.1074/jbc.M600727200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Megli FM, 2000, BIOCHEMISTRY-US, V39, P5534, DOI 10.1021/bi992779z; Mileykovskaya E, 2000, J BACTERIOL, V182, P1172, DOI 10.1128/JB.182.4.1172-1175.2000; Mileykovskaya E, 2001, FEBS LETT, V507, P187, DOI 10.1016/S0014-5793(01)02948-9; Palsdottir H, 2004, BBA-BIOMEMBRANES, V1666, P2, DOI 10.1016/j.bbamem.2004.06.012; Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200; Pummill PE, 2001, J BIOL CHEM, V276, P39832, DOI 10.1074/jbc.M105489200; Rigaud JL, 2003, METHOD ENZYMOL, V372, P65; Tlapak-Simmons VL, 2005, J BIOL CHEM, V280, P13012, DOI 10.1074/jbc.M409788200; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4246, DOI 10.1074/jbc.274.7.4246; Tlapak-Simmons VL, 1998, J BIOL CHEM, V273, P26100, DOI 10.1074/jbc.273.40.26100; Tlapak-Simmons VL, 2004, BIOCHEMISTRY-US, V43, P9234, DOI 10.1021/bi049468v; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4239, DOI 10.1074/jbc.274.7.4239; VANDENBRINKVAND.E, 2003, J BACTERIOL, V185, P3773, DOI DOI 10.1128/JB.185.13.3773-3779.2003; Ward PN, 2001, INFECT IMMUN, V69, P392, DOI 10.1128/IAI.69.1.392-399.2001; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Weigel PH, 2002, IUBMB LIFE, V54, P201, DOI 10.1080/15216540214931; WEIGEL PH, 2004, GLYCOFORUM HYALURONA; Widner B, 2005, APPL ENVIRON MICROB, V71, P3747, DOI 10.1128/AEM.71.7.3747-3752.2005; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497; Zazueta C, 2003, J MEMBRANE BIOL, V191, P113, DOI 10.1007/s00232-002-1047-z; Zhang M, 2005, J BIOL CHEM, V280, P29403, DOI 10.1074/jbc.M504955200	37	16	18	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36542	36551		10.1074/jbc.M606529200	http://dx.doi.org/10.1074/jbc.M606529200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16984914	hybrid			2023-01-03	WOS:000242220800010
J	Fahrenkopf, AM; Sectish, TC; Barger, LK; Sharek, PJ; Lewin, D; Chiang, VW; Edwards, S; Wiedermann, BL; Landrigan, CP				Fahrenkopf, Amy M.; Sectish, Theodore C.; Barger, Laura K.; Sharek, Paul J.; Lewin, Daniel; Chiang, Vincent W.; Edwards, Sarah; Wiedermann, Bernhard L.; Landrigan, Christopher P.			Rates of medication errors among depressed and burnt out residents: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							PATIENT-CARE; WORK HOURS; INTERNS; ANXIETY; INPATIENTS; EDUCATION; DISTRESS; PROGRAM; EMPATHY; EVENTS	Objective To determine the prevalence of depression and burnout among residents in paediatrics and to establish if a relation exists between these disorders and medication errors. Design Prospective cohort study. Setting Three urban freestanding children's hospitals in the United States. Participants 123 residents in three paediatric residency programmes. Main outcome measures Prevalence of depression using the Harvard national depression screening day scale, burnout using the Maslach burnout inventory, and rate of medication errors per resident month. Results 24 (20%) of the participating residents met the criteria for depression and 92 (74%) met the criteria for burnout. Active surveillance yielded 45 errors made by participants. Depressed residents made 6.2 times as many medication errors per resident month as residents who were not depressed: 1.55 (95% confidence interval 0.57 to 4.22) compared with 0.25 (0.14 to 0.46, P<0.001). Burnt out residents and non-burnt out residents made similar rates of errors per resident month: 0.45 (0.20 to 0.98) compared with 0.53 (0.21 to 1.33, P=0.2). Conclusions Depression and burnout are major problems among residents in paediatrics. Depressed residents made significantly more medical errors than their non-depressed peers; however, burnout did not seem to correlate with an increased rate of medical errors.	[Fahrenkopf, Amy M.; Chiang, Vincent W.; Landrigan, Christopher P.] Harvard Univ, Sch Med, Dept Med, Childrens Hosp, Boston, MA 02115 USA; [Sectish, Theodore C.; Sharek, Paul J.] Stanford Univ, Sch Med, Lucile Packard Childrens Hosp, Palo Alto, CA 94304 USA; [Barger, Laura K.; Edwards, Sarah; Landrigan, Christopher P.] Brigham & Womens Hosp, Div Sleep Med, Boston, MA 02115 USA; [Lewin, Daniel; Wiedermann, Bernhard L.] George Washington Univ, Sch Med, Childrens Natl Med Ctr, Washington, DC USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Lucile Packard Children's Hospital (LPCH); Stanford University; Harvard University; Brigham & Women's Hospital; Children's National Health System; George Washington University	Fahrenkopf, AM (corresponding author), Harvard Univ, Sch Med, Dept Med, Childrens Hosp, Boston, MA 02115 USA.	amy.fahrenkopf@tch.harvard.edu		Landrigan, Christopher/0000-0001-8386-4100	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS013333] Funding Source: NIH RePORTER; AHRQ HHS [K08 HS13333] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Arnedt JT, 2001, ACCIDENT ANAL PREV, V33, P337, DOI 10.1016/S0001-4575(00)00047-6; Ayas NT, 2006, JAMA-J AM MED ASSOC, V296, P1055, DOI 10.1001/jama.296.9.1055; Baer L, 2000, PSYCHOTHER PSYCHOSOM, V69, P35, DOI 10.1159/000012364; Baldwin PJ, 1997, SOC SCI MED, V45, P35, DOI 10.1016/S0277-9536(96)00306-1; Barger LK, 2005, NEW ENGL J MED, V352, P125, DOI 10.1056/NEJMoa041401; Bellini LM, 2002, JAMA-J AM MED ASSOC, V287, P3143, DOI 10.1001/jama.287.23.3143; COLFORD JM, 1989, JAMA-J AM MED ASSOC, V261, P889, DOI 10.1001/jama.261.6.889; Dean B, 2002, LANCET, V359, P1373, DOI 10.1016/S0140-6736(02)08350-2; Fletcher KE, 2005, JAMA-J AM MED ASSOC, V294, P1088, DOI 10.1001/jama.294.9.1088; Goitein L, 2005, ARCH INTERN MED, V165, P2601, DOI 10.1001/archinte.165.22.2601; Gopal R, 2005, ARCH INTERN MED, V165, P2595, DOI 10.1001/archinte.165.22.2595; Hasin DS, 2005, ARCH GEN PSYCHIAT, V62, P1097, DOI 10.1001/archpsyc.62.10.1097; HENDRIE HC, 1990, J NERV MENT DIS, V178, P204, DOI 10.1097/00005053-199003000-00009; HSU K, 1987, AM J PSYCHIAT, V144, P1561; *I MED, 1999, TO ERR IS HUM BUILD; *I MED, 1999, TO ERR IS HUMAN BUIL; Institute of Medicine, 2006, PREV MED ERR; Kaushal R, 2001, JAMA-J AM MED ASSOC, V285, P2114, DOI 10.1001/jama.285.16.2114; Landrigan CP, 2006, JAMA-J AM MED ASSOC, V296, P1063, DOI 10.1001/jama.296.9.1063; Landrigan CP, 2004, NEW ENGL J MED, V351, P1838, DOI 10.1056/NEJMoa041406; Leape LL, 2000, BMJ-BRIT MED J, V320, P725, DOI 10.1136/bmj.320.7237.725; Lockley SW, 2004, NEW ENGL J MED, V351, P1829, DOI 10.1056/NEJMoa041404; Maslach C., 1996, MASLACH BURNOUT INVE, V3rd; Peterlini M, 2002, MED EDUC, V36, P66, DOI 10.1046/j.1365-2923.2002.01104.x; Roseman C, 1995, NURS RES, V44, P226; Rothberg MB, 2005, MED CARE, V43, P785, DOI 10.1097/01.mlr.0000170408.35854.fa; SCHNEIDER SE, 1993, PSYCHOL REP, V72, P1145, DOI 10.2466/pr0.1993.72.3c.1145; Scott LD, 2006, AM J CRIT CARE, V15, P30; Shanafelt TD, 2002, ANN INTERN MED, V136, P358, DOI 10.7326/0003-4819-136-5-200203050-00008; Thomas NK, 2004, JAMA-J AM MED ASSOC, V292, P2880, DOI 10.1001/jama.292.23.2880; Vincent C, 2001, BRIT MED J, V322, P517, DOI 10.1136/bmj.322.7285.517; West CP, 2006, JAMA-J AM MED ASSOC, V296, P1071, DOI 10.1001/jama.296.9.1071; Wu AW, 2000, BRIT MED J, V320, P726, DOI 10.1136/bmj.320.7237.726	33	694	713	0	47	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAR 1	2008	336	7642					488	491		10.1136/bmj.39469.763218.BE	http://dx.doi.org/10.1136/bmj.39469.763218.BE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	274JL	18258931	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000253997500041
J	Lindqvist, L; Oberer, M; Reibarkh, M; Cencic, R; Bordeleau, ME; Vogt, E; Marintchev, A; Tanaka, J; Fagotto, F; Altmann, M; Wagner, G; Pelletier, J				Lindqvist, Lisa; Oberer, Monika; Reibarkh, Mikhail; Cencic, Regina; Bordeleau, Marie-Eve; Vogt, Emily; Marintchev, Assen; Tanaka, Junichi; Fagotto, Francois; Altmann, Michael; Wagner, Gerhard; Pelletier, Jerry			Selective Pharmacological Targeting of a DEAD Box RNA Helicase	PLOS ONE			English	Article								RNA helicases represent a large family of proteins implicated in many biological processes including ribosome biogenesis, splicing, translation and mRNA degradation. However, these proteins have little substrate specificity, making inhibition of selected helicases a challenging problem. The prototypical DEAD box RNA helicase, eIF4A, works in conjunction with other translation factors to prepare mRNA templates for ribosome recruitment during translation initiation. Herein, we provide insight into the selectivity of a small molecule inhibitor of eIF4A, hippuristanol. This coral-derived natural product binds to amino acids adjacent to, and overlapping with, two conserved motifs present in the carboxy-terminal domain of eIF4A. Mutagenesis of amino acids within this region allowed us to alter the hippuristanol-sensitivity of eIF4A and undertake structure/function studies. Our results provide an understanding into how selective targeting of RNA helicases for pharmacological intervention can be achieved.	[Lindqvist, Lisa; Cencic, Regina; Bordeleau, Marie-Eve; Pelletier, Jerry] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Oberer, Monika; Reibarkh, Mikhail; Marintchev, Assen; Wagner, Gerhard] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA USA; [Vogt, Emily; Fagotto, Francois] McGill Univ, Dept Biol, Montreal, PQ, Canada; [Tanaka, Junichi] Univ Ryukyus, Dept Chem, Biol, & Marine Sci, Nishihara, Okinawa, Japan; [Altmann, Michael] Univ Bern, Inst Biochem & Mol Med, Bern, Switzerland; [Pelletier, Jerry] McGill Univ, McGill Canc Ctr, Montreal, PQ, Canada	McGill University; Harvard University; Harvard Medical School; McGill University; University of the Ryukyus; University of Bern; McGill University	Lindqvist, L (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ, Canada.	jerry.pelletier@mcgill.ca	Fagotto, Francois/AAA-9983-2021	Fagotto, Francois/0000-0002-1495-2112; Oberer, Monika/0000-0003-2525-9513; Tanaka, Junichi/0000-0002-8672-7379; Reibarkh, Mikhail/0000-0002-6589-707X; Marintchev, Assen/0000-0002-9901-3500	CIHR [fellowship, Post-doctoral Training Grant]; NSERC CGSM [fellowship]; Max Kade Foundation [post-doctoral fellowship]; NCIC [017099]; NIH [CA 68262]; NATIONAL CANCER INSTITUTE [R01CA068262] Funding Source: NIH RePORTER	CIHR(Canadian Institutes of Health Research (CIHR)); NSERC CGSM(Natural Sciences and Engineering Research Council of Canada (NSERC)); Max Kade Foundation; NCIC(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	LL was supported by a CIHR Chemical Biology and an NSERC CGSM fellowship. RC was supported by a CIHR Cancer Consortium Post-doctoral Training Grant Award. MO was supported by a post-doctoral fellowship from the Max Kade Foundation. This work was supported by a grant from NCIC (#017099) to JP and an NIH grant (#CA 68262) to GW.	ALTMANN M, 2002, CELL FREE TRANSLATIO; Andersen CBF, 2006, SCIENCE, V313, P1968, DOI 10.1126/science.1131981; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Bono F, 2006, CELL, V126, P713, DOI 10.1016/j.cell.2006.08.006; Bordeleau ME, 2006, NAT CHEM BIOL, V2, P213, DOI 10.1038/nchembio776; Bordeleau ME, 2005, P NATL ACAD SCI USA, V102, P10460, DOI 10.1073/pnas.0504249102; Cencic R, 2007, COMB CHEM HIGH T SCR, V10, P181, DOI 10.2174/138620707780126688; Chan CC, 2004, RNA, V10, P200, DOI 10.1261/rna.5230104; CONROY SC, 1990, ARCH BIOCHEM BIOPHYS, V282, P363, DOI 10.1016/0003-9861(90)90130-Q; COPPOLECCHIA R, 1993, EMBO J, V12, P4005, DOI 10.1002/j.1460-2075.1993.tb06078.x; Cordin O, 2006, GENE, V367, P17, DOI 10.1016/j.gene.2005.10.019; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; EDERY I, 1983, J BIOL CHEM, V258, P1398; Ferraiuolo MA, 2004, P NATL ACAD SCI USA, V101, P4118, DOI 10.1073/pnas.0400933101; Fukuda T, 2007, NAT CELL BIOL, V9, P604, DOI 10.1038/ncb1577; Giaever G, 1999, NAT GENET, V21, P278, DOI 10.1038/6791; GRIFO JA, 1982, J BIOL CHEM, V257, P5246; Linder P, 2006, NUCLEIC ACIDS RES, V34, P4168, DOI 10.1093/nar/gkl468; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2180, DOI 10.1021/bi972430g; Low WK, 2005, MOL CELL, V20, P709, DOI 10.1016/j.molcel.2005.10.008; Low WK, 2007, CHEM BIOL, V14, P715, DOI 10.1016/j.chembiol.2007.05.012; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; Oberer M, 2005, GENE DEV, V19, P2212, DOI 10.1101/gad.1335305; Oguro A, 2003, RNA, V9, P394, DOI 10.1261/rna.2161303; Otero LJ, 2001, RNA, V7, P1753; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Pestova TV, 2002, GENE DEV, V16, P2906, DOI 10.1101/gad.1020902; RAY BK, 1985, J BIOL CHEM, V260, P7651; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Sengoku T, 2006, CELL, V125, P287, DOI 10.1016/j.cell.2006.01.054; Shibuya T, 2006, RNA, V12, P360, DOI 10.1261/rna.2190706; Shibuya T, 2004, NAT STRUCT MOL BIOL, V11, P346, DOI 10.1038/nsmb750; Singleton MR, 2007, ANNU REV BIOCHEM, V76, P23, DOI 10.1146/annurev.biochem.76.052305.115300; SONENBERG N, 1981, NUCLEIC ACIDS RES, V9, P1643, DOI 10.1093/nar/9.7.1643; Svitkin YV, 2001, RNA, V7, P1743; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; YODERHILL J, 1993, J BIOL CHEM, V268, P5566	41	97	97	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1583	10.1371/journal.pone.0001583	http://dx.doi.org/10.1371/journal.pone.0001583			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270573	Green Published, gold, Green Submitted			2023-01-03	WOS:000260535900019
J	Guarente, L				Guarente, Leonard			Mitochondria - A nexus for aging, calorie restriction, and sirtuins?	CELL			English	Article							LIFE-SPAN; INDUCED LONGEVITY; PROTEIN SIR2; MUTATIONS; COMPLEX; BIOGENESIS; GENERATION; PHENOTYPES; EXTENSION; OXIDATION	Recent studies of calorie restriction in several organisms demonstrate an increase in mitochondrial activity that is associated with the salutary effects of this dietary restriction regimen. In this Essay, I speculate on how an increase in mitochondrial activity might provide benefit and discuss how diet, mitochondria, and sirtuins might interact in a pathway to slow aging and associated diseases.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Guarente, L (corresponding author), MIT, Dept Biol, Cambridge, MA 02139 USA.	leng@mit.edu			NIA NIH HHS [R01 AG015339-04, R01 AG015339, R01 AG011119-08, R01 AG011119] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011119, R01AG015339] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Barja G, 2007, REJUV RES, V10, P215, DOI 10.1089/rej.2006.0516; Barros MH, 2004, J BIOL CHEM, V279, P49883, DOI 10.1074/jbc.M408918200; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Bishop NA, 2007, NATURE, V447, P545, DOI 10.1038/nature05904; Bordone L, 2007, AGING CELL, V6, P759, DOI 10.1111/j.1474-9726.2007.00335.x; Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132; Chen D, 2005, SCIENCE, V310, P1641, DOI 10.1126/science.1118357; Civitarese AE, 2007, PLOS MED, V4, P485, DOI 10.1371/journal.pmed.0040076; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633; Guarente L, 2006, NATURE, V444, P868, DOI 10.1038/nature05486; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; JIA K, 2000, AUTOPHAGY, V3, P597; Kaeberlein M, 2005, PLOS GENET, V1, P614, DOI 10.1371/journal.pgen.0010069; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Lopez-Lluch G, 2006, P NATL ACAD SCI USA, V103, P1768, DOI 10.1073/pnas.0510452103; Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343; Mattagajasingh I, 2007, P NATL ACAD SCI USA, V104, P14855, DOI 10.1073/pnas.0704329104; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607; Pamplona R, 2007, AGEING RES REV, V6, P189, DOI 10.1016/j.arr.2007.06.002; Panowski SH, 2007, NATURE, V447, P550, DOI 10.1038/nature05837; Pospisilik JA, 2007, CELL, V131, P476, DOI 10.1016/j.cell.2007.08.047; Rea SL, 2007, PLOS BIOL, V5, P2312, DOI 10.1371/journal.pbio.0050259; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Varshavsky A, 2005, TRENDS BIOCHEM SCI, V30, P283, DOI 10.1016/j.tibs.2005.04.005; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Weindruch R., 1988, RETARDATION AGING DI; YANG H, 2007, CELL, V130, P432; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	45	398	415	1	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 25	2008	132	2					171	176		10.1016/j.cell.2008.01.007	http://dx.doi.org/10.1016/j.cell.2008.01.007			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	266IM	18243090	Bronze, Green Accepted			2023-01-03	WOS:000253427700001
J	Smith, WR; Penberthy, LT; Bovbjerg, VE; McClish, DK; Roberts, JD; Dahman, B; Aisiku, IP; Levenson, JL; Roseff, SD				Smith, Wally R.; Penberthy, Lynne T.; Bovbjerg, Viktor E.; McClish, Donna K.; Roberts, John D.; Dahman, Bassarn; Aisiku, Imoigele P.; Levenson, James L.; Roseff, Susan D.			Daily assessment of pain in adults with sickle cell disease	ANNALS OF INTERNAL MEDICINE			English	Article							NITRIC-OXIDE BIOAVAILABILITY; HEALTH-CARE UTILIZATION; BELIEF MODEL; RISK-FACTORS; MANAGEMENT; ANEMIA; CHILDREN; ADOLESCENTS; HYDROXYUREA; ADHESION	Background: Researchers of sickle cell disease have traditionally used health care utilization as a proxy for pain and underlying vaso-occlusion. However, utilization may not completely reflect the amount of self-reported pain or acute, painful episodes (crises). Objective: To examine the prevalence of self-reported pain and the relationship among pain, crises, and utilization in adults with sickle cell disease. Design: Prospective cohort study. Setting: Academic and community practices in Virginia. Patients: 232 patients age 16 years or older with sickle cell disease. Measurements: Patients completed a daily diary for up to 6 months, recording their maximum pain (on a scale of 0 to 9); whether they were in a crisis (crisis day); and whether they used hospital, emergency, or unscheduled ambulatory care for pain on the, previous day (utilization day). Summary measures included both simple proportions and adjusted probabilities (for repeated measures within patients) of pain days, crisis days, and utilization days, as well as mean pain intensity. Results: Pain (with or without crisis or utilization of care) was reported on 54.5% of 31 017 analyzed patient-days (adjusted probability, 56%). Crises without utilization were reported on 12.7% of days and utilization on only 3.5% (unadjusted). In total, 29.3% of patients reported pain in greater than 95% of diary days, whereas only 14.2% reported pain in 5% or fewer diary days (adjusted). The frequency of home opiate use varied and independently predicted pain, crises, and utilization. Mean pain intensity on crisis days, noncrisis pain days, and total pain days increased as the percentage of pain days increased (P < 0.001). Intensity was significantly higher on utilization days (P < 0.001). However, utilization was not an independent predictor of crisis, after controlling for pain intensity. Limitations: The study was done in a single state. Patients did not always send in their diaries. Conclusion: Pain in adults with sickle cell disease is the rule rather than the exception and is far more prevalent and severe than previous large-scale studies have portrayed. It is mostly managed at home; therefore, its prevalence is probably underestimated by health care providers, resulting in misclassification, distorted communication, and undertreatment.	[Smith, Wally R.] Virginia Commonwealth Univ, Dept Internal Med, Div Quality Hlth Care, Richmond, VA 23298 USA	Virginia Commonwealth University	Smith, WR (corresponding author), Virginia Commonwealth Univ, Dept Internal Med, Div Quality Hlth Care, Box 980306, Richmond, VA 23298 USA.	wrsmith@vcu.edu			NHLBI NIH HHS [1R01HL64122-01A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064122] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen KD, 2006, JCR-J CLIN RHEUMATOL, V12, P118, DOI 10.1097/01.rhu.0000221801.63880.3f; Anie Kofi A, 2003, Hematol J, V4, P71, DOI 10.1038/sj.thj.6200227; Ballas SK, 2005, HEMATOL ONCOL CLIN N, V19, P785, DOI 10.1016/j.hoc.2005.07.008; Baron Michael J, 2006, J Opioid Manag, V2, P277; BECKER MH, 1974, HEALTH EDUC QUART, V2, P409, DOI 10.1177/109019817400200407; Blum A, 2005, J THROMB THROMBOLYS, V19, P83, DOI 10.1007/s11239-005-1377-7; BOBO L, 1989, SOUTHERN MED J, V82, P9, DOI 10.1097/00007611-198901000-00004; Bunn HF, 1997, NEW ENGL J MED, V337, P762, DOI 10.1056/NEJM199709113371107; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; Charache S, 1995, CONTROL CLIN TRIALS, V16, P432, DOI 10.1016/S0197-2456(95)00098-4; CHEN MS, 1986, SOC PSYCHOL QUART, V49, P45, DOI 10.2307/2786856; Dampier C, 2004, J PEDIAT HEMATOL ONC, V26, P785; Dimcevski G, 2006, EUR J GASTROEN HEPAT, V18, P755, DOI 10.1097/01.meg.0000223903.70492.c5; El Nemer W, 2007, BLOOD, V109, P3544, DOI 10.1182/blood-2006-07-035139; Elander J, 2004, J PAIN SYMPTOM MANAG, V27, P156, DOI 10.1016/j.jpainsymman.2003.12.001; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; Fuggle P, 1996, ARCH DIS CHILD, V75, P199, DOI 10.1136/adc.75.3.199; Gil KM, 2004, HEALTH PSYCHOL, V23, P267, DOI 10.1037/0278-6133.23.3.267; Gil KM, 2003, J PEDIATR PSYCHOL, V28, P363, DOI 10.1093/jpepsy/jsg026; Gil KM, 2000, CHILD HEALTH CARE, V29, P225, DOI 10.1207/S15326888CHC2904_1; Gladwin MT, 2003, CIRCULATION, V107, P271, DOI 10.1161/01.CIR.0000044943.12533.A8; Graido-Gonzalez E, 1998, BLOOD, V92, P2551, DOI 10.1182/blood.V92.7.2551.2551_2551_2555; HEBBEL RP, 1980, NEW ENGL J MED, V302, P992, DOI 10.1056/NEJM198005013021803; Hermann C, 2006, PAIN, V125, P278, DOI 10.1016/j.pain.2006.08.026; Ji RR, 2003, TRENDS NEUROSCI, V26, P696, DOI 10.1016/j.tins.2003.09.017; KAUL DK, 1989, P NATL ACAD SCI USA, V86, P3356, DOI 10.1073/pnas.86.9.3356; Kaul DK, 2000, AM J PHYSIOL-HEART C, V278, pH1799, DOI 10.1152/ajpheart.2000.278.6.H1799; Lefebvre JC, 2002, CLIN J PAIN, V18, P56, DOI 10.1097/00002508-200201000-00009; McClish DK, 2006, J WOMENS HEALTH, V15, P146, DOI 10.1089/jwh.2006.15.146; Michaels LA, 1998, BLOOD, V92, P3148, DOI 10.1182/blood.V92.9.3148.421k12_3148_3151; MURRAY N, 1988, BRIT MED J, V297, P452, DOI 10.1136/bmj.297.6646.452; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; Porter LS, 1998, INT J BEHAV MED, V5, P185, DOI 10.1207/s15327558ijbm0503_1; Powars DR, 2005, MEDICINE, V84, P363, DOI 10.1097/01.md.0000189089.45003.52; Reese FL, 1997, ANN BEHAV MED, V19, P171, DOI 10.1007/BF02883334; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799; Sakhalkar VS, 2004, AM J HEMATOL, V76, P57, DOI 10.1002/ajh.20016; Serjeant GR, 1997, LANCET, V350, P725, DOI 10.1016/S0140-6736(97)07330-3; SERJEANT GR, 1993, BLOOD REV, V7, P137, DOI 10.1016/0268-960X(93)90001-K; Setty BNY, 2003, LANCET, V362, P1450, DOI 10.1016/S0140-6736(03)14689-2; SHAPIRO BS, 1995, PAIN, V61, P139, DOI 10.1016/0304-3959(94)00164-A; Shapiro BS, 1997, J PAIN SYMPTOM MANAG, V14, P168, DOI 10.1016/S0885-3924(97)00019-5; Smith WR, 2005, J NATL MED ASSOC, V97, P183; Steinberg MH, 2003, JAMA-J AM MED ASSOC, V289, P1645, DOI 10.1001/jama.289.13.1645; Steinberg MH, 1999, NEW ENGL J MED, V340, P1021, DOI 10.1056/NEJM199904013401307; Von Korff M, 2000, SPINE, V25, P3140, DOI 10.1097/00007632-200012150-00009; Wagner MC, 2004, J LAB CLIN MED, V144, P260, DOI 10.1016/j.lab.2004.08.004; Westerman MP, 1997, AM J HEMATOL, V54, P183, DOI 10.1002/(SICI)1096-8652(199703)54:3<183::AID-AJH2>3.0.CO;2-S; [No title captured]	50	372	376	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	2008	148	2					94	101		10.7326/0003-4819-148-2-200801150-00004	http://dx.doi.org/10.7326/0003-4819-148-2-200801150-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254NZ	18195334				2023-01-03	WOS:000252594600002
J	Appleby, P; Beral, V; de Gonzalez, AB; Colin, D; Franceschi, S; Goodhill, A; Green, J; Peto, J; Plummer, M; Sweetland, S				Appleby, Paul; Beral, Valerie; de Gonzalez, Amy Berrington; Colin, Didier; Franceschi, Silvia; Goodhill, Adrian; Green, Jane; Peto, Julian; Plummer, Martyn; Sweetland, Sian		Int Collaboration Epidemiologis	Cervical cancer and hormonal contraceptives: Collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies	LANCET			English	Article							CARCINOMA IN-SITU; MEDROXYPROGESTERONE ACETATE DMPA; HUMAN-PAPILLOMAVIRUS INFECTION; COMBINED ORAL-CONTRACEPTIVES; SQUAMOUS-CELL CARCINOMA; RISK-FACTORS; INTRAEPITHELIAL NEOPLASIA; INVASIVE ADENOCARCINOMAS; ADENOSQUAMOUS CARCINOMAS; REPRODUCTIVE FACTORS	Background Combined oral contraceptives are classified by the International Agency for Research on Cancer as a cause of cervical cancer. As the incidence of cervical cancer increases with age, the public-health implications of this association depend largely on the persistence of effects long after use of oral contraceptives has ceased. Information from 24 studies worldwide is pooled here to investigate the association between cervical carcinoma and pattern of oral contraceptive use. Methods Individual data for 16 573 women with cervical cancer and 35 509 without cervical cancer were reanalysed centrally. Relative risks of cervical cancer were estimated by conditional logistic regression, stratifying by study, age, number of sexual partners, age at first intercourse, parity, smoking, and screening. Findings Among current users of oral contraceptives the risk of invasive cervical cancer increased with increasing duration of use (relative risk for 5 or more years' use versus never use, 1-90 [95% Cl 1-69-2-13]). The risk declined after use ceased, and by 10 or more years had returned to that of never users. A similar pattern of risk was seen both for invasive and in-situ cancer, and in women who tested positive for high-risk human papillornavirus. Relative risk did not vary substantially between women with different characteristics. Interpretation The relative risk of cervical cancer is increased in current users of oral contraceptives and declines after use ceases. 10 years' use of oral contraceptives from around age 20 to 30 years is estimated to increase the cumulative incidence of invasive cervical cancer by age 50 from 7.3 to 8.3 per 1000 in less developed countries and from 3.8 to 4.5 per 1000 in more developed countries.	Natl Hlth Lab Serv, Canc Epidemiol Res Grp, Johannesburg, South Africa; Canc Inst WIA, Madras, Tamil Nadu, India; Canc Res UK, Epidemiol Grp, Wolfson Inst Prevent Med, London, England; Canc Res UK, Epidemiol Unit, Oxford, England; Dept Publ Hlth, Oxford, England; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Karolinska Inst, Dept Med Epidemiol & Biostat, S-10401 Stockholm, Sweden; Inst Nacl Sante Publ, Algiers, Algeria; Inst Canc Res, Sutton, Surrey, England; London Sch Hyg & Trop Med, London WC1, England; Inst Nacl Enfermedades Neoplascias Dr Eduardo Cac, Lima, Peru; Int Agcy Res Canc, F-69372 Lyon, France; Ist Ric Farmacol Mario Negri, Milan, Italy; Lund Univ, Malmo, Sweden; Minist Sante Publ & Affaires Sociales, Bamako, Mali; Prince Songkla Univ, Hat Yai, Thailand; NSW Canc Council, Sydney, NSW, Australia; Univ Sao Paulo, BR-05508 Sao Paulo, Brazil; Univ Milan, I-20122 Milan, Italy; Univ Otago, Dunedin, New Zealand; Univ So Calif, Los Angeles, CA 90089 USA; Univ Philippines, Manila, Philippines; Univ Tromso, N-9001 Tromso, Norway; WHO, CH-1211 Geneva, Switzerland	National Health Laboratory Service; Cancer Research UK; University of London; Queen Mary University London; Cancer Research UK; Fred Hutchinson Cancer Center; Karolinska Institutet; University of London; Institute of Cancer Research - UK; University of London; London School of Hygiene & Tropical Medicine; Instituto Nacional de Enfermedades Neoplasicas; World Health Organization; International Agency for Research on Cancer (IARC); Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Lund University; Prince of Songkla University; Cancer Council New South Wales; Universidade de Sao Paulo; University of Milan; University of Otago; University of Southern California; University of the Philippines System; University of the Philippines Manila; UiT The Arctic University of Tromso; World Health Organization	Green, J (corresponding author), Univ Oxford, Nuffield Dept Clin Med, Canc Epidemiol Unit, Richard Doll Bldg,Roosevelt Dr, Oxford OX3 7LF, England.	jane.green@ceu.ox.ac.uk	de gonzalez, amy berrington/L-7017-2017; Eluf-Neto, Jose/B-2522-2009; franceschi, silvia/M-2452-2014	de gonzalez, amy berrington/0000-0002-7332-8387; Eluf-Neto, Jose/0000-0001-7504-2115; franceschi, silvia/0000-0003-4181-8071; Plummer, Martyn/0000-0001-5130-6497	Medical Research Council [G0700474] Funding Source: Medline; MRC [G0700474] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		[Anonymous], 2003, WHO CLASSIFICATION T; Appleby P, 2006, INT J CANCER, V119, P1108, DOI 10.1002/ijc.21953; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Bayo S, 2002, INT J EPIDEMIOL, V31, P202, DOI 10.1093/ije/31.1.202; BERAL V, 1988, LANCET, V2, P1331; BERRY G, 1993, INT J CANCER, V55, P228; BOSCH FX, 1992, INT J CANCER, V52, P750, DOI 10.1002/ijc.2910520514; BOYCE JG, 1977, AM J OBSTET GYNECOL, V128, P761, DOI 10.1016/0002-9378(77)90717-7; BRINTON LA, 1990, INT J EPIDEMIOL, V19, P4, DOI 10.1093/ije/19.1.4; BRINTON LA, 1986, INT J CANCER, V38, P399; CELENTANO DD, 1987, AM J EPIDEMIOL, V126, P592, DOI 10.1093/oxfordjournals.aje.a114699; Chaouki N, 1998, INT J CANCER, V75, P546, DOI 10.1002/(SICI)1097-0215(19980209)75:4&lt;546::AID-IJC9&gt;3.0.CO;2-T; Chichareon S, 1998, J NATL CANCER I, V90, P50, DOI 10.1093/jnci/90.1.50; Cogliano V, 2005, LANCET ONCOL, V6, P552, DOI 10.1016/S1470-2045(05)70273-4; *COLL GROUP HORM F, 1996, CONTRACEPTION, V54, pS13; Cuzick J, 1996, EUR J CANCER, V32A, P836, DOI 10.1016/0959-8049(95)00650-8; CUZICK J, 1990, EUR J CANCER, V26, P684, DOI 10.1016/0277-5379(90)90117-C; Daling JR, 1996, CANCER EPIDEM BIOMAR, V5, P541; de Gonzalez AB, 2007, INT J CANCER, V120, P885, DOI 10.1002/ijc.22357; Deacon JM, 2000, BRIT J CANCER, V83, P1565, DOI 10.1054/bjoc.2000.1523; EBELING K, 1987, INT J CANCER, V39, P427, DOI 10.1002/ijc.2910390402; ELUFNETO J, 1994, BRIT J CANCER, V69, P114, DOI 10.1038/bjc.1994.18; Ferlay J, 2004, GLOBOCAN 2002 CANC I; Franceschi S, 2003, INT J CANCER, V107, P127, DOI 10.1002/ijc.11350; GRAM IT, 1992, AM J OBSTET GYNECOL, V167, P40, DOI 10.1016/S0002-9378(11)91622-6; Green J, 2003, BRIT J CANCER, V89, P2078, DOI 10.1038/sj.bjc.6601296; Hammouda D, 2005, INT J CANCER, V113, P483, DOI 10.1002/ijc.20600; HERRERO R, 1990, INT J CANCER, V46, P5, DOI 10.1002/ijc.2910460103; Hildesheim A, 2001, BRIT J CANCER, V84, P1219, DOI 10.1054/bjoc.2001.1779; Hsieh CY, 1999, ANTICANCER RES, V19, P4495; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 1999, IARC MON EV CARC RIS, V72; IRWIN KL, 1988, JAMA-J AM MED ASSOC, V259, P59, DOI 10.1001/jama.259.1.59; JONES CJ, 1990, CANCER RES, V50, P3657; Kjaer SK, 1996, INT J CANCER, V65, P601, DOI 10.1002/(SICI)1097-0215(19960301)65:5<601::AID-IJC8>3.0.CO;2-6; KJAER SK, 1993, CANCER CAUSE CONTROL, V4, P513, DOI 10.1007/BF00052426; Lacey JV, 1999, CANCER EPIDEM BIOMAR, V8, P1079; LAZCANOPONCE EC, 1995, REV INVEST CLIN, V47, P377; Madeleine MM, 2001, CANCER EPIDEM BIOMAR, V10, P171; MELAMED MR, 1969, BMJ-BRIT MED J, V3, P195, DOI 10.1136/bmj.3.5664.195; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; MUNOZ N, 1993, CANCER EPIDEM BIOMAR, V2, P423; Ngelangel C, 1998, JNCI-J NATL CANCER I, V90, P43, DOI 10.1093/jnci/90.1.43; PARAZZINI F, 1988, BRIT J CANCER, V57, P201, DOI 10.1038/bjc.1988.43; Parazzini F, 1998, EUR J CANCER, V34, P884, DOI 10.1016/S0959-8049(97)10139-3; PARAZZINI F, 1992, CANCER-AM CANCER SOC, V69, P2276, DOI 10.1002/1097-0142(19920501)69:9<2276::AID-CNCR2820690912>3.0.CO;2-Q; Parkin DM, 2002, IARC SCI PUBLICATION, VVIII; PETERS RK, 1986, JNCI-J NATL CANCER I, V77, P1063; Plummer M, 2004, STAT MED, V23, P93, DOI 10.1002/sim.1485; Rajkumar T, 2006, INT J CANCER, V118, P1481; Rolon PA, 2000, INT J CANCER, V85, P486, DOI 10.1002/(SICI)1097-0215(20000215)85:4&lt;486::AID-IJC7&gt;3.0.CO;2-S; Santos C, 2001, BRIT J CANCER, V85, P966, DOI [10.1038/sj.bjc.6691948, 10.1054/bjoc.2001.1948]; Schiffman Mark, 2003, J Natl Cancer Inst Monogr, P14; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; Shapiro S, 2003, CANCER CAUSE CONTROL, V14, P485, DOI 10.1023/A:1024910808307; Sitas F, 2000, INT J CANCER, V88, P489, DOI 10.1002/1097-0215(20001101)88:3&lt;489::AID-IJC25&gt;3.0.CO;2-Q; SLATTERY ML, 1989, AM J EPIDEMIOL, V130, P248, DOI 10.1093/oxfordjournals.aje.a115331; Smith JS, 2003, LANCET, V361, P1159, DOI 10.1016/S0140-6736(03)12949-2; TALBOTT EO, 1995, J WOMENS HLTH LARCHM, V4, P387; Thomas DB, 2001, AM J EPIDEMIOL, V153, P732, DOI 10.1093/aje/153.8.732; THOMAS DB, 1995, CONTRACEPTION, V52, P307, DOI 10.1016/0010-7824(95)00215-V; THOMAS DB, 1995, CONTRACEPTION, V51, P25, DOI 10.1016/0010-7824(94)00007-J; THOMAS DB, 1992, CONTRACEPTION, V45, P299; Thomas DB, 1996, AM J EPIDEMIOL, V144, P281, DOI 10.1093/oxfordjournals.aje.a008923; Ursin G, 1996, CANCER CAUSE CONTROL, V7, P391, DOI 10.1007/BF00052946; URSIN G, 1994, LANCET, V344, P1390, DOI 10.1016/S0140-6736(94)90567-3; WORTH AJ, 1972, J OBSTET GYN BR COMM, V79, P673; Yang BH, 2004, INT J CANCER, V109, P418, DOI 10.1002/ijc.11719; YE Z, 1995, INT J EPIDEMIOL, V24, P19, DOI 10.1093/ije/24.1.19; Ylitalo N, 1999, INT J CANCER, V81, P357, DOI 10.1002/(SICI)1097-0215(19990505)81:3<357::AID-IJC8>3.3.CO;2-T; Zondervan KT, 1996, BRIT J CANCER, V73, P1291, DOI 10.1038/bjc.1996.247	70	299	313	0	34	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 10	2007	370	9599					1609	1621		10.1016/s0140-6736(07)61684-5	http://dx.doi.org/10.1016/s0140-6736(07)61684-5			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230NO	17993361				2023-01-03	WOS:000250883400020
J	Greenhalgh, T; Kristjansson, E; Robinson, V				Greenhalgh, Trisha; Kristjansson, Elizabeth; Robinson, Vivian			Realist review to understand the efficacy of school feeding programmes	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							BONE-MINERAL ACCRETION; AGED 10-12 YEARS; BREAKFAST PROGRAM; MILK INTERVENTION; NATIONAL EVALUATION; GIRLS; GROWTH; TRIAL; MASS; CHILDREN		UCL, Dept Primary Care & Populat Sci, London N19 5LW, England; Univ Ottawa, Sch Psychol, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Inst Populat Hlth, Ottawa, ON K1N 6N5, Canada	University of London; University College London; University of Ottawa; University of Ottawa	Greenhalgh, T (corresponding author), UCL, Dept Primary Care & Populat Sci, London N19 5LW, England.	p.greenhalgh@pcps.ucl.ac.uk	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088; Welch, Vivian/0000-0002-5238-7097				AGARWAL D K, 1989, Indian Journal of Medical Research Section B, V90, P163; [Anonymous], 2004, REALIST SYNTHESIS IN; BAILEY K V, 1962, Trop Geogr Med, V14, P129; BAKER IA, 1980, J EPIDEMIOL COMMUN H, V34, P31, DOI 10.1136/jech.34.1.31; Bro RT, 1996, J EDUC RES, V90, P111, DOI 10.1080/00220671.1996.9944452; BRO RT, 1994, CHILD FAM BEHAV THER, V16, P1, DOI 10.1300/J019v16n03_01; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; CHANDLER AMK, 1995, J NUTR, V125, P894; Chang Susan M., 1996, Food and Nutrition Bulletin, V17, P248; DEVADAS RP, 1979, INDIAN J NUTR DIET, V16, P335; Dixon-Woods M, 2007, QUAL RES, V7, P375, DOI DOI 10.1177/1468794107078517; Du XQ, 2005, BRIT J NUTR, V94, P1038, DOI 10.1079/BJN20051584; Du XQ, 2004, BRIT J NUTR, V92, P159, DOI 10.1079/BJN20041118; Grillenberger M, 2003, J NUTR, V133, p3957S, DOI 10.1093/jn/133.11.3957S; Jacoby Enrique, 1996, Food and Nutrition Bulletin, V17, P54; Jacoby ER, 1998, AM J CLIN NUTR, V67, p795S, DOI 10.1093/ajcn/67.4.795S; Kristjansson EA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004676.pub2; LIEBERMAN HM, 1976, J AM DIET ASSOC, V68, P132; MANN HCC, 1926, DIETS BOYS SCH AGE; Murphy SP, 2003, J NUTR, V133, p3950S, DOI 10.1093/jn/133.11.3950S; Neumann CG, 2003, J NUTR, V133, p3941S, DOI 10.1093/jn/133.11.3941S; Orr JB, 1928, LANCET, V1, P202; PAIGE DM, 1976, PEDIATRICS, V58, P697; Pawson Ray, 2005, J Health Serv Res Policy, V10 Suppl 1, P21, DOI 10.1258/1355819054308530; POWELL C, 1983, HUM NUTR-CLIN NUTR, V37, P381; Powell CA, 1998, AM J CLIN NUTR, V68, P873, DOI 10.1093/ajcn/68.4.873; Shemilt I, 2004, CHILD CARE HLTH DEV, V30, P413, DOI 10.1111/j.1365-2214.2004.00453.x; Shemilt I, 2004, CHILD CARE HLTH DEV, V30, P429, DOI 10.1111/j.1365-2214.2004.00454.x; Siekmann JH, 2003, J NUTR, V133, p3972S, DOI 10.1093/jn/133.11.3972S; Simeon DT, 1998, AM J CLIN NUTR, V67, p790S, DOI 10.1093/ajcn/67.4.790S; TISDALL FF, 1951, CAN MED ASSOC J, V64, P477; Whaley SE, 2003, J NUTR, V133, p3965S, DOI 10.1093/jn/133.11.3965S; Zhu K, 2006, AM J CLIN NUTR, V83, P714, DOI 10.1093/ajcn.83.3.714; Zhu K, 2005, AM J CLIN NUTR, V81, P1168; Zhu K, 2004, BRIT J NUTR, V92, P985, DOI 10.1079/BJN20041278	35	125	127	1	37	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 27	2007	335	7625					858	861		10.1136/bmj.39359.525174.AD	http://dx.doi.org/10.1136/bmj.39359.525174.AD			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227BA	17954518	Green Published			2023-01-03	WOS:000250631000036
J	Goldacre, B				Goldacre, Ben			Beware of mentioning psychosocial factors	BRITISH MEDICAL JOURNAL			English	Editorial Material							LOW-BACK-PAIN					ben@badscience.net		Goldacre, Ben/0000-0002-5127-4728				Buchbinder R, 2001, MED J AUSTRALIA, V175, P456, DOI 10.5694/j.1326-5377.2001.tb143675.x; Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892; Koes BW, 2006, BMJ-BRIT MED J, V332, P1430, DOI 10.1136/bmj.332.7555.1430	3	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 20	2007	335	7624					801	801		10.1136/bmj.39370.657130.59	http://dx.doi.org/10.1136/bmj.39370.657130.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	227AX	17947783	Green Published			2023-01-03	WOS:000250630700028
J	Stern, RS				Stern, Robert S.			Psoralen and ultraviolet a light therapy for psoriasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; ORAL METHOXSALEN PHOTOCHEMOTHERAPY; CHRONIC PLAQUE PSORIASIS; SQUAMOUS-CELL CARCINOMA; A RADIATION PUVA; SYSTEMIC TREATMENTS; SKIN INFLAMMATION; NESTED COHORT; RISK; CYCLOSPORINE		Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Dermatol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Stern, RS (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Dermatol, 330 Brookline Ave, Boston, MA 02215 USA.	rstern@bidmc.harvard.edu						Bongartz T, 2006, JAMA-J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275; Bongartz T, 2006, JAMA-J AM MED ASSOC, V295, P2482; Cargill M, 2007, AM J HUM GENET, V80, P273, DOI 10.1086/511051; Clark RA, 2006, J CLIN INVEST, V116, P2084, DOI 10.1172/JCI29441; *DAN MED AG, 2007, GUID CRIT SINGL REIM; de Korte J, 2004, J INVEST DERM SYMP P, V9, P140, DOI 10.1046/j.1087-0024.2003.09110.x; Detmar M, 2004, J INVEST DERMATOL, V122, pXIV, DOI 10.1046/j.0022-202X.2003.22140.x; DRAKE LA, 1994, J AM ACAD DERMATOL, V31, P643; Erkin G, 2007, J CUTAN PATHOL, V34, P213, DOI 10.1111/j.1600-0560.2006.00591.x; Fortune DG, 2004, BRIT J DERMATOL, V151, P1219, DOI 10.1111/j.1365-2133.2004.06222.x; Fortune DG, 1997, BRIT J DERMATOL, V137, P755; Griffiths C E, 2000, Health Technol Assess, V4, P1; HENSELER T, 1985, J AM ACAD DERMATOL, V13, P450, DOI 10.1016/S0190-9622(85)70188-0; Heydendael VMR, 2004, J INVEST DERM SYMP P, V9, P131, DOI 10.1111/j.1087-0024.2004.09115.x; Heydendael VMR, 2003, NEW ENGL J MED, V349, P658, DOI 10.1056/NEJMoa021359; Johansen C, 2006, J IMMUNOL, V176, P1431, DOI 10.4049/jimmunol.176.3.1431; Krueger G, 2001, ARCH DERMATOL, V137, P280; Kupper TS, 2003, NEW ENGL J MED, V349, P1987, DOI 10.1056/NEJMp038164; LASKIN JD, 1986, P NATL ACAD SCI USA, V83, P8211, DOI 10.1073/pnas.83.21.8211; Leonardi CL, 2003, NEW ENGL J MED, V349, P2014, DOI 10.1056/NEJMoa030409; Lim JL, 2005, J INVEST DERMATOL, V124, P505, DOI 10.1111/j.0022-202X.2005.23618.x; Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; Marcil I, 2001, LANCET, V358, P1042, DOI 10.1016/S0140-6736(01)06179-7; MCEVOY MT, 1987, PHARMACOL THERAPEUT, V34, P75, DOI 10.1016/0163-7258(87)90093-3; MELSKI JW, 1977, J INVEST DERMATOL, V68, P328, DOI 10.1111/1523-1747.ep12496022; MORISON WL, 1982, J AM ACAD DERMATOL, V6, P46, DOI 10.1016/S0190-9622(82)70005-2; Morison WL, 2004, PHOTODERMATOL PHOTO, V20, P315, DOI 10.1111/j.1600-0781.2004.00125.x; Myers A, 2005, RHEUMATOLOGY, V44, P773, DOI 10.1093/rheumatology/keh589; *NICE, 2006, 103 NICE, P1; Nijsten T, 2005, J AM ACAD DERMATOL, V52, P434, DOI 10.1016/j.jaad.2004.10.862; Nijsten TEC, 2003, J AM ACAD DERMATOL, V49, P644, DOI 10.1067/S0190-9622(03)01587-1; Nijsten TEC, 2003, J INVEST DERMATOL, V121, P252, DOI 10.1046/j.1523-1747.2003.12350.x; NORRIS PG, 1994, BRIT J DERMATOL, V130, P246; PARRISH JA, 1974, NEW ENGL J MED, V291, P1207, DOI 10.1056/NEJM197412052912301; Schon MP, 2005, NEW ENGL J MED, V352, P1899, DOI 10.1056/NEJMra041320; Spuls PI, 1997, BRIT J DERMATOL, V137, P943, DOI 10.1046/j.1365-2133.1997.19902071.x; Stern RS, 2006, ARCH DERMATOL, V142, P1132, DOI 10.1001/archderm.142.9.1132; Stern RS, 2004, J INVEST DERM SYMP P, V9, P136, DOI 10.1046/j.1087-0024.2003.09102.x; STERN RS, 1984, NEW ENGL J MED, V310, P1156, DOI 10.1056/NEJM198405033101805; STERN RS, 1994, J INVEST DERMATOL, V103, P534, DOI 10.1111/1523-1747.ep12395733; STERN RS, 1980, ARCH DERMATOL, V116, P1269, DOI 10.1001/archderm.116.11.1269; STERN RS, 1990, NEW ENGL J MED, V322, P1093, DOI 10.1056/NEJM199004193221601; Stern RS, 1997, NEW ENGL J MED, V336, P1041, DOI 10.1056/NEJM199704103361501; STERN RS, 1979, NEW ENGL J MED, V300, P809, DOI 10.1056/NEJM197904123001501; Stratis A, 2006, J CLIN INVEST, V116, P2094, DOI 10.1172/JCI27179; VALLAT VP, 1994, J EXP MED, V180, P283, DOI 10.1084/jem.180.1.283; Wang HL, 2006, J CLIN INVEST, V116, P2105, DOI 10.1172/JCI27180; Yan KL, 2007, J INVEST DERMATOL, V127, P312, DOI 10.1038/sj.jid.5700506	49	109	115	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 16	2007	357	7					682	690		10.1056/NEJMct072317	http://dx.doi.org/10.1056/NEJMct072317			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200EF	17699818				2023-01-03	WOS:000248746000008
J	Schmidt, BM; Ribnicky, DM; Lipsky, PE; Raskin, I				Schmidt, Barbara M.; Ribnicky, David M.; Lipsky, Peter E.; Raskin, Ilya			Revisiting the ancient concept of botanical therapeutics	NATURE CHEMICAL BIOLOGY			English	Editorial Material							NATURAL-PRODUCTS; DRUG DISCOVERY; PLANTS; INHIBITORS; CHEMISTRY; EXTRACT	Mixtures of interacting compounds produced by plants may provide important combination therapies that simultaneously affect multiple pharmacological targets and provide clinical efficacy beyond the reach of single compound-based drugs. Developing innovative scientific methods for discovery, validation, characterization and standardization of these multicomponent botanical therapeutics is essential to their acceptance into mainstream medicine.	Rutgers State Univ, Sch Biol & Environm Sci, Biotech Ctr, New Brunswick, NJ 08901 USA; Natl Inst Arthritis & Musculosketal & Skin Dis, Autoimmun Branch, NIH, Bethesda, MD 20892 USA	Rutgers State University New Brunswick; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Schmidt, BM (corresponding author), Rutgers State Univ, Sch Biol & Environm Sci, Biotech Ctr, 59 Dudley Rd, New Brunswick, NJ 08901 USA.	raskin@AESOP.Rutgers.edu			FOGARTY INTERNATIONAL CENTER [U01TW006674] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [P50AT002776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041127] Funding Source: NIH RePORTER; FIC NIH HHS [U01 TW006674] Funding Source: Medline; NCCIH NIH HHS [1-P50 AT002776-01] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Abdin MZ, 2003, PLANTA MED, V69, P289, DOI 10.1055/s-2003-38871; Agrawal L, 2006, CURR PHARM DESIGN, V12, P2031, DOI 10.2174/138161206777442100; AHMAD I, IN PRESS MICROBIOL R; Aqil Farrukh, 2006, Biotechnology Journal, V1, P1093, DOI 10.1002/biot.200600130; Bindseil KU, 2001, DRUG DISCOV TODAY, V6, P840, DOI 10.1016/S1359-6446(01)01856-6; Blomberg B, 2003, DRUGS, V63, P535, DOI 10.2165/00003495-200363060-00002; Brinker AM, 2007, PHYTOCHEMISTRY, V68, P732, DOI 10.1016/j.phytochem.2006.11.029; Burdock GA, 2006, TOXICOLOGY, V221, P17, DOI 10.1016/j.tox.2006.01.012; Butler MS, 2004, J NAT PROD, V67, P2141, DOI 10.1021/np040106y; Coppens P, 2006, TOXICOLOGY, V221, P59, DOI 10.1016/j.tox.2005.12.022; Cragg GM, 2005, J ETHNOPHARMACOL, V100, P72, DOI 10.1016/j.jep.2005.05.011; Cragg GM, 1998, MED RES REV, V18, P315, DOI 10.1002/(SICI)1098-1128(199809)18:5<315::AID-MED3>3.0.CO;2-W; Deedwania Prakash C, 2005, Curr Treat Options Cardiovasc Med, V7, P61, DOI 10.1007/s11936-005-0007-1; Demmig-Adams B, 2002, SCIENCE, V298, P2149, DOI 10.1126/science.1078002; Dewick P.M., 2002, MED NATURAL PRODUCTS, Vsecond; FARNSWORTH NR, 1976, AM J PHARM, V148, P46; GOLDBACHMANSKY R, 2006, AM COLL RHEUM P 2006; Gusman J, 2000, RRD PHYTOCHEM, P187; Hemalswarya S, 2006, PHYTOTHER RES, V20, P239, DOI 10.1002/ptr.1841; Koch MA, 2005, P NATL ACAD SCI USA, V102, P17272, DOI 10.1073/pnas.0503647102; Koehn FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038/nrd1657; KUPCHAN SM, 1972, J AM CHEM SOC, V94, P7194, DOI 10.1021/ja00775a078; Logendra S, 2006, PHYTOCHEMISTRY, V67, P1539, DOI 10.1016/j.phytochem.2006.05.015; Murphey RD, 2006, METHODS, V39, P255, DOI 10.1016/j.ymeth.2005.09.019; Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v; Nichols A, 2007, METH MOL B, V356, P379; Ong ES, 2004, J CHROMATOGR B, V812, P23, DOI 10.1016/j.jchromb.2004.07.041; Raskin I, 2004, CURR PHARM DESIGN, V10, P3419, DOI 10.2174/1381612043383070; Raskin I, 2002, TRENDS BIOTECHNOL, V20, P522, DOI 10.1016/S0167-7799(02)02080-2; Ribnicky DM, 2006, PHYTOMEDICINE, V13, P550, DOI 10.1016/j.phymed.2005.09.007; Sams-Dodd F, 2006, DRUG DISCOV TODAY, V11, P465, DOI 10.1016/j.drudis.2006.03.015; Schellenberg D, 2006, CURR MOL MED, V6, P253, DOI 10.2174/156652406776055168; Spira B, 2005, CURR PHARM ANAL, V1, P243, DOI 10.2174/157341205774597841; Tao XL, 2002, ARTHRITIS RHEUM, V46, P1735, DOI 10.1002/art.10411; WANG ZQ, 2004, 64 SCI SESS AM DIAB; WANG ZQ, 2006, 66 SCI SESS AM DIAB; Waterhouse DN, 2006, CURR CANCER DRUG TAR, V6, P455, DOI 10.2174/156800906778194586	37	235	250	1	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUL	2007	3	7					360	366		10.1038/nchembio0707-360	http://dx.doi.org/10.1038/nchembio0707-360			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181UY	17576417				2023-01-03	WOS:000247462800005
J	Richards, T				Richards, Tessa			A better way to die - Why dying and death need to be "rehabilitated" back to a more central position in society	BRITISH MEDICAL JOURNAL			English	Editorial Material												trichards@bmj.com							0	4	4	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 21	2007	334	7598					830	830		10.1136/bmj.39188.592940.59	http://dx.doi.org/10.1136/bmj.39188.592940.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	162MD	17446614	Green Published			2023-01-03	WOS:000246090800030
J	Lacroix, J; Hebert, PC; Hutchison, JS; Hume, HA; Tucci, M; Ducruet, T; Gauvin, F; Collet, JP; Toledano, BJ; Robillard, P; Joffe, A; Biarent, D; Meert, K; Peters, MJ				Lacroix, Jacques; Hebert, Paul C.; Hutchison, James S.; Hume, Heather A.; Tucci, Marisa; Ducruet, Thierry; Gauvin, France; Collet, Jean-Paul; Toledano, Baruch J.; Robillard, Pierre; Joffe, Ari; Biarent, Dominique; Meert, Kathleen; Peters, Mark J.		TRIPCI Investigators	Transfusion strategies for patients in pediatric intensive care units	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-TRANSFUSION; RANDOMIZED-TRIAL; GENERATION; MORTALITY; STORAGE	BACKGROUND: The optimal hemoglobin threshold for erythrocyte transfusions in critically ill children is unknown. We hypothesized that a restrictive transfusion strategy of using packed red cells that were leukocyte-reduced before storage would be as safe as a liberal transfusion strategy, as judged by the outcome of multiple-organ dysfunction. METHODS: In this noninferiority trial, we enrolled 637 stable, critically ill children who had hemoglobin concentrations below 9.5 g per deciliter within 7 days after admission to an intensive care unit. We randomly assigned 320 patients to a hemoglobin threshold of 7 g per deciliter for red-cell transfusion (restrictive-strategy group) and 317 patients to a threshold of 9.5 g per deciliter (liberal-strategy group). RESULTS: Hemoglobin concentrations were maintained at a mean (+/- SD) level that was 2.1 +/- 0.2 g per deciliter lower in the restrictive-strategy group than in the liberal-strategy group (lowest average levels, 8.7 +/- 0.4 and 10.8 +/- 0.5 g per deciliter, respectively; P < 0.001). Patients in the restrictive-strategy group received 44% fewer transfusions; 174 patients (54%) in that group did not receive any transfusions, as compared with 7 patients (2%) in the liberal-strategy group (P < 0.001). New or progressive multiple-organ dysfunction syndrome (the primary outcome) developed in 38 patients in the restrictive-strategy group, as compared with 39 in the liberal-strategy group (12% in both groups) (absolute risk reduction with the restrictive strategy, 0.4%; 95% confidence interval, -4.6 to 5.4). There were 14 deaths in each group within 28 days after randomization. No significant differences were found in other outcomes, including adverse events. CONCLUSIONS: In stable, critically ill children a hemoglobin threshold of 7 g per deciliter for red-cell transfusion can decrease transfusion requirements without increasing adverse outcomes.	Univ Montreal, Hop St Justine, Montreal, PQ H3T 1C5, Canada; McGill Univ, Montreal, PQ, Canada; Univ Ottawa, Ottawa, ON, Canada; Univ Toronto, Toronto, ON, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Univ Alberta, Edmonton, AB, Canada; Univ Libre Bruxelles, Brussels, Belgium; Wayne State Univ, Detroit, MI USA; Inst Child Hlth, London, England	Universite de Montreal; McGill University; University of Ottawa; University of Toronto; University of British Columbia; University of Alberta; Universite Libre de Bruxelles; Wayne State University; University of London; University College London	Lacroix, J (corresponding author), Univ Montreal, Hop St Justine, Rm 3431,3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	jacques_lacroix@ssss.gouv.qc.ca	Peters, Mark/AAD-7518-2019	Peters, Mark/0000-0003-3653-4808				[Anonymous], 1989, AM REV RESPIR DIS, V139, P1058; Armano R, 2005, CRIT CARE MED, V33, P2637, DOI 10.1097/01.CCM.0000185645.84802.73; Bell EF, 2005, PEDIATRICS, V115, P1685, DOI 10.1542/peds.2004-1884; Bilgin YM, 2004, CIRCULATION, V109, P2755, DOI 10.1161/01.CIR.0000130162.11925.21; BLACKWELDER WC, 1984, CONTROL CLIN TRIALS, V5, P97, DOI 10.1016/0197-2456(84)90116-8; BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; Desmet L, 2004, CRIT CARE CLIN, V20, P299, DOI 10.1016/S0749-0704(03)00113-1; Fergusson D, 2003, JAMA-J AM MED ASSOC, V289, P1950, DOI 10.1001/jama.289.15.1950; Garrett AD, 2003, STAT MED, V22, P741, DOI 10.1002/sim.1360; Gauvin F, 2006, TRANSFUSION, V46, P1899, DOI 10.1111/j.1537-2995.2006.00995.x; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 1999, NEW ENGL J MED, V340, P1056; Jonas RA, 2003, J THORAC CARDIOV SUR, V126, P1765, DOI 10.1016/j.jtcvs.2003.04.003; Kirpalani H, 2006, J PEDIATR-US, V149, P301, DOI 10.1016/j.jpeds.2006.05.011; Lacroix J., 2006, PEDIAT CRITICAL CARE, P1394; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; Laverdiere Caroline, 2002, Pediatr Crit Care Med, V3, P335, DOI 10.1097/00130478-200210000-00001; Leteurtre S, 2006, LANCET, V367, P897, DOI 10.1016/S0140-6736(06)68371-2; Leteurtre S, 2003, LANCET, V362, P192, DOI 10.1016/S0140-6736(03)13908-6; LUBAN NLC, 1991, TRANSFUSION, V31, P229, DOI 10.1046/j.1537-2995.1991.31391165172.x; Marshall JC, 1999, CRIT CARE MED, V27, P676, DOI 10.1097/00003246-199904000-00005; Morris KP, 2005, ARCH DIS CHILD, V90, P724, DOI 10.1136/adc.2004.062174; Nahum Elhanan, 2004, J Intensive Care Med, V19, P38, DOI 10.1177/0885066603257966; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; Proulx F, 1996, CHEST, V109, P1033, DOI 10.1378/chest.109.4.1033; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Sanchez MM, 2006, STAT MED, V25, P1169, DOI 10.1002/sim.2244; Schulz KF, 2002, LANCET, V359, P781, DOI 10.1016/S0140-6736(02)07882-0; Shanwell A, 1997, TRANSFUSION, V37, P678, DOI 10.1046/j.1537-2995.1997.37797369441.x; STACK G, 1995, TRANSFUSION, V35, P199, DOI 10.1046/j.1537-2995.1995.35395184274.x; Vamakas EC, 2006, CRIT CARE MED, V34, pS151, DOI 10.1097/01.CCM.0000214310.70642.8C; Vamvakas EC, 2003, TRANSFUSION, V43, P963, DOI 10.1046/j.1537-2995.2003.00426.x; van de Watering LMG, 1998, CIRCULATION, V97, P562; Yazer MH, 2004, TRANSFUSION, V44, P10, DOI 10.1046/j.0041-1132.2003.00518.x	34	710	726	2	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 19	2007	356	16					1609	1619		10.1056/NEJMoa066240	http://dx.doi.org/10.1056/NEJMoa066240			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158AB	17442904	Green Published			2023-01-03	WOS:000245762000003
J	Sawyer, SM; Drew, S; Yeo, MS; Britto, MT				Sawyer, Susan M.; Drew, Sarah; Yeo, Michele S.; Britto, Maria T.			Adolescents with a chronic condition: challenges living, challenges treating	LANCET			English	Review							QUALITY-OF-LIFE; CROSS-SECTIONAL SURVEY; HEALTH-CARE NEEDS; CHRONIC ILLNESS; SELF-MANAGEMENT; CYSTIC-FIBROSIS; CHRONIC DISEASE; YOUNG-ADULTS; IDENTIFYING CHILDREN; SEXUAL-BEHAVIOR	In this review, we aim to focus attention on the interaction between adolescents with chronic conditions and the health systems that support them. At least 12% of adolescents live with a chronic condition. Some conditions are characterised by increasing incidence (eg, diabetes) or improving survival rates (eg, cystic fibrosis), while others are concerning because of differentially poorer outcomes in adolescents in comparison to both children and adults leg cancer). Growing evidence suggests that young people with chronic conditions are doubly disadvantaged-engaging in risky behaviours to at least similar if not higher rates as healthy peers, while having the potential for greater adverse health outcomes from these behaviours. in addition to efforts at improving survival, in order to improve their life chances, we need to better understand how the social and emotional outcomes of young people with a chronic disease can be improved, and better support young people's emerging capacity for self-management.	Royal Childrens Hosp, Ctr Adolescent Hlth, Melbourne, Vic 3052, Australia; Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; Murdoch Childrens Res Inst, Melbourne, Vic, Australia; Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA	Royal Children's Hospital Melbourne; University of Melbourne; Murdoch Children's Research Institute; Cincinnati Children's Hospital Medical Center	Sawyer, SM (corresponding author), Royal Childrens Hosp, Ctr Adolescent Hlth, Flemington Rd, Melbourne, Vic 3052, Australia.	susan.sawyer@rch.org.au						ALDERMAN EM, 1995, J DEV BEHAV PEDIATR, V16, P339; *AUSTR I HLTH WELF, 2005, SEL CHRON DIS AUSTR; Australian Institute of Health and Welfare, 2003, AUSTR YOUNG PEOPL TH; Bearinger L H, 1992, J Prof Nurs, V8, P80, DOI 10.1016/8755-7223(92)90067-9; Bethell CD, 2002, AMBUL PEDIATR, V2, P38, DOI 10.1367/1539-4409(2002)002<0038:ICWSHC>2.0.CO;2; Bleyer WA, 1997, J ADOLESCENT HEALTH, V21, P366, DOI 10.1016/S1054-139X(97)00110-9; Bleyer WA, 2002, MED PEDIATR ONCOL, V38, P1, DOI 10.1002/mpo.1257; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Britto MT, 1998, PEDIATRICS, V101, P250, DOI 10.1542/peds.101.2.250; Britto MT, 2004, PEDIATR PULM, V37, P165, DOI 10.1002/ppul.10436; Britto MT, 1999, ARCH PEDIAT ADOL MED, V153, P27; BUCHBINDER MH, 2005, J ADOLESC HLTH, V26; Buelow JM, 2000, DIS MANAG HEALTH OUT, V8, P327, DOI 10.2165/00115677-200008060-00003; CAMPBELL PW, 1992, J PEDIATR-US, V120, P261, DOI 10.1016/S0022-3476(05)80438-X; CARROLL G, 1983, J ADOLESCENT HEALTH, V4, P261, DOI 10.1016/S0197-0070(83)80008-4; Casalino L, 2003, JAMA-J AM MED ASSOC, V289, P434, DOI 10.1001/jama.289.4.434; Choquet M, 1997, J ADOLESCENT HEALTH, V20, P62, DOI 10.1016/S1054-139X(96)00091-2; Clarke Sally-Ann, 2004, Health Qual Life Outcomes, V2, P66, DOI 10.1186/1477-7525-2-66; COUPER JJ, 1994, DIABETIC MED, V11, P666, DOI 10.1111/j.1464-5491.1994.tb00330.x; Cremeens J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-58; CROMER BA, 1990, DEV MED CHILD NEUROL, V32, P602; *DIAB CONTR COMPL, 1994, TRIAL J PEDIAT, V125, P177; DiNapoli PP, 2002, NURS CLIN N AM, V37, P565, DOI 10.1016/S0029-6465(02)00012-9; Drew S, 2003, HEALTH, V7, P181, DOI 10.1177/1363459303007002874; DREW S, 2005, STORYTELLING SELF SO, V1, P75; Edenborough FP, 2002, ACTA OBSTET GYN SCAN, V81, P689, DOI 10.1034/j.1600-0412.2002.810801.x; Eiser C, 2001, QUAL LIFE RES, V10, P347, DOI 10.1023/A:1012253723272; Eiser C, 1997, ARCH DIS CHILD, V77, P350, DOI 10.1136/adc.77.4.350; Eiser C, 2001, Health Technol Assess, V5, P1; Epping-Jordan JE, 2005, LANCET, V366, P1667, DOI 10.1016/S0140-6736(05)67342-4; Frank A. W., 2013, WOUNDED STORYTELLER; Fuster V, 2005, LANCET, V366, P1512, DOI 10.1016/S0140-6736(05)67610-6; Gage H, 2004, PATIENT EDUC COUNS, V53, P333, DOI 10.1016/j.pec.2003.06.003; Geist R, 2003, BEST PRACT RES CL GA, V17, P141, DOI 10.1016/S1521-6918(02)00142-7; Gibson PG, 2002, COCHRANE DB SYST REV, V2; Gibson PG, 2003, COCHRANE DB SYST REV, V2; Goffman E., 1968, STIGMA NOTES MANAGEM; Grundy SM, 1999, CIRCULATION, V100, P1134, DOI 10.1161/01.CIR.100.10.1134; Guevara JP, 2003, BMJ-BRIT MED J, V326, P1308, DOI 10.1136/bmj.326.7402.1308; Hardoff D, 1999, J ADOLESCENT HEALTH, V25, P35, DOI 10.1016/S1054-139X(98)00132-3; Holl RW, 1998, DIABETES CARE, V21, P787, DOI 10.2337/diacare.21.5.787; Homer CJ, 2004, AMBUL PEDIATR, V4, P436, DOI 10.1367/A03-116R.1; Jacobson AM, 1997, DIABETES CARE, V20, P811, DOI 10.2337/diacare.20.5.811; Kritsotakis G, 2004, INT J NURS STUD, V41, P43, DOI 10.1016/S0020-7489(03)00097-X; Kyngas Helvi, 2004, Nurs Health Sci, V6, P287; Levi RB, 1999, INT J CANCER, P58; Loonen HJ, 2002, MED CARE, V40, P996, DOI 10.1097/00005650-200210000-00015; Loveman E, 2003, HEALTH TECHNOL ASSES, V7, P1, DOI DOI 10.3310/HTA7220; Lozano P, 2004, ARCH PEDIAT ADOL MED, V158, P875, DOI 10.1001/archpedi.158.9.875; Mangione-Smith R, 1998, HEALTH SERV RES, V33, P1059; McPherson M, 1998, PEDIATRICS, V102, P137, DOI 10.1542/peds.102.1.137; Miauton L, 2003, EUR J PEDIATR, V162, P682, DOI 10.1007/s00431-003-1179-x; Moons P, 2001, HEART, V86, P74, DOI 10.1136/heart.86.1.74; Msall ME, 2003, PEDIATRICS, V111, P548, DOI 10.1542/peds.111.3.548; MURRAY E, 2005, COCHRANE DB SYST REV, V1; NEWACHECK PW, 1994, J PEDIATR-US, V124, P40, DOI 10.1016/S0022-3476(94)70252-7; Newacheck PW, 1998, PEDIATRICS, V102, P117, DOI 10.1542/peds.102.1.117; NEWACHECK PW, 1992, AM J PUBLIC HEALTH, V82, P364, DOI 10.2105/AJPH.82.3.364; NEWACHECK PW, 1991, AM J DIS CHILD, V145, P1367, DOI 10.1001/archpedi.1991.02160120035015; *NIH CLIN EXC, IMPR OUTC CHILDR YOU; Nikpour M, 2005, RHEUM DIS CLIN N AM, V31, P329, DOI 10.1016/j.rdc.2005.01.001; Nixon GM, 2003, ARCH DIS CHILD, V88, P265, DOI 10.1136/adc.88.3.265; *OFF TECHN ASS, 1991, AD HLTH BACKGR EFF S, P149; Olsson CA, 2003, J ADOLESCENCE, V26, P1, DOI 10.1016/S0140-1971(02)00118-5; Olsson CA, 2003, ANN ACAD MED SINGAP, V32, P43; Olsson CA., 2005, CLIN CHILD PSYCHOL P, V10, P78, DOI [10.1177/1359104505048793, DOI 10.1177/1359104505048793]; ORR DP, 1987, J ADOLESC HLTH CARE, P239; *PARL AUSTR SEN, CANC JOURN INF CHOIC; Parsons SK, 1999, INT J CANCER, P46; PATTON GC, 2007, LANCET          0327, DOI DOI 10.1016/S0140-6736(07)60366-3; PERRIN EC, 1993, PEDIATRICS, V91, P787; PERRIN JM, 1993, PEDIATRICS, V92, P876; Petersen C, 2006, EUR PSYCHOL, V11, P50, DOI 10.1027/1016-9040.11.1.50; PLESS IB, 1975, CHRONIC CHILDHOOD DI; Precht DH, 2003, PEDIATRICS, V111, pE562, DOI 10.1542/peds.111.5.e562; RADDISH M, 1993, AM J DIS CHILD, V147, P849, DOI 10.1001/archpedi.1993.02160320051018; Resnick MD, 2000, J ADOLESCENT HEALTH, V27, P1, DOI 10.1016/S1054-139X(00)00142-7; Resnick MD, 1997, JAMA-J AM MED ASSOC, V278, P823, DOI 10.1001/jama.278.10.823; Rich M, 2002, AM J HEALTH BEHAV, V26, P442, DOI 10.5993/AJHB.26.6.5; Rich M, 2000, J ADOLESCENT HEALTH, V27, P155, DOI 10.1016/S1054-139X(00)00114-2; Rosen DS, 2003, J ADOLESCENT HEALTH, V33, P309, DOI 10.1016/S1054-139X(03)00208-8; Rundall TG, 2002, BMJ-BRIT MED J, V325, P958, DOI 10.1136/bmj.325.7370.958; Sawyer MG, 2004, QUAL LIFE RES, V13, P1309, DOI 10.1023/B:QURE.0000037489.41344.b2; Sawyer SM, 2005, MED J AUSTRALIA, V183, P405, DOI 10.5694/j.1326-5377.2005.tb07103.x; Sawyer SM, 2003, J PAEDIATR CHILD H, V39, P2, DOI 10.1046/j.1440-1754.2003.00081.x; Sawyer SM, 1999, DEV MED CHILD NEUROL, V41, P671, DOI 10.1017/S0012162299001383; Schwimmer JB, 2003, JAMA-J AM MED ASSOC, V289, P1813, DOI 10.1001/jama.289.14.1813; Shah S, 2001, BRIT MED J, V322, P583, DOI 10.1136/bmj.322.7286.583; STEIN REK, 1993, J PEDIATR-US, V122, P342, DOI 10.1016/S0022-3476(05)83414-6; STERN RC, 1987, J PEDIATR-US, V111, P293, DOI 10.1016/S0022-3476(87)80090-2; STOKES T, 2004, COCHRANE DATABA 0419, DOI DOI 10.1002/14651858; Suris JC, 2005, EUR J PUBLIC HEALTH, V15, P484, DOI 10.1093/eurpub/cki001; Suris JC, 1996, J ADOLESCENT HEALTH, V19, P124, DOI 10.1016/1054-139X(95)00282-W; Thorndike AN, 1999, J NATL CANCER I, V91, P1857, DOI 10.1093/jnci/91.21.1857; Toelle BG, 2004, COCHRANE DB SYST REV, V2; Toloza SMA, 2004, ARTHRITIS RHEUM-US, V50, P3947, DOI 10.1002/art.20622; Tsai AC, 2005, AM J MANAG CARE, V11, P478; Turner B, 2003, SOC THEORY HLTH, V1, P4, DOI DOI 10.1057/PALGRAVE.STH.8700001; *US DEP HHS, 2004, NAT SURV CHILDR SPEC; Valencia L S, 2000, J Pediatr Adolesc Gynecol, V13, P53, DOI 10.1016/S1083-3188(00)00004-8; Veit FCM, 1996, MED J AUSTRALIA, V165, P131, DOI 10.5694/j.1326-5377.1996.tb124885.x; VERHULST FC, 1992, J CHILD PSYCHOL PSYC, V33, P1011, DOI 10.1111/j.1469-7610.1992.tb00922.x; Vessey J A, 1999, Pediatr Nurs, V25, P211; *VICT GOV DEP HUM, 2005, VICT BURD DIS STUD M; WAGER MD, 1986, PEDIATR RES, V20, pA158; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64; Wake M, 2000, DIABETIC MED, V17, P700, DOI 10.1046/j.1464-5491.2000.00360.x; WAKEFIELD M, 1995, AUST J PUBLIC HEALTH, V19, P309; Waters E, 2000, PEDIATRICS, V106, P1422, DOI 10.1542/peds.106.6.1422; Weingarten SR, 2002, BRIT MED J, V325, P925, DOI 10.1136/bmj.325.7370.925; WHITINGOKEEFE QE, 1991, AM J MED, V90, P711; Yeo MSM, 2005, MED J AUSTRALIA, V183, P427, DOI 10.5694/j.1326-5377.2005.tb07110.x; Yorke J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002982.pub3; YOUNG RC, 1992, J NATL MED ASSOC, V84, P267; Youngblade LM, 2003, J PEDIATR PSYCHOL, V28, P393, DOI 10.1093/jpepsy/jsg029	115	385	394	0	56	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR-MAY	2007	369	9571					1481	1489		10.1016/S0140-6736(07)60370-5	http://dx.doi.org/10.1016/S0140-6736(07)60370-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	161LW	17467519				2023-01-03	WOS:000246017700035
J	Cawthorne, P; Ford, N; Limpananont, J; Tienudom, N; Purahong, W				Cawthorne, Paul; Ford, Nathan; Limpananont, Jiraporn; Tienudom, Nimit; Purahong, Wirat			WHO must defend patients' interests, not industry	LANCET			English	Editorial Material									Med Sans Frontieres, Bangkok 10240, Thailand; Chulalongkorn Univ, Fac Pharmaceut Sci, Bangkok, Thailand; AIDS Access Fdn, Bangkok, Thailand; Thai Network People Living HIV AIDS, Bangkok, Thailand	Chulalongkorn University	Cawthorne, P (corresponding author), Med Sans Frontieres, Bangkok 10240, Thailand.	msfb-bangkok@brussels.msf.org						*ABB, 2006, ABB REP STRONG 4 Q R; [Anonymous], 2001, DECL TRIPS AGR PUBL; *BRIST MYERS SQUIB, BRIST MYERS SQUIBB C; CHAN M, 2007, COMMUNICATION   0212; Okie S, 2006, NEW ENGL J MED, V354, P1977, DOI 10.1056/NEJMp068069; Pinheiro E, 2006, AIDS, V20, P1745, DOI 10.1097/01.aids.0000242821.67001.65; REVENGA A, 2006, EC EFF AIDS TREATM E; SCHWAB S, 2007, COMMUNICATION   0117; TREERUTKUARKUL A, 2007, BANGKOK POST    0213; TREERUTKUARKUL A, 2007, BANGKOK POST    0202; *WHO, 2005, EXT REV HLTH SECT RE; Wilson D, 1999, LANCET, V354, P1893, DOI 10.1016/S0140-6736(99)06114-0; ZAMISKA N, 2007, WALL STREET J   0314	13	12	13	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 24	2007	369	9566					974	975		10.1016/S0140-6736(07)60473-5	http://dx.doi.org/10.1016/S0140-6736(07)60473-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	151JO	17382809				2023-01-03	WOS:000245286500009
J	Wharam, JF; Landon, BE; Galbraith, AA; Kleinman, KP; Soumerai, SB; Ross-Degnan, D				Wharam, J. Frank; Landon, Bruce E.; Galbraith, Alison A.; Kleinman, Ken P.; Soumerai, Stephen B.; Ross-Degnan, Dennis			Emergency department use and subsequent hospitalizations among members of a high-deductible health plan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHRONIC DISEASE SCORE; INSURANCE STATUS; CLAIMS DATA; CARE; COST; ASSOCIATION; MORTALITY; ADMISSION; COVERAGE; EVENTS	Context Patients evaluated at emergency departments often present with nonemergency conditions that can be treated in other clinical settings. High-deductible health plans have been promoted as a means of reducing overutilization but could also be related to worse outcomes if patients defer necessary care. Objectives To determine the relationship between transition to a high-deductible health plan and emergency department use for low- and high-severity conditions and to examine changes in subsequent hospitalizations. Design, Setting, and Participants Analysis of emergency department visits and subsequent hospitalizations among 8724 individuals for 1 year before and after their employers mandated a switch from a traditional health maintenance organization plan to a high-deductible health plan, compared with 59 557 contemporaneous controls who remained in the traditional plan. All persons were aged 1 to 64 years and insured by a Massachusetts health plan between March 1, 2001, and June 30, 2005. Main Outcome Measures Rates of first and repeat emergency department visits classified as low, indeterminate, or high severity during the baseline and follow-up periods, as well as rates of inpatient admission after emergency department visits. Results Between the baseline and follow-up periods, emergency department visits among members who switched to high-deductible coverage decreased from 197.5 to 178.1 per 1000 members, while visits among controls remained at approximately 220 per 1000(- 10.0% adjusted difference in difference; 95% confidence interval [CI],- 16.6% to- 2.8%; P=. 007). The high-deductible plan was not associated with a change in the rate of first visits occurring during the study period (- 4.1% adjusted difference in difference; 95% CI, - 11.8% to 4.3%). Repeat visits in the high-deductible group decreased from 334.6 to 255.3 visits per 1000 members and increased from 321.1 to 334.4 per 1000 members in controls(- 24.9% difference in difference; 95% CI, - 37.5% to - 9.7%; P=. 002). Low-severity repeat emergency department visits decreased in the high-deductible group from 142.5 to 92.1 per 1000 members and increased in controls from 128.0 to 132.5 visits per 1000 members(- 36.4% adjusted difference in difference; 95% CI, - 51.1% to - 17.2%; P <. 001), whereas a small decrease in high-severity visits in the high-deductible group could not be excluded. The percentage of patients admitted from the emergency department in the high-deductible group decreased from 11.8% to 10.9% and increased from 11.9% to 13.6% among controls (- 24.7% adjusted difference in difference; 95% CI, - 41.0% to - 3.9%; P=. 02). Conclusions Traditional health plan members who switched to high-deductible coverage visited the emergency department less frequently than controls, with reductions occurring primarily in repeat visits for conditions that were not classified as high severity, and had decreases in the rate of hospitalizations from the emergency department. Further research is needed to determine long-term health care utilization patterns under high-deductible coverage and to assess risks and benefits related to clinical outcomes.	Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Pilgrim Hlth Care, Boston, MA USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Wharam, JF (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA.	jwharam@partners.org		Wharam, James/0000-0003-2053-0757; Kleinman, Ken/0000-0002-5600-5834	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS011843] Funding Source: NIH RePORTER; AHRQ HHS [U 18 HS 11843] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Ash AS, 2003, HEALTH SERV RES, V38, P1253, DOI 10.1111/1475-6773.00175; BAKER LC, 1994, HEALTH AFFAIR, V13, P162, DOI 10.1377/hlthaff.13.5.162; Bamezai A, 2005, ANN EMERG MED, V45, P483, DOI 10.1016/j.annemergmed.2004.08.029; Billings J, 2000, Issue Brief (Commonw Fund), P1; BILLINGS J, 2000, ISSUE BRIEF COMMONW, V433, P1; BINDMAN AB, 1991, JAMA-J AM MED ASSOC, V266, P1091, DOI 10.1001/jama.266.8.1091; BLUSTEIN J, 1995, NEW ENGL J MED, V332, P1138, DOI 10.1056/NEJM199504273321706; BUNTIN MB, 2006, HLTH AFF MILLWOOD, V25, pS516; BUSH GW, PRESIDENTS PROPOSAL; CANNON MF, HLTH SAVINGS ACCOUNT; CLARK DO, 1995, MED CARE, V33, P783, DOI 10.1097/00005650-199508000-00004; Cogan JF, 2005, HEALTH AFFAIR, V24, P1447, DOI 10.1377/hlthaff.24.6.1447; Cowen ME, 2002, MED CARE, V40, P650, DOI 10.1097/00005650-200208000-00004; Cowen ME, 1998, MED CARE, V36, P1108, DOI 10.1097/00005650-199807000-00016; *CTR MED MED SERV, FACT SHEET 2007 MED; Davis Karen, 2004, Issue Brief (Commonw Fund), P1; Derlet RW, 2000, ANN EMERG MED, V35, P63, DOI 10.1016/S0196-0644(00)70105-3; Fishman PA, 1999, MED CARE, V37, P874, DOI 10.1097/00005650-199909000-00004; Ginsburg PB, 2004, NEW ENGL J MED, V351, P1591, DOI 10.1056/NEJMp048159; Herzlinger RE, 2002, HARVARD BUS REV, V80, P44; Hsu J, 2006, HEALTH SERV RES, V41, P1801, DOI 10.1111/j.1475-6773.2006.00562.x; *I MED COMM FUT EM, FUT EM CAR KEY FIND; JOHNSON RE, 1994, J CLIN EPIDEMIOL, V47, P1191, DOI 10.1016/0895-4356(94)90106-6; *KAIS FAM FDN HLTH, EMPL HLTH BEN 2006 A; KOENKER R, 1978, ECONOMETRICA, V46, P33, DOI 10.2307/1913643; Krieger N, 2003, AM J PUBLIC HEALTH, V93, P1655, DOI 10.2105/AJPH.93.10.1655; LANDA AS, MEDICAID OFFER HSA P; Lee TH, 2005, NEW ENGL J MED, V353, P1202, DOI 10.1056/NEJMp058209; Magid DJ, 1997, NEW ENGL J MED, V336, P1722, DOI 10.1056/NEJM199706123362406; Newhouse JP, 1996, FREE ALL LESSONS RAN; OGRADY KF, 1985, NEW ENGL J MED, V313, P484, DOI 10.1056/NEJM198508223130806; Palmisano DJ, 2004, JAMA-J AM MED ASSOC, V291, P2237, DOI 10.1001/jama.291.18.2237; RASELL ME, 1995, NEW ENGL J MED, V332, P1164, DOI 10.1056/NEJM199504273321711; Richardson DB, 2006, MED J AUSTRALIA, V184, P213, DOI 10.5694/j.1326-5377.2006.tb00204.x; Roblin DW, 2005, MED CARE, V43, P951, DOI 10.1097/01.mlr.0000178216.23514.b7; Ruger JP, 2003, ACAD EMERG MED, V10, P1285, DOI 10.1197/S1069-6563(03)00500-1; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; Selby JV, 1996, NEW ENGL J MED, V334, P635, DOI 10.1056/NEJM199603073341006; Shearer G, 2004, HEALTH SERV RES, V39, P1159, DOI 10.1111/j.1475-6773.2004.00280.x; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; Sox CM, 1998, AM J MED, V105, P506, DOI 10.1016/S0002-9343(98)00324-6; Sprivulis PC, 2006, MED J AUSTRALIA, V184, P208, DOI 10.5694/j.1326-5377.2006.tb00203.x; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Travers DA, 2003, ACAD EMERG MED, V10, P1337, DOI 10.1197/S1069-6563(03)00536-0; Trzeciak S, 2003, EMERG MED J, V20, P402, DOI 10.1136/emj.20.5.402; US Census Bureau, 1994, GEOGR AR REF MAN; WUERZ RC, 1992, ANN EMERG MED, V21, P669, DOI 10.1016/S0196-0644(05)82777-5; YOO H, JANUARY CENSUS SHOWS; Yu W, 2004, AM J MANAG CARE, V10, P909; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; Zhan CL, 2003, JAMA-J AM MED ASSOC, V290, P1868, DOI 10.1001/jama.290.14.1868	51	124	127	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 14	2007	297	10					1093	1102		10.1001/jama.297.10.1093	http://dx.doi.org/10.1001/jama.297.10.1093			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	145KZ	17356030	Bronze			2023-01-03	WOS:000244865200023
J	Gibney, EM				Gibney, Eric M.			Concurrent sentences - Dialysis in the state penitentiary	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Virginia Commonwealth Univ, Div Nephrol, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Hume Lee Transplant Ctr, Richmond, VA USA	Virginia Commonwealth University; Virginia Commonwealth University	Gibney, EM (corresponding author), Virginia Commonwealth Univ, Div Nephrol, Med Coll Virginia Campus, Richmond, VA 23284 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2007	356	2					108	110		10.1056/NEJMp068102	http://dx.doi.org/10.1056/NEJMp068102			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	124NE	17215527				2023-01-03	WOS:000243373700002
J	Moss, M; Burnham, EL				Moss, Marc; Burnham, Ellen Lyda			Alcohol abuse in the critically ill patient	LANCET			English	Review							INTENSIVE-CARE-UNIT; RESPIRATORY-DISTRESS-SYNDROME; DISORDERS IDENTIFICATION TEST; CARBOHYDRATE-DEFICIENT TRANSFERRIN; COMMUNITY-ACQUIRED PNEUMONIA; EPITHELIAL BARRIER FUNCTION; MULTIPLE ORGAN DYSFUNCTION; CHRONIC ETHANOL INGESTION; RISK-FACTORS; ATRIAL-FIBRILLATION	Alcohol abuse and dependence disorders are common in the 10% of hospitalised patients who need admission to the intensive care unit (ICU), but these disorders are often undiagnosed. The systemic effects from the excessive use of alcohol increase susceptibility to, or directly cause various important disorders in the critically ill. Early recognition of alcohol abuse and dependence is necessary and should prompt consideration of several alcohol-specific diagnoses that have important prognostic and therapeutic implications for these patients. We discuss the use of screening tests to improve the identification of alcohol abuse and dependence disorders, the epidemiology and pathogenesis of important alcohol-related disorders, differences in the presentation of several common alcohol-related diagnoses in the ICU, and important alcohol-specific therapies.	Univ Colorado, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA; Hlth Sci Ctr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Denver	Moss, M (corresponding author), Univ Colorado, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA.	Marc.Moss@uchsc.edu			NCRR NIH HHS [M01-RR000039] Funding Source: Medline; NIAAA NIH HHS [R01-AA014435, P50-AA013757, K23-AA013918] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA013757, R01AA014435, K23AA013918] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Agabio R, 2005, ALCOHOL ALCOHOLISM, V40, P155, DOI 10.1093/alcalc/agh106; ANDREWS BE, 1987, Q J MED, V62, P195; BARTLETT JG, 1974, AM REV RESPIR DIS, V110, P56; Bechara RI, 2004, AM J RESP CRIT CARE, V170, P188, DOI 10.1164/rccm.200304-478OC; Bercault N, 2001, CRIT CARE MED, V29, P2303, DOI 10.1097/00003246-200112000-00012; Betrosian AP, 2004, AM J MED SCI, V327, P250, DOI 10.1097/00000441-200405000-00020; Blondell RD, 2003, JAMA-J AM MED ASSOC, V289, P552, DOI 10.1001/jama.289.5.552; Blondell RD, 2002, J STUD ALCOHOL, V63, P380, DOI 10.15288/jsa.2002.63.380; Boe DM, 2001, J INFECT DIS, V184, P1134, DOI 10.1086/323661; BRADEN GL, 1993, ARCH INTERN MED, V153, P2377, DOI 10.1001/archinte.153.20.2377; Brent J, 1999, NEW ENGL J MED, V340, P832, DOI 10.1056/NEJM199903183401102; Brent J, 2001, NEW ENGL J MED, V344, P424, DOI 10.1056/NEJM200102083440605; Brown CVR, 2004, J TRAUMA, V56, P1191, DOI 10.1097/01.TA.0000130761.78627.10; Brown LAS, 2001, ALCOHOL CLIN EXP RES, V25, P1078, DOI 10.1111/j.1530-0277.2001.tb02320.x; Burnham EL, 2003, ALCOHOL CLIN EXP RES, V27, P1167, DOI 10.1097/01.ALC.0000075821.34270.98; Burnham EL, 2004, CRIT CARE MED, V32, P675, DOI 10.1097/01.CCM.0000114824.65158.4E; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Cabre E, 2000, HEPATOLOGY, V32, P36, DOI 10.1053/jhep.2000.8627; Canagasaby A, 2005, ALCOHOL ALCOHOLISM, V40, P208, DOI 10.1093/alcalc/agh156; CARPENTER JL, 1991, SOUTHERN MED J, V84, P299, DOI 10.1097/00007611-199103000-00004; Chang PH, 2001, MED CLIN N AM, V85, P1191, DOI 10.1016/S0025-7125(05)70372-2; Conigrave KM, 2003, ADDICTION, V98, P31, DOI 10.1046/j.1359-6357.2003.00581.x; Connors GJ, 2003, ADDICTION, V98, P21, DOI 10.1046/j.1359-6357.2003.00585.x; Cook CCH, 1998, ALCOHOL ALCOHOLISM, V33, P317; D'Onofrio G, 1999, NEW ENGL J MED, V340, P915, DOI 10.1056/NEJM199903253401203; Dauphine C, 2004, ARCH SURG-CHICAGO, V139, P978, DOI 10.1001/archsurg.139.9.978; Djousse L, 2004, AM J CARDIOL, V93, P710, DOI 10.1016/j.amjcard.2003.12.004; Donovan DM, 2004, J TRAUMA, V56, P873, DOI 10.1097/01.TA.0000086650.27490.4B; Dufour MC, 2003, PANCREAS, V27, P286, DOI 10.1097/00006676-200311000-00002; ELISAF M, 1994, MINER ELECTROL METAB, V20, P274; Elisaf M, 2002, DRUG ALCOHOL REV, V21, P73, DOI 10.1080/09595230220119282a; Elisaf M, 1998, ALCOHOL CLIN EXP RES, V22, P134, DOI 10.1111/j.1530-0277.1998.tb03628.x; Elisaf MS, 1997, INT J CLIN PRACT, V51, P501; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Ferguson JA, 1996, J GEN INTERN MED, V11, P410, DOI 10.1007/BF02600188; Fernandez-Sola J, 2000, ALCOHOL CLIN EXP RES, V24, P1830, DOI 10.1097/00000374-200012000-00012; FERNANDEZSOLA J, 1995, ARCH INTERN MED, V155, P1649, DOI 10.1001/archinte.155.15.1649; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; FUXENCHLOPEZ Z, 1978, ARCH INTERN MED, V138, P1815, DOI 10.1001/archinte.138.12.1815; GABOW PA, 1982, MEDICINE, V61, P141, DOI 10.1097/00005792-198205000-00002; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; Glaser DS, 1996, ANN EMERG MED, V27, P343, DOI 10.1016/S0196-0644(96)70271-8; GLUCKMAN SJ, 1978, BLOOD, V52, P551; Guidot DM, 2000, AM J PHYSIOL-LUNG C, V279, pL127, DOI 10.1152/ajplung.2000.279.1.L127; Hall W, 1997, LANCET, V349, P1897, DOI 10.1016/S0140-6736(97)04572-8; HALPERN NA, 1994, CRIT CARE MED, V22, P2001; Hasin D, 2003, ALCOHOL RES HEALTH, V27, P5; Hermans C, 1996, CLIN RHEUMATOL, V15, P193, DOI 10.1007/BF02230340; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Hodges B, 2004, PHARMACOTHERAPY, V24, P1578, DOI 10.1592/phco.24.16.1578.50945; Hoffman R S, 1989, Emerg Med Clin North Am, V7, P943; Holguin F, 1998, J CLIN INVEST, V101, P761, DOI 10.1172/JCI1396; HOYUMPA AM, 1980, AM J CLIN NUTR, V33, P2750, DOI 10.1093/ajcn/33.12.2750; HOYUMPA AM, 1986, ALCOHOL CLIN EXP RES, V10, P573, DOI 10.1111/j.1530-0277.1986.tb05147.x; JENSEN NH, 1988, INTENS CARE MED, V15, P19; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; Kershaw C, 2003, AM J RESP CRIT CARE, V167, pA251; KOLLS JK, 1995, AM J PHYSIOL-LUNG C, V268, pL991, DOI 10.1152/ajplung.1995.268.6.L991; KOSKINEN P, 1990, AM J CARDIOL, V66, P954, DOI 10.1016/0002-9149(90)90932-Q; KOSKINEN P, 1987, BRIT HEART J, V57, P468, DOI 10.1136/hrt.57.5.468; Kraemer Kevin L, 2003, Subst Abus, V24, P197, DOI 10.1023/A:1026099426602; Kraemer KL, 1997, ARCH INTERN MED, V157, P2234, DOI 10.1001/archinte.157.19.2234; Licker M, 2003, ANESTH ANALG, V97, P1558, DOI 10.1213/01.ANE.0000087799.85495.8A; Lingford-Hughes A, 2003, BRIT J PSYCHIAT, V182, P97, DOI 10.1192/bjp.182.2.97; Longabaugh R, 2001, J STUD ALCOHOL, V62, P806, DOI 10.15288/jsa.2001.62.806; Lukan JK, 2002, J TRAUMA, V53, P901, DOI 10.1097/00005373-200211000-00015; MACDONALD L, 1994, AM J EMERG MED, V12, P32, DOI 10.1016/0735-6757(94)90193-7; MacGregor R R, 1997, Curr Clin Top Infect Dis, V17, P291; MACGREGOR RR, 1974, NEW ENGL J MED, V291, P642, DOI 10.1056/NEJM197409262911302; MADDREY WC, 1990, SCAND J GASTROENTERO, V25, P118, DOI 10.3109/00365529009093136; Mandrekar P, 1999, INT IMMUNOL, V11, P1781, DOI 10.1093/intimm/11.11.1781; Marik P, 1996, ALCOHOL ALCOHOLISM, V31, P393; Martin GS, 2005, CRIT CARE, V9, pR74, DOI 10.1186/cc3025; Martin MJ, 2002, ALCOHOL CLIN EXP RES, V26, P836, DOI 10.1097/00000374-200206000-00013; Mathurin P, 2002, J HEPATOL, V36, P480, DOI 10.1016/S0168-8278(01)00289-6; Maxson PM, 1999, MAYO CLIN PROC, V74, P448; Mayo-Smith MF, 2004, ARCH INTERN MED, V164, P1405, DOI 10.1001/archinte.164.13.1405; MayoSmith MF, 1997, JAMA-J AM MED ASSOC, V278, P144, DOI 10.1001/jama.278.2.144; MCGILL V, 1995, J TRAUMA, V38, P931, DOI 10.1097/00005373-199506000-00019; Miller WR, 2006, ALCOHOL CLIN EXP RES, V30, P292, DOI 10.1111/j.1530-0277.2006.00027.x; Molina PE, 2004, ALCOHOL, V33, P217, DOI 10.1016/j.alcohol.2004.07.002; Monti PM, 1999, J CONSULT CLIN PSYCH, V67, P989, DOI 10.1037/0022-006X.67.6.989; Moss M, 2003, CRIT CARE MED, V31, P869, DOI 10.1097/01.CCM.0000055389.64497.11; Moss M, 1996, JAMA-J AM MED ASSOC, V275, P50, DOI 10.1001/jama.275.1.50; Moss M, 2000, AM J RESP CRIT CARE, V161, P414, DOI 10.1164/ajrccm.161.2.9905002; *NAT I ALC AB ALC, HELP PAT DRINK TOO M; Nelson S, 2002, NAT REV IMMUNOL, V2, P205, DOI 10.1038/nri744; NELSON S, 1989, J INFECT DIS, V160, P422, DOI 10.1093/infdis/160.3.422; Neuenschwander AU, 2002, EUR J CARDIO-THORAC, V22, P287, DOI 10.1016/S1010-7940(02)00263-4; Neumann T, 2004, ALCOHOL CLIN EXP RES, V28, P1693, DOI 10.1097/01.ALC.0000145696.58084.08; Neumann T, 2003, ADDICTION, V98, P81, DOI 10.1046/j.1359-6357.2003.00587.x; NILSSON E, 1991, J INFECT DIS, V163, P591, DOI 10.1093/infdis/163.3.591; O'Beirne J, 2000, POSTGRAD MED J, V76, P504, DOI 10.1136/pmj.76.898.504; ORTQVIST A, 1990, EUR RESPIR J, V3, P1105; Paull DE, 2004, AM J SURG, V188, P553, DOI 10.1016/j.amjsurg.2004.07.030; Puddey IB, 1999, ADDICTION, V94, P649, DOI 10.1046/j.1360-0443.1999.9456493.x; Reinert DF, 2002, ALCOHOL CLIN EXP RES, V26, P272, DOI 10.1111/j.1530-0277.2002.tb02534.x; REULER JB, 1985, NEW ENGL J MED, V312, P1035, DOI 10.1056/NEJM198504183121606; Richards JR, 2000, J EMERG MED, V19, P51, DOI 10.1016/S0736-4679(00)00180-3; Richardson JD, 2004, J AM COLL SURGEONS, V199, P133, DOI 10.1016/j.jamcollsurg.2004.02.023; RIVARA FP, 1993, JAMA-J AM MED ASSOC, V270, P1962, DOI 10.1001/jama.270.16.1962; RUBIN R, 1994, ALCOHOL CLIN EXP RES, V18, P105, DOI 10.1111/j.1530-0277.1994.tb00888.x; SACHS CW, 1990, AM REV RESPIR DIS, V141, P1249, DOI 10.1164/ajrccm/141.5_Pt_1.1249; Saitz R, 1997, MED CLIN N AM, V81, P881, DOI 10.1016/S0025-7125(05)70554-X; Saitz R, 1997, ARCH INTERN MED, V157, P1446, DOI 10.1001/archinte.157.13.1446; Saitz R, 2005, NEW ENGL J MED, V352, P596, DOI 10.1056/NEJMcp042262; Sander M, 2002, INTENS CARE MED, V28, P285, DOI 10.1007/s00134-001-1199-9; Santhosh-Kumar CR, 2000, AM J HEMATOL, V64, P71, DOI 10.1002/(SICI)1096-8652(200005)64:1&lt;71::AID-AJH13&gt;3.0.CO;2-Z; Schermer CR, 2003, J TRAUMA, V55, P849, DOI 10.1097/01.TA.0000091110.83692.38; Schiodt FV, 1997, NEW ENGL J MED, V337, P1112, DOI 10.1056/NEJM199710163371602; Servin FS, 2003, ANESTHESIOLOGY, V99, P576, DOI 10.1097/00000542-200309000-00012; Soderstrom CA, 1997, J TRAUMA, V43, P962, DOI 10.1097/00005373-199712000-00017; SONNE NM, 1992, BRIT J NEUROSURG, V6, P125, DOI 10.3109/02688699209002914; Spies C D, 2001, Curr Opin Crit Care, V7, P337; Spies CD, 1996, CRIT CARE MED, V24, P414, DOI 10.1097/00003246-199603000-00009; Spies CD, 2003, INTENS CARE MED, V29, P2230, DOI 10.1007/s00134-003-2033-3; Spies CD, 1998, ALCOHOL ALCOHOLISM, V33, P661, DOI 10.1093/alcalc/33.6.661; Spies CD, 1996, INTENS CARE MED, V22, P286, DOI 10.1007/BF01700448; SPIES CD, 1995, J TRAUMA, V39, P742, DOI 10.1097/00005373-199510000-00025; Spies CD, 2004, ANESTHESIOLOGY, V100, P1088, DOI 10.1097/00000542-200405000-00010; Spies CD, 1999, ANESTH ANALG, V88, P946, DOI 10.1097/00000539-199904000-00050; Spies CD, 1996, ACTA ANAESTH SCAND, V40, P649, DOI 10.1111/j.1399-6576.1996.tb04505.x; Stoltz DA, 2000, AM J RESP CRIT CARE, V161, P135, DOI 10.1164/ajrccm.161.1.9905016; SZABO G, 1995, J LEUKOCYTE BIOL, V58, P342, DOI 10.1002/jlb.58.3.342; Tayar J, 2002, NEW ENGL J MED, V346, P1253, DOI 10.1056/NEJM200204183461618; Thomson A D, 2000, Alcohol Alcohol Suppl, V35, P2; Thomson AD, 2002, ALCOHOL ALCOHOLISM, V37, P513, DOI 10.1093/alcalc/37.6.513; TONNESEN H, 1988, SCAND J UROL NEPHROL, V22, P175, DOI 10.1080/00365599.1988.11690408; Tonnesen H, 1999, BMJ-BRIT MED J, V318, P1311, DOI 10.1136/bmj.318.7194.1311; Tonnesen H, 1999, ALCOHOL ALCOHOLISM, V34, P148, DOI 10.1093/alcalc/34.2.148; Tonnesen H, 2003, DAN MED BULL, V50, P139; Tonnesen H, 1999, BRIT J SURG, V86, P869, DOI 10.1046/j.1365-2168.1999.01181.x; Tsai GC, 1998, ANNU REV MED, V49, P173; TURNER RC, 1989, J GEN INTERN MED, V4, P432, DOI 10.1007/BF02599697; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701; von Heymann C, 2002, J TRAUMA, V52, P95, DOI 10.1097/00005373-200201000-00017; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Weisinger JR, 1998, LANCET, V352, P391, DOI 10.1016/S0140-6736(97)10535-9; WHANG R, 1992, ARCH INTERN MED, V152, P40, DOI 10.1001/archinte.152.1.40; WILSON A, 1984, ALCOHOL CLIN EXP RES, V8, P542, DOI 10.1111/j.1530-0277.1984.tb05726.x; WRENN KD, 1991, AM J MED, V91, P119, DOI 10.1016/0002-9343(91)90003-G; WRENN KD, 1992, AM J EMERG MED, V10, P165, DOI 10.1016/0735-6757(92)90054-2	142	73	73	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	2006	368	9554					2231	2242		10.1016/S0140-6736(06)69490-7	http://dx.doi.org/10.1016/S0140-6736(06)69490-7			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	120HY	17189035				2023-01-03	WOS:000243076800031
J	Singh, S				Singh, Susheela			Hospital admissions resulting from unsafe abortion: estimates from 13 developing countries	LANCET			English	Article							SOUTH-AFRICA; EPIDEMIOLOGY; PHILIPPINES; PREGNANCY; HEALTH; LEVEL; AGE	Background Complications from unsafe abortion are believed to account for the largest proportion of hospital admissions for gynaecological services in developing countries. The WHO estimates that one in eight pregnancy-related deaths result from unsafe abortions. The social stigma and legal restrictions associated with abortion in many countries means that data on the magnitude of this problem are scarce; this article estimates the rate and numbers of hospital admissions resulting from unsafe abortions in developing countries to help quantify the problem. Methods National estimates of abortion-related hospital admissions in women aged 15-44 years were compiled for 13 developing countries: Africa (Egypt, Nigeria, and Uganda), Asia (Bangladesh, Pakistan, and the Philippines), and Latin America and the Caribbean (Brazil, Chile, Colombia, Dominican Republic, Guatemala, Mexico, and Peru). These data were combined with supplementary data from five countries in sub-Saharan Africa (Burkina Faso, Ghana, Kenya, Nigeria, and South Africa) to give estimates for the three world regions. Findings The annual hospitalisation rate varies from a low of about 3 per 1000 women in Bangladesh to a high of about 15 per 1000 in Egypt and Uganda. Nigeria, Pakistan, and the Philippines have rates of 4-7 per 1000, and two countries in Latin America with recent data have rates of almost 9 per 1000. In the developing world as a whole, an estimated five million women are admitted to hospital for treatment of complications from induced abortions each year. This equates to an average rate of 5.7 per 1000 women per year in all developing regions, excluding China. By comparison, in developed countries complications from abortion procedures or hospitalisation are rare. Interpretation These results help quantify the magnitude of the adverse health effects of unsafe abortion in developing countries and highlight the need for improved access to post-abortion care. The provision of abortion services is changing to include the drug misoprostol and this could reduce the severity of abortion complications and the number of women who are hospitalised. Researchers will need to monitor these changes to provide countries with up-to-date information on illness and death from unsafe abortion. Improved contraceptive services are necessary to prevent unintended pregnancy. However, increasing access to safe abortion services is the most effective way of preventing the burden of unsafe abortion, and remains a high priority for developing countries.	Alan Guttmacher Inst, New York, NY 10005 USA		Singh, S (corresponding author), Alan Guttmacher Inst, 120 Wall St, New York, NY 10005 USA.	ssingh@guttmacher.org						*A GUTTM I, 1999, SHAR RESP WOM SOC AB; AAHMAN E, 2004, UNSAFE ABORTION GLOB; AbouZahr C, 2000, B WORLD HEALTH ORGAN, V78, P655; Ahiadeke C, 2001, INT FAM PLAN PERSPEC, V27, P96, DOI 10.2307/2673822; [Anonymous], 2003, ADDING IT BENEFITS I; Blanchard K, 2000, J Am Med Womens Assoc (1972), V55, P189; BONGAARTS J, 1983, FERTILITY BIOL BEHAV, P39; *BRAZ MIN HLTH, SIST INF HOSP SUS SI; Carbonell J L, 1997, Eur J Contracept Reprod Health Care, V2, P181; Duggal R, 2002, ABORTION SERVICES IN; FERRANDO D, 2001, UNPUB PREVALENCIA AB; Gebreselassie H, 2005, BJOG-INT J OBSTET GY, V112, P1229, DOI 10.1111/j.1471-0528.2004.00503.x; Harlap S, 1980, HUMAN EMBRYONIC FETA, p[148, 157]; Henshaw SK, 1998, INT FAM PLAN PERSPEC, V24, P156, DOI 10.2307/2991973; HENSHAW SK, 2005, INT UN SCI STUD POP; Huntington D, 1998, INT FAM PLAN PERSPEC, V24, P25, DOI 10.2307/2991916; Jewkes R, 2005, BJOG-INT J OBSTET GY, V112, P355, DOI 10.1111/j.1471-0528.2004.00422.x; Juarez F, 2005, INT FAM PLAN PERSPEC, V31, P140, DOI 10.1363/3114005; Koopersmith TB, 1996, CONTRACEPTION, V53, P237, DOI 10.1016/0010-7824(96)00043-1; Rees H, 1997, S AFR MED J, V87, P432; Rossier C, 2006, SOC SCI MED, V62, P254, DOI 10.1016/j.socscimed.2005.05.024; Rossier C, 2003, STUD FAMILY PLANN, V34, P87, DOI 10.1111/j.1728-4465.2003.00087.x; SATHAR Z, POP ASS AM ANN M MAR; Shah L, 2004, REPROD HEALTH MATTER, V12, P9, DOI 10.1016/S0968-8080(04)24002-2; Singh S, 2005, INT FAM PLAN PERSPEC, V31, P183, DOI 10.1363/3118305; Singh S, 1997, INT FAM PLAN PERSPEC, V23, P100, DOI 10.2307/2950765; Singh S, 1997, INT FAM PLAN PERSPEC, V23, P59, DOI 10.2307/2950825; Singh S, 1994, INT FAM PLAN PERSPEC, V20, P4, DOI [10.2307/2133331, DOI 10.2307/2133331]; Singh S, 2006, INT FAM PLAN PERSPEC, V32, P136, DOI 10.1363/3213606; *WHO, 2002, EST DALYS SEX CAUS W; *WHO, 1993, INT CLASS DIS REL HL, P131; World Health Organization, 1992, PREV MAN UNS AB REP	32	189	196	2	33	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 25	2006	368	9550					1887	1892		10.1016/S0140-6736(06)69778-X	http://dx.doi.org/10.1016/S0140-6736(06)69778-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	109YQ	17126721				2023-01-03	WOS:000242345900030
J	Shojania, KG; Fletcher, KE; Saint, S				Shojania, Kaveh G.; Fletcher, Kathlyn E.; Saint, Sanjay			Graduate medical education and patient safety: A busy-and occasionally hazardous-intersection	ANNALS OF INTERNAL MEDICINE			English	Article							RESIDENT WORK HOURS; JULY PHENOMENON; COMMUNICATION FAILURES; SIGN-OUT; ERRORS; CARE; MORTALITY; MANAGEMENT; HOSPITALS; ADMISSION	A patient admitted to a teaching hospital with a mild episode of acute pancreatitis initially improved, but then her condition deteriorated and she subsequently died. The initial deterioration probably reflected bowel obstruction, as shown on an abdominal radiograph that an on-call intern forgot to review. This diagnostic delay was compounded by poor communication that resulted in a medical student inserting a feeding tube-rather than a nasogastric tube-to decompress the bowel, followed by failure to recognize how ill the patient had become. The case highlights the hazards of patient handoffs as well as the importance of clear communication techniques and knowing when to ask for help. The discussion also shows the vicious circle that results when attending physicians fail to provide effective supervision: Not only is safety compromised but trainees lose the experience of being supervised. Consequently, trainees have no models of effective supervision on which to draw when they become supervisors. They then fall into the same trap as those who taught them, busying themselves with direct patient care and providing supervision only as time allows.	Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON, Canada; Clement J Zablocki VA Med Ctr, Milwaukee, WI USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Ann Arbor VA Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI USA; Univ Michigan, Sch Med, Ann Arbor, MI USA	University of Ottawa; Ottawa Hospital Research Institute; Medical College of Wisconsin; University of Michigan System; University of Michigan	Shojania, KG (corresponding author), Ottawa Civic Hosp, Civ Campus,1053 Carling Ave,Room C403,Box 693, Ottawa, ON K1Y 4E9, Canada.	kshojania@ohri.ca	Saint, Sanjay/AAF-5126-2019		NIDDK NIH HHS [DK67451] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK067451] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arora V, 2005, QUAL SAF HEALTH CARE, V14, P401, DOI 10.1136/qshc.2005.015107; ASTION M, 2005, LAB ERRORS PATIENT S, V1, P2; Barenfanger J, 2004, AM J CLIN PATHOL, V121, P801, DOI 10.1309/9DYM6ROTM830U95Q; Barry WA, 2003, J GEN INTERN MED, V18, P639, DOI 10.1046/j.1525-1497.2003.20605.x; Bell CM, 2001, NEW ENGL J MED, V345, P663, DOI 10.1056/NEJMsa003376; Borenstein SH, 2004, J SURG RES, V122, P162, DOI 10.1016/j.jss.2004.05.014; BUCHWALD D, 1989, ARCH INTERN MED, V149, P765, DOI 10.1001/archinte.149.4.765; Chassin MR, 2002, ANN INTERN MED, V136, P826, DOI 10.7326/0003-4819-136-11-200206040-00012; Claridge JA, 2001, SURGERY, V130, P346, DOI 10.1067/msy.2001.116670; Cleary PD, 2003, ANN INTERN MED, V138, P33, DOI 10.7326/0003-4819-138-1-200301070-00009; Cram P, 2004, AM J MED, V117, P151, DOI 10.1016/j.amjmed.2004.02.035; Croskerry P, 2003, ACAD MED, V78, P775, DOI 10.1097/00001888-200308000-00003; Fletcher KE, 2005, JAMA-J AM MED ASSOC, V294, P1088, DOI 10.1001/jama.294.9.1088; Fletcher KE, 2004, ANN INTERN MED, V141, P851, DOI 10.7326/0003-4819-141-11-200412070-00009; Flynn T., 2005, ACGME B, P15; Haig KM, 2006, JT COMM J QUAL PATIE, V32, P167, DOI 10.1016/S1553-7250(06)32022-3; Hobgood C, 2005, ACAD MED, V80, P758, DOI 10.1097/00001888-200508000-00012; Hofer TP, 2002, ANN INTERN MED, V137, P327, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00008; *JOINT COMM ACCR H, 2006, GOAL 2 COMM; Kachalia Allen, 2003, Jt Comm J Qual Saf, V29, P503; Kilminster SM, 2000, MED EDUC, V34, P827, DOI 10.1046/j.1365-2923.2000.00758.x; LAINE C, 1993, JAMA-J AM MED ASSOC, V269, P374, DOI 10.1001/jama.269.3.374; Leach DC, 2005, ACGME B, P2; Ofri D, 2004, NEW ENGL J MED, V351, P1824, DOI 10.1056/NEJMp038251; Petersen L A, 1998, Jt Comm J Qual Improv, V24, P77; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Phy MP, 2004, MAYO CLIN PROC, V79, P332, DOI 10.4065/79.3.332; Pierluissi E, 2003, JAMA-J AM MED ASSOC, V290, P2838, DOI 10.1001/jama.290.21.2838; Reason J, 2000, BMJ-BRIT MED J, V320, P768, DOI 10.1136/bmj.320.7237.768; Redelmeier DA, 2005, ANN INTERN MED, V142, P115, DOI 10.7326/0003-4819-142-2-200501180-00010; Ryan J, 2005, ANN INTERN MED, V143, P917, DOI 10.7326/0003-4819-143-12-200512200-00016; Sexton JB, 2000, BMJ-BRIT MED J, V320, P745, DOI 10.1136/bmj.320.7237.745; Shojania KG, 2002, MED CLIN N AM, V86, P847, DOI 10.1016/S0025-7125(02)00016-0; Shulkin D J, 1995, Am J Med Qual, V10, P14, DOI 10.1177/0885713X9501000104; SMITH L, 2005, AHRQ WEB M M SERIAL; Sutcliffe KM, 2004, ACAD MED, V79, P186, DOI 10.1097/00001888-200402000-00019; Van Eaton EG, 2005, J AM COLL SURGEONS, V200, P538, DOI 10.1016/j.jamcollsurg.2004.11.009; Vincent C, 2000, BRIT MED J, V320, P777, DOI 10.1136/bmj.320.7237.777; WU AW, 1991, JAMA-J AM MED ASSOC, V265, P2089, DOI 10.1001/jama.265.16.2089; Wu AW, 2000, BRIT MED J, V320, P726, DOI 10.1136/bmj.320.7237.726; Zare SM, 2005, SURGERY, V138, P150, DOI 10.1016/j.surg.2005.05.011	41	56	56	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 17	2006	145	8					592	598		10.7326/0003-4819-145-8-200610170-00008	http://dx.doi.org/10.7326/0003-4819-145-8-200610170-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	095NX	17043341				2023-01-03	WOS:000241315700005
J	Tang, C; Ang, BT; Pervaiz, S				Tang, Carol; Ang, Beng T.; Pervaiz, Shazib			Cancer stem cell: target for anti-cancer therapy	FASEB JOURNAL			English	Review						tumor stem cell; side population; CD133; ROS	MANGANESE SUPEROXIDE-DISMUTASE; ACUTE MYELOID-LEUKEMIA; DRUG-INDUCED APOPTOSIS; PEROXIDE-INDUCED APOPTOSIS; INTRACELLULAR REDOX STATUS; TUMOR-INITIATING CELLS; HYDROGEN-PEROXIDE; SIDE-POPULATION; PROGENITOR CELLS; PROSPECTIVE IDENTIFICATION	Cancer has long been viewed as a heterogeneous population of cells. While the great majority of cells that make up tumors are destined to differentiate, albeit aberrantly, and eventually stop dividing, only a minority population of cells, termed cancer stem cells, possess extensive self- renewal capability and can recapitulate tumor pathophysiology in an immune- compromised animal model. Tumor- initiating cells have been identified and isolated in a variety of cancers of the blood, breast, central nervous system, pancreas, skin, head and neck, colon, and prostate. In this review we present scientific evidence supporting the cancer stem cell model of tumor progression, and discuss the experimental and therapeutic implications. The concept of cancer stem cells may have profound implications for our understanding of tumor biology and for the design of novel treatments targeted toward these cells. Current therapeutic strategies include targeting the cancer stem cell as well as its microenvironmental niche. We present an interesting, novel strategy that takes into account the reactive oxygen species status in cancer stem cells and how it might serve as a method for eradicating these cells in tumor growth.	Natl Inst Neurosci, Dept Res, Singapore 308433, Singapore; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117597, Singapore; Natl Inst Neurosci, Singapore, Singapore; Singapore Inst Clin Sci, Agcy Sci Technol & Res, Singapore, Singapore; Natl Univ Singapore, NUS, Grad Sch Integrat Sci & Engn, Singapore 117548, Singapore; Singapore MIT Alliance, Singapore, Singapore; Duke NUS, Grad Sch Med, Singapore, Singapore	National Neuroscience Institute (NNI); National University of Singapore; National Neuroscience Institute (NNI); Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Institute for Clinical Sciences (SICS); National University of Singapore; Massachusetts Institute of Technology (MIT); Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Singapore-MIT Alliance for Research & Technology Centre (SMART); National University of Singapore	Tang, C (corresponding author), Natl Inst Neurosci, Dept Res, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	carolt@pacific.net.sg; phssp@nus.edu.sg	Pervaiz, Shazib/C-4188-2015	Tang, Carol/0000-0002-1835-5083				Ahmad KA, 2004, CANCER RES, V64, P7867, DOI 10.1158/0008-5472.CAN-04-0648; Ahmad KA, 2003, ANN NY ACAD SCI, V1010, P365, DOI 10.1196/annals.1299.067; Akram S, 2006, CELL DEATH DIFFER, V13, P628, DOI 10.1038/sj.cdd.4401775; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Burdon RH, 1996, BIOCHEM SOC T, V24, P1028, DOI 10.1042/bst0241028; BURDON RH, 1989, FREE RADICAL RES COM, V7, P149, DOI 10.3109/10715768909087937; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Clement MV, 2003, CELL DEATH DIFFER, V10, P1273, DOI 10.1038/sj.cdd.4401302; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Cullen JJ, 2003, CANCER RES, V63, P1297; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Grichnik JM, 2006, J INVEST DERMATOL, V126, P142, DOI 10.1038/sj.jid.5700017; Hirpara JL, 2001, J BIOL CHEM, V276, P514, DOI 10.1074/jbc.M004687200; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim M, 2003, J NEUROSCI, V23, P10703; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Oberley LW, 2001, ANTIOXID REDOX SIGN, V3, P461, DOI 10.1089/15230860152409095; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Pervaiz S, 2002, BIOCHEM BIOPH RES CO, V290, P1145, DOI 10.1006/bbrc.2001.6274; Pervaiz S, 2004, CURR PHARM DESIGN, V10, P1969, DOI 10.2174/1381612043384411; Pervaiz S, 2002, METHOD ENZYMOL, V352, P150; Pervaiz S, 2001, ONCOGENE, V20, P6263, DOI 10.1038/sj.onc.1204840; Pervaiz S, 1999, FEBS LETT, V459, P343, DOI 10.1016/S0014-5793(99)01258-2; Pervaiz S, 2006, CURR PHARM DESIGN, V12, P4469, DOI 10.2174/138161206779010503; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Reynolds BA, 2005, NAT METHODS, V2, P333, DOI 10.1038/nmeth758; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; SHIBANUMA M, 1988, J CELL PHYSIOL, V136, P379, DOI 10.1002/jcp.1041360224; Singec I, 2006, NAT METHODS, V3, P801, DOI 10.1038/nmeth926; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; SLAGA TJ, 1981, SCIENCE, V213, P1023, DOI 10.1126/science.6791284; Smith J, 2000, P NATL ACAD SCI USA, V97, P10032, DOI 10.1073/pnas.170209797; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Taylor MD, 2005, CANCER CELL, V8, P323, DOI 10.1016/j.ccr.2005.09.001; TRUSH MA, 1991, FREE RADICAL BIO MED, V10, P201, DOI 10.1016/0891-5849(91)90077-G; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; van Rhenen A, 2005, CLIN CANCER RES, V11, P6520, DOI 10.1158/1078-0432.CCR-05-0468; Weydert C, 2003, MOL CANCER THER, V2, P361; Woodward WA, 2007, P NATL ACAD SCI USA, V104, P618, DOI 10.1073/pnas.0606599104; Zhao YF, 2001, CANCER RES, V61, P6082; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028; SCIENCE	66	193	204	1	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3777	3785		10.1096/fj.07-8560rev	http://dx.doi.org/10.1096/fj.07-8560rev			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17625071				2023-01-03	WOS:000251283500002
J	MacDonald, SM; Song, G; Poon, CS				MacDonald, Shawna M.; Song, Gang; Poon, Chi-Sang			Nonassociative Learning Promotes Respiratory Entrainment to Mechanical Ventilation	PLOS ONE			English	Article								(B)ackground. Patient-ventilator synchrony is a major concern in critical care and is influenced by phasic lung-volume feedback control of the respiratory rhythm. Routine clinical application of positive end-expiratory pressure (PEEP) introduces a tonic input which, if unopposed, might disrupt respiratory-ventilator entrainment through sustained activation of the vagally-mediated Hering-Breuer reflex. We suggest that this potential adverse effect may be averted by two differentiator forms of nonassociative learning (habituation and desensitization) of the Hering-Breuer reflex via pontomedullary pathways. Methodology/Principal Findings. We tested these hypotheses in 17 urethane-anesthetized adult Sprague-Dawley rats under controlled mechanical ventilation. Without PEEP, phrenic discharge was entrained 1:1 to the ventilator rhythm. Application of PEEP momentarily dampened the entrainment to higher ratios but this effect was gradually adapted by nonassociative learning. Bilateral electrolytic lesions of the pneumotaxic center weakened the adaptation to PEEP, whereas sustained stimulation of the pneumotaxic center weakened the entrainment independent of PEEP. In all cases, entrainment was abolished after vagotomy. Conclusions/Significance. Our results demonstrate an important functional role for pneumotaxic desensitization and extra-pontine habituation of the Hering-Breuer reflex elicited by lung inflation: acting as buffers or high-pass filters against tonic vagal volume input, these differentiator forms of nonassociative learning help to restore respiratory-ventilator entrainment in the face of PEEP. Such central sites-specific habituation and desensitization of the Hering-Breuer reflex provide a useful experimental model of nonassociative learning in mammals that is of particular significance in understanding respiratory rhythmogenesis and coupled-oscillator entrainment mechanisms, and in the clinical management of mechanical ventilation in respiratory failure.	[MacDonald, Shawna M.; Song, Gang; Poon, Chi-Sang] MIT, Harvard Massachusetts Inst Technol, Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Poon, CS (corresponding author), MIT, Harvard Massachusetts Inst Technol, Div Hlth Sci & Technol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	cpoon@mit.edu			NHLBI NIH HHS [R01 HL079503, HL072849, HL079503, R01 HL072849, R01 HL067966, HL067966] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079503, R01HL072849, R01HL067966] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allo JC, 2006, CRIT CARE MED, V34, P2997, DOI 10.1097/01.CCM.0000242520.50665.9F; BACONNIER PF, 1993, J THEOR BIOL, V164, P149, DOI 10.1006/jtbi.1993.1145; Baumer JH, 2000, ARCH DIS CHILD-FETAL, V82, pF5, DOI 10.1136/fn.82.1.F5; Beresford MW, 2000, ARCH DIS CHILD-FETAL, V82, pF14, DOI 10.1136/fn.82.1.F14; Breuer J., 1970, BREATHING, P365; Brochard L, 2002, INTENS CARE MED, V28, P1376, DOI 10.1007/s00134-002-1438-8; Chao DC, 1997, CHEST, V112, P1592, DOI 10.1378/chest.112.6.1592; Dick CR, 1996, CLIN CHEST MED, V17, P423, DOI 10.1016/S0272-5231(05)70325-7; GAUTIER H, 1981, J APPL PHYSIOL, V51, P1162, DOI 10.1152/jappl.1981.51.5.1162; GRAVES C, 1986, AM J PHYSIOL, V250, pR902, DOI 10.1152/ajpregu.1986.250.5.R902; GRIPPI MA, 1985, J APPL PHYSIOL, V58, P1360, DOI 10.1152/jappl.1985.58.4.1360; GUZ A, 1971, J PHYSIOL-LONDON, V213, P329, DOI 10.1113/jphysiol.1971.sp009385; GUZ A, 1964, CLIN SCI, V27, P293; Haberthur C, 2005, CRIT CARE, V9, pR407, DOI 10.1186/cc3735; HAMILTON RD, 1988, RESP PHYSIOL, V73, P145, DOI 10.1016/0034-5687(88)90062-X; HAMILTON RD, 1990, RESP PHYSIOL, V81, P87, DOI 10.1016/0034-5687(90)90072-7; Hering E., 1970, BREATHING, P359; Imanaka H, 2000, CRIT CARE MED, V28, P402, DOI 10.1097/00003246-200002000-00019; Kondili E, 2003, BRIT J ANAESTH, V91, P106, DOI 10.1093/bja/aeg129; Lumsden T, 1923, J PHYSIOL-LONDON, V57, P153; MADOR MJ, 1990, CHEST, V97, P877, DOI 10.1378/chest.97.4.877; Matsugu M, 1998, J COMPUT NEUROSCI, V5, P35, DOI 10.1023/A:1008826326829; McGuire M, 2007, RESP PHYSIOL NEUROBI, V158, P107, DOI 10.1016/j.resp.2007.01.017; MUZZIN S, 1992, AM J PHYSIOL, V263, pR292, DOI 10.1152/ajpregu.1992.263.2.R292; MUZZIN S, 1989, RESP PHYSIOL, V75, P157, DOI 10.1016/0034-5687(89)90060-1; Oddo M, 2006, INTENS CARE MED, V32, P501, DOI 10.1007/s00134-005-0045-x; PEPE PE, 1982, AM REV RESPIR DIS, V126, P166; PETRILLO GA, 1983, CAN J PHYSIOL PHARM, V61, P599, DOI 10.1139/y83-092; PETRILLO GA, 1984, AM J PHYSIOL, V246, pR311, DOI 10.1152/ajpregu.1984.246.3.R311; Poon Chi-Sang, 2006, Behav Brain Funct, V2, P29, DOI 10.1186/1744-9081-2-29; Poon CS, 2000, RESP PHYSIOL, V122, P83, DOI 10.1016/S0034-5687(00)00152-3; Poon CS, 2004, ADV EXP MED BIOL, V551, P95; Poon CS, 2000, NEUROSCI LETT, V284, P5, DOI 10.1016/S0304-3940(00)00993-9; Poon CS, 1997, RESP PHYSIOL, V108, P117, DOI 10.1016/S0034-5687(97)00014-5; Saito Y, 1999, DEV MED CHILD NEUROL, V41, P560, DOI 10.1017/S0012162299001188; Sharshar T, 2003, AM J RESP CRIT CARE, V168, P760, DOI 10.1164/rccm.200203-241OC; Simon PM, 1999, AM J RESP CRIT CARE, V160, P950, DOI 10.1164/ajrccm.160.3.9712057; Simon PM, 2000, J APPL PHYSIOL, V89, P760, DOI 10.1152/jappl.2000.89.2.760; Sinderby C, 1999, NAT MED, V5, P1433, DOI 10.1038/71012; Siniaia MS, 2000, J PHYSIOL-LONDON, V523, P479, DOI 10.1111/j.1469-7793.2000.t01-1-00479.x; Song G, 2006, J NEUROSCI, V26, P300, DOI 10.1523/JNEUROSCI.3029-05.2006; Song G, 2004, RESP PHYSIOL NEUROBI, V143, P281, DOI 10.1016/j.resp.2004.05.009; STANLEY NN, 1975, J APPL PHYSIOL, V38, P474, DOI 10.1152/jappl.1975.38.3.474; Thille AW, 2006, INTENS CARE MED, V32, P1515, DOI 10.1007/s00134-006-0301-8; Tobin M. J., 2006, PRINCIPLES PRACTICE, P1121; Tobin MJ, 2001, NEW ENGL J MED, V344, P1986, DOI 10.1056/NEJM200106283442606; Tobin MJ, 2001, AM J RESP CRIT CARE, V163, P1059, DOI 10.1164/ajrccm.163.5.2005125; Tryfon S, 2001, RESPIRATION, V68, P140, DOI 10.1159/000050483; VIBERT JF, 1981, BIOL CYBERN, V41, P119, DOI 10.1007/BF00335366; WIDDICOMBE J, 1961, CLIN SCI, V21, P163; YOUNES M, 1985, J APPL PHYSIOL, V59, P1072, DOI 10.1152/jappl.1985.59.4.1072; YOUNES M, 1987, J APPL PHYSIOL, V62, P1502, DOI 10.1152/jappl.1987.62.4.1502; Young DL, 2003, J APPL PHYSIOL, V94, P1213, DOI 10.1152/japplphysiol.00639.2002	53	13	14	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2007	2	9							e865	10.1371/journal.pone.0000865	http://dx.doi.org/10.1371/journal.pone.0000865			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HR	17848996	Green Published, gold			2023-01-03	WOS:000207455600012
J	Rodrigues, T; de Franca, LP; Kawai, C; de Faria, PA; Mugnol, KCU; Braga, FM; Tersariol, ILS; Smaili, SS; Nantes, IL				Rodrigues, Tiago; de Franca, Lucimar P.; Kawai, Cintia; de Faria, Priscila A.; Mugnol, Katia C. U.; Braga, Fernanda M.; Tersariol, Ivarne L. S.; Smaili, Soraya S.; Nantes, Iseli L.			Protective role of mitochondrial unsaturated lipids on the preservation of the apoptotic ability of cytochrome c exposed to singlet oxygen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; MOLECULAR-OXYGEN; METHYLENE-BLUE; DNA-REPAIR; PHOTOSENSITIZED OXIDATION; CELLULAR-DNA; DAMAGE; HYDROPEROXIDE; PEROXIDATION; MUTAGENESIS	Cytochrome c-mediated apoptosis in cells submitted to photodynamic therapy raises the question about the ability of photodynamically oxidized cytochrome c ( cytc405) to trigger apoptosis as well as the effect of membranes on protein photo-oxidation. Cytochrome c was submitted to irradiation in the presence of MB+ in phosphate buffer and in the presence of four types of phosphatidylcholine/phosphatidylethanolamine/cardiolipin ( PCPECL) liposomes ( 50/30/20%): totally saturated lipids ( tsPCPECL), totally unsaturated lipids ( tuPCPECL), partially unsaturated ( 80%) lipids, with unsaturation in the PC and PE content ( puPCPECL80), and partially unsaturated ( 20%) lipids, with unsaturation in the CL content ( puPCPECL20). Cytc405 was formed by irradiation in buffered water and in tsPCPECL and puPCPECL20 liposomes. In the presence of tuPCPECL and puPCPECL80, cytochrome c was protected from photodynamic damage ( lipid-protected cytochrome c). In CL liposomes, 25% unsaturated lipids were enough to protect cytochrome c. The presence of unsaturated lipids, in amounts varying according to the liposome composition, are crucial to protect cytochrome c. Interesting findings corroborating the unsaturated lipids as cytochrome c protectors were obtained from the analysis of the lipid-oxidized derivatives of the samples. Native cytochrome c, lipid-protected cytochrome c, and cytc405 were microinjected in aortic smooth muscle cells. Apoptosis, characterized by nucleus blebbing and chromatin condensation, was detected in cells loaded with native and lipid protected cytochrome c but not in cells loaded with cytc405. These results suggest that photodynamic therapy-promoted apoptosis is feasible due to the protective effect of the mitochondrial lipids on the cytochrome c structure and function.	Univ Mogi das Cruzes, Ctr Interdisciplinar Invest Bioquim, BR-08780911 Sao Paulo, Brazil; Univ Fed Sao Paulo, Dept Farmacol, Sao Paulo, Brazil	Universidade de Mogi das Cruzes; Universidade Federal de Sao Paulo (UNIFESP)	Nantes, IL (corresponding author), Univ Mogi das Cruzes, Ctr Interdisciplinar Invest Bioquim, Sala 1S-15, BR-08780911 Sao Paulo, Brazil.	ilnantes@umc.br	Smaili, Soraya/AAH-2129-2019; Rodrigues, Tiago/AAG-1121-2020; Nantes, Iseli Lourenço/B-9517-2012; Rodrigues, Tiago/B-8459-2012; Mugnol, Katia C. U./K-7128-2012; Dos Santos Tersariol, Ivarne Luis/G-4042-2012; Kawai, Cintia/H-2979-2013	Smaili, Soraya/0000-0001-5844-1368; Rodrigues, Tiago/0000-0003-1277-0224; Nantes, Iseli Lourenço/0000-0003-1434-3154; Rodrigues, Tiago/0000-0003-1277-0224; Mugnol, Katia C. U./0000-0002-1760-9440; Dos Santos Tersariol, Ivarne Luis/0000-0002-8399-4535; 				Agnez LF, 1996, CARCINOGENESIS, V17, P1183, DOI 10.1093/carcin/17.5.1183; Agnez-Lima LF, 2001, NUCLEIC ACIDS RES, V29, P2899, DOI 10.1093/nar/29.13.2899; Agnez-Lima LF, 2001, BIOL CHEM, V382, P1071, DOI 10.1515/BC.2001.134; Almeida AM, 1999, FREE RADICAL BIO MED, V27, P744, DOI 10.1016/S0891-5849(99)00136-7; BARR DP, 1995, J BIOL CHEM, V270, P12709, DOI 10.1074/jbc.270.21.12709; Cavalcante AKD, 2002, DNA REPAIR, V1, P1051, DOI 10.1016/S1568-7864(02)00164-7; Cosso RG, 2002, J BIOENERG BIOMEMBR, V34, P157, DOI 10.1023/A:1016075218162; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; DESAI ID, 1963, J LIPID RES, V4, P204; Estevam ML, 2004, J BIOL CHEM, V279, P39214, DOI 10.1074/jbc.M402093200; FOOTE CS, 1968, SCIENCE, V162, P963, DOI 10.1126/science.162.3857.963; FOOTE CS, 1991, PHOTOCHEM PHOTOBIOL, V54, P659, DOI 10.1111/j.1751-1097.1991.tb02071.x; Gabrielli D, 2004, PHOTOCHEM PHOTOBIOL, V79, P227, DOI 10.1562/BE-03-27.1; Grijalba MT, 1996, PHOTOCHEM PHOTOBIOL, V63, P697, DOI 10.1111/j.1751-1097.1996.tb09617.x; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; Iwahashi H, 2002, BIOCHEM J, V361, P57, DOI 10.1042/0264-6021:3610057; Jass J, 2003, METHOD ENZYMOL, V367, P199; Kawai C, 2005, J BIOL CHEM, V280, P34709, DOI 10.1074/jbc.M412532200; KELLOGG EW, 1975, J BIOL CHEM, V250, P8812; KLUCK RM, 1997, SCIENCE, V275, P7770; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Martinez GR, 2004, J AM CHEM SOC, V126, P3056, DOI 10.1021/ja039111z; Martinez GR, 2002, BIOL CHEM, V383, P607, DOI 10.1515/BC.2002.063; Martinez GR, 2003, MUTAT RES-REV MUTAT, V544, P115, DOI 10.1016/j.mrrev.2003.05.005; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; MICHAELI A, 1995, PHOTOCHEM PHOTOBIOL, V61, P255, DOI 10.1111/j.1751-1097.1995.tb03968.x; MICHAELI A, 1997, PHOTOCHEM PHOTOBIOL, V51, P299; MISKOSKI S, 1993, PHOTOCHEM PHOTOBIOL, V57, P447, DOI 10.1111/j.1751-1097.1993.tb02317.x; MONOROE BM, 1985, SINGLET O2, V1, P177; Nantes IL, 1998, FREE RADICAL BIO MED, V25, P546, DOI 10.1016/S0891-5849(98)00082-3; NANTES IL, 1995, PHOTOCHEM PHOTOBIOL, V62, P522, DOI 10.1111/j.1751-1097.1995.tb02378.x; Nantes IL, 2000, FREE RADICAL BIO MED, V28, P786, DOI 10.1016/S0891-5849(00)00170-2; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PETIT JM, 1994, EUR J BIOCHEM, V220, P871, DOI 10.1111/j.1432-1033.1994.tb18690.x; Pierlot C, 2000, METHOD ENZYMOL, V319, P3; Ravanat JL, 2004, ARCH BIOCHEM BIOPHYS, V423, P23, DOI 10.1016/j.abb.2003.10.018; Ravanat JL, 2004, BIOL CHEM, V385, P17, DOI 10.1515/BC.2004.003; Ravanat JL, 2000, J BIOL CHEM, V275, P40601, DOI 10.1074/jbc.M006681200; Ravanat JL, 2001, HELV CHIM ACTA, V84, P3702, DOI 10.1002/1522-2675(20011219)84:12<3702::AID-HLCA3702>3.0.CO;2-Y; Ruozi B, 2005, EUR J PHARM SCI, V25, P81, DOI 10.1016/j.ejps.2005.01.020; Severino D, 2003, PHOTOCHEM PHOTOBIOL, V77, P459, DOI 10.1562/0031-8655(2003)077<0459:IONCIO>2.0.CO;2; TANIELIAN C, 1994, PHOTOCHEM PHOTOBIOL, V59, P263, DOI 10.1111/j.1751-1097.1994.tb05032.x; TANIELIAN C, 1992, J PHOTOCH PHOTOBIO A, V64, P191, DOI 10.1016/1010-6030(92)85106-5; Tanielian C, 2000, PHOTOCHEM PHOTOBIOL, V71, P12, DOI 10.1562/0031-8655(2000)071<0012:MAKAOP>2.0.CO;2; TUIETE EM, 1993, J PHOTOCHEM PHOTOBIO, V21, P103; Veeramasuneni S, 1996, J COLLOID INTERF SCI, V184, P594, DOI 10.1006/jcis.1996.0656; YANG J, 1997, SCIENCE, V275, P1132	47	28	32	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25577	25587		10.1074/jbc.M700009200	http://dx.doi.org/10.1074/jbc.M700009200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17567586	hybrid			2023-01-03	WOS:000249014100044
J	Sidorenko, A; Krupenkin, T; Taylor, A; Fratzl, P; Aizenberg, J				Sidorenko, Alexander; Krupenkin, Tom; Taylor, Ashley; Fratzl, Peter; Aizenberg, Joanna			Reversible switching of hydrogel-actuated nanostructures into complex micropatterns	SCIENCE			English	Article							SHAPE-MEMORY; PHOTONIC CRYSTALS; MICROSTRUCTURES; TENSEGRITY; SURFACES	Responsive behavior, which is intrinsic to natural systems, is becoming a key requirement for advanced artificial materials and devices, presenting a substantial scientific and engineering challenge. We designed dynamic actuation systems by integrating high-aspect-ratio silicon nanocolumns, either free-standing or substrate-attached, with a hydrogel layer. The nanocolumns were put in motion by the "muscle" of the hydrogel, which swells or contracts depending on the humidity level. This actuation resulted in a fast reversible reorientation of the nanocolumns from tilted to perpendicular to the surface. By further controlling the stress field in the hydrogel, the formation of a variety of elaborate reversibly actuated micropatterns was demonstrated. The mechanics of the actuation process have been assessed. Dynamic control over the movement and orientation of surface nanofeatures at the micron and submicron scales may have exciting applications in actuators, microfluidics, or responsive materials.	Bell Labs, Alcatel Lucent, Murray Hill, NJ 07974 USA; Max Planck Inst Colloids & Interfaces, D-14424 Potsdam, Germany	Alcatel-Lucent; AT&T; Max Planck Society	Aizenberg, J (corresponding author), Bell Labs, Alcatel Lucent, 600 Mt Ave, Murray Hill, NJ 07974 USA.	jaizenberg@alcatel-lucent.com	Fratzl, Peter/H-9095-2012	Fratzl, Peter/0000-0003-4437-7830; Sidorenko, Alexander/0000-0002-3109-7605				Asher SA, 2004, NAN SCI TEC, P145; Autumn K, 2002, P NATL ACAD SCI USA, V99, P12252, DOI 10.1073/pnas.192252799; Beebe DJ, 2000, NATURE, V404, P588, DOI 10.1038/35007047; BUCKMINSTERFULL.R, 1961, PORTFOLIO ART NEWS A, V4, P112; Chiellini F, 2001, MACROMOL RAPID COMM, V22, P1284, DOI 10.1002/1521-3927(20011001)22:15<1284::AID-MARC1284>3.0.CO;2-M; Defossez M, 2003, MECH RES COMMUN, V30, P311, DOI 10.1016/S0093-6413(03)00030-2; Delamarche E, 1997, ADV MATER, V9, P741, DOI 10.1002/adma.19970090914; Gates BD, 2004, ANGEW CHEM INT EDIT, V43, P2780, DOI 10.1002/anie.200353009; Geim AK, 2003, NAT MATER, V2, P461, DOI 10.1038/nmat917; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; Iyer KS, 2003, MACROMOLECULES, V36, P6519, DOI 10.1021/ma034460z; Krupenkin TN, 2004, LANGMUIR, V20, P3824, DOI 10.1021/la036093q; Lahann J, 2003, SCIENCE, V299, P371, DOI 10.1126/science.1078933; Lee SB, 2004, J AM CHEM SOC, V126, P13400, DOI 10.1021/ja048463i; Lendlein A, 2005, NATURE, V434, P879, DOI 10.1038/nature03496; Maurer MK, 2005, ADV FUNCT MATER, V15, P1401, DOI 10.1002/adfm.200400070; Mayer M, 2004, PROTEOMICS, V4, P2366, DOI 10.1002/pmic.200300748; Minko S., 2006, RESPONSIVE POLYM MAT; OSADA Y, 1995, NATURE, V376, P219, DOI 10.1038/376219a0; OSADA Y, 1992, NATURE, V355, P242, DOI 10.1038/355242a0; Park S, 2004, SCIENCE, V303, P348, DOI 10.1126/science.1093276; Ruppert EE, 2004, INVERTEBRATE ZOOLOGY; Russell TP, 2002, SCIENCE, V297, P964, DOI 10.1126/science.1075997; Sun TL, 2005, ACCOUNTS CHEM RES, V38, P644, DOI 10.1021/ar040224c; Vukusic P, 2003, NATURE, V424, P852, DOI 10.1038/nature01941; Zhai L, 2004, NANO LETT, V4, P1349, DOI 10.1021/nl049463j	26	471	485	16	691	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 26	2007	315	5811					487	490		10.1126/science.1135516	http://dx.doi.org/10.1126/science.1135516			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129JU	17255505	Green Submitted			2023-01-03	WOS:000243726600038
J	Itani, KMF; Wilson, SE; Awad, SS; Jensen, EH; Finn, TS; Abramson, MA				Itani, Kamal M. F.; Wilson, Samuel E.; Awad, Samir S.; Jensen, Erin H.; Finn, Tyler S.; Abramson, Murray A.			Ertapenem versus cefotetan prophylaxis in elective colorectal surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURGICAL SITE INFECTION; COMPLICATED INTRAABDOMINAL INFECTIONS; ANTIMICROBIAL PROPHYLAXIS; PLUS METRONIDAZOLE; COMPARE CEFOTETAN; DOUBLE-BLIND; PREVENTION; MULTICENTER	BACKGROUND: Ertapenem, a long-acting carbapenem, may be an alternative to the recommended prophylactic antibiotic cefotetan. METHODS: In this randomized, double-blind trial, we assessed the efficacy and safety of antibiotic prophylaxis with ertapenem, as compared with cefotetan, in patients undergoing elective colorectal surgery. A successful outcome was defined as the absence of surgical-site infection, anastomotic leakage, or antibiotic use 4 weeks postoperatively. All adverse events were collected until 14 days after the administration of antibiotic prophylaxis. RESULTS: Of the 1002 patients randomly assigned to study groups, 901 (451 in the ertapenem group and 450 in the cefotetan group) qualified for the modified intention-to-treat analysis, and 672 (338 in the ertapenem group and 334 in the cefotetan group) were included in the per-protocol analysis. After adjustment for strata, in the modified intention-to-treat analysis, the rate of overall prophylactic failure was 40.2% in the ertapenem group and 50.9% in the cefotetan group (absolute difference, -10.7%; 95% confidence interval [CI], -17.1 to -4.2); in the per-protocol analysis, the failure rate was 28.0% in the ertapenem group and 42.8% in the cefotetan group (absolute difference, -14.8%; 95% CI, -21.9 to -7.5). Both analyses fulfilled statistical criteria for the superiority of ertapenem. In the modified intention-to-treat analysis, the most common reason for failure of prophylaxis in both groups was surgical-site infection: 17.1% in the ertapenem group and 26.2% in the cefotetan group (absolute difference, -9.1; 95% CI, -14.4 to -3.7). In the treated population, the overall incidence of Clostridium difficile infection was 1.7% in the ertapenem group and 0.6% in the cefotetan group (P=0.22). CONCLUSIONS: Ertapenem is more effective than cefotetan in the prevention of surgical-site infection in patients undergoing elective colorectal surgery but may be associated with an increase in C. difficile infection.	Vet Affairs Boston Healthcare Syst, W Roxbury, MA 02132 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Univ Calif Irvine, Sch Med, Orange, CA 92668 USA; Baylor Coll Med, Houston, TX 77030 USA; Houston Helathcare Syst, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA; Merck Res Labs, Upper Gwynedd, PA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Boston University; University of California System; University of California Irvine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center; Merck & Company	Itani, KMF (corresponding author), Vet Affairs Boston Healthcare Syst, 1400 VFW Pkwy,112A, W Roxbury, MA 02132 USA.	kitani@med.va.gov						[Anonymous], 1999, AM J HEALTH-SYST PH, V56, P1839; [Anonymous], 1996, INT C HARM TECHN REQ; ARNAUD JP, 1992, J HOSP INFECT, V22, P23, DOI 10.1016/S0195-6701(05)80004-0; BELLANTONE R, 1988, DRUG EXP CLIN RES, V14, P763; Bratzler DW, 2005, ARCH SURG-CHICAGO, V140, P174, DOI 10.1001/archsurg.140.2.174; Bratzler DW, 2005, AM J SURG, V189, P395, DOI 10.1016/j.amjsurg.2005.01.015; *CTR DRUG EV RES, 2006, DISC DRUGS; DELLINGER EP, 1994, CLIN INFECT DIS, V18, P422, DOI 10.1093/clinids/18.3.422; GORBACH SL, 1991, REV INFECT DIS, V13, pS815; HERSHMAN M J, 1990, Journal of the Royal College of Surgeons of Edinburgh, V35, P29; HORAN TC, 1992, AM J INFECT CONTROL, V20, P271, DOI 10.1016/S0196-6553(05)80201-9; JAGELMAN DG, 1988, AM J SURG, V155, P71, DOI 10.1016/S0002-9610(88)80217-4; Mangram AJ, 1999, AM J INFECT CONTROL, V27, P97, DOI 10.1016/S0196-6553(99)70088-X; Milsom JW, 1998, AM J SURG, V176, p46S, DOI 10.1016/S0002-9610(98)00220-7; Miransky J, 2001, DIS COLON RECTUM, V44, P1100, DOI 10.1007/BF02234629; MORTON AL, 1989, SURG GYNECOL OBSTET, V169, P41; *NAT COMM CLIN LAB, 2000, M11A5 NAT COMM CLIN; *NAT COMM CLIN LAB, 2000, M7A5 NAWT COMM CLIN; *NAT COMM CLIN LAB, 2000, M2A7 NAT COMM CLIN L; PAGE CP, 1993, ARCH SURG-CHICAGO, V128, P410; PERITI P, 1993, J CHEMOTHERAPY, V5, P37; PETITI P, 1989, DIS COLON RECTUM, V32, P121; Shah PM, 2003, J ANTIMICROB CHEMOTH, V52, P538, DOI 10.1093/jac/dkg404; SKIPPER D, 1992, J HOSP INFECT, V21, P73, DOI 10.1016/0195-6701(92)90155-F; Smith RL, 2004, ANN SURG, V239, P599, DOI 10.1097/01.sla.0000124292.21605.99; Solomkin JS, 2003, ANN SURG, V237, P235, DOI 10.1097/00000658-200302000-00013; Tang RP, 2001, ANN SURG, V234, P181, DOI 10.1097/00000658-200108000-00007; Yellin AE, 2002, INT J ANTIMICROB AG, V20, P165, DOI 10.1016/S0924-8579(02)00160-7	28	181	187	2	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 21	2006	355	25					2640	2651		10.1056/NEJMoa054408	http://dx.doi.org/10.1056/NEJMoa054408			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118QG	17182989	Bronze			2023-01-03	WOS:000242956200005
J	Willis, SL; Tennstedt, SL; Marsiske, M; Ball, K; Elias, J; Koepke, KM; Morris, JN; Rebok, GW; Unverzagt, FW; Stoddard, AM; Wright, E				Willis, Sherry L.; Tennstedt, Sharon L.; Marsiske, Michael; Ball, Karlene; Elias, Jeffrey; Koepke, Kathy Mann; Morris, John N.; Rebok, George W.; Unverzagt, Frederick W.; Stoddard, Anne M.; Wright, Elizabeth		ACTIVE Study Grp	Long-term effects of cognitive training on everyday functional outcomes in older adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALZHEIMER-DISEASE; INSTRUMENTAL ACTIVITIES; INTELLECTUAL ABILITY; AFRICAN-AMERICANS; PERFORMANCE; RISK; INTERVENTION; SPEED; AGE; DISABILITY	Context Cognitive training has been shown to improve cognitive abilities in older adults but the effects of cognitive training on everyday function have not been demonstrated. Objective To determine the effects of cognitive training on daily function and durability of training on cognitive abilities. Design, Setting, and Participants Five-year follow-up of a randomized controlled single-blind trial with 4 treatment groups. A volunteer sample of 2832 persons ( mean age, 73.6 years; 26% black), living independently in 6 US cities, was recruited from senior housing, community centers, and hospitals and clinics. The study was conducted between April 1998 and December 2004. Five-year follow-up was completed in 67% of the sample. Interventions Ten-session training for memory ( verbal episodic memory), reasoning ( inductive reasoning), or speed of processing ( visual search and identification); 4-session booster training at 11 and 35 months after training in a random sample of those who completed training. Main Outcome Measures Self-reported and performance-based measures of daily function and cognitive abilities. Results The reasoning group reported significantly less difficulty in the instrumental activities of daily living ( IADL) than the control group ( effect size, 0.29; 99% confidence interval [CI], 0.03- 0.55). Neither speed of processing training ( effect size, 0.26; 99% CI, - 0.002 to 0.51) nor memory training ( effect size, 0.20; 99% CI, - 0.06 to 0.46) had a significant effect on IADL. The booster training for the speed of processing group, but not for the other 2 groups, showed a significant effect on the performance-based functional measure of everyday speed of processing ( effect size, 0.30; 99% CI, 0.08-0.52). No booster effects were seen for any of the groups for everyday problem-solving or self-reported difficulty in IADL. Each intervention maintained effects on its specific targeted cognitive ability through 5 years ( memory: effect size, 0.23 [ 99% CI, 0.11-0.35]; reasoning: effect size, 0.26 [ 99% CI, 0.17-0.35]; speed of processing: effect size, 0.76 [ 99% CI, 0.62-0.90]). Booster training produced additional improvement with the reasoning intervention for reasoning performance ( effect size, 0.28; 99% CI, 0.12-0.43) and the speed of processing intervention for speed of processing performance ( effect size, 0.85; 99% CI, 0.61-1.09). Conclusions Reasoning training resulted in less functional decline in self-reported IADL. Compared with the control group, cognitive training resulted in improved cognitive abilities specific to the abilities trained that continued 5 years after the initiation of the intervention.	Penn State Univ, Dept Human Dev & Family Studies, State Coll, PA 16801 USA; New England Res Inst, Watertown, MA 02172 USA; Univ Florida, Inst Aging, Gainesville, FL USA; Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA; NIA, Bethesda, MD 20892 USA; NINR, Bethesda, MD 20892 USA; Hebrew Senior Life, Boston, MA USA; Johns Hopkins Univ, Dept Mental Hlth, Baltimore, MD USA; Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; HealthCore, Inc; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute of Nursing Research (NINR); Harvard University; Hebrew SeniorLife; Johns Hopkins University; Indiana University System; Indiana University-Purdue University Indianapolis	Willis, SL (corresponding author), Penn State Univ, Dept Human Dev & Family Studies, 135 E Nittany Ave,Suite 405, State Coll, PA 16801 USA.	slw@psu.edu	Kennedy, Kristen M/B-4699-2008	Kennedy, Kristen M/0000-0001-5373-9026; Marsiske, Michael/0000-0001-5973-2116; Ball, Karlene/0000-0003-1811-9870	NATIONAL INSTITUTE OF NURSING RESEARCH [U01NR004507, U01NR004508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG024102, U01AG014289, U01AG014276, U01AG014263, U01AG014260, U01AG014282] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allaire JC, 2002, PSYCHOL AGING, V17, P101, DOI 10.1037/0882-7974.17.1.101; Allaire JC, 1999, PSYCHOL AGING, V14, P627, DOI 10.1037/0882-7974.14.4.627; Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; BALL K, 2000, MOBILITY TRANSPORTAT, V5, P213; BALL KK, 1988, J OPT SOC AM A, V5, P2210, DOI 10.1364/JOSAA.5.002210; Blom G., 1958, STAT ESTIMATES TRANS; Boyle PA, 2004, CLIN NEUROPSYCHOL, V18, P75, DOI 10.1080/13854040490507172; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; Cherry KE, 2005, EXP AGING RES, V31, P261, DOI 10.1080/03610730590948186; Clark F, 1997, JAMA-J AM MED ASSOC, V278, P1321, DOI 10.1001/jama.278.16.1321; Cnaan A, 1997, STAT MED, V16, P2349, DOI 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E; Cohen J., 2013, STAT POWER ANAL BEHA; Davis RN, 2001, ALZ DIS ASSOC DIS, V15, P1, DOI 10.1097/00002093-200101000-00001; Derwinger A, 2005, GERONTOLOGY, V51, P277, DOI 10.1159/000085124; Diehl M, 2005, J APPL GERONTOL, V24, P211, DOI 10.1177/0733464804273772; Edwards JD, 2002, GERONTOLOGY, V48, P329, DOI 10.1159/000065259; Ekstrom R. B., 1976, KIT FACTOR REFERENCE, VRev; Evans DA, 2003, ARCH NEUROL-CHICAGO, V60, P185, DOI 10.1001/archneur.60.2.185; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fried TR, 2001, ARCH INTERN MED, V161, P2602, DOI 10.1001/archinte.161.21.2602; Gonda J, 1985, SCHAIE THURSTONE MEN; Hendrie HC, 2001, JAMA-J AM MED ASSOC, V285, P739, DOI 10.1001/jama.285.6.739; Jobe JB, 2001, CONTROL CLIN TRIALS, V22, P453, DOI 10.1016/S0197-2456(01)00139-8; Kane R.A., 1998, HEART LONG TERM CARE; KELLYHAYES M, 1992, AM J PUBLIC HEALTH, V82, P841, DOI 10.2105/AJPH.82.6.841; Koltai DC, 2001, NEUROPSYCHOL REHABIL, V11, P455, DOI 10.1080/09602010042000097; LAZARIDIS EN, 1994, J GERONTOL, V49, pM47, DOI 10.1093/geronj/49.2.M47; Lehmann E.L., 1975, NONPARAMETRICS STAT; O'Hara R, 2007, J PSYCHIATR RES, V41, P585, DOI 10.1016/j.jpsychires.2006.04.010; OWSLEY C, 1991, PSYCHOL AGING, V6, P403, DOI 10.1037/0882-7974.6.3.403; Owsley C, 2002, GERONTOLOGY, V48, P254, DOI 10.1159/000058360; Owsley C, 1998, JAMA-J AM MED ASSOC, V279, P1083, DOI 10.1001/jama.279.14.1083; Plehn K, 2004, CLIN NEUROPSYCHOL, V18, P101, DOI 10.1080/13854040490507190; Rasmusson DX, 1999, AGING NEUROPSYCHOL C, V6, P56, DOI 10.1076/anec.6.1.56.790; REBOK GW, 1989, DEV PSYCHOL, V25, P714, DOI 10.1037/0012-1649.25.5.714; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Roenker DL, 2003, HUM FACTORS, V45, P218, DOI 10.1518/hfes.45.2.218.27241; Royall DR, 2005, J INT NEUROPSYCH SOC, V11, P899, DOI 10.1017/S135561770505109X; Schafer J.L., 1997, ANAL INCOMPLETE MULT; Schupf N, 2005, NEUROLOGY, V65, P1218, DOI 10.1212/01.wnl.0000180970.07386.cb; Stuck AE, 1999, SOC SCI MED, V48, P445, DOI 10.1016/S0277-9536(98)00370-0; Tang MX, 2001, NEUROLOGY, V56, P49, DOI 10.1212/WNL.56.1.49; TERESI J, 1997, ADL ASSESSMENT MEASU; Thurstone L. L., 1949, EXAMINER MANUAL SRA; Wadley VG, 2003, J AM GERIATR SOC, V51, P1621, DOI 10.1046/j.1532-5415.2003.51514.x; WILLIS S, 1997, SOC MECH MAINTAINING; Willis S L, 1986, Psychol Aging, V1, P239, DOI 10.1037/0882-7974.1.3.239; Willis S L, 1987, Annu Rev Gerontol Geriatr, V7, P159; Willis SL, 1996, GERONTOLOGIST, V36, P595, DOI 10.1093/geront/36.5.595; WILLIS SL, 1983, J EDUC PSYCHOL, V75, P257, DOI 10.1037/0022-0663.75.2.257; Willis SL., 1993, MANUAL EVERYDAY PROB; Wilson B., 1985, RIVERMEAD BEHAV MEMO; WOLINSKY F, 2006, GERONTOLOGY PERSPECT; WOLINSKY FD, 1993, J GERONTOL, V48, pS93; WOLINSKY FD, 1992, J GERONTOL, V47, pS173, DOI 10.1093/geronj/47.4.S173	55	943	988	2	155	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	2006	296	23					2805	2814		10.1001/jama.296.23.2805	http://dx.doi.org/10.1001/jama.296.23.2805			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	116TR	17179457	Green Accepted, Bronze			2023-01-03	WOS:000242826400022
J	Metcalfe, C; Macdonald, IK; Murphy, EJ; Brown, KA; Raven, EL; Moody, PCE				Metcalfe, Clive; Macdonald, Isabel K.; Murphy, Emma J.; Brown, Katherine A.; Raven, Emma Lloyd; Moody, Peter C. E.			The tuberculosis prodrug isoniazid bound to activating peroxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; ARTHROMYCES-RAMOSUS PEROXIDASE; CYTOCHROME-C PEROXIDASE; MYCOBACTERIUM-TUBERCULOSIS; CATALASE-PEROXIDASE; CRYSTAL-STRUCTURE; ASCORBATE PEROXIDASE; SALICYLHYDROXAMIC ACID; BENZHYDROXAMIC ACID; ACTIVE-SITE	Isoniazid (INH, isonicotinic acid hydrazine) is one of only two therapeutic agents effective in treating tuberculosis. This prodrug is activated by the heme enzyme catalase peroxidase (KatG) endogenous to Mycobacterium tuberculosis but the mechanism of activation is poorly understood, in part because the binding interaction has not been properly established. The class I peroxidases ascorbate peroxidase (APX) and cytochrome c peroxidase (CcP) have active site structures very similar to KatG and are also capable of activating isoniazid. We report here the first crystal structures of complexes of isoniazid bound to APX and CcP. These are the first structures of isoniazid bound to any activating enzymes. The structures show that isoniazid binds close to the delta-heme edge in both APX and CcP, although the precise binding orientation varies slightly in the two cases. A second binding site for INH is found in APX at the gamma-heme edge close to the established ascorbate binding site, indicating that the gamma-heme edge can also support the binding of aromatic substrates. We also show that in an active site mutant of soybean APX (W41A) INH can bind directly to the heme iron to become an inhibitor and in a different mode when the distal histidine is replaced by alanine (H42A). These structures provide the first unambiguous evidence for the location of the isoniazid binding site in the class I peroxidases and provide rationalization of isoniazid resistance in naturally occurring KatG mutant strains of M. tuberculosis.	[Moody, Peter C. E.] Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; [Metcalfe, Clive; Macdonald, Isabel K.; Murphy, Emma J.; Raven, Emma Lloyd] Univ Leicester, Dept Chem, Leicester LE1 9HN, Leics, England; [Brown, Katherine A.] Univ London Imperial Coll Sci Technol & Med, Ctr Mol Microbiol & Infect, Div Cell & Mol Biol, Dept Life Sci, London SW7 2AZ, England	University of Leicester; University of Leicester; Imperial College London	Moody, PCE (corresponding author), Univ Leicester, Dept Biochem, Lancaster Rd, Leicester LE1 9HN, Leics, England.	peter.moody@le.ac.uk	Moody, Peter/A-6832-2008	Moody, Peter/0000-0003-1762-9238; Murphy, Emma/0000-0003-4551-8068; Raven, Emma/0000-0002-1643-8694; Metcalfe, Clive/0000-0002-7856-8574	Biotechnology and Biological Sciences Research Council [BB/C001184/1, B19083] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Badyal SK, 2006, J BIOL CHEM, V281, P24512, DOI 10.1074/jbc.M602602200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bertrand T, 2004, J BIOL CHEM, V279, P38991, DOI 10.1074/jbc.M402382200; Bodiguel J, 2001, J AM CHEM SOC, V123, P3832, DOI 10.1021/ja002674f; COCKERILL FR, 1995, J INFECT DIS, V171, P240, DOI 10.1093/infdis/171.1.240; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Delano W.L, 2002, DELANO SCI; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FISHEL LA, 1987, BIOCHEMISTRY-US, V26, P351, DOI 10.1021/bi00376a004; Haas WH, 1997, ANTIMICROB AGENTS CH, V41, P1601, DOI 10.1128/AAC.41.7.1601; Henriksen A, 1998, BIOCHEMISTRY-US, V37, P8054, DOI 10.1021/bi980234j; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; Itakura H, 1997, FEBS LETT, V412, P107, DOI 10.1016/S0014-5793(97)00751-5; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; Kapetanaki S, 2003, BIOCHEMISTRY-US, V42, P3835, DOI 10.1021/bi026992y; Lad L, 2002, EUR J BIOCHEM, V269, P3182, DOI 10.1046/j.1432-1033.2002.02998.x; Lad L, 2002, BIOCHEMISTRY-US, V41, P13774, DOI 10.1021/bi0261591; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Marttila HJ, 1998, ANTIMICROB AGENTS CH, V42, P2443, DOI 10.1128/AAC.42.9.2443; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196; Nagy JM, 1997, J BIOL CHEM, V272, P31265, DOI 10.1074/jbc.272.50.31265; Pierattelli R, 2004, J BIOL CHEM, V279, P39000, DOI 10.1074/jbc.M402384200; Poulos TL, 2007, NAT PROD REP, V24, P504, DOI 10.1039/b604195g; POULOS TL, 1980, J BIOL CHEM, V255, P575; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; ROUSE DA, 1995, ANTIMICROB AGENTS CH, V39, P2472, DOI 10.1128/AAC.39.11.2472; ROUSE DA, 1995, INFECT IMMUN, V63, P1427, DOI 10.1128/IAI.63.4.1427-1433.1995; Sharp KH, 2004, BIOCHEMISTRY-US, V43, P8644, DOI 10.1021/bi049343q; Sharp KH, 2003, NAT STRUCT BIOL, V10, P303, DOI 10.1038/nsb913; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; Tsukamoto K, 1999, BIOCHEMISTRY-US, V38, P12558, DOI 10.1021/bi982925l; Welinder K.G., 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [10.1016/0959-440x(92)90230-5, DOI 10.1016/0959-440X(92)90230-5]; *WHO, 2002, REP INF DIS; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	38	67	70	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2008	283	10					6193	6200		10.1074/jbc.M707412200	http://dx.doi.org/10.1074/jbc.M707412200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	271HM	18056997	Green Published, hybrid			2023-01-03	WOS:000253779500026
J	Klein, DF				Klein, Donald F.			The loss of serendipity in psychopharmacology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MAJOR DEPRESSION; IMIPRAMINE; PREDICTORS; DISORDERS; RELAPSE		[Klein, Donald F.] NYU, Ctr Child Study, Phyllis Green & Randolph Cowen Inst Pediat Neuros, Med Ctr,Nathan S Kline Inst Psychiat Res, New York, NY 10016 USA; [Klein, Donald F.] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA	Nathan Kline Institute for Psychiatric Research; New York University; Columbia University	Klein, DF (corresponding author), NYU, Ctr Child Study, Phyllis Green & Randolph Cowen Inst Pediat Neuros, Med Ctr,Nathan S Kline Inst Psychiat Res, Lexington Ave,14th Floor, New York, NY 10016 USA.	donaldk737@aol.com						Evins AE, 2003, J CLIN PSYCHIAT, V64, P9; KLEIN DF, 1967, ARCH GEN PSYCHIAT, V16, P118; McElroy SL, 2005, J CLIN PSYCHIAT, V66, P617, DOI 10.4088/JCP.v66n0512; McGrath PJ, 2006, AM J PSYCHIAT, V163, P1542, DOI 10.1176/appi.ajp.163.9.1542; McGrath PJ, 2000, J CLIN PSYCHIAT, V61, P518, DOI 10.4088/JCP.v61n0710; Ohlsen RI, 2005, J PSYCHOPHARMACOL, V19, P408, DOI 10.1177/0269881105053308; QUITKIN FM, 1989, ARCH GEN PSYCHIAT, V46, P787; UHLENHUTH EH, 1977, PSYCHOPHARMACOLOGY, V52, P79, DOI 10.1007/BF00426604; WIKLER A, 1953, J PHARMACOL EXP THER, V109, P8; ZITRIN CM, 1978, ARCH GEN PSYCHIAT, V35, P307	10	54	54	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	2008	299	9					1063	1065		10.1001/jama.299.9.1063	http://dx.doi.org/10.1001/jama.299.9.1063			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	269JH	18319418				2023-01-03	WOS:000253644800026
J	Mercat, A; Richard, JCM; Vielle, B; Jaber, S; Osman, D; Diehl, JL; Lefrant, JY; Prat, G; Richecoeur, J; Nieszkowska, A; Gervais, C; Baudot, J; Bouadma, L; Brochard, L				Mercat, Alain; Richard, Jean-Christophe M.; Vielle, Bruno; Jaber, Samir; Osman, David; Diehl, Jean-Luc; Lefrant, Jean-Yves; Prat, Gwenael; Richecoeur, Jack; Nieszkowska, Ania; Gervais, Claude; Baudot, Jerome; Bouadma, Lila; Brochard, Laurent		Expiratory Pressure Express Study	Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TIDAL VOLUME; MECHANICAL VENTILATION; PROTECTIVE-VENTILATION; ALVEOLAR RECRUITMENT; AIRWAY PRESSURES; PULMONARY-EDEMA; DERECRUITMENT; STRATEGY; MORTALITY; MANEUVERS	Context The need for lung protection is universally accepted, but the optimal level of positive end- expiratory pressure ( PEEP) in patients with acute lung injury ( ALI) or acute respiratory distress syndrome remains debated. Objective To compare the effect on outcome of a strategy for setting PEEP aimed at increasing alveolar recruitment while limiting hyperinflation to one aimed at minimizing alveolar distension in patients with ALI. Design, Setting, and Patients A multicenter randomized controlled trial of 767 adults ( mean [ SD] age, 59.9 [ 15.4] years) with ALI conducted in 37 intensive care units in France from September 2002 to December 2005. Intervention Tidal volume was set at 6 mL/ kg of predicted body weight in both strategies. Patients were randomly assigned to a moderate PEEP strategy ( 5- 9 cm H2O) ( minimal distension strategy; n= 382) or to a level of PEEP set to reach a plateau pressure of 28 to 30 cm H2O ( increased recruitment strategy; n= 385). Main Outcome Measures The primary end point was mortality at 28 days. Secondary end points were hospital mortality at 60 days, ventilator- free days, and organ failure - free days at 28 days. Results The 28- day mortality rate in the minimal distension group was 31.2% ( n= 119) vs 27.8% ( n= 107) in the increased recruitment group ( relative risk, 1.12 [ 95% confidence interval, 0.90- 1.40]; P=. 31). The hospital mortality rate in the minimal distension group was 39.0% ( n= 149) vs 35.4% ( n= 136) in the increased recruitment group ( relative risk, 1.10 [ 95% confidence interval, 0.92- 1.32]; P=. 30). The increased recruitment group compared with the minimal distension group had a higher median number of ventilator- free days ( 7 [ interquartile range {IQR}, 0- 19] vs 3 [ IQR, 0- 17]; P=. 04) and organ failure - free days ( 6 [ IQR, 0- 18] vs 2 [ IQR, 0- 16]; P=. 04). This strategy also was associated with higher compliance values, better oxygenation, less use of adjunctive therapies, and larger fluid requirements. Conclusions A strategy for setting PEEP aimed at increasing alveolar recruitment while limiting hyperinflation did not significantly reduce mortality. However, it did improve lung function and reduced the duration of mechanical ventilation and the duration of organ failure. Trial Registration clinicaltrials. gov Identifier: NCT00188058.	[Mercat, Alain] CHU Angers, Dept Reanimat Med & Med Hyperbare, F-49933 Angers 09, France; [Richard, Jean-Christophe M.] CHU Rouen, Serv Reanimat Med, Rouen, France; [Richard, Jean-Christophe M.] CHU Rouen, UPRES EA 38 30, Rouen, France; [Vielle, Bruno] CHU Angers, Serv Biostat & Modelisat Informat, Angers, France; [Jaber, Samir] CHU Montpellier, Serv Anesthesie Reanimat B, Montpellier, France; [Osman, David] CHU Bicetre, Assistance Publ Hop Paris, Serv Reanimat Med, Le Kremlin Bicetre, France; [Diehl, Jean-Luc] Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, Serv Reanimat Med, Paris, France; [Lefrant, Jean-Yves; Gervais, Claude] CHU Nimes, Div Anesthesie Reanimat Douleur Urgences, Unite Reanimat Chirurg, Nimes, France; [Lefrant, Jean-Yves; Gervais, Claude] CHU Nimes, Div Anesthesie Reanimat Douleur Urgences, Unite Med, Nimes, France; [Prat, Gwenael] CHU Brest, Serv Reanimat Med, F-29285 Brest, France; [Richecoeur, Jack] CH Pontoise, Serv Reanimat Polyvalente, Pontoise, France; [Nieszkowska, Ania] CHU Pitie Salpetriere, Assistance Publ Hop Paris, Serv Reanimat Med, Paris, France; [Baudot, Jerome] CH Nevers, Serv Reanimat Polyvalente, Nevers, France; [Bouadma, Lila] CHU Bichat Claude Bernard, Assistance Publ Hop Paris, Serv Reanimat Med, Paris, France; [Brochard, Laurent] CHU Henri Mondor, Assistance Publ Hop Paris, Serv Reanimat Med, INSERM,U841, F-94010 Creteil, France; [Brochard, Laurent] Univ Paris 12, Creteil, France	Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU de Rouen; CHU de Rouen; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite de Montpellier; CHU de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Universite de Montpellier; CHU de Nimes; Universite de Montpellier; CHU de Nimes; CHU Brest; Centre Hospitalier Rene Dubos, Pontoise; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Mercat, A (corresponding author), CHU Angers, Dept Reanimat Med & Med Hyperbare, 4 Rue Larrey, F-49933 Angers 09, France.	almercat@chu-angers.fr	Mercat, Alain/AFU-4426-2022					Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; ASHBAUGH DG, 1967, LANCET, V2, P319; Boussarsar M, 2002, INTENS CARE MED, V28, P406, DOI 10.1007/s00134-001-1178-1; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Brun-Buisson C, 2004, INTENS CARE MED, V30, P51, DOI 10.1007/s00134-003-2022-6; Crotti S, 2001, AM J RESP CRIT CARE, V164, P131, DOI 10.1164/ajrccm.164.1.2007011; Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; FAGON JY, 1993, INTENS CARE MED, V19, P137, DOI 10.1007/BF01720528; Ferguson ND, 2005, CRIT CARE MED, V33, P21, DOI 10.1097/01.CCM.0000150652.91411.66; Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052; Grasso S, 2005, AM J RESP CRIT CARE, V171, P1002, DOI 10.1164/rccm.200407-940OC; Grasso S, 2002, ANESTHESIOLOGY, V96, P795, DOI 10.1097/00000542-200204000-00005; Knoben JE, 1993, HDB CLIN DRUG DATA, V7th; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Maggiore SM, 2001, AM J RESP CRIT CARE, V164, P795, DOI 10.1164/ajrccm.164.5.2006071; MERCAT A, 2006, REANIMATION, V15, P74; MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774; Pelosi P, 2001, AM J RESP CRIT CARE, V164, P122, DOI 10.1164/ajrccm.164.1.2007010; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; Richard JC, 2003, CRIT CARE MED, V31, P89, DOI 10.1097/00003246-200301000-00014; Richard JC, 2001, AM J RESP CRIT CARE, V163, P1609, DOI 10.1164/ajrccm.163.7.2004215; Tobin MJ, 2000, NEW ENGL J MED, V342, P1360, DOI 10.1056/NEJM200005043421808; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Villagra A, 2002, AM J RESP CRIT CARE, V165, P165, DOI 10.1164/ajrccm.165.2.2104092; Villar J, 2006, CRIT CARE MED, V34, P1311, DOI 10.1097/01.CCM.0000215598.84885.01; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; Whitehead J, 1997, DESIGN ANAL SEQUENTI	31	838	903	2	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 13	2008	299	6					646	655		10.1001/jama.299.6.646	http://dx.doi.org/10.1001/jama.299.6.646			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261QN	18270353	Bronze			2023-01-03	WOS:000253095200022
J	Opiyo, N; Were, F; Govedi, F; Fegan, G; Wasunna, A; English, M				Opiyo, Newton; Were, Fred; Govedi, Fridah; Fegan, Greg; Wasunna, Aggrey; English, Mike			Effect of Newborn Resuscitation Training on Health Worker Practices in Pumwani Hospital, Kenya	PLOS ONE			English	Article							NEONATAL RESUSCITATION; DELIVERY; MULTICENTER	Background: Birth asphyxia kills 0.7 to 1.6 million newborns a year globally with 99% of deaths in developing countries. Effective newborn resuscitation could reduce this burden of disease but the training of health-care providers in low income settings is often outdated. Our aim was to determine if a simple one day newborn resuscitation training (NRT) alters health worker resuscitation practices in a public hospital setting in Kenya. Methods/Principal Findings: We conducted a randomised, controlled trial with health workers receiving early training with NRT (n = 28) or late training (the control group, n = 55). The training was adapted locally from the approach of the UK Resuscitation Council. The primary outcome was the proportion of appropriate initial resuscitation steps with the frequency of inappropriate practices as a secondary outcome. Data were collected on 97 and 115 resuscitation episodes over 7 weeks after early training in the intervention and control groups respectively. Trained providers demonstrated a higher proportion of adequate initial resuscitation steps compared to the control group (trained 66% vs control 27%; risk ratio 2.45, [95% CI 1.75-3.42], p<0.001, adjusted for clustering). In addition, there was a statistically significant reduction in the frequency of inappropriate and potentially harmful practices per resuscitation in the trained group (trained 0.53 vs control 0.92; mean difference 0.40, [95% CI 0.13-0.66], p = 0.004). Conclusions/Significance: Implementation of a simple, one day newborn resuscitation training can be followed immediately by significant improvement in health workers' practices. However, evidence of the effects on long term performance or clinical outcomes can only be established by larger cluster randomised trials.	[Opiyo, Newton; Fegan, Greg; English, Mike] Kenya Govt Med Res Ctr, Wellcome Trust Res Programme, Nairobi, Kenya; [Were, Fred; Wasunna, Aggrey] Univ Nairobi, Coll Hlth Sci, Dept Paediat & Child Hlth, Nairobi, Kenya; [Govedi, Fridah] Pumwani Maternity Hosp, Nairobi, Kenya; [Fegan, Greg] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London, England; [English, Mike] Univ Oxford, Dept Paediat, Oxford, England	Kenya Medical Research Institute; University of Nairobi; University of London; London School of Hygiene & Tropical Medicine; University of Oxford	Opiyo, N (corresponding author), Kenya Govt Med Res Ctr, Wellcome Trust Res Programme, Nairobi, Kenya.	nopiyo@nairobi.kemri-wellcome.org	Fegan, Greg W/O-8079-2018	Fegan, Greg W/0000-0002-2663-2765; English, Michael/0000-0002-7427-0826	Laerdal Foundation of Acute Medicine, Norway; Wellcome Trust [076827]	Laerdal Foundation of Acute Medicine, Norway; Wellcome Trust(Wellcome TrustEuropean Commission)	This study was supported in part by a grant from the Laerdal Foundation of Acute Medicine, Norway and in part by a Wellcome Trust Senior Research Fellowship awarded to Mike English (#076827). The Laerdal foundation had no role in the design or conduct of the study, made no contribution to the data analysis nor report writing and their permission to publish the results was not sought.	Baskett PJF, 2005, RESUSCITATION, V67, pS181, DOI 10.1016/j.resuscitation.2005.10.006; BERDEN H, 1983, BRIT MED J, V306, P1576; Carbine DN, 2000, PEDIATRICS, V106, P654, DOI 10.1542/peds.106.4.654; Durojaiye L, 2002, J PAEDIATR CHILD H, V38, P241, DOI 10.1046/j.1440-1754.2002.00773.x; English M, 2004, LANCET, V364, P1622, DOI 10.1016/S0140-6736(04)17318-2; HALLIDAY HL, 2001, COCHRANE DATABASE SY, V2; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; *INT LIA COMM RES, 2005, RESUSCITATION, V67; Jabbour M, 1996, ANN EMERG MED, V28, P690, DOI 10.1016/S0196-0644(96)70095-1; Jewkes F, 2003, ARCH DIS CHILD, V88, P118, DOI 10.1136/adc.88.2.118; Kamenir SA, 1997, J TROP PEDIATRICS, V43, P170, DOI 10.1093/tropej/43.3.170; MCKENNA SP, 1985, J OCCUP PSYCHOL, V58, P109, DOI 10.1111/j.2044-8325.1985.tb00186.x; O'Hare BA, 2006, J TROP PEDIATRICS, V52, P376, DOI 10.1093/tropej/fml027; OPIYO N, 2006, T R SOC TROP MED HYG, V100, P899; Quan L, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.6.e110; Rowe AK, 2002, INT J QUAL HEALTH C, V14, P521, DOI 10.1093/intqhc/14.6.521; TAN A, 2004, COCHRANE DATABASE SY; Vain NE, 2004, LANCET, V364, P597, DOI 10.1016/S0140-6736(04)16852-9; *WHO, 1997, BAS NEWB RES PRACT G; Wiswell TE, 2000, PEDIATRICS, V105, P1, DOI 10.1542/peds.105.1.1; World Health Organization, 2005, WORLD HLTH REPORT 20	21	48	48	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1599	10.1371/journal.pone.0001599	http://dx.doi.org/10.1371/journal.pone.0001599			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270586	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000260535900033
J	Lorenz, KA; Lynn, J; Dy, SM; Shugarman, LR; Wilkinson, A; Mularski, RA; Morton, SC; Hughes, RG; Hilton, LK; Maglione, M; Rhodes, SL; Rolon, C; Sun, VC; Shekelle, PG				Lorenz, Karl A.; Lynn, Joanne; Dy, Sydney M.; Shugarman, Lisa R.; Wilkinson, Anne; Mularski, Richard A.; Morton, Sally C.; Hughes, Ronda G.; Hilton, Lara K.; Maglione, Margaret; Rhodes, Shannon L.; Rolon, Cony; Sun, Virginia C.; Shekelle, Paul G.			Evidence for improving palliative care at the end of life: A systematic review	ANNALS OF INTERNAL MEDICINE			English	Review							QUALITY-OF-LIFE; OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; CANCER-PATIENTS; DOUBLE-BLIND; AROMATHERAPY MASSAGE; HEART-FAILURE; ETHICS CONSULTATIONS; FAMILY SATISFACTION; TELEPHONE SUPPORT	Background: Many persons and their families are burdened by serious chronic illness in late life. How to best support quality of life is an important consideration for care. Purpose: To assess evidence about interventions to improve palliative and end-of-life care. Data Sources: English-language citations (January 1990 to November 2005) from MEDLINE, the Database of Abstracts of Reviews of Effects, the National Consensus Project for Quality Palliative Care bibliography, and November 2005 to January 2007 updates from expert reviews and literature surveillance. Study Selection: Systematic reviews that addressed "end of life," including terminal illness (for example, advanced cancer) and chronic, eventually fatal illness with ambiguous prognosis (for example, advanced dementia), and intervention studies (randomized and nonrandomized designs) that addressed pain, dyspnea, depression, advance care planning, continuity, and caregiving. Data Extraction: Single reviewers screened 24423 titles to find 6381 relevant abstracts and reviewed 1274 articles in detail to identify 33 high-quality systematic reviews and 89 relevant intervention studies. They synthesized the evidence by using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) classification. Data Synthesis: Strong evidence supports treating cancer pain with opioids, nonsteroidals, radionuclides, and radiotherapy; dyspnea from chronic lung disease with short-term opioids; and cancer-associated depression with psychotherapy, tricyclics, and selective serotonin reuptake inhibitors. Strong evidence supports multicomponent interventions to improve continuity in heart failure. Moderate evidence supports advance care planning led by skilled facilitators who engage key decision makers and interventions to alleviate caregiver burden. Weak evidence addresses cancer-related dyspnea management, and no evidence addresses noncancer pain, symptomatic dyspnea management in advanced heart failure, or short-acting antidepressants in terminal illness. No direct evidence addresses improving continuity for patients with dementia. Evidence was weak for improving caregiver burdens in cancer and was absent for heart failure. Limitations: Variable literature indexing for advanced chronic illness and end of life limited the comprehensiveness of searches, and heterogeneity was too great to do meta-analysis. Conclusion: Strong to moderate evidence supports interventions to improve important aspects of end-of-life care. Future research should quantify these effects and address the generalizability of insights across the conditions and settings of the last part of life. Many critical issues lack high-quality evidence.	[Lorenz, Karl A.] Vet Affairs Greater Los Angeles Hlthcare Syst, Vet Integrated Palliat Program, Div Gen Internal Med, Los Angeles, CA 90073 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Lorenz, KA (corresponding author), Vet Affairs Greater Los Angeles Hlthcare Syst, Vet Integrated Palliat Program, Div Gen Internal Med, 11031 Wilshire Blvd,Code 111-G, Los Angeles, CA 90073 USA.	karl.lorenz@med.va.gov		Sun, Virginia/0000-0003-3129-4235	NCI NIH HHS [K07-CA096 783] Funding Source: Medline; PHS HHS [290-02-0003] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K07CA096783] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abernethy AP, 2003, BRIT MED J, V327, P523, DOI 10.1136/bmj.327.7414.523; Acton GJ, 2001, RES NURS HEALTH, V24, P349, DOI 10.1002/nur.1036; Adams K., 2003, PRIORITY AREAS NATL; Ahrens T, 2003, AM J CRIT CARE, V12, P317, DOI 10.4037/ajcc2003.12.4.317; ANDERSON JP, 1994, J CLIN EPIDEMIOL, V47, P761, DOI 10.1016/0895-4356(94)90173-2; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Baggs Judith Gedney, 2002, Annu Rev Nurs Res, V20, P181; Bailey FA, 2005, ARCH INTERN MED, V165, P1722, DOI 10.1001/archinte.165.15.1722; Baker R, 2000, J AM GERIATR SOC, V48, pS61, DOI 10.1111/j.1532-5415.2000.tb03143.x; Benitez-Rosario MA, 2004, CANCER-AM CANCER SOC, V101, P2866, DOI 10.1002/cncr.20712; Bookbinder M, 2005, J PAIN SYMPTOM MANAG, V29, P529, DOI 10.1016/j.jpainsymman.2004.05.011; Booth S, 2004, RESP MED, V98, P66, DOI 10.1016/j.rmed.2003.08.008; Bruera E, 2003, PALLIATIVE MED, V17, P659, DOI 10.1191/0269216303pm826oa; Bruera E, 2004, J CLIN ONCOL, V22, P185, DOI 10.1200/JCO.2004.03.172; BRUERA E, 1993, ANN INTERN MED, V119, P906, DOI 10.7326/0003-4819-119-9-199311010-00007; Brumley Richard D, 2003, J Palliat Med, V6, P715, DOI 10.1089/109662103322515220; Bucher JA, 2001, CANCER PRACT, V9, P66, DOI 10.1046/j.1523-5394.2001.009002066.x; Burgio L, 2003, GERONTOLOGIST, V43, P568, DOI 10.1093/geront/43.4.568; Burns R, 2003, GERONTOLOGIST, V43, P547, DOI 10.1093/geront/43.4.547; Cameron JI, 2004, J PSYCHOSOM RES, V57, P137, DOI 10.1016/S0022-3999(03)00609-3; Campbell ML, 2004, CRIT CARE MED, V32, P1839, DOI 10.1097/01.CCM.0000138560.56577.88; CARR D, 2002, AHRQ PUBLICATION; Casarett D, 2005, JAMA-J AM MED ASSOC, V294, P211, DOI 10.1001/jama.294.2.211; Chochinov HM, 2005, J CLIN ONCOL, V23, P5520, DOI 10.1200/JCO.2005.08.391; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Cook AM, 2001, J PAIN SYMPTOM MANAG, V22, P797, DOI 10.1016/S0885-3924(01)00315-3; Coppola KM, 2001, ARCH INTERN MED, V161, P431, DOI 10.1001/archinte.161.3.431; Detmar SB, 2002, JAMA-J AM MED ASSOC, V288, P3027, DOI 10.1001/jama.288.23.3027; Eisdorfer C, 2003, GERONTOLOGIST, V43, P521, DOI 10.1093/geront/43.4.521; Engelhardt JB, 2006, AM J MANAG CARE, V12, P93; Field MJ, 1997, APPROACHING DEATH IM; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; Furlan AD, 2006, CAN MED ASSOC J, V174, P1589, DOI 10.1503/cmaj.051528; Gillick M, 1999, J AM GERIATR SOC, V47, P227, DOI 10.1111/j.1532-5415.1999.tb04582.x; Gitlin LN, 2003, PSYCHOL AGING, V18, P361, DOI 10.1037/0882-7974.18.3.361; Gitlin LN, 2003, GERONTOLOGIST, V43, P532, DOI 10.1093/geront/43.4.532; Goldberg LR, 2003, AM HEART J, V146, P705, DOI 10.1016/S0002-8703(03)00393-4; Gomes B, 2006, BMJ-BRIT MED J, V332, P515, DOI 10.1136/bmj.38740.614954.55; GOODYER LI, 1995, BRIT J CLIN PRACT, V49, P173; Gorski Lisa A, 2003, Lippincotts Case Manag, V8, P265, DOI 10.1097/00129234-200311000-00009; Gottlieb S S, 1999, J Card Fail, V5, P188, DOI 10.1016/S1071-9164(99)90002-7; Grande GE, 2000, PALLIATIVE MED, V14, P375, DOI 10.1191/026921600701536200; Grande GE, 1999, BRIT MED J, V319, P1472, DOI 10.1136/bmj.319.7223.1472; Grosset AB, 2005, J PAIN SYMPTOM MANAG, V29, P584, DOI 10.1016/j.jpainsymman.2004.10.008; GUO B, 2004, ADV DIRECTIVES END O; Gutheil IA, 2005, HEALTH SOC WORK, V30, P107, DOI 10.1093/hsw/30.2.107; Gysels M., 2004, IMPROVING SUPPORTIVE; Haggerty JL, 2003, BRIT MED J, V327, P1219, DOI 10.1136/bmj.327.7425.1219; Hanks GW, 2002, BRIT J CANCER, V87, P733, DOI 10.1038/sj.bjc.6600522; Hanson LC, 1997, ANN INTERN MED, V126, P381, DOI 10.7326/0003-4819-126-5-199703010-00007; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; Hanson LC, 2005, J PALLIAT MED, V8, P1207, DOI 10.1089/jpm.2005.8.1207; Heffner J E, 2001, J Cardiopulm Rehabil, V21, P387, DOI 10.1097/00008483-200111000-00008; Heffner JE, 1997, AM J RESP CRIT CARE, V155, P1055, DOI 10.1164/ajrccm.155.3.9116986; HIGGINSON IJ, 2000, ROLE PALLIATIVE CARE; Hogan C, 2001, HEALTH AFFAIR, V20, P188, DOI 10.1377/hlthaff.20.4.188; Holzapfel L, 2002, INTENS CARE MED, V28, P1309, DOI 10.1007/s00134-002-1370-y; Hughes SL, 2000, JAMA-J AM MED ASSOC, V284, P2877, DOI 10.1001/jama.284.22.2877; Jack B, 2003, PALLIATIVE MED, V17, P498, DOI 10.1191/0269216303pm794oa; Jennings AL, 2002, THORAX, V57, P939, DOI 10.1136/thorax.57.11.939; Jordhoy MS, 2001, J CLIN ONCOL, V19, P3884, DOI 10.1200/JCO.2001.19.18.3884; Karel MJ, 2004, PATIENT EDUC COUNS, V55, P22, DOI 10.1016/s0738-3991(03)00246-5; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; Knols R, 2005, J CLIN ONCOL, V23, P3830, DOI 10.1200/JCO.2005.02.148; Latimer EJ, 1998, J PAIN SYMPTOM MANAG, V16, P41, DOI 10.1016/S0885-3924(98)00027-X; Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004; Levenson JW, 2000, J AM GERIATR SOC, V48, pS101, DOI 10.1111/j.1532-5415.2000.tb03119.x; Lewith GT, 2004, CHEST, V125, P1783, DOI 10.1378/chest.125.5.1783; Lilly CM, 2003, CRIT CARE MED, V31, pS394, DOI 10.1097/01.CCM.0000065279.77449.B4; Loeb M, 2006, JAMA-J AM MED ASSOC, V295, P2503, DOI 10.1001/jama.295.21.2503; Lorenz K, 2004, END OF LIFE CARE OUT; Lorenz Karl A, 2005, J Palliat Med, V8 Suppl 1, pS4; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Lynn J, 2000, J AM GERIATR SOC, V48, pS91, DOI 10.1111/j.1532-5415.2000.tb03147.x; Mahoney DF, 2003, GERONTOLOGIST, V43, P556, DOI 10.1093/geront/43.4.556; Mann WC, 1999, ARCH FAM MED, V8, P210, DOI 10.1001/archfami.8.3.210; Marinangeli F, 2004, J PAIN SYMPTOM MANAG, V27, P409, DOI 10.1016/j.jpainsymman.2003.10.006; Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006; Mazzocato C, 1999, ANN ONCOL, V10, P1511, DOI 10.1023/A:1008337624200; McAlister FA, 2004, J AM COLL CARDIOL, V44, P810, DOI 10.1016/j.jacc.2004.05.055; McDonald MV, 2005, J PAIN SYMPTOM MANAG, V29, P474, DOI 10.1016/j.jpainsymman.2004.08.018; MELIN AL, 1992, MED CARE, V30, P1004, DOI 10.1097/00005650-199211000-00004; Mercadante S, 2004, SUPPORT CARE CANCER, V12, P762, DOI 10.1007/s00520-004-0650-1; Mercadante S, 2002, EUR J CANCER, V38, P1358, DOI 10.1016/S0959-8049(02)00102-8; Molloy DW, 2000, JAMA-J AM MED ASSOC, V283, P1437, DOI 10.1001/jama.283.11.1437; Monteleoni C, 2004, BMJ-BRIT MED J, V329, P491, DOI 10.1136/bmj.329.7464.491; Morrison RS, 2005, J PALLIAT MED, V8, P1127, DOI 10.1089/jpm.2005.8.1127; Morrison RS, 2005, J AM GERIATR SOC, V53, P290, DOI 10.1111/j.1532-5415.2005.53116.x; Mularski RA, 2007, HEALTH SERV RES, V42, P1848, DOI 10.1111/j.1475-6773.2007.00721.x; *NAT CONS PROJ, NATL CONS PROJ QUAL; Pan CX, 2000, J PAIN SYMPTOM MANAG, V20, P374, DOI 10.1016/S0885-3924(00)00190-1; Patrick DL, 2003, ANN INTERN MED, V139, P410, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00006; Pearlman RA, 2005, ARCH INTERN MED, V165, P667, DOI 10.1001/archinte.165.6.667; Perry E, 2005, AM J KIDNEY DIS, V46, P111, DOI 10.1053/j.ajkd.2005.03.018; Philbin EF, 2000, AM J MED, V109, P443, DOI 10.1016/S0002-9343(00)00544-1; Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358; Rabow MW, 2004, ARCH INTERN MED, V164, P83, DOI 10.1001/archinte.164.1.83; Ram FSF, 2005, RESP MED, V99, P135, DOI 10.1016/j.rmed.2004.10.009; Ram FSF, 2004, BMJ-BRIT MED J, V329, P315, DOI 10.1136/bmj.38159.650347.55; Ratner E, 2001, J AM GERIATR SOC, V49, P778, DOI 10.1046/j.1532-5415.2001.49155.x; Ringdal GI, 2004, PALLIATIVE MED, V18, P108, DOI 10.1191/0269216304pm878oa; Ringdal GI, 2002, J PAIN SYMPTOM MANAG, V24, P53, DOI 10.1016/S0885-3924(02)00417-7; Rodrigues P, 2004, PROSTATE CANCER P D, V7, P350, DOI 10.1038/sj.pcan.4500752; Roffe L, 2005, PSYCHO-ONCOLOGY, V14, P607, DOI 10.1002/pon.889; Salman GF, 2003, J GEN INTERN MED, V18, P213, DOI 10.1046/j.1525-1497.2003.20221.x; Sarna L, 1998, Oncol Nurs Forum, V25, P1041; Schneiderman LJ, 2000, CRIT CARE MED, V28, P3920, DOI 10.1097/00003246-200012000-00033; Schneiderman LJ, 2003, JAMA-J AM MED ASSOC, V290, P1166, DOI 10.1001/jama.290.9.1166; Schwartz CE, 2002, ARCH INTERN MED, V162, P1611, DOI 10.1001/archinte.162.14.1611; Shalowitz DI, 2006, ARCH INTERN MED, V166, P493, DOI 10.1001/archinte.166.5.493; SHUKLA V, 2006, 65 CAN COORD OFF HLT; Simmons SF, 2002, CLIN J PAIN, V18, P380, DOI 10.1097/00002508-200211000-00006; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Sittl R, 2003, CLIN THER, V25, P150, DOI 10.1016/S0149-2918(03)90019-1; Smeenk FWJM, 1998, NURS RES, V47, P129, DOI 10.1097/00006199-199805000-00003; Smeenk FWJM, 1998, BRIT MED J, V316, P1939, DOI 10.1136/bmj.316.7149.1939; Smith TJ, 2002, J CLIN ONCOL, V20, P4040, DOI 10.1200/JCO.2002.02.118; Soden K, 2004, PALLIATIVE MED, V18, P87, DOI 10.1191/0269216304pm874oa; Solano JP, 2006, J PAIN SYMPTOM MANAG, V31, P58, DOI 10.1016/j.jpainsymman.2005.06.007; Song MK, 2005, MED CARE, V43, P1049, DOI 10.1097/01.mlr.0000178192.10283.b4; Song MK, 2004, NURS OUTLOOK, V52, P118, DOI 10.1016/j.outlook.2003.10.014; Sorensen S, 2002, GERONTOLOGIST, V42, P356, DOI 10.1093/geront/42.3.356; Soskis CW, 1997, SOC WORK HEALTH CARE, V25, P107, DOI 10.1300/J010v25n01_11; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Stephenson N L, 2000, Oncol Nurs Forum, V27, P67; Stuart Brad, 2003, J Palliat Med, V6, P671, DOI 10.1089/109662103768253849; Sultzer DL, 2001, J AM GERIATR SOC, V49, P1294, DOI 10.1046/j.1532-5415.2001.49256.x; Taylor SJC, 2005, BMJ-BRIT MED J, V331, P485, DOI 10.1136/bmj.38512.664167.8F; Teno J M, 2001, J Palliat Med, V4, P457, DOI 10.1089/109662101753381593; Teno JM, 2001, J PAIN SYMPTOM MANAG, V22, P752, DOI 10.1016/S0885-3924(01)00331-1; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; THOMAS K, 2004, CARING DYING HOME CO; Tolle SW, 1998, J AM GERIATR SOC, V46, P1097, DOI 10.1111/j.1532-5415.1998.tb06647.x; Tolle SW, 2000, NURS RES, V49, P310, DOI 10.1097/00006199-200011000-00003; Treece PD, 2004, CRIT CARE MED, V32, P1141, DOI 10.1097/01.CCM.0000125509.34805.0C; Tremont-Lukats IW, 2005, ANESTH ANALG, V101, P1738, DOI 10.1213/01.ANE.0000186348.86792.38; Walsh RA, 1998, BEHAV MED, V24, P61, DOI 10.1080/08964289809596382; Walsh SM, 2003, CANCER NURS, V26, P448; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Weiner P, 1999, CLIN CARDIOL, V22, P727, DOI 10.1002/clc.4960221110; Weisbord SD, 2003, NEPHROL DIAL TRANSPL, V18, P1345, DOI 10.1093/ndt/gfg105; Wenrich MD, 2003, J PAIN SYMPTOM MANAG, V25, P236, DOI 10.1016/S0885-3924(02)00694-2; Wilcock A, 2004, PALLIATIVE MED, V18, P287, DOI 10.1191/0269216304pm895oa; Wilkinson EK, 1999, PALLIATIVE MED, V13, P197, DOI 10.1191/026921699673563105; Wilkinson S, 1999, PALLIATIVE MED, V13, P409, DOI 10.1191/026921699678148345; WILSON DM, 2004, SYSTEMATIC REV END L; Windham BG, 2003, AM J MANAG CARE, V9, P447; Yin T, 2002, NURS RES, V51, P199, DOI 10.1097/00006199-200205000-00009; [No title captured]	150	398	407	1	195	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	2008	148	2					147	159		10.7326/0003-4819-148-2-200801150-00010	http://dx.doi.org/10.7326/0003-4819-148-2-200801150-00010			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	254NZ	18195339				2023-01-03	WOS:000252594600008
J	Millum, J; Emanuel, EJ				Millum, Joseph; Emanuel, Ezekiel J.			Ethics - The ethics of international research with abandoned children	SCIENCE			English	Editorial Material							CLINICAL-RESEARCH; TRIALS; TRANSMISSION; CARE		NIH, Dept Bioeth, Ctr Clin, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Emanuel, EJ (corresponding author), NIH, Dept Bioeth, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.	eemanuel@cc.nih.gov			Intramural NIH HHS [Z99 CL999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; Annas GJ, 1998, AM J PUBLIC HEALTH, V88, P560, DOI 10.2105/AJPH.88.4.560; CHRISTAKIS NA, 1988, HASTINGS CENT REP, V18, P35; Council for International Organizations of Medical Sciences WHO, 2002, INT ETH GUID BIOM RE; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; Levine C, 2004, HASTINGS CENT REP, V34, P17, DOI 10.2307/3528172; Lie RK, 2004, J MED ETHICS, V30, P190, DOI 10.1136/jme.2003.006031; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; Miller FG, 2003, HASTINGS CENT REP, V33, P19, DOI 10.2307/3528434; Nelson CA, 2007, SCIENCE, V318, P1937, DOI 10.1126/science.1143921; PACE C, 2003, SCIDEVNET       0828; Richardson HS, 2004, HASTINGS CENT REP, V34, P25, DOI 10.2307/3528248; U.S. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1979, BELM REP ETH GUID PR; Wertheimer Alan, 1999, EXPLOITATION, P10	14	58	58	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 21	2007	318	5858					1874	1875		10.1126/science.1153822	http://dx.doi.org/10.1126/science.1153822			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	243HE	18096792	Green Accepted, Green Submitted			2023-01-03	WOS:000251786600041
J	Koes, BW				Koes, Bart W.			Evidence-based management of acute low back pain	LANCET			English	Editorial Material							EUROPEAN GUIDELINES; PRIMARY-CARE		Erasmus Univ, Med Ctr, Dept Gen Practice, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Koes, BW (corresponding author), Erasmus Univ, Med Ctr, Dept Gen Practice, NL-3000 DR Rotterdam, Netherlands.	b.koes@erasmusmc.nl	Koes, Bart w/K-4614-2016	Koes, Bart w/0000-0002-0450-9969				Airaksinen O, 2006, EUR SPINE J, V15, pS192, DOI 10.1007/s00586-006-1072-1; Assendelft WJJ, 2003, ANN INTERN MED, V138, P871, DOI 10.7326/0003-4819-138-11-200306030-00008; Hancock MJ, 2007, LANCET, V370, P1638, DOI 10.1016/S0140-6736(07)61686-9; Koes BW, 2006, BMJ-BRIT MED J, V332, P1430, DOI 10.1136/bmj.332.7555.1430; Koes BW, 2001, SPINE, V26, P2504, DOI 10.1097/00007632-200111150-00022; van Tulder M, 2006, EUR SPINE J, V15, pS169, DOI 10.1007/s00586-006-1071-2; van Tulder MW, 2000, SPINE, V25, P2501, DOI 10.1097/00007632-200010010-00013; COCHRANE LIB COCHRAN	8	9	9	1	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 10	2007	370	9599					1595	1596		10.1016/S0140-6736(07)61670-5	http://dx.doi.org/10.1016/S0140-6736(07)61670-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230NO	17993348				2023-01-03	WOS:000250883400007
J	Reddy, M; Gill, SS; Kalkar, SR; Wu, W; Anderson, PJ; Rochon, PA				Reddy, Madhuri; Gill, Sudeep S.; Kalkar, Sunila R.; Wu, Wei; Anderson, Peter J.; Rochon, Paula A.			Oral drug therapy for multiple neglected tropical diseases - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							TRANSMITTED HELMINTH INFECTIONS; INTESTINAL NEMATODE INFECTIONS; RANDOMIZED CONTROLLED-TRIALS; WUCHERERIA-BANCROFTI; TRICHURIS-TRICHIURA; PYRANTEL PAMOATE; CLINICAL-TRIALS; ALBENDAZOLE; MEBENDAZOLE; EFFICACY	Context The neglected tropical diseases include 13 conditions that occur in areas of extreme poverty and are poverty promoting. The neglected tropical diseases produce a disease burden almost as great as that associated with human immunodeficiency virus/AIDS, tuberculosis, or malaria, yet are virtually unknown by health care workers in North America, because they occur almost exclusively in the poorest regions of the world. Seven of the most prevalent diseases have existing oral drug treatments. Identifying treatments that are effective against more than 1 disease could facilitate efficient and inexpensive treatment. Objectives To systematically review the evidence for drug treatments and to increase awareness that neglected tropical diseases exist and that treatments are available. Data Sources and Study Selection Using a MEDLINE search ( 1966 through June 2007), randomized controlled trials (RCTs) were reviewed that examined simultaneous treatment of 2 or more of the 7 most prevalent neglected tropical diseases using oral drug therapy. Data Synthesis Twenty-nine RCTs were identified, of which 3 targeted 4 diseases simultaneously, 20 targeted 3 diseases, and 6 targeted 2 diseases. Trials were published between 1972 and 2005 and baseline prevalence of individual diseases varied among RCTs. Albendazole plus diethylcarbamazine significantly reduced prevalence of elephantiasis (16.7% to 5.3%), hookworm (10.3% to 1.9%), roundworm (34.5% to 2.3%), and whipworm (55.5% to 40.3%). Albendazole plus ivermectin significantly reduced prevalence of elephantiasis (12.6% to 4.6%), hookworm (7.8% to 0%), roundworm (33.5% to 6.1%), and whipworm (42.7% to 8.9%). Levamisole plus mebendazole significantly reduced prevalence of hookworm (94.0% to 71.8%), roundworm (62.0% to 1.4%), and whipworm (93.1% to 74.5%). Pyrantel-oxantel significantly reduced hookworm (93.4% to 85.2%), roundworm (22.8% to 1.4%), and whipworm (86.8% to 59.5%), while albendazole alone significantly reduced prevalence of hookworm (8.1% to 1.3%), roundworm (28.4% to 0.9%), and whipworm (51.9% to 31.9%). No RCT examined treatment of river blindness or trachoma as part of an intervention to target 2 or more neglected tropical diseases. Adverse events were generally inadequately reported. Conclusions At least 2 of the most prevalent neglected tropical diseases can be treated simultaneously with existing oral drug treatments, facilitating effective and efficient treatment. Increasing awareness about neglected tropical diseases, their global impact, and the availability of oral drug treatments is an essential step in controlling these diseases.	Hebrew Rehabil Ctr, Dept Med, Boston, MA 02131 USA; Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02215 USA; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Epidemiol & Community Hlth, Kingston, ON K7L 3N6, Canada; Univ Toronto, Baycrest Kunin Lunenfeld Appl Res Unit, Dept Med, Toronto, ON, Canada; Inst Clin Evaluat Sci, Toronto, ON, Canada	Harvard University; Beth Israel Deaconess Medical Center; Queens University - Canada; Queens University - Canada; University of Toronto; University Toronto Affiliates; Baycrest; University of Toronto	Reddy, M (corresponding author), Hebrew Rehabil Ctr, Dept Med, 1200 Ctr St, Boston, MA 02131 USA.	madhurireddy@hrca.harvard.edu	Rochon, Paula A/J-2918-2016	Rochon, Paula A/0000-0002-5973-4151; Wu, Wei/0000-0002-9633-4122				Albonico M, 2004, INT J PARASITOL, V34, P1205, DOI 10.1016/j.ijpara.2004.08.001; Albonico M, 2003, B WORLD HEALTH ORGAN, V81, P343; Albonico M, 2002, T ROY SOC TROP MED H, V96, P685, DOI 10.1016/S0035-9203(02)90352-4; ALBONICO M, 1995, T ROY SOC TROP MED H, V89, P538, DOI 10.1016/0035-9203(95)90101-9; ALBONICO M, 1994, T ROY SOC TROP MED H, V88, P585, DOI 10.1016/0035-9203(94)90174-0; Albonico M, 1999, INT J EPIDEMIOL, V28, P591, DOI 10.1093/ije/28.3.591; [Anonymous], CONTR NEGL TROP DIS; *B M GAT FDN, LEAD GLOB HLTH ORG R; Balk EM, 2002, JAMA-J AM MED ASSOC, V287, P2973, DOI 10.1001/jama.287.22.2973; Barry M, 2007, NEW ENGL J MED, V356, P2561, DOI 10.1056/NEJMp078089; BARTOLONI A, 1993, TROP GEOGR MED, V45, P114; Beach MJ, 1999, AM J TROP MED HYG, V60, P479, DOI 10.4269/ajtmh.1999.60.479; BEHNKE JM, 1994, J HELMINTHOL, V68, P187, DOI 10.1017/S0022149X00014334; Belizario VY, 2003, B WORLD HEALTH ORGAN, V81, P35; Beller EM, 2002, MED J AUSTRALIA, V177, P565, DOI 10.5694/j.1326-5377.2002.tb04955.x; Bundy D. A. P., 1992, World Health Statistics Quarterly, V45, P168; Canning D, 2006, T ROY SOC TROP MED H, V100, P499, DOI 10.1016/j.trstmh.2006.02.001; CHAN M, WHO GLOB PARTN M NEG; Charoenlarp Pricha, 1993, Southeast Asian Journal of Tropical Medicine and Public Health, V24, P712; Chirac P, 2006, LANCET, V367, P1560, DOI 10.1016/S0140-6736(06)68672-8; de Silva NR, 2003, TRENDS PARASITOL, V19, P547, DOI 10.1016/j.pt.2003.10.002; Devereaux PJ, 2001, JAMA-J AM MED ASSOC, V285, P2000, DOI 10.1001/jama.285.15.2000; Druilhe P, 2005, TRENDS PARASITOL, V21, P359, DOI 10.1016/j.pt.2005.06.011; Egger M, 2003, Health Technol Assess, V7, P1; EHRENBERG JP, BMC PUBLIC HLTH, V5; FARAHMANDIAN I, 1977, CHEMOTHERAPY, V23, P98, DOI 10.1159/000221977; Fenwick A, 2005, LANCET, V365, P1029, DOI 10.1016/s0140-6736(05)71134-x; Fincham JE, 2003, ACTA TROP, V86, P315, DOI 10.1016/S0001-706X(03)00063-9; Fox LM, 2005, AM J TROP MED HYG, V73, P115, DOI 10.4269/ajtmh.2005.73.115; Gebski VJ, 2001, MED J AUSTRALIA, V175, P272, DOI 10.5694/j.1326-5377.2001.tb143565.x; *GLOB NETW NEGL TR, CONTR NTDS; Greene WL, 2000, ANN INTERN MED, V132, P715, DOI 10.7326/0003-4819-132-9-200005020-00006; HALL A, 1994, T ROY SOC TROP MED H, V88, P110, DOI 10.1016/0035-9203(94)90525-8; HOANG TK, 1993, MED PARAZITOL MOSK, V2, P27; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; Hopkins DR, 2005, AM J TROP MED HYG, V73, P669, DOI 10.4269/ajtmh.2005.73.669; Hotez P, 2005, LANCET, V365, P2089, DOI 10.1016/S0140-6736(05)66730-X; Hotez P, 2006, ADV EXP MED BIOL, V582, P23; Hotez PJ, 2007, NEW ENGL J MED, V357, P1018, DOI 10.1056/NEJMra064142; Hotez PJ, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P467; Hotez PJ, 2006, PLOS MED, V3, P576, DOI 10.1371/journal.pmed.0030102; Hotez PJ, 2004, NEW ENGL J MED, V351, P799, DOI 10.1056/NEJMra032492; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V285, P437, DOI 10.1001/jama.285.4.437; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JANCLOES MF, 1979, TROP GEOGR MED, V31, P111; Jongsuksuntigul Praphasri, 1993, Southeast Asian Journal of Tropical Medicine and Public Health, V24, P724; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Juni P, 2002, JAMA-J AM MED ASSOC, V288, P2407; Kaul S, 2006, ANN INTERN MED, V145, P62, DOI 10.7326/0003-4819-145-1-200607040-00011; KRISTOF ND, 2007, NY TIMES        0702; Leach AJ, 1997, CLIN INFECT DIS, V24, P356, DOI 10.1093/clinids/24.3.356; Legesse M, 2004, East Afr Med J, V81, P134; Legesse M, 2002, ETHIOPIAN MED J, V40, P335; Lietman TM, 2006, LANCET, V367, P395, DOI 10.1016/S0140-6736(06)68134-8; LUCAS AO, 1972, ANN TROP MED PARASIT, V66, P391, DOI 10.1080/00034983.1972.11686840; Marti H, 1996, AM J TROP MED HYG, V55, P477, DOI 10.4269/ajtmh.1996.55.477; Molyneux DH, 2005, PLOS MED, V2, P1064, DOI 10.1371/journal.pmed.0020336; Montori VM, 2001, CAN MED ASSOC J, V165, P1339; Muchiri EM, 2001, J PARASITOL, V87, P413, DOI 10.1645/0022-3395(2001)087[0413:ACSODA]2.0.CO;2; Olds GR, 1999, J INFECT DIS, V179, P996, DOI 10.1086/314686; Ortiz JJ, 2002, T ROY SOC TROP MED H, V96, P193, DOI 10.1016/S0035-9203(02)90301-9; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; PENE P, 1982, AM J TROP MED HYG, V31, P263, DOI 10.4269/ajtmh.1982.31.263; PENE P, 1981, B SOC PATHOL EXOT, V74, P590; Pildal J, 2005, BMJ-BRIT MED J, V330, P1049, DOI 10.1136/bmj.38414.422650.8F; Rahman Wahab A., 1996, Southeast Asian Journal of Tropical Medicine and Public Health, V27, P765; Rochon PA, 2004, CAN MED ASSOC J, V170, P1673, DOI 10.1503/cmaj.1031006; ROSSIGNOL JF, 1983, T ROY SOC TROP MED H, V77, P707, DOI 10.1016/0035-9203(83)90211-0; Sachs J. D., 2005, END POVERTY EC POSSI; Sachs JD, 2005, LANCET, V365, P347, DOI 10.1016/S0140-6736(05)70201-4; Sachs Jeffrey D, 2007, Sci Am, V296, p33A; Savioli L, 2003, AM J OBSTET GYNECOL, V188, P5, DOI 10.1067/mob.2003.78; *SCHIST CONTR IN, INT MASS TREATM NEGL; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SIMEON DT, 1995, J NUTR, V125, P1875, DOI 10.1093/jn/125.7.1875; SINNIAH B, 1981, ANN TROP MED PARASIT, V75, P315, DOI 10.1080/00034983.1981.11687445; Sorensen Eigil, 1996, Ceylon Medical Journal, V41, P42; SRIDHARAN R, LEPROSY; STEPHENSON LS, 1989, AM J TROP MED HYG, V41, P436, DOI 10.4269/ajtmh.1989.41.436; Sundar S, 2007, NEW ENGL J MED, V356, P2571, DOI 10.1056/NEJMoa066536; Utzinger J, 2006, PLOS MED, V3, P585, DOI 10.1371/journal.pmed.0030112; Verhagen AP, 2001, J CLIN EPIDEMIOL, V54, P651, DOI 10.1016/S0895-4356(00)00360-7; WESCHE D, 1994, PAPUA NEW GUINEA MED, V37, P7; WESCHE D, 1994, PAPUA NEW GUINEA MED, V37, P12; WHO, TRACH; *WHO, GOAL 6 COMM DIS PREV; *WHO, 1994, WHO INF CONS HOOKW I; *WHO, 2002, WHO INF CONS US PRAZ; WHO, AFR TRYP SLEEP SICKN; *WHO DEP CONTR NEG, NEGL TROP DIS HIDD S; World Health Organization, PREV CHEM HUM HELM; Xia Z H, 1992, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V10, P279; Yamey G, 2007, BMJ-BRIT MED J, V335, P269, DOI 10.1136/bmj.39281.645035.80; Yang YP, 2004, PROG SAFETY SCI TECH, V4, P285; Zu L Q, 1992, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V10, P95; 2007, LANCET, V369, P1404	97	75	76	2	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 24	2007	298	16					1911	1924		10.1001/jama.298.16.1911	http://dx.doi.org/10.1001/jama.298.16.1911			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223GC	17954542				2023-01-03	WOS:000250356700023
J	Mangione-Smith, R; DeCristofaro, AH; Setodji, CM; Keesey, J; Klein, DJ; Adams, JL; Schuster, MA; McGlynn, EA				Mangione-Smith, Rita; DeCristofaro, Alison H.; Setodji, Claude M.; Keesey, Joan; Klein, David J.; Adams, John L.; Schuster, Mark A.; McGlynn, Elizabeth A.			The quality of ambulatory care delivered to children in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							URINARY-TRACT-INFECTION; YOUNG-CHILDREN; MEDICAL-RECORDS; FEBRILE INFANTS; MANAGED CARE; ASTHMA; CONSISTENCY; PREVALENCE; PREVENTION; EMERGENCY	Background Little is known about the magnitude of deficits in the quality of care delivered to children, since comprehensive studies have been lacking. Methods We assessed the extent to which care processes recommended for pediatric outpatients are delivered. Quality indicators were developed with the use of the RAND-UCLA modified Delphi method. Parents of 1536 children who were randomly selected from 12 metropolitan areas provided written informed consent to obtain medical records from all providers who had seen the children during the 2-year period before the date of study recruitment. Trained nurses abstracted these medical records. Composite quality scores were calculated by dividing the number of times indicated care was documented as having been ordered or delivered by the number of times a care process was indicated. Results On average, according to data in the medical records, children in the study received 46.5% (95% confidence interval [CI], 44.5 to 48.4) of the indicated care. They received 67.6% (95% CI, 63.9 to 71.3) of the indicated care for acute medical problems, 53.4% (95% CI, 50.0 to 56.8) of the indicated care for chronic medical conditions, and 40.7% (95% CI, 38.1 to 43.4) of the indicated preventive care. Quality varied according to the clinical area, with the rate of adherence to indicated care ranging from 92.0% (95% CI, 89.9 to 94.1) for upper respiratory tract infections to 34.5% (95% CI, 31.0 to 37.9) for preventive services for adolescents. Conclusions Deficits in the quality of care provided to children appear to be similar in magnitude to those previously reported for adults. Strategies to reduce these apparent deficits are needed.	Univ Washington, Inst Child Hlth, Dept Pediat, Seattle, WA 98115 USA; Childrens Hosp & Reg Med Ctr, Seattle, WA USA; RAND Corp, Santa Monica, CA USA; Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA 90024 USA	University of Washington; University of Washington Seattle; Seattle Children's Hospital; RAND Corporation; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Mangione-Smith, R (corresponding author), Univ Washington, Inst Child Hlth, Dept Pediat, 6200 NE 74th St,Suite 210, Seattle, WA 98115 USA.	ritams@u.washington.edu	Adams, John/ABE-6170-2021					Adams RJ, 2001, PEDIATRICS, V107, P706, DOI 10.1542/peds.107.4.706; Adams RJ, 2001, ARCH PEDIAT ADOL MED, V155, P501, DOI 10.1001/archpedi.155.4.501; *AG HEALTHC RES QU, 2007, NAT HEALTHC QUAL REP; Baker JW, 1999, PEDIATRICS, V103, P414, DOI 10.1542/peds.103.2.414; Battleman DS, 2001, ACAD EMERG MED, V8, P709, DOI 10.1111/j.1553-2712.2001.tb00189.x; Bergman DA, 1999, PEDIATRICS, V103, P843; Bethell C, 2004, PEDIATRICS, V113, P1973; Brook RH., 1994, RAND UCLA APPROPRIAT; Caione P, 2004, BJU INT, V93, P1309, DOI 10.1111/j.1464-410X.04866.x; *CDCP, 2004, CHLAM CDC FACT SHEET; Centers of Disease Control and Prevention, 2000, SEX TRANSM DIS SURV; Christakis DA, 2001, AMBUL PEDIATR, V1, P99, DOI 10.1367/1539-4409(2001)001<0099:CAQOCF>2.0.CO;2; Diette GB, 2001, J PEDIATR-US, V138, P59, DOI 10.1067/mpd.2001.109600; Finkelstein JA, 2002, ARCH PEDIAT ADOL MED, V156, P562, DOI 10.1001/archpedi.156.6.562; Gest KL, 2000, PEDIATRICS, V106, P879; Hemingway H, 2001, NEW ENGL J MED, V344, P645, DOI 10.1056/NEJM200103013440906; HOBERMAN A, 1993, J PEDIATR-US, V123, P17, DOI 10.1016/S0022-3476(05)81531-8; *I MED, 1999, TO ERR IS HUM BUILD; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; Kemper P, 1996, INQUIRY-J HEALTH CAR, V33, P195; Kravitz RL, 1997, HEALTH POLICY, V42, P135, DOI 10.1016/S0168-8510(97)00064-X; Landon BE, 2006, ARCH INTERN MED, V166, P2511, DOI 10.1001/archinte.166.22.2511; McDermott MF, 2006, ACAD EMERG MED, V13, P345, DOI 10.1197/j.aem.2005.09.006; McGlynn E, 2000, QUALITY CARE CHILDRE; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; MCGLYNN EAD, 2007, QUALITY CARE CHILDRE; *NAT COMM QUAL ASS, 2005, 33 NAT COMM QUAL ASS; ROBERTS KB, 1983, J PEDIATR-US, V103, P864, DOI 10.1016/S0022-3476(83)80702-1; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103; Shafer MAB, 2002, JAMA-J AM MED ASSOC, V288, P2846, DOI 10.1001/jama.288.22.2846; Shekelle PG, 1998, INT J TECHNOL ASSESS, V14, P707, DOI 10.1017/S0266462300012022; Stange KC, 1998, MED CARE, V36, P851, DOI 10.1097/00005650-199806000-00009; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; *US BUR CENS, 2001, CURR POP SURV; Warman KL, 2001, PEDIATRICS, V108, P277, DOI 10.1542/peds.108.2.277; Wenger NS, 2003, ANN INTERN MED, V139, P740, DOI 10.7326/0003-4819-139-9-200311040-00008; ZUCKERMAN AE, 1975, PEDIATRICS, V56, P407; Zuckerman B, 2004, PEDIATRICS, V114, P1522, DOI 10.1542/peds.2004-0635; [No title captured], DOI DOI 10.2307/2529310	40	434	436	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 11	2007	357	15					1515	1523		10.1056/NEJMsa064637	http://dx.doi.org/10.1056/NEJMsa064637			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	218TE	17928599	Bronze			2023-01-03	WOS:000250037000008
J	Szczurko, O; Cooley, K; Busse, JW; Seely, D; Bernhardt, B; Guyatt, GH; Zhou, Q; Mills, EJ				Szczurko, Orest; Cooley, Kieran; Busse, Jason W.; Seely, Dugald; Bernhardt, Bob; Guyatt, Gordon H.; Zhou, Qi; Mills, Edward J.			Naturopathic Care for Chronic Low Back Pain: A Randomized Trial	PLOS ONE			English	Article								Objective. Chronic low back pain represents a substantial cost to employers through benefits coverage and days missed due to incapacity. We sought to explore the effectiveness of Naturopathic care on chronic low back pain. Methods. This study was a randomized clinical trial. We randomized 75 postal employees with low back pain of longer than six weeks duration to receive Naturopathic care (n = 39) or standardized physiotherapy (n = 36) over a period of 12 weeks. The study was conducted in clinics on-site in postal outlets. Participants in the Naturopathic care group received dietary counseling, deep breathing relaxation techniques and acupuncture. The control intervention received education and instruction on physiotherapy exercises using an approved education booklet. We measured low back pain using the Oswestry disability questionnaire as the primary outcome measure, and quality of life using the SF-36 in addition to low back range of motion, weight loss, and Body Mass Index as secondary outcomes. Results. Sixty-nine participants (92%) completed eight weeks or greater of the trial. Participants in the Naturopathic care group reported significantly lower back pain (-6.89, 95% CI. -9.23 to -3.54, p=<0.0001) as measured by the Oswestry questionnaire. Quality of life was also significantly improved in the group receiving Naturopathic care in all domains except for vitality. Differences for the aggregate physical component of the SF-36 was 8.47 (95% CI, 5.05 to 11.87, p=<0.0001) and for the aggregate mental component was 7.0 (95% CI, 2.25 to 11.75, p=0.0045). All secondary outcomes were also significantly improved in the group receiving Naturopathic care: spinal flexion (p<0.0001), weight-loss (p=0.0052) and Body Mass Index (20.52, 95% CI, -0.96 to -0.08, p=0.01). Conclusions. Naturopathic care provided significantly greater improvement than physiotherapy advice for patients with chronic low back pain. Trial Registration. Controlled-Trials.com ISRCTN41920953	[Busse, Jason W.; Guyatt, Gordon H.; Zhou, Qi; Mills, Edward J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Szczurko, Orest; Cooley, Kieran; Seely, Dugald; Bernhardt, Bob] Canadian Coll Naturopath Med, Div Clin Epidemiol, Toronto, ON, Canada	McMaster University	Mills, EJ (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.	millsej@mcmaster.ca	Zhou, Qi/GSM-9583-2022; Cooley, Kieran/L-3080-2019; Busse, Jason/CAH-3696-2022	Cooley, Kieran/0000-0001-7960-6504; Busse, Jason/0000-0002-0178-8712	Canada Post Corporation; Canadian Union of Postal Workers	Canada Post Corporation; Canadian Union of Postal Workers	Funding was provided by the Canada Post Corporation and Canadian Union of Postal Workers.	Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140-6736(99)01312-4; Bombardier C, 2001, J RHEUMATOL, V28, P431; Boon Heather S, 2004, BMC Complement Altern Med, V4, P14, DOI 10.1186/1472-6882-4-14; Cherkin Daniel C, 2002, J Am Board Fam Pract, V15, P463; Cherkin DC, 1998, NEW ENGL J MED, V339, P1021, DOI 10.1056/NEJM199810083391502; Frost H, 2004, BRIT MED J, V329, P708, DOI 10.1136/bmj.38216.868808.7C; Goetzel RZ, 2003, J OCCUP ENVIRON MED, V45, P5, DOI 10.1097/00043764-200301000-00007; Goldby LJ, 2006, SPINE, V31, P1083, DOI 10.1097/01.brs.0000216464.37504.64; Hopman WM, 2000, CAN MED ASSOC J, V163, P265; Jonas WB, 1998, JAMA-J AM MED ASSOC, V280, P1616, DOI 10.1001/jama.280.18.1616; Lind BK, 2005, SPINE, V30, P1454, DOI 10.1097/01.brs.0000166527.18442.10; Maetzel A, 2002, BEST PRACT RES CL RH, V16, P23, DOI 10.1053/berh.2001.0204; Manheimer E, 2005, ANN INTERN MED, V142, P651, DOI 10.7326/0003-4819-142-8-200504190-00014; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; Schulz KF, 2002, LANCET, V359, P696, DOI 10.1016/S0140-6736(02)07816-9; STRATFORD PW, 1994, PHYS THER, V74, P528, DOI 10.1093/ptj/74.6.528; Udermann Brian E, 2004, Spine J, V4, P425, DOI 10.1016/j.spinee.2004.01.016	17	23	23	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2007	2	9							e919	10.1371/journal.pone.0000919	http://dx.doi.org/10.1371/journal.pone.0000919			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HS	17878954	Green Submitted, Green Published, gold			2023-01-03	WOS:000207455700027
J	Donohue, JM; Cevasco, M; Rosenthal, MB				Donohue, Julie M.; Cevasco, Marisa; Rosenthal, Meredith B.			A decade of direct-to-consumer advertising of prescription drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROMOTION; CHOICE	Background: Evidence suggests that direct-to-consumer advertising of prescription drugs increases pharmaceutical sales and both helps to avert underuse of medicines and leads to potential overuse. Concern about such advertising has increased recently owing to the withdrawal from the market of heavily advertised drugs found to carry serious risks. Moreover, the Food and Drug Administration (FDA) has been criticized for its weak enforcement of laws regulating such advertising. Methods: We examined industry-wide trends in spending by pharmaceutical companies on direct-to-consumer advertising and promotion to physicians during the past decade. We characterized the drugs for which such advertising is used and assessed the timing of advertising after a drug is introduced. Finally, we examined trends in the FDA's regulation of drug advertising. Results: Total spending on pharmaceutical promotion grew from $11.4 billion in 1996 to $29.9 billion in 2005. Although during that time spending on direct-to-consumer advertising increased by 330%, it made up only 14% of total promotional expenditures in 2005. Direct-to-consumer campaigns generally begin within a year after the approval of a product by the FDA. In the context of regulatory changes requiring legal review before issuing letters, the number of letters sent by the FDA to pharmaceutical manufacturers regarding violations of drug-advertising regulations fell from 142 in 1997 to only 21 in 2006. Conclusions: Spending on direct-to-consumer advertising has continued to increase in recent years in spite of the criticisms leveled against it. Our findings suggest that calls for a moratorium on such advertising for new drugs would represent a dramatic departure from current practices.	Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard T.H. Chan School of Public Health; Vanderbilt University	Donohue, JM (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Crabtree Hall A613,130 DeSoto St, Pittsburgh, PA 15261 USA.	jdonohue@pitt.edu		Rosenthal, Meredith/0000-0003-3410-0184; Donohue, Julie/0000-0003-2418-6017	NCRR NIH HHS [KL2-RR024154-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024154] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Angell M., 2004, TRUTH DRUG CO; ARNOLD M, 2006, MED MARKETING ME APR, P38; BACIU A, 2006, FUTURE DRUG SAFETY P; Berndt ER, 2002, J ECON PERSPECT, V16, P45, DOI 10.1257/089533002320950975; Bradford WD, 2006, HEALTH AFFAIR, V25, P1371, DOI 10.1377/hlthaff.25.5.1371; Cassels A, 2006, BRIT MED J, V332, P1469, DOI 10.1136/bmj.332.7556.1469-a; Donohue JM, 2004, J PUBLIC POLICY MARK, V23, P115, DOI 10.1509/jppm.23.2.115.51395; Donohue JM, 2004, MED CARE, V42, P1176, DOI 10.1097/00005650-200412000-00004; DONOHUE JM, 2006, INT J PHARM MED, V20, P17; *GEN ACC OFF, 2002, FDA OV DIR TO CONS A; Gonul FF, 2001, J MARKETING, V65, P79, DOI 10.1509/jmkg.65.3.79.18329; *GOV ACC OFF, 2006, PRESCR DRUGS IMPR NE; Hollon MF, 2005, JAMA-J AM MED ASSOC, V293, P2030, DOI 10.1001/jama.293.16.2030; Iizuka T, 2005, J ECON MANAGE STRAT, V14, P701, DOI 10.1111/j.1530-9134.2005.00079.x; Iizuka T, 2004, J IND ECON, V52, P349, DOI 10.1111/j.0022-1821.2004.00230.x; Kravitz RL, 2005, JAMA-J AM MED ASSOC, V294, P2436; Kravitz RL, 2005, JAMA-J AM MED ASSOC, V293, P1995, DOI 10.1001/jama.293.16.1995; *PHARM RES MAN AM, 2005, PHRMA GUID PRINC DIR; Pines WL, 1999, FOOD DRUG LAW J, V54, P489; Risso JA, 1999, J LAW ECON, V42, P89; Rosenthal MB, 2002, NEW ENGL J MED, V346, P498, DOI 10.1056/NEJMsa012075; Rosenthal MB, 2003, FRONTIERS HLTH POLIC, V6, P1; SAUL S, 2005, NY TIMES        0702, pC13; Watson Rory, 2003, BMJ, V326, P1284, DOI 10.1136/bmj.326.7402.1284-b; Wolfe SM, 2002, NEW ENGL J MED, V346, P1424; ELECT ORANGE BOOK AP	26	340	344	3	60	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 16	2007	357	7					673	681		10.1056/NEJMsa070502	http://dx.doi.org/10.1056/NEJMsa070502			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	200EF	17699817				2023-01-03	WOS:000248746000007
J	Koopman, M; Antonini, NF; Douma, J; Wals, J; Honkoop, AH; Erdkamp, FLG; de Jong, RS; Rodenburg, CJ; Vreugdenhil, G; Loosveld, OJL; van Bochove, A; Sinnige, HAM; Creemers, GJM; Tesselaar, MET; Slee, PHTJ; Werter, MJBP; Mol, L; Dalesio, O; Punt, CJA				Koopman, Miriam; Antonini, Ninja F.; Douma, Joep; Wals, Jaap; Honkoop, Aafke H.; Erdkamp, Frans L. G.; de Jong, Robert S.; Rodenburg, Cees J.; Vreugdenhil, Gerard; Loosveld, Olaf J. L.; van Bochove, Aart; Sinnige, Harm A. M.; Creemers, Geert-Jan M.; Tesselaar, Margot E. T.; Slee, Peter H. Th J.; Werter, Marjon J. B. P.; Mol, Linda; Dalesio, Otilia; Punt, Cornelis J. A.			Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial	LANCET			English	Article							FLUOROURACIL PLUS LEUCOVORIN; 2 DIFFERENT SCHEDULES; 1ST-LINE TREATMENT; ORAL CAPECITABINE; MULTICENTER; CELECOXIB; THERAPY; FOLFIRI	Background The optimum use of cytotoxic drugs for advanced colorectal cancer has not been defined. Our aim was to investigate whether combination treatment is better than sequential administration of the same drugs in patients with advanced colorectal cancer. Methods We randomly assigned 820 patients with advanced colorectal cancer to receive either first-line treatment with capecitabine, second-line irinotecan, and third-line capecitabine plus oxaliplatin (sequential treatment; n=410) or first-line treatment capecitabine plus irinotecan and second-line capecitabine plus oxaliplatin (combination treatment; n=410). The primary endpoint was overall survival. Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov with the number NCT00312000. Findings 17 patients (nine in the sequential treatment group, eight in the combination group) were found to be ineligible and were excluded from the analysis. 675 (84%) patients died during the study: 336 in the sequential group and 339 in the combination group. Median overall survival was 16.3 (95% Cl 14.3-18.1) months for sequential treatment and 17.4 (15.2-19.2) months for combination treatment (p=0.3281). The hazard ratio for combination versus sequential treatment was 0.92 (95% Cl 0-79-1.08; p=0.3281). The frequency of grade 3-4 toxicity over all lines of treatment did not differ significantly between the two groups, except for grade 3 hand-foot syndrome, which occurred more often with sequential treatment than with combination treatment (13% vs 7%; p=0.004). Interpretation Combination treatment does not significantly improve overall survival compared with the sequential use of cytotoxic drugs in advanced colorectal cancer. Thus sequential treatment remains a valid option for patients with advanced colorectal cancer.	Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands; Netherlands Canc Inst, Biometr Dept, Amsterdam, Netherlands; Rijnstate Hosp, Arnhem, Netherlands; Atrium Med Ctr, Heerlen, Netherlands; Isala Hosp, Zwolle, Netherlands; Maasland Hosp, Sittard, Netherlands; Martini Hosp, Groningen, Netherlands; Meander Med Ctr, Amersfoort, Netherlands; Maxima Med Ctr, Veldhoven, Netherlands; Amphia Hosp, Breda, Netherlands; Zaans Med Ctr, Zaandam, Netherlands; Jeroen Bosch Hosp, Den Bosch, Netherlands; Catharina Hosp, Eindhoven, Netherlands; Leiden Univ, Med Ctr, Leiden, Netherlands; St Antonius Hosp, Nieuwegein, Netherlands; Viecuri Hosp, Venlo, Netherlands; Comprehens Canc Ctr E, Nijmegen, Netherlands	Radboud University Nijmegen; Netherlands Cancer Institute; Rijnstate Hospital; Atrium Medical Center; Maasland Hospital; Martini Hospital; Meander Medisch Centrum; Maxima Medical Center; Amphia Hospital; Jeroen Bosch Ziekenhuis; Catharina Hospital; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; St. Antonius Hospital Utrecht; VieCuri Medical Center	Punt, CJA (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	c.punt@onco.umcn.nl		Mol, Linda/0000-0002-4155-1605				Bajetta E, 2004, CANCER-AM CANCER SOC, V100, P279, DOI 10.1002/cncr.11910; Borner MM, 2005, ANN ONCOL, V16, P282, DOI 10.1093/annonc/mdi047; Borner MM, 2002, J CLIN ONCOL, V20, P1759, DOI 10.1200/JCO.2002.07.087; Colucci G, 2005, J CLIN ONCOL, V23, P4866, DOI 10.1200/JCO.2005.07.113; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Fuchs C, 2006, J CLIN ONCOL, V24, p147S; Grothey A, 2004, J CLIN ONCOL, V22, P1209, DOI 10.1200/JCO.2004.11.037; Haller DG, 2006, J CLIN ONCOL, V24, p149S; Hoff PM, 2001, J CLIN ONCOL, V19, P2282, DOI 10.1200/JCO.2001.19.8.2282; Kohne CH, 2005, J CLIN ONCOL, V23, p252S; Koopman M, 2006, ANN ONCOL, V17, P1523, DOI 10.1093/annonc/mdl179; Punt CJA, 2005, ANN ONCOL, V16, P845, DOI 10.1093/annonc/mdi196; Punt CJA, 2004, ANN ONCOL, V15, P1453, DOI 10.1093/annonc/mdh383; Rea DW, 2005, ANN ONCOL, V16, P1123, DOI 10.1093/annonc/mdi227; Rothenberg ML, 2003, J CLIN ONCOL, V21, P2059, DOI 10.1200/JCO.2003.11.126; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Seymour MT, 2007, LANCET, V370, P143, DOI 10.1016/S0140-6736(07)61087-3; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; Van Cutsem E, 2001, J CLIN ONCOL, V19, P4097, DOI 10.1200/JCO.2001.19.21.4097	22	511	518	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2007	370	9582					135	142		10.1016/S0140-6736(07)61086-1	http://dx.doi.org/10.1016/S0140-6736(07)61086-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190WP	17630036				2023-01-03	WOS:000248091600027
J	Bhargava, P; Longhi, LP				Bhargava, Parul; Longhi, Lorinda P.			Peripheral smear with Malassezia furfur	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Bhargava, P (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.	pbhargav@bidmc.harvard.edu							0	9	9	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 14	2007	356	24					E25	E25		10.1056/NEJMicm063672	http://dx.doi.org/10.1056/NEJMicm063672			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	178DR	17568022				2023-01-03	WOS:000247201900012
J	Wang, Q; Pang, YP				Wang, Qi; Pang, Yuan-Ping			Accurate Reproduction of 161 Small-Molecule Complex Crystal Structures using the EUDOC Program: Expanding the Use of EUDOC to Supramolecular Chemistry	PLOS ONE			English	Article							CHEMICAL DATABASE; DRUG-LEAD; INHIBITORS; IDENTIFICATION; QUINOXALINE; DISCOVERY; GENOME	EUDOC is a docking program that has successfully predicted small-molecule-bound protein complexes and identified drug leads from chemical databases. To expand the application of the EUDOC program to supramolecular chemistry, we tested its ability to reproduce crystal structures of small-molecule complexes. Of 161 selected crystal structures of small-molecule guest-host complexes, EUDOC reproduced all these crystal structures with guest structure mass-weighted root mean square deviations (mwRMSDs) of < 1.0 angstrom relative to the corresponding crystal structures. In addition, the average interaction energy of these 161 guest-host complexes (-50.1 kcal/mol) was found to be nearly half of that of 153 previously tested small-molecule-bound protein complexes (-108.5 kcal/mol), according to the interaction energies calculated by EUDOC. 31 of the 161 complexes could not be reproduced with mwRMSDs of < 1.0 angstrom if neighboring hosts in the crystal structure of a guest-host complex were not included as part of the multimeric host system, whereas two of the 161 complexes could not be reproduced with mwRMSDs of < 1.0 angstrom if water molecules were excluded from the host system. These results demonstrate the significant influence of crystal packing on small molecule complexation and suggest that EUDOC is able to predict small-molecule complexes and that it is useful for the design of new materials, molecular sensors, and multimeric inhibitors of protein-protein interactions.	[Wang, Qi; Pang, Yuan-Ping] Mayo Clin, Comp Aided Mol Design Lab, Rochester, MN 55905 USA	Mayo Clinic	Pang, YP (corresponding author), Mayo Clin, Comp Aided Mol Design Lab, Rochester, MN 55905 USA.	pang@mayo.edu		Pang, Yuan-Ping/0000-0003-0838-2560	U. S. Army Medical Research Acquisition Activity [W81XWH-04-2-0001]; National Institutes of Health [5R01AI054574-03]; Mayo Graduate School; Mayo Foundation for Medical Education and Research	U. S. Army Medical Research Acquisition Activity; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Graduate School; Mayo Foundation for Medical Education and Research	This work was supported by the U. S. Army Medical Research Acquisition Activity (W81XWH-04-2-0001), the National Institutes of Health (5R01AI054574-03), Mayo Graduate School, and the Mayo Foundation for Medical Education and Research.	Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890; CIEPLAK P, 1995, J COMPUT CHEM, V16, P1357, DOI 10.1002/jcc.540161106; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DESJARLAIS RL, 1990, P NATL ACAD SCI USA, V87, P6644, DOI 10.1073/pnas.87.17.6644; Dooley AJ, 2006, BIOORG MED CHEM LETT, V16, P830, DOI 10.1016/j.bmcl.2005.11.018; DUFFY EM, 1994, J AM CHEM SOC, V116, P6337, DOI 10.1021/ja00093a038; Eyal E, 2005, J MOL BIOL, V351, P431, DOI 10.1016/j.jmb.2005.05.066; Frisch M., 2016, GAUSSIAN 16, P3; LEHN JM, 1993, SCIENCE, V260, P1762, DOI 10.1126/science.8511582; Miller MA, 2002, NAT REV DRUG DISCOV, V1, P220, DOI 10.1038/nrd745; Pang YP, 2007, CLIN PHARMACOL THER, V81, P30, DOI 10.1038/sj.clpt.6100030; Pang YP, 2001, J COMPUT CHEM, V22, P1750, DOI 10.1002/jcc.1129; Pang YP, 2001, FEBS LETT, V502, P93, DOI 10.1016/S0014-5793(01)02672-2; PANG YP, 2007, IBM J RES D IN PRESS; Park JG, 2006, BIOORGAN MED CHEM, V14, P395, DOI 10.1016/j.bmc.2005.08.018; PASCAL RA, 1993, J AM CHEM SOC, V115, P8507, DOI 10.1021/ja00071a094; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Perola E, 2000, J MED CHEM, V43, P401, DOI 10.1021/jm990408a; Raves ML, 1997, NAT STRUCT BIOL, V4, P57, DOI 10.1038/nsb0197-57; REBEK J, 1986, J AM CHEM SOC, V108, P5637, DOI 10.1021/ja00278a052; Sun H, 2002, MOL PHARMACOL, V62, P220, DOI 10.1124/mol.62.2.220	21	14	14	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2007	2	6							e531	10.1371/journal.pone.0000531	http://dx.doi.org/10.1371/journal.pone.0000531			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GD	17565384	Green Submitted, Green Published, gold			2023-01-03	WOS:000207451600019
J	Roberts, PJ; Der, CJ				Roberts, P. J.; Der, C. J.			Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer	ONCOGENE			English	Review						mitogen-activated protein kinases; ERK; Ras; epidermal growth factor receptor; small molecule inhibitors; monoclonal antibodies	GROWTH-FACTOR RECEPTOR; SMALL-CELL LUNG; METASTATIC COLORECTAL-CANCER; FACIO-CUTANEOUS SYNDROME; REFRACTORY SOLID TUMORS; SIGNAL-REGULATED KINASE; HRAS MUTATION ANALYSIS; DAYS ON/7 DAYS; PHASE-I; COSTELLO-SYNDROME	Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in the regulation of normal cell proliferation, survival and differentiation. Aberrant regulation of MAPK cascades contribute to cancer and other human diseases. In particular, the extracellular signal-regulated kinase (ERK) MAPK pathway has been the subject of intense research scrutiny leading to the development of pharmacologic inhibitors for the treatment of cancer. ERK is a downstream component of an evolutionarily conserved signaling module that is activated by the Raf serine/threonine kinases. Raf activates the MAPK/ERK kinase (MEK) 1/2 dual-specificity protein kinases, which then activate ERK1/2. The mutational activation of Raf in human cancers supports the important role of this pathway in human oncogenesis. Additionally, the Raf-MEK-ERK pathway is a key downstream effector of the Ras small GTPase, the most frequently mutated oncogene in human cancers. Finally, Ras is a key downstream effector of the epidermal growth factor receptor (EGFR), which is mutationally activated and/or overexpressed in a wide variety of human cancers. ERK activation also promotes upregulated expression of EGFR ligands, promoting an autocrine growth loop critical for tumor growth. Thus, the EGFR-Ras-Raf-MEK-ERK signaling network has been the subject of intense research and pharmaceutical scrutiny to identify novel target-based approaches for cancer treatment. In this review, we summarize the current status of the different approaches and targets that are under evaluation and development for the therapeutic intervention of this key signaling pathway in human disease.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Der, CJ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, CB 7295, Chapel Hill, NC 27599 USA.	cjder@med.unc.edu		Der, Channing/0000-0002-7751-2747				Abi-Habib RJ, 2005, MOL CANCER THER, V4, P1303, DOI 10.1158/1535-7163.MCT-05-0145; Agus DB, 2005, J CLIN ONCOL, V23, P2534, DOI 10.1200/JCO.2005.03.184; Aoki Y, 2005, NAT GENET, V37, P1038, DOI 10.1038/ng1641; Arslan MA, 2006, CURR CANCER DRUG TAR, V6, P623, DOI 10.2174/156800906778742479; Awada A, 2005, BRIT J CANCER, V92, P1855, DOI 10.1038/sj.bjc.6602584; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890; Basso AD, 2006, J LIPID RES, V47, P15, DOI 10.1194/jlr.R500012-JLR200; Benson JD, 2006, NATURE, V441, P451, DOI 10.1038/nature04873; Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Bergo MO, 2002, MOL CELL BIOL, V22, P171, DOI 10.1128/MCB.22.1.171-181.2002; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Bergo MO, 2001, J BIOL CHEM, V276, P5841, DOI 10.1074/jbc.C000831200; Bier H, 1998, CANCER IMMUNOL IMMUN, V46, P167, DOI 10.1007/s002620050475; Bodart JF, 2002, CELL CYCLE, V1, P10, DOI 10.4161/cc.1.1.95; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; Carta C, 2006, AM J HUM GENET, V79, P129, DOI 10.1086/504394; Cheng KW, 2005, CANCER RES, V65, P2516, DOI 10.1158/0008-5472.CAN-05-0573; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Clarke S, 2004, J CLIN INVEST, V113, P513, DOI 10.1072/JCI200421059; Collisson EA, 2003, CANCER RES, V63, P5669; CORTES J, 2005, ASCO M, V22; Cox AD, 2002, CURR OPIN PHARMACOL, V2, P388, DOI 10.1016/S1471-4892(02)00181-9; Cox AD, 2002, CANCER BIOL THER, V1, P599, DOI 10.4161/cbt.306; Cripps MC, 2002, CLIN CANCER RES, V8, P2188; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davies M, 2006, EXPERT OPIN PHARMACO, V7, P2243, DOI 10.1517/14656566.7.16.2243; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEBONO JS, 2005, ASCO M, V22; Dias SD, 2005, CANCER RES, V65, P10686, DOI 10.1158/0008-5472.CAN-05-2632; DOI T, 2005, ASCO M, V22; Dominguez C, 2005, CURR OPIN DRUG DISC, V8, P421; Dritschilo A, 2006, CLIN CANCER RES, V12, P1251, DOI 10.1158/1078-0432.CCR-05-1260; DUESBERY N, 2006, SCI STKE; Duesbery NS, 2001, P NATL ACAD SCI USA, V98, P4089, DOI 10.1073/pnas.061031898; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Eisen T, 2006, BRIT J CANCER, V95, P581, DOI 10.1038/sj.bjc.6603291; ESCUDIER B, 2005, J CLIN ONCOL; Estep AL, 2006, AM J MED GENET A, V140A, P8, DOI 10.1002/ajmg.a.31078; Friess T, 2005, CLIN CANCER RES, V11, P5300, DOI 10.1158/1078-0432.CCR-04-2642; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; Gibson TB, 2006, CLIN COLORECTAL CANC, V6, P29, DOI 10.3816/CCC.2006.n.01; Gokhale PC, 2002, CLIN CANCER RES, V8, P3611; GORDON MS, 2005, ASCO M, V22; Grandis JR, 2004, PHARMACOL THERAPEUT, V102, P37, DOI 10.1016/j.pharmthera.2004.01.002; Grbovic OM, 2006, P NATL ACAD SCI USA, V103, P57, DOI 10.1073/pnas.0609973103; Gripp KW, 2006, AM J MED GENET A, V140A, P1, DOI 10.1002/ajmg.a.31047; Hahn W, 2006, CURR OPIN ONCOL, V18, P615, DOI 10.1097/01.cco.0000245316.82391.52; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hingorani SR, 2003, CANCER RES, V63, P5198; Hoeflich MP, 2006, CANCER RES, V66, P999, DOI 10.1158/0008-5472.CAN-05-2720; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Hynes J, 2005, CURR TOP MED CHEM, V5, P967, DOI 10.2174/1568026054985920; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jimeno A, 2006, BBA-REV CANCER, V1766, P217, DOI 10.1016/j.bbcan.2006.08.008; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kato-Stankiewicz J, 2002, P NATL ACAD SCI USA, V99, P14398, DOI 10.1073/pnas.222222699; Kerr B, 2006, J MED GENET, V43, P401, DOI 10.1136/jmg.2005.040352; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kortum RL, 2004, MOL CELL BIOL, V24, P4407, DOI 10.1128/MCB.24.10.4407-4416.2004; Lacouture ME, 2006, NAT REV CANCER, V6, P803, DOI 10.1038/nrc1970; Lancet JE, 2007, BLOOD, V109, P1387, DOI 10.1182/blood-2006-04-014357; LEE P, 2004, AACR M; Leung KF, 2006, J LIPID RES, V47, P467, DOI 10.1194/jlr.R500017-JLR200; LoRusso PM, 2005, J CLIN ONCOL, V23, P5281, DOI 10.1200/JCO.2005.14.415; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219; LYSSIKATOS J, 2004, AACR M, V45; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; Mendelsohn J, 2006, SEMIN ONCOL, V33, P369, DOI 10.1053/j.seminoncol.2006.04.003; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Mewani RR, 2004, INT J ONCOL, V24, P1181; Michaelson D, 2005, MOL BIOL CELL, V16, P1606, DOI 10.1091/mbc.E04-11-0960; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; Monia BP, 1996, P NATL ACAD SCI USA, V93, P15481, DOI 10.1073/pnas.93.26.15481; Moore M, 2005, ANN ONCOL, V16, P1688, DOI 10.1093/annonc/mdi310; MOORE MJ, 2005, ASCO M, V22; Moy B, 2006, ONCOLOGIST, V11, P1047, DOI 10.1634/theoncologist.11-10-1047; Mukherjee S, 2006, SCIENCE, V312, P1211, DOI 10.1126/science.1126867; Neckers L, 2006, CURR TOP MED CHEM, V6, P1163, DOI 10.2174/156802606777811979; Nelson MH, 2006, ANN PHARMACOTHER, V40, P261, DOI 10.1345/aph.1G387; Niihori T, 2006, NAT GENET, V38, P294, DOI 10.1038/ng1749; O'Neill LAJ, 2006, NAT REV DRUG DISCOV, V5, P549, DOI 10.1038/nrd2070; Ohren JF, 2004, NAT STRUCT MOL BIOL, V11, P1192, DOI 10.1038/nsmb859; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; Oza AM, 2003, GYNECOL ONCOL, V89, P129, DOI 10.1016/S0090-8258(02)00144-0; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Parulekar WR, 2004, JNCI-J NATL CANCER I, V96, P990, DOI 10.1093/jnci/djh182; Perez-Soler R, 2005, J CLIN ONCOL, V23, P5235, DOI 10.1200/JCO.2005.00.6916; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Reid TS, 2004, J MOL BIOL, V343, P417, DOI 10.1016/j.jmb.2004.08.056; Repasky GA, 2004, TRENDS CELL BIOL, V14, P639, DOI 10.1016/j.tcb.2004.09.014; Rinehart J, 2004, J CLIN ONCOL, V22, P4456, DOI 10.1200/JCO.2004.01.185; Rini BI, 2006, EXPERT OPIN PHARMACO, V7, P453, DOI 10.1517/14656566.7.4.453; Rodriguez-Viciana P, 2006, SCIENCE, V311, P1287, DOI 10.1126/science.1124642; Rowinsky EK, 2006, J CLIN ONCOL, V24, P2981, DOI 10.1200/JCO.2006.05.9808; Rudin CM, 2004, CLIN CANCER RES, V10, P7244, DOI 10.1158/1078-0432.CCR-04-0642; SALAZAR R, 2004, ASCO M, V22; Sausville EA, 2006, CANCER RES, V66, P3351, DOI 10.1158/0008-5472.CAN-05-3627; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Schreck R, 2006, INT J CANCER, V119, P2261, DOI 10.1002/ijc.22144; Schubbert S, 2006, NAT GENET, V38, P331, DOI 10.1038/ng1748; Schulze A, 2004, MOL BIOL CELL, V15, P3450, DOI 10.1091/mbc.E03-11-0807; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Sebolt-Leopold JS, 2006, NATURE, V441, P457, DOI 10.1038/nature04874; Sebti SM, 2003, NAT REV CANCER, V3, P945, DOI 10.1038/nrc1234; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Sharp S, 2006, ADV CANCER RES, V95, P323, DOI 10.1016/S0065-230X(06)95009-X; Sharpless NE, 2006, NAT REV DRUG DISCOV, V5, P741, DOI 10.1038/nrd2110; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Sieben NLG, 2004, J PATHOL, V202, P336, DOI 10.1002/path.1521; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; SKOBELEVA N, 2007, IN PRESS MOL CANC TH; Smith RA, 2006, CURR TOP MED CHEM, V6, P1071, DOI 10.2174/156802606777812077; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Sumimoto H, 2006, INT J CANCER, V118, P472, DOI 10.1002/ijc.21286; TABERNERO J, 2003, ASCO M, V22; Thompson N, 2005, CURR OPIN PHARMACOL, V5, P350, DOI 10.1016/j.coph.2005.04.007; Tolcher AW, 2002, CLIN CANCER RES, V8, P2530; van Steensel MAM, 2006, EXP DERMATOL, V15, P731, DOI 10.1111/j.1600-0625.2006.00474.x; Vanhoefer U, 2004, J CLIN ONCOL, V22, P175, DOI 10.1200/JCO.2004.05.114; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Winter-Vann AM, 2003, P NATL ACAD SCI USA, V100, P6529, DOI 10.1073/pnas.1135239100; Xing HR, 2003, NAT MED, V9, P1266, DOI 10.1038/nm927; Yang XD, 1999, CANCER RES, V59, P1236; Yarden Y, 2001, EUR J CANCER, V37, pS3; YEH T, 2004, AACR M, V45; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	146	2060	2161	12	421	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3291	3310		10.1038/sj.onc.1210422	http://dx.doi.org/10.1038/sj.onc.1210422			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496923				2023-01-03	WOS:000246603600016
J	Grijalva, CG; Nuorti, JP; Arbogast, PG; Martin, SW; Edwards, KM; Griffin, MR				Grijalva, Carlos G.; Nuorti, J. Pekka; Arbogast, Patrick G.; Martin, Stacey W.; Edwards, Kathryn M.; Griffin, Marie R.			Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis	LANCET			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; STREPTOCOCCUS-PNEUMONIAE; CHILDREN YOUNGER; DISEASE; PREVENTION; INFLUENZA; EFFICACY; IMPACT; TRIAL; HIV	Background Routine infant immunisation with seven-valent pneumococcal conjugate vaccine (PCV7) began in the USA in 2000. Although invasive pneumococcal disease has declined substantially, the programme's effect on hospital admissions for pneumonia is unknown. We therefore assessed the effect of the programme on rates of all-cause and pneumococcal pneumonia admissions. Methods Data from the Nationwide Inpatient Sample, the largest inpatient database available in the USA, were analysed with an interrupted time-series analysis that used pneumonia (all-cause and pneumococcal) admission rates as the main outcomes. Monthly admission rates estimated for years after the introduction of PCV7 vaccination (2001-2004) were compared with expected rates calculated from pre-PCV7 years (1997-1999). The year of vaccine introduction (2000) was excluded, and rates of admission for dehydration were assessed for comparison. Findings At the end of 2004, all-cause pneumonia admission rates had declined by 39% (95% CI 22-52) for children younger than 2 years, who were the target population of the vaccination programme. This annual decline in all-cause pneumonia admissions of 506 (291-675) per 100 000 children younger than 2 years represented about 41000 pneumonia admissions prevented in 2004. During the 8 study years, 10 659 (2%) children younger than 2 years admitted with pneumonia were coded as having pneumococcal disease; these rates declined by 65% (47-77). This decline represented about 17 fewer admissions per 100 000 children in 2004. Admission rates for dehydration for children younger than 2 years remained stable over the study period. Interpretation The reduction in all-cause pneumonia admissions in children younger than 2 years provides an estimate of the proportion of childhood pneumonias attributable to Streptococcus pneumoniae in the USA that are vaccine preventable. Our results contribute to the growing body of evidence supporting the beneficial effects of the pneumococcal conjugate vaccines in children.	Vanderbilt Univ, Sch Med, Dept Prevent Med, Village Vanderbilt,Suite 2600,1500 21st Ave, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Ctr Educ & Res Therapeut, Nashville, TN 37212 USA; VA TN Valley Hlth Care Syst, Mids Geriatr Res Educ, Nashville, TN USA; VA TN Valley Hlth Care Syst, Clin Res Ctr Excellence, Nashville, TN USA; Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Centers for Disease Control & Prevention - USA	Griffin, MR (corresponding author), Vanderbilt Univ, Sch Med, Dept Prevent Med, Village Vanderbilt,Suite 2600,1500 21st Ave, Nashville, TN 37212 USA.	marie.griffin@vanderbilt.edu		Grijalva, Carlos/0000-0002-2329-7797	AHRQ HHS [1R03 HS016784] Funding Source: Medline; PHS HHS [U38/CCU417958] Funding Source: Medline; ATSDR CDC HHS [TS-1392, TS-0825] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R03HS016784] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); ATSDR CDC HHS; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Abramson JS, 2000, PEDIATRICS, V106, P362; *AG HEALTHC RES QU, HEALTHC COST UT PR; *AG HEALTHC RES QU, 1996, HEALTHC COST UT PROJ; *AHRQ, 2002, HCUP FACT BOOK; Anderson Robert N, 2005, Natl Vital Stat Rep, V53, P1; ANDREWS BE, 1987, Q J MED, V62, P195; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; [Anonymous], 2005, MMWR MORB MORTAL WKL, V54, P893; [Anonymous], 2006, MMWR-MORBID MORTAL W, V55, P1065; Black SB, 2002, PEDIATR INFECT DIS J, V21, P810, DOI 10.1097/00006454-200209000-00005; *CDCP, COV IND VACC VACC SE; *CDCP, NAT IMM PROGR VACC C; *CDCP, INFL ACT; Cook T.D., 1979, QUASIEXPERIMENTATION; Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6; Drummond P, 2000, ARCH DIS CHILD, V83, P408, DOI 10.1136/adc.83.5.408; Farha Talal, 2005, Paediatr Respir Rev, V6, P76, DOI 10.1016/j.prrv.2005.03.001; Grijalva CG, 2006, PEDIATRICS, V118, P865, DOI 10.1542/peds.2006-0492; Grijalva CG, 2006, CLIN INFECT DIS, V43, P680, DOI 10.1086/506945; Guevara RE, 1999, AM J EPIDEMIOL, V149, P282, DOI 10.1093/oxfordjournals.aje.a009804; Hansen J, 2006, PEDIATR INFECT DIS J, V25, P779, DOI 10.1097/01.inf.0000232706.35674.2f; Healthcare Cost and Utilization Project, HEALTHC COST UT PROJ; Hebert PL, 2005, MED CARE RES REV, V62, P560, DOI 10.1177/1077558705279310; Heffernan RT, 2005, J INFECT DIS, V191, P2038, DOI 10.1086/430356; Jackson LA, 2006, INT J EPIDEMIOL, V35, P337, DOI 10.1093/ije/dyi274; Jackson ML, 2004, CLIN INFECT DIS, V39, P1642, DOI 10.1086/425615; Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060; Levine OS, 2006, LANCET, V367, P1880, DOI 10.1016/S0140-6736(06)68703-5; Little R. J., 2019, STAT ANAL MISSING DA, V793; Madhi SA, 2004, NAT MED, V10, P811, DOI 10.1038/nm1077; Marston BJ, 1997, ARCH INTERN MED, V157, P1709, DOI 10.1001/archinte.157.15.1709; McIntosh K, 2002, NEW ENGL J MED, V346, P429, DOI 10.1056/NEJMra011994; Melegaro A, 2004, EUR J EPIDEMIOL, V19, P353, DOI 10.1023/B:EJEP.0000024701.94769.98; Michelow IC, 2004, PEDIATRICS, V113, P701, DOI 10.1542/peds.113.4.701; Mulholland K, 2005, TROP MED INT HEALTH, V10, P497, DOI 10.1111/j.1365-3156.2005.01430.x; Nuorti JP, 2000, ANN INTERN MED, V132, P182, DOI 10.7326/0003-4819-132-3-200002010-00003; NUORTI JP, 2006, 5 INT S PNEUM PNEUM; O'Brien KL, 2003, VACCINE, V21, P1815, DOI 10.1016/S0264-410X(02)00807-1; Obaro SK, 2006, LANCET INFECT DIS, V6, P150, DOI 10.1016/S1473-3099(06)70411-X; Poehling KA, 2004, PEDIATRICS, V114, P755, DOI 10.1542/peds.2003-0592-F; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; Wardlaw T, 2006, LANCET, V368, P1048, DOI 10.1016/S0140-6736(06)69334-3; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823; Whitney CG, 2006, LANCET, V368, P1495, DOI 10.1016/S0140-6736(06)69637-2; 1998, MMWR MORB MORTAL WKL, V47, P797	45	502	533	0	42	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 7	2007	369	9568					1179	1186		10.1016/S0140-6736(07)60564-9	http://dx.doi.org/10.1016/S0140-6736(07)60564-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155RH	17416262				2023-01-03	WOS:000245595100029
J	Geyer, CE; Forster, J; Lindquist, D; Chan, S; Romieu, CG; Pienkowski, T; Jagiello-Gruszfeld, A; Crown, J; Chan, A; Kaufman, B; Skarlos, D; Campone, M; Davidson, N; Berger, M; Oliva, C; Rubin, SD; Stein, S; Cameron, D				Geyer, Charles E.; Forster, John; Lindquist, Deborah; Chan, Stephen; Romieu, C. Gilles; Pienkowski, Tadeusz; Jagiello-Gruszfeld, Agnieszka; Crown, John; Chan, Arlene; Kaufman, Bella; Skarlos, Dimosthenis; Campone, Mario; Davidson, Neville; Berger, Mark; Oliva, Cristina; Rubin, Stephen D.; Stein, Steven; Cameron, David			Lapatinib plus capecitabine for HER2-positive advanced breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; KINASE INHIBITOR; TRASTUZUMAB; GROWTH; SAFETY; METASTASES; SURVIVAL; EFFICACY; GW572016	BACKGROUND: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy. In this trial, we compared lapatinib plus capecitabine with capecitabine alone in such patients. METHODS: Women with HER2-positive, locally advanced or metastatic breast cancer that had progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab were randomly assigned to receive either combination therapy (lapatinib at a dose of 1250 mg per day continuously plus capecitabine at a dose of 2000 mg per square meter of body-surface area on days 1 through 14 of a 21-day cycle) or monotherapy (capecitabine alone at a dose of 2500 mg per square meter on days 1 through 14 of a 21-day cycle). The primary end point was time to progression, based on an evaluation by independent reviewers under blinded conditions. RESULTS: The interim analysis of time to progression met specified criteria for early reporting on the basis of superiority in the combination-therapy group. The hazard ratio for the independently assessed time to progression was 0.49 (95% confidence interval, 0.34 to 0.71; P<0.001), with 49 events in the combination-therapy group and 72 events in the monotherapy group. The median time to progression was 8.4 months in the combination-therapy group as compared with 4.4 months in the monotherapy group. This improvement was achieved without an increase in serious toxic effects or symptomatic cardiac events. CONCLUSIONS: Lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab.	Allegheny Gen Hosp, Allegheny Canc Ctr, Pittsburgh, PA 15212 USA; GlaxoSmithKline Inc, Greenford, Middx, England; US Oncol, Sedona, AZ USA; Univ Nottingham Hosp, Nottingham NG7 2UH, England; Ctr Reg Lutte Contre Canc Val dAurelle, Montpellier, France; Ctr Onkol Klin Nowotworow Piersi & Chirurg, Warsaw, Poland; Zaklad Opieki Zdrowotnej MSWiA, Olsztyn, Poland; Ireland Cooperat Oncol Res Grp, Dublin, Ireland; Mt Med Ctr, Perth, WA, Australia; Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel; Errikos Dynan Hosp, Athens, Greece; Ctr Rene Gauducheau, St Herblain, France; Broomfield Hosp, Chelmsford, Essex, England; GlaxoSmithKline Inc, Collegeville, PA USA; GlaxoSmithKline Inc, Greenford, Middx, England; Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland	Allegheny General Hospital; GlaxoSmithKline; US Oncology Network; University of Nottingham; All-Ireland Cooperative Oncology Research Group; Chaim Sheba Medical Center; Henry Dunant Hospital; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Mid Essex Hospital Services NHS Trust; Broomfield Hospital; GlaxoSmithKline; GlaxoSmithKline; University of Edinburgh	Geyer, CE (corresponding author), Allegheny Gen Hosp, Allegheny Canc Ctr, 320 E North Ave,5th Floor, Pittsburgh, PA 15212 USA.	cgeyer@wpahs.org	Geyer, Charles/AGY-0119-2022; Jagiello-Gruszfeld, Agnieszka i/S-6924-2018; Cameron, David A/C-7781-2013; Crown, John/AAL-3367-2020	Geyer, Charles/0000-0002-2379-5702; Jagiello-Gruszfeld, Agnieszka i/0000-0002-2698-5499; Cameron, David A/0000-0002-2717-7979; Oliva, Cristina/0000-0002-6772-8069; Crown, John/0000-0002-3125-7613; Pienkowski, Tadeusz/0000-0002-0110-5950; Chan, Stephen/0000-0001-8865-6618				Clayton AJ, 2004, BRIT J CANCER, V91, P639, DOI 10.1038/sj.bjc.6601970; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; *FOOD DRUG ADM, 2004, GUID IND DEV MED I 3; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Lin NU, 2004, J CLIN ONCOL, V22, P3608, DOI 10.1200/JCO.2004.01.175; Montemurro F, 2006, ONCOLOGIST, V11, P318, DOI 10.1634/theoncologist.11-4-318; PAMPALLONA S, 1994, J STAT PLAN INFER, V42, P19, DOI 10.1016/0378-3758(94)90187-2; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Rusnak DW, 2001, MOL CANCER THER, V1, P85; SCHWARTZ G, 2004, P AM SOC CLIN O S14S, V23, pS212; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Spector NL, 2005, J CLIN ONCOL, V23, P2502, DOI 10.1200/JCO.2005.12.157; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tripathy D, 2004, J CLIN ONCOL, V22, P1063, DOI 10.1200/JCO.2004.06.557; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168	19	2475	2571	6	188	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2006	355	26					2733	2743		10.1056/NEJMoa064320	http://dx.doi.org/10.1056/NEJMoa064320			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120UA	17192538				2023-01-03	WOS:000243110500005
J	O'Donnell, M				O'Donnell, Michael			The night Bernard Shaw taught us a lesson	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												mod@doctors.org.uk						GUINNESS A, 2000, COMMONPLACE BOOK, P29; ODONNELL M, 2005, MADNESS CREATIVITY L, P45; SHAW B, 1946, DOCTORS DILEMMA, P104; Skelton JR, 2005, BRIT J GEN PRACT, V55, P40	4	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 23	2006	333	7582					1338	1340		10.1136/bmj.39062.728900.55	http://dx.doi.org/10.1136/bmj.39062.728900.55			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185735	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000243160700032
J	Roses, RE; Xu, M; Koski, GK; Czerniecki, BJ				Roses, R. E.; Xu, M.; Koski, G. K.; Czerniecki, B. J.			Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer	ONCOGENE			English	Review						cancer; immunotherapy; Toll-like receptor; radiation	HUMAN DENDRITIC CELLS; ENHANCES TUMOR RESPONSE; TOTAL-BODY IRRADIATION; HEAT-SHOCK PROTEINS; CD8(+) T-CELLS; NF-KAPPA-B; IMMUNE-RESPONSE; GAMMA-IRRADIATION; MOUSE MODEL; MEDIATED REGRESSION	The identification of pathogen-associated molecular patterns, conserved microbial structures that act on Toll-like receptors, has led to a novel avenue of investigation aimed at developing a new generation of cancer immunotherapies. Ligation of Toll-like receptors results in the induction of robust immune responses that may be directed against tumor-associated antigens. Recent data suggest that such strategies may result in enhanced antitumor immunity. Nonetheless, as clinically effective immunotherapy for cancer remains a somewhat distant goal, attention has shifted toward multimodality approaches to cancer therapy, sometimes combining novel immune interventions and conventional treatments. The traditional view of radiation therapy as immunosuppressive has now been challenged, prompting a re-evaluation of its potential as an adjunct to immunotherapy. Radiation therapy can enhance the expression of tumor-associated antigens, induce immune-mediated targeting of tumor stroma, and diminish regulatory T cell activity. Recent evidence suggests that radiation therapy may also activate effectors of innate immunity through TLR-dependent mechanisms, thereby augmenting the adaptive immune response to cancer. In this paper, we will review evidence for enhanced tumor-directed immunity resulting from radiation exposure and early promising data suggesting synergistic effects of radiation and TLR-targeted immunotherapies.	[Roses, R. E.; Xu, M.; Czerniecki, B. J.] Hosp Univ Penn, Dept Surg, Philadelphia, PA 19104 USA; [Koski, G. K.] Cleveland Clin Fdn, Surg Res Ctr, Cleveland, OH 44195 USA	University of Pennsylvania; Pennsylvania Medicine; Cleveland Clinic Foundation	Czerniecki, BJ (corresponding author), Hosp Univ Penn, Dept Surg, 4 Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA.	brian.czerniecki@uphs.upenn.edu			NCI NIH HHS [R01-CA096997-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096997] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acker JC, 1998, RADIAT RES, V149, P350, DOI 10.2307/3579697; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Ambach A, 2004, MOL IMMUNOL, V40, P1307, DOI 10.1016/j.molimm.2004.01.002; Antony PA, 2005, J IMMUNOL, V174, P2591, DOI 10.4049/jimmunol.174.5.2591; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Bourquin C, 2006, INT J CANCER, V118, P2790, DOI 10.1002/ijc.21681; Cao MD, 2004, CELL BIOL INT, V28, P223, DOI 10.1016/j.cellbi.2003.12.006; Cao ZA, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-11; Chakraborty M, 2004, CANCER RES, V64, P4328, DOI 10.1158/0008-5472.CAN-04-0073; Chakraborty M, 2003, J IMMUNOL, V170, P6338, DOI 10.4049/jimmunol.170.12.6338; Chakravarty PK, 1999, CANCER RES, V59, P6028; Chakravarty PK, 2006, ONCOLOGY-BASEL, V70, P245, DOI 10.1159/000096288; Chiang CS, 2000, CANCER GENE THER, V7, P1172, DOI 10.1038/sj.cgt.7700217; COLE S, 1986, J INVEST DERMATOL, V87, P608, DOI 10.1111/1523-1747.ep12455853; Czerniecki BJ, 2007, CANCER RES, V67, P1842, DOI 10.1158/0008-5472.CAN-06-4038; Demaria S, 2005, CLIN CANCER RES, V11, P728; Demaria S, 2005, INT J RADIAT ONCOL, V63, P655, DOI 10.1016/j.ijrobp.2005.06.032; Demaria S, 2004, INT J RADIAT ONCOL, V58, P862, DOI 10.1016/j.ijrobp.2003.09.012; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; DUNN PL, 1991, J LEUKOCYTE BIOL, V49, P388, DOI 10.1002/jlb.49.4.388; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Hallahan DE, 1999, RADIAT RES, V152, P6, DOI 10.2307/3580044; Hallahan DE, 1998, CANCER RES, V58, P5216; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; HAREYAMA M, 1991, CANCER, V67, P2269, DOI 10.1002/1097-0142(19910501)67:9<2269::AID-CNCR2820670910>3.0.CO;2-Z; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; Hashimoto S, 1999, RADIAT RES, V151, P717, DOI 10.2307/3580211; HAUSER SH, 1993, CANCER RES, V53, P1952; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hong JH, 1999, INT J RADIAT BIOL, V75, P1421, DOI 10.1080/095530099139287; Ina Y, 2005, INT J RADIAT BIOL, V81, P721, DOI 10.1080/09553000500519808; ISHIHARA H, 1995, J RADIAT RES, V36, P112, DOI 10.1269/jrr.36.112; JAMES RFL, 1989, TRANSPLANTATION, V47, P929, DOI 10.1097/00007890-198906000-00001; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Kim KW, 2004, INT J CANCER, V109, P685, DOI 10.1002/ijc.20036; Kochling J, 2003, CLIN CANCER RES, V9, P3142; Krieg AM, 2007, J CLIN INVEST, V117, P1184, DOI 10.1172/JCI31414; Lake RA, 2005, NAT REV CANCER, V5, P397, DOI 10.1038/nrc1613; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Liao YP, 2004, J IMMUNOL, V173, P2462, DOI 10.4049/jimmunol.173.4.2462; Liu HM, 1998, BLOOD, V92, P3730, DOI 10.1182/blood.V92.10.3730.422k20_3730_3736; Lohr F, 2000, MOL THER, V2, P195, DOI 10.1006/mthe.2000.0114; Macagno A, 2007, TRENDS IMMUNOL, V28, P227, DOI 10.1016/j.it.2007.03.008; Mason KA, 2005, CLIN CANCER RES, V11, P361; McBride WH, 2004, RADIAT RES, V162, P1, DOI 10.1667/RR3196; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Merrick A, 2005, BRIT J CANCER, V92, P1450, DOI 10.1038/sj.bjc.6602518; Milas L, 2004, CANCER RES, V64, P5074, DOI 10.1158/0008-5472.CAN-04-0926; Miller GM, 2003, ONCOLOGY-BASEL, V65, P229, DOI 10.1159/000074476; NEMOTO K, 1995, J RADIAT RES, V36, P125, DOI 10.1269/jrr.36.125; Nikitina EY, 2001, INT J CANCER, V94, P825, DOI 10.1002/1097-0215(20011215)94:6<825::AID-IJC1545>3.0.CO;2-5; NORTH RJ, 1986, J EXP MED, V164, P1652, DOI 10.1084/jem.164.5.1652; Paulos CM, 2007, J CLIN INVEST, V117, P2197, DOI 10.1172/JCI32205; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Scheffer SR, 2003, INT J CANCER, V103, P205, DOI 10.1002/ijc.10777; SCHREIBER RD, 2004, CANC IMMUN S1, V5, P1; Seetharam S, 1999, INT J ONCOL, V15, P769; Shi YH, 2007, CANCER RES, V67, P1823, DOI 10.1158/0008-5472.CAN-06-2381; Shigematsu A, 2007, J RADIAT RES, V48, P51, DOI 10.1269/jrr.06048; Tsuji S, 2000, INFECT IMMUN, V68, P6883, DOI 10.1128/IAI.68.12.6883-6890.2000; van Duin D, 2006, TRENDS IMMUNOL, V27, P49, DOI 10.1016/j.it.2005.11.005; Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8; WASSERMAN J, 1989, B NEW YORK ACAD MED, V65, P36; WEICHSELBAUM RR, 1994, CANCER RES, V54, P4266; Wesa A, 2007, J IMMUNOTHER, V30, P75, DOI 10.1097/01.cji.0000211316.15278.6e; Wrzesinski C, 2007, J CLIN INVEST, V117, P492, DOI 10.1172/JCI30414; Xu SW, 2006, SURGERY, V140, P170, DOI 10.1016/j.surg.2006.03.006; Xu SW, 2003, J IMMUNOL, V171, P2251, DOI 10.4049/jimmunol.171.5.2251; Zhang B, 2007, J EXP MED, V204, P49, DOI 10.1084/jem.20062056	75	71	73	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					200	207		10.1038/sj.onc.1210909	http://dx.doi.org/10.1038/sj.onc.1210909			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176601				2023-01-03	WOS:000252163600006
J	Buckanovich, RJ; Facciabene, A; Kim, S; Benencia, F; Sasaroli, D; Balint, K; Katsaros, D; O'Brien-Jenkins, A; Gimotty, PA; Coukos, G				Buckanovich, Ronald J.; Facciabene, Andrea; Kim, Sarah; Benencia, Fabian; Sasaroli, Dimitra; Balint, Klara; Katsaros, Dionysios; O'Brien-Jenkins, Anne; Gimotty, Phyllis A.; Coukos, George			Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; EPITHELIAL OVARIAN-CANCER; NF-KAPPA-B; LYMPHOCYTE ACCUMULATION; LEUKOCYTE ADHESION; VASCULAR FUNCTION; EMERGING ROLE; EXPRESSION; ANTAGONISTS; IMMUNOTHERAPY	In spite of their having sufficient immunogenicity, tumor vaccines remain largely ineffective. The mechanisms underlying this lack of efficacy are still unclear. Here we report a previously undescribed mechanism by which the tumor endothelium prevents T cell homing and hinders tumor immunotherapy. Transcriptional profiling of microdissected tumor endothelial cells from human ovarian cancers revealed genes associated with the absence or presence of tumor-infiltrating lymphocytes (TILs). Overexpression of the endothelin B receptor (ETBR) was associated with the absence of TILs and short patient survival time. The ETBR inhibitor BQ-788 increased T cell adhesion to human endothelium in vitro, an effect countered by intercellular adhesion molecule-1 (ICAM-1) blockade or treatment with NO donors. In mice, ETBR neutralization by BQ-788 increased T cell homing to tumors; this homing required ICAM-1 and enabled tumor response to otherwise ineffective immunotherapy in vivo without changes in systemic antitumor immune response. These findings highlight a molecular mechanism with the potential to be pharmacologically manipulated to enhance the efficacy of tumor immunotherapy in humans.	[Buckanovich, Ronald J.; Facciabene, Andrea; Kim, Sarah; Benencia, Fabian; Sasaroli, Dimitra; Balint, Klara; O'Brien-Jenkins, Anne; Gimotty, Phyllis A.; Coukos, George] Univ Penn, Ctr Res Ovarian Canc Early Detect & Cure, Philadelphia, PA 19104 USA; [Buckanovich, Ronald J.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA; [Benencia, Fabian; Coukos, George] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Sasaroli, Dimitra] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Gimotty, Phyllis A.] Democritus Univ Thrace, Dept Mol Biol & Genet, Alexandroupolis 68100, Greece; [Katsaros, Dionysios] Univ Turin, Dept Obstet & Gynecol, I-10126 Turin, Italy	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Democritus University of Thrace; University of Turin	Coukos, G (corresponding author), Univ Penn, Ctr Res Ovarian Canc Early Detect & Cure, Philadelphia, PA 19104 USA.	gcks@mail.med.upenn.edu	Balint, Klara/ABB-8816-2021; Coukos, George/ABG-7389-2020; Gimotty, Phyllis/GWZ-4136-2022; Benencia, Fabian/AAH-1613-2020	Gimotty, Phyllis/0000-0002-3850-9799; Benencia, Fabian/0000-0003-3049-6150; Coukos, George/0000-0001-8813-7367	FIC NIH HHS [D43-TW00671] Funding Source: Medline; NCI NIH HHS [R01-CA098951, R01-CA112162, P50-CA083638] Funding Source: Medline; NICHD NIH HHS [K12-HD43459] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD043459] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [D43TW000671] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA112162, R01CA098951, P50CA083638] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baatz H, 2001, INFLAMM RES, V50, P534, DOI 10.1007/PL00000231; Bagnall AJ, 2006, HYPERTENSION, V48, P286, DOI 10.1161/01.HYP.0000229907.58470.4c; Bagnato A, 2005, ENDOCR-RELAT CANCER, V12, P761, DOI 10.1677/erc.1.01077; Bouzin C, 2007, J IMMUNOL, V178, P1505, DOI 10.4049/jimmunol.178.3.1505; Buckanovich RJ, 2007, J CLIN ONCOL, V25, P852, DOI 10.1200/JCO.2006.08.8583; Buckanovich RJ, 2006, CANCER BIOL THER, V5, P635, DOI 10.4161/cbt.5.6.2676; Cardillo C, 1999, HYPERTENSION, V33, P753, DOI 10.1161/01.HYP.33.2.753; Conejo-Garcia JR, 2005, BLOOD, V105, P679, DOI 10.1182/blood-2004-05-1906; Courreges MC, 2006, CANCER GENE THER, V13, P182, DOI 10.1038/sj.cgt.7700888; Cowburn PJ, 2005, EUR J HEART FAIL, V7, P37, DOI 10.1016/j.ejheart.2004.08.001; D'Orleans-Juste P, 2002, PHARMACOL THERAPEUT, V95, P221, DOI 10.1016/S0163-7258(02)00235-8; Espina V, 2006, NAT PROTOC, V1, P586, DOI 10.1038/nprot.2006.85; Feuerer M, 2006, J IMMUNOL, V176, P2857, DOI 10.4049/jimmunol.176.5.2857; Fukami T, 1996, J MED CHEM, V39, P2313, DOI 10.1021/jm9600914; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gattinoni L, 2006, NAT REV IMMUNOL, V6, P383, DOI 10.1038/nri1842; GAUTHIER TW, 1994, AM J PHYSIOL-GASTR L, V267, pG562, DOI 10.1152/ajpgi.1994.267.4.G562; Grimshaw MJ, 2004, CANCER RES, V64, P2461, DOI 10.1158/0008-5472.CAN-03-1069; Halcox JPJ, 2007, HYPERTENSION, V49, P1134, DOI 10.1161/HYPERTENSIONAHA.106.083303; Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104; Hickey MJ, 2001, CLIN SCI, V100, P1, DOI 10.1042/CS20000135; Hodi FS, 2006, ADV IMMUNOL, V90, P341, DOI 10.1016/S0065-2776(06)90009-1; Huddleston HG, 2005, GYNECOL ONCOL, V96, P77, DOI 10.1016/j.ygyno.2004.08.047; Iqbal J, 2005, MINI-REV MED CHEM, V5, P381, DOI 10.2174/1389557053544010; Kelleher ZT, 2007, J BIOL CHEM, V282, P30667, DOI 10.1074/jbc.M705929200; Korman AJ, 2006, ADV IMMUNOL, V90, P297, DOI 10.1016/S0065-2776(06)90008-X; Kubes P, 2000, GUT, V47, P6, DOI 10.1136/gut.47.1.6; Kuhlmann A, 2005, CORNEA, V24, P837, DOI 10.1097/01.ico.0000157400.81408.2b; Lelamali K, 2001, J CELL PHYSIOL, V188, P337, DOI 10.1002/jcp.1128; Levin ER, 1996, AM J NEPHROL, V16, P246, DOI 10.1159/000169004; Lopez A, 2004, CRIT CARE MED, V32, P21, DOI 10.1097/01.CCM.0000105581.01815.C6; Marasciulo FL, 2006, CURR MED CHEM, V13, P1655, DOI 10.2174/092986706777441968; Morris CD, 2005, BRIT J CANCER, V92, P2148, DOI 10.1038/sj.bjc.6602676; Motte S, 2006, PHARMACOL THERAPEUT, V110, P386, DOI 10.1016/j.pharmthera.2005.08.012; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Ng QS, 2007, LANCET ONCOL, V8, P111, DOI 10.1016/S1470-2045(07)70001-3; Peng XH, 2007, CANCER IMMUNOL IMMUN, V56, P797, DOI 10.1007/s00262-006-0240-9; Salani D, 2000, AM J PATHOL, V157, P1703, DOI 10.1016/S0002-9440(10)64807-9; Sampaio ALF, 2004, J LEUKOCYTE BIOL, V76, P210, DOI 10.1189/jlb.1003504; Sampaio ALF, 2000, J LEUKOCYTE BIOL, V67, P189, DOI 10.1002/jlb.67.2.189; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Schlom J, 2007, CLIN CANCER RES, V13, P3776, DOI 10.1158/1078-0432.CCR-07-0588; TSUKAHARA H, 1994, J BIOL CHEM, V269, P21778; WAGNER OF, 1992, J BIOL CHEM, V267, P16066; Waldow T, 2006, NITRIC OXIDE-BIOL CH, V15, P103, DOI 10.1016/j.niox.2005.12.005; Wanecek M, 2000, EUR J PHARMACOL, V407, P1, DOI 10.1016/S0014-2999(00)00675-0; Wedgwood S, 2005, AM J PHYSIOL-LUNG C, V288, pL480, DOI 10.1152/ajplung.00283.2004; Wulfing P, 2003, CLIN CANCER RES, V9, P4125; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zhang L, 2002, AM J PATHOL, V161, P2295, DOI 10.1016/S0002-9440(10)64505-1	50	382	404	1	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2008	14	1					28	36		10.1038/nm1699	http://dx.doi.org/10.1038/nm1699			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	249IV	18157142				2023-01-03	WOS:000252222400019
J	Linder, JF; Meyers, FJ				Linder, John F.; Meyers, Frederick J.			Palliative care for prison inmates - "Don't let me die in prison"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-LIFE CARE; HEALTH-CARE; ACADEMIC MEDICINE; COMMUNITY-HEALTH; SYSTEM; POPULATION; RELEASE; IMPACT; JAILS; WOMEN	The number of older inmates in US correctional facilities is increasing and with it the need for quality palliative health care services. Morbidity and mortality are high in this population. Palliative care in the correctional setting includes most of the challenges faced in the free-living community and several unique barriers to inmate care. Successful models of hospice care in prisons have been established and should be disseminated and evaluated. This article highlights why the changing demo-graphics of prison populations necessitates hospice in this setting and highlights many of the barriers that correctional and consulting physicians face while providing palliative care. Issues specific to palliative care and hospice in prison include palliative care standards, inmate-physician and inmate-family relationships, confidentiality, interdisciplinary care, do-not-resuscitate orders and advance medical directives, medical parole, and the use of inmate volunteers in prison hospice programs. We also include practical recommendations to community-based physicians working with incarcerated or recently released prisoners and describe solutions that can be implemented on an individual and systems basis.	Univ Calif Davis, Dept Internal Med, Div Hematol & Oncol, Ctr Canc, Sacramento, CA 95864 USA; Univ Calif Davis, Smith Coll, Sch Social Work, Ctr Canc, Sacramento, CA 95864 USA	University of California System; University of California Davis; Smith College; University of California System; University of California Davis	Meyers, FJ (corresponding author), Univ Calif Davis, Dept Internal Med, Div Hematol & Oncol, Ctr Canc, 4150 V St,3100, Sacramento, CA 95864 USA.	fred.meyers@ucdmc.ucdavis.edu						*AM BOARD HOSP PAL, 2007, PHYS BOARD CERT HOSP; *AM MED ASS, 2007, COD ETH POL FIND; *AMA COUNC ETH JUD, 2005, COLL ACT PAT ADV; Anno BJ., 2004, J CORRECT HEALTH CAR, V10, P287; ANNO BJ, 2004, ADDRESSING NEEDS ELD, P162; BARENS E, 1998, ANGOLA PRISON HOSPIC; BARNARD J, 1999, CONVICTED MURDERERS; Bauersmith Joan, 2002, J Palliat Med, V5, P667, DOI 10.1089/109662102320880471; BECK A, 1995, PRISONERS 1994, P15; BECK A, 2001, PRISONERS 2000, P16; Beck JA, 1999, J LAW MED ETHICS, V27, P216, DOI 10.1111/j.1748-720X.1999.tb01455.x; Bennett Ian M, 2003, Cancer Control, V10, P81; Bick J., 2002, J CORRECT HEALTH CAR, V9, P131; Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI 10.1056/NEJMsa064115; Bond GD, 2005, INT J AGING HUM DEV, V61, P161, DOI 10.2190/7H5P-2AHJ-L34Q-GW9U; Boyle Barbara A, 2002, J Palliat Med, V5, P671, DOI 10.1089/109662102320880480; Brunicardi BO, 1998, TELEMED J, V4, P49, DOI 10.1089/tmj.1.1998.4.49; Byock Ira, 2002, Correctcare, V16, P18; Byock I, 2006, J PALLIAT MED, V9, P137, DOI 10.1089/jpm.2006.9.137; *CDC, 2003, DEATHS PERC TOT DEAT; *CDC, 2004, DEATHS PERC TOT DEAT; *CDC, 2002, DEATHS PERC TOT DEAT; *CDC, 2001, DEATHS PERC TOT DEAT; *CDCP, 2007, HLTH ISS CORR; Chandler Cynthia, 2003, Berkeley Womens Law J, V18, P40; Cohn F, 1999, J LAW MED ETHICS, V27, P252, DOI 10.1111/j.1748-720X.1999.tb01459.x; Craig E., 2002, J CORRECT HEALTH CAR, V9, P149; CUMMINGS C, 1999, OLDER INMATES IMPACT, P87; Dubler NN, 1998, J LAW MED ETHICS, V26, P149, DOI 10.1111/j.1748-720X.1998.tb01670.x; Enders Sheila R, 2005, J Palliat Med, V8, P432, DOI 10.1089/jpm.2005.8.432; ENDERS SR, 2004, SIMPLE ANSWERS DIFFI, P100; Evans Carol, 2002, J Palliat Med, V5, P553, DOI 10.1089/109662102760269797; Falter Robert G., 1999, J CORRECT HEALTH CAR, V6, P149, DOI [DOI 10.1177/107834589900600202, 10.1177/107834589900600202]; Fazel S, 2001, AGE AGEING, V30, P403, DOI 10.1093/ageing/30.5.403; Freudenberg N, 2001, J URBAN HEALTH, V78, P214, DOI 10.1093/jurban/78.2.214; Gelband H, 2001, IMPROVING PALLIATIVE, P344; Haigler KO, 1994, LITERACY PRISON WALL, P187; Harris F, 2007, HEALTH SOC CARE COMM, V15, P56, DOI 10.1111/j.1365-2524.2006.00662.x; HARRISON P, 2006, PRISONERS 2005, P13; Head Barbara., 2005, J HOSPICE PALLIATIVE, V7, P354, DOI [10.1097/00129191-200511000-00016, DOI 10.1097/00129191-200511000-00016]; Hornblum AM, 1997, BRIT MED J, V315, P1437, DOI 10.1136/bmj.315.7120.1437; Kendig NE, 2004, JAMA-J AM MED ASSOC, V292, P501, DOI 10.1001/jama.292.4.501; KING AEO, 1993, FAM SOC-J CONTEMP H, V74, P145, DOI 10.1177/104438949307400302; KINSELLA C, 2004, CORRECTIONS HLTH CAR, P38; La Vigne N. G., 2005, J CONTEMP CRIM JUST, V21, P314, DOI [10.1177/1043986205281727, DOI 10.1177/1043986205281727]; Linder John F, 2002, J Palliat Med, V5, P903, DOI 10.1089/10966210260499096; Linder John F, 2002, J Palliat Med, V5, P549, DOI 10.1089/109662102760269788; Maeve MK, 1999, CRIME LAW SOCIAL CH, V31, P49, DOI 10.1023/A:1008376229520; Magee CG, 2005, AM J PUBLIC HEALTH, V95, P1712, DOI 10.2105/AJPH.2005.063677; Mathew P, 2005, CANCER-AM CANCER SOC, V104, P2197, DOI 10.1002/cncr.21468; McCue M J, 1997, Telemed J, V3, P11, DOI 10.1089/tmj.1.1997.3.11; Meyers FJ, 2003, J CLIN ONCOL, V21, P1412, DOI 10.1200/JCO.2003.01.104; MEYERS FJ, 2002, 38 ANN AM SOC CLIN O; Mitka M, 2004, JAMA-J AM MED ASSOC, V292, P423, DOI 10.1001/jama.292.4.423; MUMOLA C, 1997, PRISONERS 1996, P15; MUMOLA CJ, 2007, MED CAUSES DEATH STA, P12; NACCI P, 2002, IMPLEMENTING TELEMED, P73; National Commission on Correctional Health Care, 2003, STAND HLTH SERV PRIS; Parker FR, 1999, J LAW MED ETHICS, V27, P240, DOI 10.1111/j.1748-720X.1999.tb01458.x; *PARTN CLEAR HLTH, 2003, ER LOW HLTH LIT 1 PU; PUISIS M, 2006, CLIN PRACTICE CORREC, P608; Raimer BG, 2004, JAMA-J AM MED ASSOC, V292, P485, DOI 10.1001/jama.292.4.485; Ratcliff M, 2000, J Palliat Med, V3, P509, DOI 10.1089/jpm.2000.3.4.509; Ratcliff Margaret, 2004, J Palliat Med, V7, P373; Reviere R, 2004, J WOMEN AGING, V16, P55, DOI 10.1300/J074v16n01_05; Smith B. V., 1994, AIDS and Public Policy Journal, V9, P78; STEPHAN J, 2004, STATE PRISONER EXPEN, P9; Taylor Mark, 2007, Mod Healthc, V37, P25; Udesky L, 2005, LANCET, V366, P796, DOI 10.1016/S0140-6736(05)67197-8; *US DEP JUST, 1998, HOSP PALL CAR PRIS S; Voelker R, 2004, JAMA-J AM MED ASSOC, V291, P1549, DOI 10.1001/jama.291.13.1549; Watson R, 2004, INT J NURS STUD, V41, P119, DOI 10.1016/S0020-7489(03)00128-7; Weatherhead Kendra, 2003, Health Matrix Clevel, V13, P429; *WHO, 1990, CANC PAIN REL PALL C, P75; Yorston GA, 2006, J AM ACAD PSYCHIATRY, V34, P333; Zigmond Jessica, 2007, Mod Healthc, V37, P54; 2000, INNOVATIONS END OF L	77	46	46	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 22	2007	298	8					894	901		10.1001/jama.298.8.894	http://dx.doi.org/10.1001/jama.298.8.894			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202CS	17712073				2023-01-03	WOS:000248880200023
J	Bolton, P; Bass, J; Betancourt, T; Speelman, L; Onyango, G; Clougherty, KF; Neugebauer, R; Murray, L; Verdeli, H				Bolton, Paul; Bass, Judith; Betancourt, Theresa; Speelman, Liesbeth; Onyango, Grace; Clougherty, Kathleen F.; Neugebauer, Richard; Murray, Laura; Verdeli, Helen			Interventions for depression symptoms among adolescent survivors of war and displacement in northern Uganda - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERPERSONAL PSYCHOTHERAPY; DIFFICULTIES QUESTIONNAIRE; MENTAL-HEALTH; PRIMARY-CARE; STRENGTHS; CHILD; EFFICACY; VALIDITY; IMPACT	Context Prior qualitative work with internally displaced persons in war-affected northern Uganda showed significant mental health and psychosocial problems. Objective To assess effect of locally feasible interventions on depression, anxiety, and conduct problem symptoms among adolescent survivors of war and displacement in northern Uganda. Design, Setting, and Participants A randomized controlled trial from May 2005 through December 2005 of 314 adolescents ( aged 14-17 years) in 2 camps for internally displaced persons in northern Uganda. Interventions Locally developed screening tools assessed the effectiveness of interventions in reducing symptoms of depression and anxiety, ameliorating conduct problems, and improving function among those who met study criteria and were randomly allocated ( 105, psychotherapy-based intervention [ group interpersonal psychotherapy]; 105, activity-based intervention [ creative play]; 104, wait-control group [ individuals wait listed to receive treatment at study end]). Intervention groups met weekly for 16 weeks. Participants and controls were reassessed at end of study. Main Outcome Measures Primary measure was a decrease in score ( denoting improvement) on a depression symptom scale. Secondary measures were improvements in scores on anxiety, conduct problem symptoms, and function scales. Depression, anxiety, and conduct problems were assessed using the Acholi Psychosocial Assessment Instrument with a minimum score of 32 as the lower limit for clinically significant symptoms ( maximum scale score, 105). Results Difference in change in adjusted mean score for depression symptoms between group interpersonal psychotherapy and control groups was 9.79 points (95% confidence interval [CI], 1.66-17.93). Girls receiving group interpersonal psychotherapy showed substantial and significant improvement in depression symptoms compared with controls (12.61 points; 95% CI, 2.09-23.14). Improvement among boys was not statistically significant (5.72 points; 95% CI, - 1.86 to 13.30). Creative play showed no effect on depression severity (-2.51 points; 95% CI, - 11.42 to 6.39). There were no statistically different improvements in anxiety in either intervention group. Neither intervention improved conduct problem or function scores. Conclusions Both interventions were locally feasible. Group interpersonal psychotherapy was effective for depression symptoms among adolescent girls affected by war and displacement. Other interventions should be investigated to assist adolescent boys in this population who have symptoms of depression.	Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Refugee & Disaster Response, Dept Mental Hlth, Baltimore, MD 21205 USA; Boston Univ, Sch Publ Hlth, Appl Mental Hlth Res Grp, Ctr Int Hlth & Dev, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Francois Xavier Bagnoud Ctr Hlth & Human Rights, Dept Populat & Int Hlth, Boston, MA 02115 USA; War child Holland, Gulu, Uganda; World Vis Uganda, Kampala, Uganda; Columbia Univ, Coll Phys & Surg, New York State Psychiat Inst, Div Epidemiol, New York, NY USA; Columbia Univ, Coll Phys & Surg, Gertrude H Sergievsky Ctr, Fac Med, New York, NY USA; Columbia Univ, Teachers Coll, New York, NY 10027 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Boston University; Harvard University; Harvard T.H. Chan School of Public Health; Columbia University; New York State Psychiatry Institute; Columbia University; Columbia University; Columbia University Teachers College	Bolton, P (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Refugee & Disaster Response, Dept Mental Hlth, 615 N Wolfe St,Room E8646, Baltimore, MD 21205 USA.	pbolton@jhsph.edu		Bass, Judith/0000-0002-5192-628X				American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], CHILD SOLD GLOB REP; Araya R, 2003, LANCET, V361, P995, DOI 10.1016/S0140-6736(03)12825-5; Barenbaum J, 2004, J CHILD PSYCHOL PSYC, V45, P41, DOI 10.1046/j.0021-9630.2003.00304.x; Bolton P, 2003, JAMA-J AM MED ASSOC, V289, P3117, DOI 10.1001/jama.289.23.3117; Bolton P, 2002, SOC PSYCH PSYCH EPID, V37, P537, DOI 10.1007/s00127-002-0580-5; Bolton P, 2001, J NERV MENT DIS, V189, P238, DOI 10.1097/00005053-200104000-00005; FRIEDMAN LM, 1998, FUNDAMENTALS CLIN TR, P151; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Goodman R, 1999, J ABNORM CHILD PSYCH, V27, P17, DOI 10.1023/A:1022658222914; Hirschfeld RMA, 2000, J CLIN PSYCHIAT, V61, P268, DOI 10.4088/JCP.v61n0405; Igreja V, 2004, BRIT J PSYCHIAT, V184, P251, DOI 10.1192/bjp.184.3.251; KALKSMAVANLITH B, 2005, STATE ART PSYCHOSOCI; KASHALA E, 2006, CO EXISTING SYMPTOMS; Lin EHB, 2000, ARCH FAM MED, V9, P1052, DOI 10.1001/archfami.9.10.1052; Lustig SL, 2004, J AM ACAD CHILD PSY, V43, P24, DOI 10.1097/00004583-200401000-00012; Mufson L, 1999, ARCH GEN PSYCHIAT, V56, P573, DOI 10.1001/archpsyc.56.6.573; Mufson Laura, 2004, American Journal of Psychotherapy, V58, P220; Omar RZ, 2000, STAT MED, V19, P2675, DOI 10.1002/1097-0258(20001015)19:19<2675::AID-SIM556>3.3.CO;2-1; Patel V, 2003, LANCET, V361, P33, DOI 10.1016/S0140-6736(03)12119-8; PROSCHAN MA, 1995, AM STAT, V49, P144, DOI 10.2307/2684628; Samad L, 2005, INT J METH PSYCH RES, V14, P158, DOI 10.1002/mpr.3; Stichick T, 2001, CHILD ADOL PSYCH CL, V10, P797, DOI 10.1016/S1056-4993(18)30031-2; Sumathipala A, 2000, PSYCHOL MED, V30, P747, DOI 10.1017/S0033291799002160; Thabet AAM, 2004, CHILD ABUSE NEGLECT, V28, P77, DOI 10.1016/j.chiabu.2002.12.002; WEISSMAN MM, 1981, ARCH GEN PSYCHIAT, V38, P51; WEISSMAN MM, 2000, COMPREHENSIVE GUIDE; Young JF, 2006, J AM ACAD CHILD PSY, V45, P904, DOI 10.1097/01.chi.0000222791.23927.5f	29	340	340	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 1	2007	298	5					519	527		10.1001/jama.298.5.519	http://dx.doi.org/10.1001/jama.298.5.519			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	195US	17666672	Bronze			2023-01-03	WOS:000248438100019
J	Friedlander, RM				Friedlander, Robert M.			Arteriovenous malformations of the brain	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRACRANIAL VASCULAR MALFORMATIONS; NATURAL-HISTORY; ENDOVASCULAR TREATMENT; OLMSTED COUNTY; GRADING SYSTEM; HEMORRHAGE; RISK; RADIOSURGERY; COMPLICATIONS; FREQUENCY		Brigham & Womens Hosp, Dept Neurosurg, Div Cerebrovasc Surg, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Friedlander, RM (corresponding author), Brigham & Womens Hosp, Dept Neurosurg, Div Cerebrovasc Surg, 75 Francis St, Boston, MA 02115 USA.	rfriedlander@rics.bwh.harvard.edu	Friedlander, Robert M/A-2845-2016	Friedlander, Robert M/0000-0003-4423-9219				Al-Shahi R, 2002, J NEUROL NEUROSUR PS, V73, P547, DOI 10.1136/jnnp.73.5.547; Al-Shahi R, 2001, BRAIN, V124, P1900, DOI 10.1093/brain/124.10.1900; ApSimon HT, 2002, STROKE, V33, P2794, DOI 10.1161/01.STR.0000043674.99741.9B; Barker FG, 2003, J NEUROSURG, V99, P254, DOI 10.3171/jns.2003.99.2.0254; BATJER H, 1986, NEUROSURGERY, V18, P29, DOI 10.1227/00006123-198601000-00006; Brown RD, 1996, J NEUROSURG, V85, P29, DOI 10.3171/jns.1996.85.1.0029; BROWN RD, 1990, J NEUROSURG, V73, P859, DOI 10.3171/jns.1990.73.6.0859; Brown RD, 1996, NEUROLOGY, V46, P949, DOI 10.1212/WNL.46.4.949; CRAWFORD PM, 1986, J NEUROL NEUROSUR PS, V49, P1, DOI 10.1136/jnnp.49.1.1; Fleetwood IG, 2002, LANCET, V359, P863, DOI 10.1016/S0140-6736(02)07946-1; Flickinger JC, 2002, RADIOTHER ONCOL, V63, P347, DOI 10.1016/S0167-8140(02)00103-2; FRIEDMAN WA, 1995, J NEUROSURG, V82, P180, DOI 10.3171/jns.1995.82.2.0180; GRAF CJ, 1983, J NEUROSURG, V58, P331, DOI 10.3171/jns.1983.58.3.0331; GROSS CR, 1984, STROKE, V15, P249, DOI 10.1161/01.STR.15.2.249; HAMILTON MG, 1994, NEUROSURGERY, V34, P2; Hartmann A, 1998, STROKE, V29, P931, DOI 10.1161/01.STR.29.5.931; Hartmann A, 2002, STROKE, V33, P1816, DOI 10.1161/01.STR.0000020123.80940.B2; HEISERMAN JE, 1994, AM J NEURORADIOL, V15, P1401; Heros R C, 1993, Clin Neurosurg, V40, P139; HORTON JC, 1990, NEUROSURGERY, V27, P867, DOI 10.1227/00006123-199012000-00002; KIKUCHI K, 1994, SURG NEUROL, V41, P374, DOI 10.1016/0090-3019(94)90030-2; LASJAUNIAS P, 1988, ACTA NEUROCHIR, V91, P29, DOI 10.1007/BF01400524; LAUFER L, 1994, PEDIATR RADIOL, V24, P272, DOI 10.1007/BF02015455; MANDYBUR TI, 1990, ARCH PATHOL LAB MED, V114, P970; Maruyama K, 2005, NEW ENGL J MED, V352, P146, DOI 10.1056/NEJMoa040907; Mast H, 1997, LANCET, V350, P1065, DOI 10.1016/S0140-6736(97)05390-7; McCormick W., 1984, INTRACRANIAL ARTERIO, P44, DOI 10.1016/S1042-3680(18)30174-8; McCormick WF., 1978, WKLY UPDATE NEUROL N, V14, P2; MONTEIRO JMP, 1993, HEADACHE, V33, P563, DOI 10.1111/j.1526-4610.1993.hed3310563.x; Ogilvy CS, 2001, STROKE, V32, P1458, DOI 10.1161/01.STR.32.6.1458; ONDRA SL, 1990, J NEUROSURG, V73, P387, DOI 10.3171/jns.1990.73.3.0387; PERRET G, 1966, J NEUROSURG, V25, P467, DOI 10.3171/jns.1966.25.4.0467; Pikus HJ, 1998, J NEUROSURG, V88, P641, DOI 10.3171/jns.1998.88.4.0641; PRITZ MB, 1994, ACTA NEUROCHIR, V131, P314, DOI 10.1007/BF01808635; PRITZ MB, 1994, ACTA NEUROCHIR, V128, P150, DOI 10.1007/BF01400666; Redekop G, 1998, J NEUROSURG, V89, P539, DOI 10.3171/jns.1998.89.4.0539; SADASIVAN B, 1990, SURG NEUROL, V33, P305, DOI 10.1016/0090-3019(90)90197-W; Sirin S, 2006, NEUROSURGERY, V58, P17, DOI 10.1227/01.NEU.0000190653.42970.6B; Soderman M, 2003, EUR J RADIOL, V46, P195, DOI 10.1016/S0720-048X(03)00091-3; SPETZLER RF, 1992, J NEUROSURG, V76, P918, DOI 10.3171/jns.1992.76.6.0918; SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476; Stapf C, 2006, NEUROLOGY, V66, P1350, DOI 10.1212/01.wnl.0000210524.68507.87; Stapf C, 2006, CURR OPIN NEUROL, V19, P63, DOI 10.1097/01.wco.0000200546.14668.78; Stapf C, 2003, STROKE, V34, pE29, DOI 10.1161/01.STR.0000068784.36838.19; Stefani MA, 2002, STROKE, V33, P1220, DOI 10.1161/01.STR.0000013738.53113.33; Stieg P, 2007, INTRACRANIAL ARTERIO; Taylor CL, 2004, J NEUROSURG, V100, P810, DOI 10.3171/jns.2004.100.5.0810; Trivedi R A, 2003, J Obstet Gynaecol, V23, P484; TURJMAN F, 1995, NEUROSURGERY, V37, P856, DOI 10.1227/00006123-199511000-00002; Weber W, 2007, AM J NEURORADIOL, V28, P371; WILKINS RH, 1985, NEUROSURGERY, V16, P421, DOI 10.1227/00006123-198503000-00026	51	217	225	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2007	356	26					2704	2712		10.1056/NEJMcp067192	http://dx.doi.org/10.1056/NEJMcp067192			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	183HS	17596605				2023-01-03	WOS:000247564500008
J	Mitchell, JD; Borasio, GD				Mitchell, J. D.; Borasio, G. D.			Amyotrophic lateral sclerosis	LANCET			English	Review							QUALITY-OF-LIFE; STEM-CELL THERAPY; SELECTIVE MOTONEURON VULNERABILITY; RANDOMIZED CLINICAL-TRIAL; MOTOR-NEURON DISEASE; ALS PATIENTS; NATURAL-HISTORY; DOUBLE-BLIND; NONINVASIVE VENTILATION; PROLONGS SURVIVAL	Amyotrophic lateral sclerosis (known in the UK as motor neuron disease) is a devastating illness with uncertain pathogenesis. In this Seminar, we review its natural history, clinical features, diagnostic criteria, variant and mimic syndromes, genetic forms, and epidemiology. Several hypotheses about causes of the disorder are discussed, such as excitotoxicity and oxidant stress, and we review past and present putative disease-modifying treatments. Disease-management strategies, from telling the patient about their illness to end-of-life decisions and palliative care, are presented. We review options for control of the main symptoms of amyotrophic lateral sclerosis-including dysphagia, dysarthria, respiratory distress, pain, and psychological disorders-and care in the terminal phase. The need for good psychosocial and spiritual care of patients and families is emphasised. We conclude with an overview of some current major issues and future prospects, ranging from the search for disease markers to challenging developments such as stem-cell and gene therapy.	Royal Preston Hosp, Motor Neurone Dis Care & Res Ctr, Preston PR2 9HT, Lancs, England; Munich Univ Hosp, Dept Neurol, Interdisciplinary Ctr Palliat Med, D-81366 Munich, Germany; Munich Univ Hosp, Dept Neurol, Motor Neurone Dis Res Grp, D-81366 Munich, Germany	Royal Preston Hospital; University of Munich; University of Munich	Mitchell, JD (corresponding author), Royal Preston Hosp, Motor Neurone Dis Care & Res Ctr, Preston PR2 9HT, Lancs, England.	Douglas.Mitchell@lthtr.nhs.uk		Borasio, Gian Domenico/0000-0002-2737-3662				ALEXIANU ME, 1994, ANN NEUROL, V36, P846, DOI 10.1002/ana.410360608; Andersen PM, 2006, CURR NEUROL NEUROSCI, V6, P37, DOI 10.1007/s11910-996-0008-9; Andersen PM, 2005, EUR J NEUROL, V12, P921, DOI 10.1111/j.1468-1331.2005.01351.x; Aoki Shigeki, 2005, Radiat Med, V23, P195; APPEL SH, 2004, AMYOTROPH LATERAL S2, V5, P54; APPEL V, 1987, ANN NEUROL, V22, P328, DOI 10.1002/ana.410220308; Armon C, 2003, NEUROEPIDEMIOLOGY, V22, P217, DOI 10.1159/000070562; Armon C, 2001, NEUROEPIDEMIOLOGY, V20, P2, DOI 10.1159/000054751; Azzouz M, 2004, NATURE, V429, P413, DOI 10.1038/nature02544; Bacman SR, 2006, MOL NEUROBIOL, V33, P113, DOI 10.1385/MN:33:2:113; Beghi E, 2000, NEUROLOGY, V54, P469, DOI 10.1212/WNL.54.2.469; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; Bongioanni P, 2004, Cochrane Database Syst Rev, pCD004302, DOI 10.1002/14651858.CD004302.pub2; Borasio GD, 1998, J NEUROL, V245, P717, DOI 10.1007/s004150050273; Borasio GD, 2001, AMYOTROPH LATERAL SC, V2, P159, DOI 10.1080/146608201753275517; Borasio GD, 1998, J NEUROL SCI, V160, pS127, DOI 10.1016/S0022-510X(98)00211-1; Borasio GD, 2001, NEUROL CLIN, V19, P829, DOI 10.1016/S0733-8619(05)70049-9; BORASIO GD, 2006, PALLIATIVE CARE AMYO, P55; Bourke SC, 2006, LANCET NEUROL, V5, P140, DOI 10.1016/S1474-4422(05)70326-4; Bowser R, 2006, EXPERT REV MOL DIAGN, V6, P387, DOI 10.1586/14737159.6.3.387; Brooks BR, 2004, NEUROLOGY, V63, P1364; BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0; Brooks BR, 1996, ARCH NEUROL-CHICAGO, V53, P141; Ceroni M, 1999, NEUROLOGY, V53, P1064, DOI 10.1212/WNL.53.5.1064; Chevalier-Larsen E, 2006, BBA-MOL BASIS DIS, V1762, P1094, DOI 10.1016/j.bbadis.2006.04.002; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Chio A, 2004, J NEUROL NEUROSUR PS, V75, P645, DOI 10.1136/jnnp.2003.020347; Cudkowicz ME, 2003, NEUROLOGY, V61, P456, DOI 10.1212/WNL.61.4.456; de Carvalho M, 2005, AMYOTROPH LATERAL SC, V6, P17, DOI 10.1080/14660820410020600; de Paulis Tomas, 2003, Curr Opin Investig Drugs, V4, P863; Desnuelle C, 2001, AMYOTROPH LATERAL SC, V2, P9, DOI 10.1080/146608201300079364; Federici T, 2006, MUSCLE NERVE, V33, P302, DOI 10.1002/mus.20439; Figlewicz DA, 2003, AMYOTROPH LATERAL SC, V4, P225, DOI 10.1080/14660820310011287; GALLAGHER D, 2006, PALLIATIVE CARE AMYO, P143; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; Giess R, 2000, J NEUROL NEUROSUR PS, V69, P121, DOI 10.1136/jnnp.69.1.121; Gordon PH, 2006, NEUROLOGY, V66, P1117, DOI 10.1212/01.wnl.0000204235.81272.e2; Gordon PH, 2006, NEUROLOGY, V66, P647, DOI 10.1212/01.wnl.0000200962.94777.71; Gordon PH, 2004, NEUROLOGY, V62, P1845, DOI 10.1212/01.WNL.0000125321.92112.7E; Gregory S, 2002, NEUROLOGY, V58, P485, DOI 10.1212/WNL.58.3.485; Groeneveld GJ, 2003, ANN NEUROL, V53, P437, DOI 10.1002/ana.10554; HAVERKAMP LJ, 1995, BRAIN, V118, P707, DOI 10.1093/brain/118.3.707; HILLEL AD, 1989, NEUROEPIDEMIOLOGY, V8, P142, DOI 10.1159/000110176; Ince PG, 2005, NEUROPATH APPL NEURO, V31, P345, DOI 10.1111/j.1365-2990.2005.00686.x; Jenkinson C, 2000, J NEUROL SCI, V180, P94, DOI 10.1016/S0022-510X(00)00420-2; JONES CT, 1995, J MED GENET, V32, P290, DOI 10.1136/jmg.32.4.290; Kasarskis EJ, 1999, J NEUROL SCI, V169, P118, DOI 10.1016/S0022-510X(99)00230-0; Kasarskis EJ, 1999, NEUROLOGY, V52, P1427; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; KENNEDY WR, 1968, NEUROLOGY, V18, P671, DOI 10.1212/WNL.18.7.671; Kleopa KA, 1999, J NEUROL SCI, V164, P82, DOI 10.1016/S0022-510X(99)00045-3; Kubler A, 2005, NEUROLOGY, V64, P1775, DOI 10.1212/01.WNL.0000158616.43002.6D; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; LAMBERT R, 2006, PALLIATIVE CARE AMYO, P169; Lyall R, 2006, PALLIATIVE CARE AMYO, P63; Mazzini L, 2003, AMYOTROPH LATERAL SC, V4, P158, DOI 10.1080/14660820310014653; MCMURRAY A, 2006, PALLIATIVE CARE AMYO, P301; Meininger V, 2006, NEUROLOGY, V66, P88, DOI 10.1212/01.wnl.0000191326.40772.62; Meininger V, 2004, AMYOTROPH LATERAL SC, V5, P107, DOI 10.1080/14660820410019602; Miller RG, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001447.pub2; Miller RG, 2001, NEUROLOGY, V56, P843, DOI 10.1212/WNL.56.7.843; Miller RG, 1999, NEUROLOGY, V52, P1311, DOI 10.1212/WNL.52.7.1311; Mills KR, 2003, BRAIN, V126, P2558, DOI 10.1093/brain/awg260; Mitchell JD, 2006, AMYOTROPH LATERAL SC, V7, P67, DOI 10.1080/14660820500396984; Mitchell JD, 2000, AMYOTROPH LATERAL SC, V1, P235, DOI 10.1080/14660820050515061; MITCHELL JD, 1987, J NEUROL NEUROSUR PS, V50, P919, DOI 10.1136/jnnp.50.7.919; MITCHELL JD, 1987, NEUROL CLIN, V5, P43, DOI 10.1016/S0733-8619(18)30934-4; MITCHELL JD, 2002, COCHRANE DB SYST REV, V3; Mitsumoto H, 2005, AMYOTROPH LATERAL SC, V6, P145, DOI 10.1080/14660820510028647; Murphy PL, 2000, NEUROLOGY, V55, P1581, DOI 10.1212/WNL.55.10.1581; Mustfa N, 2006, NEUROLOGY, V66, P1211, DOI 10.1212/01.wnl.0000208957.88534.11; *NAT I CLIN EXC, 2001, GUID US RIL RIL TREA; Neary D, 2000, J NEUROL SCI, V180, P15, DOI 10.1016/S0022-510X(00)00425-1; Neudert C, 2001, J NEUROL SCI, V191, P103, DOI 10.1016/S0022-510X(01)00612-8; Neudert C, 2001, J NEUROL, V248, P612, DOI 10.1007/s004150170140; Neudert Christian, 2004, J Palliat Med, V7, P551, DOI 10.1089/1096621041838443; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; NEWRICK PG, 1985, J NEUROL NEUROSUR PS, V48, P838, DOI 10.1136/jnnp.48.8.838; OBRIEN T, 1992, BRIT MED J, V304, P471, DOI 10.1136/bmj.304.6825.471; Ochs G, 2000, AMYOTROPH LATERAL SC, V1, P201, DOI 10.1080/14660820050515197; Oliver D, 1996, J NEUROL SCI, V139, P134, DOI 10.1016/0022-510X(96)00087-1; Oliver D., 2006, PALLIATIVE CARE AMYO; Orrell RW, 2006, CURR OPIN INVEST DR, V7, P70; ORRELL RW, 2005, COCHRANE DB SYST REV, V1; Parkinson N, 2006, NEUROLOGY, V67, P1074, DOI 10.1212/01.wnl.0000231510.89311.8b; Pellegrino TR, 1998, NEUROLOGY, V50, P596; Pontieri FE, 2005, NEUROL SCI, V26, P285, DOI 10.1007/s10072-005-0474-x; Qureshi MM, 2006, AMYOTROPH LATERAL SC, V7, P173, DOI 10.1080/14660820600640596; Rabkin JG, 2005, NEUROLOGY, V65, P62, DOI 10.1212/01.wnl.0000167187.14501.0c; Rabkin JG, 2000, PSYCHOSOM MED, V62, P271, DOI 10.1097/00006842-200003000-00020; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Ryberg H, 2003, ACTA NEUROL SCAND, V108, P1, DOI 10.1034/j.1600-0404.2003.00111.x; Sancho J, 2004, CHEST, V125, P1400, DOI 10.1378/chest.125.4.1400; SCOTT A, 2006, PALLIATIVE CARE AMYO, P213; Silahtaroglu AN, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-5; Silani V, 2004, CURR NEUROVASC RES, V1, P283, DOI 10.2174/1567202043362243; Silani V, 2004, LANCET, V364, P200, DOI 10.1016/S0140-6736(04)16634-8; Silani V, 2003, AMYOTROPH LATERAL SC, V4, P8, DOI 10.1080/14660820301177; SILVERSTEIN MD, 1991, MAYO CLIN PROC, V66, P906, DOI 10.1016/S0025-6196(12)61577-8; Simmons Z, 2005, NEUROLOGIST, V11, P257, DOI 10.1097/01.nrl.0000178758.30374.34; Simmons Z, 2000, NEUROLOGY, V55, P388, DOI 10.1212/WNL.55.3.388; Stalpers LJA, 2002, NEUROLOGY, V58, P1308, DOI 10.1212/WNL.58.8.1308; Storkebaum E, 2005, NAT NEUROSCI, V8, P85, DOI 10.1038/nn1360; Strong MJ, 2005, J NEUROPATH EXP NEUR, V64, P649, DOI 10.1097/01.jnen.0000173889.71434.ea; Sykes N, 2003, LANCET ONCOL, V4, P312, DOI 10.1016/S1470-2045(03)01079-9; UMAPATHI T, COCHRANE DATABASE SY, V3; Van den Berg JP, 2005, NEUROLOGY, V65, P1264, DOI 10.1212/01.wnl.0000180717.29273.12; VANSCHAIK IN, 2005, COCHRANE DATABASE SY, V2; Veldink JH, 2002, NEW ENGL J MED, V346, P1638, DOI 10.1056/NEJMsa012739; von Lewinski F, 2005, TRENDS NEUROSCI, V28, P494, DOI 10.1016/j.tins.2005.07.001; WAGNERSONNTAG E, 2006, PALLIATIVE CARE AMYO, P95; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wasner M, 2001, J NEUROL SCI, V191, P151, DOI 10.1016/S0022-510X(01)00615-3; Weisskopf MG, 2004, AM J EPIDEMIOL, V160, P26, DOI 10.1093/aje/kwh179; Weisskopf MG, 2005, NEUROLOGY, V64, P32, DOI 10.1212/01.WNL.0000148649.17706.D9; *WORLD FED NEUR RE, ESC REV REV CRIT DIA; 1999, THERAPEUTIC DRUGS, pR37	117	444	488	1	133	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 16	2007	369	9578					2031	2041		10.1016/S0140-6736(07)60944-1	http://dx.doi.org/10.1016/S0140-6736(07)60944-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180HT	17574095				2023-01-03	WOS:000247354400028
J	Cahn, P; Sued, O				Cahn, Pedro; Sued, Omar			Raltegravir: a new anti retroviral class for salvage therapy	LANCET			English	Editorial Material							INHIBITORS; INTEGRASE; EFFICACY		Fdn Huesped, Dept Clin Res, Buenos Aires, DF, Argentina		Cahn, P (corresponding author), Fdn Huesped, Dept Clin Res, C1202ABB, Buenos Aires, DF, Argentina.	pcahn@huesped.org.ar	Sued, Omar/H-3325-2019	Sued, Omar/0000-0001-5818-770X				Cahn P, 2006, CLIN INFECT DIS, V43, P1347, DOI 10.1086/508352; COOPER D, 2007, 14 C RETR OPP INF LO; *DHHS PAN ANT GUID, 2006, GUID US ANT AG HIV 1; Grinsztejn B, 2007, LANCET, V369, P1261, DOI 10.1016/S0140-6736(07)60597-2; KASSAHUN K, 46 ANN INT C ANT AG, pA372; Katlama C, 2007, AIDS, V21, P395, DOI 10.1097/QAD.0b013e328013d9d7; MARKOWITZ M, 2006, 16 INT AIDS C TOR CA; Markowitz M, 2006, JAIDS-J ACQ IMM DEF, V43, P509, DOI 10.1097/QAI.0b013e31802b4956; Palmisono L, 2007, EXPERT REV ANTI-INFE, V5, P67, DOI 10.1586/14787210.5.1.67; Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660; STEIGBIGEL R, 2007, 14 C RETR OPP INF LO; TEPPLER H, 2006, 46 ANN INT C ANT AG	12	48	49	3	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 14	2007	369	9569					1235	1236		10.1016/S0140-6736(07)60571-6	http://dx.doi.org/10.1016/S0140-6736(07)60571-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164YA	17434380				2023-01-03	WOS:000246269700004
J	Dy, S; Lynn, J				Dy, Sydney; Lynn, Joanne			Getting services right for those sick enough to die	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CARE; PROGRAM		Johns Hopkins Univ, Baltimore, MD 21205 USA; RAND Corp, Arlington, VA 22202 USA	Johns Hopkins University; RAND Corporation	Dy, S (corresponding author), Johns Hopkins Univ, Baltimore, MD 21205 USA.	sdy@jhsph.edu						Aiken LS, 2006, J PALLIAT MED, V9, P111, DOI 10.1089/jpm.2006.9.111; American Academy of Hospice and Palliative Medicine Center to Advance Palliative Care Hospice and Palliative Nurses Association Last Acts Partnership National Hospice and Palliative Care Organization, 2004, J PALLIAT MED, V7, P611; *CMS, 2004, MED BEN POL MAN; Federal Interagency Foram on Aging-Related Statistics, 2006, OLD AM UPD 2006 KEY; FORD PE, 2003, J PALLIAT MED, V6, P645; GYSELS M, 2003, IMPROVING SUPPORTIVE; *HAST CTR, 1987, GUID TERM LIF SUST T; King N, 2005, PALLIATIVE MED, V19, P619, DOI 10.1191/0269216305pm1084oa; Kodner DL, 2006, HEALTH SOC CARE COMM, V14, P384, DOI 10.1111/j.1365-2524.2006.00655.x; Lorenz K, 2004, END OF LIFE CARE OUT; Lunney JR, 2002, J AM GERIATR SOC, V50, P1108, DOI 10.1046/j.1532-5415.2002.50268.x; LYNN J, 2004, SICK DEATH NOT GOING; *MEDPAC, 2006, REP C INCR VAL MED W, P59; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; *NAT I HLTH STAT O, 2005, J PALLIAT MED S, V8; *ONS, 2004, NAT POP PROJ; Temkin-Greener H, 2002, J AM GERIATR SOC, V50, P125, DOI 10.1046/j.1532-5415.2002.50018.x	17	20	20	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 10	2007	334	7592					511	513		10.1136/bmj.39127.653704.80	http://dx.doi.org/10.1136/bmj.39127.653704.80			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	148VV	17347238	Green Published			2023-01-03	WOS:000245106400039
J	Juliano, R				Juliano, Rudy			Clinical implications of basic research: Bugging tumors to put drugs on target	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27515 USA; Univ N Carolina, Sch Med, Carolina Ctr Canc Nanotechnol Excellence, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Juliano, R (corresponding author), Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27515 USA.							Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833; Cheong I, 2006, SCIENCE, V314, P1308, DOI 10.1126/science.1130651; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; Rolland JP, 2005, J AM CHEM SOC, V127, P10096, DOI 10.1021/ja051977c	4	7	8	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 1	2007	356	9					954	955		10.1056/NEJMcibr067638	http://dx.doi.org/10.1056/NEJMcibr067638			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HV	17329705				2023-01-03	WOS:000244496400014
J	Markowitz, AJ; McPhee, SJ				Markowitz, Amy J.; McPhee, Stephen J.			End-of-life care for homeless patients: "She says she is there to help me in any situation"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Kushel MB, 2006, JAMA-J AM MED ASSOC, V296, P2959, DOI 10.1001/jama.296.24.2959	1	2	2	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2007	297	3					305	305		10.1001/jama.297.3.305	http://dx.doi.org/10.1001/jama.297.3.305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125VT	17227982				2023-01-03	WOS:000243472300025
J	Conter, V; Valsecchi, MG; Silvestri, D; Campbell, M; Dibar, E; Magyarosy, E; Gadner, H; Stary, J; Benoit, Y; Zimmermann, M; Reiter, A; Riehm, H; Masera, G; Schrappe, M				Conter, Valentino; Valsecchi, Maria Grazia; Silvestri, Daniela; Campbell, Myriam; Dibar, Eduardo; Magyarosy, Edina; Gadner, Helmut; Stary, Jan; Benoit, Yves; Zimmermann, Martin; Reiter, Alfred; Riehm, Hansjoerg; Masera, Giuseppe; Schrappe, Martin			Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial	LANCET			English	Article							BFM STUDY-GROUP; IN-VITRO; CHILDHOOD; PREDNISONE; INTENSIFICATION; CLASSIFICATION; THERAPY	Background Studies in the 1970s and 1980s suggested that the outcome of childhood acute lymphoblastic leukaemia (ALL) could be improved by intensification of conventional continuation chemotherapy with pulses of vincristine sulfate and steroids. We aimed to investigate the efficacy and toxic effects of vincristine-dexamethasone pulses as an addition to the continuation-therapy phase in a large cohort of children with intermediate-risk disease who were treated with the Berlin-Frankfyrt-Munster (BFM) treatment strategy. Methods 3109 children, diagnosed with ALL and intermediate-risk features, were enrolled by eight participating organisations in eleven countries. All were treated with very similar protocols based on the BFM treatment strategy, which included induction, consolidation, reinduction, and continuation-therapy phases. At the beginning of the continuation-therapy phase, those patients in complete remission were randomly assigned to either a treatment or a control group. Control patients were given conventional mercaptopurine and methotrexate chemotherapy only. Patients in the treatment arm were also given pulses of vincristine (1.5 mg/m(2) weekly for 2 weeks) and dexamethasone (6 mg/m(2) daily for 7 days) every 10 weeks for six cycles. The primary outcome measure was disease-free survival. Analysis was by intention to treat. The study is registered at http://www.clinicaltrials.gov with the identifier NCT00411541. Findings 174 patients (5.6%) relapsed or died in complete remission before randomisation. Of the remaining 2935 patients, 2618 (89.2%) were randomly assigned: 1325 to the treatment group and 1293 to the control group. With median follow-up of 4.8 years, 240 children in the treatment group and 241 in the control group had relapses; 15 in the treatment group and 14 controls died in complete remission or developed second malignant neoplasms. The 5-year and 7-year disease-free survival estimates were 79.8% (SE 1.2) and 77.5% (1.5) in the treatment group and 79.2% (1.2) and 78.4% (1.3.) in the control group, respectively. Treatment with pulses of vincristine and dexamethasone was associated with a non-significant 3% relative-risk reduction (hazard ratio 0.97; 95% CI 0.81-1.15; p=0.70). Interpretation Children with intermediate-risk ALL who received intensive chemotherapy based on BFM protocols did not benefit from intensification of the continuation-therapy phase with a schedule of pulses of vincristine and dexamethasone.	Univ Milano Bicocca, Osped San Gerardo, Dept Paediat, Monza, Italy; Univ Milano Bicocca, Med Stat Unit, Dept Clin Med Biotechnol & Prevent, Monza, Italy; Hosp Roberto Del Rio, PINDA, Dept Paediat Haematol & Oncol, Santiago, Chile; Italian Hosp, Dept Paediat Haematol & Oncol, Buenos Aires, DF, Argentina; Semmelweis Univ, Dept Paediat, Budapest, Hungary; St Anna Childrens Hosp, Childrens Canc Res Inst, Vienna, Austria; Univ Hosp Motol, Dept Paediat Haematol & Oncol, Prague, Czech Republic; Ghent Univ Hosp, Dept Paediat Haematooncol, B-9000 Ghent, Belgium; European Org Res Treatment Canc, Childrens Leukemia Grp, Brussels, Belgium; Hannover Med Sch, Dept Paediat Haematol & Oncol, D-3000 Hannover, Germany; Univ Childrens Hosp, Dept Paediat Haematol & Oncol, Giessen, Germany; Univ Med Ctr Schleswig Holstein, Dept Paediat, Kiel, Germany	San Gerardo Hospital; University of Milano-Bicocca; University of Milano-Bicocca; Universidad de Chile; Hospital Italiano de Buenos Aires; Semmelweis University; Saint Anna Children's Hospital; Motol University Hospital; Ghent University; Ghent University Hospital; European Organisation for Research & Treatment of Cancer; Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Kiel; Schleswig Holstein University Hospital	Conter, V (corresponding author), Univ Milano Bicocca, Osped San Gerardo, Dept Paediat, Monza, Italy.	valentino.conter@pediatriamonza.it	Schrappe, Martin/A-8109-2010; Stary, Jan/AAB-9635-2020; Schrappe, Martin/ABA-6144-2020; Valsecchi, Maria Grazia/K-8891-2016	Valsecchi, Maria Grazia/0000-0001-5574-3504				Arico M, 2005, Leukemia, V19, P1145, DOI 10.1038/sj.leu.2403783; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BLEYER WA, 1991, J CLIN ONCOL, V9, P1012, DOI 10.1200/JCO.1991.9.6.1012; Bostrom BC, 2003, BLOOD, V101, P3809, DOI 10.1182/blood-2002-08-2454; Carroll William L, 2003, Hematology Am Soc Hematol Educ Program, P102; CHESSELLS JM, 1995, LANCET, V345, P143, DOI 10.1016/S0140-6736(95)90164-7; CLAVELL LA, 1986, NEW ENGL J MED, V315, P657, DOI 10.1056/NEJM198609113151101; Conter V, 1997, J CLIN ONCOL, V15, P2786, DOI 10.1200/JCO.1997.15.8.2786; Conter V, 2000, LEUKEMIA, V14, P2196, DOI 10.1038/sj.leu.2401963; COX DR, 1972, J R STAT SOC B, V34, P187; Gaynon PS, 2000, LEUKEMIA, V14, P2223, DOI 10.1038/sj.leu.2401939; Henze G, 1990, Haematol Blood Transfus, V33, P483; HOLLAND JF, 1972, CANCER-AM CANCER SOC, V30, P1480, DOI 10.1002/1097-0142(197212)30:6<1480::AID-CNCR2820300611>3.0.CO;2-3; JONES B, 1991, MED PEDIATR ONCOL, V19, P269, DOI 10.1002/mpo.2950190411; Kaspers GJL, 1996, MED PEDIATR ONCOL, V27, P114; KLUMPER E, 1995, BLOOD, V86, P3861, DOI 10.1182/blood.V86.10.3861.bloodjournal86103861; Masera G, 1998, INT J PEDIAT HEM ONC, V5, P141; PINKEL D, 1971, CANCER-AM CANCER SOC, V27, P247, DOI 10.1002/1097-0142(197102)27:2<247::AID-CNCR2820270202>3.0.CO;2-C; Pui CH, 2000, LEUKEMIA, V14, P2286, DOI 10.1038/sj.leu.2401938; REITER A, 1994, BLOOD, V84, P3122, DOI 10.1182/blood.V84.9.3122.3122; Richards S, 1996, LANCET, V347, P1783; Riehm H, 1990, Haematol Blood Transfus, V33, P439; Sallan S E, 1990, Haematol Blood Transfus, V33, P459; Schrappe M, 2000, LEUKEMIA, V14, P2205, DOI 10.1038/sj.leu.2401973; TUBERGEN DG, 1993, J CLIN ONCOL, V11, P527, DOI 10.1200/JCO.1993.11.3.527; Valsecchi MG, 1996, ANN ONCOL, V7, P1005; VANDERDOESVANDENBERG A, 1992, MED PEDIATR ONCOL, V20, P497, DOI 10.1002/mpo.2950200603; Veerman AJP, 1996, J CLIN ONCOL, V14, P911, DOI 10.1200/JCO.1996.14.3.911	28	79	84	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2007	369	9556					123	131		10.1016/S0140-6736(07)60073-7	http://dx.doi.org/10.1016/S0140-6736(07)60073-7			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126TK	17223475				2023-01-03	WOS:000243538200031
J	Potti, A; Dressman, HK; Bild, A; Riedel, RF; Chan, G; Sayer, R; Cragun, J; Cottrill, H; Kelley, MJ; Petersen, R; Harpole, D; Marks, J; Berchuck, A; Ginsburg, GS; Febbo, P; Lancaster, J; Nevins, JR				Potti, Anil; Dressman, Holly K.; Bild, Andrea; Riedel, Richard F.; Chan, Gina; Sayer, Robyn; Cragun, Janiel; Cottrill, Hope; Kelley, Michael J.; Petersen, Rebecca; Harpole, David; Marks, Jeffrey; Berchuck, Andrew; Ginsburg, Geoffrey S.; Febbo, Phillip; Lancaster, Johnathan; Nevins, Joseph R.			RETRACTED: Genomic signatures to guide the use of chemotherapeutics (Retracted article. See vol. 17, pg. 135, 2011)	NATURE MEDICINE			English	Article; Retracted Publication							ACUTE LYMPHOBLASTIC-LEUKEMIA; METASTATIC BREAST-CANCER; PACLITAXEL SENSITIVITY; THERAPEUTIC RESPONSE; EXPRESSION PATTERNS; SINGLE-AGENT; LUNG-CANCER; PREDICTION; RESISTANCE; MARKER	Using in vitro drug sensitivity data coupled with Affymetrix microarray data, we developed gene expression signatures that predict sensitivity to individual chemotherapeutic drugs. Each signature was validated with response data from an independent set of cell line studies. We further show that many of these signatures can accurately predict clinical response in individuals treated with these drugs. Notably, signatures developed to predict response to individual agents, when combined, could also predict response to multidrug regimens. Finally, we integrated the chemotherapy response signatures with signatures of oncogenic pathway deregulation to identify new therapeutic strategies that make use of all available drugs. The development of gene expression profiles that can predict response to commonly used cytotoxic agents provides opportunities to better use these drugs, including using them in combination with existing targeted therapies.	Duke Univ, Duke Inst Gen Sci & Policy, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Univ S Florida, Div Gynecol Surg Oncol, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA; Univ S Florida, Res Inst, Tampa, FL 33612 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA	Duke University; Duke University; Duke University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Duke University; Duke University	Nevins, JR (corresponding author), Duke Univ, Duke Inst Gen Sci & Policy, Box 3383, Durham, NC 27710 USA.	nevin001@mc.duke.edu	Kelley, Michael/AAC-8939-2019; Riedel, Richard/HHM-4275-2022	Kelley, Michael/0000-0001-9523-6080; 	NATIONAL CANCER INSTITUTE [U54CA112952, R01CA106520] Funding Source: NIH RePORTER; NCI NIH HHS [U54 CA112952-02, R01CA106520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Blagosklonny MV, 2005, CELL CYCLE, V4, P1693, DOI 10.4161/cc.4.12.2259; Breathnach OS, 2001, J CLIN ONCOL, V19, P1734, DOI 10.1200/JCO.2001.19.6.1734; Broxterman HJ, 2005, DRUG RESIST UPDATE, V8, P183, DOI 10.1016/j.drup.2005.07.002; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; DeVita V. T., 2005, CANC PRINCIPLES PRAC; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Emi M, 2005, BREAST CANCER RES, V7, pR940, DOI 10.1186/bcr1323; Gyorffy B, 2006, INT J CANCER, V118, P1699, DOI 10.1002/ijc.21570; Herbst RS, 2006, J CLIN ONCOL, V24, P190, DOI 10.1200/JCO.2005.04.8678; Holleman A, 2004, NEW ENGL J MED, V351, P533, DOI 10.1056/NEJMoa033513; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.2307/1390807; Langer R, 2005, CLIN CANCER RES, V11, P7462, DOI 10.1158/1078-0432.CCR-05-0042; Lugthart S, 2005, CANCER CELL, V7, P375, DOI 10.1016/j.ccr.2005.03.002; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Minna JD, 2004, SCIENCE, V304, P1458, DOI 10.1126/science.1099578; Modi S, 2005, CANCER INVEST, V23, P483, DOI 10.1080/07357900500201301; Pittman J, 2004, BIOSTATISTICS, V5, P587, DOI 10.1093/biostatistics/kxh011; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Rouzier R, 2005, P NATL ACAD SCI USA, V102, P8315, DOI 10.1073/pnas.0408974102; Sargent DJ, 2005, J CLIN ONCOL, V23, P2020, DOI 10.1200/JCO.2005.01.112; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; Takahashi T, 2005, MOL CANCER THER, V4, P1039, DOI 10.1158/1535-7163.MCT-04-0282; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998	25	435	480	0	47	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2006	12	11					1294	1300		10.1038/nm1491	http://dx.doi.org/10.1038/nm1491			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17057710				2023-01-03	WOS:000241844900027
J	Korenromp, EL; Kayondo, JK				Korenromp, Eline L.; Kayondo, Jane Kengeya			Reduced mortality with home-based HIV treatment in Uganda	LANCET			English	Editorial Material							MALARIA		[Korenromp, Eline L.] Global Fund Fight AIDS TB & Malaria, CH-1214 Geneva, Switzerland; [Korenromp, Eline L.] Univ Med Ctr, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Kayondo, Jane Kengeya] WHO, UNICEF UNDP World Bank, Special Programme Res & Training Trop Dis, CH-1211 Geneva, Switzerland	Erasmus University Rotterdam; Erasmus MC; The World Bank; World Health Organization	Korenromp, EL (corresponding author), Global Fund Fight AIDS TB & Malaria, CH-1214 Geneva, Switzerland.	eline.korenromp@theglobalfund.org						Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Corbett EL, 2002, LANCET, V359, P2177, DOI 10.1016/S0140-6736(02)09095-5; Feachem RGA, 2004, TROP MED INT HEALTH, V9, P1139, DOI 10.1111/j.1365-3156.2004.01343.x; Hawley WA, 2003, AM J TROP MED HYG, V68, P121, DOI 10.4269/ajtmh.2003.68.121; *INT AIDS SOC, 2007, SYDN DECL GOOD RES D; JOHANSSON EW, 2007, MALARIA CHILDREN PRO; Mermin J, 2008, LANCET, V371, P752, DOI 10.1016/S0140-6736(08)60345-1; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; UNAIDS, 2007, 2006 UNAIDS ANN REP; Vitoria M, 2006, ANTIRETROVIRAL THERA; World Health Organization HIV/AIDS Programme, 2007, TASK SHIFT TACKL HLT; World Health Organization HIV/AIDS Programme UNAIDS, 2007, GUID PROV IN HIV TES	12	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 1	2008	371	9614					703	705		10.1016/S0140-6736(08)60320-7	http://dx.doi.org/10.1016/S0140-6736(08)60320-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268RI	18313487				2023-01-03	WOS:000253596700007
J	Okie, S				Okie, Susan			Dr. Pou and the hurricane - Implications for patient care during disasters	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		[Anonymous], AHRQ PUBLICATION; BRADLEY CW, 2007, COMMUNICATION   1022; Deichmann R, 2007, CODE BLUE KATRINA PH; KONIGSMARK AR, 2006, US TODAY        0719, pA3; SCELFO J, 2007, NEWSWEEK        0903	5	37	38	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 3	2008	358	1					1	5		10.1056/NEJMp0707917	http://dx.doi.org/10.1056/NEJMp0707917			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	246TW	18172168				2023-01-03	WOS:000252031200001
J	Dimopoulos, M; Spencer, A; Attal, M; Prince, HM; Harousseau, J; Dmoszynska, A; San Miguel, J; Hellmann, A; Facon, T; Foa, R; Corso, A; Masliak, Z; Olesnyckyj, M; Yu, ZN; Patin, J; Zeldis, JB; Knight, RD				Dimopoulos, Meletios; Spencer, Andrew; Attal, Michael; Prince, H. Miles; Harousseau, Jean-Luc; Dmoszynska, Anna; San Miguel, Jesus; Hellmann, Andrzej; Facon, Thierry; Foa, Robin; Corso, Alessandro; Masliak, Zvenyslava; Olesnyckyj, Marta; Yu, Zhinuan; Patin, John; Zeldis, Jerome B.; Knight, Robert D.		Multiple Myeloma 010 Study	Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DRUG-RESISTANCE; THALIDOMIDE; COMBINATION; THERAPY; ANALOGS; CELLS	Background Lenalidomide is a structural analogue of thalidomide with similar but more potent biologic activity. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide plus dexamethasone in the treatment of relapsed or refractory multiple myeloma. Methods Of 351 patients who had received at least one previous antimyeloma therapy, 176 were randomly assigned to receive 25 mg of oral lenalidomide and 175 to receive placebo on days 1 to 21 of a 28-day cycle. In addition, all patients received 40 mg of oral dexamethasone on days 1 to 4, 9 to 12, and 17 to 20 for the first four cycles and subsequently, after the fourth cycle, only on days 1 to 4. Patients continued in the study until the occurrence of disease progression or unacceptable toxic effects. The primary end point was time to progression. Results The time to progression was significantly longer in the patients who received lenalidomide plus dexamethasone (lenalidomide group) than in those who received placebo plus dexamethasone (placebo group) (median, 11.3 months vs. 4.7 months; P<0.001). A complete or partial response occurred in 106 patients in the lenalidomide group (60.2%) and in 42 patients in the placebo group (24.0%, P<0.001), with a complete response in 15.9% and 3.4% of patients, respectively (P<0.001). Overall survival was significantly improved in the lenalidomide group (hazard ratio for death, 0.66; P=0.03). Grade 3 or 4 adverse events that occurred in more than 10% of patients in the lenalidomide group were neutropenia (29.5%, vs. 2.3% in the placebo group), thrombocytopenia (11.4% vs. 5.7%), and venous thromboembolism (11.4% vs. 4.6%). Conclusions Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma. (ClinicalTrials.gov number, NCT00424047.).	Univ Athens, Sch Med, GR-11527 Athens, Greece; Alfred Hosp, Melbourne, Vic, Australia; Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia; CHU Purpan, Toulouse, France; CHR Hotel Dieu, Nantes, France; Univ Sch Med, Lublin, Poland; Hosp Univ Salamanca, Salamanca, Spain; Med Univ Gdansk, Gdansk, Poland; Hop Claude Huriez, Lille, France; Univ Roma La Sapienza, Rome, Italy; Policlin San Matteo, Fdn Ist Ricovero & Cura Carattere Sci, I-27100 Pavia, Italy; Inst Blood Pathol & Transfus Med, Lvov, Ukraine; Celgene, Summit, NJ USA	Athens Medical School; National & Kapodistrian University of Athens; Florey Institute of Neuroscience & Mental Health; Peter Maccallum Cancer Center; CHU de Toulouse; Nantes Universite; CHU de Nantes; Medical University of Lublin; University of Salamanca; Fahrenheit Universities; Medical University Gdansk; Universite de Lille - ISITE; CHU Lille; Sapienza University Rome; IRCCS Fondazione San Matteo; National Academy of Medical Sciences of Ukraine; Institute of Blood Pathology & Transfusion Medicine; Bristol-Myers Squibb; Celgene Corporation	Dimopoulos, M (corresponding author), Univ Athens, Sch Med, Alexandra Hosp, Vas Sophias 80, Athens 11528, Greece.	mdimop@med.uoa.gr	2007, Secribsal/A-1556-2012; San-Miguel, Jesús F./V-8977-2018; Dimopoulos, Meletios Athanasios/AAD-4130-2019	San-Miguel, Jesús F./0000-0002-9183-4857; Dimopoulos, Meletios/0000-0001-8990-3254				Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x; Boyle P, 2005, ANN ONCOL, V16, P481, DOI 10.1093/annonc/mdi098; Dimopoulos MA, 2001, ANN ONCOL, V12, P991, DOI 10.1023/A:1011132808904; Dimopoulos MA, 2004, AM J MED, V117, P508, DOI 10.1016/j.amjmed.2004.03.040; Garcia-Sanz R, 2004, LEUKEMIA, V18, P856, DOI 10.1038/sj.leu.2403322; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Kumar S, 2005, NAT CLIN PRACT ONCOL, V2, P262, DOI 10.1038/ncponc0174; Marriott JB, 2002, CLIN EXP IMMUNOL, V130, P75, DOI 10.1046/j.1365-2249.2002.01954.x; Richardson PG, 2006, BLOOD, V108, P3458, DOI 10.1182/blood-2006-04-015909; Richardson PG, 2002, BLOOD, V100, P3063, DOI 10.1182/blood-2002-03-0996; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Singhal S, 2000, NEW ENGL J MED, V342, P364	13	1140	1211	1	55	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 22	2007	357	21					2123	2132		10.1056/NEJMoa070594	http://dx.doi.org/10.1056/NEJMoa070594			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	233FT	18032762	Bronze			2023-01-03	WOS:000251076500004
J	Palumbo, A; Boccadoro, M				Palumbo, Antonio; Boccadoro, Mario			A new standard of care for elderly patients with myeloma	LANCET			English	Editorial Material							MULTIPLE-MYELOMA; PLUS THALIDOMIDE; PREDNISONE; MELPHALAN		Univ Turin, Azienda Osped San Giovanni Battista, Div Ematol, I-10126 Turin, Italy	A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Turin	Palumbo, A (corresponding author), Univ Turin, Azienda Osped San Giovanni Battista, Div Ematol, I-10126 Turin, Italy.	appalumbo@yahoo.com		Boccadoro, Mario/0000-0001-8130-5209				Anderson KC, 2007, EXP HEMATOL, V35, P155, DOI 10.1016/j.exphem.2007.01.024; [Anonymous], 1998, J Clin Oncol, V16, P3832; El Accaoui RN, 2007, THROMB HAEMOSTASIS, V97, P1031, DOI 10.1160/TH06-09-0494; Facon T, 2007, LANCET, V370, P1209, DOI 10.1016/S0140-6736(07)61537-2; Ghobrial IM, 2007, EXPERT OPIN EMERG DR, V12, P155, DOI 10.1517/14728214.12.1.155; Hulin C, 2007, J CLIN ONCOL, V25, p441s; LUDWIG H, 2007, HEMATOLOGICA, V92, pS166; Morgan GJ, 2006, LANCET ONCOL, V7, P316, DOI 10.1016/S1470-2045(06)70657-X; Palumbo A, 2006, LANCET, V367, P825, DOI 10.1016/S0140-6736(06)68338-4	9	8	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 6	2007	370	9594					1191	1192		10.1016/S0140-6736(07)61522-0	http://dx.doi.org/10.1016/S0140-6736(07)61522-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219NM	17920906				2023-01-03	WOS:000250091900004
J	Osborne, M				Osborne, Molly			Intensive insulin therapy in the medical	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97239 USA	Oregon Health & Science University	Osborne, M (corresponding author), Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Mail COde L102,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.							Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521	1	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 18	2007	147	6					412	413		10.7326/0003-4819-147-6-200709180-00011	http://dx.doi.org/10.7326/0003-4819-147-6-200709180-00011			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214GY	17876023				2023-01-03	WOS:000249726200006
J	Mitsumoto, H; Rabkin, JG				Mitsumoto, Hiroshi; Rabkin, Judith G.			Palliative care for patients with amyotrophic lateral sclerosis - "Prepare for the worst and hope for the best"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; TERM MECHANICAL VENTILATION; SERIOUSLY ILL PATIENTS; ALS PATIENTS; NONINVASIVE VENTILATION; ASSISTED SUICIDE; CANCER-PATIENTS; STAGE ALS; CAREGIVERS	Amyotrophic lateral sclerosis (ALS) is a devastating terminal neurodegenerative disease with a highly predictable clinical course such that palliative care should begin at or soon after diagnosis. The outcome is certain in most cases. The only medication approved for treatment in the United States, riluzole, extends life by about 2 months. Virtually all skeletal muscles eventually are affected. Multiple problems require a multidisciplinary approach including aggressive symptomatic management, rehabilitation to maintain motor function, nutritional and respiratory support, augmentative communication devices, and psychological support for both patients and families because family members so often play a central role in management and care. Social, bioethical, and financial issues as well as advance directives should be addressed long before enteral feeding or assistive ventilatory support might be considered. Goals of care should be assessed on an ongoing basis. Presenting the unusual case of a patient with ALS who is also a prominent neurologist specializing in ALS, we enumerate issues in management and palliative care applicable to ALS but also to other fatal, progressive neurologic diseases such as Huntington's chorea and late-stage Parkinson disease.	Columbia Univ, Coll Phys & Surg, Dept Psychiat, Eleanor & Lou Gehrig ALS MDA Ctr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Neurol Inst, Dept Psychiat, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, New York, NY 10032 USA	Columbia University; Columbia University; New York State Psychiatry Institute	Rabkin, JG (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Psychiat, Eleanor & Lou Gehrig ALS MDA Ctr, 1051 Riverside Dr, New York, NY 10032 USA.	jgr1@columbia.edu						Albert SM, 1999, NEUROLOGY, V53, P278, DOI 10.1212/WNL.53.2.278; Albert SM, 2005, NEUROLOGY, V65, P68, DOI 10.1212/01.wnl.0000168161.54833.bb; Albert SM, 2001, J NEUROL SCI, V191, P115, DOI 10.1016/S0022-510X(01)00614-1; Andersen PM, 2006, CURR NEUROL NEUROSCI, V6, P37, DOI 10.1007/s11910-996-0008-9; Bascom PB, 2002, JAMA-J AM MED ASSOC, V288, P91, DOI 10.1001/jama.288.1.91; Belsh JM, 1999, NEUROLOGY, V53, pS26; Borasio GD, 1998, J NEUROL, V245, P717, DOI 10.1007/s004150050273; Bourke SC, 2006, LANCET NEUROL, V5, P140, DOI 10.1016/S1474-4422(05)70326-4; Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; CHAD DA, 2006, AMYOTROPH LATERAL SC, P201; Chen ML, 2004, SUPPORT CARE CANCER, V12, P469, DOI 10.1007/s00520-004-0636-z; Chio A, 2005, NEUROLOGY, V64, P1780, DOI 10.1212/01.WNL.0000162034.06268.37; Cummings JL, 2006, CNS SPECTRUMS, V11, P1; CWIK VA, 2006, AMYOTROPHIC LATERAL, P99; DELBENE ML, 2003, AMYOTROPH LATERAL S1, V4, P64; Desport JC, 1999, NEUROLOGY, V53, P1059, DOI 10.1212/WNL.53.5.1059; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; GANZINI L, 2005, AMYOTROPHIC LATERAL, P811; GELINAS D, 2001, AMYOTROPHIC LATERAL, P47; Gelinas DF, 1998, J NEUROL SCI, V160, pS134, DOI 10.1016/S0022-510X(98)00212-3; GIRGIS A, 1995, J CLIN ONCOL, V13, P2449, DOI 10.1200/JCO.1995.13.9.2449; Goldstein LH, 2006, PSYCHOL MED, V36, P865, DOI 10.1017/S0033291706007124; Goldstein LH, 2000, J NEUROL SCI, V180, P101, DOI 10.1016/S0022-510X(00)00416-0; Gordon PH, 2006, AMYOTROPHIC LATERAL, P227; Hayase T, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-25; Hayashi H, 2003, NEUROLOGY, V61, P135, DOI 10.1212/01.WNL.0000069925.02052.1F; HOERTH CL, 2006, AMYOTROPHIC LATERAL, P117; *I MED, 1997, APPR DEATH IMPR CAR, P31; Jackson CE, 2006, AMYOTROPH LATERAL SC, P649; Kaub-Wittemer D, 2003, J PAIN SYMPTOM MANAG, V26, P890, DOI 10.1016/S0885-3924(03)00323-3; Krivickas LS, 1997, J NEUROL SCI, V152, pS82, DOI 10.1016/S0022-510X(97)00251-7; KRIVIKAS LS, 2006, AMYOTROPHIC LATERAL, P691; Lamont EB, 2003, JAMA-J AM MED ASSOC, V290, P98, DOI 10.1001/jama.290.1.98; Larson AM, 2006, JAMA-J AM MED ASSOC, V295, P2168, DOI 10.1001/jama.295.18.2168; LI TM, 1990, J NEUROL NEUROSUR PS, V53, P1043, DOI 10.1136/jnnp.53.12.1043; Lo B, 2005, JAMA-J AM MED ASSOC, V294, P1810, DOI 10.1001/jama.294.14.1810; Lomen-Hoerth C, 2002, NEUROLOGY, V59, P1077, DOI 10.1212/WNL.59.7.1077; Lyall RA, 2001, NEUROLOGY, V57, P153, DOI 10.1212/WNL.57.1.153; Lyall RA, 2001, BRAIN, V124, P2000, DOI 10.1093/brain/124.10.2000; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; MAZZINI L, 1995, J NEUROL, V242, P695, DOI 10.1007/BF00866922; McCluskey L, 2004, AMYOTROPH LATERAL SC, V5, P131, DOI 10.1080/14660820410020772; McGuire V, 2006, AMYOTROPHIC LATERAL, P17; Meier DE, 2002, NEW ENGL J MED, V346, P1087, DOI 10.1056/NEJM200204043461413; Miller RG, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001447.pub2; Miller RG, 1999, NEUROLOGY, V52, P1311, DOI 10.1212/WNL.52.7.1311; Miller RG, 2000, NEUROLOGY, V54, P53, DOI 10.1212/WNL.54.1.53; Miller RG, 2006, AMYOTROPH LATERAL SC, V7, P56; MILLER RG, 2006, AMYOTROPHIC LATERAL, P633; Mitsumoto H, 2005, AMYOTROPH LATERAL SC, V6, P145, DOI 10.1080/14660820510028647; Mitsumoto H, 2003, AMYOTROPH LATERAL SC, V4, P177, DOI 10.1080/14660820310011728; MITSUMOTO H, 2001, AMYOTROPHIC LATERAL, P27; Mitsumoto HM, 2006, AMYOTROPHIC LATERAL, P605; MONTGOMERY GK, 1987, NEUROL CLIN, V5, P61, DOI 10.1016/S0733-8619(18)30935-6; MOSS AH, 1993, NEUROLOGY, V43, P438, DOI 10.1212/WNL.43.2.438; Moss AH, 1996, CHEST, V110, P249, DOI 10.1378/chest.110.1.249; Mustfa N, 2006, NEUROLOGY, V66, P1211, DOI 10.1212/01.wnl.0000208957.88534.11; Nagai M, 2007, NAT NEUROSCI, V10, P615, DOI 10.1038/nn1876; NAKAJIMA T, 2006, AMYOTROPH LATERAL S1, V7, P45; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Neudert C, 2001, J NEUROL, V248, P612, DOI 10.1007/s004150170140; Nijboer C, 1999, CANCER, V86, P577, DOI 10.1002/(SICI)1097-0142(19990815)86:4<577::AID-CNCR6>3.0.CO;2-S; Olney RK, 2005, NEUROLOGY, V65, P1774, DOI 10.1212/01.wnl.0000188759.87240.8b; Olney RK, 2005, NEUROLOGY, V65, P9, DOI 10.1212/01.wnl.0000171741.00711.b5; Pasinelli P, 2006, NAT REV NEUROSCI, V7, P710, DOI 10.1038/nrn1971; Patrick DL, 1997, ANN INTERN MED, V127, P509, DOI 10.7326/0003-4819-127-7-199710010-00002; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Rabkin JG, 2005, NEUROLOGY, V65, P62, DOI 10.1212/01.wnl.0000167187.14501.0c; Rabkin JG, 2000, PSYCHOSOM MED, V62, P271, DOI 10.1097/00006842-200003000-00020; RABKIN JG, 1995, GOOD DOCTORS GOOD PA; Rabkin JG, 2006, AMYOTROPH LATERAL SC, V7, P86, DOI 10.1080/14660820500515021; Rabow MW, 2004, JAMA-J AM MED ASSOC, V291, P483, DOI 10.1001/jama.291.4.483; Ringholz GM, 2005, NEUROLOGY, V65, P586, DOI 10.1212/01.wnl.0000172911.39167.b6; Rowland L. P., 2005, MERRITTS NEUROLOGY, P861; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; SHOESMITH CL, 2006, AMYOTROPH LATERAL S1, V7, P101; Silani V, 1999, NEUROLOGY, V53, pS37; SIMPSON EP, 2006, AMYOTROPH LATERAL S1, V7, P64; Smyth A, 1997, J NEUROL SCI, V152, pS93, DOI 10.1016/S0022-510X(97)00253-0; Srinivasan J, 2006, MUSCLE NERVE, V34, P359, DOI 10.1002/mus.20555; STILLMAN MJ, 2001, AMYTROPHIC LATERAL S, P359; SYKES NP, 2006, AMYOTROPHIC LATERAL, P783; Traynor BJ, 2003, J NEUROL NEUROSUR PS, V74, P1258, DOI 10.1136/jnnp.74.9.1258; VACHON ML, HDB PSYCHIAT PALLIAT, P303; Van den Berg JP, 2005, NEUROLOGY, V65, P1264, DOI 10.1212/01.wnl.0000180717.29273.12; Verma A, 2006, MUSCLE NERVE, V34, P235, DOI 10.1002/mus.20545; Wood JD, 2003, NEUROPATH APPL NEURO, V29, P529, DOI 10.1046/j.0305-1846.2003.00518.x; Yoshor D, 2005, NEUROSURGERY, V57, P984, DOI 10.1227/01.NEU.0000180028.64385.d3; ZOCCOLELLA S, 2006, AMYOTROPH LATERAL S1, V7, P100	91	73	75	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2007	298	2					207	216		10.1001/jama.298.2.207	http://dx.doi.org/10.1001/jama.298.2.207			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188HI	17622602				2023-01-03	WOS:000247910600026
J	Pao, M; Ballard, ED; Rosenstein, DL				Pao, Maryland; Ballard, Elizabeth D.; Rosenstein, Donald L.			Growing up in the hospital	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CHILDREN; DEPRESSION; ADOLESCENT; PREVALENCE; CARE		NIMH, NIH, Clin Res Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Pao, M (corresponding author), NIMH, NIH, Clin Res Ctr, 6-5340, Bethesda, MD 20892 USA.	paom@mail.nih.gov	Ballard, Elizabeth/O-6856-2017	Ballard, Elizabeth/0000-0001-5304-0127				Anderson GM, 2000, CHILD ADOL PSYCH CL, V9, P23; Armstrong FD, 2006, MENT RETARD DEV D R, V12, P168, DOI 10.1002/mrdd.20114; BENNETT DS, 1994, J PEDIATR PSYCHOL, V19, P149, DOI 10.1093/jpepsy/19.2.149; Bhutta AT, 2002, CLIN PERINATOL, V29, P357, DOI 10.1016/S0095-5108(02)00011-8; Dejong M, 2006, PSYCHO-ONCOLOGY, V15, P553, DOI 10.1002/pon.1002; Drotar D, 2006, CHILD HEALTH CARE, V35, P91, DOI 10.1207/s15326888chc3501_8; Erikson E.H., 1968, IDENTICHNOST YUNOST; Jellinek M., 2002, BRIGHT FUTURES PRACT; Kanner L, 1937, J PEDIATR-US, V11, P418, DOI 10.1016/S0022-3476(37)80027-X; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Mahan, 2005, M CHILDRENS PSYCHOSO; Mayes LC, 2003, CHILD ADOL PSYCH CL, V12, P401, DOI 10.1016/S1056-4993(03)00022-1; Newacheck PW, 1998, AM J PUBLIC HEALTH, V88, P610, DOI 10.2105/AJPH.88.4.610; OWENS PL, 2003, CARE CHILDEN ADOLESC; Peebles-Kleiger MJ, 2000, B MENNINGER CLIN, V64, P257; PERRIN JM, 1993, PEDIATRICS, V92, P876; Schechter NL, 1997, PEDIATRICS, V99, P890, DOI 10.1542/peds.99.6.890; Stuber ML, 2006, CHILD ADOL PSYCH CL, V15, P597, DOI 10.1016/j.chc.2006.02.006; Stuber ML, 2006, CNS SPECTRUMS, V11, P137, DOI 10.1017/S1092852900010671; Suris JC, 2004, ARCH DIS CHILD, V89, P938, DOI 10.1136/adc.2003.045369; THOMASGARD M, 1995, J DEV BEHAV PEDIATR, V16, P47; Uman LS, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005179; Yoshida K, 2005, NEUROPSYCHOBIOLOGY, V52, P55, DOI 10.1159/000086605; Zielinski Tanya A., 2000, Prim Care Companion J Clin Psychiatry, V2, P153	24	19	19	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2007	297	24					2752	2755		10.1001/jama.297.24.2752	http://dx.doi.org/10.1001/jama.297.24.2752			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	182UE	17595276				2023-01-03	WOS:000247528700025
J	Wadman, M				Wadman, Meredith			Meeting in the middle	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 7	2007	447	7145					629	629		10.1038/447629a	http://dx.doi.org/10.1038/447629a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	175RI	17554281	Bronze			2023-01-03	WOS:000247030700014
J	Levine, OS; Cutts, FT				Levine, Orin S.; Cutts, Felicity T.			Pneumococcal vaccination and public health	LANCET			English	Editorial Material							CONJUGATE VACCINE; DISEASE		Johns Hopkins Bloomberg Sch Publ Hlth, GAVIs PneumoADIP, Baltimore, MD 21205 USA; Londe Maures, Provence, France	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Levine, OS (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, GAVIs PneumoADIP, Baltimore, MD 21205 USA.	olevine@jhsph.edu						*CDCP, 2005, MMWR-MORBID MORTAL W, V54, P893; Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6; Grijalva CG, 2007, LANCET, V369, P1179, DOI 10.1016/S0140-6736(07)60564-9; Madhi SA, 2007, VACCINE, V25, P2413, DOI 10.1016/j.vaccine.2006.09.010; Ray GT, 2006, PEDIATR INFECT DIS J, V25, P494, DOI 10.1097/01.inf.0000222403.42974.8b; Victora CG, 2004, AM J PUBLIC HEALTH, V94, P400, DOI 10.2105/AJPH.94.3.400; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823	7	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 7	2007	369	9568					1144	1145		10.1016/S0140-6736(07)60539-X	http://dx.doi.org/10.1016/S0140-6736(07)60539-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	155RH	17416242				2023-01-03	WOS:000245595100005
J	Casarett, DJ; Quill, TE				Casarett, David J.; Quill, Timothy E.			"I'm not ready for hospice": Strategies for timely and effective hospice discussions	ANNALS OF INTERNAL MEDICINE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; PATIENT PREFERENCES; ACUTE EXACERBATION; PALLIATIVE CARE; ADVANCED CANCER; NURSING-HOMES; END; SURVIVAL; LIFE; MANAGEMENT	Hospice programs offer unique benefits for patients who are near the end of life and their families, and growing evidence indicates that hospice can provide high-quality care. Despite these benefits, many patients do not enroll in hospice, and those who enroll generally do so very late in the course of their illness. Some barriers to hospice referral arise from the requirements of hospice eligibility, which will be difficult to eliminate without major changes to hospice organization and financing. However, the challenges of discussing hospice create other barriers that are more easily remedied. The biggest communication barrier is that physicians are often unsure of how to talk with patients clearly and directly about their poor prognosis and limited treatment options (both requirements of hospice referral) without depriving them of hope. This article describes a structured strategy for discussing hospice, based on techniques of effective communication that physicians use in other "bad news" situations. This strategy can make hospice discussions both more compassionate and more effective.	Univ Penn, Philadelphia, PA 19104 USA; Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA; Univ Rochester, Med Ctr, Ctr Eth Humanities & Palliat Care, Rochester, NY 14642 USA	University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Pennsylvania Medicine; Philadelphia Veterans Affairs Medical Center; University of Rochester	Casarett, DJ (corresponding author), 3615 Chestnut St, Philadelphia, PA 19104 USA.	casarett@mail.med.upenn.edu						Alla F, 2000, AM HEART J, V139, P895, DOI 10.1016/S0002-8703(00)90023-1; [Anonymous], HOSPICE J; BRODY H, 1989, HASTINGS CENT REP, V19, P5, DOI 10.2307/3562634; Bruera E, 2001, J CLIN ONCOL, V19, P2883, DOI 10.1200/JCO.2001.19.11.2883; BUCKMAN R, 1992, BREAK BAD NEWS; Byock IR, 1996, J PAIN SYMPTOM MANAG, V11, P69, DOI 10.1016/0885-3924(95)00154-9; Casarett D, 2006, J AM GERIATR SOC, V54, P472, DOI 10.1111/j.1532-5415.2005.00628.x; Casarett D, 2005, J AM GERIATR SOC, V53, P249, DOI 10.1111/j.1532-5415.2005.53110.x; Casarett D, 2002, ALZ DIS ASSOC DIS, V16, P116, DOI 10.1097/00002093-200204000-00009; Casarett D, 2001, J CLIN ONCOL, V19, P2057, DOI 10.1200/JCO.2001.19.7.2057; Casarett D, 2005, JAMA-J AM MED ASSOC, V294, P211, DOI 10.1001/jama.294.2.211; Casarett DJ, 2004, J AM GERIATR SOC, V52, P1923, DOI 10.1111/j.1532-5415.2004.52520.x; Christakis NA, 2003, SOC SCI MED, V57, P465, DOI 10.1016/S0277-9536(02)00370-2; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; CONILL C, 1990, CANCER, V65, P1864, DOI 10.1002/1097-0142(19900415)65:8<1864::AID-CNCR2820650832>3.0.CO;2-U; Connors AF, 1996, AM J RESP CRIT CARE, V154, P959, DOI 10.1164/ajrccm.154.4.8887592; Costello R, 1997, AM J MED, V102, P239, DOI 10.1016/S0002-9343(97)00017-X; Daugherty CK, 2002, J CLIN ONCOL, V20, P2752, DOI 10.1200/JCO.2002.20.11.2752; Emanuel EJ, 1999, NEW ENGL J MED, V341, P956, DOI 10.1056/NEJM199909233411306; Eng C, 1997, J AM GERIATR SOC, V45, P223, DOI 10.1111/j.1532-5415.1997.tb04513.x; Feuer DJ, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001219, DOI 10.1002/14651858.CD001219]; Grisso T, 1998, ASSESSING COMPETENCE; Higashi H, 2003, JPN J CLIN ONCOL, V33, P357, DOI 10.1093/jjco/hyg061; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; Holmes WC, 2002, J GEN INTERN MED, V17, P677, DOI 10.1046/j.1525-1497.2002.00746.x; Kutner JS, 2001, J PAIN SYMPTOM MANAG, V21, P473, DOI 10.1016/S0885-3924(01)00281-0; Lamont EB, 2001, ANN INTERN MED, V134, P1096, DOI 10.7326/0003-4819-134-12-200106190-00009; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; Luchins DJ, 1997, J AM GERIATR SOC, V45, P1054, DOI 10.1111/j.1532-5415.1997.tb05966.x; McGorty EK, 2003, J EVAL CLIN PRACT, V9, P363, DOI 10.1046/j.1365-2753.2003.00406.x; Miller SC, 2003, J PAIN SYMPTOM MANAG, V26, P791, DOI 10.1016/S0885-3924(03)00284-7; Miller SC, 2002, J AM GERIATR SOC, V50, P507, DOI 10.1046/j.1532-5415.2002.50118.x; Miller Susan C, 2003, J Palliat Med, V6, P725, DOI 10.1089/109662103322515239; MOR V, 1984, CANCER-AM CANCER SOC, V53, P2002, DOI 10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W; Morrison RS, 2000, JAMA-J AM MED ASSOC, V284, P47, DOI 10.1001/jama.284.1.47; *NAT HOSP PALL CAR, 2006, NAT TREND SUMM 2004; PORTENOY RK, 1994, EUR J CANCER, V30A, P1326, DOI 10.1016/0959-8049(94)90182-1; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; Quill TE, 2001, ANN INTERN MED, V135, P551, DOI 10.7326/0003-4819-135-7-200110020-00022; Reese DJ, 1999, SOC WORK, V44, P549, DOI 10.1093/sw/44.6.549; Ripamonti C, 2002, INT J GYNECOL CANCER, V12, P135, DOI 10.1046/j.1525-1438.2002.01103.x; Ryan SD, 2004, CLIN GERIATR MED, V20, P783, DOI 10.1016/j.cger.2004.07.012; SCULLY T, 2002, COMMUNICATION   0524; SENEFF MG, 1995, JAMA-J AM MED ASSOC, V274, P1852, DOI 10.1001/jama.274.23.1852; Sloan JA, 2001, J CLIN ONCOL, V19, P3539, DOI 10.1200/JCO.2001.19.15.3539; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; TRAVER GA, 1979, AM REV RESPIR DIS, V119, P895; Vainio A, 1996, J PAIN SYMPTOM MANAG, V12, P3, DOI 10.1016/0885-3924(96)00042-5; Vigano A, 2000, ARCH INTERN MED, V160, P861, DOI 10.1001/archinte.160.6.861	52	85	86	1	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2007	146	6					443	449		10.7326/0003-4819-146-6-200703200-00011	http://dx.doi.org/10.7326/0003-4819-146-6-200703200-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	150CC	17371889				2023-01-03	WOS:000245192200006
J	Saha, V				Saha, Vaskar			Simplifying treatment for children with ALL	LANCET			English	Editorial Material							ACUTE LYMPHOBLASTIC-LEUKEMIA; DELAYED INTENSIFICATION; DEXAMETHASONE; SURVIVAL		Univ Manchester, Paterson Inst Canc Res, Canc Res UK Childrens Canc Grp, Manchester M20 4BX, Lancs, England	Cancer Research UK; Paterson Institute for Cancer Research; University of Manchester	Saha, V (corresponding author), Univ Manchester, Paterson Inst Canc Res, Canc Res UK Childrens Canc Grp, Manchester M20 4BX, Lancs, England.	vaskar.saha@cancer.org.uk		Saha, Vaskar/0000-0002-2916-9649				Arico M, 2005, HAEMATOLOGICA, V90, P1186; Bostrom BC, 2003, BLOOD, V101, P3809, DOI 10.1182/blood-2002-08-2454; Conter V, 2007, LANCET, V369, P123, DOI 10.1016/S0140-6736(07)60073-7; Eden OB, 2000, LEUKEMIA, V14, P2307, DOI 10.1038/sj.leu.2401962; Lange BJ, 2002, BLOOD, V99, P825, DOI 10.1182/blood.V99.3.825; Mitchell CD, 2005, BRIT J HAEMATOL, V129, P734, DOI 10.1111/j.1365-2141.2005.05509.x; *MRC UKALL TRIALS, 1986, LANCET, V327, P408; Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603; Richards S, 1996, LANCET, V347, P1783; Roy A, 2005, BRIT J HAEMATOL, V129, P35, DOI 10.1111/j.1365-2141.2005.05425.x; Schrappe M, 2000, LEUKEMIA, V14, P2193, DOI 10.1038/sj.leu.2401977; TUBERGEN DG, 1993, J CLIN ONCOL, V11, P527, DOI 10.1200/JCO.1993.11.3.527	12	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2007	369	9556					82	83		10.1016/S0140-6736(07)60043-9	http://dx.doi.org/10.1016/S0140-6736(07)60043-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126TK	17223452				2023-01-03	WOS:000243538200005
J	Ji, SR; Wu, Y; Zhu, L; Potempa, LA; Sheng, FL; Lu, W; Zhao, J				Ji, Shang-Rong; Wu, Yi; Zhu, Li; Potempa, Lawrence A.; Sheng, Fen-Ling; Lu, Wei; Zhao, Jing			Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m)	FASEB JOURNAL			English	Article						inflammation; cardiovascular disease; protein-membrane interaction	LOW-DENSITY-LIPOPROTEIN; FC-GAMMA-RI; CARDIOVASCULAR-DISEASE; COMPLEMENT ACTIVATION; PENTAMERIC SYMMETRY; ENDOTHELIAL-CELLS; HUMAN NEUTROPHILS; BINDING; ATHEROSCLEROSIS; IDENTIFICATION	Emerging evidence indicates that C-reactive protein (CRP) has at least two conformationally distinct isoforms, i.e., pentameric CRP (pCRP) and monomeric CRP (mCRP or CRP subunit). Both CRP isoforms are proposed to play roles in inflammation and may participate in the pathogenesis of cardiovascular disease. However, the origin of mCRP in situ and the interplay between the two CRP isoforms under physiological/ pathological circumstances remain elusive. Herein, by probing conformational alteration, neoepitope expression, and direct visualization using electron-microscopy, we have shown that calcium-dependent binding of pCRP to membranes, including liposomes and cell membranes, led to a rapid but partial structural change, producing molecules that express CRP subunit antigenicity but with retained native pentameric conformation. This hybrid molecule is herein termed mCRP(m). The formation of mCRPm was associated with significantly enhanced complement fixation. mCRP(m) can further detach from membrane to form the well-recognized mCRP isoform converted in solution (mCRP(s)) and exert potent stimulatory effects on endothelial cells. The membrane-induced pCRP dissociation not only provides a physiologically relevant scenario for mCRP formation but may represent an important mechanism for regulating CRP function.	Lanzhou Univ, Inst Biophys, MOE Key Lab Arid & Grassland Ecol, Lanzhou 730000, Peoples R China; Lanzhou Univ, Inst Cell Biol, Lanzhou 730000, Peoples R China; Lanzhou Univ, Instrumental Anal Res Ctr, Lanzhou 730000, Peoples R China; Immtech Pharmaceut Inc, Vernon Hills, IL USA	Lanzhou University; Lanzhou University; Lanzhou University	Wu, Y (corresponding author), Lanzhou Univ, Inst Biophys, MOE Key Lab Arid & Grassland Ecol, Life Sci Bldg,Rm 227, Lanzhou 730000, Peoples R China.	wuy@lzu.edu.cn		Wu, Yi/0000-0003-0365-5590; Ji, Shang-Rong/0000-0001-8595-3756				Agrawal A, 2001, J IMMUNOL, V166, P3998, DOI 10.4049/jimmunol.166.6.3998; Bang R, 2005, J BIOL CHEM, V280, P25095, DOI 10.1074/jbc.M504782200; Bhakdi S, 2004, CIRCULATION, V109, P1870, DOI 10.1161/01.CIR.0000124228.08972.26; Bharadwaj D, 1999, J EXP MED, V190, P585, DOI 10.1084/jem.190.4.585; Ciubotaru I, 2005, EXP BIOL MED, V230, P762, DOI 10.1177/153537020523001010; CROWELL RE, 1991, J IMMUNOL, V147, P3445; Devaraj S, 2005, ARTERIOSCL THROM VAS, V25, P1359, DOI 10.1161/01.ATV.0000168573.10844.ae; Diehl EE, 2000, AM J MED SCI, V319, P79, DOI 10.1097/00000441-200002000-00002; Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353; Ji SR, 2006, ARTERIOSCL THROM VAS, V26, P935, DOI 10.1161/01.ATV.0000206211.21895.73; Ji SR, 2006, INT J BIOCHEM CELL B, V38, P648, DOI 10.1016/j.biocel.2005.11.004; Jialal I, 2004, HYPERTENSION, V44, P6, DOI 10.1161/01.HYP.0000130484.20501.df; Khreiss T, 2005, CIRC RES, V97, P690, DOI 10.1161/01.RES.0000183881.11739.CB; Khreiss T, 2004, CIRCULATION, V109, P2016, DOI 10.1161/01.CIR.0000125527.41598.68; Khreiss T, 2002, J BIOL CHEM, V277, P40775, DOI 10.1074/jbc.M205378200; Lougheed M, 1997, J BIOL CHEM, V272, P12938, DOI 10.1074/jbc.272.20.12938; Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; Pepys MB, 2006, NATURE, V440, P1217, DOI 10.1038/nature04672; POTEMPA LA, 1987, MOL IMMUNOL, V24, P531, DOI 10.1016/0161-5890(87)90028-9; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; Schwedler SB, 2006, AM J KIDNEY DIS, V47, P212, DOI 10.1053/j.ajkd.2005.10.028; Schwedler SB, 2005, CIRCULATION, V112, P1016, DOI 10.1161/CIRCULATIONAHA.105.556530; Sepulveda JL, 2005, CURR OPIN CARDIOL, V20, P407; Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Szalai Alexander J, 2004, Clin Dev Immunol, V11, P221, DOI 10.1080/17402520400001751; Tabas I, 2005, ARTERIOSCL THROM VAS, V25, P2255, DOI 10.1161/01.ATV.0000184783.04864.9f; Taskinen S, 2002, BIOCHEM J, V367, P403, DOI 10.1042/BJ20020492; Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9; TUCCI A, 1983, J IMMUNOL, V131, P2416; Verma S, 2004, CIRCULATION, V109, P1914, DOI 10.1161/01.CIR.0000127085.32999.64; VIGUSHIN DM, 1993, J CLIN INVEST, V91, P1351, DOI 10.1172/JCI116336; Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6; VOLANAKIS JE, 1979, NATURE, V281, P155, DOI 10.1038/281155a0; Wang HW, 2001, BIOCHEM BIOPH RES CO, V288, P75, DOI 10.1006/bbrc.2001.5733; Wilson AM, 2006, INT J CARDIOL, V106, P291, DOI 10.1016/j.ijcard.2005.01.068; Wu Y, 2003, ACTA CRYSTALLOGR D, V59, P922, DOI 10.1107/S0907444903004414; Wu Y, 2002, BIOCHEMISTRY-MOSCOW+, V67, P1377, DOI 10.1023/A:1021862027061; Wu Y, 2003, P NATL ACAD SCI USA, V100, P2082, DOI 10.1073/pnas.0435872100; Yasojima K, 2001, AM J PATHOL, V158, P1039, DOI 10.1016/S0002-9440(10)64051-5; Yeh ETH, 2005, CIRC RES, V97, P609, DOI 10.1161/01.RES.0000186188.38344.13; YING SC, 1989, J IMMUNOL, V143, P221; Zouki C, 2001, J IMMUNOL, V167, P5355, DOI 10.4049/jimmunol.167.9.5355	44	148	158	0	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2007	21	1					284	294		10.1096/fj.06-6722com	http://dx.doi.org/10.1096/fj.06-6722com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	121AX	17116742				2023-01-03	WOS:000243130200031
J	Cheong, I; Huang, X; Bettegowda, C; Diaz, LA; Kinzler, KW; Zhou, SB; Vogelstein, B				Cheong, Ian; Huang, Xin; Bettegowda, Chetan; Diaz, Luis A., Jr.; Kinzler, Kenneth W.; Zhou, Shibin; Vogelstein, Bert			A bacterial protein enhances the release and efficacy of liposomal cancer drugs	SCIENCE			English	Article							BACTERIOLYTIC THERAPY; EXPERIMENTAL-TUMORS; ENDOTHELIAL-CELLS	Clostridium novyi-NT is an anaerobic bacterium that can infect hypoxic regions within experimental tumors. Because C. novyi-NT lyses red blood cells, we hypothesized that its membrane-disrupting properties could be exploited to enhance the release of liposome-encapsulated drugs within tumors. Here, we show that treatment of mice bearing large, established tumors with C. novyi-NT plus a single dose of liposomal doxorubicin often led to eradication of the tumors. The bacterial factor responsible for the enhanced drug release was identified as a previously unrecognized protein termed liposomase. This protein could potentially be incorporated into diverse experimental approaches for the specific delivery of chemotherapeutic agents to tumors.	Johns Hopkins Kimmel Comprehens Canc Ctr, Howard Hughes Med Inst, Baltimore, MD 21231 USA; Johns Hopkins Kimmel Comprehens Canc Ctr, Ludwig Ctr Canc Genet & Therapeut, Baltimore, MD 21231 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Zhou, SB (corresponding author), Johns Hopkins Kimmel Comprehens Canc Ctr, Howard Hughes Med Inst, Baltimore, MD 21231 USA.	sbzhou@jhmi.edu; vogelbe@jhmi.edu	Diaz, Luis A/A-6018-2008	Cheong, Ian/0000-0002-3062-6878; Diaz, Luis/0000-0002-7079-8914	NCI NIH HHS [CA062924] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA062924] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal N, 2004, P NATL ACAD SCI USA, V101, P15172, DOI 10.1073/pnas.0406242101; Barbe S, 2006, J APPL MICROBIOL, V101, P571, DOI 10.1111/j.1365-2672.2006.02886.x; BETTEGWODA C, IN PRESS NAT BIOTECH; Dang LH, 2001, P NATL ACAD SCI USA, V98, P15155, DOI 10.1073/pnas.251543698; Drummond DC, 1999, PHARMACOL REV, V51, P691; Fang J, 2003, ADV EXP MED BIOL, V519, P29; Govindan SV, 2005, TECHNOL CANCER RES T, V4, P375, DOI 10.1177/153303460500400406; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Jaeger KE, 1999, ANNU REV MICROBIOL, V53, P315, DOI 10.1146/annurev.micro.53.1.315; Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; Ryan RM, 2006, BIOESSAYS, V28, P84, DOI 10.1002/bies.20336; Sakurai J, 2004, J BIOCHEM, V136, P569, DOI 10.1093/jb/mvh161; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Thurston G, 1998, J CLIN INVEST, V101, P1401, DOI 10.1172/JCI965; VONHOFF DD, 2006, CANC MED, P600; Yamamoto M, 2005, TECHNOL CANCER RES T, V4, P315, DOI 10.1177/153303460500400402	18	122	135	4	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 24	2006	314	5803					1308	1311		10.1126/science.1130651	http://dx.doi.org/10.1126/science.1130651			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108BR	17124324				2023-01-03	WOS:000242215800046
J	Finfer, S; Bellomo, R				Finfer, Simon; Bellomo, Rinaldo		Saline Versus Albumin	Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SATE) study	BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED-TRIALS	Objective To determine whether outcomes of resuscitation with albumin or saline in the intensive care unit depend on patients' baseline serum albumin concentration. Design Analysis of data from a double blind, randomised controlled trial. Setting Intensive care units of 16 hospitals in Australia and New Zealand. Participants 6045 participants in the saline versus albumin fluid evaluation (SAFE) study. Interventions Fluid resuscitation with 4% albumin or saline in patients with a baseline serum albumin concentration of 25 g/l or less or more than 25 g/l. Main outcome measures Primary outcome was all cause mortality at 28 days. Secondary outcomes were length of stay in the intensive care unit, length of stay in hospital, duration of renal replacement therapy, and duration of mechanical ventilation. Main results The odds ratios for death for albumin compared with saline for patients with a baseline serum albumin concentration of 25 g/l or less and more than 25 g/l were 0.87 and 1.09, respectively (ratio of odds ratios 0.80, 95% confidence interval 0.63 to 1.02); P = 0.08 for heterogeneity. No significant interaction was found between baseline serum albumin concentration as a continuous variable and the effect of albumin and saline on mortality. No consistent interaction was found between baseline serum albumin concentration and treatment effects on length of stay in the intensive care unit, length of hospital stay, duration of renal replacement therapy, or duration of mechanical ventilation. Conclusion The outcomes of resuscitation with albumin and saline are similar irrespective of patients' baseline serum albumin concentration.	Australian & New Zealand Intens Care Soc, Clin Trials Grp, Carlton, Vic 3053, Australia		Finfer, S (corresponding author), Australian & New Zealand Intens Care Soc, Clin Trials Grp, Carlton, Vic 3053, Australia.	sfinfer@george.org.au	Carroll, Rosemary/W-5427-2018; Cooper, D. James/G-7961-2013; Higgins, Alisa/AAM-8088-2020; ODonnell, Jane/GEX-9181-2022; Joyce, Christopher/B-7437-2013	Carroll, Rosemary/0000-0002-2162-2744; Cooper, D. James/0000-0002-5872-9051; Higgins, Alisa/0000-0001-8295-7559; ODonnell, Jane/0000-0002-9554-5497; Bellomo, Rinaldo/0000-0002-1650-8939; Bates, Samantha Jean/0000-0002-8613-1946; Neal, Bruce/0000-0002-0490-7465; Myburgh, John/0000-0003-4088-7016; Stephens, Dianne/0000-0002-3785-6828; Finfer, Simon/0000-0002-2785-5864; MacMahon, Stephen/0000-0003-2064-7699; McEvoy, Suzanne/0000-0002-9804-4276; Woodward, Mark/0000-0001-9800-5296; French, Craig/0000-0003-1363-9711				*ANZICS CLIN TRIAL, SAL VS ALB FLUID EV; Cook D, 2004, NEW ENGL J MED, V350, P2294, DOI 10.1056/NEJMe048095; Finfer S, 2004, NEW ENGL J MED, V350, P2247; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Roberts I, 1998, BMJ-BRIT MED J, V317, P235; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 2004, CRIT CARE MED, V32, P2029, DOI 10.1097/01.CCM.0000142574.00425.E9; 2004, COCHRANE DATABASE SY	8	142	155	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 18	2006	333	7577					1044	1046		10.1136/bmj.38985.398704.7C	http://dx.doi.org/10.1136/bmj.38985.398704.7C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108HB	17040925	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000242229800015
J	Inzucchi, SE				Inzucchi, Silvio E.			Management of hyperglycemia in the hospital setting	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; INPATIENT GLUCOSE MANAGEMENT; INSULIN INFUSION PROTOCOL; TIGHT GLYCEMIC CONTROL; DIABETIC-PATIENTS; INFECTIOUS COMPLICATIONS; STRESS HYPERGLYCEMIA; WOUND-INFECTION; BLOOD-GLUCOSE; MORTALITY		Yale Univ, Sch Med, Endocrinol Sect, New Haven, CT 06520 USA	Yale University	Inzucchi, SE (corresponding author), Yale Univ, Sch Med, Endocrinol Sect, 333 Cedar St,LLCI 101, New Haven, CT 06520 USA.	silvio.inzucchi@yale.edu	Inzucchi, Silvio/ABF-4121-2021					*AACE ADA CONS DEV, 2006, INP DIAB GLYC CONTR; [Anonymous], 2005, DIABETES CARE, V28, pS4; Bryer-Ash M, 2005, DIABETES CARE, V28, P973, DOI 10.2337/diacare.28.4.973; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Chaudhuri A, 2004, CIRCULATION, V109, P849, DOI 10.1161/01.CIR.0000116762.77804.FC; Cheung NW, 2006, DIABETES CARE, V29, P765, DOI 10.2337/diacare.29.04.06.dc05-1894; Clausen TD, 2005, DIABETES CARE, V28, P990; Clement S, 2004, DIABETES CARE, V27, P553, DOI 10.2337/diacare.27.2.553; Clement S, 2004, DIABETES CARE, V27, P1255; Clement S, 2004, DIABETES CARE, V27, P856; *CLINICALTRIALS GO, NORM INT CAR EV SURV; Cryer PE, 2006, DIABETOLOGIA, V49, P1722, DOI 10.1007/s00125-006-0306-4; Edelman SV, 2005, SOUTH MED J, V98, P363, DOI 10.1097/01.SMJ.0000149424.50849.00; Falciglia M D, 2006, 66 SCI SESS AM DIAB; FathOrdoubadi F, 1997, CIRCULATION, V96, P1152, DOI 10.1161/01.CIR.96.4.1152; Furnary AP, 1999, ANN THORAC SURG, V67, P352, DOI 10.1016/S0003-4975(99)00014-4; Furnary AP, 2003, J THORAC CARDIOV SUR, V125, P1007, DOI 10.1067/mtc.2003.181; Garber Alan J, 2004, Endocr Pract, V10, P77; Goldberg PA, 2004, DIABETES CARE, V27, P461, DOI 10.2337/diacare.27.2.461; GOLDBERG PA, 2005, DIABETES SPECTRUM, V18, P188, DOI DOI 10.2337/DIASPECT.18.3.188]; Golden SH, 1999, DIABETES CARE, V22, P1408, DOI 10.2337/diacare.22.9.1408; Hirsch IB, 2005, NEW ENGL J MED, V352, P174, DOI 10.1056/NEJMra040832; Hruska LA, 2005, J CARDIAC SURG, V20, P403, DOI 10.1111/j.1540-8191.2005.200472.x; Inzucchi SE, 2005, DIABETES CARE, V28, P976, DOI 10.2337/diacare.28.4.976; Kosiborod M, 2005, CIRCULATION, V111, P3078, DOI 10.1161/CIRCULATIONAHA.104.517839; Krinsley, 2005, MAYO CLIN PROC, V80, P1101; Krinsley JS, 2004, MAYO CLIN PROC, V79, P992, DOI 10.4065/79.8.992; Krinsley JS, 2003, MAYO CLIN PROC, V78, P1471, DOI 10.4065/78.12.1471; Ku SY, 2005, JT COMM J QUAL PATIE, V31, P141, DOI 10.1016/S1553-7250(05)31019-1; Lazar HL, 2004, CIRCULATION, V109, P1497, DOI 10.1161/01.CIR.0000121747.71054.79; Malmberg K, 1999, CIRCULATION, V99, P2626, DOI 10.1161/01.CIR.99.20.2626; Malmberg K, 2005, EUR HEART J, V26, P650, DOI 10.1093/eurheartj/ehi199; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; Markovitz Lawrence J, 2002, Endocr Pract, V8, P10; Mehta SR, 2005, JAMA-J AM MED ASSOC, V293, P437; Meijering S, 2006, CRIT CARE, V10, DOI 10.1186/cc3981; Metchick LN, 2002, AM J MED, V113, P317, DOI 10.1016/S0002-9343(02)01213-5; Moghissi ES, 2005, ENDOCRIN METAB CLIN, V34, P99, DOI 10.1016/j.ecl.2004.11.001; Pinto DS, 2005, J AM COLL CARDIOL, V46, P178, DOI 10.1016/j.jacc.2005.03.052; Pittas AG, 2004, ARCH INTERN MED, V164, P2005, DOI 10.1001/archinte.164.18.2005; Pomposelli JJ, 1998, JPEN-PARENTER ENTER, V22, P77, DOI 10.1177/014860719802200277; Queale WS, 1997, ARCH INTERN MED, V157, P545, DOI 10.1001/archinte.157.5.545; Riddle MC, 2005, ENDOCRIN METAB CLIN, V34, P77, DOI 10.1016/j.ecl.2004.12.002; Svensson AM, 2005, EUR HEART J, V26, P1255, DOI 10.1093/eurheartj/ehi230; Trence DL, 2003, J CLIN ENDOCR METAB, V88, P2430, DOI 10.1210/jc.2003-030347; Umpierrez GE, 2002, J CLIN ENDOCR METAB, V87, P978, DOI 10.1210/jc.87.3.978; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Zerr KJ, 1997, ANN THORAC SURG, V63, P356	51	253	268	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 2	2006	355	18					1903	1911		10.1056/NEJMcp060094	http://dx.doi.org/10.1056/NEJMcp060094			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100TM	17079764				2023-01-03	WOS:000241691700008
J	Annas, GJ				Annas, George J.			Hunger strikes at Guantanamo - Medical ethics and human rights in a "legal black hole''	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA.			Annas, George/0000-0001-5836-7831				Annas GJ, 2005, NEW ENGL J MED, V352, P2127, DOI 10.1056/NEJMlim044131; ANNAS GJ, 1982, HASTINGS CENT REP, V12, P21, DOI 10.2307/3561359; ANNAS GJ, 1995, BRIT MED J, V311, P1114, DOI 10.1136/bmj.311.7013.1114; Beam TE, 2003, MILITARY MED ETHICS; BUKOVSKY V, 2003, BEING HUMAN READINGS, P218; Center for Constitutional Rights, 2005, GUANT PRIS HUNG STRI; *DEP DEF, 2006, 231008E DOD; *DEP DEF ASS SECR, 2006, MED ROUNDT; Golden Tim, 2006, N Y Times Web, pA20; Gordan England Memorandum for Secretaries of the Military Departments, 2006, COMMUNICATION   0707; *J WIER FDN HLTH H, 1995, ASS HUNG STRIK MAN P; Nicholl DJ, 2006, LANCET, V367, P811, DOI 10.1016/S0140-6736(06)68326-8; Oguz NY, 2005, J MED ETHICS, V31, P169, DOI 10.1136/jme.2004.006973; Okie S, 2005, NEW ENGL J MED, V353, P2529, DOI 10.1056/NEJMp058296; Reyes Hernan, 1998, MED ETHICAL ASPECTS, P291; SCHMITT E, 2006, NY TIMES        0222, pA5; Silove D, 1996, JAMA-J AM MED ASSOC, V276, P410; Silver M, 2005, STANFORD LAW REV, V58, P631; Situation of Detainees at Guant anamo Bay, 2006, SIT DET GUANT BAY; Wilks M, 2006, BRIT MED J, V332, P560, DOI 10.1136/bmj.332.7541.560; *WORLD MED ASS, 1991, DECL HUNG STRIK	21	41	42	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 28	2006	355	13					1377	1382		10.1056/NEJMhle062316	http://dx.doi.org/10.1056/NEJMhle062316			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	088EF	17005959	Green Published			2023-01-03	WOS:000240793600017
J	Shuchman, M				Shuchman, Miriam			Delaying generic competition - Corporate payoffs and the future of plavix	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Buffalo Sch Med & Biomed Sci, Dept Psychiat, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Shuchman, M (corresponding author), Univ Buffalo Sch Med & Biomed Sci, Dept Psychiat, Buffalo, NY 14260 USA.								0	14	14	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 28	2006	355	13					1297	1300		10.1056/NEJMp068193	http://dx.doi.org/10.1056/NEJMp068193			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	088EF	17005945				2023-01-03	WOS:000240793600001
J	Thomas, KJ; MacPherson, H; Thorpe, L; Brazier, J; Fitter, M; Campbell, MJ; Roman, M; Walters, SJ; Nicholl, J				Thomas, K. J.; MacPherson, H.; Thorpe, L.; Brazier, J.; Fitter, M.; Campbell, M. J.; Roman, M.; Walters, S. J.; Nicholl, J.			Randomised controlled trial of a short course of traditional acupuncture compared with usual care for persistent non-specific low back pain	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH; COMPLEMENTARY; FRAMEWORK; SF-36	Objective To determine whether a short course of traditional acupuncture improves longer term outcomes for patients with persistent non-specific low back pain in primary care. Design Pragmatic, open, randomised controlled trial. Setting Three private acupuncture clinics and 18 general practices in York, England. Participants 241 adults aged 18-65 with non-specific low back pain of 4-52 weeks' duration. Interventions 10 individualised acupuncture treatments from one of six qualified acupuncturists (160 patients) or usual care only (81 patients). Main outcome measures The primary outcome was SF-36 bodily pain, measured at 12 and 24 months. Other outcomes included reported use of analgesics, scores on the Oswestry pain disability index, safety, and patient satisfaction. Results 39 general practitioners referred 289 patients of whom 241 were randomised. At 12 months average SF-36 pain scores increased by 33.2 to 64.0 in the acupuncture group and by 27.9 to 58.3 in the control group. Adjusting for baseline score and for any clustering by acupuncturist, the estimated intervention effect was 5.6 points (95% confidence interval - 0.2 to 11.4) at 12 months (n = 213) and 8.0 points (2.8 to 13.2) at 24 months (n = 182). The magnitude of the difference between the groups was about 10%-15% of the final pain score in the control group. Functional disability was not improved. No serious or life threatening events were reported. Conclusions Weak evidence was found of an effect of acupuncture on persistent non-specific low back pain at 12 months, but stronger evidence of a small benefit at 24 months. Referral to a qualified traditional acupuncturist for a short course of treatment seems safe and acceptable to patients with low back pain.	Fdn Tradit Chinese Med, York YO24 1ET, N Yorkshire, England; Univ Sheffield, Sch Hlth & Related Res, Sheffield S10 2TN, S Yorkshire, England; Selby & York Primary Care Trust, York, N Yorkshire, England	University of Sheffield	MacPherson, H (corresponding author), Fdn Tradit Chinese Med, York YO24 1ET, N Yorkshire, England.	hm18@york.ac.uk	Nicholl, Jon/B-8257-2008; Campbell, Michael J/I-4253-2014; brazier, john e/B-1936-2008	Campbell, Michael J/0000-0003-3529-2739; Brazier, John/0000-0001-8645-4780; Walters, Stephen/0000-0001-9000-8126; MacPherson, Hugh/0000-0003-4255-4768				Angst F, 2001, ARTHRIT RHEUM-ARTHR, V45, P384, DOI 10.1002/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0; *BMJ PUBL GROUP, 2003, CLIN EV LOW BACK PAI; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Bronfort G, 1999, PAIN, V83, P201, DOI 10.1016/S0304-3959(99)00103-7; *CLIN STAND ADV GR, 1994, BACK PAIN EP COSTS; CROFT P, 1997, HLTH CARE NEEDS ASSE; *DEP HLTH, 1999, PREV BACK PAIN GREAT; DEYO R, 1992, USERS MANUAL LOW BAC; Dincer F, 2003, COMPLEMENT THER MED, V11, P235, DOI 10.1016/S0965-2299(03)00124-9; Fairbank J C, 1980, Physiotherapy, V66, P271; Furlan AD, 2005, SPINE, V30, P944, DOI 10.1097/01.brs.0000158941.21571.01; Kalauokalani D, 2001, SPINE, V26, P1418, DOI 10.1097/00007632-200107010-00005; Kaptchuk TJ, 1998, LANCET, V351, P1722, DOI 10.1016/S0140-6736(97)10111-8; Lee KJ, 2005, BRIT MED J, V330, P142, DOI 10.1136/bmj.330.7483.142; Lewith GT, 2002, AM J PUBLIC HEALTH, V92, P1604, DOI 10.2105/AJPH.92.10.1604; MacAuley D, 2004, BRIT MED J, V329, P694, DOI 10.1136/bmj.329.7468.694; MacPherson H, 2004, COMPLEMENT THER MED, V12, P38, DOI 10.1016/S0965-2299(03)00125-0; MacPherson H, 2003, J ALTERN COMPLEM MED, V9, P869, DOI 10.1089/107555303771952226; MacPherson H, 1999, Complement Ther Med, V7, P83; MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486; Meenan R, 2001, J Health Serv Res Policy, V6, P38, DOI 10.1258/1355819011927189; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Ratcliffe J, 2006, BRIT MED J, V333, P626, DOI 10.1136/bmj.38932.806134.7C; Thomas K J, 1999, Complement Ther Med, V7, P91, DOI 10.1016/S0965-2299(99)80087-9; Thomas KJ, 2003, FAM PRACT, V20, P575, DOI 10.1093/fampra/cmg514; THOMAS KJ, 1997, COMPLEMENTARY THERAP, V5, P94; Thomaseth K, 2001, SIMULAT PRACT THEORY, V9, P1, DOI 10.1016/S0928-4869(01)00038-6; Thompson I, 2005, LANG LEARN TECHNOL, V9, P1; Ware J. E., 1993, SF36 HLTH SURVEY MAN; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	30	136	145	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 23	2006	333	7569					623	626		10.1136/bmj.38878.907361.7C	http://dx.doi.org/10.1136/bmj.38878.907361.7C			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	089KD	16980316	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000240878500014
J	Bijlsma, JWJ; Jacobs, JWG				Bijlsma, Johannes W. J.; Jacobs, Johannes W. G.			Glucocorticoid chronotherapy in rheumatoid arthritis	LANCET			English	Editorial Material							CONTROLLED CLINICAL-TRIAL; PREDNISONE THERAPY; TIGHT CONTROL; DOUBLE-BLIND; MANAGEMENT; METHOTREXATE; RECOMMENDATIONS; EFFICACY; PLACEBO		[Bijlsma, Johannes W. J.; Jacobs, Johannes W. G.] Univ Med Ctr Utrecht, Dept Rheumatol & Clin Immunol, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Bijlsma, JWJ (corresponding author), Univ Med Ctr Utrecht, Dept Rheumatol & Clin Immunol, NL-3508 GA Utrecht, Netherlands.	j.w.j.bijlsma@umcutrecht.nl						Arvidson NG, 1997, ANN RHEUM DIS, V56, P27, DOI 10.1136/ard.56.1.27; Bakker MF, 2007, ANN RHEUM DIS, V66, P56, DOI 10.1136/ard.2007.078360; Bijlsma JWJ, 2007, ANN RHEUM DIS, V66, P1409, DOI 10.1136/ard.2007.076463; Buttgereit F, 2008, LANCET, V371, P205, DOI 10.1016/S0140-6736(08)60132-4; Combe B, 2007, ANN RHEUM DIS, V66, P34, DOI 10.1136/ard.2005.044354; Crofford LJ, 1997, J CLIN ENDOCR METAB, V82, P1279, DOI 10.1210/jc.82.4.1279; Da Silva JAP, 2006, ANN RHEUM DIS, V65, P285, DOI 10.1136/ard.2005.038638; Hoes JN, 2007, ANN RHEUM DIS, V66, P1560, DOI 10.1136/ard.2007.072157; Jacobs JWG, 2006, ARTHRITIS RHEUM, V54, P1422, DOI 10.1002/art.21809; Kirwan JR, 2007, COCHRANE DB SYST REV, V1; Maini RN, 2006, ARTHRITIS RHEUM-US, V54, P2817, DOI 10.1002/art.22033; Smolen JS, 2007, LANCET, V370, P1861, DOI 10.1016/S0140-6736(07)60784-3; Straub RH, 2007, ARTHRITIS RHEUM, V56, P399, DOI 10.1002/art.22368; van Everdingen AA, 2002, ANN INTERN MED, V136, P1, DOI 10.7326/0003-4819-136-1-200201010-00006; Verstappen SMM, 2007, ANN RHEUM DIS, V66, P1443, DOI 10.1136/ard.2007.071092	15	22	23	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 19	2008	371	9608					183	184		10.1016/S0140-6736(08)60114-2	http://dx.doi.org/10.1016/S0140-6736(08)60114-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	252UK	18207003				2023-01-03	WOS:000252471900007
J	Iams, JD; Romero, R; Culhane, JF; Goldenberg, RL				Iams, Jay D.; Romero, Roberto; Culhane, Jennifer F.; Goldenberg, Robert L.			Preterm birth 2 - Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth	LANCET			English	Review							RANDOMIZED CONTROLLED-TRIAL; ELECTIVE CERVICAL CERCLAGE; PLACEBO-CONTROLLED TRIAL; LOW-DOSE ASPIRIN; BACTERIAL VAGINOSIS; HIGH-RISK; PERIODONTAL-DISEASE; PREGNANT-WOMEN; PRENATAL-CARE; BED REST	Interventions to reduce the morbidity and mortality of preterm birth can be primary (directed to all women), secondary (aimed at eliminating or reducing existing risk), or tertiary (intended to improve outcomes for preterm infants). Most efforts so far have been tertiary interventions, such as regionalised care, and treatment with antenatal corticosteroids, tocolytic agents, and antibiotics. These measures have reduced perinatal morbidity and mortality; but the incidence of preterm birth is increasing. Advances in primary and secondary care, following strategies used for other complex health problems, such as cervical cancer, will be needed to prevent prematurity-related illness in infants and children.	[Iams, Jay D.] Ohio State Univ, Dept Obstet & Gynecol, Columbus, OH 43210 USA; [Romero, Roberto] NICHHD, Perinatol Res Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; [Romero, Roberto] NICHHD, Perinatol Res Branch, NIH, Dept Hlth & Human Serv, Detroit, MI USA; [Romero, Roberto] Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI USA; [Culhane, Jennifer F.; Goldenberg, Robert L.] Drexel Univ, Coll Med, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA	University System of Ohio; Ohio State University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Wayne State University; Drexel University	Iams, JD (corresponding author), 1654 Upham Dr, Columbus, OH 43210 USA.	iams.1@osu.edu	Romero, Roberto/A-5268-2019	Romero, Roberto/0000-0002-4448-5121	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD002400] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD002400] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		*ACOG, 2001, OBSTET GYNECOL, V98, P708; ACOG Committee on Obstetric Practice, 2005, Obstet Gynecol, V106, P1143; Adams MM, 2000, JAMA-J AM MED ASSOC, V283, P1591, DOI 10.1001/jama.283.12.1591; ALEXANDER GRR, 2006, PRETERM BIRTH CAUSES, P636; Alfirevic Z, 2007, ULTRASOUND OBST GYN, V29, P47, DOI 10.1002/uog.3908; Althuisius S, 2002, ULTRASOUND OBST GYN, V20, P163, DOI 10.1046/j.1469-0705.2002.00770.x; Althuisius SM, 2003, AM J OBSTET GYNECOL, V189, P907, DOI 10.1067/S0002-9378(03)00718-X; Althuisius SM, 2001, AM J OBSTET GYNECOL, V185, P1106, DOI 10.1067/mob.2001.118655; Althuisius SM, 2000, AM J OBSTET GYNECOL, V183, P823, DOI 10.1067/mob.2000.108874; American College of Obstetricians and Gynecologists, 2005, Obstet Gynecol, V106, P665; American College of Obstetricians and Gynecologists Committee on Practice Bulletins, 2003, OBSTET GYNECOL, V101, P1039; Ananth CV, 2006, AM J OBSTET GYNECOL, V195, P643, DOI 10.1016/j.ajog.2006.05.022; Ancel PY, 2004, HUM REPROD, V19, P734, DOI 10.1093/humrep/deh107; ANDERSEN HF, 1990, AM J OBSTET GYNECOL, V163, P859, DOI 10.1016/0002-9378(90)91084-P; Andrews WW, 2006, AM J OBSTET GYNECOL, V194, P617, DOI 10.1016/j.ajog.2005.11.049; Andrews WW, 2003, OBSTET GYNECOL, V101, P847, DOI 10.1016/S0029-7844(03)00172-8; Anotayanonth S, 2004, Cochrane Database Syst Rev, pCD004352, DOI 10.1002/14651858.CD004352.pub2; Armstrong J, 2007, AM J OBSTET GYNECOL, V196, P194, DOI 10.1016/j.ajog.2006.12.022; Bailit JL, 2007, AM J OBSTET GYNECOL, V196, P219, DOI 10.1016/j.ajog.2006.12.021; BAKKETEIG LS, 1981, PRETERM LABOR, P17; BEHRMAN RE, 2006, COMMITTEE UNDERSTAND; Berghella V, 1999, AM J OBSTET GYNECOL, V181, P809, DOI 10.1016/S0002-9378(99)70306-6; Berghella V, 2005, OBSTET GYNECOL, V106, P181, DOI 10.1097/01.AOG.0000168435.17200.53; Berghella V, 2004, AM J OBSTET GYNECOL, V191, P1311, DOI 10.1016/j.ajog.2004.06.054; Berghella V, 2002, AM J OBSTET GYNECOL, V187, P747, DOI 10.1067/mob.2002.124289; Brown HL, 1999, AM J OBSTET GYNECOL, V180, P798, DOI 10.1016/S0002-9378(99)70650-2; BRYCE RL, 1991, BRIT J OBSTET GYNAEC, V98, P1001, DOI 10.1111/j.1471-0528.1991.tb15338.x; Burguet A, 2004, BJOG-INT J OBSTET GY, V111, P258, DOI 10.1046/j.1471-0528.2003.00037.x; Callaghan WM, 2006, PEDIATRICS, V118, P1566, DOI 10.1542/peds.2006-0860; Carey JC, 2000, NEW ENGL J MED, V342, P534, DOI 10.1056/NEJM200002243420802; Caritis S, 1998, NEW ENGL J MED, V338, P701, DOI 10.1056/NEJM199803123381101; Caritis S, 2006, AM J OBSTET GYNECOL, V195, pS2, DOI 10.1016/j.ajog.2006.10.003; *CDCP, 2006, SEX TRANSM DIS TREAT; COPPER RL, 1994, OBSTET GYNECOL, V84, P490; Crowther CA, 2002, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001060; CZEIZEL AE, 1994, ARCH GYNECOL OBSTET, V255, P131; da Fonseca EB, 2003, AM J OBSTET GYNECOL, V188, P419, DOI 10.1067/mob.2003.41; DEPP R, 1993, AM J OBSTET GYNECOL, V169, P352; Deulofeut R, 2005, OBSTET GYNECOL, V105, P525, DOI 10.1097/01.AOG.0000154156.51578.50; DEVOE LD, 1995, AM J OBSTET GYNECOL, V173, P1120; Di Renzo GC, 1998, PRENAT NEONAT MED, V3, P147; Dodd JM, 2006, COCHRANE DB SYST REV, V1; Dodd JM, 2006, COCHRANE DB SYST REV, V1; Duley L, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004659.pub2; Dyson DC, 1998, NEW ENGL J MED, V338, P15, DOI 10.1056/NEJM199801013380103; ELDER HA, 1971, AM J OBSTET GYNECOL, V111, P441, DOI 10.1016/0002-9378(71)90793-9; ESCHENBACH DA, 1991, AM J OBSTET GYNECOL, V164, P734, DOI 10.1016/0002-9378(91)90506-M; Espinoza J, 2006, AM J OBSTET GYNECOL, V194, P630, DOI 10.1016/j.ajog.2005.11.050; FIORE MC, 2000, TREATING TOBACCO USE; Fonseca EB, 2007, NEW ENGL J MED, V357, P462, DOI 10.1056/NEJMoa067815; Gichangi PB, 1997, AM J OBSTET GYNECOL, V177, P680, DOI 10.1016/S0002-9378(97)70164-9; Goldenberg RL, 2006, AM J OBSTET GYNECOL, V194, P650, DOI 10.1016/j.ajog.2006.01.004; Goldenberg RL, 2001, AM J OBSTET GYNECOL, V185, P643, DOI 10.1067/mob.2001.116752; Goldenberg RL, 1998, AM J PUBLIC HEALTH, V88, P233, DOI 10.2105/AJPH.88.2.233; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; Goldenberg RL, 2006, AM J OBSTET GYNECOL, V195, P792, DOI 10.1016/j.ajog.2006.05.050; Grant A, 1996, BRIT J OBSTET GYNAEC, V103, P1197, DOI 10.1111/j.1471-0528.1996.tb09628.x; Groom KM, 2004, EUR J OBSTET GYN R B, V112, P158, DOI 10.1016/S0301-2115(03)00289-6; Guzman ER, 2001, ULTRASOUND OBST GYN, V18, P195, DOI 10.1046/j.0960-7692.2001.525.x; Guzman ER, 1998, ULTRASOUND OBST GYN, V12, P323, DOI 10.1046/j.1469-0705.1998.12050323.x; Haas JS, 2005, ARCH PEDIAT ADOL MED, V159, P58, DOI 10.1001/archpedi.159.1.58; Harnett EL, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.03.047; Hassan SS, 2001, AM J OBSTET GYNECOL, V184, P1325, DOI 10.1067/mob.2001.115119; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; Healy AJ, 2006, OBSTET GYNECOL, V107, P625, DOI 10.1097/01.AOG.0000201978.83607.96; Heath VCF, 1998, ULTRASOUND OBST GYN, V12, P312, DOI 10.1046/j.1469-0705.1998.12050312.x; Heijnen EMEW, 2007, LANCET, V369, P743, DOI 10.1016/S0140-6736(07)60360-2; HERRON MA, 1982, OBSTET GYNECOL, V59, P452; Higgins SP, 2004, AUST NZ J OBSTET GYN, V44, P228, DOI 10.1111/j.1479-828X.2004.00220.x; Hodnett E. D., 2003, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD000198; HOFMEYR GJ, 2006, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001059.PUB2; HUESTON WJ, 1995, OBSTET GYNECOL, V86, P705, DOI 10.1016/0029-7844(95)00202-3; IAMS JD, 1995, AM J OBSTET GYNECOL, V172, P1097, DOI 10.1016/0002-9378(95)91469-2; IAMS JD, 1990, AM J PERINAT, V7, P170, DOI 10.1055/s-2007-999473; Iams JD, 1998, AM J OBSTET GYNECOL, V178, P1035, DOI 10.1016/S0002-9378(98)70544-7; Iams JD, 1996, NEW ENGL J MED, V334, P567, DOI 10.1056/NEJM199602293340904; Iams JD, 2001, AM J OBSTET GYNECOL, V184, P652, DOI 10.1067/mob.2001.111248; Jain T, 2004, NEW ENGL J MED, V350, P1639, DOI 10.1056/NEJMsa032073; Jakobsson M, 2007, OBSTET GYNECOL, V109, P309, DOI 10.1097/01.AOG.0000253239.87040.23; JOESOEF MR, 1995, AM J OBSTET GYNECOL, V173, P1527, DOI 10.1016/0002-9378(95)90644-4; JOSEPH KS, 2007, BMC PREGNANCY CHILDB, V28, P7; KEIRSE MJNC, 1990, BRIT J OBSTET GYNAEC, V97, P149, DOI 10.1111/j.1471-0528.1990.tb01740.x; Kekki M, 2001, OBSTET GYNECOL, V97, P643, DOI 10.1016/S0029-7844(01)01321-7; Kenyon SL, 2001, LANCET, V357, P979, DOI 10.1016/S0140-6736(00)04233-1; Kigozi GG, 2003, AM J OBSTET GYNECOL, V189, P1398, DOI 10.1067/S0002-9378(03)00777-4; King J, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001992.pub2; King JF, 2003, COCHRANE DB SYST REV, V1; Kiss H, 2004, BMJ-BRIT MED J, V329, P371, DOI 10.1136/bmj.38169.519653.EB; Kitzman H, 1997, JAMA-J AM MED ASSOC, V278, P644, DOI 10.1001/jama.278.8.644; Klebanoff MA, 2001, NEW ENGL J MED, V345, P487, DOI 10.1056/NEJMoa003329; KLEBANOFF MA, 1995, AM J OBSTET GYNECOL, V172, P1540, DOI 10.1016/0002-9378(95)90493-X; Klerman LV, 2001, AM J PUBLIC HEALTH, V91, P105; Kramer MS, 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD000032; Kurkinen-Raty M, 2000, BRIT J OBSTET GYNAEC, V107, P1427, DOI 10.1111/j.1471-0528.2000.tb11660.x; Kurup M, 1999, AM J OBSTET GYNECOL, V181, P240, DOI 10.1016/S0002-9378(99)70542-9; Lamont RF, 2005, BJOG-INT J OBSTET GY, V112, P67, DOI 10.1111/j.1471-0528.2005.00589.x; Lamont RF, 2003, OBSTET GYNECOL, V101, P516, DOI 10.1016/S0029-7844(02)03054-5; Larsson PG, 2006, BJOG-INT J OBSTET GY, V113, P629, DOI 10.1111/j.1471-0528.2006.00946.x; LAUNER LJ, 1990, BRIT J OBSTET GYNAEC, V97, P62, DOI 10.1111/j.1471-0528.1990.tb01718.x; LAZAR P, 1984, BRIT J OBSTET GYNAEC, V91, P731, DOI 10.1111/j.1471-0528.1984.tb04841.x; Leitich H, 1999, AM J OBSTET GYNECOL, V181, P1465, DOI 10.1016/S0002-9378(99)70407-2; LEVENO KJ, 1986, OBSTET GYNECOL, V68, P434, DOI 10.1097/00006250-198609000-00031; Levine RJ, 1997, NEW ENGL J MED, V337, P69, DOI 10.1056/NEJM199707103370201; Lu MC, 2006, MATERN CHILD HLTH J, V10, pS107, DOI 10.1007/s10995-006-0118-7; Lumley J., 2004, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001055.PUB2; Lumley J, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-299; Mackenzie R, 2006, AM J OBSTET GYNECOL, V194, P1234, DOI 10.1016/j.ajog.2005.06.049; MACNAUGHTON MC, 1993, BRIT J OBSTET GYNAEC, V100, P516; Martensson A, 2004, ACTA AGR SCAND B-S P, V54, P1, DOI 10.1080/09064710410024417; Massett HA, 2003, AM J PREV MED, V24, P120, DOI 10.1016/S0749-3797(02)00572-X; Matijevic R, 2006, ACTA OBSTET GYN SCAN, V85, P1342, DOI 10.1080/00016340600935722; Mazaki-Tovi S, 2007, SEMIN PERINATOL, V31, P142, DOI 10.1053/j.semperi.2007.04.001; McDonald H, 2007, COCHRANE DB SYST REV, V1; McDonald HM, 1997, BRIT J OBSTET GYNAEC, V104, P1391, DOI 10.1111/j.1471-0528.1997.tb11009.x; MEIS PJ, 1995, AM J OBSTET GYNECOL, V173, P597, DOI 10.1016/0002-9378(95)90288-0; Meis PJ, 2003, NEW ENGL J MED, V348, P2379, DOI 10.1056/NEJMoa035140; Mercer B, 2005, AM J OBSTET GYNECOL, V193, P1175, DOI 10.1016/j.ajog.2005.05.040; Mercer BM, 1999, AM J OBSTET GYNECOL, V181, P1216, DOI 10.1016/S0002-9378(99)70111-0; Mercer BM, 1997, JAMA-J AM MED ASSOC, V278, P989, DOI 10.1001/jama.278.12.989; Michalowicz BS, 2006, NEW ENGL J MED, V355, P1885, DOI 10.1056/NEJMoa062249; Min JK, 2006, J OBSTET GYNAECOL CA, V28, P799, DOI 10.1016/S1701-2163(16)32246-0; Mittendorf R, 1997, LANCET, V350, P1517, DOI 10.1016/S0140-6736(97)24047-X; Moore S, 2004, BRIT DENT J, V197, P251, DOI 10.1038/sj.bdj.4811620; Moreau C, 2005, BJOG-INT J OBSTET GY, V112, P430, DOI 10.1111/j.1471-0528.2004.00478.x; MUELLERHEUBACH E, 1989, AM J OBSTET GYNECOL, V160, P1172, DOI 10.1016/0002-9378(89)90183-X; NAGEY DA, 1993, OBSTET GYNECOL, V82, P319; Nanda K, 2002, COCHRANE DB SYST REV, V4; Offenbacher S, 2006, OBSTET GYNECOL, V107, P29, DOI 10.1097/01.AOG.0000190212.87012.96; OLDS DL, 1986, PEDIATRICS, V77, P16; Olsen SF, 2000, BRIT J OBSTET GYNAEC, V107, P382, DOI 10.1111/j.1471-0528.2000.tb13235.x; OLSEN SF, 1992, LANCET, V339, P1003, DOI 10.1016/0140-6736(92)90533-9; Papatsonis D, 2005, COCHRANE DB SYST REV, V3; PAPIERNIK E, 1985, PEDIATRICS, V76, P154; Papiernik E, 2007, MATERN CHILD HLTH J, V11, P407, DOI 10.1007/s10995-007-0217-0; Patton PE, 2004, AM J OBSTET GYNECOL, V190, P1669, DOI 10.1016/j.ajog.2004.02.046; Petersen R, 2006, TOB CONTROL, V15, P30, DOI 10.1136/tc.2005.012187; Petrini JR, 2005, OBSTET GYNECOL, V105, P267, DOI 10.1097/01.AOG.0000150560.24297.4f; Phibbs CS, 2007, NEW ENGL J MED, V356, P2165, DOI 10.1056/NEJMsa065029; Pompeii LA, 2005, OBSTET GYNECOL, V106, P1279, DOI 10.1097/01.AOG.0000189080.76998.f8; Poston L, 2006, LANCET, V367, P1145, DOI 10.1016/S0140-6736(06)68433-X; Pretorius C, 2007, J PERINAT MED, V35, P93, DOI 10.1515/JPM.2007.039; Quinlivan JA, 2004, BJOG-INT J OBSTET GY, V111, P571, DOI 10.1111/j.1471-0528.2004.00146.x; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; Ricketts SA, 2005, AM J PUBLIC HEALTH, V95, P1952, DOI 10.2105/AJPH.2004.047068; Riggs MA, 2004, CLIN OBSTET GYNECOL, V47, P796, DOI 10.1097/01.grf.0000141450.61310.81; Riskin A, 2004, BJOG-INT J OBSTET GY, V111, P1365, DOI 10.1111/j.1471-0528.2004.00268.x; Roberts D, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub2; Romero R, 2004, AM J OBSTET GYNECOL, V190, P1509, DOI 10.1016/j.ajog.2004.01.002; ROMERO R, 1989, OBSTET GYNECOL, V73, P576; ROMERO R, 2004, PRETERM BIRTH, P28; Rosenstein I J, 2000, Infect Dis Obstet Gynecol, V8, P158, DOI 10.1155/S1064744900000211; Rumbold A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004227.pub2; Rumbold AR, 2006, NEW ENGL J MED, V354, P1796, DOI 10.1056/NEJMoa054186; RUSH RW, 1984, BRIT J OBSTET GYNAEC, V91, P724, DOI 10.1111/j.1471-0528.1984.tb04840.x; Rust OA, 2001, AM J OBSTET GYNECOL, V185, P1098, DOI 10.1067/mob.2001.118163; Sadler L, 2004, JAMA-J AM MED ASSOC, V291, P2100, DOI 10.1001/jama.291.17.2100; Sakai M, 2006, AM J OBSTET GYNECOL, V194, P14, DOI 10.1016/j.ajog.2005.06.014; Salihu Hamisu M, 2003, Matern Child Health J, V7, P219, DOI 10.1023/A:1027319517405; Sanchez-Ramos L, 2005, OBSTET GYNECOL, V105, P273, DOI 10.1097/01.AOG.0000150559.59531.b2; Saurel-Cubizolles MJ, 2004, J EPIDEMIOL COMMUN H, V58, P395, DOI 10.1136/jech.2003.008029; Shah NR, 2000, AM J OBSTET GYNECOL, V182, P465, DOI 10.1016/S0002-9378(00)70240-7; Shennan A, 2006, BJOG-INT J OBSTET GY, V113, P65, DOI 10.1111/j.1471-0528.2005.00788.x; SIBAI BM, 1993, NEW ENGL J MED, V329, P1213, DOI 10.1056/NEJM199310213291701; Smaill F., 2001, COCHRANE DB SYST REV, V2, DOI [DOI 10.1002/14651858.CD000490, 10.1002/14651858.CD000490]; Smuts CM, 2003, OBSTET GYNECOL, V101, P469, DOI 10.1016/S0029-7844(02)02585-1; Sosa C, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003581.pub2, DOI 10.1002/14651858.CD003581.PUB2]; Stamilio DM, 2007, AM J OBSTET GYNECOL, V196, P93, DOI 10.1016/j.ajog.2006.09.029; Taipale P, 1998, OBSTET GYNECOL, V92, P902, DOI 10.1016/S0029-7844(98)00346-9; To MS, 2004, LANCET, V363, P1849, DOI 10.1016/S0140-6736(04)16351-4; To MS, 2002, ULTRASOUND OBST GYN, V19, P475, DOI 10.1046/j.1469-0705.2002.00673.x; Towers CV, 2000, OBSTET GYNECOL, V95, P291, DOI 10.1016/S0029-7844(99)00528-1; Ugwumadu A, 2003, LANCET, V361, P983, DOI 10.1016/S0140-6736(03)12823-1; Ugwumadu A, 2006, OBSTET GYNECOL, V107, P863, DOI 10.1097/01.AOG.0000202399.13074.98; Vahratian A, 2004, AM J EPIDEMIOL, V160, P886, DOI 10.1093/aje/kwh305; VERGNES JN, 2007, AM J OBSTET GYNECOL, V196; Vermeulen GM, 1999, BRIT J OBSTET GYNAEC, V106, P652, DOI 10.1111/j.1471-0528.1999.tb08363.x; VILLAR J, 1992, NEW ENGL J MED, V327, P1266, DOI 10.1056/NEJM199210293271803; Wapner RJ, 2006, AM J OBSTET GYNECOL, V195, P633, DOI 10.1016/j.ajog.2006.03.087; Warner B, 2004, PEDIATRICS, V113, P35, DOI 10.1542/peds.113.1.35; White Deborah E, 2006, Health Care Women Int, V27, P777, DOI 10.1080/07399330600880335; Yeast JD, 1998, AM J OBSTET GYNECOL, V178, P131, DOI 10.1016/S0002-9378(98)70639-8; Yost NP, 2006, OBSTET GYNECOL, V107, P793, DOI 10.1097/01.AOG.0000206757.92602.b5	182	319	330	3	49	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 12	2008	371	9607					164	175		10.1016/S0140-6736(08)60108-7	http://dx.doi.org/10.1016/S0140-6736(08)60108-7			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	252ND	18191687				2023-01-03	WOS:000252452300031
J	Brunkhorst, FM; Engel, C; Bloos, F; Meier-Hellmann, A; Ragaller, M; Weiler, N; Moerer, O; Gruendling, M; Oppert, M; Grond, S; Olthoff, D; Jaschinski, U; John, S; Rossaint, R; Welte, T; Schaefer, M; Kern, P; Kuhnt, E; Kiehntopf, M; Hartog, C; Natanson, C; Loeffler, M; Reinhart, K				Brunkhorst, Frank M.; Engel, Christoph; Bloos, Frank; Meier-Hellmann, Andreas; Ragaller, Max; Weiler, Norbert; Moerer, Onnen; Gruendling, Matthias; Oppert, Michael; Grond, Stefan; Olthoff, Derk; Jaschinski, Ulrich; John, Stefan; Rossaint, Rolf; Welte, Tobias; Schaefer, Martin; Kern, Peter; Kuhnt, Evelyn; Kiehntopf, Michael; Hartog, Christiane; Natanson, Charles; Loeffler, Markus; Reinhart, Konrad		German Competence Network Sepsis	Intensive insulin therapy and pentastarch resuscitation in severe sepsis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYDROXYETHYL STARCH; RENAL-FUNCTION; CRITICALLY-ILL; HYPOGLYCEMIA; REPLACEMENT; MULTICENTER; GELATIN; FAILURE; SURGERY; LESIONS	Background: The role of intensive insulin therapy in patients with severe sepsis is uncertain. Fluid resuscitation improves survival among patients with septic shock, but evidence is lacking to support the choice of either crystalloids or colloids. Methods: In a multicenter, two-by-two factorial trial, we randomly assigned patients with severe sepsis to receive either intensive insulin therapy to maintain euglycemia or conventional insulin therapy and either 10% pentastarch, a low-molecular-weight hydroxyethyl starch (HES 200/0.5), or modified Ringer's lactate for fluid resuscitation. The rate of death at 28 days and the mean score for organ failure were coprimary end points. Results: The trial was stopped early for safety reasons. Among 537 patients who could be evaluated, the mean morning blood glucose level was lower in the intensive-therapy group (112 mg per deciliter [6.2 mmol per liter]) than in the conventional-therapy group (151 mg per deciliter [8.4 mmol per liter], P<0.001). However, at 28 days, there was no significant difference between the two groups in the rate of death or the mean score for organ failure. The rate of severe hypoglycemia (glucose level, <= 40 mg per deciliter [2.2 mmol per liter]) was higher in the intensive-therapy group than in the conventional-therapy group (17.0% vs. 4.1%, P<0.001), as was the rate of serious adverse events (10.9% vs. 5.2%, P=0.01). HES therapy was associated with higher rates of acute renal failure and renal-replacement therapy than was Ringer's lactate. Conclusions: The use of intensive insulin therapy placed critically ill patients with sepsis at increased risk for serious adverse events related to hypoglycemia. As used in this study, HES was harmful, and its toxicity increased with accumulating doses. (ClinicalTrials.gov number, NCT00135473.).	[Brunkhorst, Frank M.; Bloos, Frank; Hartog, Christiane; Reinhart, Konrad] Univ Jena, Dept Anesthesiol & Intens Care Med, D-07747 Jena, Germany; [Kiehntopf, Michael] Univ Jena, Inst Clin Chem & Lab Med, D-07747 Jena, Germany; [Engel, Christoph; Loeffler, Markus] Univ Leipzig, Inst Med Informat Stat & Epidemiol, Leipzig, Germany; [Kuhnt, Evelyn] Univ Leipzig, Coordinat Ctr Clin Trials, Leipzig, Germany; [Meier-Hellmann, Andreas] HELIOS Klin, Dept Anesthesiol & Intens Care Med, Erfurt, Germany; [Ragaller, Max] Tech Univ Dresden, Univ Hosp, Dept Anesthesiol & Intens Care Med, Dresden, Germany; [Weiler, Norbert] Univ Hosp Schleswig Holstein, Dept Anesthesiol & Intens Care Med, Kiel, Germany; [Moerer, Onnen] Univ Goettingen, Dept Anesthesiol & Intens Care Med, Gottingen, Germany; [Gruendling, Matthias] Univ Greifswald, Dept Anesthesiol & Intens Care Med, Greifswald, Germany; [Oppert, Michael] Univ Med Ctr, Charite, Dept Nephrol & Med Intens Care, Berlin, Germany; [Grond, Stefan] Univ Halle Wittenberg, Dept Anesthesiol & Intens Care Med, Halle, Germany; [Olthoff, Derk] Univ Hosp, Dept Anesthesiol & Intens Care Med, Leipzig, Germany; [Jaschinski, Ulrich] Klinikum Augsburg, Dept Anesthesiol & Crit Care Med, Augsburg, Germany; [John, Stefan] Univ Erlangen Nurnberg, Dept Hypertens & Nephrol, Erlangen, Germany; [Rossaint, Rolf] Rhein Westfal TH Aachen, Univ Hosp Aachen, Dept Anesthesiol & Intens Care Med, Aachen, Germany; [Welte, Tobias] Otto von Guericke Univ, Dept Pulm & Crit Care Med, Magdeburg, Germany; [Welte, Tobias] Hannover Med Sch, Dept Pulm & Crit Care Med, D-30623 Hannover, Germany; [Schaefer, Martin] Staedt Klinikum Brandenburg, Dept Anesthesiol & Intens Care Med, Brandenburg, Germany; [Kern, Peter] Staedt Krankenhaus Dresden Friedrichstadt, Dept Anesthesiol & Intens Care Med, Dresden, Germany; [Natanson, Charles] NIH, Dept Crit Care Med, Bethesda, MD 20892 USA	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Leipzig University; Leipzig University; Helios Kliniken; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Gottingen; Ernst Moritz Arndt Universitat Greifswald; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Martin Luther University Halle Wittenberg; Leipzig University; Klinikum Augsburg; University of Erlangen Nuremberg; RWTH Aachen University; RWTH Aachen University Hospital; Otto von Guericke University; Hannover Medical School; Technische Universitat Dresden; Municipal Hospital Dresden; National Institutes of Health (NIH) - USA	Reinhart, K (corresponding author), Univ Jena, Dept Anesthesiol & Intens Care Med, Erlanger Allee 101, D-07747 Jena, Germany.	konrad.reinhart@med.uni-jena.de	Moerer, Onnen/K-6349-2019; Weiler, Norbert/E-5356-2010; Bloos, Frank/AAY-8265-2020	Bloos, Frank/0000-0002-0767-7941; Engel, Christoph/0000-0002-7247-282X; Trips, Evelyn/0000-0002-6530-5855; Grundling, Matthias/0000-0001-8043-7293; Brunkhorst, Frank Martin/0000-0002-8132-8651; Hartog, Christiane/0000-0003-1098-9775				Arellano R, 2005, ANESTH ANALG, V100, P1846, DOI 10.1213/01.ANE.0000152008.04333.53; Auwerda JJA, 2002, ANN INTERN MED, V137, P1013, DOI 10.7326/0003-4819-137-12-200212170-00037; Barron ME, 2004, ARCH SURG-CHICAGO, V139, P552, DOI 10.1001/archsurg.139.5.552; BAUER P, 1994, BIOMETRICS, V50, P1029, DOI 10.2307/2533441; Beyer R, 1997, BRIT J ANAESTH, V78, P44, DOI 10.1093/bja/78.1.44; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Brunkhorst FM, 2005, INFECTION, V33, P19; Christidis C, 2001, J HEPATOL, V35, P726, DOI 10.1016/S0168-8278(01)00200-8; Cittanova ML, 1996, LANCET, V348, P1620, DOI 10.1016/S0140-6736(96)07588-5; Cryer PE, 2004, NEW ENGL J MED, V350, P2272, DOI 10.1056/NEJMra031354; Dellinger RP, 2004, CRIT CARE MED, V32, P1448; Egi M, 2006, ANESTHESIOLOGY, V105, P244, DOI 10.1097/00000542-200608000-00006; Haynes GR, 2004, ANESTHESIOLOGY, V101, P560, DOI 10.1097/00000542-200408000-00055; Hoffmann JN, 2002, ANESTHESIOLOGY, V97, P460, DOI 10.1097/00000542-200208000-00025; Jonville-Bera A, 2001, NEW ENGL J MED, V345, P622, DOI 10.1056/NEJM200108233450818; LEGENDRE C, 1993, LANCET, V342, P248, DOI 10.1016/0140-6736(93)92345-T; Liet Jean-Michel, 2003, Pediatr Crit Care Med, V4, P305, DOI 10.1097/01.PCC.0000074262.84240.1E; *MEDWATCH, 2004, WHAT IS SER ADV EV; Moreno R, 1999, INTENS CARE MED, V25, P686, DOI 10.1007/s001340050931; MORISAKI H, 1994, J APPL PHYSIOL, V77, P1507, DOI 10.1152/jappl.1994.77.3.1507; Perazella MA, 2003, AM J MED SCI, V325, P349, DOI 10.1097/00000441-200306000-00006; Pillebout E, 2005, AM J TRANSPLANT, V5, P1120, DOI 10.1111/j.1600-6143.2005.00852.x; ROBERTS I, 2004, COCHRANE DB SYST REV, V4; Sakr Y, 2007, BRIT J ANAESTH, V98, P216, DOI 10.1093/bja/ael333; Schmidt-Hieber M, 2006, EUR J HAEMATOL, V77, P83, DOI 10.1111/j.1600-0609.2006.00657.x; Schortgen F, 2001, LANCET, V357, P911, DOI 10.1016/S0140-6736(00)04211-2; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; Van den Berghe G, 2003, CRIT CARE MED, V31, P359, DOI 10.1097/01.CCM.0000045568.12881.10; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; van Rijen EAM, 1998, CLIN DIAGN LAB IMMUN, V5, P543, DOI 10.1128/CDLI.5.4.543-549.1998; Vogt N, 1999, ANAESTHESIA, V54, P121, DOI 10.1046/j.1365-2044.1999.00649.x; Wiedermann CJ, 2004, WIEN KLIN WOCHENSCHR, V116, P583, DOI 10.1007/s00508-004-0237-3; Wiesen P, 2005, ACTA ANAESTH BELG, V56, P257; Wilkes MM, 2001, ANN THORAC SURG, V72, P527, DOI 10.1016/S0003-4975(01)02745-X; Wilson M, 2007, DIABETES CARE, V30, P1005, DOI 10.2337/dc06-1964; Winkelmayer WC, 2003, KIDNEY INT, V64, P1046, DOI 10.1046/j.1523-1755.2003.00186.x	37	1952	2070	3	115	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 10	2008	358	2					125	139		10.1056/NEJMoa070716	http://dx.doi.org/10.1056/NEJMoa070716			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	249CJ	18184958	Green Submitted, Green Published			2023-01-03	WOS:000252204200004
J	Nichol, KL; Nordin, JD; Nelson, DB; Mullooly, JP; Hak, E				Nichol, Kristin L.; Nordin, James D.; Nelson, David B.; Mullooly, John P.; Hak, Eelko			Effectiveness of influenza vaccine in the community-dwelling elderly	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; FUNCTIONAL STATUS; PROGNOSTIC INDEX; MORTALITY; VALIDATION; OLDER; HOSPITALIZATIONS; BENEFITS; US; EFFICACY	Background Reliable estimates of the effectiveness of influenza vaccine among persons 65 years of age and older are important for informed vaccination policies and programs. Short-term studies may provide misleading pictures of long-term benefits, and residual confounding may have biased past results. This study examined the effectiveness of influenza vaccine in seniors over the long term while addressing potential bias and residual confounding in the results. Methods Data were pooled from 18 cohorts of community-dwelling elderly members of one U.S. health maintenance organization (HMO) for 1990-1991 through 1999-2000 and of two other HMOs for 1996-1997 through 1999-2000. Logistic regression was used to estimate the effectiveness of the vaccine for the prevention of hospitalization for pneumonia or influenza and death after adjustment for important covariates. Additional analyses explored for evidence of bias and the potential effect of residual confounding. Results There were 713,872 person-seasons of observation. Most high-risk medical conditions that were measured were more prevalent among vaccinated than among unvaccinated persons. Vaccination was associated with a 27% reduction in the risk of hospitalization for pneumonia or influenza (adjusted odds ratio, 0.73; 95% confidence interval [CI], 0.68 to 0.77) and a 48% reduction in the risk of death (adjusted odds ratio, 0.52; 95% CI, 0.50 to 0.55). Estimates were generally stable across age and risk subgroups. In the sensitivity analyses, we modeled the effect of a hypothetical unmeasured confounder that would have caused overestimation of vaccine effectiveness in the main analysis; vaccination was still associated with statistically significant - though lower - reductions in the risks of both hospitalization and death. Conclusions During 10 seasons, influenza vaccination was associated with significant reductions in the risk of hospitalization for pneumonia or influenza and in the risk of death among community-dwelling elderly persons. Vaccine delivery to this high-priority group should be improved.	Minneapolis Vet Affairs Med Ctr, Med Serv, Minneapolis, MN USA; Minneapolis Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; Univ Minnesota, Minneapolis, MN USA; HealthPartners Res Fdn, Minneapolis, MN USA; Kaiser Permanente NW, Portland, OR USA; Univ Med Ctr, Julius Ctr Hlth Serv & Primary Care, Utrecht, Netherlands	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; HealthPartners Institute for Education & Research; Kaiser Permanente; Utrecht University; Utrecht University Medical Center	Nichol, KL (corresponding author), VA Med Ctr, Med Serv, 111,1 Vet Dr, Minneapolis, MN 55417 USA.	nicho014@umn.edu	Nelson, David/G-7142-2011	Nelson, David/0000-0003-1163-1222; Nordin, James/0000-0002-3359-5843				*ADV COMM IMM PRAC, 2006, MMWR-MORBID MORTAL W, V55, P800; Advisory Committee on Immunization Practices, 2006, MMWR Recomm Rep, V55, P1; BANTHIN JS, 1996, 15 AG HEALTHC RES PO; Carey EC, 2004, J GEN INTERN MED, V19, P1027, DOI 10.1111/j.1525-1497.2004.40016.x; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P958; Fry AM, 2005, JAMA-J AM MED ASSOC, V294, P2712, DOI 10.1001/jama.294.21.2712; Fukuda K, 2006, NEW ENGL J MED, V355, P2586, DOI 10.1056/NEJMe068257; Fulop T, 1999, J GERONTOL A-BIOL, V54, pM59, DOI 10.1093/gerona/54.2.M59; Glezen WP, 2006, INT J EPIDEMIOL, V35, P352, DOI 10.1093/ije/dyi293; Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105; GROSS PA, 1989, VACCINE, V7, P303, DOI 10.1016/0264-410X(89)90190-4; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; Hak E, 2006, INT J EPIDEMIOL, V35, P800, DOI 10.1093/ije/dyl068; Hak E, 2004, J INFECT DIS, V189, P450, DOI 10.1086/381165; Hak E, 2002, J EPIDEMIOL COMMUN H, V56, P951, DOI 10.1136/jech.56.12.951; Herrera GA, 2007, VACCINE, V25, P154, DOI 10.1016/j.vaccine.2006.05.129; Jackson LA, 2006, INT J EPIDEMIOL, V35, P345, DOI 10.1093/ije/dyi275; Jacobson RA, 2007, VACCINE, V25, P3153, DOI 10.1016/j.vaccine.2007.01.047; Jefferson T, 2006, LANCET, V367, P986; Jefferson T, 2005, LANCET, V366, P1165, DOI 10.1016/S0140-6736(05)67339-4; Jefferson TO, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001269.pub3; Jefferson T, 2006, BMJ-BRIT MED J, V333, P912, DOI 10.1136/bmj.38995.531701.80; Jordan R, 2006, VACCINE, V24, P1047, DOI 10.1016/j.vaccine.2005.09.017; King JC, 2006, NEW ENGL J MED, V355, P2523, DOI 10.1056/NEJMoa055414; Lee SJ, 2006, JAMA-J AM MED ASSOC, V295, P801, DOI 10.1001/jama.295.7.801; LETHRIDGECEJKU M, 2006, VITAL HLTH STAT 10, V228; Lin DY, 1998, BIOMETRICS, V54, P948, DOI 10.2307/2533848; Mac Donald R, 1999, AM J PREV MED, V16, P173, DOI 10.1016/S0749-3797(98)00159-7; Mayo NE, 2005, MED CARE, V43, P1194, DOI 10.1097/01.mlr.0000185749.04875.cb; McElhaney JE, 2005, VACCINE, V23, pS10, DOI 10.1016/j.vaccine.2005.04.019; Mokdad AH, 2000, DIABETES CARE, V23, P1278, DOI 10.2337/diacare.23.9.1278; MORGENSTERN H, 1995, ANNU REV PUBL HEALTH, V16, P61, DOI 10.1146/annurev.pu.16.050195.000425; Nichol KL, 2003, NEW ENGL J MED, V348, P1322, DOI 10.1056/NEJMoa025028; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; Nichol KL, 2005, DRUG AGING, V22, P495, DOI 10.2165/00002512-200522060-00004; Nordin J, 2001, J INFECT DIS, V184, P665, DOI 10.1086/323085; Ohmit SE, 2006, NEW ENGL J MED, V355, P2513, DOI 10.1056/NEJMoa061850; Piedra PA, 2005, VACCINE, V23, P1540, DOI 10.1016/j.vaccine.2004.09.025; Reichert TA, 2001, NEW ENGL J MED, V344, P889, DOI 10.1056/NEJM200103223441204; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Schwartz B, 2006, J INFECT DIS, V194, pS147, DOI 10.1086/507556; Simonsen L, 2005, ARCH INTERN MED, V165, P265, DOI 10.1001/archinte.165.3.265; Targonski PV, 2007, VACCINE, V25, P3066, DOI 10.1016/j.vaccine.2007.01.025; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2987, DOI 10.1001/jama.285.23.2987	47	485	505	0	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 4	2007	357	14					1373	1381		10.1056/NEJMoa070844	http://dx.doi.org/10.1056/NEJMoa070844			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216QA	17914038				2023-01-03	WOS:000249892900003
J	Wright, AA; Katz, IT				Wright, Alexi A.; Katz, Ingrid T.			Letting go of the rope - Aggressive treatment, hospice care, and open access	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CANCER; LIFE; END						Wright, Alexi/T-5793-2019	Katz, Ingrid/0000-0002-3014-238X				Earle CC, 2004, J CLIN ONCOL, V22, P315, DOI 10.1200/JCO.2004.08.136; Finn JW, 2002, P AN M AM SOC CLIN, P21; Lamont EB, 2001, ANN INTERN MED, V134, P1096, DOI 10.7326/0003-4819-134-12-200106190-00009; *NAT HOSP PALL CAR, 2006, 2005 NAT SUMM HOSP C, P4; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458	5	61	61	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 26	2007	357	4					324	327		10.1056/NEJMp078074	http://dx.doi.org/10.1056/NEJMp078074			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	193OL	17652646				2023-01-03	WOS:000248283500002
J	Schmoll, HJ; Sargent, D				Schmoll, Hans-Joachim; Sargent, Daniel			Single agent fluorouracil for-first-line treatment of advanced colorectal cancer as standard?	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; COMBINATION CHEMOTHERAPY; OXALIPLATIN; IRINOTECAN; LEUCOVORIN		Univ Halle Wittenberg, Dept Haematol Oncol, Internal Med Clin, D-06120 Halle, Germany; Mayo Clin, Rochester, MN USA	Martin Luther University Halle Wittenberg; Mayo Clinic	Schmoll, HJ (corresponding author), Univ Halle Wittenberg, Dept Haematol Oncol, Internal Med Clin, D-06120 Halle, Germany.		Schmoll, Hans-Joachim/AAG-5888-2019; schmoll, hans-joachim/AAO-5219-2021	schmoll, hans-joachim/0000-0001-8705-0593; Sargent, Daniel/0000-0002-2684-4741				BOUCHE O, 2007, J CLIN ONCOL S, V18, P4069; Falcone A, 2007, J CLIN ONCOL, V25, P1670, DOI 10.1200/JCO.2006.09.0928; FUCHS C, 2007, J CLIN ONCOL S, V18, P4027; Grothey A, 2004, J CLIN ONCOL, V22, P1209, DOI 10.1200/JCO.2004.11.037; Koopman M, 2007, LANCET, V370, P135, DOI 10.1016/S0140-6736(07)61086-1; SALTZ L, 2007, J CLIN ONCOL S, V18, P4028; Saunders M, 2006, BRIT J CANCER, V95, P131, DOI 10.1038/sj.bjc.6603233; Schrag D, 2004, NEW ENGL J MED, V351, P317, DOI 10.1056/NEJMp048143; Seymour MT, 2007, LANCET, V370, P143, DOI 10.1016/S0140-6736(07)61087-3; Souglakos J, 2006, BRIT J CANCER, V94, P798, DOI 10.1038/sj.bjc.6603011; VANCUTSEM E, 2007, J CLIN ONCOL S, V18, P4000	11	29	30	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 14	2007	370	9582					105	107		10.1016/S0140-6736(07)61062-9	http://dx.doi.org/10.1016/S0140-6736(07)61062-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190WP	17630019				2023-01-03	WOS:000248091600004
J	Wilson, JF				Wilson, Jennifer Fisher			Strategies to stop abuse of prescribed opioid drugs	ANNALS OF INTERNAL MEDICINE			English	News Item							CHRONIC PAIN; ASSOCIATION; DISORDERS					jenwilson@acponline.org	Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136				Gourlay DL, 2005, PAIN MED, V6, P107, DOI 10.1111/j.1526-4637.2005.05031.x; GOURLAY DL, 2004, DRUG TESTING CLIN PR, P4349; Hariharan J, 2007, J GEN INTERN MED, V22, P485, DOI 10.1007/s11606-006-0084-1; Ives TJ, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-46; Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006; Sullivan MD, 2006, ARCH INTERN MED, V166, P2087, DOI 10.1001/archinte.166.19.2087; Sullivan MD, 2005, PAIN, V119, P95, DOI 10.1016/j.pain.2005.09.020; Turk DC, 2002, CLIN J PAIN, V18, P355, DOI 10.1097/00002508-200211000-00003; Webster LR, 2005, PAIN MED, V6, P432, DOI 10.1111/j.1526-4637.2005.00072.x	9	10	10	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2007	146	12					897	900		10.7326/0003-4819-146-12-200706190-00017	http://dx.doi.org/10.7326/0003-4819-146-12-200706190-00017			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180FF	17577013				2023-01-03	WOS:000247347100013
J	Ewy, GA				Ewy, Gordon A.			Cardiac arrest - guideline changes urgently needed	LANCET			English	Editorial Material							CARDIOPULMONARY-RESUSCITATION; CARDIOCEREBRAL RESUSCITATION; PERFUSION-PRESSURE; SURVIVAL; VENTILATION		Univ Arizona, Coll Med, Tucson, AZ 85724 USA	University of Arizona	Ewy, GA (corresponding author), Univ Arizona, Coll Med, Tucson, AZ 85724 USA.	gaewy@aol.com						[Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Assar D, 2000, RESUSCITATION, V45, P7, DOI 10.1016/S0300-9572(00)00152-0; Aufderheide Tom P, 2004, Crit Care Med, V32, pS345, DOI 10.1097/01.CCM.0000134335.46859.09; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; BERG RA, 1993, CIRCULATION, V88, P1907, DOI 10.1161/01.CIR.88.4.1907; CHANDRA NC, 1994, CIRCULATION, V90, P3070, DOI 10.1161/01.CIR.90.6.3070; Ewy GA, 2005, CIRCULATION, V111, P2134, DOI 10.1161/01.CIR.0000162503.57657.FA; Ewy GA, 2000, NEW ENGL J MED, V342, P1599, DOI 10.1056/NEJM200005253422109; Holmberg M, 1998, RESUSCITATION, V36, P29, DOI 10.1016/S0300-9572(97)00089-0; Int Liaison Comm Resuscitation, 2005, RESUSCITATION, V67, P181, DOI 10.1016/j.resuscitation.2005.09.010; Kellum MJ, 2006, AM J MED, V119, P335, DOI 10.1016/j.amjmed.2005.11.014; KERN KB, 1988, RESUSCITATION, V16, P241, DOI 10.1016/0300-9572(88)90111-6; Kern KB, 2002, CIRCULATION, V105, P645, DOI 10.1161/hc0502.102963; Meursing BTJ, 2005, RESUSCITATION, V64, P279, DOI 10.1016/j.resuscitation.2004.10.016; Nagao K, 2007, LANCET, V369, P920; NOC M, 1995, CHEST, V108, P821, DOI 10.1378/chest.108.3.821; SANDERS AB, 1985, AM J EMERG MED, V3, P11, DOI 10.1016/0735-6757(85)90003-8; VANHOEYWEGHEN RJ, 1993, RESUSCITATION, V26, P47, DOI 10.1016/0300-9572(93)90162-J; YANG LY, 1994, CRIT CARE MED, V22, P879, DOI 10.1097/00003246-199405000-00027	19	40	43	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 17	2007	369	9565					882	884		10.1016/S0140-6736(07)60422-X	http://dx.doi.org/10.1016/S0140-6736(07)60422-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	148BQ	17368131				2023-01-03	WOS:000245049900005
J	Martell, BA; O'Connor, PG; Kerns, RD; Becker, WC; Morales, KH; Kosten, TR; Fiellin, DA				Martell, Bridget A.; O'Connor, Patrick G.; Kerns, Robert D.; Becker, William C.; Morales, Knashawn H.; Kosten, Thomas R.; Fiellin, David A.			Systematic review: Opioid treatment for chronic back pain: Prevalence, efficacy, and association with addiction	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIALS; CHRONIC NONCANCER PAIN; PRIMARY-CARE; TRANSDERMAL FENTANYL; NONMALIGNANT PAIN; PATIENT CHARACTERISTICS; CONTROLLED-RELEASE; CONSORT STATEMENT; NEUROPATHIC PAIN; CLINICAL-TRIALS	Background: The prevalence, efficacy, and risk for addiction for persons receiving opioids for chronic back pain are unclear. Purpose: To determine the prevalence of opioid treatment, whether opioid medications are effective, and the prevalence of substance use disorders among patients receiving opioid medications for chronic back pain. Data Sources: English-language studies from MEDLINE (1966-March 2005), EMBASE (1966-March 2005), Cochrane Central Register of Controlled Clinical Trials (to 4th quarter 2004), Psychinfo (1966-March 2005), and retrieved references. Study Selection: Articles that studied an adult, nonobstetric sample; used oral, topical, or transdermal opioids; and focused on treatment for chronic back pain. Data Extraction: Two investigators independently extracted data and determined study quality. Data Synthesis: Opioid prescribing varied by treatment setting (range, 3% to 66%). Meta-analysis of the 4 studies assessing the efficacy of opioids compared with placebo or a nonopioid control did not show reduced pain with opioids (g, -0.199 composite standardized mean difference [95% CI, -0.49 to 0.11]; P = 0.136). Meta-analysis of the 5 studies directly comparing the efficacy of different opioids demonstrated a nonsignificant reduction in pain from baseline (g, -0.93 composite standardized mean difference [CI, -1.89 to -0,03]; P = 0.055). The prevalence of lifetime substance use disorders ranged from 36% to 56%, and the estimates of the prevalence of current substance use disorders were as high as 43%. Aberrant medication-taking behaviors ranged from 5% to 24%. Limitations: Retrieval and publication biases and poor study quality. No trial evaluating the efficacy of opioids was longer than 16 weeks. Conclusions: Opioids are commonly prescribed for chronic back pain and may be efficacious for short-term pain relief. Long-term efficacy (>= 16 weeks) is unclear. Substance use disorders are common in patients taking opioids for back pain, and aberrant medication-taking behaviors occur in up to 24% of cases.	Yale Univ, Sch Med, New Haven, CT 06520 USA; VA Connecticut Hlth Care Syst, West Haven, CT USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; University of Pennsylvania	Fiellin, DA (corresponding author), Yale Univ, Sch Med, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.	david.fiellin@yale.edu	Kosten, Thomas/AAI-5998-2021	Becker, William/0000-0002-0788-1467; Fiellin, David/0000-0002-4006-010X				Abrams KR, 2000, METHODS METAANALYSIS; Adams NJ, 2001, J PAIN SYMPTOM MANAG, V22, P791, DOI 10.1016/S0885-3924(01)00320-7; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Bramley-Moore Susan R., 1998, Australian Journal of Hospital Pharmacy, V28, P83; Breckenridge J, 2003, J PAIN, V4, P344, DOI 10.1016/S1526-5900(03)00638-2; BRETT AS, 2004, J WATCH, V24, P157; Brown RL, 1996, J FAM PRACTICE, V43, P152; Cassidy JD, 1998, SPINE, V23, P1860, DOI 10.1097/00007632-199809010-00012; Chabal C, 1997, CLIN J PAIN, V13, P150, DOI 10.1097/00002508-199706000-00009; Chou R, 2003, J PAIN SYMPTOM MANAG, V26, P1026, DOI 10.1016/j.jpainsymman.2003.03.003; CLARK ME, 2005, OPIOID THERAPY CHRON; Compton P, 1998, J PAIN SYMPTOM MANAG, V16, P355, DOI 10.1016/S0885-3924(98)00110-9; Compton P, 2003, J PAIN, V4, P511, DOI 10.1016/j.jpain.2003.08.003; Coste J, 1999, MED CARE, V37, P1294, DOI 10.1097/00005650-199912000-00012; Cox D.R., 1989, CONCISE ENCY STAT; Dellemijn PLI, 2001, EUR J PAIN-LONDON, V5, P333, DOI 10.1053/eujp.2001.0240; DEYO RA, 1988, ARCH PHYS MED REHAB, V69, P174; Deyo RA, 2001, NEW ENGL J MED, V344, P363, DOI 10.1056/NEJM200102013440508; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Eisenberg E, 2005, JAMA-J AM MED ASSOC, V293, P3043, DOI 10.1001/jama.293.24.3043; Elliott AM, 1999, LANCET, V354, P1248, DOI 10.1016/S0140-6736(99)03057-3; Fanciullo GJ, 2002, SPINE, V27, P201, DOI 10.1097/00007632-200201150-00016; Fillingim RB, 2003, SPINE, V28, P143, DOI 10.1097/00007632-200301150-00010; FRANCE RD, 1984, SOC SCI MED, V19, P1379, DOI 10.1016/0277-9536(84)90027-3; Fries JF, 2004, ARTHRITIS RES THER, V6, pR250, DOI 10.1186/ar1170; Gammaitoni AR, 2003, PAIN MED, V4, P21, DOI 10.1046/j.1526-4637.2003.03002.x; Gilron I, 2005, NEW ENGL J MED, V352, P1324, DOI 10.1056/NEJMoa042580; GRAVEN S, 2000, P 9 WORLD C PAIN PRO, V16, P554; HALE M, 1997, PAIN RES MANAG, V2, P33; Hale ME, 2005, J PAIN, V6, P21, DOI 10.1016/j.jpain.2004.09.005; Hale ME, 1999, CLIN J PAIN, V15, P179, DOI 10.1097/00002508-199909000-00004; HART LG, 1995, SPINE, V20, P11, DOI 10.1097/00007632-199501000-00003; HEDGES LV, 1985, STAT METHODS META AN; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; *IMMPAACT, 2005, PAIN, V113, P9; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jamison RN, 1998, SPINE, V23, P2591, DOI 10.1097/00007632-199812010-00014; Kuntz D, 1996, PRESSE MED, V25, P1171; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; Libretto SE, 2002, CLIN DRUG INVEST, V22, P473, DOI 10.2165/00044011-200222070-00009; Long DM, 1996, J SPINAL DISORD, V9, P40; Mahowald ML, 2005, ARTHRITIS RHEUM-US, V52, P312, DOI 10.1002/art.20784; Manchikanti Laxmaiah, 2004, Pain Physician, V7, P431; Manchikanti Laxmaiah, 2004, Pain Physician, V7, P71; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; Mohler D.M., 2001, LANCET, V357, P1191; Moulin Y, 2001, Infirm Que, V9, P53; Muller FO, 1998, ARZNEIMITTEL-FORSCH, V48, P675; Normand SLT, 1999, STAT MED, V18, P321, DOI 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.3.CO;2-G; Nyiendo J, 2001, J MANIP PHYSIOL THER, V24, P543, DOI 10.1067/mmt.2001.118978; Ossipov MH, 2005, BIOPOLYMERS, V80, P319, DOI 10.1002/bip.20254; Pitkala KH, 2002, J AM GERIATR SOC, V50, P1861, DOI 10.1046/j.1532-5415.2002.50517.x; POLATIN PB, 1993, SPINE, V18, P66, DOI 10.1097/00007632-199301000-00011; READY LB, 1982, PAIN, V12, P285, DOI 10.1016/0304-3959(82)90160-9; Reid MC, 2002, J GEN INTERN MED, V17, P173, DOI 10.1046/j.1525-1497.2002.10435.x; Richards P, 2002, PAIN MED, V3, P176; Ringe JD, 2002, RHEUMATOL INT, V22, P199, DOI 10.1007/s00296-002-0217-8; Salzman RT, 1999, J PAIN SYMPTOM MANAG, V18, P271, DOI 10.1016/S0885-3924(99)00079-2; *SAMHSA OFF APPL S, 2004, NAT SURV DRUG AB HLT; Sanchez-Meca J, 2003, PSYCHOL METHODS, V8, P448, DOI 10.1037/1082-989X.8.4.448; Savage SR, 1999, MED CLIN N AM, V83, P761, DOI 10.1016/S0025-7125(05)70133-4; Schnitzer TJ, 2004, J PAIN SYMPTOM MANAG, V28, P72, DOI 10.1016/j.jpainsymman.2003.10.015; Schofferman J, 1999, CLIN J PAIN, V15, P136, DOI 10.1097/00002508-199906000-00011; Simpson RK, 1997, J PAIN SYMPTOM MANAG, V14, P218, DOI 10.1016/S0885-3924(97)00183-8; SORENSEN HT, 1992, DAN MED BULL, V39, P464; TENNANT F, 1993, LANCET, V342, P1047, DOI 10.1016/0140-6736(93)92900-E; THUREL C, 1991, CURR THER RES CLIN E, V50, P463; Trafton JA, 2004, DRUG ALCOHOL DEPEN, V73, P23, DOI 10.1016/j.drugalcdep.2003.08.007; Turk DC, 1997, CLIN J PAIN, V13, P330, DOI 10.1097/00002508-199712000-00011; *VA NAT PAIN MAN, 2005, VA OFF QUAL PERF OP; van Tulder MW, 2000, SPINE, V25, P2501, DOI 10.1097/00007632-200010010-00013; *WHO, 2005, WHOS PAIN REL LADD; Zacny J, 2003, DRUG ALCOHOL DEPEN, V69, P215, DOI 10.1016/S0376-8716(03)00003-6; ZENZ M, 1992, J PAIN SYMPTOM MANAG, V7, P69, DOI 10.1016/0885-3924(92)90116-Y; 2004, LETT DRUGS THER, V47, P97	77	536	555	0	48	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2007	146	2					116	127		10.7326/0003-4819-146-2-200701160-00006	http://dx.doi.org/10.7326/0003-4819-146-2-200701160-00006			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	131WF	17227935				2023-01-03	WOS:000243901000005
J	Sun, JJ; Vernier, G; Wigelsworth, DJ; Collier, RJ				Sun, Jianjun; Vernier, Gregory; Wigelsworth, Darran J.; Collier, R. John			Insertion of anthrax protective antigen into liposomal membranes - Effects of a receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN; PROTEIN TRANSLOCATION; CRYSTAL-STRUCTURE; CHELATING LIPIDS; LETHAL FACTOR; FRAGMENT-B; LOW-PH; PORE; CELLS; CONVERSION	Protective antigen (PA), the receptor-binding component of anthrax toxin, heptamerizes and inserts into the endosomal membrane at acidic pH, forming a pore that mediates translocation of the enzymic components of the toxin to the cytosol. When the heptameric pre-insertion form of PA (the prepore) is acidified in solution, it rapidly loses the ability to insert into membranes. To maximize insertion into model membranes, we examined two ways to bind the protein to large unilamellar vesicles (LUV). One involved attaching a His tag to the von Willebrand factor A domain of one of the PA receptors, ANTXR2, and using this protein as a bridge to bind PA to LUV containing a nickel-chelating lipid. The other involved using a His tag fused to the C terminus of PA to bind the protein directly to LUV containing the same lipid. Both ways enhanced pore formation at pH 5.0 strongly and about equally, as measured by the release of K+. Controls showed that pore formation in this system faithfully reproduced that in vivo. We also showed that binding unmodified ANTXR2 von Willebrand factor A to the prepore in solution enhanced its pore forming activity by slowing its inactivation at acidic pH. These findings indicate that an important role of PA receptors is to promote partitioning of PA into the bilayer by maintaining the prepore close to the target membrane and presumably in the optimal orientation as it undergoes the acidic pH-dependent conformational transition to the pore.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Collier, RJ (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	jcollier@hms.harvard.edu	Sun, Jianjun/B-1525-2009	Collier, R John/0000-0002-2427-4239	NIAID NIH HHS [P01 AI 56013, AI 48489, R01 AI 22021] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI056013, R01AI048489, R01AI022021] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barth H, 2004, MICROBIOL MOL BIOL R, V68, P373, DOI 10.1128/MMBR.68.3.373-402.2004; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; BOQUET P, 1979, EUR J BIOCHEM, V100, P483, DOI 10.1111/j.1432-1033.1979.tb04192.x; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Bubeck D, 2005, NAT STRUCT MOL BIOL, V12, P615, DOI 10.1038/nsmb955; CABIAUX V, 1989, J BIOL CHEM, V264, P4928; CABIAUX V, 1984, BIOCHIM BIOPHYS ACTA, V775, P31, DOI 10.1016/0005-2736(84)90231-1; Chikh GG, 2002, BBA-BIOMEMBRANES, V1567, P204, DOI 10.1016/S0005-2736(02)00618-1; Collier RJ, 2003, ANNU REV CELL DEV BI, V19, P45, DOI 10.1146/annurev.cellbio.19.111301.140655; Dalla Serra M, 2003, METHOD ENZYMOL, V372, P99; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; FALMAGNE P, 1982, TOXICON, V20, P243, DOI 10.1016/0041-0101(82)90209-4; JANSONS VK, 1983, BIOCHIM BIOPHYS ACTA, V735, P433, DOI 10.1016/0005-2736(83)90159-1; KOEHLER TM, 1991, MOL MICROBIOL, V5, P1501, DOI 10.1111/j.1365-2958.1991.tb00796.x; Krantz BA, 2006, J MOL BIOL, V355, P968, DOI 10.1016/j.jmb.2005.11.030; Krantz BA, 2005, SCIENCE, V309, P777, DOI 10.1126/science.1113380; KUBALEK EW, 1994, J STRUCT BIOL, V113, P117, DOI 10.1006/jsbi.1994.1039; Lacy DB, 2004, P NATL ACAD SCI USA, V101, P13147, DOI 10.1073/pnas.0405405101; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; MILNE JC, 1995, MOL MICROBIOL, V15, P661, DOI 10.1111/j.1365-2958.1995.tb02375.x; Mogridge J, 2002, P NATL ACAD SCI USA, V99, P7045, DOI 10.1073/pnas.052160199; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Nguyen TL, 2004, J BIOMOL STRUCT DYN, V22, P253, DOI 10.1080/07391102.2004.10531226; Nieba L, 1997, ANAL BIOCHEM, V252, P217, DOI 10.1006/abio.1997.2326; Pack DW, 1997, CHEM PHYS LIPIDS, V86, P135, DOI 10.1016/S0009-3084(97)02662-5; PAPINI E, 1987, EUR J BIOCHEM, V169, P629, DOI 10.1111/j.1432-1033.1987.tb13654.x; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Qa'dan M, 2005, MOL CELL BIOL, V25, P5492, DOI 10.1128/MCB.25.13.5492-5498.2005; Rainey GJA, 2005, P NATL ACAD SCI USA, V102, P13278, DOI 10.1073/pnas.0505865102; Santelli E, 2004, NATURE, V430, P905, DOI 10.1038/nature02763; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Sellman BR, 2001, J BIOL CHEM, V276, P8371, DOI 10.1074/jbc.M008309200; Sellman BR, 2001, SCIENCE, V292, P695, DOI 10.1126/science.109563; Tuthill TJ, 2006, J VIROL, V80, P172, DOI 10.1128/JVI.80.1.172-180.2006; Wigelsworth DJ, 2004, J BIOL CHEM, V279, P23349, DOI 10.1074/jbc.M401292200; Wolfe JT, 2005, J BIOL CHEM, V280, P39417, DOI 10.1074/jbc.M509049200; Zhang S, 2004, BIOPHYS J, V87, P3842, DOI 10.1529/biophysj.104.050864	38	42	42	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1059	1065		10.1074/jbc.M609869200	http://dx.doi.org/10.1074/jbc.M609869200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17107945	hybrid			2023-01-03	WOS:000243295200029
J	Bailey, MS; de Silva, HJ				Bailey, Mark S.; de Silva, H. Janaka			Sri Lankan sanni masks: an ancient classification of disease	BRITISH MEDICAL JOURNAL			English	Editorial Material									Army Med Directorate, Surrey GU15 4NP, England; Univ Kelaniya, Dept Med, Ragama, Sri Lanka	University Kelaniya	Bailey, MS (corresponding author), Army Med Directorate, Surrey GU15 4NP, England.	mark@ramc.org	Bailey, Mark S./D-3854-2013	Bailey, Mark S./0000-0003-4840-5093				Bartlett A, 1989, Int J Soc Psychiatry, V35, P245, DOI 10.1177/002076408903500305; Kapferer B., 2005, TOVIL EXORCISM HEALI; Kapferer Bruce, 1991, CELEBRATION DEMONS E; OBEYESEKERE G, 1969, COMP STUD SOC HIST, V11, P174, DOI 10.1017/S0010417500005260; PERTOLD O, 1930, CEREMONIAL DANCES SI; Wijesuriya B., 2001, TRADITIONAL SINHALES; Wirz Paul, 1954, EXORCISM ART HEALING	7	6	6	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1327	1328		10.1136/bmj.39055.445417.BE	http://dx.doi.org/10.1136/bmj.39055.445417.BE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185730	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000243160700027
J	Taylor, DM				Taylor, David McD			Reverse triage: useful for day-to-day access block?	LANCET			English	Editorial Material							AMBULANCE DIVERSION		Austin Hosp, Dept Emergency Med, Heidelberg, Vic 3084, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health	Taylor, DM (corresponding author), Austin Hosp, Dept Emergency Med, Heidelberg, Vic 3084, Australia.	david.taylor@austin.org.au						Dara SI, 2005, CRIT CARE MED, V33, P2667, DOI 10.1097/01.CCM.0000151062.00501.60; Fatovich DM, 2003, EMERG MED J, V20, P406, DOI 10.1136/emj.20.5.406; Kelen GD, 2006, LANCET, V368, P1984, DOI 10.1016/S0140-6736(06)69808-5; Lane HC, 2001, JAMA-J AM MED ASSOC, V286, P2595, DOI 10.1001/jama.286.20.2595; Miro O, 1999, Eur J Emerg Med, V6, P105; Richardson DB, 2006, MED J AUSTRALIA, V184, P213, DOI 10.5694/j.1326-5377.2006.tb00204.x; Schneider SM, 2003, ANN EMERG MED, V42, P167, DOI 10.1067/mem.2003.258; Schull MJ, 2003, ANN EMERG MED, V41, P467, DOI 10.1067/mem.2003.23; SPIVULIS PC, 2006, MED J AUSTRALIA, V184, P208; Vilke GM, 2004, J EMERG MED, V26, P189, DOI 10.1016/j.jemermed.2003.07.003	10	5	5	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 2	2006	368	9551					1940	1941						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	113JD	17141684				2023-01-03	WOS:000242593300005
J	Roche, CJ; Dantsker, D; Samuni, U; Friedman, JM				Roche, Camille J.; Dantsker, David; Samuni, Uri; Friedman, Joel M.			Nitrite reductase activity of sol-gel-encapsulated deoxyhemoglobin - Influence of quaternary and tertiary structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADULT HEMOGLOBIN; T-STATE; OXIDE BINDING; FUNCTIONAL-CHARACTERIZATION; GEMINATE RECOMBINATION; AFFINITY CONFORMATIONS; ALLOSTERIC REGULATION; MAXIMUM-ENTROPY; ALPHA-SUBUNIT; RED-CELL	Nitrite reductase activity of deoxyhemoglobin (HbA) in the red blood cell has been proposed as a non-nitric-oxide synthase source of deliverable nitric oxide (NO) within the vasculature. An essential element in this scheme is the dependence of this reaction on the quaternary/tertiary structure of HbA. In the present work sol-gel encapsulation is used to trap and stabilize deoxy-HbA in either the T or R quaternary state, thus allowing for the clear-cut monitoring of nitrite reductase activity as a function of quaternary state with and without effectors. The results indicate that reaction is not only R-T-dependent but also heterotropic effector-dependent within a given quaternary state. The use of the maximum entropy method to analyze carbon monoxide ( CO) recombination kinetics from fully and partially liganded sol-gel-encapsulated T-state species provides a framework for understanding effector modulation of T-state reactivity by influencing the distribution of high and low reactivity T-state conformations.	Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Friedman, JM (corresponding author), Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	jfriedma@aecom.yu.edu			NHLBI NIH HHS [P01HL071064] Funding Source: Medline; NIAID NIH HHS [R01AI052258] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL071064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052258] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbruzzetti S, 2001, J NANOSCI NANOTECHNO, V1, P407, DOI 10.1166/jnn.2001.058; ACHARYA AS, 1983, J BIOL CHEM, V258, P2296; Ackers GK, 2004, METHOD ENZYMOL, V379, P3; Ackers GK, 2002, P NATL ACAD SCI USA, V99, P9777, DOI 10.1073/pnas.152225999; ALAYASH AI, 1993, ARCH BIOCHEM BIOPHYS, V303, P332, DOI 10.1006/abbi.1993.1292; ALPERT B, 1979, CHEM PHYS LETT, V64, P11, DOI 10.1016/0009-2614(79)87265-6; Angelo M, 2006, P NATL ACAD SCI USA, V103, P8366, DOI 10.1073/pnas.0600942103; ANTONINI E, HEMOGLOBINS MYGLOBIN; Bettati S, 1997, J BIOL CHEM, V272, P32050, DOI 10.1074/jbc.272.51.32050; Bonaventura C, 1999, J BIOL CHEM, V274, P8686, DOI 10.1074/jbc.274.13.8686; Bonaventura C, 1998, BIOCHEMISTRY-US, V37, P496, DOI 10.1021/bi971574s; Bruno S, 2001, PROTEIN SCI, V10, P2401, DOI 10.1110/ps.20501; Colombo MF, 1996, J BIOL CHEM, V271, P4895; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; Crawford JH, 2006, BLOOD, V107, P566, DOI 10.1182/blood-2005-07-2668; Dantsker D, 2005, J BIOL CHEM, V280, P38740, DOI 10.1074/jbc.M506333200; Das TK, 2004, J BIOL CHEM, V279, P10433, DOI 10.1074/jbc.M309590200; Das TK, 1999, BIOSPECTROSCOPY, V5, pS64, DOI 10.1002/(SICI)1520-6343(1999)5:5+<S64::AID-BSPY7>3.0.CO;2-W; Dejam A, 2004, BLOOD CELL MOL DIS, V32, P423, DOI 10.1016/j.bcmd.2004.02.002; Dejam A, 2005, BLOOD, V106, P734, DOI 10.1182/blood-2005-02-0567; DOYLE MP, 1981, J BIOL CHEM, V256, P2393; DUDDELL DA, 1980, PHOTOCHEM PHOTOBIOL, V31, P479, DOI 10.1111/j.1751-1097.1980.tb03732.x; FAULKNER KM, 1995, J BIOL CHEM, V270, P13604, DOI 10.1074/jbc.270.23.13604; FRIEDMAN JM, 1980, NATURE, V284, P570, DOI 10.1038/284570a0; Gladwin MT, 2005, NAT CHEM BIOL, V1, P245, DOI 10.1038/nchembio1005-245; Gladwin MT, 2005, AM J RESP CELL MOL, V32, P363, DOI 10.1165/rcmb.F294; Gladwin MT, 2004, FREE RADICAL BIO MED, V36, P707, DOI 10.1016/j.freeradbiomed.2003.11.032; Gladwin MT, 2005, NAT CHEM BIOL, V1, P308, DOI 10.1038/nchembio1105-308; Goldbeck RA, 2004, BIOCHEMISTRY-US, V43, P12065, DOI 10.1021/bi0493923; Goldbeck RA, 2001, BIOPHYS J, V81, P2919, DOI 10.1016/S0006-3495(01)75932-2; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; Henry ER, 2002, BIOPHYS CHEM, V98, P149, DOI 10.1016/S0301-4622(02)00091-1; HOFRICHTER J, 1985, BIOCHEMISTRY-US, V24, P2667, DOI 10.1021/bi00332a012; Huang KT, 2005, J BIOL CHEM, V280, P31126, DOI 10.1074/jbc.M501496200; Huang Z, 2005, J CLIN INVEST, V115, P2099, DOI 10.1172/JCI24650; Huang Z, 2002, BIOCHEM BIOPH RES CO, V292, P812, DOI 10.1006/bbrc.2002.6730; Huang Z, 2001, BBA-GEN SUBJECTS, V1568, P252, DOI 10.1016/S0304-4165(01)00227-6; Hui HL, 2004, BIOCHEMISTRY-US, V43, P7843, DOI 10.1021/bi030263g; Imai K, 2002, BIOPHYS CHEM, V98, P79, DOI 10.1016/S0301-4622(02)00086-8; JUSZCZAK L, 2006, RAMAN SPECTROSCOPY, V36, P350; Karasik E, 2004, BIOCHEMISTRY-US, V43, P7851, DOI 10.1021/bi0302649; Kavanaugh JS, 2005, BIOCHEMISTRY-US, V44, P6101, DOI 10.1021/bi047813a; Khan I, 2001, BIOCHEMISTRY-US, V40, P7581, DOI 10.1021/bi010051o; Khan I, 2000, BIOCHEMISTRY-US, V39, P16099, DOI 10.1021/bi000536x; LALEZARI I, 1990, BIOCHEMISTRY-US, V29, P1515, DOI 10.1021/bi00458a024; Luchsinger BP, 2005, J INORG BIOCHEM, V99, P912, DOI 10.1016/j.jinorgbio.2004.12.010; Manjula BN, 1998, PROTEIN ENG, V11, P583, DOI 10.1093/protein/11.7.583; Miyazaki G, 1999, J MOL BIOL, V292, P1121, DOI 10.1006/jmbi.1999.3124; MOZZARELLI A, 1991, NATURE, V351, P416, DOI 10.1038/351416a0; Mueser TC, 2000, BIOCHEMISTRY-US, V39, P15353, DOI 10.1021/bi0012944; Nagababu E, 2003, J BIOL CHEM, V278, P46349, DOI 10.1074/jbc.M307572200; Parsegian VA, 2002, INT REV CYTOL, V215, P1; PERUTZ MF, 1976, BIOCHEMISTRY-US, V15, P378, DOI 10.1021/bi00647a022; PERUTZ MF, 1974, BIOCHEMISTRY-US, V13, P2163, DOI 10.1021/bi00707a026; Peterson ES, 2004, BIOCHEMISTRY-US, V43, P4832, DOI 10.1021/bi035481o; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P4346, DOI 10.1021/bi9708693; Salvay AG, 2003, BIOPHYS J, V84, P564, DOI 10.1016/S0006-3495(03)74876-0; Samuni U, 2006, BIOCHEMISTRY-US, V45, P2820, DOI 10.1021/bi050010i; Samuni U, 2004, BIOCHEMISTRY-US, V43, P13674, DOI 10.1021/bi048531d; Samuni U, 2003, BIOCHEMISTRY-US, V42, P8272, DOI 10.1021/bi020648j; Samuni U, 2002, J BIOL CHEM, V277, P25783, DOI 10.1074/jbc.M200301200; SHIBAYAMA N, 1995, J MOL BIOL, V251, P203, DOI 10.1006/jmbi.1995.0427; Shibayama N, 2001, FEBS LETT, V492, P50, DOI 10.1016/S0014-5793(01)02225-6; SIEMIARCZUK A, 1990, J PHYS CHEM-US, V94, P1661, DOI 10.1021/j100367a080; SIEMIARCZUK A, 1989, J PHYS CHEM-US, V93, P7609, DOI 10.1021/j100359a017; SILVA MM, 1992, J BIOL CHEM, V267, P17248; STEINBACH PJ, 1992, BIOPHYS J, V61, P235, DOI 10.1016/S0006-3495(92)81830-1; Tsuneshige A, 2004, J BIOL CHEM, V279, P48959, DOI 10.1074/jbc.M405909200; Tsuneshige A, 2002, BIOPHYS CHEM, V98, P49, DOI 10.1016/S0301-4622(02)00084-4; Unzai S, 1996, J BIOL CHEM, V271, P12451, DOI 10.1074/jbc.271.21.12451; Viappiani C, 2004, P NATL ACAD SCI USA, V101, P14414, DOI 10.1073/pnas.0405987101	72	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36874	36882		10.1074/jbc.M603914200	http://dx.doi.org/10.1074/jbc.M603914200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	16984908	hybrid			2023-01-03	WOS:000242220800046
J	Ginsburg, PB				Ginsburg, Paul B.			Recalibrating Medicare payments for inpatient care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Ctr Studying Hlth Syst Change, Washington, DC USA		Ginsburg, PB (corresponding author), Ctr Studying Hlth Syst Change, Washington, DC USA.							BERENSON RA, 2006, HLTH AFFAIRS    0725; GINSBURG PB, 2005, PRICE ISNT RIGHT INA; *MED PAYM ADV COMM, 2005, REP C PHYS OWN SPEC; 2006, FED REG, V71, P47915	4	7	7	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2006	355	20					2061	2064		10.1056/NEJMp068203	http://dx.doi.org/10.1056/NEJMp068203			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	104YU	17108339				2023-01-03	WOS:000241997300001
J	Endo, Y; Sakai, R; Ouchi, M; Onimatsu, H; Hioki, M; Kagawa, S; Uno, F; Watanabe, Y; Urata, Y; Tanaka, N; Fujiwara, T				Endo, Y.; Sakai, R.; Ouchi, M.; Onimatsu, H.; Hioki, M.; Kagawa, S.; Uno, F.; Watanabe, Y.; Urata, Y.; Tanaka, N.; Fujiwara, T.			Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation	ONCOGENE			English	Article						adenovirus; telomerase; dendritic cell; uric acid; danger signal	DENDRITIC CELLS; URIC-ACID; CANCER; PA28	Dendritic cells ( DCs) are the most potent antigen-presenting cells and acquire cellular antigens and danger signals from dying cells to initiate antitumor immune responses via direct cell- to- cell interaction and cytokine production. The optimal forms of tumor cell death for priming DCs for the release of danger signals are not fully understood. OBP- 301 ( Telomelysin) is a telomerase-specific replication- competent adenovirus that induces selective E1 expression and exclusively kills human cancer cells. Here, we show that OBP- 301 replication produced the endogenous danger signaling molecule, uric acid, in infected human tumor cells, which in turn stimulated DCs to produce interferon-gamma ( IFN-gamma) and interleukin 12 ( IL- 12). Subsequently, IFN-gamma release upregulated the endogenous expression of the proteasome activator PA28 in tumor cells and resulted in the induction of cytotoxic T- lymphocytes. Our data suggest that virus- mediated oncolysis might be the effective stimulus for immature DCs to induce specific activity against human cancer cells.	[Endo, Y.; Sakai, R.; Hioki, M.; Kagawa, S.; Uno, F.; Fujiwara, T.] Okayama Univ Hosp, Ctr Gene & Cell Therapy, Okayama 7008558, Japan; [Endo, Y.; Sakai, R.; Hioki, M.; Kagawa, S.; Uno, F.; Tanaka, N.; Fujiwara, T.] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Surg, Div Surg Oncol, Okayama, Japan; [Ouchi, M.; Onimatsu, H.; Watanabe, Y.; Urata, Y.] Oncolys BioPharma Inc, Tokyo, Japan	Okayama University; Okayama University; Oncolys BioPharma	Fujiwara, T (corresponding author), Okayama Univ Hosp, Ctr Gene & Cell Therapy, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	toshi_f@md.okayama-u.ac.jp	Kagawa, Shunsuke/B-2189-2011	Kagawa, Shunsuke/0000-0002-3610-8211				Aliberti J, 2003, J IMMUNOL, V170, P5349, DOI 10.4049/jimmunol.170.11.5349; Bartholomae WC, 2004, J IMMUNOL, V173, P1012, DOI 10.4049/jimmunol.173.2.1012; Glantzounis GK, 2005, CURR PHARM DESIGN, V11, P4145, DOI 10.2174/138161205774913255; Ho LJ, 2001, J IMMUNOL, V166, P1499, DOI 10.4049/jimmunol.166.3.1499; Hu DE, 2004, CANCER RES, V64, P5059, DOI 10.1158/0008-5472.CAN-04-1586; Kawashima T, 2004, CLIN CANCER RES, V10, P285, DOI 10.1158/1078-0432.CCR-1075-3; Lenaerts L, 2006, ANTIVIR RES, V71, P172, DOI 10.1016/j.antiviral.2006.04.007; LINDENMANN J, 1967, J EXP MED, V126, P93, DOI 10.1084/jem.126.1.93; Manjili MH, 2005, IMMUNOBIOLOGY, V210, P295, DOI 10.1016/j.imbio.2005.04.002; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Sijts A, 2002, MOL IMMUNOL, V39, P165, DOI 10.1016/S0161-5890(02)00099-8; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; Sun Y, 2002, CANCER RES, V62, P2875; Taki M, 2005, ONCOGENE, V24, P3130, DOI 10.1038/sj.onc.1208460; Umeoka T, 2004, CANCER RES, V64, P6259, DOI 10.1158/0008-5472.CAN-04-1335; Watanabe T, 2006, EXP CELL RES, V312, P256, DOI 10.1016/j.yexcr.2005.10.026	16	72	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2375	2381		10.1038/sj.onc.1210884	http://dx.doi.org/10.1038/sj.onc.1210884			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17982491	Green Submitted			2023-01-03	WOS:000254844900002
J	Szoka, F				Szoka, Francis			Molecular biology - The art of assembly	SCIENCE			English	Editorial Material							NONHUMAN-PRIMATES; SIRNA; NANOPARTICLES; DELIVERY; GENE		Univ Calif San Francisco, Dept Biopharmaceut Sci & Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Szoka, F (corresponding author), Univ Calif San Francisco, Dept Biopharmaceut Sci & Pharmaceut Chem, San Francisco, CA 94143 USA.	szoka@cgl.ucsf.edu	FRECHET, Jean M/P-1497-2016					Couzin J, 2002, SCIENCE, V298, P2296, DOI 10.1126/science.298.5602.2296; Heidel JD, 2007, P NATL ACAD SCI USA, V104, P5715, DOI 10.1073/pnas.0701458104; Li SD, 2008, MOL THER, V16, P163, DOI 10.1038/sj.mt.6300323; Marques JT, 2005, NAT BIOTECHNOL, V23, P1399, DOI 10.1038/nbt1161; Noble CO, 2004, EXPERT OPIN THER TAR, V8, P335, DOI 10.1517/14728222.8.4.335; Peer D, 2008, SCIENCE, V319, P627, DOI 10.1126/science.1149859; Rozema DB, 2007, P NATL ACAD SCI USA, V104, P12982, DOI 10.1073/pnas.0703778104; Ruiz-Perez B, 2003, J INFECT DIS, V188, P378, DOI 10.1086/376556; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688	10	16	18	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 1	2008	319	5863					578	579		10.1126/science.1154253	http://dx.doi.org/10.1126/science.1154253			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257AQ	18239114				2023-01-03	WOS:000252772000027
J	Nelson, CA; Zeanah, CH; Fox, NA; Marshall, PJ; Smyke, AT; Guthrie, D				Nelson, Charles A., III; Zeanah, Charles H.; Fox, Nathan A.; Marshall, Peter J.; Smyke, Anna T.; Guthrie, Donald			Cognitive recovery in socially deprived young children: The Bucharest early intervention project	SCIENCE			English	Article							INTERNATIONAL RESEARCH COLLABORATION; ETHICAL CONSIDERATIONS; BRAIN; DEPRIVATION	In a randomized controlled trial, we compared abandoned children reared in institutions to abandoned children placed in institutions but then moved to foster care. Young children living in institutions were randomly assigned to continued institutional care or to placement in foster care, and their cognitive development was tracked through 54 months of age. The cognitive outcome of children who remained in the institution was markedly below that of never- institutionalized children and children taken out of the institution and placed into foster care. The improved cognitive outcomes we observed at 42 and 54 months were most marked for the youngest children placed in foster care. These results point to the negative sequelae of early institutionalization, suggest a possible sensitive period in cognitive development, and underscore the advantages of family placements for young abandoned children.	Harvard Univ, Sch Med, Boston, MA 02215 USA; Childrens Hosp, Boston, MA 02215 USA; Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70112 USA; Univ Maryland, College Pk, MD 20742 USA; Temple Univ, Philadelphia, PA 19122 USA; Univ Calif Los Angeles, Los Angeles, CA 90095 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Tulane University; University System of Maryland; University of Maryland College Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of California System; University of California Los Angeles	Nelson, CA (corresponding author), Harvard Univ, Sch Med, Boston, MA 02215 USA.	charles.nelson@childrens.harvard.edu	Zeanah, Charles H/AAO-3756-2020	Zeanah, Charles/0000-0002-7004-6819				Bayley N., 2006, BAYLEY SCALES INFANT, V3rd; BRUER JT, 2001, CRITICAL THINKING CR, P209; Chugani HT, 2001, NEUROIMAGE, V14, P1290, DOI 10.1006/nimg.2001.0917; CURTIS JW, 2003, RESILIENCE VULNERABI, P463; Eluvathingal TJ, 2006, PEDIATRICS, V117, P2093, DOI 10.1542/peds.2005-1727; Gunnar MR, 2001, DEV COGN NEUROSCI, P617; *HARC ASS, 2000, WECHSL PRESCH PRIM S; HARLOW HF, 1971, P NATL ACAD SCI USA, V68, P1534, DOI 10.1073/pnas.68.7.1534; Johnson DE, 2000, MINN SYM CHILD PSYCH, V31, P113; JOHNSON DE, 1992, JAMA-J AM MED ASSOC, V268, P3446, DOI 10.1001/jama.268.24.3446; Lindsey JC, 1999, CLIN NEUROPHARMACOL, V22, P44, DOI 10.1097/00002826-199901000-00009; Little R, 1996, BIOMETRICS, V52, P1324, DOI 10.2307/2532847; MORISON SJ, 1995, MERRILL PALMER QUART, V41, P411; Rutter M, 1998, J CHILD PSYCHOL PSYC, V39, P465, DOI 10.1017/S0021963098002236; Rutter ML, 2001, BRIT J PSYCHIAT, V179, P97, DOI 10.1192/bjp.179.2.97; Sanchez MM, 2001, DEV PSYCHOPATHOL, V13, P419, DOI 10.1017/S0954579401003029; Smyke AT, 2007, J CHILD PSYCHOL PSYC, V48, P210, DOI 10.1111/j.1469-7610.2006.01694.x; TANNER JM, 1973, TXB PEDIAT; Wassenaar DR, 2006, INF MENTAL HLTH J, V27, P577, DOI 10.1002/imhj.20108; Weijer C, 2004, NAT MED, V10, P570, DOI 10.1038/nm0604-570; Zeanah CH, 2003, DEV PSYCHOPATHOL, V15, P885, DOI 10.1017/S0954579403000452; Zeanah CH, 2000, J DEV BEHAV PEDIATR, V21, P230; ZEANAH CH, 2006, HDB EARLY CHILDHOOD, P424; Zeanah CH, 2006, INF MENTAL HLTH J, V27, P581, DOI 10.1002/imhj.20117; Zeanah CH, 2006, INF MENTAL HLTH J, V27, P559, DOI 10.1002/imhj.20107	25	578	587	3	131	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	2007	318	5858					1937	1940		10.1126/science.1143921	http://dx.doi.org/10.1126/science.1143921			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	243HE	18096809				2023-01-03	WOS:000251786600063
J	Wildman, MJ; Sanderson, C; Groves, J; Reeves, BC; Ayres, J; Harrison, D; Young, D; Rowan, K				Wildman, Martin J.; Sanderson, Colin; Groves, Jayne; Reeves, Barnaby C.; Ayres, Jon; Harrison, David; Young, Duncan; Rowan, Kathy			Implications of prognostic pessimism in patients with chronic obstructive pulmonary disease (COPD) or asthma admitted to intensive care in the UK within the COPD and asthma outcome study (CAOS): multicentre observational cohort study	BRITISH MEDICAL JOURNAL			English	Article							MIX PROGRAM DATABASE; ADMISSIONS; DECISIONS; ADULT; UNITS	Objective To determine whether clinicians' prognoses in patients with severe acute exacerbations of obstructive lung disease admitted to intensive care match observed outcomes in terms of survival. Design Prospective cohort study. Setting 92 intensive care units and three respiratory high dependency units in the United Kingdom. Participants 832 patients aged 45 years and older with breathlessness, respiratory failure, or change in mental status because of an exacerbation of COPD, asthma, or a combination of the two. Main outcome measures Outcome predicted by clinicians. Observed survival at 180 days. Results 517 patients (621/6) survived to 180 days. Clinicians' prognoses were pessimistic, with a mean predicted survival of 49% at 180 days. For the fifth of patients with the poorest prognosis according to the clinician, the predicted survival rate was 10% and the actual rate was 40%. Information from a database covering 74% of intensive care units in the UK suggested no material difference between units that participated and those that did not. Patients recruited were similar to those not recruited in the same units. Conclusions Because decisions on whether to admit patients with COPD or asthma to intensive care for intubation depend on clinicians' prognoses, some patients who might otherwise survive are probably being denied admission because of unwarranted prognostic pessimism.	No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England; London Sch Hyg & Trop Med, London WC1, England; Birmingham Heartlands Hosp, Birmingham B9 5ST, W Midlands, England; Intens Care Natl Audit & Res Ctr, London, England; John Radcliffe Hosp, Adult Intens Care Unit, Oxford OX3 9DU, England	Northern General Hospital; University of London; London School of Hygiene & Tropical Medicine; Heart of England NHS Foundation Trust; University of Birmingham; Intensive Care National Audit & Research Centre; University of Oxford	Wildman, MJ (corresponding author), No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England.	martin.wildman@sth.nhs.uk	Sanderson, Colin F/O-9877-2014; Harrison, David A/O-4355-2018; Young, John D/M-9756-2016	Harrison, David A/0000-0002-9002-9098; Rowan, Kathryn/0000-0001-8217-5602; Young, John Duncan/0000-0002-6838-4835; Sanderson, Colin/0000-0002-4838-6112				Britton M, 2003, RESP MED, V97, pS71, DOI 10.1016/S0954-6111(03)80027-6; Connors AF, 1996, AM J RESP CRIT CARE, V154, P959, DOI 10.1164/ajrccm.154.4.8887592; Escher M, 2004, BRIT MED J, V329, P425, DOI 10.1136/bmj.329.7463.425; Harrison DA, 2004, CRIT CARE, V8, pR99, DOI 10.1186/cc2834; Joynt GM, 2001, INTENS CARE MED, V27, P1459, DOI 10.1007/s001340101041; PARSONS V, 1980, J MED ETHICS, V6, P173, DOI 10.1136/jme.6.4.173; PEARLMAN RA, 1987, CHEST, V91, P515, DOI 10.1378/chest.91.4.515; Wildman MJ, 2005, CRIT CARE, V9, DOI 10.1186/cc3719; Wildman MJ, 2007, RESP MED, V101, P1994, DOI 10.1016/j.rmed.2007.04.002; Wildman MJ, 2003, QJM-INT J MED, V96, P583, DOI 10.1093/qjmed/hcg104	10	85	91	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	DEC 1	2007	335	7630					1132	1134		10.1136/bmj.39371.524271.55	http://dx.doi.org/10.1136/bmj.39371.524271.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	240OE	17975254	Green Published, Bronze, Green Submitted, Green Accepted			2023-01-03	WOS:000251596100033
J	Alley, DE; Chang, VW				Alley, Dawn E.; Chang, Virginia W.			The changing relationship of obesity and disability, 1988-2004	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS-INDEX; UNITED-STATES; RECENT TRENDS; RISK-FACTORS; PREVALENCE; OVERWEIGHT; AGE; DISEASE; HEALTH; POPULATION	Context Recent studies suggest that the obese population may have been growing healthier since the 1960s, as indicated by a decrease in mortality and cardiovascular risk factors. However, whether these improvements have conferred decreased risk for disability is unknown. The obese population may be living longer with better-controlled risk factors but paradoxically experiencing more disability. Objective To determine whether the association between obesity and disability has changed over time. Design, Setting, and Participants Adults aged 60 years and older (N = 9928) with measured body mass index from 2 waves of the nationally representative National Health and Nutrition Examination Surveys (NHANES III [1988-1994] and NHANES 19992004). Main Outcome Measures Reports of much difficulty or inability to perform tasks in 2 disability domains: functional limitations (walking one-fourth mile, walking up 10 steps, stooping, lifting 10 lb, walking between rooms, and standing from an armless chair) and activities of daily living (ADL) limitations (transferring, eating, and dressing). Results Among obese individuals, the prevalence of functional impairment increased 5.4% (from 36.8%-42.2%; P = .03) between the 2 surveys, and ADL impairment did not change. At time 1 (1988-1994), the odds of functional impairment for obese individuals were 1.78 times greater than for normal-weight individuals (95% confidence interval [CI], 1.47-2.16). At time 2 (1999-2004), this odds ratio increased to 2.75 (95% CI, 2.39-3.17), because the odds of functional impairment increased by 43% (OR 1.43; 95% CI, 1.18-1.75) among obese individuals during this period, but did not change among nonobese individuals. With respect to ADL impairment, odds for obese individuals were not significantly greater than for individuals with normal weight (OR, 1.31; 95% CI, 0.92-1.88) at time 1, but increased to 2.05 (95% CI, 1.45-2.88) at time 2. This was because the odds of ADL impairment did not change for obese individuals but decreased by 34% among nonobese individuals (OR, 0.66; 95% CI, 0.50-0.88). Conclusions Recent cardiovascular improvements have not been accompanied by reduced disability within the obese older population. Rather, obese participants surveyed during 1999-2004 were more likely to report functional impairments than obese participants surveyed during 1988-1994, and reductions in ADL impairment observed for nonobese older individuals did not occur in those who were obese. Over time, declines in obesity-related mortality, along with a younger age at onset of obesity, could lead to an increased burden of disability within the obese older population.	Univ Penn, Robert Wood Johnson Hlth & Soc Scholars Program, Philadelphia, PA 19104 USA; Univ Penn, Philadelphia Vet Affairs Med Ctr, Dept Med,Sch Med, Dept Sociol, Philadelphia, PA 19104 USA	Robert Wood Johnson Foundation (RWJF); University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Alley, DE (corresponding author), Univ Penn, Robert Wood Johnson Hlth & Soc Scholars Program, 3641 Locust Walk,Ste 302, Philadelphia, PA 19104 USA.	alley@wharton.upenn.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD043459] Funding Source: NIH RePORTER; NICHD NIH HHS [K12-HD043459] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams KF, 2006, NEW ENGL J MED, V355, P763, DOI 10.1056/NEJMoa055643; Callahan D, 1999, JAMA-J AM MED ASSOC, V282, P2077, DOI 10.1001/jama.282.21.2077; Calle EE, 2005, NEW ENGL J MED, V353, P2197, DOI 10.1056/NEJM200511173532020; Chang VW, 2005, ARCH INTERN MED, V165, P2122, DOI 10.1001/archinte.165.18.2122; Doshi JA, 2007, HEALTH AFFAIR, V26, P1111, DOI 10.1377/hlthaff.26.4.1111; Ferraro KF, 2002, AM J PUBLIC HEALTH, V92, P834, DOI 10.2105/AJPH.92.5.834; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Fontaine K R, 2001, Obes Rev, V2, P173, DOI 10.1046/j.1467-789x.2001.00032.x; Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187; Freedman VA, 1999, DEMOGRAPHY, V36, P461, DOI 10.2307/2648084; Freedman VA, 2004, DEMOGRAPHY, V41, P417, DOI 10.1353/dem.2004.0022; Freedman VA, 2003, HEALTH AFFAIR, V22, P154, DOI 10.1377/hlthaff.22.4.154; Freedman VA, 2002, JAMA-J AM MED ASSOC, V288, P3137, DOI 10.1001/jama.288.24.3137; Fried TR, 2001, ARCH INTERN MED, V161, P2602, DOI 10.1001/archinte.161.21.2602; GELMAN A, 2007, DATA ANAL USING REGR, P533; Gregg EW, 2005, JAMA-J AM MED ASSOC, V293, P1868, DOI 10.1001/jama.293.15.1868; Himes CL, 2000, DEMOGRAPHY, V37, P73, DOI 10.2307/2648097; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P94, DOI DOI 10.1001/JAMA.1963.03060120024016; Kramarow E, 2007, HEALTH AFFAIR, V26, P1417, DOI 10.1377/hlthaff.26.5.1417; Krauss R M, 1998, Circulation, V98, P1472; Lawlor DA, 2006, OBESITY, V14, P2294, DOI 10.1038/oby.2006.269; Manton KG, 2001, P NATL ACAD SCI USA, V98, P6354, DOI 10.1073/pnas.111152298; Mcgee DL, 2005, ANN EPIDEMIOL, V15, P87, DOI 10.1016/j.annepidem.2004.05.012; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523; National Center for Health Statistics, NAT HLTH NUTR EX SUR; Preston SH, 2005, NEW ENGL J MED, V352, P1135, DOI 10.1056/NEJMe058009; Reynolds SL, 2005, GERONTOLOGIST, V45, P438, DOI 10.1093/geront/45.4.438; Schoeni RF, 2001, J GERONTOL B-PSYCHOL, V56, pS206, DOI 10.1093/geronb/56.4.S206; Sturm R, 2004, HEALTH AFFAIR, V23, P199, DOI 10.1377/hlthaff.23.2.199; VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1	32	317	319	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2007	298	17					2020	2027		10.1001/jama.298.17.2020	http://dx.doi.org/10.1001/jama.298.17.2020			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	228GP	17986695	Bronze			2023-01-03	WOS:000250718200022
J	Kamerow, D				Kamerow, Douglas			Wham, bam, thank you CAM	BRITISH MEDICAL JOURNAL			English	Editorial Material							ALTERNATIVE MEDICINE; COMPLEMENTARY					dkamerow@bmj.com		Kamerow, Douglas/0000-0001-7000-9957				Franck L, 2007, BRIT MED J, V334, P506, DOI 10.1136/bmj.39122.512211.BE; Franck L, 2007, BRIT MED J, V334, P507; Shekelle PG, 2005, ANN INTERN MED, V142, P1042, DOI 10.7326/0003-4819-142-12_Part_2-200506211-00003	3	3	3	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	SEP 29	2007	335	7621					647	647		10.1136/bmj.39349.437442.43	http://dx.doi.org/10.1136/bmj.39349.437442.43			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	218AY	17901515	Green Published			2023-01-03	WOS:000249989600038
J	Allen, EA; Pasley, BN; Duong, T; Freeman, RD				Allen, Elena A.; Pasley, Brian N.; Duong, Thang; Freeman, Ralph D.			Transcranial magnetic stimulation elicits coupled neural and hemodynamic consequences	SCIENCE			English	Article							HUMAN MOTOR CORTEX; BLOOD-FLOW; REGIONAL EXCITABILITY; CORTICAL EXCITABILITY; VISUAL-CORTEX; BRAIN; MODULATION; RAT; OSCILLATIONS; OXYGENATION	Transcranial magnetic stimulation (TMS) is an increasingly common technique used to selectively modify neural processing. However, application of TMS is limited by uncertainty concerning its physiological effects. We applied TMS to the cat visual cortex and evaluated the neural and hemodynamic consequences. Short TMS pulse trains elicited initial activation (similar to 1 minute) and prolonged suppression (5 to 10 minutes) of neural responses. Furthermore, TMS disrupted the temporal structure of activity by altering phase relationships between neural signals. Despite the complexity of this response, neural changes were faithfully reflected in hemodynamic signals; quantitative coupling was present over a range of stimulation parameters. These results demonstrate long-lasting neural responses to TMS and support the use of hemodynamic-based neuroimaging to effectively monitor these changes over time.	Univ Calif Berkeley, Sch Optometry, Helen Wills Neurosci Inst, Grp Vis Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Freeman, RD (corresponding author), Univ Calif Berkeley, Sch Optometry, Helen Wills Neurosci Inst, Grp Vis Sci, Berkeley, CA 94720 USA.	freeman@neurovision.berkeley.edu			NATIONAL EYE INSTITUTE [R01EY001175, P30EY003176] Funding Source: NIH RePORTER; NEI NIH HHS [EY03176, EY01175] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BARKER AT, 1985, LANCET, V1, P1106; Berwick J, 2002, J CEREBR BLOOD F MET, V22, P670, DOI 10.1097/00004647-200206000-00005; Cooke SF, 2006, BRAIN, V129, P1659, DOI 10.1093/brain/awl082; DUVERNOY HM, 1981, BRAIN RES BULL, V7, P519, DOI 10.1016/0361-9230(81)90007-1; Fitzgerald PB, 2006, CLIN NEUROPHYSIOL, V117, P2584, DOI 10.1016/j.clinph.2006.06.712; GEORE MS, 2007, TRANSCRANIAL MAGNETI; GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630; Holscher C, 1997, J NEUROSCI, V17, P6470; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; Jacobs J, 2007, J NEUROSCI, V27, P3839, DOI 10.1523/JNEUROSCI.4636-06.2007; Maeda F, 2000, CLIN NEUROPHYSIOL, V111, P800, DOI 10.1016/S1388-2457(99)00323-5; Niessing J, 2005, SCIENCE, V309, P948, DOI 10.1126/science.1110948; Pascual-Leone A, 1998, J CLIN NEUROPHYSIOL, V15, P333, DOI 10.1097/00004691-199807000-00005; Pascual-Leone A, 2000, CURR OPIN NEUROBIOL, V10, P232, DOI 10.1016/S0959-4388(00)00081-7; PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847; Pasley BN, 2007, NEUROIMAGE, V36, P269, DOI 10.1016/j.neuroimage.2006.09.015; Paus T, 1998, J NEUROPHYSIOL, V79, P1102, DOI 10.1152/jn.1998.79.2.1102; Sack AT, 2003, BRAIN RES REV, V43, P41, DOI 10.1016/S0165-0173(03)00191-7; Shmuel A, 2006, NAT NEUROSCI, V9, P569, DOI 10.1038/nn1675; Siebner HR, 2001, NEUROIMAGE, V14, P883, DOI 10.1006/nimg.2001.0889; Singh N, 2007, PROG NEUROBIOL, V81, P29, DOI 10.1016/j.pneurobio.2006.11.009; Suh M, 2005, J NEUROSCI, V25, P68, DOI 10.1523/JNEUROSCI.2823-04.2005; Takano B, 2004, NEUROIMAGE, V23, P849, DOI 10.1016/j.neuroimage.2004.06.032; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Thompson JK, 2003, SCIENCE, V299, P1070, DOI 10.1126/science.1079220; von Stein A, 2000, INT J PSYCHOPHYSIOL, V38, P301, DOI 10.1016/S0167-8760(00)00172-0; Wang H, 1996, NEUROREPORT, V7, P521, DOI 10.1097/00001756-199601310-00035; Wespatat V, 2004, J NEUROSCI, V24, P9067, DOI 10.1523/JNEUROSCI.2221-04.2004; Zheng Y, 2002, NEUROIMAGE, V16, P617, DOI 10.1006/nimg.2002.1078	30	226	239	2	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 28	2007	317	5846					1918	1921		10.1126/science.1146426	http://dx.doi.org/10.1126/science.1146426			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214US	17901333				2023-01-03	WOS:000249764300039
J	Meyer, TW; Hostetter, TH				Meyer, Timothy W.; Hostetter, Thomas H.			Uremia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHRONIC KIDNEY-DISEASE; QUALITY-OF-LIFE; GLOMERULAR-FILTRATION-RATE; STAGE RENAL-DISEASE; P-CRESOL; COGNITIVE IMPAIRMENT; INSULIN-RESISTANCE; HEMODIALYSIS; DIALYSIS; FAILURE		Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA; Stanford Univ, Sch Med, Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	Yeshiva University; Albert Einstein College of Medicine; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Hostetter, TH (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Rm 615,Ullmann Bldg,1300 Morris Pk Ave, Bronx, NY 10461 USA.	thostett@aecom.yu.edu			NIDDK NIH HHS [R33 DK71251, R21 DK077326] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK077326, R33DK071251] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Avesani CM, 2006, KIDNEY INT, V70, pS8, DOI 10.1038/sj.ki.5001969; Axelsson J, 2006, KIDNEY INT, V69, P596, DOI 10.1038/sj.ki.5000089; BABB AL, 1981, AM J KIDNEY DIS, V1, P46, DOI 10.1016/S0272-6386(81)80011-X; Bammens B, 2003, KIDNEY INT, V64, P2238, DOI 10.1046/j.1523-1755.2003.00310.x; Bammens B, 2006, KIDNEY INT, V69, P1081, DOI 10.1038/sj.ki.5000115; Blake C, 2004, NEPHROL DIAL TRANSPL, V19, P3124, DOI 10.1093/ndt/gfh538; Boccardo P, 2004, SEMIN THROMB HEMOST, V30, P579, DOI 10.1055/s-2004-835678; Brouns R, 2004, CLIN NEUROL NEUROSUR, V107, P1, DOI 10.1016/j.clineuro.2004.07.012; Canaud Bernard, 2006, Hemodial Int, V10 Suppl 1, pS5, DOI 10.1111/j.1542-4758.2006.01183.x; Capeillere-Blandin C, 2004, BBA-MOL BASIS DIS, V1689, P91, DOI 10.1016/j.bbadis.2004.02.008; Chang JM, 2000, AM J KIDNEY DIS, V35, P189, DOI 10.1016/S0272-6386(00)70325-8; Chertow GM, 2006, KIDNEY INT, V70, P24, DOI 10.1038/sj.ki.5001544; Coresh J, 2005, J AM SOC NEPHROL, V16, P180, DOI 10.1681/ASN.2004070539; De Deyn PP, 2001, KIDNEY INT, V59, pS77, DOI 10.1046/j.1523-1755.2001.59780077.x; De Smet R, 2003, CLIN CHEM, V49, P470, DOI 10.1373/49.3.470; Dember LM, 2006, SEMIN DIALYSIS, V19, P105, DOI 10.1111/j.1525-139X.2006.00134.x; Depner TA, 2001, SEMIN DIALYSIS, V14, P246, DOI 10.1046/j.1525-139X.2001.00072.x; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Eloot S, 2005, KIDNEY INT, V67, P1566, DOI 10.1111/j.1523-1755.2005.00238.x; Fine RN, 2002, PEDIATR TRANSPLANT, V6, P47, DOI 10.1034/j.1399-3046.2002.1p067.x; GIOVANNETTI S, 1964, LANCET, V1, P1000; GOTCH FA, 1985, KIDNEY INT, V28, P526, DOI 10.1038/ki.1985.160; Griva K, 2006, NEPHROL DIAL TRANSPL, V21, P3275, DOI 10.1093/ndt/gfl385; Hailpern SM, 2007, J AM SOC NEPHROL, V18, P2205, DOI 10.1681/ASN.2006101165; Hanly PJ, 2001, NEW ENGL J MED, V344, P102, DOI 10.1056/NEJM200101113440204; Himmelfarb J, 2000, KIDNEY INT, V58, P2571, DOI 10.1046/j.1523-1755.2000.00443.x; Himmelfarb J, 2002, KIDNEY INT, V62, P1524, DOI 10.1046/j.1523-1755.2002.00600.x; Himmelfarb J, 2002, KIDNEY INT, V61, P705, DOI 10.1046/j.1523-1755.2002.00151.x; Johansen KL, 1999, ADV RENAL REPLACE TH, V6, P141, DOI 10.1016/S1073-4449(99)70032-4; JOHNSON WJ, 1972, MAYO CLIN PROC, V47, P21; KAHN T, 1987, AM J PHYSIOL, V252, pF785; Kobayashi S, 2005, AM J KIDNEY DIS, V45, P275, DOI 10.1053/j.ajkd.2004.09.034; Komiyama Y, 2005, CLIN BIOCHEM, V38, P36, DOI 10.1016/j.clinbiochem.2004.08.005; Kopple JD, 2000, KIDNEY INT, V57, P1688, DOI 10.1046/j.1523-1755.2000.00014.x; Krishnan AV, 2005, BRAIN, V128, P2164, DOI 10.1093/brain/awh558; Kurella M, 2004, J AM GERIATR SOC, V52, P1863, DOI 10.1111/j.1532-5415.2004.52508.x; Lesaffer G, 2000, NEPHROL DIAL TRANSPL, V15, P50, DOI 10.1093/ndt/15.1.50; Martinez AW, 2005, J AM SOC NEPHROL, V16, P3430, DOI 10.1681/ASN.2005030310; Mehta RL, 2001, KIDNEY INT, V60, P1154, DOI 10.1046/j.1523-1755.2001.0600031154.x; Meyer TW, 2004, J AM SOC NEPHROL, V15, P1927, DOI 10.1097/01.asn.0000131521.62256.f0; Miyata T, 2001, KIDNEY INT, V59, pS25; Mucsi F, 2005, NEPHROL DIAL TRANSPL, V20, P571, DOI 10.1093/ndt/gfh654; Murray AM, 2006, NEUROLOGY, V67, P216, DOI 10.1212/01.wnl.0000225182.15532.40; NIWA T, 1991, NEPHROL DIAL TRANSPL, V6, P105, DOI 10.1093/ndt/6.2.105; Norden AGW, 2004, KIDNEY INT, V66, P1994, DOI 10.1111/j.1523-1755.2004.00970.x; Ohtsuki S, 2004, BIOL PHARM BULL, V27, P1489, DOI 10.1248/bpb.27.1489; Palevsky PM, 2005, CLIN TRIALS, V2, P423, DOI 10.1191/1740774505cn116oa; Perl J, 2006, KIDNEY INT, V70, P1687, DOI 10.1038/sj.ki.5001791; Perlman RL, 2005, AM J KIDNEY DIS, V45, P658, DOI 10.1053/j.ajkd.2004.12.021; Pierratos A, 2004, KIDNEY INT, V65, P1975, DOI 10.1111/j.1523-1755.2004.00603.x; Pirisino R, 2005, MED SCI MONITOR, V11, pRA257; Raj DSC, 2000, NEPHROL DIAL TRANSPL, V15, P58, DOI 10.1093/ndt/15.1.58; Ravani P, 2005, J AM SOC NEPHROL, V16, P2449, DOI 10.1681/ASN.2005010076; Rigalleau V, 2005, CURR OPIN CLIN NUTR, V8, P463, DOI 10.1097/01.mco.0000172590.32564.b9; Rocco MV, 1997, AM J KIDNEY DIS, V29, P888, DOI 10.1016/S0272-6386(97)90463-7; Schneditz D, 2001, SEMIN DIALYSIS, V14, P271, DOI 10.1046/j.1525-139X.2001.00066.x; Schreiner G, 1960, UREMIA, P55; Shinohara K, 2002, J AM SOC NEPHROL, V13, P1894, DOI 10.1097/01.ASN.0000019900.87535.43; SIMENHOFF ML, 1978, KIDNEY INT, pS16; SIMENHOFF ML, 1977, NEW ENGL J MED, V297, P132, DOI 10.1056/NEJM197707212970303; SMITH JL, 1994, TOXICOL APPL PHARM, V125, P296, DOI 10.1006/taap.1994.1076; Suri RS, 2007, KIDNEY INT, V71, P349, DOI 10.1038/sj.ki.5002032; US Renal Data System, 2006, USRDS 2006 ANN DAT R; Valderrabano F, 2001, AM J KIDNEY DIS, V38, P443, DOI 10.1053/ajkd.2001.26824; Vanholder R, 2003, KIDNEY INT, V63, P1934, DOI 10.1046/j.1523-1755.2003.00924.x; Verroust PJ, 2002, KIDNEY INT, V62, P745, DOI 10.1046/j.1523-1755.2002.00501.x; Vinsonneau C, 2006, LANCET, V368, P379, DOI 10.1016/S0140-6736(06)69111-3; Weissinger EM, 2004, NEPHROL DIAL TRANSPL, V19, P3068, DOI 10.1093/ndt/gfh509; WELT LG, 1964, T ASSOC AM PHYSICIAN, V77, P169; Zoccali C, 2006, KIDNEY INT, V70, P26, DOI 10.1038/sj.ki.5000417	71	321	357	0	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 27	2007	357	13					1316	1325		10.1056/NEJMra071313	http://dx.doi.org/10.1056/NEJMra071313			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214BR	17898101				2023-01-03	WOS:000249711500008
J	Culleton, BF; Walsh, M; Klarenbach, SW; Mortis, G; Scott-Douglas, N; Quinn, RR; Tonelli, M; Donnelly, S; Friedrich, MG; Kumar, A; Mahallati, H; Hemmelgarn, BR; Manns, BJ				Culleton, Bruce F.; Walsh, Michael; Klarenbach, Scott W.; Mortis, Garth; Scott-Douglas, Narine; Quinn, Robert R.; Tonelli, Marcello; Donnelly, Sarah; Friedrich, Matthias G.; Kumar, Andreas; Mahallati, Houman; Hemmelgarn, Brenda R.; Manns, Braden J.			Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STAGE RENAL-DISEASE; RECEIVING HEMODIALYSIS; PERITONEAL-DIALYSIS; HOME HEMODIALYSIS; BLOOD-PRESSURE; COST-UTILITY; FOLLOW-UP; HYPERTROPHY; SURVIVAL; IMPROVEMENT	Context Morbidity and mortality rates in hemodialysis patients remain excessive. Alterations in the delivery of dialysis may lead to improved patient outcomes. Objective To compare the effects of frequent nocturnal hemodialysis vs conventional hemodialysis on change in left ventricular mass and health-related quality of life over 6 months. Design, Setting, and Participants A 2-group, parallel, randomized controlled trial conducted at 2 Canadian university centers between August 2004 and December 2006. A total of 52 patients undergoing hemodialysis were recruited. Intervention Participants were randomly assigned in a 1:1 ratio to receive nocturnal hemodialysis 6 times weekly or conventional hemodialysis 3 times weekly. Main Outcome Measures The primary outcome was change in left ventricular mass, as measured by cardiovascular magnetic resonance imaging. The secondary outcomes were patient-reported quality of life, blood pressure, mineral metabolism, and use of medications. Results Frequent nocturnal hemodialysis significantly improved the primary outcome (mean left ventricular mass difference between groups, 15.3 g, 95% confidence interval [CI], 1.0 to 29.6 g; P = .04). Frequent nocturnal hemodialysis did not significantly improve quality of life (difference of change in EuroQol 5-D index from baseline, 0.05; 95% CI, -0.07 to 0.17; P = .43). However, frequent nocturnal hemodialysis was associated with clinically and statistically significant improvements in selected kidney-specific domains of quality of life (P = .01 for effects of kidney disease and P = .02 for burden of kidney disease). Frequent nocturnal hemodialysis was also associated with improvements in systolic blood pressure (P = .01 after adjustment) and mineral metabolism, including a reduction in or discontinuation of antihypertensive medications (16/26 patients in the nocturnal hemodialysis group vs 3/25 patients in the conventional hemodialysis group; P < .001) and oral phosphate binders (19/26 patients in the nocturnal hemodialysis group vs 3/25 patients in the conventional dialysis group; P < .001). No benefit in anemia management was seen with nocturnal hemodialysis. Conclusion This preliminary study revealed that, compared with conventional hemodialysis (3 times weekly), frequent nocturnal hemodialysis improved left ventricular mass, reduced the need for blood pressure medications, improved some measures of mineral metabolism, and improved selected measures of quality of life.	Univ Calgary, Dept Med, Calgary, AB, Canada; Alberta Kidney Dis Network, Edmonton, AB, Canada; Univ Calgary, Libin Cardiovasc Inst Alberta, Calgary, AB T2N 1N4, Canada; Univ Alberta, Dept Med, Edmonton, AB T6G 2M7, Canada; Univ Calgary, Dept Community Hlth Sci, Calgary, AB T2N 1N4, Canada; Univ Calgary, Cardiovasc Magnet Resonance Ctr, Libin Cardiovasc Inst Alberta, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Radiol, Calgary, AB T2N 1N4, Canada	University of Calgary; Libin Cardiovascular Institute Of Alberta; University of Calgary; University of Alberta; University of Calgary; Libin Cardiovascular Institute Of Alberta; University of Calgary; University of Calgary	Culleton, BF (corresponding author), Foothills Prov Gen Hosp, Room C210,1403 29th St NW, Calgary, AB T2N 2T9, Canada.	bruce_culleton@baxter.com	Hemmelgarn, Brenda R./I-6894-2012; Tonelli, Marcello/B-3028-2009; Quinn, Robert R/E-7017-2011; Walsh, Michael/ABE-1278-2021; Manns, Braden J/I-8942-2012; Friedrich, Matthias/H-8474-2015	Tonelli, Marcello/0000-0002-0846-3187; Walsh, Michael/0000-0001-8292-2014; Friedrich, Matthias/0000-0003-1204-5647				Ayus JC, 2005, J AM SOC NEPHROL, V16, P2778, DOI 10.1681/ASN.2005040392; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Chan CT, 2003, HYPERTENSION, V42, P925, DOI 10.1161/01.HYP.0000097605.35343.64; Chan CT, 2002, KIDNEY INT, V61, P2235, DOI 10.1046/j.1523-1755.2002.00362.x; Collins AJ, 2007, AM J KIDNEY DIS, V49, P135, DOI 10.1053/j.ajkd.2006.09.020; Cooper BA, 2004, PERITON DIALYSIS INT, V24, P176; CULLETON BF, 2003, J AM SOC NEPHROL, V14, pS220; Devereux RB, 2004, JAMA-J AM MED ASSOC, V292, P2350, DOI 10.1001/jama.292.19.2350; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; Foley RN, 1998, KIDNEY INT, V54, P1720, DOI 10.1046/j.1523-1755.1998.00154.x; FOLEY RN, 1995, KIDNEY INT, V47, P186, DOI 10.1038/ki.1995.22; Hanly PJ, 2001, NEW ENGL J MED, V344, P102, DOI 10.1056/NEJM200101113440204; Heidenheim AP, 2003, AM J KIDNEY DIS, V42, pS36, DOI 10.1016/S0272-6386(03)00536-5; Kind P, 1998, BMJ-BRIT MED J, V316, P736, DOI 10.1136/bmj.316.7133.736; Kliger AS, 2007, CLIN J AM SOC NEPHRO, V2, P390, DOI 10.2215/CJN.03110906; Korevaar JC, 2003, KIDNEY INT, V64, P2222, DOI 10.1046/j.1523-1755.2003.00321.x; Kroeker A, 2003, AM J KIDNEY DIS, V42, pS49, DOI 10.1016/S0272-6386(03)00538-9; Laupacis A, 1996, KIDNEY INT, V50, P235, DOI 10.1038/ki.1996.307; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Lo WK, 2003, KIDNEY INT, V64, P649, DOI 10.1046/j.1523-1755.2003.00098.x; London GM, 2001, J AM SOC NEPHROL, V12, P2759, DOI 10.1681/ASN.V12122759; McFarlane PA, 2003, KIDNEY INT, V64, P1004, DOI 10.1046/j.1523-1755.2003.00157.x; McPhatter LL, 1999, ADV RENAL REPLACE TH, V6, P358, DOI 10.1016/S1073-4449(99)70048-8; Mucsi I, 1998, KIDNEY INT, V53, P1399, DOI 10.1046/j.1523-1755.1998.00875.x; Myerson SG, 2002, HYPERTENSION, V39, P750, DOI 10.1161/hy0302.104674; Nesrallah G, 2003, AM J KIDNEY DIS, V42, pS13, DOI 10.1016/S0272-6386(03)00532-8; Nesrallah GE, 2004, SEMIN DIALYSIS, V17, P131, DOI 10.1111/j.0894-0959.2004.17210.x; Paniagua R, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1351307; Piccoli GB, 2005, KIDNEY INT, V68, P2913, DOI 10.1111/j.1523-1755.2005.00583_11.x; SAMAK MJ, 2003, CIRCULATION, V108, P2154; SILBERBERG JS, 1989, KIDNEY INT, V36, P286, DOI 10.1038/ki.1989.192; Suri RS, 2007, KIDNEY INT, V71, P349, DOI 10.1038/sj.ki.5002032; Walsh M, 2005, KIDNEY INT, V67, P1500, DOI 10.1111/j.1523-1755.2005.00228.x; Walsh Michael, 2006, BMC Nephrol, V7, P2, DOI 10.1186/1471-2369-7-2; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545; Zoccali C, 2004, KIDNEY INT, V65, P1492, DOI 10.1111/j.1523-1755.2004.00530.x	38	504	552	1	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 19	2007	298	11					1291	1299		10.1001/jama.298.11.1291	http://dx.doi.org/10.1001/jama.298.11.1291			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	211LA	17878421	Bronze			2023-01-03	WOS:000249524100019
J	Wood, GJ; Shega, JW; Lynch, B; Von Roenn, JH				Wood, Gordon J.; Shega, Joseph W.; Lynch, Beth; Von Roenn, Jamie H.			Management of intractable nausea and vomiting in patients at the end of life - " I was feeling nauseous all of the time ... nothing was working"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HIGH-DOSE METOCLOPRAMIDE; OPIOID-INDUCED NAUSEA; DOUBLE-BLIND; TERMINAL CANCER; ANTIEMETIC EFFICACY; RELEASE METOCLOPRAMIDE; INTESTINAL-OBSTRUCTION; POSTOPERATIVE NAUSEA; CONTROLLED ANALGESIA; ANTICIPATORY NAUSEA	Nausea and vomiting, symptoms that occur commonly near the end of life, represent a substantial source of physical and psychological distress for patients and families. In the context of the case of MrQ, a 50-year-old man with metastatic esophageal cancer admitted to the hospital with intractable nausea and vomiting, we review the evaluation and treatment of this symptom complex. A thorough history and physical examination are essential first steps in the management of these patients because they define the severity of the symptoms and clues to their underlying etiology. Once the most likely cause is determined, the clinician discerns the mechanism, specific transmitters, and receptors by which this etiology is triggering nausea and vomiting. Subsequent pharmacological management focuses on prescribing the appropriate antagonist to the implicated receptors. If symptoms are refractory despite adequate dosage and around-the-clock prophylactic administration, an empirical trial combining several therapies to block multiple emetic pathways should be attempted. Less traditional agents are also discussed, although evidence for their use is limited. Often, oral administration of medication is not feasible and alternate routes such as rectal suppositories, subcutaneous infusions, and orally dissolvable tablets should be considered. Using this step-wise approach, nausea and vomiting can be successfully managed in most patients at the end of life.	Northwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Wood, GJ (corresponding author), Univ Pittsburgh, Inst Enhance Palliat Care, Sect Palliat Care & Med Eth, Sch Med,Dept Med,Div Gen Internal Med, 200 Lothrop St,Suite 933 W, Pittsburgh, PA 15213 USA.	woodgj@upmc.edu						ALDRETE JA, 1995, J PAIN SYMPTOM MANAG, V10, P544, DOI 10.1016/0885-3924(95)00104-7; ANDRYKOWSKI MA, 1990, PSYCHOSOM MED, V52, P458, DOI 10.1097/00006842-199007000-00008; Ashby MA, 1999, MED J AUSTRALIA, V170, P68, DOI 10.5694/j.1326-5377.1999.tb126885.x; BAINES M, 1985, LANCET, V2, P990; BARDFELD PA, 1966, J AMER MED ASSOC, V196, P796; Barnes S, 2006, J PAIN SYMPTOM MANAG, V32, P208, DOI 10.1016/j.jpainsymman.2006.04.005; BARTON MD, 1975, ANESTHESIOLOGY, V42, P508, DOI 10.1097/00000542-197504000-00028; BEAL JE, 1995, J PAIN SYMPTOM MANAG, V10, P89, DOI 10.1016/0885-3924(94)00117-4; Bentley A, 2001, PALLIATIVE MED, V15, P247, DOI 10.1191/026921601678576239; Berger A, 2007, PRINCIPLES PRACTICE, P139; Bernard SA, 2000, J CLIN ONCOL, V18, P1780, DOI 10.1200/JCO.2000.18.8.1780; Bittinger M, 1999, CLIN AUTON RES, V9, P75, DOI 10.1007/BF02311763; Blair SL, 2001, ANN SURG ONCOL, V8, P632, DOI 10.1007/s10434-001-0632-1; BORISON HL, 1953, PHARMACOL REV, V5, P193; Braude D, 2006, AM J EMERG MED, V24, P177, DOI 10.1016/j.ajem.2005.08.017; Brooksbank MA, 2002, PALLIATIVE MED, V16, P520, DOI 10.1191/0269216302pm590oa; Bruera E, 2004, J PAIN SYMPTOM MANAG, V28, P381, DOI 10.1016/j.jpainsymman.2004.01.009; Bruera E, 1987, J Pain Symptom Manage, V2, P19, DOI 10.1016/S0885-3924(87)80041-6; BRUERA E, 1994, J PAIN SYMPTOM MANAG, V9, P515, DOI 10.1016/0885-3924(94)90113-9; Bruera E, 1996, J PAIN SYMPTOM MANAG, V11, P147, DOI 10.1016/0885-3924(95)00161-1; Bruera E, 2000, J PAIN SYMPTOM MANAG, V19, P427, DOI 10.1016/S0885-3924(00)00138-X; BRUERA ED, 1994, CANCER, V74, P3204, DOI 10.1002/1097-0142(19941215)74:12<3204::AID-CNCR2820741220>3.0.CO;2-G; BRUERA ED, 1995, CANCER, V75, P1733; BURISH TG, 1992, J PAIN SYMPTOM MANAG, V7, P287, DOI 10.1016/0885-3924(92)90062-M; Burmeister MA, 2003, BRIT J ANAESTH, V90, P194, DOI 10.1093/bja/aeg047; CAMPORA E, 1991, J PAIN SYMPTOM MANAG, V6, P428, DOI 10.1016/0885-3924(91)90041-2; CARPENTER DO, 1990, CAN J PHYSIOL PHARM, V68, P230, DOI 10.1139/y90-036; Casarett DJ, 2001, ANN INTERN MED, V135, P32, DOI 10.7326/0003-4819-135-1-200107030-00011; Chang VT, 2000, CANCER, V88, P2164, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5; COLE RM, 1994, J PAIN SYMPTOM MANAG, V9, P48, DOI 10.1016/0885-3924(94)90147-3; Cowan JD, 2001, SUPPORT CARE CANCER, V9, P403, DOI 10.1007/s005200100235; Critchley P, 2001, J PAIN SYMPTOM MANAG, V22, P631, DOI 10.1016/S0885-3924(01)00323-2; Currow DC, 1997, J PAIN SYMPTOM MANAG, V13, P302, DOI 10.1016/S0885-3924(97)00079-1; DALAL S, 2007, PRINCIPLES PRACTICE, P151; Davis MP, 2000, SUPPORT CARE CANCER, V8, P444, DOI 10.1007/s005200000151; DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C; Ernst AA, 2000, ANN EMERG MED, V36, P89, DOI 10.1067/mem.2000.108652; Fainsinger R, 1991, J Palliat Care, V7, P5; Fainsinger RL, 2000, PALLIATIVE MED, V14, P257, DOI 10.1191/026921600666097479; Fallon MT, 1998, BRIT MED J, V317, P81, DOI 10.1136/bmj.317.7150.81; Familoni BO, 2006, IEEE T BIO-MED ENG, V53, P1038, DOI 10.1109/TBME.2006.873395; Feuer DJ., 2000, COCHRANE DB SYST REV, V2000; Flynn J, 1992, J Palliat Care, V8, P46; Gagnon P, 2000, J PAIN SYMPTOM MANAG, V19, P412, DOI 10.1016/S0885-3924(00)00143-3; Gan TJ, 2003, ANESTH ANALG, V97, P62, DOI 10.1213/01.ANE.0000068580.00245.95; Glare P, 2004, SUPPORT CARE CANCER, V12, P432, DOI 10.1007/s00520-004-0629-y; GonzalezRosales F, 1997, J PAIN SYMPTOM MANAG, V14, P311, DOI 10.1016/S0885-3924(97)00229-7; GRALLA RJ, 1981, NEW ENGL J MED, V305, P905, DOI 10.1056/NEJM198110153051601; GROND S, 1994, J PAIN SYMPTOM MANAG, V9, P372, DOI 10.1016/0885-3924(94)90174-0; Grunberg SM, 2004, CANCER-AM CANCER SOC, V100, P2261, DOI 10.1002/cncr.20230; GUTNER LB, 1952, J CLIN INVEST, V31, P259, DOI 10.1172/JCI102601; HAGEN NA, 1991, J PAIN SYMPTOM MANAG, V6, P125, DOI 10.1016/0885-3924(91)90961-3; Hall W, 2005, LANCET ONCOL, V6, P35, DOI 10.1016/S1470-2045(05)70024-3; Hardy J, 2002, SUPPORT CARE CANCER, V10, P231, DOI 10.1007/s00520-001-0332-1; Haug TT, 2002, GEN HOSP PSYCHIAT, V24, P81, DOI 10.1016/S0163-8343(01)00184-0; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Jackson W Clay, 2003, J Palliat Med, V6, P251, DOI 10.1089/109662103764978506; KAUFMANN MA, 1994, ANESTH ANALG, V78, P988; KENNY GNC, 1994, ANAESTHESIA, V49, P6, DOI 10.1111/j.1365-2044.1994.tb03576.x; Klepstad P, 2003, PALLIATIVE MED, V17, P679, DOI 10.1191/0269216303pm835oa; Kris MG, 2006, J CLIN ONCOL, V24, P2932, DOI 10.1200/JCO.2006.06.9591; Lang IM, 1999, DIGEST DIS SCI, V44, p58S; Lawlor PG, 2000, ARCH INTERN MED, V160, P786, DOI 10.1001/archinte.160.6.786; Liaw CC, 2003, AM J CLIN ONCOL-CANC, V26, P12, DOI 10.1097/00000421-200302000-00003; Lichter I, 1993, J Palliat Care, V9, P19; Ljutic D, 2002, KIDNEY BLOOD PRESS R, V25, P61, DOI 10.1159/000049437; Lo B, 2005, JAMA-J AM MED ASSOC, V294, P1810, DOI 10.1001/jama.294.14.1810; LOPRINZI CL, 1990, JNCI-J NATL CANCER I, V82, P1127, DOI 10.1093/jnci/82.13.1127; LUND B, 1989, SURG GYNECOL OBSTET, V169, P213; Lundstrom S, 2005, J PAIN SYMPTOM MANAG, V30, P570, DOI 10.1016/j.jpainsymman.2005.05.017; MALIK IA, 1995, AM J CLIN ONCOL-CANC, V18, P170, DOI 10.1097/00000421-199504000-00017; Mannix K, 2006, CLIN MED, V6, P144, DOI 10.7861/clinmedicine.6-2-144; MARTY M, 1990, NEW ENGL J MED, V322, P816, DOI 10.1056/NEJM199003223221205; MCGEE JL, 1979, AM J HOSP PHARM, V36, P633, DOI 10.1093/ajhp/36.5.633; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V28, P412, DOI 10.1016/j.jpainsymman.2004.01.007; Meuser T, 2001, PAIN, V93, P247, DOI 10.1016/S0304-3959(01)00324-4; Mok TSK, 2007, ANN ONCOL, V18, P768, DOI 10.1093/annonc/mdl465; Morrow GR, 2002, PSYCHOPHYSIOLOGY, V39, P491, DOI 10.1017/S0048577202991195; Morrow GR, 1996, ONCOLOGY, V53, P4, DOI 10.1159/000227633; MORROW GR, 1984, J CLIN ONCOL, V2, P1170, DOI 10.1200/JCO.1984.2.10.1170; Mystakidou K, 1998, J PAIN SYMPTOM MANAG, V15, P176, DOI 10.1016/S0885-3924(97)00349-7; Mystakidou K, 1998, CANCER-AM CANCER SOC, V83, P1214, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1214::AID-CNCR22>3.3.CO;2-3; Norval DA, 2004, SAMJ S AFR MED J, V94, P450; ORDOG GJ, 1984, ANN EMERG MED, V13, P253, DOI 10.1016/S0196-0644(84)80473-4; Pan CX, 2000, J PAIN SYMPTOM MANAG, V20, P374, DOI 10.1016/S0885-3924(00)00190-1; Passik SD, 2002, J PAIN SYMPTOM MANAG, V23, P526, DOI 10.1016/S0885-3924(02)00391-3; Pereira J, 1996, J PALLIAT CARE, V12, P47, DOI 10.1177/082585979601200210; Pick N, 1996, J AM GERIATR SOC, V44, P763, DOI 10.1111/j.1532-5415.1996.tb03731.x; Porcel JM, 1998, J PAIN SYMPTOM MANAG, V15, P265; PORTENOY RK, 1994, QUAL LIFE RES, V3, P183, DOI 10.1007/BF00435383; Priestman T J, 1990, Clin Oncol (R Coll Radiol), V2, P71, DOI 10.1016/S0936-6555(05)80790-3; PYYKKO I, 1985, ACTA OTO-LARYNGOL, V99, P588, DOI 10.3109/00016488509182265; REUBEN DB, 1986, ARCH INTERN MED, V146, P2021, DOI 10.1001/archinte.146.10.2021; Rhodes VA, 2001, CA-CANCER J CLIN, V51, P232, DOI 10.3322/canjclin.51.4.232; RHODES VA, 1994, CANCER NURS, V17, P45; Ripamonti C, 2001, SUPPORT CARE CANCER, V9, P223, DOI 10.1007/s005200000198; Ripamonti C., 2004, OXFORD TXB PALLIATIV, V3, P496; ROBBINS EL, 1975, J AM GERIATR SOC, V23, P38, DOI 10.1111/j.1532-5415.1975.tb00378.x; SALLER R, 1986, J CLIN PHARMACOL, V26, P115, DOI 10.1002/j.1552-4604.1986.tb02918.x; SIMMS SG, 1993, NURS RES, V42, P234; SONG HY, 1994, RADIOLOGY, V193, P689, DOI 10.1148/radiology.193.3.7526414; Srivastava M, 2003, J PAIN SYMPTOM MANAG, V25, P578, DOI 10.1016/S0885-3924(03)00143-X; Starke PR, 2005, NEW ENGL J MED, V352, P2653, DOI 10.1056/NEJM200506233522522; Stephenson J, 2006, SUPPORT CARE CANCER, V14, P348, DOI 10.1007/s00520-005-0897-1; Storey P, 1990, J Pain Symptom Manage, V5, P33, DOI 10.1016/S0885-3924(05)80007-7; Sussman G, 1999, CLIN THER, V21, P1216, DOI 10.1016/S0149-2918(00)80024-7; Taixiang W, 2005, Cochrane Database Syst Rev, pCD004540; Theobald DE, 2002, J PAIN SYMPTOM MANAG, V23, P442, DOI 10.1016/S0885-3924(02)00381-0; Thompson DS, 2000, PSYCHOSOMATICS, V41, P356, DOI 10.1176/appi.psy.41.4.356; Traldi A, 1965, Cancro, V18, P336; Veehof LJG, 1999, EUR J CLIN PHARMACOL, V55, P533, DOI 10.1007/s002280050669; Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602; Vutyavanich T, 2001, OBSTET GYNECOL, V97, P577, DOI 10.1016/S0029-7844(00)01228-X; WALDER AD, 1994, ANAESTHESIA, V49, P804; Weschules Douglas J, 2006, Am J Hosp Palliat Care, V23, P135, DOI 10.1177/104990910602300211; Weschules DJ, 2005, J PALLIAT MED, V8, P1135, DOI 10.1089/jpm.2005.8.1135; Wickham Rita, 2004, Clin J Oncol Nurs, V8, P91; Winkelbauer FW, 1996, AM J ROENTGENOL, V166, P79, DOI 10.2214/ajr.166.1.8571911	118	57	58	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 12	2007	298	10					1196	1207		10.1001/jama.298.10.1196	http://dx.doi.org/10.1001/jama.298.10.1196			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	209FK	17848654				2023-01-03	WOS:000249374200025
J	Cuzick, J; Ambroisine, L; Davidson, N; Jakesz, R; Kaufmann, M; Regan, M; Sainsbury, R				Cuzick, J.; Ambroisine, L.; Davidson, N.; Jakesz, R.; Kaufmann, M.; Regan, M.; Sainsbury, R.		LHRH agonists Early Breast Canc Ov	Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials	LANCET			English	Article							QUALITY-OF-LIFE; OVARIAN SUPPRESSION; GOSERELIN; CHEMOTHERAPY; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; THERAPY; WOMEN	Background Several trials have been done to assess treatment of premenopausal breast cancer with luteinising-hormone-releasing hormone (LHRH) agonists, but results have been inconclusive, especially for patients with hormone-receptor-positive cancer. Methods We collected individual patients' data from published trials and did analyses focused on women with tumours positive for oestrogen receptor, progesterone receptor, or both. The main endpoints were recurrence and death after recurrence. Findings We obtained data for 11906 premenopausal women with early breast cancer randomised in 16 trials. When used as the only systemic adjuvant treatment, LHRH agonists did not significantly reduce recurrence (28.4% relative reduction, 95% CI consistent with 50.5% reduction to 3.5% increase, p=0.08) or death after recurrence (17.8%, 52.8% reduction to 42.9% increase, p=0.49) in hormone-receptor-positive cancers. Addition of LHRH agonists to tamoxifen, chemotherapy, or both reduced recurrence by 12.7% (2.4-21.9, p=0.02); and death after recurrence by 15.1% (1.8-26.7, p=0.03). LHRH agonists showed similar efficacy to chemotherapy (recurrence 3.9% increase, 7.7% reduction to 17.0% increase; death after recurrence 6.7% reduction, 20.7% reduction to 9.6% increase; both not significant). No trials had assessed an LHRH agonist versus chemotherapy with tamoxifen in both arms. LHRH agonists were ineffective in hormone-receptor-negative tumours. Interpretation LHRH agonists provide an additional class of agents for treatment of premenopausal women with hormone-receptor-positive breast cancer. Optimum duration of use is unknown.	Univ London, Queen Marys Sch Med & Dent, Canc Res UK Ctr Epidemiol Math & Stat, Wolfson Inst Prevent Med, London EC1M 6BQ, England; Johns Hopkins Univ, Sydney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; Med Univ Vienna, Vienna, Austria; Goethe Univ Frankfurt, Frauenklin, D-6000 Frankfurt, Germany; Dana Farber Canc Inst, Boston, MA 02115 USA; UCL, Dept Surg, London, England	Cancer Research UK; University of London; Queen Mary University London; Johns Hopkins University; Johns Hopkins Medicine; Medical University of Vienna; Goethe University Frankfurt; Harvard University; Dana-Farber Cancer Institute; University of London; University College London	Cuzick, J (corresponding author), Univ London, Queen Marys Sch Med & Dent, Canc Res UK Ctr Epidemiol Math & Stat, Wolfson Inst Prevent Med, London EC1M 6BQ, England.	jack.cuzick@cancer.org.uk						Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Arriagada R, 2005, ANN ONCOL, V16, P389, DOI 10.1093/annonc/mdi085; Baum M, 2006, EUR J CANCER, V42, P895, DOI 10.1016/j.ejca.2005.12.013; Bernhard J, 2007, J CLIN ONCOL, V25, P263, DOI 10.1200/JCO.2005.04.5393; Bliss JM, 2007, JNCI-J NATL CANCER I, V99, P516, DOI 10.1093/jnci/djk109; Boccardo F, 2000, J CLIN ONCOL, V18, P2718, DOI 10.1200/JCO.2000.18.14.2718; Castiglione-Gertsch M, 2003, JNCI-J NATL CANCER I, V95, P1833, DOI 10.1093/jnci/djg119; Davidson NE, 2005, J CLIN ONCOL, V23, P5973, DOI 10.1200/JCO.2005.05.551; de Haes H, 2003, J CLIN ONCOL, V21, P4510, DOI 10.1200/JCO.2003.11.064; De Placido S, 2005, BRIT J CANCER, V92, P467, DOI 10.1038/sj.bjc.6602355; FALKSON CI, 1991, EUR J CANCER, V27, P1208, DOI 10.1016/0277-5379(91)90082-O; Francis P., 2003, Breast, V12, pS44, DOI 10.1016/S0960-9776(03)80143-1; Gnant M, 2004, BREAST CANCER RES TR, V88, pS8; Jakesz R, 2002, J CLIN ONCOL, V20, P4621, DOI 10.1200/JCO.2002.09.112; Jonat W, 2002, J CLIN ONCOL, V20, P4628, DOI 10.1200/JCO.2002.05.042; Kaufmann M, 2004, J CLIN ONCOL, V22, p24S; Kaufmann M, 2003, EUR J CANCER, V39, P1711, DOI 10.1016/S0959-8049(03)00392-7; Mitsuyama Shosyu, 2005, Gan To Kagaku Ryoho, V32, P2071; Petrek JA, 2006, J CLIN ONCOL, V24, P1045, DOI 10.1200/JCO.2005.03.3969; Roche H, 2006, ANN ONCOL, V17, P1221, DOI 10.1093/annonc/mdl107; Sharp Sterne J, 1997, STATA TECH B, V7, P9; von Minckwitz G, 2006, EUR J CANCER, V42, P1780, DOI 10.1016/j.ejca.2006.04.006; Wallwiener D, 2004, J CLIN ONCOL, V22, p10S	23	288	310	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 20	2007	369	9574					1711	1723						13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	169ZT	17512856				2023-01-03	WOS:000246631300027
J	Chan, EY; Ruest, A; Meade, MO; Cook, DJ				Chan, Ee Yuee; Ruest, Annie; Meade, Maureen O.; Cook, Deborah J.			Oral decontamination for prevention of pneumonia in mechanically ventilated adults: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY-TRACT INFECTIONS; SELECTIVE DECONTAMINATION; DIGESTIVE-TRACT; NOSOCOMIAL PNEUMONIA; CHLORHEXIDINE; HETEROGENEITY; COLONIZATION; PROPHYLAXIS; MORTALITY; QUALITY	Objective To evaluate the effect of oral decontamination on the incidence of ventilator associated pneumonia and mortality in mechanically ventilated adults. Design Systematic review and meta-analysis. Data sources Medline, Embase, CINAHL, the Cochrane Library, trials registers, reference lists, conference proceedings, and investigators in the specialty. Review methods Two independent reviewers screened studies for inclusion, assessed trial quality, and extracted data. Eligible trials were randomised controlled trials enrolling mechanically ventilated adults that compared the effects of daily oral application of antibiotics or antiseptics with no prophylaxis. Results 11 trials totalling 3242 patients met the inclusion criteria. Among four trials with 1098 patients, oral application of antibiotics did not significantly reduce the incidence of ventilator associated pneumonia (relative risk 0.69, 95% confidence interval 0.41 to 1.18). In seven trials with 2144 patients, however, oral application of antiseptics significantly reduced the incidence of ventilator associated pneumonia (0.56, 0.39 to 0.81). When the results of the 11 trials were pooled, rates of ventilator associated pneumonia were lower among patients receiving either method of oral decontamination (0.61, 0.45 to 0.82). Mortality was not influenced by prophylaxis with either antibiotics (0.94, 0.73 to 1.21) or antiseptics (0.96, 0.69 to 1.33) nor was duration of mechanical ventilation or stay in the intensive care unit. Conclusions Oral decontamination of mechanically ventilated adults using antiseptics is associated with a lower risk of ventilator associated pneumonia. Neither antiseptic nor antibiotic oral decontamination reduced mortality or duration of mechanical ventilation or stay in the intensive care unit.	Tan Tock Seng Hosp, Dept Nursing Serv, Singapore, Singapore; Ctr Hosp Univ Quebec Hotel Dieu, Dept Med, Quebec City, PQ, Canada; Ctr Hosp Univ Quebec Hotel Dieu, Dept Med Biol, Quebec City, PQ, Canada; McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol, Hamilton, ON L8S 4L8, Canada; McMaster Univ, Dept Biostat, Hamilton, ON, Canada	Tan Tock Seng Hospital; Laval University; Laval University; McMaster University; McMaster University; McMaster University	Chan, EY (corresponding author), Tan Tock Seng Hosp, Dept Nursing Serv, Singapore, Singapore.	ee_yuee_chan@ttsh.com.sg		Chan, Ee-Yuee/0000-0001-8662-4487				AbeleHorn M, 1997, INTENS CARE MED, V23, P187, DOI 10.1007/s001340050314; AERDTS SJA, 1993, BRIT MED J, V307, P525; Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; BRUNBUISSON C, 1989, ANN INTERN MED, V110, P873, DOI 10.7326/0003-4819-110-11-873; Camus C, 2005, CRIT CARE MED, V33, P307, DOI 10.1097/01.CCM.0000152224.01949.01; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; Chlebicki MN, 2007, CRIT CARE MED, V35, P595, DOI 10.1097/01.CCM.0000253395.70708.AC; D'Amico R, 1998, BMJ-BRIT MED J, V316, P1275, DOI 10.1136/bmj.316.7140.1275; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Devereaux PJ, 2005, BMJ-BRIT MED J, V331, P313, DOI 10.1136/bmj.38503.623646.8F; Dodek P, 2004, ANN INTERN MED, V141, P305, DOI 10.7326/0003-4819-141-4-200408170-00011; ESTES RJ, 1995, INTENS CARE MED, V21, P365, DOI 10.1007/BF01705418; FLEISS JL, 1973, EDUC PSYCHOL MEAS, V33, P613, DOI 10.1177/001316447303300309; GASTINNE H, 1992, NEW ENGL J MED, V326, P594, DOI 10.1056/NEJM199202273260903; Genuit T, 2001, Surg Infect (Larchmt), V2, P5, DOI 10.1089/109629601750185316; Grap MJ, 2004, HEART LUNG, V33, P83, DOI 10.1016/j.hrtlng.2003.12.004; Hatala R, 2005, CAN MED ASSOC J, V172, P661, DOI 10.1503/cmaj.1031920; Heyland D, 2006, NEW ENGL J MED, V355, P2619, DOI 10.1056/NEJMoa052904; HEYLAND DK, 1994, CHEST, V105, P1221, DOI 10.1378/chest.105.4.1221; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Houston S, 2002, AM J CRIT CARE, V11, P567, DOI 10.4037/ajcc2002.11.6.567; HURLEY JC, 1995, ANTIMICROB AGENTS CH, V39, P941, DOI 10.1128/AAC.39.4.941; KERVER AJH, 1988, CRIT CARE MED, V16, P1087, DOI 10.1097/00003246-198811000-00001; Kollef MH, 2000, CRIT CARE, V4, P327, DOI 10.1186/cc716; KOLLEF MH, 1994, CHEST, V105, P1101, DOI 10.1378/chest.105.4.1101; LIBERATI A, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000022.PUB2; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Mori H, 2006, INTENS CARE MED, V32, P230, DOI 10.1007/s00134-005-0014-4; Nathens AB, 1999, ARCH SURG-CHICAGO, V134, P170, DOI 10.1001/archsurg.134.2.170; Ogata J, 2004, CAN J ANAESTH, V51, P932, DOI 10.1007/BF03018895; Pineda LA, 2006, CRIT CARE, V10, DOI 10.1186/cc4837; PINGLETON SK, 1992, CHEST, V102, pS553, DOI 10.1378/chest.102.5_Supplement_1.553S; PITTET D, 2003, PREVENTION CONTROL N, P532; PUGIN J, 1991, JAMA-J AM MED ASSOC, V265, P2704, DOI 10.1001/jama.265.20.2704; Rello J, 2002, CHEST, V122, P2115, DOI 10.1378/chest.122.6.2115; RELLO J, IN PRESS INTENSIVE C; RODRIGUEZROLDAN JM, 1990, CRIT CARE MED, V18, P1239, DOI 10.1097/00003246-199011000-00011; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Silvestri L, 2004, EUR RESPIR J, V23, P921, DOI 10.1183/09031936.04.00109704; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; American Medical Association, 2004, MMWR Recomm Rep, V53, P1; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2	44	217	231	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 28	2007	334	7599					889	893		10.1136/bmj.39136.528160.BE	http://dx.doi.org/10.1136/bmj.39136.528160.BE			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164FB	17387118	Bronze, Green Published			2023-01-03	WOS:000246217800030
J	Staack, RF				Staack, Roland F.			Piperazine designer drugs of abuse	LANCET			English	Editorial Material							BENZYLPIPERAZINE; ECSTASY		Univ Munich, Inst Forens Med, Dept Forens Toxicol, D-80337 Munich, Germany	University of Munich	Staack, RF (corresponding author), Univ Munich, Inst Forens Med, Dept Forens Toxicol, D-80337 Munich, Germany.	rstaack@gmx.de						Balmelli C, 2001, DEUT MED WOCHENSCHR, V126, P809, DOI 10.1055/s-2001-15702; Baumann MH, 2005, NEUROPSYCHOPHARMACOL, V30, P550, DOI 10.1038/sj.npp.1300585; Drug Enforcement Administration (DEA) Department of Justice, 2004, Fed Regist, V69, P12794; *EUR MON CTR DRUGS, 2007, EUR EMCDDA JOINT REP; Gee Paul, 2005, N Z Med J, V118, pU1784; Klaassen T, 1998, PSYCHIAT RES, V79, P207, DOI 10.1016/S0165-1781(98)00044-4; Maurer HH, 2004, CLIN CHEM LAB MED, V42, P1310, DOI 10.1515/CCLM.2004.250; Peters FT, 2003, J MASS SPECTROM, V38, P659, DOI 10.1002/jms.483; Staack RF, 2005, CURR DRUG METAB, V6, P259, DOI 10.2174/1389200054021825; Wikstrom M, 2004, J ANAL TOXICOL, V28, P67, DOI 10.1093/jat/28.1.67; Wood DM, 2007, LANCET, V369, P1490, DOI 10.1016/S0140-6736(07)60674-6	11	30	31	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR-MAY	2007	369	9571					1411	1413		10.1016/S0140-6736(07)60646-1	http://dx.doi.org/10.1016/S0140-6736(07)60646-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	161LW	17467496				2023-01-03	WOS:000246017700008
J	Mutrie, N; Campbell, AM; Whyte, F; McConnachie, A; Emslie, C; Lee, L; Kearney, N; Walker, A; Ritchie, D				Mutrie, Nanette; Campbell, Anna M.; Whyte, Fiona; McConnachie, Alex; Emslie, Carol; Lee, Laura; Kearney, Nora; Walker, Andrew; Ritchie, Diana			Benefits of supervised group exercise programme for women being treated for early stage breast cancer: pragmatic randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PHYSICAL-ACTIVITY LEVELS; FUNCTIONAL ASSESSMENT; DIAGNOSIS; SURVIVORS; VALIDATION; HEALTH	Objectives To determine functional and psychological benefits of a 12 week supervised group exercise programme during treatment for early stage breast cancer, with six month follow-up. Design Pragmatic randomised controlled prospective open trial. Setting Three National Health Service oncology clinics in Scotland and community exercise facilities. Participants 203 women entered the study; 177 completed the six month follow-up. Interventions Supervised 12 week group exercise programme in addition to usual care, compared with usual care. Main outcome measures Functional assessment of cancer therapy (FACT) questionnaire, Beck depression inventory, positive and negative affect scale, body mass index, seven day recall of physical activity, 12 minute walk test, and assessment of shoulder mobility. Results Mixed effects models with adjustment for baseline values, study site, treatment at baseline, and age gave intervention effect estimates (intervention minus control) at 12 weeks of 129 (95% confidence interval 83 to 176) for metres walked in 12 minutes, 182 (75 to 289) for minutes of moderate intensity activity reported in a week, 2.6 (1.6 to 3.7) for shoulder mobility, 2.5 (1.0 to 3.9) for breast cancer specific subscale of quality of life, and 4.0 (1.8 to 6.3) for positive mood. No significant effect was seen for general quality of life (FACT-G), which was the primary outcome. At the six month follow-up, most of these effects were maintained and an intervention effect for breast cancer specific quality of life emerged. No adverse effects were noted. Conclusion Supervised group exercise provided functional and psychological benefit after a 12 week intervention and six months later. Clinicians should encourage activity for their patients. Policy makers should consider the inclusion of exercise opportunities in cancer rehabilitation services.	Univ Strathclyde, Dept Sport Culture & Arts, Glasgow G13 1PP, Lanark, Scotland; Univ Glasgow, Nursing & Midwifery Sch, Glasgow G12 8LW, Lanark, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland; MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland; Univ Stirling, Canc Care Res Ctr, Dept Nursing & Midwifery, Stirling FK9 4LA, Scotland; Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland	University of Strathclyde; University of Glasgow; University of Glasgow; MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Stirling; Beatson Oncology Centre	Mutrie, N (corresponding author), Univ Strathclyde, Dept Sport Culture & Arts, Glasgow G13 1PP, Lanark, Scotland.	nanette.mutrie@strath.ac.uk		Emslie, Carol/0000-0003-2170-2039	Medical Research Council [MC_U130059811] Funding Source: Medline; MRC [MC_U130059811] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Beck A.T., 1996, PSYCHOL CORP; Beck A.T., 1996, MANUAL BDI 2, DOI [10.1037/t00742-000, DOI 10.1037/T00742-000]; Brady MJ, 1997, J CLIN ONCOL, V15, P974, DOI 10.1200/JCO.1997.15.3.974; CAMPBELL A, 2007, CLIN EFFECTIVENESS N, V9, P211; Campbell Anna, 2005, Eur J Oncol Nurs, V9, P56, DOI 10.1016/j.ejon.2004.03.007; Cancer Research UK, BREAST CANC SURV STA; CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570; Coleman MP, 2004, BRIT J CANCER, V90, P1367, DOI 10.1038/sj.bjc.6601696; Courneya KS, 2003, PSYCHO-ONCOLOGY, V12, P357, DOI 10.1002/pon.658; Courneya KS, 1999, ANN BEHAV MED, V21, P171, DOI 10.1007/BF02908298; Courneya KS, 2002, PHYSICIAN SPORTSMED, V30, P33, DOI 10.3810/psm.2002.08.402; Demark-Wahnefried W, 2005, J CLIN ONCOL, V23, P5814, DOI 10.1200/JCO.2005.01.230; EMSLIE C, IN PRESS HLTH ED RES; Fallowfield LJ, 1999, BREAST CANCER RES TR, V55, P189; Halverstadt A, 2000, ESSENTIAL EXERCISES; Holmes MD, 2005, JAMA-J AM MED ASSOC, V293, P2479, DOI 10.1001/jama.293.20.2479; Irwin ML, 2004, MED SCI SPORT EXER, V36, P1484, DOI 10.1249/01.MSS.0000074670.03001.98; Irwin ML, 2003, CANCER-AM CANCER SOC, V97, P1746, DOI 10.1002/cncr.11227; LOTHER M, 1999, BRIT J SPORT MED, V33, P1; LOWTHER M, 1999, BRIT J SPORT MED, V33, P1; MARCUS BH, 1994, J APPL SOC PSYCHOL, V24, P489, DOI 10.1111/j.1559-1816.1994.tb00595.x; Markes M, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005001; MCGAVIN CR, 1976, BMJ-BRIT MED J, V1, P822, DOI 10.1136/bmj.1.6013.822; McNeely ML, 2006, CAN MED ASSOC J, V175, P34, DOI 10.1503/cmaj.051073; Oldervoll LM, 2004, EUR J CANCER, V40, P951, DOI 10.1016/j.ejca.2003.12.005; Segal R, 2001, J CLIN ONCOL, V19, P657, DOI 10.1200/JCO.2001.19.3.657; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Wilmoth MC, 2004, ONCOL NURS FORUM, V31, P1069, DOI 10.1188/04.ONF.1069-1075	28	264	274	2	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 10	2007	334	7592					517	520B		10.1136/bmj.39094.648553.AE	http://dx.doi.org/10.1136/bmj.39094.648553.AE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	148VV	17307761	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000245106400041
J	Yennurajalingam, S; Bruera, E				Yennurajalingam, Sriram; Bruera, Eduardo			Palliative management of fatigue at the close of life - "It feels like my body is just worn out"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							QUALITY-OF-LIFE; CANCER-RELATED FATIGUE; PATIENT-CONTROLLED METHYLPHENIDATE; DOUBLE-BLIND; MULTIPLE-SCLEROSIS; COGNITIVE IMPAIRMENT; PHYSICAL-ACTIVITY; HEMOGLOBIN LEVEL; CONTROLLED-TRIAL; UNITED-STATES	Fatigue is the most common chronic symptom associated with cancer and other chronic progressive diseases. The assessment and treatment of fatigue at or near the end of life can be complex. Some of the challenges include its subjective nature, with great variability in its source, how it is expressed, and how it is perceived, requiring treatment to be based on patient report of frequency and severity; its multidimensional character; and the limited understanding of its pathophysiology. Using the case of an 82-year-old retired nurse with fatigue that could be explained by a number of concurrent conditions, including anemia, weight loss, depression and isolation, dyspnea, deconditioning, and medications, the authors illustrate the clinical approach to assess and treat fatigue at the end of life.	Univ Texas, MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Unit 008, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Bruera, E (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Unit 008, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ebruera@mdanderson.org	Bruera, Eduardo/AAA-1550-2022					Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; Agteresch HJ, 2000, J NATL CANCER I, V92, P321, DOI 10.1093/jnci/92.4.321; ARMITAGE JO, 1998, CLIN ONCOL UPDATES, V1, P1; BEAL JE, 1995, J PAIN SYMPTOM MANAG, V10, P89, DOI 10.1016/0885-3924(94)00117-4; Belza B, 2001, NURS RES, V50, P195, DOI 10.1097/00006199-200107000-00003; Berman RS, 1999, ANN SURG, V229, P1, DOI 10.1097/00000658-199901000-00001; Block SD, 2006, J PALLIAT MED, V9, P751, DOI 10.1089/jpm.2006.9.751; Breitbart W, 1997, J PAIN SYMPTOM MANAG, V13, P128, DOI 10.1016/S0885-3924(96)00316-8; Bruera E, 2003, J CLIN ONCOL, V21, P4439, DOI 10.1200/JCO.2003.06.156; Bruera E, 2006, J CLIN ONCOL, V24, P2073, DOI 10.1200/JCO.2005.02.8506; Bruera E, 1998, Cancer Prev Control, V2, P74; Bruera E, 2003, J PAIN SYMPTOM MANAG, V26, P1049, DOI 10.1016/S0885-3924(03)00332-4; BRUERA E, 1985, CANCER TREAT REP, V69, P751; BRUERA E, 1992, PAIN, V48, P163, DOI 10.1016/0304-3959(92)90053-E; Bruera E, 2000, J PAIN SYMPTOM MANAG, V19, P427, DOI 10.1016/S0885-3924(00)00138-X; Bruera E, 1991, J Palliat Care, V7, P6; CALMAN KC, 1984, J MED ETHICS, V10, P124, DOI 10.1136/jme.10.3.124; CARDENAS DD, 1982, NEPHRON, V30, P336, DOI 10.1159/000182512; Cella D, 2001, J CLIN ONCOL, V19, P3385, DOI 10.1200/JCO.2001.19.14.3385; Cella D.F, 1997, MANUAL FUNCTIONAL AS; Chang VT, 2000, CANCER, V88, P2164, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5; Coats AJS, 2002, INT J CARDIOL, V85, P133, DOI 10.1016/S0167-5273(02)00242-5; Conill C, 1997, J PAIN SYMPTOM MANAG, V14, P328, DOI 10.1016/S0885-3924(97)00263-7; Coodley GO, 1997, AIDS, V11, P1347, DOI 10.1097/00002030-199711000-00008; Courneya KS, 2003, J CLIN ONCOL, V21, P1660, DOI 10.1200/JCO.2003.04.093; DELLACUNA GR, 1989, EUR J CANCER CLIN ON, V25, P1817; Demetri GD, 1998, J CLIN ONCOL, V16, P3412, DOI 10.1200/JCO.1998.16.10.3412; Dimeo FC, 1999, CANCER, V85, P2273, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2273::AID-CNCR24>3.0.CO;2-B; Dittner AJ, 2004, J PSYCHOSOM RES, V56, P157, DOI 10.1016/S0022-3999(03)00371-4; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; Dunst J, 2000, SEMIN ONCOL, V27, P4; Eisenstaedt R, 2006, BLOOD REV, V20, P213, DOI 10.1016/j.blre.2005.12.002; Fishbain DA, 2005, PAIN MED, V6, P299, DOI 10.1111/j.1526-4637.2005.00044.x; Fishbain DA, 2003, PAIN MED, V4, P51, DOI 10.1046/j.1526-4637.2003.03008.x; Glaus A, 1996, SUPPORT CARE CANCER, V4, P82, DOI 10.1007/BF01845757; Guralnik JM, 2004, BLOOD, V104, P2263, DOI 10.1182/blood-2004-05-1812; Gutstein HB, 2001, CANCER-AM CANCER SOC, V92, P1678, DOI 10.1002/1097-0142(20010915)92:6+<1678::AID-CNCR1496>3.0.CO;2-R; Hamerman D, 1999, J AM GERIATR SOC, V47, P1016, DOI 10.1111/j.1532-5415.1999.tb01299.x; Hann DM, 1998, QUAL LIFE RES, V7, P301, DOI 10.1023/A:1024929829627; Hardy JR, 2001, PALLIATIVE MED, V15, P3, DOI 10.1191/026921601673324846; Homsi J, 2001, Am J Hosp Palliat Care, V18, P403, DOI 10.1177/104990910101800610; Inoue A, 2003, SUPPORT CARE CANCER, V11, P528, DOI 10.1007/s00520-003-0488-y; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Jason L A, 1999, J Health Psychol, V4, P9, DOI 10.1177/135910539900400103; Jenkins C, 1998, J PALLIATIVE CARE, V14, P18, DOI 10.1177/082585979801400104; Jenkins CA, 1998, J PALLIATIVE CARE, V14, P55, DOI 10.1177/082585979801400410; Johnson SK, 1999, ANN BEHAV MED, V21, P258, DOI 10.1007/BF02884843; Kasper S, 2005, AM J GERIAT PSYCHIAT, V13, P884, DOI 10.1176/appi.ajgp.13.10.884; Krupp LB, 2003, CNS DRUGS, V17, P225, DOI 10.2165/00023210-200317040-00002; Lander M, 2000, CLIN GERIATR MED, V16, P335, DOI 10.1016/S0749-0690(05)70060-4; Lawlor PG, 2000, ARCH INTERN MED, V160, P786, DOI 10.1001/archinte.160.6.786; Lawlor PG, 2002, CANCER-AM CANCER SOC, V94, P1836, DOI 10.1002/cncr.10389; Lawrence D.P., 2004, J NATL CANCER INST M, P40; Lee BN, 2004, NEUROIMMUNOMODULAT, V11, P279, DOI 10.1159/000079408; Liao S, 2000, J AM GERIATR SOC, V48, P426, DOI 10.1111/j.1532-5415.2000.tb04702.x; Lissoni P, 1996, EUR J CANCER, V32A, P1340, DOI 10.1016/0959-8049(96)00136-0; MacDonald N, 2003, J AM COLL SURGEONS, V197, P143, DOI 10.1016/S1072-7515(03)00382-X; MACVICAR MG, 1986, CANC B, V385, P235; Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N; Meyers CA, 2005, CANCER-AM CANCER SOC, V104, P788, DOI 10.1002/cncr.21234; Michalaki V, 2004, BRIT J CANCER, V90, P2312, DOI 10.1038/sj.bjc.6601814; Mock V, 2001, CANCER PRACT, V9, P119, DOI 10.1046/j.1523-5394.2001.009003119.x; Mock V, 2005, PSYCHO-ONCOL, V14, P464, DOI 10.1002/pon.863; MOERTEL CG, 1974, CANCER-AM CANCER SOC, V33, P1607, DOI 10.1002/1097-0142(197406)33:6<1607::AID-CNCR2820330620>3.0.CO;2-V; Morley JE, 1999, NUTRITION, V15, P499, DOI 10.1016/S0899-9007(99)00057-X; Morrison RS, 2003, J GERONTOL A-BIOL, V58, P76; Moss RB, 1999, J CLIN IMMUNOL, V19, P314, DOI 10.1023/A:1020595709352; Munch TN, 2005, J PALLIAT MED, V8, P1144, DOI 10.1089/jpm.2005.8.1144; Murtagh John, 2003, Aust Fam Physician, V32, P873; *NAT COMPR CANC NE, 2006, NAT COMPRE CANC NETW; Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945; Neuenschwander H, 1997, SUPPORT CARE CANCER, V5, P252, DOI 10.1007/s005200050069; Oldervoll LM, 2006, J PAIN SYMPTOM MANAG, V31, P421, DOI 10.1016/j.jpainsymman.2005.10.004; Ooi WL, 1997, JAMA-J AM MED ASSOC, V277, P1299, DOI 10.1001/jama.277.16.1299; Osterborg A, 2002, J CLIN ONCOL, V20, P2486, DOI 10.1200/JCO.2002.10.101; Penninx BWJH, 2003, AM J MED, V115, P104, DOI 10.1016/S0002-9343(03)00263-8; Pereira J, 1997, CANCER-AM CANCER SOC, V79, P835; Piper B F, 1998, Oncol Nurs Forum, V25, P677; Plioplys AV, 1997, NEUROPSYCHOBIOLOGY, V35, P16, DOI 10.1159/000119325; POPIELA T, 1989, EUR J CANCER CLIN ON, V25, P1823; Portenoy R K, 1999, Oncologist, V4, P1; Prue G, 2006, EUR J CANCER, V42, P846, DOI 10.1016/j.ejca.2005.11.026; Rammohan KW, 2002, J NEUROL NEUROSUR PS, V72, P179, DOI 10.1136/jnnp.72.2.179; Ream E, 1996, INT J NURS STUD, V33, P519, DOI 10.1016/0020-7489(96)00004-1; REIFE CM, 1995, MED CLIN N AM, V79, P299, DOI 10.1016/S0025-7125(16)30069-4; Respini D, 2003, CRIT REV ONCOL HEMAT, V47, P273, DOI 10.1016/S1040-8428(02)00176-2; ReyesTeran G, 1996, AIDS, V10, P1501, DOI 10.1097/00002030-199611000-00007; ROCKEY DC, 1993, NEW ENGL J MED, V329, P1691, DOI 10.1056/NEJM199312023292303; Schwartz A, 1999, J Nurs Meas, V7, P35; Schwartz Anna L, 2002, Oncol Nurs Forum, V29, pE85, DOI 10.1188/02.ONF.E85-E90; Segal RJ, 2003, J CLIN ONCOL, V21, P1653, DOI 10.1200/JCO.2003.09.534; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; Shasha D, 2003, CANCER, V98, P1072, DOI 10.1002/cncr.11616; Slatkin Neal E, 2003, J Support Oncol, V1, P53; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; SMETS EMA, 1993, BRIT J CANCER, V68, P220, DOI 10.1038/bjc.1993.319; Somogyi-Zalud E, 2000, J AM GERIATR SOC, V48, pS131, DOI 10.1111/j.1532-5415.2000.tb03122.x; Stein KD, 1998, CANCER PRACT, V6, P143, DOI 10.1046/j.1523-5394.1998.006003143.x; Stone P, 2000, ANN ONCOL, V11, P561, DOI 10.1023/A:1008331230608; Strasser F, 2002, HEMATOL ONCOL CLIN N, V16, P589, DOI 10.1016/S0889-8588(02)00011-4; Tisdale MJ, 1997, NUTRITION, V13, P1, DOI 10.1016/S0899-9007(96)00313-9; Tomassini V, 2004, J NEUROL SCI, V218, P103, DOI 10.1016/j.jns.2003.11.005; Valentine AD, 1998, SEMIN ONCOL, V25, P39; Walke LM, 2004, ARCH INTERN MED, V164, P2321, DOI 10.1001/archinte.164.21.2321; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Webster K, 1998, ONCOLOGY-NY, V12, P697; Wigmore SJ, 2000, NUTR CANCER, V36, P177, DOI 10.1207/S15327914NC3602_6; Winningham ML, 2001, CANCER-AM CANCER SOC, V92, P988, DOI 10.1002/1097-0142(20010815)92:4+<988::AID-CNCR1411>3.0.CO;2-O; Wolfe F, 1996, J RHEUMATOL, V23, P1407; Working Group of the Royal Australasian College of Physicians, 2002, MED J AUST S, V176, pS23; WYSENBEEK AJ, 1993, BRIT J RHEUMATOL, V32, P633; Yavuzsen T, 2005, J CLIN ONCOL, V23, P8500, DOI 10.1200/JCO.2005.01.8010; Zakai NA, 2005, ARCH INTERN MED, V165, P2214, DOI 10.1001/archinte.165.19.2214	113	46	46	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	2007	297	3					295	304		10.1001/jama.297.3.295	http://dx.doi.org/10.1001/jama.297.3.295			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	125VT	17227981				2023-01-03	WOS:000243472300024
J	Sandler, A; Gray, R; Perry, MC; Brahmer, J; Schiller, JH; Dowlati, A; Lilenbaum, R; Johnson, DH				Sandler, Alan; Gray, Robert; Perry, Michael C.; Brahmer, Julie; Schiller, Joan H.; Dowlati, Afshin; Lilenbaum, Rogerio; Johnson, David H.			Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	41st Annual Meeting of the American-Society-of-Clinical-Oncology	MAY 13-17, 2005	Orlando, FL	Amer Soc Clin Oncol			ENDOTHELIAL GROWTH-FACTOR; MICROVESSEL DENSITY; BREAST-CANCER; EXPRESSION; RECEPTORS; VEGF; ANTIBODY; THERAPY; TUMORS; TRIAL	BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers. METHODS: Between July 2001 and April 2004, the Eastern Cooperative Oncology Group (ECOG) conducted a randomized study in which 878 patients with recurrent or advanced non-small-cell lung cancer (stage IIIB or IV) were assigned to chemotherapy with paclitaxel and carboplatin alone (444) or paclitaxel and carboplatin plus bevacizumab (434). Chemotherapy was administered every 3 weeks for six cycles, and bevacizumab was administered every 3 weeks until disease progression was evident or toxic effects were intolerable. Patients with squamous-cell tumors, brain metastases, clinically significant hemoptysis, or inadequate organ function or performance status (ECOG performance status, >1) were excluded. The primary end point was overall survival. RESULTS: The median survival was 12.3 months in the group assigned to chemotherapy plus bevacizumab, as compared with 10.3 months in the chemotherapy-alone group (hazard ratio for death, 0.79; P=0.003). The median progression-free survival in the two groups was 6.2 and 4.5 months, respectively (hazard ratio for disease progression, 0.66; P<0.001), with corresponding response rates of 35% and 15% (P<0.001). Rates of clinically significant bleeding were 4.4% and 0.7%, respectively (P<0.001). There were 15 treatment-related deaths in the chemotherapy-plus-bevacizumab group, including 5 from pulmonary hemorrhage. CONCLUSIONS: The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths.	Vanderbilt Univ, Nashville, TN USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Missouri, Ellis Fischel Canc Ctr, Columbia, MO USA; Johns Hopkins Univ, Baltimore, MD USA; Univ Wisconsin, Madison, WI USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Mt Sinai Hosp, Miami, FL USA	Vanderbilt University; Harvard University; Dana-Farber Cancer Institute; University of Missouri System; University of Missouri Columbia; Johns Hopkins University; University of Wisconsin System; University of Wisconsin Madison; University Hospitals of Cleveland	Sandler, A (corresponding author), Vanderbilt Ingram Canc Ctr, 2220 Pierce Ave, Nashville, TN 37232 USA.	alan.sandler@vanderbilt.edu	Johnson, David H./A-7437-2009		NCI NIH HHS [CA49957, CA14548, CA66636, CA21076, CA16116, CA12046, CA23318, CA31946, CA21115] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA014548, U10CA023318, U10CA049957, U10CA016116, U10CA012046, U10CA031946, U10CA066636, U10CA021076, U10CA021115] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Borgstrom P, 1999, ANTICANCER RES, V19, P4203; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; BROWN LF, 1993, CANCER RES, V53, P4727; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Giantonio BJ, 2005, J CLIN ONCOL, V23, p1S; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; James K, 1999, J NATL CANCER I, V91, P523, DOI 10.1093/jnci/91.6.523; Jemal A, 2005, CA-CANCER J CLIN, V55, P259; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; JENNISON C, 1989, J R STAT SOC B, V51, P305; Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022; Jubb AM, 2006, J CLIN ONCOL, V24, P217, DOI 10.1200/JCO.2005.01.5388; Kabbinavar F. F., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P488; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOZLOFF M, 2005, J CLIN ONCOL S, V23, p16S; Mattern J, 1996, BRIT J CANCER, V73, P931, DOI 10.1038/bjc.1996.166; Miller KD, 2005, BREAST CANCER RES TR, V94, pS6; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Seto T, 2006, LUNG CANCER-J IASLC, V53, P91, DOI 10.1016/j.lungcan.2006.02.009; Willett CG, 2004, NAT MED, V10, P649, DOI 10.1038/nm0604-649c; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988	25	4630	4871	9	410	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 14	2006	355	24					2542	2550		10.1056/NEJMoa061884	http://dx.doi.org/10.1056/NEJMoa061884			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	116BZ	17167137				2023-01-03	WOS:000242778800006
J	Ratcliffe, J; Thomas, KJ; MacPherson, H; Brazier, J				Ratcliffe, J.; Thomas, K. J.; MacPherson, H.; Brazier, J.			A randomised controlled trial of acupuncture care for persistent low back pain: cost effectiveness analysis	BRITISH MEDICAL JOURNAL			English	Article							UK		Univ Sheffield, Sch Hlth & Related Res, Sheffield S10 2TN, S Yorkshire, England; Fdn Tradit Chinese Med, York YO24 1ET, N Yorkshire, England	University of Sheffield	Ratcliffe, J (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Sheffield S10 2TN, S Yorkshire, England.	j.ratcliffe@sheffield.ac.uk	brazier, john e/B-1936-2008; Ratcliffe, Julie/G-3169-2017	Ratcliffe, Julie/0000-0001-7365-1988; Brazier, John/0000-0001-8645-4780; MacPherson, Hugh/0000-0003-4255-4768				Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8; *BRIT MED ASS ROYA, 2002, BRIT NAT FORM; *CLIN STAND ADV GR, 1994, BACK PAIN EP COSTS; *DEP HLTH, 1999, PREV BACK PAIN GREAT; Ezzo J, 2000, PAIN, V86, P217, DOI 10.1016/S0304-3959(99)00304-8; Frost H, 2004, BRIT MED J, V329, P708, DOI 10.1136/bmj.38216.868808.7C; Glick H A, 2001, Expert Rev Pharmacoecon Outcomes Res, V1, P25, DOI 10.1586/14737167.1.1.25; HM Treasury, 2003, GREEN BOOK APPR EV C; MacPherson H, 2004, COMPLEMENT THER MED, V12, P136, DOI 10.1016/j.ctim.2004.07.043; Manca A, 2004, BMJ-BRIT MED J, V329, P1381, DOI 10.1136/bmj.38282.607859.AE; Manca A, 2005, APPL HEALTH ECON HEA, V4, P65, DOI 10.2165/00148365-200504020-00001; Maniadakis N, 2000, PAIN, V84, P95, DOI 10.1016/S0304-3959(99)00187-6; MATHEWS JNS, 1990, BRIT MED J, V300, P230; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; National Institute for Clinical Excellence, 2004, GUID METH TECHN APPR; Netten A., 2001, UNIT COSTS HLTH SOCI; *NHS EX, 2004, NHS REF COSTS; *OFF NAT STAT, NEW EARN SURV 2003; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Thomas KJ, 2006, BMJ-BRIT MED J, V333, P623, DOI 10.1136/bmj.38878.907361.7C; Thompson SG, 2000, BRIT MED J, V320, P1197, DOI 10.1136/bmj.320.7243.1197; Wonderling D, 2004, BMJ-BRIT MED J, V328, P747, DOI 10.1136/bmj.38033.896505.EB	22	84	90	1	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 23	2006	333	7569					626	628A		10.1136/bmj.38932.806134.7C	http://dx.doi.org/10.1136/bmj.38932.806134.7C			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	089KD	16980315	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000240878500015
J	Berenguer, C; Boudouresque, F; Dussert, C; Daniel, L; Muracciole, X; Grino, M; Rossi, D; Mabrouk, K; Figarella-Branger, D; Martin, PM; Ouafik, L				Berenguer, C.; Boudouresque, F.; Dussert, C.; Daniel, L.; Muracciole, X.; Grino, M.; Rossi, D.; Mabrouk, K.; Figarella-Branger, D.; Martin, P-M; Ouafik, L'Houcine			Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells	ONCOGENE			English	Article						prostate cancer; LNCaP cells; adrenomedullin; adrenomedullin receptors; neuroendocrine differentiation; LNCaP xenograft; androgen; regulation; cGMP-dependent protein kinase G	DEPENDENT PROTEIN-KINASE; CANCER CELLS; IN-VITRO; DIFFERENTIATION; GENE; ANGIOGENESIS; PROGRESSION; EXPRESSION; PEPTIDE; GROWTH	Neuroendocrine (NE) differentiation in prostate cancer (CaP) has been reported to be an early marker associated with the development of androgen independence. The mechanisms by which CaP acquires NE properties are poorly understood. In this study, a putative role of adrenomedullin (AM) in the NE differentiation was investigated. The expression of AM and AM receptors (calcitonin receptor-like receptor (CRLR)/receptor activity modifying protein-2 and -3 (RAMP2 and RAMP3) was evaluated after experimental manipulation of androgen status. Levels of AM mRNA and immunoreactive AM (ir-AM) increased four-to sevenfold in androgen-sensitive LNCaP cells after androgen withdrawal in vitro and in LNCaP xenograftsin animals after castration. Treatment of LNCaP cells with androgen analogue (dihydrotestosterone; 10(-9) M) prevented the increase in AM mRNA and ir-AM levels. Interestingly, the expression of CRLR, RAMP2 and RAMP3 is not regulated by androgen status. We demonstrate that in the presence of serum, AM is able to induce an NE phenotype in LNCaP cells via CRLR/ RAMP2 and RAMP3, which includes extension of neuritic processes and expression of the neuron-specific enolase (NSE), producing cGMP in a dose-dependent manner, which is mediated by a pertussis toxin-sensitive GTP-binding protein. 8-bromo-cGMP mimicked the effects of AM on cell differentiation. We demonstrate that AM induces a G-kinase I alpha translocation to the nucleus. The protein kinase G inhibitor KT-5823 inhibited the neurite outgrowth induced by both AM and 8-bromo-cGMP. In noncastrated animals, administration of AM enhanced expression of NSE and chromogranin A in LNCaP xenografts with a significant increase of NSE levels in serum and no changes in tumor growth. In castrated animals, intraperitoneal injection of AM resulted in a 240 +/- 18% ( P<0.001) increase in tumor volume 36 days after treatment, indicating that the nature of effect of AM in CaP depends on the presence or absence of endogenous androgen. Together, these results demonstrate that AM may function as a mediator of NE-like differentiation in culture as well as in vivo and indicate that its product ion may be important for tumor resurgence following androgen ablation.	[Berenguer, C.; Boudouresque, F.; Dussert, C.; Martin, P-M; Ouafik, L'Houcine] Univ Aix Marseille 2, Fac Med Secteur Nord, IFR Jean Roche, Expt Cancerol Lab, F-13916 Marseille 20, France; [Berenguer, C.; Boudouresque, F.; Dussert, C.; Martin, P-M; Ouafik, L'Houcine] INSERM E 359, Marseille, France; [Daniel, L.; Figarella-Branger, D.] Univ Aix Marseille 2, Fac Med, Lab Adhes & Signalisat EA3281, Marseille, France; [Muracciole, X.] Assistance Publ Hop Marseille, CHU Timone, Serv Radiotherapie, Marseille, France; [Grino, M.] INSERM, UMR 626, Marseille, France; [Rossi, D.] Assistance Publ Hop Marseille, CHU Nord, Serv Urol, Marseille, France; [Mabrouk, K.] CNRS, FRE 2738, Marseille, France; [Martin, P-M; Ouafik, L'Houcine] Assistance Publ Hop Marseille, CHU Nord, Lab Transfer Oncol Biol & Mol, Marseille, France	UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Ouafik, L (corresponding author), Univ Aix Marseille 2, Fac Med Secteur Nord, IFR Jean Roche, Expt Cancerol Lab, Bd Pierre Dramard, F-13916 Marseille 20, France.	lhoucine.ouafik@univmed.fr	Grino, Michel/GYD-8559-2022; Grino, Michel/O-5361-2017; Grino, Michel/M-7548-2017; Muracciole, Xavier/P-5640-2016; daniel, laurent/R-2826-2016	daniel, laurent/0000-0002-7539-0109; Ouafik, L'Houcine/0000-0002-4848-1232				Abasolo I, 2003, MOL CELL ENDOCRINOL, V199, P179, DOI 10.1016/S0303-7207(02)00229-0; Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; Chung TDK, 1999, PROSTATE, V38, P199; Costantini LC, 2000, EXP NEUROL, V164, P60, DOI 10.1006/exnr.2000.7417; Cox ME, 1999, CANCER RES, V59, P3821; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; Fernandez-Sauze S, 2004, INT J CANCER, V108, P797, DOI 10.1002/ijc.11663; GKONOS PJ, 1995, UROL RES, V23, P81, DOI 10.1007/BF00307937; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Kim J, 2002, CANCER RES, V62, P1549; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Nikitenko LL, 2006, BRIT J CANCER, V94, P1, DOI 10.1038/sj.bjc.6602832; Ouafik L, 2002, AM J PATHOL, V160, P1279, DOI 10.1016/S0002-9440(10)62555-2; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Rocchi P, 2001, CANCER RES, V61, P1196; Spiotto MT, 2000, PROSTATE, V42, P186, DOI 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E	19	34	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					506	518		10.1038/sj.onc.1210656	http://dx.doi.org/10.1038/sj.onc.1210656			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637748				2023-01-03	WOS:000252426100011
J	Grol, R; Berwick, D; Wensing, M				Grol, Richard; Berwick, Donald; Wensing, Michel			On the trail of quality and safety in health care	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SERVICES RESEARCH; IMPROVEMENT		[Grol, Richard; Wensing, Michel] Ctr Qual Care Res, NL-6500 HB Nijmegen, Netherlands; [Berwick, Donald] Inst Healthcare Improvement, Cambridge, MA 02138 USA	Radboud University Nijmegen; Institute for Healthcare Improvement	Grol, R (corresponding author), Ctr Qual Care Res, POB 9101,114, NL-6500 HB Nijmegen, Netherlands.	r.grol@kwazo.umcn.nl	Wensing, Michel/D-3998-2009; Grol, Richard/C-8523-2013; Wensing, Michel/H-8113-2014	Wensing, Michel/0000-0001-6569-8137				Berwick DM, 2005, HEALTH SERV RES, V40, P317, DOI 10.1111/j.1475-6773.2005.0n359.x; Dash P, 2003, BRIT MED J, V327, P1339, DOI 10.1136/bmj.327.7427.1339; Davidoff F, 2005, QUAL SAF HEALTH CARE, V14, P319, DOI 10.1136/qshc.2005.014787; Ferlie EB, 2001, MILBANK Q, V79, P281, DOI 10.1111/1468-0009.00206; Greenhalgh T, 2004, MILBANK Q, V82, P581, DOI 10.1111/j.0887-378X.2004.00325.x; Grimshaw JM, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8060; GROL IR, 2005, IMPROVING PATIENT CA; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Grol R, 1997, BRIT MED J, V315, P418, DOI 10.1136/bmj.315.7105.418; Grol R BR, 2004, QUALITY IMPROVEMENT; Grol RPTM, 2007, MILBANK Q, V85, P93, DOI 10.1111/j.1468-0009.2007.00478.x; Institute of Medicine, 2006, PERF MEAS ACC IMPR; Leatherman Sheila, 2004, BMJ, V328, pE288, DOI 10.1136/bmj.328.7445.E288; Lomas J, 2003, BMJ-BRIT MED J, V327, P1301, DOI 10.1136/bmj.327.7427.1301; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Rosenberg RN, 2003, JAMA-J AM MED ASSOC, V289, P1305, DOI 10.1001/jama.289.10.1305; Schoen C, 2006, HEALTH AFFAIR, V25, pW457, DOI 10.1377/hlthaff.25.w457; Seddon ME, 2001, QUAL HEALTH CARE, V10, P152, DOI 10.1136/qhc.0100152..; Sung NS, 2003, JAMA-J AM MED ASSOC, V289, P1278, DOI 10.1001/jama.289.10.1278; TETROE J, IN PRESS MILBANK Q; van Roosmalen MS, 2007, QUAL SAF HEALTH CARE, V16, P105, DOI 10.1136/qshc.2006.018580	21	88	89	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 12	2008	336	7635					74	76		10.1136/bmj.39413.486944.AD	http://dx.doi.org/10.1136/bmj.39413.486944.AD			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	253BX	18187724	Green Published			2023-01-03	WOS:000252494800027
J	Chan, PS; Krumholz, HM; Nichol, G; Nallamothu, BK				Chan, Paul S.; Krumholz, Harlan M.; Nichol, Graham; Nallamothu, Brahmajee K.		Amer Heart Assoc	Delayed time to defibrillation after in-hospital cardiac arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMERICAN-HEART-ASSOCIATION; HEALTH-CARE PROFESSIONALS; AUSTRALIAN RESUSCITATION COUNCIL; ADVANCED LIFE-SUPPORT; CARDIOPULMONARY-RESUSCITATION; RECOMMENDED GUIDELINES; UTSTEIN STYLE; STROKE FOUNDATION; TASK-FORCE; STATEMENT	Background: Expert guidelines advocate defibrillation within 2 minutes after an in-hospital cardiac arrest caused by ventricular arrhythmia. However, empirical data on the prevalence of delayed defibrillation in the United States and its effect on survival are limited. Methods: We identified 6789 patients who had cardiac arrest due to ventricular fibrillation or pulseless ventricular tachycardia at 369 hospitals participating in the National Registry of Cardiopulmonary Resuscitation. Using multivariable logistic regression, we identified characteristics associated with delayed defibrillation. We then examined the association between delayed defibrillation (more than 2 minutes) and survival to discharge after adjusting for differences in patient and hospital characteristics. Results: The overall median time to defibrillation was 1 minute (interquartile range, <1 to 3 minutes); delayed defibrillation occurred in 2045 patients (30.1%). Characteristics associated with delayed defibrillation included black race, noncardiac admitting diagnosis, and occurrence of cardiac arrest at a hospital with fewer than 250 beds, in an unmonitored hospital unit, and during after-hours periods (5 p.m. to 8 a.m. or weekends). Delayed defibrillation was associated with a significantly lower probability of surviving to hospital discharge (22.2%, vs. 39.3% when defibrillation was not delayed; adjusted odds ratio, 0.48; 95% confidence interval, 0.42 to 0.54; P<0.001). In addition, a graded association was seen between increasing time to defibrillation and lower rates of survival to hospital discharge for each minute of delay (P for trend <0.001). Conclusions: Delayed defibrillation is common and is associated with lower rates of survival after in-hospital cardiac arrest.	St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA; Univ Michigan, Div Cardiovasc Med, Ann Arbor, MI 48109 USA; Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT USA; Yale Univ, Sch Med, Dept Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06510 USA; Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA; Univ Washington, Harborview Ctr Prehosp Emergency Care, Seattle, WA 98195 USA; Vet Affairs Ann Arbor Hlth Serv Res & Dev Ctr Exc, Ann Arbor, MI USA	Saint Luke's Hospital - Missouri; Saint Luke's Mid America Heart Institute; University of Michigan System; University of Michigan; Yale University; Yale University; Yale University; Yale University; Harborview Medical Center; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System	Chan, PS (corresponding author), St Lukes Hosp, Mid Amer Heart Inst, 5th Fl,4401 Wornall Rd, Kansas City, MO 64111 USA.	pchan@cc-pc.com	Nichol, Graham/Z-4996-2019; , Harlan/AAI-2875-2020		NATIONAL CENTER FOR RESEARCH RESOURCES [K12RR017607] Funding Source: NIH RePORTER; NCRR NIH HHS [K12 RR017607-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ballew KA, 1995, RESUSCITATION, V30, P203, DOI 10.1016/0300-9572(95)00894-2; Castren M, 2005, RESUSCITATION, V64, P293, DOI 10.1016/j.resuscitation.2004.08.017; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; Cummins RO, 1997, ANN EMERG MED, V29, P647, DOI 10.1016/S0196-0644(97)70255-5; Cummins RO, 1997, CIRCULATION, V95, P2213, DOI 10.1161/01.CIR.95.8.2213; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; Ewy GA, 2000, J AM COLL CARDIOL, V35, P830; Fredriksson M, 2006, RESUSCITATION, V68, P351, DOI 10.1016/j.resuscitation.2005.07.011; Hajbaghery MA, 2005, RESUSCITATION, V66, P317, DOI 10.1016/j.resuscitation.2005.04.004; Herlitz J, 2005, RESUSCITATION, V66, P159, DOI 10.1016/j.resuscitation.2005.03.018; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; JENNETT B, 1975, LANCET, V1, P480; Kaye W, 2005, RESUSCITATION, V65, P285, DOI 10.1016/j.resuscitation.2004.12.020; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Skrifvars MB, 2003, RESUSCITATION, V56, P275, DOI 10.1016/S0300-9572(02)00373-8; ZARITSKY A, 1995, RESUSCITATION, V30, P95, DOI 10.1016/0300-9572(95)00884-V; ZARITSKY A, 1995, CIRCULATION, V92, P2006, DOI 10.1161/01.CIR.92.7.2006	18	415	427	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 3	2008	358	1					9	17		10.1056/NEJMoa0706467	http://dx.doi.org/10.1056/NEJMoa0706467			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246TW	18172170	Bronze			2023-01-03	WOS:000252031200003
J	Cunningham, D; Starling, N; Rao, S; Iveson, T; Nicolson, M; Coxon, F; Middleton, G; Daniel, F; Oates, J; Norman, AR				Cunningham, David; Starling, Naureen; Rao, Sheela; Iveson, Timothy; Nicolson, Marianne; Coxon, Fareeda; Middleton, Gary; Daniel, Francis; Oates, Jacqueline; Norman, Andrew Richard		Natl Canc Res Inst United Kingdom	Capecitabine and oxaliplatin for advanced esophagogastric cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METASTATIC COLORECTAL-CANCER; ORAL FLUOROPYRIMIDINE CARBAMATE; FLUOROURACIL PLUS LEUCOVORIN; ADVANCED GASTRIC-CANCER; PHASE-III; INTRAVENOUS FLUOROURACIL; 1ST-LINE THERAPY; SUPPORTIVE CARE; FINAL REPORT; CISPLATIN	Background: We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for untreated advanced esophagogastric cancer. Methods: In a two-by-two design, we randomly assigned 1002 patients to receive triplet therapy with epirubicin and cisplatin plus either fluorouracil (ECF) or capecitabine (ECX) or triplet therapy with epirubicin and oxaliplatin plus either fluorouracil (EOF) or capecitabine (EOX). The primary end point was noninferiority in overall survival for the triplet therapies containing capecitabine as compared with fluorouracil and for those containing oxaliplatin as compared with cisplatin. Results: For the capecitabine-fluorouracil comparison, the hazard ratio for death in the capecitabine group was 0.86 (95% confidence interval [CI], 0.80 to 0.99); for the oxaliplatin-cisplatin comparison, the hazard ratio for the oxaliplatin group was 0.92 (95% CI, 0.80 to 1.10). The upper limit of the confidence intervals for both hazard ratios excluded the predefined noninferiority margin of 1.23. Median survival times in the ECF, ECX, EOF, and EOX groups were 9.9 months, 9.9 months, 9.3 months, and 11.2 months, respectively; survival rates at 1 year were 37.7%, 40.8%, 40.4%, and 46.8%, respectively. In the secondary analysis, overall survival was longer with EOX than with ECF, with a hazard ratio for death of 0.80 in the EOX group (95% CI, 0.66 to 0.97; P=0.02). Progression-free survival and response rates did not differ significantly among the regimens. Toxic effects of capecitabine and fluorouracil were similar. As compared with cisplatin, oxaliplatin was associated with lower incidences of grade 3 or 4 neutropenia, alopecia, renal toxicity, and thromboembolism but with slightly higher incidences of grade 3 or 4 diarrhea and neuropathy. Conclusions: Capecitabine and oxaliplatin are as effective as fluorouracil and cisplatin, respectively, in patients with previously untreated esophagogastric cancer. (Current Controlled Trials number, ISRCTN51678883.).	Royal Marsden Hosp Natl Hlth Serv Fdn Trust, Surrey, England; Royal Marsden Hosp Natl Hlth Serv Fdn Trust, London, England; Southampton Univ Hosp Natl Hlth Serv Trust, Southampton, Hants, England; Salisbury Hosp Natl Hlth Serv Fdn Trust, Salisbury, Wilts, England; Aberdeen Royal Infirm, Aberdeen, Scotland; No Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England; St Lukes Canc Ctr, Guildford, Surrey, England; Plymouth Oncol Ctr, Plymouth, Devon, England	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of Southampton; University Hospital Southampton NHS Foundation Trust; Salisbury District Hospital; University of Aberdeen	Cunningham, D (corresponding author), Royal Marsden Hosp Natl Hlth Serv Fdn Trust, Surrey, England.			Middleton, Gary/0000-0001-5695-3474; Starling, Naureen/0000-0002-1496-6792; Cunningham, David/0000-0001-5158-1069; Iveson, Timothy/0000-0002-4681-2712				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; ALBATRAN S, 2006, J CLIN ONCOL, V24, pS18; Borner MM, 2002, EUR J CANCER, V38, P349, DOI 10.1016/S0959-8049(01)00371-9; Budman DR, 1998, J CLIN ONCOL, V16, P1795, DOI 10.1200/JCO.1998.16.5.1795; CASSIDY J, 2007, J CLIN ONCOL S, V25, pS18; Cho EK, 2005, ONCOLOGY-BASEL, V68, P333, DOI 10.1159/000086972; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; Dank M, 2005, J CLIN ONCOL, V23, p308S; Diaz-Rubio E, 2007, J CLIN ONCOL, V25, P4224, DOI 10.1200/JCO.2006.09.8467; Evans TRJ, 2002, ANN ONCOL, V13, P1469, DOI 10.1093/annonc/mdf243; Glimelius B, 1997, ANN ONCOL, V8, P163, DOI 10.1023/A:1008243606668; Hoff PM, 2001, J CLIN ONCOL, V19, P2282, DOI 10.1200/JCO.2001.19.8.2282; Kang Y, 2006, J CLIN ONCOL, V24, p183S; Liu G, 1997, J CLIN ONCOL, V15, P110, DOI 10.1200/JCO.1997.15.1.110; Miwa M, 1998, EUR J CANCER, V34, P1274, DOI 10.1016/S0959-8049(98)00058-6; MURAD AM, 1993, CANCER, V72, P37, DOI 10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Porschen R, 2007, J CLIN ONCOL, V25, P4217, DOI 10.1200/JCO.2006.09.2684; PYRHONEN S, 1995, BRIT J CANCER, V71, P587, DOI 10.1038/bjc.1995.114; Ross P, 2002, J CLIN ONCOL, V20, P1996, DOI 10.1200/JCO.2002.08.105; Sumpter K, 2005, BRIT J CANCER, V92, P1976, DOI 10.1038/sj.bjc.6602572; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Twelves C, 2005, NEW ENGL J MED, V352, P2696, DOI 10.1056/NEJMoa043116; Van Cutsem E, 2001, J CLIN ONCOL, V19, P4097, DOI 10.1200/JCO.2001.19.21.4097; Van Cutsem E, 2006, J CLIN ONCOL, V24, P4991, DOI 10.1200/JCO.2006.06.8429; Wagner AD, 2006, J CLIN ONCOL, V24, P2903, DOI 10.1200/JCO.2005.05.0245; Webb A, 1997, J CLIN ONCOL, V15, P261, DOI 10.1200/JCO.1997.15.1.261	27	1688	1766	0	63	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 3	2008	358	1					36	46		10.1056/NEJMoa073149	http://dx.doi.org/10.1056/NEJMoa073149			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246TW	18172173				2023-01-03	WOS:000252031200006
J	Ahmed, N; Saini, V; Raghuvanshi, S; Khurana, JP; Tyagi, AK; Tyagi, AK; Hasnain, SE				Ahmed, Niyaz; Saini, Vikram; Raghuvanshi, Saurabh; Khurana, Jitendra P.; Tyagi, Akhilesh K.; Tyagi, Anil K.; Hasnain, Seyed E.			Molecular Analysis of a Leprosy Immunotherapeutic Bacillus Provides Insights into Mycobacterium Evolution	PLOS ONE			English	Article							PHYLOGENETIC ANALYSIS; TUBERCULOSIS COMPLEX; GENETIC-ANALYSIS; GYRB GENES; VACCINE; IDENTIFICATION; POLYMORPHISM; MULTIDRUG; SEQUENCES; BCG	Background. Evolutionary dynamics plays a central role in facilitating the mechanisms of species divergence among pathogenic and saprophytic mycobacteria. The ability of mycobacteria to colonize hosts, to proliferate and to cause diseases has evolved due to its predisposition to various evolutionary forces acting over a period of time. Mycobacterium indicus pranii (MIP), a taxonomically unknown 'generalist' mycobacterium, acts as an immunotherapeutic against leprosy and is approved for use as a vaccine against it. The large-scale field trials of this MIP based leprosy vaccine coupled with its demonstrated immunomodulatory and adjuvant property has led to human clinical evaluations of MIP in interventions against HIV-AIDS, psoriasis and bladder cancer. MIP, commercially available as 'Immuvac', is currently the focus of advanced phase III clinical trials for its antituberculosis efficacy. Thus a comprehensive analysis of MIP vis-a-vis evolutionary path, underpinning its immanent immunomodulating properties is of the highest desiderata. Principal Findings. Genome wide comparisons together with molecular phylogenetic analyses by fluorescent amplified fragment length polymorphism (FAFLP), enterobacterial repetitive intergenic consensus (ERIC) based genotyping and candidate orthologues sequencing revealed that MIP has been the predecessor of highly pathogenic Mycobacterium avium intracellulare complex (MAIC) that did not resort to parasitic adaptation by reductional gene evolution and therefore, preferred a free living life-style. Further analysis suggested a shared aquatic phase of MAIC bacilli with the early pathogenic forms of Mycobacterium, well before the latter diverged as 'specialists'. Conclusions/Significance. This evolutionary paradigm possibly affirms to marshal our understanding about the acquisition and optimization of virulence in mycobacteria and determinants of boundaries therein.	[Hasnain, Seyed E.] Univ Hyderabad, Hyderabad 500134, Andhra Pradesh, India; [Ahmed, Niyaz] Ctr DNA Fingerprinting & Diagnost CDFD, Pathogen Evolut Lab, Hyderabad, Andhra Pradesh, India; [Saini, Vikram; Raghuvanshi, Saurabh; Khurana, Jitendra P.; Tyagi, Akhilesh K.] Univ Delhi, Interdisciplinary Ctr Plant Gen, Dept Plant Mol Biol, New Delhi, India; [Saini, Vikram; Tyagi, Anil K.] Univ Delhi, Dept Biochem, New Delhi, India; [Hasnain, Seyed E.] Univ Hyderabad, Inst Life Sci, Hyderabad 500134, Andhra Pradesh, India; [Hasnain, Seyed E.] Indian Inst Sci, Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560012, Karnataka, India	University of Hyderabad; Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD); University of Delhi; University of Delhi; University of Hyderabad; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); Indian Institute of Science (IISC) - Bangalore	Hasnain, SE (corresponding author), Univ Hyderabad, Hyderabad 500134, Andhra Pradesh, India.	vc@uohyd.ernet.in	Saini, Vikram/B-4547-2009; Ahmed, Niyaz/D-2589-2010	Saini, Vikram/0000-0002-0258-2871; Ahmed, Niyaz/0000-0001-6425-7583; Hasnain, Seyed/0000-0002-2967-0791	Department of Biotechnology of the Indian Ministry of Science and Technology [BT/PR4127/MED/12/165/2003]; CSIR, India	Department of Biotechnology of the Indian Ministry of Science and Technology(Department of Biotechnology (DBT) India); CSIR, India(Council of Scientific & Industrial Research (CSIR) - India)	This work was supported by a research grant (BT/PR4127/MED/12/165/2003) to NA, JPK, AKT, AKT and SEH from the Department of Biotechnology of the Indian Ministry of Science and Technology. VS acknowledges CSIR, India for research studentship (CSIR JRF/SRF).	Ahmed N, 2003, INFECT GENET EVOL, V2, P193, DOI 10.1016/S1567-1348(02)00100-4; Akbar S, 1997, MOL MICROBIOL, V24, P567, DOI 10.1046/j.1365-2958.1997.3631732.x; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; Chaudhuri Prabir, 2003, J Indian Med Assoc, V101, P559; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cousins DV, 2003, INT J SYST EVOL MICR, V53, P1305, DOI 10.1099/ijs.0.02401-0; Dagan T, 2006, MOL BIOL EVOL, V23, P310, DOI 10.1093/molbev/msj036; Danelishvili L, 2007, P NATL ACAD SCI USA, V104, P11038, DOI 10.1073/pnas.0610746104; de Bruyn G, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001166; Devulder G, 2005, INT J SYST EVOL MICR, V55, P293, DOI 10.1099/ijs.0.63222-0; Flint JL, 2004, P NATL ACAD SCI USA, V101, P12598, DOI 10.1073/pnas.0404892101; French MA, 2004, AIDS, V18, P1615, DOI 10.1097/01.aids.0000131375.21070.06; Gutierrez MC, 2005, PLOS PATHOG, V1, P55, DOI 10.1371/journal.ppat.0010005; Kaufmann SHE, 2005, NAT MED, V11, pS33, DOI 10.1038/nm1221; Kharkar Rajendra, 2002, J Indian Med Assoc, V100, P578; Kong Y, 2006, J CLIN MICROBIOL, V44, P3940, DOI 10.1128/JCM.01146-06; KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; Marri PR, 2006, CAN J MICROBIOL, V52, P560, DOI 10.1139/W06-001; Matte-Tailliez O, 2002, MOL BIOL EVOL, V19, P631, DOI 10.1093/oxfordjournals.molbev.a004122; Patel Naresh, 2002, J Indian Med Assoc, V100, P191; Rao KR, 2005, J CLIN MICROBIOL, V43, P5978, DOI 10.1128/JCM.43.12.5978-5982.2005; Rath N, 2003, INT J DERMATOL, V42, P756; Raviglione MC, 2007, NEW ENGL J MED, V356, P656, DOI 10.1056/NEJMp068273; REDDI PP, 1994, INT J LEPROSY, V62, P229; Rook GAW, 2007, IMMUNOBIOLOGY, V212, P461, DOI 10.1016/j.imbio.2007.03.003; Rosas-Magallanes V, 2006, MOL BIOL EVOL, V23, P1129, DOI 10.1093/molbev/msj120; Sechi LA, 1998, J CLIN MICROBIOL, V36, P128, DOI 10.1128/JCM.36.1.128-132.1998; Sharma P, 2005, LEPROSY REV, V76, P127; Siddiqi N, 1998, MEM I OSWALDO CRUZ, V93, P589, DOI 10.1590/S0074-02761998000500006; SINGH IG, 1992, INFECT IMMUN, V60, P257, DOI 10.1128/IAI.60.1.257-263.1992; SOINI H, 1994, J CLIN MICROBIOL, V32, P2944, DOI 10.1128/JCM.32.12.2944-2947.1994; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; Stinear TP, 2000, J BACTERIOL, V182, P6322, DOI 10.1128/JB.182.22.6322-6330.2000; Talwar G P, 1999, Int Rev Immunol, V18, P229, DOI 10.3109/08830189909043027; TALWAR GP, 1990, VACCINE, V8, P121, DOI 10.1016/0264-410X(90)90134-8; Talwar GP, 2008, INFECT GENET EVOL, V8, P100, DOI 10.1016/j.meegid.2007.07.009; YADAVA A, 1991, SCAND J IMMUNOL, V34, P23, DOI 10.1111/j.1365-3083.1991.tb01517.x; Yamamoto S, 1996, INT J SYST BACTERIOL, V46, P506, DOI 10.1099/00207713-46-2-506; YAMAMOTO S, 1995, APPL ENVIRON MICROB, V61, P1104, DOI 10.1128/AEM.61.3.1104-1109.1995; ZAHEER SA, 1993, J INFECT DIS, V167, P401, DOI 10.1093/infdis/167.2.401	42	32	33	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2007	2	10							e968	10.1371/journal.pone.0000968	http://dx.doi.org/10.1371/journal.pone.0000968			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HU	17912347	Green Published, gold, Green Submitted			2023-01-03	WOS:000207455900006
J	Roberts, WT; Timmis, AD				Roberts, Will T.; Timmis, Adam D.			Change page - Patients with cardiac chest pain should call emergency services	BRITISH MEDICAL JOURNAL			English	Editorial Material									London Chest Hosp, Dept Cardiol, London E2 9JX, England	University of London; Queen Mary University London	Timmis, AD (corresponding author), London Chest Hosp, Dept Cardiol, London E2 9JX, England.	adamtimmis@mac.com							0	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 29	2007	335	7621					669	669		10.1136/bmj.39342.693252.47	http://dx.doi.org/10.1136/bmj.39342.693252.47			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	218AY	17901519	Green Published			2023-01-03	WOS:000249989600045
J	van der Worp, HB; van Gijn, J				van der Worp, H. Bart; van Gijn, Jan			Acute ischemic stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MIDDLE CEREBRAL-ARTERY; COMPUTED-TOMOGRAPHY; POOLED ANALYSIS; INFARCTION; THROMBOEMBOLISM; HYPERGLYCEMIA; THROMBOLYSIS; METAANALYSIS; ASSOCIATION; PROGNOSIS		Univ Med Ctr Utrecht, Dept Neurol, Rudolf Magnus Inst Neurosci, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	van der Worp, HB (corresponding author), Univ Med Ctr Utrecht, Dept Neurol, Rudolf Magnus Inst Neurosci, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	h.b.vanderworp@umcutrecht.nl	van Gijn, Jan/A-9444-2008					Adams, 2007, STROKE, V38, pE38, DOI 10.1161/STROKEAHA.106.110011; Adams HP, 2007, STROKE, V38, P1655, DOI 10.1161/STROKEAHA.107.181486; Albers GW, 2006, ANN NEUROL, V60, P508, DOI 10.1002/ana.20976; Alexandrov AV, 2004, NEW ENGL J MED, V351, P2170, DOI 10.1056/NEJMoa041175; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Broderick J, 2004, STROKE, V35, P904, DOI 10.1161/01.STR.0000121641.77121.98; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Chalela JA, 2007, LANCET, V369, P293, DOI 10.1016/S0140-6736(07)60151-2; Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5; Chen ZM, 2000, STROKE, V31, P1240, DOI 10.1161/01.STR.31.6.1240; Clarke J, 2005, LANCET, V365, P764, DOI 10.1016/S0140-6736(05)17983-5; Dennis M, 2005, LANCET, V365, P755, DOI 10.1016/S0140-6736(05)17982-3; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Douglas VC, 2005, NEUROLOGY, V64, P422, DOI 10.1212/01.WNL.0000150903.38639.E1; Feigin VL, 2003, LANCET NEUROL, V2, P43, DOI 10.1016/S1474-4422(03)00266-7; Flint AC, 2007, STROKE, V38, P1274, DOI 10.1161/01.STR.0000260187.33864.a7; Francis CW, 2007, NEW ENGL J MED, V356, P1438, DOI 10.1056/NEJMcp067264; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; Graham GD, 2003, STROKE, V34, P2847, DOI 10.1161/01.STR.0000101752.23813.C3; Gray CS, 2004, STROKE, V35, P122, DOI 10.1161/01.STR.0000106916.81680.C0; GUBITZ G, 2004, COCHRANE DB SYST REV, V3; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Hacke W, 2003, CEREBROVASC DIS, V16, P311, DOI 10.1159/000072554; Hacke W, 2004, LANCET, V363, P768; Halkes PHA, 2006, LANCET, V367, P1665; HANKEY GJ, 1990, BMJ-BRIT MED J, V300, P1485, DOI 10.1136/bmj.300.6738.1485; Hofmeijer J, 2003, CRIT CARE MED, V31, P617, DOI 10.1097/01.CCM.0000050446.16158.80; Holzer M, 2002, NEW ENGL J MED, V346, P549; Johnston SC, 2002, NEW ENGL J MED, V347, P1687, DOI 10.1056/NEJMcp020891; Kelly J, 2001, STROKE, V32, P262, DOI 10.1161/01.STR.32.1.262; Khatri P, 2007, STROKE, V38, P431, DOI 10.1161/01.STR.0000254524.23708.c9; Kidwell CS, 2003, STROKE, V34, P2729, DOI 10.1161/01.STR.0000097608.38779.CC; Lees KR, 2006, NEW ENGL J MED, V354, P588, DOI 10.1056/NEJMoa052980; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Molina CA, 2006, STROKE, V37, P425, DOI 10.1161/01.STR.0000199064.94588.39; Muir KW, 2006, LANCET NEUROL, V5, P755, DOI 10.1016/S1474-4422(06)70545-2; Norrving B, 2003, LANCET NEUROL, V2, P238, DOI 10.1016/S1474-4422(03)00352-1; O'Collins VE, 2006, ANN NEUROL, V59, P467, DOI 10.1002/ana.20741; Paciaroni M, 2007, STROKE, V38, P423, DOI 10.1161/01.STR.0000254600.92975.1f; Patel SC, 2001, JAMA-J AM MED ASSOC, V286, P2830, DOI 10.1001/jama.286.22.2830; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Sacco RL, 2006, STROKE, V37, P577, DOI 10.1161/01.STR.0000199147.30016.74; Sandercock P, 1997, LANCET, V349, P1569; Shuaib A, 2007, NEW ENGL J MED, V357, P562, DOI 10.1056/NEJMoa070240; *STROK UN TRIAL CO, 2002, COCHRANE DB SYST REV, V1; The ESPRIT Study Group, 2007, LANCET, V369, P274; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; van Breda Eric J, 2005, BMC Cardiovasc Disord, V5, P24, DOI 10.1186/1471-2261-5-24; VANDERWORP HB, IN PRESS BRAIN; Wahlgren N, 2007, LANCET, V369, P826; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4; Wardlaw J M, 2003, Cochrane Database Syst Rev, pCD000213; Willmot M, 2004, HYPERTENSION, V43, P18, DOI 10.1161/01.HYP.0000105052.65787.35; Wintermark M, 2006, STROKE, V37, P979, DOI 10.1161/01.STR.0000209238.61459.39	58	195	207	1	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 9	2007	357	6					572	579		10.1056/NEJMcp072057	http://dx.doi.org/10.1056/NEJMcp072057			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	197VP	17687132				2023-01-03	WOS:000248584900008
J	Catovsky, D; Richards, S; Matutes, E; Oscier, D; Dyer, MJS; FBezares, R; Pettitt, AR; Hamblin, T; Milligan, DW; Child, JA; Hamilton, MS; Dearden, CE; Smith, AG; Bosanquet, AG; Davis, Z; Brito-Babapulle, V; Else, M; Wade, R; Hillmen, P				Catovsky, D.; Richards, S.; Matutes, E.; Oscier, D.; Dyer, M. J. S.; FBezares, R.; Pettitt, A. R.; Hamblin, T.; Milligan, D. W.; Child, J. A.; Hamilton, M. S.; Dearden, C. E.; Smith, A. G.; Bosanquet, A. G.; Davis, Z.; Brito-Babapulle, V.; Else, M.; Wade, R.; Hillmen, P.		NCRI Haematological Oncol; NCRI Chronic Lymphocytic	Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial	LANCET			English	Article							GENE MUTATION STATUS; 1ST-LINE THERAPY; REGIMEN; CHEMOIMMUNOTHERAPY; COMBINATION; CLADRIBINE; RITUXIMAB; ZAP-70; CHLORAMBUCIL; MULTICENTER	Background Previous studies of patients with chronic lymphocytic leukaemia reported high response rates to fludarabine combined with cyclophosphamide. We aimed to establish whether this treatment combination provided greater survival benefit than did chlorambucil or fludarabine. Methods 777 patients with chronic lymphocytic leukaemia requiring treatment were randomly assigned to fludarabine (n=194) or fludarabine plus cyclophosphamide (196) for six courses, or chlorambucil (387) for 12 courses. The primary endpoint was overall survival, with secondary endpoints of response rates, progression-free survival, toxic effects, and quality of life. Analysis was by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number NCT 58585610. Findings There was no significant difference in overall survival between patients given fludarabine plus cyclophosphamide, fludarabine, or chlorambucil. Complete and overall response rates were better with fludarabine plus cyclophosphamide than with fludarabine (complete response rate 38% vs 15%, respectively; overall response rate 94% vs 80%, respectively; p < 0.0001 for both comparisons), which were in turn better than with chlorambucil (complete response rate 7%, overall response rate 72%; p=0.006 and 0.04, respectively). Progression-free survival at 5 years was significantly better with fludarabine plus cyclophosphamide (36%) than with fludarabine (10%) or chlorambucil (10%; p < 0.00005). Fludarabine plus cyclophosphamide was the best combination for all ages, including patients older than 70 years, and in prognostic groups defined by immunoglobulin heavy chain gene (V,,) mutation status and cytogenetics, which were tested in 533 and 579 cases, respectively. Patients had more neutropenia and days in hospital with fludarabine plus cyclophosphamide, or fludarabine, than with chlorambucil. There was less haemolytic anaemia with fludarabine plus cyclophosphamide (5%) than with fludarabine (11%) or chlorambucil (12%). Quality of life was better for responders, but preliminary analyses showed no significant difference between treatments. A meta-analysis of these data and those of two published phase III trials showed a consistent benefit for the fludarabine plus cyclophosphamide regimen in terms of progression-free survival. Interpretation Fludarabine plus cyclophosphamide should now become the standard treatment for chronic lymphocytic leukaemia and the basis for new protocols that incorporate monoclonal antibodies.	Inst Canc Res, Sect Haematooncol, Sutton SM2 5NG, Surrey, England; Clin Trial Serv Unit, Oxford, England; Royal Bournemouth Hosp, Bournemouth, Dorset, England; Leicester Royal Infirm, Leicester, Leics, England; Hosp Alvarez, Buenos Aires, DF, Argentina; Univ Liverpool, Liverpool L69 3BX, Merseyside, England; Birmingham Heartlands Hosp, Birmingham B9 5ST, W Midlands, England; Gen Infirm, Leeds LS1 3EX, W Yorkshire, England; Southampton Gen Hosp, Southampton SO9 4XY, Hants, England; Bath Canc Res, Bath, Avon, England; Good Hope Hosp, Sutton Coldfield, England	University of London; Institute of Cancer Research - UK; University of Oxford; University of Leicester; University of Liverpool; Heart of England NHS Foundation Trust; University of Birmingham; Leeds General Infirmary; University of Southampton; Heart of England NHS Foundation Trust; Good Hope Hospital	Catovsky, D (corresponding author), Inst Canc Res, Sect Haematooncol, Brookes Lawley Bldg,15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	daniel.catovsky@icr.ac.uk	; Dyer, Martin/F-2691-2014	Wade, Rachel/0000-0001-9826-6322; Dyer, Martin/0000-0002-5033-2236	Medical Research Council [MC_U132670597, MC_U137686856] Funding Source: Medline; MRC [MC_U132670597, MC_U137686856] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ABE O, 1992, LANCET, V339, P71; [Anonymous], 1999, J Natl Cancer Inst, V91, P861; [Anonymous], 1988, BRIT MED J, V296, P320; Barlogie B, 2006, NEW ENGL J MED, V354, P1021, DOI 10.1056/NEJMoa053583; Byrd JC, 2006, J CLIN ONCOL, V24, P437, DOI 10.1200/JCO.2005.03.1021; Cheson BD, 1996, BLOOD, V87, P4990, DOI 10.1182/blood.V87.12.4990.bloodjournal87124990; Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056/NEJMoa023143; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Eichhorst BF, 2006, BLOOD, V107, P885, DOI 10.1182/blood-2005-06-2395; Flinn IW, 2007, J CLIN ONCOL, V25, P793, DOI 10.1200/JCO.2006.08.0762; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; Hillmen P, 2005, BLOOD, V106, p214A; Johnson S, 1996, Lancet, V347, P1432; Keating MJ, 2005, J CLIN ONCOL, V23, P4079, DOI 10.1200/JCO.2005.12.051; Krober A, 2006, J CLIN ONCOL, V24, P969, DOI 10.1200/JCO.2005.03.7184; Leporrier M, 2001, BLOOD, V98, P2319, DOI 10.1182/blood.V98.8.2319; Lozanski G, 2004, BLOOD, V103, P3278, DOI 10.1182/blood-2003-10-3729; Machin D., 1987, STAT TABLES DESIGN C; Moreau EJ, 1997, AM J CLIN PATHOL, V108, P378; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; O'Brien SM, 2001, J CLIN ONCOL, V19, P1414, DOI 10.1200/JCO.2001.19.5.1414; Oscier DG, 2006, BLOOD, V108, P299; Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139; Osuji NC, 2005, HAEMATOLOGICA, V90, P1435; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Pettitt AR, 2006, LEUKEMIA, V20, P1441, DOI 10.1038/sj.leu.2404265; Rai KR, 2000, NEW ENGL J MED, V343, P1750, DOI 10.1056/NEJM200012143432402; Rassenti LZ, 2004, NEW ENGL J MED, V351, P893, DOI 10.1056/NEJMoa040857; Robak T, 2000, BLOOD, V96, P2723; Robak T, 2006, BLOOD, V108, P473, DOI 10.1182/blood-2005-12-4828; Robak T, 2005, HAEMATOLOGICA, V90, P994; Steurer M, 2006, CANCER TREAT REV, V32, P377, DOI 10.1016/j.ctrv.2006.05.002; Wierda W, 2005, J CLIN ONCOL, V23, P4070, DOI 10.1200/JCO.2005.12.516; Zhu Q, 2004, LEUKEMIA LYMPHOMA, V45, P2239, DOI 10.1080/10428190412331283260	35	573	601	0	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 21	2007	370	9583					230	239		10.1016/S0140-6736(07)61125-8	http://dx.doi.org/10.1016/S0140-6736(07)61125-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	194MG	17658394				2023-01-03	WOS:000248347900027
J	Richards, T				Richards, Tessa			Who is at the helm on patient journeys?	BRITISH MEDICAL JOURNAL			English	Editorial Material												trichards@bmj.com						2007, BRIT MED J, V334, P1130	1	3	3	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 14	2007	335	7610					76	76		10.1136/bmj.39272.484248.59	http://dx.doi.org/10.1136/bmj.39272.484248.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192JM	17626961	Green Published			2023-01-03	WOS:000248197500031
J	Spinewine, A; Schmader, KE; Barber, N; Hughes, C; Lapane, KL; Swine, C; Hanlon, JT				Spinewine, Anne; Schmader, Kenneth E.; Barber, Nick; Hughes, Carmel; Lapane, Kate L.; Swine, Christian; Hanlon, Joseph T.			Prescribing in elderly people 1 - Appropriate prescribing in elderly people: how well can it be measured and optimised?	LANCET			English	Review							RANDOMIZED CONTROLLED-TRIAL; INAPPROPRIATE MEDICATION USE; DRUG-RELATED MORBIDITY; NURSING-HOME RESIDENTS; QUALITY-OF-CARE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CLINICAL PHARMACIST INTERVENTION; HOSPITALIZED OLDER-ADULTS; LONG-TERM-CARE; POTENTIALLY INAPPROPRIATE	Prescription of medicines is a fundamental component of the care of elderly people, and optimisation of drug prescribing for this group of patients has become an important public-health issue worldwide. Several characteristics of ageing and geriatric medicine affect medication prescribing for elderly people and render the selection of appropriate pharmacotherapy a challenging and complex process. In the first paper in this series we aim to define and categorise appropriate prescribing in elderly people, critically review the instruments that are available to measure it and discuss their predictive validity, critically review recent randomised controlled intervention studies that assessed the effect of optimisation strategies on the appropriateness of prescribing in elderly people, and suggest directions for future research and practice.	Catholic Univ Louvain, Ctr Clin Pharm, Sch Pharm, B-1200 Brussels, Belgium; Duke Univ, Med Ctr, Sch Med, Dept Geriatr Med, Durham, England; Duke Univ, Med Ctr, Aging Ctr, Durham, England; Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC USA; Univ London, Sch Pharm, Dept Practice & Policy, London, England; Queens Univ, Sch Pharm, Belfast, Antrim, North Ireland; Brown Med Sch, Dept Community Hlth, Providence, RI USA; Catholic Univ Louvain, Mt Godinne Univ Hosp, Dept Geriatr Med, B-1200 Brussels, Belgium; Univ Pittsburgh, Inst Aging, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Geriatr Med, Pittsburgh, PA USA; Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA USA; Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res, Pittsburgh, PA USA; Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA	Universite Catholique Louvain; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of London; University College London; University of London School of Pharmacy; Queens University Belfast; Brown University; Universite Catholique Louvain; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System	Spinewine, A (corresponding author), Catholic Univ Louvain, Ctr Clin Pharm, Sch Pharm, UCL 73-70,Ave E Mounier 73, B-1200 Brussels, Belgium.	anne.spinewine@facm.ucl.ac.be			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS016394] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD049109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI051324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027017, R01AG014158, P30AG024827] Funding Source: NIH RePORTER; AHRQ HHS [U18HS016394] Funding Source: Medline; NIAID NIH HHS [K24AI051324-01] Funding Source: Medline; NIA NIH HHS [R01 AG027017, P30 AG024827, R01AG14158] Funding Source: Medline; NICHD NIH HHS [K12HD049109] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Allard J, 2001, CAN MED ASSOC J, V164, P1291; Anderson G M, 1997, J Eval Clin Pract, V3, P283, DOI 10.1046/j.1365-2753.1997.t01-1-00005.x; Andrade SE, 2003, ARCH INTERN MED, V163, P2052, DOI 10.1001/archinte.163.17.2052; [Anonymous], CONSULT PHARM; [Anonymous], 2003, PRINCIPLES GERIATRIC; Aparasu Rajender R, 2004, Am J Geriatr Pharmacother, V2, P102, DOI 10.1016/S1543-5946(04)90015-3; Barber N, 2005, J CLIN PHARM THER, V30, P533, DOI 10.1111/j.1365-2710.2005.00681.x; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; BEERS MH, 1993, J AM GERIATR SOC, V41, P802, DOI 10.1111/j.1532-5415.1993.tb06173.x; Bernabei R, 1999, J GERONTOL A-BIOL, V54, pM25, DOI 10.1093/gerona/54.1.M25; Blakey SA, 2000, PHARMACOTHERAPY, V20, P1198, DOI 10.1592/phco.20.15.1198.34581; Bogardus ST, 2004, J AM GERIATR SOC, V52, P99, DOI 10.1111/j.1532-5415.2004.52017.x; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; BRADLEY EH, 2004, ISSUE BRIEF COMMONW, V724, P1; Bregnhoj L, 2005, EUR J CLIN PHARMACOL, V61, P769, DOI 10.1007/s00228-005-0963-0; Briesacher BA, 2005, ARCH INTERN MED, V165, P1280, DOI 10.1001/archinte.165.11.1280; Britten N, 2003, QUAL SAF HEALTH CARE, V12, P246, DOI 10.1136/qhc.12.4.246; BROOK RH, 1977, NEW ENGL J MED, V296, P170, DOI 10.1056/NEJM197701202960311; Buetow SA, 1997, SOC SCI MED, V45, P261, DOI 10.1016/S0277-9536(96)00342-5; Bungard TJ, 2001, DRUGS, V61, P2021, DOI 10.2165/00003495-200161140-00002; Campbell SM, 2001, J CLIN PHARM THER, V26, P5, DOI 10.1046/j.1365-2710.2001.00331.x; Carder PC, 2003, J CLIN PHARM THER, V28, P409, DOI 10.1046/j.0269-4727.2003.00511.x; Chang CM, 2005, PHARMACOTHERAPY, V25, P831, DOI 10.1592/phco.2005.25.6.831; Chin MH, 1999, ACAD EMERG MED, V6, P1232, DOI 10.1111/j.1553-2712.1999.tb00139.x; Chutka DS, 2004, MAYO CLIN PROC, V79, P122, DOI 10.4065/79.1.122; Coleman EA, 1999, J AM GERIATR SOC, V47, P775, DOI 10.1111/j.1532-5415.1999.tb03832.x; Cowper PA, 1998, PHARMACOTHERAPY, V18, P327; Cribb A, 1997, HEALTH CARE ANAL, V5, P292, DOI 10.1007/BF02678527; Crotty M, 2004, AGE AGEING, V33, P612, DOI 10.1093/ageing/afh213; Crotty Maria, 2004, Am J Geriatr Pharmacother, V2, P257, DOI 10.1016/j.amjopharm.2005.01.001; *DEP HLTH, 1999, CROWN REP REV PRESCR; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; ELLIOTT A, 2001, AUST J HOSP PHARM, V31, P19; Elliott RA, 2001, INTERN MED J, V31, P529, DOI 10.1046/j.1445-5994.2001.00139.x; Feinstein AR, 1997, AM J MED, V103, P529, DOI 10.1016/S0002-9343(97)00244-1; Feldstein A, 2006, J AM GERIATR SOC, V54, P450, DOI 10.1111/j.1532-5415.2005.00618.x; Fialova D, 2005, JAMA-J AM MED ASSOC, V293, P1348, DOI 10.1001/jama.293.11.1348; Fick D, 2001, J MANAGE CARE PHARM, V7, P407, DOI [10.18553/jmcp.2001.7.5.407, DOI 10.18553/JMCP.2001.7.5.407]; Fick DM, 2004, AM J MANAG CARE, V10, P761; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; Fillenbaum Gerda G, 2004, Am J Geriatr Pharmacother, V2, P92, DOI 10.1016/S1543-5946(04)90014-1; Fitzgerald LS, 1997, ANN PHARMACOTHER, V31, P543, DOI 10.1177/106002809703100503; Flanagan PS, 2004, ANN PHARMACOTHER, V38, P20, DOI 10.1345/aph.1D295; Fossey J, 2006, BMJ-BRIT MED J, V332, P756, DOI 10.1136/bmj.38782.575868.7C; Franic DM, 2006, PHARMACOTHERAPY, V26, P768, DOI 10.1592/phco.26.6.768; Fu AZ, 2004, J AM GERIATR SOC, V52, P1934, DOI 10.1111/j.1532-5415.2004.52522.x; Fuat A, 2003, BRIT MED J, V326, P196, DOI 10.1136/bmj.326.7382.196; Furniss L, 2000, BRIT J PSYCHIAT, V176, P563, DOI 10.1192/bjp.176.6.563; GARRARD J, 1995, AM J PUBLIC HEALTH, V85, P771, DOI 10.2105/AJPH.85.6.771; GOSNEY M, 1984, LANCET, V2, P564; Grymonpre RE, 2001, INT J PHARM PRACT, V9, P235, DOI DOI 10.1111/j.2042-7174.2001.tb01054.x; Gupta S, 1996, CLIN THER, V18, P183, DOI 10.1016/S0149-2918(96)80189-5; Gurwitz JH, 2002, ARCH INTERN MED, V162, P1670, DOI 10.1001/archinte.162.15.1670; GURWITZ JH, 1990, J AM GERIATR SOC, V38, P542, DOI 10.1111/j.1532-5415.1990.tb02406.x; Hajjar ER, 2005, J AM GERIATR SOC, V53, P1518, DOI 10.1111/j.1532-5415.2005.53523.x; Hammersley VS, 2006, J CLIN PHARM THER, V31, P223, DOI 10.1111/j.1365-2710.2006.00723.x; Hanlon Joseph T, 2004, Am J Geriatr Pharmacother, V2, P3, DOI 10.1016/S1543-5946(04)90002-5; Hanlon JT, 2001, J AM GERIATR SOC, V49, P200, DOI 10.1046/j.1532-5415.2001.49042.x; Hanlon JT, 2004, ANN PHARMACOTHER, V38, P9, DOI 10.1345/aph.1D313; Hanlon JT, 2002, MED CARE, V40, P166, DOI 10.1097/00005650-200202000-00011; Hanlon JT, 2002, J AM GERIATR SOC, V50, P26, DOI 10.1046/j.1532-5415.2002.50004.x; Hanlon JT, 1996, AM J MED, V100, P428, DOI 10.1016/S0002-9343(97)89519-8; HANLON JT, 1992, J CLIN EPIDEMIOL, V45, P1045, DOI 10.1016/0895-4356(92)90144-C; Heisler M, 2004, MED CARE, V42, P626, DOI 10.1097/01.mlr.0000129352.36733.cc; Higashi T, 2005, ANN INTERN MED, V143, P274, DOI 10.7326/0003-4819-143-4-200508160-00008; Higashi T, 2004, ANN INTERN MED, V140, P714, DOI 10.7326/0003-4819-140-9-200405040-00011; Holland R, 2005, BMJ-BRIT MED J, V330, P293, DOI 10.1136/bmj.38338.674583.AE; Holmes HM, 2006, ARCH INTERN MED, V166, P605, DOI 10.1001/archinte.166.6.605; Hughes CM, 1999, BRIT MED J, V319, P1060, DOI 10.1136/bmj.319.7216.1060; Hughes CM, 2000, MED CARE, V38, P1164, DOI 10.1097/00005650-200012000-00003; Judge J, 2006, J AM MED INFORM ASSN, V13, P385, DOI 10.1197/jamia.M1945; Juurlink DN, 2003, JAMA-J AM MED ASSOC, V289, P1652, DOI 10.1001/jama.289.13.1652; Kassam R, 2003, ANN PHARMACOTHER, V37, P40; Klarin I, 2005, DRUG AGING, V22, P69, DOI 10.2165/00002512-200522010-00005; Ko DT, 2005, ARCH INTERN MED, V165, P2486, DOI 10.1001/archinte.165.21.2486; Krska J, 2001, AGE AGEING, V30, P205, DOI 10.1093/ageing/30.3.205; Kunin CM, 2004, ARCH INTERN MED, V164, P1701, DOI 10.1001/archinte.164.15.1701-a; Kuzuya M, 2006, J AM GERIATR SOC, V54, P598, DOI 10.1111/j.1532-5415.2006.00659.x; Laroche ML, 2007, BRIT J CLIN PHARMACO, V63, P177, DOI 10.1111/j.1365-2125.2006.02831.x; Laroche ML, 2006, DRUG AGING, V23, P49, DOI 10.2165/00002512-200623010-00005; Larson EB, 2001, ANN INTERN MED, V134, P997, DOI 10.7326/0003-4819-134-10-200105150-00013; Lau DT, 2005, ARCH INTERN MED, V165, P68, DOI 10.1001/archinte.165.1.68; Lilford R, 2004, LANCET, V363, P1147, DOI 10.1016/S0140-6736(04)15901-1; Lloyd F., 2007, INT J PHARM PRACT, V15, P31, DOI [10.1211/ijpp.15.1.0006, DOI 10.1211/ijpp.15.1.0006]; LUISI AF, 1995, PHARMACOTHERAPY, V15, P124; Mackinnon Neil J, 2002, J Manag Care Pharm, V8, P365; Majumdar SR, 2004, ANN INTERN MED, V141, P366, DOI 10.7326/0003-4819-141-5-200409070-00011; Mangoni AA, 2004, BRIT J CLIN PHARMACO, V57, P6, DOI 10.1046/j.1365-2125.2003.02007.x; Marshall MN, 2003, QUAL SAF HEALTH CARE, V12, P8, DOI 10.1136/qhc.12.1.8; Masoudi FA, 2004, CIRCULATION, V110, P724, DOI 10.1161/01.CIR.0000138934.28340.ED; McLeod PJ, 1997, CAN MED ASSOC J, V156, P385; Mendelson G, 1998, J AM GERIATR SOC, V46, P1423, DOI 10.1111/j.1532-5415.1998.tb06011.x; Meredith S, 2002, J AM GERIATR SOC, V50, P1484, DOI 10.1046/j.1532-5415.2002.50402.x; Morris CJ, 2003, J CLIN PHARM THER, V28, P295, DOI 10.1046/j.1365-2710.2003.00496.x; Morris CJ, 2002, INT J QUAL HEALTH C, V14, P183, DOI 10.1093/oxfordjournals.intqhc.a002610; Naugler C T, 2000, Can J Clin Pharmacol, V7, P103; NELSON EA, 1992, GERONTOLOGIST, V32, P17, DOI 10.1093/geront/32.1.17; Oborne CA, 1997, BRIT J CLIN PHARMACO, V43, P91, DOI 10.1111/j.1365-2125.1997.tb00038.x; Oborne CA, 2003, AGE AGEING, V32, P102; Oborne CA, 2002, AGE AGEING, V31, P435, DOI 10.1093/ageing/31.6.435; Onder G, 2003, EUR J CLIN PHARMACOL, V59, P157, DOI 10.1007/s00228-003-0600-8; Onder G, 2005, EUR J CLIN PHARMACOL, V61, P453, DOI 10.1007/s00228-005-0928-3; Page Robert L 2nd, 2006, Am J Geriatr Pharmacother, V4, P297; PATTERSON SP, IN PRESS PHARM WORLD; Perri M, 2005, ANN PHARMACOTHER, V39, P405, DOI 10.1345/aph.1E230; Peterson JF, 2005, ARCH INTERN MED, V165, P802, DOI 10.1001/archinte.165.7.802; Pimlott NJG, 2003, CAN MED ASSOC J, V168, P835; Pitkala KH, 2001, DRUG AGING, V18, P143, DOI 10.2165/00002512-200118020-00007; Pronovost PJ, 2004, LANCET, V363, P1061, DOI 10.1016/S0140-6736(04)15843-1; Rahme E, 2005, AM J MED, V118, P1262, DOI 10.1016/j.amjmed.2005.03.026; Raivio MM, 2006, DRUG AGING, V23, P333, DOI 10.2165/00002512-200623040-00006; Rask KJ, 2005, AM J MANAG CARE, V11, P145; Ray WA, 2001, MED CARE, V39, P425, DOI 10.1097/00005650-200105000-00003; Roberts MS, 2001, BRIT J CLIN PHARMACO, V51, P257, DOI 10.1046/j.1365-2125.2001.00347.x; Robertson HA, 2002, CLIN THER, V24, P1595, DOI 10.1016/S0149-2918(02)80063-7; Rollnick S, 2005, BMJ-BRIT MED J, V331, P961, DOI 10.1136/bmj.331.7522.961; Saltvedt I, 2005, EUR J CLIN PHARMACOL, V61, P921, DOI 10.1007/s00228-005-0046-2; SAMSA GP, 1994, J CLIN EPIDEMIOL, V47, P891, DOI 10.1016/0895-4356(94)90192-9; Schiff GD, 1998, JAMA-J AM MED ASSOC, V279, P1024, DOI 10.1001/jama.279.13.1024; Schmader KE, 2004, AM J MED, V116, P394, DOI 10.1016/j.amjmed.2003.10.031; Schmader KE, 1997, ANN PHARMACOTHER, V31, P529, DOI 10.1177/106002809703100501; Sellors J, 2003, CAN MED ASSOC J, V169, P17; Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003; Simon SR, 2005, J AM GERIATR SOC, V53, P2165, DOI 10.1111/j.1532-5415.2005.00498.x; Simon SR, 2006, J AM GERIATR SOC, V54, P963, DOI 10.1111/j.1532-5415.2006.00734.x; Simonson W, 2005, DRUG AGING, V22, P559, DOI 10.2165/00002512-200522070-00002; Sloane PD, 2004, ARCH INTERN MED, V164, P2031, DOI 10.1001/archinte.164.18.2031; Solomon DH, 2003, J AM GERIATR SOC, V51, P902, DOI 10.1046/j.1365-2389.2003.513331.x; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Spinewine A, 2006, J AM GERIATR SOC, V54, P720, DOI 10.1111/j.1532-5415.2006.00668_8.x; Spinewine A, 2005, BMJ-BRIT MED J, V331, P935, DOI 10.1136/bmj.38551.410012.06; Spinewine A, 2007, J AM GERIATR SOC, V55, P658, DOI 10.1111/j.1532-5415.2007.01132.x; Steel N, 2004, QUAL SAF HEALTH CARE, V13, P260, DOI 10.1136/qshc.2004.010280; Stein CM, 2001, MED CARE, V39, P436; Steinman MA, 2006, J AM GERIATR SOC, V54, P1516, DOI 10.1111/j.1532-5415.2006.00889.x; Strandberg TE, 2006, AM HEART J, V152, P585, DOI 10.1016/j.ahj.2006.02.006; Strothers HS, 2005, J AM GERIATR SOC, V53, P456, DOI 10.1111/j.1532-5415.2005.53164.x; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Tamblyn R, 2003, CAN MED ASSOC J, V169, P549; Tinetti ME, 2004, NEW ENGL J MED, V351, P2870, DOI 10.1056/NEJMsb042458; *UN DIV SOC POL DE, 2002, 2 WORLD ASS AG MADR; Unutzer J, 2004, J AM GERIATR SOC, V52, P1916, DOI 10.1111/j.1532-5415.2004.52519.x; van Eijk MEC, 2001, BRIT MED J, V322, P654, DOI 10.1136/bmj.322.7287.654; Viktil KK, 2004, ANN PHARMACOTHER, V38, P942, DOI 10.1345/aph.1D531; Wenger NS, 2001, ANN INTERN MED, V135, P642, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00002; Williams ME, 2004, J AM GERIATR SOC, V52, P93, DOI 10.1111/j.1532-5415.2004.52016.x; Woodhouse KW, 1997, AGE AGEING, V26, P245, DOI 10.1093/ageing/26.4.245; Zermansky AG, 2001, BRIT MED J, V323, P1340, DOI 10.1136/bmj.323.7325.1340; Zermansky AG, 2006, AGE AGEING, V35, P586, DOI 10.1093/ageing/afl075; Zuckerman IH, 2006, MED CARE, V44, P722, DOI 10.1097/01.mlr.0000215849.15769.be	152	686	708	3	78	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 14	2007	370	9582					173	184		10.1016/S0140-6736(07)61091-5	http://dx.doi.org/10.1016/S0140-6736(07)61091-5			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190WP	17630041				2023-01-03	WOS:000248091600032
J	Panowski, SH; Wolff, S; Aguilaniu, H; Durieux, J; Dillin, A				Panowski, Siler H.; Wolff, Suzanne; Aguilaniu, Hugo; Durieux, Jenni; Dillin, Andrew			PHA-4/Foxa mediates diet-restriction-induced longevity of C-elegans	NATURE			English	Article							SUPEROXIDE-DISMUTASE GENE; NUCLEAR FACTOR 3-GAMMA; LIFE-SPAN; CAENORHABDITIS-ELEGANS; INSULIN-RECEPTOR; GLUCOSE-HOMEOSTASIS; OXIDATIVE STRESS; DAF-16; EXPRESSION; HEPATOCYTE	Reduced food intake as a result of dietary restriction increases the lifespan of a wide variety of metazoans and delays the onset of multiple age-related pathologies. Dietary restriction elicits a genetically programmed response to nutrient availability that cannot be explained by a simple reduction in metabolism or slower growth of the organism. In the nematode worm Caenorhabditis elegans, the transcription factor PHA-4 has an essential role in the embryonic development of the foregut and is orthologous to genes encoding the mammalian family of Foxa transcription factors, Foxa1, Foxa2 and Foxa3. Foxa family members have important roles during development, but also act later in life to regulate glucagon production and glucose homeostasis, particularly in response to fasting. Here we describe a newly discovered, adult-specific function for PHA-4 in the regulation of diet-restriction-mediated longevity in C. elegans. The role of PHA-4 in lifespan determination is specific for dietary restriction, because it is not required for the increased longevity caused by other genetic pathways that regulate ageing.	Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA	Salk Institute	Dillin, A (corresponding author), Salk Inst Biol Studies, Mol & Cell Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dillin@salk.edu						Apfeld J, 1999, NATURE, V402, P804, DOI 10.1038/45544; AVERY L, 1993, GENETICS, V133, P897; Azzaria M, 1996, DEV BIOL, V178, P289, DOI 10.1006/dbio.1996.0219; BRENNER S, 1974, GENETICS, V77, P71; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Dillin A, 2002, SCIENCE, V298, P830, DOI 10.1126/science.1074240; Fujii M, 1998, DNA Res, V5, P25, DOI 10.1093/dnares/5.1.25; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Gaudet J, 2002, SCIENCE, V295, P821, DOI 10.1126/science.1065175; GIGLIO AM, 1994, BIOCHEM MOL BIOL INT, V33, P41; GIGLIO MP, 1994, BIOCHEM MOL BIOL INT, V33, P37; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; HOPE IA, 1999, C ELEGANS PRACTICAL, P88; Horner MA, 1998, GENE DEV, V12, P1947, DOI 10.1101/gad.12.13.1947; Houthoofd K, 2003, EXP GERONTOL, V38, P947, DOI 10.1016/S0531-5565(03)00161-X; Hunter T, 1997, J BIOL CHEM, V272, P28652, DOI 10.1074/jbc.272.45.28652; Kaestner KH, 1999, GENE DEV, V13, P495, DOI 10.1101/gad.13.4.495; Kaestner KH, 1998, MOL CELL BIOL, V18, P4245, DOI 10.1128/MCB.18.7.4245; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Li WQ, 2003, GENE DEV, V17, P844, DOI 10.1101/gad.1066503; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; MANGO SE, 1994, DEVELOPMENT, V120, P3019; McElwee J, 2003, AGING CELL, V2, P111, DOI 10.1046/j.1474-9728.2003.00043.x; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Pierce SB, 2001, GENE DEV, V15, P672, DOI 10.1101/gad.867301; Puig O, 2005, GENE DEV, V19, P2435, DOI 10.1101/gad.1340505; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Shen W, 2001, J BIOL CHEM, V276, P42812, DOI 10.1074/jbc.M106344200; Shih DQ, 1999, P NATL ACAD SCI USA, V96, P10152, DOI 10.1073/pnas.96.18.10152; Suzuki N, 1996, DNA Res, V3, P171, DOI 10.1093/dnares/3.3.171; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Tsuchiya T, 2004, PHYSIOL GENOMICS, V17, P307, DOI 10.1152/physiolgenomics.00039.2004; Tu MP, 2002, AGING CELL, V1, P75, DOI 10.1046/j.1474-9728.2002.00010.x; Wolff S, 2006, CELL, V124, P1039, DOI 10.1016/j.cell.2005.12.042; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147; Zhang LP, 2005, CELL METAB, V2, P141, DOI 10.1016/j.cmet.2005.07.002	50	406	446	7	76	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 31	2007	447	7144					550	+		10.1038/nature05837	http://dx.doi.org/10.1038/nature05837			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	172YZ	17476212				2023-01-03	WOS:000246842000039
J	Hill, J; Treasure, T				Hill, Jennifer; Treasure, Tom		Guideline Dev Grp	Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients having surgery: summary of NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROPHYLAXIS		Guys & St Thomas Hosp, London SE1, England; Royal Coll Surgeons England, Natl Collaborating Ctr Acute Care, London WC2A 3PE, England	Guy's & St Thomas' NHS Foundation Trust; Royal College of Surgeons of England	Treasure, T (corresponding author), Guys & St Thomas Hosp, London SE1, England.	tom.treasure@gmail.com						Burns PJ, 2001, J ROY COLL SURG EDIN, V46, P329; Choudhry NK, 2006, BMJ-BRIT MED J, V332, P141, DOI 10.1136/bmj.38698.709572.55; Kakkar AK, 2004, J THROMB HAEMOST, V2, P221, DOI 10.1111/j.1538-7933.2004.00588.x; *NAT I HLTH CLIN E, 2007, RED RISK VEN THROMB	4	50	63	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 19	2007	334	7602					1053	1054		10.1136/bmj.39174.678032.AD	http://dx.doi.org/10.1136/bmj.39174.678032.AD			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	174AL	17510154	Green Published			2023-01-03	WOS:000246913500036
J	Papadakis, M; Fee, P; Wilhelm, T; Andrew, D; Connolly, J				Papadakis, Michael; Fee, Peter; Wilhelm, Thomas; Davenport, Andrew; Connolly, John			Facial weakness in a haemodialysis patient	LANCET			English	Editorial Material							NEUROTOXICITY; ACYCLOVIR; DIALYSIS		UCL, Ctr Nephrol, London NW3 2QG, England; Royal Free Hosp, Dept Radiol, London NW3 2QG, England	University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Connolly, J (corresponding author), UCL, Ctr Nephrol, London NW3 2QG, England.	J.Connolly@medsch.ucl.ac.uk						DAVENPORT A, 1992, AM J KIDNEY DIS, V20, P647, DOI 10.1016/S0272-6386(12)70234-2; Davenport A, 2001, AM J KIDNEY DIS, V37, P457, DOI 10.1053/ajkd.2001.22068; LEONARD A, 1975, ANN INTERN MED, V82, P650, DOI 10.7326/0003-4819-82-5-650; MACDIARMAIDGORDON AR, 1992, NEPHRON, V62, P280, DOI 10.1159/000187059	4	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 24	2007	369	9562					714	714		10.1016/S0140-6736(07)60324-9	http://dx.doi.org/10.1016/S0140-6736(07)60324-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	141RO	17321322				2023-01-03	WOS:000244596600038
J	MacArthur, RD; Novak, RM; Peng, G; Chen, L; Xiang, Y; Hullsiek, KH; Kozal, MJ; van den Berg-Wolf, M; Henely, C; Schmetter, B; Dehlinger, M				MacArthur, Rodger D.; Novak, Richard M.; Peng, Grace; Chen, Li; Xiang, Ying; Hullsiek, Katherine Huppler; Kozal, Michael J.; van den Berg-Wolf, Mary; Henely, Christopher; Schmetter, Barry; Dehlinger, Marjorie		CPCRA 058 Study Team; Terry Beirn Community Programs	A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial	LANCET			English	Article							COMBINATION THERAPY; HIV-RNA; NELFINAVIR; LAMIVUDINE; INFECTION; APOPTOSIS; DRUGS; COUNT; AIDS	Background Long-term data from randomised trials on the consequences of treatment with a protease inhibitor (PI), non-nucleoside reverse transcriptase inhibitor (NNRTI), or both are lacking. Here, we report results from the FIRST trial, which compared initial treatment strategies for clinical, immunological, and virological outcomes. Methods Between 1999 and 2002, 1397 antiretroviral-treatment-naive patients, presenting at 18 clinical trial units with 80 research sites in the USA, were randomly assigned in a ratio of 1:1:1 to a protease inhibitor (PI) strategy (PI plus nucleoside reverse transcriptase inhibitor [NRTI]; n=470), a non-nucleoside reverse transcriptase inhibitor (NNRTI) strategy (NNRTI plus NRTI; n=463), or a three-class strategy (PI plus NNRTI plus NRTI; n=464). Primary endpoints were a composite of an AIDS-defining event, death, or CD4 cell count decline to less than 200 cells per mm(3) for the PI versus NNRTI comparison, and average change in CD4 cell count at or after 32 months for the three-class versus combined two-class comparison. Analyses were by intention-to-treat. This study is registered with ClinicalTrials.gov, number NCT00000922. Findings 1397 patients were assessed for the composite endpoint. A total of 388 participants developed the composite endpoint, 302 developed AIDS or died, and 188 died. NNRTI versus PI hazard ratios (HRs) for the composite endpoint, for AIDS or death, for death, and for virological failure were 1.02 (95% Cl 0.79-1.31), 1.07 (0.80-1.41), 0.95 (0.66-1.37), and 0.66 (0.56-0.78), respectively. 1196 patients were assessed for the three-class versus combined two-class primary endpoint. Mean change in CD4 cell count at or after 32 months was +234 cells per mm(3) and +227 cells per mm(3) for the three-class and the combined two-class strategies (p=0.62), respectively. HRs (three-class vs combined two-class) for AIDS or death and virological failure were 1.15 (0.91-1.45) and 0.87 (0.75-1.00), respectively. HRs (three-class vs combined two-class) for AIDS or death were similar for participants with baseline CD4 cell counts of 200 cells per mm3 or less and of more than 200 cells per mm(3) (p=0.38 for interaction), and for participants with baseline HIV RNA concentrations less than 100000 copies per ml, and 100000 copies per mL or more (p=0.26 for interaction). Participants assigned the three-class strategy were significantly more likely to discontinue treatment because of toxic effects than were those assigned to the two-class strategies (HR 1.58; p<0.0001). Interpretation Initial treatment with either an NNRTI-based regimen or a PI-based regimen, but not both together, is a good strategy for long-term antiretroviral management in treatment-naive patients with HIV.	Wayne State Univ, Detroit, MI USA; Univ Illinois, Chicago, IL USA; Univ Minnesota, Minneapolis, MN USA; Yale Univ, New Haven, CT USA; Temple Univ, Philadelphia, PA 19122 USA; Meridian Hlth Syst, Neptune, NJ USA; Social & Sci Syst, Silver Spring, MD USA; NIAID, Div AIDS, Bethesda, MD 20892 USA	Wayne State University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Minnesota System; University of Minnesota Twin Cities; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Social & Scientific Systems; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	MacArthur, RD (corresponding author), Div Infect Dis, UHC 7D,4201 St Antoine, Detroit, MI 48201 USA.	rdmacarthur@mac.com		Kozal, Michael/0000-0002-3100-8254; , Michael/0000-0002-7719-7396	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI046362, U01AI042170] Funding Source: NIH RePORTER; NIAID NIH HHS [5U01AI042170-10, 5U01AI046362-03] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benito JM, 2002, AIDS RES HUM RETROV, V18, P1379, DOI 10.1089/088922202320935456; CDC, 1993, MMWR-MORBID MORTAL W, V41, P1; *DEP HLTH HUM SERV, 2006, GUID US ANT AG HIV 1; Fitzmaurice GM, 2004, APPL LONGITUDINAL AN; Friedl AC, 2001, AIDS, V15, P1793, DOI 10.1097/00002030-200109280-00008; Johnson Victoria A, 2004, Top HIV Med, V12, P119; KOZAL MJ, 2006, 15 INT HIV DRUG RES; Ledergerber B, 2004, LANCET, V364, P51, DOI 10.1016/S0140-6736(04)16589-6; MacArthur RD, 2005, HIV CLIN TRIALS, V6, P127, DOI 10.1310/A9B9-RQD7-U8KA-503U; MacArthur RD, 2004, HIV CLIN TRIALS, V5, P361, DOI 10.1310/WEQG-QTHL-DL3X-FTXC; MacArthur RD, 2001, CONTROL CLIN TRIALS, V22, P176, DOI 10.1016/S0197-2456(01)00111-8; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; *NIH DIV AIDS, 1998, TABL GRAD SEV AD ADV; Olsen CH, 2005, AIDS, V19, P319; Phenix BN, 2000, AIDS RES HUM RETROV, V16, P559, DOI 10.1089/088922200308972; Phillips AN, 2004, AIDS, V18, P1795, DOI 10.1097/00002030-200409030-00008; Podzamczer D, 2002, ANTIVIR THER, V7, P81; Raffanti SP, 2004, JAIDS-J ACQ IMM DEF, V37, P1147, DOI 10.1097/01.qai.0000136738.24090.d0; Robbins GK, 2003, NEW ENGL J MED, V349, P2293, DOI 10.1056/NEJMoa030264; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Torti C, 2005, J ANTIMICROB CHEMOTH, V56, P190, DOI 10.1093/jac/dki172; van Leeuwen R, 2003, AIDS, V17, P987, DOI 10.1097/00002030-200305020-00007; Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354; Yeni P, 2006, LANCET, V368, P287, DOI 10.1016/S0140-6736(06)69074-0	24	106	114	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 16	2006	368	9553					2125	2135		10.1016/S0140-6736(06)69861-9	http://dx.doi.org/10.1016/S0140-6736(06)69861-9			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EZ	17174704				2023-01-03	WOS:000242856900020
J	Nair, KS; Rizza, RA; O'Brien, P; Dhatariya, K; Short, KR; Nehra, A; Vittone, JL; Klee, GG; Basu, A; Basu, R; Cobelli, C; Toffolo, G; Dalla Man, C; Tindall, DJ; Melton, L; Smith, GE; Khosla, S; Jensen, MD				Nair, K. Sreekumaran; Rizza, Robert A.; O'Brien, Peter; Dhatariya, Ketan; Short, Kevin R.; Nehra, Ajay; Vittone, Janet L.; Klee, George G.; Basu, Ananda; Basu, Rita; Cobelli, Claudio; Toffolo, Gianna; Dalla Man, Chiara; Tindall, Donald J.; Melton, L. Joseph, III; Smith, Glenn E.; Khosla, Sundeep; Jensen, Michael D.			DHEA in elderly women and DHEA or testosterone in elderly men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL DENSITY; DEHYDROEPIANDROSTERONE REPLACEMENT THERAPY; BODY-COMPOSITION; MUSCLE STRENGTH; HEALTHY-MEN; FAT; SULFATE; PERFORMANCE; DECLINE; MASS	BACKGROUND Dehydroepiandrosterone (DHEA) and testosterone are widely promoted as antiaging supplements, but the long-term benefits, as compared with potential harm, are unknown. METHODS We performed a 2-year, placebo-controlled, randomized, double-blind study involving 87 elderly men with low levels of the sulfated form of DHEA and bioavailable testosterone and 57 elderly women with low levels of sulfated DHEA. Among the men, 29 received DHEA, 27 received testosterone, and 31 received placebo. Among the women, 27 received DHEA and 30 received placebo. Outcome measures included physical performance, body composition, bone mineral density (BMD), glucose tolerance, and quality of life. RESULTS As compared with the change from baseline to 24 months in the placebo group, subjects who received DHEA for 2 years had an increase in plasma levels of sulfated DHEA by a median of 3.4 microg per milliliter (9.2 micromol per liter) in men and by 3.8 microg per milliliter (10.3 micromol per liter) in women. Among men who received testosterone, the level of bioavailable testosterone increased by a median of 30.4 ng per deciliter (1.1 nmol per liter), as compared with the change in the placebo group. A separate analysis of men and women showed no significant effect of DHEA on body-composition measurements. Neither hormone altered the peak volume of oxygen consumed per minute, muscle strength, or insulin sensitivity. Men who received testosterone had a slight increase in fat-free mass, and men in both treatment groups had an increase in BMD at the femoral neck. Women who received DHEA had an increase in BMD at the ultradistal radius. Neither treatment improved the quality of life or had major adverse effects. CONCLUSIONS Neither DHEA nor low-dose testosterone replacement in elderly people has physiologically relevant beneficial effects on body composition, physical performance, insulin sensitivity, or quality of life.	Mayo Clin & Mayo Fdn, Div Endocrinol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Urol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Psychol, Rochester, MN 55905 USA; Univ Padua, Dept Informat Engn, Padua, Italy	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Padua	Nair, KS (corresponding author), Mayo Clin & Mayo Fdn, Div Endocrinol, 200 1st St SW,5-194 Joseph, Rochester, MN 55905 USA.	nair.ree@mayo.edu	Short, Kevin R/AAC-2553-2020; Khosla, Sundeep/AAE-6170-2020	Short, Kevin R/0000-0001-6704-9587; Khosla, Sundeep/0000-0002-2936-4372; DALLA MAN, CHIARA/0000-0002-4908-0596; Smith, Glenn/0000-0003-1506-9484	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000585] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00585] Funding Source: Medline; NIA NIH HHS [P01 AG14283] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1993, HLTH STAT QUEST HSQ; Arlt W, 2001, J CLIN ENDOCR METAB, V86, P4686, DOI 10.1210/jc.86.10.4686; Balagopal P, 2001, AM J PHYSIOL-ENDOC M, V280, pE203, DOI 10.1152/ajpendo.2001.280.2.E203; BARRETTCONNOR E, 1986, NEW ENGL J MED, V315, P1519, DOI 10.1056/NEJM198612113152405; Basu R, 2003, DIABETES, V52, P3014; Basu R, 2003, DIABETES, V52, P1738, DOI 10.2337/diabetes.52.7.1738; Baulieu EE, 2000, P NATL ACAD SCI USA, V97, P4279, DOI 10.1073/pnas.97.8.4279; Clarke BL, 2002, CALCIFIED TISSUE INT, V70, P137, DOI 10.1007/s00223-001-1072-4; Dalla Man C, 2002, IEEE T BIO-MED ENG, V49, P419, DOI 10.1109/10.995680; Dhatariya KK, 2003, MAYO CLIN PROC, V78, P1257, DOI 10.4065/78.10.1257; Diamond P, 1996, J ENDOCRINOL, V150, pS43; Flynn MA, 1999, J CLIN ENDOCR METAB, V84, P1527, DOI 10.1210/jc.84.5.1527; Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724; HELZLSOUER KJ, 1992, CANCER RES, V52, P1; JENSEN MD, 1993, MAYO CLIN PROC, V68, P867, DOI 10.1016/S0025-6196(12)60695-8; JENSEN MD, 1995, AM J CLIN NUTR, V61, P274, DOI 10.1093/ajcn/61.2.274; Kaufman JM, 2005, ENDOCR REV, V26, P833, DOI 10.1210/er.2004-0013; Khosla S, 1998, J CLIN ENDOCR METAB, V83, P2266, DOI 10.1210/jc.83.7.2266; LABRIE F, 1991, MOL CELL ENDOCRINOL, V78, pC113, DOI 10.1016/0303-7207(91)90116-A; Labrie F, 1997, J CLIN ENDOCR METAB, V82, P3498, DOI 10.1210/jc.82.10.3498; Lasco A, 2001, EUR J ENDOCRINOL, V145, P457, DOI 10.1530/eje.0.1450457; Levine JA, 2000, J APPL PHYSIOL, V88, P452, DOI 10.1152/jappl.2000.88.2.452; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MORALES AJ, 1994, J CLIN ENDOCR METAB, V78, P1360, DOI 10.1210/jc.78.6.1360; Morales AJ, 1998, CLIN ENDOCRINOL, V49, P421, DOI 10.1046/j.1365-2265.1998.00507.x; MORALES AJ, 1995, J CLIN ENDOCR METAB, V80, P2799; MORTOLA JF, 1990, J CLIN ENDOCR METAB, V71, P696, DOI 10.1210/jcem-71-3-696; nap, 2004, BIOLOGICAL CONFINEMENT OF GENETICALLY ENGINEERED ORGANISMS, P1; NESTLER JE, 1988, J CLIN ENDOCR METAB, V66, P57, DOI 10.1210/jcem-66-1-57; NORDIN BEC, 1985, J CLIN ENDOCR METAB, V60, P651, DOI 10.1210/jcem-60-4-651; ORENTREICH N, 1992, J CLIN ENDOCR METAB, V75, P1002, DOI 10.1210/jc.75.4.1002; Page ST, 2005, J CLIN ENDOCR METAB, V90, P1502, DOI 10.1210/jc.2004-1933; Prestwood KM, 2003, JAMA-J AM MED ASSOC, V290, P1042, DOI 10.1001/jama.290.8.1042; Proctor DN, 1996, J APPL PHYSIOL, V81, P2495, DOI 10.1152/jappl.1996.81.6.2495; Roth GS, 2002, SCIENCE, V297, P811, DOI 10.1126/science.1071851; Schwartz AG, 2004, AGEING RES REV, V3, P171, DOI 10.1016/j.arr.2003.05.001; SHEPHERD A, 1984, AM J PHYSIOL, V246, pE123, DOI 10.1152/ajpendo.1984.246.2.E123; Snyder PJ, 1999, J CLIN ENDOCR METAB, V84, P2647, DOI 10.1210/jc.84.8.2647; Tan KCB, 1998, CLIN ENDOCRINOL, V48, P187, DOI 10.1046/j.1365-2265.1998.3721211.x; TURNER RT, 1990, AM J PHYSIOL, V258, pE673, DOI 10.1152/ajpendo.1990.258.4.E673; VALENTI G, 2002, 84 ANN M END SOC SAN; Villareal DT, 2000, CLIN ENDOCRINOL, V53, P561, DOI 10.1046/j.1365-2265.2000.01131.x; Villareal DT, 2004, JAMA-J AM MED ASSOC, V292, P2243, DOI 10.1001/jama.292.18.2243; Wolf OT, 1997, J CLIN ENDOCR METAB, V82, P2363, DOI 10.1210/jc.82.7.2363	45	415	432	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 19	2006	355	16					1647	1659		10.1056/NEJMoa054629	http://dx.doi.org/10.1056/NEJMoa054629			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	096DN	17050889				2023-01-03	WOS:000241357300006
J	Maisels, MJ; McDonagh, AF				Maisels, M. Jeffrey; McDonagh, Antony F.			Phototherapy for neonatal jaundice	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLUE-LIGHT PHOTOTHERAPY; BRONZE BABY SYNDROME; BILIRUBIN LEVELS; CONTROLLED-TRIAL; HYPERBILIRUBINEMIA; RISK; INTENSITY; INFANTS; HOME; MORBIDITY	A male infant weighing 3400 g was born at 37 weeks' gestation after an uncomplicated pregnancy. The mother is a 24-year-old primipara who has type A Rh-positive blood. The infant's course in the hospital nursery was uncomplicated. Although his mother needed considerable help in establishing effective breast-feeding, he was exclusively breast-fed. Jaundice was noted at the age of 34 hours. The total serum bilirubin level was 7.5 mg per deciliter (128 mu mol per liter). The infant was discharged at the age of 40 hours and is seen in the pediatrician's office 2 days later, now with marked jaundice. The results of his physical examination are otherwise normal, but his weight, at 3020 g, is 11% below his birth weight. His total serum bilirubin level is 19.5 mg per deciliter (333 mu mol per liter), and his conjugated (direct) bilirubin level 0.6 mg per deciliter (10 mu mol per liter). The complete blood count and peripheral-blood smear are normal. The infant has type A Rh-positive blood. The pediatrician consults a neonatologist regarding the need for phototherapy.	[Maisels, M. Jeffrey] William Beaumont Hosp, Dept Pediat, Royal Oak, MI 48073 USA; [McDonagh, Antony F.] Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA USA	Beaumont Health; University of California System; University of California San Francisco	Maisels, MJ (corresponding author), William Beaumont Hosp, Dept Pediat, 3601 W 13 Mile Rd, Royal Oak, MI 48073 USA.	jmaisels@beaumont.edu	Kemeny, Lajos/ABF-1339-2021	Kemeny, Lajos/0000-0002-2119-9501				*AM AC PED SUBC HY, 2004, PEDIATRICS, V0114, P01138; Aspberg S, 2007, PEDIAT ALLERG IMM-UK, V18, P313, DOI 10.1111/j.1399-3038.2006.00518.x; Avery GB, 2005, NEONATOLOGY PATHOPHY, V6th, P768; Bauer J, 2004, ARCH DERMATOL, V140, P493, DOI 10.1001/archderm.140.4.493; Bhutani VK, 2006, JOGNN-J OBST GYN NEO, V35, P444, DOI 10.1111/J.1552-6909.2006.00044.x; CREMER RJ, 1958, LANCET, V1, P1094; Csoma Z, 2007, PEDIATRICS, V119, P1036, DOI 10.1542/peds.2007-0180; Dahlquist G, 2003, DIABETES CARE, V26, P247, DOI 10.2337/diacare.26.1.247-a; Djokomuljanto S, 2006, ARCH DIS CHILD-FETAL, V91, pF439, DOI 10.1136/adc.2006.095687; DOLLBERG S, 1995, AM J PERINAT, V12, P55, DOI 10.1055/s-2007-994402; Eggert LD, 2006, PEDIATRICS, V117, pE855, DOI 10.1542/peds.2005-1338; EGGERT LD, 1985, PEDIATRICS, V76, P579; EGGERT P, 1984, EUR J PEDIATR, V142, P58, DOI 10.1007/BF00442593; GARG AK, 1995, PEDIATRICS, V95, P914; Gartner L M, 2001, J Perinatol, V21 Suppl 1, pS25, DOI 10.1038/sj.jp.7210629; Hansen TWR, 1996, CLIN PEDIATR, V35, P309, DOI 10.1177/000992289603500604; Hansen TWR, 1997, ACTA PAEDIATR, V86, P843; HOLTROP PC, 1992, PEDIATRICS, V90, P674; JAHRIG K, 1982, ACTA PAEDIATR SCAND, V71, P293, DOI 10.1111/j.1651-2227.1982.tb09417.x; JAHRIG K, 1993, PHOTOTHERAPY TREATIN; JOHN E, 1975, AUST PAEDIATR J, V11, P49; Kaplan M, 2006, ARCH DIS CHILD, V91, P31, DOI 10.1136/adc.2005.081224; Kaplan M, 2003, PEDIATRICS, V111, P886, DOI 10.1542/peds.111.4.886; Kaplan M, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.4.e47; KEENAN WJ, 1985, PEDIATRICS, V75, P417; Keren R, 2005, ARCH DIS CHILD, V90, P415, DOI 10.1136/adc.2004.060079; KOPELMAN AE, 1972, J PEDIATR-US, V81, P466, DOI 10.1016/S0022-3476(72)80172-0; LIGHTNER DA, 1984, ACCOUNTS CHEM RES, V17, P417, DOI 10.1021/ar00108a002; Maayan-Metzger A, 2001, AM J PERINAT, V18, P393, DOI 10.1055/s-2001-18698; Maisels MJ, 2007, J PERINATOL, V27, P565, DOI 10.1038/sj.jp.7211789; Maisels MJ, 2006, J PERINATOL, V26, P498, DOI 10.1038/sj.jp.7211552; Maisels M J, 2001, J Perinatol, V21 Suppl 1, pS93, DOI 10.1038/sj.jp.7210642; Maisels MJ, 2006, PEDIATRICS, V118, P276, DOI 10.1542/peds.2005-3042; Maisels M. Jeffrey, 1992, P507; Maisels MJ, 1996, PEDIATRICS, V98, P283; Maisels MJ, 2004, PEDIATRICS, V114, P297; Maisels MJ, 2003, ARCH DIS CHILD-FETAL, V88, pF459, DOI 10.1136/fn.88.6.F459; Maisels MJ, 2000, MG CLIN PED, P177; Maisels MJ, 2002, ARCH PEDIAT ADOL MED, V156, P669, DOI 10.1001/archpedi.156.7.669; Maisels MJ, 1998, PEDIATRICS, V101, P995, DOI 10.1542/peds.101.6.995; Maisels MJ, 2001, PEDIATRICS, V108, P763; MALLON E, 1995, J AM ACAD DERMATOL, V33, P333, DOI 10.1016/0190-9622(95)91428-5; MCDONAGH AF, 1986, NEW ENGL J MED, V314, P121; MCDONAGH AF, 1990, CLIN PERINATOL, V17, P359, DOI 10.1016/S0095-5108(18)30572-4; McDonagh AF, 2006, PEDIATRICS, V118, P1185, DOI 10.1542/peds.2006-0594; MESSNER KH, 1978, INVEST OPHTH VIS SCI, V17, P178; Myara A, 1997, BIOL NEONATE, V71, P75; Newman TB, 2001, AMBUL PEDIATR, V1, P126, DOI 10.1367/1539-4409(2001)001<0126:LTTE>2.0.CO;2; Newman TB, 2000, ARCH PEDIAT ADOL MED, V154, P1140, DOI 10.1001/archpedi.154.11.1140; Newman TB, 1999, PEDIATRICS, V104, P1198; OSHEA TM, 1992, PEDIATRICS, V90, P888; Paller AS, 1997, PEDIATRICS, V100, P360, DOI 10.1542/peds.100.3.360; Patra K, 2004, J PEDIATR-US, V144, P626, DOI 10.1016/j.jpeds.2004.01.054; ROGERSON AG, 1986, CLIN PEDIATR, V25, P296, DOI 10.1177/000992288602500602; RUBALTELLI FF, 1983, PEDIATR RES, V17, P327, DOI 10.1203/00006450-198305000-00004; Sedlak TW, 2004, PEDIATRICS, V113, P1776, DOI 10.1542/peds.113.6.1776; Seidman Daniel S, 2003, J Perinatol, V23, P123, DOI 10.1038/sj.jp.7210862; SLATER L, 1984, PEDIATRICS, V73, P515; Steiner LA, 2007, PEDIATRICS, V120, P27, DOI 10.1542/peds.2006-2910; Suresh GK, 2004, PEDIATRICS, V114, P917, DOI 10.1542/peds.2004-0899; TAN KL, 1982, PEDIATR RES, V16, P670, DOI 10.1203/00006450-198208000-00018; TAN KL, 1992, ACTA PAEDIATR, V81, P870, DOI 10.1111/j.1651-2227.1992.tb12126.x; Tan KL, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e13; TONZ O, 1975, HELV PAEDIATR ACTA, V30, P47; VALAES T, 1994, PEDIATRICS, V93, P1; Vreman HJ, 2004, SEMIN PERINATOL, V28, P326, DOI 10.1053/j.semperi.2004.09.003; Yetman RJ, 1998, J PEDIATR-US, V133, P705, DOI 10.1016/S0022-3476(98)70117-9	67	310	325	11	71	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 28	2008	358	9					920	928		10.1056/NEJMct0708376	http://dx.doi.org/10.1056/NEJMct0708376			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266JD	18305267				2023-01-03	WOS:000253430200007
J	Slot, KB; Berge, E; Dorman, P; Lewis, S; Dennis, M; Sandercock, P				Slot, Karsten Bruins; Berge, Eivind; Dorman, Paul; Lewis, Steff; Dennis, Martin; Sandercock, Peter		Oxfordshire Community Stroke Proje; Int Stroke Trial; Lothiar Stroke Register	Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies	BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY-STROKE; CASE-FATALITY; ATRIAL-FIBRILLATION; RANDOMIZED-TRIAL; SIMPLE QUESTIONS; SUBTYPES; EPIDEMIOLOGY; PROJECT; REGISTRY; METHODOLOGY	Objective To estimate the impact on long term survival of functional status at six months after ischaemic stroke. Design Prospective cohort study. Settings Three cohorts: Oxfordshire community stroke project, Lothian stroke register, and the first international stroke trial (in the United Kingdom). Participants 7710 patients with ischaemic stroke registered between 1981 and 2000 and followed up for a maximum of 19 years. Main outcome measures Functional status at six months after stroke assessed with modified Rankin scale or "two simple questions." Mortality during follow-up. Survival analysis with Kaplan-Meier curves, log rank test, and Cox's regression model. Results In a combined analysis of all three cohorts, among patients who survived to assessment six months after the index stroke, the subsequent median length of survival among those independent in daily living and those dependent was 9.7 years (95% conifidence interval 8.9 to 10.6) and 6.0 years (5.7 to 6.4), respectively. In a combined analysis of the Oxfordshire and Lothian cohorts, subsequent median survival felt progressively from 12.9 years (10.0 to 15.9) for patients with. a Rankin score of 0-1 at six months after the stroke to 2.5 years (1.4 to 3.5) for patients with a Rankin score of 5. All previously stated differences in median survival were significant (log rank test P<0.001). The influence of functional outcome on survival remained significant (P<0.05) in each cohort after adjustment for relevant covariates (such as age, presence of atrial fibrillation, visible infarct on computed tomography, subtype of stroke) in a Cox's regression model. Conclusion Functional status six months after an ischaemic stroke is associated with long term survival. Early interventions that reduce dependency at six months might have positive effects on long term survival.	[Slot, Karsten Bruins; Berge, Eivind] Ullevaal Univ Hosp, Dept Internal Med, NO-0407 Oslo, Norway; [Dorman, Paul] Newcastle Gen Hosp, Dept Neurol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; [Lewis, Steff; Dennis, Martin; Sandercock, Peter] Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Oslo; Newcastle General Hospital; University of Edinburgh	Slot, KB (corresponding author), Ullevaal Univ Hosp, Dept Internal Med, NO-0407 Oslo, Norway.	karsten.bruins.slot@medisin.uio.no		Sandercock, Peter/0000-0001-8484-0135; dennis, martin/0000-0003-1148-8972; Lewis, Steff/0000-0003-1210-2314				BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; Carolei A, 1997, STROKE, V28, P2500, DOI 10.1161/01.STR.28.12.2500; Carter KN, 2007, CEREBROVASC DIS, V23, P162, DOI 10.1159/000097054; Dennis M, 1997, CEREBROVASC DIS, V7, P22, DOI 10.1159/000108159; Dewey HM, 2003, CEREBROVASC DIS, V15, P133, DOI 10.1159/000067142; Di Carlo A, 2006, J NEUROL SCI, V244, P143, DOI 10.1016/j.jns.2006.01.016; Ellekjaer H, 1997, STROKE, V28, P2180, DOI 10.1161/01.STR.28.11.2180; Feigin VL, 2003, LANCET NEUROL, V2, P43, DOI 10.1016/S1474-4422(03)00266-7; Gerzeli S, 2005, NEUROL SCI, V26, P72, DOI 10.1007/s10072-005-0439-0; HATTON TJ, 2003, EMIGRATION UK 1870 1; Jamrozik K, 1999, STROKE, V30, P2105, DOI 10.1161/01.STR.30.10.2105; Johansson B, 2000, STROKE, V31, P481, DOI 10.1161/01.STR.31.2.481; Jorgensen HS, 1996, STROKE, V27, P1765, DOI 10.1161/01.STR.27.10.1765; Kolominsky-Rabas PL, 2006, STROKE, V37, P1179, DOI 10.1161/01.STR.0000217450.21310.90; Kolominsky-Rabas PL, 2001, STROKE, V32, P2735, DOI 10.1161/hs1201.100209; LAURIA G, 1995, STROKE, V26, P1787, DOI 10.1161/01.STR.26.10.1787; Lin HJ, 1996, STROKE, V27, P1760, DOI 10.1161/01.STR.27.10.1760; LINDLEY RI, 1994, CEREBROVASC DIS, V4, P314, DOI 10.1159/000108501; *OFF NAT STAT, IMPL 2001 CENS REP; Samsa GP, 1999, J CLIN EPIDEMIOL, V52, P259, DOI 10.1016/S0895-4356(98)00151-6; Samsa GP, 2001, STROKE, V32, P669, DOI 10.1161/01.STR.32.3.669; Sandercock P, 1997, LANCET, V349, P1569; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Smadja D, 2001, STROKE, V32, P2741, DOI 10.1161/hs1201.099385; Spieler JF, 2004, CEREBROVASC DIS, V17, P134, DOI 10.1159/000075782; Strong K, 2007, LANCET NEUROL, V6, P182, DOI 10.1016/S1474-4422(07)70031-5; Thrift AG, 2001, STROKE, V32, P1732, DOI 10.1161/01.STR.32.8.1732; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wilson JTL, 2005, STROKE, V36, P777, DOI 10.1161/01.STR.0000157596.13234.95	31	134	140	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 16	2008	336	7640					376	379		10.1136/bmj.39456.688333.BE	http://dx.doi.org/10.1136/bmj.39456.688333.BE			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268AP	18230644	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000253550600041
J	Brochard, L				Brochard, Laurent			Sedation in the intensive-care unit: good and bad?	LANCET			English	Editorial Material							MECHANICAL VENTILATION		[Brochard, Laurent] Ctr Hosp Albert Chenevier Henri Mondor, AP HP, Med Intens Care Unit, Creteil, France; [Brochard, Laurent] INSERM, U841, F-94000 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Brochard, L (corresponding author), Ctr Hosp Albert Chenevier Henri Mondor, AP HP, Med Intens Care Unit, Creteil, France.	laurent.brochard@hmn.aphp.fr						Cook DJ, 2001, CHEST, V120, p469S, DOI 10.1378/chest.120.6_suppl.469S; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Krishnan JA, 2004, AM J RESP CRIT CARE, V169, P673, DOI 10.1164/rccm.200306-761OC; THORENS JB, 1995, CRIT CARE MED, V23, P1807, DOI 10.1097/00003246-199511000-00004	5	11	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 12	2008	371	9607					95	97		10.1016/S0140-6736(08)60082-3	http://dx.doi.org/10.1016/S0140-6736(08)60082-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	252ND	18191669				2023-01-03	WOS:000252452300006
J	Spruit, MA; Vanderhoven-Augustin, I; Janssen, PP; Wouters, EFM				Spruit, Martijn A.; Vanderhoven-Augustin, Ingrid; Janssen, Paul P.; Wouters, Emiel F. M.			Integration of pulmonary rehabilitation in COPD	LANCET			English	Editorial Material							DISEASE; MANAGEMENT		[Spruit, Martijn A.; Vanderhoven-Augustin, Ingrid; Janssen, Paul P.; Wouters, Emiel F. M.] Ctr Integrated Rehabil Organ Failure, NL-6085 NM Horn, Netherlands; [Wouters, Emiel F. M.] Univ Hosp Maastricht, Maastricht, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC)	Spruit, MA (corresponding author), Ctr Integrated Rehabil Organ Failure, NL-6085 NM Horn, Netherlands.	martijnspruit@proteion.nl	Wouters, Emiel/ABD-6200-2021					Baarends EM, 1997, EUR RESPIR J, V10, P2807, DOI 10.1183/09031936.97.10122807; Griffiths TL, 2001, THORAX, V56, P779, DOI 10.1136/thorax.56.10.779; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Jones Paul W, 2005, COPD, V2, P75; LACASSE Y, 2007, COCHRANE DB SYST REV, V3; Marquis Karine, 2005, J Cardiopulm Rehabil, V25, P226, DOI 10.1097/00008483-200507000-00010; Nici L, 2006, AM J RESP CRIT CARE, V173, P1390, DOI 10.1164/rccm.200508-1211ST; Redelmeier DA, 1997, AM J RESP CRIT CARE, V155, P1278, DOI 10.1164/ajrccm.155.4.9105067; Ries AL, 2007, CHEST, V131, p4S, DOI 10.1378/chest.06-2418; Rutten FH, 2005, EUR HEART J, V26, P1887, DOI 10.1093/eurheartj/ehi291; Spruit MA, 2007, SPORTS MED, V37, P501, DOI 10.2165/00007256-200737060-00004; Weitzenblum E, 2004, SLEEP MED REV, V8, P281, DOI 10.1016/j.smrv.2004.03.006; Wilt TJ, 2007, ANN INTERN MED, V147, P639, DOI 10.7326/0003-4819-147-9-200711060-00009; Wouters EFM, 2004, LANCET, V364, P883, DOI 10.1016/S0140-6736(04)16984-5	14	93	95	1	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 5	2008	371	9606					12	13		10.1016/S0140-6736(08)60048-3	http://dx.doi.org/10.1016/S0140-6736(08)60048-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248YH	18177760				2023-01-03	WOS:000252192600010
J	Ramagopalan, SV; Knight, M; Ebers, GC; Knight, JC				Ramagopalan, Sreeram V.; Knight, Marian; Ebers, George C.; Knight, Julian C.			Origins of magic: review of genetic and epigenetic effects	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							COMMON VARIANT; HARRY-POTTER; CHILDHOOD; ADULT	Objective To assess the evidence for a genetic basis to magic. Design Literature review. Setting Harry Potter novels of J K Rowling. Participants Muggles, witches, wizards, and squibs. Interventions Limited. Main outcome measures Family and twin studies, magical ability, and specific magical skills. Results Magic shows strong evidence of heritability, with familial aggregation and concordance in twins. Evidence suggests magical ability to be a quantitative trait. Specific magical skills, notably being able to speak to snakes, predict the future, and change hair colour, all seem heritable. Conclusions A multilocus model with a dominant gene for magic might exist, controlled epistatically by one or more loci, possibly recessive in nature. Magical enhancers regulating gene expression may be involved, combined with mutations at specific genes implicated in speech and hair colour such as FOXP2 and MCR1.	[Ramagopalan, Sreeram V.; Ebers, George C.; Knight, Julian C.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; [Ramagopalan, Sreeram V.; Ebers, George C.] Univ Oxford, Dept Clin Neurol, Oxford OX1 2JD, England; [Knight, Marian] Univ Oxford, Natl Perinatal Epidemiol Unit, Oxford OX1 2JD, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Oxford	Knight, JC (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.	julian@well.ox.ac.uk	Knight, Julian/C-7242-2009; Knight, Julian Charles/W-2399-2019; Knight, Marian/B-6225-2009	Knight, Julian/0000-0002-0377-5536; Knight, Julian Charles/0000-0002-0377-5536; Knight, Marian/0000-0002-1984-4575; Ebers, George/0000-0003-4771-4177	Wellcome Trust [074318] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Beaumont KA, 2007, HUM MOL GENET, V16, P2249, DOI 10.1093/hmg/ddm177; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Carlborg O, 2004, NAT REV GENET, V5, P618, DOI 10.1038/nrg1407; Craig JM, 2005, NATURE, V436, P776, DOI 10.1038/436776a; Curto M, 2008, BRIT J CANCER, V98, P256, DOI 10.1038/sj.bjc.6604002; Dodd AN, 2005, NATURE, V437, P318, DOI 10.1038/437318d; Falconer D. S., 1989, Introduction to quantitative genetics.; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Kadota M, 2007, PLOS GENET, V3, P768, DOI 10.1371/journal.pgen.0030081; Peltonen L, 2000, NAT REV GENET, V1, P182, DOI 10.1038/35042049; Risch N, 2001, CANCER EPIDEM BIOMAR, V10, P733; Rowling J.K., 2003, H POTTER ORDER PHOEN; Rowling JK., 1997, H POTTER PHILOS STON; Rowling JK., 1998, HARRY POTTER CHAMBER; ROWLING JK, 2000, H POTTER GOBLET FIRE; Rowling JK., 2005, H POTTER HALF BLOOD; ROWLING JK, 1999, H POTTER PRISONER A; Rowling JK, 2007, HARRY POTTER DEATHLY; Vernes SC, 2006, HUM MOL GENET, V15, P3154, DOI 10.1093/hmg/ddl392; Weedon MN, 2007, NAT GENET, V39, P1245, DOI 10.1038/ng2121	22	2	3	2	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 22	2007	335	7633					1299	1301		10.1136/bmj.39414.582639.BE	http://dx.doi.org/10.1136/bmj.39414.582639.BE			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248UO	18156238	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000252182700019
J	Mitchell, SL; Burns, RB				Mitchell, Susan L.; Burns, Risa B.			A 93-year-old man with advanced dementia and eating problems	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							NURSING-HOME RESIDENTS; OF-LIFE CARE; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; SEVERE COGNITIVE IMPAIRMENT; END-STAGE DEMENTIA; ADVANCED ALZHEIMERS-DISEASE; ARTIFICIAL NUTRITION; FEEDING TUBES; HOSPICE CARE; OLDER-ADULTS	More than 5 million Americans have dementia, a leading cause of death among persons older than 65 years in the United States. Eating problems typically develop during the advanced stage of dementia, which requires decision making to direct care toward either palliation or more aggressive measures, such as tube feeding. The case of Mr P, a 93-year-old man with end-stage dementia and recent hip fracture, illustrates the issues involved in this challenging crossroads when his daughter is confronted with his failure to orally maintain adequate hydration and nutrition. The discussion reviews the epidemiology and natural history of advanced dementia, the barriers to providing palliative care to patients with this condition, the role of pharmacotherapy, and the treatment options for feeding problems and the advantages and disadvantages of each option, and suggests an approach to help clinicians provide effective and compassionate decision support to patients with advanced dementia and their family members.	Harvard Univ, Sch Med, Boston, MA USA; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Hebrew Sr Life Inst Aging Res, Boston, MA USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Mitchell, SL (corresponding author), Hebrew Rehabil Ctr Aged, 1200 Ctr St, Boston, MA 02131 USA.	smitchell@hrca.harvard.edu						Ahronheim JC, 1996, ARCH INTERN MED, V156, P2094, DOI 10.1001/archinte.156.18.2094; Ahronheim JC, 2001, J AM GERIATR SOC, V49, P148, DOI 10.1046/j.1532-5415.2001.49035.x; *AM AC HOSP PALL M, POS STAT STAT ART NU; [Anonymous], ALZH DIS FACTS FIG 2; Beard CM, 1996, ANN EPIDEMIOL, V6, P195, DOI 10.1016/1047-2797(95)00068-2; Berger A, 2001, J AM GERIATR SOC, V49, P1570, DOI 10.1046/j.1532-5415.2001.4911257.x; BourdelMarchasson I, 1997, INT J QUAL HEALTH C, V9, P297, DOI 10.1093/intqhc/9.4.297; Brickner Leslea, 2004, J Palliat Med, V7, P411, DOI 10.1089/1096621041349518; BUCHANAN A, 1986, MILBANK Q, V64, P17, DOI 10.2307/3349960; Callahan CM, 2000, J AM GERIATR SOC, V48, P1048, DOI 10.1111/j.1532-5415.2000.tb04779.x; Callahan CM, 1999, J AM GERIATR SOC, V47, P1105, DOI 10.1111/j.1532-5415.1999.tb05235.x; Carey TS, 2006, AM J MED, V119, DOI 10.1016/j.amjmed.2005.11.021; Casarett D, 2005, NEW ENGL J MED, V353, P2607, DOI 10.1056/NEJMsb052907; Casarett DJ, 2001, J AM GERIATR SOC, V49, P1493, DOI 10.1046/j.1532-5415.2001.4911242.x; Chen JH, 2007, J GERONTOL A-BIOL, V62, P531, DOI 10.1093/gerona/62.5.531; Chen JH, 2006, J AM GERIATR SOC, V54, P290, DOI 10.1111/j.1532-5415.2005.00524.x; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; Christakis NA, 1996, J GEN INTERN MED, V11, P422, DOI 10.1007/BF02600190; Clarfield AM, 2006, J GERONTOL A-BIOL, V61, P621, DOI 10.1093/gerona/61.6.621; *DHHS CTR MED MED, NURS HOM COMP; Engel SE, 2006, J AM GERIATR SOC, V54, P1567, DOI 10.1111/j.1532-5415.2006.00900.x; Farlow MR, 2007, AM J MED, V120, P388, DOI 10.1016/j.amjmed.2006.08.036; FINUCANE TE, 1995, J AM GERIATR SOC, V43, P447, DOI 10.1111/j.1532-5415.1995.tb05822.x; Finucane TE, 1996, LANCET, V348, P1421, DOI 10.1016/S0140-6736(96)03369-7; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; FRIED TR, 1995, J GEN INTERN MED, V10, P246, DOI 10.1007/BF02599879; Ganguli M, 1999, J AM GERIATR SOC, V47, P842, DOI 10.1111/j.1532-5415.1999.tb03842.x; Gessert CE, 2000, J AM GERIATR SOC, V48, P1593, DOI 10.1111/j.1532-5415.2000.tb03869.x; Gill SS, 2007, ANN INTERN MED, V146, P775, DOI 10.7326/0003-4819-146-11-200706050-00006; Gillick M R, 2001, J Am Med Dir Assoc, V2, P305, DOI 10.1016/S1525-8610(04)70227-3; Gillick M. R., 2002, ALZHEIMERS CARE QUAR, V3, P227; Gillick MR, 2000, NEW ENGL J MED, V342, P206, DOI 10.1056/NEJM200001203420312; Gillick Muriel R, 2004, J Aging Soc Policy, V16, P1, DOI 10.1300/J031v16n03_01; GROBER ME, 1995, J AM GERIATR SOC, V43, P528, DOI 10.1111/j.1532-5415.1995.tb06100.x; HANRAHAN P, 1995, J AM GERIATR SOC, V43, P56, DOI 10.1111/j.1532-5415.1995.tb06243.x; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Hoffer LJ, 2006, BRIT MED J, V333, P1214, DOI 10.1136/bmj.39021.785197.47; Kayser-Jones J, 1999, J AM GERIATR SOC, V47, P1187, DOI 10.1111/j.1532-5415.1999.tb05198.x; Kiely DK, 2006, ALZ DIS ASSOC DIS, V20, P176, DOI 10.1097/00002093-200607000-00009; Kovach CR, 1996, AM J ALZHEIMERS DIS, V11, P7, DOI DOI 10.1177/153331759601100402; Langmore SE, 2007, ARCH NEUROL-CHICAGO, V64, P58, DOI 10.1001/archneur.64.1.58; Larson EB, 2004, ANN INTERN MED, V140, P501, DOI 10.7326/0003-4819-140-7-200404060-00008; LONGMAN AJ, 1994, OMEGA, V27, P163; LUCHINS DJ, 1993, J AM GERIATR SOC, V41, P25; Luchins DJ, 1997, J AM GERIATR SOC, V45, P1054, DOI 10.1111/j.1532-5415.1997.tb05966.x; Marsh GW, 2000, APPL NURS RES, V13, P187, DOI 10.1053/apnr.2000.7654; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; MCCANN RM, FEEDING TUBE PLACEME; Meier DE, 2001, ARCH INTERN MED, V161, P594, DOI 10.1001/archinte.161.4.594; Miller SC, 2001, AM J MED, V111, P38, DOI 10.1016/S0002-9343(01)00747-1; Miller SC, 2002, J AM GERIATR SOC, V50, P507, DOI 10.1046/j.1532-5415.2002.50118.x; Mitchell S L, 2001, J Am Med Dir Assoc, V2, P10, DOI 10.1097/00130535-200101000-00003; Mitchell SL, 1997, ARCH INTERN MED, V157, P327, DOI 10.1001/archinte.157.3.327; Mitchell SL, 2004, ARCH INTERN MED, V164, P321, DOI 10.1001/archinte.164.3.321; Mitchell SL, 2005, J AM GERIATR SOC, V53, P299, DOI 10.1111/j.1532-5415.2005.53118.x; Mitchell SL, 2003, JAMA-J AM MED ASSOC, V290, P73, DOI 10.1001/jama.290.1.73; Mitchell SL, 2003, J AM GERIATR SOC, V51, P129, DOI 10.1034/j.1601-5215.2002.51021.x; Mitchell SL, 2001, J AM GERIATR SOC, V49, P313, DOI 10.1046/j.1532-5415.2001.4930313.x; Mitchell SL, 2000, J AM GERIATR SOC, V48, P391, DOI 10.1111/j.1532-5415.2000.tb04696.x; Mitchell SL, 2004, JAMA-J AM MED ASSOC, V291, P2734, DOI 10.1001/jama.291.22.2734; MITCHELL SL, 2000, MAKING CHOICES LONG; Mitchell SL, 2007, J PAIN SYMPTOM MANAG, V34, P7, DOI 10.1016/j.jpainsymman.2007.01.003; Mitchell SL, 2006, ALZ DIS ASSOC DIS, V20, P166, DOI 10.1097/00002093-200607000-00008; Mitchell Susan L, 2003, J Am Med Dir Assoc, V4, P27, DOI 10.1097/00130535-200301000-00005; Mitchell Susan L, 2004, J Palliat Med, V7, P808, DOI 10.1089/jpm.2004.7.808; Monteleoni C, 2004, BMJ-BRIT MED J, V329, P491, DOI 10.1136/bmj.329.7464.491; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Murphy K, 1997, J AM GERIATR SOC, V45, P1104, DOI 10.1111/j.1532-5415.1997.tb05974.x; *NAT CTR HLTH STAT, TABL 2 PERC TOT DEAT; *NAT CTR HLTH STAT, 2000, DEATHS PERC TOT DEAT; *NAT CTR HLTH STAT, 2005, NAT VIT STAT REP, V53, P29; *NAT HOSP PALL CAR, NHPCOS FACT FIG 2005; National Hospice Organization, 1996, MED GUID DET PROGN S; National Institutes of Health, 2005, STAT OF THE SCI C ST; Pasman HRW, 2005, ARCH INTERN MED, V165, P1729, DOI 10.1001/archinte.165.15.1729; PECK A, 1990, J AM GERIATR SOC, V38, P1195, DOI 10.1111/j.1532-5415.1990.tb01498.x; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; REISBERG B, 1988, PSYCHOPHARMACOL BULL, V24, P653; Sachs GA, 2004, J GEN INTERN MED, V19, P1057, DOI 10.1111/j.1525-1497.2004.30329.x; Schneider LS, 2006, NEW ENGL J MED, V355, P1525, DOI 10.1056/NEJMoa061240; Schonwetter Ronald S, 2003, Am J Hosp Palliat Care, V20, P105, DOI 10.1177/104990910302000208; Shega Joseph W, 2003, J Palliat Med, V6, P885, DOI 10.1089/109662103322654767; Sieger CE, 2002, J AM GERIATR SOC, V50, P544, DOI 10.1046/j.1532-5415.2002.50124.x; Teno JM, 2002, JAMA-J AM MED ASSOC, V287, P3211, DOI 10.1001/jama.287.24.3211; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; The AM, 2002, BRIT MED J, V325, P1326, DOI 10.1136/bmj.325.7376.1326; van der Steen JT, 2005, MED DECIS MAKING, V25, P210, DOI 10.1177/0272989X05275400; Volandes AE, 2007, ARCH INTERN MED, V167, P828, DOI 10.1001/archinte.167.8.828; VOLICER BJ, 1993, J AM GERIATR SOC, V41, P535, DOI 10.1111/j.1532-5415.1993.tb01891.x; Volicer L, 1997, J AM GERIATR SOC, V45, P1147, DOI 10.1111/j.1532-5415.1997.tb05982.x; VOLICER L, 1994, J GERIATR PSYCH NEUR, V7, P227, DOI 10.1177/089198879400700406; Volicer L, 2001, ALZ DIS ASSOC DIS, V15, P194, DOI 10.1097/00002093-200110000-00005; Volicer L, 2001, CLIN GERIATR MED, V17, P377, DOI 10.1016/S0749-0690(05)70074-4; Wang SY, 1997, J AM GERIATR SOC, V45, P1189, DOI 10.1111/j.1532-5415.1997.tb03768.x; Warden Victoria, 2003, J Am Med Dir Assoc, V4, P9, DOI 10.1097/00130535-200301000-00002; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Wolfson C, 2001, NEW ENGL J MED, V344, P1111, DOI 10.1056/NEJM200104123441501; Won A, 1999, J AM GERIATR SOC, V47, P936, DOI 10.1111/j.1532-5415.1999.tb01287.x	101	28	28	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2007	298	21					2527	2536		10.1001/jama.298.17.jrr70001	http://dx.doi.org/10.1001/jama.298.17.jrr70001			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	237GJ	17986683				2023-01-03	WOS:000251361900018
J	Posner, MR; Hershock, DM; Blajman, CR; Mickiewicz, E; Winquist, E; Gorbounova, V; Tjulandin, S; Shin, DM; Cullen, K; Ervin, TJ; Murphy, BA; Raez, LE; Cohen, RB; Spaulding, M; Tishler, RB; Roth, B; Viroglio, RD; Venkatesan, V; Romanov, I; Agarwala, S; Harter, KW; Dugan, M; Cmelak, A; Markoe, AM; Read, PW; Steinbrenner, L; Colevas, AD; Norris, CM; Haddad, RI				Posner, Marshall R.; Hershock, Diane M.; Blajman, Cesar R.; Mickiewicz, Elizabeth; Winquist, Eric; Gorbounova, Vera; Tjulandin, Sergei; Shin, Dong M.; Cullen, Kevin; Ervin, Thomas J.; Murphy, Barbara A.; Raez, Luis E.; Cohen, Roger B.; Spaulding, Monica; Tishler, Roy B.; Roth, Berta; del Carmen Viroglio, Rosana; Venkatesan, Varagur; Romanov, Ilya; Agarwala, Sanjiv; Harter, K. William; Dugan, Matthew; Cmelak, Anthony; Markoe, Arnold M.; Read, Paul W.; Steinbrenner, Lynn; Colevas, A. Dimitrios; Norris, Charles M., Jr.; Haddad, Robert I.		Tax 324 Study Grp	Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; PHASE-III TRIAL; INDUCTION CHEMOTHERAPY; RADIATION-THERAPY; I-II; RANDOMIZED-TRIAL; ACTIVE-DRUG; RADIOTHERAPY; PRESERVATION; CARBOPLATIN	Background A randomized phase 3 trial of the treatment of squamous-cell carcinoma of the head and neck compared induction chemotherapy with docetaxel plus cisplatin and fluorouracil (TPF) with cisplatin and fluorouracil (PF), followed by chemoradiotherapy. Methods We randomly assigned 501 patients (all of whom had stage III or IV disease with no distant metastases and tumors considered to be unresectable or were candidates for organ preservation) to receive either TPF or PF induction chemotherapy, followed by chemoradiotherapy with weekly carboplatin therapy and radiotherapy for 5 days per week. The primary end point was overall survival. Results With a minimum of 2 years of follow-up (greater/equal 3 years for 69% of patients), significantly more patients survived in the TPF group than in the PF group (hazard ratio for death, 0.70; P=0.006). Estimates of overall survival at 3 years were 62% in the TPF group and 48% in the PF group; the median overall survival was 71 months and 30 months, respectively (P=0.006). There was better locoregional control in the TPF group than in the PF group (P=0.04), but the incidence of distant metastases in the two groups did not differ significantly (P=0.14). Rates of neutropenia and febrile neutropenia were higher in the TPF group; chemotherapy was more frequently delayed because of hematologic adverse events in the PF group. Conclusions Patients with squamous-cell carcinoma of the head and neck who received docetaxel plus cisplatin and fluorouracil induction chemotherapy plus chemoradiotherapy had a significantly longer survival than did patients who received cisplatin and fluorouracil induction chemotherapy plus chemoradiotherapy.	Dana Farber Canc Inst, Boston, MA 02115 USA; Sanofi Aventis, Malvern, PA USA; Hosp Iturraspe, Buenos Aires, Santa Fe, Argentina; Inst Angel H Roffo, Buenos Aires, DF, Argentina; London Reg Canc Ctr, London, ON N6A 4L6, Canada; Russian Acad Med Sci, Canc Res Ctr, Moscow, Russia; Emory Winship Canc Inst, Atlanta, GA USA; Univ Maryland, Greenbaum Canc Ctr, Baltimore, MD 21201 USA; Maine Ctr Canc Med & Blood Disorders, Scarborough, ME USA; Vanderbilt Univ, Nashville, TN USA; Metro Nashville Gen Hosp, Nashville, TN USA; Univ Miami, Sylvester Canc Ctr, Miami, FL 33152 USA; Univ Virginia, Charlottesville, VA USA; Vet Affairs Western New York Healthcare Syst, Buffalo, NY USA; Univ Pittsburgh, Pittsburgh, PA USA; Vincent T Lombardi Canc Res Ctr, Washington, DC USA	Harvard University; Dana-Farber Cancer Institute; Sanofi-Aventis; Western University (University of Western Ontario); Russian Academy of Medical Sciences; University System of Maryland; University of Maryland Baltimore; Vanderbilt University; University of Miami; University of Virginia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Posner, MR (corresponding author), Dana Farber Canc Inst, 44 Binney St,SW 430, Boston, MA 02115 USA.	marshall_posner@dfci.harvard.edu	Ray, Dana M/C-3470-2013; Raez, Luis/AAL-8829-2020; Shin, Dong Moon/G-9649-2013; Romanov, Ilya/O-8613-2017; colevas, alexander/AAP-2415-2021; Tjulandin, Sergei/Y-5069-2018	Raez, Luis/0000-0003-2669-5771; Shin, Dong Moon/0000-0002-8245-4174; Romanov, Ilya/0000-0002-5421-5985; Haddad, Robert/0000-0003-1413-0079				Adelstein DJ, 2003, J CLIN ONCOL, V21, P92, DOI 10.1200/JCO.2003.01.008; Bensadoun RJ, 2006, INT J RADIAT ONCOL, V64, P983, DOI 10.1016/j.ijrobp.2005.09.041; Bernier J, 2004, NEW ENGL J MED, V350, P1945, DOI 10.1056/NEJMoa032641; BERNIER J, 2006, J CLIN ONCOL S, V24, P18; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; CATIMEL G, 1994, ANN ONCOL, V5, P533, DOI 10.1093/oxfordjournals.annonc.a058908; Chitapanarux I, 2007, EUR J CANCER, V43, P1399, DOI 10.1016/j.ejca.2007.03.022; Colevas AD, 1999, J CLIN ONCOL, V17, P3503, DOI 10.1200/JCO.1999.17.11.3503; Colevas AD, 2002, AM J CLIN ONCOL-CANC, V25, P153, DOI 10.1097/00000421-200204000-00010; Cooper JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMoa032646; Denis F, 2004, J CLIN ONCOL, V22, P69, DOI 10.1200/JCO.2004.08.021; Domenge C, 2000, BRIT J CANCER, V83, P1594, DOI 10.1054/bjoc.2000.1512; DOUPLE EB, 1985, CANCER TREAT REV, V12, P111, DOI 10.1016/0305-7372(85)90026-X; Dreyfuss AI, 1996, J CLIN ONCOL, V14, P1672, DOI 10.1200/JCO.1996.14.5.1672; FLEMING ID, 1998, AJCC CANC STAGING HD; Forastiere AA, 2006, J CLIN ONCOL, V24, p284S; Forastiere AA, 2003, NEW ENGL J MED, V349, P2091, DOI 10.1056/NEJMoa031317; Haddad R, 2003, CANCER, V97, P412, DOI 10.1002/cncr.11063; JACOBS MC, 1989, INT J RADIAT ONCOL, V17, P361, DOI 10.1016/0360-3016(89)90451-3; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jeremic B, 2004, J CLIN ONCOL, V22, P3540, DOI 10.1200/JCO.2004.10.076; Lefebvre JL, 1996, J NATL CANCER I, V88, P890, DOI 10.1093/jnci/88.13.890; Lefebvre JL, 2004, J CLIN ONCOL, V22, p495S; PACCAGNELLA A, 1994, J NATL CANCER I, V86, P265, DOI 10.1093/jnci/86.4.265; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Posner MR, 2001, J CLIN ONCOL, V19, P1096, DOI 10.1200/JCO.2001.19.4.1096; Posner MR, 2004, SEMIN ONCOL, V31, P778, DOI 10.1053/j.seminoncol.2004.09.007; Schrijvers D, 2004, ANN ONCOL, V15, P638, DOI 10.1093/annonc/mdh145; Vermorken JB, 2007, NEW ENGL J MED, V357, P1695, DOI 10.1056/NEJMoa071028	30	1191	1260	0	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 25	2007	357	17					1705	1715		10.1056/NEJMoa070956	http://dx.doi.org/10.1056/NEJMoa070956			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223FN	17960013				2023-01-03	WOS:000250355100006
J	Xie, LL; Jiang, Y; Ouyang, P; Chen, J; Doan, H; Herndon, B; Sylvester, JE; Zhang, K; Molteni, A; Reichle, M; Zhang, RQ; Haub, MD; Baybutt, RC; Wang, WQ				Xie, Linglin; Jiang, Yu; Ouyang, Ping; Chen, Jie; Doan, Hieu; Herndon, Betty; Sylvester, Jessica E.; Zhang, Ke; Molteni, Agostino; Reichle, Marie; Zhang, Rongqing; Haub, Mark D.; Baybutt, Richard C.; Wang, Weiqun			Effects of dietary calorie restriction or exercise on the PI3K and ras signaling pathways in the skin of mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; ENERGY RESTRICTION; INTESTINAL TUMORIGENESIS; MESSENGER-RNA; CANCER; PROTEIN; RATS; CARCINOGENESIS; INHIBITION; EXPRESSION	Weight control by exercise and dietary calorie restriction (DCR) has been associated with reduced cancer risk, but the underlying mechanisms are not well understood. This study was designed to compare the effects of weight loss by increasing physical activity or decreasing calorie intake on tumor promoter-induced Ras-MAPK and PI3K-Akt pathways. SENCAR mice were randomly assigned to one of the following five groups: ad libitum-fed sedentary control, ad libitum-fed exercise (AL+Exe), exercise but pair-fed at the amount as controls (PF+Exe), 20% DCR, and 20% DCR plus exercise (DCR+Exe). After 10 weeks, body weight and body fat significantly decreased in the groups of DCR, DCR + Exe, and PF + Exe when compared with the controls. AL + Exe did not induce weight loss due to, at least in part, increased food intake. Plasma IGF-1 levels reduced significantly in DCR and DCR+Exe but not PF+Exe. The protein H-Ras and activated Ras-GTP significantly decreased in TPA-induced skin tissues of DCR-fed mice but not exercised mice. PI3K protein, phosphoserine Akt, and p42/p44-MAPK were reduced, however, in both DCR and PF+Exe groups. Immunohistochemistry demonstrated that the significantly reduced H-Ras occurred in subcutaneous fat cells, while the reduced PI3K and PCNA took place only in the epidermis. Plasma leptin decreased in PF + Exe, DCR, and DCR + Exe, while the caspase-3 activity increased in DCR+Exe only. Genomic microarray analysis further indicated that the expression of 34 genes relevant to PI3K and 31 genes to the MAPK pathway were significantly regulated by either DCR or PF+Exe treatments. The reduced PI3K in PF+Exe mice was partially reversed by IGF-1 treatment. The overall results of this study demonstrated that DCR abrogated both Ras and PI3K signaling, which might inhibit TPA-induced proliferation and anti-apoptosis. Selective inhibition of PI3K by PF+Exe but not AL+Exe seems more attributable to the magnitude of the caloric deficit and/or body fat loss than diet versus exercise comparison.	Kansas State Univ, Dept Human Nutr, Manhattan, KS 66506 USA; Kansas State Univ, Dept Human Nutr, Manhattan, KS 66506 USA; Kansas State Univ, Dept Stat, Manhattan, KS 66506 USA; Univ Missouri, Sch Med, Kansas City, MO 64108 USA	Kansas State University; Kansas State University; Kansas State University; University of Missouri System; University of Missouri Kansas City	Wang, WQ (corresponding author), Kansas State Univ, Dept Human Nutr, Manhattan, KS 66506 USA.	wwang@ksu.edu	Haub, Mark/E-7846-2010		NATIONAL CANCER INSTITUTE [R01CA106397] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015563] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106397] Funding Source: Medline; NCRR NIH HHS [P20 RR15563] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Badman MK, 2005, SCIENCE, V307, P1909, DOI 10.1126/science.1109951; Benito M, 1996, INT J BIOCHEM CELL B, V28, P499, DOI 10.1016/1357-2725(95)00168-9; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bergstrom A, 2001, INT J CANCER, V91, P421, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1053&gt;3.0.CO;2-T; Berstein L M, 2005, Adv Gerontol, V16, P51; Birt DF, 2001, CANCER EPIDEM BIOMAR, V10, P679; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; BOUTWELL RK, 1964, PROG EXP TUMOR RES, V4, P207; Dean DJ, 1998, AGING-CLIN EXP RES, V10, P303, DOI 10.1007/BF03339792; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Efron B., 1986, STAT SCI, P54; Figlewicz DP, 2001, PHYSIOL BEHAV, V73, P229, DOI 10.1016/S0031-9384(01)00486-3; GARROW JS, 1995, EUR J CLIN NUTR, V49, P1; HAGAN H, 2003, EMBO REP, V3, P418; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; HURSTING SD, 1994, P NATL ACAD SCI USA, V91, P7036, DOI 10.1073/pnas.91.15.7036; HURSTING SD, 1993, CANCER RES, V53, P2750; International Agency for Research on Cancer, 2002, IARC HDB CANC PREV, V6; Kishimoto H, 2003, CELL STRUCT FUNCT, V28, P11; KLURFELD DM, 1989, J NUTR, V119, P286, DOI 10.1093/jn/119.2.286; Kritchevsky D, 2003, J NUTR, V133, p3827S, DOI 10.1093/jn/133.11.3827S; KRITCHEVSKY D, 1995, EUR J CANCER PREV, V4, P445, DOI 10.1097/00008469-199512000-00002; Liu YH, 2002, CANCER EPIDEM BIOMAR, V11, P299; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Lu J, 2007, EXP BIOL MED, V232, P473; Mai V, 2003, CANCER RES, V63, P1752; MARIANO B, 1987, ANNU REV BIOCHEM, V56, P779; Mastorakos G, 2005, HORM METAB RES, V37, P577, DOI 10.1055/s-2005-870426; Michna L, 2006, CARCINOGENESIS, V27, P2108, DOI 10.1093/carcin/bgl057; Miyazawa-Hoshimoto S, 2005, AM J PHYSIOL-ENDOC M, V288, pE1128, DOI 10.1152/ajpendo.00003.2004; Mukherjee P, 1999, JNCI-J NATL CANCER I, V91, P512, DOI 10.1093/jnci/91.6.512; Palmqvist R, 2002, GUT, V50, P642, DOI 10.1136/gut.50.5.642; POLLARD M, 1984, CANCER TREAT REP, V68, P405; Proebstle TM, 1996, EUR J CANCER, V32A, P1664, DOI 10.1016/0959-8049(95)00534-X; Przybyszewski J, 2001, CARCINOGENESIS, V22, P1421, DOI 10.1093/carcin/22.9.1421; Rambaratsingh RA, 2003, J BIOL CHEM, V278, P52792, DOI 10.1074/jbc.M308240200; ROEBUCK BD, 1981, CANCER RES, V41, P888; Roth GS, 2002, HORM METAB RES, V34, P378, DOI 10.1055/s-2002-33469; Rusch HP, 1944, CANCER RES, V4, P116; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Smolle J, 1995, AM J DERMATOPATH, V17, P555, DOI 10.1097/00000372-199512000-00005; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; WEINDRUCH R, 1988, RETARDATION AGING DI, P73; Werner H, 2000, CELL MOL LIFE SCI, V57, P932, DOI 10.1007/PL00000735; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Wu YP, 2003, CANCER RES, V63, P4384; Wu YP, 2002, CANCER RES, V62, P1030; Zhu ZJ, 2002, MOL CARCINOGEN, V35, P51, DOI 10.1002/mc.10073	54	44	46	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28025	28035		10.1074/jbc.M604857200	http://dx.doi.org/10.1074/jbc.M604857200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17646168	Green Submitted, hybrid			2023-01-03	WOS:000249455600052
J	Callan, B; Gillespie, I				Callan, Benedicte; Gillespie, Iain			The path to new medicines	NATURE			English	Editorial Material									OECD, Div Biotechnol, Paris, France	Organisation for Economic Co-operation & Development (OECD)	Callan, B (corresponding author), OECD, Div Biotechnol, Paris, France.								0	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 13	2007	449	7159					164	165		10.1038/449164a	http://dx.doi.org/10.1038/449164a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	209NF	17851511				2023-01-03	WOS:000249394500035
J	Hotez, PJ; Molyneux, DH; Fenwick, A; Kumaresan, J; Sachs, SE; Sachs, JD; Savioli, L				Hotez, Peter J.; Molyneux, David H.; Fenwick, Alan; Kumaresan, Jacob; Sachs, Sonia Ehrlich; Sachs, Jeffrey D.; Savioli, Lorenzo			Current concepts - Control of neglected tropical diseases	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TRANSMITTED HELMINTH INFECTIONS; LYMPHATIC FILARIASIS; HEALTH; SCHISTOSOMIASIS; CHEMOTHERAPY; HOOKWORM; LEISHMANIASIS; OPPORTUNITIES; ELIMINATION; INTEGRATION		George Washington Univ, Sabin Vaccine Inst, Washington, DC 20037 USA; George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20037 USA; Univ Liverpool Liverpool Sch Trop Med, Lymphat Filariasis Support Ctr, Liverpool, Merseyside, England; Univ Liverpool Liverpool Sch Trop Med, Global Alliance Eliminate Lymphat Filariasis, Liverpool, Merseyside, England; Univ London Imperial Coll Sci Technol & Med, Schistosomiasis Control Initiat, London, England; Int Trachoma Initiat, New York, NY USA; Columbia Univ, Earth Inst, New York, NY USA; WHO, Dept Neglected Trop Dis, Geneva, Switzerland	George Washington University; George Washington University; Liverpool School of Tropical Medicine; University of Liverpool; Liverpool School of Tropical Medicine; Imperial College London; Columbia University; World Health Organization	Hotez, PJ (corresponding author), George Washington Univ, Sabin Vaccine Inst, Ross Hall 736,2300 Eye St NW, Washington, DC 20037 USA.	mtmpjh@gwumc.edu	Loukas, Alex/B-7355-2014	Loukas, Alex/0000-0002-0896-8441; Hotez, Peter/0000-0001-8770-1042				Albonico M, 2004, INT J PARASITOL, V34, P1205, DOI 10.1016/j.ijpara.2004.08.001; Alvar J, 2006, TRENDS PARASITOL, V22, P552, DOI 10.1016/j.pt.2006.09.004; Alvar J, 2006, ADV PARASIT, V61, P223, DOI 10.1016/S0065-308X(05)61006-8; [Anonymous], 2006, Wkly Epidemiol Rec, V81, P221; Basanez MG, 2006, PLOS MED, V3, P1454, DOI 10.1371/journal.pmed.0030371; Bergquist NR, 2005, TRENDS PARASITOL, V21, P112, DOI 10.1016/j.pt.2005.01.001; Bethony J, 2006, LANCET, V367, P1521, DOI 10.1016/S0140-6736(06)68653-4; Blackburn BG, 2006, AM J TROP MED HYG, V75, P650, DOI 10.4269/ajtmh.2006.75.650; Bleakley H, 2007, Q J ECON, V122, P73, DOI 10.1162/qjec.121.1.73; Boatin BA, 2006, ADV PARASIT, V61, P349, DOI 10.1016/S0065-308X(05)61009-3; Borkow G, 2006, PARASITE IMMUNOL, V28, P605, DOI 10.1111/j.1365-3024.2006.00918.x; Brady MA, 2006, TRENDS PARASITOL, V22, P285, DOI 10.1016/j.pt.2006.05.007; Brooker S, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-99; Canning D, 2006, T ROY SOC TROP MED H, V100, P499, DOI 10.1016/j.trstmh.2006.02.001; Capron A, 2005, TRENDS PARASITOL, V21, P143, DOI 10.1016/j.pt.2005.01.003; Chirac P, 2006, LANCET, V367, P1560, DOI 10.1016/S0140-6736(06)68672-8; Coler RN, 2005, TRENDS PARASITOL, V21, P244, DOI 10.1016/j.pt.2005.03.006; Croft SL, 2006, INDIAN J MED RES, V123, P399; Croft SL, 2005, TRENDS PARASITOL, V21, P508, DOI 10.1016/j.pt.2005.08.026; de Silva NR, 2003, TRENDS PARASITOL, V19, P547, DOI 10.1016/j.pt.2003.10.002; Desjeux P, 2001, T ROY SOC TROP MED H, V95, P239, DOI 10.1016/S0035-9203(01)90223-8; Druilhe P, 2005, TRENDS PARASITOL, V21, P359, DOI 10.1016/j.pt.2005.06.011; El-Sayed NM, 2005, SCIENCE, V309, P404, DOI 10.1126/science.1112181; Engels D, 2005, WORLD CL PARASITES, V10, P207; Fenwick A, 2006, T ROY SOC TROP MED H, V100, P200, DOI 10.1016/j.trstmh.2005.03.014; Fenwick A, 2005, LANCET, V365, P1029, DOI 10.1016/s0140-6736(05)71134-x; Fevre EM, 2006, ADV PARASIT, V61, P167, DOI 10.1016/S0065-308X(05)61005-6; Frick KD, 2003, AM J TROP MED HYG, V69, P1; Hotez P, 2006, ADV EXP MED BIOL, V582, P23; Hotez PJ, 2006, TRENDS PARASITOL, V22, P327, DOI 10.1016/j.pt.2006.05.004; Hotez PJ, 2006, VACCINE, V24, P5787, DOI 10.1016/j.vaccine.2006.05.008; Hotez PJ, 2006, PLOS MED, V3, P576, DOI 10.1371/journal.pmed.0030102; Hotez PJ, 2004, J INVEST MED, V52, P246, DOI 10.1136/jim-52-04-32; HOTEZ PJ, 2006, BROWN WORLD AFFAIRS, V12, P247; Hunt P, 2006, T ROY SOC TROP MED H, V100, P603, DOI 10.1016/j.trstmh.2006.03.001; Kabatereine NB, 2006, TRENDS PARASITOL, V22, P332, DOI 10.1016/j.pt.2006.05.001; Kjetland EF, 2006, AIDS, V20, P593, DOI 10.1097/01.aids.0000210614.45212.0a; Kumaresan J, 2005, EYE, V19, P1067, DOI 10.1038/sj.eye.6701963; Lammie PJ, 2006, TRENDS PARASITOL, V22, P313, DOI 10.1016/j.pt.2006.05.009; Laxminarayan R, 2006, LANCET, V367, P1193, DOI 10.1016/S0140-6736(06)68440-7; LEVINE R, 2004, MILLIONS SAVED PROVE, P83; *MED FRONT, CAMP ACC ESS MED; Mohammed KA, 2006, TRENDS PARASITOL, V22, P340, DOI 10.1016/j.pt.2006.05.010; Molyneux DH, 2005, PLOS MED, V2, P1064, DOI 10.1371/journal.pmed.0020336; Molyneux DH, 2006, LANCET, V367, P966, DOI 10.1016/S0140-6736(06)68404-3; Molyneux DH, 2004, LANCET, V364, P380, DOI 10.1016/S0140-6736(04)16728-7; Morel CM, 2005, SCIENCE, V309, P401, DOI 10.1126/science.1115538; Osei-Atweneboano MY, 2007, LANCET, V369, P2021, DOI 10.1016/S0140-6736(07)60942-8; Ottesen EA, 2006, ADV PARASIT, V61, P395, DOI 10.1016/S0065-308X(05)61010-X; *PAN AM HLTH ORG, 2006, 15 M SO CON INT COMM; Rabinovich NR, 2006, TRENDS PARASITOL, V22, P277, DOI 10.1016/j.pt.2006.05.008; Ramaiah KD, 2000, PARASITOL TODAY, V16, P251, DOI 10.1016/S0169-4758(00)01643-4; Ramzy RMR, 2006, LANCET, V367, P1980; Ramzy RMR, 2006, LANCET, V367, P992, DOI 10.1016/S0140-6736(06)68426-2; Raso G, 2004, INT J EPIDEMIOL, V33, P1092, DOI 10.1093/ije/dyh241; Remme JHF, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P433; Renslo AR, 2006, NAT CHEM BIOL, V2, P701, DOI 10.1038/nchembio837; Ruiz-Tiben E, 2006, ADV PARASIT, V61, P275, DOI 10.1016/S0065-308X(05)61007-X; Sachs JD, 2006, SCIENCE, V311, P1521, DOI 10.1126/science.1126851; Savioli L, 2002, WORLD CL PARASITES, V2, P25; Steinmann P, 2006, LANCET INFECT DIS, V6, P411, DOI 10.1016/S1473-3099(06)70521-7; Taylor MJ, 2005, ADV PARASIT, V60, P245, DOI 10.1016/S0065-308X(05)60004-8; Utzinger J, 2005, ACTA TROP, V96, P69, DOI 10.1016/j.actatropica.2005.08.004; Weil GJ, 2007, TRENDS PARASITOL, V23, P78, DOI 10.1016/j.pt.2006.12.001; *WHO, WHO GLOB HLTH ATL; WHO, 2006, PREV CHEM HUM HELM; *WHO, 2006, WKLY EPIDEMIOL REC, V81, P71; *WHO, 2005, WKLY EPIDEMIOL REC, V80, P289; *WHO, 2006, WKLY EPIDEMIOL REC, V81, P173; WHO, 2005, 3 GLOB M PARTN PAR C; WHO, 2002, WHO TECHN REP SER, V912; WHO (World Health Organization), 2006, 59 WORLD HLTH ASS; World Health Organization, 2004, WORLD HLTH REP 2004; Xiao SH, 2005, ACTA TROP, V94, P1, DOI 10.1016/j.actatropica.2005.01.013; Yamagata Y, 2006, ADV PARASIT, V61, P129, DOI 10.1016/S0065-308X(05)61004-4	75	1046	1088	3	203	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 6	2007	357	10					1018	1027		10.1056/NEJMra064142	http://dx.doi.org/10.1056/NEJMra064142			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206VK	17804846				2023-01-03	WOS:000249210800008
J	Okie, S				Okie, Susan			An elusive balance - Residents' work hours and the continuity of care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ADVERSE EVENTS											Barger LK, 2006, PLOS MED, V3, P2440, DOI 10.1371/journal.pmed.0030487; Petersen L A, 1998, Jt Comm J Qual Improv, V24, P77; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Vidyarthi AR, 2006, J HOSP MED, V1, P257, DOI 10.1002/jhm.103	4	67	68	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2007	356	26					2665	2667		10.1056/NEJMp078085	http://dx.doi.org/10.1056/NEJMp078085			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	183HS	17596598				2023-01-03	WOS:000247564500001
J	Bishop, NA; Guarente, L				Bishop, Nicholas A.; Guarente, Leonard			Two neurons mediate diet-restriction-induced longevity in C-elegans	NATURE			English	Article							LIFE-SPAN; CAENORHABDITIS-ELEGANS; CHEMOSENSORY NEURONS; CALORIC RESTRICTION; LARVAL DEVELOPMENT; OXIDATIVE STRESS; METABOLIC-RATE; GENETICS; INTERFERENCE; SPECIFY	Dietary restriction extends lifespan and retards age-related disease in many species and profoundly alters endocrine function in mammals. However, no causal role of any hormonal signal in diet-restricted longevity has been demonstrated. Here we show that increased longevity of diet-restricted Caenorhabditis elegans requires the transcription factor gene skn-1 acting in the ASIs, a pair of neurons in the head. Dietary restriction activates skn-1 in these two neurons, which signals peripheral tissues to increase metabolic activity. These findings demonstrate that increased lifespan in a diet-restricted metazoan depends on cell non-autonomous signalling from central neuronal cells to non-neuronal body tissues, and suggest that the ASI neurons mediate diet-restriction-induced longevity by an endocrine mechanism.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Guarente, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	leng@mit.edu						Alcedo J, 2004, NEURON, V41, P45, DOI 10.1016/S0896-6273(03)00816-X; An JH, 2003, GENE DEV, V17, P1882, DOI 10.1101/gad.1107803; Apfeld J, 1999, NATURE, V402, P804, DOI 10.1038/45544; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; Bartke A, 2001, NATURE, V414, P412, DOI 10.1038/35106646; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; Braeckman BP, 2002, AGING CELL, V1, P82, DOI 10.1046/j.1474-9728.2002.00021.x; BRENNER S, 1974, GENETICS, V77, P71; de Cabo R, 2003, EXP GERONTOL, V38, P631, DOI 10.1016/S0531-5565(03)00055-X; Dowell P, 2005, ANNU REV BIOCHEM, V74, P515, DOI 10.1146/annurev.biochem.73.011303.074027; Golden TR, 2002, AGING CELL, V1, P117, DOI 10.1046/j.1474-9728.2002.00015.x; Houthoofd K, 2003, EXP GERONTOL, V38, P947, DOI 10.1016/S0531-5565(03)00161-X; Houthoofd K, 2002, EXP GERONTOL, V37, P1359, DOI 10.1016/S0531-5565(02)00172-9; Houthoofd K, 2002, EXP GERONTOL, V37, P1371, DOI 10.1016/S0531-5565(02)00173-0; Jansen G, 1999, NAT GENET, V21, P414, DOI 10.1038/7753; Jin Y., 1999, C ELEGANS PRACTICAL, P69; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kim K, 2005, DEV BIOL, V286, P136, DOI 10.1016/j.ydbio.2005.07.024; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Lawless JF., 2011, STAT MODELS METHODS, V2nd ed.; Li C, 2005, PARASITOLOGY, V131, pS109, DOI 10.1017/S0031182005009376; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; McKay RM, 2003, DEV CELL, V4, P131, DOI 10.1016/S1534-5807(02)00411-2; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mobbs CV, 2001, J GERONTOL A-BIOL, V56, P34, DOI 10.1093/gerona/56.suppl_1.34; Peckol EL, 1999, DEVELOPMENT, V126, P1891; Ren PF, 1996, SCIENCE, V274, P1389, DOI 10.1126/science.274.5291.1389; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Walker G, 2005, MECH AGEING DEV, V126, P929, DOI 10.1016/j.mad.2005.03.014; Wang D, 2005, NATURE, V436, P593, DOI 10.1038/nature04010; Wilson MA, 2006, AGING CELL, V5, P59, DOI 10.1111/j.1474-9726.2006.00192.x; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	37	483	507	1	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 31	2007	447	7144					545	+		10.1038/nature05904	http://dx.doi.org/10.1038/nature05904			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	172YZ	17538612				2023-01-03	WOS:000246842000038
J	Hayee, B; Forgacs, I				Hayee, Bu'Hussain; Forgacs, Ian			Psychological approach to managing irritable bowel syndrome	BMJ-BRITISH MEDICAL JOURNAL			English	Review							FUNCTIONAL GASTROINTESTINAL DISORDERS; COGNITIVE-BEHAVIOR THERAPY; METAANALYSIS; ANTIDEPRESSANTS; HYPNOTHERAPY; MEDICATIONS; DEPRESSION; MANAGEMENT		Kings Coll Hosp London, Dept Gastroenterol, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital	Forgacs, I (corresponding author), Kings Coll Hosp London, Dept Gastroenterol, Denmark Hill, London SE5 9RS, England.	ian.forgacs@kcl.ac.uk		Hayee, Bu'Hussain/0000-0003-1670-8815				BERGERON CM, 1985, AM J GASTROENTEROL, V80, P448; Creed F, 2006, GUT, V55, P1065, DOI 10.1136/gut.2005.086348; CREED F, 1994, BRIT MED J, V309, P1647, DOI 10.1136/bmj.309.6969.1647; DeRubeis RJ, 2005, ARCH GEN PSYCHIAT, V62, P409, DOI 10.1001/archpsyc.62.4.409; Furukawa TA, 2002, BMJ-BRIT MED J, V325, P991, DOI 10.1136/bmj.325.7371.991; Herschbach P, 1999, PSYCHOSOM MED, V61, P148, DOI 10.1097/00006842-199903000-00005; Heymann-Monnikes I, 2000, AM J GASTROENTEROL, V95, P981; Hutton J, 2005, EUR J GASTROEN HEPAT, V17, P11, DOI 10.1097/00042737-200501000-00003; Jackson JL, 2000, AM J MED, V108, P65, DOI 10.1016/S0002-9343(99)00299-5; JONES J, 2000, BRIT SOC GASTROENTER; Jones R, 2006, ALIMENT PHARM THER, V24, P879, DOI 10.1111/j.1365-2036.2006.03044.x; Kennedy T, 2005, BRIT MED J, V331, P435, DOI 10.1136/bmj.38545.505764.06; Lackner JA, 2004, J CONSULT CLIN PSYCH, V72, P1100, DOI 10.1037/0022-006X.72.6.1100; Lea R, 2004, Minerva Med, V95, P443; Longstreth GF, 2006, GASTROENTEROLOGY, V130, P1480, DOI 10.1053/j.gastro.2005.11.061; Olden KW, 2005, CNS SPECTRUMS, V10, P891, DOI 10.1017/S1092852900019866; Parry S, 2005, EUR J GASTROEN HEPAT, V17, P5, DOI 10.1097/00042737-200501000-00002; *ROYAL COL PSYCH, COGN BEH THER; RUMSEY N, 1991, CONFIDENT MANAGEMENT, P33; St John of God Health Care, 2019, OUR VIS; Tack J, 2006, GUT, V55, P1095, DOI 10.1136/gut.2005.077503; Talley NJ, 2006, GUT, V55, P1694, DOI 10.1136/gut.2006.108837; Toner BB, 2005, CNS SPECTRUMS, V10, P883, DOI 10.1017/S1092852900019854; Whorwell PJ, 2006, INT J CLIN EXP HYP, V54, P21, DOI 10.1080/00207140500323006; Whorwell PJ, 2005, ALIMENT PHARM THER, V22, P1061, DOI 10.1111/j.1365-2036.2005.02697.x; Wilhelmsen I, 2000, GUT, V47, P73; Wilson S, 2006, ALIMENT PHARM THER, V24, P769, DOI 10.1111/j.1365-2036.2006.03028.x	27	26	28	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 26	2007	334	7603					1105	1109		10.1136/bmj.39199.679236.AE	http://dx.doi.org/10.1136/bmj.39199.679236.AE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	174XB	17525453	Green Published			2023-01-03	WOS:000246975000035
J	Goldenberg, DM; Sharkey, RM				Goldenberg, D. M.; Sharkey, R. M.			Novel radiolabeled antibody conjugates	ONCOGENE			English	Review						cancer; monoclonal antibodies; pretargeting; radioimmunotherapy; radionuclides	NON-HODGKINS-LYMPHOMA; MEDULLARY-THYROID CANCER; CEA MONOCLONAL-ANTIBODY; CARCINOEMBRYONIC-ANTIGEN RADIOIMMUNOTHERAPY; GENETICALLY-ENGINEERED ANTIBODIES; INDIUM-111-LABELED DTPA DIMER; I-131-LABELED BIVALENT HAPTEN; METASTATIC COLORECTAL-CANCER; ONCOLOGIC DRUG DEVELOPMENT; PHASE-I TRIAL	This article reviews the development of radioimmuno-conjugates as a new class of cancer therapeutics. Numerous conjugates involving different antigen targets, anti body forms, radionuclides and methods of radiochemistry have been studied in the half-century since radioactive antibodies were first used in model systems to selectively target radiation to tumors. Whereas directly conjugated antibodies, fragments and subfragments have shown promise preclinically, the same approaches have not gained success in patients except in radiosensitive hematological neoplasms, or in settings involving minimal or locoregional disease. The separation of tumor targeting from the delivery of the therapeutic radionuclide in a multistep process called pretargeting has the potential to overcome many of the limitations of conventional, or one-step, radio immunotherapy, with initial preclinical and clinical data showing increased sensitivity, specificity and higher radiation doses delivered. Our particular focus in pretargeting is the use of bispecific, trimeric (three Fab's) constructs made by a new antibody engineering method termed 'dock-and-lock.'	Garden State Canc Ctr, Ctr Mol Med & Immunol, Belleville, NJ 07109 USA		Goldenberg, DM (corresponding author), Garden State Canc Ctr, Ctr Mol Med & Immunol, 820 Belleville Ave, Belleville, NJ 07109 USA.	dmg.gscancer@att.net			NATIONAL CANCER INSTITUTE [P01CA103985] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA103985] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELNABI HH, 1990, J NUCL MED, V31, P1975; ABDELNABI HH, 1987, RADIOLOGY, V164, P617, DOI 10.1148/radiology.164.3.3303117; Alvarez RD, 1997, GYNECOL ONCOL, V65, P94, DOI 10.1006/gyno.1996.4577; Alvarez RD, 2002, CLIN CANCER RES, V8, P2806; Axworthy DB, 2000, P NATL ACAD SCI USA, V97, P1802, DOI 10.1073/pnas.97.4.1802; BALE W F, 1957, Adv Biol Med Phys, V5, P285; BALE WF, 1960, CANCER RES, V20, P1488; Batra SK, 2002, CURR OPIN BIOTECH, V13, P603, DOI 10.1016/S0958-1669(02)00352-X; BEHR TM, 1995, CANCER RES, V55, P3825; Binz HK, 2005, NAT BIOTECHNOL, V23, P1257, DOI 10.1038/nbt1127; Boerman OC, 1999, CANCER RES, V59, P4400; Boerman OC, 2003, J NUCL MED, V44, P400; BUCHSBAUM DJ, 1995, CANCER RES, V55, pS5729; Cardillo TM, 2002, INT J CANCER, V97, P386, DOI 10.1002/ijc.1613; Chatal JF, 2006, J CLIN ONCOL, V24, P1705, DOI 10.1200/JCO.2005.04.4917; CHETANNEAU A, 1994, NUCL MED COMMUN, V15, P972, DOI 10.1097/00006231-199412000-00009; Colcher D, 1998, Q J NUCL MED, V42, P225; Crow DM, 2005, BIOCONJUGATE CHEM, V16, P1117, DOI 10.1021/bc0500948; Davis TA, 2004, CLIN CANCER RES, V10, P7792, DOI 10.1158/1078-0432.CCR-04-0756; DENARDO GL, 1995, INT J BIOL MARKER, V10, P67, DOI 10.1177/172460089501000201; DeNardo SJ, 1997, P NATL ACAD SCI USA, V94, P4000, DOI 10.1073/pnas.94.8.4000; DeNardo SJ, 1997, J NUCL MED, V38, P1180; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Forero A, 2005, CANCER BIOTHER RADIO, V20, P467, DOI 10.1089/cbr.2005.20.467; Gautherot E, 1997, CANCER, V80, P2618; Gautherot E, 2000, J NUCL MED, V41, P480; Gestin JF, 2001, J NUCL MED, V42, P146; Goetz C, 2003, J NEURO-ONCOL, V62, P321, DOI 10.1023/A:1023309927635; Gold DV, 2003, CLIN CANCER RES, V9, p3929S; Goldenberg D M, 1990, Cancer Treat Res, V51, P273; Goldenberg D M, 1997, J Nucl Med Technol, V25, P18; Goldenberg D. M., 1992, International Journal of Biological Markers, V7, P183; GOLDENBERG DM, 1980, SCIENCE, V208, P1284, DOI 10.1126/science.7375942; GOLDENBERG DM, 1974, CANCER RES, V34, P1; GOLDENBERG DM, 1990, CANCER RES, V50, pS909; GOLDENBERG DM, 1992, J NUCL MED, V33, P803; Goldenberg DM, 2006, J CLIN ONCOL, V24, P823, DOI 10.1200/JCO.2005.03.8471; GOLDENBERG DM, 1978, NEW ENGL J MED, V298, P1384, DOI 10.1056/NEJM197806222982503; GOLDENBERG DM, 1991, J CLIN ONCOL, V9, P548, DOI 10.1200/JCO.1991.9.4.548; GOLDENBERG DM, 1993, J NUCL MED, V34, P61; Goldenberg DM, 2001, CRIT REV ONCOL HEMAT, V39, P195; GOODWIN DA, 1994, CANCER RES, V54, P5937; GOODWIN DA, 1986, NUCL MED BIOL, V13, P383, DOI 10.1016/0883-2897(86)90015-2; Graves SS, 2003, CLIN CANCER RES, V9, P3712; Griffiths GL, 2004, J NUCL MED, V45, P30; Hernandez MC, 2004, INT J RADIAT ONCOL, V59, P1274, DOI 10.1016/j.ijrobp.2004.02.065; JAIN R K, 1991, Current Opinion in Oncology, V3, P1105, DOI 10.1097/00001622-199112000-00020; Jana S, 2006, SEMIN NUCL MED, V36, P51, DOI 10.1053/j.semnuclmed.2005.09.001; KAMINSKI MS, 1993, NEW ENGL J MED, V329, P459, DOI 10.1056/NEJM199308123290703; Karacay H, 2000, BIOCONJUGATE CHEM, V11, P842, DOI 10.1021/bc0000379; Karacay H, 2005, CLIN CANCER RES, V11, P7879, DOI 10.1158/1078-0432.CCR-05-1246; Karacay H, 2002, BIOCONJUGATE CHEM, V13, P1054, DOI 10.1021/bc0200172; Kelloff G, 2005, CLIN CANCER RES, V11, P2785, DOI 10.1158/1078-0432.CCR-04-2626; Kelloff GJ, 2005, CLIN CANCER RES, V11, P7967, DOI 10.1158/1078-0432.CCR-05-1302; Kelly MP, 2006, J NUCL MED, V47, P716; Kenanova Vania, 2006, Expert Opin Drug Deliv, V3, P53, DOI 10.1517/17425247.3.1.53; KIM EE, 1980, CANCER RES, V40, P3008; KORNGOLD L, 1954, CANCER RES, V14, P96; Kraeber-Bodere F, 2006, J NUCL MED, V47, P247; Kraeber-Bodere F, 2003, CLIN CANCER RES, V9, p3973S; Kraeber-Bodere F, 2002, MOL CANCER THER, V1, P267; Kraeber-Bodere F, 1999, CLIN CANCER RES, V5, p3190S; LAMKI LM, 1990, RADIOLOGY, V174, P147, DOI 10.1148/radiology.174.1.2294542; LARSON SM, 1990, CANCER RES, V50, pS892; LEDOUSSAL JM, 1993, J NUCL MED, V34, P1662; LEDOUSSAL JM, 1989, J NUCL MED, V30, P1358; Liersch T, 2005, J CLIN ONCOL, V23, P6763, DOI 10.1200/JCO.2005.18.622; MACH JP, 1980, ONCODEV BIOL MED, V1, P49; MACH JP, 1983, CANCER RES, V43, P5593; Mahe MA, 1999, CLIN CANCER RES, V5, p3249S; Masters GR, 2006, GYNECOL ONCOL, V102, P462, DOI 10.1016/j.ygyno.2005.12.004; McBride WJ, 2006, J NUCL MED, V47, P1678; MCCARDLE RJ, 1966, J NUCL MED, V7, P837; Meredith RF, 2001, CANCER BIOTHER RADIO, V16, P305, DOI 10.1089/108497801753131381; Meredith RF, 2006, INT J RADIAT ONCOL, V66, pS23, DOI 10.1016/j.ijrobp.2006.05.068; Meredith RF, 2006, INT J RADIAT ONCOL, V66, pS15, DOI 10.1016/j.ijrobp.2006.04.059; MURRAY JL, 1994, CANCER, V73, P1057, DOI 10.1002/1097-0142(19940201)73:3+<1057::AID-CNCR2820731345>3.0.CO;2-3; Paganelli G, 2006, NEUROL RES, V28, P518, DOI 10.1179/016164106X116782; PATT YZ, 1990, J CLIN ONCOL, V8, P1246, DOI 10.1200/JCO.1990.8.7.1246; PELTIER P, 1993, J NUCL MED, V34, P1267; PRESSMAN D, 1953, CANCER, V6, P619, DOI 10.1002/1097-0142(195305)6:3<619::AID-CNCR2820060319>3.0.CO;2-Y; REARDAN DT, 1985, NATURE, V316, P265, DOI 10.1038/316265a0; Reardon DA, 2006, J CLIN ONCOL, V24, P115, DOI 10.1200/JCO.2005.03.4082; Richman CM, 2005, CLIN CANCER RES, V11, P5920, DOI 10.1158/1078-0432.CCR-05-0211; Riva P, 1999, ACTA ONCOL, V38, P351; Rossi EA, 2006, P NATL ACAD SCI USA, V103, P6841, DOI 10.1073/pnas.0600982103; Rossi EA, 2005, CLIN CANCER RES, V11, p7122S, DOI 10.1158/1078-0432.CCR-1004-0020; Rossi EA, 2003, CLIN CANCER RES, V9, p3886S; Sharkey RM, 2006, CANCER INVEST, V24, P82, DOI 10.1080/07357900500449553; Sharkey RM, 2005, CLIN CANCER RES, V11, p7109S, DOI 10.1158/1078-0432.CCR-1004-0009; Sharkey RM, 2005, NAT MED, V11, P1250, DOI 10.1038/nm1322; Sharkey RM, 2005, LEUKEMIA, V19, P1064, DOI 10.1038/sj.leu.2403751; Sharkey RM, 2005, J NUCL MED, V46, P620; SHARKEY RM, 1990, CANCER RES, V50, P2330; Sharkey RM, 2005, J NUCL MED, V46, p115S; Sharkey RM, 2003, J NUCL MED, V44, P2000; Sharkey RM, 2003, CLIN CANCER RES, V9, p3897S; Sharkey RM, 2003, CANCER RES, V63, P354; SHARKEY RM, 2007, IN PRESS CLIN CANC R; SIEGEL JA, 1990, CANCER RES, V50, pS1039; SLAVINCHIORINI DC, 1993, INT J CANCER, V53, P97, DOI 10.1002/ijc.2910530119; STICKNEY DR, 1991, CANCER RES, V51, P6650; Unterhalt M, 2006, ANN HEMATOL, V85, P36; VANNAGELL JR, 1980, CANCER RES, V40, P502; Vuillez JP, 1999, CLIN CANCER RES, V5, p3259S; Wittel UA, 2005, NUCL MED BIOL, V32, P157, DOI 10.1016/j.nucmedbio.2004.11.003; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Witzig TE, 2006, BEST PRACT RES CL HA, V19, P655, DOI 10.1016/j.beha.2006.05.002; Wong JYC, 2006, INT J RADIAT ONCOL, V66, pS74, DOI 10.1016/j.ijrobp.2005.05.029; Wong JYC, 2003, CLIN CANCER RES, V9, P5842; Wu Anna M, 2004, Methods Mol Biol, V248, P209; Zalutsky MR, 2006, J NUCL MED, V47, P1238; Zalutsky MR, 2006, CLIN CANCER RES, V12, P1958, DOI 10.1158/1078-0432.CCR-06-0405	113	56	67	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3734	3744		10.1038/sj.onc.1210373	http://dx.doi.org/10.1038/sj.onc.1210373			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530026	Green Published			2023-01-03	WOS:000246816100015
J	Maheswaran, R; Pearson, T; Munro, J; Jiwa, M; Campbell, MJ; Nicholl, J				Maheswaran, Ravi; Pearson, Tim; Munro, James; Jiwa, Moyez; Campbell, Michael J.; Nicholl, Jon			Impact of NHS walk-in centres on primary care access times: ecological study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROVIDERS	Objective To examine whether walk-in centres contribute to shorter waiting times for a general practice appointment. Design Ecological study. Setting 2 509 general practices in 56 primary care trusts in England; 32 walk-in centres within 3 km of one of these practices. Main outcome measure Waiting time to next available general practitioner appointment (April 2003 to December 2004), from national monthly primary care access survey. Results The percentage of practices achieving the target waiting time of less than 48 hours to see a general practitioner increased from 67% to 87% over the 21 month study period (adjusted odds ratio 1.07 (95% confidence interval 1.06 to 1.08) per increase in month). Achievement of the waiting time target decreased with increasing multiple deprivation (0.57 (0.49 to 0.67) for most versus least deprived third) and increased with increasing practice population size (1.02 (1.00 to 1.04) per 1000 increase). No evidence was found that increasing distance from a walk-in centre was associated with decreasing odds of achieving the waiting time target (1.00 (0.99 to 1.01) per km increase). Increasing "exposure" to a walk-in centre, modelled with a distance decay function based on attendance rates, also showed little evidence of association with achievement of the waiting time target (1.02 (0.97 to 1.08) for interquartile range increase). No evidence existed that the rate of increase in achieving the 48 hour target over time was enhanced by proximity or "exposure" to a walk-in centre. Results were similar when the analysis was rerun with data for 2003 only (done because pressure in 2004 to meet the government's deadline might have led to other changes that could have masked any walk-in centre effect). Conclusions No evidence existed that walk-in centres shortened waiting times for access to primary care, and the results do not support the use of walk-in centres for this purpose.	Univ Sheffield, Publ Hlth GIS Unit, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England; Univ Sheffield, Hlth Serv Res Unit, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England; Univ Sheffield, Inst Gen Practice, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England	University of Sheffield; University of Sheffield; University of Sheffield	Maheswaran, R (corresponding author), Univ Sheffield, Publ Hlth GIS Unit, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England.	r.maheswaran@sheffield.ac.uk	Jiwa, Moyez/A-1325-2008; Campbell, Michael J/I-4253-2014; Nicholl, Jon/B-8257-2008	Campbell, Michael J/0000-0003-3529-2739; Jiwa, Moyez/0000-0002-0948-4166; Maheswaran, Ravi/0000-0002-3899-4421				Chalder M, 2003, BRIT MED J, V326, P532, DOI 10.1136/bmj.326.7388.532; *DEP HLTH, ROCROR0120 DEP HLTH; *DEP HLTH, ROCROR0120; Department of Health, 2002, DEL NHS PLAN NEXT ST; *DH PMDU JOINT WOR, PCAS VAL; Hsu RT, 2003, BRIT MED J, V326, P530, DOI 10.1136/bmj.326.7388.530; Jackson CJ, 2005, FAM PRACT, V22, P269, DOI 10.1093/fampra/cmi018; *OFF DEP PRIM MIN, 2004, SUP OUTP AR LOW LAYE; Pope C, 2005, PUBLIC HEALTH, V119, P39, DOI 10.1016/j.puhe.2003.12.014; Rosen R, 2002, J ADV NURS, V39, P241, DOI 10.1046/j.1365-2648.2002.02270.x; *ROYAL COLL GEN PR, 1999, DISC PAP IMPL GEN PR; Salisbury C, 2002, BRIT J GEN PRACT, V52, P554	12	14	14	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 21	2007	334	7598					838	841		10.1136/bmj.39122.704051.55	http://dx.doi.org/10.1136/bmj.39122.704051.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	162MD	17350967	Green Published, Bronze			2023-01-03	WOS:000246090800034
J	Perrier, E				Perrier, Emilie			A patient's journey - Intensive care	BMJ-BRITISH MEDICAL JOURNAL			English	Article												azanome@hotmail.com							0	1	1	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 14	2007	334	7597					796	797		10.1136/bmj.39157.723090.BE	http://dx.doi.org/10.1136/bmj.39157.723090.BE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161SX	17431267	Green Published, Bronze			2023-01-03	WOS:000246037300032
J	Halton, TL; Willett, WC; Liu, SM; Manson, JE; Albert, CM; Rexrode, K; Hu, FB				Halton, Thomas L.; Willett, Walter C.; Liu, Simin; Manson, JoAnn E.; Albert, Christine M.; Rexrode, Kathryn; Hu, Frank B.			Low-carbohydrate-diet score and the risk of coronary heart disease in women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-PROTEIN; WEIGHT-LOSS; FAT; COHORT; MEN	BACKGROUND: Low-carbohydrate diets have been advocated for weight loss and to prevent obesity, but the long-term safety of these diets has not been determined. METHODS: We evaluated data on 82,802 women in the Nurses' Health Study who had completed a validated food-frequency questionnaire. Data from the questionnaire were used to calculate a low-carbohydrate-diet score, which was based on the percentage of energy as carbohydrate, fat, and protein (a higher score reflects a higher intake of fat and protein and a lower intake of carbohydrate). The association between the low-carbohydrate-diet score and the risk of coronary heart disease was examined. RESULTS: During 20 years of follow-up, we documented 1994 new cases of coronary heart disease. After multivariate adjustment, the relative risk of coronary heart disease comparing highest and lowest deciles of the low-carbohydrate-diet score was 0.94 (95% confidence interval [CI], 0.76 to 1.18; P for trend=0.19). The relative risk comparing highest and lowest deciles of a low-carbohydrate-diet score on the basis of the percentage of energy from carbohydrate, animal protein, and animal fat was 0.94 (95% CI, 0.74 to 1.19; P for trend=0.52), whereas the relative risk on the basis of the percentage of energy from intake of carbohydrates, vegetable protein, and vegetable fat was 0.70 (95% CI, 0.56 to 0.88; P for trend=0.002). A higher glycemic load was strongly associated with an increased risk of coronary heart disease (relative risk comparing highest and lowest deciles, 1.90; 95% CI, 1.15 to 3.15; P for trend=0.003). CONCLUSIONS: Our findings suggest that diets lower in carbohydrate and higher in protein and fat are not associated with increased risk of coronary heart disease in women. When vegetable sources of fat and protein are chosen, these diets may moderately reduce the risk of coronary heart disease.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; University of California System; University of California Los Angeles; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Hu, FB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	frank.hu@channing.harvard.edu	Liu, Simin/I-3689-2014; Rexrode, Kathryn M/I-1177-2018; Hu, Frank/C-1919-2013; Liu, Simin/GSN-4159-2022	Liu, Simin/0000-0003-2098-3844; Rexrode, Kathryn/0000-0003-3387-8429; Albert, Christine/0000-0002-2081-1121	NATIONAL CANCER INSTITUTE [P01CA087969] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060712, R01HL034594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058845, P30DK040561] Funding Source: NIH RePORTER; NCI NIH HHS [CA87969] Funding Source: Medline; NHLBI NIH HHS [HL34594, HL60712] Funding Source: Medline; NIDDK NIH HHS [DK58845, P30 DK040561, P30 DK040561-11] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AHA, 2006, AHA REC; *AM HEART ASS, 2002, AM HEART ASS STAT HI; [Anonymous], 1997, J AM DIET ASSOC, V97, P71; Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84; ATKINS RC, 1998, ATKINS NEWDIET REVOL; *DEP AGR, 1993, COMP FOODS RAW PROC; EADES MR, 1999, PROTEIN POWER; GABH Rose, 1982, WHO MONOGRAPH SERIES; Halton TL, 2004, J AM COLL NUTR, V23, P373, DOI 10.1080/07315724.2004.10719381; HELLER RF, 1993, CARBOHYDRATE ADDICTS; Howard BV, 2006, JAMA-J AM MED ASSOC, V295, P655, DOI 10.1001/jama.295.6.655; Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492; Hu FB, 2002, JAMA-J AM MED ASSOC, V288, P2569, DOI 10.1001/jama.288.20.2569; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Hu FB, 1999, AM J CLIN NUTR, V70, P221; Jeor STS, 2001, CIRCULATION, V104, P1869, DOI 10.1161/hc4001.096152; Knight EL, 2003, ANN INTERN MED, V138, P460, DOI 10.7326/0003-4819-138-6-200303180-00009; Krauss RM, 1996, CIRCULATION, V94, P1795, DOI 10.1161/01.CIR.94.7.1795; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; Liu SM, 2000, AM J CLIN NUTR, V71, P1455; Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414; MCGEE DL, 1984, AM J EPIDEMIOL, V119, P667, DOI 10.1093/oxfordjournals.aje.a113788; Nordmann, 2006, ARCH INTERN MED, V166, P932; Nordmann AJ, 2006, ARCH INTERN MED, V166, P285, DOI 10.1001/archinte.166.3.285; Oakes, 1984, ANAL SURVIVAL DATA, DOI DOI 10.1201/9781315137438; Oomen CM, 2001, LANCET, V357, P746, DOI 10.1016/S0140-6736(00)04166-0; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Pietinen P, 1997, AM J EPIDEMIOL, V145, P876, DOI 10.1093/oxfordjournals.aje.a009047; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; SEARS B, 1995, ZONE DIET ROAD MAP L; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Stein K, 2000, J AM DIET ASSOC, V100, P760, DOI 10.1016/S0002-8223(00)00219-4; STEWARD HL, 1995, SUGAR BUSTERS; Thomas PR, 1995, WEIGHING OPTIONS CRI; Willett W., 1998, NUTR EPIDEMIOLOGY; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; 1998, OBES RES, V6, P464	37	331	338	4	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2006	355	19					1991	2002		10.1056/NEJMoa055317	http://dx.doi.org/10.1056/NEJMoa055317			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	102SG	17093250				2023-01-03	WOS:000241833000007
J	Watts, G				Watts, Geoff			Europe seeks to boost research	BRITISH MEDICAL JOURNAL			English	Editorial Material												geoff@scileg.freeserve.co.uk						European Federation of Pharmaceutical Industries and Associations, 2007, PHARM IND FIG; *INN MED IN, 2007, ASS EC SOC EFF; *INN MED IN, 2006, STRAT RES AG	3	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAR 1	2008	336	7642					474	475		10.1136/bmj.39475.547199.AD	http://dx.doi.org/10.1136/bmj.39475.547199.AD			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	274JL	18309998	Green Published			2023-01-03	WOS:000253997500035
J	Dolinay, T; Wu, W; Kaminski, N; Ifedigbo, E; Kaynar, AM; Szilasi, M; Watkins, SC; Ryter, SW; Hoetzel, A; Choi, AMK				Dolinay, Tamas; Wu, Wei; Kaminski, Naftali; Ifedigbo, Emeka; Kaynar, A. Murat; Szilasi, Maria; Watkins, Simon C.; Ryter, Stefan W.; Hoetzel, Alexander; Choi, Augustine M. K.			Mitogen-Activated Protein Kinases Regulate Susceptibility to Ventilator-Induced Lung Injury	PLOS ONE			English	Article								Background: Mechanical ventilation causes ventilator-induced lung injury in animals and humans. Mitogen-activated protein kinases have been implicated in ventilator-induced lung injury though their functional significance remains incomplete. We characterize the role of p38 mitogen-activated protein kinase/mitogen activated protein kinase kinase-3 and c-Jun-NH(2)-terminal kinase-1 in ventilator-induced lung injury and investigate novel independent mechanisms contributing to lung injury during mechanical ventilation. Methodology and Principle Findings: C57/BL6 wild-type mice and mice genetically deleted for mitogen-activated protein kinase kinase-3 (mkk-3(-/-)) or c-Jun-NH(2)-terminal kinase-1 (jnk1(-/-)) were ventilated, and lung injury parameters were assessed. We demonstrate that mkk3(-/-) or jnk1(-/-) mice displayed significantly reduced inflammatory lung injury and apoptosis relative to wild-type mice. Since jnk1(-/-) mice were highly resistant to ventilator-induced lung injury, we performed comprehensive gene expression profiling of ventilated wild- type or jnk1(-/-) mice to identify novel candidate genes which may play critical roles in the pathogenesis of ventilator-induced lung injury. Microarray analysis revealed many novel genes differentially expressed by ventilation including matrix metalloproteinase-8 (MMP8) and GADD45 alpha. Functional characterization of MMP8 revealed that mmp8(-/-) mice were sensitized to ventilator-induced lung injury with increased lung vascular permeability. Conclusions: We demonstrate that mitogen-activated protein kinase pathways mediate inflammatory lung injury during ventilator-induced lung injury. C-Jun-NH(2)-terminal kinase was also involved in alveolo-capillary leakage and edema formation, whereas MMP8 inhibited alveolo-capillary protein leakage.			Dolinay, T (corresponding author), Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15260 USA.	amchoi@rics.bwh.harvard.edu	Kaynar, Ata Murat/ABI-6877-2020; Dolinay, Tamas/ABG-1399-2020; Watkins, Simon/ABG-2590-2021	Kaynar, Ata Murat/0000-0001-8847-0450; Watkins, Simon/0000-0003-4092-1552; Kaminski, Naftali/0000-0001-5917-4601	NIH [R01-HL60234, R01-HL55330, R01-HL079904, P01-HL70807]; American Heart Association [0335035N]; Deutsche Forschungsgemeinschaft [HO 2464/1-1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055330, R01HL079904, P01HL070807, R01HL060234] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	NIH grants R01-HL60234, R01-HL55330, R01-HL079904, and P01-HL70807 awarded to A.M.K. Choi, an award from the American Heart Association to S. W. Ryter, (AHA #0335035N) and a grant from the Deutsche Forschungsgemeinschaft to Alexander Hoetzel (DFG HO 2464/1-1).	Abdulnour REE, 2006, AM J PHYSIOL-LUNG C, V291, pL345, DOI 10.1152/ajplung.00453.2005; Altemeier WA, 2005, J IMMUNOL, V175, P3369, DOI 10.4049/jimmunol.175.5.3369; Belperio JA, 2002, J CLIN INVEST, V110, P1703, DOI 10.1172/JCI200215849; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002; Bregeon F, 2002, RESP PHYSIOL NEUROBI, V132, P191, DOI 10.1016/S1569-9048(02)00069-1; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Chess PR, 2005, J APPL PHYSIOL, V99, P1226, DOI 10.1152/japplphysiol.01105.2004; Crimi E, 2006, AM J RESP CRIT CARE, V174, P178, DOI 10.1164/rccm.200507-1178OC; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; de Prost N, 2007, J APPL PHYSIOL, V102, P794, DOI 10.1152/japplphysiol.00742.2006; Dolinay T, 2006, PHYSIOL GENOMICS, V26, P68, DOI 10.1152/physiolgenomics.00110.2005; Fayolle C, 2008, J INVEST DERMATOL, V128, P196, DOI 10.1038/sj.jid.5700963; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Grasso S, 2002, ANESTHESIOLOGY, V96, P795, DOI 10.1097/00000542-200204000-00005; Grigoryev DN, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-r34; Gutierrez-Fernandez A, 2007, FASEB J, V21, P2580, DOI 10.1096/fj.06-7860com; Hales CA, 2001, RESP PHYSIOL, V124, P159, DOI 10.1016/S0034-5687(00)00193-6; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; Jones JCR, 2005, J CELL SCI, V118, P2557, DOI 10.1242/jcs.02395; KOHNO K, 2004, AM J PHYSIOL-LUNG C, pL184; Li LF, 2004, AM J RESP CRIT CARE, V169, P518, DOI 10.1164/rccm.200305-660OC; Li LF, 2007, CRIT CARE, V11, DOI 10.1186/cc5704; Ma SF, 2005, AM J PHYSIOL-LUNG C, V289, pL468, DOI 10.1152/ajplung.00109.2005; Matthay MA, 2002, AM J PHYSIOL-LUNG C, V283, pL678, DOI 10.1152/ajplung.00154.2002; Matute-Bello G, 1999, J IMMUNOL, V163, P2217; MatuteBello G, 1997, AM J RESP CRIT CARE, V156, P1969, DOI 10.1164/ajrccm.156.6.96-12081; Mayr VD, 2006, CRIT CARE, V10, DOI 10.1186/cc5086; Moitra J, 2007, TRANSL RES, V150, P253, DOI 10.1016/j.trsl.2007.03.013; Morse D, 2003, J BIOL CHEM, V278, P36993, DOI 10.1074/jbc.M302942200; Morse D, 2003, AM J PHYSIOL-LUNG C, V285, pL250, DOI 10.1152/ajplung.00387.2002; Nakamura M, 2004, AM J PATHOL, V164, P1949, DOI 10.1016/S0002-9440(10)63755-8; Ning W, 2004, PHYSIOL GENOMICS, V18, P70, DOI 10.1152/physiolgenomics.00221.2003; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 2003, AM J PATHOL, V163, P2555, DOI 10.1016/S0002-9440(10)63610-3; Oudin S, 2002, AM J RESP CELL MOL, V27, P107, DOI 10.1165/ajrcmb.27.1.4766; Owen CA, 2004, J IMMUNOL, V172, P7791, DOI 10.4049/jimmunol.172.12.7791; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Petrache I, 2003, AM J RESP CELL MOL, V28, P574, DOI 10.1165/rcmb.2002-0075OC; Quinn DA, 2002, J APPL PHYSIOL, V93, P517, DOI 10.1152/japplphysiol.00570.2001; Shaulian E, 1999, J BIOL CHEM, V274, P29595, DOI 10.1074/jbc.274.42.29595; Song RP, 2003, AM J PATHOL, V163, P231, DOI 10.1016/S0002-9440(10)63646-2; Tester AM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000312; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Tschumperlin DJ, 2000, AM J RESP CRIT CARE, V162, P357, DOI 10.1164/ajrccm.162.2.9807003; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uhlig U, 2002, EUR RESPIR J, V20, P946, DOI 10.1183/09031936.02.01612001; Usatyuk PV, 2004, J BIOL CHEM, V279, P11789, DOI 10.1074/jbc.M311184200; von Bethmann AN, 1998, AM J RESP CRIT CARE, V157, P263, DOI 10.1164/ajrccm.157.1.9608052; Winkler MK, 2003, AM J PHYSIOL-LUNG C, V284, pL557, DOI 10.1152/ajplung.00195.2002; Wu W, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-309; Yang KY, 2003, AM J RESP CRIT CARE, V167, P1567, DOI 10.1164/rccm.200207-664OC; Zerbini LF, 2004, P NATL ACAD SCI USA, V101, P13618, DOI 10.1073/pnas.0402069101	54	76	81	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2008	3	2							e1601	10.1371/journal.pone.0001601	http://dx.doi.org/10.1371/journal.pone.0001601			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367ES	18270588	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000260535900035
J	Butcher, J				Butcher, James			Mind games do they work?	BRITISH MEDICAL JOURNAL			English	Editorial Material							RISK					james@two-cultures.com						Karp A, 2006, DEMENT GERIATR COGN, V21, P65, DOI 10.1159/000089919; Willis SL, 2006, JAMA-J AM MED ASSOC, V296, P2805, DOI 10.1001/jama.296.23.2805; Wilson RS, 2007, NEUROLOGY, V69, P1911, DOI 10.1212/01.wnl.0000271087.67782.cb	3	7	7	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 2	2008	336	7638					246	248		10.1136/bmj.39462.534630.AD	http://dx.doi.org/10.1136/bmj.39462.534630.AD			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261TM	18244994	Green Published			2023-01-03	WOS:000253102900033
J	Diaz, R; Goyal, A; Mehta, SR; Afzal, R; Xavier, D; Pais, P; Chrolavicius, S; Zhu, J; Kazmi, K; Liu, LS; Budaj, A; Zubaid, M; Avezum, A; Ruda, M; Yusuf, S				Diaz, Rafael; Goyal, Abhinav; Mehta, Shamir R.; Afzal, Rizwan; Xavier, Denis; Pais, Prem; Chrolavicius, Susan; Zhu, Jun; Kazmi, Khawar; Liu, Lisheng; Budaj, Andrzej; Zubaid, Mohammad; Avezum, Alvaro; Ruda, Mikhail; Yusuf, Salim			Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							METABOLIC CHANGES; RANDOMIZED-TRIAL; INFUSION; MORTALITY; REINFARCTION; HEPARIN; CREATE	Context The clinical benefit of glucose-insulin-potassium (GIK) infusion in patients with ST-segment elevation myocardial infarction (STEMI) is unclear. While some smaller trials suggest benefit, in the CREATE-ECLA trial, GIK infusion had no effect on 30-day mortality in 20 201 patients. Objectives To determine the association between GIK infusion therapy and 30-day and 6-month outcomes in patients with STEMI. Design, Setting, and Participants Primary analysis of the OASIS-6 GIK randomized controlled trial of 2748 patients with acute STEMI; prespecified analyses of the combined trial data from the OASIS-6 GIK and CREATE-ECLA GIK trial populations of 22 943 patients with acute STEMI; subgroup analysis on the timing of initiation of GIK infusion therapy and outcomes; and post hoc analyses exploring whether GIK infusion may cause early harm by increasing glucose and potassium levels and net fluid gain. Intervention High-dose GIK solution consisting of 25% glucose, 50 U/L of regular insulin, and 80 mEq/L of potassium infused at 1.5 mL/kg per hour for 24 hours. Main Outcome Measures Mortality rates at 30 days and 6 months in the OASIS-6 GIK trial and rates of death, heart failure, and the composite of death or heart failure at 3 and 30 days in the combined OASIS-6 GIK and CREATE-ECLA GIK trial populations. Results At 6 months, 148 (10.8%) GIK infusion patients and 143 (10.4%) control patients died in the OASIS-6 trial ( hazard ratio [HR], 1.04; 95% CI, 0.83-1.31; P=.72); 153 (11.1%) GIK patients and 185 (13.5%) control patients had heart failure ( HR, 0.83; 95% CI, 0.67-1.02; P=.08); and 240 (17.5%) GIK patients and 264 (19.2%) control patients had a composite of death or heart failure ( HR, 0.91; 95% CI, 0.76-1.08; P=.27). In the prespecified analyses of the combined trial data, there were 712 deaths (6.2%) in the GIK group and 632 deaths (5.5%) in the control group at 3 days ( HR, 1.13; 95% CI, 1.02-1.26; P=.03). This difference disappeared by 30 days, with 1108 deaths (9.7%) in the GIK group and 1068 (9.3%) in the control group ( HR, 1.04; 95% CI, 0.96-1.13; P=.33). GIK therapy increased levels of glucose, potassium, and net fluid gain postinfusion, all 3 of which predicted death after adjusting for multiple confounders. Adjusting for glucose, potassium, and net fluid gain eliminated the apparent increase in mortality at 3 days observed with GIK infusion, suggesting a direct association with these factors. Administration of GIK infusion within 4 hours of symptom onset yielded no benefit compared with later initiation. Conclusions Infusion of GIK provided no benefit and may cause early harm following STEMI. Avoidance of infusion-related hyperglycemia, hyperkalemia, and net fluid gain may be advisable in future studies of metabolic modulation in patients with STEMI. Trial Registration clinicaltrials.gov Identifier: NCT00064428.	Emory Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA; Etud Cardiol Latin Amer, Rosario, Argentina; Emory Sch Med, Atlanta, GA USA; Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada; McMaster Univ, Dept Med, Hamilton, ON, Canada; Natl Acad Hlth Sci, St Johns Med Coll, Bangalore, Karnataka, India; Chinese Hypertens League Inst, Cardiovasc Inst, Beijing, Peoples R China; Chinese Hypertens League Inst, Fu Wai Hosp, Beijing, Peoples R China; Aga Khan Univ, Karachi, Pakistan; Grochowski Hosp, Dept Cardiol, Postgrad Med Sch, Warsaw, Poland; Mubarak Al Kabeer Hosp, Safat, Kuwait; Dante Pazzanese Cardiol Inst, Sao Paulo, Brazil; Cardiol Res Ctr, Moscow 121552, Russia	Emory University; Rollins School Public Health; Emory University; McMaster University; Population Health Research Institute; McMaster University; St. John's National Academy of Health Sciences; St. John's Medical College; Chinese Hypertension League; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Hypertension League; Aga Khan University; Centre of Postgraduate Medical Education - Poland; Mubarak Al-Kabeer Hospital; Instituto Dante Pazzanese de Cardiologia; National Medical Research Center of Cardiology	Goyal, A (corresponding author), Emory Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd NE,Room 456, Atlanta, GA 30322 USA.	agoyal4@sph.emory.edu	Avezum, Alvaro AA/K-6137-2016; Avezum, Alvaro/AAP-7687-2020; Goyal, Abhinav/J-5086-2012; Lutay, Yaroslav/GLT-9262-2022	Avezum, Alvaro AA/0000-0002-3073-6890; Goyal, Abhinav/0000-0002-6286-2349; Yusuf, Salim/0000-0003-4776-5601; Budaj, Andrzej/0000-0002-6395-2098				DALBY AJ, 1981, CARDIOVASC RES, V15, P588, DOI 10.1093/cvr/15.10.588; FathOrdoubadi F, 1997, CIRCULATION, V96, P1152, DOI 10.1161/01.CIR.96.4.1152; *IMMEDIATE TRIAL, IMM MYOC MET ENH IN; MAROKO PR, 1972, CIRCULATION, V45, P1160, DOI 10.1161/01.CIR.45.6.1160; Mehta SR, 2005, JAMA-J AM MED ASSOC, V293, P437; OPIE LH, 1975, CIRCULATION, V52, P49, DOI 10.1161/01.CIR.52.1.49; RACKLEY CE, 1981, AM HEART J, V102, P1038, DOI 10.1016/0002-8703(81)90488-9; ROGERS WJ, 1976, AM HEART J, V92, P441, DOI 10.1016/S0002-8703(76)80043-9; ROGERS WJ, 1979, AM J CARDIOL, V43, P801, DOI 10.1016/0002-9149(79)90081-X; WHITLOW PL, 1982, AM J CARDIOL, V49, P811, DOI 10.1016/0002-9149(82)91963-4; Yusuf S, 2006, JAMA-J AM MED ASSOC, V295, P1519; Yusuf S, 2005, JAMA-J AM MED ASSOC, V293, P427; Yusuf S, 2004, AM HEART J, V148, P1068, DOI 10.1016/j.ahj.2004.08.033	13	139	147	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 28	2007	298	20					2399	2405		10.1001/jama.298.20.2399	http://dx.doi.org/10.1001/jama.298.20.2399			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234KR	18042917				2023-01-03	WOS:000251163400020
J	Heath, I				Heath, Iona			The blind leading the blind	BRITISH MEDICAL JOURNAL			English	Editorial Material												iona.heath@dst.pipex.com							0	3	3	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 15	2007	335	7619					540	540		10.1136/bmj.39331.651250.59	http://dx.doi.org/10.1136/bmj.39331.651250.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215ED	17855320	Green Published			2023-01-03	WOS:000249790200030
J	Okin, PM; Devereux, RB; Harris, KE; Jern, S; Kjeldsen, SE; Julius, S; Edelman, JM; Dahlof, B				Okin, Peter M.; Devereux, Richard B.; Harris, Katherine E.; Jern, Sverker; Kjeldsen, Sverre E.; Julius, Stevo; Edelman, Jonathan M.; Dahloef, Bjoem		LIFE Study Investigators	Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients	ANNALS OF INTERNAL MEDICINE			English	Article							END-POINT REDUCTION; LOSARTAN INTERVENTION; SYSTEMIC HYPERTENSION; STRAIN PATTERN; ANTIHYPERTENSIVE TREATMENT; CARDIOVASCULAR MORBIDITY; PREVENTION; RISK; PREDICTION; MORTALITY	Background: Reduction of electrocardiographic left ventricular hypertrophy (LVH) has been associated with decreased cardiovascular death, stroke, myocardial infarction, and atrial fibrillation. However, whether reduction of electrocardiographic LVH is associated with decreased heart failure is unclear. Objective: To examine the relation of reduction of electrocardio graphic LVH to incident heart failure. Design: Multicenter cohort study derived from a randomized, con trolled trial. Setting: Losartan Intervention For Endpoint reduction in hyperten sion study. Patients: 8479 hypertensive patients without history of heart failure who were randomly assigned to losartan or atenolol treatment. Measurements: Change in Cornell product electrocardiographic LVH between baseline and in-study electrocardiograms, examined as both a continuous variable and a dichotomous variable (above or below the median decrease of 236 mm . msec) to predict heart failure hospitalization occurring after the 6-month follow-up visit. Results: During mean follow-up of 4.7 years (SD, 1.1 years), 214 patients were hospitalized for heart failure (2.5%): 77 patients with an in-treatment decrease of 236 mm . msec or more (4.4 per 1000 patient-years) and 137 patients with a reduction less than 236 mm msec during treatment (6.8 per 1000 patient-years). In a univariate Cox analysis in which change in Cornell product was treated as a time-varying continuous variable, decrease in Cornell product during treatment was associated with a decreased risk for new-onset heart failure, with a 24% lower risk for heart failure for every 817-mm . msec (1 SD of the mean) lower Cornell product (hazard ratio, 0.76 [95% Cl, 0.72 to 0.80]). In a parallel analysis in which change in Cornell product was entered as a time-varying dichotomous variable, a greater-than-median in-treatment decrease in Cornell product (236 mm . msec) was associated with a 43% lower risk for heart failure (hazard ratio, 0.57 [CI, 0.44 to 0.761). After adjustment for treatment, baseline risk factors for heart failure, baseline and in-treatment blood pressure, and baseline severity of electrocardiographic LVH, in-treatment decrease of Cornell product LVH in time-varying multivariate Cox models remained strongly associated with new heart failure hospitalization, with a 19% lower risk for every 817-mm . msec lower Cornell product treated as a continuous variable (hazard ratio, 0.81 [CI, 0.77 to 0.85]) or a 36% decreased rate of new heart failure in patients with an in-treatment reduction in Cornell product of 236 mm . msec or more (hazard ratio, 0.64 [Cl, 0.47 to 0.89]; P < 0.001 for all comparisons). Limitations: Use of electrocardiographic LVH to select patients may have increased risk compared with unselected hypertensive patients, and use of hospitalization for heart failure as the end point will underestimate the incidence of new heart failure. Conclusion: Reduction in Cornell product electrocardiographic LVH during antihypertensive therapy is associated with fewer hospitalizations for heart failure, independent of blood pressure lowering, treatment method, and other risk factors for heart failure.	Cornell Univ, Weill Med Coll, New York, NY 10021 USA; Amgen Inc, San Francisco, CA USA; Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden; Ullevaal Univ Hosp, Oslo, Norway; Univ Michigan, Med Ctr, Ann Arbor, MI 48109 USA; Merck & Co Inc, Whitehouse Stn, NJ USA	Cornell University; Amgen; Sahlgrenska University Hospital; University of Oslo; University of Michigan System; University of Michigan; Merck & Company	Okin, PM (corresponding author), Cornell Univ, Weill Med Coll, 525 E 68th St, New York, NY 10021 USA.	pokin@med.cornell.edu						[Anonymous], 1967, J AMER MED ASSOC, V202, P1028, DOI 10.1001/jama.1967.03130240070013; Arnold JMO, 2003, CIRCULATION, V107, P1284, DOI 10.1161/01.CIR.0000054165.93055.42; ARONOW WS, 1991, AM J CARDIOL, V67, P295, DOI 10.1016/0002-9149(91)90562-Y; Aronow WS, 1998, J AM GERIATR SOC, V46, P1280, DOI 10.1111/j.1532-5415.1998.tb04546.x; Aurigemma GP, 2001, J AM COLL CARDIOL, V37, P1042, DOI 10.1016/S0735-1097(01)01110-X; Baker DW, 2002, J CARD FAIL, V8, P333, DOI 10.1054/jcaf.2002.127769; Bibbins-Domingo K, 2004, CIRCULATION, V110, P1424, DOI 10.1161/01.CIR.0000141726.01302.83; Carr AA, 2005, AM J CARDIOL, V96, P1530, DOI 10.1016/j.amjcard.2005.07.061; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; COX DR, 1972, J R STAT SOC B, V34, P187; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Dahlof B, 1997, AM J HYPERTENS, V10, P705; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Dahlof B, 1998, HYPERTENSION, V32, P989, DOI 10.1161/01.HYP.32.6.989; Drazner MH, 2004, J AM COLL CARDIOL, V43, P2207, DOI 10.1016/j.jacc.2003.11.064; Effects of treatment on morbidity in hypertension, 1970, JAMA-J AM MED ASSOC, V213, P1143, DOI DOI 10.1001/JAMA.213.7.1143; Fagard RH, 2004, HYPERTENSION, V44, P459, DOI 10.1161/01.HYP.0000142169.17298.54; Gottdiener JS, 2000, J AM COLL CARDIOL, V35, P1628, DOI 10.1016/S0735-1097(00)00582-9; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; Ingelsson E, 2005, JAMA-J AM MED ASSOC, V294, P334, DOI 10.1001/jama.294.3.334; Jessup M, 2003, NEW ENGL J MED, V348, P2007, DOI 10.1056/NEJMra021498; KALBFLEISCH JD, 1980, STAT ANAL FAILURE TI, V101, P199; KANNEL WB, 1983, AM J MED, V75, P4, DOI 10.1016/0002-9343(83)90111-0; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; Lloyd-Jones DM, 2002, CIRCULATION, V106, P3068, DOI 10.1161/01.CIR.0000039105.49749.6F; Mathew J, 2001, CIRCULATION, V104, P1615, DOI 10.1161/hc3901.096700; MOLLOY TJ, 1992, J AM COLL CARDIOL, V20, P1180, DOI 10.1016/0735-1097(92)90376-X; Okin PM, 2003, CIRCULATION, V108, P684, DOI 10.1161/01.CIR.0000083724.28630.C3; Okin PM, 2004, JAMA-J AM MED ASSOC, V292, P2343, DOI 10.1001/jama.292.19.2343; OKIN PM, 1995, J AM COLL CARDIOL, V25, P417, DOI 10.1016/0735-1097(94)00371-V; Okin PM, 2006, CIRCULATION, V113, P67, DOI 10.1161/CIRCULATIONAHA.105.569491; Okin PM, 2004, HYPERTENSION, V44, P48, DOI 10.1161/01.HYP.0000132556.91792.6a; Okin PM, 2001, J AM COLL CARDIOL, V38, P514, DOI 10.1016/S0735-1097(01)01378-X; Psaty BN, 2003, JAMA-J AM MED ASSOC, V289, P2534, DOI 10.1001/jama.289.19.2534; Snapinn SM, 2005, AM STAT, V59, P301, DOI 10.1198/000313005X70371; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; Turnbull F, 2003, LANCET, V362, P1527; Verdecchia P, 2005, HYPERTENSION, V45, P412, DOI 10.1161/01.HYP.0000154822.37141.f6; Wachtell K, 2002, CIRCULATION, V106, P227, DOI 10.1161/01.CIR.0000021601.49664.2A; Wachtell K, 2001, AM J CARDIOL, V87, P54, DOI 10.1016/S0002-9149(00)01272-8; Wachtell K, 2000, AM J CARDIOL, V85, P466, DOI 10.1016/S0002-9149(99)00773-0	42	103	108	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 4	2007	147	5					311	319		10.7326/0003-4819-147-5-200709040-00006	http://dx.doi.org/10.7326/0003-4819-147-5-200709040-00006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207ZO	17785486				2023-01-03	WOS:000249289800004
J	Horwitz, LI; Kosiborod, M; Lin, ZQ; Krumholz, HM				Horwitz, Leora I.; Kosiborod, Mikhail; Lin, Zhenqiu; Krumholz, Harlan M.			Changes in outcomes for internal medicine inpatients after work-hour regulations	ANNALS OF INTERNAL MEDICINE			English	Article							COMMUNICATION FAILURES; PATIENT-CARE; RESIDENTS; QUALITY; STAFF; REDUCTION; EVENTS; IMPACT	Background: Limits on resident work hours are intended to reduce fatigue-related errors, but may raise risk by increasing transfers of responsibility for patients. Objective: To examine changes in outcomes for internal medicine patients after the implementation of work-hour regulations. Design: Retrospective cohort study. Setting: Urban, academic medical center. Patients: 14 260 consecutive patients discharged from the teaching (housestaff) service and 6664 consecutive patients discharged from the nonteaching (hospitalist) service between 1 July 2002 and 30 June 2004. Measurements: Outcomes included intensive care unit utilization, length of stay, discharge disposition, 30-day readmission rate to the study institution, pharmacist interventions to prevent error, drug-drug interactions and in-hospital death. Results: The teaching service had net improvements in 3 outcomes. Relative to changes experienced by the nonteaching service, the rate of intensive care unit utilization decreased by 2.1% (95% Cl, -3.3% to -0.7%; P = 0.002), the rate of discharge to home or rehabilitation facility versus elsewhere improved by 5.3% (Cl, 2.6% to 7.6%; P < 0.001), and pharmacist interventions to prevent error were reduced by 1.92 interventions per 100 patient-days (Cl, -2.74 to -1.03 interventions per 100 patient-days; P < 0.001). Teaching and nonteaching services had similar changes over time in length of stay, 30-day readmission rate, and adverse drug-drug interactions. In-hospital death was uncommon in both groups, and change over time was similar in the 2 groups. Limitations: The study was a retrospective, nonrandomized design that assessed a limited number of outcomes. Teaching and nonteaching cohorts may not have been affected similarly by secular trends in patient care. Conclusions: After the implementation of work-hour regulations, 3 of 7 outcomes improved for patients in the teaching service relative to those in the nonteaching service. The authors found no evidence of adverse unintended consequences after the institution of work-hour regulations.	Yale Univ, Sch Med, Sect Gen Internal Med, New Haven, CT 06520 USA; Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA; Univ Missouri, Kansas City, MO 64110 USA; Mid Amer Heart Inst, Kansas City, MO USA	Yale University; Yale University; University of Missouri System; University of Missouri Kansas City; Saint Luke's Mid America Heart Institute	Horwitz, LI (corresponding author), Yale Univ, Sch Med, Sect Gen Internal Med, IE-61 SHM,333 Cedar St,POB 208088, New Haven, CT 06520 USA.	leora.horwitz@yale.edu	Horwitz, Leora/ABD-1292-2020; , Harlan/AAI-2875-2020; Horwitz, Leora/A-6959-2009; Kosiborod, Mikhail/HDO-1541-2022	Horwitz, Leora/0000-0003-1800-6040; Kosiborod, Mikhail/0000-0002-3750-9789				*ACCR COUNC GRAD M, 2002, STAT JUST IMP FIN AP; *ACCR COUNC GRAD M, 2004, COMM PROGR REQ VF; Ai CR, 2003, ECON LETT, V80, P123, DOI 10.1016/S0165-1765(03)00032-6; Arora V, 2005, QUAL SAF HEALTH CARE, V14, P401, DOI 10.1136/qshc.2005.015107; Bailit JL, 2004, OBSTET GYNECOL, V103, P613, DOI 10.1097/01.AOG.0000119225.57285.c1; Bollschweiler E, 2001, LANGENBECK ARCH SURG, V386, P104, DOI 10.1007/s004230000188; Britt LD, 2005, ANN SURG, V241, P856; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chassin MR, 2002, ANN INTERN MED, V136, P826, DOI 10.7326/0003-4819-136-11-200206040-00012; *CTR SAF EM CAR, 2003, ACAD EMERG MED, V10, P364; DAIGLER GE, 1990, AM J DIS CHILD, V144, P799, DOI 10.1001/archpedi.1990.02150310067030; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Efron B., 1993, INTRO BOOTSTRAP; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Fletcher KE, 2005, JAMA-J AM MED ASSOC, V294, P1088, DOI 10.1001/jama.294.9.1088; Fletcher KE, 2004, ANN INTERN MED, V141, P851, DOI 10.7326/0003-4819-141-11-200412070-00009; Gandhi TK, 2005, ANN INTERN MED, V142, P352, DOI 10.7326/0003-4819-142-5-200503010-00010; GARNICK DW, 1995, HEALTH SERV RES, V29, P679; Harrell Frank E., 2001, REGRESSION MODELING; *HCUP CCS, 2007, HEALTHC COST UT PROJ; Horwitz LI, 2006, ARCH INTERN MED, V166, P1173, DOI 10.1001/archinte.166.11.1173; Howard DL, 2004, J GEN INTERN MED, V19, P1, DOI 10.1111/j.1525-1497.2004.30336.x; Iezzoni LI, 1997, ANN INTERN MED, V127, P666, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00048; Kaafarani HMA, 2005, J SURG RES, V126, P167, DOI 10.1016/j.jss.2004.12.024; LAINE C, 1993, JAMA-J AM MED ASSOC, V269, P374, DOI 10.1001/jama.269.3.374; Landrigan CP, 2004, NEW ENGL J MED, V351, P1838, DOI 10.1056/NEJMoa041406; LOFGREN RP, 1990, J GEN INTERN MED, V5, P501, DOI 10.1007/BF02600880; Mann F A, 1993, Invest Radiol, V28, P92, DOI 10.1097/00004424-199301000-00032; Mycyk MB, 2005, AM J HEALTH-SYST PH, V62, P1592, DOI 10.2146/ajhp040527; Nuckols TK, 2005, J GEN INTERN MED, V20, P873, DOI 10.1111/j.1525-1497.2005.0133.x; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Poulose BK, 2005, ANN SURG, V241, P847, DOI 10.1097/01.sla.0000164075.18748.38; Schenarts P, 2005, AM J SURG, V190, P147, DOI 10.1016/j.amjsurg.2005.03.026; Sutcliffe KM, 2004, ACAD MED, V79, P186, DOI 10.1097/00001888-200402000-00019; VIDYARTHI AR, 2006, AHRQ WEBM M	36	77	77	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 17	2007	147	2					97	103		10.7326/0003-4819-147-2-200707170-00163	http://dx.doi.org/10.7326/0003-4819-147-2-200707170-00163			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192CV	17548401				2023-01-03	WOS:000248179300004
J	Prendergast, A; Tudor-Williams, G; Jeena, P; Burchett, S; Goulder, P				Prendergast, Andrew; Tudor-Williams, Gareth; Jeena, Prakash; Burchett, Sandra; Goulder, Philip			International perspectives, progress, and future challenges of paediatric HIV infection	LANCET			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; MOTHER-TO-CHILD; ACTIVE ANTIRETROVIRAL THERAPY; PNEUMOCYSTIS-CARINII-PNEUMONIA; LATE POSTNATAL TRANSMISSION; MATERNAL VIRAL LOAD; BREAST-FED CHILDREN; HIV-1-INFECTED CHILDREN; DISEASE PROGRESSION; LYMPHOCYTE RESPONSE	Paediatric HIV infection is a growing health challenge worldwide, with an estimated 1500 new infections every day. in developed countries, well established prevention programmes keep mother-to-child transmission rates at less than 2%. However, in developing countries, where transmission rates are 25-40%, interventions are available to only 5-10% of women. Children with untreated natural infection progress rapidly to disease, especially in resource-poor settings where mortality is greater than 50% by 2 years of age. As in adult infection, antiretroviral therapy has the potential to rewrite the natural history of HIV, but is accessible only to a small number of children needing therapy. We focus on the clinical and immunological features of HIV that are specific to paediatric infection, and the formidable challenges ahead to ensure that all children worldwide have access to interventions that have proved successful in developed countries.	Univ Oxford, Dept Paediat, Oxford OX1 3SY, England; Univ London Imperial Coll Sci Technol & Med, Dept Paediat, Div Med, London, England; Univ Kwazulu Natal, Dept Child Life & Hlth, HIV Pathogenesis Programme, Durban, South Africa; Harvard Univ, Sch Med, Div Infect Dis, Childrens Hosp Boston, Boston, MA USA; Harvard Univ, Sch Med, Partners AIDS Res Ctr, Massachusetts Gen Hosp, Charlestown, MA USA	University of Oxford; Imperial College London; University of Kwazulu Natal; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital	Goulder, P (corresponding author), Univ Oxford, Dept Paediat, Peter Medawar Bldg Pathogen Res, Oxford OX1 3SY, England.	philip.goulder@ndm.ox.ac.uk		Prendergast, Andrew/0000-0001-7904-7992	MRC [G0500384] Funding Source: UKRI; Medical Research Council [G0500384] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Aboulker JP, 2004, AIDS, V18, P237, DOI [10.1097/01.aids.0000111388.02002.6b, 10.1097/00002030-200401230-00013]; Aboulker JP, 2001, ARCH DIS CHILD, V84, P230, DOI 10.1136/adc.84.3.230; ABOUYA YL, 1992, AM REV RESPIR DIS, V145, P617, DOI 10.1164/ajrccm/145.3.617; Abrams EJ, 1998, J INFECT DIS, V178, P101, DOI 10.1086/515596; ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462; Alimenti A, 2003, PEDIATR INFECT DIS J, V22, P782, DOI 10.1097/01.inf.0000086400.93257.74; Allen TM, 2005, J VIROL, V79, P12952, DOI 10.1128/JVI.79.20.12952-12960.2005; ANDIMAN WA, 1985, LANCET, V2, P1390; [Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; [Anonymous], 2006, Lancet, V368, P424; BARLOWMOSHA L, 2005, 3 INT AIDS SOC C HIV; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; BENTWICH Z, 1995, IMMUNOL TODAY, V16, P187, DOI 10.1016/0167-5699(95)80119-7; Berhane R, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.1.e7; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; Boerma JT, 2006, B WORLD HEALTH ORGAN, V84, P145, DOI 10.2471/BLT.05.025189; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Brahmbhatt H, 2003, AIDS, V17, P2539, DOI 10.1097/00002030-200311210-00020; Brambilla P, 2001, AIDS, V15, P2415, DOI 10.1097/00002030-200112070-00009; BWAYO J, 1995, AM J OBSTET GYNECOL, V172, P700, DOI 10.1016/0002-9378(95)90597-9; CASSOL S, 1991, J CLIN MICROBIOL, V29, P667, DOI 10.1128/JCM.29.4.667-671.1991; *CDCP, 2004, CAS HIV INF AIDS US; Centers for Disease Control and Prevention (CDC), 2006, MMWR Morb Mortal Wkly Rep, V55, P592; Chiappini E, 2006, AIDS, V20, P207, DOI 10.1097/01.aids.0000200529.64113.3e; Chiappini E, 2003, J MED VIROL, V70, P506, DOI 10.1002/jmv.10424; *CHILDR HIV ASS UK, 2004, GUID PREV OPP INF OI; Chintu C, 2004, LANCET, V364, P1865, DOI 10.1016/S0140-6736(04)17442-4; Chintu C, 2002, LANCET, V360, P985, DOI 10.1016/S0140-6736(02)11082-8; Chokephaibulkit K, 2005, AIDS, V19, P1495, DOI 10.1097/01.aids.0000183625.97170.59; Chouquet C, 1999, STAT MED, V18, P815, DOI 10.1002/(SICI)1097-0258(19990415)18:7&lt;815::AID-SIM74&gt;3.0.CO;2-G; Colebunders R, 2006, LANCET INFECT DIS, V6, P53, DOI 10.1016/S1473-3099(05)70327-3; Coovadia HM, 2007, LANCET, V369, P1107, DOI 10.1016/S0140-6736(07)60283-9; CORBETT A, 2005, INT C ANT AG CHEM; Coutsoudis A, 2004, J INFECT DIS, V189, P2154, DOI 10.1086/420834; CREEK T, 2007, 14 C RETR OPP INF LO; Dabis F, 2003, LANCET, V362, P1597, DOI 10.1016/S0140-6736(03)14839-8; Dabis F, 2001, AIDS, V15, P771, DOI 10.1097/00002030-200104130-00013; DATTA P, 1994, J INFECT DIS, V170, P1134, DOI 10.1093/infdis/170.5.1134; De Cock KM, 2002, LANCET, V360, P67, DOI 10.1016/S0140-6736(02)09337-6; de Martino M, 2000, JAMA-J AM MED ASSOC, V284, P190, DOI 10.1001/jama.284.2.190; De Rossi A, 2005, ANTIVIR THER, V10, P63; Dunn DT, 2003, LANCET, V362, P1605, DOI 10.1016/S0140-6736(03)14793-9; Elenga N, 2005, PEDIATR INFECT DIS J, V24, P1077, DOI 10.1097/01.inf.0000190008.91534.b7; Eley B, 2006, T ROY SOC TROP MED H, V100, P19, DOI 10.1016/j.trstmh.2005.04.015; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; ESHLEMAN SH, 2005, 12 C RETR OPP INF; *EUR COLL STUD, 1992, LANCET, V335, P1007; Fassinou P, 2004, AIDS, V18, P1905, DOI 10.1097/00002030-200409240-00006; Fawzi WW, 1999, PEDIATR INFECT DIS J, V18, P127, DOI 10.1097/00006454-199902000-00009; Feeney ME, 2005, J IMMUNOL, V174, P7524, DOI 10.4049/jimmunol.174.12.7524; Feeney ME, 2004, J VIROL, V78, P8927, DOI 10.1128/JVI.78.16.8927-8930.2004; Ferrantelli F, 2004, J INFECT DIS, V189, P2167, DOI 10.1086/420833; Fiscus SA, 2007, J CLIN MICROBIOL, V45, P2274, DOI 10.1128/JCM.00813-07; Florence E, 2004, INT J STD AIDS, V15, P538, DOI 10.1258/0956462041558159; Fraaij PLA, 2005, CLIN INFECT DIS, V40, P604, DOI 10.1086/427696; French MA, 2004, AIDS, V18, P1615, DOI 10.1097/01.aids.0000131375.21070.06; Geffin R, 2003, VIROLOGY, V310, P207, DOI 10.1016/S0042-6822(03)00137-5; Giaquinto C, 2005, CLIN INFECT DIS, V40, P458, DOI 10.1086/427287; Gibb DM, 2003, BMJ-BRIT MED J, V327, P1019, DOI 10.1136/bmj.327.7422.1019; Gibb DM, 1997, ARCH DIS CHILD, V77, P478, DOI 10.1136/adc.77.6.478; Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157; Goulder PJR, 2004, NEW ENGL J MED, V351, P2013; Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Graham SM, 2004, INT J TUBERC LUNG D, V8, P648; Hartmann SU, 2006, J HUM LACT, V22, P75, DOI 10.1177/0890334405280650; Hawkins D, 2005, HIV MED, V6, P107, DOI 10.1111/j.1468-1293.2005.00302.x; Heymann J, 2007, AIDS CARE, V19, P337, DOI 10.1080/09540120600763225; *HLTH PROT AG CTR, UNPUB Q SURV TABL NU; Hoffman IF, 1999, AIDS, V13, P487, DOI 10.1097/00002030-199903110-00007; Iliff PJ, 2005, AIDS, V19, P699, DOI 10.1097/01.aids.0000166093.16446.c9; Ioannidis JPA, 2004, AIDS, V18, P99, DOI 10.1097/00002030-200401020-00012; *IT MULT STUD, 1988, LANCET, V332, P1043; Jeena PM, 1996, TUBERCLE LUNG DIS, V77, P437, DOI 10.1016/S0962-8479(96)90117-3; Jeena PM, 1996, ANN TROP PAEDIATR, V16, P361, DOI 10.1080/02724936.1996.11747852; Jeena PM, 2002, INT J TUBERC LUNG D, V6, P672; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; John GC, 2001, J INFECT DIS, V183, P206, DOI 10.1086/317918; John-Stewart GC, 2007, J INFECT DIS, V196, P1, DOI 10.1086/518516; Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113; KLINE M, 2007, 14 C RETR OPP INF LO; Kline MW, 2006, PEDIATRICS, V117, P1388, DOI 10.1542/peds.2005-1348; Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Kourtis AP, 1996, NEW ENGL J MED, V335, P1431, DOI 10.1056/NEJM199611073351904; Kuhn L, 2004, AIDS, V18, P1281, DOI 10.1097/00002030-200406180-00006; Kuhn L, 1999, J INFECT DIS, V179, P52, DOI 10.1086/314551; Lackritz E M, 1998, AIDS, V12 Suppl A, pS81; LEPAGE P, 1989, AIDS, V3, P221, DOI 10.1097/00002030-198904000-00005; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992; Lichterfeld M, 2004, J EXP MED, V200, P701, DOI 10.1084/jem.20041270; LIDINJANSSON G, 1994, PEDIATRICS, V94, P815; Lindegren ML, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.4.e46; Little K, 2007, INT J EPIDEMIOL, V36, P679, DOI 10.1093/ije/dym019; Lockman S, 2007, NEW ENGL J MED, V356, P135, DOI 10.1056/NEJMoa062876; Lucas SB, 1996, BRIT MED J, V312, P335, DOI 10.1136/bmj.312.7027.335; Luzuriaga K, 2000, J VIROL, V74, P6984, DOI 10.1128/JVI.74.15.6984-6991.2000; Luzuriaga K, 2006, LANCET, V368, P511, DOI 10.1016/S0140-6736(06)69159-9; Madhi SA, 2000, INT J TUBERC LUNG D, V4, P448; Madhi SA, 2000, CLIN INFECT DIS, V31, P170, DOI 10.1086/313925; MALIN AS, 1995, LANCET, V346, P1258, DOI 10.1016/S0140-6736(95)91862-0; Martinez-Picado J, 2006, J VIROL, V80, P3617, DOI 10.1128/JVI.80.7.3617-3623.2006; Matano T, 1998, J VIROL, V72, P164, DOI 10.1128/JVI.72.1.164-169.1998; Mayaux MJ, 1996, JAMA-J AM MED ASSOC, V275, P606, DOI 10.1001/jama.275.8.606; McIntyre J, 2006, CURR OPIN INFECT DIS, V19, P33, DOI 10.1097/01.qco.0000200290.99790.72; MCKINNEY RE, 1991, NEW ENGL J MED, V324, P1018, DOI 10.1056/NEJM199104113241503; Melvin AJ, 2001, AIDS RES HUM RETROV, V17, P1117, DOI 10.1089/088922201316912727; Menson EN, 2006, BMJ-BRIT MED J, V332, P1183, DOI 10.1136/bmj.332.7551.1183; Mofenson LM, 2003, LANCET, V362, P1625, DOI 10.1016/S0140-6736(03)14825-8; Moodley D, 2003, J INFECT DIS, V187, P725, DOI 10.1086/367898; Moss WJ, 2003, B WORLD HEALTH ORGAN, V81, P61; Mphatswe W, 2007, AIDS, V21, P1253, DOI 10.1097/QAD.0b013e3281a3bec2; Mukadi YD, 1997, AIDS, V11, P1151, DOI 10.1097/00002030-199709000-00011; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; NESHEIM SR, 1994, AIDS, V8, P1293, DOI 10.1097/00002030-199409000-00012; Newell ML, 2006, T ROY SOC TROP MED H, V100, P1, DOI 10.1016/j.trstmh.2005.05.012; Newell ML, 2004, LANCET, V364, P1236, DOI 10.1016/S0140-6736(04)17140-7; Newell ML, 2004, AIDS, V18, pS27, DOI 10.1097/00002030-200406002-00004; Nightingale S, 2006, J TROP PEDIATRICS, V52, P235, DOI 10.1093/tropej/fml033; Nolan ML, 2002, AIDS, V16, P1991, DOI 10.1097/00002030-200210180-00003; Nyandiko WM, 2006, JAIDS-J ACQ IMM DEF, V43, P418, DOI 10.1097/01.qai.0000243122.52282.89; O'Brien DP, 2007, CLIN INFECT DIS, V44, P1245, DOI 10.1086/513433; Oberdorfer P, 2006, J PAEDIATR CHILD H, V42, P283, DOI 10.1111/j.1440-1754.2006.00855.x; Obimbo EM, 2004, PEDIATR INFECT DIS J, V23, P536, DOI 10.1097/01.inf.0000129692.42964.30; ONYANGO C, 2007, 14 C RETR OPP INF LO; Otieno F A, 2002, East Afr Med J, V79, P111; Otieno RO, 2006, AIDS, V20, P275, DOI 10.1097/01.aids.0000200533.56490.b7; Owens DK, 1996, JAMA-J AM MED ASSOC, V275, P1342, DOI 10.1001/jama.275.17.1342; *PAED EUR NETW TRE, PENPACT 1; Palumbo PE, 1998, JAMA-J AM MED ASSOC, V279, P756, DOI 10.1001/jama.279.10.756; Pillay T, 2005, J VIROL, V79, P12100, DOI 10.1128/JVI.79.18.12100-12105.2005; Rabkin M, 2002, LANCET, V360, P1503, DOI 10.1016/S0140-6736(02)11478-4; Reddi Anand, 2007, BMC Pediatr, V7, P13, DOI 10.1186/1471-2431-7-13; Resino S, 2003, CLIN INFECT DIS, V37, P1216, DOI 10.1086/378804; Rhoads MP, 2006, HIV MED, V7, P16, DOI 10.1111/j.1468-1293.2005.00337.x; Rich JD, 1999, ANN INTERN MED, V130, P37, DOI 10.7326/0003-4819-130-1-199901050-00007; Rodriguez WR, 2005, PLOS MED, V2, P663, DOI 10.1371/journal.pmed.0020182; Rogerson SR, 2004, T ROY SOC TROP MED H, V98, P544, DOI 10.1016/j.trstmh.2003.12.011; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rouet F, 2005, J CLIN MICROBIOL, V43, P2709, DOI 10.1128/JCM.43.6.2709-2717.2005; Rouet F, 2001, AIDS, V15, P1849, DOI 10.1097/00002030-200109280-00015; Rouet F, 2006, J TROP PEDIATRICS, V52, P346, DOI 10.1093/tropej/fml024; Rouet F, 2006, AIDS, V20, P2315, DOI 10.1097/QAD.0b013e328010943b; Schmid GP, 2004, LANCET, V363, P482, DOI 10.1016/S0140-6736(04)15497-4; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Schreibman T, 2004, CLIN INFECT DIS, V38, P257, DOI 10.1086/380792; Sharland M, 2004, HIV MED, V5, P61, DOI 10.1111/j.1468-1293.2004.00227.x; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; Shingadia D, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.6.e80; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Spira R, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e56; Steinmann G G, 1986, Curr Top Pathol, V75, P43; Taha TE, 2007, J INFECT DIS, V196, P10, DOI 10.1086/518511; THEA DM, 1993, NEW ENGL J MED, V329, P1696, DOI 10.1056/NEJM199312023292304; Tindyebwa D., 2004, HDB PAEDIAT AIDS AFR; UNAIDS, 2008, REP GLOB AIDS EP; *UNAIDS UNICEF USA, 2004, CHILDR BRINK 2004 JO; *UNAIDS WHO, 2006, AIDS EP UPD; *US PHS INF DIS SO, 2002, GUID PREV OPP INF HI; Van Dyke RB, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.4.e61; WADE AM, 1992, PEDIATR INFECT DIS J, V11, P1018, DOI 10.1097/00006454-199211120-00006; Walters S, 2006, ADV EXP MED BIOL, V582, P221; Watson DC, 1999, PEDIATR INFECT DIS J, V18, P682, DOI 10.1097/00006454-199908000-00006; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; WEMIN L, 2006, PEPFAR ANN M; Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6; WHO, 2006, ANT DRUGS TREAT PREG; *WHO, 2000, NEW DAT PREV MOTH CH; *WHO, 2007, M IMM STRAT ADV GROU; WHO/UNAIDS, 2003, TREAT 3 MILL 2005 MA; Wilfert CM, 2007, J INFECT DIS, V195, P165, DOI 10.1086/510255; Williams AJ, 2001, AIDS, V15, P335, DOI 10.1097/00002030-200102160-00006; *WORK GROUP ANT TH, 2006, GUID US ANT AG PED H; World Health Organisation, 2006, ANT THER HIV INF INF; World Health Organisation, 2005, WORLD HLTH REP MAK E; World Health Organization, 2006, CONS STAT WHO HIV IN; World Health Organization, 2006, WHO CAS DEF HIV SURV; World Health Organization, 2003, SCAL ANT THER RES LT; World Health Organization (WHO), 2006, GUID COTR PROPH HIV; Wu XL, 2006, J VIROL, V80, P835, DOI 10.1128/JVI.80.2.835-844.2006	181	80	82	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 7	2007	370	9581					68	80		10.1016/S0140-6736(07)61051-4	http://dx.doi.org/10.1016/S0140-6736(07)61051-4			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187QE	17617274				2023-01-03	WOS:000247862300032
J	Iheanacho, I				Iheanacho, Ike			All together now	BRITISH MEDICAL JOURNAL			English	Editorial Material												iiheanacho@bmjgroup.com							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 9	2007	334	7605					1224	1224		10.1136/bmj.39234.611505.59	http://dx.doi.org/10.1136/bmj.39234.611505.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	179GF	17556482	Green Published			2023-01-03	WOS:000247277000043
J	Aelony, Y				Aelony, Yossef			Talc pleurodesis and acute respiratory distress syndrome	LANCET			English	Editorial Material							MALIGNANT PLEURAL EFFUSION; POUDRAGE; SLURRY		Harbor UCLA Med Ctr, Torrance, CA 90502 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Aelony, Y (corresponding author), Harbor UCLA Med Ctr, Torrance, CA 90502 USA.	y.aelony@cox.net						Aelony Y, 2004, AM J RESP CRIT CARE, V169, P1075; Aelony Y, 1998, CHEST, V113, P1007, DOI 10.1378/chest.113.4.1007; AELONY Y, 2002, CHEST, V165, pA35; BOUTIN C, 1991, PRACTICAL THORACOSCO, P68; Dresler CM, 2005, CHEST, V127, P909, DOI 10.1378/chest.127.3.909; Ferrer J, 2001, CHEST, V119, P1901, DOI 10.1378/chest.119.6.1901; Janssen JP, 2007, LANCET, V369, P1535, DOI 10.1016/S0140-6736(07)60708-9; Manes Nuria, 2000, Chest, V118, p131S; Montes JF, 2003, AM J RESP CRIT CARE, V168, P348, DOI 10.1164/rccm.200207-767OC; Rehse DH, 1999, AM J SURG, V177, P437, DOI 10.1016/S0002-9610(99)00075-6; RINALDO JE, 1983, J THORAC CARDIOV SUR, V85, P523; SANCHEZARMENGOL A, 1993, CHEST, V104, P1482, DOI 10.1378/chest.104.5.1482; Tremblay A, 2006, CHEST, V129, P362, DOI 10.1378/chest.129.2.362; Viallat JR, 1996, CHEST, V110, P1387, DOI 10.1378/chest.110.6.1387; Yim APC, 1996, ANN THORAC SURG, V62, P1655, DOI 10.1016/S0003-4975(96)00808-9	15	11	11	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 5	2007	369	9572					1494	1496		10.1016/S0140-6736(07)60685-0	http://dx.doi.org/10.1016/S0140-6736(07)60685-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164EI	17482965				2023-01-03	WOS:000246215800005
J	Wilan, K				Wilan, Ken			Susan Wood	NATURE BIOTECHNOLOGY			English	Biographical-Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2007	25	5					495	495		10.1038/nbt0507-495	http://dx.doi.org/10.1038/nbt0507-495			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	166HK	17483824				2023-01-03	WOS:000246369400006
J	Kostis, WJ; Demissie, K; Marcella, SW; Shao, YH; Wilson, AC; Moreyra, AE				Kostis, William J.; Demissie, Kitaw; Marcella, Stephen W.; Shao, Yu-Hsuan; Wilson, Alan C.; Moreyra, Abel E.		MIDAS 10 Study Grp	Weekend versus weekday admission and mortality from myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ASSOCIATION TASK-FORCE; PRACTICE GUIDELINES COMMITTEE; ACUTE CORONARY SYNDROMES; IN-HOSPITAL MORTALITY; AMERICAN-COLLEGE; ACC/AHA GUIDELINES; UNSTABLE ANGINA; OUTCOMES; MANAGEMENT; STATEWIDE	BACKGROUND: Management of acute myocardial infarction requires urgent diagnostic and therapeutic procedures, which may not be uniformly available throughout the week. METHODS: We examined differences in mortality between patients admitted on weekends and those admitted on weekdays for a first acute myocardial infarction, using the Myocardial Infarction Data Acquisition System. All such admissions in New Jersey from 1987 to 2002 (231,164) were included and grouped in 4-year intervals. RESULTS: There were no significant differences in demographic characteristics, coexisting conditions, or infarction site between patients admitted on weekends and those admitted on weekdays. However, patients admitted on weekends were less likely to undergo invasive cardiac procedures, especially on the first and second days of hospitalization (P<0.001). In the interval from 1999 to 2002 (59,786 admissions), mortality at 30 days was significantly higher for patients admitted on weekends (12.9% vs. 12.0%, P=0.006). The difference became significant the day after admission (3.3% vs. 2.7%, P<0.001) and persisted at 1 year (1% absolute difference in mortality). The difference in mortality at 30 days remained significant after adjustment for demographic characteristics, coexisting conditions, and site of infarction (hazard ratio, 1.048; 95% confidence interval [CI], 1.022 to 1.076; P<0.001), but it became nonsignificant after additional adjustment for invasive cardiac procedures (hazard ratio, 1.023; 95% CI, 0.997 to 1.049; P=0.09). CONCLUSIONS: For patients with myocardial infarction, admission on weekends is associated with higher mortality and lower use of invasive cardiac procedures. Our findings suggest that the higher mortality on weekends is mediated in part by the lower rate of invasive procedures, and we speculate that better access to care on weekends could improve the outcome for patients with acute myocardial infarction.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Sch Publ Hlth, Dept Epidemiol, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Kostis, WJ (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Sch Publ Hlth, Dept Epidemiol, 1 Robert Wood Johnson Pl,POB 19, New Brunswick, NJ 08903 USA.	kostiswj@umdnj.edu	Shao, Yu-Hsuan Joni/AFE-6001-2022	Shao, Yu-Hsuan/0000-0002-0757-1901; Kostis, William/0000-0002-0543-9798				ABBUD ZA, 1995, AM HEART J, V130, P51, DOI 10.1016/0002-8703(95)90235-X; Al Falluji N, 2002, AM HEART J, V144, P636, DOI 10.1067/mhj.2002.124351; Alpert JS, 2001, J AM COLL CARDIOL, V37, P973; Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4; Anderson HV, 2005, CIRCULATION, V112, P2786, DOI 10.1161/CIRCULATIONAHA.105.553727; Angus DC, 2006, CRIT CARE MED, V34, P1016, DOI 10.1097/01.CCM.0000206105.05626.15; Antman Elliott M, 2004, J Am Coll Cardiol, V44, P671, DOI 10.1016/j.jacc.2004.07.002; ANTMAN EM, 2005, J AM COLL CARDIOL, V45, P1376; Babaev A, 2005, JAMA-J AM MED ASSOC, V294, P448, DOI 10.1001/jama.294.4.448; Barnett MJ, 2002, MED CARE, V40, P530, DOI 10.1097/00005650-200206000-00010; Bell CM, 2001, NEW ENGL J MED, V345, P663, DOI 10.1056/NEJMsa003376; Bell CM, 2004, AM J MED, V117, P175, DOI 10.1016/j.amjmed.2004.02.047; BELL CM, 2001, NEW ENGL J MED, V345, P1580; Braunwald E, 2002, J AM COLL CARDIOL, V40, P1366, DOI 10.1016/S0735-1097(02)02336-7; Cannon Christopher, 2003, J Invasive Cardiol, V15 Suppl B, p22B; Cram P, 2004, AM J MED, V117, P151, DOI 10.1016/j.amjmed.2004.02.035; Eagle KA, 2005, J AM COLL CARDIOL, V46, P1242, DOI 10.1016/j.jacc.2004.12.083; ELLIS SG, 1995, CIRCULATION, V92, P741, DOI 10.1161/01.CIR.92.4.741; Fox KAA, 2005, LANCET, V366, P914, DOI 10.1016/S0140-6736(05)67222-4; JARO MA, 1989, J AM STAT ASSOC, V84, P414, DOI 10.2307/2289924; KOSTIS JB, 1994, CIRCULATION, V90, P1715, DOI 10.1161/01.CIR.90.4.1715; Kostis JB, 2001, AM J CARDIOL, V88, P837, DOI 10.1016/S0002-9149(01)01888-4; Magid DJ, 2005, JAMA-J AM MED ASSOC, V294, P803, DOI 10.1001/jama.294.7.803; MOREYRA AE, 1998, DIS MANAGE CLIN OUTC, V6, P175; Peters RW, 1996, AM J CARDIOL, V78, P1198, DOI 10.1016/S0002-9149(96)00595-4; Quaas A, 2004, POSTGRAD MED J, V80, P411, DOI 10.1136/pgmj.2003.011247; Ryan JW, 2005, CIRCULATION, V112, P3049, DOI 10.1161/CIRCULATIONAHA.105.582346; SHENG A, 1993, J GEN INTERN MED, V8, P573, DOI 10.1007/BF02599642; Smith SC, 2001, CIRCULATION, V103, P3019, DOI 10.1161/01.CIR.103.24.3019; VANDERPALEN J, 1995, NEW ZEAL MED J, V108, P332	30	475	478	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 15	2007	356	11					1099	1109		10.1056/NEJMoa063355	http://dx.doi.org/10.1056/NEJMoa063355			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	145PO	17360988				2023-01-03	WOS:000244877200003
J	Chien, CV				Chien, Colleen V.			HIV/AIDS Drugs for Sub-Saharan Africa: How Do Brand and Generic Supply Compare?	PLOS ONE			English	Article							ANTIRETROVIRAL DRUGS; ACCESS; TRADE	Background. Significant quantities of antiretroviral drugs (ARVs) to treat HIV/AIDS have been procured for Sub-Saharan Africa for the first time in their 20-year history. This presents a novel opportunity to empirically study the roles of brand and generic suppliers in providing access to ARVs. Methodology/Principal Findings. An observational study of brand and generic supply based on a dataset of 2,162 orders of AIDS drugs for Sub-Saharan Africa reported to the Global Price Reporting Mechanism at the World Health Organization from January 2004-March 2006 was performed. Generic companies supplied 63% of the drugs studied, at prices that were on average about a third of the prices charged by brand companies. 96% of the procurement was of first line drugs, which were provided mostly by generic firms, while the remaining 4%, of second line drugs, was sourced primarily from brand companies. 85% of the generic drugs in the sample were manufactured in India, where the majority of the drugs procured were ineligible for patent protection. The remaining 15% was manufactured in South Africa, mostly under voluntary licenses provided by brand companies to a single generic company. In Sub-Saharan African countries, four first line drugs in the dataset were widely patented, however no general deterrent to generic purchasing based on a patent was detected. Conclusions/Significance. Generic and brand companies have played distinct roles in increasing the availability of ARVs in Sub-Saharan Africa. Generic companies provided most of the drugs studied, at prices below those charged by brand companies, and until now, almost exclusively supplied several fixed-dose combination drugs. Brand companies have supplied almost all second line drugs, signed voluntary licenses with generic companies, and are not strictly enforcing patents in certain countries. Further investigation into how price reductions in second line drugs can be achieved and the cheapest drugs can actually be procured is warranted.	Fenwick & W LLP, Oakland, CA USA		Chien, CV (corresponding author), Fenwick & W LLP, Oakland, CA USA.	colleenchien@gmail.com			Stanford Center for Law and the Biosciences at Stanford Law School	Stanford Center for Law and the Biosciences at Stanford Law School	This paper was written with the generous support of the Stanford Center for Law and the Biosciences at Stanford Law School, at which the author was a Fellow during its writing. The Center played no role in any part of the conception, analysis, or approval of the manuscript.	Abbott FM, 2005, AM J INT LAW, V99, P317, DOI 10.2307/1562501; Attaran A, 2001, JAMA-J AM MED ASSOC, V286, P1886, DOI 10.1001/jama.286.15.1886; *AVERT, 2006, PRES EM PLAN AIDS RE; Bartram D, 2006, COMPUTER-BASED TESTING AND THE INTERNET: ISSUES AND ADVANCES, P13; BOULET P, 2006, PATENT STATUS HIV AI; Butler D, 2005, NATURE, V436, P156, DOI 10.1038/436156a; CAMP R, 2006, ANTIRETROVIRALS PIPE; Cohen JC, 2005, GLOBALIZATION HEALTH, V1, DOI 10.1186/1744-8603-1-17; *FOOD DRUG ADM, 2005, FDA CONSUM, V39, P3; Ford N, 2006, LANCET, V367, P794, DOI 10.1016/S0140-6736(06)68313-X; *GLAXOSMITHKLINE, 2006, GSK PAT PAT APPL COM; *GLOB FUND FIGHT A, 2006, DISTR FUND 5 ROUNDS; Grace C, 2004, EFFECT CHANGING INTE; HAMILTON D, 2006, GOOD DEED AIDS DRUG; *HOFFMANLAROCHE, 2004, REM BARR INCR ACC RO; Kober K, 2004, LANCET, V364, P103, DOI 10.1016/S0140-6736(04)16597-5; KULLINAN K, 2006, ASPENS GENERICS ENSU; *LAW COLL HIV AIDS, 2006, ACC MED POSTTRIPS RE; Lee K, 2004, JAMA-J AM MED ASSOC, V291, P2636, DOI 10.1001/jama.291.21.2636; Medecins Sans Frontieres, 2006, UNT WEB PRIC RED PRI; THOEN E, 2003, DRUG PATENTS SPOTLIG; UNAIDS, 2006, REP GLOB AIDS EP; Vasan A, 2006, B WORLD HEALTH ORGAN, V84, P393, DOI 10.2471/BLT.05.025684; Westerhaus M, 2006, PLOS MED, V3, P1230, DOI 10.1371/journal.pmed.0030332; *WHO, 2006, REP WHO UNA IN PRESS; *WHO, 2006, GLOB PRIC REP MECH; *WHO, 2006, WEIGHT AV PRIC ARVS; *WHO, 2006, AIDS MED DIAGN SERV; WHO, 2004, SCAL ANT THER RES LI; *WORLD COMM ADV BO, 2005, WORLD COMM ADV BOARD; World Health Organization, 2006, ANT THER HIV INF AD; 2006, EC TIMES        0905; 2006, MED NEWS TODAY  1206	33	46	48	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2007	2	3							e278	10.1371/journal.pone.0000278	http://dx.doi.org/10.1371/journal.pone.0000278			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DN	17372625	gold, Green Submitted, Green Published			2023-01-03	WOS:000207444800001
J	Gardner, CD; Kiazand, A; Alhassan, S; Kim, S; Stafford, RS; Balise, RR; Kraemer, HC; King, AC				Gardner, Christopher D.; Kiazand, Alexandre; Alhassan, Sofiya; Kim, Soowon; Stafford, Randall S.; Balise, Raymond R.; Kraemer, Helena C.; King, Abby C.			Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-FAT DIET; DENSITY-LIPOPROTEIN CHOLESTEROL; LOW-CARBOHYDRATE-DIET; BLOOD-PRESSURE; HIGH-PROTEIN; MONOUNSATURATED FAT; PHYSICAL-ACTIVITY; RANDOMIZED-TRIAL; BODY-COMPOSITION; ENERGY DENSITY	Context Popular diets, particularly those low in carbohydrates, have challenged current recommendations advising a low-fat, high-carbohydrate diet for weight loss. Potential benefits and risks have not been tested adequately. Objective To compare 4 weight-loss diets representing a spectrum of low to high carbohydrate intake for effects on weight loss and related metabolic variables. Design, Setting, and Participants Twelve-month randomized trial conducted in the United States from February 2003 to October 2005 among 311 free-living, over-weight/ obese ( body mass index, 27-40) nondiabetic, premenopausal women. Intervention Participants were randomly assigned to follow the Atkins (n=77), Zone (n=79), LEARN (n=79), or Ornish (n= 76) diets and received weekly instruction for 2 months, then an additional 10-month follow-up. Main Outcome Measures Weight loss at 12 months was the primary outcome. Secondary outcomes included lipid profile (low-density lipoprotein, high-density lipoprotein, and non-high-density lipoprotein cholesterol, and triglyceride levels), percentage of body fat, waist-hip ratio, fasting insulin and glucose levels, and blood pressure. Outcomes were assessed at months 0, 2, 6, and 12. The Tukey studentized range test was used to adjust for multiple testing. Results Weight loss was greater for women in the Atkins diet group compared with the other diet groups at 12 months, and mean 12-month weight loss was significantly different between the Atkins and Zone diets ( P <. 05). Mean 12-month weight loss was as follows: Atkins, - 4.7 kg (95% confidence interval [CI], - 6.3 to - 3.1 kg), Zone, - 1.6 kg ( 95% CI, - 2.8 to - 0.4 kg), LEARN, - 2.6 kg (- 3.8 to - 1.3 kg), and Ornish, - 2.2 kg (- 3.6 to - 0.8 kg). Weight loss was not statistically different among the Zone, LEARN, and Ornish groups. At 12 months, secondary outcomes for the Atkins group were comparable with or more favorable than the other diet groups. Conclusions In this study, premenopausal overweight and obese women assigned to follow the Atkins diet, which had the lowest carbohydrate intake, lost more weight and experienced more favorable overall metabolic effects at 12 months than women assigned to follow the Zone, Ornish, or LEARN diets. While questions remain about long-term effects and mechanisms, a low-carbohydrate, high-protein, high-fat diet may be considered a feasible alternative recommendation for weight loss.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Stanford Prevent Res Ctr, Stanford, CA 94305 USA	Stanford University; Stanford University	Gardner, CD (corresponding author), Hoover Pavil,N229,211 Quarry Rd, Stanford, CA 94305 USA.	cgardner@stanford.edu	King, Abby/AAD-5257-2021; Stafford, Randall/F-3974-2017	Stafford, Randall/0000-0003-1805-1271; Balise, Raymond/0000-0002-9856-5901; Kim, Soowon/0000-0002-6637-0018; King, Abby/0000-0002-7949-8811	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT001098] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; *AM COLL SPORTS ME, 2000, PHYS FITN TEST INT; Appel LJ, 2003, JAMA-J AM MED ASSOC, V289, P2083, DOI 10.1001/jama.289.16.2083; Appel LJ, 2005, JAMA-J AM MED ASSOC, V294, P2455, DOI 10.1001/jama.294.19.2455; Atkins RC, 2002, ATKINS NEW DIET REVO; Berneis KK, 2002, J LIPID RES, V43, P1363, DOI 10.1194/jlr.R200004-JLR200; Blackburn GL, 2001, CLEV CLIN J MED, V68, P761, DOI 10.3949/ccjm.68.9.761; Bravata DM, 2003, JAMA-J AM MED ASSOC, V289, P1837, DOI 10.1001/jama.289.14.1837; Brehm BJ, 2003, J CLIN ENDOCR METAB, V88, P1617, DOI 10.1210/jc.2002-021480; BROWNELL KD, 2000, LEARN MANUAL WEIGHT; Connor WE, 1997, NEW ENGL J MED, V337, P562; Dansinger ML, 2005, JAMA-J AM MED ASSOC, V293, P43, DOI 10.1001/jama.293.1.43; Drewnowski A, 2004, AM J PREV MED, V27, P154, DOI 10.1016/j.amepre.2004.06.011; Ello-Martin JA, 2005, AM J CLIN NUTR, V82, p236S, DOI 10.1093/ajcn/82.1.236S; Farnsworth E, 2003, AM J CLIN NUTR, V78, P31, DOI 10.1093/ajcn/78.1.31; Finkelstein EA, 2005, ANNU REV PUBL HEALTH, V26, P239, DOI 10.1146/annurev.publhealth.26.021304.144628; Foster GD, 2005, AM J CLIN NUTR, V82, p230S, DOI 10.1093/ajcn/82.1.230S; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; FREEDMAN M, 2001, OBESITY REV S1, V9, P1, DOI DOI 10.1038/0BY.2001.113; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gardner CD, 1996, JAMA-J AM MED ASSOC, V276, P875, DOI 10.1001/jama.276.11.875; Gardner CD, 2000, AM J CARDIOL, V86, P299, DOI 10.1016/S0002-9149(00)00918-8; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857; Katan MB, 1997, NEW ENGL J MED, V337, P563; Kim S, 2006, INT J EPIDEMIOL, V35, P60, DOI 10.1093/ije/dyi255; King AC, 1998, MED SCI SPORT EXER, V30, P1086, DOI 10.1097/00005768-199807000-00011; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Krauss RM, 2006, AM J CLIN NUTR, V83, P1025, DOI 10.1093/ajcn/83.5.1025; LOTT JA, 1975, CLIN CHEM, V21, P1754; Luscombe-Marsh ND, 2005, AM J CLIN NUTR, V81, P762, DOI 10.1093/ajcn/81.4.762; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; *NIH, 1998, OBES RES S2, V6, pS51, DOI DOI 10.1001/JAMA.2012.39; Noakes M, 2005, AM J CLIN NUTR, V81, P1298; Nordmann AJ, 2006, ARCH INTERN MED, V166, P285, DOI 10.1001/archinte.166.3.285; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Ornish D., 2001, EAT MORE WEIGH LESS; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987; SAMPSON EJ, 1975, CLIN CHEM, V21, P1983; SEARS B, 1995, ENTER ZONE; Stern L, 2004, ANN INTERN MED, V140, P778, DOI 10.7326/0003-4819-140-10-200405180-00007; Stevens VJ, 2001, ANN INTERN MED, V134, P1, DOI 10.7326/0003-4819-134-1-200101020-00007; TRINDER P., 1969, Journal of Clinical Pathology, V22, P158, DOI 10.1136/jcp.22.2.158; WARNICK GR, 1978, J LIPID RES, V19, P65; Weigle DS, 2005, AM J CLIN NUTR, V82, P41, DOI 10.1093/ajcn/82.1.41; WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801; WOOD PD, 1991, NEW ENGL J MED, V325, P461, DOI 10.1056/NEJM199108153250703; Yancy WS, 2004, ANN INTERN MED, V140, P769, DOI 10.7326/0003-4819-140-10-200405180-00006	49	658	673	1	95	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 7	2007	297	9					969	977		10.1001/jama.297.9.969	http://dx.doi.org/10.1001/jama.297.9.969			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143CP	17341711	Bronze			2023-01-03	WOS:000244697900026
J	Ziegler, S; Bosshard, G				Ziegler, Stephen; Bosshard, Georg			Role of non-governmental organisations in physician assisted suicide	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SWITZERLAND		Indiana Univ Purdue Univ, Sch Publ & Environm Affairs, Ft Wayne, IN 46805 USA; Univ Zurich, Inst Legal Med, Zurich, Switzerland	Purdue University System; Indiana University Purdue University Fort Wayne; University of Zurich	Ziegler, S (corresponding author), Indiana Univ Purdue Univ, Sch Publ & Environm Affairs, Ft Wayne, IN 46805 USA.	zieglers@ipfw.edu						BARNETT EH, 1999, OREGONIAN       0311, pD1; Battin M., 2005, ENDING LIFE ETHICS W; Bosshard G, 2003, SWISS MED WKLY, V133, P310; Bosshard G, 2003, INT J LEGAL MED, V117, P106, DOI 10.1007/s00414-002-0346-3; Bosshard G, 2002, SWISS MED WKLY, V132, P527; CHRISTIE T, 2006, REGISTER GUARD  1023; Dyer C, 2006, BRIT MED J, V332, P1169, DOI 10.1136/bmj.332.7551.1169; Faber-Langendoen K, 2000, ANN INTERN MED, V132, P482, DOI 10.7326/0003-4819-132-6-200003210-00010; Hurst SA, 2003, BRIT MED J, V326, P271, DOI 10.1136/bmj.326.7383.271; LEE BC, 2004, PHYS ASSISTED DYING, P190; LEE BC, 1997, OREGON HLTH LAW MANU, V2, P1; MINELLI L, 2000, AKTUELLE JURISTISCHE, V9, P474; Ogden RD, 2001, DEATH STUD, V25, P387, DOI 10.1080/074811801750257491; *OR DEP HUM SERV, 2006, 8 ANN REP OR DEATH D; RIPPE KP, 2003, QUALITATSSICHERUNG F; *SWISS NAT ADV COM, 2006, 13 SWISS NAT ADV COM; *TASK FORC IMPR CA, 2005, OREG DEATH DIGN ACT; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6; Werth JL, 2000, PSYCHOL PUBLIC POL L, V6, P348, DOI 10.1037//1076-8971.6.2.348; *WORLD FED RIGHT D, OUR MEMB	20	26	26	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 10	2007	334	7588					295	298		10.1136/bmj.39100.417072.BE	http://dx.doi.org/10.1136/bmj.39100.417072.BE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	142MN	17289733	Green Published			2023-01-03	WOS:000244654100032
J	Reilly, JJ; Kelly, L; Montgomery, C; Williamson, A; Fisher, A; McColl, JH; Lo Conte, R; Paton, JY; Grant, S				Reilly, John J.; Kelly, Louise; Montgomery, Colette; Williamson, Avril; Fisher, Abigail; McColl, John H.; Lo Conte, Rossella; Paton, James Y.; Grant, Stanley			Physical activity to prevent obesity in young children: cluster randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	52nd Annual Meeting of the American-College-of-Sports-Medicine	JUN 01-04, 2005	Nashville, TN	Amer Coll Sports Med			FUNDAMENTAL MOVEMENT SKILLS; INTERVENTIONS; BEHAVIOR	Objective To assess whether a physical activity intervention reduces body mass index in young children. Design Cluster randomised controlled single blinded trial over 12 months. Setting Thirty six nurseries m Glasgow, Scotland. Participants 545 children in their preschool year, mean age 4.2 years (SD 0.2) at baseline. Intervention Enhanced physical activity programme in nursery (three 30 minute sessions a week over 24 weeks) plus home based health education aimed at increasing physical activity through play and reducing sedentary behaviour. Main outcome measure Body mass index, expressed as a standard deviation score relative to UK 1990 reference data. Secondary measures were objectively measured physical activity and sedentary behaviour; fundamental movement skills; and evaluation of tire process. Results Group allocation had no significant effect on the primary outcome measure at six and 12 months or on measures of physical activity and sedentary behaviour by accelerometry. Children in the intervention group had significantly higher performance in movement: Skills tests than control children at six month follow-up (P = 0.0027; 95% confidence interval 0.3 to 1.3) after adjustment for sex and baseline performance. Conclusions Physical activity can significantly improve motor skills but did not reduce body mass index in young children in this trial.	Univ Glasgow, Yorkhill Hosp, Div Dev Med, Glasgow G3 8SJ, Lanark, Scotland; Glasgow City Council, Dept Educ, Glasgow G1 1HL, Lanark, Scotland; Univ Glasgow, Fac Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow; University of Glasgow	Reilly, JJ (corresponding author), Univ Glasgow, Yorkhill Hosp, Div Dev Med, Glasgow G3 8SJ, Lanark, Scotland.	jjr2y@clinmed.gla.ac.uk	Grant, Stanley Baugh/AAD-5326-2022	Grant, Stanley Baugh/0000-0001-6221-7211; McColl, John/0000-0002-6008-2349				COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; Fisher A, 2005, MED SCI SPORT EXER, V37, P684, DOI 10.1249/01.MSS.0000159138.48107.7D; Gortmaker SL, 1999, ARCH PEDIAT ADOL MED, V153, P409, DOI 10.1001/archpedi.153.4.409; Hardeman W, 2000, INT J OBESITY, V24, P131, DOI 10.1038/sj.ijo.0801100; Koplan JP, 1999, JAMA-J AM MED ASSOC, V282, P1579, DOI 10.1001/jama.282.16.1579; *NHS, 2003, NHS QUAL IMPR IND CH; Okely AD, 2004, RES Q EXERCISE SPORT, V75, P238, DOI 10.1080/02701367.2004.10609157; Puyau MR, 2002, OBES RES, V10, P150, DOI 10.1038/oby.2002.24; Reilly JJ, 2002, ARCH DIS CHILD, V86, P392, DOI 10.1136/adc.86.6.392; Reilly JJ, 2003, P NUTR SOC, V62, P611, DOI 10.1079/PNS2003276; Reilly JJ, 2003, OBES RES, V11, P1155, DOI 10.1038/oby.2003.158; Robinson TN, 1999, JAMA-J AM MED ASSOC, V282, P1561, DOI 10.1001/jama.282.16.1561; Sahota P, 2001, BMJ-BRIT MED J, V323, P1029, DOI 10.1136/bmj.323.7320.1029; SUMMERBELL CD, 2006, COCHRANE LIB; Swinburn B, 1999, PREV MED, V29, P563, DOI 10.1006/pmed.1999.0585	15	284	287	2	53	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 18	2006	333	7577					1041	1043		10.1136/bmj.38979.623773.55	http://dx.doi.org/10.1136/bmj.38979.623773.55			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	108HB	17028105	Green Published, Bronze			2023-01-03	WOS:000242229800014
J	Marks, LS; Mazer, NA; Mostaghel, E; Hess, DL; Dorey, FJ; Epstein, JI; Veltri, RW; Makarov, DV; Partin, AW; Bostwick, DG; Macairan, ML; Nelson, PS				Marks, Leonard S.; Mazer, Norman A.; Mostaghel, Elahe; Hess, David L.; Dorey, Frederick J.; Epstein, Jonathan I.; Veltri, Robert W.; Makarov, Danil V.; Partin, Alan W.; Bostwick, David G.; Macairan, Maria Luz; Nelson, Peter S.			Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANDROGEN DEFICIENCY; SAW PALMETTO; OLDER MEN; CANCER; DIHYDROTESTOSTERONE; FINASTERIDE; BIOPSY; RISK; RECOMMENDATIONS; HYPERTROPHY	Context Prostate safety is a primary concern when aging men receive testosterone replacement therapy (TRT), but little information is available regarding the effects of TRT on prostate tissue in men. Objective To determine the effects of TRT on prostate tissue of aging men with low serum testosterone levels. Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial of 44 men, aged 44 to 78 years, with screening serum testosterone levels lower than 300 ng/dL ( < 10.4 nmol/L) and related symptoms, conducted at a US community-based research center between February 2003 and November 2004. Intervention Participants were randomly assigned to receive 150 mg of testosterone enanthate or matching placebo intramuscularly every 2 weeks for 6 months. Main Outcome Measures The primary outcome measure was the 6-month change in prostate tissue androgen levels ( testosterone and dihydrotestosterone). Secondary outcome measures included 6-month changes in prostate-related clinical features, histology, biomarkers, and epithelial cell gene expression. Results Of the 44 men randomized, 40 had prostate biopsies performed both at baseline and at 6 months and qualified for per-protocol analysis ( TRT, n= 21; placebo, n= 19). Testosterone replacement therapy increased serum testosterone levels to the mid-normal range ( median at baseline, 282 ng/dL [9.8 nmol/L]; median at 6 months, 640 ng/dL [22.2 nmol/L]) with no significant change in serum testosterone levels in matched, placebo-treated men. However, median prostate tissue levels of testosterone (0.91 ng/g) and dihydrotestosterone (6.79 ng/g) did not change significantly in the TRT group. No treatment-related change was observed in prostate histology, tissue biomarkers ( androgen receptor, Ki-67, CD34), gene expression ( including AR, PSA, PAP2A, VEGF, NXK3, CLU [ Clusterin]), or cancer incidence or severity. Treatment-related changes in prostate volume, serum prostate-specific antigen, voiding symptoms, and urinary flow were minor. Conclusions These preliminary data suggest that in aging men with late-onset hypogonadism, 6 months of TRT normalizes serum androgen levels but appears to have little effect on prostate tissue androgen levels and cellular functions. Establishment of prostate safety for large populations of older men undergoing longer duration of TRT requires further study.	Univ Calif Los Angeles, Geffen Sch Med, Dept Urol, Los Angeles, CA 90024 USA; Urol Sci Res Fdn, Culver City, CA USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Oregon Natl Primate Res Ctr, Beaverton, OR USA; Univ So Calif, Childrens Hosp, Sch Med, Dept Biostat, Los Angeles, CA 90027 USA; Johns Hopkins Univ, Brady Urol Inst, Baltimore, MD USA; Bostwick Labs, Richmond, VA USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Boston University; Oregon Health & Science University; Oregon National Primate Research Center; Children's Hospital Los Angeles; University of Southern California; Johns Hopkins University; University of Washington; University of Washington Seattle	Marks, LS (corresponding author), Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA.	lsmarks@ucla.edu	Mazer, Norman A/HGU-8266-2022	Makarov, Danil/0000-0002-0565-9272	NATIONAL CANCER INSTITUTE [P50CA097186, P50CA058236] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065204] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amory JK, 2002, J AM GERIATR SOC, V50, P1698, DOI 10.1046/j.1532-5415.2002.50462.x; Bhasin S, 2003, J ANDROL, V24, P299; Bhasin S, 2001, AM J PHYSIOL-ENDOC M, V281, pE1172, DOI 10.1152/ajpendo.2001.281.6.E1172; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; COFFEY DS, 1990, UROL CLIN N AM, V17, P461; Dobs AS, 1999, J CLIN ENDOCR METAB, V84, P3469, DOI 10.1210/jc.84.10.3469; Ferrando AA, 2001, CRIT CARE MED, V29, P1936, DOI 10.1097/00003246-200110000-00015; FOWLER JE, 1981, J UROLOGY, V126, P372, DOI 10.1016/S0022-5347(17)54531-0; Gann PH, 1996, J NATL CANCER I, V88, P1118, DOI 10.1093/jnci/88.16.1118; Gaylis FD, 2005, J UROLOGY, V174, P534, DOI 10.1097/01.ju.0000165166.36280.60; Hammes A, 2005, CELL, V122, P751, DOI 10.1016/j.cell.2005.06.032; Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724; Heller CG, 1944, J AMER MED ASSOC, V126, P472, DOI 10.1001/jama.1944.02850430006003; Hijazi RA, 2005, ANNU REV MED, V56, P117, DOI 10.1146/annurev.med.56.082103.104518; Hsing Ann W., 2002, Prostate, V52, P213, DOI 10.1002/pros.10108; Huggins C, 1940, J UROLOGY, V43, P705, DOI 10.1016/S0022-5347(17)71453-X; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; IMPERATO.J, 1974, SCIENCE, V186, P1213, DOI 10.1126/science.186.4170.1213; JOHNSON D E, 1977, Urology, V9, P137, DOI 10.1016/0090-4295(77)90182-0; Kamischke A, 1999, J ANDROL, V20, P601; KARR JP, 1984, UROLOGY, V23, P276, DOI 10.1016/S0090-4295(84)90047-5; Kupelian V, 2006, J CLIN ENDOCR METAB, V91, P843, DOI 10.1210/jc.2005-1326; Liverman CT, 2004, TESTOSTERONE AGING C; Loughlin KR, 1997, J UROLOGY, V157, P1845, DOI 10.1016/S0022-5347(01)64881-X; Marks LS, 2004, UROLOGY, V64, P765, DOI 10.1016/j.urology.2004.05.047; Marks LS, 1997, J UROLOGY, V157, P2171, DOI 10.1016/S0022-5347(01)64707-4; Marks LS, 2001, UROLOGY, V57, P191, DOI 10.1016/S0090-4295(00)00972-9; Marks LS, 2001, UROLOGY, V57, P999, DOI 10.1016/S0090-4295(00)01052-9; Marks LS, 2000, J UROLOGY, V163, P1451, DOI 10.1016/S0022-5347(05)67641-0; MCCONNELL JD, 1992, J CLIN ENDOCR METAB, V74, P505, DOI 10.1210/jc.74.3.505; Meikle AW, 1997, UROLOGY, V49, P191; Mohler JL, 2004, J UROLOGY, V171, P2277, DOI 10.1097/01.ju.0000127739.88383.79; Morley JE, 2000, J LAB CLIN MED, V135, P370, DOI 10.1067/mlc.2000.106455; Morley JE, 2000, METABOLISM, V49, P1239, DOI 10.1053/meta.2000.8625; Nelson PS, 2002, NUCLEIC ACIDS RES, V30, P218, DOI 10.1093/nar/30.1.218; Nieschlag E, 2005, EUR UROL, V48, P1, DOI 10.1016/j.eururo.2005.04.027; OESTERLING JE, 1986, J UROLOGY, V136, P1030, DOI 10.1016/S0022-5347(17)45198-6; Parsons JK, 2005, CANCER EPIDEM BIOMAR, V14, P2257, DOI 10.1158/1055-9965.EPI-04-0715; Pritchard CC, 2001, P NATL ACAD SCI USA, V98, P13266, DOI 10.1073/pnas.221465998; RESKO JA, 1980, J CLIN ENDOCR METAB, V50, P900, DOI 10.1210/jcem-50-5-900; Rhoden EL, 2003, J UROLOGY, V170, P2348, DOI 10.1097/01.ju.0000091104.71869.8e; Rhoden EL, 2004, NEW ENGL J MED, V350, P482, DOI 10.1056/NEJMra022251; Roehl KA, 2002, J UROLOGY, V167, P2435, DOI 10.1016/S0022-5347(05)64999-3; Schaeffer EM, 2004, NEW ENGL J MED, V350, P2004; Schroeder ET, 2004, J CLIN ENDOCR METAB, V89, P4863, DOI 10.1210/jc.2004-0784; Shirai T, 2000, MUTAT RES-REV MUTAT, V462, P219, DOI 10.1016/S1383-5742(00)00039-9; Snyder PJ, 2000, J CLIN ENDOCR METAB, V85, P2670, DOI 10.1210/jc.85.8.2670; Tenover J L, 2000, Mayo Clin Proc, V75 Suppl, pS77; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Udayakumar TS, 1998, ANAT REC, V252, P637; WALSH PC, 1983, J CLIN INVEST, V72, P1772, DOI 10.1172/JCI111137; Wang C, 2000, J CLIN ENDOCR METAB, V85, P2839, DOI 10.1210/jc.85.8.2839; WU CP, 1991, PROG CLIN BIOL RES, V370, P249	53	285	301	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2006	296	19					2351	2361		10.1001/jama.296.19.2351	http://dx.doi.org/10.1001/jama.296.19.2351			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104ZI	17105798	Bronze			2023-01-03	WOS:000241998700023
J	Buytaert, E; Matroule, JY; Durinck, S; Close, P; Kocanova, S; Vandenheede, JR; Witte, PA; Piette, J; Agostinis, P				Buytaert, E.; Matroule, J. Y.; Durinck, S.; Close, P.; Kocanova, S.; Vandenheede, J. R.; de Witte, P. A.; Piette, J.; Agostinis, P.			Molecular effectors and modulators of hypericin-mediated cell death in bladder cancer cells	ONCOGENE			English	Article						photodynamic therapy; microarrays; p38(MAPK)	ACTIVATED PROTEIN-KINASE; PHOTODYNAMIC THERAPY; P38 MAPK; SIGNALING PATHWAYS; UP-REGULATION; ER STRESS; EXPRESSION; GENE; TRANSCRIPTION; INHIBITION	Photodynamic therapy (PDT) is an anticancer approach utilizing a light-absorbing molecule and visible light irradiation to generate, in the presence of O-2, cytotoxic reactive oxygen species, which cause tumor ablation. Given that the photosensitizer hypericin is under consideration for PDT treatment of bladder cancer we used oligonucleotide microarrays in the T24 bladder cancer cell line to identify differentially expressed genes with therapeutic potential. This study reveals that the expression of several genes involved in various metabolic processes, stress-induced cell death, autophagy, proliferation, inflammation and carcinogenesis is strongly affected by PDT and pinpoints the coordinated induction of a cluster of genes involved in the unfolded protein response pathway after endoplasmic reticulum stress and in antioxidant response. Analysis of PDT-treated cells after p38(MAPK) inhibition or silencing unraveled that the induction of an important subset of differentially expressed genes regulating growth and invasion, as well as adaptive mechanisms against oxidative stress, is governed by this stress-activated kinase. Moreover, p38(MAPK) inhibition blocked autonomous regrowth and migration of cancer cells escaping PDT-induced cell death. This analysis identifies new molecular effectors of the cancer cell response to PDT opening attractive avenues to improve the therapeutic efficacy of hypericin-based PDT of bladder cancer.	[Buytaert, E.; Kocanova, S.; Vandenheede, J. R.; Agostinis, P.] Catholic Univ Louvain, Fac Med, Dept Mol & Cell Biol, Brabant, Belgium; [Matroule, J. Y.; Close, P.; Piette, J.] Univ Liege, Lab Virol & Immunol, Liege, Belgium; [Durinck, S.] Catholic Univ Louvain, Dept Elect Engn, ESAT SCD, Brabant, Belgium; [de Witte, P. A.] Catholic Univ Louvain, Fac Pharm, Lab Pharmaceut Biol & Phytopharmacol, Brabant, Belgium	Universite Catholique Louvain; University of Liege; Universite Catholique Louvain; Universite Catholique Louvain	Agostinis, P (corresponding author), KULeuven, Dept Mol & Cell Biol, Herestr 49,Campus Gasthuisberg, B-3000 Louvain, Brabant, Belgium.	patrizia.agostinis@med.kuleuven.be	Agostinis, Patrizia/AAO-2468-2020; Agostinis, Patrizia/ABI-1177-2020	Agostinis, Patrizia/0000-0003-1314-2115; de Witte, Peter/0000-0002-9989-9567; CLOSE, PIERRE/0000-0002-8844-9616				Agostinis P, 2004, PHOTOCH PHOTOBIO SCI, V3, P721, DOI 10.1039/b315237e; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Birney E, 2006, NUCLEIC ACIDS RES, V34, pD556, DOI 10.1093/nar/gkj133; Bostrom PJ, 2000, INT J CANCER, V88, P417, DOI 10.1002/1097-0215(20001101)88:3<417::AID-IJC14>3.3.CO;2-7; Buytaert E, 2006, FASEB J, V20, P756, DOI 10.1096/fj.05-4305fje; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Caristi S, 2005, J BIOL CHEM, V280, P14433, DOI 10.1074/jbc.M410725200; Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894; D'Hallewin MA, 2002, BJU INT, V89, P760, DOI 10.1046/j.1464-410X.2002.02690.x; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Durinck S, 2005, BIOINFORMATICS, V21, P3439, DOI 10.1093/bioinformatics/bti525; Elenitoba-Johnson KSJ, 2003, P NATL ACAD SCI USA, V100, P7259, DOI 10.1073/pnas.1137463100; Espel E, 2005, SEMIN CELL DEV BIOL, V16, P59, DOI 10.1016/j.semcdb.2004.11.008; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hashimoto S, 2000, CLIN EXP ALLERGY, V30, P48; Hendrickx N, 2003, J BIOL CHEM, V278, P52231, DOI 10.1074/jbc.M307591200; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Hori O, 2006, MOL CELL BIOL, V26, P4257, DOI 10.1128/MCB.02055-05; Huang XK, 2005, CANCER RES, V65, P3470, DOI 10.1158/0008-5472.CAN-04-2807; Imasato A, 2002, J BIOL CHEM, V277, P47444, DOI 10.1074/jbc.M208140200; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Johansson N, 2000, J CELL SCI, V113, P227; Kamuhabwa A, 2004, PHOTOCH PHOTOBIO SCI, V3, P772, DOI 10.1039/b315586b; Kocanova S, 2007, APOPTOSIS, V12, P731, DOI 10.1007/s10495-006-0016-x; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; LIN Z, 2004, MOL CELL PROTEOMICS, V820; Liu RY, 2000, J BIOL CHEM, V275, P21086, DOI 10.1074/jbc.M001281200; Lou H, 2006, MOL PHARMACOL, V69, P1662, DOI 10.1124/mol.105.019794; Ma YJ, 2004, J BIOL CHEM, V279, P13792, DOI 10.1074/jbc.M313724200; Makowski M, 2003, CLIN CANCER RES, V9, P5417; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Oh-Hashi K, 2001, FREE RADICAL BIO MED, V30, P213, DOI 10.1016/S0891-5849(00)00461-5; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Park JI, 2003, ONCOGENE, V22, P4314, DOI 10.1038/sj.onc.1206478; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Sanchez-Carbayo M, 2002, CANCER RES, V62, P6973; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Sengupta N, 2004, J R SOC PROMO HEALTH, V124, P228, DOI 10.1177/146642400412400520; Suarez-Cuervo C, 2004, CLIN EXP METASTAS, V21, P525, DOI 10.1007/s10585-004-3503-x; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Tsai PW, 2003, J BIOL CHEM, V278, P5750, DOI 10.1074/jbc.M204863200; Van de Putte M, 2005, BRIT J CANCER, V92, P1406, DOI 10.1038/sj.bjc.6602512; Verwanger T, 2002, INT J ONCOL, V21, P1353; Volanti C, 2004, ONCOGENE, V23, P8649, DOI 10.1038/sj.onc.1207871; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wild PJ, 2005, MOL CANCER THER, V4, P516, DOI 10.1158/1535-7163.MCT-04-0141; Wong S, 2004, LASER SURG MED, V35, P336, DOI 10.1002/lsm.20110; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	55	75	76	0	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1916	1929		10.1038/sj.onc.1210825	http://dx.doi.org/10.1038/sj.onc.1210825			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17952126	Green Published			2023-01-03	WOS:000254150600011
J	Nelson, HD				Nelson, Heidi D.			Menopause	LANCET			English	Review							QUALITY-OF-LIFE; HEALTHY POSTMENOPAUSAL WOMEN; SYMPTOMATIC PERIMENOPAUSAL WOMEN; RANDOMIZED CONTROLLED-TRIAL; ESTROGEN PLUS PROGESTIN; HOT FLASHES; DOUBLE-BLIND; BLACK COHOSH; BREAST-CANCER; VASOMOTOR SYMPTOMS	Menopause is the time of life when menstrual cycles cease, and is caused by reduced secretion of the ovarian hormones oestrogen and progesterone. Although menopause is a normal event for women, individual experiences vary, and some women seek medical advice for the management of symptoms. Many symptoms have been attributed to menopause, but only vasomotor dysfunction and vaginal dryness are consistently associated with this time of life in epidemiological studies. Other common symptoms such as mood changes, sleep disturbances, urinary incontinence, cognitive changes, somatic complaints, sexual dysfunction, and reduced quality of life may be secondary to other symptoms, or related to other causes. Trials of therapies for vasomotor dysfunction have shown improvements with oestrogen, gabapentin, paroxetine, and clonidine, but little or no benefit with other agents; adverse effects of these treatments must also be considered. Many questions about menopausal transition and its effects on health have not been adequately addressed.	Oregon Hlth & Sci Univ, Oregon Evidence Based Practice Ctr, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA; Providence Hlth & Serv, Womens & Childrens Hlth Res Ctr, Portland, OR USA	Oregon Health & Science University; Oregon Health & Science University	Nelson, HD (corresponding author), Oregon Hlth & Sci Univ, Oregon Evidence Based Practice Ctr, Dept Med Informat & Clin Epidemiol, Mailcode BICC,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	nelsonh@ohsu.edu						Aiello EJ, 2004, MENOPAUSE, V11, P382, DOI 10.1097/01.GME.0000113932.56832.27; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Atkinson C, 2004, BREAST CANCER RES, V6, pR170, DOI 10.1186/bcr773; Avis Nancy E, 2005, Am J Med, V118 Suppl 12B, P37, DOI 10.1016/j.amjmed.2005.09.057; Avis Nancy E., 1994, Annals of Epidemiology, V4, P214; Avis NE, 2003, MED CARE, V41, P1262, DOI 10.1097/01.MLR.0000093479.39115.AF; Avis NE, 2001, SOC SCI MED, V52, P345, DOI 10.1016/S0277-9536(00)00147-7; Baber R J, 1999, Climacteric, V2, P85, DOI 10.3109/13697139909025571; Baksu A, 2005, INT J GYNECOL OBSTET, V91, P58, DOI 10.1016/j.ijgo.2005.04.011; BALK E, 2005, 126 AHRQ; Barnhart KT, 1999, J CLIN ENDOCR METAB, V84, P3896, DOI 10.1210/jc.84.11.3896; Barton DL, 1998, J CLIN ONCOL, V16, P495, DOI 10.1200/JCO.1998.16.2.495; BERGMANS MGM, 1987, MATURITAS, V9, P227, DOI 10.1016/0378-5122(87)90005-3; BOULET MJ, 1994, MATURITAS, V19, P157, DOI 10.1016/0378-5122(94)90068-X; Bromberger JT, 2007, J AFFECT DISORDERS, V103, P267, DOI 10.1016/j.jad.2007.01.034; Brown WJ, 2002, INT J BEHAV MED, V9, P53, DOI 10.1207/S15327558IJBM0901_04; Busch CM, 1994, J AGING HEALTH, V6, P209; Cagnacci A, 2003, MATURITAS, V44, P103, DOI 10.1016/S0378-5122(02)00317-1; Carpenter JS, 2007, ONCOLOGIST, V12, P124, DOI 10.1634/theoncologist.12-1-124; Carpenter Janet S, 2002, Oncol Nurs Forum, V29, pE16, DOI 10.1188/02.ONF.E16-E25; Carranza-Lira S, 2001, INT J FERTIL WOMEN M, V46, P296; CASPER RF, 1985, CLIN ENDOCRINOL, V22, P293, DOI 10.1111/j.1365-2265.1985.tb03243.x; Cassidy A, 2006, P NUTR SOC, V65, P76, DOI 10.1079/PNS2005476; CHENOY R, 1994, BRIT MED J, V308, P501, DOI 10.1136/bmj.308.6927.501; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Cleary C., 1994, COMPLEMENT THER MED, V2, P181, DOI [10.1016/0965-2299(94)90017-5, DOI 10.1016/0965-2299(94)90017-5]; de Wit H, 2001, PSYCHONEUROENDOCRINO, V26, P697, DOI 10.1016/S0306-4530(01)00024-5; Dennerstein L, 1999, J NERV MENT DIS, V187, P685, DOI 10.1097/00005053-199911000-00006; Dennerstein L, 2000, OBSTET GYNECOL, V96, P351, DOI 10.1016/S0029-7844(00)00930-3; Dennerstein L, 2002, FERTIL STERIL, V77, pS42; Dennerstein L, 2001, J NERV MENT DIS, V189, P84, DOI 10.1097/00005053-200102000-00003; Dennerstein L, 2001, FERTIL STERIL, V76, P456, DOI 10.1016/S0015-0282(01)01978-1; Dennerstein Lorraine, 2005, Am J Med, V118 Suppl 12B, P59, DOI 10.1016/j.amjmed.2005.09.034; Dodin S, 2005, J CLIN ENDOCR METAB, V90, P1390, DOI 10.1210/jc.2004-1148; Dudley E C, 1998, Climacteric, V1, P18, DOI 10.3109/13697139809080677; Freedman RR, 1999, AM J OBSTET GYNECOL, V181, P66, DOI 10.1016/S0002-9378(99)70437-0; FREEDMAN RR, 1995, J CLIN ENDOCR METAB, V80, P2354, DOI 10.1210/jc.80.8.2354; Freeman EW, 2006, ARCH GEN PSYCHIAT, V63, P375, DOI 10.1001/archpsyc.63.4.375; Frei-Kleiner S, 2005, MATURITAS, V51, P397, DOI 10.1016/j.maturitas.2004.10.003; Ghali WA, 1997, AM J MED, V103, P3, DOI 10.1016/S0002-9343(97)90049-8; Glazer Greer, 2002, Health Care Women Int, V23, P612, DOI 10.1080/07399330290107377; Gold EB, 2000, AM J EPIDEMIOL, V152, P463, DOI 10.1093/aje/152.5.463; Gold EB, 2001, AM J EPIDEMIOL, V153, P865, DOI 10.1093/aje/153.9.865; Gordon PR, 2006, MENOPAUSE, V13, P568, DOI 10.1097/01.gme.0000196595.82452.ca; Grady D, 2007, OBSTET GYNECOL, V109, P823, DOI 10.1097/01.AOG.0000258278.73505.fa; Grady Deborah, 2005, Am J Med, V118 Suppl 12B, P163, DOI 10.1016/j.amjmed.2005.09.051; GREENE JG, 1976, J PSYCHOSOM RES, V20, P425, DOI 10.1016/0022-3999(76)90005-2; Guttuso T, 2003, OBSTET GYNECOL, V101, P337, DOI 10.1016/S0029-7844(02)02712-6; Haines CJ, 2005, MATURITAS, V52, P264, DOI 10.1016/j.maturitas.2005.03.012; HALLSTROM T, 1985, ACTA OBSTET GYN SCAN, P13; Hardy R, 2002, SOC SCI MED, V55, P1975, DOI 10.1016/S0277-9536(01)00326-4; Harlow SD, 2006, J CLIN ENDOCR METAB, V91, P3432, DOI 10.1210/jc.2005-2810; Heyerick A, 2006, MATURITAS, V54, P164, DOI 10.1016/j.maturitas.2005.10.005; HICKOK LR, 1993, OBSTET GYNECOL, V82, P919; Hidalgo LA, 2005, GYNECOL ENDOCRINOL, V21, P257, DOI 10.1080/09513590500361192; Hilditch JR, 1996, MATURITAS, V24, P161, DOI 10.1016/0378-5122(96)01038-9; Huang MI, 2006, FERTIL STERIL, V86, P700, DOI 10.1016/j.fertnstert.2006.02.100; HUDSON TS, 1998, J NATUROPATHIC MED, V7, P73; Jacobson JS, 2001, J CLIN ONCOL, V19, P2739, DOI 10.1200/JCO.2001.19.10.2739; Jeri AR, 2002, FEMALE PATIENT, V27, P35; Johnston JM, 2006, J WOMENS HEALTH, V15, P1184, DOI 10.1089/jwh.2006.15.1184; KAUFERT PA, 1992, MATURITAS, V14, P143, DOI 10.1016/0378-5122(92)90006-P; Kerr EA, 2005, ANN INTERN MED, V142, P154, DOI 10.7326/0003-4819-142-2-200501180-00021; Kimmick GG, 2006, BREAST J, V12, P114, DOI 10.1111/j.1075-122X.2006.00218.x; Knight D C, 1999, Climacteric, V2, P79, DOI 10.3109/13697139909025570; Komesaroff P A, 2001, Climacteric, V4, P144; Koster A, 2002, Arch Womens Ment Health, V5, P9, DOI 10.1007/s007370200017; Kravitz HM, 2003, MENOPAUSE, V10, P19, DOI 10.1097/01.GME.0000030707.35686.5A; Krebs EE, 2004, OBSTET GYNECOL, V104, P824, DOI 10.1097/01.AOG.0000140688.71638.d3; Landgren MB, 2005, MATURITAS, V50, P222, DOI 10.1016/j.maturitas.2004.06.001; Leonetti HB, 1999, OBSTET GYNECOL, V94, P225, DOI 10.1016/S0029-7844(99)00266-5; Lewis JE, 2006, MENOPAUSE, V13, P631, DOI 10.1097/01.gme.0000191882.59799.67; Loprinzi CL, 2000, LANCET, V356, P2059, DOI 10.1016/S0140-6736(00)03403-6; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; Maartens LWF, 2002, MATURITAS, V42, P195, DOI 10.1016/S0378-5122(02)00038-5; MacLennan A, 2001, Climacteric, V4, P58, DOI 10.1080/713605036; Maclennan A H, 2004, Cochrane Database Syst Rev, pCD002978, DOI 10.1002/14651858.CD002978.pub2; MAKKONEN M, 1993, GYNECOL ENDOCRINOL, V7, P135, DOI 10.3109/09513599309152493; Mansfield PK, 2004, WOMEN HEALTH ISS, V14, P220, DOI 10.1016/j.whi.2004.08.002; MCKINLAY SM, 1989, MENOPAUSE EVALUATION, P137; Meeuwsen IB, 2002, MATURITAS, V41, P35, DOI 10.1016/S0378-5122(01)00251-1; Melby MK, 2005, HUM REPROD UPDATE, V11, P495, DOI 10.1093/humupd/dmi018; Mishra GD, 2003, QUAL LIFE RES, V12, P405, DOI 10.1023/A:1023421128141; Mitchell ES, 1996, MATURITAS, V25, P1, DOI 10.1016/0378-5122(96)01047-X; MORRISON JC, 1980, AM J OBSTET GYNECOL, V138, P99, DOI 10.1016/0002-9378(80)90017-4; Munoz GH, 2003, MATURITAS, V44, pS59, DOI 10.1016/S0378-5122(02)00349-3; *N AM MEN SOC, MEN GUID; *N AM MEN SOC, 2004, MENOPAUSE, V11, P589; Nedrow A, 2006, ARCH INTERN MED, V166, P1453, DOI 10.1001/archinte.166.14.1453; Nelson H.D., 2005, MANAGEMENT MENOPAUSE; Nelson HD, 2004, JAMA-J AM MED ASSOC, V291, P1610, DOI 10.1001/jama.291.13.1610; Nelson HD, 2004, JAMA-J AM MED ASSOC, V291, P1621, DOI 10.1001/jama.291.13.1621; Nelson HD, 2006, JAMA-J AM MED ASSOC, V295, P2057, DOI 10.1001/jama.295.17.2057; NELSON HD, DRUG CLASS REV ESTRO; Newton KM, 2006, ANN INTERN MED, V145, P869, DOI 10.7326/0003-4819-145-12-200612190-00003; *NIH, 2004, ASS IMPR MEAS HOT FL; Osmers R, 2005, OBSTET GYNECOL, V105, P1074, DOI 10.1097/01.AOG.0000158865.98070.89; Pandya KJ, 2005, LANCET, V366, P818, DOI 10.1016/S0140-6736(05)67215-7; Pockaj BA, 2006, J CLIN ONCOL, V24, P2836, DOI 10.1200/JCO.2005.05.4296; Rachev E, 2001, CURR MED RES OPIN, V17, P105; Randolph JF, 2006, J CLIN ENDOCR METAB, V91, P3034, DOI 10.1210/jc.2006-0243; Reddy SY, 2006, OBSTET GYNECOL, V108, P41, DOI 10.1097/01.AOG.0000222383.43913.ed; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Russo Roberto, 2003, Acta Biomed, V74, P137; SCHIFF I, 1980, JAMA-J AM MED ASSOC, V244, P1443, DOI 10.1001/jama.244.13.1443; Sherburn M, 2001, OBSTET GYNECOL, V98, P628, DOI 10.1016/S0029-7844(01)01508-3; Sloan JA, 2001, J CLIN ONCOL, V19, P4280, DOI 10.1200/JCO.2001.19.23.4280; Soules M R, 2001, Menopause, V8, P402, DOI 10.1097/00042192-200111000-00004; Stearns V, 2005, J CLIN ONCOL, V23, P6919, DOI 10.1200/JCO.2005.10.081; Stearns V, 2003, JAMA-J AM MED ASSOC, V289, P2827, DOI 10.1001/jama.289.21.2827; Stephenson J, 2003, JAMA-J AM MED ASSOC, V289, P537, DOI 10.1001/jama.289.5.537; Taffe JR, 2002, MENOPAUSE, V9, P32, DOI 10.1097/00042192-200201000-00006; Tice JA, 2003, JAMA-J AM MED ASSOC, V290, P207, DOI 10.1001/jama.290.2.207; Uebelhack R, 2006, OBSTET GYNECOL, V107, P247, DOI 10.1097/01.AOG.0000196504.49378.83; *US PREV SERV TASK, HORM REPL THER PREV; van de Weijer PHM, 2002, MATURITAS, V42, P187, DOI 10.1016/S0378-5122(02)00080-4; Verhoeven MO, 2005, MENOPAUSE, V12, P412, DOI 10.1097/01.gme.0000170603.63022.62; Vesco KK, 2007, CLIMACTERIC, V10, P448, DOI 10.1080/13697130701611267; Whiting PW, 2002, MED J AUSTRALIA, V177, P440, DOI 10.5694/j.1326-5377.2002.tb04886.x; Williamson J, 2002, BJOG-INT J OBSTET GY, V109, P1050, DOI 10.1111/j.1471-0528.2002.01504.x; Winther K, 2005, CLIMACTERIC, V8, P162, DOI 10.1080/13697130500117987; Woods NF, 1997, RES NURS HEALTH, V20, P119, DOI 10.1002/(SICI)1098-240X(199704)20:2<119::AID-NUR4>3.0.CO;2-N; Wren BG, 2003, MENOPAUSE, V10, P13, DOI 10.1097/01.GME.0000025416.53837.00; Wuttke W, 2003, MATURITAS, V44, pS67, DOI 10.1016/S0378-5122(02)00350-X	125	456	470	10	82	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 1	2008	371	9614					760	770		10.1016/S0140-6736(08)60346-3	http://dx.doi.org/10.1016/S0140-6736(08)60346-3			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268RI	18313505				2023-01-03	WOS:000253596700030
J	Kinane, TB; Grabowski, EF; Sharma, A; Nimkin, K; King, ME; Cornell, LD; Fracchia, MS; Harris, NL; Harris, S; Hales, CA				Kinane, T. Bernard; Grabowski, Eric F.; Sharma, Amita; Nimkin, Katherine; King, Mary Etta; Cornell, Lynn D.; Fracchia, Mary Shannon; Harris, Nancy Lee; Harris, Scott; Hales, Charles A.			Case 7-2008: A 17-year-old girl with chest pain and hemoptysis - Membranous glomerulonephritis with the nephrotic syndrome and pulmonary embolus.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RIGHT-VENTRICULAR DYSFUNCTION; TISSUE-PLASMINOGEN ACTIVATOR; VENOUS THROMBOEMBOLISM; POSTTHROMBOTIC SYNDROME; FOLLOW-UP; NEPHROPATHY; CHILDREN; THROMBOSIS; THERAPY; THROMBOLYSIS		[Kinane, T. Bernard; Grabowski, Eric F.; Sharma, Amita; King, Mary Etta] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [Nimkin, Katherine] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Cornell, Lynn D.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Kinane, T. Bernard; Grabowski, Eric F.; Sharma, Amita; King, Mary Etta] Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA; [Nimkin, Katherine] Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; [Cornell, Lynn D.] Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University	Kinane, TB (corresponding author), Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.							A National Cooperative Study, 1973, CIRCULATION S2, V47, pII1; Brown JH, 1998, NEPHROL DIAL TRANSPL, V13, P443, DOI 10.1093/oxfordjournals.ndt.a027844; Cannizzaro V, 2005, J PEDIAT HEMATOL ONC, V27, P688, DOI 10.1097/01.mph.0000193489.80612.d4; Cattran DC, 2001, KIDNEY INT, V59, P1484, DOI 10.1046/j.1523-1755.2001.0590041484.x; Cattran DC, 1997, KIDNEY INT, V51, P901, DOI 10.1038/ki.1997.127; CATTRAN DC, 1989, NEW ENGL J MED, V320, P210, DOI 10.1056/NEJM198901263200403; Cornell LD, 2005, CURR OPIN NEPHROL HY, V14, P229, DOI 10.1097/01.mnh.0000165888.83125.07; DAGATI VD, 2006, HEPTINSTALLS PATHOLO, P517; Dong B, 2006, COCHRANE DB SYST REV, V2; Fasano R, 2005, J PEDIAT HEMATOL ONC, V27, P692, DOI 10.1097/01.mph.0000194021.40839.05; Goldenberg NA, 2007, BLOOD, V110, P45, DOI 10.1182/blood-2006-12-061234; GRABOWSKI EF, 2006, CURRENT PEDIAT THERA, P933; Grifoni S, 2000, CIRCULATION, V101, P2817, DOI 10.1161/01.CIR.101.24.2817; JENNETTE JC, 1983, KIDNEY INT, V24, P377, DOI 10.1038/ki.1983.170; Kanda H, 2005, LUPUS, V14, P288, DOI 10.1191/0961203305lu2076oa; Konstantinides S, 1998, AM J CARDIOL, V82, P966, DOI 10.1016/S0002-9149(98)00513-X; Konstantinides S, 2002, NEW ENGL J MED, V347, P1143, DOI 10.1056/NEJMoa021274; Kronenberg F, 2004, KIDNEY INT, V66, P348, DOI 10.1111/j.1523-1755.2004.00737.x; Kucher N, 2005, CIRCULATION, V112, pE28, DOI 10.1161/CIRCULATIONAHA.105.551374; Lee BH, 2006, PEDIATR NEPHROL, V21, P1707, DOI 10.1007/s00467-006-0246-8; McConnell MV, 1996, AM J CARDIOL, V78, P469, DOI 10.1016/S0002-9149(96)00339-6; MEHLS O, 1987, J PEDIATR-US, V110, P862, DOI 10.1016/S0022-3476(87)80397-9; Perna A, 2004, AM J KIDNEY DIS, V44, P385, DOI 10.1053/j.ajkd.2004.05.020; PONTICELLI C, 1995, KIDNEY INT, V48, P1600, DOI 10.1038/ki.1995.453; Ribeiro A, 1997, AM HEART J, V134, P479, DOI 10.1016/S0002-8703(97)70085-1; SCHIEPPATI A, 1993, NEW ENGL J MED, V329, P85, DOI 10.1056/NEJM199307083290203; Schulman S, 2006, J THROMB HAEMOST, V4, P734, DOI 10.1111/j.1538-7836.2006.01795.x; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; STEVENSON GF, 1949, J PEDIATR-US, V34, P62, DOI 10.1016/S0022-3476(49)80200-9; van der Meer RW, 2005, RADIOLOGY, V235, P798, DOI 10.1148/radiol.2353040593; van Ommen CH, 2001, J PEDIATR-US, V139, P676, DOI 10.1067/mpd.2001.118192; Vieillard-Baron A, 2001, INTENS CARE MED, V27, P1481, DOI 10.1007/s001340101032; von Depka M, 2000, BLOOD, V96, P3364; Wang M, 2003, J PEDIAT HEMATOL ONC, V25, P379, DOI 10.1097/00043426-200305000-00006	35	4	4	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 28	2008	358	9					941	952		10.1056/NEJMcpc0708507	http://dx.doi.org/10.1056/NEJMcpc0708507			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266JD	18305270				2023-01-03	WOS:000253430200011
J	Fung, CH; Lim, YW; Mattke, S; Damberg, C; Shekelle, PG				Fung, Constance H.; Lim, Yee-Wei; Mattke, Soeren; Damberg, Cheryl; Shekelle, Paul G.			Systematic review: The evidence that publishing patient care performance data improves quality of care	ANNALS OF INTERNAL MEDICINE			English	Review							NEW-YORK-STATE; ARTERY-BYPASS-SURGERY; PAY-FOR-PERFORMANCE; HEALTH PLAN CHOICES; CARDIAC-SURGERY; HOSPITAL PERFORMANCE; CONSUMER REPORTS; MARKET SHARE; UNINTENDED CONSEQUENCES; MEDICAID BENEFICIARIES	Background: Previous reviews have shown inconsistent effects of publicly reported performance data on quality of care, but many new studies have become available in the 7 years since the last systematic review. Purpose: To synthesize the evidence for using publicly reported performance data to improve quality. Data Sources: Web of Science, MEDLINE, EconLit, and Wilson Business Periodicals (1999-2006) and independent review of articles (1986-1999) identified in a previous systematic review. Only sources published in English were included. Study Selection: Peer-reviewed articles assessing the effects of public release of performance data on selection of providers, quality improvement activity, clinical outcomes (effectiveness, patient safety, and patient-centeredness), and unintended consequences. Data Extraction: Data on study participants, reporting system or level, study design, selection of providers, quality improvement activity, outcomes, and unintended consequences were extracted. Data Synthesis: Forty-five articles published since 1986 (27 of which were published since 1999) evaluated the impact of public reporting on quality. Many focus on a select few reporting systems. Synthesis of data from 8 health plan-level studies suggests modest association between public reporting and plan selection. Synthesis of 11 studies, all hospital-level, suggests stimulation of quality improvement activity. Review of 9 hospital-level and 7 individual provider-level studies shows inconsistent association between public reporting and selection of hospitals and individual providers. Synthesis of 11 studies, primarily hospital-level, indicates inconsistent association between public reporting and improved effectiveness. Evidence on the impact of public reporting on patient safety and patient-centeredness is scant. Limitations: Heterogeneity made comparisons across studies challenging. Only peer-reviewed, English-language articles were included. Conclusion: Evidence is scant, particularly about individual providers and practices. Rigorous evaluation of many major public reporting systems is lacking. Evidence suggests that publicly releasing performance data stimulates quality improvement activity at the hospital level. The effect of public reporting on effectiveness, safety, and patient-centeredness remains uncertain.			Fung, CH (corresponding author), 10880 Wilshire Blvd,300, Los Angeles, CA 90024 USA.		Wilkins, Thad/G-2541-2010					*AG HEALTHC RES QU, 2004, NAT HEALTHC QUAL REP; *AG HEALTHC RES QU, CAHPS OV; Asch SM, 2004, ANN INTERN MED, V141, P938, DOI 10.7326/0003-4819-141-12-200412210-00010; Asch SM, 2006, NEW ENGL J MED, V354, P1147, DOI 10.1056/NEJMsa044464; Baker DW, 2003, MED CARE, V41, P729, DOI 10.1097/00005650-200306000-00006; Baker DW, 2002, MED CARE, V40, P879, DOI 10.1097/00005650-200210000-00006; Barry CA, 2000, BRIT MED J, V320, P1246, DOI 10.1136/bmj.320.7244.1246; Bates DW, 2001, J AM MED INFORM ASSN, V8, P299, DOI 10.1136/jamia.2001.0080299; Beaulieu ND, 2002, J HEALTH ECON, V21, P43, DOI 10.1016/S0167-6296(01)00126-6; Bentley J M, 1998, Jt Comm J Qual Improv, V24, P40; BERWICK DM, 1990, JAMA-J AM MED ASSOC, V263, P247, DOI 10.1001/jama.263.2.247; Berwick DM, 2003, MED CARE, V41, pI30; Bost J E, 2001, Manag Care Interface, V14, P50; Burack JH, 1999, ANN THORAC SURG, V68, P1195, DOI 10.1016/S0003-4975(99)00907-8; Centers for Medicare & Medicaid Services, HOSP COMP; Chassin MR, 2002, HEALTH AFFAIR, V21, P40, DOI 10.1377/hlthaff.21.4.40; Clough JD, 2002, AM J MED QUAL, V17, P47, DOI 10.1177/106286060201700202; Cochrane Effective Practice and Organisation of Care Review Group, 2002, DAT COLL CHECKL; Dranove D, 2003, J POLIT ECON, V111, P555, DOI 10.1086/374180; DZIUBAN SW, 1994, ANN THORAC SURG, V58, P1871, DOI 10.1016/0003-4975(94)91730-2; Farley DO, 2002, MED CARE RES REV, V59, P319, DOI 10.1177/1077558702059003005; Farley DO, 2002, HEALTH SERV RES, V37, P985, DOI 10.1034/j.1600-0560.2002.62.x; Ghali WA, 1997, JAMA-J AM MED ASSOC, V277, P379, DOI 10.1001/jama.277.5.379; GRADE Working Group, GRAD REC ASS DEV EV; Grimshaw J, 2003, QUAL SAF HEALTH CARE, V12, P298, DOI 10.1136/qhc.12.4.298; Grumbach K, 1998, NEW ENGL J MED, V339, P1516, DOI 10.1056/NEJM199811193392106; Handler JA, 2000, ACAD EMERG MED, V7, P1183, DOI 10.1111/j.1553-2712.2000.tb00462.x; Hannan EL, 1997, AM HEART J, V134, P55, DOI 10.1016/S0002-8703(97)70106-6; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; HANNAN EL, 1994, ANN THORAC SURG, V58, P1852, DOI 10.1016/0003-4975(94)91726-4; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; Harris KM, 2002, HEALTH SERV RES, V37, P551, DOI 10.1111/1475-6773.00037; Henley E, 2005, J FAM PRACTICE, V54, P609; Hibbard JH, 2003, HEALTH AFFAIR, V22, P84, DOI 10.1377/hlthaff.22.2.84; Hibbard JH, 2000, HEALTH AFFAIR, V19, P138, DOI 10.1377/hlthaff.19.5.138; Hibbard JH, 2005, HEALTH AFFAIR, V24, P1150, DOI 10.1377/hlthaff.24.4.1150; Hibbard JH, 1997, HEALTH AFFAIR, V16, P172, DOI 10.1377/hlthaff.16.6.172; Institute of Medicine, CROSS QUAL CHASM; Jha AK, 2006, HEALTH AFFAIR, V25, P844, DOI 10.1377/hlthaff.25.3.844; Jin GZ, 2006, J HEALTH ECON, V25, P248, DOI 10.1016/j.jhealeco.2005.06.002; Kaiser Family Foundation, 2004, NAT SURV CONS EXP PA; Kuperman G J, 2001, Jt Comm J Qual Improv, V27, P509; Lannon CM, 2001, PEDIATRICS, V107, P1473; Lansky D, 2002, HEALTH AFFAIR, V21, P52, DOI 10.1377/hlthaff.21.4.52; Lohr K., 1990, MED STRATEGY QUALITY; Longo DR, 1997, JAMA-J AM MED ASSOC, V278, P1579, DOI 10.1001/jama.278.19.1579; Luce JM, 1996, WESTERN J MED, V164, P410; Mannion Russell, 2005, J Health Serv Res Policy, V10, P18; Marshall MN, 2003, HEALTH AFFAIR, V22, P134, DOI 10.1377/hlthaff.22.3.134; Marshall MN, 2000, JAMA-J AM MED ASSOC, V283, P1866, DOI 10.1001/jama.283.14.1866; Marvel MK, 1999, JAMA-J AM MED ASSOC, V281, P283, DOI 10.1001/jama.281.3.283; McCormick D, 2002, JAMA-J AM MED ASSOC, V288, P1484, DOI 10.1001/jama.288.12.1484; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Mennemeyer ST, 1997, INQUIRY-J HEALTH CAR, V34, P117; Moscucci M, 2005, J AM COLL CARDIOL, V45, P1759, DOI 10.1016/j.jacc.2005.01.055; Mukamel DB, 2000, HEALTH SERV RES, V35, P319; Mukamel DB, 2004, INQUIRY-J HEALTH CAR, V41, P435, DOI 10.5034/inquiryjrnl_41.4.435; Mukamel DB, 1998, MED CARE, V36, P945, DOI 10.1097/00005650-199807000-00002; Mukamel DB, 2002, HEALTH SERV RES, V37, P1129, DOI 10.1111/1475-6773.10212; Narins CR, 2005, ARCH INTERN MED, V165, P83, DOI 10.1001/archinte.165.1.83; *NAT COMM QUAL ASS, 2005, STAT HEALTHC QUAL; *NCQA, NCQA HLTH PLAN REP C; *NJ DEP HLTH SEN S, 2005 HMO NJ PERF REP; Nugent WC, 1999, ANN THORAC SURG, V68, P1201; *NY STAT DEP HLTH, HEART DIS; *OFF INSP GEN JUN, EXT REV HOSP QUAL ST; Omoigui NA, 1996, CIRCULATION, V93, P27, DOI 10.1161/01.CIR.93.1.27; *PAC BUS GROUP HLT, VAL BAS PURCH; Peterson ED, 1998, J AM COLL CARDIOL, V32, P993, DOI 10.1016/S0735-1097(98)00332-5; Rainwater J A, 1998, Jt Comm J Qual Improv, V24, P31; Robinson S, 1997, JOINT COMM J QUAL IM, V23, P239, DOI 10.1016/S1070-3241(16)30313-3; Romano PS, 2004, MED CARE, V42, P367, DOI 10.1097/01.mlr.0000118872.33251.11; Rosenthal G E, 1998, Jt Comm J Qual Improv, V24, P347; Rosenthal G E, 1997, Am J Med Qual, V12, P103, DOI 10.1177/0885713X9701200204; Rosenthal MB, 2005, JAMA-J AM MED ASSOC, V294, P1788, DOI 10.1001/jama.294.14.1788; Scanlon DP, 2002, J HEALTH ECON, V21, P19, DOI 10.1016/S0167-6296(01)00111-4; Schauffler HH, 2001, ANNU REV PUBL HEALTH, V22, P69, DOI 10.1146/annurev.publhealth.22.1.69; Schneider EC, 1996, NEW ENGL J MED, V335, P251, DOI 10.1056/NEJM199607253350406; Schneider EC, 2001, QUAL HEALTH CARE, V10, P96, DOI 10.1136/qhc.10.2.96; Sofaer S, 2005, HEALTH SERV RES, V40, P2018, DOI 10.1111/j.1475-6773.2005.00473.x; Spranca M, 2000, HEALTH SERV RES, V35, P933; Tu JV, 2003, INT J QUAL HEALTH C, V15, P131, DOI 10.1093/intqhc/mzg015; *US C, 2006, NEXT GEN HLTH INF TO; *US DEP HHS, HOSP COMP; VLADECK BC, 1988, HEALTH AFFAIR, V7, P122, DOI 10.1377/hlthaff.7.1.122; Wedig GJ, 2002, J HEALTH ECON, V21, P1031, DOI 10.1016/S0167-6296(02)00075-9; Werner RM, 2005, CIRCULATION, V111, P1257, DOI 10.1161/01.CIR.0000157729.59754.09; Werner RM, 2005, JAMA-J AM MED ASSOC, V293, P1239, DOI 10.1001/jama.293.10.1239; [No title captured]	89	636	641	2	84	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	2008	148	2					111	123		10.7326/0003-4819-148-2-200801150-00006	http://dx.doi.org/10.7326/0003-4819-148-2-200801150-00006			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	254NZ	18195336				2023-01-03	WOS:000252594600004
J	Chan, BL; Witt, R; Charrow, AP; Magee, A; Howard, R; Pasquina, PF; Heilman, KM; Tsao, JW				Chan, Brenda L.; Witt, Richard; Charrow, Alexandra P.; Magee, Amanda; Howard, Robin; Pasquina, Paul F.; Heilman, Kenneth M.; Tsao, Jack W.			Mirror therapy for phantom limb pain	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Walter Reed Army Med Ctr, Washington, DC 20307 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Uniformed Services University of the Health Sciences - USA	Chan, BL (corresponding author), Walter Reed Army Med Ctr, Washington, DC 20307 USA.	jtsao@usuhs.mil						HENSON RA, 1977, BRIT MED BULL, V33, P91, DOI 10.1093/oxfordjournals.bmb.a071431; MELZACK R, 1990, TRENDS NEUROSCI, V13, P88, DOI 10.1016/0166-2236(90)90179-E; Ramachandran VS, 1996, P ROY SOC B-BIOL SCI, V263, P377, DOI 10.1098/rspb.1996.0058; Ramachandran VS, 1998, BRAIN, V121, P1603, DOI 10.1093/brain/121.9.1603; Rossi S, 2002, CLIN NEUROPHYSIOL, V113, P16, DOI 10.1016/S1388-2457(01)00725-8	5	343	352	4	95	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 22	2007	357	21					2206	2207		10.1056/NEJMc071927	http://dx.doi.org/10.1056/NEJMc071927			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	233FT	18032777	Bronze			2023-01-03	WOS:000251076500030
J	Westaby, S; Archer, N; Manning, N; Adwani, S; Grebenik, C; Ormerod, O; Pillai, R; Wilson, N				Westaby, Stephen; Archer, Nicholas; Manning, Nicola; Adwani, Satish; Grebenik, Catherine; Ormerod, Oliver; Pillai, Ravi; Wilson, Neil			Comparison of hospital episode statistics and central cardiac audit database in public reporting of congenital heart surgery mortality	BRITISH MEDICAL JOURNAL			English	Article							SURGICAL MORTALITY	Objective To verify or refute the value of hospital episode statistics (HES) in determining 30 day mortality after open congenital cardiac surgery in infants nationally in comparison with central cardiac audit database (CCAD) information. Design External review of paediatric cardiac surgical outcomes in England (HES) and all UK units (CCAD), as derived from each database. Setting Congenital heart surgery centres in the United Kingdom. Data sources HES for congenital heart surgery and corresponding information from CCAD for the period 1 April 2000 to 31 March 2002. HES was restricted to the 11 English centres; CCAD covered all 13 UK centres. Main outcome measure Mortality within 30 days of open heart surgery in infants aged under 12 months. Results In a direct comparison for the years when data from the 11 English centres were available from both databases, HES omitted between 5% and 38% of infants operated on in each centre. A median 40% (range 0-73%) shortfall occurred in identification of deaths by HES. As a result, mean 30 day mortality was underestimated at 4% by HES as compared with 8% for CCAD. In CCAD, between 1% and 23% of outcomes were missing in nine of 11 English centres used in the comparison (predominantly those for overseas patients). Accordingly, CCAD mortality could also be underestimated. Oxford provided the most complete dataset to HES, including all deaths recorded by CCAD. From three years of CCAD, Oxford's infant mortality from open cardiac surgery (10%) was not statistically different from the mean for all 13 UK centres (8%), in marked contrast to the conclusions drawn from HES for two of those years. Conclusions Hospital episode statistics are unsatisfactory for the assessment of activity and outcomes in congenital heart surgery. The central cardiac audit database is more accurate and complete, but furtherwork is needed to achieve fully comprehensive risk stratified mortality data. Given unresolved limitations in data quality, commercial organisations should reconsider placing centre specific or surgeon specific mortality data in the public domain.	Oxford Radcliffe Hosp NHS Trust, Dept Cardiac Surg, Oxford OX3 9DU, England; Oxford Radcliffe Hosp NHS Trust, Dept Paediat Cardiol, Oxford OX3 9DU, England; Oxford Radcliffe Hosp NHS Trust, Dept Anaesthet, Oxford OX3 9DU, England; Oxford Radcliffe Hosp NHS Trust, Dept Cardiol, Oxford OX3 9DU, England	Oxford University Hospitals NHS Foundation Trust; University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of Oxford	Westaby, S (corresponding author), Oxford Radcliffe Hosp NHS Trust, Dept Cardiac Surg, Oxford OX3 9DU, England.	swestaby@AHF.org.uk						Aylin P, 2004, BRIT MED J, V329, P825, DOI 10.1136/bmj.329.7470.825; Bristol Royal Infirmary Inquiry, 2001, CM5207; Burack JH, 1999, ANN THORAC SURG, V68, P1195, DOI 10.1016/S0003-4975(99)00907-8; Gibbs JL, 2004, BRIT MED J, V328, P611, DOI 10.1136/bmj.38027.613403.F6; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; Mack MJ, 2005, J THORAC CARDIOV SUR, V129, P1309, DOI 10.1016/j.jtcvs.2004.10.036; Marshall EG, 1998, BRIT MED J, V316, P1701, DOI 10.1136/bmj.316.7146.1701; Ryan TJ, 2007, CIRCULATION, V115, P1508, DOI 10.1161/CIRCULATIONAHA.106.686725; Schneider EC, 1996, NEW ENGL J MED, V335, P251, DOI 10.1056/NEJM199607253350406; Shahian DM, 2007, CIRCULATION, V115, P1518, DOI 10.1161/CIRCULATIONAHA.106.633008; Shahian DM, 2005, ANN THORAC SURG, V80, P2106, DOI 10.1016/j.athoracsur.2005.06.078; SPIEGELHALTER DJ, 2000, OVERVIEW STAT EVIDEN; *THAM VALL STRAT H, 2005, REP PAED CARD SURG S; WESTABY S, 2002, BR J CARDIOL ACUTE I, V9, P5	14	59	61	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 13	2007	335	7623					759	A762		10.1136/bmj.39318.644549.AE	http://dx.doi.org/10.1136/bmj.39318.644549.AE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224AX	17884862	hybrid, Green Submitted, Green Published			2023-01-03	WOS:000250418600034
J	Ribera, JM; Oriol, A				Ribera, Josep-Maria; Oriol, Albert			A step forward in therapy for ALL in infants	LANCET			English	Editorial Material							ACUTE LYMPHOBLASTIC-LEUKEMIA; CELL TRANSPLANTATION; CHILDREN; CHEMOTHERAPY; REMISSION		Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, Inst Catala Oncol, Dept Clin Haematol, Badalona 08916, Spain	Autonomous University of Barcelona; Catalan Institute of Oncology; Hospital Germans Trias i Pujol	Ribera, JM (corresponding author), Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, Inst Catala Oncol, Dept Clin Haematol, Badalona 08916, Spain.	jribera@iconcologia.net	Ribera, JM/B-8181-2009; Oriol, Albert/K-9923-2017	Ribera, JM/0000-0003-1042-6024; Oriol, Albert/0000-0001-6804-2221				Balduzzi A, 2005, LANCET, V366, P635, DOI 10.1016/S0140-6736(05)66998-X; Inukai T, 2006, LEUKEMIA, V20, P2119, DOI 10.1038/sj.leu.2404429; Jansen MWJC, 2007, LEUKEMIA, V21, P633, DOI 10.1038/sj.leu.2404578; Mann G, 2007, LEUKEMIA, V21, P642, DOI 10.1038/sj.leu.2404577; Pieters R, 2007, LANCET, V370, P240, DOI 10.1016/S0140-6736(07)61126-X; Pui CH, 2002, LANCET, V359, P1909, DOI 10.1016/S0140-6736(02)08782-2; Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603; Ribera JM, 2007, J CLIN ONCOL, V25, P16, DOI 10.1200/JCO.2006.06.8312; Sanders JE, 2005, BLOOD, V105, P3749, DOI 10.1182/blood-2004-08-3312; Satwani P, 2007, BIOL BLOOD MARROW TR, V13, P218, DOI 10.1016/j.bbmt.2006.09.013; Stam RW, 2006, BRIT J HAEMATOL, V132, P539, DOI 10.1111/j.1365-2141.2005.05909.x; Thompson PA, 2007, CANCER CHEMOTH PHARM, V59, P847, DOI 10.1007/s00280-006-0388-1	12	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 21	2007	370	9583					198	200		10.1016/S0140-6736(07)61101-5	http://dx.doi.org/10.1016/S0140-6736(07)61101-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	194MG	17658376				2023-01-03	WOS:000248347900006
J	Nachega, JB; Hislop, M; Dowdy, DW; Chaisson, RE; Regensberg, L; Maartens, G				Nachega, Jean B.; Hislop, Michael; Dowdy, David W.; Chaisson, Richard E.; Regensberg, Leon; Maartens, Gary			Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	13th Conference on Retroviruses and Opportunistic Infections	FEB 05-09, 2006	Denver, CO				ACTIVE ANTIRETROVIRAL THERAPY; TRIPLE-COMBINATION THERAPY; DRUG-RESISTANCE MUTATIONS; SOCIETY-USA PANEL; PROTEASE INHIBITORS; VIRAL SUPPRESSION; TREATMENT FAILURE; PHARMACY RECORDS; INFECTED ADULTS; EFAVIRENZ	Background: Adherence of 95% or more to unboosted protease regimens is required for optimal virologic suppression in HIV-1 infected patients. Whether the same is true for nonnucleoside reverse transcriptase inhibitor (NNRTI)-based therapy is unclear. Objective: To assess the relationship between adherence to NNRTI-based therapy and viral load in treatment-naive patients. Design: Observational cohort study. Setting: Private-sector HIV and AIDS disease management program in South Africa. Patients: 2821 adults infected with HIV who began NNRTI-based therapy between January 1998 and March 2003 (2764 patients [98%] were enrolled after December 2000). Measurements: Adherence was assessed by monthly pharmacy claims. The primary end point was sustained viral load suppression (< 400 copies/mL) in 100% of recorded viral load measurements throughout follow-up. Secondary end points included time to initial viral load suppression and time to subsequent virologic failure (< 400 copies/mL). Results: The median follow-up period was 2.2 years (interquartile range, 1.7 to 2.7 years). The proportion of patients with sustained viral load suppression ranged from 13% (41 of 325 patients) in patients who filled less than 50% of antiretroviral drug prescriptions to 73% (725 of 997 patients) in those who filled 100% of antiretroviral drug prescriptions. Each 10% increase in pharmacy claim adherence greater than 50% was associated with a mean absolute increase of 0.10 in the proportion of patients with sustained virologic suppression (P < 0.001). Predictors for shorter time to virologic failure after initial suppression in multivariable Cox regression included CD4(+) T-cell counts of 0.50 x 10(9) cells/L or less (hazard ratio, 1.60 [95% CI, 1.22 to 2.10] vs. CD4(+) T-cell counts > 0.20 x 10(9) cells/L), baseline viral load greater than 10(5) copies/mL (hazard ratio, 1.39 [CI 1.14 to 1.70]), nevirapine-based regimen (hazard ratio, 1.43 [CI 1.16 to 1.75]), and low pharmacy claim adherence (hazard ratio, 1.58 [CI 1.48 to 1.69], per 10% decrease in adherence to 50%). Limitations: Observational study with adherence stratification at study end and lack of standardized timing for outcome measurement. Conclusion: Virologic outcomes improve in a linear dose-response manner as adherence to NNRTI-based regimens increases beyond 50%.	Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Baltimore, MD USA; Univ Cape Town, Groote Schuur Hosp, ZA-7700 Rondebosch, South Africa; Aid AIDS Dis Management Programme Pty Ltd, Cape Town, South Africa	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; University of Cape Town	Nachega, JB (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St,Suite W5031, Baltimore, MD 21205 USA.	jnachega@jhsph.edu	Maartens, Gary/S-2788-2019; Maartens, Gary/F-3836-2014	Maartens, Gary/0000-0003-3080-6606; Maartens, Gary/0000-0003-3080-6606; Nachega, Jean/0000-0002-2862-4443	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI068582, R01AI055359, R01AI016137] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 016137, R01 AI 5535901, K23 AI068582-01] Funding Source: Medline; PHS HHS [5 T32 GMO7309] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Arnsten JH, 2001, CLIN INFECT DIS, V33, P1417, DOI 10.1086/323201; Bacheler LT, 2000, ANTIMICROB AGENTS CH, V44, P2475, DOI 10.1128/AAC.44.9.2475-2484.2000; Bangsberg DR, 2006, CLIN INFECT DIS, V43, P939, DOI 10.1086/507526; Bangsberg DR, 2006, AIDS, V20, P223, DOI 10.1097/01.aids.0000199825.34241.49; Bangsberg DR, 2004, J ANTIMICROB CHEMOTH, V53, P696, DOI 10.1093/jac/dkh162; Bangsberg DR, 2003, AIDS, V17, P1925, DOI 10.1097/00002030-200309050-00011; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; Bartlett JA, 2001, AIDS, V15, P1369, DOI 10.1097/00002030-200107270-00006; Benatar SR, 2004, NEW ENGL J MED, V351, P81, DOI 10.1056/NEJMhpr033471; Choo PW, 1999, MED CARE, V37, P846, DOI 10.1097/00005650-199909000-00002; Dezii C M, 2001, Manag Care, V10, P42; Dybul M, 2002, ANN INTERN MED, V137, P381, DOI 10.7326/0003-4819-137-5_Part_2-200209031-00001; Egger M, 2006, J INFECT DIS, V194, P612, DOI 10.1086/506362; Gross R, 2006, J INFECT DIS, V194, P1108, DOI 10.1086/507680; Grossberg R, 2004, J CLIN EPIDEMIOL, V57, P1107, DOI 10.1016/j.jclinepi.2004.04.002; Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827; Harrigan PR, 2005, J INFECT DIS, V191, P339, DOI 10.1086/427192; Hogg RS, 2002, AIDS, V16, P1051, DOI 10.1097/00002030-200205030-00012; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; Maggiolo F, 2005, CLIN INFECT DIS, V40, P158, DOI 10.1086/426595; Marzolini C, 2001, AIDS, V15, P71, DOI 10.1097/00002030-200101050-00011; Miller V, 1999, J INFECT DIS, V180, P530, DOI 10.1086/314890; Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679; Mocroft A, 1998, AIDS, V12, P2161, DOI 10.1097/00002030-199816000-00011; Moore RD, 2005, JAIDS-J ACQ IMM DEF, V39, P195; Nachega JB, 2006, JAIDS-J ACQ IMM DEF, V43, P78, DOI 10.1097/01.qai.0000225015.43266.46; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; Sethi AK, 2003, CLIN INFECT DIS, V37, P1112, DOI 10.1086/378301; Siddique MA, 2006, J INFECT DIS, V194, P661, DOI 10.1086/505913; Smith PF, 2005, ANTIMICROB AGENTS CH, V49, P3558, DOI 10.1128/AAC.49.8.3558-3561.2005; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Steiner JF, 1997, J CLIN EPIDEMIOL, V50, P105, DOI 10.1016/S0895-4356(96)00268-5; van Leth F, 2004, LANCET, V363, P1253, DOI 10.1016/S0140-6736(04)15997-7; Wong MD, 2004, J GEN INTERN MED, V19, P366, DOI 10.1111/j.1525-1497.2004.30429.x; Wood E, 2006, AIDS, V20, P1117, DOI 10.1097/01.aids.0000226951.49353.ed; Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251	37	273	281	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 17	2007	146	8					564	U16		10.7326/0003-4819-146-8-200704170-00007	http://dx.doi.org/10.7326/0003-4819-146-8-200704170-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	158FV	17438315				2023-01-03	WOS:000245778000003
J	Wilcox, AJ; Lie, RT; Solvoll, K; Taylor, J; McConnaughey, DR; Abyholm, F; Vindenes, H; Vollset, SE; Drevon, CA				Wilcox, Allen J.; Lie, Rov Terje; Solvoll, Kari; Taylor, Jack; McConnaughey, D. Robert; Abyholm, Frank; Vindenes, Hallvard; Vollset, Stein Emil; Drevon, Christian A.			Folic acid supplements and risk of facial clefts: national population based case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FOOD FREQUENCY QUESTIONNAIRE; OROFACIAL CLEFTS	Objective To explore the role of folic acid supplements, dietary folates, and multivitamins in the prevention of facial clefts. Design National population based case-control study. Setting Infants born 1996-2001 in Norway. Participants 377 infants with cleft lip with or without cleft palate; 196 infants with cleft palate alone; 763 controls. Main outcome measures Association of facial clefts with maternal intake of folic acid supplements, multivitamins, and folates in diet. Results Folic acid supplementation during early pregnancy (>= 400 mu g/day) was associated with a reduced risk of isolated cleft lip with or without cleft palate after adjustment for multivitamins, smoking, and other potential confounding factors (adjusted odds ratio 0.61, 95% confidence interval 0.39 to 0.96). Independent of supplements, diets rich in fruits, vegetables, and other high folate containing foods reduced the risk somewhat (adjusted odds ratio 0.75, 0.50 to 1.11). The lowest risk of cleft lip was among women with folate rich diets who also took folic acid supplements and multivitamins (0.36, 0.17 to 0.77). Folic acid provided no protection against cleft palate alone (1.07, 0.56 to 2.03). Conclusions Folic acid supplements during early pregnancy seem to reduce the risk of isolated cleft lip (with or without cleft palate) by about a third. Other vitamins and dietary factors may provide additional benefit.	NIEHS, Epidemiol Branch, NIH, Res Triangle Pk, NC 27709 USA; Univ Bergen, Dept Publ Hlth & Primary Care, Sect Epidemiol & Med Stat, N-5020 Bergen, Norway; Univ Oslo, Fac Med, Inst Basic Med Sci, Dept Nutr, Oslo, Norway; WESTAT Corp, Durham, NC USA; Univ Oslo, Rikshosp, Dept Plast Surg, N-0027 Oslo, Norway; Haukeland Hosp, Dept Plast Surg, N-5021 Bergen, Norway	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Bergen; University of Oslo; Westat; University of Oslo; National Hospital Norway; University of Bergen; Haukeland University Hospital	Wilcox, AJ (corresponding author), NIEHS, Epidemiol Branch, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	wilcox@niehs.nih.gov	Wilcox, Allen J/C-7723-2019; Drevon, Christian A/F-6012-2010; taylor, jack a/C-7154-2019	Wilcox, Allen J/0000-0002-3376-1311; taylor, jack a/0000-0001-5303-6398	Intramural NIH HHS [Z99 ES999999] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES049027, Z01ES049033] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andersen LF, 2003, EUR J CLIN NUTR, V57, P279, DOI 10.1038/sj.ejcn.1601519; Bailey LB, 2005, AM J CLIN NUTR, V81, p1213S; Christensen K., 2002, CLEFT LIP PALATE ORI, P101; Hayes C, 1996, AM J EPIDEMIOL, V143, P1229, DOI 10.1093/oxfordjournals.aje.a008710; Itikala PR, 2001, TERATOLOGY, V63, P79, DOI 10.1002/1096-9926(200102)63:2&lt;79::AID-TERA1013&gt;3.0.CO;2-3; MOSSEY PA, 2002, CLEFT LIP PALATE ORI, P170; MUNGER RG, 2002, CLEFT LIP PALATE ORI, P170; NES M, 1992, EUR J CLIN NUTR, V46, P809; Rosenberg IH, 2005, AM J CLIN NUTR, V82, P279, DOI 10.1093/ajcn/82.2.279; Shaw GM, 2006, EPIDEMIOLOGY, V17, P285, DOI 10.1097/01.ede.0000208348.30012.35; SHAW GM, 1995, LANCET, V346, P393, DOI 10.1016/S0140-6736(95)92778-6; SOLVOLL K, 1993, SCAND J NUTR, V37, P150; van Rooij IALM, 2004, PREV MED, V39, P689, DOI 10.1016/j.ypmed.2004.02.036; Werler MM, 1999, AM J EPIDEMIOL, V150, P675, DOI 10.1093/oxfordjournals.aje.a010070	14	226	245	0	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 3	2007	334	7591					464	467		10.1136/bmj.39079.618287.0B	http://dx.doi.org/10.1136/bmj.39079.618287.0B			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144NB	17259187	Bronze, Green Published			2023-01-03	WOS:000244802000033
J	Braun, U; Beyth, RJ; Ford, ME; McCullough, LB				Braun, Ursula; Beyth, Rebecca J.; Ford, Marvella E.; McCullough, Laurence B.			Defining limits in care of terminally ill patients	BRITISH MEDICAL JOURNAL			English	Editorial Material							OF-LIFE DECISIONS; PREVENTIVE ETHICS; END		Michael E DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Sect Geriat, Houston, TX 77030 USA; Michael E DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Sect Hlth Serv Res, Houston, TX 77030 USA; N Florida S Georgia Vet Hlth Syst, Gainesville, FL 32608 USA; Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Hlth Dispar Res Programme, Charleston, SC 29425 USA; Baylor Coll Med, Ctr Med Eth & Hlth Policy, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Medical University of South Carolina; Baylor College of Medicine	Braun, U (corresponding author), Michael E DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Sect Geriat, 2002 Holcombe Blvd, Houston, TX 77030 USA.	ubraun@bcm.tmc.edu						[Anonymous], 1986, HIST THEORY INFORM C; Back Anthony L, 2003, Ann Intern Med, V138, P439; Baker R, 2000, J AM GERIATR SOC, V48, pS61, DOI 10.1111/j.1532-5415.2000.tb03143.x; Borum ML, 2000, J AM GERIATR SOC, V48, pS194, DOI 10.1111/j.1532-5415.2000.tb03132.x; BRETT AS, 1986, NEW ENGL J MED, V315, P1347, DOI 10.1056/NEJM198611203152109; Buchanan Allen E., 1989, DECIDING OTHERS ETHI; Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3; Chervenak FA, 1996, WOMEN HEALTH ISS, V6, P304, DOI 10.1016/1049-3867(96)00020-5; Field MJ, 1997, APPROACHING DEATH IM; FORROW L, 1993, J CLIN ETHIC, V4, P287; Goold SD, 2000, JAMA-J AM MED ASSOC, V283, P909, DOI 10.1001/jama.283.7.909; Gregory J., 1998, J GREGORYS WRITINGS, P161; LO B, 1995, JAMA-J AM MED ASSOC, V274, P1634, DOI 10.1001/jama.274.20.1634; Ravitsky V, 2005, BRIT MED J, V330, P415, DOI 10.1136/bmj.330.7488.415; Sullivan AM, 2003, J GEN INTERN MED, V18, P685, DOI 10.1046/j.1525-1497.2003.21215.x	15	18	18	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 3	2007	334	7587					239	241		10.1136/bmj.39048.475046.68	http://dx.doi.org/10.1136/bmj.39048.475046.68			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	135SD	17272566	Green Published			2023-01-03	WOS:000244172400028
J	Frith, L				Frith, Lucy			HIV self-testing: a time to revise current policy	LANCET			English	Article							HOME; NORMALIZATION; PREFERENCES; COLLECTION; PREVENTION		Univ Liverpool, Div Primary Care, Liverpool L69 3GB, Merseyside, England	University of Liverpool	Frith, L (corresponding author), Univ Liverpool, Div Primary Care, Whelan Bldg,Brownlow Hill, Liverpool L69 3GB, Merseyside, England.	L.J.Frith@liverpool.ac.uk	Frith, Lucy/AAW-6711-2020	Frith, Lucy/0000-0002-8506-0699				[Anonymous], 2000, CAN MED ASSOC J, V162, P1545; Branson BM, 1998, JAMA-J AM MED ASSOC, V280, P1699, DOI 10.1001/jama.280.19.1699; *BRIT ASS SEX HLTH, 2005, UK NAT GUID HIV TEST; De Cock KM, 1998, BMJ-BRIT MED J, V316, P290, DOI 10.1136/bmj.316.7127.290; *FDA, 2005, APPR VAL OV THE COUN; Marks G, 2005, JAIDS-J ACQ IMM DEF, V39, P446, DOI 10.1097/01.qai.0000151079.33935.79; Phillips KA, 2003, AM J PREV MED, V24, P340, DOI 10.1016/S0749-3797(03)00019-9; Rogstad KE, 2003, SEX TRANSM INFECT, V79, P243, DOI 10.1136/sti.79.3.243; Rosenbrock R, 2000, SOC SCI MED, V50, P1607, DOI 10.1016/S0277-9536(99)00469-4; Spielberg F, 2004, LANCET INFECT DIS, V4, P640, DOI 10.1016/S1473-3099(04)01150-8; Spielberg F, 2003, JAIDS-J ACQ IMM DEF, V32, P318, DOI 10.1097/00126334-200303010-00012; Spielberg F, 2001, SEX TRANSM DIS, V28, P51, DOI 10.1097/00007435-200101000-00012; Spielberg F, 2003, HOME SELF TESTING HI; *UK DEP HLTH, 2004, CHOOS HLTH MAK HLTH; *UK GEN MED COUNC, 2000, ANT TEST HIV; *UK HUM GEN COMM, 2005, NONC DNA TEST; US Food and Drug Administration, 2004, FDA APPR 1 OR FLUID; Wright AA, 2006, NEW ENGL J MED, V354, P437, DOI 10.1056/NEJMp058302	18	38	39	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 20	2007	369	9557					243	245		10.1016/S0140-6736(07)60113-5	http://dx.doi.org/10.1016/S0140-6736(07)60113-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	128XG	17240291				2023-01-03	WOS:000243692400033
J	Bendell, J				Bendell, Johanna			Optimum chemotherapy for metastatic colorectal cancer	LANCET			English	Editorial Material							FLUOROURACIL PLUS LEUCOVORIN; RANDOMIZED CONTROLLED-TRIAL; OXALIPLATIN; IRINOTECAN; INTERGROUP; GERCOR; BOLUS		Duke Univ, Med Ctr, Durham, NC 27710 USA	Duke University	Bendell, J (corresponding author), Duke Univ, Med Ctr, Durham, NC 27710 USA.	bende007@mc.duke.edu						deGramont A, 1997, J CLIN ONCOL, V15, P808, DOI 10.1200/JCO.1997.15.2.808; FALCONE A, 2006, J CLIN ONCOL S, V24, P3513; FUCHS C, 2006, J CLIN ONCOL, V24, P3506; Goldberg RM, 2006, J CLIN ONCOL, V24, P3347, DOI 10.1200/JCO.2006.06.1317; Goldberg RM, 2002, J CLIN ONCOL, V20, P4591, DOI 10.1200/JCO.2002.03.039; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; Grothey A, 2004, J CLIN ONCOL, V22, P1209, DOI 10.1200/JCO.2004.11.037; HOCHSTER H, 2006, 2006 GASTR CANC S SA; Maindrault-Goebel F., 2006, J CLIN ONCOL, V24, P3504, DOI [10.1200/jco.2006.24.18_suppl.3504, DOI 10.1200/JCO.2006.24.18_SUPPL.3504]; Tournigand C, 2006, J CLIN ONCOL, V24, P394, DOI 10.1200/JCO.2005.03.0106; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113	11	7	8	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 9	2006	368	9552					2039	2041		10.1016/S0140-6736(06)69818-8	http://dx.doi.org/10.1016/S0140-6736(06)69818-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	114JY	17161715				2023-01-03	WOS:000242663700006
J	Poole, CJ; Earl, HM; Hiller, L; Dunn, JA; Bathers, S; Grieve, RJ; Spooner, DA; Agrawal, RK; Fernando, IN; Brunt, AM; O'Reilly, SM; Crawford, SM; Rea, DW; Simmonds, P; Mansi, JL; Stanley, A; Harvey, P; McAdam, K; Foster, L; Leonard, RCF; Twelves, CJ				Poole, Christopher J.; Earl, Helena M.; Hiller, Louise; Dunn, Janet A.; Bathers, Sarah; Grieve, Robert J.; Spooner, David A.; Agrawal, Rajiv K.; Fernando, Indrajit N.; Brunt, A. Murray; O'Reilly, Susan M.; Crawford, S. Michael; Rea, Daniel W.; Simmonds, Peter; Mansi, Janine L.; Stanley, Andrew; Harvey, Peter; McAdam, Karen; Foster, Liz; Leonard, Robert C. F.; Twelves, Christopher J.		Neat Investigators; SCTBG	Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; POSITIVE AXILLARY NODES; RANDOMIZED-TRIAL; EUROPEAN-ORGANIZATION; PREMENOPAUSAL WOMEN; CLINICAL-TRIALS; CHEMOTHERAPY; DOXORUBICIN; CMF; RISK	BACKGROUND: The National Epirubicin Adjuvant Trial (NEAT) and the BR9601 trial examined the efficacy of anthracyclines in the adjuvant treatment of early breast cancer. METHODS: In NEAT, we compared four cycles of epirubicin followed by four cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) with six cycles of CMF alone. In the BR9601 trial, we compared four cycles of epirubicin followed by four cycles of CMF, with eight cycles of CMF alone every 3 weeks. The primary end points were relapse-free and overall survival. The secondary end points were adverse effects, dose intensity, and quality of life. RESULTS: The two trials included 2391 women with early breast cancer; the median follow-up was 48 months. Relapse-free and overall survival rates were significantly higher in the epirubicin-CMF groups than in the CMF-alone groups (2-year relapse-free survival, 91% vs. 85%; 5-year relapse-free survival, 76% vs. 69%; 2-year overall survival, 95% vs. 92%; 5-year overall survival, 82% vs. 75%; P<0.001 by the log-rank test for all comparisons). Hazard ratios for relapse (or death without relapse) (0.69; 95% confidence interval [CI], 0.58 to 0.82; P<0.001) and death from any cause (0.67; 95% CI, 0.55 to 0.82; P<0.001) favored epirubicin plus CMF over CMF alone. Independent prognostic factors were nodal status, tumor grade, tumor size, and estrogen-receptor status (P<0.001 for all four factors) and the presence or absence of vascular or lymphatic invasion (P=0.01). These factors did not significantly interact with the effect of epirubicin plus CMF. The overall incidence of adverse effects was significantly higher with epirubicin plus CMF than with CMF alone but did not significantly affect the delivered-dose intensity or the quality of life. CONCLUSIONS: Epirubicin plus CMF is superior to CMF alone as adjuvant treatment for early breast cancer.	Univ Birmingham, Inst Canc Studies, Canc Res UK Clin Trials Unit, Birmingham B15 2TT, W Midlands, England; Addenbrookes Hosp, Cambridge, England; Walsgrave Gen Hosp, Radiotherapy & Oncol Ctr, Coventry, W Midlands, England; Queen Elizabeth Hosp, Ctr Canc, Birmingham, W Midlands, England; Royal Shrewsbury Hosp, Shrewsbury, Shrops, England; Clatterbridge Hosp, Wirral, Merseyside, England; Airedale Dist Gen Hosp, Keighley, Yorks, England; Royal S Hampshire Hosp, Southampton, Hants, England; Univ London St Georges Hosp, London, England; City Hosp, Birmingham, W Midlands, England; St James Univ Hosp, Leeds, W Yorkshire, England; Peterborough Dist Gen Hosp, Peterborough, Cambs, England; Scottish Canc Therapy Network, Edinburgh, Midlothian, Scotland; Swansea Canc Ctr, Swansea, W Glam, Wales; Bradford Royal Infirm, Bradford BD9 6RJ, W Yorkshire, England	Cancer Research UK; University of Birmingham; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Birmingham; St Georges University London; University of Birmingham; Saint James's University Hospital; Bradford Royal Infirmary	Poole, CJ (corresponding author), Univ Birmingham, Inst Canc Studies, Canc Res UK Clin Trials Unit, Birmingham B15 2TT, W Midlands, England.	poolecj@aol.com	Harvey, Peter/AAB-3147-2019	Dunn, Janet/0000-0001-7313-4446; Earl, Helena/0000-0003-1549-8094				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; ABE O, 1992, LANCET, V339, P71; Abe O, 1998, LANCET, V352, P930; Adenis A, 2001, J CLIN ONCOL, V19, P602, DOI 10.1200/JCO.2001.19.3.602; Bonadonna G, 2004, J CLIN ONCOL, V22, P1614, DOI 10.1200/JCO.2004.07.190; BONADONNA G, 1995, JAMA-J AM MED ASSOC, V273, P542; BONADONNA G, 1981, NEW ENGL J MED, V304, P10, DOI 10.1056/NEJM198101013040103; Buzdar AU, 2005, J CLIN ONCOL, V23, P3676, DOI 10.1200/JCO.2005.07.032; BUZZONI R, 1991, J CLIN ONCOL, V9, P2134, DOI 10.1200/JCO.1991.9.12.2134; Coombes RC, 1996, J CLIN ONCOL, V14, P35, DOI 10.1200/JCO.1996.14.1.35; COX DR, 1972, J R STAT SOC B, V34, P187; Crump M, 2003, J CLIN ONCOL, V21, P3066, DOI 10.1200/JCO.2003.08.137; DAY RS, 1986, CANCER RES, V46, P3876; DETOURMIGNIES L, 1992, J CLIN ONCOL, V10, P1430, DOI 10.1200/JCO.1992.10.9.1430; *EARL BREAST CANC, 1990, TREATM EAR BREAST CA, V1; Earl Helena, 2004, Expert Rev Anticancer Ther, V4, P189, DOI 10.1586/14737140.4.2.189; ENGELSMAN E, 1991, EUR J CANCER, V27, P966, DOI 10.1016/0277-5379(91)90259-G; Gianni L, 2005, J CLIN ONCOL, V23, p7S; Goldhirsch A, 1998, ANN ONCOL, V9, P489, DOI 10.1023/A:1008236502420; GOLDIE JH, 1979, CANCER TREAT REP, V63, P1727; GOLDIE JH, 1982, CANCER TREAT REP, V66, P439; HABESHAW T, 1991, J CLIN ONCOL, V9, P295, DOI 10.1200/JCO.1991.9.2.295; Hopwood P, 2005, J CLIN ONCOL, V23, p43S; HUNTER M, 1992, PSYCHOL HEALTH, V7, P45, DOI 10.1080/08870449208404294; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Leonard RCF, 2004, JNCI-J NATL CANCER I, V96, P1076, DOI 10.1093/jnci/djh188; Levine MN, 1998, J CLIN ONCOL, V16, P2651, DOI 10.1200/JCO.1998.16.8.2651; MOLITERNI A, 1991, J CLIN ONCOL, V9, P1124, DOI 10.1200/JCO.1991.9.7.1124; Norton L, 1991, Important Adv Oncol, P57; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Praga C, 2005, J CLIN ONCOL, V23, P4179, DOI 10.1200/JCO.2005.05.029; Pulsoni A, 2002, BLOOD, V100, P1972, DOI 10.1182/blood-2001-12-0312; Qian W, 2000, STAT MED, V19, P2657; Sprangers MAG, 1996, J CLIN ONCOL, V14, P2756, DOI 10.1200/JCO.1996.14.10.2756	35	157	164	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 2	2006	355	18					1851	1862		10.1056/NEJMoa052084	http://dx.doi.org/10.1056/NEJMoa052084			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100TM	17079759	Green Published			2023-01-03	WOS:000241691700003
J	Wolf, SL; Winstein, CJ; Miller, JP; Taub, E; Uswatte, G; Morris, D; Giuliani, C; Light, KE; Nichols-Larsen, D				Wolf, Steven L.; Winstein, Carolee J.; Miller, J. Philip; Taub, Edward; Uswatte, Gitendra; Morris, David; Giuliani, Carol; Light, Kathye E.; Nichols-Larsen, Deborah		EXCITE Investigators	Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke - The EXCITE randomized clinical trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; MOTOR FUNCTION-TEST; LEARNED NONUSE; FORCED-USE; HEMIPLEGIC PATIENT; SUBACUTE STROKE; IMPACT SCALE; UPPER-LIMB; REHABILITATION; RELIABILITY	Context Single-site studies suggest that a 2-week program of constraint-induced movement therapy (CIMT) for patients more than 1 year after stroke who maintain some hand and wrist movement can improve upper extremity function that persists for at least 1 year. Objective To compare the effects of a 2-week multisite program of CIMT vs usual and customary care on improvement in upper extremity function among patients who had a first stroke within the previous 3 to 9 months. Design and Setting The Extremity Constraint Induced Therapy Evaluation (EXCITE) trial, a prospective, single-blind, randomized, multisite clinical trial conducted at 7 US academic institutions between January 2001 and January 2003. Participants Two hundred twenty-two individuals with predominantly ischemic stroke. Interventions Participants were assigned to receive either CIMT (n = 106; wearing a restraining mitt on the less-affected hand while engaging in repetitive task practice and behavioral shaping with the hemiplegic hand) or usual and customary care (n = 116; ranging from no treatment after concluding formal rehabilitation to pharmacologic or physiotherapeutic interventions); patients were stratified by sex, prestroke dominant side, side of stroke, and level of paretic arm function. Main Outcome Measures The Wolf Motor Function Test (WMFT), a measure of laboratory time and strength-based ability and quality of movement (functional ability), and the Motor Activity Log (MAL), a measure of how well and how often 30 common daily activities are performed. Results From baseline to 12 months, the CIMT group showed greater improvements than the control group in both the WMFT Performance Time (decrease in mean time from 19.3 seconds to 9.3 seconds [52% reduction] vs from 24.0 seconds to 17.7 seconds [26% reduction]; between-group difference, 34% [95% confidence interval {CI}, 12%-51%]; P < .001) and in the MAL Amount of Use (on a 0-5 scale, increase from 1.21 to 2.13 vs from 1.15 to 1.65; between-group difference, 0.43 [95% CI, 0.05-0.80]; P < .001) and MAL Quality of Movement (on a 0-5 scale, increase from 1.26 to 2.23 vs 1.18 to 1.66; between-group difference, 0.48 [95% CI, 0.13-0.84]; P < .001). The CIMT group achieved a decrease of 19.5 in self-perceived hand function difficulty (Stroke Impact Scale hand domain) vs a decrease of 10.1 for the control group (between-group difference, 9.42 [95% CI, 0.27-18.57]; P = .05). Conclusion Among patients who had a stroke within the previous 3 to 9 months, CIMT produced statistically significant and clinically relevant improvements in arm motor function that persisted for at least 1 year.	Emory Univ, Sch Med, Ctr Rehabil Med, Dept Rehabil Med, Atlanta, GA 30322 USA; Ohio State Univ, Sch Allied Hlth Profess, Columbus, OH 43210 USA; Univ Florida, Dept Phys Therapy, Coll Publ Hlth & Hlth Profess, Gainesville, FL USA; Univ N Carolina, Sch Med, Div Phys Therapy, Dept Allied Hlth Sci, Chapel Hill, NC 27515 USA; Univ Alabama, Dept Psychol, Birmingham, AL 35294 USA; Univ Alabama, Dept Phys Therapy, Birmingham, AL 35294 USA; Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA; Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA USA; Univ So Calif, Keck Sch Med, Dept Biokinesiol, Los Angeles, CA USA; Univ So Calif, Keck Sch Med, Dept Phys Therapy, Los Angeles, CA USA	Emory University; University System of Ohio; Ohio State University; State University System of Florida; University of Florida; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Washington University (WUSTL); University of Southern California; University of Southern California; University of Southern California	Wolf, SL (corresponding author), Emory Univ, Sch Med, Ctr Rehabil Med, Dept Rehabil Med, 1441 Clifton Rd NE, Atlanta, GA 30322 USA.	swolf@emory.edu	Wolf, Steve/F-6588-2010; Uswatte, Gitendra/C-4913-2009; Morris, David/AFV-2928-2022; Larsen, Deborah/E-3465-2011	Wolf, Steve/0000-0002-9446-8995; Winstein, Carolee/0000-0001-9789-4626; Miller, J Philip/0000-0003-4568-6846	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037606] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 37606] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alberts JL, 2004, NEUROREHAB NEURAL RE, V18, P250, DOI 10.1177/1545968304271370; Barreca S, 2003, NEUROREHAB NEURAL RE, V17, P220, DOI 10.1177/0888439003259415; Bobath B., 1978, ADULT HEMIPLEGIA EVA; Dettmers C, 2005, ARCH PHYS MED REHAB, V86, P204, DOI 10.1016/j.apmr.2004.05.007; Duncan P, 2003, STROKE, V34, P2173, DOI 10.1161/01.STR.0000083699.95351.F2; Duncan PW, 2005, STROKE, V36, pE100, DOI 10.1161/01.STR.0000180861.54180.FF; Duncan PW, 1999, STROKE, V30, P2131, DOI 10.1161/01.STR.30.10.2131; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fritz SL, 2005, STROKE, V36, P1172, DOI 10.1161/01.STR.0000165922.96430.d0; Kunkel A, 1999, ARCH PHYS MED REHAB, V80, P624, DOI 10.1016/S0003-9993(99)90163-6; Kwakkel G, 2003, STROKE, V34, P2181, DOI 10.1161/01.STR.0000087172.16305.CD; Lai SM, 2002, STROKE, V33, P1840, DOI 10.1161/01.STR.0000019289.15440.F2; Liepert J, 2000, STROKE, V31, P1210, DOI 10.1161/01.STR.31.6.1210; Liepert J, 2001, J NEUROL, V248, P315, DOI 10.1007/s004150170207; Miltner WHR, 1999, STROKE, V30, P586, DOI 10.1161/01.STR.30.3.586; Morris D M, 2001, Top Stroke Rehabil, V8, P16; Morris DM, 2001, ARCH PHYS MED REHAB, V82, P750, DOI 10.1053/apmr.2001.23183; Nichols-Larsen DS, 2005, STROKE, V36, P1480, DOI 10.1161/01.STR.0000170706.13595.4f; Page SJ, 2004, ARCH PHYS MED REHAB, V85, P14, DOI 10.1016/S0003-9993(03)00481-7; Panyan M. V., 1980, USE SHAPING; Pierce SR, 2003, NEUROREHAB NEURAL RE, V17, P214, DOI 10.1177/0888439003259424; Schmidt R.A., 2011, HUMAN KINETICS; Studenski S, 2005, STROKE, V36, P1764, DOI 10.1161/01.STR.0000174192.87887.70; Suputtitada Areerat, 2004, Journal of the Medical Association of Thailand, V87, P1482; Tarkka IM, 2005, AM J PHYS MED REHAB, V84, P501, DOI 10.1097/01.phm.0000166881.71097.9d; Taub E, 2005, STROKE, V36, P1301, DOI 10.1161/01.STR.0000166043.27545.e8; Taub E, 1998, REHABIL PSYCHOL, V43, P152, DOI 10.1037/0090-5550.43.2.152; Taub E, 2002, NAT REV NEUROSCI, V3, P228, DOI 10.1038/nrn754; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; TAUB E, 1994, J EXP ANAL BEHAV, V61, P281, DOI 10.1901/jeab.1994.61-281; Taub E, 1980, BEHAV PSYCHOL REHABI, P371; Uswatte G, 2006, NEUROLOGY, V67, P1189, DOI 10.1212/01.wnl.0000238164.90657.c2; Uswatte G, 2005, REHABIL PSYCHOL, V50, P34, DOI 10.1037/0090-5550.50.1.34; Uswatte G, 2005, STROKE, V36, P2493, DOI 10.1161/01.STR.0000185928.90848.2e; van der Lee JH, 1999, ARCH PHYS MED REHAB, V80, P1606, DOI 10.1016/S0003-9993(99)90339-8; WEINSTEIN CJ, 1991, CONT MANAGEMENT MOTO; Winstein CJ, 2003, NEUROREHAB NEURAL RE, V17, P137, DOI 10.1177/0888439003255511; WOLF SL, 1989, EXP NEUROL, V104, P125, DOI 10.1016/S0014-4886(89)80005-6; WOLF SL, 1983, PHYS THER, V63, P1393, DOI 10.1093/ptj/63.9.1393; Wolf SL, 2002, NEUROLOGIST, V8, P325, DOI 10.1097/00127893-200211000-00001; Wolf SL, 2001, STROKE, V32, P1635, DOI 10.1161/01.STR.32.7.1635	43	1264	1330	4	178	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	2006	296	17					2095	2104		10.1001/jama.296.17.2095	http://dx.doi.org/10.1001/jama.296.17.2095			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100KM	17077374	Bronze			2023-01-03	WOS:000241668000021
J	Jin, LQ; Hope, KJ; Zhai, QL; Smadja-Joffe, F; Dick, JE				Jin, Liqing; Hope, Kristin J.; Zhai, Qiongli; Smadja-Joffe, Florence; Dick, John E.			Targeting of CD44 eradicates human acute myeloid leukemic stem cells	NATURE MEDICINE			English	Article							PRIMITIVE HEMATOPOIETIC-CELLS; BONE-MARROW; ADHESION MOLECULES; NOD/SCID MICE; SCID MICE; IN-VITRO; DIFFERENTIATION; TRANSPLANTATION; IDENTIFICATION; PROGENITORS	The long-term survival of patients with acute myeloid leukemia (AML) is dismally poor. A permanent cure of AML requires elimination of leukemic stem cells (LSCs), the only cell type capable of initiating and maintaining the leukemic clonal hierarchy. We report a therapeutic approach using an activating monoclonal antibody directed to the adhesion molecule CD44. In vivo administration of this antibody to nonobese diabetic-severe combined immune-deficient mice transplanted with human AML markedly reduced leukemic repopulation. Absence of leukemia in serially transplanted mice demonstrated that AML LSCs are directly targeted. Mechanisms underlying this eradication included interference with transport to stem cell-supportive microenvironmental niches and alteration of AML-LSC fate, identifying CD44 as a key regulator of AML LSCs. The finding that AML LSCs require interaction with a niche to maintain their stem cell properties provides a therapeutic strategy to eliminate quiescent AML LSCs and may be applicable to other types of cancer stem cells.	Univ Toronto, Hlth Network, Div Cell & Mol Biol, Toronto, ON M5G 1L7, Canada; Hop St Louis, INSERM, U718, F-75475 Paris, France	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Dick, JE (corresponding author), Univ Toronto, Hlth Network, Div Cell & Mol Biol, Toronto Med Discovery Tower,101 Coll St,Suite 8-3, Toronto, ON M5G 1L7, Canada.	jdick@uhnres.utoronto.ca		Dick, John/0000-0002-9527-8317; Hope, Kristin/0000-0003-1449-4948				Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Avigdor A, 2004, BLOOD, V103, P2981, DOI 10.1182/blood-2003-10-3611; Bendall LJ, 2000, LEUKEMIA, V14, P1239, DOI 10.1038/sj.leu.2401830; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Cancelas JA, 2006, NAT MED, V12, P278, DOI 10.1038/nm0306-278; Charrad RS, 2002, BLOOD, V99, P290, DOI 10.1182/blood.V99.1.290; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; Gadhoum Z, 2004, BLOOD, V103, P1059, DOI 10.1182/blood-2003-04-1218; Guan Y, 2000, LEUKEMIA, V14, P2135, DOI 10.1038/sj.leu.2401975; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Jo DY, 2000, J CLIN INVEST, V105, P101, DOI 10.1172/JCI7954; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; KORTLEPEL K, 1993, LEUKEMIA, V7, P1174; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood-2005-04-1417; Legras S, 1998, BLOOD, V91, P3401, DOI 10.1182/blood.V91.9.3401.3401_3401_3413; LIESVELD JL, 1991, EXP HEMATOL, V19, P63; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Madlambayan GJ, 2005, EXP HEMATOL, V33, P1229, DOI 10.1016/j.exphem.2005.05.018; Mazurier F, 2003, NAT MED, V9, P959, DOI 10.1038/nm886; Mazurier F, 2004, BLOOD, V103, P545, DOI 10.1182/blood-2003-05-1558; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; Nilsson SK, 2003, BLOOD, V101, P856, DOI 10.1182/blood-2002-05-1344; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; REUSSBORST MA, 1992, ANN HEMATOL, V65, P169, DOI 10.1007/BF01703110; SINGH S, 2003, CANCER RES, V63, P5281; Tallman Martin S, 2005, Hematology Am Soc Hematol Educ Program, P143; Tavor S, 2004, CANCER RES, V64, P2817, DOI 10.1158/0008-5472.CAN-03-3693; TILL JE, 1980, BIOCHIM BIOPHYS ACTA, V605, P431, DOI 10.1016/0304-419X(80)90009-8; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779; Woerner SM, 1995, CLIN CANCER RES, V1, P1125; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	37	913	1001	6	123	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1167	1174		10.1038/nm1483	http://dx.doi.org/10.1038/nm1483			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	16998484				2023-01-03	WOS:000241102200033
J	Summermatter, S; Mainieri, D; Russell, AP; Seydoux, J; Montani, JP; Buchala, A; Solinas, G; Dulloo, AG				Summermatter, S.; Mainieri, D.; Russell, A. P.; Seydoux, J.; Montani, J. P.; Buchala, A.; Solinas, G.; Dulloo, A. G.			Thrifty metabolism that favors fat storage after caloric restriction: a role for skeletal muscle phosphatidylinositol-3-kinase activity and AMP-activated protein kinase	FASEB JOURNAL			English	Article						thermogenesis; weight cycling; catch-up growth; obesity; diabetes	STEAROYL-COA DESATURASE-1; CATCH-UP FAT; DE-NOVO LIPOGENESIS; DIRECTLY STIMULATES THERMOGENESIS; LIPID OXIDATION; WEIGHT-LOSS; UNCOUPLING PROTEIN-3; ENERGY-METABOLISM; ADIPOSE-TISSUE; BODY-WEIGHT	Energy conservation directed at accelerating body fat recovery (or catch-up fat) contributes to obesity relapse after slimming and to excess fat gain during catch-up growth after malnutrition. To investigate the mechanisms underlying such thrifty metabolism for catch-up fat, we tested whether during refeeding after caloric restriction rats exhibiting catch-up fat driven by suppressed thermogenesis have diminished skeletal muscle phosphatidylinositol-3-kinase (PI3K) activity or AMP-activated protein kinase (AMPK) signaling-two pathways required for hormone-induced thermogenesis in ex vivo muscle preparations. The results show that during isocaloric refeeding with a low-fat diet, at time points when body fat, circulating free fatty acids, and intramyocellular lipids in refed animals do not exceed those of controls, muscle insulin receptor substrate 1-associated PI3K activity (basal and in vivo insulin-stimulated) is lower than that in controls. Isocaloric refeeding with a high-fat diet, which exacerbates the suppression of thermogenesis, results in further reductions in muscle PI3K activity and in impaired AMPK phosphorylation (basal and in vivo leptin-stimulated). It is proposed that reduced skeletal muscle PI3K/AMPK signaling and suppressed thermogenesis are interdependent. Defective PI3K or AMPK signaling will reduce the rate of substrate cycling between de novo lipogenesis and lipid oxidation, leading to suppressed thermogenesis, which accelerates body fat recovery and furthermore sensitizes skeletal muscle to dietary fat-induced impairments in PI3K/AMPK signaling.	[Summermatter, S.; Mainieri, D.; Montani, J. P.; Solinas, G.; Dulloo, A. G.] Univ Fribourg, Dept Med, Div Physiol, CH-1700 Fribourg, Switzerland; [Buchala, A.] Univ Fribourg, Dept Biol, CH-1700 Fribourg, Switzerland; [Russell, A. P.] Deakin Univ, Sch Exercise & Nutr Sci, Ctr Phys Act & Nutr, Melbourne, Vic, Australia; [Seydoux, J.] Univ Geneva, Fac Med, Dept Basic Neurosci, Geneva, Switzerland	University of Fribourg; University of Fribourg; Deakin University; University of Geneva	Dulloo, AG (corresponding author), Univ Fribourg, Dept Med, Div Physiol, Rue Musee 5, CH-1700 Fribourg, Switzerland.	abdul.dulloo@unifr.ch	Buchala, Antony/A-2656-2012; Solinas, Giovanni/P-6596-2017; Solinas, Giovanni/R-4777-2019	Solinas, Giovanni/0000-0002-0140-2621; Solinas, Giovanni/0000-0002-0140-2621; Russell, Aaron/0000-0002-7323-9501; Summermatter, Serge/0000-0003-4870-0148; DULLOO, Abdul/0000-0003-3877-6149; MAINIERI, DAVIDE/0000-0003-0797-5794				Aguilar V, 2007, CELL METAB, V5, P476, DOI 10.1016/j.cmet.2007.05.006; ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; Barnes BR, 2002, DIABETES, V51, P2703, DOI 10.2337/diabetes.51.9.2703; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; BOYLE PC, 1978, PHYSIOL BEHAV, V21, P261, DOI 10.1016/0031-9384(78)90050-1; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; Cannon B, 2006, BBA-BIOENERGETICS, V1757, P449, DOI 10.1016/j.bbabio.2006.05.016; Cettour-Rose P, 2005, DIABETES, V54, P751, DOI 10.2337/diabetes.54.3.751; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Crescenzo R, 2003, FEBS LETT, V544, P138, DOI 10.1016/S0014-5793(03)00491-5; Crescenzo R, 2003, DIABETES, V52, P1090, DOI 10.2337/diabetes.52.5.1090; Crescenzo R, 2006, DIABETES, V55, P2286, DOI 10.2337/db06-0312; Dobrzyn A, 2005, AM J PHYSIOL-ENDOC M, V288, pE599, DOI 10.1152/ajpendo.00439.2004; Dulloo AG, 1998, AM J CLIN NUTR, V68, P599, DOI 10.1093/ajcn/68.3.599; Dulloo AG, 2004, PHYSIOL BEHAV, V83, P587, DOI 10.1016/j.physbeh.2004.07.028; Dulloo AG, 2004, INT J OBESITY, V28, pS29, DOI 10.1038/sj.ijo.0802861; DULLOO AG, 1990, AM J CLIN NUTR, V52, P415, DOI 10.1093/ajcn/52.3.415; Dulloo AG, 2001, INT J OBESITY, V25, pS22, DOI 10.1038/sj.ijo.0801907; Dulloo AG, 2002, INT J OBESITY, V26, pS46, DOI 10.1038/sj.ijo.0802127; Dulloo AG, 2002, FEBS LETT, V515, P109, DOI 10.1016/S0014-5793(02)02449-3; DULLOO AG, 1995, AM J PHYSIOL-REG I, V269, pR365, DOI 10.1152/ajpregu.1995.269.2.R365; ENTENMAN C, 1957, METHOD ENZYMOL, V3, P299, DOI 10.1016/S0076-6879(57)03395-9; Evans SA, 2005, AM J PHYSIOL-REG I, V288, pR1468, DOI 10.1152/ajpregu.00602.2004; Harper ME, 2001, BIOCHEM SOC T, V29, P768, DOI 10.1042/bst0290768; HARRIS RBS, 1984, J NUTR, V114, P1143, DOI 10.1093/jn/114.6.1143; HILL JO, 1984, AM J PHYSIOL, V247, pR318, DOI 10.1152/ajpregu.1984.247.2.R318; Hood DA, 2001, J APPL PHYSIOL, V90, P1137, DOI 10.1152/jappl.2001.90.3.1137; Hutchinson DS, 2006, DIABETES, V55, P682, DOI 10.2337/diabetes.55.03.06.db05-0901; Keys A., 1950, BIOL HUMAN STARVATIO, V2; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Liu Y, 2006, BIOCHEM BIOPH RES CO, V339, P701, DOI 10.1016/j.bbrc.2005.11.068; MacLean PS, 2004, AM J PHYSIOL-REG I, V287, pR1306, DOI 10.1152/ajpregu.00463.2004; Mainieri D, 2006, FASEB J, V20, P1751, DOI 10.1096/fj.06-5934fje; MILLER DS, 1959, BRIT J NUTR, V13, P501, DOI 10.1079/BJN19590064; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; Park SH, 2002, J APPL PHYSIOL, V93, P2081, DOI 10.1152/japplphysiol.00504.2002; Pirola L, 2001, J BIOL CHEM, V276, P21544, DOI 10.1074/jbc.M011330200; Rahman SM, 2003, P NATL ACAD SCI USA, V100, P11110, DOI 10.1073/pnas.1934571100; Russell AP, 2003, FEBS LETT, V551, P104, DOI 10.1016/S0014-5793(03)00875-5; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Slawik M, 2006, AGEING RES REV, V5, P144, DOI 10.1016/j.arr.2006.03.004; Solinas G, 2006, ENDOCRINOLOGY, V147, P31, DOI 10.1210/en.2005-1033; Solinas G, 2004, FEBS LETT, V577, P539, DOI 10.1016/j.febslet.2004.10.066; Sriwijitkamol A, 2006, AM J PHYSIOL-ENDOC M, V290, pE925, DOI 10.1152/ajpendo.00429.2005; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Weyer C, 2000, AM J CLIN NUTR, V72, P946; Yang YA, 2003, EXP CELL RES, V282, P132, DOI 10.1016/S0014-4827(02)00023-X	49	41	41	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2008	22	3					774	785		10.1096/fj.07-8972com	http://dx.doi.org/10.1096/fj.07-8972com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	17928359	Green Submitted			2023-01-03	WOS:000254143700016
J	Meade, MO; Cook, DJ; Guyatt, GH; Slutsky, AS; Arabi, YM; Cooper, DJ; Davies, AR; Hand, LE; Zhou, Q; Thabane, L; Austin, P; Lapinsky, S; Baxter, A; Russell, J; Skrobik, Y; Ronco, JJ; Stewart, TE				Meade, Maureen O.; Cook, Deborah J.; Guyatt, Gordon H.; Slutsky, Arthur S.; Arabi, Yaseen M.; Cooper, D. James; Davies, Andrew R.; Hand, Lori E.; Zhou, Qi; Thabane, Lehana; Austin, Peggy; Lapinsky, Stephen; Baxter, Alan; Russell, James; Skrobik, Yoanna; Ronco, Juan J.; Stewart, Thomas E.		Lung Open Ventilation Study	Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MECHANICAL VENTILATION; PROTECTIVE-VENTILATION; OUTCOMES; DISEASE	Context Low- tidal- volume ventilation reduces mortality in critically ill patients with acute lung injury and acute respiratory distress syndrome. Instituting additional strategies to open collapsed lung tissue may further reduce mortality. Objective To compare an established low- tidal- volume ventilation strategy with an experimental strategy based on the original "open-lung approach," combining low tidal volume, lung recruitment maneuvers, and high positive- end - expiratory pressure. Design and Setting Randomized controlled trial with concealed allocation and blinded data analysis conducted between August 2000 and March 2006 in 30 intensive care units in Canada, Australia, and Saudi Arabia. Patients Nine hundred eighty- three consecutive patients with acute lung injury and a ratio of arterial oxygen tension to inspired oxygen fraction not exceeding 250. Interventions The control strategy included target tidal volumes of 6 mL/kg of predicted body weight, plateau airway pressures not exceeding 30 cm H2O, and conventional levels of positive end- expiratory pressure ( n= 508). The experimental strategy included target tidal volumes of 6 mL/kg of predicted body weight, plateau pressures not exceeding 40 cm H2O, recruitment maneuvers, and higher positive end- expiratory pressures ( n= 475). Main Outcome Measure All- cause hospital mortality. Results Eighty- five percent of the 983 study patients met criteria for acute respiratory distress syndrome at enrollment. Tidal volumes remained similar in the 2 groups, and mean positive end- expiratory pressures were 14.6 ( SD, 3.4) cm H2O in the experimental group vs 9.8 ( SD, 2.7) cm H2O among controls during the first 72 hours ( P <. 001). All- cause hospital mortality rates were 36.4% and 40.4%, respectively ( relative risk [ RR], 0.90; 95% confidence interval [ CI], 0.77- 1.05; P=. 19). Barotrauma rates were 11.2% and 9.1%( RR, 1.21; 95% CI, 0.83- 1.75; P=. 33). The experimental group had lower rates of refractory hypoxemia ( 4.6% vs 10.2%; RR, 0.54; 95% CI, 0.34- 0.86; P =.01), death with refractory hypoxemia ( 4.2% vs 8.9%; RR, 0.56; 95% CI, 0.34- 0.93; P =.03), and previously defined eligible use of rescue therapies ( 5.1% vs 9.3%; RR, 0.61; 95% CI, 0.38- 0.99; P =.045). Conclusions For patients with acute lung injury and acute respiratory distress syndrome, a multifaceted protocolized ventilation strategy designed to recruit and open the lung resulted in no significant difference in all- cause hospital mortality or barotrauma compared with an established low- tidal- volume protocolized ventilation strategy. This "open-lung" strategy did appear to improve secondary end points related to hypoxemia and use of rescue therapies. Trial Registration clinicaltrials. gov Identifier: NCT00182195.	[Meade, Maureen O.; Cook, Deborah J.; Guyatt, Gordon H.; Hand, Lori E.; Zhou, Qi; Thabane, Lehana; Austin, Peggy] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; [Meade, Maureen O.; Cook, Deborah J.; Guyatt, Gordon H.; Hand, Lori E.; Zhou, Qi; Thabane, Lehana; Austin, Peggy] McMaster Univ, Dept Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; [Slutsky, Arthur S.; Lapinsky, Stephen; Stewart, Thomas E.] Univ Toronto, Toronto, ON, Canada; [Arabi, Yaseen M.] King Saud Bin Abdulaziz Univ, Riyadh, Saudi Arabia; [Cooper, D. James; Davies, Andrew R.] Monash Univ, Melbourne, Vic 3004, Australia; [Baxter, Alan] Univ Ottawa, Ottawa, ON, Canada; [Russell, James; Ronco, Juan J.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Skrobik, Yoanna] Univ Montreal, Montreal, PQ, Canada	McMaster University; McMaster University; University of Toronto; King Saud Bin Abdulaziz University for Health Sciences; Monash University; University of Ottawa; University of British Columbia; Universite de Montreal	Meade, MO (corresponding author), McMaster Univ, Dept Med, 1200 Main St W,Room 210C, Hamilton, ON L8N 3Z5, Canada.	meadema@hhsc.ca	Slutsky, Arthur/M-3325-2019; Skrobik, Yoanna/K-8165-2014; Zhou, Qi/GSM-9583-2022; Skrobik, Yoanna/J-6393-2013; Lapinsky, Stephen/C-4624-2015; Martin, Claudio/G-3327-2011; Arabi, Yaseen/ABF-3316-2020; Cooper, D. James/G-7961-2013	Skrobik, Yoanna/0000-0002-5315-6020; Lapinsky, Stephen/0000-0002-6930-0306; Arabi, Yaseen/0000-0001-5735-6241; Cooper, D. James/0000-0002-5872-9051				Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; EFRON B, 1981, BIOMETRIKA, V68, P589, DOI 10.1093/biomet/68.3.589; Ely EW, 2001, CHEST, V120, p454S, DOI 10.1378/chest.120.6_suppl.454S; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052; Gattinoni L, 1998, AM J RESP CRIT CARE, V158, P3, DOI 10.1164/ajrccm.158.1.9708031; Hager DN, 2005, AM J RESP CRIT CARE, V172, P1241, DOI 10.1164/rccm.200501-048CP; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Hudson LD, 1999, CHEST, V116, p74S, DOI 10.1378/chest.116.suppl_1.74S-a; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; MERCAT A, 2006, INTENS CARE MED, V32, pS97; MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Rubenfeld GD, 2004, CRIT CARE MED, V32, P1289, DOI 10.1097/01.CCM.0000127266.39560.96; Slutsky AS, 1999, CHEST, V116, p9S, DOI 10.1378/chest.116.suppl_1.9S-a; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; Tobin MJ, 2001, NEW ENGL J MED, V344, P1986, DOI 10.1056/NEJM200106283442606; Tremblay LN, 2006, INTENS CARE MED, V32, P24, DOI 10.1007/s00134-005-2817-8; Villar J, 2006, CRIT CARE MED, V34, P1311, DOI 10.1097/01.CCM.0000215598.84885.01	22	902	976	2	38	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 13	2008	299	6					637	645		10.1001/jama.299.6.637	http://dx.doi.org/10.1001/jama.299.6.637			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261QN	18270352	Bronze			2023-01-03	WOS:000253095200021
J	Claxton, K; Lindsay, AB; Buxton, MJ; Culyer, AJ; McCabe, C; Walker, S; Sculpher, MJ				Claxton, Karl; Lindsay, Andrew Briggs; Buxton, Martin J.; Culyer, Anthony J.; McCabe, Christopher; Walker, Simon; Sculpher, Mark J.			Value based pricing for NHS drugs: an opportunity not to be missed?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Claxton, Karl; Walker, Simon; Sculpher, Mark J.] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; [Claxton, Karl; Culyer, Anthony J.] Univ York, Dept Econ & Related Studies, York YO10 5DD, N Yorkshire, England; [Lindsay, Andrew Briggs] Univ Glasgow, Glasgow, Lanark, Scotland; [Buxton, Martin J.] Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England; [Culyer, Anthony J.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; [McCabe, Christopher] Univ Leeds, Inst Hlth Sci, Leeds, W Yorkshire, England	University of York - UK; University of York - UK; University of Glasgow; Brunel University; University of Toronto; University of Leeds	Sculpher, MJ (corresponding author), Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England.	mjs23@york.ac.uk	McCabe, Christopher/E-2051-2016	Walker, Simon Mark/0000-0002-5750-3691; Sculpher, Mark/0000-0003-3746-9913	Medical Research Council [MC_U145079308] Funding Source: Medline; MRC [MC_U145079308] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		[Anonymous], 2007, PHARM PRIC REG SCHEM; Claxton KP, 2006, PHARMACOECONOMICS, V24, P1055, DOI 10.2165/00019053-200624110-00003; Collier J, 2008, BRIT MED J, V336, P56, DOI 10.1136/bmj.39454.496748.80; Collier J, 2007, BRIT MED J, V334, P435, DOI 10.1136/bmj.39136.464421.BE; Culyer Anthony, 2007, J Health Serv Res Policy, V12, P56, DOI 10.1258/135581907779497567; *DEP BUS ENT REG R, 2007, INT GOV RESP OFF FAI; MARTIN S, 2007, 24 U YORK CTR HLTH E; *NIH CLIN EXC, 2008, HC27I STAT OFF NIH C; *NIH CLIN EXC, 2007, CLIN PUBL HLTH DIR P	9	129	133	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 2	2008	336	7638					251	254		10.1136/bmj.39434.500185.25	http://dx.doi.org/10.1136/bmj.39434.500185.25			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261TM	18244997	Green Published, Green Submitted			2023-01-03	WOS:000253102900036
J	Peer, D; Park, EJ; Morishita, Y; Carman, CV; Shimaoka, M				Peer, Dan; Park, Eun Jeong; Morishita, Yoshiyuki; Carman, Christopher V.; Shimaoka, Motomu			Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target	SCIENCE			English	Article							SMALL INTERFERING RNAS; GENE	Cyclin D1 ( CyD1) is a pivotal cell cycle - regulatory molecule and a well- studied therapeutic target for cancer. Although CyD1 is also strongly up- regulated at sites of inflammation, its exact roles in this context remain uncharacterized. To address this question, we developed a strategy for selectively silencing CyD1 in leukocytes in vivo. Targeted stabilized nanoparticles ( tsNPs) were loaded with CyD1 - small interfering RNA ( siRNA). Antibodies to beta(7) integrin ( beta(7) I) were then used to target specific leukocyte subsets involved in gut inflammation. Systemic application of beta(7) I-tsNPs silenced CyD1 in leukocytes and reversed experimentally induced colitis in mice by suppressing leukocyte proliferation and T helper cell 1 cytokine expression. This study reveals CyD1 to be a potential anti- inflammatory target, and suggests that the application of similar modes of targeting by siRNA may be feasible in other therapeutic settings.	[Peer, Dan; Park, Eun Jeong; Morishita, Yoshiyuki; Shimaoka, Motomu] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA; [Peer, Dan; Park, Eun Jeong; Morishita, Yoshiyuki; Shimaoka, Motomu] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA; [Carman, Christopher V.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; [Carman, Christopher V.] Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Shimaoka, M (corresponding author), Harvard Univ, Sch Med, Immune Dis Inst, 200 Longwood Ave, Boston, MA 02115 USA.	shimaoka@cbrinstitute.org	Park, Eun Jeong/AAV-2056-2020; Carman, Christopher V./AAX-8995-2020; Peer, Dan/A-1785-2011; Carman, Christopher/L-8108-2016	Park, Eun Jeong/0000-0002-4288-5893; Carman, Christopher V./0000-0001-7358-2548; Peer, Dan/0000-0001-8238-0673; Carman, Christopher/0000-0001-7358-2548	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063421] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL048675, P01 HL048675-150013, HL048675] Funding Source: Medline; NIAID NIH HHS [R01 AI063421, R01 AI063421-04, AI63421] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREW DP, 1994, J IMMUNOL, V153, P3847; Behlke MA, 2006, MOL THER, V13, P644, DOI 10.1016/j.ymthe.2006.01.001; Dass CR, 2004, J MOL MED, V82, P579, DOI 10.1007/s00109-004-0558-8; Dykxhoorn DM, 2006, ANNU REV BIOMED ENG, V8, P377, DOI 10.1146/annurev.bioeng.8.061505.095848; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Heidel JD, 2007, P NATL ACAD SCI USA, V104, P5715, DOI 10.1073/pnas.0701458104; Iorns E, 2007, NAT REV DRUG DISCOV, V6, P556, DOI 10.1038/nrd2355; Li SD, 2006, MOL PHARMACEUT, V3, P579, DOI 10.1021/mp060039w; Lindsay JO, 2004, DIGEST DIS SCI, V49, P1327, DOI 10.1023/B:DDAS.0000037830.22065.71; Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122; Peer D, 2003, BBA-BIOMEMBRANES, V1612, P76, DOI 10.1016/S0005-2736(03)00106-8; Peer D, 2007, P NATL ACAD SCI USA, V104, P4095, DOI 10.1073/pnas.0608491104; Schiffelers RM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh140; Shaw S K, 1995, Semin Immunol, V7, P335, DOI 10.1016/1044-5323(95)90014-4; Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101; Sorgi FL, 1997, GENE THER, V4, P961, DOI 10.1038/sj.gt.3300484; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; Takeshita F, 2005, P NATL ACAD SCI USA, V102, P12177, DOI 10.1073/pnas.0501753102; van Dekken H, 2007, ACTA HISTOCHEM, V109, P266, DOI 10.1016/j.acthis.2007.02.007; Yang RY, 2006, CELL CYCLE, V5, P180, DOI 10.4161/cc.5.2.2306	21	415	466	7	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 1	2008	319	5863					627	630		10.1126/science.1149859	http://dx.doi.org/10.1126/science.1149859			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257AQ	18239128	Green Accepted			2023-01-03	WOS:000252772000043
J	Coates, AL				Coates, Allan L.			Guiding aerosol deposition in the lung	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DELIVERY		Univ Toronto, Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Coates, AL (corresponding author), Univ Toronto, Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada.							COATES AL, 2006, KENDIGS DISORDERS RE, P268; Dames P, 2007, NAT NANOTECHNOL, V2, P495, DOI 10.1038/nnano.2007.217; Koehler DR, 2005, J GENE MED, V7, P1409, DOI 10.1002/jgm.797; Laube BL, 2000, CHEST, V118, P1069, DOI 10.1378/chest.118.4.1069; SMALDONE GC, 1991, AM REV RESPIR DIS, V143, P727, DOI 10.1164/ajrccm/143.4_Pt_1.727	5	23	24	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 17	2008	358	3					304	305		10.1056/NEJMcibr0707489	http://dx.doi.org/10.1056/NEJMcibr0707489			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LS	18199871				2023-01-03	WOS:000252375600015
J	Bohrer, RA				Bohrer, Robert A.			Reach-through claims for drug target patents: Rx for pharmaceutical policy	NATURE BIOTECHNOLOGY			English	Editorial Material								Recognizing the value of the discovery and validation of new pharmaceutical targets would be a major step forward for pharmaceutical policy.	Calif Weatern Sch Law, San Diego, CA 92101 USA		Bohrer, RA (corresponding author), Calif Weatern Sch Law, 225 Cedar St, San Diego, CA 92101 USA.	rab@cwsl.edu						*AM HOSP FORM SERV, 2002, 2406 AM HOSP FORM SE; Angell M., 2004, TRUTH DRUG CO THEY D; Avorn J, 2004, POWERFUL MED BENEFIT; Bohrer RA, 2000, NEW ENGL J MED, V343, P1416; *TRIL COOP, 2001, MUT UND SEARCH EX CO; *US C, 1998, INCR COMP GEN DRUGS	6	6	7	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2008	26	1					55	57		10.1038/nbt0108-55	http://dx.doi.org/10.1038/nbt0108-55			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	249IW	18183015				2023-01-03	WOS:000252222500019
J	Brown, H				Brown, Hannah			Who cares for baby?	BRITISH MEDICAL JOURNAL			English	Article								Divisions between maternal and child health services in the developing world, first reported 20 years ago, left services for newborns overlooked. Today, neonatal mortality is still unacceptably high. Hannah Brown reports on initiatives trying to bridge the gap.				Hannah@two-cultures.com						*H KELL INT, 2002, OV NUTR SECT SERV CA; ROSENFIELD A, 1985, LANCET, V2, P83; Starrs AM, 2006, LANCET, V368, P1130, DOI 10.1016/S0140-6736(06)69385-9; World Health Organization, WORLD HLTH REP 2005	4	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 20	2007	335	7624					798	800		10.1136/bmj.39365.579016.94	http://dx.doi.org/10.1136/bmj.39365.579016.94			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227AX	17947782	Green Published			2023-01-03	WOS:000250630700027
J	Asano, R; Watanabe, Y; Kawaguchi, H; Fukazawa, H; Nakanishi, T; Umetsu, M; Hayashi, H; Katayose, Y; Unno, M; Kudo, T; Kumagai, I				Asano, Ryutaro; Watanabe, Yasuhiro; Kawaguchi, Hiroko; Fukazawa, Hidesuke; Nakanishi, Takeshi; Umetsu, Mitsuo; Hayashi, Hiroki; Katayose, Yu; Unno, Michiaki; Kudo, Toshio; Kumagai, Izumi			Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-RECEPTOR; MONOCLONAL-ANTIBODY; REFOLDING SYSTEM; EFFICIENT ROUTE; KINASE-ACTIVITY; DIABODY; EGFR; EFFICACY; ANTIGEN; HETERODIMERIZATION	We previously reported the marked in vitro and in vivo antitumor activity of hEx3, a humanized diabody (small recombinant bispecific antibody) with epidermal growth factor receptor (EGFR) and CD3 retargeting. Here, we fabricated a tetravalent IgG-like bispecific antibody with two kinds of single-chain Fv (scFv), i.e. humanized anti-EGFR scFv and anti-CD3 scFv, that contains the same four variable domains as hEx3, on the platform of human IgG1 (hEx3-scFv-Fc). hEx3-scFv-Fc prepared from mammalian cells showed specific binding to both EGFR and CD3 target antigens. At one-thousandth (0.1-100 fmol/ml) of the dose of normal hEx3, hEx3-scFv-Fc showed intense cytotoxicity to an EGFR-positive cell line in a growth-inhibition assay using lymphokine-activated killer cells with the T-cell phenotype (T-LAK cells). The enhanced antitumor effect was more clearly observed when peripheral blood mononuclear cells (PBMCs) were used as effector cells, indicating the utility of IgG-like fabrication. These results suggested that the intense antitumor activity is attributable to the multivalency and the presence of the fused human Fc, a hypothesis that was supported by the results of flow cytometry, PBMC proliferation assay, and protein kinase inhibition assay. Furthermore, the growth inhibition effects of hEx3-scFv-Fc were considerably superior to those of the approved therapeutic antibody, cetuximab, which recognizes the same EGFR antigen even when using PBMCs as effector cells. The high potency of hEx3-scFv-Fc may translate into improved antitumor therapy and lower costs of production because of the smaller doses needed.	Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 980, Japan; Tohoku Univ, Grad Sch Med, Dept Surg, Div Gastroenterol Surg, Sendai, Miyagi 980, Japan; Tohoku Univ, Cell Res Ctr Biomed Res, Inst Dev Aging & Canc, Sendai, Miyagi 980, Japan	Tohoku University; Tohoku University; Tohoku University	Kumagai, I (corresponding author), Aoba 6-6-11-606,Aoba-ku, Sendai, Miyagi, Japan.	kmiz@kuma.che.tohoku.ac.jp	Unno, Michiaki/A-8633-2010; Unno, Michiaki/AAX-5246-2020; Asano, Ryutaro/G-7822-2016	Unno, Michiaki/0000-0002-2145-6416; Unno, Michiaki/0000-0002-2145-6416; Hayashi, Hiroki/0000-0001-9953-603X				Adair John R., 1994, Human Antibodies and Hybridomas, V5, P41; Asano R, 2002, J BIOCHEM, V132, P903, DOI 10.1093/oxfordjournals.jbchem.a003303; Asano R, 2002, FEBS LETT, V528, P70, DOI 10.1016/S0014-5793(02)03254-4; Asano R, 2006, CLIN CANCER RES, V12, P4036, DOI 10.1158/1078-0432.CCR-06-0059; BOHLEN H, 1993, CANCER RES, V53, P4310; Bremer E, 2005, J BIOL CHEM, V280, P10025, DOI 10.1074/jbc.M413673200; Cao Y, 2003, ADV DRUG DELIVER REV, V55, P171, DOI 10.1016/S0169-409X(02)00178-3; Carter P, 2001, J IMMUNOL METHODS, V248, P7, DOI 10.1016/S0022-1759(00)00339-2; Coloma MJ, 1997, J IMMUNOL, V158, P733; FischerColbrie J, 1997, ANTICANCER RES, V17, P613; GILL GN, 1984, J BIOL CHEM, V259, P7755; Hayashi H, 2004, CANCER IMMUNOL IMMUN, V53, P497, DOI 10.1007/s00262-003-0465-9; Jung G, 2001, INT J CANCER, V91, P225, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1038>3.3.CO;2-7; Kodama H, 2002, IMMUNOL LETT, V81, P99, DOI 10.1016/S0165-2478(01)00343-1; Kontermann RE, 2005, ACTA PHARMACOL SIN, V26, P1, DOI 10.1111/j.1745-7254.2005.00008.x; Kufer P, 2004, TRENDS BIOTECHNOL, V22, P238, DOI 10.1016/j.tibtech.2004.03.006; Levene AP, 2005, J ROY SOC MED, V98, P146, DOI 10.1258/jrsm.98.4.146; Lu D, 2004, J BIOL CHEM, V279, P2856, DOI 10.1074/jbc.M310132200; Lu D, 2003, J IMMUNOL METHODS, V279, P219, DOI 10.1016/S0022-1759(03)00251-5; Marvin JS, 2005, ACTA PHARMACOL SIN, V26, P649, DOI 10.1111/j.1745-7254.2005.00119.x; Merchant AM, 1998, NAT BIOTECHNOL, V16, P677, DOI 10.1038/nbt0798-677; Pfosser A, 1999, INT J CANCER, V80, P612, DOI 10.1002/(SICI)1097-0215(19990209)80:4<612::AID-IJC21>3.0.CO;2-K; Porebska I, 2000, TUMOR BIOL, V21, P105, DOI 10.1159/000030116; Reichert JM, 2005, NAT BIOTECHNOL, V23, P1073, DOI 10.1038/nbt0905-1073; Reusch U, 2006, CLIN CANCER RES, V12, P183, DOI 10.1158/1078-0432.CCR-05-1855; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; Shahied LS, 2004, J BIOL CHEM, V279, P53907, DOI 10.1074/jbc.M407888200; Takemura S, 2000, PROTEIN ENG, V13, P583, DOI 10.1093/protein/13.8.583; Takemura S, 2002, CANCER IMMUNOL IMMUN, V51, P33, DOI 10.1007/s00262-001-0245-3; TOSI E, 1995, INT J CANCER, V62, P643, DOI 10.1002/ijc.2910620525; Wu AM, 2005, NAT BIOTECHNOL, V23, P1137, DOI 10.1038/nbt1141; Wu AM, 1996, IMMUNOTECHNOLOGY, V2, P21, DOI 10.1016/1380-2933(95)00027-5; Xie ZG, 2005, J IMMUNOL METHODS, V296, P95, DOI 10.1016/j.jim.2004.11.005; Zuo Z, 2000, PROTEIN ENG, V13, P361, DOI 10.1093/protein/13.5.361	34	46	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27659	27665		10.1074/jbc.M704719200	http://dx.doi.org/10.1074/jbc.M704719200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17644522	hybrid			2023-01-03	WOS:000249455600013
J	Sweeney, MO; Bank, AJ; Nsah, E; Koullick, M; Zeng, QC; Hettrick, D; Sheldon, T; Lamas, GA				Sweeney, Michael O.; Bank, Alan J.; Nsah, Emmanuel; Koullick, Maria; Zeng, Qian Cathy; Hettrick, Douglas; Sheldon, Todd; Lamas, Gervasio A.		SAVE PACe Trial	Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERM-FOLLOW-UP; SINGLE-CHAMBER; HEART-FAILURE; ATRIOVENTRICULAR INTERVAL; ACTIVATION; TRIAL; MODE; DYSFUNCTION; ACCURACY; PRESSURE	Background Conventional dual-chamber pacing maintains atrioventricular synchrony but results in high percentages of ventricular pacing, which causes ventricular desynchronization and has been linked to an increased risk of atrial fibrillation in patients with sinus-node disease. Methods We randomly assigned 1065 patients with sinus-node disease, intact atrioventricular conduction, and a normal QRS interval to receive conventional dual-chamber pacing (535 patients) or dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization (530 patients). The primary end point was time to persistent atrial fibrillation. Results The mean (+/-SD) follow-up period was 1.7+/-1.0 years when the trial was stopped because it had met the primary end point. The median percentage of ventricular beats that were paced was lower in dual-chamber minimal ventricular pacing than in conventional dual-chamber pacing (9.1% vs. 99.0%, P<0.001), whereas the percentage of atrial beats that were paced was similar in the two groups (71.4% vs. 70.4%, P=0.96). Persistent atrial fibrillation developed in 110 patients, 68 (12.7%) in the group assigned to conventional dual-chamber pacing and 42 (7.9%) in the group assigned to dual-chamber minimal ventricular pacing. The hazard ratio for development of persistent atrial fibrillation in patients with dual-chamber minimal ventricular pacing as compared with those with conventional dual-chamber pacing was 0.60 (95% confidence interval, 0.41 to 0.88; P=0.009), indicating a 40% reduction in relative risk. The absolute reduction in risk was 4.8%. The mortality rate was similar in the two groups (4.9% in the group receiving dual-chamber minimal ventricular pacing vs. 5.4% in the group receiving conventional dual-chamber pacing, P=0.54). Conclusions Dual-chamber minimal ventricular pacing, as compared with conventional dual-chamber pacing, prevents ventricular desynchronization and moderately reduces the risk of persistent atrial fibrillation in patients with sinus-node disease.	Brigham & Womens Hosp, Cardiac Arrhythmia Serv, Boston, MA 02115 USA; St Paul Heart Clin, St Paul, MN USA; Peninsula Cardiol Assoc, Salisbury, MD USA; Medtronic, Minneapolis, MN USA; Mt Sinai Med Ctr, Miami Beach, FL 33140 USA	Harvard University; Brigham & Women's Hospital; Medtronic; Mount Sinai Medical Center	Sweeney, MO (corresponding author), Brigham & Womens Hosp, Cardiac Arrhythmia Serv, 75 Francis St, Boston, MA 02115 USA.	mosweeney@partners.org						Andersen HR, 1997, LANCET, V350, P1210, DOI 10.1016/S0140-6736(97)03425-9; Andersen HR, 1998, CIRCULATION, V98, P1315, DOI 10.1161/01.CIR.98.13.1315; CALKINS H, 1992, PACE, V15, P1674, DOI 10.1111/j.1540-8159.1992.tb02954.x; Connolly SJ, 2000, NEW ENGL J MED, V342, P1385, DOI 10.1056/NEJM200005113421902; COX DR, 1972, J R STAT SOC B, V34, P187; Fuster V, 2001, J AM COLL CARDIOL, V38, P1231, DOI 10.1016/S0735-1097(01)01587-X; Gillis AM, 2002, J CARDIOVASC ELECTR, V13, P542, DOI 10.1046/j.1540-8167.2002.00542.x; Glotzer TV, 2003, CIRCULATION, V107, P1614, DOI 10.1161/01.CIR.0000057981.70380.45; Gregoratos Gabriel, 2002, Circulation, V106, P2145, DOI 10.1161/01.CIR.0000035996.46455.09; Healey JS, 2006, CIRCULATION, V114, P11, DOI 10.1161/CIRCULATIONAHA.105.610303; Kanzaki H, 2004, J AM COLL CARDIOL, V44, P1619, DOI 10.1016/j.jacc.2004.07.036; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLEIN LS, 1990, CIRCULATION, V82, P60, DOI 10.1161/01.CIR.82.1.60; Lamas GA, 2002, NEW ENGL J MED, V346, P1854, DOI 10.1056/NEJMoa013040; Lamas GA, 1998, NEW ENGL J MED, V338, P1097, DOI 10.1056/NEJM199804163381602; MABO P, 1991, PACE, V14, P2133, DOI 10.1111/j.1540-8159.1991.tb06484.x; Melzer C, 2005, PACE, V28, P521, DOI 10.1111/j.1540-8159.2005.09470.x; Nahlawi M, 2004, J AM COLL CARDIOL, V44, P1883, DOI 10.1016/j.jacc.2004.06.074; Nielsen JC, 2003, J AM COLL CARDIOL, V42, P614, DOI 10.1016/S0735-1097(03)00757-5; Nielsen JC, 1998, CIRCULATION, V97, P987; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Olshansky B, 2007, CIRCULATION, V115, P9, DOI 10.1161/CIRCULATIONAHA.106.629428; Orlov MV, 2007, PACE, V30, P404, DOI 10.1111/j.1540-8159.2007.00682.x; Passman RS, 2004, J CARDIOVASC ELECTR, V15, P773, DOI 10.1046/j.1540-8167.2004.03537.x; PRINZEN F, 2007, CLIN CARDIAC PACING, P291; Prinzen FW, 2002, PACE, V25, P484, DOI 10.1046/j.1460-9592.2002.00484.x; PRINZEN FW, 1995, AM HEART J, V130, P1045, DOI 10.1016/0002-8703(95)90207-4; Purerfellner H, 2004, PACE, V27, P983, DOI 10.1111/j.1540-8159.2004.00569.x; PURERFELLNER H, 2004, PACING CLIN ELECTROP, V27; Sweeney MO, 2006, CIRCULATION, V113, P2082, DOI 10.1161/CIRCULATIONAHA.105.608356; Sweeney MO, 2005, J CARDIOVASC ELECTR, V16, P811, DOI 10.1111/j.1540-8167.2005.40766.x; Sweeney MO, 2003, CIRCULATION, V107, P2932, DOI 10.1161/01.CIR.0000072769.17295.B1; Toff WD, 2005, NEW ENGL J MED, V353, P145, DOI 10.1056/NEJMoa042283; van Oosterhout MFM, 1998, CIRCULATION, V98, P588, DOI 10.1161/01.CIR.98.6.588; Wiggers CJ, 1925, AM J PHYSIOL, V73, P346, DOI 10.1152/ajplegacy.1925.73.2.346; Wilkoff BL, 2002, JAMA-J AM MED ASSOC, V288, P3115; Ziegler PD, 2006, HEART RHYTHM, V3, P1445, DOI 10.1016/j.hrthm.2006.07.030	37	317	335	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 6	2007	357	10					1000	1008		10.1056/NEJMoa071880	http://dx.doi.org/10.1056/NEJMoa071880			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206VK	17804844				2023-01-03	WOS:000249210800006
J	Frosch, WA				Frosch, William A.			"Taking the waters" - springs, wells, and spas	FASEB JOURNAL			English	Editorial Material									Weill Cornell Med Coll, Dept Psychiat, New York, NY 10021 USA	Cornell University	Frosch, WA (corresponding author), Weill Cornell Med Coll, Dept Psychiat, 525 E 68th St, New York, NY 10021 USA.	wafrosc@med.cornell.edu						CROUTIER AL, 1992, TAKING WATERS SPIRIT, P110; CUNLIFFE B, 1987, CITY BATH, P104; PORTER R, 1990, MED HIST S, V10, pR7	3	15	15	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					1948	1950		10.1096/fj.07-0702ufm	http://dx.doi.org/10.1096/fj.07-0702ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	17592155				2023-01-03	WOS:000247500300002
J	Hudes, G; Carducci, M; Tomczak, P; Dutcher, J; Figlin, R; Kapoor, A; Staroslawska, E; Sosman, J; McDermott, D; Bodrogi, I; Kovacevic, Z; Lesovoy, V; Schmidt-Wolf, IGH; Barbarash, O; Gokmen, E; O'Toole, T; Lustgarten, S; Moore, L; Motzer, RJ				Hudes, Gary; Carducci, Michael; Tomczak, Piotr; Dutcher, Janice; Figlin, Robert; Kapoor, Anil; Staroslawska, Elzbieta; Sosman, Jeffrey; McDermott, David; Bodrogi, Istvan; Kovacevic, Zoran; Lesovoy, Vladimir; Schmidt-Wolf, Ingo G. H.; Barbarash, Olga; Gokmen, Erhan; O'Toole, Timothy; Lustgarten, Stephanie; Moore, Laurence; Motzer, Robert J.		Global ARCC Trial	Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-DOSE INTERLEUKIN-2; RANDOMIZED PHASE-II; PROGNOSTIC-FACTORS; MAMMALIAN TARGET; 13-CIS-RETINOIC ACID; MTOR INHIBITOR; CANCER; CCI-779; TRIAL; RAPAMYCIN	BACKGROUND: Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease. METHODS: In this multicenter, phase 3 trial, we randomly assigned 626 patients with previously untreated, poor-prognosis metastatic renal-cell carcinoma to receive 25 mg of intravenous temsirolimus weekly, 3 million U of interferon alfa (with an increase to 18 million U) subcutaneously three times weekly, or combination therapy with 15 mg of temsirolimus weekly plus 6 million U of interferon alfa three times weekly. The primary end point was overall survival in comparisons of the temsirolimus group and the combination-therapy group with the interferon group. RESULTS: Patients who received temsirolimus alone had longer overall survival (hazard ratio for death, 0.73; 95% confidence interval [CI], 0.58 to 0.92; P=0.008) and progression-free survival (P < 0.001) than did patients who received interferon alone. Overall survival in the combination-therapy group did not differ significantly from that in the interferon group (hazard ratio, 0.96; 95% CI, 0.76 to 1.20; P=0.70). Median overall survival times in the interferon group, the temsirolimus group, and the combination-therapy group were 7.3, 10.9, and 8.4 months, respectively. Rash, peripheral edema, hyperglycemia, and hyperlipidemia were more common in the temsirolimus group, whereas asthenia was more common in the interferon group. There were fewer patients with serious adverse events in the temsirolimus group than in the interferon group (P=0.02). CONCLUSIONS: As compared with interferon alfa, temsirolimus improved overall survival among patients with metastatic renal-cell carcinoma and a poor prognosis. The addition of temsirolimus to interferon did not improve survival.	Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA; Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; Oddzial Chemioterapii, Klin Onkol, Poznan, Poland; Our Lady Mercy Med Ctr, Bronx, NY USA; Univ Calif Los Angeles, Los Angeles, CA USA; McMaster Univ, Hamilton, ON, Canada; Lublin Oncol Ctr, Lublin, Poland; Vanderbilt Univ, Med Ctr, Nashville, TN USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Natl Inst Oncol, Budapest, Hungary; Mil Med Acad, Belgrade, Serbia; Reg Clin Ctr Urol & Nephrol, Kharkov, Ukraine; Univ Bonn, D-5300 Bonn, Germany; Kemerovo State Med Acad, Reg Clin Hosp, Kemerovo, Russia; Ege Univ, Fac Med, Izmir, Turkey; Wyeth Res, Cambridge, MA USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Fox Chase Cancer Center; Johns Hopkins University; Johns Hopkins Medicine; University of California System; University of California Los Angeles; McMaster University; Vanderbilt University; Harvard University; Beth Israel Deaconess Medical Center; National Institute of Oncology Hungary; University of Bonn; Kemerovo State Medical Academy; Ege University; Pfizer; Memorial Sloan Kettering Cancer Center	Hudes, G (corresponding author), Fox Chase Canc Ctr, Dept Med Oncol, Rm 307,333 Cottman Ave, Philadelphia, PA 19111 USA.	gary.hudes@fccc.edu	Toon, Christopher W/G-3610-2012; Carducci, Michael/R-8164-2019; Kapoor, Anil/AAQ-7184-2021; Barbarash, Olga/A-4834-2017	Kapoor, Anil/0000-0001-9180-8029; Laber, Damian/0000-0003-1041-4429; Motzer, Robert/0000-0001-6925-2327; Barbarash, Olga/0000-0002-4642-3610				Aass N, 2005, J CLIN ONCOL, V23, P4172, DOI 10.1200/JCO.2005.07.114; ATKINS MB, 1993, J CLIN ONCOL, V11, P661, DOI 10.1200/JCO.1993.11.4.661; Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185; Bukowski RM, 2004, CLIN CANCER RES, V10, p6310S, DOI 10.1158/1078-0432.CCR-050000; Del Bufalo D, 2006, CANCER RES, V66, P5549, DOI 10.1158/0008-5472.CAN-05-2825; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; Harding MW, 2003, CLIN CANCER RES, V9, P2882; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hidalgo M, 2006, CLIN CANCER RES, V12, P5755, DOI 10.1158/1078-0432.CCR-06-0118; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Ko Y., 2004, P AN M AM SOC CLIN, V22, p14S; McDermott DF, 2005, J CLIN ONCOL, V23, P133, DOI 10.1200/JCO.2005.03.206; McDermott DF, 2005, J CLIN ONCOL, V23, P2877; Mekhail TM, 2005, J CLIN ONCOL, V23, P832, DOI 10.1200/JCO.2005.05.179; Motzer RJ, 2002, J CLIN ONCOL, V20, P289, DOI 10.1200/JCO.2002.20.1.289; Motzer RJ, 2000, J CLIN ONCOL, V18, P2972, DOI 10.1200/JCO.2000.18.16.2972; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Negrier S, 1998, NEW ENGL J MED, V338, P1272, DOI 10.1056/NEJM199804303381805; Negrier S, 2002, ANN ONCOL, V13, P1460, DOI 10.1093/annonc/mdf257; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Pantuck AJ, 2003, CLIN CANCER RES, V9, P4641; Raymond E, 2004, J CLIN ONCOL, V22, P2336, DOI 10.1200/JCO.2004.08.116; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Skotnicki JS, 2001, CLIN CANCER RES, V7, p3749S; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249	30	3029	3137	1	125	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 31	2007	356	22					2271	2281		10.1056/NEJMoa066838	http://dx.doi.org/10.1056/NEJMoa066838			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	172PO	17538086				2023-01-03	WOS:000246816500006
J	Wagner, AK; Ross-Degnan, D; Gurwitz, JH; Zhang, F; Gilden, DB; Cosler, L; Soumerai, SB				Wagner, Anita K.; Ross-Degnan, Dennis; Gurwitz, Jerry H.; Zhang, Fang; Gilden, Daniel B.; Cosler, Leon; Soumerai, Stephen B.			Effect of New York state regulatory action on benzodiazepine prescribing and hip fracture rates	ANNALS OF INTERNAL MEDICINE			English	Article							TRIPLICATE PRESCRIPTION PROGRAM; RISK-FACTORS; MEDICATION USE; OLDER-PEOPLE; HALF-LIFE; FALLS; SURVEILLANCE; PATTERNS; DOSAGE; IMPACT	Background: Medicare Part D excludes benzodiazepines from coverage, and numerous state government policies limit use of benzodiazepines. No data indicate that such policies have decreased the incidence of hip fracture. Objective: To assess whether a statewide policy that decreased the use of benzodiazepines among elderly persons by more than 50% has decreased the incidence of hip fracture. Design: A quasi-experiment comparing changes in outcomes before and after a policy change in a study U.S. state (New York) and a control state (New Jersey). Setting: Two U.S. state Medicaid programs, 1988-1990. Patients: Medicaid enrollees in New York (n = 51529) and New Jersey (n = 42 029) who received or did not receive a benzodiazepine. Measurements: Benzodiazepine prescribing and hazard ratios for hip fracture, adjusted for age and eligibility category. Intervention: A statewide policy, implemented in New York in 1989, that required triplicate forms for benzodiazepine prescribing to allow surveillance by health authorities. Results: The triplicate prescription policy immediately resulted in a 60.3% (95% CI, -66.3% to -54.2%) reduction in benzodiazepine use among women and 58.5% (-64.3% to -52.8%) among men. Benzodiazepine use in New Jersey remained stable. Hazard ratios for hip fracture that were adjusted for age and eligibility category did not change in New York or New Jersey when the periods before and after use of the triplicate prescription policy were compared (change from 1.2 to 1.1 among female benzodiazepine recipients [P = 0.70], 1.3 to 1.1 [P = 0.08] among female nonrecipients, 0.8 to 1.1 [P = 0.56] among male recipients, and 1.1 to 1.3 [P = 0.46] among male nonrecipients). Limitations: Information was lacking on race, benzodiazepine dose, and other potential determinants of continued benzodiazepine prescribing. Conclusions: Policies that lead to substantial reductions in the use of benzodiazepines among elderly persons do not necessarily lead to decreased incidence of hip fracture. Limitations on coverage of benzodiazepines under Medicare Part D may not achieve this widely assumed clinical benefit.	Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Pilgrim Hlth Care, Boston, MA 02215 USA; Univ Massachusetts, Sch Med, Meyers Primary Care Inst, Fallon Fdn, Worcester, MA 01605 USA; Fallon Community Hlth Plan, Worcester, MA USA; JEN Associates Inc, Cambridge, MA USA; New York State Dept Hlth, Albany Coll Pharm & Management Reports & Res Unit, Off Medicaid Management, Albany, NY USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; University of Massachusetts System; University of Massachusetts Worcester; State University of New York (SUNY) System	Soumerai, SB (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA.	ssoumerai@hms.harvard.edu	Zhang, Fang/HHN-2153-2022		AHRQ HHS [U 18 HS 11843] Funding Source: Medline; NIA NIH HHS [R01 AG19808-01A1] Funding Source: Medline; NIDA NIH HHS [R01DA10 371-01] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS011843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019808] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010371] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		[Anonymous], 1979, QUASIEXPERIMENTATION; Bambauer KZ, 2005, PSYCHIAT SERV, V56, P1143, DOI 10.1176/appi.ps.56.9.1143; CUMMING RG, 1993, MED J AUSTRALIA, V158, P414, DOI 10.5694/j.1326-5377.1993.tb121839.x; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; EADIE JL, 1993, IMPACT PRESCRIPTION, V179; ENSRUD KE, 1996, EPIDEMIOLOGY, V7, P335; FEDERSPIEL CF, 1976, MED CARE, V14, P166, DOI 10.1097/00005650-197602000-00006; GALES BJ, 1995, ANN PHARMACOTHER, V29, P354, DOI 10.1177/106002809502900402; GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905; HENNESSEY S, 2005, PHARMACOEPIDEMIOLOGY; HERINGS RMC, 1995, ARCH INTERN MED, V155, P1801, DOI 10.1001/archinte.155.16.1801; Hosmer D. W., 1999, APPL SURVIVAL ANAL; Karagas MR, 1996, AM J EPIDEMIOL, V143, P677; KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248; Kleinbaum D.G., 1996, SURVIVAL ANAL SELF L; Koski K, 1998, GERONTOLOGY, V44, P232, DOI 10.1159/000022017; LIU BA, 1995, J AM GERIATR SOC, V43, P1141, DOI 10.1111/j.1532-5415.1995.tb07016.x; LURIE P, 1992, JAMA-J AM MED ASSOC, V268, P472; *NAT PHARM COUNC, 2003, PHARM BEN STAT MED A; Neutel CI, 1996, AGE AGEING, V25, P273, DOI 10.1093/ageing/25.4.273; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; Pearson SA, 2006, ARCH INTERN MED, V166, P572, DOI 10.1001/archinte.166.5.572; Pierfitte C, 2001, BMJ-BRIT MED J, V322, P704, DOI 10.1136/bmj.322.7288.704; RAY WA, 1992, J CLIN EPIDEMIOL, V45, P703, DOI 10.1016/0895-4356(92)90047-Q; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; Ray WA, 2000, J AM GERIATR SOC, V48, P682, DOI 10.1111/j.1532-5415.2000.tb04729.x; Ross-Degnan D, 2004, INT J PSYCHIAT MED, V34, P103, DOI 10.2190/8FR4-QYY1-7MYG-2AGJ; ROSSDEGNAN D, 1993, JAMA-J AM MED ASSOC, V270, P1937, DOI 10.1001/jama.270.16.1937; SAS Institute Inc, 1999, SAS STAT US GUID VER; Schneeweiss S, 2005, J AM GERIATR SOC, V53, P948, DOI 10.1111/j.1532-5415.2005.53303.x; Sgadari A, 2000, J CLIN PSYCHOPHARM, V20, P234, DOI 10.1097/00004714-200004000-00017; Simoni-Wastila L, 2004, CLIN THER, V26, P322, DOI 10.1016/S0149-2918(04)90030-6; Sloan FA, 1999, AM J PUBLIC HEALTH, V89, P935, DOI 10.2105/AJPH.89.6.935; SOROCK GS, 1988, ARCH INTERN MED, V148, P2441, DOI 10.1001/archinte.148.11.2441; TAGGART HM, 1988, J AM GERIATR SOC, V36, P1006, DOI 10.1111/j.1532-5415.1988.tb04367.x; Tamblyn R, 2005, J AM GERIATR SOC, V53, P233, DOI 10.1111/j.1532-5415.2005.53108.x; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; VanHaaren AM, 2001, PHARMACOTHERAPY, V21, P1159, DOI 10.1592/phco.21.15.1159.33898; WADHWANI A, 2006, TENNESSEAN      0223; Wagner AK, 2004, ARCH INTERN MED, V164, P1567, DOI 10.1001/archinte.164.14.1567; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; Wang PS, 2001, AM J PSYCHIAT, V158, P892, DOI 10.1176/appi.ajp.158.6.892; WEINTRAUB M, 1991, JAMA-J AM MED ASSOC, V266, P2392, DOI 10.1001/jama.266.17.2392; WEINTRAUB M, 1993, CLIN PHARMACOL THER, V54, P252, DOI 10.1038/clpt.1993.145; ZULLICH SG, 1992, ANN PHARMACOTHER, V26, P539	46	52	53	2	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2007	146	2					96	103		10.7326/0003-4819-146-2-200701160-00004	http://dx.doi.org/10.7326/0003-4819-146-2-200701160-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131WF	17227933				2023-01-03	WOS:000243901000003
J	Young, J; Forster, A				Young, John; Forster, Anne			Rehabilitation after stroke	BMJ-BRITISH MEDICAL JOURNAL			English	Review							TRAINING CARE GIVERS; EXERCISE THERAPY; TIME		Univ Leeds, Aca Unit Elderly Care & Rehabil, Bradford BD5 0NA, W Yorkshire, England; Bradford Teaching Hosp NHS Fdn Trust, Bradford BD5 0NA, W Yorkshire, England	University of Leeds	Young, J (corresponding author), Univ Leeds, Aca Unit Elderly Care & Rehabil, Bradford BD5 0NA, W Yorkshire, England.	john.young@bradfordhospitals.nhs.uk		young, john/0000-0003-4085-9306; Forster, Anne/0000-0001-7466-4414				Anderson C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000443.pub2; Brady MC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000425.pub4; Department of Health, 2001, NAT SERV FRAM OLD PE; Duncan PW, 2005, STROKE, V36, pE100, DOI 10.1161/01.STR.0000180861.54180.FF; ELLIS G, 2006, CEREBROVASC DIS, V21, P120; FORSTER A, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001919; Hackett ML, 2005, STROKE, V36, P2296, DOI 10.1161/01.STR.0000183622.75135.a4; Han B, 1999, STROKE, V30, P1478, DOI 10.1161/01.STR.30.7.1478; Intercollegiate working Party for Stroke, 2004, NAT CLIN GUID STROK; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P406, DOI 10.1016/S0003-9993(95)80568-0; KALRA L, 1993, STROKE, V24, P1462, DOI 10.1161/01.STR.24.10.1462; Kalra L, 2004, BMJ-BRIT MED J, V328, P1099, DOI 10.1136/bmj.328.7448.1099; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; Langhorne P, 2002, AGE AGEING, V31, P365, DOI 10.1093/ageing/31.5.365; Langhorne P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000197.pub3; McKevitt C, 2004, STROKE, V35, P1499, DOI 10.1161/01.STR.0000127532.64840.36; Outpatient Service Trialists, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.cd002925, 10.1002/14651858.CD002925, DOI 10.1002/14651858.CD002925]; Patel A, 2004, BMJ-BRIT MED J, V328, P1102, DOI 10.1136/bmj.328.7448.1102; POLLOCK A, 2007, IN PRESS COCHRANE DA; *SIGN, 2002, SIGN PUBL, V64; van der Lee JH, 2001, CLIN REHABIL, V15, P20, DOI 10.1191/026921501677557755; Van Peppen RPS, 2004, CLIN REHABIL, V18, P833, DOI 10.1191/0269215504cr843oa; Walker MF, 2004, STROKE, V35, P2226, DOI 10.1161/01.STR.0000137766.17092.fb; World Health Organization, 2000, WORLD HLTH REP 2000; Young J, 2003, REV CLIN GERONTOL, V13, P55	25	97	102	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 13	2007	334	7584					86	90		10.1136/bmj.39059.456794.68	http://dx.doi.org/10.1136/bmj.39059.456794.68			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	127DZ	17218714	Green Published			2023-01-03	WOS:000243566800032
J	Yeh, LLL; Liu, JY; Lin, KS; Liu, YS; Chiou, JM; Liang, KY; Tsai, TF; Wang, LH; Chen, CT; Huang, CY				Yeh, Lan Lan Liang; Liu, Jah-Yao; Lin, Kao-Si; Liu, Yu-Shen; Chiou, Jeng-Min; Liang, Kung-Yee; Tsai, Te-Feng; Wang, Li-Hsiang; Chen, Chiung-Tong; Huang, Ching-Yi			A Randomised Placebo-Controlled Trial of a Traditional Chinese Herbal Formula in the Treatment of Primary Dysmenorrhoea	PLOS ONE			English	Article							WOMEN; MEDICINE; PREVALENCE; SEVERITY; EFFICACY; PAIN	Background. Most traditional Chinese herbal formulas consist of at least four herbs. Four-Agents-Decoction (Si Wu Tang) is a documented eight hundred year old formula containing four herbs and has been widely used to relieve menstrual discomfort in Taiwan. However, no specific effect had been systematically evaluated. We applied Western methodology to assess its effectiveness and safety for primary dysmenorrhoea and to evaluate the compliance and feasibility for a future trial. Methodology/Principal Findings. A randomised, double-blind, placebo-controlled, pilot clinical trial was conducted in an ad hoc clinic setting at a teaching hospital in Taipei, Taiwan. Seventy-eight primary dysmenorrheic young women were enrolled after 326 women with self-reported menstrual discomfort in the Taipei metropolitan area of Taiwan were screened by a questionnaire and subsequently diagnosed by two gynaecologists concurrently with pelvic ultrasonography. A dosage of 15 odorless capsules daily for five days starting from the onset of bleeding or pain was administered. Participants were followed with two to four cycles for an initial washout interval, one to two baseline cycles, three to four treatment cycles, and three follow-up cycles. Study outcome was pain intensity measured by using unmarked horizontal visual analog pain scale in an online daily diary submitted directly by the participants for 5 days starting from the onset of bleeding or pain of each menstrual cycle. Overall-pain was the average pain intensity among days in pain and peak-pain was the maximal single-day pain intensity. At the end of treatment, both the overall-pain and peak-pain decreased in the Four-Agents-Decoction (Si Wu Tang) group and increased in the placebo group; however, the differences between the two groups were not statistically significant. The trends persisted to follow-up phase. Statistically significant differences in both peak-pain and overall-pain appeared in the first follow-up cycle, at which the reduced peak-pain in the Four-Agents-Decoction (Si Wu Tang) group did not differ significantly by treatment length. However, the reduced peak-pain did differ profoundly among women treated for four menstrual cycles (2.69 (2.06) cm, mean (standard deviation), for the 20 women with Four-Agents-Decoction and 4.68 (3.16) for the 22 women with placebo, p = .020.) There was no difference in adverse symptoms between the Four-Agents-Decoction (Si Wu Tang) and placebo groups. Conclusion/significance. Four-Agents-Decoction (Si Wu Tang) therapy in this pilot post-market clinical trial, while meeting the standards of conventional medicine, showed no statistically significant difference in reducing menstrual pain intensity of primary dysmenorrhoea at the end of treatment. Its use, with our dosage regimen and treatment length, was not associated with adverse reactions. The finding of statistically significant pain-reducing effect in the first follow-up cycle was unexpected and warrants further study. A larger similar trial among primary dysmenorrheic young women with longer treatment phase and multiple batched study products can determine the definitive efficacy of this historically documented formula. Trial Registration. Controlled-Trials.com ISRCTN23374750	[Yeh, Lan Lan Liang; Huang, Ching-Yi] Natl Hlth Res Inst, Div Clin Res, Zhunan, Taiwan; [Liu, Jah-Yao] Natl Def Med Ctr, Tri Serv Gen Hosp, Dept Obstet & Gynaecol, Taipei, Taiwan; [Lin, Kao-Si; Wang, Li-Hsiang] Natl Def Med Ctr, Tri Serv Gen Hosp, Dept Chinese Med, Taipei, Taiwan; [Liu, Yu-Shen] Taipei Municipal Hosp, Zhongxiao Branch, Sect Obstet & Gynaecol, Taipei, Taiwan; [Chiou, Jeng-Min] Acad Sinica, Inst Stat Sci, Taipei 11529, Taiwan; [Liang, Kung-Yee] Natl Hlth Res Inst, Div Biostat & Bioinformat, Zhunan, Taiwan; [Tsai, Te-Feng] Taipei Municipal Hosp, Zhongxiao Branch, Sect Chinese Med, Taipei, Taiwan; [Chen, Chiung-Tong] Natl Hlth Res Inst, Div Biotechnol & Pharmaceut Res, Zhunan, Taiwan	National Health Research Institutes - Taiwan; National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; Tri-Service General Hospital; Taipei Municipal WanFang Hospital; Academia Sinica - Taiwan; National Health Research Institutes - Taiwan; Taipei Municipal WanFang Hospital; National Health Research Institutes - Taiwan	Yeh, LLL (corresponding author), Natl Hlth Res Inst, Div Clin Res, Zhunan, Taiwan.	lanlanliang2@yahoo.com	Chiou, Jeng-Min/AAQ-3736-2021; Chen, Chiung-Tong/D-2075-2010	Chiou, Jeng-Min/0000-0003-4554-9454	Department of Health, Taiwan; Office of National Science and Technology Program for Biotechnology and Pharmaceuticals, Taiwan; Tri-Service General Hospital of National Defense Medical Centre [TSGH-C94-62]	Department of Health, Taiwan; Office of National Science and Technology Program for Biotechnology and Pharmaceuticals, Taiwan; Tri-Service General Hospital of National Defense Medical Centre	This study was an intramural research with additional funding support from other government agencies between 2003 and 2004: Department of Health, Taiwan and The Office of National Science and Technology Program for Biotechnology and Pharmaceuticals, Taiwan. These two funding agencies executed periodical monitoring and auditing. Post hoc study funding was partially supported by a grant (TSGH-C94-62) from the Tri-Service General Hospital of National Defense Medical Centre. Nobody from the government funding agencies or the three companies participated in study design or in the collection, analysis, and interpretation of data, and had no involvement in the authors' work. The investigators solely determined to write this report and made the decision to submit it for publication as part of research activity.	Altunyurt S, 2005, J REPROD MED, V50, P251; ANDERSCH B, 1982, AM J OBSTET GYNECOL, V144, P655, DOI 10.1016/0002-9378(82)90433-1; Bensoussan A, 1998, JAMA-J AM MED ASSOC, V280, P1585, DOI 10.1001/jama.280.18.1585; CHAO PDL, 2005, YB CHINESE MED PHARM, V21, P413; Coco AS, 1999, AM FAM PHYSICIAN, V60, P489; De Smet PAGM, 2002, NEW ENGL J MED, V347, P2046, DOI 10.1056/NEJMra020398; Diggle P., 2002, J R STAT SOC, DOI DOI 10.2307/2983303; Dmitrovic R, 2000, ACTA OBSTET GYN SCAN, V79, P1112, DOI 10.1034/j.1600-0412.2000.0790121112.x; Dmitrovic R, 2003, EUR J OBSTET GYN R B, V107, P191, DOI 10.1016/S0301-2115(02)00372-X; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; Harlow SD, 1996, BRIT J OBSTET GYNAEC, V103, P1134, DOI 10.1111/j.1471-0528.1996.tb09597.x; Hillen TIJ, 1999, J ADOLESCENT HEALTH, V25, P40, DOI 10.1016/S1054-139X(98)00147-5; HROBJARTSSON A, 2002, HAST CENT S, P107; Hsieh KH, 1996, PEDIAT ALLERG IMM-UK, V7, P130, DOI 10.1111/j.1399-3038.1996.tb00120.x; Huskisson E., 1983, PAIN MEASUREMENT ASS, P33; Jensen MP, 2003, J PAIN, V4, P407, DOI 10.1016/S1526-5900(03)00716-8; Kennedy S, 2006, FERTIL STERIL, V86, P762, DOI 10.1016/j.fertnstert.2006.02.092; KLEIN JR, 1981, PEDIATRICS, V68, P661; Kotani N, 1997, AM J CHINESE MED, V25, P205, DOI 10.1142/S0192415X9700024X; Marjoribanks J., 2003, COCHRANE DB SYST REV, V4, DOI [10.1002/14651858.CD001751, DOI 10.1002/14651858.CD001751]; Milsom I, 2002, CLIN THER, V24, P1384, DOI 10.1016/S0149-2918(02)80043-1; Mol BWJ, 1998, FERTIL STERIL, V70, P1101, DOI 10.1016/S0015-0282(98)00355-0; Ng T P, 1992, Ann Acad Med Singap, V21, P323; Pedron-Nuevo N, 1998, Ginecol Obstet Mex, V66, P492; Proctor ML, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002120; ROBINSON JC, 1992, AM J OBSTET GYNECOL, V166, P578; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X; Wang L, 2004, OCCUP ENVIRON MED, V61, P1021, DOI 10.1136/oem.2003.012302; Ziaei S, 2001, BRIT J OBSTET GYNAEC, V108, P1181, DOI 10.1111/j.1471-0528.2003.00279.x; Zondervan KT, 1998, BRIT J OBSTET GYNAEC, V105, P93, DOI 10.1111/j.1471-0528.1998.tb09357.x	30	49	49	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2007	2	8							e719	10.1371/journal.pone.0000719	http://dx.doi.org/10.1371/journal.pone.0000719			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HN	17710126	Green Submitted, Green Published, gold			2023-01-03	WOS:000207455200003
J	Vigne, P; Frelin, C				Vigne, Paul; Frelin, Christian			A Low Protein Diet Increases the Hypoxic Tolerance in Drosophila	PLOS ONE			English	Article								Dietary restriction is well known to increase the life span of a variety of organisms from yeast to mammals, but the relationships between nutrition and the hypoxic tolerance have not yet been considered. Hypoxia is a major cause of cell death in myocardial infarction and stroke. Here we forced hypoxia-related death by exposing one-day-old male Drosophila to chronic hypoxia (5% O-2) and analysed their survival. Chronic hypoxia reduced the average life span from 33.6 days to 6.3 days when flies were fed on a rich diet. A demographic analysis indicated that chronic hypoxia increased the slope of the mortality trajectory and not the short-term risk of death. Dietary restriction produced by food dilution, by yeast restriction, or by amino acid restriction partially reversed the deleterious action of hypoxia. It increased the life span of hypoxic flies up to seven days, which represented about 25% of the life time of an hypoxic fly. Maximum survival of hypoxic flies required only dietary sucrose, and it was insensitive to drugs such as rapamycin and resveratrol, which increase longevity of normoxic animals. The results thus uncover a new link between protein nutrition, nutrient signalling, and resistance to hypoxic stresses.	[Vigne, Paul; Frelin, Christian] Fac Med Nice, INSERM, F-06034 Nice, France; [Vigne, Paul; Frelin, Christian] Univ Nice Sophia Antipolis, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur	Frelin, C (corresponding author), Fac Med Nice, INSERM, U210, F-06034 Nice, France.	cfrelin@unice.fr			Institut National de la Sante et de la Recherche Medicale; Federation pour la Recherche sur le Cerveau; University of Nice Sophia Antipolis	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Federation pour la Recherche sur le Cerveau; University of Nice Sophia Antipolis	This work was supported by the Institut National de la Sante et de la Recherche Medicale, Federation pour la Recherche sur le Cerveau, and the University of Nice Sophia Antipolis.	Ahmet I, 2005, CIRCULATION, V112, P3115, DOI 10.1161/CIRCULATIONAHA.105.563817; Arquier N, 2006, BIOCHEM J, V393, P471, DOI 10.1042/BJ20050675; Broughton SJ, 2005, P NATL ACAD SCI USA, V102, P3105, DOI 10.1073/pnas.0405775102; CARVALHO GB, 2005, NAT METH, V2, P755; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Colombani J, 2003, CELL, V114, P739, DOI 10.1016/S0092-8674(03)00713-X; Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Haddad GG, 1997, P NATL ACAD SCI USA, V94, P10809, DOI 10.1073/pnas.94.20.10809; HOLLINGS.MJ, 1970, J INSECT PHYSIOL, V16, P1017, DOI 10.1016/0022-1910(70)90195-2; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Lavista-Llanos S, 2002, MOL CELL BIOL, V22, P6842, DOI 10.1128/MCB.22.19.6842-6853.2002; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Mair W, 2005, PLOS BIOL, V3, P1305, DOI 10.1371/journal.pbio.0030223; Mair W, 2003, SCIENCE, V301, P1731, DOI 10.1126/science.1086016; Mattson Mark P, 2004, NeuroRx, V1, P111, DOI 10.1007/BF03206571; Min KJ, 2006, MECH AGEING DEV, V127, P93, DOI 10.1016/j.mad.2005.09.004; Min KJ, 2006, MECH AGEING DEV, V127, P643, DOI 10.1016/j.mad.2006.02.005; O'Farrell PH, 2001, J CLIN INVEST, V107, P671, DOI 10.1172/JCI12562; Partridge L, 2005, MECH AGEING DEV, V126, P938, DOI 10.1016/j.mad.2005.03.023; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137; VANHERREWEGE J, 1974, EXP GERONTOL, V9, P191; Walker DW, 2006, CURR BIOL, V16, P674, DOI 10.1016/j.cub.2006.01.057; Walker G, 2005, MECH AGEING DEV, V126, P929, DOI 10.1016/j.mad.2005.03.014; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789	27	18	20	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e56	10.1371/journal.pone.0000056	http://dx.doi.org/10.1371/journal.pone.0000056			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183686	Green Published, gold, Green Submitted			2023-01-03	WOS:000207443600056
J	Cripe, LD				Cripe, Larry D.			Hope is the thing with feathers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												lcripe@iupui.edu							0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	2006	296	15					1815	1816		10.1001/jama.296.15.1815	http://dx.doi.org/10.1001/jama.296.15.1815			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	095ST	17047201				2023-01-03	WOS:000241329300001
J	Kalus, RM; Shojania, KG; Amory, JK; Saint, S				Kalus, Robert M.; Shojania, Kaveh G.; Amory, John K.; Saint, Sanjay			Lost in transcription	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PHYSICIAN ORDER ENTRY; ERRORS; SYSTEMS; SAFETY		Univ Washington, Dept Internal Med, Div Gen Internal Med, Seattle, WA 98104 USA; Ottawa Hlth Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; Univ Ottawa, Dept Med, Ottawa, ON, Canada; Ann Arbor Vet Affairs Hlth Serv Res & Dev Ctr Exc, Ann Arbor, MI USA; Univ Michigan, Sch Med, Ann Arbor, MI USA	University of Washington; University of Washington Seattle; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Michigan System; University of Michigan	Kalus, RM (corresponding author), Univ Washington, Dept Internal Med, Div Gen Internal Med, Box 359702, Seattle, WA 98104 USA.	rkalus@u.washington.edu	Saint, Sanjay/AAF-5126-2019	Amory, John/0000-0002-7419-435X	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011540] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K23HD045386] Funding Source: NIH RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Grove ML, 2003, BMJ-BRIT MED J, V326, P1145, DOI 10.1136/bmj.326.7399.1145-b; Kaushal R, 2003, ARCH INTERN MED, V163, P1409, DOI 10.1001/archinte.163.12.1409; Kohn LT, 2000, ERR IS HUMAN BUILDIN; Koppel R, 2005, JAMA-J AM MED ASSOC, V293, P1197, DOI 10.1001/jama.293.10.1197; Lesar TS, 1997, ARCH INTERN MED, V157, P1569, DOI 10.1001/archinte.157.14.1569; LOMAESTRO BM, 1992, JAMA-J AM MED ASSOC, V268, P2031, DOI 10.1001/jama.1992.03490150083021; Moore TJ, 2004, AM J HEALTH-SYST PH, V61, P1380, DOI 10.1093/ajhp/61.13.1380; Shojania KG, 2002, MED CLIN N AM, V86, P847, DOI 10.1016/S0025-7125(02)00016-0	9	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 5	2006	355	14					1487	1491		10.1056/NEJMcps054086	http://dx.doi.org/10.1056/NEJMcps054086			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	090UA	17021325				2023-01-03	WOS:000240976200012
J	Miller, K; Wang, ML; Gralow, J; Dickler, M; Cobleigh, M; Perez, EA; Shenkier, T; Cella, D; Davidson, NE				Miller, Kathy; Wang, Molin; Gralow, Julie; Dickler, Maura; Cobleigh, Melody; Perez, Edith A.; Shenkier, Tamara; Cella, David; Davidson, Nancy E.			Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; COMBINED BIOLOGICAL THERAPY; QUALITY-OF-LIFE; RESISTANCE; ANGIOGENESIS; TARGET; CELLS; TRIAL	Background: In an open-label, randomized, phase 3 trial, we compared the efficacy and safety of paclitaxel with that of paclitaxel plus bevacizumab, a monoclonal antibody against vascular endothelial growth factor, as initial treatment for metastatic breast cancer. Methods: We randomly assigned patients to receive 90 mg of paclitaxel per square meter of body-surface area on days 1, 8, and 15 every 4 weeks, either alone or with 10 mg of bevacizumab per kilogram of body weight on days 1 and 15. The primary end point was progression-free survival; overall survival was a secondary end point. Results: From December 2001 through May 2004, a total of 722 patients were enrolled. Paclitaxel plus bevacizumab significantly prolonged progression-free survival as compared with paclitaxel alone (median, 11.8 vs. 5.9 months; hazard ratio for progression, 0.60; P<0.001) and increased the objective response rate (36.9% vs. 21.2%, P<0.001). The overall survival rate, however, was similar in the two groups (median, 26.7 vs. 25.2 months; hazard ratio, 0.88; P=0.16). Grade 3 or 4 hypertension (14.8% vs. 0.0%, P<0.001), proteinuria (3.6% vs. 0.0%, P<0.001), headache (2.2% vs. 0.0%, P=0.008), and cerebrovascular ischemia (1.9% vs. 0.0%, P=0.02) were more frequent in patients receiving paclitaxel plus bevacizumab. Infection was more common in patients receiving paclitaxel plus bevacizumab (9.3% vs. 2.9%, P<0.001), but febrile neutropenia was uncommon (<1% overall). Conclusions: Initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab prolongs progression-free survival, but not overall survival, as compared with paclitaxel alone. (ClinicalTrials.gov number, NCT00028990.).	Indiana Univ, Ctr Canc, Indiana Canc Pavil, Indianapolis, IN 46202 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Puget Sound Oncol Consortium, Seattle, WA USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; Mayo Clin, Jacksonville, FL 32224 USA; British Columbia Canc Agcy, Vancouver Canc Ctr, Vancouver, BC V5Z 4E6, Canada; Evanston NW Healthcare, Evanston, IL USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL USA; Johns Hopkins Kimmel Comprehens Canc Ctr, Baltimore, MD USA	Indiana University System; Indiana University-Purdue University Indianapolis; Harvard University; Dana-Farber Cancer Institute; Memorial Sloan Kettering Cancer Center; Rush University; Mayo Clinic; British Columbia Cancer Agency; NorthShore University Health System; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Johns Hopkins University; Johns Hopkins Medicine	Miller, K (corresponding author), Indiana Univ, Ctr Canc, Indiana Canc Pavil, 535 Barnhill Dr,RT473, Indianapolis, IN 46202 USA.	kathmill@iupui.edu		Cobleigh, Melody/0000-0001-6385-4693	NCI NIH HHS [CA16116, CA21115, CA23318, CA49883, CA66636] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA066636, U10CA016116, U10CA021115, U10CA049883, U10CA023318] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brady MJ, 1997, J CLIN ONCOL, V15, P974, DOI 10.1200/JCO.1997.15.3.974; BROUTYBOYE D, 1995, CANCER RES, V55, P1633; Cobleigh MA, 2001, BREAST CANCER RES TR, V69, P301; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Fitzmaurice GM, 2001, STAT MED, V20, P1009, DOI 10.1002/sim.718; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GASPARINI G, 1999, BREAST CANC MOL GENE, P347; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hari M, 2006, MOL CANCER THER, V5, P270, DOI 10.1158/1535-7163.MCT-05-0190; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; JENNISON C, 1989, J R STAT SOC B, V51, P305; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kerbel RS, 2001, CANCER METAST REV, V20, P79, DOI 10.1023/A:1013172910858; Miller KD, 2003, ANN ONCOL, V14, P20, DOI 10.1093/annonc/mdg033; Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098; Miller KD, 2001, J CLIN ONCOL, V19, P1195, DOI 10.1200/JCO.2001.19.4.1195; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Pegram M, 2006, BREAST CANCER RES TR, V100, pS28; Pegram MD, 2002, SEMIN ONCOL, V29, P29, DOI 10.1053/sonc.2002.34053; Relf M, 1997, CANCER RES, V57, P963; Sandler A, 2007, NEW ENGL J MED, V356, P318; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Skillings JR, 2005, J CLIN ONCOL, V23, p196S; Sledge G, 2007, J CLIN ONCOL, V25; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Sweeney CJ, 2001, CANCER RES, V61, P3369; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Wagner LI, 2006, BREAST CANCER RES TR, V100, pS239	30	2448	2576	1	199	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 27	2007	357	26					2666	2676		10.1056/NEJMoa072113	http://dx.doi.org/10.1056/NEJMoa072113			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245UO	18160686	Bronze			2023-01-03	WOS:000251964500005
J	Armitage, JN; Sibanda, N; Cathcart, PJ; Emberton, M; van der Meulen, JHP				Armitage, James N.; Sibanda, Nokuthaba; Cathcart, Paul J.; Emberton, Mark; van der Meulen, Jan H. P.			Mortality in men admitted to hospital with acute urinary retention: database analysis	BRITISH MEDICAL JOURNAL			English	Article							BENIGN PROSTATIC HYPERPLASIA; ICD-9-CM ADMINISTRATIVE DATA; CLINICAL COMORBIDITY INDEX; RISK-FACTORS; POPULATION; MANAGEMENT; HEALTH; SCORES; BPH	Objectives To investigate mortality in men admitted to hospital with acute urinary retention and to report on the effects of comorbidity on mortality. Design Analysis of the hospital episode statistics database linked to the mortality database of the Office for National Statistics. Setting NHS hospital trusts in England, 1998-2005. Participants All men aged over 45 who were admitted to NHS hospitals in England with a first episode of acute urinary retention. Main outcome measures Mortality in the first year after acute urinary retention and standardised mortality ratio against the general population. Results During the study period, 176 046 men aged over 45 were admitted to hospital with a first episode of acute urinary retention. In 100 067 men with spontaneous acute urinary retention, the one year mortality was 4.1% in men aged 45-54 and 32.8% in those 85 and over. In 75 979 men with precipitated acute urinary retention, mortality was 9.5% and 45.4%, respectively. In men with spontaneous acute urinary retention aged 75-84, the most prevalent age group, the one year mortality was 12.5% in men without comorbidity and 28.8% in men with comorbidity. The corresponding figures for men with precipitated acute urinary retention were 18.1% and 40.5%. Compared with the general population, the highest relative increase in mortality was in men aged 4554 (standardised mortality ratio 10.0 for spontaneous and 23.6 for precipitated acute urinary retention) and the lowest for men 85 and over (1.7 and 2.4, respectivety). Conclusions Mortality in men admitted to hospital with acute urinary retention is high and increases strongly with age and comorbidity. Patients might benefit from multidisciplinary care to identify and treat comorbid conditions.	Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England; Royal Coll Surgeons England, Clin Effectiveness Unit, London WC2A 3PE, England; UCL Hosp, Div Surg & Intervent Sci, London NW1 2BU, England	University of London; London School of Hygiene & Tropical Medicine; Royal College of Surgeons of England; University College London Hospitals NHS Foundation Trust; University of London; University College London	van der Meulen, JHP (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England.	jan.vandermeulen@lshtm.ac.uk		van der Meulen, Jan/0000-0002-9451-2335; Sibanda, Nokuthaba/0000-0003-2283-7277				Breslow N E, 1987, IARC Sci Publ, P1; Cathcart P, 2006, J UROLOGY, V176, P200, DOI 10.1016/S0022-5347(06)00509-X; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Jacobsen SJ, 1997, J UROLOGY, V158, P481, DOI 10.1016/S0022-5347(01)64508-7; Kirby RS, 2005, UROLOGY, V66, P52, DOI 10.1016/j.urology.2005.07.004; Manikandan R, 2004, BJU INT, V93, P84, DOI 10.1111/j.1464-410X.2004.04562.x; McNeill SA, 2004, J UROLOGY, V171, P2316, DOI 10.1097/01.ju.0000127743.80759.7a; McVary KT, 2006, AM J MANAG CARE, V12, pS122; Meigs JB, 1999, J UROLOGY, V162, P376, DOI 10.1016/S0022-5347(05)68563-1; Michel MC, 2004, J UROLOGY, V172, P1390, DOI 10.1097/01.ju.0000139995.85780.d8; *NAT CTR HLTH OUTC, HOSP EP STAT HES CON; Nuttall M, 2006, J CLIN EPIDEMIOL, V59, P265, DOI 10.1016/j.jclinepi.2005.07.015; *OFF NAT STAT, HOM OFF UK STAT; *OFF POP CENS SURV, 1987, CLASS SURG OP PROC; Ozden C, 2007, EUR UROL, V51, P199, DOI 10.1016/j.eururo.2006.05.040; Pickard R, 1998, BRIT J UROL, V81, P712; Roberts SE, 2003, BRIT MED J, V327, P771, DOI 10.1136/bmj.327.7418.771; Roche JJW, 2005, BMJ-BRIT MED J, V331, P1374, DOI 10.1136/bmj.38643.663843.55; Roehrborn CG, 2000, EUR UROL, V37, P528, DOI 10.1159/000020189; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1085, DOI 10.1016/0895-4356(93)90106-B; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; Schneeweiss S, 2000, INT J EPIDEMIOL, V29, P891, DOI 10.1093/ije/29.5.891; Verhamme KMC, 2005, EUR UROL, V47, P494, DOI 10.1016/j.eururo.200411.011	23	40	40	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 8	2007	335	7631					1199	+		10.1136/bmj.39377.617269.55	http://dx.doi.org/10.1136/bmj.39377.617269.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242ER	17991937	Green Submitted, Green Published, Green Accepted, Bronze			2023-01-03	WOS:000251707800034
J	Corson, TW; Crews, CM				Corson, Timothy W.; Crews, Craig M.			Molecular understanding and modern application of traditional medicines: Triumphs and trials	CELL			English	Article							TRIPTERYGIUM-WILFORDII; ANTIMALARIAL; TRIPTOLIDE; RECEPTOR; CURCUMIN	Traditional medicines provide fertile ground for modern drug development, but first they must pass along a pathway of discovery, isolation, and mechanistic studies before eventual deployment in the clinic. Here, we highlight the challenges along this route, focusing on the compounds artemisinin, triptolide, celastrol, capsaicin, and curcumin.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06511 USA; Yale Univ, Dept Chem & Pharmacol, New Haven, CT 06511 USA	Yale University; Yale University	Crews, CM (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06511 USA.	craig.crews@yale.edu	Corson, Timothy W./B-6851-2009; Crews, Craig M./ABH-9346-2020	Corson, Timothy W./0000-0002-1402-7875; Crews, Craig M./0000-0002-8456-2005	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062120] Funding Source: NIH RePORTER; NIAID NIH HHS [AI055194] Funding Source: Medline; NIGMS NIH HHS [R01 GM062120-11, R01 GM062120, GM062120] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal BB, 2007, ADV EXP MED BIOL, V595, P1; ASAWAMAHASAKDA W, 1994, ANTIMICROB AGENTS CH, V38, P1854, DOI 10.1128/AAC.38.8.1854; Brinker AM, 2005, J CHROMATOGR A, V1070, P65, DOI 10.1016/j.chroma.2005.02.083; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cortright DN, 2007, BBA-MOL BASIS DIS, V1772, P978, DOI 10.1016/j.bbadis.2007.03.003; Dasgupta P, 1997, BRIT J UROL, V80, P845, DOI 10.1046/j.1464-410X.1997.00424.x; Eckstein-Ludwig U, 2003, NATURE, V424, P957, DOI 10.1038/nature01813; Efferth T, 2007, PLANTA MED, V73, P299, DOI 10.1055/s-2007-967138; GREENWOOD D, 1992, J ANTIMICROB CHEMOTH, V30, P417, DOI 10.1093/jac/30.4.417; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Hsu CH, 2007, ADV EXP MED BIOL, V595, P471; Immke DC, 2006, SEMIN CELL DEV BIOL, V17, P582, DOI 10.1016/j.semcdb.2006.09.004; Leuenroth SJ, 2005, CHEM BIOL, V12, P1259, DOI 10.1016/j.chembiol.2005.09.009; Leuenroth SJ, 2007, P NATL ACAD SCI USA, V104, P4389, DOI 10.1073/pnas.0700499104; Liu CZ, 2006, APPL MICROBIOL BIOT, V72, P11, DOI 10.1007/s00253-006-0452-0; Mahdi JG, 2006, CELL PROLIFERAT, V39, P147, DOI 10.1111/j.1365-2184.2006.00377.x; Qiu Daoming, 2003, Drugs R D, V4, P1, DOI 10.2165/00126839-200304010-00001; Ro DK, 2006, NATURE, V440, P940, DOI 10.1038/nature04640; Schmidt BM, 2007, NAT CHEM BIOL, V3, P360, DOI 10.1038/nchembio0707-360; Sethi G, 2007, BLOOD, V109, P2727, DOI 10.1182/blood-2006-10-050807; Sharma RA, 2005, EUR J CANCER, V41, P1955, DOI 10.1016/j.ejca.2005.05.009; Tao XL, 2000, RHEUM DIS CLIN N AM, V26, P29, DOI 10.1016/S0889-857X(05)70118-6; Vennerstrom JL, 2004, NATURE, V430, P900, DOI 10.1038/nature02779; Yang D, 1998, J ORG CHEM, V63, P6446, DOI 10.1021/jo981362g	24	415	438	5	111	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 7	2007	130	5					769	774		10.1016/j.cell.2007.08.021	http://dx.doi.org/10.1016/j.cell.2007.08.021			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	212GI	17803898	Bronze, Green Accepted, Green Submitted			2023-01-03	WOS:000249581500007
J	Manson, JE; Allison, MA; Rossouw, JE; Carr, JJ; Langer, RD; Hsia, J; Kuller, LH; Cochrane, BB; Hunt, JR; Ludlam, SE; Pettinger, MB; Gass, M; Margolis, KL; Nathan, L; Ockene, JK; Prentice, RL; Robbins, J; Stefanick, ML; Rossouw, JE; Ludlam, S; Cochrane, BB; Hunt, JR; Lund, B; Prentice, R; Carr, JJ; O'Rourke, C; Du, L; Pillsbury, S; Hightower, C; Ellison, R; Tan, J; Wassertheil-Smoller, S; Magnani, M; Noble, DH; Dellicarpini, T; Manson, JE; Bueche, M; McGinnis, AD; Rybicki, FJ; Assaf, AR; Sloane, G; Phillips, LS; Butler, V; Huber, M; Vitali, J; Hsia, J; LeBrun, C; Palm, R; Embersit, D; Whitlock, E; Arnold, K; Sidney, S; Cantrell, V; Kotchen, JM; Feltz, C; Howard, BV; Thomas-Geevarghese, A; Boggs, G; Jelinick, JS; Greenland, P; Neuman, A; Carlson-Lund, G; Giovanazzi, SM; Stefanick, ML; Swope, S; Jackson, R; Toussant, K; Lewis, CE; Pierce, P; Stallings, C; Wactawski-Wende, J; Goel, S; Laughlin, R; Robbins, J; Zaragoza, S; Macias, D; Belisle, D; Nathan, L; Voigt, B; Goldin, J; Woo, M; Langer, RD; Allison, MA; Lien, X; Wright, CM; Gass, M; Sheridan, S; Robinson, JG; Feddersen, D; Kelly-Brake, K; Carroll, J; Ockene, J; Churchill, L; Lasser, NL; Miller, B; Maldjian, PD; Pierre-Louis, J; Fishman, J; O'Sullivan, MJ; Fernandez, D; Margolis, KL; Bjerk, CL; Truwit, C; Hearity, JA; Hyslop, WB; Darroch, K; Murphy, C; Heiss, G; Kuller, LH; Edmundowicz, D; Ives, D; Johnson, KC; Satterfield, S; Connelly, SA; Jones, EL; Brzyski, R; Nashawati, MA; Torchia, S; Rodriguez, A; Garza, R; Nentwich, P; Sarto, GE; Broderick, L; Sweitzer, NK; Nabel, E; Rossouw, JE; Ludlam, SE; Pottern, L; McGowan, J; Ford, L; Geller, N; Prentice, RL; Anderson, G; LaCroix, A; Kooperberg, CL; Patterson, RE; McTiernan, A; Shumaker, S; Stein, E; Cummings, S; Wassertheil-Smoller, S; Hays, J; Manson, JE; Assaf, AR; Phillips, L; Beresford, S; Hsia, J; Chlebowski, R; Whitlock, E; Caan, B; Kotchen, JM; Howard, BV; Van Horn, L; Black, H; Stefanick, ML; Lane, D; Jackson, R; Lewis, CE; Bassford, T; Wactawski-Wende, J; Robbins, J; Hubbell, FA; Judd, H; Langer, RD; Gass, M; Limacher, M; Curb, D; Wallace, R; Ockene, J; Lasser, N; O'Sullivan, MJ; Margolis, KL; Brunner, R; Heiss, G; Kuller, LH; Johnson, KC; Brzyski, R; Sarto, GE; Bonds, D; Hendrix, S				Manson, JoAnn E.; Allison, Matthew A.; Rossouw, Jacques E.; Carr, J. Jeffrey; Langer, Robert D.; Hsia, Judith; Kuller, Lewis H.; Cochrane, Barbara B.; Hunt, Julie R.; Ludlam, Shari E.; Pettinger, Mary B.; Gass, Margery; Margolis, Karen L.; Nathan, Lauren; Ockene, Judith K.; Prentice, Ross L.; Robbins, John; Stefanick, Marcia L.; Rossouw, J. E.; Ludlam, S.; Cochrane, B. B.; Hunt, J. R.; Lund, B.; Prentice, R.; Carr, J. J.; O'Rourke, C.; Du, L.; Pillsbury, S.; Hightower, C.; Ellison, R.; Tan, J.; Wassertheil-Smoller, S.; Magnani, M.; Noble, D. H.; Dellicarpini, T.; Manson, J. E.; Bueche, M.; McGinnis, A. D.; Rybicki, F. J.; Assaf, A. R.; Sloane, G.; Phillips, L. S.; Butler, V.; Huber, M.; Vitali, J.; Hsia, J.; LeBrun, C.; Palm, R.; Embersit, D.; Whitlock, E.; Arnold, K.; Sidney, S.; Cantrell, V.; Kotchen, J. M.; Feltz, C.; Howard, B. V.; Thomas-Geevarghese, A.; Boggs, G.; Jelinick, J. S.; Greenland, P.; Neuman, A.; Carlson-Lund, G.; Giovanazzi, S. M.; Stefanick, M. L.; Swope, S.; Jackson, R.; Toussant, K.; Lewis, C. E.; Pierce, P.; Stallings, C.; Wactawski-Wende, J.; Goel, S.; Laughlin, R.; Robbins, J.; Zaragoza, S.; Macias, D.; Belisle, D.; Nathan, L.; Voigt, B.; Goldin, J.; Woo, M.; Langer, R. D.; Allison, M. A.; Lien, X.; Wright, C. M.; Gass, M.; Sheridan, S.; Robinson, J. G.; Feddersen, D.; Kelly-Brake, K.; Carroll, J.; Ockene, J.; Churchill, L.; Lasser, N. L.; Miller, B.; Maldjian, P. D.; Pierre-Louis, J.; Fishman, J.; O'Sullivan, M. J.; Fernandez, D.; Margolis, K. L.; Bjerk, C. L.; Truwit, C.; Hearity, J. A.; Hyslop, W. B.; Darroch, K.; Murphy, C.; Heiss, G.; Kuller, L. H.; Edmundowicz, D.; Ives, D.; Johnson, K. C.; Satterfield, S.; Connelly, S. A.; Jones, E. L.; Brzyski, R.; Nashawati, M. A.; Torchia, S.; Rodriguez, A.; Garza, R.; Nentwich, P.; Sarto, G. E.; Broderick, L.; Sweitzer, N. K.; Nabel, E.; Rossouw, J. E.; Ludlam, S. E.; Pottern, L.; McGowan, J.; Ford, L.; Geller, N.; Prentice, R. L.; Anderson, G.; LaCroix, A.; Kooperberg, C. L.; Patterson, R. E.; McTiernan, A.; Shumaker, S.; Stein, E.; Cummings, S.; Wassertheil-Smoller, S.; Hays, J.; Manson, J. E.; Assaf, A. R.; Phillips, L.; Beresford, S.; Hsia, J.; Chlebowski, R.; Whitlock, E.; Caan, B.; Kotchen, J. M.; Howard, B. V.; Van Horn, L.; Black, H.; Stefanick, M. L.; Lane, D.; Jackson, R.; Lewis, C. E.; Bassford, T.; Wactawski-Wende, J.; Robbins, J.; Hubbell, F. A.; Judd, H.; Langer, R. D.; Gass, M.; Limacher, M.; Curb, D.; Wallace, R.; Ockene, J.; Lasser, N.; O'Sullivan, M. J.; Margolis, K. L.; Brunner, R.; Heiss, G.; Kuller, L. H.; Johnson, K. C.; Brzyski, R.; Sarto, G. E.; Bonds, D.; Hendrix, S.		WHI WHI-CACS Investigators	Estrogen therapy and coronary-artery calcification	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSTMENOPAUSAL HORMONE-THERAPY; REPLACEMENT THERAPY; COMPUTED-TOMOGRAPHY; HEART-DISEASE; CALCIUM; WOMEN; CT; ATHEROSCLEROSIS; QUANTIFICATION; ASSOCIATION	Background: Calcified plaque in the coronary arteries is a marker for atheromatous-plaque burden and is predictive of future risk of cardiovascular events. We examined the relationship between estrogen therapy and coronary-artery calcium in the context of a randomized clinical trial. Methods: In our ancillary substudy of the Women's Health Initiative trial of conjugated equine estrogens (0.625 mg per day) as compared with placebo in women who had undergone hysterectomy, we performed computed tomography of the heart in 1064 women aged 50 to 59 years at randomization. Imaging was conducted at 28 of 40 centers after a mean of 7.4 years of treatment and 1.3 years after the trial was completed (8.7 years after randomization). Coronary-artery calcium (or Agatston) scores were measured at a central reading center without knowledge of randomization status. Results: The mean coronary-artery calcium score after trial completion was lower among women receiving estrogen (83.1) than among those receiving placebo (123.1) (P=0.02 by rank test). After adjustment for coronary risk factors, the multivariate odds ratios for coronary-artery calcium scores of more than 0, 10 or more, and 100 or more in the group receiving estrogen as compared with placebo were 0.78 (95% confidence interval, 0.58 to 1.04), 0.74 (0.55 to 0.99), and 0.69 (0.48 to 0.98), respectively. The corresponding odds ratios among women with at least 80% adherence to the study estrogen or placebo were 0.64 (P=0.01), 0.55 (P<0.001), and 0.46 (P=0.001). For coronary-artery calcium scores of more than 300 (vs. <10), the multivariate odds ratio was 0.58 (P=0.03) in an intention-to-treat analysis and 0.39 (P=0.004) among women with at least 80% adherence. Conclusions: Among women 50 to 59 years old at enrollment, the calcified-plaque burden in the coronary arteries after trial completion was lower in women assigned to estrogen than in those assigned to placebo. However, estrogen has complex biologic effects and may influence the risk of cardiovascular events and other outcomes through multiple pathways. (ClinicalTrials.gov number, NCT00000611.).	Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA; Univ Calif San Diego, San Diego, CA 92103 USA; NHLBI, NIH, Bethesda, MD 20892 USA; Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA; Geisinger Hlth Syst, Danville, PA USA; George Washington Univ, Washington, DC USA; Univ Pittsburgh, Pittsburgh, PA USA; Univ Washington, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Cincinnati, Cincinnati, OH USA; Healthpartners Res Fdn, Minneapolis, MN USA; Univ Minnesota, Minneapolis, MN USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ Massachusetts, Sch Med, Worcester, MA USA; Univ Calif Davis, Sacramento, CA 95817 USA; Stanford Univ, Palo Alto, CA 94304 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Wake Forest University; Geisinger Health System; George Washington University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University System of Ohio; University of Cincinnati; HealthPartners Institute for Education & Research; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California Los Angeles; University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Davis; Stanford University	Manson, JE (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med, 900 Commonwealth Ave E,3rd Fl, Boston, MA 02215 USA.	jmanson@rics.bwh.harvard.edu	Truwit, Charles/AAL-7140-2021; Greenland, Philip/ABD-5528-2021; Wactawski-Wende, Jean/AGH-5457-2022; Carr, John/AAN-7531-2021	Truwit, Charles/0000-0001-8598-9812; Wactawski-Wende, Jean/0000-0003-3096-9595; Carr, John/0000-0002-4398-8237; Margolis, Karen/0000-0003-1862-7402; Allison, Matthew/0000-0003-0777-8272				AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T; Akhrass F, 2003, J CLIN ENDOCR METAB, V88, P5611, DOI 10.1210/jc.2003-031008; Allison MA, 2004, ARTERIOSCL THROM VAS, V24, P331, DOI 10.1161/01.ATV.0000110786.02097.0c; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2003, ANN EPIDEMIOL, V13, pS5, DOI 10.1016/S1047-2797(03)00043-7; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Arad Y, 2000, J AM COLL CARDIOL, V36, P1253, DOI 10.1016/S0735-1097(00)00872-X; Barrett-Connor E, 2005, MENOPAUSE, V12, P40, DOI 10.1097/00042192-200512010-00009; Budoff MJ, 2006, CIRCULATION, V114, P1761, DOI 10.1161/CIRCULATIONAHA.106.178458; Budoff MJ, 2005, J WOMENS HEALTH, V14, P410, DOI 10.1089/jwh.2005.14.410; Carr JJ, 2005, RADIOLOGY, V234, P35, DOI 10.1148/radiol.2341040439; Carr JJ, 2000, AM J ROENTGENOL, V174, P915, DOI 10.2214/ajr.174.4.1740915; Chae CU, 2004, CLIN TRIALS HEART DI, P349; Cheng YLJ, 2003, AM J CARDIOL, V92, P498, DOI 10.1016/S0002-9149(03)00714-8; Detrano RC, 2005, RADIOLOGY, V236, P477, DOI 10.1148/radiol.2362040513; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Greenland P, 2004, JAMA-J AM MED ASSOC, V291, P210, DOI 10.1001/jama.291.2.210; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 2003, NEW ENGL J MED, V348, P645, DOI 10.1056/NEJMsb022365; Han C, 2004, STAT MED, V23, P3671, DOI 10.1002/sim.1925; Harman SM, 2005, CLIMACTERIC, V8, P3, DOI 10.1080/13697130500042417; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hsia, 2006, ARCH INTERN MED, V166, P759; Hsia J, 2006, ARCH INTERN MED, V166, P357, DOI 10.1001/archinte.166.3.357; Manson JE, 2006, MENOPAUSE, V13, P139, DOI 10.1097/01.gme.0000177906.94515.ff; MAUTNER GC, 1994, RADIOLOGY, V192, P619, DOI 10.1148/radiology.192.3.8058924; Mendelsohn ME, 2005, SCIENCE, V308, P1583, DOI 10.1126/science.1112062; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Mikkola TS, 2002, CARDIOVASC RES, V53, P605, DOI 10.1016/S0008-6363(01)00466-7; *NAT I AG, 2007, ELITE EARL VERS LAT; Phillips LS, 2005, FERTIL STERIL, V83, P558, DOI 10.1016/j.fertnstert.2004.11.012; Raggi P, 2004, J AM COLL CARDIOL, V43, P1663, DOI 10.1016/j.jacc.2003.09.068; Robins JM, 2000, BIOMETRICS, V56, P779, DOI 10.1111/j.0006-341X.2000.00779.x; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rumberger JA, 1996, MAYO CLIN PROC, V71, P369, DOI 10.4065/71.4.369; Sangiorgi G, 1998, J AM COLL CARDIOL, V31, P126, DOI 10.1016/S0735-1097(97)00443-9; Schisterman EF, 2002, J WOMEN HEALTH GEN-B, V11, P631, DOI 10.1089/152460902760360577; Stary HC, 2001, AM J CARDIOL, V88, p16E; Stefanick ML, 2003, ANN EPIDEMIOL, V13, pS78, DOI 10.1016/S1047-2797(03)00045-0; Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432	40	519	547	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2007	356	25					2591	2602		10.1056/NEJMoa071513	http://dx.doi.org/10.1056/NEJMoa071513			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180GN	17582069				2023-01-03	WOS:000247351200006
J	Beral, V; Bull, D; Green, J; Reeves, G				Beral, Valerie; Bull, Diana; Green, Jane; Reeves, Gillian		Million Women Study Collaborators	Ovarian cancer and hormone replacement therapy in the Million Women Study	LANCET			English	Article							NONCONTRACEPTIVE ESTROGEN USE; RISK; HEALTH	Background Ovarian cancer is the fourth most common cancer in women in the UK, with about 6700 developing the malignancy and 4600 dying from it every year. However, there is limited information about the risk of ovarian cancer associated with the use of hormone replacement therapy (HRT). Methods 948 576 postmenopausal women from the UK Million Women Study who did not have previous cancer or bilateral oophorectomy were followed-up for an average of 5.3 years for incident ovarian cancer and 6.9 years for death. Information on HRT use was obtained at recruitment and updated where possible. Relative risks for ovarian cancer were calculated, stratified by age and hysterectomy status, and adjusted by area of residence, socioeconomic group, time since menopause, parity; body-mass index, alcohol consumption, and use of oral contraceptives. Findings When they last reported HRT use, 287143 women (30%) were current users and 186 751 (20%) were past users. During follow-up, 2273 incident ovarian cancers and 15 91 deaths from the malignancy were recorded. Current users were significantly more likely to develop and die from ovarian cancer than never users (relative risk 1.20 [95% Cl 1.09-1.32; p=0.0002] for incident disease and 1.23 [1.09-1.38; p=0.0006] for death). For current users of HRT incidence of ovarian cancer increased with increasing duration of use, but did not differ significantly by type of preparation used, its constituents, or mode of administration. Risks associated with HRT varied significantly according to tumour histology (p < 0.0001), and in women with epithelial tumours the relative risk for current versus never use of HRT was greater for serous than for mucinous, endometroid, or clear cell tumours (1.53 [1.31-1.79], 0.72 [0.52-1.00], 1.05 [0.77-1.43], or 0.77 [0.48-1.23], respectively). Past users of HRT were not at an increased risk of ovarian cancer (0.98 [0.88-1.11] and 0.97 [0.84-1.11], respectively, for incident and fatal disease). Over 5 years, the standardised. incidence rates for ovarian cancer in current and never users of HRT were 2.6 (2.4-2.9) and 2.2 (2.1-2.3) per 1000, respectively-ie, one extra ovarian cancer in roughly 2500 users; death rates were 1.6 (1.4-1.8) and 1.3 (1.2-1.4) per 1000, respectively-ie, one extra ovarian cancer death in roughly 3300 users. Interpretation Women who use HRT are at an increased risk of both incident and fatal ovarian cancer. Since 1991, use of HRT has resulted in some 1300 additional ovarian cancers and 1000 additional deaths from the malignancy in the UK.	Mill Women Study Coordinating Ctr, Canc Res UK Epidemiol Unit, Oxford OX3 7LF, England	Cancer Research UK; University of Oxford	Beral, V (corresponding author), Mill Women Study Coordinating Ctr, Canc Res UK Epidemiol Unit, Richard Doll Bldg,Roosevelt Dr, Oxford OX3 7LF, England.	pa.valerie.beral@ceu.ox.ac.uk			MRC [G0700474] Funding Source: UKRI; Medical Research Council [G0700474] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739; Bakken L, 2004, INT J CANCER, V112, P130, DOI 10.1002/ijc.20389; Banks E, 2001, J Epidemiol Biostat, V6, P357; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Beral V, 2005, LANCET, V365, P1543, DOI 10.1016/S0140-6736(05)66455-0; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Beral V, 1999, J Epidemiol Biostat, V4, P191; BOSETTI C, 2001, JAMA-J AM MED ASSOC, V285, P308; Folsom AR, 2004, EPIDEMIOLOGY, V15, P100, DOI 10.1097/01.ede.0000091606.31903.8e; Glud E, 2004, ARCH INTERN MED, V164, P2253, DOI 10.1001/archinte.164.20.2253; HARTGE P, 1988, AM J EPIDEMIOL, V127, P990, DOI 10.1093/oxfordjournals.aje.a114902; Hempling RE, 1997, OBSTET GYNECOL, V89, P1012, DOI 10.1016/S0029-7844(97)00118-X; *IARC, 1999, IARC MON EV CARC RIS, V72; KAUFMAN DW, 1989, AM J EPIDEMIOL, V130, P1142, DOI 10.1093/oxfordjournals.aje.a115441; Lacey JV, 2006, JNCI-J NATL CANCER I, V98, P1397, DOI 10.1093/jnci/djj375; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; LAVECCHIA C, 1982, J NATL CANCER I, V69, P1207; LUNN M, 1995, BIOMETRICS, V51, P524, DOI 10.2307/2532940; Pike MC, 2004, FERTIL STERIL, V82, P186, DOI 10.1016/j.fertnstert.2004.03.013; Purdie DM, 1999, BRIT J CANCER, V81, P559, DOI 10.1038/sj.bjc.6690731; Reeves GK, 2006, LANCET ONCOL, V7, P910, DOI 10.1016/S1470-2045(06)70911-1; Riman T, 2002, JNCI-J NATL CANCER I, V94, P497, DOI 10.1093/jnci/94.7.497; Risch HA, 1996, GYNECOL ONCOL, V63, P254, DOI 10.1006/gyno.1996.0315; Risch HA, 1996, AM J EPIDEMIOL, V144, P363, DOI 10.1093/oxfordjournals.aje.a008937; Rodriguez C, 2001, JAMA-J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460; The Million Women Study Collaborative Group, 1999, BREAST CANCER RES, V1, P73, DOI DOI 10.1186/BCR16; WEISS NS, 1982, J NATL CANCER I, V68, P95; World Health Organization, 2022, INT CLASS DIS, V11th	28	298	314	1	29	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 20	2007	369	9574					1703	1710		10.1016/S0140-6736(07)60534-0	http://dx.doi.org/10.1016/S0140-6736(07)60534-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	169ZT	17512855				2023-01-03	WOS:000246631300026
J	Dhanasekaran, DN; Johnson, GL				Dhanasekaran, D. N.; Johnson, G. L.			MAPKs: function, regulation, role in cancer and therapeutic targeting	ONCOGENE			English	Editorial Material									Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Johnson, GL (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA.	glj@med.unc.edu							0	88	90	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3097	3099		10.1038/sj.onc.1210395	http://dx.doi.org/10.1038/sj.onc.1210395			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496908	Bronze			2023-01-03	WOS:000246603600001
J	Janssen, JP; Collier, G; Astoul, P; Tassi, GF; Noppen, M; Rodriguez-Panadero, F; Loddenkemper, R; Herth, FJF; Gasparani, S; Marquette, CH; Becke, B; Froudarakis, ME; Driesen, P; Bolliger, CT; Tschopp, JM				Janssen, Julius P.; Collier, Gareth; Astoul, Phillippe; Tassi, Gian Franco; Noppen, Marc; Rodriguez-Panadero, Francisco; Loddenkemper, Robert; Herth, Felix J. F.; Gasparani, Stefano; Marquette, Charles H.; Becke, Birgit; Froudarakis, Marios E.; Driesen, Peter; Bolliger, Chris T.; Tschopp, Jean-Marie			Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study	LANCET			English	Article							RESPIRATORY-FAILURE; SLURRY PLEURODESIS; PARTICLE-SIZE; THORACOSCOPY; EXPERIENCE; RATS	Background Talc is the most effective chemical pleurodesis agent for patients with malignant pleural effusion. However, concerns have arisen about the safety of intrapleural application of talc, after reports of development of acute respiratory distress syndrome in 1-9% of treated patients. Our aim was to establish whether use of large-particle-size talc is safe in patients with malignant pleural effusion. Methods We did a multicentre, open-label, prospective cohort study of 558 patients with malignant pleural effusion who underwent thoracoscopy and talc poudrage with 4 g of calibrated French large-particle talc in 13 European hospitals, and one in South Africa. The primary endpoint was the occurrence of acute respiratory distress syndrome after talc pleurodesis. Findings No patients developed acute respiratory distress syndrome (frequency 0%, one-sided 95% Cl 0-0.54%). 11 (2%) patients died within 30 days. Additionally, seven patients had non-fatal post-thoracoscopy complications (1.2%), including one case of respiratory failure due to unexplained bilateral pneumothorax. Interpretation Use of large-particle talc for pleurodesis in malignant pleural effusion is safe, and not associated with the development of acute respiratory distress syndrome.	Canisius Wilhelmina Hosp, Dept Pulm Dis B01, NL-6500 GS Nijmegen, Netherlands; Hop St Marguerite, Marseille, France; Spedali Civil Brescia, I-25125 Brescia, Italy; Univ Hosp UZ Brussels, Brussels, Belgium; Hosp Univ Virgen Rocio Sevilla, Seville, Spain; Lungenklin Heckeshorn, Berlin, Germany; Univ Heidelberg, Thoraxklin, Heidelberg, Germany; Azienda Osped Riuniti, Ancona, Italy; Ctr Hosp Reg Univ Lille, Lille, France; Johanniter Krankenhaus, Treuenbrietzen, Germany; Univ Hosp Heraklion, Iraklion, Crete, Greece; St Elizabeth Hosp, Turnhout, Belgium; Tygerberg Acad Hosp, Cape Town, South Africa; Ctr Valaisan Pneumol, Montana, Switzerland	Canisius-Wilhelmina Hospital; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Hospital Spedali Civili Brescia; University Hospital Brussels; Virgen del Rocio University Hospital; Ruprecht Karls University Heidelberg; Universite de Lille - ISITE; CHU Lille; University Hospital of Heraklion	Janssen, JP (corresponding author), Canisius Wilhelmina Hosp, Dept Pulm Dis B01, Postbox 9015, NL-6500 GS Nijmegen, Netherlands.	j.janssen@cwz.nl	RODRIGUEZ-PANADERO, FRANCISCO/E-5832-2012; Marquette, Charles Hugo/O-4084-2016; IBIS, ENF. RESPIRATO/P-3887-2015	RODRIGUEZ-PANADERO, FRANCISCO/0000-0002-9640-7926; Marquette, Charles Hugo/0000-0002-0846-9941; Driesen, Peter/0000-0002-8509-8750				AELONY Y, 1991, ANN INTERN MED, V115, P778, DOI 10.7326/0003-4819-115-10-778; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bethune N, 1935, J THORAC SURG, V4, P251, DOI [10.1016/S0096-5588(20)32384-9, DOI 10.1016/S0096-5588(20)32384-9]; BRESTICKER MA, 1993, ANN THORAC SURG, V55, P364, DOI 10.1016/0003-4975(93)90998-W; Campos JRM, 1997, LANCET, V349, P251, DOI 10.1016/S0140-6736(05)64860-X; Cardillo G, 2002, EUR J CARDIO-THORAC, V21, P302, DOI 10.1016/S1010-7940(01)01130-7; de Campos JRM, 2001, CHEST, V119, P801, DOI 10.1378/chest.119.3.801; Ferrer J, 2002, CHEST, V122, P1018, DOI 10.1378/chest.122.3.1018; Ferrer J, 2001, CHEST, V119, P1901, DOI 10.1378/chest.119.6.1901; Fraticelli A, 2002, CHEST, V122, P1737, DOI 10.1378/chest.122.5.1737; Froudarakis ME, 2006, CHEST, V129, P356, DOI 10.1378/chest.129.2.356; HAUPT GJ, 1960, JAMA-J AM MED ASSOC, V73, P173; Janssen J P, 2004, Monaldi Arch Chest Dis, V61, P35; JANSSEN JP, 1994, EUR RESPIR J, V7, P1281, DOI 10.1183/09031936.94.07071281; JIMENEZ GN, 2005, NEUMOSUR, V17, P197; KENNEDY L, 1995, CHEST, V107, P1707, DOI 10.1378/chest.107.6.1707; KENNEDY L, 1994, CHEST, V106, P342, DOI 10.1378/chest.106.2.342; Maskell NA, 2004, AM J RESP CRIT CARE, V170, P377, DOI 10.1164/rccm.200311-1579OC; MATHLOUTHI A, 1992, REV MAL RESPIR, V9, P617; Rehse DH, 1999, AM J SURG, V177, P437, DOI 10.1016/S0002-9610(99)00075-6; RINALDO JE, 1983, J THORAC CARDIOV SUR, V85, P523; Rodriguez-Panadero F, 2006, EUR RESPIR J, V28, P409, DOI 10.1183/09031936.06.00013706; Sahn SA, 2000, AM J RESP CRIT CARE, V162, P2023, DOI 10.1164/ajrccm.162.6.pc09-00a; Sahn SA, 2002, J BRONCHOLOGY, V9, P223; Viallat JR, 1996, CHEST, V110, P1387, DOI 10.1378/chest.110.6.1387; WALKERRENARD PB, 1994, ANN INTERN MED, V120, P56, DOI 10.7326/0003-4819-120-1-199401010-00010; WEISSBERG D, 1993, J THORAC CARDIOV SUR, V106, P689, DOI 10.1016/S0022-5223(19)33712-2; Werebe EC, 1999, CHEST, V115, P190, DOI 10.1378/chest.115.1.190	28	207	214	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 5	2007	369	9572					1535	1539		10.1016/S0140-6736(07)60708-9	http://dx.doi.org/10.1016/S0140-6736(07)60708-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164EI	17482984				2023-01-03	WOS:000246215800027
J	Wheeler, AP; Bernard, GR				Wheeler, Arthur P.; Bernard, Gordon R.			Acute lung injury and the acute respiratory distress syndrome: a clinical review	LANCET			English	Review							INHALED NITRIC-OXIDE; POSITIVE-PRESSURE VENTILATION; END-EXPIRATORY PRESSURE; TIDAL VOLUME VENTILATION; CRITICALLY-ILL PATIENTS; FREQUENCY OSCILLATORY VENTILATION; EXTRACORPOREAL CO2 REMOVAL; PARTIAL LIQUID VENTILATION; HIGH-DOSE CORTICOSTEROIDS; GAMMA-LINOLENIC ACID	Acute respiratory distress syndrome and acute lung injury are well defined and readily recognised clinical disorders caused by many clinical insults to the lung or because of predispositions to lung injury. That this process is common in intensive care is well established. The mainstay of treatment for this disorder is provision of excellent supportive care since these patients are critically ill and frequently have coexisting conditions including sepsis and multiple organ failure. Refinements in ventilator and fluid management supported by data from prospective randomised trials have increased the methods available to effectively manage this disorder.	Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Med Intens Care Unit, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Bernard, GR (corresponding author), Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA.	gordon.bernard@vanderbilt.edu						Abraham E, 1999, CRIT CARE MED, V27, P1478, DOI 10.1097/00003246-199908000-00013; Adhikari N, 2004, JAMA-J AM MED ASSOC, V291, P1629, DOI 10.1001/jama.291.13.1629; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Antonelli M, 1998, NEW ENGL J MED, V339, P429, DOI 10.1056/NEJM199808133390703; Anzueto A, 1996, NEW ENGL J MED, V334, P1417, DOI 10.1056/NEJM199605303342201; ARDS Clinical Trials Network, 2003, CRIT CARE MED, V31, P2592, DOI 10.1097/01.CCM.0000090001.91640.45; Arroliga AC, 2002, CHEST, V121, P1972, DOI 10.1378/chest.121.6.1972; ASHBAUGH DG, 1967, LANCET, V2, P319; ASHBAUGH DG, 1985, ARCH SURG-CHICAGO, V120, P530; Attia J, 2001, ARCH INTERN MED, V161, P1268, DOI 10.1001/archinte.161.10.1268; Bernard GR, 2000, JAMA-J AM MED ASSOC, V283, P2568, DOI 10.1001/jama.283.19.2568; Bernard GR, 1997, CHEST, V112, P164, DOI 10.1378/chest.112.1.164; BERNARD GR, 1987, NEW ENGL J MED, V317, P1565, DOI 10.1056/NEJM198712173172504; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BO G, 1977, J APPL PHYSIOL, V42, P476, DOI 10.1152/jappl.1977.42.4.476; BONE RC, 1987, CHEST, V92, P1032, DOI 10.1378/chest.92.6.1032; BONE RC, 1978, CRIT CARE MED, V6, P136, DOI 10.1097/00003246-197805000-00002; BRIGHAM KL, 1974, J CLIN INVEST, V54, P792, DOI 10.1172/JCI107819; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; Brochard L, 1999, CRIT CARE MED, V27, P1661, DOI 10.1097/00003246-199908000-00055; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; Brower RG, 1999, CRIT CARE MED, V27, P1492, DOI 10.1097/00003246-199908000-00015; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Brower RG, 2002, AM J RESP CRIT CARE, V166, P1515, DOI 10.1164/ajrccm.166.11.340; BROWER RG, 2003, AM J RESP CRIT CARE, V167, pA616; BRUNET F, 1993, CHEST, V104, P889, DOI 10.1378/chest.104.3.889; Carmichael LC, 2003, AM J RESP CRIT CARE, V167, P933, DOI 10.1164/ajrccm.167.6.950; Carmichael LC, 1996, J CRIT CARE, V11, P9, DOI 10.1016/S0883-9441(96)90015-5; Chatte G, 1997, AM J RESP CRIT CARE, V155, P473, DOI 10.1164/ajrccm.155.2.9032181; Cheng IW, 2005, CRIT CARE MED, V33, P63, DOI 10.1097/01.CCM.0000149836.76063.71; Cook DJ, 2002, CRIT CARE MED, V30, P1472, DOI 10.1097/00003246-200207000-00012; Crotti S, 2001, AM J RESP CRIT CARE, V164, P131, DOI 10.1164/ajrccm.164.1.2007011; Davey-Quinn A, 1999, ANAESTH INTENS CARE, V27, P357, DOI 10.1177/0310057X9902700404; Davidson TA, 1999, JAMA-J AM MED ASSOC, V281, P354, DOI 10.1001/jama.281.4.354; de Durante G, 2002, AM J RESP CRIT CARE, V165, P1271, DOI 10.1164/rccm.2105050; Dellinger RP, 1998, CRIT CARE MED, V26, P15, DOI 10.1097/00003246-199801000-00011; Dellinger RP, 2000, CRIT CARE MED, V28, P572, DOI 10.1097/00003246-200002000-00050; Dellinger RP, 1999, INTENS CARE MED, V25, P881, DOI 10.1007/s001340050973; Derdak S, 2002, AM J RESP CRIT CARE, V166, P801, DOI 10.1164/rccm.2108052; DOUGLAS WW, 1977, AM REV RESPIR DIS, V115, P559; Dube DS, 2005, CHEST, V127, P683, DOI 10.1378/chest.127.2.683; Eichacker PQ, 2002, AM J RESP CRIT CARE, V166, P1510, DOI 10.1164/rccm.200208-956OC; EISENBERG PR, 1987, AM REV RESPIR DIS, V136, P662, DOI 10.1164/ajrccm/136.3.662; Eisner MD, 2001, AM J RESP CRIT CARE, V164, P231, DOI 10.1164/ajrccm.164.2.2011093; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; Ely EW, 2002, ANN INTERN MED, V136, P25, DOI 10.7326/0003-4819-136-1-200201010-00007; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Esteban A, 2000, AM J RESP CRIT CARE, V161, P1450, DOI 10.1164/ajrccm.161.5.9902018; FALKE KJ, 1972, J CLIN INVEST, V51, P2315, DOI 10.1172/JCI107042; Ferguson ND, 2005, CRIT CARE MED, V33, P479, DOI 10.1097/01.CCM.0000155785.23200.9E; Foti G, 2000, INTENS CARE MED, V26, P501, DOI 10.1007/s001340051196; Frank JA, 2002, AM J RESP CRIT CARE, V165, P242, DOI 10.1164/ajrccm.165.2.2108087; Gadek JE, 1999, CRIT CARE MED, V27, P1409, DOI 10.1097/00003246-199908000-00001; Gajic O, 2004, CRIT CARE MED, V32, P1817, DOI 10.1097/01.CCM.0000133019.52531.30; GATTINONI L, 1987, AM REV RESPIR DIS, V136, P730, DOI 10.1164/ajrccm/136.3.730; Gattinoni L, 2001, NEW ENGL J MED, V345, P568, DOI 10.1056/NEJMoa010043; GATTINONI L, 1994, JAMA-J AM MED ASSOC, V271, P1772, DOI 10.1001/jama.271.22.1772; GATTINONI L, 1986, JAMA-J AM MED ASSOC, V256, P881, DOI 10.1001/jama.256.7.881; GATTINONI L, 1988, ANESTHESIOLOGY, V69, P824, DOI 10.1097/00000542-198812000-00005; Gattinoni L, 1998, AM J RESP CRIT CARE, V158, P3, DOI 10.1164/ajrccm.158.1.9708031; Goss CH, 2003, CRIT CARE MED, V31, P1607, DOI 10.1097/01.CCM.0000063475.65751.1D; Grasso S, 2002, ANESTHESIOLOGY, V96, P795, DOI 10.1097/00000542-200204000-00005; Greene KE, 1999, AM J RESP CRIT CARE, V160, P1843, DOI 10.1164/ajrccm.160.6.9901117; Guerin C, 2004, JAMA-J AM MED ASSOC, V292, P2379, DOI 10.1001/jama.292.19.2379; Gunther A, 2000, AM J RESP CRIT CARE, V161, P454; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; HEFFNER JE, 1995, AM JR ESP CRIT CARE, V159, P1849; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; HICKLING KG, 1994, CRIT CARE MED, V22, P1568, DOI 10.1097/00003246-199422100-00011; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; Hirschl RB, 2002, AM J RESP CRIT CARE, V165, P781, DOI 10.1164/ajrccm.165.6.2003052; Hirschl RB, 1996, JAMA-J AM MED ASSOC, V275, P383, DOI 10.1001/jama.275.5.383; HOOPER RG, 1990, CHEST, V97, P138, DOI 10.1378/chest.97.1.138; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; Hough CL, 2005, CRIT CARE MED, V33, P527, DOI 10.1097/01.ccm.0000155782.86244.42; HUMPHREY H, 1990, CHEST, V97, P1176, DOI 10.1378/chest.97.5.1176; Idell S, 2003, CRIT CARE MED, V31, pS213, DOI 10.1097/01.CCM.0000057846.21303.AB; JARDIN F, 1990, ANESTHESIOLOGY, V72, P966, DOI 10.1097/00000542-199006000-00003; JEPSEN S, 1992, CRIT CARE MED, V20, P918, DOI 10.1097/00003246-199207000-00004; Johannigman JA, 2003, J TRAUMA, V54, P320, DOI 10.1097/01.TA.0000043923.19107.B6; Kollef MH, 1997, CRIT CARE MED, V25, P567, DOI 10.1097/00003246-199704000-00004; KOLOBOW T, 1987, AM REV RESPIR DIS, V135, P312; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; LAMM WJE, 1994, AM J RESP CRIT CARE, V150, P184, DOI 10.1164/ajrccm.150.1.8025748; Lapinsky SE, 1999, INTENS CARE MED, V25, P1297, DOI 10.1007/s001340051061; LESSARD MR, 1994, ANESTHESIOLOGY, V80, P983, DOI 10.1097/00000542-199405000-00006; LUCE JM, 1988, AM REV RESPIR DIS, V138, P62, DOI 10.1164/ajrccm/138.1.62; Luhr OR, 1999, AM J RESP CRIT CARE, V159, P1849, DOI 10.1164/ajrccm.159.6.9808136; Lundin S, 1999, INTENS CARE MED, V25, P911, DOI 10.1007/s001340050982; Mancebo J, 2003, INTENS CARE MED, V29, pS64; Mangialardi RJ, 2000, CRIT CARE MED, V28, P3137, DOI 10.1097/00003246-200009000-00001; Marelich GP, 2000, CHEST, V118, P459, DOI 10.1378/chest.118.2.459; Marshall RP, 2002, CHEST, V121, p68S, DOI 10.1378/chest.121.3_suppl.68S; Martin GS, 2002, CRIT CARE MED, V30, P2175, DOI 10.1097/00003246-200210000-00001; Matthay MA, 2004, CRIT CARE MED, V32, pS229, DOI 10.1097/01.CCM.0000126121.56990.D3; MATTHAY MA, 1994, SEMIN RESP CRIT CARE, V15, P271, DOI 10.1055/s-2007-1006373; Matthay MA, 1998, CRIT CARE MED, V26, P1, DOI 10.1097/00003246-199801000-00001; MAUNDER RJ, 1986, JAMA-J AM MED ASSOC, V255, P2463, DOI 10.1001/jama.255.18.2463; McIntyre RC, 2000, CRIT CARE MED, V28, P3314, DOI 10.1097/00003246-200009000-00034; Meade MO, 2004, CRIT CARE MED, V32, P946, DOI 10.1097/01.CCM.0000120056.76356.AD; MEDURI GU, 1994, CHEST, V105, P1516, DOI 10.1378/chest.105.5.1516; Meduri GU, 1998, JAMA-J AM MED ASSOC, V280, P159, DOI 10.1001/jama.280.2.159; MEDURI GU, 1991, CHEST, V100, P943, DOI 10.1378/chest.100.4.943; Mehta S, 2001, CRIT CARE MED, V29, P1360, DOI 10.1097/00003246-200107000-00011; Messerole E, 2002, AM J RESP CRIT CARE, V165, P1359, DOI 10.1164/rccm.2107005; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; MITCHELL JP, 1992, AM REV RESPIR DIS, V145, P990, DOI 10.1164/ajrccm/145.5.990; Monchi M, 1998, AM J RESP CRIT CARE, V158, P1076, DOI 10.1164/ajrccm.158.4.9802009; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MONTRAVERS P, 1993, CHEST, V103, P1017, DOI 10.1378/chest.103.4.1017; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; Moss M, 1996, JAMA-J AM MED ASSOC, V275, P50, DOI 10.1001/jama.275.1.50; Nakos G, 2000, AM J RESP CRIT CARE, V161, P360, DOI 10.1164/ajrccm.161.2.9810037; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pacht ER, 2003, CRIT CARE MED, V31, P491, DOI 10.1097/01.CCM.0000049952.96496.3E; Parsons PE, 2005, CRIT CARE MED, V33, P1, DOI 10.1097/01.CCM.0000149854.61192.DC; Patroniti N, 2003, CRIT CARE, V7, P105, DOI 10.1186/cc1883; Pelosi P, 1998, AM J RESP CRIT CARE, V157, P387, DOI 10.1164/ajrccm.157.2.97-04023; PEPE PE, 1984, NEW ENGL J MED, V311, P281, DOI 10.1056/NEJM198408023110502; PETTY TL, 1990, DM-DIS MON, V36, P3; Petty TL, 2003, AM J RESP CRIT CARE, V167, P933; PONTOPPIDAN H, 1972, NEW ENGL J MED, V287, P799, DOI 10.1056/NEJM197210192871605; RADERMACHER P, 1990, ANESTHESIOLOGY, V72, P238, DOI 10.1097/00000542-199002000-00005; RANERI VM, 1999, JAMA-J AM MED ASSOC, V282, P54; RASANEN J, 1991, CRIT CARE MED, V19, P1234; Ricard JD, 2003, AM J RESP CRIT CARE, V167, P1297, DOI 10.1164/rccm.2303003; Rice TW, 2005, NUTRITION, V21, P786, DOI 10.1016/j.nut.2004.11.014; Richard C, 2003, JAMA-J AM MED ASSOC, V290, P2713, DOI 10.1001/jama.290.20.2713; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Rizvi K, 2005, CRIT CARE MED, V33, P98, DOI 10.1097/01.CCM.0000150650.70142.E9; Rubenfeld GD, 1999, CHEST, V116, P1347, DOI 10.1378/chest.116.5.1347; Rubenfeld GD, 2004, CRIT CARE MED, V32, P1289, DOI 10.1097/01.CCM.0000127266.39560.96; Schwarz MI, 2004, CHEST, V125, P1530, DOI 10.1378/chest.125.4.1530; SHAPIRO BA, 1984, CRIT CARE MED, V12, P127, DOI 10.1097/00003246-198402000-00011; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SPRAGG RG, 1994, CHEST, V105, P195, DOI 10.1378/chest.105.1.195; Spragg RG, 2004, NEW ENGL J MED, V351, P884, DOI 10.1056/NEJMoa033181; Spragg RG, 2003, AM J RESP CRIT CARE, V167, P1562, DOI 10.1164/rccm.200207-782OC; SPRUNG CL, 1984, NEW ENGL J MED, V311, P1137, DOI 10.1056/NEJM198411013111801; Steinberg KP, 2006, NEW ENGL J MED, V354, P1671; STEWART T, 2002, AM J RESP CRIT CARE, V166, P1510; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; Stocker R, 1997, CHEST, V111, P1008, DOI 10.1378/chest.111.4.1008; Suchyta MR, 2003, CHEST, V124, P1871, DOI 10.1378/chest.124.5.1871; SUCHYTA MR, 1993, RESPIRATION, V60, P103; Taylor RW, 2004, JAMA-J AM MED ASSOC, V291, P1603, DOI 10.1001/jama.291.13.1603; Thompson BT, 2001, CHEST, V120, P1622, DOI 10.1378/chest.120.5.1622; THOMSEN GE, 1995, AM J RESP CRIT CARE, V152, P965, DOI 10.1164/ajrccm.152.3.7663811; Tobin MJ, 2000, NEW ENGL J MED, V342, P1360, DOI 10.1056/NEJM200005043421808; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Troncy E, 1998, AM J RESP CRIT CARE, V157, P1483, DOI 10.1164/ajrccm.157.5.9707090; TSUNO K, 1990, J APPL PHYSIOL, V69, P956, DOI 10.1152/jappl.1990.69.3.956; Valta P, 1999, CRIT CARE MED, V27, P2367, DOI 10.1097/00003246-199911000-00008; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Villagra A, 2002, AM J RESP CRIT CARE, V165, P165, DOI 10.1164/ajrccm.165.2.2104092; Walmrath D, 2002, EUR RESPIR J, V19, P805, DOI 10.1183/09031936.02.00243402; Walmrath D, 1996, AM J RESP CRIT CARE, V154, P57, DOI 10.1164/ajrccm.154.1.8680699; WANG BM, 1996, AM J RESP CRIT CARE, V154, pA392; Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; WEG JG, 1994, JAMA-J AM MED ASSOC, V272, P1433, DOI 10.1001/jama.272.18.1433; Weg JG, 1998, NEW ENGL J MED, V338, P341, DOI 10.1056/NEJM199802053380601; WEIGELT JA, 1985, ARCH SURG-CHICAGO, V120, P536; Weinert CR, 2003, AM J RESP CRIT CARE, V167, P1304, DOI 10.1164/rccm.200205-478OC; WEINERT GR, 1987, AM REV RESPIR DIS, V156, P1120; Wheeler A, 1998, JAMA-J AM MED ASSOC, V280, P2074, DOI 10.1001/jama.280.24.2074; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; Wiedemann HP, 2000, JAMA-J AM MED ASSOC, V283, P1995; Wiedemann HP, 2002, CRIT CARE MED, V30, P1; Wiswell TE, 1999, AM J RESP CRIT CARE, V160, P1188, DOI 10.1164/ajrccm.160.4.9808118; Wongsurakiat P, 2004, CHEST, V126, P1281, DOI 10.1378/chest.126.4.1281; WRIGHT PE, 1994, CHEST, V106, P1517, DOI 10.1378/chest.106.5.1517; Young MP, 2004, CRIT CARE MED, V32, P1260, DOI 10.1097/01.CCM.0000127784.54727.56; YU MH, 1993, CRIT CARE MED, V21, P830, DOI 10.1097/00003246-199306000-00009; YU MH, 1993, CRIT CARE MED, V21, P1635, DOI 10.1097/00003246-199311000-00010; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193; Zeiher BG, 2004, CRIT CARE MED, V32, P1695, DOI 10.1097/01.CCM.0000133332.48386.85; Zilberberg MD, 1998, AM J RESP CRIT CARE, V157, P1159, DOI 10.1164/ajrccm.157.4.9704088	181	617	695	2	81	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 5	2007	369	9572					1553	1564		10.1016/S0140-6736(07)60604-7	http://dx.doi.org/10.1016/S0140-6736(07)60604-7			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164EI	17482987				2023-01-03	WOS:000246215800030
J	Mercola, M				Mercola, Mark			Chemical probes of neural stem cell self-renewal	NATURE CHEMICAL BIOLOGY			English	Editorial Material							BREAST-CANCER; IDENTIFICATION	A chemical- genetic study indicates that modulation of neurotransmitter signaling affects the self- renewal capacity of neural stem cells in culture. Although the mechanisms of action are not resolved, the research points to a potential therapeutic target class for treatment of brain tumors.	Burnham Inst Med Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Mercola, M (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mmercola@burnham.org						Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Diamandis P, 2007, NAT CHEM BIOL, V3, P268, DOI 10.1038/nchembio873; Lalonde FM, 2003, BREAST, V12, P280, DOI 10.1016/S0960-9776(03)00061-4; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Owens DF, 2002, NEURON, V36, P989, DOI 10.1016/S0896-6273(02)01136-4; Pomeroy SL, 2004, NEURON GLIA BIOL, V1, P127, DOI 10.1017/S1740925X04000286; Singh SK, 2003, CANCER RES, V63, P5821	10	2	2	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450			NAT CHEM BIOL	Nat. Chem. Biol.	MAY	2007	3	5					246	247		10.1038/nchembio0507-246	http://dx.doi.org/10.1038/nchembio0507-246			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	159FP	17438546				2023-01-03	WOS:000245851100005
J	Ludwig, DS				Ludwig, David S.			Clinical update: the low-glycaemic-index diet	LANCET			English	Article							FAT; CARBOHYDRATE; GLUCOSE; WEIGHT; RISK		Childrens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital	Ludwig, DS (corresponding author), Childrens Hosp, Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.	david.ludwig@childrens.harvard.edu		Ludwig, David/0000-0003-3307-8544				Alfenas RCG, 2005, DIABETES CARE, V28, P2123, DOI 10.2337/diacare.28.9.2123; Brand-Miller J, 2003, DIABETES CARE, V26, P2261, DOI 10.2337/diacare.26.8.2261; Canadian Diabetes Association, 1999, CAN J DIABETES CARE, V23, P56; Chiasson Jean-Louis, 2006, Endocr Pract, V12 Suppl 1, P25; Connor H, 2003, DIABETIC MED, V20, P786, DOI 10.1046/j.1464-5491.2003.01104.x; EATON SB, 1985, NEW ENGL J MED, V312, P283, DOI 10.1056/NEJM198501313120505; Ebbeling C B, 2001, Adv Pediatr, V48, P179; Flint A, 2004, BRIT J NUTR, V91, P979, DOI 10.1079/BJN20041124; Foster-Powell K, 2002, AM J CLIN NUTR, V76, P5, DOI 10.1093/ajcn/76.1.5; Gardner CD, 2007, JAMA-J AM MED ASSOC, V297, P969, DOI 10.1001/jama.297.9.969; JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362; Lichtenstein AH, 2003, J WOMEN HEALTH GEN-B, V12, P109, DOI 10.1089/154099903321576493; Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414; Pawlak DB, 2004, LANCET, V364, P778, DOI 10.1016/S0140-6736(04)16937-7; Perlstein R., 1997, Australian Journal of Nutrition and Dietetics, V54, P57; Pittas AG, 2005, DIABETES CARE, V28, P2939, DOI 10.2337/diacare.28.12.2939; *UN FAO, 1997, JOINT FAO WHO EXP CO; Willett WC, 2002, AM J MED, V113, P47, DOI 10.1016/S0002-9343(01)00992-5; Wolever TMS, 1996, J NUTR, V126, P2807; WOLEVER TMS, 1991, AM J CLIN NUTR, V54, P846, DOI 10.1093/ajcn/54.5.846	20	36	36	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 17	2007	369	9565					890	892		10.1016/S0140-6736(07)60427-9	http://dx.doi.org/10.1016/S0140-6736(07)60427-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	148BQ	17368136				2023-01-03	WOS:000245049900010
J	Le Foll, B; Wertheim, C; Goldberg, SR				Le Foll, Bernard; Wertheim, Carrie; Goldberg, Steven R.			High Reinforcing Efficacy of Nicotine in Non-Human Primates	PLOS ONE			English	Article							CONDITIONED PLACE PREFERENCES; PROGRESSIVE RATIO SCHEDULE; ADMINISTER PURE NICOTINE; DOPAMINE D-3 RECEPTOR; MONOAMINE-OXIDASE; INTRAVENOUS NICOTINE; DRAMATICALLY INCREASES; FIXED-RATIO; BEHAVIOR; DRUG	Although tobacco appears highly addictive in humans, there has been persistent controversy about the ability of its psychoactive ingredient nicotine to induce self-administration behavior in laboratory animals, bringing into question nicotine's role in reinforcing tobacco smoking. Because of ethical difficulties in inducing nicotine dependence in naive human subjects, we explored reinforcing effects of nicotine in experimentally-naive non-human primates given access to nicotine for periods of time up to two years. Five squirrel monkeys with no experimental history were allowed to intravenously self-administer nicotine by pressing one of two levers. The number of presses on the active lever needed to obtain each injection was fixed (fixed-ratio schedule) or increased progressively with successive injections during the session (progressive-ratio schedule), allowing evaluation of both reinforcing and motivational effects of nicotine under conditions of increasing response cost. Over time, a progressive shift toward high rates of responding on the active lever, but not the inactive lever, developed. The monkeys' behavior was clearly directed toward nicotine self-administration, rather than presentation of environmental stimuli associated with nicotine injection. Both schedules of reinforcement revealed a high motivation to self-administer nicotine, with monkeys continuing to press the lever when up to 600 lever-presses were needed for each injection of nicotine. Thus, nicotine, by itself, in the absence of behavioral or drug-exposure history, is a robust and highly effective reinforcer of drug-taking behavior in a non-human primate model predictive of human behavior. This supports the use of nicotinic ligands for the treatment of smokers, and this novel preclinical model offers opportunities to test future medications for the treatment of nicotine dependence.	[Le Foll, Bernard; Wertheim, Carrie; Goldberg, Steven R.] NIDA, Preclin Pharmacol Sect, NIH, Dept Hlth & Human Serv, Baltimore, MD 20892 USA; [Le Foll, Bernard] Ctr Addict & Mental Hlth, Translat Addict Res Lab, Toronto, ON, Canada; [Le Foll, Bernard] Univ Toronto, Toronto, ON, Canada	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA); University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto	Le Foll, B (corresponding author), NIDA, Preclin Pharmacol Sect, NIH, Dept Hlth & Human Serv, Baltimore, MD 20892 USA.	bernard_lefoll@camh.net	Le Foll, Bernard/K-2952-2014	Le Foll, Bernard/0000-0002-6406-4973	Intramural Research Program of the National Institute on Drug Abuse; National Institutes of Health; Department of Health and Human Services; NATIONAL INSTITUTE ON DRUG ABUSE [ZIFDA000001, Z02DA000001, Z01DA000001, ZIADA000001] Funding Source: NIH RePORTER	Intramural Research Program of the National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Health and Human Services; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This study was supported by the Intramural Research Program of the National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services.	Agatsuma S, 2006, HUM MOL GENET, V15, P2721, DOI 10.1093/hmg/ddl206; ATOR NA, 1983, PHARMACOL BIOCHEM BE, V19, P993, DOI 10.1016/0091-3057(83)90406-9; BELLUZZI JD, 2004, NEUROPSYCHOPHARMACOL; Bruijnzeel AW, 2003, SYNAPSE, V50, P20, DOI 10.1002/syn.10242; Caggiula AR, 2001, PHARMACOL BIOCHEM BE, V70, P515, DOI 10.1016/S0091-3057(01)00676-1; Caggiula AR, 2002, PHYSIOL BEHAV, V77, P683, DOI 10.1016/S0031-9384(02)00918-6; Cohen C, 2005, NEUROPSYCHOPHARMACOL, V30, P145, DOI 10.1038/sj.npp.1300541; Corrigall W A, 1999, Nicotine Tob Res, V1, P11, DOI 10.1080/14622299050011121; Dar R, 2004, PSYCHOPHARMACOLOGY, V173, P18, DOI 10.1007/s00213-004-1781-2; Dar R, 2002, ADDICT RES THEORY, V10, P545, DOI 10.1080/1606635021000041753; DELAGARZA R, 1987, DRUG ALCOHOL DEPEN, V19, P17, DOI 10.1016/0376-8716(87)90083-4; DENEAU GA, 1967, ANN NY ACAD SCI, V142, P277, DOI 10.1111/j.1749-6632.1967.tb13730.x; Donny EC, 1999, PSYCHOPHARMACOLOGY, V147, P135, DOI 10.1007/s002130051153; Donny EC, 2003, PSYCHOPHARMACOLOGY, V169, P68, DOI 10.1007/s00213-003-1473-3; Donny EC, 2000, PSYCHOPHARMACOLOGY, V151, P392, DOI 10.1007/s002130000497; Fowler JS, 1996, NATURE, V379, P733, DOI 10.1038/379733a0; Fowler JS, 1996, P NATL ACAD SCI USA, V93, P14065, DOI 10.1073/pnas.93.24.14065; Garrett BE, 2001, J PHARMACOL EXP THER, V296, P486; GLOWA JR, 1983, SCIENCE, V220, P333; GOLDBERG SR, 1973, J PHARMACOL EXP THER, V186, P18; GOLDBERG SR, 1981, SCIENCE, V214, P573; GOLDBERG SR, 1983, PHARMACOL BIOCHEM BE, V19, P1011, DOI 10.1016/0091-3057(83)90408-2; GOLDBERG SR, 2005, PSYCHOPHARMACOLOGY B; Goldstein MG, 2000, CLIN PRACTICE GUIDEL; Griffiths R, 1979, ADV BEHAV PHARMACOL, V2, P163; Grigson PS, 1997, BEHAV NEUROSCI, V111, P129, DOI 10.1037/0735-7044.111.1.129; Guillem K, 2005, J NEUROSCI, V25, P8593, DOI 10.1523/JNEUROSCI.2139-05.2005; Harvey DM, 2004, PSYCHOPHARMACOLOGY, V175, P134, DOI 10.1007/s00213-004-1818-6; HENNINGFIELD JE, 1985, J PHARMACOL EXP THER, V234, P1; HENNINGFIELD JE, 1983, PHARMACOL BIOCHEM BE, V19, P1021, DOI 10.1016/0091-3057(83)90409-4; Hill R. T., 1970, AMPHETAMINE RELATED, P781; Justinova Z, 2003, PSYCHOPHARMACOLOGY, V169, P135, DOI 10.1007/s00213-003-1484-0; Laviolette SR, 2003, MOL PSYCHIATR, V8, P50, DOI 10.1038/sj.mp.4001197; Le Foll B, 2006, BEHAV PHARMACOL, V17, P195; Le Foll B, 2005, TRENDS PHARMACOL SCI, V26, P287, DOI 10.1016/j.tips.2005.04.005; Le Foll B, 2005, J PHARMACOL EXP THER, V312, P875, DOI 10.1124/jpet.104.077974; Le Foll B, 2005, NEUROPSYCHOPHARMACOL, V30, P720, DOI 10.1038/sj.npp.1300622; Le Foll B, 2005, PSYCHOPHARMACOLOGY, V178, P481, DOI 10.1007/s00213-004-2021-5; Le Foll B, 2006, PSYCHOPHARMACOLOGY, V184, P367, DOI 10.1007/s00213-005-0155-8; Le Foll B, 2005, NEUROPHARMACOLOGY, V49, P525, DOI 10.1016/j.neuropharm.2005.04.022; Le Foll B, 2004, NEUROREPORT, V15, P2139, DOI 10.1097/00001756-200409150-00028; Manzardo AM, 2002, BRAIN RES, V924, P10, DOI 10.1016/S0006-8993(01)03215-2; Markou A, 2004, ANN NY ACAD SCI, V1025, P491, DOI 10.1196/annals.1316.061; Olausson P, 2004, PSYCHOPHARMACOLOGY, V171, P173, DOI 10.1007/s00213-003-1575-y; Olausson P, 2003, NEUROPSYCHOPHARMACOL, V28, P1264, DOI 10.1038/sj.npp.1300173; Paterson NE, 2004, PSYCHOPHARMACOLOGY, V172, P179, DOI 10.1007/s00213-003-1637-1; Perkins KA, 2004, PSYCHOPHARMACOLOGY, V175, P256, DOI 10.1007/s00213-004-1930-7; ROBERTS DCS, 1993, PSYCHOPHARMACOLOGY, V111, P215, DOI 10.1007/BF02245526; ROBINSON JH, 1992, PSYCHOPHARMACOLOGY, V108, P397, DOI 10.1007/BF02247412; Samaha AN, 2005, TRENDS PHARMACOL SCI, V26, P82, DOI 10.1016/j.tips.2004.12.007; SANNERUD CA, 1994, EUR J PHARMACOL, V271, P461, DOI 10.1016/0014-2999(94)90807-9; SLIFER BL, 1985, PHARMACOL BIOCHEM BE, V22, P61, DOI 10.1016/0091-3057(85)90487-3; Soria R, 1996, PSYCHOPHARMACOLOGY, V128, P221, DOI 10.1007/s002130050129; SPEALMAN RD, 1982, J PHARMACOL EXP THER, V223, P402; SPEAR DJ, 1991, PHARMACOL BIOCHEM BE, V38, P411, DOI 10.1016/0091-3057(91)90300-Q; STOLERMAN IP, 1991, TRENDS PHARMACOL SCI, V12, P467, DOI 10.1016/0165-6147(91)90638-9; Tanda G, 2000, NAT NEUROSCI, V3, P1073, DOI 10.1038/80577; Villegier AS, 2006, NEUROPSYCHOPHARMACOL, V31, P1704, DOI 10.1038/sj.npp.1300987; Wakasa Yoshio, 1995, Japanese Journal of Psychopharmacology, V15, P53; WEST R, 1992, PSYCHOPHARMACOLOGY, V108, P408, DOI 10.1007/BF02247413; YANAGITA T, 1977, PREDICTING DEPENDENC, P231	61	55	55	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2007	2	2							e230	10.1371/journal.pone.0000230	http://dx.doi.org/10.1371/journal.pone.0000230			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DK	17311094	gold, Green Submitted, Green Published			2023-01-03	WOS:000207444500011
J	Kurella, M; Covinsky, KE; Collins, AJ; Chertow, GM				Kurella, Manjula; Covinsky, Kenneth E.; Collins, Alan J.; Chertow, Glenn M.			Octogenarians and nonagenarians starting dialysis in the United States	ANNALS OF INTERNAL MEDICINE			English	Article							STAGE RENAL-DISEASE; REPLACEMENT THERAPY; DECISION-MAKING; INITIATION; SURVIVAL; HEMODIALYSIS; PREVALENCE; VALIDATION; COHORT	Background: The elderly constitute the fastest-growing segment of the end-stage renal disease (ESRD) population, but the epidemiology and outcomes of dialysis among the very elderly, that is, those 80 years of age and older, have not been previously examined at a national level. Objective: To describe recent trends in the incidence and outcomes of octogenarians and nonagenarians starting dialysis. Design: Observational study. Setting: U.S. Renal Data System, a comprehensive, national registry of patients with ESRD. Participants: Octogenarians and nonagenarians initiating dialysis between 1996 and 2003. Measurements: Rates of dialysis initiation and survival. Results: The number of octogenarians and nonagenarians starting dialysis increased from 7054 persons in 1996 to 13 577 persons in 2003, corresponding to an average annual increase in dialysis initiation of 9.8%. After we accounted for population growth, the rate of dialysis initiation increased by 57% (rate ratio, 1.57 [95% CI, 1.53 to 1.62]) between 1996 and 2003. One-year mortality for octogenarians and nonagenarians after dialysis initiation was 46%. Compared with octogenarians and nonagenarians initiating dialysis in 1996, those starting dialysis in 2003 had a higher glomerular filtration rate and less morbidity related to chronic kidney disease but no difference in 1-year survival. Clinical characteristics strongly associated with death were older age, nonambulatory status, and more comorbid conditions. Limitations: Survival of patients with incident ESRD who did not begin dialysis could not be assessed. Conclusions: The number of octogenarians and nonagenarians initiating dialysis has increased considerably over the past decade, while overall survival for patients on dialysis remains modest. Estimates of prognosis based on patient characteristics, when considered in conjunction with individual values and preferences, may aid in dialysis decision making for the very elderly.	Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA; San Francisco VA Med Ctr, San Francisco, CA 94143 USA; US Renal Data Syst, Minneapolis, MN USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Kurella, M (corresponding author), Univ Calif San Francisco, Div Nephrol, UCSF Laurel Heights,Suite 430,3333 Calif St, San Francisco, CA 94143 USA.	manjula.kurella@ucsf.edu	Tamura, Manjula Kurella/C-8284-2014	Tamura, Manjula Kurella/0000-0001-5227-2479; Chertow, Glenn/0000-0002-7599-0534	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058411] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K24AG029812] Funding Source: NIH RePORTER; NIA NIH HHS [K24 AG029812] Funding Source: Medline; NIDDK NIH HHS [R01 DK01005, R01 DK58411] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arias Elizabeth, 2004, Natl Vital Stat Rep, V52, P1; Beddhu S, 2003, J AM SOC NEPHROL, V14, P2305, DOI 10.1097/01.ASN.0000080184.67406.11; BURNS A, 2005, AM SOC NEPHR REN WEE; Centers for Disease Control and Prevention, NAT CTR HLTH STAT NC; CHESTER AC, 1979, ARCH INTERN MED, V139, P1001, DOI 10.1001/archinte.139.9.1001; Collins AJ, 2005, AM J KIDNEY DIS, V45, pV, DOI 10.1053/j.ajkd.2004.10.009; Cooper BA, 2004, PERITON DIALYSIS INT, V24, P176; Hsu CY, 2004, ANN INTERN MED, V141, P95, DOI 10.7326/0003-4819-141-2-200407200-00007; Joly D, 2003, J AM SOC NEPHROL, V14, P1012, DOI 10.1097/01.ASN.0000054493.04151.80; Korevaar JC, 2001, LANCET, V358, P1046, DOI 10.1016/S0140-6736(01)06180-3; Lamping DL, 2000, LANCET, V356, P1543, DOI 10.1016/S0140-6736(00)03123-8; Lee SJ, 2006, JAMA-J AM MED ASSOC, V295, P801, DOI 10.1001/jama.295.7.801; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Longenecker JC, 2000, J AM SOC NEPHROL, V11, P520, DOI 10.1681/ASN.V113520; McDonald S, 2005, ADV CHRONIC KIDNEY D, V12, P32, DOI 10.1053/j.ackd.2004.10.011; Moss AH, 2001, AM J KIDNEY DIS, V37, P1081; Munshi SK, 2001, NEPHROL DIAL TRANSPL, V16, P128, DOI 10.1093/ndt/16.1.128; Muntner P, 2003, J AM SOC NEPHROL, V14, P1568, DOI 10.1097/01.ASN.0000067420.83632.C1; Peri UN, 2001, NEPHROL DIAL TRANSPL, V16, P2201, DOI 10.1093/ndt/16.11.2201; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; PORT FK, 1992, AM J KIDNEY DIS, V20, P3; Rohrich B, 1996, NEPHROL DIAL TRANSPL, V11, P2412, DOI 10.1093/oxfordjournals.ndt.a027205; Smith C, 2003, NEPHRON CLIN PRACT, V95, pC40, DOI 10.1159/000073708; Traynor JP, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000025294.40179.E8; Vandelli L, 1996, NEPHROL DIAL TRANSPL, V11, P89	25	399	419	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 6	2007	146	3					177	183		10.7326/0003-4819-146-3-200702060-00006	http://dx.doi.org/10.7326/0003-4819-146-3-200702060-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	132QN	17283348				2023-01-03	WOS:000243957400003
J	Shepherd, CB				Shepherd, Charles B.			Shark cartilage in the water - Effective legislation is already in place but is not being properly used	BRITISH MEDICAL JOURNAL			English	Letter												charlesbshepherd@lineone.net						Campbell D, 1997, BRIT MED J, V315, P625; DYER O, 1994, BRIT MED J, V308, P158, DOI 10.1136/bmj.308.6922.158; Waxman J, 2006, BRIT MED J, V333, P1129, DOI 10.1136/bmj.39037.692743.59	3	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	DEC 9	2006	333	7580					1222	1222		10.1136/bmj.39051.725162.3A	http://dx.doi.org/10.1136/bmj.39051.725162.3A			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JW	17158403	Green Published			2023-01-03	WOS:000243009600031
J	Berer, M				Berer, Marge			Hospital admission for complications of unsafe abortion	LANCET			English	Editorial Material									Reprod Hlth Matters, London NW5 1TL, England		Berer, M (corresponding author), Reprod Hlth Matters, London NW5 1TL, England.	RHMjournal@compuserve.com						AAHMAN E, 2004, UNSAFE ABORTION GLOB; Berer M, 2004, REPROD HEALTH MATTER, V12, P1, DOI 10.1016/S0968-8080(04)24024-1; Chowdury SNM, 2004, REPROD HEALTH MATTER, V12, P95; Dickson KE, 2003, STUD FAMILY PLANN, V34, P277, DOI 10.1111/j.1728-4465.2003.00277.x; Hessini L, 2005, REPROD HEALTH MATTER, V13, P88, DOI 10.1016/S0968-8080(05)25168-6; Iyengar SD, 2005, REPROD HEALTH MATTER, V13, P13, DOI 10.1016/S0968-8080(05)26217-1; Kestler E, 2006, REPROD HEALTH MATTER, V14, P138, DOI 10.1016/S0968-8080(06)27235-5; Lane SD, 1998, SOC SCI MED, V47, P1089, DOI 10.1016/S0277-9536(98)00129-4; Misago C, 1998, INT J EPIDEMIOL, V27, P833, DOI 10.1093/ije/27.5.833; Oye-Adeniran BA, 2002, REPROD HEALTH MATTER, V10, P18, DOI 10.1016/S0968-8080(02)00024-1; Singh S, 2006, LANCET, V368, P1887, DOI 10.1016/S0140-6736(06)69778-X; Walker D, 2004, REPROD HEALTH MATTER, V12, P27, DOI 10.1016/S0968-8080(04)24019-8	12	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 25	2006	368	9550					1848	1849		10.1016/S0140-6736(06)69752-3	http://dx.doi.org/10.1016/S0140-6736(06)69752-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	109YQ	17126700				2023-01-03	WOS:000242345900006
J	Hajji, N; Wallenborg, K; Vlachos, P; Nyman, U; Hermanson, O; Joseph, B				Hajji, N.; Wallenborg, K.; Vlachos, P.; Nyman, U.; Hermanson, O.; Joseph, B.			Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells	ONCOGENE			English	Article						NSCLC; apoptosis; HDAC inhibitor; AIF; Bcl-xL	HISTONE DEACETYLASE INHIBITORS; CANCER CELLS; ANTICANCER AGENTS; EXPRESSION; RESISTANT; BCL-2; AMPLIFICATION; THERAPY; PROTEIN; POINT	Commonly used regimens in cancer therapy rely on the induction of apoptotic cell death, and drug resistance can be attributed, at least in part, to a disabled apoptotic program. Non-small cell lung carcinomas (NSCLC), exhibit an intrinsic resistance to chemotherapy. Here, we show that co-treatment with etoposide (VP16) and the pan-histone deacetylase (HDAC) inhibitor trichostatin A (TSA), but not valproic acid (VPA), induced apoptotic cell death in drug-resistant NSCLC cells. Co-treatment, but not single treatment, with VP16 and TSA induced apoptosis in a caspase-dependent manner accompanied by a crucial decrease in Bcl-xL expression allowing Bax activation and subsequent initiation of the apoptosis inducingfactor (AIF)-dependent death pathway. Importantly, AIF proved to be required for the effects of TSA/VP16 as RNA knockdown of AIF resulted in a complete abolishment of TSA/VP16-induced apoptotic cell death in drug-resistant NSCLC cells. Our results thus provide evidence for the requirement of both caspase-dependent and caspase-independent apoptotic pathways in TSA/VP16-mediated death of drug-resistant NSCLC cells, and extend previous suggestions that HDAC inhibitors in combination with conventional chemotherapeutic drugs could be valuable in the treatment of NSCLC cancer and other malignancies in which Bcl-xL is overexpressed.	[Hajji, N.; Vlachos, P.; Nyman, U.; Joseph, B.] Karolinska Inst, Inst Environm Med, Div Toxicol & Neurotoxicol, SE-17177 Stockholm, Sweden; [Wallenborg, K.; Hermanson, O.] Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Joseph, B (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol & Neurotoxicol, Box 210, SE-17177 Stockholm, Sweden.	bertrand.joseph@ki.se	hajji, nabil/AAV-1435-2020; Nyman, Ulrika/D-3708-2013; , Ola/AAF-5126-2021	Hermanson, Ola/0000-0001-9320-7921				Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Choi YH, 2005, INT J ONCOL, V27, P473; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Gallego MA, 2004, ONCOGENE, V23, P6282, DOI 10.1038/sj.onc.1207835; Geng L, 2006, CANCER RES, V66, P11298, DOI 10.1158/0008-5472.CAN-06-0049; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Henderson C, 2003, DRUG RESIST UPDATE, V6, P247, DOI 10.1016/S1368-7646(03)00067-0; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; Joseph B, 2001, ONCOGENE, V20, P2877, DOI 10.1038/sj.onc.1204402; Karczmarek-Borowska B, 2006, LUNG CANCER, V51, P61, DOI 10.1016/j.lungcan.2005.08.010; Komatsu N, 2006, ONCOL REP, V15, P187; Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/713803693; La Thangue NB, 2004, J CHEMOTHERAPY, V16, P64, DOI 10.1179/joc.2004.16.Supplement-1.64; Lei XY, 2007, ACTA BIOCH BIOPH SIN, V39, P344, DOI 10.1111/j.1745-7270.2007.00286.x; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Marks PA, 2005, CELL CYCLE, V4, P549, DOI 10.4161/cc.4.4.1564; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Peart MJ, 2005, P NATL ACAD SCI USA, V102, P3697, DOI 10.1073/pnas.0500369102; Pham NA, 2001, EXP CELL RES, V264, P345, DOI 10.1006/excr.2000.5148; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Rundall BK, 2005, SURGERY, V138, P360, DOI 10.1016/j.surg.2005.06.016; Schniewind Bodo, 2006, J Carcinog, V5, P25, DOI 10.1186/1477-3163-5-25; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Yu XD, 2002, J NATL CANCER I, V94, P504; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zangemeister-Wittke U, 2000, CLIN CANCER RES, V6, P2547; ZHIVOTOVSKY B, 1994, FEBS LETT, V351, P150, DOI 10.1016/0014-5793(94)00827-2; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452	36	50	52	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	22					3134	3144		10.1038/sj.onc.1210976	http://dx.doi.org/10.1038/sj.onc.1210976			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071312				2023-01-03	WOS:000255897600006
J	Pandharipande, PP; Pun, BT; Herr, DL; Maze, M; Girard, TD; Miller, RR; Shintani, AK; Thompson, JL; Jackson, JC; Deppen, SA; Stiles, RA; Dittus, RS; Bernard, GR; Ely, EW				Pandharipande, Pratik P.; Pun, Brenda T.; Herr, Daniel L.; Maze, Mervyn; Girard, Timothy D.; Miller, Russell R.; Shintani, Ayumi K.; Thompson, Jennifer L.; Jackson, James C.; Deppen, Stephen A.; Stiles, Renee A.; Dittus, Robert S.; Bernard, Gordon R.; Ely, E. Wesley			Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients - The MENDS randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; CONFUSION ASSESSMENT METHOD; DELIRIUM; RELIABILITY; AGITATION; DURATION; VALIDITY; ICU; INTERRUPTION	Context Lorazepam is currently recommended for sustained sedation of mechanically ventilated intensive care unit ( ICU) patients, but this and other benzodiazepine drugs may contribute to acute brain dysfunction, ie, delirium and coma, associated with prolonged hospital stays, costs, and increased mortality. Dexmedetomidine induces sedation via different central nervous system receptors than the benzodiazepine drugs and may lower the risk of acute brain dysfunction. Objective To determine whether dexmedetomidine reduces the duration of delirium and coma in mechanically ventilated ICU patients while providing adequate sedation as compared with lorazepam. Design, Setting, Patients, and Intervention Double- blind, randomized controlled trial of 106 adult mechanically ventilated medical and surgical ICU patients at 2 tertiary care centers between August 2004 and April 2006. Patients were sedated with dexmedetomidine or lorazepam for as many as 120 hours. Study drugs were titrated to achieve the desired level of sedation, measured using the Richmond Agitation-Sedation Scale ( RASS). Patients were monitored twice daily for delirium using the Confusion Assessment Method for the ICU ( CAM- ICU). Main Outcome Measures Days alive without delirium or coma and percentage of days spent within 1 RASS point of the sedation goal. Results Sedation with dexmedetomidine resulted in more days alive without delirium or coma ( median days, 7.0 vs 3.0; P=. 01) and a lower prevalence of coma ( 63% vs 92%; P <. 001) than sedation with lorazepam. Patients sedated with dexmedetomidine spent more time within 1 RASS point of their sedation goal compared with patients sedated with lorazepam ( median percentage of days, 80% vs 67%; P=. 04). The 28- day mortality in the dexmedetomidine group was 17% vs 27% in the lorazepam group ( P=. 18) and cost of care was similar between groups. More patients in the dexmedetomidine group ( 42% vs 31%; P=. 61) were able to complete post- ICU neuropsychological testing, with similar scores in the tests evaluating global cognitive, motor speed, and attention functions. The 12- month time to death was 363 days in the dexmedetomidine group vs 188 days in the lorazepam group ( P=. 48). Conclusion In mechanically ventilated ICU patients managed with individualized targeted sedation, use of a dexmedetomidine infusion resulted in more days alive without delirium or coma and more time at the targeted level of sedation than with a lorazepam infusion.	Vanderbilt Univ, Sch Med, Dept Anesthesiol, Div Crit Care, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Dept Med, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Div Allergy Pulm Crit Care Med, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Accreditat & Stand, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Nursing, Nashville, TN 37240 USA; VA Tennessee Valley Geriatr Res Educ & Clin Ctr, Nashville, TN USA; Washington Hosp Ctr, Dept Surg & Surg Crit Care, Washington, DC 20010 USA; Univ London Imperial Coll Sci Technol & Med, Dept Anaesthet Pain Med & Intens Care, London, England	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; MedStar Washington Hospital Center; Imperial College London	Pandharipande, PP (corresponding author), 526 MAB,1211 21st Ave S, Nashville, TN 37212 USA.	pratik.pandharipande@vanderbilt.edu	Girard, Timothy/I-3008-2019; Herr, Daniel/X-4215-2019; Ely, E. Wesley/Z-2018-2019	Girard, Timothy/0000-0002-9833-4871; Ely, E. Wesley/0000-0003-3957-2172; Herr, Daniel/0000-0001-8533-9000; Pandharipande, Pratik/0000-0002-1389-8580	NIA NIH HHS [AG0727201] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bourne RS, 2004, ANAESTHESIA, V59, P374, DOI 10.1111/j.1365-2044.2004.03664.x; Brattebo G, 2002, BMJ-BRIT MED J, V324, P1386, DOI 10.1136/bmj.324.7350.1386; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Chambers JM., 1983, GRAPHICAL METHODS DA; Devlin JW, 2006, CRIT CARE MED, V34, P556, DOI 10.1097/01.CCM.0000199058.88904.D6; Dubois MJ, 2001, INTENS CARE MED, V27, P1297, DOI 10.1007/s001340101017; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Ely EW, 2001, INTENS CARE MED, V27, P1892, DOI 10.1007/s00134-001-1132-2; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Ibacache ME, 2004, ANESTH ANALG, V98, P60, DOI 10.1213/01.ANE.0000094947.20838.8E; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; JORM AF, 1991, PSYCHOL MED, V21, P785, DOI 10.1017/S0033291700022418; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kress JP, 2003, AM J RESP CRIT CARE, V168, P1457, DOI 10.1164/rccm.200303-455OC; LEVANEN J, 1995, ANESTHESIOLOGY, V82, P1117, DOI 10.1097/00000542-199505000-00005; Lin SM, 2004, CRIT CARE MED, V32, P2254, DOI 10.1097/01.CCM.0000145587.16421.BB; Maldonado J, 2003, AM SOC AN ANN M SAN, V99, pA465; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; Maze M, 2001, CRIT CARE CLIN, V17, P881, DOI 10.1016/S0749-0704(05)70185-8; Mehta S, 2006, CRIT CARE MED, V34, P374, DOI 10.1097/01.CCM.0000196830.61965.F1; Mihic SJ, 1997, ALCOHOL HEALTH RES W, V21, P127; Nelson LE, 2003, ANESTHESIOLOGY, V98, P428, DOI 10.1097/00000542-200302000-00024; Nelson LE, 2002, NAT NEUROSCI, V5, P979, DOI 10.1038/nn913; Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; PANDHARIPANDE P, IN PRESS J TRAUMA; Pandharipande P, 2006, CRIT CARE CLIN, V22, P313, DOI 10.1016/j.ccc.2006.02.010; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Slomka J, 2000, Am J Crit Care, V9, P412; Spreen O., 1998, COMPENDIUM NEUROPSYC, Vsecond; TANIOS MA, 2005, P AM THORAC SOC, V2, pA793; van der Mast RC, 1998, J GERIATR PSYCH NEUR, V11, P138, DOI 10.1177/089198879801100304; VanderMast RC, 1996, J PSYCHOSOM RES, V41, P109, DOI 10.1016/0022-3999(96)00006-2; Weinert C R, 2001, Am J Crit Care, V10, P156; Weinert CR, 2007, CRIT CARE MED, V35, P393, DOI 10.1097/01.CCM.0000254339.18639.1D; WIJDICKS EFM, 2002, NEUROLOGIC COMPLICAT; Young C, 2000, CRIT CARE MED, V28, P854, DOI 10.1097/00003246-200003000-00041; SOCIAL SECURITY DEAT	44	898	956	2	51	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 12	2007	298	22					2644	2653		10.1001/jama.298.22.2644	http://dx.doi.org/10.1001/jama.298.22.2644			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239VJ	18073360	Bronze			2023-01-03	WOS:000251546100016
J	Facon, T; Mary, JY; Hulin, C; Benbouker, L; Attal, M; Pegourie, B; Renaud, M; Guillerm, JLHG; Ahletaix, C; Dib, M; Voillat, L; Maisonneuve, H; Troncy, J; Dervaux, W; Monconduit, M; Martin, C; Casassus, P; Jaubert, J; Jardel, H; Doyen, C; Kolb, B; Anglaret, B; Grosbois, B; Yakoub-Agha, I; Mathiot, C; Avet-Loiseau, H				Facon, Thierry; Mary, Jean Yves; Hulin, Cyrille; Benbouker, Lofti; Attal, Michel; Pegourie, Brigitte; Renaud, Marc; Guillerm, Jean Luc Harousseau Gaelle; Ahletaix, Carine; Dib, Mamoun; Voillat, Laurent; Maisonneuve, Herve; Troncy, Jacques; Dervaux, Weronique; Monconduit, Mathieu; Martin, Claude; Casassus, Philippe; Jaubert, Jerome; Jardel, Henry; Doyen, Chantal; Kolb, Brigitte; Anglaret, Bruno; Grosbois, Bernard; Yakoub-Agha, Ibrahim; Mathiot, Claire; Avet-Loiseau, Herve		Intergroupe Francophone Mye	Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial	LANCET			English	Article							REQUIRING PROLONGED OBSERVATION; STAGING SYSTEM; IMPROVES SURVIVAL; CHEMOTHERAPY; DEXAMETHASONE; DESIGN	Background In multiple myeloma, combination chemotherapy with melphalan plus prednisone is still regarded as the standard of care in elderly patients. We assessed whether the addition of thalidomide to this combination, or reduced-intensity stem cell transplantation, would improve survival. Methods Between May 22, 2000, and Aug 8, 2005, 447 previously untreated patients with multiple myeloma, who were aged between 65 and 75 years, were randomly assigned to receive either melphalan and prednisone (MP; n=196), melphalan and prednisone plus thalidomide (MPT, n=125), or reduced-intensity stem cell transplantation using melphalan 100 mg/m(2) (MEL100; n=126). The primary endpoint was overall survival. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00367185. Findings After a median follow-up of 51.5 months (IQR 34.4-63.2), median overall survival times were 33.2 months (13.8-54.8) for MP, 51.6 months (26.6-not reached) for MPT, and 38.3 months (13.0-61.6) for MEL100. The MPT regimen was associated with a significantly better overall survival than was the MP regimen (hazard ratio 0.59, 95% CI 0.46-0.81, p=0.0006) or MEL100 regimen (0.69, 0.49-0.96, p=0.027). No difference was seen for MEL100 versus MP (0.86, 0.65-1.15, p=0.32). Interpretation The results of our trial provide strong evidence to indicate that the use of thalidomide in combination with melphalan and prednisone should, at present, be the reference treatment for previously untreated elderly patients with multiple myeloma.	CHU Lille, Serv Hematol, F-59037 Lille, France; Univ Paris 07, Hop St Louis, INSERM, U717, Paris, France; CHU, Serv Hematol, Nancy, France; CHU, Serv Hematol, Tours, France; CHU, Serv Hematol, Toulouse, France; CHU, Serv Hematol, Grenoble, France; CHU, Serv Hematol, Poitiers, France; CHU, Serv Hematol, Nantes, France; CHU, Serv Hematol, Brest, France; CHU, Serv Hematol, Clermont Ferrand, France; CHU, Serv Hematol, Angers, France; CHU, Serv Hematol, Besancon, France; CH, Serv Hematol, La Roche, Yon, France; CHU, Hop Edouard Herriot, Serv Hematol, Lyon, France; CH, Serv Hematol, Metz, France; Ctr Henri Becquerel, Serv Hematol, F-76038 Rouen, France; CH, Serv Hematol, Annecy, France; CHU, Serv Hematol, Bobigny, France; CHU, Serv Hematol, St Etienne, France; CH, Serv Hematol, Vannes, France; UCL, Serv Hematol, Yvoir, Belgium; CHU, Serv Hematol, Reims, France; CH, Serv Hematol, Valence, France; CHU, Serv Hematol, Rennes, France; Inst Curie, Hematol Lab, Paris, France; CHU, Hematol Lab, Nantes, France	Universite de Lille - ISITE; CHU Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU de Nancy; CHU Tours; CHU de Toulouse; CHU Grenoble Alpes; CHU Poitiers; Nantes Universite; CHU de Nantes; CHU Brest; Universite de Bretagne Occidentale; CHU Clermont Ferrand; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite de Franche-Comte; CHU Besancon; CHU Lyon; CHR Metz-Thionville; UNICANCER; Centre Henri Becquerel; Centre Hospitalier Annecy Genevois; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; CHU de St Etienne; Universite Catholique Louvain; CHU de Reims; CHU Rennes; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Nantes Universite; CHU de Nantes	Facon, T (corresponding author), CHU Lille, Hop Claude Huriez, Serv Malad Sang, Rue Michel Polonovski, F-59037 Lille, France.	t-facon@chru-lille.fr	Yakoub-Agha, Ibrahim/R-7872-2018; Avet-Loiseau, Herve/P-8872-2014	Yakoub-Agha, Ibrahim/0000-0003-4524-8782; Avet-Loiseau, Herve/0000-0002-3050-0140				ALEXANIAN R, 1969, J AMER MED ASSOC, V208, P1680, DOI 10.1001/jama.208.9.1680; [Anonymous], 1998, J Clin Oncol, V16, P3832; Attal M, 2003, NEW ENGL J MED, V349, P2495, DOI 10.1056/NEJMoa032290; Attal M, 2006, BLOOD, V108, P3289, DOI 10.1182/blood-2006-05-022962; Barlogie B, 2006, NEW ENGL J MED, V354, P1021, DOI 10.1056/NEJMoa053583; Bataille R, 1997, NEW ENGL J MED, V336, P1657, DOI 10.1056/NEJM199706053362307; Byar DP., 1988, CANC CLIN TRIALS MET, P423; Child JA, 2003, NEW ENGL J MED, V348, P1875, DOI 10.1056/NEJMoa022340; COX DR, 1972, J R STAT SOC B, V34, P187; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; Facon T, 2006, BLOOD, V107, P1292, DOI 10.1182/blood-2005-04-1588; Facon T, 2001, BLOOD, V97, P1566, DOI 10.1182/blood.V97.6.1566; Greipp PR, 2005, J CLIN ONCOL, V23, P3412, DOI 10.1200/JCO.2005.04.242; Hulin C, 2007, J CLIN ONCOL, V25, p441s; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Mateos MV, 2006, BLOOD, V108, P2165, DOI 10.1182/blood-2006-04-019778; Oakes, 1984, ANAL SURVIVAL DATA, DOI DOI 10.1201/9781315137438; Palumbo A, 2004, BLOOD, V104, P3052, DOI 10.1182/blood-2004-02-0408; Palumbo A, 1999, BLOOD, V94, P1248, DOI 10.1182/blood.V94.4.1248.416k09_1248_1253; Palumbo A, 2006, LANCET, V367, P825, DOI 10.1016/S0140-6736(06)68338-4; Palumbo A, 2007, J CLIN ONCOL, V25, P4459, DOI 10.1200/JCO.2007.12.3463; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Rajkumar SV, 2006, J CLIN ONCOL, V24, P431, DOI 10.1200/JCO.2005.03.0221; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102	25	678	697	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 6	2007	370	9594					1209	1218		10.1016/S0140-6736(07)61537-2	http://dx.doi.org/10.1016/S0140-6736(07)61537-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219NM	17920916				2023-01-03	WOS:000250091900021
J	Watkinson, A; Nicholson, A				Watkinson, A.; Nicholson, A.			Rational imaging - Uterine artery embolisation to treat uterine fibroids	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SURGERY		Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England; Peninsula Med Sch, Exeter EX2 5DW, Devon, England; St James Hosp, Leeds Teaching Hosp, Leeds LS9 7TF, W Yorkshire, England	University of Exeter; University of Exeter; Saint James's University Hospital; University of Leeds	Watkinson, A (corresponding author), Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England.	Anthony.Watkinson@rdeft.nhs.uk						Edwards RD, 2007, NEW ENGL J MED, V356, P360; Glomset O, 2006, ACTA RADIOL, V47, P179, DOI 10.1080/02841850500447211; Gupta JK, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005073.pub2; Hehenkamp WJK, 2005, AM J OBSTET GYNECOL, V193, P1618, DOI 10.1016/j.ajog.2005.05.017; Mara M, 2006, EUR J OBSTET GYN R B, V126, P226, DOI 10.1016/j.ejogrb.2005.10.008; *NAT I HLTH CLIN E, 2007, CG44 NICE; RAVINA JH, 1995, PRESSE MED, V24, P1754; *ROYAL COLL OBST G, 2000, CLIN REC US UT ART E; Spies JB, 2005, OBSTET GYNECOL, V106, P1309, DOI 10.1097/01.AOG.0000188386.53878.49; Stewart EA, 2006, FERTIL STERIL, V85, P22, DOI 10.1016/j.fertnstert.2005.04.072; WALKER WJ, 2003, BJOG, V110, P1139	11	8	8	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 6	2007	335	7622					720	722		10.1136/bmj.39251.440069.AD	http://dx.doi.org/10.1136/bmj.39251.440069.AD			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220KY	17916857	Green Published			2023-01-03	WOS:000250156800036
J	Abraham, JM; Sato, F; Cheng, YL; Paun, B; Kan, T; Olaru, A; Jin, Z; Yang, J; Agarwal, R; David, S; Hamilton, JP; Ito, T; Mori, Y; Meltzer, SJ				Abraham, John M.; Sato, Fumiaki; Cheng, Yulan; Paun, Bogdan; Kan, Takatsugu; Olaru, Alexandru; Jin, Zhe; Yang, Jian; Agarwal, Rachana; David, Stefan; Hamilton, James P.; Ito, Tetsuo; Mori, Yuriko; Meltzer, Stephen J.			Novel Decapeptides that Bind Avidly and Deliver Radioisotope to Colon Cancer Cells	PLOS ONE			English	Article							MONOCLONAL-ANTIBODY; BREAST-CANCER; LOW-GRADE; THERAPY; CHEMOTHERAPY; TRASTUZUMAB; TRIAL; PLUS; RADIOIMMUNOTHERAPY; PEPTIDES	Background. The rapidly growing field of targeted tumor therapy often utilizes an antibody, sometimes tagged with a tumor-ablating material such as radioisotope, directed against a specific molecule. Methodology/Principal Findings. This report describes the discovery of nine novel decapeptides which can be radioactively labeled, bind to, and deliver P-32 to colon cancer cells. The decapeptides vary from one another by one to three amino acids and demonstrate vastly different binding abilities. The most avidly binding decapeptide can permanently deliver very high levels of radioisotope to the adenocarcinoma cancer cell lines at an efficiency 35 to 150 times greater than to a variety of other cell types, including cell lines derived from other types of cancer or from normal tissue. Conclusions/Significance. This experimental approach represents a new example of a strategy, termed peptide binding therapy, for the potential treatment of colorectal and other adenocarcinomas.	[Abraham, John M.; Sato, Fumiaki; Cheng, Yulan; Paun, Bogdan; Kan, Takatsugu; Olaru, Alexandru; Jin, Zhe; Yang, Jian; Agarwal, Rachana; David, Stefan; Hamilton, James P.; Ito, Tetsuo; Mori, Yuriko; Meltzer, Stephen J.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Meltzer, Stephen J.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Abraham, JM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.	jabrah14@jhmi.edu			National Cancer Institute [2RO1CA095323-14, 2RO1CA07705709, 1R01CA001808-05, 7R21/R33CA106763]; NATIONAL CANCER INSTITUTE [R01CA077057, R01CA001808, R01CA095323, R21CA106763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK067872] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants 2RO1CA095323-14, 2RO1CA07705709, 1R01CA001808-05 and 7R21/ R33CA106763 from the National Cancer Institute.	Aina OH, 2005, MOL CANCER THER, V4, P806, DOI 10.1158/1535-7163.MCT-05-0029; Aina OH, 2002, BIOPOLYMERS, V66, P184, DOI 10.1002/bip.10257; Boerman OC, 2007, ANTI-CANCER AGENT ME, V7, P335, DOI 10.2174/187152007780618126; Cilley JC, 2007, EXPERT OPIN BIOL TH, V7, P739, DOI 10.1517/14712598.7.5.739; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Davis TA, 2000, J CLIN ONCOL, V18, P3135, DOI 10.1200/JCO.2000.18.17.3135; Edwards BK, 2005, JNCI-J NATL CANCER I, V97, P1407, DOI 10.1093/jnci/dji289; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kreitman RJ, 2003, CURR OPIN MOL THER, V5, P44; Kreitman RJ, 2006, AAPS J, V8, pE532, DOI 10.1208/aapsj080363; Kreitman RJ, 2006, CURR DRUG TARGETS, V7, P1301, DOI 10.2174/138945006778559139; Nahta R, 2007, ONCOGENE, V26, P3637, DOI 10.1038/sj.onc.1210379; Okarvi SM, 2004, MED RES REV, V24, P357, DOI 10.1002/med.20002; Presta LG, 1997, CANCER RES, V57, P4593; Rini BI, 2007, CLIN CANCER RES, V13, p741S, DOI 10.1158/1078-0432.CCR-06-2110; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Siberil S, 2007, CRIT REV ONCOL HEMAT, V62, P26, DOI 10.1016/j.critrevonc.2006.12.003; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Tan-Chiu E, 2005, J CLIN ONCOL, V23, P7811, DOI 10.1200/JCO.2005.02.4091; Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620; Vose JM, 2004, ONCOLOGIST, V9, P160, DOI 10.1634/theoncologist.9-2-160; Wangler C, 2007, PROTEIN PEPTIDE LETT, V14, P273, DOI 10.2174/092986607780090874; Wiseman GA, 2001, CRIT REV ONCOL HEMAT, V39, P181, DOI 10.1016/S1040-8428(01)00107-X; Wu AM, 2005, NAT BIOTECHNOL, V23, P1137, DOI 10.1038/nbt1141; Zafir-Lavie I, 2007, ONCOGENE, V26, P3714, DOI 10.1038/sj.onc.1210372	25	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2007	2	10							e964	10.1371/journal.pone.0000964	http://dx.doi.org/10.1371/journal.pone.0000964			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HU	17912343	gold, Green Published, Green Submitted			2023-01-03	WOS:000207455900002
J	Powrie, RO				Powrie, Raymond O.			A 30-year-old woman with chronic hypertension trying to conceive	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							BLOOD-PRESSURE-MEASUREMENT; CARDIOVASCULAR-DISEASE; PREGNANCY HYPERTENSION; PREVENT PREECLAMPSIA; RISK-FACTORS; VITAMIN-C; URIC-ACID; WOMEN; NIFEDIPINE; DISORDERS	Mrs F is a 30-year-old woman with a history of chronic hypertension and possible preeclampsia during her first pregnancy. She is currently trying to conceive and wants to know how her hypertension will affect a future pregnancy and how it should best be managed, both now and during a pregnancy. The management of chronic hypertension before, during, and after a pregnancy is discussed with an emphasis on the goals of treatment and safety of medications during pregnancy and with breastfeeding. Preeclampsia is the most common complication of chronic hypertension in pregnancy and is a particular worry for Mrs F because she may have had it with her prior pregnancy. The current understanding of the pathogenesis of this enigmatic illness is therefore also reviewed, along with its implications for long-term maternal health.	Brown Univ, Women & Infants Hosp, Sch Med, Providence, RI 02905 USA; Harvard Univ, Sch Med, Boston, MA USA	Brown University; Women & Infants Hospital Rhode Island; Harvard University; Harvard Medical School	Powrie, RO (corresponding author), Brown Univ, Women & Infants Hosp, Sch Med, 101 Dudley St,Ste 1200, Providence, RI 02905 USA.	raymond_powrie@brown.edu						Abalos E, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002252.pub3; *AM COLL OBST GYN, 2001, ACOG PRACT B, V29; American Academy of Pediatrics Committee on Drugs, 2001, Pediatrics, V108, P776; [Anonymous], 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002863; ARMARIO P, 1994, DRUG SAFETY, V11, P80, DOI 10.2165/00002018-199411020-00002; Askie LM, 2007, LANCET, V369, P1791, DOI 10.1016/S0140-6736(07)60712-0; August P, 2004, AM J OBSTET GYNECOL, V191, P1666, DOI 10.1016/j.ajog.2004.03.029; Ayala DE, 2001, HYPERTENSION, V38, P753, DOI 10.1161/01.HYP.38.3.753; Beilin LJ, 2006, HYPERTENSION, V47, P1035, DOI 10.1161/01.HYP.0000218586.21932.3c; BEROYZ G, 1994, LANCET, V343, P619; Borghi C, 2002, J HYPERTENS, V20, pS52; Bortolus R, 2000, BRIT J OBSTET GYNAEC, V107, P792, DOI 10.1111/j.1471-0528.2000.tb13342.x; Briggs G., 2005, DRUGS PREGNANCY LACT; Brown DW, 2006, STROKE, V37, P1055, DOI 10.1161/01.STR.0000206284.96739.ee; Burkman R, 2004, AM J OBSTET GYNECOL, V190, pS5, DOI 10.1016/j.ajog.2004.01.061; CAMPESE VM, 1989, AM J HYPERTENS, V2, pS34, DOI 10.1093/ajh/2.2.34S; Caritis S, 1998, NEW ENGL J MED, V338, P701, DOI 10.1056/NEJM199803123381101; CHILDRESS CH, 1994, OBSTET GYNECOL, V83, P616, DOI 10.1097/00006250-199404000-00024; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Churchill D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004451.pub2; Coccagna G, 2006, CLIN EXP HYPERTENS, V28, P217, DOI 10.1080/10641960600549090; COCKBURN J, 1982, LANCET, V1, P647; Coomarasamy A, 2003, BJOG-INT J OBSTET GY, V110, P882; Cooper WO, 2006, NEW ENGL J MED, V354, P2443, DOI 10.1056/NEJMoa055202; Danzi S, 2003, CURR HYPERTENS REP, V5, P513, DOI 10.1007/s11906-003-0060-7; Dekker G, 2001, LANCET, V357, P209, DOI 10.1016/S0140-6736(00)03599-6; Duckitt K, 2005, BRIT MED J, V330, P565, DOI 10.1136/bmj.38380.674340.E0; Duggan PM, 1998, AUST NZ J OBSTET GYN, V38, P197, DOI 10.1111/j.1479-828X.1998.tb03001.x; Duley L, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001449.pub2, 10.1002/14651858.CD001449.pub3]; Duley L, 2002, LANCET, V359, P1877, DOI 10.1016/s0140-6736(02)08778-0; DULEY L, 2004, COCHRANE DATABASE SC; FARMAKIDES G, 1992, CLIN OBSTET GYNECOL, V35, P387; FERRAZZANI S, 1994, AM J OBSTET GYNECOL, V171, P506, DOI 10.1016/0002-9378(94)90290-9; Funai EF, 2005, EPIDEMIOLOGY, V16, P206, DOI 10.1097/01.ede.0000152912.02042.cd; Gupta M, 1997, BRIT J OBSTET GYNAEC, V104, P350, DOI 10.1111/j.1471-0528.1997.tb11467.x; HALE TW, 2006, MED MOTHERS MILK; HARTIKAINENSORRI AL, 1987, OBSTET GYNECOL, V69, P598; Haukkamaa L, 2004, AM J CARDIOL, V93, P805, DOI 10.1016/j.amjcard.2003.11.065; Hayes SN, 2002, J HYPERTENS, V20, pS47; Hershkovitz R, 2005, HYPERTENS PREGNANCY, V24, P273, DOI 10.1080/10641950500280995; Hofmeyr GJ, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001059.pub2, 10.1002/14651858.CD001059.pub4, 10.1002/14651858.CD001059.pub5]; JOUPPILA P, 1986, BRIT J OBSTET GYNAEC, V93, P543, DOI 10.1111/j.1471-0528.1986.tb07951.x; Kristensen J, 2005, BJOG-INT J OBSTET GY, V112, P403, DOI 10.1111/j.1471-0528.2005.00437.x; Lenders JWM, 2005, LANCET, V366, P665, DOI 10.1016/S0140-6736(05)67139-5; Levine RJ, 2006, NEW ENGL J MED, V355, P992, DOI 10.1056/NEJMoa055352; Lim KH, 1998, AM J OBSTET GYNECOL, V178, P1067, DOI 10.1016/S0002-9378(98)70549-6; Lippi G, 2007, CLIN LAB, V53, P173; Magee L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004351.pub2; Magee L A, 2004, Expert Opin Drug Saf, V3, P25, DOI 10.1517/14740338.3.1.25; Magee LA, 2001, BEST PRACT RES CL OB, V15, P827, DOI 10.1053/beog.2001.0232; Magee LA, 2003, BMJ-BRIT MED J, V327, P955, DOI 10.1136/bmj.327.7421.955; Magee LA, 2000, EUR J OBSTET GYN R B, V88, P15, DOI 10.1016/S0301-2115(99)00113-X; Martin JN, 2005, OBSTET GYNECOL, V105, P246, DOI 10.1097/01.AOG.0000151116.84113.56; MATTSSON C, NAT CLIN PRACT NEPHR; McBride SM, 2005, ENDOCRINE, V28, P199, DOI 10.1385/ENDO:28:2:199; Milne F, 2005, BRIT MED J, V330, P576, DOI 10.1136/bmj.330.7491.576; MULROW C, 2000, AHRQ PUBLICATION; Natarajan P, 1999, AM J OBSTET GYNECOL, V181, P1203, DOI 10.1016/S0002-9378(99)70109-2; Neilson JP, 2000, COCHRANE DB SYST REV, V2; North American Association for the Study of Obesity NHL Blood Institute NIoHNOEI, 2000, PRACTICAL GUIDE IDEN; Os I, 2004, BLOOD PRESSURE, V13, P272, DOI 10.1080/08037050410024330; Ostchega Y, 2005, J HUM HYPERTENS, V19, P885, DOI 10.1038/sj.jhh.1001905; Papageorghiou AT, 2005, BJOG-INT J OBSTET GY, V112, P703, DOI 10.1111/j.1471-0528.2005.00519.x; Pickering TG, 2005, CIRCULATION, V111, P697, DOI 10.1161/01.CIR.0000154900.76284.F6; Pomini F, 2001, J Matern Fetal Med, V10, P398, DOI 10.1080/714052781; Poston L, 2006, LANCET, V367, P1145, DOI 10.1016/S0140-6736(06)68433-X; Quan A, 2006, EARLY HUM DEV, V82, P23, DOI 10.1016/j.earlhumdev.2005.11.001; QUAN A, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002146; Rao P Syamasundar, 2005, Curr Cardiol Rep, V7, P425, DOI 10.1007/s11886-005-0060-0; Ray JG, 2005, LANCET, V366, P1797, DOI 10.1016/S0140-6736(05)67726-4; Redman CW, 2005, SCIENCE, V308, P1592, DOI 10.1126/science.1111726; REDMAN CWG, 1977, BRIT J OBSTET GYNAEC, V84, P419, DOI 10.1111/j.1471-0528.1977.tb12616.x; Rey E, 1997, CAN MED ASSOC J, V157, P1245; REYNODLS B, 1984, ARCH DIS CHILD, V59, P10611; Richardson AD, 2000, INT J CLIN PHARM TH, V38, P75; Richardson DK, 2001, JAMA-J AM MED ASSOC, V286, P1498, DOI 10.1001/jama.286.12.1498; Roberts JM, 2005, HYPERTENSION, V46, P1263, DOI 10.1161/01.HYP.0000188703.27002.14; Roberts JM, 2005, LANCET, V366, P961, DOI 10.1016/S0140-6736(05)67349-7; Rumbold AR, 2006, NEW ENGL J MED, V354, P1796, DOI 10.1056/NEJMoa054186; SACERDOTE A, 2005, CURR HYPERTENS REP; Safar ME, 2004, AM J HYPERTENS, V17, P82, DOI 10.1016/S0895-7061(03)01008-2; Salem MM, 2002, SEMIN NEPHROL, V22, P17, DOI 10.1053/snep.2002.28640; Sciscione AC, 2003, OBSTET GYNECOL, V101, P511, DOI 10.1016/S0029-7844(02)02733-3; Sibai B, 2005, LANCET, V365, P785, DOI 10.1016/S0140-6736(05)71003-5; SIBAI BM, 1984, AM J OBSTET GYNECOL, V150, P831, DOI 10.1016/0002-9378(84)90458-7; Sibai BM, 1998, NEW ENGL J MED, V339, P667, DOI 10.1056/NEJM199809033391004; SIBAI BM, 1986, AM J OBSTET GYNECOL, V155, P1011, DOI 10.1016/0002-9378(86)90336-4; Sibai BM, 2002, OBSTET GYNECOL, V100, P369, DOI 10.1016/S0029-7844(02)02128-2; Smith GCS, 2001, LANCET, V357, P2002, DOI 10.1016/S0140-6736(00)05112-6; Stergiou George S, 2004, Expert Rev Cardiovasc Ther, V2, P359, DOI 10.1586/14779072.2.3.359; Sullivan MHF, 1999, AM J OBSTET GYNECOL, V181, P508, DOI 10.1016/S0002-9378(99)70587-9; TURNBULL JM, 1995, JAMA-J AM MED ASSOC, V274, P1299, DOI 10.1001/jama.274.16.1299; Villamor E, 2006, LANCET, V368, P1164, DOI 10.1016/S0140-6736(06)69473-7; von Dadelszen P, 2006, OBSTET GYNECOL, V107, P209; von Dadelszen P, 2005, OBSTET GYNECOL, V106, P335, DOI 10.1097/01.AOG.0000171121.31564.14; von Dadelszen P, 2000, LANCET, V355, P87, DOI 10.1016/S0140-6736(98)08049-0; von Dadelszen P, 2003, HYPERTENS PREGNANCY, V22, P143, DOI 10.1081/PRG-120021060; Walker JJ, 2000, LANCET, V356, P1260, DOI 10.1016/S0140-6736(00)02800-2; WALTERS BNJ, 1986, CLIN SCI, V71, P589, DOI 10.1042/cs0710589; Webster J, 1996, J CARDIOVASC PHARM, V27, pS49, DOI 10.1097/00005344-199627003-00007; Wolf M, 2004, J CLIN ENDOCR METAB, V89, P6239, DOI 10.1210/jc.2004-0548	101	11	12	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 3	2007	298	13					1548	1558		10.1001/jama.298.13.1548	http://dx.doi.org/10.1001/jama.298.13.1548			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216EE	17911500				2023-01-03	WOS:000249860500027
J	Thompson, WW; Price, C; Goodson, B; Shay, DK; Benson, P; Hinrichsen, VL; Lewis, E; Eriksen, E; Ray, P; Marcy, SM; Dunn, J; Jackson, LA; Lieu, TA; Black, S; Stewart, G; Weintraub, ES; Davis, RL; DeStefano, F				Thompson, William W.; Price, Cristofer; Goodson, Barbara; Shay, David K.; Benson, Patti; Hinrichsen, Virginia L.; Lewis, Edwin; Eriksen, Eileen; Ray, Paula; Marcy, S. Michael; Dunn, John; Jackson, Lisa A.; Lieu, Tracy A.; Black, Steve; Stewart, Gerrie; Weintraub, Eric S.; Davis, Robert L.; DeStefano, Frank		Vaccine Safety Datalink Team	Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VACCINE SAFETY DATALINK; DEVELOPMENTAL DISORDERS; METHYLMERCURY EXPOSURE; CONFOUNDER-SELECTION; UNITED-KINGDOM; CELL-DEATH; INFANTS; NEURODEVELOPMENT; NEUROTOXICITY; ACTIVATION	Background It has been hypothesized that early exposure to thimerosal, a mercury-containing preservative used in vaccines and immune globulin preparations, is associated with neuropsychological deficits in children. Methods We enrolled 1047 children between the ages of 7 and 10 years and administered standardized tests assessing 42 neuropsychological outcomes. (We did not assess autism-spectrum disorders.) Exposure to mercury from thimerosal was determined from computerized immunization records, medical records, personal immunization records, and parent interviews. Information on potential confounding factors was obtained from the interviews and medical charts. We assessed the association between current neuropsychological performance and exposure to mercury during the prenatal period, the neonatal period (birth to 28 days), and the first 7 months of life. Results Among the 42 neuropsychological outcomes, we detected only a few significant associations with exposure to mercury from thimerosal. The detected associations were small and almost equally divided between positive and negative effects. Higher prenatal mercury exposure was associated with better performance on one measure of language and poorer performance on one measure of attention and executive functioning. Increasing levels of mercury exposure from birth to 7 months were associated with better performance on one measure of fine motor coordination and on one measure of attention and executive functioning. Increasing mercury exposure from birth to 28 days was associated with poorer performance on one measure of speech articulation and better performance on one measure of fine motor coordination. Conclusions Our study does not support a causal association between early exposure to mercury from thimerosal-containing vaccines and immune globulins and deficits in neuropsychological functioning at the age of 7 to 10 years.	Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA 30333 USA; ABT Associates Inc, Cambridge, MA 02138 USA; Grp Hlth Ctr Hlth Studies, Seattle, WA USA; Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Kaiser Permanente, Div Res, Oakland, CA USA; Vaccine Study Ctr, Oakland, CA USA; Univ Calif Los Angeles, Ctr Vaccine Res, Torrance, CA USA; So Calif Kaiser Permanente, Los Angeles, CA USA; RTI Int, Atlanta, GA USA; Stanford Univ, Palo Alto, CA 94304 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; ABT Associates; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Kaiser Permanente; University of California System; University of California Los Angeles; Kaiser Permanente; Research Triangle Institute; Stanford University	Thompson, WW (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, MS A32,1600 Clifton Rd NE, Atlanta, GA 30333 USA.	wct2@cdc.gov		Shay, David/0000-0001-9619-4820				Abramson JS, 1999, PEDIATRICS, V104, P570, DOI 10.1542/peds.104.3.570; Andrews N, 2004, PEDIATRICS, V114, P584, DOI 10.1542/peds.2003-1177-L; [Anonymous], 1999, PEDIATRICS, V104, P568; Ball LK, 2001, PEDIATRICS, V107, P1147, DOI 10.1542/peds.107.5.1147; Baskin DS, 2003, TOXICOL SCI, V74, P361, DOI 10.1093/toxsci/kfg126; BRADLEY RH, 1984, DEV PSYCHOL, V20, P315, DOI 10.1037/0012-1649.20.2.315; Budtz-Jorgensen E, 2007, ANN EPIDEMIOL, V17, P27, DOI 10.1016/j.annepidem.2006.05.007; Burbacher TM, 2005, ENVIRON HEALTH PERSP, V113, P1015, DOI 10.1289/ehp.7712; Chen RT, 2000, B WORLD HEALTH ORGAN, V78, P186; Chen RT, 1997, PEDIATRICS, V99, P765, DOI 10.1542/peds.99.6.765; Crump KS, 1998, RISK ANAL, V18, P701, DOI 10.1023/B:RIAN.0000005917.52151.e6; Davidson PU, 2001, JAMA-J AM MED ASSOC, V285, P1291, DOI 10.1001/jama.285.10.1291-a; Davidson PW, 1998, JAMA-J AM MED ASSOC, V280, P701, DOI 10.1001/jama.280.8.701; Goldfrank LR, 2002, GOLDFRANKS TOXICOLOG; Goth SR, 2006, ENVIRON HEALTH PERSP, V114, P1083, DOI 10.1289/ehp.8881; Grandjean P, 1999, AM J EPIDEMIOL, V150, P301, DOI 10.1093/oxfordjournals.aje.a010002; Havarinasab S, 2006, TOXICOL APPL PHARM, V214, P43, DOI 10.1016/j.taap.2005.12.004; Havarinasab S, 2005, TOXICOL APPL PHARM, V204, P109, DOI 10.1016/j.taap.2004.08.019; Heron J, 2004, PEDIATRICS, V114, P577, DOI 10.1542/peds.2003-1176-L; Hornig M, 2004, MOL PSYCHIATR, V9, P833, DOI 10.1038/sj.mp.4001529; Hunter JE, 2002, HUM COMMUN RES, V28, P552, DOI 10.1093/hcr/28.4.552; Jacobson JL, 2001, NEUROTOXICOLOGY, V22, P667, DOI 10.1016/S0161-813X(01)00040-7; James SJ, 2005, NEUROTOXICOLOGY, V26, P1, DOI 10.1016/j.neuro.2004.07.012; KIM JO, 1981, SOCIOL METHOD RES, V10, P187, DOI 10.1177/004912418101000203; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; *MED EC, 1995, PHYS DESK REF; Medical Economics, 1999, PHYS DESK REF, V53rd; Mutkus L, 2005, BIOL TRACE ELEM RES, V105, P71, DOI 10.1385/BTER:105:1-3:071; Parran DK, 2005, TOXICOL SCI, V86, P132, DOI 10.1093/toxsci/kfi175; Pichichero ME, 2002, LANCET, V360, P1737, DOI 10.1016/S0140-6736(02)11682-5; PRICE C, 2007, INFANT ENV EXPOSURE, V1; Stern Alan H, 2004, Environ Health, V3, P2, DOI 10.1186/1476-069X-3-2; Stewart G, 2007, INFANT ENV EXPOSURE, VII; Totsika Vasiliki, 2004, Child Adolesc Ment Health, V9, P25, DOI 10.1046/j.1475-357X.2003.00073.x; Verstraeten T, 2003, PEDIATRICS, V112, P1039, DOI 10.1542/peds.112.2.e98; Waly M, 2004, MOL PSYCHIATR, V9, P358, DOI 10.1038/sj.mp.4001476	36	174	182	0	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 27	2007	357	13					1281	1292		10.1056/NEJMoa071434	http://dx.doi.org/10.1056/NEJMoa071434			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214BR	17898097				2023-01-03	WOS:000249711500004
J	Singh, S				Singh, Seema			From exotic spice to modern drug?	CELL			English	Editorial Material								The global demand for more affordable therapeutics and concerns about side effects of commonly used drugs are refocusing interest on Eastern traditional medicines, particularly those of India and China.											0	158	165	0	16	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 7	2007	130	5					765	768		10.1016/j.cell.2007.08.024	http://dx.doi.org/10.1016/j.cell.2007.08.024			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	212GI	17803897	Bronze			2023-01-03	WOS:000249581500006
J	Tung, A				Tung, Avery			The other side	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 15	2007	298	7					722	723		10.1001/jama.298.7.722	http://dx.doi.org/10.1001/jama.298.7.722			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	199XP	17699001				2023-01-03	WOS:000248728800001
J	Gazelle, G				Gazelle, Gail			Understanding hospice - An underutilized option for life's final chapter	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARE		MD Can Help, Boston, MA USA		Gazelle, G (corresponding author), MD Can Help, Boston, MA USA.							Emanuel L L, 2000, J Palliat Med, V3, P419, DOI 10.1089/jpm.2000.3.4.419; National Hospice and Palliative Care Organization, 2006, NHCPOS FACTS FIG 200; Schnipper L, 1998, J CLIN ONCOL, V16, P1986; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011	5	48	48	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 26	2007	357	4					321	324		10.1056/NEJMp078067	http://dx.doi.org/10.1056/NEJMp078067			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	193OL	17652645				2023-01-03	WOS:000248283500001
J	Manheimer, E; Linde, K; Lao, LX; Bouter, LM; Berman, BM				Manheimer, Eric; Linde, Klaus; Lao, Lixing; Bouter, Lex M.; Berman, Brian M.			Meta-analysis: Acupuncture for osteoarthritis of the knee	ANNALS OF INTERNAL MEDICINE			English	Review							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RANDOMIZED CONTROLLED-TRIAL; CONTROLLED CLINICAL-TRIALS; LOW-BACK-PAIN; HIP OSTEOARTHRITIS; ADJUNCTIVE THERAPY; SYSTEMATIC REVIEWS; PRAGMATIC TRIALS; HEALTH-CARE; PLACEBO	Background: Knee osteoarthritis is a major cause of pain and functional limitation. Purpose: To evaluate the effects of acupuncture for treating knee osteoarthritis. Data Sources: Cochrane Central Register of Controlled Trials MEDLINE, and EMBASE databases to January 2007. No language restrictions were applied. Study Selection: Randomized trials longer than 6 weeks in duration that compared needle acupuncture with a sham, usual care, or waiting list control group for patients with knee osteoarthritis. Data Extraction: Two authors independently agreed on eligibility, assessed methodological quality and acupuncture adequacy, and extracted outcome data on pain and function measures. Data Synthesis: Eleven trials met the selection criteria, and 9 reported sufficient data for pooling. Standardized mean differences were calculated by using differences in improvements from baseline between patients assigned to acupuncture and those assigned to control groups. Compared with patients in waiting list control groups, patients who received acupuncture reported clinically relevant short-term improvements in pain (standardized mean difference, -0.96 [95% CI, -1.21 to -0.701) and function (standardized mean difference, -0.93 [CI, -1.16 to -0.69]). Patients who received acupuncture also reported clinically relevant short- and long-term improvements in pain and function compared with patients in usual care control groups. Compared with a sham control, acupuncture provided clinically irrelevant short-term improvements in pain (standardized mean difference, -0.35 [CI, -0.55 to -0.15]) and function (standardized mean difference, -0.35 [CI, -0.56 to -0.141) and clinically irrelevant long-term improvements in pain (standardized mean difference, -0.13 [CI, -0.24 to -0.01]) and function (standardized mean difference, -0.14 [CI, -0.26 to -0.031). Limitation: Sham-controlled trials had heterogeneous results that were probably due to the variability of acupuncture and sham protocols, patient samples, and settings. Conclusions: Sham-controlled trials show clinically irrelevant shortterm benefits of acupuncture for treating knee osteoarthritis. Waiting list-controlled trials suggest clinically relevant benefits, some of which may be due to placebo or expectation effects.	Univ Maryland, Ctr Integrat Med, Sch Med, Baltimore, MD 21207 USA; Tech Univ Munich, D-8000 Munich, Germany; Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands	University System of Maryland; University of Maryland Baltimore; Technical University of Munich; Vrije Universiteit Amsterdam	Manheimer, E (corresponding author), Univ Maryland, Ctr Integrat Med, Sch Med, 2200 Kernan Dr,Kernan Hosp Mans, Baltimore, MD 21207 USA.		Bouter, Lex/X-1003-2019; Lao, Lixing/I-7979-2013	Bouter, Lex/0000-0002-2659-5482; Linde, Klaus/0000-0002-2902-970X; Lao, Lixing/0000-0003-0198-9714	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [P01AT002605] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R24AT001293] Funding Source: NIH RePORTER; NCCIH NIH HHS [P01 AT002605-01A1, R24 AT001293] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Angst F, 2002, J RHEUMATOL, V29, P131; Ausiello JC, 2002, J RHEUMATOL, V29, P999; Bellamy N, 2005, CLIN EXP RHEUMATOL, V23, pS148; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Berman BM, 1999, RHEUMATOLOGY, V38, P346, DOI 10.1093/rheumatology/38.4.346; Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006; Birch S, 2006, J ALTERN COMPLEM MED, V12, P303, DOI 10.1089/acm.2006.12.303; Birch S, 2004, J ALTERN COMPLEM MED, V10, P481, DOI 10.1089/1075553041323911; Birch S, 1998, JAPANESE ACUPUNCTURE; Bjordal JM, 2004, BMJ-BRIT MED J, V329, P1317, DOI 10.1136/bmj.38273.626655.63; Blower AL, 1997, ALIMENT PHARM THERAP, V11, P283, DOI 10.1046/j.1365-2036.1997.d01-604.x; Cherkin DC, 2003, ANN INTERN MED, V138, P898, DOI 10.7326/0003-4819-138-11-200306030-00011; Cherkin DC, 2005, ANN INTERN MED, V142, P872, DOI 10.7326/0003-4819-142-10-200505170-00019; CHRISTENSEN BV, 1992, ACTA ANAESTH SCAND, V36, P519, DOI 10.1111/j.1399-6576.1992.tb03511.x; Christensen R, 2007, ANN RHEUM DIS, V66, P433, DOI 10.1136/ard.2006.065904; *COCHR COLL NORD C, 2003, REV MAN REVMAN COMP; DEEKS JJ, 2003, STANDARD STAT ALGORI; DEEKS JJ, 2005, COCHRANE HDB SYSTEMA; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Ernst E, 1997, SCAND J RHEUMATOL, V26, P444, DOI 10.3109/03009749709065717; Ernst E, 2006, RHEUMATOLOGY, V45, P125, DOI 10.1093/rheumatology/kei256; Ezzo J, 2001, ARTHRITIS RHEUM, V44, P819, DOI 10.1002/1529-0131(200104)44:4<819::AID-ANR138>3.0.CO;2-P; Felson DT, 1998, ARTHRITIS RHEUM, V41, P1343, DOI 10.1002/1529-0131(199808)41:8<1343::AID-ART3>3.0.CO;2-9; Fransen M, 2003, COCHRANE DB SYST REV; Furlan AD, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001351.pub2; Glanville JM, 2006, J MED LIBR ASSOC, V94, P130; GREENLAND S, 1994, AM J EPIDEMIOL, V140, P290, DOI 10.1093/oxfordjournals.aje.a117248; Hernandez-Diaz S, 2000, ARCH INTERN MED, V160, P2093, DOI 10.1001/archinte.160.14.2093; Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Kalauokalani D, 2001, SPINE, V26, P1418, DOI 10.1097/00007632-200107010-00005; Kwon YD, 2006, RHEUMATOLOGY, V45, P1331, DOI 10.1093/rheumatology/kel207; LEBARS D, 1979, PAIN, V6, P283, DOI 10.1016/0304-3959(79)90049-6; Lethbridge-Cejku M, 2004, VITAL HLTH STAT, V10, P1; Linde K, 2001, BMC Complement Altern Med, V1, P3; Linde Klaus, 2004, Z Arztl Fortbild Qualitatssich, V98, P467; MACDONALD AJR, 1983, ANN ROY COLL SURG, V65, P44; MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486; McGettigan P, 2006, JAMA-J AM MED ASSOC, V296, P1633, DOI 10.1001/jama.296.13.jrv60011; Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104; Moerman DE, 2002, ANN INTERN MED, V136, P471, DOI 10.7326/0003-4819-136-6-200203190-00011; Molsberger A, 1994, Schmerz, V8, P37, DOI 10.1007/BF02527508; Ng MML, 2003, J ALTERN COMPLEM MED, V9, P641, DOI 10.1089/107555303322524490; OLIVERIA SA, 1995, ARTHRITIS RHEUM, V38, P1134, DOI 10.1002/art.1780380817; Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016; Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202; Peat G, 2001, ANN RHEUM DIS, V60, P91, DOI 10.1136/ard.60.2.91; PETROU P, 1988, SCAND J ACUPUNCT, V3, P113; Roland M, 1998, BRIT MED J, V316, P285, DOI 10.1136/bmj.316.7127.285; Sangdee Chaichan, 2002, BMC Complement Altern Med, V2, P3, DOI 10.1186/1472-6882-2-3; Scharf HP, 2006, ANN INTERN MED, V145, P12, DOI 10.7326/0003-4819-145-1-200607040-00005; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schulz KF, 2002, LANCET, V359, P696, DOI 10.1016/S0140-6736(02)07816-9; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; Takeda W, 1994, Arthritis Care Res, V7, P118, DOI 10.1002/art.1790070304; Towheed TE, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004257.pub2; Tukmachi Emad, 2004, Acupunct Med, V22, P14; Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6; van Tulder M, 2003, SPINE, V28, P1290, DOI 10.1097/01.BRS.0000065484.95996.AF; Vas J, 2004, BMJ-BRIT MED J, V329, P1216, DOI 10.1136/bmj.38238.601447.3A; Wegman A, 2004, J RHEUMATOL, V31, P344; White A, 2007, RHEUMATOLOGY, V46, P384, DOI 10.1093/rheumatology/kel413; White A, 2001, BRIT MED J, V323, P485, DOI 10.1136/bmj.323.7311.485; White P, 2004, ANN INTERN MED, V141, P911, DOI 10.7326/0003-4819-141-12-200412210-00007; Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7; Witt CM, 2006, ARTHRITIS RHEUM-US, V54, P3485, DOI 10.1002/art.22154; World Health Organization, 1991, PROP STAND INT AC NO; Yurtkuran M, 1999, Am J Acupunct, V27, P133; 2001, MMWR MORB MORTAL WKL, V51, P948	70	158	166	1	30	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2007	146	12					868	877		10.7326/0003-4819-146-12-200706190-00008	http://dx.doi.org/10.7326/0003-4819-146-12-200706190-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180FF	17577006	Green Published			2023-01-03	WOS:000247347100005
J	Ebbeling, CB; Leidig, MM; Feldman, HA; Lovesky, MM; Ludwig, DS				Ebbeling, Cara B.; Leidig, Michael M.; Feldman, Henry A.; Lovesky, Margaret M.; Ludwig, David S.			Effects of a low-glycemic load vs low-fat diet in obese young adults - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORAL GLUCOSE-TOLERANCE; WEIGHT-LOSS; LOW-CARBOHYDRATE; RISK-FACTORS; INSULIN SENSITIVITY; METABOLIC SYNDROME; LDL-CHOLESTEROL; PUBLIC-HEALTH; HEART-DISEASE; OVERWEIGHT	Context The results of clinical trials involving diet in the treatment of obesity have been inconsistent, possibly due to inherent physiological differences among study participants. Objective To determine whether insulin secretion affects weight loss with 2 popular diets. Design, Setting, and Participants Randomized trial of obese young adults ( aged 18-35 years; n= 73) conducted from September 2004 to December 2006 in Boston, Mass, and consisting of a 6-month intensive intervention period and a 12-month follow-up period. Serum insulin concentration at 30 minutes after a 75-g dose of oral glucose was determined at baseline as a measure of insulin secretion. Outcomes were assessed at 6, 12, and 18 months. Missing data were imputed conservatively. Interventions A low - glycemic load (40% carbohydrate and 35% fat) vs low-fat (55% carbohydrate and 20% fat) diet. Main Outcome Measures Body weight, body fat percentage determined by dual-energy x-ray absorptiometry, and cardiovascular disease risk factors. Results Change in body weight and body fat percentage did not differ between the diet groups overall. However, insulin concentration at 30 minutes after a dose of oral glucose was an effect modifier ( group x time x insulin concentration at 30 minutes: P=.02 for body weight and P=.01 for body fat percentage). For those with insulin concentration at 30 minutes above the median (57.5 mu IU/mL; n= 28), the low - glycemic load diet produced a greater decrease in weight ( - 5.8 vs - 1.2 kg; P=. 004) and body fat percentage ( - 2.6% vs - 0.9%; P=. 03) than the low-fat diet at 18 months. There were no significant differences in these end points between diet groups for those with insulin concentration at 30 minutes below the median level ( n= 28). Insulin concentration at 30 minutes after a dose of oral glucose was not a significant effect modifier for cardiovascular disease risk factors. In the full cohort, plasma high-density lipoprotein cholesterol and triglyceride concentrations improved more on the low - glycemic load diet, whereas low-density lipoprotein cholesterol concentration improved more on the low-fat diet. Conclusions Variability in dietary weight loss trials may be partially attributable to differences in hormonal response. Reducing glycemic load may be especially important to achieve weight loss among individuals with high insulin secretion. Regardless of insulin secretion, a low - glycemic load diet has beneficial effects on high-density lipoprotein cholesterol and triglyceride concentrations but not on low-density lipoprotein cholesterol concentration.	Childrens Hosp Boston, Dept Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital	Ludwig, DS (corresponding author), Childrens Hosp Boston, Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.	david.ludwig@childrens.harvard.edu	Feldman, Henry/M-2302-2013	Ludwig, David/0000-0003-3307-8544	NCRR NIH HHS [M01 RR02172] Funding Source: Medline; NIDDK NIH HHS [P30 DK040561, P30 DK040561-12, R01 DK59240] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059240, P30DK040561] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; Astrup A, 2001, INT J OBESITY, V25, pS46, DOI [10.1038/sj.ijo.0801698, 10.1038/sj/ijo/0801698]; BOUCHARD C, 1983, AM J CLIN NUTR, V37, P461, DOI 10.1093/ajcn/37.3.461; Brand-Miller JC, 2003, J NUTR, V133, P2728, DOI 10.1093/jn/133.9.2728; Bray GA, 1998, AM J CLIN NUTR, V68, P1157, DOI 10.1093/ajcn/68.6.1157; Chevenne D, 1998, CLIN CHEM, V44, P354; Chiu KC, 2002, METABOLISM, V51, P115, DOI 10.1053/meta.2002.29027; Cornier MA, 2005, OBES RES, V13, P703, DOI 10.1038/oby.2005.79; Dansinger ML, 2005, JAMA-J AM MED ASSOC, V293, P43, DOI 10.1001/jama.293.1.43; de Castro JM, 2006, J NUTR, V136, P1382, DOI 10.1093/jn/136.5.1382; Ebbeling C B, 2001, Adv Pediatr, V48, P179; Ebbeling CB, 2005, AM J CLIN NUTR, V81, P976; Ebbeling CB, 2003, ARCH PEDIAT ADOL MED, V157, P773, DOI 10.1001/archpedi.157.8.773; Ebbeling CB, 2005, HDB PEDIAT OBESITY E; Foster-Powell K, 2002, AM J CLIN NUTR, V76, P5, DOI 10.1093/ajcn/76.1.5; Gardner CD, 2007, JAMA-J AM MED ASSOC, V297, P969, DOI 10.1001/jama.297.9.969; Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404; Halton TL, 2006, NEW ENGL J MED, V355, P1991, DOI 10.1056/NEJMoa055317; Heymsfield SB, 2007, AM J CLIN NUTR, V85, P346, DOI 10.1093/ajcn/85.2.346; Hill JO, 2000, J NUTR, V130, p284S, DOI 10.1093/jn/130.2.284S; KADOWAKI T, 1984, DIABETOLOGIA, V26, P44, DOI 10.1007/BF00252262; Katz DS, 2005, MED RAD DIA IMG, P1, DOI 10.1007/3-540-26984-3_1; Klein S, 2004, DIABETES CARE, V27, P2067, DOI 10.2337/diacare.27.8.2067; Lau C, 2006, AM J CLIN NUTR, V84, P641, DOI 10.1093/ajcn/84.3.641; Lewis CE, 2000, AM J EPIDEMIOL, V151, P1172, DOI 10.1093/oxfordjournals.aje.a010167; Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414; Ludwig DS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.3.e26; McAuley KA, 2005, DIABETOLOGIA, V48, P8, DOI 10.1007/s00125-004-1603-4; McKeown NM, 2004, DIABETES CARE, V27, P538, DOI 10.2337/diacare.27.2.538; McMillan-Price J, 2006, ARCH INTERN MED, V166, P1466, DOI 10.1001/archinte.166.14.1466; MONCHER FJ, 1991, CLIN PSYCHOL REV, V11, P247, DOI 10.1016/0272-7358(91)90103-2; Nordmann AJ, 2006, ARCH INTERN MED, V166, P285, DOI 10.1001/archinte.166.3.285; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Pawlak DB, 2004, LANCET, V364, P778, DOI 10.1016/S0140-6736(04)16937-7; PHILLIPS DIW, 1994, DIABETIC MED, V11, P286, DOI 10.1111/j.1464-5491.1994.tb00273.x; Pi-Sunyer FX, 2002, AM J CLIN NUTR, V76, p290S, DOI 10.1093/ajcn/76.1.290S; Pittas AG, 2005, DIABETES CARE, V28, P2939, DOI 10.2337/diacare.28.12.2939; Raben A, 2002, Obes Rev, V3, P245, DOI 10.1046/j.1467-789X.2002.00080.x; Rifai N, 1998, CLIN CHEM, V44, P1242; Rolls BJ, 2000, J NUTR, V130, p268S, DOI 10.1093/jn/130.2.268S; Rosal MC, 2001, J AM DIET ASSOC, V101, P332, DOI 10.1016/S0002-8223(01)00086-4; Sacks FM, 2002, AM J MED, V113, P13, DOI 10.1016/S0002-9343(01)00987-1; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; Sloth B, 2004, AM J CLIN NUTR, V80, P337, DOI 10.1093/ajcn/80.2.337; Vella J., 2002, LEARNING LISTEN LEAR; Yancy WS, 2004, ANN INTERN MED, V140, P769, DOI 10.7326/0003-4819-140-10-200405180-00006	48	273	278	3	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 16	2007	297	19					2092	2102		10.1001/jama.297.19.2092	http://dx.doi.org/10.1001/jama.297.19.2092			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	167UG	17507345				2023-01-03	WOS:000246477400022
J	Thamer, M; Zhang, Y; Kaufman, J; Cotter, D; Dong, F; Hernan, MA				Thamer, Mae; Zhang, Yi; Kaufman, James; Cotter, Dennis; Dong, Fan; Hernan, Miguel A.			Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STAGE RENAL-DISEASE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; PERFORMANCE MEASURES PROJECT; HEMOGLOBIN LEVELS; ANEMIA; MANAGEMENT; MORTALITY; SURVIVAL; FAILURE	Context Epoetin therapy for dialysis-related anemia is the single largest Medicare drug expenditure. The type of facility ( profit, chain, and affiliation status) at which a patient receives dialysis might affect epoetin dosing patterns and has implications for future epoetin policies. Objective To examine the association between dialysis facility ownership and the dose of epoetin administered. Design, Setting, and Participants Data from the US Renal Data System were used to identify 159 522 adult Medicare-eligible, end-stage renal disease patients receiving in-center hemodialysis during November and December 2004. Regression models were used to estimate the mean epoetin dose and dose adjustment by profit, chain, and affiliation status. Main Outcome Measures Weekly mean epoetin dose administered in December 2004 and the adjustment in dose between November and December 2004. Results Compared with patients in nonprofit dialysis facilities (n= 28 199), patients in large for-profit dialysis chain facilities ( n= 106 116) were consistently administered the highest doses of epoetin regardless of anemia status. Compared with nonprofit facilities, for-profit facilities administered, on average, an additional 3306 U/wk of epoetin. Among the 6 large chain facilities with a similar patient case-mix, the average dose of epoetin ranged from 17 832 U/wk at chain 5 ( nonprofit facilities with a mean hematocrit level of 34.6%) to 24 986 U/wk at chain 2 ( for-profit facilities with a mean hematocrit level of 36.5%). Dosing adjustments also differed by type of facility. On average, compared with nonprofit facilities, for-profit facilities increased epoetin doses 3-fold for patients with hematocrit levels of less 33% and also increased the doses among patients with hematocrit levels in the recommended target of 33% to 36%, especially in the largest for-profit chain facilities. The greatest difference in dosing practice patterns between facilities was found among patients with hematocrit levels of less than 33%. Conclusions Dialysis facility organizational status and ownership are associated with variation in epoetin dosing in the United States. Different epoetin dosing patterns suggest that large for-profit chain facilities used larger dose adjustments and targeted higher hematocrit levels.	Med Technol & Practice Patterns Inst, Bethesda, MD 20814 USA; Vet Affairs Healthcare Syst, Renal Sect, Boston, MA USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Boston University; Harvard University; Harvard T.H. Chan School of Public Health	Cotter, D (corresponding author), Med Technol & Practice Patterns Inst, 4733 Bethesda Ave,Suite 510, Bethesda, MD 20814 USA.	dcott@mtppi.org		Hernan, Miguel/0000-0003-1619-8456	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066011] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK066011-01A2] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMSON JW, 1989, Q J MED, V73, P1093; [Anonymous], 2001, Am J Kidney Dis, V37, pS182; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Coladonato JA, 2002, J AM SOC NEPHROL, V13, P1288, DOI 10.1097/01.ASN.0000013294.11876.80; Collins AJ, 2007, AM J KIDNEY DIS, V49, P135, DOI 10.1053/j.ajkd.2006.09.020; Cotter D, 2006, HEALTH AFFAIR, V25, P1249, DOI 10.1377/hlthaff.25.5.1249; *CTR MED MED SERV, 2004, ANN REP ESRD CLIN PE; *DAV INC, 2006, ANN REP; DELISSOVOY G, 1994, MED CARE, V32, P130, DOI 10.1097/00005650-199402000-00004; DEPALMA JR, 2000, DIALYSIS TRANSPLANT, V29, P677; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; ESCHBACH JW, 1985, KIDNEY INT, V28, P1, DOI 10.1038/ki.1985.109; ESCHBACH JW, 1989, NEW ENGL J MED, V321, P158, DOI 10.1056/NEJM198907203210305; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; Foley RN, 2000, KIDNEY INT, V58, P1325, DOI 10.1046/j.1523-1755.2000.00289.x; Frankenfield DL, 2004, KIDNEY INT, V65, P1426, DOI 10.1111/j.1523-1755.2004.00515.x; Garg PP, 1999, NEW ENGL J MED, V341, P1653, DOI 10.1056/NEJM199911253412205; GOOZNER M, 1999, CHICAGO TRIBUNE 0524, pA1; GRAY BH, 1986, NEW ENGL J MED, V314, P1523, DOI 10.1056/NEJM198606053142335; HELD PJ, 1990, AM J KIDNEY DIS, V15, P441, DOI 10.1016/S0272-6386(12)70362-1; Kalantar-Zadeh K, 2003, AM J KIDNEY DIS, V42, P761, DOI 10.1016/S0272-6386(03)00915-6; KDOQI, 2006, Am J Kidney Dis, V47, pS16; LAUPACIS A, 1991, TRANSPL P, V23, P1825; *NAT I DIAB DIG KI, 2005, US REN DAT SYST 2006; NISSENSON AR, 1993, KIDNEY INT, V43, pS120; Parfrey PS, 2005, J AM SOC NEPHROL, V16, P2180, DOI 10.1681/ASN.2004121039; SCHLESINGER M, 1989, MED CARE, V27, P244, DOI 10.1097/00005650-198903000-00003; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Steinbrook R, 2007, NEW ENGL J MED, V356, P4, DOI 10.1056/NEJMp068296; Szczech LA, 2006, KIDNEY INT, V69, P2094, DOI 10.1038/sj.ki.5000267; TAMG DC, 1999, KIDNEY INT S, V69, pS107; Thamer M, 2006, AM J KIDNEY DIS, V48, P77, DOI 10.1053/j.ajkd.2006.03.040; US Renal Data System, 2006, US REN DAT SYST ANN; van Manen JG, 2002, AM J KIDNEY DIS, V40, P82, DOI 10.1053/ajkd.2002.33916; Zhang Y, 2004, AM J KIDNEY DIS, V44, P866, DOI 10.1053/j.ajkd.2004.08.002; 2001, AM J KIDNEY DIS, V38, P442	37	97	98	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 18	2007	297	15					1667	1674		10.1001/jama.297.15.1667	http://dx.doi.org/10.1001/jama.297.15.1667			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157UR	17440144	Bronze			2023-01-03	WOS:000245747400020
J	Fernandez, F; Morishita, W; Zuniga, E; Nguyen, J; Blank, M; Malenka, RC; Garner, CC				Fernandez, Fabian; Morishita, Wade; Zuniga, Elizabeth; Nguyen, James; Blank, Martina; Malenka, Robert C.; Garner, Craig C.			Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome	NATURE NEUROSCIENCE			English	Article							LONG-TERM POTENTIATION; TS65DN MOUSE; ABNORMALITIES; STORAGE; MICE; LTP	Ts65Dn mice, a model for Down syndrome, have excessive inhibition in the dentate gyrus, a condition that could compromise synaptic plasticity and mnemonic processing. We show that chronic systemic treatment of these mice with GABA(A) antagonists at non-epileptic doses causes a persistent post-drug recovery of cognition and long-term potentiation. These results suggest that over-inhibition contributes to intellectual disabilities associated with Down syndrome and that GABA(A) antagonists may be useful therapeutic agents for this disorder.	Stanford Univ, Nancy Pritzker Lab, Dept Psychiat & Behav Sci, Palo Alto, CA 94305 USA	Stanford University	Garner, CC (corresponding author), Stanford Univ, Nancy Pritzker Lab, Dept Psychiat & Behav Sci, Palo Alto, CA 94305 USA.	cgarner@stanford.edu		Fernandez, Fabian-Xose/0000-0002-4288-5383; Garner, Craig/0000-0003-1970-5417				Belichenko PV, 2004, J COMP NEUROL, V480, P281, DOI 10.1002/cne.20337; Costa ACS, 2005, NEUROSCI LETT, V382, P317, DOI 10.1016/j.neulet.2005.03.031; Gerlai R, 1998, BEHAV BRAIN RES, V95, P91, DOI 10.1016/S0166-4328(97)00214-3; HANSON JE, IN PRESS J PHYSL LON; Holtzman DM, 1996, P NATL ACAD SCI USA, V93, P13333, DOI 10.1073/pnas.93.23.13333; Ivic L, 2003, J BIOL CHEM, V278, P49279, DOI 10.1074/jbc.M304034200; Kleschevnikov AM, 2004, J NEUROSCI, V24, P8153, DOI 10.1523/JNEUROSCI.1766-04.2004; Kurt MA, 2000, BRAIN RES, V858, P191, DOI 10.1016/S0006-8993(00)01984-3; LANDFIELD PW, 1981, SCIENCE, V214, P581, DOI 10.1126/science.6270791; LEVY S, 1953, JAMA-J AM MED ASSOC, V153, P1260, DOI 10.1001/jama.1953.02940310028007; MCGAUGH JL, 1966, SCIENCE, V153, P1351, DOI 10.1126/science.153.3742.1351; Nadel L, 2003, GENES BRAIN BEHAV, V2, P156, DOI 10.1034/j.1601-183X.2003.00026.x; Pastalkova E, 2006, SCIENCE, V313, P1141, DOI 10.1126/science.1128657; Seregaza Z, 2006, BEHAV GENET, V36, P387, DOI 10.1007/s10519-006-9056-9; Whitlock JR, 2006, SCIENCE, V313, P1093, DOI 10.1126/science.1128134	15	376	394	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1097-6256			NAT NEUROSCI	Nat. Neurosci.	APR	2007	10	4					411	413		10.1038/nn1860	http://dx.doi.org/10.1038/nn1860			3	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	150PL	17322876				2023-01-03	WOS:000245228600008
J	Franck, L; Chantler, C; Dixon, M				Franck, Linda; Chantler, Cyril; Dixon, Michael			Should NICE evaluate complementary and alternative medicine?	BRITISH MEDICAL JOURNAL			English	Article									UCL, Inst Child Hlth, London WC1N 1EH, England; Kings Fund, London W1G OAN, England; NHS Alliance, Nottingham DN22 6JD, England	University of London; University College London	Franck, L (corresponding author), UCL, Inst Child Hlth, London WC1N 1EH, England.	l.franck@ich.ucl.ac.uk	; Colquhoun, David/C-1664-2008	Franck, Linda/0000-0003-4291-9181; Colquhoun, David/0000-0002-4263-017X					0	15	15	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 10	2007	334	7592					506	506		10.1136/bmj.39122.512211.BE	http://dx.doi.org/10.1136/bmj.39122.512211.BE			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148VV	17347233	Green Submitted, Green Published			2023-01-03	WOS:000245106400034
J	Grady, D				Grady, Deborah			Management of menopausal symptoms	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONJUGATED EQUINE ESTROGENS; HORMONE REPLACEMENT THERAPY; MILD COGNITIVE IMPAIRMENT; HOT FLASHES; POSTMENOPAUSAL WOMEN; BREAST-CANCER; DOUBLE-BLIND; VASOMOTOR SYMPTOMS; VAGINAL ATROPHY; PLUS PROGESTIN		Univ Calif San Francisco, Womens Hlth Clin Res Ctr, San Francisco, CA 94115 USA; San Francisco VA Med Ctr, San Francisco, CA USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Grady, D (corresponding author), Univ Calif San Francisco, Womens Hlth Clin Res Ctr, 1635 Divisadero St,Suite 600, San Francisco, CA 94115 USA.							Aiello EJ, 2004, MENOPAUSE, V11, P382, DOI 10.1097/01.GME.0000113932.56832.27; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Avis NE, 2001, SOC SCI MED, V52, P345, DOI 10.1016/S0277-9536(00)00147-7; Barton DL, 1998, J CLIN ONCOL, V16, P495, DOI 10.1200/JCO.1998.16.2.495; Cardozo L, 1998, OBSTET GYNECOL, V92, P722, DOI 10.1016/S0029-7844(98)00175-6; CASPER RF, 1985, CLIN ENDOCRINOL, V22, P293, DOI 10.1111/j.1365-2265.1985.tb03243.x; Dennerstein L, 2000, OBSTET GYNECOL, V96, P351, DOI 10.1016/S0029-7844(00)00930-3; EPOCRATES, EPOCRATES RX PRO LIS; Ettinger Bruce, 2005, Am J Med, V118 Suppl 12B, P74, DOI 10.1016/j.amjmed.2005.09.035; Evans ML, 2005, OBSTET GYNECOL, V105, P161, DOI 10.1097/01.AOG.0000147840.06947.46; FREEDMAN RR, 1992, AM J OBSTET GYNECOL, V167, P436, DOI 10.1016/S0002-9378(11)91425-2; Gold EB, 2000, AM J EPIDEMIOL, V152, P463, DOI 10.1093/aje/152.5.463; Goldberg, 1996, J CLIN ONCOL, V14, P2411, DOI 10.1200/JCO.1996.14.8.2411; GOLDBERG RM, 1994, J CLIN ONCOL, V12, P155, DOI 10.1200/JCO.1994.12.1.155; Gomes MPV, 2004, ARCH INTERN MED, V164, P1965, DOI 10.1001/archinte.164.18.1965; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; Grady Deborah, 2005, Am J Med, V118 Suppl 12B, P163, DOI 10.1016/j.amjmed.2005.09.051; Guttuso T, 2003, OBSTET GYNECOL, V101, P337, DOI 10.1016/S0029-7844(02)02712-6; Henriksson L, 1996, AM J OBSTET GYNECOL, V174, P85, DOI 10.1016/S0002-9378(96)70378-2; Jin Y, 2005, JNCI-J NATL CANCER I, V97, P30, DOI 10.1093/jnci/dji005; Judd HL, 1996, JAMA-J AM MED ASSOC, V275, P370, DOI 10.1001/jama.1996.03530290040035; Kimmick GG, 2006, BREAST J, V12, P114, DOI 10.1111/j.1075-122X.2006.00218.x; Kronenberg F, 2002, ANN INTERN MED, V137, P805, DOI 10.7326/0003-4819-137-10-200211190-00009; KRONENBERG F, 1990, ANN NY ACAD SCI, V592, P52; KRONENBERG F, 1992, J THERM BIOL, V17, P43, DOI 10.1016/0306-4565(92)90018-B; KRONENBERG F, 1990, ANN NY ACAD SCI, V592, P123; Landgren MB, 2005, MATURITAS, V50, P222, DOI 10.1016/j.maturitas.2004.06.001; LEIBLUM S, 1983, JAMA-J AM MED ASSOC, V249, P2195, DOI 10.1001/jama.249.16.2195; Lethaby A., 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000402, DOI 10.1002/14651858.CD000402, 10.1002/14651858.CD000402.pub2]; Loprinzi CL, 2002, J CLIN ONCOL, V20, P1578, DOI 10.1200/JCO.20.6.1578; Loprinzi CL, 2000, LANCET, V356, P2059, DOI 10.1016/S0140-6736(00)03403-6; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; Low Dog Tieraona, 2005, Am J Med, V118 Suppl 12B, P98; *N AM MEN SOC, 2004, MENOPAUSE, V11, P589; NACHTIGALL LE, 1994, FERTIL STERIL, V61, P178; Nelson H D, 2005, Evid Rep Technol Assess (Summ), P1; Nelson HD, 2004, JAMA-J AM MED ASSOC, V291, P1610, DOI 10.1001/jama.291.13.1610; Nikander E, 2005, FERTIL STERIL, V83, P137, DOI 10.1016/j.fertnstert.2004.09.003; Notelovitz M, 2000, OBSTET GYNECOL, V95, P726, DOI 10.1016/S0029-7844(99)00643-2; Pandya KJ, 2005, LANCET, V366, P818, DOI 10.1016/S0140-6736(05)67215-7; Pandya KJ, 2000, ANN INTERN MED, V132, P788, DOI 10.7326/0003-4819-132-10-200005160-00004; Randolph JF, 2004, J CLIN ENDOCR METAB, V89, P1555, DOI 10.1210/jc.2003-031183; Rioux JE, 2000, MENOPAUSE, V7, P156, DOI 10.1097/00042192-200007030-00005; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; SCHIFF I, 1980, JAMA-J AM MED ASSOC, V244, P1443, DOI 10.1001/jama.244.13.1443; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Society of Obstetricians and Gynaecologists of Canada, 2005, Int J Gynaecol Obstet, V88, P222; Soules MR, 2005, MENOPAUSE, V12, P117, DOI 10.1097/00042192-200512020-00001; Stearns V, 2005, J CLIN ONCOL, V23, P6919, DOI 10.1200/JCO.2005.10.081; Stearns V, 2003, JNCI-J NATL CANCER I, V95, P1758, DOI 10.1093/jnci/djg108; Stearns V, 2003, JAMA-J AM MED ASSOC, V289, P2827, DOI 10.1001/jama.289.21.2827; Stephenson J, 2003, JAMA-J AM MED ASSOC, V289, P537, DOI 10.1001/jama.289.5.537; SUCKLING J, 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001500.PUB2; Suvanto-Luukkonen E, 2005, MENOPAUSE, V12, P18, DOI 10.1097/00042192-200512010-00006; Utian WH, 1999, AM J OBSTET GYNECOL, V181, P71, DOI 10.1016/S0002-9378(99)70438-2; Utian WH, 2001, FERTIL STERIL, V75, P1065, DOI 10.1016/S0015-0282(01)01791-5; *WOM HLTH IN, SCI RES WEBS; *WRIT GROUP PEPI T, 1996, ARCH INTERN MED, V275, P370; 2004, QUESTIONS ANSWERS HO	60	115	126	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 30	2006	355	22					2338	2347		10.1056/NEJMcp054015	http://dx.doi.org/10.1056/NEJMcp054015			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110CG	17135587				2023-01-03	WOS:000242355300009
J	List, A; Dewald, G; Bennett, J; Giagounidis, A; Raza, A; Feldman, E; Powell, B; Greenberg, P; Thomas, D; Stone, R; Reeder, C; Wride, K; Patin, J; Schmidt, M; Zeldis, J; Knight, R				List, Alan; Dewald, Gordon; Bennett, John; Giagounidis, Aristotle; Raza, Azra; Feldman, Eric; Powell, Bayard; Greenberg, Peter; Thomas, Deborah; Stone, Richard; Reeder, Craig; Wride, Kenton; Patin, John; Schmidt, Michele; Zeldis, Jerome; Knight, Robert		Myelodysplastic Syndrome-003	Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LONG ARM; CLASSIFICATION; PROGNOSIS; CRITERIA; LIFE	Background: Severe, often refractory anemia is characteristic of the myelodysplastic syndrome associated with chromosome 5q31 deletion. We investigated whether lenalidomide (CC5013) could reduce the transfusion requirement and suppress the abnormal 5q31- clone in patients with this disorder. Methods: One hundred forty-eight patients received 10 mg of lenalidomide for 21 days every 4 weeks or daily. Hematologic, bone marrow, and cytogenetic changes were assessed after 24 weeks of treatment by an intention-to-treat analysis. Results: Among the 148 patients, 112 had a reduced need for transfusions (76%; 95% confidence interval [CI], 68 to 82) and 99 patients (67%; 95% CI, 59 to 74) no longer required transfusions, regardless of the karyotype complexity. The response to lenalidomide was rapid (median time to response, 4.6 weeks; range, 1 to 49) and sustained; the median duration of transfusion independence had not been reached after a median of 104 weeks of follow-up. The maximum hemoglobin concentration reached a median of 13.4 g per deciliter (range, 9.2 to 18.6), with a corresponding median rise of 5.4 g per deciliter (range, 1.1 to 11.4), as compared with the baseline nadir value before transfusion. Among 85 patients who could be evaluated, 62 had cytogenetic improvement, and 38 of the 62 had a complete cytogenetic remission. There was complete resolution of cytologic abnormalities in 38 of 106 patients whose serial bone marrow samples could be evaluated. Moderate-to-severe neutropenia (in 55% of patients) and thrombocytopenia (in 44%) were the most common reasons for interrupting treatment or adjusting the dose of lenalidomide. Conclusions: Lenalidomide can reduce transfusion requirements and reverse cytologic and cytogenetic abnormalities in patients who have the myelodysplastic syndrome with the 5q31 deletion. (ClinicalTrials.gov number, NCT00065156.)	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Div, Tampa, FL 33612 USA; Mayo Clin, Rochester, MN USA; Univ Rochester, Rochester, NY USA; St Johannes Hosp, Duisburg, Germany; Univ Massachusetts, Worcester, MA 01605 USA; Cornell Med Ctr, New York, NY USA; Wake Forest Univ, Winston Salem, NC 27109 USA; Stanford Univ, Stanford, CA 94305 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Mayo Clin, Scottsdale, AZ USA; Celgene Corp, Warren, NJ USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Mayo Clinic; University of Rochester; St. Johannes Hospital; University of Massachusetts System; University of Massachusetts Worcester; Cornell University; Wake Forest University; Stanford University; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Dana-Farber Cancer Institute; Mayo Clinic; Mayo Clinic Phoenix; Bristol-Myers Squibb; Celgene Corporation	List, A (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Div, SRB-4,12902 Magnolia Dr, Tampa, FL 33612 USA.	heberten@moffitt.usf.edu	Giagounidis, Aristoteles/ABE-3927-2020; Giagounidis, Aristoteles/S-7097-2019	Giagounidis, Aristoteles/0000-0003-4083-4109; LIST, ALAN/0000-0002-1647-2972				BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb02771.x; Bernasconi P, 2005, LEUKEMIA, V19, P1424, DOI 10.1038/sj.leu.2403806; Boultwood J, 2002, BLOOD, V99, P4638, DOI 10.1182/blood.V99.12.4638; Cheson BD, 2000, BLOOD, V96, P3671; DEWALD GW, 1985, BLOOD, V66, P189; Giagounidis AAN, 2004, LEUKEMIA, V18, P113, DOI 10.1038/sj.leu.2403189; Greenberg, 1998, BLOOD, V91, P1100; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; List A, 2005, NEW ENGL J MED, V352, P549, DOI 10.1056/NEJMoa041668; LIST AF, 2005, HAEMATOLOGICA, V90, pA307; Malcovati L, 2005, J CLIN ONCOL, V23, P7594, DOI 10.1200/JCO.2005.01.7038; *NIH DIV CANC TREA, 1998, COMM TOX CRIT VERS 2; Oliva EN, 2005, LEUKEMIA RES, V29, P1217, DOI 10.1016/j.leukres.2005.03.004; Pedersen-Bjergaard J, 2002, BLOOD, V99, P1909, DOI 10.1182/blood.V99.6.1909; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; VANDENBERGHE H, 1974, NATURE, V251, P437, DOI 10.1038/251437a0; Vardiman JW, 2002, BLOOD, V100, P2292, DOI 10.1182/blood-2002-04-1199	18	942	978	1	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 5	2006	355	14					1456	1465		10.1056/NEJMoa061292	http://dx.doi.org/10.1056/NEJMoa061292			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	090UA	17021321				2023-01-03	WOS:000240976200007
J	Srivastava, R				Srivastava, Ranjana			In search of redemption	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												docranjana@gmail.com							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 26	2007	298	24					2837	2839		10.1001/jama.298.24.2837	http://dx.doi.org/10.1001/jama.298.24.2837			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RW	18159047				2023-01-03	WOS:000251816000001
J	DeVita, MA; Caplan, AL				DeVita, Michael A.; Caplan, Arthur L.			Caring for organs or for patients? Ethical concerns about the uniform anatomical gift act (2006)	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICIAN ORDERS; LIFE; PREFERENCES; PROGRAM; CARE; END	In 2006, the National Conference of Commissioners on Uniform State Laws rewrote the Uniform Anatomical Gift Act. To overcome the problem of family members prohibiting organ donation from their deceased loved ones even when a donor card existed, the commissioners modified the act to prevent end-of-life care from precluding organ donation, An unintended consequence of the new wording creates the potential for end-of-life care that prioritizes care of the potential donor organs over care and comfort of the dying person. The commissioners have now revised the act, but the original version has already been legislated in many states, with others poised to follow. To protect dying patients' wishes about their end-of-life care, states that have legislated or are considering the original act must replace it with the revised version. A long-term and important ethical precept must stand: Care of dying patients takes precedence over organs. Another laudable goal must be promoted as well: Organ donation is an important part of end-of-life care.	Univ Pittsburgh, Presbyterian Hosp, Med Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Pittsburgh, PA USA; Univ Penn, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania	DeVita, MA (corresponding author), Univ Pittsburgh, Presbyterian Hosp, Med Ctr, Rm C-111,200 Lothrop St, Pittsburgh, PA 15213 USA.							Arnold RM, 1996, CRIT CARE CLIN, V12, P29, DOI 10.1016/S0749-0704(05)70213-X; CAPLAN A, 2007, LAW MUST RIGHT DYING, pA16; *COMM INCR RAT ORG, 2006, ORG DON OPP ACT, P109; Hickman SE, 2004, J AM GERIATR SOC, V52, P1424, DOI 10.1111/j.1532-5415.2004.52402.x; Lee MA, 2000, J AM GERIATR SOC, V48, P1219, DOI 10.1111/j.1532-5415.2000.tb02594.x; Siminoff LA, 2006, J GEN INTERN MED, V21, P995, DOI 10.1007/BF02743151; Steinhauser KE, 2001, J PAIN SYMPTOM MANAG, V22, P727, DOI 10.1016/S0885-3924(01)00334-7; Truog RD, 2001, CRIT CARE MED, V29, P2332, DOI 10.1097/00003246-200112000-00017	8	21	21	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 18	2007	147	12					876	879		10.7326/0003-4819-147-12-200712180-00008	http://dx.doi.org/10.7326/0003-4819-147-12-200712180-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	243HO	18087059				2023-01-03	WOS:000251787600008
J	Davenport, A; Gura, V; Ronco, C; Beizai, M; Ezon, C; Rambod, E				Davenport, Andrew; Gura, Victor; Ronco, Claudio; Beizai, Masoud; Ezon, Carlos; Rambod, Edmond			A wearable haemodialysis device for patients with end-stage renal failure: a pilot study	LANCET			English	Article							REPLACEMENT THERAPY; DIALYSIS; DISEASE; WALES	Background More frequent haemodialysis can improve both survival and quality of life of patients with chronic kidney disease. However, there is little capacity in the UK to allow patients to have more frequent haemodialysis treatments in hospital and satellite haemodialysis units. New means of delivering haemodialysis are therefore required. Our aim was to assess the safety and efficiency of a wearable haemodialysis device. Methods Eight patients with end-stage kidney failure (five men, three women, mean age 51.7 [SD 13.8] years) who were established on regular haemodialysis were fitted with a wearable haemodialysis device for 4-8 h. Patients were given unfractionated heparin for anticoagulation, as they would be for standard haemodialysis. Findings There were no important cardiovascular changes and no adverse changes in serum electrolytes or acid-base balance. There was no evidence of clinically significant haemolysis in any patient. Mean blood flow was 58 . 6 (SD 11 . 7) mL/min, with a dialysate flow of 47.1 (7.8) mL/min. The mean plasma urea. clearance rate was 22.7 (5.2) mL/min and the mean plasma creatinine clearance rate was 20.7 (4-8) mL/min. Clotting of the vascular access occurred in two patients when the dose of heparin was decreased and the partial thromboplastin time returned towards the normal reference range in both of these patients. The fistula needle became dislodged in one patient, but safety mechanisms prevented blood loss, the needle was replaced, and treatment continued. Interpretation This wearable haemodialysis device shows promising safety and efficacy results, although further studies will be necessary to confirm these results.	Royal Free & Univ Coll Hosp Med Sch, Ctr Nephrol, Div Med, London, England; Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Los Angeles, CA USA; Osped San Bortolo, Div Nefrol, Vicenza, Italy; Xcorporeal Inc, Los Angeles, CA USA; BioQuantetics Inc, Los Angeles, CA USA	University of London; University College London; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; ULSS 8 Berica; Ospedale San Bortolo di Vicenza	Davenport, A (corresponding author), Royal Free & Univ Coll Med Sch, UCL Ctr Nephrol, Rowland Hill St, London NW3 2PF, England.	andrew.davenport@royalfree.nhs.uk	Gura, Victor/HGA-8677-2022	Ronco, Claudio/0000-0002-6697-4065				Blagg Christopher R, 2006, Hemodial Int, V10, P371, DOI 10.1111/j.1542-4758.2006.00132.x; Daugirdas JT, 2005, SEMIN NEPHROL, V25, P76, DOI 10.1016/j.semnephrol.2004.09.013; Davenport Andrew, 2006, Hemodial Int, V10, P162; Eloot S, 2007, AM J KIDNEY DIS, V50, P279, DOI 10.1053/j.ajkd.2007.05.009; Foley RN, 2005, J AM SOC NEPHROL, V16, P489, DOI 10.1681/ASN.2004030203; Gura V, 2006, ASAIO J, V52, P59, DOI 10.1097/01.mat.0000195283.58995.83; Gura V, 2005, CONTRIB NEPHROL, V149, P325, DOI 10.1159/000085694; GURA V, IN PRESS KIDNEY INT; Kutner N G, 1998, Geriatr Nephrol Urol, V8, P77, DOI 10.1023/A:1008384814079; Lindsay RM, 2004, CURR OPIN NEPHROL HY, V13, P631, DOI 10.1097/00041552-200411000-00008; Lindsay RM, 2003, AM J KIDNEY DIS, V42, pS5, DOI 10.1016/S0272-6386(03)00531-6; MACTIER R, 2007, MODULE 3A HAEMODIALY; Nissenson Allen R, 2005, Hemodial Int, V9, P210, DOI 10.1111/j.1492-7535.2005.01135.x; Pierratos A, 2006, Minerva Urol Nefrol, V58, P99; Raj DSC, 1999, AM J KIDNEY DIS, V34, P597, DOI 10.1016/S0272-6386(99)70382-3; Roderick P, 2005, HEALTH TECHNOL ASSES, V9, P1; Stephens R L, 1976, Proc Eur Dial Transplant Assoc, V12, P511; Twardowski ZJ, 2007, BLOOD PURIFICAT, V25, P90, DOI 10.1159/000096403; White P, 2006, QJM-INT J MED, V99, P445, DOI 10.1093/qjmed/hcl054	19	130	139	3	45	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 15	2007	370	9604					2005	2010		10.1016/S0140-6736(07)61864-9	http://dx.doi.org/10.1016/S0140-6736(07)61864-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242BD	18083402				2023-01-03	WOS:000251698600027
J	Okitsu, SL; Silvie, O; Westerfeld, N; Curcic, M; Kammer, AR; Mueller, MS; Sauerwein, RW; Robinson, JA; Genton, B; Mazier, D; Zurbriggen, R; Pluschke, G				Okitsu, Shinji L.; Silvie, Olivier; Westerfeld, Nicole; Curcic, Marija; Kammer, Andreas R.; Mueller, Markus S.; Sauerwein, Robert W.; Robinson, John A.; Genton, Blaise; Mazier, Dominique; Zurbriggen, Rinaldo; Pluschke, Gerd			A Virosomal Malaria Peptide Vaccine Elicits a Long-Lasting Sporozoite-Inhibitory Antibody Response in a Phase 1a Clinical Trial	PLOS ONE			English	Article							PLASMODIUM-FALCIPARUM; CIRCUMSPOROZOITE PROTEIN; INFLUENZA VIROSOMES; DELIVERY-SYSTEM; CHILDREN; INDUCTION; IMMUNITY; DISEASE; DESIGN; MEMORY	Objectives. Peptides delivered on the surface of influenza virosomes have been shown to induce solid humoral immune responses in experimental animals. High titers of peptide-specific antibodies were also induced in a phase 1a clinical trial in volunteers immunized with virosomal formulations of two peptides derived from the circumsporozoite protein (CSP) and the apical membrane antigen 1 (AMA-1) of Plasmodium falciparum. The main objective of this study was to perform a detailed immunological and functional analysis of the CSP-specific antibodies elicited in this phase 1a trial. Methodology/Principal Findings. 46 healthy malaria-naive adults were immunized with virosomal formulations of two peptide-phosphatidylethanolamine conjugates, one derived from the NANP repeat region of P. falciparum CSP ( designated UK-39) the other from P. falciparum AMA-1 ( designated AMA49-C1). The two antigens were delivered in two different concentrations, alone and in combination. One group was immunized with empty virosomes as control. In this report we show a detailed analysis of the antibody response against UK-39. Three vaccinations with a 10 mg dose of UK-39 induced high titers of sporozoite-binding antibodies in all volunteers. This IgG response was affinity maturated and long-lived. Co-administration of UK-39 and AMA49-C1 loaded virosomes did not interfere with the immunogenicity of UK-39. Purified total IgG from UK-39 immunized volunteers inhibited sporozoite migration and invasion of hepatocytes in vitro. Sporozoite inhibition closely correlated with titers measured in immunogenicity assays. Conclusions. Virosomal delivery of a short, conformationally constrained peptide derived from P. falciparum CSP induced a long-lived parasite-inhibitory antibody response in humans. Combination with a second virosomally-formulated peptide derived from P. falciparum AMA-1 did not interfere with the immunogenicity of either peptide, demonstrating the potential of influenza virosomes as a versatile, human-compatible antigen delivery platform for the development of multivalent subunit vaccines.	[Okitsu, Shinji L.; Curcic, Marija; Mueller, Markus S.; Genton, Blaise; Pluschke, Gerd] Swiss Trop Inst, CH-4002 Basel, Switzerland; [Silvie, Olivier; Mazier, Dominique] CHU Pitie Salpetriere, Fac Med Pierre & Marie Curie, UPMC, INSERM,UMR S Immunobiol Cellulaire & Mol Infect P, Paris, France; [Westerfeld, Nicole; Kammer, Andreas R.; Zurbriggen, Rinaldo] Pevion Biotech, Basel, Switzerland; [Sauerwein, Robert W.] Radboud Univ Nijmegen Med Ctr, Dept Med Microbiol, Nijmegen, Netherlands; [Robinson, John A.] Univ Zurich, Inst Organ Chem, Zurich, Switzerland	University of Basel; Swiss Tropical & Public Health Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Radboud University Nijmegen; University of Zurich	Pluschke, G (corresponding author), Swiss Trop Inst, CH-4002 Basel, Switzerland.	Gerd.Pluschke@unibas.ch	Sauerwein, Robert/C-8519-2013; Silvie, Olivier/AAF-5437-2021; Silvie, Olivier/K-7290-2017	Silvie, Olivier/0000-0002-0525-6940; Silvie, Olivier/0000-0002-0525-6940	Pevion Biotech, Switzerland	Pevion Biotech, Switzerland	This study was supported by Pevion Biotech, Switzerland.	Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6; Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; Amacker M, 2005, INT IMMUNOL, V17, P695, DOI 10.1093/intimm/dxh249; Bachmann MF, 1997, ANNU REV IMMUNOL, V15, P235, DOI 10.1146/annurev.immunol.15.1.235; Bisang C, 1998, J AM CHEM SOC, V120, P7439, DOI 10.1021/ja980444j; CLYDE DF, 1973, AM J MED SCI, V266, P169, DOI 10.1097/00000441-197309000-00002; FERREIRA MU, 1995, J IMMUNOL METHODS, V187, P297, DOI 10.1016/0022-1759(95)00186-4; Genton B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001018; Ghasparian A, 2006, CHEM COMMUN, P174, DOI 10.1039/b510812h; Good MF, 2005, TRENDS PARASITOL, V21, P29, DOI 10.1016/j.pt.2004.10.006; Greenwood B, 2005, ACTA TROP, V95, P298, DOI 10.1016/j.actatropica.2005.04.017; Greenwood BM, 2005, LANCET, V365, P1487, DOI 10.1016/S0140-6736(05)66420-3; Huckriede A, 2003, VACCINE, V21, P925, DOI 10.1016/S0264-410X(02)00542-X; James WPT, 2006, INT J PEDIATR OBES, V1, P7, DOI 10.1080/17477160600630404; Kappe SHI, 2004, TRENDS PARASITOL, V20, P13, DOI 10.1016/j.pt.2003.10.011; MAZIER D, 1986, SCIENCE, V231, P156, DOI 10.1126/science.3510455; McHeyzer-Williams LJ, 2005, ANNU REV IMMUNOL, V23, P487, DOI 10.1146/annurev.immunol.23.021704.115732; MOORTHY VS, 2005, PROGR DEV VACCINE AI; Moreno R, 2001, CHEMBIOCHEM, V2, P838, DOI 10.1002/1439-7633(20011105)2:11<838::AID-CBIC838>3.0.CO;2-4; Mota MM, 2001, SCIENCE, V291, P141, DOI 10.1126/science.291.5501.141; Mueller MS, 2003, INFECT IMMUN, V71, P4749, DOI 10.1128/IAI.71.8.4749-4758.2003; Nevill CG, 1996, TROP MED INT HEALTH, V1, P139; Okitsu SL, 2007, CHEM BIOL, V14, P577, DOI 10.1016/j.chembiol.2007.04.008; OKITSU SL, 2007, PEPTIDES; Pfeiffer B, 2003, ANGEW CHEM INT EDIT, V42, P2368, DOI 10.1002/anie.200250348; Poltl-Frank F, 1999, CLIN EXP IMMUNOL, V117, P496; Pulendran B, 2006, CELL, V124, P849, DOI 10.1016/j.cell.2006.02.019; Silvie O, 2003, NAT MED, V9, P93, DOI 10.1038/nm808; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Targett GA, 2005, TRENDS PARASITOL, V21, P499, DOI 10.1016/j.pt.2005.08.018; Tongren JE, 2004, TRENDS PARASITOL, V20, P604, DOI 10.1016/j.pt.2004.09.005; Vanderberg JP, 2004, INT J PARASITOL, V34, P991, DOI 10.1016/j.ijpara.2004.05.005; Waters A, 2006, CELL, V124, P689, DOI 10.1016/j.cell.2006.02.011; Zurbriggen R, 2003, VACCINE, V21, P921, DOI 10.1016/S0264-410X(02)00541-8	34	44	47	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2007	2	12							e1278	10.1371/journal.pone.0001278	http://dx.doi.org/10.1371/journal.pone.0001278			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10JD	18060072	Green Published, gold, Green Submitted			2023-01-03	WOS:000207459400025
J	Corwin, HL; Gettinger, A; Fabian, TC; May, A; Pearl, RG; Heard, S; An, R; Bowers, PJ; Burton, P; Klausner, MA; Corwin, MJ				Corwin, Howard L.; Gettinger, Andrew; Fabian, Timothy C.; May, Addison; Pearl, Ronald G.; Heard, Stephen; An, Robert; Bowers, Peter J.; Burton, Paul; Klausner, Mark A.; Corwin, Michael J.		EPO Critical Care Trials Grp	Efficacy and safety of epoetin alfa in critically ill patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; PLACEBO-CONTROLLED TRIAL; BLOOD-TRANSFUSION; CRITICAL ILLNESS; CANCER-PATIENTS; DOUBLE-BLIND; ANEMIA; DISEASE	Background Anemia, which is common in the critically ill, is often treated with red-cell transfusions, which are associated with poor clinical outcomes. We hypothesized that therapy with recombinant human erythropoietin (epoetin alfa) might reduce the need for red-cell transfusions. Methods In this prospective, randomized, placebo-controlled trial, we enrolled 1460 medical, surgical, or trauma patients between 48 and 96 hours after admission to the intensive care unit. Epoetin alfa (40,000 U) or placebo was administered weekly, for a maximum of 3 weeks; patients were followed for 140 days. The primary end point was the percentage of patients who received a red-cell transfusion. Secondary end points were the number of red-cell units transfused, mortality, and the change in hemoglobin concentration from baseline. Results As compared with the use of placebo, epoetin alfa therapy did not result in a decrease in either the number of patients who received a red-cell transfusion (relative risk for the epoetin alfa group vs. the placebo group, 0.95; 95% confidence interval [CI], 0.85 to 1.06) or the mean (+/-SD) number of red-cell units transfused (4.5+/-4.6 units in the epoetin alfa group and 4.3+/-4.8 units in the placebo group, P=0.42). However, the hemoglobin concentration at day 29 increased more in the epoetin alfa group than in the placebo group (1.6+/-2.0 g per deciliter vs. 1.2+/-1.8 g per deciliter, P<0.001). Mortality tended to be lower at day 29 among patients receiving epoetin alfa (adjusted hazard ratio, 0.79; 95% CI, 0.56 to 1.10); this effect was also seen in prespecified analyses in those with a diagnosis of trauma (adjusted hazard ratio, 0.37; 95% CI, 0.19 to 0.72). A similar pattern was seen at day 140 (adjusted hazard ratio, 0.86; 95% CI, 0.65 to 1.13), particularly in those with trauma (adjusted hazard ratio, 0.40; 95% CI, 0.23 to 0.69). As compared with placebo, epoetin alfa was associated with a significant increase in the incidence of thrombotic events (hazard ratio, 1.41; 95% CI, 1.06 to 1.86). Conclusions The use of epoetin alfa does not reduce the incidence of red-cell transfusion among critically ill patients, but it may reduce mortality in patients with trauma. Treatment with epoetin alfa is associated with an increase in the incidence of thrombotic events.	Dartmouth Coll, Hitchcock Med Ctr, Lebanon, NH 03756 USA; Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; Vanderbilt Univ, Med Ctr, Nashville, TN USA; Stanford Univ, Med Ctr, Stanford, CA 94305 USA; Univ Massachusetts, Mem Med Ctr, Worcester, MA 01605 USA; Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA; Boston Univ, Sch Med, Boston, MA 02118 USA; BattelleCRO, Newton, MA USA	Dartmouth College; University of Tennessee System; University of Tennessee Health Science Center; Vanderbilt University; Stanford University; University of Massachusetts System; University of Massachusetts Worcester; Johnson & Johnson; Johnson & Johnson USA; Boston University	Corwin, HL (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	howard.l.corwin@hitchcock.org		Corwin, Michael/0000-0002-6591-209X				Bohlius J, 2006, JNCI-J NATL CANCER I, V98, P708, DOI 10.1093/jnci/djj189; Brines M, 2006, KIDNEY INT, V70, P246, DOI 10.1038/sj.ki.5001546; Coleman T, 2004, CRIT CARE, V8, P337, DOI 10.1186/cc2897; Corwin HL, 2002, JAMA-J AM MED ASSOC, V288, P2827, DOI 10.1001/jama.288.22.2827; CORWIN HL, 1995, CHEST, V108, P767, DOI 10.1378/chest.108.3.767; Corwin HL, 2000, CRIT CARE MED, V28, P3098, DOI 10.1097/00003246-200008000-00079; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; Corwin HL, 1999, CRIT CARE MED, V27, P2346, DOI 10.1097/00003246-199911000-00004; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 1999, NEW ENGL J MED, V340, P1056; Henke M, 2003, LANCET, V362, P1255, DOI 10.1016/S0140-6736(03)14567-9; Leyland-Jones B, 2005, J CLIN ONCOL, V23, P5960, DOI 10.1200/JCO.2005.06.150; Maiese K, 2005, JAMA-J AM MED ASSOC, V293, P90, DOI 10.1001/jama.293.1.90; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; Napolitano LM, 2004, CRIT CARE CLIN, V20, P255, DOI 10.1016/j.ccc.2003.12.002; Rodriquez RM, 2001, J CRIT CARE, V16, P36, DOI 10.1053/jcrc.2001.21795; Rogiers P, 1997, INTENS CARE MED, V23, P159, DOI 10.1007/s001340050310; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Taylor RW, 2006, CRIT CARE MED, V34, P2302, DOI 10.1097/01.CCM.0000234034.51040.7F; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499	20	377	395	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 6	2007	357	10					965	976		10.1056/NEJMoa071533	http://dx.doi.org/10.1056/NEJMoa071533			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206VK	17804841				2023-01-03	WOS:000249210800003
J	Stiell, IG; Spaite, DW; Field, B; Nesbitt, LP; Munkley, D; Maloney, J; Dreyer, J; Toohey, LL; Campeau, T; Dagnone, E; Lyver, M; Wells, GA; Stempien, MW; Parkinson, CI; Waldbillig, D; Ballah, KW; Jones, GJ; Halladay, MR; Dreyer, JF; Boyle, KA; Munkley, DP; Toohey, LGL; Maloney, JP; Trickett, JP; Arcieri, V; Fader, JW; Lees, MGJ; LaBarre, DD; Lepage, RS; Michaud, S; Affleck, AW; Tyson, TA; Fedoruk, JC; Gobet, M				Stiell, Ian G.; Spaite, Daniel W.; Field, Brian; Nesbitt, Lisa P.; Munkley, Doug; Maloney, Justin; Dreyer, Jon; Toohey, Lorraine Luinstra; Campeau, Tony; Dagnone, Eugene; Lyver, Marion; Wells, George A.; Stempien, M. W.; Parkinson, C. I.; Waldbillig, D.; Ballah, K. W.; Jones, G. J.; Halladay, M. R.; Dreyer, J. F.; Boyle, K. A.; Munkley, D. P.; Toohey, L. G. Luinstra; Maloney, J. P.; Trickett, J. P.; Arcieri, V.; Fader, J. W.; Lees, M. G. J.; LaBarre, D. D.; Lepage, R. S.; Michaud, S.; Affleck, A. W.; Tyson, T. A.; Fedoruk, J. C.; Gobet, M.		OPALS Study Grp	Advanced life support for out-of-hospital respiratory distress	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIAC-ARREST; PREHOSPITAL TREATMENT; PULMONARY-EDEMA; PATIENT; TRIAL; OPALS; NITROGLYCERIN; METHODOLOGY; RATIONALE; MORPHINE	Background: Respiratory distress is a common symptom of patients transported to hospitals by emergency medical services (EMS) personnel. The benefit of advanced life support for such patients has not been established. Methods: The Ontario Prehospital Advanced Life Support (OPALS) Study was a controlled clinical trial that was conducted in 15 cities before and after the implementation of a program to provide advanced life support for patients with out-of-hospital respiratory distress. Paramedics were trained in standard advanced life support, including endotracheal intubation and the administration of intravenous drugs. Results: The clinical characteristics of the 8138 patients in the two phases of the study were similar. During the first phase, no patients were treated by paramedics trained in advanced life support; during the second phase, 56.6% of patients received this treatment. Endotracheal intubation was performed in 1.4% of the patients, and intravenous drugs were administered to 15.0% during the second phase. This phase of the study was also marked by a substantial increase in the use of nebulized salbutamol and sublingual nitroglycerin for the relief of symptoms. The rate of death among all patients decreased significantly, from 14.3% to 12.4% (absolute difference, 1.9%; 95% confidence interval [CI], 0.4 to 3.4; P=0.01) from the basic-life-support phase to the advanced-life-support phase (adjusted odds ratio, 1.3; 95% CI, 1.1 to 1.5). Conclusions: The addition of a specific regimen of out-of-hospital advanced-life-support interventions to an existing EMS system that provides basic life support was associated with a decrease in the rate of death of 1.9 percentage points among patients with respiratory distress.	Univ Ottawa, Ottawa Hlth Res Inst, Dept Emergency Med, Ottawa, ON, Canada; Univ Ottawa, Ottawa Hlth Res Inst, Dept Epidemiol & Community Med, Ottawa, ON, Canada; Univ Ottawa, Ottawa Hlth Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; Univ Arizona, Dept Emergency Med, Tucson, AZ USA; Queens Univ, Dept Emergency Med, Kingston, ON, Canada; Ontario Minist Hlth & Long Term Care, Emergency Hlth Serv, Toronto, ON, Canada; Niagara Reg Base Hosp, Niagara Falls, ON, Canada; Univ Western Ontario, Div Emergency Med, London, ON, Canada; Joseph Brant Mem Hosp, Burlington, ON, Canada; Interdev Technol, Toronto, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Arizona; Queens University - Canada; Western University (University of Western Ontario)	Stiell, IG (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, Dept Emergency Med, Ottawa, ON, Canada.			Stiell, Ian/0000-0002-2583-6408; Spaite, Daniel/0000-0003-2601-6476				Bertini G, 1997, ANN EMERG MED, V30, P493, DOI 10.1016/S0196-0644(97)70009-X; BRUNS BM, 1992, AM J EMERG MED, V10, P53, DOI 10.1016/0735-6757(92)90127-J; Craven RA, 2000, ACAD EMERG MED, V7, P1065, DOI 10.1111/j.1553-2712.2000.tb02102.x; EMERMAN CL, 1990, AM J EMERG MED, V8, P512, DOI 10.1016/0735-6757(90)90153-Q; Gardtman M, 2000, Eur J Emerg Med, V7, P15; HOFFMAN JR, 1987, CHEST, V92, P586, DOI 10.1378/chest.92.4.586; Kallio Tarja, 2003, Prehosp Emerg Care, V7, P209, DOI 10.1080/10903120390936798; KELSEY SF, 1991, CONTROL CLIN TRIALS, V12, P525; Kosowsky J M, 2001, Prehosp Emerg Care, V5, P190, DOI 10.1080/10903120190940119; Maio RF, 1999, ANN EMERG MED, V33, P423, DOI 10.1016/S0196-0644(99)70307-0; MCCAIG LF, 2002, ADV DATA VITAL HLTH, V326; MOSESSO VN, 2003, PREHOSP EMERG CARE, P713; QUADREL M, 1995, ANN EMERG MED, V26, P469, DOI 10.1016/S0196-0644(95)70116-8; Stiell IG, 1998, ANN EMERG MED, V32, P180, DOI 10.1016/S0196-0644(98)70135-0; Stiell IG, 2004, NEW ENGL J MED, V351, P647, DOI 10.1056/NEJMoa040325; Stiell IG, 1999, JAMA-J AM MED ASSOC, V281, P1175, DOI 10.1001/jama.281.13.1175; Stiell IG, 1999, ANN EMERG MED, V34, P256, DOI 10.1016/S0196-0644(99)70241-6; WEISS SJ, 1994, ANN EMERG MED, V24, P873, DOI 10.1016/S0196-0644(94)70205-5; WUERZ R, 1994, ANN EMERG MED, V23, P31, DOI 10.1016/S0196-0644(94)70004-4; WUERZ RC, 1992, ANN EMERG MED, V21, P669, DOI 10.1016/S0196-0644(05)82777-5	20	73	73	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 24	2007	356	21					2156	2164		10.1056/NEJMoa060334	http://dx.doi.org/10.1056/NEJMoa060334			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170ON	17522399				2023-01-03	WOS:000246673100005
J	Bramkamp, M; Rock, T; Schneemann, M; Binggeli, C; Kucher, N				Bramkamp, Matthias; Rock, Tobias; Schneemann, Markus; Binggeli, Christian; Kucher, Nils			Radiotherapy and the heart	LANCET			English	Editorial Material							ARTERY		Univ Zurich Hosp, Dept Internal Med, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Cardiol, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	Bramkamp, M (corresponding author), Univ Zurich Hosp, Dept Internal Med, CH-8091 Zurich, Switzerland.	Matthias.Bramkamp@usz.ch						JOSEPH A, 1995, J INTERV CARDIOL, V8, P355, DOI 10.1111/j.1540-8183.1995.tb00557.x; Miltenyi Zsofia, 2004, Cardiovasc Radiat Med, V5, P38, DOI 10.1016/j.carrad.2004.04.004; SCHULMAN HE, 1994, CHEST, V105, P1881, DOI 10.1378/chest.105.6.1881; VANSON JAM, 1992, J THORAC CARDIOV SUR, V104, P1539, DOI 10.1016/S0022-5223(19)33881-4	4	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 20	2007	369	9574					1762	1762		10.1016/S0140-6736(07)60783-1	http://dx.doi.org/10.1016/S0140-6736(07)60783-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	169ZT	17512861				2023-01-03	WOS:000246631300032
J	Bethard, S				Bethard, Suzanne			Taking my poison	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												sbethard@stanford.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	2006	296	22					2657	2658		10.1001/jama.296.22.2657	http://dx.doi.org/10.1001/jama.296.22.2657			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115WY	17164443				2023-01-03	WOS:000242765700001
J	Zangarelli, A; Chanseaume, E; Morio, B; Brugere, C; Mosoni, L; Rousset, P; Giraudet, C; Patrac, V; Gachon, P; Boirie, Y; Walrand, S				Zangarelli, Aude; Chanseaume, Emilie; Morio, Beatrice; Brugere, Corinne; Mosoni, Laurent; Rousset, Paulette; Giraudet, Christophe; Patrac, Veronique; Gachon, Pierre; Boirie, Yves; Walrand, Stephane			Synergistic effects of caloric restriction with maintained protein intake on skeletal muscle performance in 21-month-old rats: a mitochondria-mediated pathway	FASEB JOURNAL			English	Article						age; skeletal muscle; mitochondria; caloric restriction; protein intake	LOWERS OXIDATIVE DAMAGE; DNA DELETION MUTATIONS; MYOSIN HEAVY-CHAIN; DIETARY RESTRICTION; RADICAL GENERATION; CONTRACTILE TYPE; PROTON LEAK; SHORT-TERM; COMPLEX-I; AGE	Caloric restriction (CR) delays the onset of age-related mitochondrial abnormalities but does not prevent the decline in ATP production needed to sustain muscle protein fractional synthesis rate (FSR) and contractile activity. We hypothesized that improving mitochondrial activity and FSR using a CR diet with maintained protein intakes could enhance myofibrillar protein FSR and consequently improve muscle strength in aging rats. Wistar rats (21 months old) were fed either an ad libitum (AL), 40% protein-energy restricted (PER) or 40% AL-isonitrogenous energy restricted (ER) diet for 5 months. ATP production, electron transport chain activity, reactive oxygen species (ROS) generation, protein carbonyl content and FSR were determined in both tibialis anterior (TA) and soleus muscle mitochondria. Myosin and actin FSR and grip force were also investigated. The ER diet led to improved mitochondrial activity and ATP production in the TA and soleus muscles in comparison with PER. Furthermore, mitochondrial FSR in the TA was enhanced under the ER diet but diminished under the PER. Mitochondrial protein carbonyl content was decreased by both the ER and PER diets. The ER diet was able to improve myosin and actin FSR and grip force. Therefore, the synergistic effects of CR with maintained protein intake may help to limit the progression of sarcopenia by optimizing the turnover rates and functions of major proteins in skeletal muscle. -Zangarelli, A., Chanseaume, E., Morio, B., Brugere, C., Mosoni, L., Rousset, P., Giraudet, C., Patrac, V., Gachon, P., Boirie, Y., Walrand, S. Synergistic effects of caloric restriction with maintained protein intake on skeletal muscle performance in 21-month-old rats: a mitochondriamediated pathway.	UNH, UMR1019, INRA, Clermont Ferrand, France; Univ Clemont 1, UFR Med, Clermont Ferrand, France; UMR1019, Clermont Ferrand, France; CRNH Auvergne, Clermont Ferrand, France; CHU Clermont Ferrand, Hop Gabriel Montpied, Clermont Ferrand, France	INRAE; CHU Clermont Ferrand	Zangarelli, A (corresponding author), Univ Auvergne, CHU Clermont Ferrand, INRA, Ctr Rech Nutr Humaine,Unite Nutr Humaine, Clermont Ferrand, France.	boirie@sancy.clermont.inra.fr	Morio, Béatrice/G-3571-2018; Malpuech-Brugère, Corinne/D-6848-2017	Morio, Béatrice/0000-0002-2418-1438; Malpuech-Brugère, Corinne/0000-0001-9286-4647; Walrand, Stephane/0000-0002-4349-3664; Mosoni, Laurent/0000-0002-5409-6760				AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; Anderson J, 2003, CONTEMP THEATRE REV, V13, P47, DOI 10.1080/10267160302725; Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081; Bach-Rojecky Lidija, 2005, Acta Pharmaceutica (Zagreb), V55, P115; BAUMANN PQ, 1994, AM J PHYSIOL, V267, pE203, DOI 10.1152/ajpendo.1994.267.2.E203; Bevilacqua L, 2004, AM J PHYSIOL-ENDOC M, V286, pE852, DOI 10.1152/ajpendo.00367.2003; Boirie Y, 2001, DIABETES, V50, P2652, DOI 10.2337/diabetes.50.12.2652; BOTTINELLI R, 1994, J MUSCLE RES CELL M, V15, P413, DOI 10.1007/BF00122115; Bua EA, 2004, FASEB J, V18, P582, DOI 10.1096/fj.03-0668fje; Bua EA, 2002, J APPL PHYSIOL, V92, P2617, DOI 10.1152/japplphysiol.01102.2001; Caldefie-Chezet F, 2002, CLIN CHIM ACTA, V319, P9, DOI 10.1016/S0009-8981(02)00015-3; Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502; Castaneda C, 2000, J Nutr Health Aging, V4, P85; CASTANEDA C, 1995, AM J CLIN NUTR, V62, P30, DOI 10.1093/ajcn/62.1.30; Clark BD, 2004, J ORTHOP SPORT PHYS, V34, P244, DOI 10.2519/jospt.2004.34.5.244; Conley KE, 2000, J PHYSIOL-LONDON, V526, P211, DOI 10.1111/j.1469-7793.2000.00211.x; Drew B, 2003, AM J PHYSIOL-REG I, V284, pR474, DOI 10.1152/ajpregu.00455.2002; Fecho K, 2005, PHYSIOL BEHAV, V85, P177, DOI 10.1016/j.physbeh.2005.03.018; Gredilla R, 2004, ANN NY ACAD SCI, V1019, P333, DOI 10.1196/annals.1297.057; Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje; Gueguen N, 2005, MOL CELL BIOCHEM, V276, P15, DOI 10.1007/s11010-005-2464-y; Gueguen N, 2005, COMP BIOCHEM PHYS B, V140, P287, DOI 10.1016/j.cbpc.2004.10.014; Guillet C, 2004, FASEB J, V18, P1586, DOI 10.1096/fj.03-1341fje; Guillet C, 2004, EXP GERONTOL, V39, P745, DOI 10.1016/j.exger.2004.02.011; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; Judge S, 2005, FASEB J, V19, P419, DOI 10.1096/fj.04-2622fje; Kayo T, 2001, P NATL ACAD SCI USA, V98, P5093, DOI 10.1073/pnas.081061898; Kehl LJ, 2000, PAIN, V85, P333, DOI 10.1016/S0304-3959(99)00282-1; Lal SB, 2001, J GERONTOL A-BIOL, V56, pB116, DOI 10.1093/gerona/56.3.B116; Lass A, 1998, FREE RADICAL BIO MED, V25, P1089, DOI 10.1016/S0891-5849(98)00144-0; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; Mayhew M, 1998, BIOCHEM BIOPH RES CO, V251, P95, DOI 10.1006/bbrc.1998.9438; Minet-Quinard R, 2000, JPEN-PARENTER ENTER, V24, P30, DOI 10.1177/014860710002400130; Minet-Quinard R, 1999, AM J PHYSIOL-ENDOC M, V276, pE558, DOI 10.1152/ajpendo.1999.276.3.E558; Miro O, 2000, CARDIOVASC RES, V47, P624, DOI 10.1016/S0008-6363(00)00122-X; MOSONI L, 1995, AM J PHYSIOL-ENDOC M, V268, pE328, DOI 10.1152/ajpendo.1995.268.2.E328; Nagai M, 2000, BIOGERONTOLOGY, V1, P321, DOI 10.1023/A:1026590819033; Ouhabi R, 1998, ANAL BIOCHEM, V263, P169, DOI 10.1006/abio.1998.2776; Payne AM, 2003, J APPL PHYSIOL, V95, P2554, DOI 10.1152/japplphysiol.00758.2003; Pette D, 2001, INT J SPORT NUTR EXE, V11, pS3, DOI 10.1123/ijsnem.11.s1.s3; Pugh TD, 1999, NEUROBIOL AGING, V20, P157, DOI 10.1016/S0197-4580(99)00043-3; Raha S, 2002, FREE RADICAL BIO MED, V32, P421, DOI 10.1016/S0891-5849(01)00816-4; Ramamurthy B, 2001, FASEB J, V15, P2415, DOI 10.1096/fj.01-0183com; Ramsey JJ, 2000, FREE RADICAL BIO MED, V29, P946, DOI 10.1016/S0891-5849(00)00417-2; Reid MB, 2001, ACTA PHYSIOL SCAND, V171, P225, DOI 10.1046/j.1365-201x.2001.00824.x; Rooyackers OE, 1996, P NATL ACAD SCI USA, V93, P15364, DOI 10.1073/pnas.93.26.15364; Saks VA, 1998, MOL CELL BIOCHEM, V184, P81, DOI 10.1023/A:1006834912257; Sanz A, 2004, J BIOENERG BIOMEMBR, V36, P545, DOI 10.1007/s10863-004-9001-7; Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Sreekumar R, 2002, AM J PHYSIOL-ENDOC M, V283, pE38, DOI 10.1152/ajpendo.00387.2001; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; WALRAND S, 2003, AMINO METABOLISM THE, P389; Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com; Yarovaya NO, 2002, BIOGERONTOLOGY, V3, P25, DOI 10.1023/A:1015295011131; YOUNGMAN LD, 1992, P NATL ACAD SCI USA, V89, P9112, DOI 10.1073/pnas.89.19.9112; Zainal TA, 2000, FASEB J, V14, P1825, DOI 10.1096/fj.99-0881com; Zangarelli A, 2004, ANAL BIOCHEM, V327, P55, DOI 10.1016/j.ab.2003.11.024	60	53	53	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2439	2450		10.1096/fj.05-4544com	http://dx.doi.org/10.1096/fj.05-4544com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17142793				2023-01-03	WOS:000242490700004
J	Goldie, SJ; Yazdanpanah, Y; Losina, E; Weinstein, MC; Anglaret, X; Walensky, RP; Hsu, HE; Kimmel, A; Holmes, C; Kaplan, JE; Freedberg, KA				Goldie, Sue J.; Yazdanpanah, Yazdan; Losina, Elena; Weinstein, Milton C.; Anglaret, Xavier; Walensky, Rochelle P.; Hsu, Heather E.; Kimmel, April; Holmes, Charles; Kaplan, Jonathan E.; Freedberg, Kenneth A.			Cost-effectiveness of HIV treatment in resource-poor settings - The case of Cote d'Ivoire	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; HIV-1-INFECTED ADULTS; COTRIMOXAZOLE PROPHYLAXIS; TRIMETHOPRIM-SULFAMETHOXAZOLE; DEVELOPING-COUNTRIES; VIROLOGICAL FAILURE; VIRAL LOAD; INTERVENTIONS; ABIDJAN; COMBINATION	BACKGROUND: As antiretroviral therapy is increasingly used in settings with limited resources, key questions about the timing of treatment and use of diagnostic tests to guide clinical decisions must be addressed. METHODS: We assessed the cost-effectiveness of treatment strategies for a cohort of adults in Cote d'Ivoire who were infected with the human immunodeficiency virus (HIV) (mean age, 33 years; CD4 cell count, 331 per cubic millimeter; HIV RNA level, 5.3 log copies per milliliter). Using a computer-based simulation model that incorporates the CD4 cell count and HIV RNA level as predictors of disease progression, we compared the long-term clinical and economic outcomes associated with no treatment, trimethoprim-sulfamethoxazole prophylaxis alone, antiretroviral therapy alone, and prophylaxis with antiretroviral therapy. RESULTS: Undiscounted gains in life expectancy ranged from 10.7 months with antiretroviral therapy and prophylaxis initiated on the basis of clinical criteria to 45.9 months with antiretroviral therapy and prophylaxis initiated on the basis of CD4 testing and clinical criteria, as compared with trimethoprim-sulfamethoxazole prophylaxis alone. The incremental cost per year of life gained was $240 (in 2002 U.S. dollars) for prophylaxis alone, $620 for antiretroviral therapy and prophylaxis without CD4 testing, and $1,180 for antiretroviral therapy and prophylaxis with CD4 testing, each compared with the next least expensive strategy. None of the strategies that used antiretroviral therapy alone were as cost-effective as those that also used trimethoprim-sulfamethoxazole prophylaxis. Life expectancy was increased by 30% with use of a second line of antiretroviral therapy after failure of the first-line regimen. CONCLUSIONS: A strategy of trimethoprim-sulfamethoxazole prophylaxis and antiretroviral therapy, with the use of clinical criteria alone or in combination with CD4 testing to guide the timing of treatment, is an economically attractive health investment in settings with limited resources.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Program Hlth Decis Sci, Boston, MA 02115 USA; Fac Med Lille, Ctr Hosp Tourcoing, Serv Univ Malad Infect & Voyageur, F-59045 Lille, France; CNRS, URA 362, Lab Rech Econ & Sociales, Lille, France; Boston Univ, Sch Publ Hlth, Boston, MA USA; INSERM, U593, Bordeaux, France; Programme PAC CI, Abidjan, Cote Ivoire; Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Pittsburgh, Sch Med, Sect Decis Sci & Clin Syst Modeling, Pittsburgh, PA USA; Ctr Dis Control & Prevent, Atlanta, GA USA	Harvard University; Harvard T.H. Chan School of Public Health; Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Boston University; Institut National de la Sante et de la Recherche Medicale (Inserm); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Centers for Disease Control & Prevention - USA	Goldie, SJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Program Hlth Decis Sci, 718 Huntington Ave,2nd Fl, Boston, MA 02115 USA.	sue_goldie@harvard.edu	Anglaret, Xavier/T-2757-2019; Anglaret, Xavier/F-7333-2013	Losina, ELENA/0000-0002-3424-0892; Anglaret, Xavier/0000-0003-3319-8423; Hsu, Heather/0000-0002-5863-1804; Walensky, Rochelle P./0000-0002-8795-379X	NIAID NIH HHS [K25 AI050436, K25-AI50436, K23 AI001794, K24-AI062476, K24 AI062476, R01-AI058736, K23-AI01794, R01 AI058736] Funding Source: Medline; PHS HHS [U64/CCU 114927, U64/CCU 119525] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI062476, K23AI001794, K25AI050436, R01AI058736] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIDS Epidemic Update, 2004, AIDS EP UPD; Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; Anglaret X, 2003, AIDS, V17, P575, DOI 10.1097/00002030-200303070-00013; [Anonymous], 2001, MACR HLTH INV HLTH E; [Anonymous], 2002, WORLD MORTALITY 2000; Aseffa A, 1997, E AFR MED J, V74, P708; CLEARY S, 2004, COST EFFECTIVENESS A; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; Cole SR, 2003, AM J EPIDEMIOL, V158, P687, DOI 10.1093/aje/kwg206; Deeks SG, 2002, AIDS, V16, P201, DOI 10.1097/00002030-200201250-00009; Deeks SG, 2000, J INFECT DIS, V181, P946, DOI 10.1086/315334; Djomand G, 2003, AIDS, V17, pS5, DOI 10.1097/00002030-200317003-00002; Evans DB, 2005, BMJ-BRIT MED J, V331, P1137, DOI 10.1136/bmj.331.7525.1137; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Forsythe SS, 1998, AIDS, V12, pS11; Freedberg KA, 2001, NEW ENGL J MED, V344, P824, DOI 10.1056/NEJM200103153441108; Goldie SJ, 2005, NEW ENGL J MED, V353, P2158, DOI 10.1056/NEJMsa044278; Goldie SJ, 2003, AM J MED, V115, P632, DOI 10.1016/j.amjmed.2003.07.007; Ivers LC, 2005, CLIN INFECT DIS, V41, P217, DOI 10.1086/431199; Johns B, 2005, HEALTH POLICY PLANN, V20, P1, DOI 10.1093/heapol/czi001; Kumarasamy N, 2004, JAIDS-J ACQ IMM DEF, V37, P1574, DOI 10.1097/00126334-200412150-00007; Kuntz KM, 2001, EC EVALUATION HLTH C, P141; Lamptey P, 2005, PLOS MED, V2, P102, DOI 10.1371/journal.pmed.0020039; Landman R, 2003, AIDS, V17, P1017, DOI 10.1097/00002030-200305020-00010; Laurent C, 2004, LANCET, V364, P29, DOI 10.1016/S0140-6736(04)16586-0; Laurent C, 2005, JAIDS-J ACQ IMM DEF, V38, P14, DOI 10.1097/00126334-200501010-00003; Ledergerber B, 2004, LANCET, V364, P51, DOI 10.1016/S0140-6736(04)16589-6; Levitz SM, 1998, NEW ENGL J MED, V338, P1074, DOI 10.1056/NEJM199804093381517; LOSINA E, 2002, INT AIDS C BARC JUL; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; Marseille E, 1999, LANCET, V354, P803, DOI 10.1016/S0140-6736(99)80009-9; Marseille E, 2002, LANCET, V359, P1851, DOI 10.1016/S0140-6736(02)08705-6; Matheron S, 2006, AIDS, V20, P459, DOI 10.1097/01.aids.0000199829.57112.2f; Matheron S, 2003, AIDS, V17, P2593, DOI 10.1097/00002030-200312050-00006; *MED FRONT, 2005, UNT WEB PRIC RED PRI; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Mermin J, 2004, LANCET, V364, P1428, DOI 10.1016/S0140-6736(04)17225-5; Moatti JP, 2003, NAT MED, V9, P1449, DOI 10.1038/nm1203-1449; *MULT AIDS COH STU, 1995, PUBL US DAT; Murray CJL, 2003, LANCET, V361, P717, DOI 10.1016/S0140-6736(03)12655-4; Musgrove P, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P271; *OANDA CORP, NOM INT EXCH RAT YEA; Palella FJ, 2003, ANN INTERN MED, V138, P620, DOI 10.7326/0003-4819-138-8-200304150-00007; Salomon JA, 2005, PLOS MED, V2, P50, DOI 10.1371/journal.pmed.0020016; Schwartlander B, 2001, SCIENCE, V292, P2434, DOI 10.1126/science.1062876; Seyler C, 2003, ANTIVIR THER, V8, P385; Sow A I, 1999, Dakar Med, V44, P20; *UNAIDS SECR, 2003, SOURC PRIC SEL DRUGS; van Oosterhout JJG, 2005, JAIDS-J ACQ IMM DEF, V39, P626; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; Weinstein MC., 1996, COST EFFECTIVENESS H; *WHO, 2004, IND CSTS PER PAT PER; *WHO, AIDS MED DIAGN SERV; *WHO CHOICE, 2004, PRIC HOSP HLTH CTR; *WHO CHOICE, 2006, PRIC HOSP HLTH CTR; *WORLD BANK, 2002, WORLD BANK DEV IND 2; World Health Organization, 2003, SCAL ANT THER RES LT; Wright JC, 1998, NEW ENGL J MED, V339, P380, DOI 10.1056/NEJM199808063390606; Yazdanpanah Y, 2005, AIDS, V19, P1299, DOI 10.1097/01.aids.0000180101.80888.c6	59	220	225	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 14	2006	355	11					1141	1153		10.1056/NEJMsa060247	http://dx.doi.org/10.1056/NEJMsa060247			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	083NJ	16971720				2023-01-03	WOS:000240462800008
J	Varady, KA; Roohk, DJ; McEvoy-Hein, BK; Gaylinn, BD; Thorner, MO; Hellerstein, MK				Varady, K. A.; Roohk, D. J.; McEvoy-Hein, B. K.; Gaylinn, B. D.; Thorner, M. O.; Hellerstein, M. K.			Modified alternate-day fasting regimens reduce cell proliferation rates to a similar extent as daily calorie restriction in mice	FASEB JOURNAL			English	Article						cancer; insulin-like growth factor-1; insulin-like growth factor binding protein-3	GROWTH-FACTOR-I; SPONTANEOUS TUMORIGENESIS; MAMMARY CARCINOGENESIS; DIETARY RESTRICTION; ENERGY RESTRICTION; BINDING PROTEIN-3; DNA-SYNTHESIS; CANCER; GHRELIN; INSULIN	Calorie restriction (CR) and alternate-day fasting (ADF) reduce cancer risk and reduce cell proliferation rates. Whether modified ADF regimens (i.e., allowing a portion of energy needs to be consumed on the fast day) work, as well as true ADF or CR to reduce global cell proliferation rates, remains unresolved. Here, we measured the effects of true ADF, modified ADF, and daily CR on cell proliferation rates in mice. Thirty female C57BL/6J mice were randomized to one of five interventions for 4 wk: 1) CR-25% (25% reduction in daily energy intake), 2) ADF-75% (75% reduction on fast day), 3) ADF-85% (85% reduction on fast day), 4) ADF-100% (100% reduction on fast day), and 5) control (ad libitum intake). Body weights of the ADF groups did not differ from controls, whereas the CR-25% group weighed less than all other groups posttreatment. Epidermal cell proliferation decreased (P < 0.01) by 29, 20, and 31% in the CR-25%, ADF-85% and ADF-100% groups, respectively, relative to controls. Proliferation rates of splenic T cells were reduced (P < 0.01) by 37, 32, and 31% in the CR- 25%, ADF-85%, and ADF-100% groups, respectively, and mammary epithelial cell proliferation was 70, 65, and 62% lower (P < 0.01), compared with controls. Insulin-like growth factor-1 levels were reduced (P < 0.05) in the CR- 25% and ADF-100% groups only. In summary, modified ADF, allowing the consumption of 15% of energy needs on the restricted intake day, decreases global cell proliferation similarly as true ADF and daily CR without reducing body weight.	[Varady, K. A.; Roohk, D. J.; McEvoy-Hein, B. K.; Hellerstein, M. K.] Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA; [Gaylinn, B. D.; Thorner, M. O.] Univ Virginia, Div Endocrinol & Metab, Dept Internal Med, Charlottesville, VA USA	University of California System; University of California Berkeley; University of Virginia	Varady, KA (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Morgan Hall,Rm 308, Berkeley, CA 94720 USA.	kvarady@nature.berkeley.edu; march@nture.berkeley.edu	Gaylinn, Bruce/AAD-4663-2020	Gaylinn, Bruce/0000-0003-1195-0864	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076037] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK076037, R01 DK076037-04] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berrigan D, 2002, CARCINOGENESIS, V23, P817, DOI 10.1093/carcin/23.5.817; Collins ML, 2003, J APPL PHYSIOL, V94, P2203, DOI 10.1152/japplphysiol.00691.2002; Fontana L, 2007, JAMA-J AM MED ASSOC, V297, P986, DOI 10.1001/jama.297.9.986; Giovannucci E, 1999, HORM RES, V51, P34, DOI 10.1159/000053160; Gualillo O, 2002, OBES RES, V10, P682, DOI 10.1038/oby.2002.92; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Heilbronn LK, 2005, OBES RES, V13, P574, DOI 10.1038/oby.2005.61; Heilbronn LK, 2005, AM J CLIN NUTR, V81, P69; Higgins SC, 2007, ANN MED, V39, P116, DOI 10.1080/07853890601149179; Hsieh EA, 2005, AM J PHYSIOL-ENDOC M, V288, pE965, DOI 10.1152/ajpendo.00368.2004; Hsieh EA, 2004, J INVEST DERMATOL, V123, P530, DOI 10.1111/j.0022-202X.2004.23303.x; HURSTING SD, 1994, P NATL ACAD SCI USA, V91, P7036, DOI 10.1073/pnas.91.15.7036; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Ikeyama S, 2003, EXP GERONTOL, V38, P431, DOI 10.1016/S0531-5565(02)00239-5; Jenkins PJ, 2004, EUR J ENDOCRINOL, V151, pS17, DOI 10.1530/eje.0.151S017; Jolly CA, 2005, CURR OPIN CLIN NUTR, V8, P382, DOI 10.1097/01.mco.0000172577.56396.7a; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Lawrence CB, 2002, ENDOCRINOLOGY, V143, P155, DOI 10.1210/en.143.1.155; Lev-Ran A, 1998, MECH AGEING DEV, V102, P95, DOI 10.1016/S0047-6374(98)00027-X; Liu Jianhua, 2004, Growth Hormone & IGF Research, V14, P131; LOK E, 1988, CANCER LETT, V38, P249, DOI 10.1016/0304-3835(88)90016-X; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; Macallan DC, 1998, P NATL ACAD SCI USA, V95, P708, DOI 10.1073/pnas.95.2.708; Mai V, 2003, CANCER RES, V63, P1752; MERRY B, 1994, EFFECTS DIET AGING; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; Neese RA, 2002, P NATL ACAD SCI USA, V99, P15345, DOI 10.1073/pnas.232551499; Neese RA, 2001, ANAL BIOCHEM, V298, P189, DOI 10.1006/abio.2001.5375; NELSON JF, 1982, BIOL REPROD, V27, P327, DOI 10.1095/biolreprod27.2.327; Patel AC, 2004, J NUTR, V134, p3394S, DOI 10.1093/jn/134.12.3394S; Rocha NS, 2002, TERATOGEN CARCIN MUT, V22, P129, DOI 10.1002/tcm.10005; SIEGEL I, 1988, CANCER INVEST, V6, P677, DOI 10.3109/07357908809078034; Stewart JW, 2005, CARCINOGENESIS, V26, P1077, DOI 10.1093/carcin/bgi051; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Varady KA, 2007, J LIPID RES, V48, P2212, DOI 10.1194/jlr.M700223-JLR200; Varady KA, 2007, J APPL PHYSIOL, V103, P547, DOI 10.1152/japplphysiol.00209.2007; Yakar S, 2005, CYTOKINE GROWTH F R, V16, P407, DOI 10.1016/j.cytogfr.2005.01.010; Zhu ZJ, 1999, CARCINOGENESIS, V20, P1721, DOI 10.1093/carcin/20.9.1721	39	28	28	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					2090	2096		10.1096/fj.07-098178	http://dx.doi.org/10.1096/fj.07-098178			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18184721	Green Accepted			2023-01-03	WOS:000256352700048
J	Campbell, BH				Campbell, Bruce H.			Listening to Leviticus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												bcampbel@mcw.edu						*BIBLE, LEVITICUS, V17, P10	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	2008	299	8					879	880		10.1001/jama.299.8.879	http://dx.doi.org/10.1001/jama.299.8.879			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266DZ	18314424				2023-01-03	WOS:000253413200001
J	Balch, WE; Morimoto, RI; Dillin, A; Kelly, JW				Balch, William E.; Morimoto, Richard I.; Dillin, Andrew; Kelly, Jeffery W.			Adapting proteostasis for disease intervention	SCIENCE			English	Review							RESTRICTION-INDUCED LONGEVITY; UNFOLDED PROTEIN RESPONSE; HEAT-SHOCK RESPONSE; ENDOPLASMIC-RETICULUM; CAENORHABDITIS-ELEGANS; MOLECULAR CHAPERONES; ALZHEIMERS-DISEASE; ER STRESS; C-ELEGANS; TOXICITY	The protein components of eukaryotic cells face acute and chronic challenges to their integrity. Eukaryotic protein homeostasis, or proteostasis, enables healthy cell and organismal development and aging and protects against disease. Here, we describe the proteostasis network, a set of interacting activities that maintain the health of proteome and the organism. Deficiencies in proteostasis lead to many metabolic, oncological, neurodegenerative, and cardiovascular disorders. Small- molecule or biological proteostasis regulators that manipulate the concentration, conformation, quaternary structure, and/ or the location of protein( s) have the potential to ameliorate some of the most challenging diseases of our era.	[Kelly, Jeffery W.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; [Kelly, Jeffery W.] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; [Balch, William E.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; [Balch, William E.] Scripps Res Inst, Inst Childhood & Neglected Dis, La Jolla, CA 92037 USA; [Morimoto, Richard I.] Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Rice Inst Biomed Res, Evanston, IL 60208 USA; [Dillin, Andrew] Salk Inst Biol Studies, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Northwestern University; Salk Institute	Kelly, JW (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jkelly@scripps.edu	Longo, Kenneth A/A-5631-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK075295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038109, R37GM038109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG026647, P01AG004342, R01AG018917] Funding Source: NIH RePORTER; NIA NIH HHS [AG 18917, AG026647, AG04342] Funding Source: Medline; NIDDK NIH HHS [DK46336, DK75295] Funding Source: Medline; NIGMS NIH HHS [GM38109, R37 GM038109] Funding Source: Medline; NINDS NIH HHS [NS50636] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Behrends C, 2006, MOL CELL, V23, P887, DOI 10.1016/j.molcel.2006.08.017; Bishop NA, 2007, NATURE, V447, P545, DOI 10.1038/nature05904; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Cohen E, 2006, SCIENCE, V313, P1604, DOI 10.1126/science.1124646; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Derham BK, 1997, BIOCHEM J, V328, P763; Erickson RR, 2006, J GERONTOL A-BIOL, V61, P435, DOI 10.1093/gerona/61.5.435; Fan JQ, 1999, NAT MED, V5, P112, DOI 10.1038/4801; Fiebiger E, 2004, MOL BIOL CELL, V15, P1635, DOI 10.1091/mbc.E03-07-0506; Geller R, 2007, GENE DEV, V21, P195, DOI 10.1101/gad.1505307; Gidalevitz T, 2006, SCIENCE, V311, P1471, DOI 10.1126/science.1124514; Golde Todd E., 2006, Current Alzheimer Research, V3, P421, DOI 10.2174/156720506779025189; Hammarstrom P, 2003, SCIENCE, V299, P713, DOI 10.1126/science.1079589; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kitamura A, 2006, NAT CELL BIOL, V8, P1163, DOI 10.1038/ncb1478; Liu XL, 2004, J AM SOC NEPHROL, V15, P1731, DOI 10.1097/01.ASN.0000129826.28932.FD; Massey AC, 2006, CELL CYCLE, V5, P1292, DOI 10.4161/cc.5.12.2865; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Morley JF, 2004, MOL BIOL CELL, V15, P657, DOI 10.1091/mbc.E03-07-0532; Morley JF, 2002, P NATL ACAD SCI USA, V99, P10417, DOI 10.1073/pnas.152161099; Mu TW, 2008, PLOS BIOL, V6, P253, DOI 10.1371/journal.pbio.0060026; Namba Y, 1991, No To Shinkei, V43, P57; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Panowski SH, 2007, NATURE, V447, P550, DOI 10.1038/nature05837; Qu BH, 1997, J BIOL CHEM, V272, P15739, DOI 10.1074/jbc.272.25.15739; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Tam S, 2006, NAT CELL BIOL, V8, P1155, DOI 10.1038/ncb1477; Tang Yun-Chi, 2007, Cell, V128, P412; Wang XD, 2006, CELL, V127, P803, DOI 10.1016/j.cell.2006.09.043; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Westerheide SD, 2004, J BIOL CHEM, V279, P56053, DOI 10.1074/jbc.M409267200; Westerheide SD, 2005, J BIOL CHEM, V280, P33097, DOI 10.1074/jbc.R500010200; Wiseman RL, 2007, CELL, V131, P809, DOI 10.1016/j.cell.2007.10.025; Zhang QH, 2004, P NATL ACAD SCI USA, V101, P4752, DOI 10.1073/pnas.0400924101	39	1675	1717	10	245	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 15	2008	319	5865					916	919		10.1126/science.1141448	http://dx.doi.org/10.1126/science.1141448			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	262RM	18276881				2023-01-03	WOS:000253165700035
J	Emmelot-Vonk, MH; Verhaar, HJJ; Pour, HRN; Aleman, A; Lock, TMTW; Bosch, JLHR; Grobbee, DE; van der Schouw, YT				Emmelot-Vonk, Marielle H.; Verhaar, Harald J. J.; Pour, Hamid R. Nakhai; Aleman, Andre; Lock, Tycho M. T. W.; Bosch, J. L. H. Ruud; Grobbee, Diederick E.; van der Schouw, Yvonne T.			Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; HORMONE-BINDING GLOBULIN; SENSITIVITY CHECK INDEX; LATE-ONSET HYPOGONADISM; REPLACEMENT THERAPY; METABOLIC SYNDROME; INSULIN SENSITIVITY; ALZHEIMER-DISEASE; PROSTATE-CANCER; MUSCLE STRENGTH	Context Serum testosterone levels decline significantly with aging. Testosterone supplementation to older men might beneficially affect the aging processes. Objective To investigate the effect of testosterone supplementation on functional mobility, cognitive function, bone mineral density, body composition, plasma lipids, quality of life, and safety parameters in older men with low normal testosterone levels. Design, Setting, and Participants Double-blind, randomized, placebo-controlled trial of 237 healthy men between the ages of 60 and 80 years with a testosterone level lower than 13.7 nmol/L conducted from January 2004 to April 2005 at a university medical center in the Netherlands. Intervention Participants were randomly assigned to receive 80 mg of testosterone undecenoate or a matching placebo twice daily for 6 months. Main Outcome Measures Functional mobility (Stanford Health Assessment questionnaire, timed get up and go test, isometric handgrip strength, isometric leg extensor strength), cognitive function (8 different cognitive instruments), bone mineral density of the hip and lumbar spine (dual-energy x-ray absorptiometry scanning), body composition (total body dual-energy x-ray absorptiometry and abdominal ultrasound of fat mass), metabolic risk factors (fasting plasma lipids, glucose, and insulin), quality of life (Short-Form Health 36 Survey and the Questions on Life Satisfaction Modules), and safety parameters (serum prostate-specific antigen level, ultrasonographic prostate volume, International Prostate Symptom score, serum levels of creatinine, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltransferase, hemoglobin, and hematocrit). Results A total of 207 men completed the study. During the study, lean body mass increased and fat mass decreased in the testosterone group compared with the placebo group but these factors were not accompanied by an increase of functional mobility or muscle strength. Cognitive function and bone mineral density did not change. Insulin sensitivity improved but high-density lipoprotein cholesterol decreased; by the end of the study, 47.8% in the testosterone group vs 35.5% in the placebo group had the metabolic syndrome (P=.07). Quality-of -life measures were no different except for one hormone-related quality-of-life measure that improved. No negative effects on prostate safety were detected. Conclusion Testosterone supplementation during 6 months to older men with a low normal testosterone concentration did not affect functional status or cognition but increased lean body mass and had mixed metabolic effects. Trial Registration isrctn.org Identifier: ISRCTN23688581.	[Emmelot-Vonk, Marielle H.; Verhaar, Harald J. J.; Pour, Hamid R. Nakhai] Univ Med Ctr Utrecht, Dept Geriatr Med, NL-3508 GA Utrecht, Netherlands; [Lock, Tycho M. T. W.; Bosch, J. L. H. Ruud] Univ Med Ctr Utrecht, Dept Urol, NL-3508 GA Utrecht, Netherlands; [Emmelot-Vonk, Marielle H.; Pour, Hamid R. Nakhai; Grobbee, Diederick E.; van der Schouw, Yvonne T.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands; [Aleman, Andre] Univ Groningen, BCN Neuroimaging Ctr, Groningen, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Groningen	Emmelot-Vonk, MH (corresponding author), Univ Med Ctr Utrecht, Dept Geriatr Med, POB 85500,Room B05-256, NL-3508 GA Utrecht, Netherlands.	m.h.emmelotvonk@umcutrecht.nl	Grobbee, Diederick/C-7651-2014; van der Schouw, Yvonne T./F-8327-2014; Aleman, Andre/E-1341-2012	Grobbee, Diederick/0000-0003-4472-4468; van der Schouw, Yvonne T./0000-0002-4605-435X; 				Badia X, 1997, EUR UROL, V31, P129; BAILLIE SP, 1992, AGE AGEING, V21, P139, DOI 10.1093/ageing/21.2.139; Barrett-Connor E, 1999, J CLIN ENDOCR METAB, V84, P3681, DOI 10.1210/jc.84.10.3681; Benton A., 1983, CONTRIBUTION NEUROPS; Bhasin S, 2003, J ANDROL, V24, P299; Bhasin S, 1997, J CLIN ENDOCR METAB, V82, P1659, DOI 10.1210/jc.82.6.1659; Bonora E, 2000, DIABETES CARE, V23, P57, DOI 10.2337/diacare.23.1.57; Boyanov M A, 2003, Aging Male, V6, P1; Cherrier MM, 2001, NEUROLOGY, V57, P80, DOI 10.1212/WNL.57.1.80; Cherrier MM, 2005, NEUROLOGY, V64, P2063, DOI 10.1212/01.WNL.0000165995.98986.F1; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; *COMM ASS NEED CLI, 2004, REPL THER TEST AG CL; Curran MJ, 1999, UROLOGY, V53, P423, DOI 10.1016/S0090-4295(98)00348-3; Ferrando AA, 2002, AM J PHYSIOL-ENDOC M, V282, pE601, DOI 10.1152/ajpendo.00362.2001; Gaylis FD, 2005, J UROLOGY, V174, P534, DOI 10.1097/01.ju.0000165166.36280.60; Gouras GK, 2000, P NATL ACAD SCI USA, V97, P1202, DOI 10.1073/pnas.97.3.1202; Hamilton A, 1994, J Hand Ther, V7, P163; Hanninen T, 1996, AGE AGEING, V25, P201, DOI 10.1093/ageing/25.3.201; Haren MT, 2005, MATURITAS, V50, P124, DOI 10.1016/j.maturitas.2004.05.002; Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724; Herschbach P, 2001, EUR J ENDOCRINOL, V145, P255, DOI 10.1530/eje.0.1450255; Houwing NS, 2003, PHARMACOTHERAPY, V23, P1257, DOI 10.1592/phco.23.12.1257.32707; Hrebicek J, 2002, J CLIN ENDOCR METAB, V87, P144, DOI 10.1210/jc.87.1.144; HUBER D, 1988, PHARMACOPSYCHIATRY, V21, P453, DOI 10.1055/s-2007-1017050; Isidori AM, 2005, CLIN ENDOCRINOL, V63, P280, DOI 10.1111/j.1365-2265.2005.02339.x; JANOWSKY JS, 1994, BEHAV NEUROSCI, V108, P325, DOI 10.1037/0735-7044.108.2.325; Janowsky JS, 2006, NEUROSCIENCE, V138, P1015, DOI 10.1016/j.neuroscience.2005.09.007; Kapoor D, 2006, EUR J ENDOCRINOL, V154, P899, DOI 10.1530/eje.1.02166; Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402; Kenny AM, 2002, J GERONTOL A-BIOL, V57, pM321, DOI 10.1093/gerona/57.5.M321; Kenny AM, 2001, J GERONTOL A-BIOL, V56, pM266, DOI 10.1093/gerona/56.5.M266; Kenny AM, 2004, J GERONTOL A-BIOL, V59, P75; Kupelian V, 2006, J CLIN ENDOCR METAB, V91, P843, DOI 10.1210/jc.2005-1326; Laaksonen DE, 2004, DIABETES CARE, V27, P1036, DOI 10.2337/diacare.27.5.1036; Lakka HM, 2002, JAMA-J AM MED ASSOC, V288, P2709, DOI 10.1001/jama.288.21.2709; LEE F, 1985, PROSTATE, V7, P117, DOI 10.1002/pros.2990070202; LEZAK MD, 1995, NEUROPSYCHOLOGIAL AS; Lu PH, 2006, ARCH NEUROL-CHICAGO, V63, P177, DOI 10.1001/archneur.63.2.nct50002; Ly LP, 2001, J CLIN ENDOCR METAB, V86, P4078, DOI 10.1210/jc.86.9.4078; Marks LS, 2006, JAMA-J AM MED ASSOC, V296, P2351, DOI 10.1001/jama.296.19.2351; Moffat SD, 2004, NEUROLOGY, V62, P188, DOI 10.1212/WNL.62.2.188; Moffat SD, 2002, J CLIN ENDOCR METAB, V87, P5001, DOI 10.1210/jc.2002-020419; Moncada I, 2006, AGING MALE, V9, P189, DOI 10.1080/13685530601003180; Morley JE, 2001, J LAB CLIN MED, V137, P231, DOI 10.1067/mlc.2001.113504; Muller M, 2005, NEUROLOGY, V64, P866, DOI 10.1212/01.WNL.0000153072.54068.E3; Nieschlag E, 2006, J ANDROL, V27, P135, DOI 10.2164/jandrol.05047; Orwoll E, 2006, ARCH INTERN MED, V166, P2124, DOI 10.1001/archinte.166.19.2124; Ottenbacher KJ, 2006, J AM GERIATR SOC, V54, P1666, DOI 10.1111/j.1532-5415.2006.00938.x; Papasozomenos SC, 2002, P NATL ACAD SCI USA, V99, P1140, DOI 10.1073/pnas.032646799; Park N C, 2003, Aging Male, V6, P86, DOI 10.1080/713604766; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Pour HRN, 2006, TRIALS, V7, DOI 10.1186/1745-6215-7-24; Reitan R. M., 1985, HALSTEAD REITAN NEUR, V4; Rhoden EL, 2004, NEW ENGL J MED, V350, P482, DOI 10.1056/NEJMra022251; Rhodes T, 1999, J UROLOGY, V161, P1174, DOI 10.1016/S0022-5347(01)61621-5; Samson MM, 2000, AGE AGEING, V29, P235, DOI 10.1093/ageing/29.3.235; Schaap LA, 2005, CLIN ENDOCRINOL, V63, P152, DOI 10.1111/j.1365-2265.2005.02315.x; Schatzl G, 2001, PROSTATE, V47, P52; Schnabel PG, 2007, CLIN ENDOCRINOL, V66, P579, DOI 10.1111/j.1365-2265.2007.02781.x; Scuteri A, 2005, DIABETES CARE, V28, P882, DOI 10.2337/diacare.28.4.882; SIEGERT CEH, 1984, CLIN RHEUMATOL, V3, P305, DOI 10.1007/BF02032335; Sih R, 1997, J CLIN ENDOCR METAB, V82, P1661, DOI 10.1210/jc.82.6.1661; Silverman I, 1999, PSYCHONEUROENDOCRINO, V24, P813, DOI 10.1016/S0306-4530(99)00031-1; Snyder PJ, 1999, J CLIN ENDOCR METAB, V84, P2647, DOI 10.1210/jc.84.8.2647; STANLEY HL, 1991, J AM GERIATR SOC, V39, P766, DOI 10.1111/j.1532-5415.1991.tb02698.x; TENOVER JS, 1992, J CLIN ENDOCR METAB, V75, P1092, DOI 10.1210/jc.75.4.1092; Tirassa P, 1997, J NEUROSCI RES, V47, P198, DOI 10.1002/(SICI)1097-4547(19970115)47:2<198::AID-JNR8>3.0.CO;2-A; Tracz MJ, 2006, J CLIN ENDOCR METAB, V91, P2011, DOI 10.1210/jc.2006-0036; Tremblay AJ, 2004, CLIN BIOCHEM, V37, P785, DOI 10.1016/j.clinbiochem.2004.03.008; VANDENBERG SG, 1978, PERCEPT MOTOR SKILL, V47, P599, DOI 10.2466/pms.1978.47.2.599; Vermeulen A, 1999, J CLIN ENDOCR METAB, V84, P3666, DOI 10.1210/jc.84.10.3666; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Whitsel EA, 2001, AM J MED, V111, P261, DOI 10.1016/S0002-9343(01)00833-6; Wittert GA, 2003, J GERONTOL A-BIOL, V58, P618; Yaffe K, 2002, J AM GERIATR SOC, V50, P707, DOI 10.1046/j.1532-5415.2002.50166.x; ZMUDA JM, 1993, METABOLISM, V42, P446, DOI 10.1016/0026-0495(93)90101-S	77	368	379	0	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	2008	299	1					39	52		10.1001/jama.2007.51	http://dx.doi.org/10.1001/jama.2007.51			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247BL	18167405	Bronze			2023-01-03	WOS:000252052000015
J	Ismail, S; Mulley, G				Ismail, Sadia; Mulley, Graham			Visiting times	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Ismail, Sadia] Pinderfields Gen Hosp, Wakefield WF1 4DG, England; [Mulley, Graham] St James Univ Hosp, Leeds, W Yorkshire, England	Pinderfields Hospital; Saint James's University Hospital	Ismail, S (corresponding author), Pinderfields Gen Hosp, Wakefield WF1 4DG, England.	sadiaismail@doctors.org							0	6	6	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 22	2007	335	7633					1316	1317		10.1136/bmj.39420.392373.BE	http://dx.doi.org/10.1136/bmj.39420.392373.BE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248UO	18156246	Bronze, Green Published, Green Submitted			2023-01-03	WOS:000252182700029
J	Sorensen, HT; Horvath-Puho, E; Pedersen, L; Baron, JA; Prandoni, P				Sorensen, Henrik Toft; Horvath-Puho, Erzsebet; Pedersen, Lars; Baron, John A.; Prandoni, Paolo			Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study	LANCET			English	Article							DEEP-VEIN THROMBOSIS; ACUTE MYOCARDIAL-INFARCTION; PULMONARY-EMBOLISM; RISK-FACTORS; GENERAL-POPULATION; SUBCLINICAL ATHEROSCLEROSIS; DISEASE; EPIDEMIOLOGY; STROKE; DIAGNOSIS	Background In some studies, venous thromboembolism has been associated with atherosclerosis and with the risk of arterial cardiovascular events such as myocardial infarction and stroke. Other studies, however, do not show this association. To help clarify these discrepant findings, we aimed to investigate the risk of arterial cardiovascular events in patients who were diagnosed with venous thromboembolism. Methods We undertook a 20-year population-based cohort study using data from nationwide Danish medical databases. After excluding those with known cardiovascular disease, we assessed the risk of myocardial infarction and stroke in 25199 patients with deep venous thrombosis, 16925 patients with pulmonary embolism, and 163 566 population controls. Findings For patients with deep venous thrombosis, the relative risks varied from 1.60 for myocardial infarction (95% Cl 1.35-1-91) to 2.19 (1.85-2.60) for stroke in the first year after the thrombotic event. For patients with pulmonary embolism, the relative risks in that year were 2.60 (2.14-3.14) for myocardial infarction and 2.93 (2.34-3.66) for stroke. The relative risks were also raised, though less markedly, during the subsequent 20 years of follow-up, with 20-40% increases in risk for arterial cardiovascular events. Relative risks were similar for those with provoked and unprovoked deep venous thrombosis and pulmonary embolism. Interpretation Patients with venous thromboembolism have a substantially increased long-term risk of subsequent arterial cardiovascular events.	Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus C, Denmark; Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; Dartmouth Med Sch, Dept Med, Hanover, NH USA; Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH USA; Univ Padua, Dept Med & Surg Sci, Thromboembolism Unit, I-35100 Padua, Italy	Aarhus University; Boston University; Dartmouth College; Dartmouth College; University of Padua	Sorensen, HT (corresponding author), Aarhus Univ Hosp, Dept Clin Epidemiol, Ole Worms Alle 1150, DK-8000 Aarhus C, Denmark.	hts@dce.au.dk	Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040; Horvath-Puho, Erzsebet/0000-0002-3594-2212				Ageno W, 2006, J THROMB HAEMOST, V4, P1914, DOI 10.1111/j.1538-7836.2006.02132.x; Agnelli G, 2006, J THROMB HAEMOST, V4, P1886, DOI 10.1111/j.1538-7836.2006.02138.x; Anand SS, 1999, JAMA-J AM MED ASSOC, V282, P2058, DOI 10.1001/jama.282.21.2058; Andersen TF, 1999, DAN MED BULL, V46, P263; Becattini C, 2005, EUR HEART J, V26, P77, DOI 10.1093/eurheartj/ehi018; Boersma E, 2003, LANCET, V361, P847, DOI 10.1016/S0140-6736(03)12712-2; Bova C, 2006, THROMB HAEMOSTASIS, V96, P132, DOI 10.1160/TH-06-05-0231; *DAN SOC THROMB HE, 2000, 3 DAN SOC THROMB HEM; Eliasson A, 2006, J THROMB HAEMOST, V4, P1897, DOI 10.1111/j.1538-7836.2006.02152.x; Fowkes FJI, 2003, EUR J VASC ENDOVASC, V25, P1, DOI 10.1053/ejvs.2002.1778; Frank L, 2000, SCIENCE, V287, P2398, DOI 10.1126/science.287.5462.2398; Glynn RJ, 2005, AM J EPIDEMIOL, V162, P975, DOI 10.1093/aje/kwi309; Goldhaber SZ, 1997, JAMA-J AM MED ASSOC, V277, P642, DOI 10.1001/jama.277.8.642; GOLDHABER SZ, 1983, AM J MED, V74, P1023, DOI 10.1016/0002-9343(83)90805-7; Goon PKY, 2006, THROMB HAEMOSTASIS, V96, P111, DOI 10.1160/TH06-07-0380; Hansson PO, 1997, ARCH INTERN MED, V157, P1665, DOI 10.1001/archinte.157.15.1665; Heit JA, 2000, ARCH INTERN MED, V160, P809, DOI 10.1001/archinte.160.6.809; Heit JA, 2006, J THROMB THROMBOLYS, V21, P23, DOI 10.1007/s11239-006-5572-y; Heit JA, 2005, J THROMB HAEMOST, V3, P1611, DOI 10.1111/j.1538-7836.2005.01415.x; Hong C, 2005, ATHEROSCLEROSIS, V183, P169, DOI 10.1016/j.atherosclerosis.2005.03.047; Johnsen SP, 2002, J CLIN EPIDEMIOL, V55, P602, DOI 10.1016/S0895-4356(02)00391-8; KNIFFIN WD, 1994, ARCH INTERN MED, V154, P861, DOI 10.1001/archinte.154.8.861; Kyrle PA, 2005, LANCET, V365, P1163, DOI 10.1016/S0140-6736(05)71880-8; Leppala JM, 1999, EUR J EPIDEMIOL, V15, P155, DOI 10.1023/A:1007504310431; Libby P, 2000, CLIN CARDIOL, V23, P3, DOI 10.1002/clc.4960231103; Lowe GDO, 2006, J THROMB HAEMOST, V4, P1882, DOI 10.1111/j.1538-7836.2006.02130.x; Madsen M, 2003, J CLIN EPIDEMIOL, V56, P124, DOI 10.1016/S0895-4356(02)00591-7; Prandoni P, 2006, J THROMB HAEMOST, V4, P1891, DOI 10.1111/j.1538-7836.2006.02058.x; Prandoni P, 2003, NEW ENGL J MED, V348, P1435, DOI 10.1056/NEJMoa022157; Ray JG, 2004, J THROMB HAEMOST, V2, P695, DOI 10.1111/j.1538-7836.2004.00705.x; Reich LM, 2006, J THROMB HAEMOST, V4, P1909, DOI 10.1111/j.1538-7836.2006.02121.x; SAMKOFF JS, 1981, AM J EPIDEMIOL, V114, P488, DOI 10.1093/oxfordjournals.aje.a113214; Schulman S, 2000, NEW ENGL J MED, V342, P1953, DOI 10.1056/NEJM200006293422604; Schulman S, 2006, J THROMB HAEMOST, V4, P734, DOI 10.1111/j.1538-7836.2006.01795.x; Sorensen H T, 1997, Int J Risk Saf Med, V10, P1, DOI 10.3233/JRS-1997-10101; Sorensen HT, 2000, NEW ENGL J MED, V343, P1846, DOI 10.1056/NEJM200012213432504; Sorensen HT, 1998, NEW ENGL J MED, V338, P1169, DOI 10.1056/NEJM199804233381701; Tsai AW, 2002, ARCH INTERN MED, V162, P1182, DOI 10.1001/archinte.162.10.1182; van der Hagen PB, 2006, J THROMB HAEMOST, V4, P1903, DOI 10.1111/j.1538-7836.2006.02096.x; Warlow C, 2003, LANCET, V362, P1211, DOI 10.1016/S0140-6736(03)14544-8; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	41	300	311	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 24	2007	370	9601					1773	1779						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234DI	18037081				2023-01-03	WOS:000251140500021
J	Malhotra, A				Malhotra, Atul			Low-tidal-volume ventilation in the acute respiratory distress syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INDUCED LUNG INJURY; MECHANICAL VENTILATION; DAILY INTERRUPTION; SURVIVING SEPSIS; STRATEGY; TRIAL; HYPERCAPNIA; GUIDELINES; REDUCTION; CAMPAIGN		Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Brigham & Womens Hosp, Sleep Med Div, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Malhotra, A (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care, 75 Francis St, Boston, MA 02115 USA.	amalhotra1@partners.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060292, R01HL073146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K23AG024837] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; BERNARD GR, 1994, J CRIT CARE, V9, P72, DOI 10.1016/0883-9441(94)90033-7; Borges JB, 2006, NEW ENGL J MED, V355, P319; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; Brower RG, 1999, CRIT CARE MED, V27, P1492, DOI 10.1097/00003246-199908000-00015; Carson SS, 2006, CRIT CARE MED, V34, P1326, DOI 10.1097/01.CCM.0000215513.63207.7F; Carvalho CRR, 1997, AM J RESP CRIT CARE, V156, P1458, DOI 10.1164/ajrccm.156.5.9604081; Cho MH, 2006, ANN THORAC SURG, V82, P261, DOI 10.1016/j.athoracsur.2006.02.022; Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4; Dellinger RP, 2004, CRIT CARE MED, V32, P1448; Derdak S, 2002, AM J RESP CRIT CARE, V166, P801, DOI 10.1164/rccm.2108052; Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014; Dreyfuss D, 1998, INTENS CARE MED, V24, P102, DOI 10.1007/s001340050529; Eichacker PQ, 2006, NEW ENGL J MED, V355, P1640, DOI 10.1056/NEJMp068197; FARIDY EE, 1966, J APPL PHYSIOL, V21, P1453, DOI 10.1152/jappl.1966.21.5.1453; Gajic O, 2005, INTENS CARE MED, V31, P922, DOI 10.1007/s00134-005-2625-1; Hager DN, 2005, AM J RESP CRIT CARE, V172, P1241, DOI 10.1164/rccm.200501-048CP; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; Kacmarek RM, 2006, AM J RESP CRIT CARE, V173, P882, DOI 10.1164/rccm.200508-1196OC; Kacmarek Robert M, 2005, Crit Care Med, V33, pS148, DOI 10.1097/01.CCM.0000156786.43935.A0; Kahn JM, 2005, CRIT CARE MED, V33, P766, DOI 10.1097/01.CCM.0000157786.41506.24; Kallet Richard H, 2002, Respir Care, V47, P898; Kavanagh BP, 2006, MINERVA ANESTESIOL, V72, P567; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; MacIntyre NR, 2005, CHEST, V128, p561S, DOI 10.1378/chest.128.5_suppl_2.561S; Malhotra A, 2002, NEW ENGL J MED, V346, P296; Matthay MA, 2002, AM J PHYSIOL-LUNG C, V283, pL678, DOI 10.1152/ajplung.00154.2002; MEAD J, 1970, J APPL PHYSIOL, V28, P596, DOI 10.1152/jappl.1970.28.5.596; MEADE MO, 2007, AM J RESP CRIT CARE, V175, pA506; MERCAT A, 2007, AM J RESP CRIT CARE, V175, pA507; Piantadosi CA, 2004, ANN INTERN MED, V141, P460, DOI 10.7326/0003-4819-141-6-200409210-00012; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Slutsky AS, 1999, CHEST, V116, p9S, DOI 10.1378/chest.116.suppl_1.9S-a; Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092; SLUTSKY AS, 1993, CHEST, V104, P1833, DOI 10.1378/chest.104.6.1833; SLUTSKY AS, 1994, CHEST, V106, P656; Spragg RG, 2004, NEW ENGL J MED, V351, P884, DOI 10.1056/NEJMoa033181; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; Terragni PP, 2007, AM J RESP CRIT CARE, V175, P160, DOI 10.1164/rccm.200607-915OC; Tobin MJ, 2000, NEW ENGL J MED, V342, P1360, DOI 10.1056/NEJM200005043421808; Tobin MJ, 2001, NEW ENGL J MED, V344, P1986, DOI 10.1056/NEJM200106283442606; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Villar J, 2005, Minerva Anestesiol, V71, P255; Villar J, 2006, CRIT CARE MED, V34, P1311, DOI 10.1097/01.CCM.0000215598.84885.01; Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7	47	139	148	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 13	2007	357	11					1113	1120		10.1056/NEJMct074213	http://dx.doi.org/10.1056/NEJMct074213			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	209KK	17855672	Green Accepted			2023-01-03	WOS:000249387200007
J	Sims-Mourtada, J; Izzo, JG; Ajani, J; Chao, KSC				Sims-Mourtada, J.; Izzo, J. G.; Ajani, J.; Chao, K. S. C.			Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport	ONCOGENE			English	Article						hedgehog; multiple drug resistance; drug transport; chemoresistance	MULTIDRUG-RESISTANCE; STEM-CELLS; MUTATIONS; PTCH	A major obstacle to successful chemotherapy is intrinsic or acquired multi-drug resistance (MDR). The most common cause of MDR involves increased drug efflux from cancer cells mediated by members of the ATP-binding cassette (ABC) transporter family. The regulation of ABC transporters in the context of cancer is poorly understood, and clinical efforts to inhibit their function have not been fruitful. Constitutive activation of the Hedgehog (Hh) pathway has been shown to contribute to the growth and maintenance of various cancers. Here, we show that inhibition of Hh signaling increases the response of cancer cells to multiple structurally unrelated chemotherapies. We further show that Hh pathway activation induces chemoresistance in part by increasing drug efflux in an ABC transporter-dependent manner. We found that Hh signaling regulates the expression of the ABC transporter proteins multi-drug resistance protein-1 (MDR1, ABCB1, P-glycoprotein) and (BCRP, ABCG2), and that targeted knockdown of MDR1 and BCRP expression by small interfering RNA partially reverses Hh-induced chemoresistance. These results suggest that the Hh pathway may be a target to overcome MDR and increase chemotherapeutic response.	Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Chao, KSC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, 1515 Holcombe Blvd,Unit 97, Houston, TX 77030 USA.	cchao@mdanderson.org			NCI NIH HHS [P50 CA97007, CA89198, CA121551] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097007, R21CA121551, R01CA089198] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Bunting KD, 2000, BLOOD, V96, P902, DOI 10.1182/blood.V96.3.902.015k40_902_909; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chintamani, 2005, WORLD J SURG ONCOL, V3, P61; Doyle LA, 2003, ONCOGENE, V22, P7340, DOI 10.1038/sj.onc.1206938; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Kubo A, 2004, AM J GASTROENTEROL, V99, P582, DOI 10.1111/j.1572-0241.2004.04131.x; Lindstrom E, 2006, HUM MUTAT, V27, P215, DOI 10.1002/humu.20296; Okano-Uchida T, 2004, P NATL ACAD SCI USA, V101, P1211, DOI 10.1073/pnas.0307972100; Perez-Tomas R, 2006, CURR MED CHEM, V13, P1859, DOI 10.2174/092986706777585077; Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X; Ruel L, 2003, NAT CELL BIOL, V5, P907, DOI 10.1038/ncb1052; Sims-Mourtada J, 2006, CLIN CANCER RES, V12, P6565, DOI 10.1158/1078-0432.CCR-06-0176; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; Takara K, 2006, CURR PHARM DESIGN, V12, P273, DOI 10.2174/138161206775201965; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	17	177	185	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5674	5679		10.1038/sj.onc.1210356	http://dx.doi.org/10.1038/sj.onc.1210356			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17353904				2023-01-03	WOS:000248801900014
J	Agarwal, N; Pacher, P; Tegeder, I; Amaya, F; Constantin, CE; Brenner, GJ; Rubino, T; Michalski, CW; Marsicano, G; Monory, K; Mackie, K; Marian, C; Batkai, S; Parolaro, D; Fischer, MJ; Reeh, P; Kunos, G; Kress, M; Lutz, B; Woolf, CJ; Kuner, R				Agarwal, Nitin; Pacher, Pal; Tegeder, Irmgard; Amaya, Fumimasa; Constantin, Cristina E.; Brenner, Gary J.; Rubino, Tiziana; Michalski, Christoph W.; Marsicano, Giovanni; Monory, Krisztina; Mackie, Ken; Marian, Claudiu; Batkai, Sandor; Parolaro, Daniela; Fischer, Michael J.; Reeh, Peter; Kunos, George; Kress, Michaela; Lutz, Beat; Woolf, Clifford J.; Kuner, Rohini			Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors	NATURE NEUROSCIENCE			English	Article							IN-SITU HYBRIDIZATION; DORSAL-ROOT GANGLIA; NEUROPATHIC PAIN; ENDOGENOUS CANNABINOIDS; SPINAL NEURONS; KNOCKOUT MICE; WIN 55,212-2; RATS; CB1; HYPERALGESIA	Although endocannabinoids constitute one of the first lines of defense against pain, the anatomical locus and the precise receptor mechanisms underlying cannabinergic modulation of pain are uncertain. Clinical exploitation of the system is severely hindered by the cognitive deficits, memory impairment, motor disturbances and psychotropic effects resulting from the central actions of cannabinoids. We deleted the type 1 cannabinoid receptor (CB1) specifically in nociceptive neurons localized in the peripheral nervous system of mice, preserving its expression in the CNS, and analyzed these genetically modified mice in preclinical models of inflammatory and neuropathic pain. The nociceptor-specific loss of CB1 substantially reduced the analgesia produced by local and systemic, but not intrathecal, delivery of cannabinoids. We conclude that the contribution of CB1-type receptors expressed on the peripheral terminals of nociceptors to cannabinoid-induced analgesia is paramount, which should enable the development of peripherally acting CB1 analgesic agonists without any central side effects.	Univ Heidelberg, Inst Pharmacol, D-69120 Heidelberg, Germany; NIH, NIAAA, Lab Physiol Studies, Bethesda, MD 20892 USA; Univ Frankfurt Klinikum, D-60590 Frankfurt, Germany; Massachusetts Gen Hosp, Harvard Med Sch, Dept Anesthesia & Crit Care, Charlestown, MA 02129 USA; Med Univ Innsbruck, Dept Physiol & Med Phys, Div Physiol, A-6020 Innsbruck, Austria; Univ Mainz, Dept Physiol Chem, D-55099 Mainz, Germany; Univ Washington, Sch Med, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Erlangen Nurnberg, Inst Physiol & Pathophysiol, D-91054 Erlangen, Germany	Ruprecht Karls University Heidelberg; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Goethe University Frankfurt; Goethe University Frankfurt Hospital; Harvard University; Massachusetts General Hospital; Medical University of Innsbruck; Johannes Gutenberg University of Mainz; University of Washington; University of Washington Seattle; University of Erlangen Nuremberg	Kuner, R (corresponding author), Univ Heidelberg, Inst Pharmacol, Im Neuenheimer Feld, D-69120 Heidelberg, Germany.	rohini.kuner@pharma.uni-heidelberg.de	Brenner, Gary/AAI-1293-2019; Tegeder, Irmgard/AAM-2246-2020; Lutz, Beat/AAG-4538-2022; Mackie, Kenneth P/B-7358-2011; Fischer, Michael/F-7976-2010; Michalski, Christoph/U-9167-2019; Woolf, Clifford/A-9784-2010; Batkai, Sandor/H-7983-2014; Batkai, Sandor/G-3889-2010; amaya, fumimasa/AAD-7176-2020; Mackie, Ken/E-3715-2013; Kuner, Rohini/AGU-0204-2022; Tegeder, Irmgard/AAM-2266-2020; Reeh, Peter W./J-8981-2012; Lutz, Beat/AFK-6229-2022; Marsicano, Giovanni/I-9603-2016; Rubino, Tiziana/AAC-8210-2020; Pacher, Pal/B-6378-2008; Fischer, Michael J.M./P-8715-2014	Brenner, Gary/0000-0002-4586-1723; Tegeder, Irmgard/0000-0001-7524-8025; Mackie, Ken/0000-0001-8501-6199; Tegeder, Irmgard/0000-0001-7524-8025; Reeh, Peter W./0000-0002-4367-094X; Pacher, Pal/0000-0001-7036-8108; Kress, Michaela/0000-0002-8921-7470; Fischer, Michael J.M./0000-0002-3811-7066; amaya, fumimasa/0000-0003-2934-0845; Marsicano, Giovanni/0000-0003-3804-1951; RUBINO, Tiziana/0000-0002-3128-6377	Intramural NIH HHS [Z01 AA000375-02] Funding Source: Medline; NIDA NIH HHS [R01 DA011322-02, K02 DA000286, K02 DA000286-04, DA00286, R01 DA011322, DA11322] Funding Source: Medline; NINDS NIH HHS [NS039518, NS 038253, R01 NS039518-01A2, R01 NS038253, R37 NS039518, R01 NS038253-01S1, R01 NS039518] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038253, R01NS039518, R37NS039518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000350, Z01AA000375] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA000286, R01DA011322] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Agarwal N, 2004, GENESIS, V38, P122, DOI 10.1002/gene.20010; Azad SC, 2004, J NEUROSCI, V24, P9953, DOI 10.1523/JNEUROSCI.2134-04.2004; Binzen U, 2006, NEUROSCIENCE, V142, P527, DOI 10.1016/j.neuroscience.2006.06.020; Bridges D, 2003, NEUROSCIENCE, V119, P803, DOI 10.1016/S0306-4522(03)00200-8; Bridges D, 2001, BRIT J PHARMACOL, V133, P586, DOI 10.1038/sj.bjp.0704110; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Coutts AA, 2002, J COMP NEUROL, V448, P410, DOI 10.1002/cne.10270; Decosterd I, 2000, PAIN, V87, P149, DOI 10.1016/S0304-3959(00)00276-1; Dogrul A, 2003, PAIN, V105, P11, DOI 10.1016/S0304-3959(03)00068-X; Finn DP, 2003, NEUROPHARMACOLOGY, V45, P594, DOI 10.1016/S0028-3908(03)00235-1; Fox A, 2001, PAIN, V92, P91, DOI 10.1016/S0304-3959(00)00474-7; Freund TF, 2003, PHYSIOL REV, V83, P1017, DOI 10.1152/physrev.00004.2003; Hartmann B, 2004, NEURON, V44, P637, DOI 10.1016/j.neuron.2004.10.029; Hohmann AG, 1999, NEUROSCIENCE, V90, P923, DOI 10.1016/S0306-4522(98)00524-7; Ibrahim MM, 2006, PAIN, V122, P36, DOI 10.1016/j.pain.2005.12.018; Janson W., 2003, Current Pharmaceutical Biotechnology, V4, P270, DOI 10.2174/1389201033489766; Ji RR, 1999, NAT NEUROSCI, V2, P1114, DOI 10.1038/16040; Johanek LM, 2001, PAIN, V93, P303, DOI 10.1016/S0304-3959(01)00336-0; Kolesnikov YA, 1996, J PHARMACOL EXP THER, V279, P502; Kress M, 1999, J NEUROPHYSIOL, V81, P2612, DOI 10.1152/jn.1999.81.6.2612; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Mackie K, 2006, AAPS J, V8, pE298, DOI 10.1007/BF02854900; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839; MARTIN WJ, 1993, BRAIN RES, V629, P300, DOI 10.1016/0006-8993(93)91334-O; Martin WJ, 1999, PAIN, V82, P199, DOI 10.1016/S0304-3959(99)00045-7; Meng ID, 1998, NATURE, V395, P381, DOI 10.1038/26481; Mitrirattanakul S, 2006, PAIN, V126, P102, DOI 10.1016/j.pain.2006.06.016; Oliver D, 2004, SCIENCE, V304, P265, DOI 10.1126/science.1094113; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Pascual D, 2005, PAIN, V118, P23, DOI 10.1016/j.pain.2005.07.008; Patwardhan AM, 2006, P NATL ACAD SCI USA, V103, P11393, DOI 10.1073/pnas.0603861103; PERTWEE RG, 1972, BRIT J PHARMACOL, V46, P753, DOI 10.1111/j.1476-5381.1972.tb06900.x; Piomelli Daniele, 2005, Curr Opin Investig Drugs, V6, P672; Quartilho A, 2003, ANESTHESIOLOGY, V99, P955, DOI 10.1097/00000542-200310000-00031; Richardson JD, 1998, PAIN, V75, P111, DOI 10.1016/S0304-3959(97)00213-3; Rubino T, 2000, J NEUROCHEM, V75, P2080, DOI 10.1046/j.1471-4159.2000.0752080.x; SHIRE D, 1995, J BIOL CHEM, V270, P3726, DOI 10.1074/jbc.270.8.3726; Sokal DM, 2003, NEUROPHARMACOLOGY, V45, P404, DOI 10.1016/S0028-3908(03)00195-3; TSAY DG, 1987, INVEST RADIOL, V22, P556, DOI 10.1097/00004424-198707000-00005; Ulugol A, 2004, NEUROSCI LETT, V371, P167, DOI 10.1016/j.neulet.2004.08.061; Valiveti S, 2004, PHARM RES-DORDR, V21, P1137, DOI 10.1023/B:PHAM.0000032999.31948.2e; Walker JM, 2005, HANDB EXP PHARMACOL, V168, P509; Wang L, 2003, P NATL ACAD SCI USA, V100, P1393, DOI 10.1073/pnas.0336351100; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780	46	422	441	1	44	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1097-6256			NAT NEUROSCI	Nat. Neurosci.	JUL	2007	10	7					870	879		10.1038/nn1916	http://dx.doi.org/10.1038/nn1916			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	183GH	17558404	Green Accepted			2023-01-03	WOS:000247560200017
J	Mitani, Y; Oue, N; Matsumura, S; Yoshida, K; Noguchi, T; Ito, M; Tanaka, S; Kuniyasu, H; Kamata, N; Yasui, W				Mitani, Y.; Oue, N.; Matsumura, S.; Yoshida, K.; Noguchi, T.; Ito, M.; Tanaka, S.; Kuniyasu, H.; Kamata, N.; Yasui, W.			Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy	ONCOGENE			English	Article						reg IV; apoptosis; 5-fluorouracil; serum tumor marker; SAGE; gastric cancer	DIHYDROPYRIMIDINE DEHYDROGENASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; CELL-LINE TMK-1; GENE-EXPRESSION; COLONIC CARCINOMAS; SERIAL ANALYSIS; APOPTOSIS; SENSITIVITY; METASTASIS; SEARCH	Regenerating gene family, member 4 (Reg IV), a secreted protein, is overexpressed in several cancers, including gastric cancer (GC). In the present study, we measured Reg IV levels in sera from patients with GC by enzyme-linked immunosorbent assay. We also examined the effect of forced Reg IV expression on the apoptotic susceptibility to 5-fluorouracil(5-FU). Forced expression of Reg IV inhibited 5-FU-induced apoptosis. Induction of Bcl-2 and dihydropyrimidine dehydrogenase was involved in inhibition of apoptosis. Among 36 GC patients treated with a combination chemotherapy of low-dose 5-FU and cisplatin, all 14 Reg IV-positive patients showed no change or disease progression. The serum Reg IV concentration was similar between healthy individuals mean +/- s.e., (0.52 +/- 0.05 ng/ml) and patients with chronic-active gastritis (0.36 +/- 0.09 ng/ml). However, the serum Reg IV concentration in presurgical GC patients was signifi. cantly elevated (1.96 +/- 0.17 ng/ml), even at stage I. The diagnostic sensitivity of serum Reg IV (36.1%) was superior to that of serum carcinoembryonic antigen (11.5%) or carbohydrate antigen 19-9 (13.1%). These results indicate that expression of Reg IV is a marker for prediction of resistance to 5-FU-based chemotherapy in patients with GC. Serum Reg IV represents a novel biomarker for GC.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Oral & Maxillofacial Surg, Div Cervico Gnathostomatol, Hiroshima, Japan; Hiroshima Univ, Dept Surg Oncol, Res Inst Radiat Biol & Med, Hiroshima, Japan; Oita Univ, Fac Med, Dept Oncol Sci Surg 2, Oita 87011, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Med & Mol Sci, Hiroshima, Japan; Nara Med Univ, Dept Mol Pathol, Kashihara, Nara 634, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Oita University; Hiroshima University; Nara Medical University	Yasui, W (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	wyasui@hiroshima-u.ac.jp	Mitani, Yoshitsugu/ABA-2736-2021	Mitani, Yoshitsugu/0000-0002-8661-4702				ALLEY MC, 1988, CANCER RES, V48, P589; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Aung PP, 2006, ONCOGENE, V25, P2546, DOI 10.1038/sj.onc.1209279; Bishnupuri KS, 2006, GASTROENTEROLOGY, V130, P137, DOI 10.1053/j.gastro.2005.10.001; Buckhaults P, 2001, CANCER RES, V61, P6996; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRIS BE, 1990, CANCER RES, V50, P197; Hartupee JC, 2001, BBA-GENE STRUCT EXPR, V1518, P287, DOI 10.1016/S0167-4781(00)00284-0; Hohenberger P, 2003, LANCET, V362, P305, DOI 10.1016/S0140-6736(03)13975-X; Inada T, 2000, ANTICANCER RES, V20, P2457; Ishikawa Y, 2000, JPN J CANCER RES, V91, P105, DOI 10.1111/j.1349-7006.2000.tb00866.x; Kari C, 2003, CANCER RES, V63, P1; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kim R, 1999, INT J ONCOL, V15, P921; Kochi Mitsugu, 2000, Gastric Cancer, V3, P177, DOI 10.1007/PL00011715; Kuramochi H, 2006, INT J CANCER, V119, P522, DOI 10.1002/ijc.21692; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; OCHIAI A, 1985, JPN J CANCER RES, V76, P1064; Oue N, 2005, J PATHOL, V207, P185, DOI 10.1002/path.1827; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; SOBIN LH, 2002, TNM CLASSIFICATION M, P65; Tahara E, 2005, CANCER IMMUNOL IMMUN, V54, P729, DOI 10.1007/s00262-004-0645-2; Takebe N, 2001, CANCER GENE THER, V8, P966, DOI 10.1038/sj.cgt.7700393; Ukon K, 2005, CANCER RES, V65, P1055; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Violette S, 2003, INT J CANCER, V103, P185, DOI 10.1002/ijc.10788; YASUI W, 1993, INT J CANCER, V53, P36, DOI 10.1002/ijc.2910530108; Yasui W, 2004, CANCER SCI, V95, P385, DOI 10.1111/j.1349-7006.2004.tb03220.x; YASUI W, 1988, CANCER RES, V48, P137	33	91	101	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4383	4393		10.1038/sj.onc.1210215	http://dx.doi.org/10.1038/sj.onc.1210215			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17237819	Green Submitted			2023-01-03	WOS:000247620000006
J	Leonard, JP; Goldenberg, DM				Leonard, J. P.; Goldenberg, D. M.			Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies	ONCOGENE			English	Review						non-Hodgkin's lymphoma; B-cell; CD20; CD22; efficacy; epratuzumab	NON-HODGKINS-LYMPHOMA; LL2 MONOCLONAL-ANTIBODY; Y-90 IBRITUMOMAB TIUXETAN; IODINE I-131 TOSITUMOMAB; MULTICENTER PHASE-II; LOW-GRADE; FOLLICULAR LYMPHOMA; IMMUNOGLOBULIN SUPERFAMILY; RADIOLABELED ANTIBODIES; HISTORICAL-PERSPECTIVE	The vast majority of non-Hodgkin's lymphomas are of B-cell phenotype. Development of unlabeled or radiolabeled therapeutic monoclonal antibodies against the cell surface antigen, CD20, has revolutionized the treatment of these malignancies. It is clear that antibodies targeting other B-cell-specific molecules, such as CD22, also offer potential therapeutic benefit. Epratuzumab is a humanized anti-CD22 monoclonal, which has undergone preclinical and phase I/II clinical evaluation in patients with indolent or aggressive lymphoma. Data suggest that this agent is well tolerated, and can induce tumor regressions. Trials are currently evaluating its safety and activity in combination with rituximab (chimeric anti-CD20) and standard chemotherapy are ongoing. Initial results suggest that these regimens have acceptable toxicity, and that epratuzumab warrants further evaluation as an adjunct to standard lymphoma treatment regimens.	Cornell Univ, Weill Med Coll, Ctr Lymphoma & Myeloma, Dept Med, New York, NY 10021 USA; New York Presbyterian Hosp, New York, NY 10021 USA; Garden State Canc Ctr, Ctr Mol Med & Immunol, Belleville, NJ USA; Immunomedics Inc, Morris Plains, NJ USA	Cornell University; NewYork-Presbyterian Hospital; Immunomedics Inc	Leonard, JP (corresponding author), Cornell Univ, Weill Med Coll, Ctr Lymphoma & Myeloma, Dept Med, Starr Bldg,Room 340,520 E 70th St, New York, NY 10021 USA.	jpleonar@med.cornell.edu	Leonard, John/M-4379-2014	Leonard, John/0000-0002-5083-1115				Ansell SM, 2002, J CLIN ONCOL, V20, P3885, DOI 10.1200/JCO.2002.10.143; ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023; BAUM RP, 1994, CANCER, V73, P896, DOI 10.1002/1097-0142(19940201)73:3+<896::AID-CNCR2820731322>3.0.CO;2-H; BECKER WS, 1995, CANCER RES, V55, pS5771; Behr TM, 1999, CLIN CANCER RES, V5, p3304S; BEHR TM, 2002, TUMOR TARGET, V3, P32; BLEND MJ, 1995, CANCER RES, V55, pS5764; BUCHSBAUM DJ, 1992, CANCER RES, V52, P6476; Carnahan J, 2003, CLIN CANCER RES, V9, p3982S; Carnahan J, 2007, MOL IMMUNOL, V44, P1331, DOI 10.1016/j.molimm.2006.05.007; Cesano A, 2002, BLOOD, V100, p350A; CHAOUCHI N, 1995, J IMMUNOL, V154, P3096; CHATAL JF, 2005, P SOC NUCL MED, pP155; Cheson BD, 2005, BIODRUGS, V19, P309, DOI 10.2165/00063030-200519050-00004; Cheson BD, 2003, BLOOD, V101, P391, DOI 10.1182/blood-2002-06-1793; Chow KU, 2002, HAEMATOLOGICA, V87, P33; Coffey J, 2003, EUR J NUCL MED MOL I, V30, pS28, DOI 10.1007/s00259-003-1157-6; Coiffier B, 2005, J CLIN ONCOL, V23, P6387, DOI 10.1200/JCO.2005.05.015; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Coiffier B, 1998, BLOOD, V92, P1927; Czuczman MS, 2004, J CLIN ONCOL, V22, P4711, DOI 10.1200/JCO.2004.04.020; Davis TA, 2004, CLIN CANCER RES, V10, P7792, DOI 10.1158/1078-0432.CCR-04-0756; Davis TA, 2000, J CLIN ONCOL, V18, P3135, DOI 10.1200/JCO.2000.18.17.3135; Dorner T, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1942; DORKEN B, 1986, J IMMUNOL, V136, P4470; Dosik AD, 2006, CANCER-AM CANCER SOC, V106, P616, DOI 10.1002/cncr.21606; EMMANOUILIDES C, 2004, P AN M AM SOC CLIN, V23, P6580; ENGEL P, 1993, J IMMUNOL, V150, P4719; ENGEL P, 1995, J EXP MED, V181, P1581, DOI 10.1084/jem.181.4.1581; Fisher Richard I, 2004, Hematology Am Soc Hematol Educ Program, P221; Friedberg Jonathan W, 2004, Expert Rev Anticancer Ther, V4, P18, DOI 10.1586/14737140.4.1.18; FURMAN RR, 2006, CANC TREAT RES, V131, P141; GALLAGHER CJ, 1986, J CLIN ONCOL, V4, P1470, DOI 10.1200/JCO.1986.4.10.1470; GASPARINI M, 1995, TUMORI, V81, P173, DOI 10.1177/030089169508100304; Ghielmini M, 2004, BLOOD, V103, P4416, DOI 10.1182/blood-2003-10-3411; Golay J, 2000, BLOOD, V95, P3900; Goldenberg DM, 2003, CANCER IMMUNOL IMMUN, V52, P281, DOI 10.1007/s00262-002-0348-5; GOLDENBERG DM, 1991, J CLIN ONCOL, V9, P548, DOI 10.1200/JCO.1991.9.4.548; Goldenberg DM, 2001, CRIT REV ONCOL HEMAT, V39, P195; Gordon LI, 2004, CLIN LYMPHOMA, V5, P98, DOI 10.3816/CLM.2004.n.015; GREINER TC, 1995, CANCER-AM CANCER SOC, V75, P370, DOI 10.1002/1097-0142(19950101)75:1+<370::AID-CNCR2820751319>3.0.CO;2-Q; Griffiths GL, 2003, J NUCL MED, V44, P77; Grillo-Lopez AJ, 2000, SEMIN ONCOL, V27, P9, DOI 10.1053/sonc.2000.20444; Hainsworth JD, 2004, SEMIN ONCOL, V31, P17, DOI 10.1053/j.seminoncol.2003.12.005; Harjunpaa A, 2000, SCAND J IMMUNOL, V51, P634; Hiddemann W, 2005, J CLIN ONCOL, V23, P6394, DOI 10.1200/JCO.2005.07.019; Jazirehi AR, 2005, CANCER RES, V65, P264; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Johnson P, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50025; JUWEID M, 1995, CANCER RES, V55, pS5899; Juweid ME, 1999, CLIN CANCER RES, V5, p3292S; Kaminski MS, 2005, NEW ENGL J MED, V352, P441, DOI 10.1056/NEJMoa041511; KAMINSKI MS, 1992, J CLIN ONCOL, V10, P1696, DOI 10.1200/JCO.1992.10.11.1696; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KREITMAN RJ, 1993, CANCER RES, V53, P819; Lamonica D, 2002, CANCER BIOTHER RADIO, V17, P689, DOI 10.1089/108497802320970307; LAW CL, 1993, J IMMUNOL, V151, P175; Leonard John P, 2005, Hematology Am Soc Hematol Educ Program, P335; Leonard JP, 2005, J CLIN ONCOL, V23, P5044, DOI 10.1200/JCO.2005.13.821; Leonard JP, 2003, J CLIN ONCOL, V21, P3051, DOI 10.1200/JCO.2003.01.082; Leonard JP, 2004, CLIN CANCER RES, V10, P5327, DOI 10.1158/1078-0432.CCR-04-0294; Leung SO, 1995, MOL IMMUNOL, V32, P1413, DOI 10.1016/0161-5890(95)00080-1; Linden O, 2002, ACTA ONCOL, V41, P297, DOI 10.1080/02841860260088854; Linden O, 1999, CLIN CANCER RES, V5, p3287S; Linden O, 2005, CLIN CANCER RES, V11, P5215, DOI 10.1158/1078-0432.CCR-05-0172; Maloney DG, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30156; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; Micallef INM, 2006, CANCER-AM CANCER SOC, V107, P2826, DOI 10.1002/cncr.22342; Morschhauser F, 2005, BLOOD, V106, p683A; Morschhauser F, 2004, BLOOD, V104, p41A; MURTHY S, 1992, EUR J NUCL MED, V19, P394; Newton DL, 2001, CRIT REV ONCOL HEMAT, V39, P79, DOI 10.1016/S1040-8428(01)00116-0; Newton DL, 2001, BLOOD, V97, P528, DOI 10.1182/blood.V97.2.528; Nitschke L, 2005, CURR OPIN IMMUNOL, V17, P290, DOI 10.1016/j.coi.2005.03.005; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; PAWLAKBYCZKOWSKA EJ, 1989, CANCER RES, V49, P4568; Postema EJ, 2003, CLIN CANCER RES, V9, p3995S; Press OW, 2003, SEMIN ONCOL, V30, P10, DOI 10.1053/sonc.2003.23798; PRESS OW, 1989, J CLIN ONCOL, V7, P1027, DOI 10.1200/JCO.1989.7.8.1027; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Sharkey RM, 2005, J NUCL MED, V46, p115S; Sharkey RM, 2003, J NUCL MED, V44, P2000; Sharkey Robert M, 2005, Expert Rev Clin Immunol, V1, P47, DOI 10.1586/1744666X.1.1.47; SHIH LB, 1994, INT J CANCER, V56, P538, DOI 10.1002/ijc.2910560413; SIEGEL JA, 1991, ANTIBODY IMMUNOCONJ, V4, P649; Silverman DH, 2004, CANCER TREAT REV, V30, P165, DOI 10.1016/j.ctrv.2003.07.006; Skarin AT, 1997, CA-CANCER J CLIN, V47, P351, DOI 10.3322/canjclin.47.6.351; Skvortsova I, 2005, J RADIAT RES, V46, P241, DOI 10.1269/jrr.46.241; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; Stein R, 2004, CLIN CANCER RES, V10, P2868, DOI 10.1158/1078-0432.CCR-03-0493; STEIN R, 1993, CANCER IMMUNOL IMMUN, V37, P293, DOI 10.1007/BF01518451; STEIN R, 1994, DRUGS FUTURE, V18, P997; Steinfeld SD, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2018; Steinfeld SD, 2006, EXPERT OPIN BIOL TH, V6, P943, DOI 10.1517/14712598.6.9.943; Strauss SJ, 2006, J CLIN ONCOL, V24, P3880, DOI 10.1200/JCO.2006.05.6291; Tedder TF, 2005, ADV IMMUNOL, V88, P1, DOI 10.1016/S0065-2776(05)88001-0; Teeling JL, 2004, BLOOD, V104, P1793, DOI 10.1182/blood-2004-01-0039; Theuer Charles P, 2004, Biotechnol Annu Rev, V10, P265; Tuscano JM, 1999, BLOOD, V94, P1382, DOI 10.1182/blood.V94.4.1382.416k14_1382_1392; Vose JM, 2004, ONCOLOGIST, V9, P160, DOI 10.1634/theoncologist.9-2-160; Vose JM, 2000, LEUKEMIA LYMPHOMA, V38, P91, DOI 10.3109/10428190009060322; Wagner HN, 2002, J NUCL MED, V43, P267; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; WILSON GL, 1993, J IMMUNOL, V150, P5013; Winter Jane N, 2004, Hematology Am Soc Hematol Educ Program, P203; Witzig TE, 2004, DRUGS TODAY, V40, P111, DOI 10.1358/dot.2004.40.2.799423; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Zelenetz AD, 2002, BLOOD, V100, p357A; Zinzani PL, 2005, SEMIN ONCOL, V32, pS4, DOI 10.1053/j.seminoncol.2005.01.008	111	72	103	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3704	3713		10.1038/sj.onc.1210370	http://dx.doi.org/10.1038/sj.onc.1210370			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530024				2023-01-03	WOS:000246816100013
J	Stinchcombe, TE; Socinski, MA				Stinchcombe, T. E.; Socinski, M. A.			Bevacizumab in the treatment of non-small-cell lung cancer	ONCOGENE			English	Review						monoclonal antibody; targeted therapy; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; MONOCLONAL-ANTIBODY; BIOLOGIC MARKERS; PLUS CARBOPLATIN; CLINICAL-TRIAL; PHASE-II; CHEMOTHERAPY; COMBINATION; ANGIOGENESIS	Lung cancer is the leading cause of cancer death in the United States. The majority of patients present with advanced disease, and treatment with standard cytotoxic chemotherapy improves survival and quality of life in patients with a preserved functional status. However, the prognosis is poor with the majority of patients dying in less than a year. Treatment with standard cytotoxic chemotherapy has reached a therapeutic plateau, and new therapeutic approaches have investigated therapies that target the specific molecular pathways involved in carcinogenesis and angiogenesis. The most promising strategy for inhibiting angiogenesis involves agents that either target the proangiogenesis growth factor, vascular endothelial growth factor A (VEGF) by preventing binding to the receptor or inhibiting the downstream signaling of the vascular endothelial growth factor receptor. The only therapeutic agent approved for the treatment of lung cancer is bevacizumab, a monoclonal antibody that binds to VEGF. A recent phase III trial revealed a statistically significant improvement in response rate, progression free and overall survival with combination of bevacizumab with chemotherapy over chemotherapy alone. Attempts to identify surrogate markers of antiangiogenesis activity are currently ongoing, and may assist in the selection of patients for antiangiogenesis therapy and the development of this class of agents.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Multidisciplinary Thorac Oncol Program, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Socinski, MA (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Multidisciplinary Thorac Oncol Program, 3009 Old Clin Bldg,CB 7305, Chapel Hill, NC 27599 USA.	Socinski@med.unc.edu						Adjei AA, 2006, J CLIN ONCOL, V24, P4054, DOI 10.1200/JCO.2006.07.4658; Bates DO, 2001, J PHYSIOL-LONDON, V533, P263, DOI 10.1111/j.1469-7793.2001.0263b.x; Brahmer JR, 2006, J CLIN ONCOL, V24, p373S; Brewer GJ, 2000, CLIN CANCER RES, V6, P1; BULZEBRUCK H, 1992, CANCER-AM CANCER SOC, V70, P1102, DOI 10.1002/1097-0142(19920901)70:5<1102::AID-CNCR2820700514>3.0.CO;2-5; CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748; D'Amico TA, 1999, J THORAC CARDIOV SUR, V117, P736, DOI 10.1016/S0022-5223(99)70294-1; Davis DW, 2003, BRIT J CANCER, V89, P8, DOI 10.1038/sj.bjc.6601035; Delbaldo C, 2004, JAMA-J AM MED ASSOC, V292, P470, DOI 10.1001/jama.292.4.470; Douillard JY, 2005, J CLIN ONCOL, V23, p624S; Dowlati A, 2006, J CLIN ONCOL, V24, p370S; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Dy GK, 2006, CLIN LUNG CANCER, V7, pS145, DOI 10.3816/CLC.2006.s.006; Fehrenbacher L, 2006, J CLIN ONCOL, V24, p379S; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FOLKMAN J, 1990, CANCER METAST REV, V9, P171, DOI 10.1007/BF00046358; Folkman J, 1992, Semin Cancer Biol, V3, P65; FONTANINI G, 1995, J PATHOL, V177, P57, DOI 10.1002/path.1711770110; Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843; Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859; Herbst RS, 2005, J CLIN ONCOL, V23, P3243, DOI 10.1200/JCO.2005.18.853; Herbst RS, 2005, J CLIN ONCOL, V23, P2544, DOI 10.1200/JCO.2005.02.477; Herbst RS, 2002, J CLIN ONCOL, V20, P3804, DOI 10.1200/JCO.2002.05.102; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644; Lucchi M, 1997, EUR J CARDIO-THORAC, V12, P535, DOI 10.1016/S1010-7940(97)00218-2; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Margolin K, 2001, J CLIN ONCOL, V19, P851, DOI 10.1200/JCO.2001.19.3.851; Morgan B, 2003, J CLIN ONCOL, V21, P3955, DOI 10.1200/JCO.2003.08.092; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pfister DG, 2004, J CLIN ONCOL, V22, P330, DOI 10.1200/JCO.2004.09.053; Robinson CJ, 2001, J CELL SCI, V114, P853; SANDLER A, 2006, J CLIN ONCOLOGY 2006, V24; SANDLER A, 2006, 4I ANN M AM SOC CLIN; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Schellinger PD, 1999, J NEURO-ONCOL, V44, P275, DOI 10.1023/A:1006308808769; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Treat J, 2005, J CLIN ONCOL, V23, p627S; Ushijima C, 2001, LUNG CANCER-J IASLC, V34, P233, DOI 10.1016/S0169-5002(01)00246-X; Wakelee HA, 2006, CANCER-AM CANCER SOC, V106, P2208, DOI 10.1002/cncr.21869; Wakelee HA, 2006, CLIN LUNG CANCER, V8, P18, DOI 10.3816/CLC.2006.n.028; Winton T, 2005, NEW ENGL J MED, V352, P2589, DOI 10.1056/NEJMoa043623; Yanagawa H, 1999, CANCER IMMUNOL IMMUN, V48, P396, DOI 10.1007/s002620050592; Yano S, 2000, AM J PATHOL, V157, P1893, DOI 10.1016/S0002-9440(10)64828-6; Yano T, 2000, EUR J CANCER, V36, P601, DOI 10.1016/S0959-8049(99)00327-5	50	21	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3691	3698		10.1038/sj.onc.1210366	http://dx.doi.org/10.1038/sj.onc.1210366			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530022				2023-01-03	WOS:000246816100011
J	Ravdin, PM; Cronin, KA; Howlader, N; Berg, CD; Chlebowski, RT; Feuer, EJ; Edwards, BK; Berry, DA				Ravdin, Peter M.; Cronin, Kathleen A.; Howlader, Nadia; Berg, Christine D.; Chlebowski, Rowan T.; Feuer, Eric J.; Edwards, Brenda K.; Berry, Donald A.			The decrease in breast-cancer incidence in 2003 in the United States.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HORMONE REPLACEMENT THERAPY	An initial analysis of data from the National Cancer Institute's Surveillance, Epidemiology, and End Results ( SEER) registries shows that the age-adjusted incidence rate of breast cancer in women in the United States fell sharply ( by 6.7%) in 2003, as compared with the rate in 2002. Data from 2004 showed a leveling off relative to the 2003 rate, with little additional decrease. Regression analysis showed that the decrease began in mid-2002 and had begun to level off by mid-2003. A comparison of incidence rates in 2001 with those in 2004 ( omitting the years in which the incidence was changing) showed that the decrease in annual age-adjusted incidence was 8.6% (95% confidence interval [CI], 6.8 to 10.4). The decrease was evident only in women who were 50 years of age or older and was more evident in cancers that were estrogen-receptor - positive than in those that were estrogen-receptor - negative. The decrease in breast-cancer incidence seems to be temporally related to the first report of the Women's Health Initiative and the ensuing drop in the use of hormone-replacement therapy among postmenopausal women in the United States. The contributions of other causes to the change in incidence seem less likely to have played a major role but have not been excluded.	Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA; NCI, Div Canc Prevent, Bethesda, MD 20892 USA; Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA	University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute	Ravdin, PM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biostat, 1515 Holcombe Blvd, Houston, TX 77030 USA.							Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Buist DSM, 2004, OBSTET GYNECOL, V104, P1042, DOI 10.1097/01.AOG.0000143826.38439.af; Collaborative Group on Hormonal Factors in Breast Cancer, 1997, LANCET, V350, P1484; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Freedman Andrew N., 2004, EJC Supplements, V2, P17; Haller DG, 2006, J CLIN ONCOL, V24, p149S; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; Howe HL, 2006, CANCER-AM CANCER SOC, V107, P1711, DOI 10.1002/cncr.22193; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; *NAT CTR HLTH STAT, 2006, DHHS PUBL, P313; Porter PL, 1999, J NATL CANCER I, V91, P2020, DOI 10.1093/jnci/91.23.2020; POWLES TJ, 1995, LANCET, V345, P1442, DOI 10.1016/S0140-6736(95)92632-1; Prasad R, 2003, CANCER, V98, P2539, DOI 10.1002/cncr.11836; Ravdin PM, 2006, BREAST CANCER RES TR, V100, pS6; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; DRUG TOPICS DRUGS UN	18	706	722	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 19	2007	356	16					1670	1674		10.1056/NEJMsr070105	http://dx.doi.org/10.1056/NEJMsr070105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158AB	17442911				2023-01-03	WOS:000245762000012
J	Berman, B				Berman, Brian			A 60-year-old woman considering acupuncture for knee pain	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; INTRAARTICULAR HYALURONIC-ACID; ALTERNATIVE MEDICINE; ELECTRICAL-STIMULATION; PLACEBO CONTROLS; UNITED-STATES; OSTEOARTHRITIS; ELECTROACUPUNCTURE; COMPLEMENTARY; ARTHRITIS	Mrs A, an active 60-year-old woman, has a history of degenerative osteoarthritis of her knee with pain that has progressed over the past 8 years. She has undergone arthroscopic surgery for a meniscal tear and has taken nonsteroidal anti-inflammatory drugs ( NSAIDs), glucosamine, and chondroitin sulfate occasionally, but generally does not like taking medications. She is open to other therapeutic approaches and wants to know if acupuncture can help the pain, improve function, and stop her condition from progressing. The evidence for the effectiveness of acupuncture for knee pain and other common treatments, including exercise, NSAIDs, glucosamine and chondroitin, and intra-articular knee injections are compared, and costs and methods of acupuncture and selecting an acupuncturist are discussed.	Univ Maryland, Sch Med, Kernan Hosp Mans, Ctr Integrat Med, Baltimore, MD 21207 USA	University System of Maryland; University of Maryland Baltimore	Berman, B (corresponding author), Univ Maryland, Sch Med, Kernan Hosp Mans, Ctr Integrat Med, 2200 Kernan Dr, Baltimore, MD 21207 USA.	bberman@compmed.umm.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [U01AT000171] Funding Source: NIH RePORTER	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Altman RD, 2004, J RHEUMATOL, V31, P5; Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905; [Anonymous], COCHRANE HDB SYSTEMA; Arrich J, 2005, CAN MED ASSOC J, V172, DOI 10.1503/cmaj.1041203; Arroll B, 2004, BMJ-BRIT MED J, V328, P869, DOI 10.1136/bmj.38039.573970.7C; Barnes Patricia M, 2004, Adv Data, P1; Bellamy N, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005321.pub2; Berman BM, 2002, ARCH INTERN MED, V162, P766, DOI 10.1001/archinte.162.7.766; Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006; Berman BM, 2000, PAIN, V85, P313, DOI 10.1016/S0304-3959(00)00258-X; Birch S, 2006, J ALTERN COMPLEM MED, V12, P303, DOI 10.1089/acm.2006.12.303; Bjordal JM, 2004, BMJ-BRIT MED J, V329, P1317, DOI 10.1136/bmj.38273.626655.63; Bleumink GS, 2003, DRUGS, V63, P525, DOI 10.2165/00003495-200363060-00001; Burr DB, 2004, J RHEUMATOL, V31, P77; CHENG X, 1987, KCHINESE ACUPUNCTURE, P361; CHRISTENSEN BV, 1992, ACTA ANAESTH SCAND, V36, P519, DOI 10.1111/j.1399-6576.1992.tb03511.x; Clegg DO, 2006, NEW ENGL J MED, V354, P795, DOI 10.1056/NEJMoa052771; Cohen J., 1988, STAT POWER ANAL BEHA, P18, DOI [10.4324/9780203771587, DOI 10.1016/B978-0-12-179060-8.50006-2]; *COMM US COMPL ALT, 2005, COMPL ALT MED US; DENNISON E, 2003, RHEUMATOLOGY, P1781; ECKMAN P, 2002, CONT CHINESE MED ACU, P12; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 2001, AM J MED, V110, P481, DOI 10.1016/S0002-9343(01)00651-9; Eskinazi D, 1998, J ALTERN COMPLEM MED, V4, P459, DOI 10.1089/acm.1998.4.459; Eskinazi D P, 1996, J Altern Complement Med, V2, P3, DOI 10.1089/acm.1996.2.3; FAIRCLOUGH JA, 2003, RHEUMATOLOGY, P661; Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003-4819-133-8-200010170-00016; Felson DT, 2000, ANN INTERN MED, V133, P726, DOI 10.7326/0003-4819-133-9-200011070-00015; FELSON DT, 2003, OSTEOARTHRITIS, P9; FEMANDES JC, 2002, BIORHEOLOGY, V39, P237; Fransen M, 2003, COCHRANE DB SYST REV, V3; Furlan AD, 2006, CAN MED ASSOC J, V174, P1589, DOI 10.1503/cmaj.051528; Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1; Herman Carla J, 2004, Prev Chronic Dis, V1, pA12; Hernandez-Diaz S, 2000, ARCH INTERN MED, V160, P2093, DOI 10.1001/archinte.160.14.2093; Hernandez-Diaz Sonia, 2001, American Journal of Medicine, V110, p20S; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1541, DOI 10.1002/art.1780381104; Huang MH, 2003, SEMIN ARTHRITIS RHEU, V32, P398, DOI 10.1053/sarh.2003.50021; Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037; Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F; HUNTER DJ, 2004, AM COLL RHEUM 68 ANN; JANSEN G, 1989, NEUROSCI LETT, V97, P305, DOI 10.1016/0304-3940(89)90615-0; Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742; KABATZINN J, 1985, J BEHAV MED, V8, P163, DOI 10.1007/BF00845519; *KAIS FAM FDN HLTH, 2004, EMPL HLTH BEN 2004 A; KASHIBA H, 1991, AM J CHINESE MED, V19, P189, DOI 10.1142/S0192415X91000260; Kirkley A, 1999, J BONE JOINT SURG AM, V81A, P539, DOI 10.2106/00004623-199904000-00012; Langevin HM, 2001, FASEB J, V15, P2275, DOI 10.1096/fj.01-0015hyp; Lao L, 1996, J Altern Complement Med, V2, P27, DOI 10.1089/acm.1996.2.27; Lao LX, 2004, BRAIN RES, V1020, P18, DOI 10.1016/j.brainres.2004.01.092; Larson AM, 2005, HEPATOLOGY, V42, P1364, DOI 10.1002/hep.20948; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Lee GS, 2003, BRAIN RES BULL, V62, P161, DOI 10.1016/j.brainresbull.2003.09.007; LEONG M L, 1987, Alternative Medicine, V2, P103; LEWITH GT, 1984, SOC SCI MED, V19, P1367, DOI 10.1016/0277-9536(84)90026-1; Lin FY, 2004, BMJ-BRIT MED J, V329, P324, DOI 10.1136/bmj.38159.639028.7C; Lo GH, 2003, JAMA-J AM MED ASSOC, V290, P3115, DOI 10.1001/jama.290.23.3115; Lorig K, 1998, ARTHRIT CARE RES, V11, P448, DOI 10.1002/art.1790110604; MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486; McAlindon TE, 2000, JAMA-J AM MED ASSOC, V283, P1469, DOI 10.1001/jama.283.11.1469; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Michel BA, 2005, ARTHRITIS RHEUM-US, V52, P779, DOI 10.1002/art.20867; Osiri M, 2000, COCHRANE DB SYST REV, V4, DOI [10.1002/14651858.CD002823, DOI 10.1002/14651858.CD002823]; Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016; Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202; POMERANZ B, 1988, SCI BASIS ACUPUNCTUR; PRADHAN EK, 2005, 2005 AM COLL RHEUM A; Quandt SA, 2005, ARTHRIT RHEUM-ARTHR, V53, P748, DOI 10.1002/art.21443; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Ramsey SD, 2001, ARTHRIT RHEUM-ARTHR, V45, P222, DOI 10.1002/1529-0131(200106)45:3<222::AID-ART252>3.0.CO;2-N; Rao JK, 1999, ANN INTERN MED, V131, P409, DOI 10.7326/0003-4819-131-6-199909210-00003; Richy F, 2003, ARCH INTERN MED, V163, P1514, DOI 10.1001/archinte.163.13.1514; Rodriguez LAG, 2000, EPIDEMIOLOGY, V11, P382, DOI 10.1097/00001648-200007000-00004; Scharf HP, 2006, ANN INTERN MED, V145, P12, DOI 10.7326/0003-4819-145-1-200607040-00005; Tang NM, 1997, PAIN, V71, P71, DOI 10.1016/S0304-3959(97)03341-1; Towheed TE, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002946.pub2; TOWHEED TE, 2003, COCHRANE DB SYST REV, V2; Tramer MR, 2000, PAIN, V85, P169, DOI 10.1016/S0304-3959(99)00267-5; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; Unschuld Paul O., 1985, MED CHINA HIST IDEAS; *US COMM HLTH ED L, 2004, CTR DIS CONTR ROL CO; Vas J, 2004, BMJ-BRIT MED J, V329, P1216, DOI 10.1136/bmj.38238.601447.3A; VINCENT C, 1995, J ROY SOC MED, V88, P199; Wan Y, 2001, PAIN, V91, P5, DOI 10.1016/S0304-3959(00)00416-4; Watkins PB, 2006, JAMA-J AM MED ASSOC, V296, P87, DOI 10.1001/jama.296.1.87; Whelton A., 1999, AM J MED, V106, p13S, DOI [10.1016/S0002-9343(99)00113-8, DOI 10.1016/S0002-9343(99)00113-8, 10.1016/s0002-9343(99)00113-8]; White A, 2007, RHEUMATOLOGY, V46, P384, DOI 10.1093/rheumatology/kel413; White AR, 2001, COMPLEMENT THER MED, V9, P237, DOI 10.1054/ctim.2001.0489; White P, 2004, ANN INTERN MED, V141, P911, DOI 10.7326/0003-4819-141-12-200412210-00007; Wilcox CM, 2006, CLIN GASTROENTEROL H, V4, P1082, DOI 10.1016/j.cgh.2006.04.010; Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7; Wu CW, 2005, CLIN GERIATR MED, V21, P589, DOI 10.1016/j.cger.2005.02.008; Wyatt FB, 2001, J STRENGTH COND RES, V15, P337; Yelin E, 1998, OSTEOARTHRITIS, P23; Zhang LX, 1997, BRAIN RES, V745, P158, DOI 10.1016/S0006-8993(96)01095-5; Zhang RX, 2005, J ALTERN COMPLEM MED, V11, P135, DOI 10.1089/acm.2005.11.135; 2002, Z RHEUMATOL, V61, P229	97	14	17	3	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 18	2007	297	15					1697	1707		10.1001/jama.297.15.1697	http://dx.doi.org/10.1001/jama.297.15.1697			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	157UR	17440146				2023-01-03	WOS:000245747400023
J	Gale, CR; Deary, IJ; Batty, GD; Schoon, I				Gale, Catharine R.; Deary, Ian J.; Batty, G. David; Schoon, Ingrid			IQ in childhood and vegetarianism in adulthood: 1970 British cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MENTAL SURVEY 1932; MORTALITY; INTELLIGENCE; MIDSPAN; ABILITY; LINKING; HEALTH; DIETS; RISK; LIFE	Objective To examine the relation between IQ in childhood and vegetarianism in adulthood. Design Prospective cohort study in which IQ was assessed by tests of mental ability at age 10 years and vegetarianism by self-report at age 30 years. Setting Great Britain. Participants 8170 men and women aged 30 years participating in the 1970 British cohort study, a national birth cohort. Main outcome measures Self-reported vegetarianism and type of diet followed. Results 366 (4.5%) participants said they were vegetarian, although 123 (33.6%) admitted eating fish or chicken. Vegetarians were more likely to be female, to be of higher social class (both in childhood and currently), and to have attained higher academic or vocational qualifications, although these socioeconomic advantages were not reflected in their income. Higher IQ at age 10 years was associated with an increased likelihood of being vegetarian at age 30 (odds ratio for one standard deviation increase in childhood IQ score 1.38, 95% confidence interval 1.24 to 1.53). IQ remained a statistically significant predictor of being vegetarian as an adult after adjustment for social class (both in childhood and currently), academic or vocational qualifications, and sex (1.20, 1.06 to 1.36). Exclusion of those who said they were vegetarian but ate fish or chicken had little effect on the strength of this association. Conclusion Higher scores for IQ in childhood are associated with an increased likelihood of being a vegetarian as an adult.	Univ Southampton, Med Res Council, Epidemiol Resource Ctr, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England; Univ Edinburgh, Dept Psychol, Edinburgh, Midlothian, Scotland; Univ Glasgow, Med Res Council, Social & Publ Hlth Sci Unit, Glasgow, Lanark, Scotland; City Univ London, Dept Psychol, London, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Southampton; University of Edinburgh; MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Glasgow; City University London	Gale, CR (corresponding author), Univ Southampton, Med Res Council, Epidemiol Resource Ctr, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England.	crg@mrc.soton.ac.uk	Deary, Ian J/C-6297-2009; Schoon, Ingrid/AAC-5715-2019; Gale, Catharine R/B-1653-2012; Schoon, Ingrid/E-7430-2010; Batty, GD/Y-4401-2018	Deary, Ian J/0000-0002-1733-263X; Schoon, Ingrid/0000-0002-4262-3711; Batty, GD/0000-0003-1822-5753; Gale, Catharine/0000-0002-3361-8638	Economic and Social Research Council [RES-225-25-2001] Funding Source: researchfish; Medical Research Council [U1475000002] Funding Source: researchfish; MRC [MC_U130059821] Funding Source: UKRI; Medical Research Council [MC_U130059821] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Batty GD, 2005, PAEDIATR PERINAT EP, V19, P452, DOI 10.1111/j.1365-3016.2005.00671.x; Batty GD, 2004, BMJ-BRIT MED J, V329, P585, DOI 10.1136/bmj.329.7466.585; BATTY GD, 2006, IN PRESS J EPIDEMIOL; CARROLL J, 2006, HUMAN COGNITIVE ABIL; DEARY I, 2006, IN PRESS INTELLIGENC; Elliott C., 1978, BRIT ABILITY SCALES; FRANKLIN B, 1962, AUTOBIOGRAPHY B FRAN; Fu CH, 2006, AM J CARDIOL, V97, P380, DOI 10.1016/j.amjcard.2005.08.057; Hart CL, 2003, PSYCHOSOM MED, V65, P877, DOI 10.1097/01.PSY.0000088584.82822.86; Hemmingsson T, 2006, INT J EPIDEMIOL, V35, P665, DOI 10.1093/ije/dyi321; Key TJ, 2006, P NUTR SOC, V65, P35, DOI 10.1079/PNS2005481; Key TJ, 1999, AM J CLIN NUTR, V70, p516S, DOI 10.1093/ajcn/70.3.516s; Martin LT, 2004, J EPIDEMIOL COMMUN H, V58, P674, DOI 10.1136/jech.2003.016444; Schoon I., 2003, CHANGING BRITAIN CHA; Taylor MD, 2003, J EPIDEMIOL COMMUN H, V57, P464, DOI 10.1136/jech.57.6.464	15	52	52	0	26	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 3	2007	334	7587					245	248B		10.1136/bmj.39030.675069.55	http://dx.doi.org/10.1136/bmj.39030.675069.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	135SD	17175567	Bronze, Green Published			2023-01-03	WOS:000244172400030
J	Grossmann, M; Topliss, DJ				Grossmann, Mathis; Topliss, Duncan J.			A cool case: hypothermia and adrenal failure	LANCET			English	Editorial Material							HEMORRHAGE		Austin Hosp, Dept Med, Heidelberg, Vic 3084, Australia; Alfred Hosp, Dept Endocrinol & Diabet, Melbourne, Vic, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Florey Institute of Neuroscience & Mental Health	Grossmann, M (corresponding author), Austin Hosp, Dept Med, Heidelberg, Vic 3084, Australia.	mathisg@unimelb.edu.au	Topliss, Duncan/AAK-7082-2020	Topliss, Duncan/0000-0003-4763-3385				Caron P, 1998, J CLIN ENDOCR METAB, V83, P1437, DOI 10.1210/jc.83.5.1437; Kovacs KA, 2001, MEDICINE, V80, P45, DOI 10.1097/00005792-200101000-00005; RAO RH, 1995, MED CLIN N AM, V79, P107, DOI 10.1016/S0025-7125(16)30087-6; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; RuDusky BM, 2004, AM J CARDIOL, V93, P671, DOI 10.1016/j.amjcard.2003.10.065	5	1	1	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 16	2006	368	9553					2184	2184		10.1016/S0140-6736(06)69866-8	http://dx.doi.org/10.1016/S0140-6736(06)69866-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EZ	17174711				2023-01-03	WOS:000242856900027
J	Hoffer, LJ				Hoffer, L. John			Controversy - Tube feeding in advanced dementia: the metabolic perspective	BRITISH MEDICAL JOURNAL			English	Article							NUTRITION; HYDRATION; CARE		McGill Univ, Fac Med, Montreal, PQ, Canada	McGill University	Hoffer, LJ (corresponding author), Jewish Gen Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	l.hoffer@mcgill.ca						Casarett D, 2005, NEW ENGL J MED, V353, P2607, DOI 10.1056/NEJMsb052907; Chernoff Ronni, 2006, Nutr Clin Pract, V21, P142, DOI 10.1177/0115426506021002142; Fine Robert L, 2006, Nutr Clin Pract, V21, P118, DOI 10.1177/0115426506021002118; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; GALANOS AN, 1994, J AM GERIATR SOC, V42, P368, DOI 10.1111/j.1532-5415.1994.tb07483.x; Gillick MR, 2000, NEW ENGL J MED, V342, P206, DOI 10.1056/NEJM200001203420312; Harris D, 2005, J ROY SOC MED, V98, P411, DOI 10.1258/jrsm.98.9.411; Hoffer LJ, 2006, MODERN NUTR HLTH DIS, P730; Jotkowitz AB, 2005, J AM GERIATR SOC, V53, P881, DOI 10.1111/j.1532-5415.2005.53271.x; McCann R, 1999, JAMA-J AM MED ASSOC, V282, P1380, DOI 10.1001/jama.282.14.1380; McNamara EP, 2001, P NUTR SOC, V60, P179, DOI 10.1079/PNS200083; Monteleoni C, 2004, BMJ-BRIT MED J, V329, P491, DOI 10.1136/bmj.329.7464.491; QUILL TE, 1989, ARCH INTERN MED, V149, P1937, DOI 10.1001/archinte.149.9.1937; Roberts SB, 2006, PHYSIOL REV, V86, P651, DOI 10.1152/physrev.00019.2005; Skelly RH, 2002, CURR OPIN CLIN NUTR, V5, P35, DOI 10.1097/00075197-200201000-00007; Truog RD, 2005, ARCH INTERN MED, V165, P2574, DOI 10.1001/archinte.165.22.2574; Wang SY, 1997, J AM GERIATR SOC, V45, P1189, DOI 10.1111/j.1532-5415.1997.tb03768.x; Wilson MMG, 2003, J APPL PHYSIOL, V95, P1728, DOI 10.1152/japplphysiol.00313.2003	18	29	30	1	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	DEC 9	2006	333	7580					1214	1215		10.1136/bmj.39021.785197.47	http://dx.doi.org/10.1136/bmj.39021.785197.47			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	119JW	17158389	Green Published			2023-01-03	WOS:000243009600019
J	Lewis, K; Ausubel, FM				Lewis, Kim; Ausubel, Frederick M.			Prospects for plant-derived antibacterials	NATURE BIOTECHNOLOGY			English	Editorial Material							MULTIDRUG PUMP; ANTIBIOTIC-ACTIVITY; BERBERINE; RESISTANCE; IDENTIFICATION; INHIBITORS; METABOLITES; POTENTIATE; AGENTS		Northeastern Univ, Antimicrobial Discovery Ctr, Boston, MA 02115 USA; Northeastern Univ, Dept Biol, Boston, MA 02115 USA; Harvard Univ, Dept Genet, Sch Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02114 USA	Northeastern University; Northeastern University; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Lewis, K (corresponding author), Northeastern Univ, Antimicrobial Discovery Ctr, Boston, MA 02115 USA.	k.lewis@neu.edu; ausubel@molbio.mgh.harvard.edu			NIAID NIH HHS [AI059483, AI064332] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064332, R21AI059483] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adonizio AL, 2006, J ETHNOPHARMACOL, V105, P427, DOI 10.1016/j.jep.2005.11.025; AMIN AH, 1969, CAN J MICROBIOL, V15, P1067, DOI 10.1139/m69-190; Ball AR, 2006, ACS CHEM BIOL, V1, P594, DOI 10.1021/cb600238x; Bauer G, 2004, J ANTIMICROB CHEMOTH, V53, P592, DOI 10.1093/jac/dkh125; Bauer WD, 2004, CURR OPIN PLANT BIOL, V7, P429, DOI 10.1016/j.pbi.2004.05.008; Belofsky G, 2006, J NAT PROD, V69, P261, DOI 10.1021/np058057s; Belofsky G, 2004, J NAT PROD, V67, P481, DOI 10.1021/np030409c; Bryskier A, 2005, ANTIMICROBIAL AGENTS: ANTIBACTERIALS AND ANTIFUNGALS, P1; Dixon RA, 2001, NATURE, V411, P843, DOI 10.1038/35081178; Gibbons S, 2004, NAT PROD REP, V21, P263, DOI 10.1039/b212695h; Hammerschmidt R, 1999, ANNU REV PHYTOPATHOL, V37, P285, DOI 10.1146/annurev.phyto.37.1.285; HAN GY, 1981, ACTA CHIM SINICA, V39, P433; Hsieh PC, 1998, P NATL ACAD SCI USA, V95, P6602, DOI 10.1073/pnas.95.12.6602; Hung DT, 2005, SCIENCE, V310, P670, DOI 10.1126/science.1116739; Lewis K, 2001, J MOL MICROB BIOTECH, V3, P247; Lomovskaya O, 2001, ANTIMICROB AGENTS CH, V45, P105, DOI 10.1128/AAC.45.1.105-116.2001; LOMOVSKAYA O, 1992, P NATL ACAD SCI USA, V89, P8938, DOI 10.1073/pnas.89.19.8938; Morel C, 2003, J AGR FOOD CHEM, V51, P5677, DOI 10.1021/jf0302714; Moy TI, 2006, P NATL ACAD SCI USA, V103, P10414, DOI 10.1073/pnas.0604055103; Nikaido H, 1998, CURR OPIN MICROBIOL, V1, P516, DOI 10.1016/S1369-5274(98)80083-0; Pankey GA, 2005, J ANTIMICROB CHEMOTH, V56, P470, DOI 10.1093/jac/dki248; Severina II, 2001, IUBMB LIFE, V52, P321, DOI 10.1080/152165401317291183; Silver LL, 2006, IDRUGS, V9, P394; Stermitz FR, 2000, P NATL ACAD SCI USA, V97, P1433, DOI 10.1073/pnas.030540597; Stermitz FR, 2002, PLANTA MED, V68, P1140, DOI 10.1055/s-2002-36347; Stermitz FR, 2003, BIOORG MED CHEM LETT, V13, P1915, DOI 10.1016/S0960-894X(03)00316-0; Tegos G, 2002, ANTIMICROB AGENTS CH, V46, P3133, DOI 10.1128/AAC.46.10.3133-3141.2002; Teplitski M, 2000, MOL PLANT MICROBE IN, V13, P637, DOI 10.1094/MPMI.2000.13.6.637	28	269	281	0	53	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2006	24	12					1504	1507		10.1038/nbt1206-1504	http://dx.doi.org/10.1038/nbt1206-1504			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	116IL	17160050				2023-01-03	WOS:000242795800024
J	Moghimi, SM; Hamad, I; Andresen, TL; Jorgensen, K; Szebeni, J				Moghimi, S. Moein; Hamad, Islam; Andresen, Thomas L.; Jorgensen, Kent; Szebeni, Janos			Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production	FASEB JOURNAL			English	Article						stealth liposomes; anaphylactic reactions; complement system; steric stabilization; SC5b-9; C3a-desarg	ENCAPSULATED HEMOGLOBIN; SURFACE-CHARGE; POLY(ETHYLENE GLYCOL); GLOBULAR HEAD; IN-VITRO; BINDING; PATHWAY; DOXORUBICIN; C1Q; PHARMACOKINETICS	Methoxy(polyethylene glycol), mPEG, -grafted liposomes are known to exhibit prolonged circulation time in the blood, but their infusion into a substantial percentage of human subjects triggers immediate non-IgE-mediated hypersensitivity reactions. These reactions are strongly believed to arise from anaphylatoxin production through complement activation. Despite the general view that vesicle surface camouflaging with mPEG should dramatically suppress complement activation, here we show that bilayer enrichment of noncomplement activating liposomes [di-palmitoylphosphatidylcholine (DPPC) vesicles] with phospholipid-mPEG conjugate induces complement activation resulting in vesicle recognition by macrophage complement receptors. The extent of vesicle uptake, however, is dependent on surface mPEG density. We have delineated the likely structural features of phospholipid-mPEG conjugate responsible for PEGylated liposome-induced complement activation in normal as well as C1q-deficient human sera, using DPPC vesicles bearing the classical as well as newly synthesized lipid-mPEG conjugates. With PEGylated DPPC vesicles, the net anionic charge on the phosphate moiety of phospholipid-mPEG conjugate played a key role in activation of both classical and alternative pathways of complement and anaphylatoxin production (reflected in significant rises in SC5b-9, C4d, and C3a-desarg levels in normal human sera as well as SC5b-9 in EGTA-chelated/Mg2+ supplemented serum), since methylation of the phosphate oxygen of phospholipid-mPEG conjugate, and hence the removal of the negative charge, totally prevented complement activation. To further corroborate on the role of the negative charge in complement activation, vesicles bearing anionic phospholipid-mPEG conjugates, but not the methylated phospholipid-mPEG, were shown to significantly decrease serum hemolytic activity and increase plasma thromboxane B2 levels in rats. In contrast to liposomes, phospholipid-mPEG micelles had no effect on complement activation, thus suggesting a possible role for vesicular zwitterionic phospholipid head-groups as an additional factor contributing to PEGylated liposome-mediated complement activation. Our findings provide a rational conceptual basis for development of safer vesicles for site-specific drug delivery and controlled release at pathological sites.	Univ Brighton, Sch Pharm, Mol Targeting & Polymer Toxicol Grp, Brighton BN2 4GJ, E Sussex, England; Tech Univ Denmark, LiPlasome Pharm AS, DK-2800 Lyngby, Denmark; Hungarian Acad Sci, Nephrol Res Grp, Budapest, Hungary; Semmelweis Univ, Inst Pathophysiol, Budapest, Hungary	University of Brighton; Technical University of Denmark; Hungarian Academy of Sciences; Semmelweis University	Moghimi, SM (corresponding author), Univ Brighton, Sch Pharm, Mol Targeting & Polymer Toxicol Grp, Cockcroft Bldg,Lewes Rd, Brighton BN2 4GJ, E Sussex, England.	s.m.moghimi@brighton.ac.uk	Andresen, Thomas L/B-5324-2012; Hamad, Islam/AAY-2540-2020	Moghimi, Seyed Moein/0000-0003-0836-926X; Andresen, Thomas Lars/0000-0002-1048-127X				Alberts DS, 1997, DRUGS, V54, P30, DOI 10.2165/00003495-199700544-00007; Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833; ALVING CR, 1991, CRIT REV IMMUNOL, V10, P441; Andresen Thomas L., 2005, Current Drug Delivery, V2, P353, DOI 10.2174/156720105774370203; Andresen TL, 2004, J MED CHEM, V47, P1694, DOI 10.1021/jm031029r; Andresen TL, 2005, PROG LIPID RES, V44, P68, DOI 10.1016/j.plipres.2004.12.001; Bradley AJ, 1999, BBA-BIOMEMBRANES, V1418, P19, DOI 10.1016/S0005-2736(99)00013-9; Bradley AJ, 1998, ARCH BIOCHEM BIOPHYS, V357, P185, DOI 10.1006/abbi.1998.0798; Bradley AJ, 1999, BIOCHEMISTRY-US, V38, P8112, DOI 10.1021/bi990480a; Chanan-Khan A, 2003, ANN ONCOL, V14, P1430, DOI 10.1093/annonc/mdg374; Chiu GNC, 2001, BBA-BIOMEMBRANES, V1510, P56, DOI 10.1016/S0005-2736(00)00335-7; CHONN A, 1991, J IMMUNOL, V146, P4234; DEVINE DV, 1994, BBA-BIOMEMBRANES, V1191, P43, DOI 10.1016/0005-2736(94)90231-3; FRIES LF, 1984, J EXP MED, V160, P1640, DOI 10.1084/jem.160.6.1640; Gaboriaud C, 2004, TRENDS IMMUNOL, V25, P368, DOI 10.1016/j.it.2004.04.008; Gaboriaud C, 2003, J BIOL CHEM, V278, P46974, DOI 10.1074/jbc.M307764200; Garbuzenko O, 2005, LANGMUIR, V21, P2560, DOI 10.1021/la0479105; Gbadamosi JK, 2002, FEBS LETT, V532, P338, DOI 10.1016/S0014-5793(02)03710-9; Gulati S, 2002, J IMMUNOL, V168, P4078, DOI 10.4049/jimmunol.168.8.4078; KENWORTHY AK, 1995, BIOPHYS J, V68, P1921, DOI 10.1016/S0006-3495(95)80369-3; Kishore U, 2003, J IMMUNOL, V171, P812, DOI 10.4049/jimmunol.171.2.812; Klint C, 2000, SCAND J IMMUNOL, V52, P103; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; Moghimi SM, 2006, BIOMATERIALS, V27, P136, DOI 10.1016/j.biomaterials.2005.05.082; Moghimi SM, 2003, PROG LIPID RES, V42, P463, DOI 10.1016/S0163-7827(03)00033-X; Moghimi SM, 2001, PHARMACOL REV, V53, P283; Moghimi SM, 2002, J CONTROL RELEASE, V78, P55, DOI 10.1016/S0168-3659(01)00481-3; Moghimi SM, 2005, FASEB J, V19, P311, DOI 10.1096/fj.04-2747rev; Moghimi SM, 2001, PHARM RES-DORDR, V18, P1, DOI 10.1023/A:1011054123304; MOORE FD, 1982, J IMMUNOL, V128, P1302; Price ME, 2001, BBA-BIOMEMBRANES, V1512, P191, DOI 10.1016/S0005-2736(01)00330-3; SAVAY S, 2002, BIOCHIM BIOPHYS ACTA, V1559, P29; Sohn JH, 2003, NAT MED, V9, P206, DOI 10.1038/nm814; SZEBENI J, 1994, BIOCHEM BIOPH RES CO, V205, P255, DOI 10.1006/bbrc.1994.2658; Szebeni J, 2006, AM J PHYSIOL-HEART C, V290, pH1050, DOI 10.1152/ajpheart.00622.2005; Szebeni J, 2002, J LIPOSOME RES, V12, P165, DOI 10.1081/LPR-120004790; Szebeni J, 1996, BBA-BIOMEMBRANES, V1285, P127, DOI 10.1016/S0005-2736(96)00201-5; Szebeni J, 2000, J LIPOSOME RES, V10, P467, DOI 10.3109/08982100009031112; Szebeni J, 1997, TRANSFUSION, V37, P150, DOI 10.1046/j.1537-2995.1997.37297203517.x; Szebeni J, 2000, AM J PHYSIOL-HEART C, V279, pH1319, DOI 10.1152/ajpheart.2000.279.3.H1319; Szebeni J, 2003, METHOD ENZYMOL, V373, P136; Tirosh O, 1998, BIOPHYS J, V74, P1371, DOI 10.1016/S0006-3495(98)77849-X; UZIELY B, 1995, J CLIN ONCOL, V13, P1777, DOI 10.1200/JCO.1995.13.7.1777; Webb MS, 1998, BBA-BIOMEMBRANES, V1372, P272, DOI 10.1016/S0005-2736(98)00077-7; Zalipsky S., 2004, PCT Patent Application, Patent No. [WO 2004/078121, 2004078121]	45	156	161	1	47	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2591	+		10.1096/fj.06-6186fje	http://dx.doi.org/10.1096/fj.06-6186fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065229				2023-01-03	WOS:000242490700034
J	Ho, PM; Peterson, ED; Wang, L; Magid, DJ; Fihn, SD; Larsen, GC; Jesse, RA; Rumsfeld, JS				Ho, P. Michael; Peterson, Eric D.; Wang, Li; Magid, David J.; Fihn, Stephan D.; Larsen, Greg C.; Jesse, Robert A.; Rumsfeld, John S.			Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIPLATELET THERAPY; PLATELET ACTIVATION; ASPIRIN THERAPY; UNSTABLE ANGINA; DRUG-THERAPY; WITHDRAWAL; RISK; PREVENTION; HEPARIN; DISCONTINUATION	Context It is unknown whether patients are at increased short- term risk for adverse events following clopidogrel cessation. Objective To assess the rates of adverse events after stopping treatment with clopidogrel in a national sample of patients with acute coronary syndrome ( ACS). Design, Setting, and Patients Retrospective cohort study of 3137 patients with ACS discharged from 127 Veterans Affairs hospitals between October 1, 2003, and March 31, 2005, with posthospital treatment with clopidogrel. Main Outcome Measure Rate of all- cause mortality or acute myocardial infarction ( AMI) after stopping treatment with clopidogrel. Results Mean ( SD) follow- up after stopping treatment with clopidogrel was 196 ( 152) days for medically treated patients with ACS without stents ( n= 1568) and 203 ( 148) days for patients with ACS treated with percutaneous coronary intervention ( PCI) ( n= 1569). Among medically treated patients, mean ( SD) duration of clopidogrel treatment was 302 ( 151) days and death or AMI occurred in 17.1%( n= 268) of patients, with 60.8%( n= 163) of events occurring during 0 to 90 days, 21.3% ( n= 57) during 91 to 180 days, and 9.7% ( n= 26) during 181 to 270 days after stopping treatment with clopidogrel. In multivariable analysis including adjustment for duration of clopidogrel treatment, the first 90- day interval after stopping treatment with clopidogrel was associated with a significantly higher risk of adverse events ( incidence rate ratio [ IRR], 1.98; 95% confidence interval [ CI], 1.46- 2.69 vs the interval of 91- 180 days). Similarly, among PCI- treated patients with ACS, mean( SD) duration of clopidogrel treatment was 278 ( 169) days and death or AMI occurred in 7.9% ( n= 124) of patients, with 58.9% ( n= 73) of events occurring during 0 to 90 days, 23.4% ( n= 29) during 91 to 180 days, and 6.5% ( n= 8) during 181 to 270 days after stopping clopidogrel treatment. In multivariable analysis including adjustment for duration of clopidogrel treatment, the first 90- day interval after stopping clopidogrel treatment was associated with a significantly higher risk of adverse events ( IRR, 1.82; 95% CI, 1.17- 2.83). Conclusions We observed a clustering of adverse events in the initial 90 days after stopping clopidogrel among both medically treated and PCI- treated patients with ACS, supporting the possibility of a clopidogrel rebound effect. Additional studies are needed to confirm the clustering of events after stopping clopidogrel, including associations with cardiovascular mortality and reasons for stopping clopidogrel, as well as to determine the mechanism of this phenomenon, and to identify strategies to reduce early events after clopidogrel cessation.	[Ho, P. Michael; Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO 80220 USA; [Ho, P. Michael; Magid, David J.; Rumsfeld, John S.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA; [Peterson, Eric D.] Duke Clin Res Inst, Durham, NC USA; [Wang, Li; Fihn, Stephan D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA; [Ho, P. Michael; Magid, David J.; Rumsfeld, John S.] Kaiser Permanente Colorado, Inst Hlth Res, Aurora, CO USA; [Larsen, Greg C.] VA Med Ctr, Portland, OR USA; [Jesse, Robert A.] Richmond VA Med Ctr, Richmond, VA USA; [Jesse, Robert A.] Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Kaiser Permanente; Hunter Holmes McGuire Veterinary Affairs Medical Center; Virginia Commonwealth University	Rumsfeld, JS (corresponding author), Denver VA Med Ctr, 111B,1055 Clermont St, Denver, CO 80220 USA.	John.Rumsfeld@va.gov	Fihn, Stephan/ABA-1040-2020; Peterson, Eric David/ABF-5033-2021					Anderson JL, 2007, J AM COLL CARDIOL, V50, P652, DOI 10.1016/j.jacc.2007.02.028; Angiolillo DJ, 2006, DIABETES, V55, P780, DOI 10.2337/diabetes.55.03.06.db05-1394; Bhatt DL, 2006, NEW ENGL J MED, V354, P1706, DOI 10.1056/NEJMoa060989; Biondi-Zoccai GGL, 2006, EUR HEART J, V27, P2667, DOI 10.1093/eurheartj/ehl334; Burger W, 2005, J INTERN MED, V257, P399, DOI 10.1111/j.1365-2796.2005.01477.x; Caetano PA, 2006, CLIN THER, V28, P1411, DOI 10.1016/j.clinthera.2006.09.021; Campo G, 2007, J AM COLL CARDIOL, V50, P1132, DOI 10.1016/j.jacc.2007.04.092; Collet JP, 2006, EUR HEART J SUPPL, V8, pG46, DOI 10.1093/eurheartj/sul055; Collet JP, 2004, CIRCULATION, V110, P2361, DOI 10.1161/01.CIR.0000145171.89690.B4; Cowper DC, 2002, ANN EPIDEMIOL, V12, P462, DOI 10.1016/S1047-2797(01)00285-X; Diener HC, 2004, LANCET, V364, P331, DOI 10.1016/S0140-6736(04)16721-4; Ferrari E, 2005, J AM COLL CARDIOL, V45, P456, DOI 10.1016/j.jacc.2004.11.041; GRANGER CB, 1995, CIRCULATION, V91, P1929, DOI 10.1161/01.CIR.91.7.1929; Grines CL, 2007, J AM DENT ASSOC, V138, P652, DOI 10.14219/jada.archive.2007.0237; Ho PM, 2006, ARCH INTERN MED, V166, P1836, DOI 10.1001/archinte.166.17.1836; Holmes DR, 2007, J AM COLL CARDIOL, V50, P109, DOI 10.1016/j.jacc.2007.04.032; Lauer MA, 2001, CIRCULATION, V104, P2772, DOI 10.1161/hc4801.100358; Maulaz AB, 2005, ARCH NEUROL-CHICAGO, V62, P1217, DOI 10.1001/archneur.62.8.1217; Maynard C, 2006, ARCH INTERN MED, V166, P1410, DOI 10.1001/archinte.166.13.1410; Mehta SR, 2001, LANCET, V358, P527, DOI 10.1016/S0140-6736(01)05701-4; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Petersen LA, 1999, J GEN INTERN MED, V14, P555, DOI 10.1046/j.1525-1497.1999.10198.x; Rosamond W, 2007, CIRCULATION, V115, pE69, DOI 10.1161/CIRCULATIONAHA.106.179918; Serebruany VL, 2006, INT J CLIN PRACT, V60, P863, DOI 10.1111/j.1742-1241.2006.00999.x; Serebruany VL, 2006, AM J MED, V119, DOI 10.1016/j.amjmed.2005.11.007; Sohn Min-Woong, 2006, Popul Health Metr, V4, P7, DOI 10.1186/1478-7954-4-7; Sohn Min-Woong, 2006, Popul Health Metr, V4, P2, DOI 10.1186/1478-7954-4-2; STEINER JF, 1988, MED CARE, V26, P814, DOI 10.1097/00005650-198808000-00007; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; THEROUX P, 1992, NEW ENGL J MED, V327, P141, DOI 10.1056/NEJM199207163270301; Valgimigli M, 2007, J AM COLL CARDIOL, V50, P138, DOI 10.1016/j.jacc.2007.04.029; Xiao ZH, 1998, CIRCULATION, V97, P251, DOI 10.1161/01.CIR.97.3.251; Yusuf S, 2001, NEW ENGL J MED, V345, P494	33	290	308	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 6	2008	299	5					532	539		10.1001/jama.299.5.532	http://dx.doi.org/10.1001/jama.299.5.532			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RB	18252883	Bronze			2023-01-03	WOS:000252886100018
J	Yin, W; Basu, A; Zhang, JX; Rabbani, A; Meltzer, DO; Alexander, GC				Yin, Wesley; Basu, Anirban; Zhang, James X.; Rabbani, Atonu; Meltzer, David O.; Alexander, G. Caleb			The effect of the medicare Part D prescription benefit on drug utilization and expenditures	ANNALS OF INTERNAL MEDICINE			English	Article							COVERAGE	Background: information about the effect of the Medicare Part D Prescription Drug Benefit on drug utilization and expenditures is limited. Objective: To estimate changes in prescription utilization and out-of-pocket expenditures attributable to Part D among a sample of persons eligible for the benefit. Design: Generalized estimating equations were used to estimate changes in expenditures and utilization among beneficiaries. A control group was included to control for secular trends unrelated to the Part D benefit. Setting: National pharmacy chain representing approximately 15% of all U.S. retail pharmacy sales. Participants: Persons age 66 to 79 years (those eligible for Part D) and a control group of persons age 60 to 63 years (those ineligible for Part D). The final sample represented approximately 5.1 million unique beneficiaries and 1.8 million unique control individuals. Measurements: Prescription utilization (measured in pill-days) and out-of-pocket expenditures, as determined from pharmacy claims from September 2004 to April 2007. Results: During the penalty-free Part D enrollment period (January 2006 to May 2006), average monthly drug utilization increased by 1.1% (95% CI, 0.5% to 1.7%; P< 0.001) and out-of-pocket expenditures decreased by 8.8% (CI, 6.6% to 11.0%; P < 0.001). After enrollment stabilized (June 2006 to April 2007), average monthly drug utilization increased by 5.9% (CI, 5.1% to 6.7%; P < 0.001) and out-of-pocket expenditures decreased by 13.1 % (CI, 9.6% to 16.6%; P = 0.003). Compared with eligible non-enrollees, enrollees had higher out-of-pocket expenditures and utilization at baseline but experienced significantly larger decreases in expenditures and increases in utilization after enrollment. Limitations: Analyses were limited to claims within 1 pharmacy chain. The effect of the "doughnut hole" and the effect of changes on clinical outcomes were not evaluated. Conclusion: The Medicare Part D prescription benefit resulted in modest increases in average drug utilization and decreases in average out-of-pocket expenditures among Part D beneficiaries. Further research is needed to examine patterns among other beneficiaries and to evaluate the effect of these changes on health outcomes.	[Alexander, G. Caleb] Univ Chicago, Chicago, IL 60637 USA; Harvard Univ, Robert Wood Johnson Scholars Hlth Policy Program, Cambridge, MA 02138 USA; Univ Chicago, Harris Sch Publ Policy, Ctr Hlth & Social Sci, Chicago, IL 60637 USA; MacLean Ctr Clin Med Eth, Chicago, IL USA; Univ Illinois, Chicago Sch Pharm, Chicago, IL USA; Virginia Commonwealth Univ, Richmond, VA USA	University of Chicago; Harvard University; Robert Wood Johnson Foundation (RWJF); University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Virginia Commonwealth University	Alexander, GC (corresponding author), Univ Chicago, 5841 S Maryland,MC 2007, Chicago, IL 60637 USA.	galexand@uchicago.edu	Zhang, James/HHS-8616-2022; Zhang, James X./AFN-7901-2022; Meltzer, David/C-2926-2009; Rabbani, Atonu/R-3033-2017	Zhang, James X./0000-0002-6251-0474; Meltzer, David/0000-0003-2790-7393; Rabbani, Atonu/0000-0002-3821-4106	AHRQ HHS [K08 HS15699-01A1] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS015699] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Bach PB, 2006, NEW ENGL J MED, V354, P2312, DOI 10.1056/NEJMp068108; Berkowitz SA, 2007, JAMA-J AM MED ASSOC, V297, P868, DOI 10.1001/jama.297.8.868; Cline RR, 2003, AAPS PHARMSCI, V5; *CTR MED MED SERV, MED DRUG PLANS STRON; Doherty RB, 2004, ANN INTERN MED, V141, P391, DOI 10.7326/0003-4819-141-5-200409070-00100; Gaynor M, 2006, 12758 NBER; Geronimus AT, 1998, AM J EPIDEMIOL, V148, P475; Heiss F, 2006, HEALTH AFFAIR, V25, pW344, DOI 10.1377/hlthaff.25.w344; HOLLAND PW, 1986, J AM STAT ASSOC, V81, P945, DOI 10.2307/2289064; *KAIS FAM FDN, 2006, CHARTP SEN EARL EXP; *KAIS FAM FDN, 2006, PUBL KAIS FAM FDN, V7453; *KAIS FAM FDN, 2006, PUBL KAIS FAM FDN, V7201; KHAN N, 2007, 12848 NBER; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Lichtenberg FR, 2007, HEALTH AFFAIR, V26, P1735, DOI 10.1377/hlthaff.26.6.1735; Manning WG, 1998, J HEALTH ECON, V17, P283, DOI 10.1016/S0167-6296(98)00025-3; Manning WG, 2005, J HEALTH ECON, V24, P465, DOI 10.1016/j.jhealeco.2004.09.011; Pauly MV, 2004, HEALTH AFFAIR, V23, P113, DOI 10.1377/hlthaff.23.1.113; RUBIN DB, 1974, J EDUC PSYCHOL, V66, P688, DOI 10.1037/h0037350; Stuart B, 2006, MED CARE, V44, P243, DOI 10.1097/01.mlr.0000199652.15293.fc	20	145	145	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 5	2008	148	3					169	177		10.7326/0003-4819-148-3-200802050-00200	http://dx.doi.org/10.7326/0003-4819-148-3-200802050-00200			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	258DX	18180465				2023-01-03	WOS:000252849700001
J	Lundberg, P; El-Andaloussi, S; Sutlu, T; Johansson, H; Langel, U				Lundberg, Pontus; El-Andaloussi, S.; Sutlu, T.; Johansson, H.; Langel, U.			Delivery of short interfering RNA using endosomolytic cell-penetrating peptides	FASEB JOURNAL			English	Article						CPP; gene silencing; siRNA; oligonucleotides; RNA interference	MAMMALIAN-CELLS; NUCLEIC-ACIDS; TAT; OLIGONUCLEOTIDES; MACROPINOCYTOSIS; PROTEINS; ENHANCE; CARRIER; ESCAPE; VECTOR	Cell- penetrating peptides ( CPPs) are peptides able to promote uptake of various cargos, including proteins and plasmids. Advances in recent years imply the uptake to be endocytic, where the current hurdle for efficient intracellular delivery is material being retained in the endosomes. In this study we wanted to compare the ability of various established CPPs to deliver siRNA and induce gene silencing of luciferase, with a novel designed penetratin analog having endosomolytic properties, using a noncovalent strategy. In principal, the penetratin analog EB1 will, upon protonation in the early- late endosomes, be able to form an amphipathic alpha helix resulting in permeabilization of the endosomal membrane. We demonstrate that even though all CPPs evaluated in this study can form complexes with siRNA, there is not a direct relationship between the complex formation ability and delivery efficacy. More important, although all CPPs significantly promote siRNA uptake, in some cases no gene silencing effect can be observed unless endosomal escape is induced. We find the designed endosomolytic peptide EB1 to be far more effective both in forming complexes and transporting biologically active siRNA than its parent peptide penetratin. We believe that developing CPPs with increased endosomolytical properties is a necessary step toward achieving biological effects at low concentrations for future in vivo applications.	Stockholm Univ, Dept Neurochem, S-10691 Stockholm, Sweden	Stockholm University	Lundberg, P (corresponding author), Stockholm Univ, Dept Neurochem, Svante Arrhenius Vag 21A, S-10691 Stockholm, Sweden.	pontus@neurochem.su.se	Johansson, Henrik J/O-3363-2014; Sutlu, Tolga/E-1190-2012	Johansson, Henrik J/0000-0003-4729-4205; Sutlu, Tolga/0000-0002-7813-8734; Langel, Ulo/0000-0001-6107-0844				Davidson BL, 2004, LANCET NEUROL, V3, P145, DOI 10.1016/S1474-4422(04)00678-7; Davidson TJ, 2004, J NEUROSCI, V24, P10040, DOI 10.1523/JNEUROSCI.3643-04.2004; El-Andaloussi S, 2005, J CONTROL RELEASE, V110, P189, DOI 10.1016/j.jconrel.2005.09.012; El-Andaloussi S, 2005, CURR PHARM DESIGN, V11, P3597, DOI 10.2174/138161205774580796; El-Andaloussi S, 2006, J GENE MED, V8, P1262, DOI 10.1002/jgm.950; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Goncalves C, 2004, MOL THER, V10, P373, DOI 10.1016/j.ymthe.2004.05.023; Kang SH, 1998, BIOCHEMISTRY-US, V37, P6235, DOI 10.1021/bi980300h; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630; Magzoub M, 2005, BIOCHEMISTRY-US, V44, P14890, DOI 10.1021/bi051356w; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Morris MC, 1999, NUCLEIC ACIDS RES, V27, P3510, DOI 10.1093/nar/27.17.3510; Petersen H, 2002, BIOMACROMOLECULES, V3, P926, DOI 10.1021/bm025539z; Shiraishi T, 2005, CHEM BIOL, V12, P923, DOI 10.1016/j.chembiol.2005.06.009; Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385; Turner JJ, 2005, NUCLEIC ACIDS RES, V33, P27, DOI 10.1093/nar/gki142; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996	20	246	283	1	70	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2664	2671		10.1096/fj.06-6502com	http://dx.doi.org/10.1096/fj.06-6502com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17463227				2023-01-03	WOS:000249237500008
J	Pieters, R; Schrappe, M; De Lorenzo, P; Hann, I; De Rossi, G; Felice, M; Hovi, L; LeBlanc, T; Szczepanski, T; Ferster, A; Janka, G; Rubnitz, J; Silverman, L; Stary, J; Campbell, M; Li, CK; Mann, G; Suppiah, R; Biondi, A; Vora, A; Valsecchi, MG				Pieters, Rob; Schrappe, Martin; De Lorenzo, Paola; Hann, Ian; De Rossi, Giulio; Felice, Maria; Hovi, Liisa; LeBlanc, Thierry; Szczepanski, Tomasz; Ferster, Alice; Janka, Gritta; Rubnitz, Jeffrey; Silverman, Lewis; Stary, Jan; Campbell, Myriam; Li, Chi-Kong; Mann, Georg; Suppiah, Ram; Biondi, Andrea; Vora, Ajay; Valsecchi, Maria Grazia			A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial	LANCET			English	Article							MLL GENE; CYTOSINE-ARABINOSIDE; PROGNOSTIC-FACTORS; CHEMOTHERAPY; THERAPY; REARRANGEMENTS; EXPERIENCE; SURVIVAL	Background Acute lymphoblastic leukaemia in infants younger than 1 year is rare, and infants with the disease have worse outcomes than do older children. We initiated an international study to investigate the effects of a new hybrid treatment protocol with elements designed to treat both acute lymphoblastic: leukaemia and acute myeloid leukaemia, and to identify any prognostic factors for outcome in infants. We also did a randomised trial to establish the value of a late intensification course. Methods Patients aged 0-12 months were enrolled by 17 study groups in 22 countries between 1999 and 2005. Eligible patients were stratified for risk according to their peripheral blood response to a 7-day prednisone prophase, and then given a hybrid regimen based on the standard protocol for acute lymphoblastic leukaemia, with some elements designed for treatment of acute myeloid leukaemia. Before the maintenance phase, a subset of patients in complete remission were randomly assigned to receive either standard treatment or a more intensive chemotherapy course with high-dose cytarabine and methotrexate. The primary outcomes were event-free survival (EFS) for the initial cohort of patients and disease-free survival (DFS) for the patients randomly assigned to a treatment group. Data were analysed on an intention-to-treat basis. This trial was registered with ClinicalTrials.gov, number NCT 00015873, and at controlled-trials.com, number ISRCTN24251487. Findings In the 482 enrolled patients who underwent hybrid treatment, 260 (58%) were in complete remission at a median follow-up of 38 (range 1-78) months, and EFS at 4 years was 47.0% (SE 2.6, 95% CI 41.9-52.1). Of 445 patients in complete remission after 5 weeks of induction treatment, 191 were randomised: 95 patients to receive a late intensification course, and 96 to a control group. At a median follow-up of 42 (range 1-73) months, 60 patients in the treatment group and 57 controls were disease-free. DFS at 4 years did not differ between the two groups (60.9% [SE 5.2] for treatment group vs 57.0% [5.5] for controls; p=0.81). During the intensification phase, of 71 patients randomly assigned to the treatment group, and for whom toxicity data were available, 35 (49%) had infections, 21 (30%) patients had mucositis, 22 (31%) patients had toxic effects on the liver, and 2 (3%) had neurotoxicity. All types of rearrangements in the (mixed lineage leukaemia) MLL gene, very high white blood cell count, age of younger than 6 months, and a poor response to the prednisone prophase were independently associated with inferior outcomes. Interpretation Patients treated with our hybrid protocol, and especially those who responded poorly to prednisone, had higher EFS than most reported outcomes for treatment of infant ALL. Delayed intensification of chemotherapy did not benefit patients.	Sophia Childrens Univ Hosp, Erasmus MC, Dept Paediat Oncol & Haematol, NL-3015 GJ Rotterdam, Netherlands; Univ Med Ctr Schleswig Holstein, Kiel, Germany; Univ Milano Bicocca, Dept Clin Med & Prevent, Milan, Italy; Great Ormond St Hosp Sick Children, London WC1N 3JH, England; Sheffield Childrens Hosp, Sheffield, S Yorkshire, England; Univ Milano Bicocca, San Gerardo Hosp, Monza, Italy; Children Hosp Bambino Gesu, Rome, Italy; Argentina Hosp Pediat, Buenos Aires, DF, Argentina; Univ Helsinki, Helsinki, Finland; Hop St Louis, Paris, France; Med Univ Silesia, Zabrze, Poland; Hop Univ Enfants Reine Fabiola, Brussels, Belgium; Univ Hosp Hamburg Eppendorf, Hamburg, Germany; St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Charles Univ Prague, Sch Med 2, Prague, Czech Republic; Univ Hosp Motol, Prague, Czech Republic; Hosp Roberto del Rio, Santiago, Chile; Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China; St Anna Childrens Hosp, A-1090 Vienna, Austria; Womens & Childrens Hosp, Adelaide, SA, Australia	Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Milano-Bicocca; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; San Gerardo Hospital; University of Milano-Bicocca; IRCCS Bambino Gesu; University of Helsinki; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Medical University Silesia; University of Hamburg; University Medical Center Hamburg-Eppendorf; St Jude Children's Research Hospital; Harvard University; Dana-Farber Cancer Institute; Charles University Prague; Motol University Hospital; Universidad de Chile; Chinese University of Hong Kong; Prince of Wales Hospital; Saint Anna Children's Hospital; Womens & Childrens Hospital Australia	Pieters, R (corresponding author), Sophia Childrens Univ Hosp, Erasmus MC, Dept Paediat Oncol & Haematol, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands.	rob.picters@erasmusmc.nl	Rubnitz, Jeffrey E/N-2619-2018; Stary, Jan/AAB-9635-2020; Valsecchi, Maria Grazia/K-8891-2016; Li, Chi-kong/J-8456-2013; Biondi, Andrea/AAX-1865-2020; Schrappe, Martin/A-8109-2010; Biondi, Andrea/K-9997-2016; Schrappe, Martin/ABA-6144-2020	Rubnitz, Jeffrey E/0000-0001-9885-3527; Valsecchi, Maria Grazia/0000-0001-5574-3504; Li, Chi-kong/0000-0002-2810-5758; Biondi, Andrea/0000-0002-6757-6173; Szczepanski, Tomasz/0000-0001-5336-261X	Medical Research Council [G0300130] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Biondi A, 2000, BLOOD, V96, P24, DOI 10.1182/blood.V96.1.24; Biondi A, 2006, HAEMATOLOGICA, V91, P534; Chessells JM, 2002, BRIT J HAEMATOL, V117, P306, DOI 10.1046/j.1365-2141.2002.03442.x; Creutzig U, 2005, LEUKEMIA, V19, P2030, DOI 10.1038/sj.leu.2403920; Dordelmann M, 1999, BLOOD, V94, P1209, DOI 10.1182/blood.V94.4.1209.416k05_1209_1217; Fayers PM, 1997, STAT MED, V16, P1413, DOI 10.1002/(SICI)1097-0258(19970630)16:12<1413::AID-SIM578>3.3.CO;2-L; FERSTER A, 1994, BRIT J HAEMATOL, V86, P284, DOI 10.1111/j.1365-2141.1994.tb04727.x; Frankel LS, 1997, J PEDIAT HEMATOL ONC, V19, P35, DOI 10.1097/00043426-199701000-00005; Heerema NA, 1999, LEUKEMIA, V13, P679, DOI 10.1038/sj.leu.2401413; Hilden JM, 2006, BLOOD, V108, P441, DOI 10.1182/blood-2005-07-3011; Jansen MWJC, 2007, LEUKEMIA, V21, P633, DOI 10.1038/sj.leu.2404578; Kosaka Y, 2004, BLOOD, V104, P3527, DOI 10.1182/blood-2004-04-1390; Lauer SJ, 1998, J PEDIAT HEMATOL ONC, V20, P229, DOI 10.1097/00043426-199805000-00008; Leung W, 2000, LEUKEMIA, V14, P1185, DOI 10.1038/sj.leu.2401818; Ludwig WD, 1998, BLOOD, V92, P1898; Marco F, 2000, J CLIN ONCOL, V18, P3256, DOI 10.1200/JCO.2000.18.18.3256; MARUBINI E, 1995, ANAL SURVIVAL DATA C, P171; Nagayama J, 2006, BLOOD, V107, P4663, DOI 10.1182/blood-2005-11-4728; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Pieters R, 1998, LEUKEMIA, V12, P1344, DOI 10.1038/sj.leu.2401129; Pieters R., 2003, CONTEMPORARY CLIN NE, P61; Pui CH, 2002, LANCET, V359, P1909, DOI 10.1016/S0140-6736(02)08782-2; Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603; Reaman GH, 1999, J CLIN ONCOL, V17, P445, DOI 10.1200/JCO.1999.17.2.445; REITER A, 1994, BLOOD, V84, P3122, DOI 10.1182/blood.V84.9.3122.3122; Sanders JE, 2005, BLOOD, V105, P3749, DOI 10.1182/blood-2004-08-3312; Silverman LB, 1997, CANCER-AM CANCER SOC, V80, P2285; Stam RW, 2006, BRIT J HAEMATOL, V132, P539, DOI 10.1111/j.1365-2141.2005.05909.x; Stam RW, 2003, BLOOD, V101, P1270, DOI 10.1182/blood-2002-05-1600; WHITE JC, 1987, J CLIN INVEST, V79, P380, DOI 10.1172/JCI112823; WILEY JS, 1982, J CLIN INVEST, V69, P479, DOI 10.1172/JCI110472	31	411	434	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 21	2007	370	9583					240	250		10.1016/S0140-6736(07)61126-X	http://dx.doi.org/10.1016/S0140-6736(07)61126-X			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	194MG	17658395				2023-01-03	WOS:000248347900028
J	Sullivan, PS; Campsmith, ML; Nakamura, GV; Begley, EB; Schulden, J; Nakashima, AK				Sullivan, Patrick S.; Campsmith, Michael L.; Nakamura, Glenn V.; Begley, Elin B.; Schulden, Jeffrey; Nakashima, Allyn K.			Patient and Regimen Characteristics Associated with Self-Reported Nonadherence to Antiretroviral Therapy	PLOS ONE			English	Article							HIV BEHAVIORAL SURVEILLANCE; MEDICATION ADHERENCE; VIRAL SUPPRESSION; CLINICAL-TRIALS; DRUG-USE; INFECTION; IMPACT; RISK; OUTCOMES; INDIVIDUALS	Background. Nonadherence to antiretroviral therapy (ARVT) is an important behavioral determinant of the success of ARVT. Nonadherence may lead to virological failure, and increases the risk of development of drug resistance. Understanding the prevalence of nonadherence and associated factors is important to inform secondary HIV prevention efforts. Methodology/Principal Findings. We used data from a cross-sectional interview study of persons with HIV conducted in 18 U. S. states from 2000-2004. We calculated the proportion of nonadherent respondents (took <95% of prescribed doses in the past 48 hours), and the proportion of doses missed. We used multivariate logistic regression to describe factors associated with nonadherence. Nine hundred and fifty-eight (16%) of 5,887 respondents reported nonadherence. Nonadherence was significantly (p<0.05) associated with black race and Hispanic ethnicity; age <40 years; alcohol or crack use in the prior 12 months; being prescribed >= 4 medications; living in a shelter or on the street; and feeling "blue" >= 14 of the past 30 days. We found weaker associations with having both male-male sex and injection drug use risks for HIV acquisition; being prescribed ARVT for >= 21 months; and being prescribed a protease inhibitor (PI)-based regimen not boosted with ritonavir. The median proportion of doses missed was 50%. The most common reasons for missing doses were forgetting and side effects. Conclusions/Significance. Self-reported recent nonadherence was high in our study. Our data support increased emphasis on adherence in clinical settings, and additional research on how providers and patients can overcome barriers to adherence.	[Sullivan, Patrick S.; Campsmith, Michael L.; Nakamura, Glenn V.; Begley, Elin B.; Schulden, Jeffrey; Nakashima, Allyn K.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Sullivan, PS (corresponding author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.	pss0@cdc.gov		Sullivan, Patrick Sean/0000-0002-7728-0587	Centers for Disease Control and Prevention	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Funding support for data collection was provided to the project sites by the Centers for Disease Control and Prevention. No external funding was used to support the analysis of these data.	Altice FL, 2001, J ACQ IMMUN DEF SYND, V28, P47, DOI 10.1097/00042560-200109010-00008; Ammassari A, 2004, PSYCHOSOMATICS, V45, P394, DOI 10.1176/appi.psy.45.5.394; Ammassari A, 2002, JAIDS, V31, pS123, DOI 10.1097/00126334-200212153-00007; Antinori A, 2004, ANTIVIR THER, V9, P291; Arnsten JH, 2002, J GEN INTERN MED, V17, P377, DOI 10.1007/s11606-002-0044-3; Bartenstein P, 2002, AKTUEL NEUROL, V29, P1, DOI 10.1055/s-2002-20000; Berg KM, 2004, J GEN INTERN MED, V19, P1111, DOI 10.1111/j.1525-1497.2004.30445.x; Bottonari KA, 2005, AIDS PATIENT CARE ST, V19, P719, DOI 10.1089/apc.2005.19.719; Buehler JW, 1996, PUBLIC HEALTH REP, V111, P133; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Carrieri MP, 2006, JAIDS-J ACQ IMM DEF, V41, P477, DOI 10.1097/01.qai.0000186364.27587.0e; Chander G, 2006, DRUGS, V66, P769, DOI 10.2165/00003495-200666060-00004; Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891; COHEN M, 2006, 13 C RETR OPP INF DE; Fairley CK, 2005, HIV MED, V6, P366, DOI 10.1111/j.1468-1293.2005.00322.x; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; Fletcher CV, 2005, JAIDS-J ACQ IMM DEF, V40, P301, DOI 10.1097/01.qai.0000180078.53321.6a; Gallagher KM, 2007, PUBLIC HEALTH REP, V122, P32, DOI 10.1177/00333549071220S106; Glass TR, 2006, JAIDS-J ACQ IMM DEF, V41, P385, DOI 10.1097/01.qai.0000186371.95301.52; Gordillo V, 1999, AIDS, V13, P1763, DOI 10.1097/00002030-199909100-00021; GROSS R, 2006, 13 C RETR OPP INF DE; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Holmes WC, 2002, J GEN INTERN MED, V17, P677, DOI 10.1046/j.1525-1497.2002.00746.x; Howard AA, 2002, AIDS, V16, P2175, DOI 10.1097/00002030-200211080-00010; Kerr Thomas, 2005, Curr HIV/AIDS Rep, V2, P200, DOI 10.1007/s11904-005-0017-3; Lafeuillade A, 2001, INT J STD AIDS, V12, P18, DOI 10.1258/0956462011924290; Lansky A, 2007, PUBLIC HEALTH REP, V122, P16, DOI 10.1177/00333549071220S104; Lichtenstein KA, 2005, JAIDS-J ACQ IMM DEF, V39, P395, DOI 10.1097/01.qai.0000167478.28051.3a; Maggiolo F, 2005, CLIN INFECT DIS, V40, P158, DOI 10.1086/426595; Maisto SA, 2003, AM J ADDICTION, V12, pS12, DOI 10.1111/j.1521-0391.2003.tb00493.x; Mannheimer S, 2002, CLIN INFECT DIS, V34, P1115, DOI 10.1086/339074; Martini M, 2004, EUR J EPIDEMIOL, V19, P585, DOI 10.1023/B:EJEP.0000032353.03967.ef; Moss AR, 2004, CLIN INFECT DIS, V39, P1190, DOI 10.1086/424008; Murri R, 2004, J GEN INTERN MED, V19, P1104, DOI 10.1111/j.1525-1497.2004.30248.x; Nieuwkerk PT, 2005, JAIDS-J ACQ IMM DEF, V38, P445, DOI 10.1097/01.qai.0000147522.34369.12; NILSSON SL, 2006, AIDS CARE, V18, P246; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Piliero Peter J, 2003, J Am Acad Nurse Pract, V15, P305, DOI 10.1111/j.1745-7599.2003.tb01313.x; Reynolds NR, 2004, CURR HIV RES, V2, P207, DOI 10.2174/1570162043351309; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; Santos CP, 2005, AIDS, V19, pS14, DOI 10.1097/01.aids.0000191485.92285.c7; Selnes OA, 2002, JAIDS-J ACQ IMM DEF, V31, pS132, DOI 10.1097/00126334-200212153-00009; Silverberg MJ, 2007, ARCH INTERN MED, V167, P684, DOI 10.1001/archinte.167.7.684; Simoni JM, 2006, AIDS BEHAV, V10, P227, DOI 10.1007/s10461-006-9078-6; Sledjeski EM, 2005, AIDS PATIENT CARE ST, V19, P728, DOI 10.1089/apc.2005.19.728; Smith RJ, 2006, P ROY SOC B-BIOL SCI, V273, P617, DOI 10.1098/rspb.2005.3352; Starace F, 2002, JAIDS, V31, pS136, DOI 10.1097/00126334-200212153-00010; Stirratt MJ, 2006, AIDS BEHAV, V10, P483, DOI 10.1007/s10461-006-9106-6; Trotta MP, 2003, AIDS, V17, P1099, DOI 10.1097/00002030-200305020-00026; *US DEP HHS, 2006, GUID US ANT AG HIV 1; Van Wijngaerden E, 2002, AIDS RES HUM RETROV, V18, P327, DOI 10.1089/088922202753519098; Vlahov D, 2001, AIDS, V15, P2311, DOI 10.1097/00002030-200111230-00013; Vrijens B, 2005, STAT MED, V24, P2719, DOI 10.1002/sim.2130; Wagner G, 2004, JAIDS-J ACQ IMM DEF, V35, P203, DOI 10.1097/00126334-200402010-00016; Wagner GJ, 2002, AIDS PATIENT CARE ST, V16, P599, DOI 10.1089/108729102761882134; Walsh JC, 2002, AIDS, V16, P269, DOI 10.1097/00002030-200201250-00017; Walster C. I., 1999, Fish Veterinary Journal, P54; WEISER B, 1994, P NATL ACAD SCI USA, V91, P8037, DOI 10.1073/pnas.91.17.8037; Weiser SD, 2004, HIV CLIN TRIALS, V5, P278, DOI 10.1310/LNHD-K1R7-HQP5-HJCQ; Wood E, 2004, JAIDS-J ACQ IMM DEF, V35, P261, DOI 10.1097/00126334-200403010-00006	60	54	56	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2007	2	6							e552	10.1371/journal.pone.0000552	http://dx.doi.org/10.1371/journal.pone.0000552			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GE	17579723	Green Published, gold, Green Submitted			2023-01-03	WOS:000207451700017
J	Pengel, LHM; Refshauge, KM; Maher, CG; Nicholas, MK; Herbert, RD; McNair, P				Pengel, Liset H. M.; Refshauge, Kathryn M.; Maher, Christopher G.; Nicholas, Michael K.; Herbert, Robert D.; McNair, Peter			Physiotherapist-directed exercise, advice, or both for subacute low back pain - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							GRADED ACTIVITY; CLINICAL-TRIAL; SICK LEAVE; THERAPY; INTERVENTION; CARE; DISABILITY; GUIDELINES; OUTCOMES; PROGRAM	Background: Advice and exercise are widely recommended for subacute low back pain, but the effectiveness of these interventions is unclear. Objective: To investigate the effectiveness of physiotherapist-prescribed exercise, advice, or both for subacute low back pain. Design: Factorial randomized, placebo-controlled trial. Setting: 7 university hospitals and primary care clinics in Australia and New Zealand. Patients: 259 persons with subacute low back pain (>6 weeks and <3 months in duration). Intervention: Participants received 12 physiotherapist-directed exercise or sham exercise sessions and 3 physiotherapist-directed advice or sham advice sessions over 6 weeks. Measurements: Primary outcomes were average pain over the past week (scale, 0 to 10), function (Patient-Specific Functional Scale), and global perceived effect (11-point scale) at 6 weeks and 12 months. Secondary outcomes were disability (Roland-Morris Disability Questionnaire), number of health care contacts, and depression (Depression Anxiety Stress Scales-21). Results: Exercise and advice were each slightly more effective than placebo at 6 weeks but not at 12 months. The effect of advice on the pain scale was -0.7 point (95% CI, -1.2 to -0.2 point; P = 0.011) at 6 weeks and -0.4 point (CI, - 1.0 to 0.3 point P = 0.27) at 12 months, whereras the effect of exercise was -0.8 point (CI, -1.3 to -0.3 point; P 0.004) at 6 weeks and -0.5 point (CI, -1.1 to 0.2 point P 0.14) at 12 months. The effect of advice on the function scale was 0.7 point (CI, 0.1 to 1.3 points; P = 0.014) at 6 weeks and 0.6 point (CI, 0.1 to 1.2 points; P 0.023) at 12 months, and the effect of exercise was 0.4 point (CI, -0.2 to 1.0 point; P = 0.174) at 6 weeks and 0.5 point (CI, -0.1 to 1.0 point; P = 0.094) at 12 months. The effect of advice on the global perceived effect scale was 0.8 point (CI, 0.3 to 1.2 points; P < 0.001) at 6 weeks and 0.3 point (CI, -0.2 to 0.9 point; P = 0.24) at 12 months, and the effect of exercise was 0.5 point (CI, 0.1 to 1.0 point; P = 0.017) at 6 weeks and 0.4 point (CI, -0.1 to 1.0 point; P = 0.134) at 12 months. When administered together, exercise and advice had larger effects on all outcomes at 6 weeks (effect on pain, -1.5 [CI -2.2 to -0.7 point; P = 0.001], with similar results for other primary outcomes); however, by 12 months, there was a statistically significant effect only for function (effect 1.1 points [CI, 0.3 to 1.8 points]; P = 0.005). Limitation: Physiotherapists were not blinded. Conclusions: in participants with subacute low back pain, physiotherapist- directed exercise and advice were each slightly more effective than placebo at 6 weeks. The effect was greatest when the interventions were combined. At 12 months, the only effect that persisted was a small effect on participant-reported function.	Univ Sydney, Fac Hlth Sci, Discipline Physiotherapy, Lidcombe, NSW 1825, Australia; Royal Coll Surgeons England, London, England; Royal N Shore Hosp, St Leonards, NSW 2065, Australia; Univ Auckland Technol, Auckland, New Zealand	University of Sydney; Royal College of Surgeons of England; Royal North Shore Hospital; Auckland University of Technology; University of Auckland	Maher, CG (corresponding author), Univ Sydney, Fac Hlth Sci, Discipline Physiotherapy, POB 170, Lidcombe, NSW 1825, Australia.	c.maher@usyd.edu.au	Maher, Christopher/AAC-6267-2019	Maher, Christopher/0000-0002-1628-7857; Pengel, Liset/0000-0001-9620-8639; refshauge, kathryn/0000-0002-8127-6847; Herbert, Rob/0000-0003-4188-9195				[Anonymous], 2003, APPL LONGITUDINAL AN; BORKOVEC TD, 1972, J BEHAV THER EXP PSY, V3, P257, DOI 10.1016/0005-7916(72)90045-6; Britt H, 2005, GEN PRACTICE ACTIVIT; Cherkin DC, 1998, NEW ENGL J MED, V339, P1021, DOI 10.1056/NEJM199810083391502; Cherkin DC, 1996, SPINE, V21, P345, DOI 10.1097/00007632-199602010-00019; Chok B, 1999, PHYS THER, V79, P1032, DOI 10.1093/ptj/79.11.1032; DAVIES JE, 1979, RHEUMATOL REHABIL, V18, P243, DOI 10.1093/rheumatology/18.4.243; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Frost H, 2004, BRIT MED J, V329, P708, DOI 10.1136/bmj.38216.868808.7C; Hagen EM, 2000, SPINE, V25, P1973, DOI 10.1097/00007632-200008010-00017; Hayden JA, 2005, ANN INTERN MED, V142, P765, DOI 10.7326/0003-4819-142-9-200505030-00013; Hayden JA, 2005, ANN INTERN MED, V142, P776, DOI 10.7326/0003-4819-142-9-200505030-00014; Hides JA, 1996, SPINE, V21, P2763, DOI 10.1097/00007632-199612010-00011; INDAHL A, 1995, SPINE, V20, P473, DOI 10.1097/00007632-199502001-00011; Jellema P, 2005, BMJ-BRIT MED J, V331, P84, DOI 10.1136/bmj.38495.686736.E0; Koes BW, 2006, BMJ-BRIT MED J, V332, P1430, DOI 10.1136/bmj.332.7555.1430; Koes BW, 2001, SPINE, V26, P2504, DOI 10.1097/00007632-200111150-00022; LINDSTROM I, 1992, PHYS THER, V72, P279, DOI 10.1093/ptj/72.4.279; Linton SJ, 2000, SPINE, V25, P2825, DOI 10.1097/00007632-200011010-00017; Lovibond PF, 1998, J ABNORM PSYCHOL, V107, P520, DOI 10.1037/0021-843X.107.3.520; Mannion AF, 1999, SPINE, V24, P2435, DOI 10.1097/00007632-199912010-00004; Moffett JK, 1999, BRIT MED J, V319, P279, DOI 10.1136/bmj.319.7205.279; Nicholas M., 2004, MUSCULOSKELETAL PHYS, V2nd; NICHOLAS MK, 1992, PAIN, V48, P339, DOI 10.1016/0304-3959(92)90082-M; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Pengel HM, 2002, CLIN REHABIL, V16, P811, DOI 10.1191/0269215502cr562oa; Pengel LHM, 2003, BMJ-BRIT MED J, V327, P323, DOI 10.1136/bmj.327.7410.323; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Ross RG, 1997, ASSESSMENT OCCUPATIO, P123; Schiltenwolf M, 2006, EUR SPINE J, V15, P1083, DOI 10.1007/s00586-005-0008-5; Staal JB, 2004, ANN INTERN MED, V140, P77, DOI 10.7326/0003-4819-140-2-200401200-00007; Storheim K, 2003, J REHABIL MED, V35, P132, DOI 10.1080/16501970310010484; van Tulder M, 2003, SPINE, V28, P1290, DOI 10.1097/01.BRS.0000065484.95996.AF; Vlaeyen JWS, 2002, PAIN RES CL, V12, P83; Walker BF, 2004, J MANIP PHYSIOL THER, V27, P327, DOI 10.1016/j.jmpt.2004.04.006; Westaway MD, 1998, J ORTHOP SPORT PHYS, V27, P331, DOI 10.2519/jospt.1998.27.5.331	36	116	120	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 5	2007	146	11					787	796		10.7326/0003-4819-146-11-200706050-00007	http://dx.doi.org/10.7326/0003-4819-146-11-200706050-00007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175HR	17548410				2023-01-03	WOS:000247005200004
J	Narod, SA				Narod, Steven A.			Ovarian cancer and HRT in the Million Women Study	LANCET			English	Editorial Material							POSTMENOPAUSAL WOMEN; ORAL-CONTRACEPTIVES; ESTROGEN POTENCY; PROGESTIN; BREAST		Womens Coll Res Inst, Toronto, ON M5G 1N8, Canada	University of Toronto; University Toronto Affiliates; Womens College Hospital	Narod, SA (corresponding author), Womens Coll Res Inst, Toronto, ON M5G 1N8, Canada.	steven.narod@wchospital.ca	Narod, Steven A/AAA-6112-2022					Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Beral V, 2007, LANCET, V369, P1703, DOI 10.1016/S0140-6736(07)60534-0; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Maxwell GL, 2006, GYNECOL ONCOL, V103, P535, DOI 10.1016/j.ygyno.2006.03.046; Ravdin PM, 2006, BREAST CANCER RES TR, V100, pS6; Rodriguez GC, 1998, J SOC GYNECOL INVEST, V5, P271, DOI 10.1016/S1071-5576(98)00017-3; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Schildkraut JM, 2002, JNCI-J NATL CANCER I, V94, P32	9	5	6	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 20	2007	369	9574					1667	1668		10.1016/S0140-6736(07)60535-2	http://dx.doi.org/10.1016/S0140-6736(07)60535-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	169ZT	17512836				2023-01-03	WOS:000246631300004
J	Dentali, F; Douketis, JD; Gianni, M; Lim, W; Crowther, MA				Dentali, Francesco; Douketis, James D.; Gianni, Monica; Lim, Wendy; Crowther, Mark A.			Meta-analysis: Anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients	ANNALS OF INTERNAL MEDICINE			English	Review							MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; LOW-DOSE HEPARIN; FATAL PULMONARY-EMBOLISM; PLACEBO-CONTROLLED TRIAL; UNFRACTIONATED HEPARIN; NONSURGICAL PATIENTS; CLINICAL-TRIALS; RISK-FACTORS; INPATIENTS	Background: Underutilization of anticoagulant prophylaxis may be due to lack of evidence that prophylaxis prevents clinically important outcomes in hospitalized medical patients at risk for venous thromboembolism. Purpose: To assess the effects of anticoagulant prophylaxis in reducing clinically important outcomes in hospitalized medical patients. Data Sources: MEDLINE, EMBASE, and Cochrane databases were searched to September 2006 without language restrictions. Study selection: Randomized trials comparing anticoagulant prophylaxis with no treatment in hospitalized medical patients. Data Extraction: Any symptomatic pulmonary embolism (PE), fatal PE, symptomatic deep venous thrombosis, all-cause mortality, and major bleeding. Pooled relative risks and associated 95% Cls were calculated. For treatment effects that were statistically significant, the authors determined the absolute risk reduction and the number needed to treat for benefit (NNTB) to prevent an outcome. Data Synthesis: 9 studies (n = 19 958) were included. During anticoagulant prophylaxis, patients had significant reductions in any PE (relative risk, 0.43 [Cl, 0.26 to 0.71]; absolute risk reduction, 0.29%; NNTB, 345) and fatal PE (relative risk, 0.38 [Cl, 0.21 to 0.69]; absolute risk reduction, 0.25%; NNTB, 400), a nonsignificant reduction in symptomatic deep venous thrombosis (relative risk, 0.47 [Cl, 0.22 to 1.00]), and a nonsignificant increase in major bleeding (relative risk, 1.32 [Cl, 0.73 to 2.37]). Anticoagulant prophylaxis had no effect on all-cause mortality (relative risk, 0.97 [Cl, 0.79 to 1.19]). Limitations: 2 of 9 included studies were not double-blind. Conclusions: Anticoagulant prophylaxis is effective in preventing symptomatic venous thromboembolism during anticoagulant prophylaxis in at-risk hospitalized medical patients. Additional research is needed to determine the risk for venous thromboembolism in these patients after prophylaxis has been stopped.	McMaster Univ, Hamilton, ON, Canada; St Josephs Healthcare Hamilton, Hamilton, ON, Canada	McMaster University; McMaster University	Douketis, JD (corresponding author), St Josephs Hosp, Room F-544,50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	jdouket@mcmaster.ca	Douketis, James/AAO-5659-2021					Alikhan R, 2004, ARCH INTERN MED, V164, P963, DOI 10.1001/archinte.164.9.963; ALLEN TW, 1996, J AM OSTEOPATH ASSOC, V96, P335; BELCH JJ, 1981, SCOT MED J, V26, P115, DOI 10.1177/003693308102600205; Bergmann JF, 1996, LANCET, V348, P205, DOI 10.1016/S0140-6736(05)66160-0; Bergmann JF, 1996, THROMB HAEMOSTASIS, V76, P529; CADE JF, 1982, CRIT CARE MED, V10, P448, DOI 10.1097/00003246-198207000-00006; Caprini JA, 2002, INT ANGIOL, V21, P78; Cohen AT, 2006, BMJ-BRIT MED J, V332, P325, DOI 10.1136/bmj.38733.466748.7C; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; DAHAN R, 1986, HAEMOSTASIS, V16, P159; de Lissovoy G, 2002, AM J MANAG CARE, V8, P1082; Desjardins L, 2004, ARCH PATHOL LAB MED, V128, P519; Fraisse F, 2000, AM J RESP CRIT CARE, V161, P1109, DOI 10.1164/ajrccm.161.4.9807025; Gallus AS, 1998, HAEMOSTASIS, V28, P71; Gardlund B, 1996, LANCET, V347, P1357; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; Girolami B, 2003, BLOOD, V101, P2955, DOI 10.1182/blood-2002-07-2201; Goldhaber SZ, 2000, CHEST, V118, P1680, DOI 10.1378/chest.118.6.1680; GRAVES EJ, 1997, VITAL HLTH STAT, V1, P145; HALKIN H, 1982, ANN INTERN MED, V96, P561, DOI 10.7326/0003-4819-96-5-561; Harenberg J, 1996, HAEMOSTASIS, V26, P127; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; IBARRAPEREZ C, 1988, ANGIOLOGY, V39, P505, DOI 10.1177/000331978803900603; Kahn SR, 2007, THROMB RES, V119, P145, DOI 10.1016/j.thromres.2006.01.011; Kleber FX, 2003, AM HEART J, V145, P614, DOI 10.1067/mhj.2003.189; Labarere J, 2004, J INTERN MED, V256, P338, DOI 10.1111/j.1365-2796.2004.01365.x; Lamy Andre, 2002, Can Respir J, V9, P169; Lechler E, 1996, HAEMOSTASIS, V26, P49; Lederle FA, 2006, AM J MED, V119, P54, DOI 10.1016/j.amjmed.2005.03.049; Lederle FA, 1998, ANN INTERN MED, V128, P768, DOI 10.7326/0003-4819-128-9-199805010-00011; Leizorovicz A, 2004, CIRCULATION, V110, P874, DOI 10.1161/01.CIR.0000138928.83266.24; Lowe GDO, 2003, LANCET, V362, P504, DOI 10.1016/S0140-6736(03)14149-9; MACLURE M, 1987, AM J EPIDEMIOL, V126, P161, DOI 10.1093/aje/126.2.161; Mahe I, 2005, EUR J CLIN PHARMACOL, V61, P347, DOI 10.1007/s00228-005-0944-3; MANTEL N, 1959, J NATL CANCER I, V22, P719; Martel N, 2005, BLOOD, V106, P2710, DOI 10.1182/blood-2005-04-1546; McGinn T, 2004, CAN MED ASSOC J, V171, P1369, DOI 10.1503/cmaj.1031981; Mesko JW, 2001, J ARTHROPLASTY, V16, P679, DOI 10.1054/arth.2001.25506; Mismetti P, 2000, THROMB HAEMOSTASIS, V83, P14; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Nuijten Mark J. C., 2002, Recenti Progressi in Medicina, V93, P80; PIRONE F, 1988, Clinica Terapeutica, V126, P267; Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103; Samama MM, 2000, ARCH INTERN MED, V160, P3415, DOI 10.1001/archinte.160.22.3415; Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x; SHOJANIA KG, 2006, MAKING HLTH CARE SAF; Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; Stratton MA, 2000, ARCH INTERN MED, V160, P334, DOI 10.1001/archinte.160.3.334; Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761; Vaitkus PT, 2002, VASC MED, V7, P269, DOI 10.1191/1358863x02vm449oa	51	391	406	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 20	2007	146	4					278	288		10.7326/0003-4819-146-4-200702200-00007	http://dx.doi.org/10.7326/0003-4819-146-4-200702200-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	137CS	17310052				2023-01-03	WOS:000244271000006
J	Teichman, PG; Donchin, Y; Kot, RJ				Teichman, Peter G.; Donchin, Yoel; Kot, Raphael J.			Current concepts - International aeromedical evacuation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; SERIOUS DIVING ACCIDENTS; AIR-TRAVEL; CRITICALLY-ILL; MEDICAL REPATRIATION; OXYGEN-SATURATION; ADVERSE EVENTS; INTENSIVE-CARE; TRANSPORT; DISEASE		Victoria Healthcare Int, Ho Chi Minh City, Vietnam; Family Med Practice Vietnam, Ho Chi Minh City, Vietnam; Hadassah Med Org, Patient Safety Unit, Jerusalem, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center	Teichman, PG (corresponding author), Victoria Healthcare Int, 79 Dien Bien Phu St,Da Kao Ward,Dist 1, Ho Chi Minh City, Vietnam.	keqfap@yahoo.co.nz						Aerospace Med Assoc, 2003, AVIAT SPACE ENVIR MD, V74, pA1; *AIR MED PHYS ASS, 1999, AIR MED PHYS HDB, V7, P4; *AM AIRL, ACC PASS MISC MED CO; Andersson N, 2003, AVIAT SPACE ENVIR MD, V74, P138; [Anonymous], 2004, WORLD REP ROAD TRAFF; *ASS AIR MED SERV, ATL DAT AIR MED SERV; BENDRICK GA, 1995, AVIAT SPACE ENVIR MD, V66, P40; Buckland L, 2003, ARCH DIS CHILD-FETAL, V88, pF513, DOI 10.1136/fn.88.6.F513; Caldwell J A, 2001, Air Med J, V20, P25; Carey MJ, 1996, ANN EMERG MED, V28, P424, DOI 10.1016/S0196-0644(96)70009-4; Castillo CY, 1999, AVIAT SPACE ENVIR MD, V70, P103; *CDCP, QUEST ANSW EX ORD AD; Christopher GW, 1999, EMERG INFECT DIS, V5, P241, DOI 10.3201/eid0502.990208; Coker RK, 2002, THORAX, V57, P289; CRIPPEN D, 1990, AM J EMERG MED, V8, P551, DOI 10.1016/0735-6757(90)90163-T; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; *DEP STAT, 2005, US DEP STAT FOR AFF, V7; Dewhurst AT, 2001, ANAESTHESIA, V56, P882, DOI 10.1046/j.1365-2044.2001.02059-2.x; DILLARD TA, 1993, CHEST, V103, P422, DOI 10.1378/chest.103.2.422; Dinges DF, 1995, J SLEEP RES, V4, P4, DOI 10.1111/j.1365-2869.1995.tb00220.x; Edgington B H, 1992, J Air Med Transp, V11, P11, DOI 10.1016/S1046-9095(05)80058-3; Essebag V, 2003, CHEST, V124, P1937, DOI 10.1378/chest.124.5.1937; FLEETER JS, 1998, AC SOC AM 136 M NORF; *FLIGHT SAF FDN, INT NON SCHED PASS A; *FLIGHT SAF FDN, 2002, REP SHOW DIFF RESP I; Gilligan JE, 1999, MED J AUSTRALIA, V171, P617, DOI 10.5694/j.1326-5377.1999.tb123822.x; GONG H, 1992, CHEST, V101, P1104, DOI 10.1378/chest.101.4.1104; GORE JM, 1989, ARCH INTERN MED, V149, P353, DOI 10.1001/archinte.149.2.353; Grines CL, 2002, J AM COLL CARDIOL, V39, P1713, DOI 10.1016/S0735-1097(02)01870-3; Humphreys S, 2005, ANAESTHESIA, V60, P458, DOI 10.1111/j.1365-2044.2005.04124.x; *IATA, 2005, INT AIR TRANSP ASS P; JOHNSON A, 1977, AVIAT SPACE ENVIR MD, V48, P546; KAPLAN L, 1987, ANN EMERG MED, V16, P55, DOI 10.1016/S0196-0644(87)80287-1; Kashani KB, 2006, CURR OPIN CRIT CARE, V12, P43, DOI 10.1097/01.ccx.0000198057.35212.3e; KRAMER MR, 1995, CHEST, V108, P1292, DOI 10.1378/chest.108.5.1292; LAVERNHE JP, 1985, AVIAT SPACE ENVIR MD, V56, P367; Leggat PA, 2002, J TRAVEL MED, V9, P59, DOI 10.2310/7060.2002.21444; LYONS TJ, 1995, AVIAT SPACE ENVIR MD, V66, P927; Lyznicki JM, 2000, AVIAT SPACE ENVIR MD, V71, P827; MACDONALD E, 2002, AIR MED PHYS HDB S, P64; Maegele M, 2005, CRIT CARE MED, V33, P1136, DOI 10.1097/01.CCM.0000163269.42524.50; McInnes R, 2002, J TRAVEL MED, V9, P297, DOI 10.2310/7060.2002.30168; MELAMED Y, 1981, AVIAT SPACE ENVIR MD, V52, P480; Mortazavi A, 2003, AVIAT SPACE ENVIR MD, V74, P922; PARSONS CJ, 1982, CAN MED ASSOC J, V126, P237; Patel D, 2000, J TRAVEL MED, V7, P64; Schroder S, 2004, ANAESTHESIST, V53, P1093, DOI 10.1007/s00101-004-0748-3; Shelton S L, 2000, Prehosp Emerg Care, V4, P361, DOI 10.1080/10903120090941128; Shibolet O, 2005, LIVER TRANSPLANT, V11, P650, DOI 10.1002/lt.20399; Shirley PJ, 2000, HOSP MED, V61, P406, DOI 10.12968/hosp.2000.61.6.1356; Straumann E, 1999, HEART, V82, P415, DOI 10.1136/hrt.82.4.415; Thomson David P, 2003, Prehosp Emerg Care, V7, P265, DOI 10.1080/10903120390936923; VANN RD, 1993, AVIAT SPACE ENVIR MD, V64, P801; Veldman Alex, 2004, Air Med J, V23, P24, DOI 10.1016/j.amj.2003.12.009; VIELLETTE PR, 2001, FLIGHT SAFETY DI APR, P39; Wallace PGM, 1999, BRIT MED J, V319, P368, DOI 10.1136/bmj.319.7206.368; *WHO, WHO GLOB OUTBR AL RE; *WHO DEP COMM DIS, 2004, TRANSP INF SUBST; Wilde H, 2003, J TRAVEL MED, V10, P315; World Health Organization (WHO), 2005, INT TRAV HLTH; Wright MC, 2006, QUAL SAF HEALTH CARE, V15, P258, DOI 10.1136/qshc.2005.017566; 2006, UN AIRLINES CONTRACT	62	45	48	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2007	356	3					262	270		10.1056/NEJMra063651	http://dx.doi.org/10.1056/NEJMra063651			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126BV	17229953				2023-01-03	WOS:000243488100008
J	Newton, KM; Reed, SD; LaCroix, AZ; Grothaus, LC; Ehrlich, K; Guiltinan, J				Newton, Katherine M.; Reed, Susan D.; LaCroix, Andrea Z.; Grothaus, Louis C.; Ehrlich, Kelly; Guiltinan, Jane			Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							ESTROGEN PLUS PROGESTIN; QUALITY-OF-LIFE; CONTROLLED CLINICAL-TRIAL; HEALTH INITIATIVE MEMORY; POPULATION-BASED SURVEY; POSTMENOPAUSAL WOMEN; DOUBLE-BLIND; HOT FLUSHES; BREAST-CANCER; PERIMENOPAUSAL WOMEN	Background: Herbal supplements are widely used for vasomotor Symptoms. Objective: To test the efficacy of 3 herbal regimens and hormone therapy for relief of vasomotor symptoms compared with placebo. Design: 1-year randomized, double-blind, placebo-controlled trial conducted from May 2001 to September 2004. Setting: Group Health, Washington State. Participants: 351 women age 45 to 55 years with 2 or more vasomotor symptoms per day; 52% of the women were in menopausal transition and 48% were postmenopausal. Measurements: Rate and intensity of vasomotor symptoms (1 mild to 3 = severe), and Wiklund Vasomotor Symptom Subscale. Interventions: 1) Black cohosh, 160 mg daily; 2) multibotanical with black cohosh, 200 mg daily, and 9 other ingredients; 3) multibotanical plus dietary soy counseling; 4) conjugated equine estrogen, 0.625 mg daily, with or without medroxyprogesterone acetate, 2.5 mg daily; or 5) placebo. Results: Vasomotor symptoms per day, symptom intensity, Wiklund Vasomotor Symptom Subscale score did not differ between the herbal interventions and placebo at 3, 6, or 12 months or for the average over all the follow-up time points (P > 0.05 for all comparisons) with 1 exception: At 12 months, symptom intensity was significantly worse with the multibotanical plus soy intervention than with placebo (P = 0.016). The difference in vasomotor symptoms per day between placebo and any of the herbal treatments at any time point was less than 1 symptom per day; for the average over all the follow-up time points, the difference was less than 0.55 symptom per day. The difference for hormone therapy versus placebo was - 4.06 vasomotor symptoms per day for the average over all the follow-up time points (95% Cl, -5.93 to - 2.19 symptoms per day; P < 0.001). Limitations: The trial did not simulate the whole-person approach used by naturopathic physicians. Differences between treatment groups smaller than 1.5 Vasomotor symptoms per day cannot be ruled out. Conclusion: Black cohosh used in isolation, or as part of a multibotanical regimen, shows little potential as an important therapy for relief of vasomotor symptoms.	Univ Washington, Ctr Hlth Studies, Grp Hlth, Seattle, WA 98101 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Bastyr Univ, Kenmore, WA USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Newton, KM (corresponding author), Univ Washington, Ctr Hlth Studies, Grp Hlth, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.	newton.k@ghc.org		Reed, Susan/0000-0001-7532-3785	NIA NIH HHS [R01AG17057] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG017057] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albertazzi P, 1998, OBSTET GYNECOL, V91, P6, DOI 10.1016/S0029-7844(97)00597-8; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; BAIRD DD, 1995, J CLIN ENDOCR METAB, V80, P1685, DOI 10.1210/jc.80.5.1685; Beresford SAA, 2001, PREV MED, V32, P230, DOI 10.1006/pmed.2000.0806; Brzezinski A, 1997, MENOPAUSE, V4, P89; Burke GL, 2003, MENOPAUSE, V10, P147, DOI 10.1097/00042192-200310020-00006; Center for Drug Evaluation and Research, 2003, GUID IND ESTR ESTR P; Crisafulli A, 2004, MENOPAUSE, V11, P400, DOI 10.1097/01.GME.0000109314.11228.E5; Dalais F S, 1998, Climacteric, V1, P124, DOI 10.3109/13697139809085527; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Faure ED, 2002, MENOPAUSE, V9, P329, DOI 10.1097/00042192-200209000-00005; Frankenfeld CL, 2003, AM J CLIN NUTR, V77, P674, DOI 10.1093/ajcn/77.3.674; Frei-Kleiner S, 2005, MATURITAS, V51, P397, DOI 10.1016/j.maturitas.2004.10.003; Han KK, 2002, OBSTET GYNECOL, V99, P389, DOI 10.1016/S0029-7844(01)01744-6; Hirata JD, 1997, FERTIL STERIL, V68, P981, DOI 10.1016/S0015-0282(97)00397-X; Jacobson JS, 2001, J CLIN ONCOL, V19, P2739, DOI 10.1200/JCO.2001.19.10.2739; Keenan NL, 2003, MENOPAUSE, V10, P507, DOI 10.1097/01.GME.0000064865.58809.3E; MURKIES AL, 1995, MATURITAS, V21, P189, DOI 10.1016/0378-5122(95)00899-V; Newton KM, 2002, OBSTET GYNECOL, V100, P18, DOI 10.1016/S0029-7844(02)02005-7; Newton KM, 2005, MATURITAS, V52, P134, DOI 10.1016/j.maturitas.2005.01.007; Oldendick R, 2000, SOUTH MED J, V93, P375; Osmers R, 2005, OBSTET GYNECOL, V105, P1074, DOI 10.1097/01.AOG.0000158865.98070.89; Penotti M, 2003, FERTIL STERIL, V79, P1112, DOI 10.1016/S0015-0282(03)00158-4; Pockaj BA, 2006, J CLIN ONCOL, V24, P2836, DOI 10.1200/JCO.2005.05.4296; Quella SK, 2000, J CLIN ONCOL, V18, P1068, DOI 10.1200/JCO.2000.18.5.1068; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Scambia G, 2000, MENOPAUSE, V7, P105, DOI 10.1097/00042192-200007020-00006; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; St Germain A, 2001, MENOPAUSE, V8, P17, DOI 10.1097/00042192-200101000-00005; Stoll W., 1987, THERAPEUTIKON, V1, P23; U.S Food and Drug Administration (FDA) National Adverse Drug Reaction Directory, 1970, COSTART; Upmalis DH, 2000, MENOPAUSE, V7, P236, DOI 10.1097/00042192-200007040-00005; Van Patten CL, 2002, J CLIN ONCOL, V20, P1449, DOI 10.1200/JCO.20.6.1449; Verhoeven MO, 2005, MENOPAUSE, V12, P412, DOI 10.1097/01.gme.0000170603.63022.62; Washburn S, 1999, MENOPAUSE, V6, P7; WIKLUND I, 1991, CONTROL CLIN TRIALS, V12, pS204, DOI 10.1016/S0197-2456(05)80024-8; WIKLUND I, 1992, MATURITAS, V14, P211, DOI 10.1016/0378-5122(92)90116-L; Wiklund IK, 1999, INT J CLIN PHARM RES, V19, P89; Wuttke W, 2003, MATURITAS, V44, pS67, DOI 10.1016/S0378-5122(02)00350-X	40	198	208	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 19	2006	145	12					869	879		10.7326/0003-4819-145-12-200612190-00003	http://dx.doi.org/10.7326/0003-4819-145-12-200612190-00003			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	120BB	17179056	Green Published			2023-01-03	WOS:000243057400001
J	Boockvar, KS; Meier, DE				Boockvar, Kenneth S.; Meier, Diane E.			Palliative care for frail older adults - "There are things I can't do anymore that I wish I could ..."	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-LIFE CARE; INSTRUMENTAL ACTIVITIES; FUNCTIONAL DECLINE; PHYSICAL FRAILTY; CONTROLLED-TRIAL; WOMENS HEALTH; DOUBLE-BLIND; END; DISABILITY; HOSPICE	Frailty in older adults is increasingly a recognized syndrome of decline, sometimes subtle, in function and health that may be amenable to available approaches to care. Frailty manifests the following core clinical features: loss of strength, weight loss, low levels of activity, poor endurance or fatigue, and slowed performance. The presence of 3 or more of these features is associated with adverse outcomes including falls, new or worsened function impairment, hospitalization, and death. In this article, we use the case of Mrs K to describe the challenges of recognizing frailty in clinical practice, common problems and symptoms that frail older adults experience, and approaches to these issues that clinicians may incorporate into their practices. We discuss the importance of advance care planning, provider-patient communication, and appropriate palliative care and hospice referral for frail older adults. Frailty is associated with symptomatic long-term disease, decline in function, and abbreviated survival. Therefore, when frailty is severe, delivery of palliative care focused on relief of discomfort and enhancement of quality of life is highly appropriate. The application of multidisciplinary, team-based palliative approaches and of up-to-date geriatrics knowledge is beneficial for treating these patients because of the complexity of their coexisting social, psychological, and medical needs.	James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA; CUNY Mt Sinai Sch Med, New York, NY 10029 USA; Jewish Home & Hosp, New York, NY USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Boockvar, KS (corresponding author), James J Peters Vet Affairs Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.	kenneth.boockvar@mssm.edu	Boockvar, Kenneth S./H-9259-2019	Boockvar, Kenneth/0000-0003-1165-5558				Agency for Healthcare Research and Quality Centers for Disease Control, PHYS ACT OLD AM BEN; Bandeen-Roche K, 2006, J GERONTOL A-BIOL, V61, P262, DOI 10.1093/gerona/61.3.262; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; Block SD, 2006, J PALLIAT MED, V9, P751, DOI 10.1089/jpm.2006.9.751; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Boockvar K, 2004, ARCH INTERN MED, V164, P545, DOI 10.1001/archinte.164.5.545; Bookbinder M, 1996, J PAIN SYMPTOM MANAG, V12, P334, DOI 10.1016/S0885-3924(96)00204-7; Cappola AR, 2001, J CLIN ENDOCR METAB, V86, P4139, DOI 10.1210/jc.86.9.4139; Christakis NA, 2003, SOC SCI MED, V57, P465, DOI 10.1016/S0277-9536(02)00370-2; Cohen HJ, 1997, J GERONTOL A-BIOL, V52, pM201, DOI 10.1093/gerona/52A.4.M201; Cohen HJ, 2002, NEW ENGL J MED, V346, P905, DOI 10.1056/NEJMsa010285; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Crotty Maria, 2004, Am J Geriatr Pharmacother, V2, P257, DOI 10.1016/j.amjopharm.2005.01.001; *CTR ADV PALL CAR, AB US; Doyle D, 1998, OXFORD TXB PALLIATIV; Emanuel EJ, 1999, NEW ENGL J MED, V341, P956, DOI 10.1056/NEJM199909233411306; Emanuel EJ, 2000, ANN INTERN MED, V132, P451, DOI 10.7326/0003-4819-132-6-200003210-00005; Ensrud KE, 2002, J AM GERIATR SOC, V50, P1629, DOI 10.1046/j.1532-5415.2002.50453.x; Ferrell B, 2002, J AM GERIATR SOC, V50, pS205, DOI 10.1046/j.1532-5415.50.6s.1.x; Ferrell BA, 2000, CLIN GERIATR MED, V16, P853, DOI 10.1016/S0749-0690(05)70048-3; Ferrucci L, 2004, J AM GERIATR SOC, V52, P625, DOI 10.1111/j.1532-5415.2004.52174.x; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; Finlay IG, 2002, ANN ONCOL, V13, P257, DOI 10.1093/annonc/mdf668; Flint AJ, 1998, DRUG AGING, V13, P269, DOI 10.2165/00002512-199813040-00003; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Fried LP, 2004, J GERONTOL A-BIOL, V59, P255; Guideline for the prevention of falls in older persons, 2001, J AM GERIATR SOC, V49, P664, DOI DOI 10.1046/J.1532-5415.2001.49115.X; Hanlon JT, 2001, J AM GERIATR SOC, V49, P200, DOI 10.1046/j.1532-5415.2001.49042.x; Hardy SE, 2004, JAMA-J AM MED ASSOC, V291, P1596, DOI 10.1001/jama.291.13.1596; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; Jones DM, 2004, J AM GERIATR SOC, V52, P1929, DOI 10.1111/j.1532-5415.2004.52521.x; Larsson L, 2000, DRUG AGING, V17, P303, DOI 10.2165/00002512-200017040-00006; Latham N.K., 2003, COCHRANE DB SYST REV, V2; Latham NK, 2003, J AM GERIATR SOC, V51, P291, DOI 10.1046/j.1532-5415.2003.51101.x; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Lee SJ, 2006, JAMA-J AM MED ASSOC, V295, P801, DOI 10.1001/jama.295.7.801; Lorenz KA, 2004, J AM GERIATR SOC, V52, P725, DOI 10.1111/j.1532-5415.2004.52209.x; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; Mackin RS, 2005, PSYCHIAT CLIN N AM, V28, P805, DOI 10.1016/j.psc.2005.09.009; Manfredi PL, 2000, J PAIN SYMPTOM MANAG, V20, P166, DOI 10.1016/S0885-3924(00)00163-9; Marchandin H, 2001, PATHOL BIOL, V49, P522, DOI 10.1016/S0369-8114(01)00212-7; Miller SC, 2003, J PAIN SYMPTOM MANAG, V26, P791, DOI 10.1016/S0885-3924(03)00284-7; Milne AC, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003288.pub2; Morley JE, 1997, CLIN GERIATR MED, V13, P685, DOI 10.1016/s0749-0690(18)30144-7; Morrison RS, 2004, NEW ENGL J MED, V350, P2582, DOI 10.1056/NEJMcp035232; Morrison RS, 2003, PAIN, V103, P303, DOI 10.1016/S0304-3959(02)00458-X; Morrison RS., 2003, GERIATRIC PALLIATIVE, V1st; Mottram P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003491.pub2; MULROW CD, 1994, JAMA-J AM MED ASSOC, V271, P519, DOI 10.1001/jama.271.7.519; *NAT COMPR CANC NE, GUID SUPP CAR PALL C; *NAT HOSP PALL CAR, 1996, MED GUID DET PROGN S; Nourhashemi F, 2001, J GERONTOL A-BIOL, V56, pM448, DOI 10.1093/gerona/56.7.M448; Pantilat SZ, 2004, JAMA-J AM MED ASSOC, V291, P2476, DOI 10.1001/jama.291.20.2476; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Rabow MW, 2004, JAMA-J AM MED ASSOC, V291, P483, DOI 10.1001/jama.291.4.483; Reuben DB, 2005, J AM GERIATR SOC, V53, P970, DOI 10.1111/j.1532-5415.2005.53307.x; Reuben DB, 2006, GERIATRICS YOUR FING; Saliba D, 2001, J AM GERIATR SOC, V49, P1691, DOI 10.1046/j.1532-5415.2001.49281.x; Sarkisian CA, 2001, J AM GERIATR SOC, V49, P134, DOI 10.1046/j.1532-5415.2001.49033.x; Schatzberg AF, 2002, AM J GERIAT PSYCHIAT, V10, P541, DOI 10.1176/appi.ajgp.10.5.541; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; Shanmugham B, 2005, PSYCHIAT CLIN N AM, V28, P821, DOI 10.1016/j.psc.2005.09.012; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Smith Thomas J, 2003, J Palliat Med, V6, P699, DOI 10.1089/109662103322515202; Snyder PJ, 2004, NEW ENGL J MED, V350, P440, DOI 10.1056/NEJMp038207; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; STUCK AE, 1995, NEW ENGL J MED, V333, P1184, DOI 10.1056/NEJM199511023331805; Studenski S, 2004, J AM GERIATR SOC, V52, P1560, DOI 10.1111/j.1532-5415.2004.52423.x; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Walston J, 2002, ARCH INTERN MED, V162, P2333, DOI 10.1001/archinte.162.20.2333; WALSTON JD, 2003, GERIATRIC PALLIATIVE; Williamson JD, 1996, J AM GERIATR SOC, V44, P1429, DOI 10.1111/j.1532-5415.1996.tb04066.x; Wolf SL, 2003, J AM GERIATR SOC, V51, P1693, DOI 10.1046/j.1532-5415.2003.51552.x; Woods NF, 2005, J AM GERIATR SOC, V53, P1321, DOI 10.1111/j.1532-5415.2005.53405.x; Yeh SS, 2000, J AM GERIATR SOC, V48, P485, DOI 10.1111/j.1532-5415.2000.tb04993.x	77	65	66	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	2006	296	18					2245	2253		10.1001/jama.296.18.2245	http://dx.doi.org/10.1001/jama.296.18.2245			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	102QM	17090771				2023-01-03	WOS:000241827700025
J	Mermin, J; Were, W; Ekwaru, JP; Moore, D; Downing, R; Behumbiize, P; Lule, JR; Coutinho, A; Tappero, J; Bunnell, R				Mermin, Jonathan; Were, Willy; Ekwaru, John Paul; Moore, David; Downing, Robert; Behumbiize, Prosper; Lule, John R.; Coutinho, Alex; Tappero, Jordan; Bunnell, Rebecca			Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study	LANCET			English	Article							SUB-SAHARAN AFRICA; COTRIMOXAZOLE PROPHYLAXIS; GENDER-DIFFERENCES; THERAPY; AIDS; PROGRESSION; LESSONS	Background Antiretroviral therapy (ART) is increasingly available in Africa, but physicians and clinical services are few. We therefore assessed the effect of a home-based ART programme in Uganda on mortality, hospital admissions, and orphanhood in people with HIV-1 and their household members. Methods In 2001, we enrolled and followed up 466 HIV-infected adults and 1481 HIV-uninfected household members in a prospective cohort study. After 5 months, we provided daily co-trimoxazole (160 mg trimethoprim and 800 mg sulfamethoxazole) prophylaxis to HIV-infected participants. Between May, 2003, and December, 2005, we followed up 138 infected adults who were eligible and 907 new HIV-infected participants and their HIV-negative household members in a study of ART (mainly stavudine, lamivudine, and nevirapine). Households were visited every week by lay providers, and no dinic visits were scheduled after enrolment. We compared rates of death, hospitalisation, and orphanhood during diffierent study periods and calculated the number needed to treat to prevent an outcome. Findings 233 (17%) of 1373 participants with HIV and 40 (1%) of 4601 HIV-uninfected household members died. During the first 16 weeks of ART and co-trimoxazole, mortality in HIV-infected participants was 55% lower than that during co-trimoxazole alone (14 vs 16 deaths per 100 person-years; adjusted hazard ratio 0 . 45, 95% CI 0 . 27-0.74, p=0.0018), and after 16 weeks, was reduced by 92% (3 vs 16 deaths per 100 person-years; 0 . 08, 0.06-0.13, p<0.0001). Compared with no intervention, ART and co-trimoxazole were associated with a 95% reduction in mortality in HIV-indected participants (5 vs 27 deaths per 100 person-years; 0.05, 0.03-0.08, p<0.0001), 81% reduction in mortality in their uninfected children younger than 10 years (0 . 2 vs 1 . 2 deaths per 100 person-years; 0 . 19, 0.06-0.59, p=0.004), and a 93% estimated reduction in orphanhood (0 . 9 vs 12.8 per 100 person-years of adults treated; 0.07, 0.04-0 . 13, p<0 . 0001). Interpretation Expansion of access to ART and co-trimoxazole prophylaxis could substantially reduce mortality and orphanhood among adults with HIV and their families living in resource-poor settings.	[Mermin, Jonathan] Kenya Govt Med Res Ctr, Ctr Dis Control & Prevent Kenya, Coordinating Off Global Hlth, Nairobi, Kenya; [Mermin, Jonathan; Were, Willy; Ekwaru, John Paul; Moore, David; Downing, Robert; Behumbiize, Prosper; Lule, John R.; Tappero, Jordan; Bunnell, Rebecca] Ctr Dis Control & Prevent Uganda, Global AIDS Program, Natl Ctr HIV Viral Hepatitis Sexually Transmitted, Entebbe, Uganda; [Moore, David] Univ British Columbia, Fac Med, Dept Med, Vancouver, BC V5Z 1M9, Canada; [Coutinho, Alex] AIDS Support Org, Kampala, Uganda	Kenya Medical Research Institute; University of British Columbia	Mermin, J (corresponding author), Kenya Govt Med Res Ctr, Ctr Dis Control & Prevent Kenya, Coordinating Off Global Hlth, Mbagathi Rd, Nairobi, Kenya.	jhm7@cdc.gov	Mermin, Jonathan/J-9847-2012					Akileswaran C, 2005, CLIN INFECT DIS, V41, P376, DOI 10.1086/431482; Altman DG, 1999, BRIT MED J, V319, P1492, DOI 10.1136/bmj.319.7223.1492; Badri M, 2004, AIDS, V18, P1159, DOI 10.1097/00002030-200405210-00009; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; Braga P, 2007, AIDS PATIENT CARE ST, V21, P321, DOI 10.1089/apc.2006.0111; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Calmy A, 2004, AIDS, V18, P2353; Colebunders R, 2005, PLOS MED, V2, P941, DOI 10.1371/journal.pmed.0020276; El-Ghannam Ashraf Ragab, 2003, J Health Soc Policy, V16, P1, DOI 10.1300/J045v16n04_01; Hilbe J., 2003, GEN ESTIMATING EQUAT; IWASA S, PLANNING HLTH INFRAS; Kober K, 2004, LANCET, V364, P103, DOI 10.1016/S0140-6736(04)16597-5; Laurent C, 2005, CLIN INFECT DIS, V41, P108, DOI 10.1086/430712; Losina E, 2007, ANTIVIR THER, V12, P543; Lule JR, 2005, AM J TROP MED HYG, V73, P926, DOI 10.4269/ajtmh.2005.73.926; Mermin J, 2006, LANCET, V367, P1256, DOI 10.1016/S0140-6736(06)68541-3; Mermin J, 2005, AIDS, V19, P1035, DOI 10.1097/01.aids.0000174449.32756.c7; Miles K, 2007, B WORLD HEALTH ORGAN, V85, P555, DOI 10.2471/BLT.06.033076; Nduati R, 2001, LANCET, V357, P1651, DOI 10.1016/S0140-6736(00)04820-0; Nicastri E, 2005, AIDS, V19, P577, DOI 10.1097/01.aids.0000163934.22273.06; PAPPAS G, 2006, AIDS PUBLIC POLICY J, V19, P75; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Samb B, 2007, NEW ENGL J MED, V357, P2510, DOI 10.1056/NEJMsb071889; Severe P, 2005, NEW ENGL J MED, V353, P2325, DOI 10.1056/NEJMoa051908; Spacek LA, 2006, CLIN INFECT DIS, V42, P252, DOI 10.1086/499044; Sterne JAC, 2005, LANCET, V366, P378, DOI 10.1016/S0140-6736(05)67022-5; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; van Oosterhout JJ, 2005, TROP MED INT HEALTH, V10, P464, DOI 10.1111/j.1365-3156.2005.01409.x; Walker AS, 2007, CLIN INFECT DIS, V44, P1361, DOI 10.1086/515396; Weidle PJ, 2006, LANCET, V368, P1587, DOI 10.1016/S0140-6736(06)69118-6; WHO, WORK TOG HLTH WORLD; *WHO UNAIDS, AIDS EP UPD 2006; Wools-Kaloustian K, 2006, AIDS, V20, P41, DOI 10.1097/01.aids.0000196177.65551.ea	33	144	149	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 1	2008	371	9614					752	759		10.1016/S0140-6736(08)60345-1	http://dx.doi.org/10.1016/S0140-6736(08)60345-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	268RI	18313504				2023-01-03	WOS:000253596700029
J	Vermorken, JB; Remenar, E; van Herpen, C; Gorlia, T; Mesia, R; Degardin, M; Stewart, JS; Jelic, S; Betka, J; Preiss, JH; van den Weyngaert, D; Awada, A; Cupissol, D; Kienzer, HR; Rey, A; Desaunois, I; Bernier, J; Lefebvre, JL				Vermorken, Jan B.; Remenar, Eva; van Herpen, Carla; Gorlia, Thierry; Mesia, Ricard; Degardin, Marian; Stewart, John S.; Jelic, Svetislav; Betka, Jan; Preiss, Joachim H.; van den Weyngaert, Danielle; Awada, Ahmad; Cupissol, Didier; Kienzer, Heinz R.; Rey, Augustin; Desaunois, Isabelle; Bernier, Jacques; Lefebvre, Jean-Louis		EORTC 24971 TAX 323 Stu	Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; PHASE-III TRIAL; NEOADJUVANT CHEMOTHERAPY; ACCELERATED RADIOTHERAPY; INDUCTION CHEMOTHERAPY; SURVIVAL; THERAPY; CHEMORADIOTHERAPY; MANAGEMENT	Background Phase 2 studies suggest that the standard regimen of cisplatin and fluorouracil (PF) plus docetaxel (TPF) improves outcomes in squamous-cell carcinoma of the head and neck. We compared TPF with PF as induction chemotherapy in patients with locoregionally advanced, unresectable disease. Methods We randomly assigned eligible patients between the ages of 18 and 70 years who had stage III or stage IV disease and no distant metastases to receive either TPF (docetaxel and cisplatin, day 1; fluorouracil by continuous infusion, days 1 to 5) or PF every 3 weeks for four cycles. Patients without progression of disease received radiotherapy within 4 to 7 weeks after completing chemotherapy. The primary end point was progression-free survival. Results A total of 358 patients underwent randomization, with 177 assigned to the TPF group and 181 to the PF group. At a median follow-up of 32.5 months, the median progression-free survival was 11.0 months in the TPF group and 8.2 months in the PF group (hazard ratio for disease progression or death in the TPF group, 0.72; P = 0.007). Treatment with TPF resulted in a reduction in the risk of death of 27% (P = 0.02), with a median overall survival of 18.8 months, as compared with 14.5 months in the PF group. There were more grade 3 or 4 events of leukopenia and neutropenia in the TPF group and more grade 3 or 4 events of thrombocytopenia, nausea, vomiting, stomatitis, and hearing loss in the PF group. The rates of death from toxic effects were 2.3% in the TPF group and 5.5% in the PF group. Conclusions As compared with the standard regimen of cisplatin and fluorouracil, induction chemotherapy with the addition of docetaxel significantly improved progression-free and overall survival in patients with unresectable squamous-cell carcinoma of the head and neck.	Univ Ziekenhuis Antwerpen, Dept Med Oncol, B-2650 Edegem, Belgium; Natl Inst Oncol, Budapest, Hungary; Univ Med Ctr Nijmegen, Nijmegen, Netherlands; EORTC Data Ctr, Brussels, Belgium; Inst Catala Oncol, Barcelona, Spain; Ctr Oscar Lambret, F-59020 Lille, France; Charing Cross Hosp, London, England; Inst Oncol & Radiol, Belgrade, Serbia; Univ Hosp Motol, Prague, Czech Republic; Caritasklin St Theresia, Saarbrucken, Germany; Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium; Inst Jules Bordet, B-1000 Brussels, Belgium; Ctr Reg Lutte Contre Canc Val Aurelle, Montpellier, France; Kaiser Franz Josef Spital, Vienna, Austria; Sanofi Aventis Global Oncol, Paris, France; Clin Genolier, Genolier, Switzerland	University of Antwerp; National Institute of Oncology Hungary; Radboud University Nijmegen; European Organisation for Research & Treatment of Cancer; Catalan Institute of Oncology; UNICANCER; Centre Oscar Lambret; Imperial College London; Institute for Oncology & Radiology of Serbia (IORS); Motol University Hospital; Institut Jules Bordet; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Kaiser-Franz-Josef Hospital; Sanofi-Aventis; Sanofi France; Clinique de Genolier	Vermorken, JB (corresponding author), Univ Ziekenhuis Antwerpen, Dept Med Oncol, Wilrijkstr 10, B-2650 Edegem, Belgium.	jan.b.vermorken@uza.be	AWADA, AHMAD/ABF-1137-2020; van Herpen, Carla/N-3576-2014; Bernier, Jacques/AAE-7248-2020; Betka, Jan/H-7497-2017	Bernier, Jacques/0000-0002-0138-9906; Betka, Jan/0000-0001-8772-317X				Adelstein DJ, 2006, J CLIN ONCOL, V24, P2624, DOI 10.1200/JCO.2005.05.3629; Adelstein DJ, 2003, J CLIN ONCOL, V21, P92, DOI 10.1200/JCO.2003.01.008; Beauchesne PD, 2006, J CLIN ONCOL, V24, p75S; Bourhis J, 2006, LANCET, V368, P843, DOI 10.1016/S0140-6736(06)69121-6; Budach W, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-28; DIMERY IW, 1993, JNCI-J NATL CANCER I, V85, P95, DOI 10.1093/jnci/85.2.95; Domenge C, 2000, BRIT J CANCER, V83, P1594, DOI 10.1054/bjoc.2000.1512; FREEDMAN LS, 1976, BIOMETRICS, V32, P691, DOI 10.2307/2529759; Hitt R, 2005, J CLIN ONCOL, V23, P8636, DOI 10.1200/JCO.2004.00.1990; HITT R, 2006, J CLIN ONCOL, V24, P1015; HITT R, 2006, J CLIN ONCOL, V24, pS18; LEFEBVRE JL, 2005, ANN ONCOL S, V16, P7; PACCAGNELLA A, 1994, J NATL CANCER I, V86, P265, DOI 10.1093/jnci/86.4.265; PACCAGNELLA A, 2006, J CLIN ONCOL, V24, pS18; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Pignon JP, 2004, ANTI-CANCER DRUG, V15, P331, DOI 10.1097/00001813-200404000-00004; Posner MR, 2007, NEW ENGL J MED, V357, P1705, DOI 10.1056/NEJMoa070956; Posner MR, 2005, ONCOLOGIST, V10, P11, DOI 10.1634/theoncologist.10-90003-11; ROONEY M, 1985, CANCER, V55, P1123, DOI 10.1002/1097-0142(19850301)55:5<1123::AID-CNCR2820550530>3.0.CO;2-8; Schrijvers D, 2004, ANN ONCOL, V15, P638, DOI 10.1093/annonc/mdh145; Schrijvers D, 2000, Oncologist, V5, P199, DOI 10.1634/theoncologist.5-3-199; Seiwert TY, 2005, BRIT J CANCER, V92, P1341, DOI 10.1038/sj.bjc.6602510; SLUD EV, 1984, BIOMETRICS, V40, P587, DOI 10.2307/2530903; Zorat PL, 2004, JNCI-J NATL CANCER I, V96, P1714, DOI 10.1093/jnci/djh306	25	1181	1248	0	44	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 25	2007	357	17					1695	1704		10.1056/NEJMoa071028	http://dx.doi.org/10.1056/NEJMoa071028			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223FN	17960012	Green Published			2023-01-03	WOS:000250355100005
J	Page, L; Drife, J				Page, Lesley; Drife, Jim			Do we have enough evidence to judge midwife led maternity units safe?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Kings Coll London, Florence Nightingale Sch Nursing & Midwifery, London SE1 9NH, England	University of London; King's College London	Page, L (corresponding author), Kings Coll London, Florence Nightingale Sch Nursing & Midwifery, London SE1 9NH, England.	Lesley.page@kcl.ac.uk							0	2	2	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	SEP 29	2007	335	7621					642	643		10.1136/bmj.39343.471227.AD	http://dx.doi.org/10.1136/bmj.39343.471227.AD			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	218AY	17901510	Green Published			2023-01-03	WOS:000249989600034
J	Seymour, MT; Maughan, TS; Ledermann, JA; Topham, C; James, R; Gwyther, SJ; Smith, DB; Shepherd, S; Maraveyas, A; Ferry, DR; Meade, AM; Thompson, L; Griffiths, GO; Parmar, MKB; Stephens, RJ				Seymour, Matthew T.; Maughan, Timothy S.; Ledermann, Jonathan A.; Topham, Clare; James, Roger; Gwyther, Stephen J.; Smith, David B.; Shepherd, Stephen; Maraveyas, Anthony; Ferry, David R.; Meade, Angela M.; Thompson, Lindsay; Griffiths, Gareth O.; Parmar, Mahesh K. B.; Stephens, Richard J.		FOCUS Trial Investigators; Nat Canc Res Inst Colorectal Clin	Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial	LANCET			English	Article							FLUOROURACIL-LEUCOVORIN; 1ST-LINE TREATMENT; CONTINUOUS-INFUSION; PLUS IRINOTECAN; FOLINIC ACID; PHASE-II; OXALIPLATIN; BOLUS; 5-FLUOROURACIL; SURVIVAL	Background In the non-curative setting, the sequence in which anticancer agents are used, singly or in combination, may be important if patients are to receive the maximum period of disease control with the minimum of adverse effects. We compared sequential and combination chemotherapy strategies in patients with unpretreated advanced or metastatic colorectal cancer, who were regarded as not potentially curable irrespective of response. Methods We studied patients with advanced colorectal cancer, starting treatment with non-curative intent. 2135 unpretreated patients were randomly assigned to three treatment strategies in the ratio 1:1:1. Strategy A (control group) was single-agent fluorouracil (given with levofolinate over 48 h every 2 weeks) until failure, then single-agent irinotecan. Strategy B was fluorouracil until failure, then combination chemotherapy. Strategy C was combination chemotherapy from the outset. Within strategies B and Q patients were randomly assigned to receive, as the combination regimen, fluorouracil plus irinotecan (groups B-ir and C-ir) or fluorouracil plus oxaliplatin (groups B-ox and C-ox). The primary endpoint was overall survival, analysed by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN 79877428. Results Median survival of patients allocated to control strategy A was 13.9 months. Median survival of each of the other groups was longer (B-ir 15.0, B-ox 15.2, C-ir 16.7, and C-ox 15.4 months). However, log-rank comparison of each group against control showed that only C-ir - the first-line combination strategy including irinotecan-satisfied the statistical test for superiority (p=0.01). Overall comparison of strategy B with strategy C was within the predetermined non-inferiority boundary of HR=1.18 or less (HR=1.06, 90% CI 0.97-1.17). Interpretation Our data challenge the assumption that, in this non-curative setting, maximum tolerable treatment must necessarily be used first-line. The staged approach of initial single-agent treatment upgraded to combination when required is not worse than first-line combination, and is an alternative option for discussion with patients.	Cookridge Hosp, Gastrointestinal Canc Res Unit, Leeds LS16 6QB, W Yorkshire, England; Velindre Hosp, Cardiff, S Glam, Wales; UCL Hosp, London, England; St Lukes Canc Ctr, Guildford, Surrey, England; Mid Kent Oncol Ctr, Maidstone, Kent, England; E Surrey Hosp, Redhill, Surrey, England; Clatterbridge Ctr Oncol, Wirral, Merseyside, England; Cheltenham Gen Hosp, Cheltenham, Glos, England; Princess Royal Hosp, Kingston Upon Hull, N Humberside, England; New Cross Hosp, Wolverhampton, W Midlands, England; MRC, Clin Trials Unit, London, England	Cookridge Hospital; Velindre Hospital; University College London Hospitals NHS Foundation Trust; University of London; University College London; East Surrey Hospital; Clatterbridge Cancer Centre; Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General Hospital; New Cross Hospital; Medical Research Council Clinical Trials Unit	Seymour, MT (corresponding author), Cookridge Hosp, Gastrointestinal Canc Res Unit, Leeds LS16 6QB, W Yorkshire, England.	matt.seymour@leedsth.nhs.uk	Maughan, Tim/AAV-7636-2021; Maraveyas, Anthony/GXH-7747-2022	Seymour, Matthew/0000-0002-2441-9629; Griffiths, Gareth/0000-0002-9579-8021	MRC [MC_U122861325] Funding Source: UKRI; Medical Research Council [MC_U122861325] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; BRAUN MS, 2006, J CLIN ONCOL S, V24, P10009; Burge ME, 2006, BRIT J CANCER, V94, P1281, DOI 10.1038/sj.bjc.6603084; Cao SS, 2000, CANCER RES, V60, P3717; Cheeseman SL, 2002, BRIT J CANCER, V87, P393, DOI 10.1038/sj.bjc.6600467; Chester JD, 2000, ANN ONCOL, V11, P235, DOI 10.1023/A:1008356017611; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; deGramont A, 1997, J CLIN ONCOL, V15, P808, DOI 10.1200/JCO.1997.15.2.808; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Fischel JL, 1998, CLIN CANCER RES, V4, P2529; Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136; Giacchetti S, 1999, ANN ONCOL, V10, P663, DOI 10.1023/A:1008347829017; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; Grothey A, 2004, J CLIN ONCOL, V22, P1209, DOI 10.1200/JCO.2004.11.037; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Hurwitz HI, 2005, J CLIN ONCOL, V23, P3502, DOI 10.1200/JCO.2005.10.017; Leonard P, 2002, BRIT J CANCER, V87, P1216, DOI 10.1038/sj.bjc.6600641; Maughan TS, 2003, LANCET, V361, P457, DOI 10.1016/S0140-6736(03)12461-0; *MED RES COUNC, 2005, MRC GOOD RES PRACT; *NAT I CLIN EXC, 2002, 33 NAT I CLIN EXC; PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896; PLUZANSKA A, 2005, J CLIN ONCOL, V23, P3517; Rothenberg ML, 2003, J CLIN ONCOL, V21, P2059, DOI 10.1200/JCO.2003.11.126; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; *WHO INT AG RES CA, GLOBOCAN 2002; Wolmark N, 1998, J CLIN ONCOL, V16, P301; World Health Organization, 1979, WHO HDB REP RES CANC; 2007, LANCET, V370, P135	32	445	459	1	32	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 14	2007	370	9582					143	152		10.1016/S0140-6736(07)61087-3	http://dx.doi.org/10.1016/S0140-6736(07)61087-3			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	190WP	17630037				2023-01-03	WOS:000248091600028
J	Wilcken, N; Stockler, M				Wilcken, Nicholas; Stockler, Martin			Ovarian suppression for early breast cancer	LANCET			English	Editorial Material							ADJUVANT ENDOCRINE THERAPY; PATIENTS PREFERENCES; WOMEN		Westmead & Nepean Hosp, Dept Med Oncol, Westmead, NSW 2145, Australia; Univ Sydney, Natl Hlth & Med Res Council Clin Trials Ctr, Westmead, NSW 2145, Australia; Royal Prince Alfred Hosp, Sydney Canc Ctr, Sydney, NSW, Australia; Concord Hosp, Sydney Canc Ctr, Sydney, NSW, Australia	Nepean Hospital; University of Sydney; University of Sydney; Concord Repatriation General Hospital; University of Sydney	Wilcken, N (corresponding author), Westmead & Nepean Hosp, Dept Med Oncol, Westmead, NSW 2145, Australia.	nicholas_wilcken@wmi.usyd.edu.au	Stockler, Martin R/N-3859-2016	Stockler, Martin R/0000-0003-3793-8724				Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; Cuzick J, 2007, LANCET, V369, P1711; Dellapasqua S, 2005, J CLIN ONCOL, V23, P1736, DOI 10.1200/JCO.2005.11.050; Duric VM, 2005, BRIT J CANCER, V93, P1319, DOI 10.1038/sj.bjc.6602874; Duric VM, 2005, ANN ONCOL, V16, P1786, DOI 10.1093/annonc/mdi370; Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312; Thewes B, 2005, LANCET ONCOL, V6, P581, DOI 10.1016/S1470-2045(05)70254-0	8	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 20	2007	369	9574					1668	1670		10.1016/S0140-6736(07)60758-2	http://dx.doi.org/10.1016/S0140-6736(07)60758-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	169ZT	17512837				2023-01-03	WOS:000246631300005
J	van der Heide, A; Onwuteaka-Philipsen, BD; Rurup, ML; Buiting, HM; van Delden, JJM; Hanssen-de Wolf, JE; Janssen, AGJM; Pasman, HRW; Rietjens, JAC; Prins, CJM; Deerenberg, IM; Gevers, JKM; van der Maas, PJ; van der Wal, G				van der Heide, Agnes; Onwuteaka-Philipsen, Bregje D.; Rurup, Mette L.; Buiting, Hilde M.; van Delden, Johannes J. M.; Hanssen-de Wolf, Johanna E.; Janssen, Anke G. J. M.; Pasman, H. Roeline W.; Rietjens, Judith A. C.; Prins, Cornelis J. M.; Deerenberg, Ingeborg M.; Gevers, Joseph K. M.; van der Maas, Paul J.; van der Wal, Gerrit			End-of-life practices in the Netherlands under The Euthanasia Act	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERMINAL SEDATION; DECISION-MAKING; DEATH; EXPERIENCES; BELGIUM; OPIOIDS; CARE	BACKGROUND: In 2002, an act regulating the ending of life by a physician at the request of a patient with unbearable suffering came into effect in the Netherlands. In 2005, we performed a follow-up study of euthanasia, physician-assisted suicide, and other end-of-life practices. METHODS: We mailed questionnaires to physicians attending 6860 deaths that were identified from death certificates. The response rate was 77.8%. RESULTS: In 2005, of all deaths in the Netherlands, 1.7% were the result of euthanasia and 0.1% were the result of physician-assisted suicide. These percentages were significantly lower than those in 2001, when 2.6% of all deaths resulted from euthanasia and 0.2% from assisted suicide. Of all deaths, 0.4% were the result of the ending of life without an explicit request by the patient. Continuous deep sedation was used in conjunction with possible hastening of death in 7.1% of all deaths in 2005, significantly increased from 5.6% in 2001. In 73.9% of all cases of euthanasia or assisted suicide in 2005, life was ended with the use of neuromuscular relaxants or barbiturates; opioids were used in 16.2% of cases. In 2005, 80.2% of all cases of euthanasia or assisted suicide were reported. Physicians were most likely to report their end-of-life practices if they considered them to be an act of euthanasia or assisted suicide, which was rarely true when opioids were used. CONCLUSIONS: The Dutch Euthanasia Act was followed by a modest decrease in the rates of euthanasia and physician-assisted suicide. The decrease may have resulted from the increased application of other end-of-life care interventions, such as palliative sedation.	Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; Univ Med Ctr, Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; Stat Netherlands, Voorburg, Netherlands	Erasmus University Rotterdam; Erasmus MC; Vrije Universiteit Amsterdam; Utrecht University; Utrecht University Medical Center; University of Amsterdam; Academic Medical Center Amsterdam	van der Heide, A (corresponding author), Erasmus MC, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands.	a.vanderheide@erasmusmc.nl						[Anonymous], 1993, HIST PUBLIC HLTH; Bercovitch M, 2004, CANCER-AM CANCER SOC, V101, P1473, DOI 10.1002/cncr.20485; Blank RH, 2005, END OF LIFE DECISION; Deliens L, 2003, LANCET, V362, P1239, DOI 10.1016/S0140-6736(03)14520-5; Deliens L, 2000, LANCET, V356, P1806, DOI 10.1016/S0140-6736(00)03233-5; den Hartogh G, 2003, MED CONTACT, V58, P1063; Drazen JM, 2003, NEW ENGL J MED, V349, P1109, DOI 10.1056/NEJMp038146; FOLEYY K, 2002, CASE ASSISTED SUICID; Ganzini L, 2000, NEW ENGL J MED, V342, P1538; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Ganzini L, 2002, NEW ENGL J MED, V347, P582, DOI 10.1056/NEJMsa020562; Morita T, 2001, J PAIN SYMPTOM MANAG, V21, P282, DOI 10.1016/S0885-3924(01)00258-5; Murray SA, 2005, BRIT MED J, V330, P611, DOI 10.1136/bmj.330.7492.611; Onwuteaka-Philipsen BD, 2005, BMJ-BRIT MED J, V331, P1065; Onwuteaka-Philipsen BD, 2003, LANCET, V362, P395, DOI 10.1016/S0140-6736(03)14029-9; Quill T.E., 2004, PHYS ASSISTED DYING; Quill TE, 2004, NEW ENGL J MED, V350, P2029, DOI 10.1056/NEJMp038216; Rietjens JAC, 2006, ARCH INTERN MED, V166, P749, DOI 10.1001/archinte.166.7.749; Rietjens JAC, 2004, ANN INTERN MED, V141, P178, DOI 10.7326/0003-4819-141-3-200408030-00006; Rurup M L, 2006, Ned Tijdschr Geneeskd, V150, P618; *STAT COMM EUTH, 1985, REP EUTH; Sykes N, 2003, LANCET ONCOL, V4, P312, DOI 10.1016/S1470-2045(03)01079-9; Thorns A, 2000, LANCET, V356, P398, DOI 10.1016/S0140-6736(00)02534-4; Tolle SW, 2004, J CLIN ETHIC, V15, P111; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; vanderWal G, 1996, NEW ENGL J MED, V335, P1706	28	274	280	0	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 10	2007	356	19					1957	1965		10.1056/NEJMsa071143	http://dx.doi.org/10.1056/NEJMsa071143			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	165KX	17494928	Bronze			2023-01-03	WOS:000246305500007
J	Koh, THHG; Butow, PN; Coory, M; Budge, D; Collie, LA; Whitehall, J; Tattersall, MH				Koh, Tieh Hee Hai Guan; Butow, Phyllis N.; Coory, Michael; Budge, Donna; Collie, Li-An; Whitehall, John; Tattersall, Martin H.			Provision of taped conversations with neonatologists to mothers of babies in intensive care: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CANCER-PATIENTS; POSTNATAL DEPRESSION; CONSULTATION; INFORMATION; AUDIOTAPES	Objective To determine whether providing mothers of babies in neonatal intensive care units with audiotapes of their conversations with a neonatologist improves recall of information and psychological wellbeing. Design Randomised, single blinded trial. Setting Neonatal intensive care unit, north Queensland, Australia. Participants 200 mothers of babies in a neonatal intensive care unit. Interventions Mothers given (n=102) or not given (n=98) audiotapes of their conversations with a neonatologist. Main outcome measures Recall of information, attitudes to and use of the tape, satisfaction with conversations, postnatal depression, anxiety, general health, and stress about parenting, at 10 days and four and 12 months. Results 91% 0=93) of mothers in the tape group listened to the tape (once by day 10, twice by four months, and three times by 12 months; range 1-10). At 10 days and four months, mothers in the tape group recalled significantly more information about diagnosis, treatment, and outcome than mothers in the control group. At four months mothers in the tape group were 75% more likely to recall all of the information about treatment than mothers in the control group (59% v 34%; risk ratio 1.75, 95% confidence interval 1.27 to 2.4). Six mothers, all in the control group, could not recall their conversations. No statistically significant differences were found between the groups in satisfaction with conversations (10 days), postnatal depression and anxiety scores (10 days, four and 12 months), and stress about parenting (12 months). Conclusion Providing the mothers of babies in neonatal intensive care units with audiotapes of conversations with a neonatologist enhanced their recall of information (up to four months). The taped conversations did not affect the mothers' wellbeing or satisfaction with the neonatologist.	Townsville Hosp, Inst Womens & Childrens Hlth, Douglas, Qld 4814, Australia; James Cook Univ N Queensland, Sch Med, Douglas, Qld, Australia; Univ Sydney, Med Psychol Res Unit, Sydney, NSW 2006, Australia; Queensland Hlth, Sch Populat Hlth, Brisbane, Qld, Australia; Univ Sydney, Fac Med, Sydney, NSW 2006, Australia	James Cook University; University of Sydney; Queensland Health; University of Queensland; University of Sydney	Koh, THHG (corresponding author), Townsville Hosp, Inst Womens & Childrens Hlth, Douglas, Qld 4814, Australia.	guan_koh@health.qld.gov.au						Abidin R. R, 1990, PARENTING STRESS IND, DOI DOI 10.4236/PSYCH.2018.97104; ALROOMI L, 1995, LANCET, V345, P1020; Brown R, 1997, ANN ONCOL, V8, P877, DOI 10.1023/A:1008213630112; BUTT HR, 1977, ANN INTERN MED, V86, P478, DOI 10.7326/0003-4819-86-4-478; Buunk B.P., 1990, HDB FAMILY MEASUREME, P106; CASSILETH BR, 1980, ANN INTERN MED, V92, P832, DOI 10.7326/0003-4819-92-6-832; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Hagan R, 2004, BJOG-INT J OBSTET GY, V111, P641, DOI 10.1111/j.1471-0528.2004.00165.x; Hogbin B, 1992, PSYCHO-ONCOLOGY, V1, P147; Koh THHG, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004502.pub2; MCHUGH P, 1995, BRIT J CANCER, V71, P388, DOI 10.1038/bjc.1995.79; Ong LML, 2000, J CLIN ONCOL, V18, P3052, DOI 10.1200/JCO.2000.18.16.3052; SARASON IG, 1987, J SOC PERS RELAT, V4, P497, DOI 10.1177/0265407587044007; SCOTT JT, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001539; Snowdon C, 1997, SOC SCI MED, V45, P1337, DOI 10.1016/S0277-9536(97)00063-4; Spielberger C.D., 1970, MANUAL STATE TRAIT A, DOI 10.2307/1831273; Tattersall MH, 2002, LANCET ONCOL, V3, P431, DOI 10.1016/S1470-2045(02)00790-8; TATTERSALL MHN, 1994, J CLIN ONCOL, V12, P1305, DOI 10.1200/JCO.1994.12.6.1305; 1987, BR J PSYCHIAT, V150, P782	19	35	35	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 6	2007	334	7583					28	31		10.1136/bmj.39017.675648.BE	http://dx.doi.org/10.1136/bmj.39017.675648.BE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125CH	17142256	Bronze, Green Published			2023-01-03	WOS:000243418600036
J	T Brown, C; Yap, T; Cromwell, DA; Rixon, L; Steed, L; Mulligan, K; Mundy, A; Newman, SP; van der Meulen, J; Emberton, M				T Brown, Christian; Yap, Tet; Cromwell, David A.; Rixon, Lorna; Steed, Liz; Mulligan, Kathleen; Mundy, Anthony; Newman, Stanton P.; van der Meulen, Jan; Emberton, Mark			Self management for men with lower urinary tract symptoms: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							BENIGN PROSTATIC HYPERPLASIA; INTERVENTIONS; HEALTH; INDEX	Objective To evaluate the effectiveness of self management as a first line intervention for men with lower urinary tract symptoms. Design Randomised controlled trial. Setting A teaching hospital and a district general hospital in London. Participants 140 men (mean age 63 (SD 10.7) years), recruited between January 2003 and April 2004, referred by general practitioners to urological outpatient departments with uncomplicated lower urinary tract symptoms. Interventions Self management and standard care (n=73) or standard care alone (n=67). The self management group took part in three small group sessions comprising education, lifestyle advice, and training in problem solving and goal setting skills. Main outcome measures The primary outcome measure was treatment failure measured at 3, 6, and 12 months. Symptom severity (international prostate symptom score; higher scores represent a poorer outcome) was used as a secondary outcome. Results At three months, treatment failure had occurred in 7 (10%) of the self management group and in 27 (42%) of the standard care group (difference=32%, 95% confidence interval 18% to 46%). Corresponding differences in the frequency of treatment failure were 42% (27% to 57%) at six months and 48% (32% to 64%) at 12 months. At three months, the mean international prostate symptom score was 10.7 in the self management group and 16.4 in the standard care group (difference=5.7, 3.7 to 7.7). Corresponding differences in score were 6.5 (4.3 to 8.7) at six months and 5.1 (2.7 to 7.6) at 12 months. Conclusions Self management significantly reduced the frequency of treatment failure and reduced urinary symptoms. Because of the large observed benefit of self management, the results of this study support the case for a large multicentre trial to confirm whether self management could be considered as first line treatment for men with lower urinary tract symptoms.	Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England; Royal Coll Surgeons England, Clin Effectiveness Unit, London WC2A 3PE, England; UCL, Ctr Behav & Social Sci Med, Unit Hlth Psychol, London WC1E 6BT, England; UCL, Inst Urol, London W1W 7EY, England	University of London; London School of Hygiene & Tropical Medicine; Royal College of Surgeons of England; University of London; University College London; University of London; University College London	van der Meulen, J (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, Keppel St, London WC1E 7HT, England.	Jan.vanderMeulen@LSHTM.ac.uk	Mulligan, Kathleen/M-6670-2019; Newman, Stanton P/D-3972-2011; Cromwell, David/AAD-6519-2019	Mulligan, Kathleen/0000-0002-6003-3029; van der Meulen, Jan/0000-0002-9451-2335; Newman, Stanton/0000-0001-6712-6079				*AM UR ASS, 2003, GUID MAN BEN PROST H; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; BARRY MJ, 1995, J UROLOGY, V154, P1770, DOI 10.1016/S0022-5347(01)66780-6; BARRY MJ, 1995, MED CARE, V33, P135; Brown CT, 2003, BJU INT, V92, P53, DOI 10.1046/j.1464-410X.2003.04268.x; Brown CT, 2004, EUR UROL, V46, P254, DOI 10.1016/j.eururo.2004.02.008; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Madersbacher S, 2004, EUR UROL, V46, P547, DOI 10.1016/j.eururo.2004.07.016	8	66	71	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 6	2007	334	7583					25	28		10.1136/bmj.39010.551319.AE	http://dx.doi.org/10.1136/bmj.39010.551319.AE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125CH	17118949	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000243418600035
J	Puhan, MA; Busching, G; Schunemann, HJ; vanOort, E; Zaugg, C; Frey, M				Puhan, Milo A.; Buesching, Gilbert; Schuenemann, Holger J.; vanOort, Evelien; Zaugg, Christian; Frey, Martin			Interval versus continuous high-intensity exercise in chronic obstructive pulmonary disease - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-LIFE; CHRONIC RESPIRATORY QUESTIONNAIRE; CHRONIC HEART-FAILURE; AIR-FLOW OBSTRUCTION; CLINICAL-TRIAL; EQUIVALENCE TRIALS; COPD PATIENTS; REHABILITATION; EXACERBATION; READMISSION	Background: Guidelines recommend high-intensity continuous exercise to reduce peripheral muscle dysfunction in patients with chronic obstructive pulmonary disease but acknowledge that interval exercise might be an equally effective alternative that is better tolerated by patients. Objective: To assess whether interval exercise is no less effective than high-intensity continuous exercise and whether it is tolerated better by patients with severe chronic obstructive pulmonary disease. Design: Randomized, noninferiority trial. Setting: Publicly funded rehabilitation hospital in Switzerland. Patients: 98 patients with severe chronic obstructive pulmonary disease, with or without recent exacerbations. Intervention: 12 to 15 supervised interval or high-intensity continuous exercise sessions (over 3 weeks) followed by exercise at home. Measurements: Health-related quality of life determined by using the Chronic Respiratory Questionnaire (CRQ) (scores from 1 [most severe impairment] to 7 [no impairment]) after 5 weeks and number of unintended breaks during supervised exercise. Results: Both groups experienced large improvements in health-related quality of life (increase of CRQ total scores of 1.00 [SD, 0.98] for the interval exercise group and 1.02 [SD, 1.05] for the continuous exercise group). Adjusted between-group differences between the interval exercise group and the continuous exercise group (-0.05 [95% CI, -0.42 to -0.32] for CRQ and 1.1 meters [CI, -25.4 to 27.6 meters] for 6-minute walking distance) were within the a priori defined boundaries of noninferiority (0.5 for CRQ and 45 meters for 6-minute walking distance). Twenty-one (47.9%) patients using interval exercise and 11 (24.0%) patients using continuous exercise were able to adhere to the protocol (difference, 23.9 percentage points [CI, 5.0 to 42.8 percentage points]; P = 0.014). The median number of unintended breaks lasting 1 minute or more was 2 (interquartile range, 0 to 16) for patients in the interval exercise group and 11 interquartile range, 2 to 26) for patients in the continuous exercise group (P = 0.023). Limitations: The study focused on initiation of exercise and not on outpatient or home-based maintenance of exercise. Conclusions: Clinicians and patients can choose either of the 2 exercise plans to initiate physical exercise.	Univ Zurich, Zurich, Switzerland; Klin Barmelweid, Barmelweid, Switzerland; McMaster Univ, Hamilton, ON, Canada; Univ Buffalo, Buffalo, NY USA; Italian Natl Canc Inst Regina Elena, Rome, Italy; Univ Basel, Basel, Switzerland	University of Zurich; McMaster University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Basel	Puhan, MA (corresponding author), Univ Zurich Hosp, Horten Ctr, Postfach Nord, CH-8091 Zurich, Switzerland.	milo.puhan@usz.ch	Puhan, Milo/ABE-6298-2020	Puhan, Milo/0000-0003-4721-1879; Schunemann, Holger/0000-0003-3211-8479				*AM THOR SOC EUR R, 2004, MAN STAB COPD PULM R; American Thoracic Society, 1999, AM J RESP CRIT CARE, V159, P1666; BENNETT KJ, 1996, QUALITY LIFE PHARMAC, P253; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Cambach W, 1997, EUR RESPIR J, V10, P104, DOI 10.1183/09031936.97.10010104; Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322; Coppoolse R, 1999, EUR RESPIR J, V14, P258, DOI 10.1034/j.1399-3003.1999.14b04.x; Cote CG, 2005, EUR RESPIR J, V26, P630, DOI 10.1183/09031936.05.00045505; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Decramer M, 1997, EUR RESPIR J, V10, P417, DOI 10.1183/09031936.97.10020417; Fleming TR, 2000, AM HEART J, V139, pS171, DOI 10.1016/S0002-8703(00)90067-X; Garcia-Aymerich J, 2003, THORAX, V58, P100, DOI 10.1136/thorax.58.2.100; GOTZSCHE PC, 1996, BMJ-BRIT MED J, V313, P36; Greene WL, 2000, ANN INTERN MED, V132, P715, DOI 10.7326/0003-4819-132-9-200005020-00006; Griffiths TL, 2000, LANCET, V355, P362, DOI 10.1016/S0140-6736(99)07042-7; Hinz A, 2001, PSYCHOTHER PSYCH MED, V51, P193, DOI 10.1055/s-2001-13279; KAELIN ME, 1999, AM SOC EX PHYS 2 ANN; Lacasse Y, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003793.PUB2; Maltais F, 1997, AM J RESP CRIT CARE, V155, P555, DOI 10.1164/ajrccm.155.2.9032194; McAlister FA, 2001, AM J MED, V111, P553, DOI 10.1016/S0002-9343(01)00900-7; Meyer K, 1996, EUR HEART J, V17, P1040; Meyer K, 1997, MED SCI SPORT EXER, V29, P306, DOI 10.1097/00005768-199703000-00004; Moody A, 2004, THORAX, V59, P1; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; Pitta F, 2005, AM J RESP CRIT CARE, V171, P972, DOI 10.1164/rccm.200407-855OC; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Puhan MA, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-54; Puhan MA, 2005, THORAX, V60, P367, DOI 10.1136/thx.2004.033274; Puhan MA, 2004, RESP MED, V98, P1195, DOI 10.1016/j.rmed.2004.04.011; Puhan MA, 2004, RESP MED, V98, P342, DOI 10.1016/j.rmed.2003.10.013; Puhan Milo A, 2004, BMC Pulm Med, V4, P5, DOI 10.1186/1471-2466-4-5; Puhan Milo A, 2004, Health Qual Life Outcomes, V2, P1; Redelmeier DA, 1997, AM J RESP CRIT CARE, V155, P1278, DOI 10.1164/ajrccm.155.4.9105067; Sabapathy S, 2004, THORAX, V59, P1026, DOI 10.1136/thx.2004.026617; Schunemann H, 2004, THORAX, V59, P81; Schunemann HJ, 2005, EUR RESPIR J, V25, P31, DOI 10.1183/09031936.04.00029704; Schunemann HJ, 2003, J CLIN EPIDEMIOL, V56, P1170, DOI 10.1016/S0895-4356(03)00115-X; Schunemann HJ, 2003, MED DECIS MAKING, V23, P140, DOI 10.1177/0272989X03251243; Troosters T, 2001, J Cardiopulm Rehabil, V21, P10, DOI 10.1097/00008483-200101000-00004; Troosters T, 2000, AM J MED, V109, P207, DOI 10.1016/S0002-9343(00)00472-1; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Vogiatzis I, 2002, EUR RESPIR J, V20, P12, DOI 10.1183/09031936.02.01152001; WIJKSTRA PJ, 1994, EUR RESPIR J, V7, P269, DOI 10.1183/09031936.94.07020269	43	86	97	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 5	2006	145	11					816	825		10.7326/0003-4819-145-11-200612050-00006	http://dx.doi.org/10.7326/0003-4819-145-11-200612050-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114PE	17146066				2023-01-03	WOS:000242677300003
J	Chertow, DS; Tan, ET; Maslanka, SE; Schulte, J; Bresnitz, EA; Weisman, RS; Bernstein, J; Marcus, SM; Kumar, S; Malecki, J; Sobel, J; Braden, CR				Chertow, Daniel S.; Tan, Esther T.; Maslanka, Susan E.; Schulte, Joann; Bresnitz, Eddy A.; Weisman, Richard S.; Bernstein, Jeffrey; Marcus, Steven M.; Kumar, Savita; Malecki, Jean; Sobel, Jeremy; Braden, Christopher R.			Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TOXIN	Context Botulism is a potentially lethal paralytic disease caused primarily by toxins of the anaerobic, spore-forming bacterium Clostridium botulinum. Although botulinum toxin A is available by prescription for cosmetic and therapeutic use, no cases of botulism with detectable serum toxin have previously been attributed to cosmetic or therapeutic botulinum toxin injections. On November 27, 2004, 4 suspected botulism case-patients with a link to cosmetic botulinum toxin injections were reported to the Centers for Disease Control and Prevention. Objective To investigate the clinical, epidemiological, and laboratory aspects of 4 suspected cases of iatrogenic botulism. Design, Setting, and Patients Case series on 4 botulism case-patients. Main Outcome Measures Clinical characteristics of the 4 case-patients, epidemiological associations, and mouse bioassay neutralization test results from case-patient specimens and a toxin sample. Results Clinical characteristics of the 4 case-patients were consistent with those of naturally occurring botulism. All case-patients had been injected with a highly concentrated, unlicensed preparation of botulinum toxin A and may have received doses 2857 times the estimated human lethal dose by injection. Pretreatment serum toxin levels in 3 of the 4 case-patients were equivalent to 21 to 43 times the estimated human lethal dose; pretreatment serum from the fourth epidemiologically linked case-patient was not available. A 100-mu g vial of toxin taken from the same manufacturer's lot as toxin administered to the case-patients contained a toxin amount sufficient to kill approximately 14 286 adults by injection if disseminated evenly. Conclusions These laboratory-confirmed cases of botulism demonstrate that clinical use of unlicensed botulinum toxin A can result in severe, life-threatening illness. Further education and regulation are needed to prevent the inappropriate marketing, sale, and clinical use of unlicensed botulinum toxin products.	Florida Dept Hlth, Bur Epidemiol, Div Dis Control, Tallahassee, FL 32399 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Foodborne Bacterial & Mycot Dis, Natl Ctr Zoonot Vectorborne & Enter Dis, Atlanta, GA USA; State New Jersey Dept Hlth & Senior Serv, Div Epidemiol Environm & Occupat Hlth, Trenton, NJ USA; Univ Miami, Miller Sch Med, Miami, FL 33152 USA; Florida Poison Informat Ctr, Miami, FL USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA; New Jersey Poison Informat & Educ Syst, Newark, NJ USA; Florida Dept Hlth, Palm Beach Cty Hlth Dept, Div Epidemiol & Dis Control, W Palm Beach, FL USA	Florida Department of Health; Centers for Disease Control & Prevention - USA; University of Miami; Rutgers State University New Brunswick; Rutgers State University Medical Center; Florida Department of Health	Chertow, DS (corresponding author), Florida Dept Hlth, Bur Epidemiol, Div Dis Control, 2585 Merchants Row Blvd,Prather Bldg,Room 310F, Tallahassee, FL 32399 USA.	sindia4@hotmail.com						Bakheit AMO, 1997, J NEUROL NEUROSUR PS, V62, P198, DOI 10.1136/jnnp.62.2.198; *CDCP, SEL AG PROGR; Centers for Disease Control and Prevention, 1998, HDB EPID CLIN LAB WO; Chang GY, 2003, EUR NEUROL, V49, P151, DOI 10.1159/000069073; COMELLA CL, 1992, NEUROLOGY, V42, P1307, DOI 10.1212/WNL.42.7.1307; HERRERO BA, 1967, EXP MOL PATHOL, V6, P84, DOI 10.1016/0014-4800(67)90007-X; *MICR INC, 1974, MICR HEALTHC SER DAT; Sandrock CE, 2001, CHEST, V120, P562, DOI 10.1378/chest.120.2.562; SCOTT AB, 1988, MOVEMENT DISORD, V3, P333, DOI 10.1002/mds.870030409; TACKET CO, 1984, AM J MED, V76, P794, DOI 10.1016/0002-9343(84)90988-4	10	90	97	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2006	296	20					2476	2479		10.1001/jama.296.20.2476	http://dx.doi.org/10.1001/jama.296.20.2476			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	107KR	17119144	Bronze			2023-01-03	WOS:000242171000029
J	Halpern, SD; Hansen-Flaschen, J				Halpern, Scott D.; Hansen-Flaschen, John			Terminal withdrawal of life-sustaining supplemental oxygen	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ASSISTED SUICIDE; ASSOCIATION; SEDATION; THERAPY; SUPPORT; DISEASE; CARE		Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Bioeth, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Halpern, SD (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 711 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	scott.halpern@uphs.upenn.edu		Hansen-Flaschen, John/0000-0003-1989-7244				Abernethy AP, 2005, PALLIATIVE MED, V19, P168, DOI 10.1177/026921630501900219; Abrahm JL, 2002, CHEST, V121, P220, DOI 10.1378/chest.121.1.220; Alpers A, 1997, JAMA-J AM MED ASSOC, V277, P1705, DOI 10.1001/jama.277.21.1705; Ashby M, 2005, PALLIATIVE MED, V19, P389, DOI 10.1191/0269216305pm1043oa; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Booth S, 2004, RESP MED, V98, P66, DOI 10.1016/j.rmed.2003.08.008; Bruera E, 2003, PALLIATIVE MED, V17, P659, DOI 10.1191/0269216303pm826oa; Capellier G, 1999, Minerva Anestesiol, V65, P388; Chan JD, 2004, CHEST, V126, P286, DOI 10.1378/chest.126.1.286; Cohen LM, 1996, GEN HOSP PSYCHIAT, V18, P431, DOI 10.1016/S0163-8343(96)00091-6; DAVIS WB, 1983, NEW ENGL J MED, V309, P878, DOI 10.1056/NEJM198310133091502; *ESRD NETW NEW ENG, 2002, 2001 ANN REP CTR MED, P60; Gallagher Romayne, 2004, J Pain Palliat Care Pharmacother, V18, P3; Hjalmarsen A, 1999, EUR NEUROL, V42, P27, DOI 10.1159/000008065; Kampelmacher MJ, 1997, EUR RESPIR J, V10, P828; Lo B, 2005, JAMA-J AM MED ASSOC, V294, P1810, DOI 10.1001/jama.294.14.1810; Luce JM, 2000, AM J RESP CRIT CARE, V162, P2029, DOI 10.1164/ajrccm.162.6.1-00; Miller FG, 2000, ANN INTERN MED, V132, P470, DOI 10.7326/0003-4819-132-6-200003210-00008; Pearlman RA, 2005, J GEN INTERN MED, V20, P234, DOI 10.1111/j.1525-1497.2005.40225.x; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DEC FOR LIF SUST TRE, P3; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; Rubenfeld GD, 2004, CRIT CARE CLIN, V20, P435, DOI 10.1016/j.ccc.2004.03.005; Waugh Jonathan B, 2004, Respir Care, V49, P902	23	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2006	296	11					1397	1400		10.1001/jama.296.11.1397	http://dx.doi.org/10.1001/jama.296.11.1397			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	085HS	16985234				2023-01-03	WOS:000240595800029
J	Sulmasy, DP				Sulmasy, Daniel P.			Spiritual issues in the care of dying patients "... it's okay between me and God"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; TERMINALLY-ILL PATIENTS; INAPPROPRIATE TREATMENT; TREATMENT PREFERENCES; ASSISTED SUICIDE; END; PHYSICIANS; ATTITUDES; CANCER; RELIGION	Spiritual issues arise frequently in the care of dying patients, yet health care professionals may not recognize them, may not believe they have a duty to address these issues, and may not understand how best to respond to their patients' spiritual needs. The case of a patient with a strong religious belief in a miraculous cure of metastatic pancreatic cancer is used to explore how better understanding of this belief and more explicitly spiritual conversation with the patient by his treating team might have provided opportunities for an improved plan of care. This article distinguishes spirituality from religion; describes the salient spiritual needs of patients at the end of life as encompassing questions of meaning, value, and relationship; delineates the role physicians ought to play in ascertaining and responding to those needs; and discusses the particular issue of miracles, arguing that expectations of miraculous cure ought not preclude referral to hospice care.	St Vincents Hosp Manhattan, John J Conley Dept Eth, New York, NY 10011 USA; New York Med Coll, Valhalla, NY 10595 USA	Saint Vincents Hospital Manhattan; New York Medical College	Sulmasy, DP (corresponding author), St Vincents Hosp Manhattan, John J Conley Dept Eth, 153 W 11th St, New York, NY 10011 USA.	daniel_sulmasy@nymc.edu						Astrow AB, 2005, J CLIN ONCOL, V23, P2569, DOI 10.1200/JCO.2005.07.151; Astrow AB, 2001, AM J MED, V110, P283; BLACK BC, DENIAL CONTEXT ILLNE; Brett AS, 2003, ARCH INTERN MED, V163, P1645, DOI 10.1001/archinte.163.14.1645; Buckley Jenny, 2004, Nurs Stand, V19, P33; Burker EJ, 2005, J BEHAV MED, V28, P513, DOI 10.1007/s10865-005-9025-4; Buryska JF, 2001, J MED ETHICS, V27, P118, DOI 10.1136/jme.27.2.118; Byock I, 2003, ANN INTERN MED, V138, P335, DOI 10.7326/0003-4819-138-4-200302180-00013; Clarfield AM, 2006, J GERONTOL A-BIOL, V61, P621, DOI 10.1093/gerona/61.6.621; Clark D, 2001, J Palliat Med, V4, P353, DOI 10.1089/109662101753123977; Cohen CB, 2001, HASTINGS CENT REP, V31, P29, DOI 10.2307/3527702; Cohen SR, 1996, CANCER-AM CANCER SOC, V77, P576, DOI 10.1002/(SICI)1097-0142(19960201)77:3<576::AID-CNCR22>3.0.CO;2-0; Cohen SR, 1997, PALLIATIVE MED, V11, P3; Connors RB, 1996, HASTINGS CENT REP, V26, P23, DOI 10.2307/3527604; Coyle Nessa, 2003, J Support Oncol, V1, P206; Crawley L, 2000, JAMA-J AM MED ASSOC, V284, P2518, DOI 10.1001/jama.284.19.2518; Curlin FA, 2005, J GEN INTERN MED, V20, P629, DOI 10.1111/j.1525-1497.2005.0119.x; Daaleman TP, 2000, JAMA-J AM MED ASSOC, V284, P2514, DOI 10.1001/jama.284.19.2514; Du Val G, 2001, J MED ETHICS, V27, pI24, DOI 10.1136/jme.27.suppl_1.i24; Dugan D O, 1995, HEC Forum, V7, P228, DOI 10.1007/BF01463335; Dula A, 2005, CLIN GERIATR MED, V21, P239, DOI 10.1016/j.cger.2004.10.003; DuVal G, 2004, J GEN INTERN MED, V19, P251, DOI 10.1111/j.1525-1497.2004.21238.x; Ehman JW, 1999, ARCH INTERN MED, V159, P1803, DOI 10.1001/archinte.159.15.1803; El-Rayes Basil F, 2003, Clin Adv Hematol Oncol, V1, P430; Ellis MR, 1999, J FAM PRACTICE, V48, P105; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V284, P2460, DOI 10.1001/jama.284.19.2460; Epstein RM, 1999, JAMA-J AM MED ASSOC, V282, P833, DOI 10.1001/jama.282.9.833; Fisch MJ, 2003, J CLIN ONCOL, V21, P2754, DOI 10.1200/JCO.2003.06.093; Goldstein D, 2004, INTERN MED J, V34, P475, DOI 10.1111/j.1444-0903.2004.00658.x; Graves Darci L, 2002, Acad Med, V77, P1167, DOI 10.1097/00001888-200211000-00035; Heeren O, 2001, INT J GERIATR PSYCH, V16, P203, DOI 10.1002/1099-1166(200102)16:2<203::AID-GPS306>3.0.CO;2-M; Hills Judith, 2005, J Palliat Med, V8, P782, DOI 10.1089/jpm.2005.8.782; Johnson KS, 2005, J AM GERIATR SOC, V53, P711, DOI 10.1111/j.1532-5415.2005.53224.x; *JOINT COMM ACCR H, 2004, SPIR ASS; Kaldjian LC, 1998, AIDS, V12, P103, DOI 10.1097/00002030-199801000-00012; King DE, 2004, TEACH LEARN MED, V16, P64, DOI 10.1207/s15328015tlm1601_13; KING DE, 1994, J FAM PRACTICE, V39, P349; Kristeller JL, 1999, PSYCHO-ONCOLOGY, V8, P451, DOI 10.1002/(SICI)1099-1611(199909/10)8:5<451::AID-PON422>3.3.CO;2-V; LAPUMA J, 1992, AM J MED, V92, P346, DOI 10.1016/0002-9343(92)90262-A; LeFavi Robert G, 2003, J Pastoral Care Counsel, V57, P281; Lo B, 2002, JAMA-J AM MED ASSOC, V287, P749, DOI 10.1001/jama.287.6.749; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; MacLean CD, 2003, J GEN INTERN MED, V18, P38, DOI 10.1046/j.1525-1497.2003.20403.x; Maugans TA, 1996, ARCH FAM MED, V5, P11, DOI 10.1001/archfami.5.1.11; MAUGANS TA, 1991, J FAM PRACTICE, V32, P210; Moadel A, 1999, PSYCHO-ONCOL, V8, P378, DOI 10.1002/(SICI)1099-1611(199909/10)8:5<378::AID-PON406>3.0.CO;2-A; Monroe MH, 2003, ARCH INTERN MED, V163, P2751, DOI 10.1001/archinte.163.22.2751; O'Connell KA, 2006, SOC SCI MED, V62, P1486, DOI 10.1016/j.socscimed.2005.08.001; OCONNELL LJ, 2006, TIME LISTENING CARIN; Orr RD, 1997, J MED ETHICS, V23, P142, DOI 10.1136/jme.23.3.142; Pargament KI, 2000, J CLIN PSYCHOL, V56, P519, DOI 10.1002/(SICI)1097-4679(200004)56:4<519::AID-JCLP6>3.3.CO;2-T; Perron V, 2001, PRIMARY CARE, V28, P427, DOI 10.1016/S0095-4543(05)70032-4; Post SG, 2000, ANN INTERN MED, V132, P578, DOI 10.7326/0003-4819-132-7-200004040-00010; Puchalski Christina M, 2002, J Palliat Med, V5, P289, DOI 10.1089/109662102753641287; Puchalski CM, 1998, ACAD MED, V73, P970, DOI 10.1097/00001888-199809000-00015; RINPOCHE S, 2002, TIBETAN BOOK LIVING, P199; Steinhauser KE, 2006, ARCH INTERN MED, V166, P101, DOI 10.1001/archinte.166.1.101; Suarez-Almazor ME, 2002, J CLIN ONCOL, V20, P2134, DOI 10.1200/JCO.2002.08.025; Sulmasy Daniel P, 2002, Ethical Perspect, V9, P103, DOI 10.2143/EP.9.2.503850; Sulmasy Daniel P, 2002, Gerontologist, V42 Spec No 3, P24; Sulmasy DP, 1999, ACAD MED, V74, P1002, DOI 10.1097/00001888-199909000-00012; Sulmasy DP, 1997, THEOR MED, V18, P63, DOI 10.1023/A:1005749217702; Sulmasy DP, 1997, JAMA-J AM MED ASSOC, V277, P1854; SULMASY DP, 2001, J GEN INTERN MED S1, V16, P223; SULMASY DP, IN PRESS BALM GILEAD; SULMASY DP, 1997, HEALERS CALLING SPIR, P66; Sulmasy DP, 2006, REBIRTH CLIN INTRO S; Torke Alexia M, 2005, J Palliat Med, V8, P593, DOI 10.1089/jpm.2005.8.593; Wagner JT, 1996, CRIT CARE CLIN, V12, P15, DOI 10.1016/S0749-0704(05)70212-8; Wilson KG, 2000, ARCH INTERN MED, V160, P2454, DOI 10.1001/archinte.160.16.2454; [No title captured]; 2006, CBS NEWS        0413	72	124	125	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2006	296	11					1385	1392		10.1001/jama.296.11.1385	http://dx.doi.org/10.1001/jama.296.11.1385			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	085HS	16985231				2023-01-03	WOS:000240595800026
J	Lee, S; Spencer, ND				Lee, Seunghwan; Spencer, Nicholas D.			Materials science - Sweet, hairy, soft, and slippery	SCIENCE			English	Editorial Material							POLYMER BRUSHES; LUBRICATION; FRICTION; SURFACES; HYDROGELS; FORCES; MUCIN		[Lee, Seunghwan; Spencer, Nicholas D.] ETH, Dept Mat, Surface Sci & Technol Lab, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Lee, S (corresponding author), ETH, Dept Mat, Surface Sci & Technol Lab, CH-8093 Zurich, Switzerland.	spencer@mat.ethz.ch	Spencer, NIcholas D./A-5843-2008; Lee, Seunghwan/K-8382-2014; Spencer, Nicholas/M-9647-2019	Spencer, NIcholas D./0000-0002-7873-7905; Lee, Seunghwan/0000-0002-0797-1446; Spencer, Nicholas/0000-0002-7873-7905				BANSIL R, 1995, ANNU REV PHYSIOL, V57, P635, DOI 10.1146/annurev.ph.57.030195.003223; Celli J, 2005, BIOMACROMOLECULES, V6, P1329, DOI 10.1021/bm0493990; DEGENNES PG, 1980, MACROMOLECULES, V13, P1069, DOI 10.1021/ma60077a009; Dowson D., 1998, HIST TRIBOLOGY; DROBEK T, 2007, LANGMUIR; Gong JP, 2006, SOFT MATTER, V2, P544, DOI 10.1039/b603209p; Han L, 2007, BIOPHYS J, V92, P1384, DOI 10.1529/biophysj.106.091397; Klein J, 2006, P I MECH ENG J-J ENG, V220, P691, DOI 10.1243/13506501JET143; Klein J, 1998, ACTA POLYM, V49, P617, DOI 10.1002/(SICI)1521-4044(199810)49:10/11<617::AID-APOL617>3.3.CO;2-#; KLEIN J, 1994, NATURE, V370, P634, DOI 10.1038/370634a0; Kobayashi M, 2007, SOFT MATTER, V3, P740, DOI 10.1039/b615780g; Lee S, 2005, TRIBOL INT, V38, P922, DOI 10.1016/j.triboint.2005.07.017; Lee S, 2008, LUBR SCI, V20, P21, DOI 10.1002/ls.50; Moore D.F., 1972, FRICTION LUBRICATION; Muller M, 2003, TRIBOL LETT, V15, P395, DOI 10.1023/B:TRIL.0000003063.98583.bb; Raviv U, 2002, LANGMUIR, V18, P7482, DOI 10.1021/la020002s; Tanaka Y, 2005, PROG POLYM SCI, V30, P1, DOI 10.1016/j.progpolymsci.2004.11.003	17	184	191	7	150	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 1	2008	319	5863					575	576		10.1126/science.1153273	http://dx.doi.org/10.1126/science.1153273			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257AQ	18239111				2023-01-03	WOS:000252772000024
J	Sigal, RJ; Kenny, GP; Boule, NG; Wells, GA; Prud'homme, D; Fortier, M; Reid, RD; Tulloch, H; Coyle, D; Phillips, P; Jennings, A; Jaffey, J				Sigal, Ronald J.; Kenny, Glen P.; Boule, Normand G.; Wells, George A.; Prud'homme, Denis; Fortier, Michelle; Reid, Robert D.; Tulloch, Heather; Coyle, Douglas; Phillips, Penny; Jennings, Alison; Jaffey, James			Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes - A Randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							INSULIN-RESISTANCE; EXERCISE; METAANALYSIS; PLASMA; COMPLICATIONS; INTENSITY; MELLITUS; ADULTS; MUSCLE; WOMEN	Background: Previous trials have evaluated the effects of aerobic training alone and of resistance training alone on glycemic control in type 2 diabetes, as assessed by hemoglobin A(1c) values. However, none could assess incremental effects of combined aerobic and resistance training compared with either type of exercise alone. Objective: To determine the effects of aerobic training alone, resistance training alone, and combined exercise training on hemoglobin A(1c) values in patients with type 2 diabetes. Design: Randomized, controlled trial. Setting: 8 community-based facilities. Patients: 2151 adults age 39 to 70 years with type 2 diabetes. A negative result on a stress test or clearance by a cardiologist, and adherence to exercise during a 4-week run-in period, were required before randomization. Interventions: Aerobic training, resistance training, or both types of exercise (combined exercise training). A sedentary control group was included. Exercise training was performed 3 times weekly for 22 weeks (weeks 5 to 26 of the study). Measurements: The primary outcome was the change in hemoglobin A,, value at 6 months. Secondary outcomes were changes in body composition, plasma lipid values, and blood pressure. Results: The absolute change in the hemoglobin A, value in the combined exercise training group compared with the control group was -0.51 percentage point (95% Cl, -0.87 to -0.14) in the aerobic training group and -0.38 percentage point (Cl, -0.72 to -0.22) in the resistance training group. Combined exercise training resulted in an additional change in the hemoglobin A, value of -0.46 percentage point (Cl, -0.83 to -0.09) compared with aerobic training alone and -0.59 percentage point (Cl, -0.95 to -0.23) compared with resistance training alone. Changes in blood pressure and lipid values did not statistically significantly differ among groups. Adverse events were more common in the exercise groups. Limitations: The generalizability of the results to patients who are less adherent to exercise programs is uncertain. The participants were not blinded, and the total duration of exercise was greater in the combined exercise training group than in the aerobic and resistance training groups. Conclusion: Either aerobic or resistance training alone improves glycemic control in type 2 diabetes, but the improvements are greatest with combined aerobic and resistance training.	Univ Calgary, Calgary, AB T2N 2T9, Canada; Univ Ottawa, Hlth Res Inst, Prevent & Rehabil Ctr, Clin Epidemiol Program, Ottawa, ON, Canada	University of Calgary; University of Ottawa; Ottawa Hospital Research Institute	Sigal, RJ (corresponding author), Univ Calgary, 7th Floor,N Tower,Foothills Med Ctr,140329 St NW, Calgary, AB T2N 2T9, Canada.	rsigal@ucalgary.ca	Sigal, Ronald/AAU-6081-2020; Sigal, Ron/AAK-7627-2020	Coyle, Doug/0000-0003-3492-2268				Boule NG, 2001, JAMA-J AM MED ASSOC, V286, P1218, DOI 10.1001/jama.286.10.1218; Canadian Diabetes Association, 1999, CAN J DIABETES CARE, V23, P56; Castaneda C, 2002, DIABETES CARE, V25, P2335, DOI 10.2337/diacare.25.12.2335; Cuff DJ, 2003, DIABETES CARE, V26, P2977, DOI 10.2337/diacare.26.11.2977; Deschenes MR, 2002, AM J PHYS MED REHAB, V81, pS3, DOI 10.1097/01.PHM.0000029722.06777.E9; Dunstan DW, 2002, DIABETES CARE, V25, P1729, DOI 10.2337/diacare.25.10.1729; Dunstan DW, 1998, DIABETES RES CLIN PR, V40, P53, DOI 10.1016/S0168-8227(98)00027-8; Evans WJ, 1996, GERIATRICS, V51, P46; Eves ND, 2006, DIABETES CARE, V29, P1933, DOI 10.2337/dc05-1981; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gavin JR, 1997, DIABETES CARE, V20, P1183; Goodpaster BH, 1997, DIABETES, V46, P1579, DOI 10.2337/diabetes.46.10.1579; Heymsfield SB, 1998, HDB OBESITY, P41; Holten MK, 2004, DIABETES, V53, P294, DOI 10.2337/diabetes.53.2.294; Ivy J, 2002, HDB EXERCISE DIABETE, V2nd, P23; Kraus WE, 2002, NEW ENGL J MED, V347, P1483, DOI 10.1056/NEJMoa020194; Kyle UG, 2001, NUTRITION, V17, P248, DOI 10.1016/S0899-9007(00)00553-0; Lemieux S, 1996, DIABETES CARE, V19, P983, DOI 10.2337/diacare.19.9.983; PELLETT PL, 1990, AM J CLIN NUTR, V51, P711, DOI 10.1093/ajcn/51.5.711; Selvin E, 2004, ANN INTERN MED, V141, P421, DOI 10.7326/0003-4819-141-6-200409210-00007; Snowling NJ, 2006, DIABETES CARE, V29, P2518, DOI 10.2337/dc06-1317; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Thomas DR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002968.pub2; Willey KA, 2003, DIABETES CARE, V26, P1580, DOI 10.2337/diacare.26.5.1580; WVANS WJ, 1996, GERIATRICS, V51, P46	25	763	797	4	134	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 18	2007	147	6					357	369		10.7326/0003-4819-147-6-200709180-00005	http://dx.doi.org/10.7326/0003-4819-147-6-200709180-00005			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214GY	17876019				2023-01-03	WOS:000249726200001
J	Danzon, PM				Danzon, Patricia M.			At what price?	NATURE			English	Editorial Material							DISCRIMINATION		Univ Penn, Wharton Sch, Hlth Care Management Dept, Philadelphia, PA 19104 USA	University of Pennsylvania	Danzon, PM (corresponding author), Univ Penn, Wharton Sch, Hlth Care Management Dept, Philadelphia, PA 19104 USA.							[Anonymous], 2001, MACR HLTH INV HLTH E; BRITTIN RV, 1992, B COUNCIL RES MUSIC, V113, P1; Danzon P., 2003, HLTH AFFAIRS; Danzon Patricia M, 2003, Int J Health Care Finance Econ, V3, P183, DOI 10.1023/A:1025384819575; Danzon PM, 2005, HEALTH ECON, V14, P269, DOI 10.1002/hec.931; DANZON PM, 1997, INT J EC BUSINESS, V4, P301; DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; Dumoulin J, 2001, INT J BIOTECHNOLOGY, V3, P338; HAUSMAN JA, 1988, RAND J ECON, V19, P253, DOI 10.2307/2555703; Maskus Keith E., 2001, PARALLEL IMPORTS PHA; Ramsey FP, 1927, ECON J, V37, P47, DOI 10.2307/2222721; VARIAN HR, 1985, AM ECON REV, V75, P870; *WORLD TRAD ORG, 2003, WTGCM82 WORLD TRAD O; *WORLD TRAD ORG, 2003, WTL540 WORLD TRAD RO	14	22	22	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 13	2007	449	7159					176	179		10.1038/449176a	http://dx.doi.org/10.1038/449176a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	209NF	17851515				2023-01-03	WOS:000249394500039
J	Birrell, SN; Butler, LM; Harris, JM; Buchanan, G; Tilley, WD				Birrell, Stephen N.; Butler, Lisa M.; Harris, Jonathan M.; Buchanan, Grant; Tilley, Wayne D.			Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer	FASEB JOURNAL			English	Review						hormone replacement therapy; medroxyprogesterone acetate; estrogen signaling	HORMONE REPLACEMENT THERAPY; PROSTATE-SPECIFIC ANTIGEN; NIPPLE ASPIRATE FLUID; CAG REPEAT LENGTH; MAMMARY-GLAND DEVELOPMENT; MEDROXYPROGESTERONE ACETATE; ESTROGEN-RECEPTOR; POSTMENOPAUSAL WOMEN; PROGESTERONE-RECEPTORS; CELL-PROLIFERATION	There is now considerable evidence that using a combination of synthetic progestins and estro-gens in hormone replacement therapy ( HRT) increases the risk of breast cancer compared with estrogen alone. Furthermore, the World Health Organization has recently cited combination contraceptives, which contain synthetic progestins, as potentially carcinogenic to humans, particularly for increased breast cancer risk. Given the above observations and the current trend toward progestin-only contraception, it is important that we have a comprehensive understanding of how progestins act in the millions of women worldwide who regularly take these medications. While synthetic progestins, such as medroxyprogesterone acetate ( MPA), which are currently used in both HRT and oral contraceptives were designed to act exclusively through the progesterone receptor, it is clear from both clinical and experimental settings that their effects may be mediated, in part, by binding to the androgen receptor ( AR). Disruption of androgen action by synthetic progestins may have serious deleterious side effects in the breast, where the balance between estrogen signaling and androgen signaling plays a critical role in breast homeostasis. Here, we review the role of androgen signaling in the normal breast and in breast cancer and present new data demonstrating that androgen receptor function can be perturbed by low doses of MPA, similar to doses achieved in serum of women taking HRT. We propose that the observed excess of breast malignancies associated with combined HRT may be explained, in part, by synthetic progestins such as MPA acting as endocrine disruptors to negate the protective effects of androgen signaling in the breast. Understanding the role of androgen signaling in the breast and how this is modulated by synthetic progestins is necessary to determine how combined HRT alters breast cancer risk, and to inform the development of optimal preventive and treatment strategies for this disease.	Univ Adelaide, Hanson Inst, Dame Roma Mitchell Canc Res Labs, Adelaide, SA 5005, Australia; Queensland Univ Technol, Sch Life Sci, Brisbane, Qld, Australia	Hanson Institute; University of Adelaide; Queensland University of Technology (QUT)	Tilley, WD (corresponding author), Univ Adelaide, Hanson Inst, Dame Roma Mitchell Canc Res Labs, POB 14,Rundle Mall, Adelaide, SA 5005, Australia.	wayne.tilley@lvms.sd.gov.au	Butler, Lisa/AAP-9088-2020; Butler, Lisa M/C-9843-2010	Butler, Lisa/0000-0003-2698-3220; Harris, Jonathan/0000-0003-4209-2380; Tilley, Wayne/0000-0003-1893-2626				Agoff SN, 2003, AM J CLIN PATHOL, V120, P725, DOI 10.1309/42F00D0DJD0J5EDT; Anim JT, 2005, ACTA HISTOCHEM, V107, P87, DOI 10.1016/j.acthis.2005.01.002; Bentel JM, 1999, MOL CELL ENDOCRINOL, V154, P11, DOI 10.1016/S0303-7207(99)00109-4; Birrell SN, 1998, J MAMMARY GLAND BIOL, V3, P95, DOI 10.1023/A:1018730519839; BIRRELL SN, 1995, J CLIN ONCOL, V13, P1572, DOI 10.1200/JCO.1995.13.7.1572; BIRRELL SN, 1995, J STEROID BIOCHEM, V52, P459, DOI 10.1016/0960-0760(95)00005-K; Boonyaratanakornkit V, 2004, ESSAYS BIOCHEM, V40, P105, DOI 10.1042/bse0400105; Brys M, 2000, Med Sci Monit, V6, P433; Buchanan G, 2005, CANCER RES, V65, P8487, DOI 10.1158/0008-5472.CAN-04-3077; BURGER HG, 2006, MENOPAUSE; Campagnoli C, 2005, J STEROID BIOCHEM, V96, P95, DOI 10.1016/j.jsbmb.2005.02.014; Campagnoli C, 2005, J STEROID BIOCHEM, V97, P441, DOI 10.1016/j.jsbmb.2005.08.015; Chabbert-Buffet N, 2005, HUM REPROD UPDATE, V11, P293, DOI 10.1093/humupd/dmi002; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Clark James H, 2006, Nucl Recept Signal, V4, pe023; Cline JM, 1996, AM J OBSTET GYNECOL, V174, P93, DOI 10.1016/S0002-9378(96)70379-4; Cogliano V, 2005, LANCET ONCOL, V6, P552, DOI 10.1016/S1470-2045(05)70273-4; Collins JA, 2005, HUM REPROD UPDATE, V11, P545, DOI 10.1093/humupd/dmi028; Conneely OM, 2003, J MAMMARY GLAND BIOL, V8, P205, DOI 10.1023/A:1025952924864; Cox DG, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1602; Dagan E, 2002, EUR J HUM GENET, V10, P724, DOI 10.1038/sj.ejhg.5200880; DAUVOIS S, 1991, CANCER RES, V51, P3131; de Lignieres B, 2002, CLIMACTERIC, V5, P332, DOI 10.1080/713605312; DELAUNOIT Y, 1991, CANCER RES, V51, P2797; DEWINTER JAR, 1991, J HISTOCHEM CYTOCHEM, V39, P927, DOI 10.1177/39.7.1865110; Dimitrakakis C, 2002, FERTIL STERIL, V77, pS26; Dunning AM, 1999, CARCINOGENESIS, V20, P2131, DOI 10.1093/carcin/20.11.2131; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fournier A, 2005, INT J CANCER, V114, P448, DOI 10.1002/ijc.20710; Ghatge RP, 2005, BREAST CANCER RES, V7, pR1036, DOI 10.1186/bcr1340; Giguere Y, 2001, CANCER RES, V61, P5869; Given HF, 2000, EUR J CANCER, V36, P533, DOI 10.1016/S0959-8049(99)00310-X; Graham JD, 1997, ENDOCR REV, V18, P502, DOI 10.1210/er.18.4.502; Greeve MA, 2004, J MOL ENDOCRINOL, V32, P793, DOI 10.1677/jme.0.0320793; HACKENBERG R, 1993, BREAST CANCER RES TR, V25, P217, DOI 10.1007/BF00689836; HACKENBERG R, 1991, CANCER RES, V51, P5722; Haiman CA, 2002, CANCER RES, V62, P1045; Haiman CA, 2003, BREAST CANCER RES TR, V77, P27, DOI 10.1023/A:1021112121782; Hall RE, 1996, BRIT J CANCER, V74, P1175, DOI 10.1038/bjc.1996.513; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; Hewitt SC, 2000, BREAST CANCER RES, V2, P345, DOI 10.1186/bcr79; Honma N, 2003, HISTOPATHOLOGY, V42, P120, DOI 10.1046/j.1365-2559.2003.01542.x; INGLE JN, 1991, CANCER-AM CANCER SOC, V67, P886, DOI 10.1002/1097-0142(19910215)67:4<886::AID-CNCR2820670405>3.0.CO;2-O; IOBAGIU C, 2005, BREAST CANC RES TREA, P1; JANSSEN PJ, 1994, J HISTOCHEM CYTOCHEM, V42, P1169, DOI 10.1177/42.8.8027537; Kadouri L, 2001, BRIT J CANCER, V85, P36, DOI 10.1054/bjoc.2001.1777; Kandouz M, 1999, J STEROID BIOCHEM, V69, P463, DOI 10.1016/S0960-0760(99)00069-2; Katzenellenbogen BS, 2004, SEMIN ONCOL, V31, P28, DOI 10.1053/j.seminoncol.2004.01.004; Kemppainen JA, 1999, MOL ENDOCRINOL, V13, P440, DOI 10.1210/me.13.3.440; Klaiber EL, 2005, FERTIL STERIL, V84, P1589, DOI 10.1016/j.fertnstert.2005.08.010; Kristiansen M, 2005, J MED GENET, V42, P877, DOI 10.1136/jmg.2005.032433; Kristiansen M, 2002, J MED GENET, V39, P30, DOI 10.1136/jmg.39.1.30; KuenenBoumeester V, 1996, EUR J CANCER, V32A, P1560, DOI 10.1016/0959-8049(96)00112-8; Kuhl H, 2004, CLIMACTERIC, V7, P319, DOI 10.1080/13697130400003337; Labrie F, 2003, ENDOCR REV, V24, P152, DOI 10.1210/er.2001-0031; Labrie F, 2003, ANN ENDOCRINOL-PARIS, V64, P95; LANGER M, 1990, ARCH GYNECOL OBSTET, V247, P203, DOI 10.1007/BF02389545; Lapointe J, 1999, ENDOCRINOLOGY, V140, P416, DOI 10.1210/en.140.1.416; LEA OA, 1989, CANCER RES, V49, P7162; Lee SA, 2005, BRIT J CANCER, V92, P2049, DOI 10.1038/sj.bjc.6602617; Li XT, 2004, MECH AGEING DEV, V125, P669, DOI 10.1016/j.mad.2004.04.007; Liao DJ, 2002, J STEROID BIOCHEM, V80, P175, DOI 10.1016/S0960-0760(01)00185-6; Liede A, 2003, CANCER EPIDEM BIOMAR, V12, P848; Lillie EO, 2004, CANCER RES, V64, P1237, DOI 10.1158/0008-5472.CAN-03-2887; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; MARTEL C, 1994, MOL CELL ENDOCRINOL, V104, P103, DOI 10.1016/0303-7207(94)90056-6; Menin C, 2001, CANCER LETT, V168, P31, DOI 10.1016/S0304-3835(01)00473-6; Moinfar F, 2003, CANCER-AM CANCER SOC, V98, P703, DOI 10.1002/cncr.11532; Nachtigall LE, 2000, MENOPAUSE, V7, P243, DOI 10.1097/00042192-200007040-00006; Ortmann J, 2002, GYNECOL ENDOCRINOL, V16, P113, DOI 10.1080/713603030; Ouatas T, 2003, CLIN CANCER RES, V9, P3763; Panet-Raymond V, 2000, MOL CELL ENDOCRINOL, V167, P139, DOI 10.1016/S0303-7207(00)00279-3; Park SS, 2000, IPAP CONFERENCE SER, V1, P60, DOI 10.1109/KDEX.1999.836610; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; Pike MC, 2000, STEROIDS, V65, P659, DOI 10.1016/S0039-128X(00)00122-7; POULIN R, 1989, ENDOCRINOLOGY, V125, P392, DOI 10.1210/endo-125-1-392; Rebbeck TR, 1999, AM J HUM GENET, V64, P1371, DOI 10.1086/302366; Riva C, 2005, VIRCHOWS ARCH, V447, P695, DOI 10.1007/s00428-005-0003-6; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Santen RJ, 2003, STEROIDS, V68, P953, DOI 10.1016/S0039-128X(03)00138-7; Sauter ER, 2004, CANCER DETECT PREV, V28, P27, DOI 10.1016/j.cdp.2003.11.003; Sauter ER, 2004, INT J CANCER, V108, P588, DOI 10.1002/ijc.11607; Sauter ER, 2002, ENVIRON HEALTH PERSP, V110, P241, DOI 10.1289/ehp.02110241; Schindler AE, 2003, MATURITAS, V46, pS7, DOI 10.1016/j.maturitas.2003.09.014; Schippinger W, 2006, VIRCHOWS ARCH, V449, P24, DOI 10.1007/s00428-006-0213-6; Shah NR, 2005, MENOPAUSE, V12, P668, DOI 10.1097/01.gme.0000184221.63459.e1; Sitruk-Ware R, 2004, MATURITAS, V47, P277, DOI 10.1016/j.maturitas.2004.01.001; Soderqvist G, 2004, MATURITAS, V49, P90, DOI 10.1016/j.maturitas.2004.06.008; Somboonporn W, 2004, ENDOCR REV, V25, P374, DOI 10.1210/er.2003-0016; Speroff L, 2004, MATURITAS, V49, P51, DOI 10.1016/j.maturitas.2004.06.006; Spurdle AB, 2005, BREAST CANCER RES, V7, pR176, DOI 10.1186/bcr971; Spurdle AB, 1999, JNCI-J NATL CANCER I, V91, P961, DOI 10.1093/jnci/91.11.961; Stahlberg C, 2003, ACTA OBSTET GYN SCAN, V82, P335, DOI 10.1034/j.1600-0412.2003.00055.x; Stahlberg C, 2004, INT J CANCER, V109, P721, DOI 10.1002/ijc.20016; Suter NM, 2003, CANCER EPIDEM BIOMAR, V12, P127; TEULINGS FAG, 1980, CANCER RES, V40, P2557; TORMEY DC, 1983, ANN INTERN MED, V98, P139, DOI 10.7326/0003-4819-98-2-139; Tran N, 2004, CANCER EPIDEM BIOMAR, V13, P2133; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Wang W, 2005, CANCER EPIDEM BIOMAR, V14, P2990, DOI 10.1158/1055-9965.EPI-05-0310; Wood CE, 2007, BREAST CANCER RES TR, V101, P125, DOI 10.1007/s10549-006-9276-y; Yeh SY, 2003, J EXP MED, V198, P1899, DOI 10.1084/jem.20031233; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; Yu H, 2000, BREAST CANCER RES TR, V59, P153, DOI 10.1023/A:1006356502820; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zhou J, 2000, FASEB J, V14, P1725, DOI 10.1096/fj.99-0863com; Zhuang YH, 2003, CELL TISSUE RES, V311, P217, DOI 10.1007/s00441-002-0683-z	107	67	70	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2007	21	10					2285	2293		10.1096/fj.06-7518com	http://dx.doi.org/10.1096/fj.06-7518com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17413000				2023-01-03	WOS:000248454400003
J	Markowitz, AJ; Rabow, MW				Markowitz, Amy J.; Rabow, Michael W.			Palliative management of fatigue at the close of life: "It feels like my body is just worn out"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Yennurajalingam S, 2007, JAMA-J AM MED ASSOC, V297, P295, DOI 10.1001/jama.297.3.295	1	11	12	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2007	298	2					217	217		10.1001/jama.298.2.217	http://dx.doi.org/10.1001/jama.298.2.217			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188HI	17622603				2023-01-03	WOS:000247910600027
J	White, DB; Curtis, JR; Wolf, LE; Prendergast, TJ; Taichman, DB; Kuniyoshi, G; Acerra, F; Lo, B; Luce, JM				White, Douglas B.; Curtis, J. Randall; Wolf, Leslie E.; Prendergast, Thomas J.; Taichman, Darren B.; Kuniyoshi, Gary; Acerra, Frank; Lo, Bernard; Luce, John M.			Life support for patients without a surrogate decision maker: Who decides?	ANNALS OF INTERNAL MEDICINE			English	Article							INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; TREATMENT PREFERENCES; SUSTAINING TREATMENT; ADVANCE DIRECTIVES; WITHDRAWAL; PHYSICIANS; FUTILITY; CAPACITY; POLICY	Background: Physicians in intensive care units have withdrawn life support in incapacitated patients who lack surrogate decision makers and advance directives, yet little is known about how often this occurs or under what circumstances. Objective: To determine the proportion of deaths in intensive care units that occur in patients who lack decision-making capacity and a surrogate and the process that physicians use to make these decisions. Design: Multicenter, prospective cohort study. Setting: Intensive care units of 7 medical centers in 2004 to 2005. Patients: 3011 consecutive critically ill adults. Measurements: Attending physicians completed a questionnaire about the decision-making process for each incapacitated patient without a surrogate or advance directive for whom they considered limiting life support. Results: Overall, 5.5% (25 of 451 patients) of deaths in intensive care units occurred in incapacitated patients who lacked a surrogate decision maker and an advance directive. This percentage ranged from 0% to 27% across the 7 centers. Physicians considered limiting life support in 37 such patients or would have considered it if a surrogate had been available. In 6 patients, there was prospective hospital review of the decision, and in 1 patient, there was court review. In the remaining 30 patients, the decision was made by the intensive care unit team alone or by the intensive care unit team plus another attending physician. The authors found wide variability in hospital policies, professional society guidelines, and state laws regarding who should make life-support decisions for this patient population. Thirty-six of 37 life-support decisions were made in a manner inconsistent with American College of Physicians guidelines for judicial review. Limitations: The results are based on physicians' self-reported practices and may not match actual practices. The number of incapacitated patients without surrogates in the study is small. Conclusions: Incapacitated patients without surrogates accounted for approximately 1 in 20 deaths in intensive care units. Most life-support decisions were made by physicians without institutional or judicial review.	Univ Calif San Francisco, Program Med Eth, San Francisco, CA 94143 USA; San Francisco Gen Hosp, San Francisco, CA 94110 USA; Univ Washington, Sch Med, Seattle, WA 98195 USA; Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA; Univ Penn, Philadelphia, PA 19104 USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Beth Israel Deaconess Med Ctr, New York, NY 10003 USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of Washington; University of Washington Seattle; Dartmouth College; University of Pennsylvania; Oregon Health & Science University; Harvard University; Beth Israel Deaconess Medical Center	White, DB (corresponding author), Univ Calif San Francisco, Program Med Eth, 521 Parnassus Ave,Suite C-126,Box 0903, San Francisco, CA 94143 USA.	dwhite@medicine.ucsf.edu		Wolf, Leslie/0000-0002-4660-8383	NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024130] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL068593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NCRR NIH HHS [KL2 RR024130] Funding Source: Medline; NHLBI NIH HHS [K24 HL 68593] Funding Source: Medline; NIMH NIH HHS [MH 42459] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		American Medical Association, 2004, COD MED ETH CURR OP; Arnold RM, 2003, CRIT CARE MED, V31, pS347, DOI 10.1097/01.CCM.0000065123.23736.12; ASCH DA, 1995, AM J RESP CRIT CARE, V151, P288, DOI 10.1164/ajrccm.151.2.7842181; Beauchamp T. L., 2012, PRINCIPLES BIOMEDICA, VVII-a; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; COHEN LM, 1993, ARCH INTERN MED, V153, P2481, DOI 10.1001/archinte.153.21.2481; Cohen S, 2005, INTENS CARE MED, V31, P1215, DOI 10.1007/s00134-005-2742-x; COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; Curtis JR, 2003, J CRIT CARE, V18, P22, DOI 10.1053/jcrc.2003.YJCRC5; FADER AM, 1989, J AM GERIATR SOC, V37, P544, DOI 10.1111/j.1532-5415.1989.tb05687.x; Fine RL, 2003, ANN INTERN MED, V138, P743, DOI 10.7326/0003-4819-138-9-200305060-00011; Fischer GS, 1998, J GEN INTERN MED, V13, P447, DOI 10.1046/j.1525-1497.1998.00133.x; Gillick Muriel R, 1995, J Ethics Law Aging, V1, P87; Halevy A, 1996, JAMA-J AM MED ASSOC, V276, P571, DOI 10.1001/jama.276.7.571; Hoffmann D, 2000, J LAW MED ETHICS, V28, P30, DOI 10.1111/j.1748-720X.2000.tb00314.x; Karp N., 2003, INCAPACITATED ALONE; KRUSE JA, 1988, JAMA-J AM MED ASSOC, V260, P1739, DOI 10.1001/jama.260.12.1739; Layde P M, 1995, Arch Fam Med, V4, P518, DOI 10.1001/archfami.4.6.518; *LEV CAR STUD INV, 2004, CRIT CARE MED, V32, P1149; LO B, 1987, NEW ENGL J MED, V317, P46, DOI 10.1056/NEJM198707023170110; Lo B, 2003, JAMA-J AM MED ASSOC, V290, P1208, DOI 10.1001/jama.290.9.1208; LO B, 1985, ARCH INTERN MED, V145, P1115, DOI 10.1001/archinte.145.6.1115; MARINER WK, 1984, J AM GERIATR SOC, V32, P739, DOI 10.1111/j.1532-5415.1984.tb04173.x; Norris WM, 2005, CHEST, V127, P2180, DOI 10.1378/chest.127.6.2180; PEARLMAN RA, 1982, ANN INTERN MED, V97, P420, DOI 10.7326/0003-4819-97-3-420; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; Snyder L, 2005, ANN INTERN MED, V142, P560, DOI 10.7326/0003-4819-142-7-200504050-00014; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; White DB, 2006, CRIT CARE MED, V34, P2053, DOI 10.1097/01.CCM.0000227654.38708.C1; Wolf Leslie E, 2004, IRB, V26, P14, DOI 10.2307/3563582; 1996, J AM GERIATR SOC, V44, P986	33	72	72	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2007	147	1					34	40		10.7326/0003-4819-147-1-200707030-00006	http://dx.doi.org/10.7326/0003-4819-147-1-200707030-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186MN	17606959				2023-01-03	WOS:000247782900005
J	Lewis, MH; Gohagan, JK; Merenstein, DJ				Huckaby Lewis, Michelle; Gohagan, John K.; Merenstein, Daniel J.			The locality rule and the physician's dilemma - Local medical practices vs the national standard of care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Johns Hopkins Berman Inst Bioeth, Greenwall Fellowship Program Bioeth & Hlth Policy, Baltimore, MD 21201 USA; Johns Hopkins Sch Med, Robert Wood Johnson Clin Scholars Program, Baltimore, MD USA; Georgetown Univ, Dept Family Med, Washington, DC USA; NCI, Div Canc Prevent, US Natl Inst Hlth, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lewis, MH (corresponding author), Johns Hopkins Berman Inst Bioeth, Greenwall Fellowship Program Bioeth & Hlth Policy, 100 N Charles St,Suite 740, Baltimore, MD 21201 USA.	michellelewismd@yahoo.com						CRAMM T, 2002, WAKE FOREST LAW REV, V37, P699; Eddy DM, 2001, J HEALTH POLIT POLIC, V26, P387, DOI 10.1215/03616878-26-2-387; Garner B. A., 2004, BLACKS LAW DICT, V8th; GROSS SR, 1991, WISC LAW REV, P1113; Merenstein D, 2004, JAMA-J AM MED ASSOC, V291, P15, DOI 10.1001/jama.291.1.15; Peters Jr. Philip G., 2000, WASHINGTON LEE LAW R, V57, P163; Peters PG, 2002, IOWA LAW REV, V87, P909; SWARTZ LC, 2005, 3698 PBI; WALTZ JR, 1969, DEPAUL L REV, V18, P408; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0	10	33	33	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2007	297	23					2633	2637		10.1001/jama.297.23.2633	http://dx.doi.org/10.1001/jama.297.23.2633			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180HB	17579232				2023-01-03	WOS:000247352600027
J	Vincent, JL; Patel, GH; Fox, MD; Snyder, AZ; Baker, JT; Van Essen, DC; Zempel, JM; Snyder, LH; Corbetta, M; Raichle, ME				Vincent, J. L.; Patel, G. H.; Fox, M. D.; Snyder, A. Z.; Baker, J. T.; Van Essen, D. C.; Zempel, J. M.; Snyder, L. H.; Corbetta, M.; Raichle, M. E.			Intrinsic functional architecture in the anaesthetized monkey brain	NATURE			English	Article							MACAQUE MONKEY; PARIETAL LOBE; DEFAULT MODE; CONNECTIONS; NETWORKS; CORTEX; ORGANIZATION; DYNAMICS; IMAGES; AREAS	The traditional approach to studying brain function is to measure physiological responses to controlled sensory, motor and cognitive paradigms. However, most of the brain's energy consumption is devoted to ongoing metabolic activity not clearly associated with any particular stimulus or behaviour(1). Functional magnetic resonance imaging studies in humans aimed at understanding this ongoing activity have shown that spontaneous fluctuations of the blood-oxygen-level-dependent signal occur continuously in the resting state. In humans, these fluctuations are temporally coherent within widely distributed cortical systems that recapitulate the functional architecture of responses evoked by experimentally administered tasks(2-6\). Here, we show that the same phenomenon is present in anaesthetized monkeys even at anaesthetic levels known to induce profound loss of consciousness. We specifically demonstrate coherent spontaneous fluctuations within three well known systems ( oculomotor, somatomotor and visual) and the 'default' system, a set of brain regions thought by some to support uniquely human capabilities. Our results indicate that coherent system fluctuations probably reflect an evolutionarily conserved aspect of brain functional organization that transcends levels of consciousness.	Washington Univ, Dept Radiol, St Louis, MO 63110 USA; Washington Univ, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Washington Univ, Dept Biomed Engn, St Louis, MO 63110 USA; Harvard Univ, Dept Psychol, Ctr Brain Sci, Cambridge, MA 02138 USA; Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Harvard University; Harvard University; Massachusetts General Hospital	Raichle, ME (corresponding author), Washington Univ, Dept Radiol, St Louis, MO 63110 USA.	marc@npg.wustl.edu	anand, amit/A-7222-2009; Kennedy, Kristen M/B-4699-2008; Patel, Gaurav/AAW-3195-2021; Snyder, Lawrence H/A-4593-2017; Corbetta, Maurizio/AAZ-5219-2020; Vincent, Justin L/B-5033-2012; Fox, Michael D./AAZ-3928-2020	Kennedy, Kristen M/0000-0001-5373-9026; Patel, Gaurav/0000-0003-0028-2098; Fox, Michael D./0000-0001-8848-6399; Baker, Justin/0000-0002-6629-2195; CORBETTA, MAURIZIO/0000-0001-8295-3304	NINDS NIH HHS [F31 NS051972] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Addis DR, 2007, NEUROPSYCHOLOGIA, V45, P1363, DOI 10.1016/j.neuropsychologia.2006.10.016; Baker JT, 2006, CEREB CORTEX, V16, P447, DOI 10.1093/cercor/bhi124; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Black KJ, 2004, METHOD ENZYMOL, V385, P91; Brodmann K., 1994, LOCALISATION CEREBRA; Buzsaki G, 2004, SCIENCE, V304, P1926, DOI 10.1126/science.1099745; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Fiser J, 2004, NATURE, V431, P573, DOI 10.1038/nature02907; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2006, P NATL ACAD SCI USA, V103, P10046, DOI 10.1073/pnas.0604187103; GATTASS R, 1988, J NEUROSCI, V8, P1831; Greene JD, 2001, SCIENCE, V293, P2105, DOI 10.1126/science.1062872; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Karnath HO, 2001, NAT REV NEUROSCI, V2, P568, DOI 10.1038/35086057; Kenet T, 2003, NATURE, V425, P954, DOI 10.1038/nature02078; Lancaster JL, 1995, HUM BRAIN MAPP, V3, P209, DOI 10.1002/hbm.460030305; Lewis JW, 2000, J COMP NEUROL, V428, P112, DOI 10.1002/1096-9861(20001204)428:1<112::AID-CNE8>3.0.CO;2-9; Llinas R.R, 2001, I VORTEX NEURONS SEL, Vfirst; MacLean JN, 2005, NEURON, V48, P811, DOI 10.1016/j.neuron.2005.09.035; MAUNSELL JHR, 1987, J COMP NEUROL, V266, P535, DOI 10.1002/cne.902660407; MORCOM AM, IN PRESS NEUROIMAGE; Raichle ME, 2006, SCIENCE, V314, P1249, DOI 10.1126/science.1134405; Raichle ME, 2006, ANNU REV NEUROSCI, V29, P449, DOI 10.1146/annurev.neuro.29.051605.112819; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Saxe R, 2003, NEUROIMAGE, V19, P1835, DOI 10.1016/S1053-8119(03)00230-1; Shulman GL, 1997, J COGNITIVE NEUROSCI, V9, P648, DOI 10.1162/jocn.1997.9.5.648; SUZUKI WA, 1994, J COMP NEUROL, V350, P497, DOI 10.1002/cne.903500402; Tulving E., 2005, MISSING LINK COGNITI, P4, DOI 10.1093/ACPROF:OSO/9780195161564.001.0001; VANESSEN DC, 1984, VISION RES, V24, P429, DOI 10.1016/0042-6989(84)90041-5; VANESSEN DC, 1982, J NEUROSCI, V2, P265; Vincent JL, 2006, J NEUROPHYSIOL, V96, P3517, DOI 10.1152/jn.00048.2006; Vogeley K, 2003, TRENDS COGN SCI, V7, P38, DOI 10.1016/S1364-6613(02)00003-7; Wagner AD, 2005, TRENDS COGN SCI, V9, P445, DOI 10.1016/j.tics.2005.07.001	33	1317	1342	3	98	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 3	2007	447	7140					83	U4		10.1038/nature05758	http://dx.doi.org/10.1038/nature05758			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	163GY	17476267	Green Published			2023-01-03	WOS:000246149300048
J	Diamandis, P; Wildenhain, J; Clarke, ID; Sacher, AG; Graham, J; Bellows, DS; Ling, EKM; Ward, RJ; Jamieson, LG; Tyers, M; Dirks, PB				Diamandis, Phedias; Wildenhain, Jan; Clarke, Ian D.; Sacher, Adrian G.; Graham, Jeremy; Bellows, David S.; Ling, Erick K. M.; Ward, Ryan J.; Jamieson, Leanne G.; Tyers, Mike; Dirks, Peter B.			Chemical genetics reveals a complex functional ground state of neural stem cells	NATURE CHEMICAL BIOLOGY			English	Article							SELF-RENEWAL; ADULT NEUROGENESIS; BRAIN-TUMORS; MEDULLOBLASTOMA; IDENTIFICATION; MOLECULES; HEDGEHOG; DISEASE; CANCER; EGF	The identification of self- renewing and multipotent neural stem cells ( NSCs) in the mammalian brain holds promise for the treatment of neurological diseases and has yielded new insight into brain cancer(1 - 3). However, the complete repertoire of signaling pathways that governs the proliferation and self-renewal of NSCs, which we refer to as the 'ground state', remains largely uncharacterized. Although the candidate gene approach has uncovered vital pathways in NSC biology(4 - 8), so far only a few highly studied pathways have been investigated. Based on the intimate relationship between NSC self- renewal and neurosphere proliferation(8), we undertook a chemical genetic screen for inhibitors of neurosphere proliferation in order to probe the operational circuitry of the NSC. The screen recovered small molecules known to affect neurotransmission pathways previously thought to operate primarily in the mature central nervous system; these compounds also had potent inhibitory effects on cultures enriched for brain cancer stem cells. These results suggest that clinically approved neuromodulators may remodel the mature central nervous system and find application in the treatment of brain cancer.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Ctr, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Program Dev & Stem Cell Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Banting Inst, Dept Lab Med & Pathobiol, Fac Med, Toronto, ON M5G 1L5, Canada; Hosp Sick Children, Div Neurosurg, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Tyers, M (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	tyers@mshri.on.ca; peter.dirks@sickkids.ca	Wildenhain, Jan/Q-6596-2019; Tyers, Michael/ABE-3194-2021; Sacher, Adrian/I-8080-2016; Wildenhain, Jan/E-5597-2011	Wildenhain, Jan/0000-0002-5461-3828; Sacher, Adrian/0000-0001-7865-2701; Wildenhain, Jan/0000-0002-5461-3828; Diamandis, Phedias/0000-0001-5291-9068				Ahn S, 2005, NATURE, V437, P894, DOI 10.1038/nature03994; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; BUTTERWORTH RF, 1975, CAN J BIOCHEM CELL B, V53, P308, DOI 10.1139/o75-043; Chambers JM, 1983, GRAPHICAL METHODS DA; Chen SB, 2006, P NATL ACAD SCI USA, V103, P17266, DOI 10.1073/pnas.0608156103; Corcoran RB, 2001, J NEURO-ONCOL, V53, P307, DOI 10.1023/A:1012260318979; Enver T, 1998, CELL, V94, P9, DOI 10.1016/S0092-8674(00)81215-5; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Ge SY, 2007, TRENDS NEUROSCI, V30, P1, DOI 10.1016/j.tins.2006.11.001; Gritti A, 1999, J NEUROSCI, V19, P3287; Groszer M, 2006, P NATL ACAD SCI USA, V103, P111, DOI 10.1073/pnas.0509939103; Hagg T, 2005, TRENDS NEUROSCI, V28, P589, DOI 10.1016/j.tins.2005.08.009; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Hitoshi S, 2002, GENE DEV, V16, P846, DOI 10.1101/gad.975202; Kevorkov D, 2005, J BIOMOL SCREEN, V10, P557, DOI 10.1177/1087057105276989; Lalonde FM, 2003, BREAST, V12, P280, DOI 10.1016/S0960-9776(03)00061-4; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; MacDonald ML, 2006, NAT CHEM BIOL, V2, P329, DOI 10.1038/nchembio790; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Sharom JR, 2004, CURR OPIN CHEM BIOL, V8, P81, DOI 10.1016/j.cbpa.2003.12.007; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Taylor MD, 2005, CANCER CELL, V8, P323, DOI 10.1016/j.ccr.2005.09.001; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	31	121	125	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1552-4450			NAT CHEM BIOL	Nat. Chem. Biol.	MAY	2007	3	5					268	273		10.1038/nchembio873	http://dx.doi.org/10.1038/nchembio873			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	159FP	17417631				2023-01-03	WOS:000245851100010
J	Zafir-Lavie, I; Michaeli, Y; Reiter, Y				Zafir-Lavie, I.; Michaeli, Y.; Reiter, Y.			Novel antibodies as anticancer agents	ONCOGENE			English	Review						antibody; cancer immunotherapy; tumor antigens; anti tumor mechanisms; targeted therapy; antibody fusions	GROWTH-FACTOR RECEPTOR; SINGLE-CHAIN ANTIBODY; T-CELL-RECEPTOR; PHASE-I TRIAL; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTATIC BREAST-CANCER; RIBOSOME-INACTIVATING PROTEINS; HUMAN RECOMBINANT ANTIBODIES; CD19 BISPECIFIC ANTIBODIES; COLONY-STIMULATING FACTOR	In recent years antibodies, whether generated by traditional hybridoma technology or by recombinant DNA strategies, have evolved from Paul Ehrlich's 'magic bullets' to a modern age 'guided missile'. In the recent years of immunologic research, we are witnessing development in the fields of antigen screening and protein engineering in order to create specific anticancer remedies. The developments in the field of recombinant DNA, protein engineering and cancer biology have let us gain insight into many cancer-related mechanisms. Moreover, novel techniques have facilitated tools allowing unique distinction between malignantly transformed cells, and regular ones. This understanding has paved the way for the rational design of a new age of pharmaceuticals: monoclonal antibodies and their fragments. Antibodies can select antigens on both a specific and a high-affinity account, and further implementation of these qualities is used to target cancer cells by specifically identifying exogenous antigens of cancer cell populations. The structure of the antibody provides plasticity resonating from its functional sites. This review will screen some of the many novel antibodies and antibody-based approaches that are being currently developed for clinical applications as the new generation of anticancer agents.	Technion Israel Inst Technol, Fac Biol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Reiter, Y (corresponding author), Technion Israel Inst Technol, Fac Biol, Room 333, IL-32000 Haifa, Israel.	reiter@tx.technion.ac.il						ABASTADO JP, 1989, RES IMMUNOL, V140, P581, DOI 10.1016/0923-2494(89)90121-1; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Agus DB, 2005, J CLIN ONCOL, V23, P2534, DOI 10.1200/JCO.2005.03.184; Albanell J, 2003, ADV EXP MED BIOL, V532, P253; Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; Alvarez RD, 2000, CLIN CANCER RES, V6, P3081; Andersen PS, 1996, P NATL ACAD SCI USA, V93, P1820, DOI 10.1073/pnas.93.5.1820; ANTMAN KH, 1980, CELL, V19, P627, DOI 10.1016/S0092-8674(80)80039-0; Archer GE, 1999, CLIN CANCER RES, V5, P2646; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BAGSHAWE KD, 1988, BRIT J CANCER, V58, P700, DOI 10.1038/bjc.1988.293; BAGSHAWE KD, 1987, BRIT J CANCER, V55, P299, DOI 10.1038/bjc.1987.58; Bagshawe KD, 1996, TRANSPLANT P, V28, P3156; Barbieri L, 2000, J DRUG TARGET, V8, P281, DOI 10.3109/10611860008997906; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; BARTHELEMY I, 1993, J BIOL CHEM, V268, P6541; Barzilay E, 2005, BIOCHEM BIOPH RES CO, V330, P561, DOI 10.1016/j.bbrc.2005.03.014; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BASELGA J, 2001, EJC SUPPL, V37, P16; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; Beers R, 2000, CLIN CANCER RES, V6, P2835; Bergamaschi G, 1996, BRIT J HAEMATOL, V93, P789, DOI 10.1046/j.1365-2141.1996.d01-1730.x; BIOCCA S, 1990, EMBO J, V9, P101, DOI 10.1002/j.1460-2075.1990.tb08085.x; Birchler M, 1999, NAT BIOTECHNOL, V17, P984, DOI 10.1038/13679; Birkle S, 2003, BIOCHIMIE, V85, P455, DOI 10.1016/S0300-9084(03)00006-3; BODMER WF, 1993, ANN NY ACAD SCI, V690, P42; Bolognesi A, 2002, J BIOL CHEM, V277, P13709, DOI 10.1074/jbc.M111514200; Brandl M, 1999, EXP HEMATOL, V27, P1264, DOI 10.1016/S0301-472X(99)00072-7; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Cao YH, 2004, SEMIN CANCER BIOL, V14, P139, DOI 10.1016/j.semcancer.2003.09.018; Cardoso L.R., 2002, Planta daninha, V20, P1, DOI 10.1590/S0100-83582002000400001; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Challita-Eid PM, 1998, J IMMUNOL, V161, P3729; Chang K, 1996, P NATL ACAD SCI USA, V93, P136, DOI 10.1073/pnas.93.1.136; CHARI RVJ, 1995, CANCER RES, V55, P4079; Chen X, 1998, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V20, P351; Chen YT, 1998, P NATL ACAD SCI USA, V95, P6919, DOI 10.1073/pnas.95.12.6919; Cheng TL, 1999, BRIT J CANCER, V79, P1378, DOI 10.1038/sj.bjc.6690221; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Cohen CJ, 2002, CANCER RES, V62, P5835; Cohen CJ, 2003, J MOL RECOGNIT, V16, P324, DOI 10.1002/jmr.640; Cohen CJ, 2003, J IMMUNOL, V170, P4349, DOI 10.4049/jimmunol.170.8.4349; Cohen Cyril J, 2003, Methods Mol Biol, V207, P269; Colombo MP, 2002, CYTOKINE GROWTH F R, V13, P155, DOI 10.1016/S1359-6101(01)00032-6; Connor JP, 2004, J IMMUNOTHER, V27, P211, DOI 10.1097/00002371-200405000-00005; Csoka M, 1996, LEUKEMIA, V10, P1765; de Graaf M, 2002, BRIT J CANCER, V86, P811, DOI 10.1038/sj.bjc.6600143; Denkberg G, 2003, J IMMUNOL, V171, P2197, DOI 10.4049/jimmunol.171.5.2197; Denkberg G, 2002, J IMMUNOL, V169, P4399, DOI 10.4049/jimmunol.169.8.4399; Denkberg G, 2002, P NATL ACAD SCI USA, V99, P9421, DOI 10.1073/pnas.132285699; Denkberg G, 2006, AUTOIMMUN REV, V5, P252, DOI 10.1016/j.autrev.2005.07.004; Deshane J, 1995, J CLIN INVEST, V96, P2980, DOI 10.1172/JCI118370; DESHANE J, 1995, GYNECOL ONCOL, V59, P8, DOI 10.1006/gyno.1995.1260; DiJoseph JF, 2006, CLIN CANCER RES, V12, P242, DOI 10.1158/1078-0432.CCR-05-1905; Dreier T, 2003, J IMMUNOL, V170, P4397, DOI 10.4049/jimmunol.170.8.4397; Dreier T, 2002, INT J CANCER, V100, P690, DOI 10.1002/ijc.10557; DUC HT, 1993, INT IMMUNOL, V5, P427, DOI 10.1093/intimm/5.4.427; Dudley ME, 2003, NAT REV CANCER, V3, P666, DOI 10.1038/nrc1167; Eichhorn ME, 2004, DRUG RESIST UPDATE, V7, P125, DOI 10.1016/j.drup.2004.03.001; ENDO Y, 1987, J BIOL CHEM, V262, P5908; Endo Y, 1988, Cancer Treat Res, V37, P75; Engberg J, 1999, IMMUNOTECHNOLOGY, V4, P273; Engelhard VH, 2002, IMMUNOL REV, V188, P136, DOI 10.1034/j.1600-065X.2002.18812.x; Esteva FJ, 2002, J CLIN ONCOL, V20, P1800, DOI 10.1200/JCO.2002.07.058; FALINI B, 1992, LANCET, V339, P1195, DOI 10.1016/0140-6736(92)91135-U; FAVALORO EJ, 1987, DIS MARKERS, V5, P215; Ferguson KM, 2004, BIOCHEM SOC T, V32, P742, DOI 10.1042/BST0320742; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; FitzGerald K, 1997, PROTEIN ENG, V10, P1221, DOI 10.1093/protein/10.10.1221; Fleischhauer K, 1996, J IMMUNOL, V157, P787; Foon KA, 2004, INT J RADIAT ONCOL, V58, P984, DOI 10.1016/j.ijrobp.2003.09.098; Francis RJ, 2002, BRIT J CANCER, V87, P600, DOI 10.1038/sj.bjc.6600517; Fraser HM, 2005, J CLIN ENDOCR METAB, V90, P1114, DOI 10.1210/jc.2004-1572; FROSCHER BG, 1986, J EXP MED, V164, P196, DOI 10.1084/jem.164.1.196; Gargano N, 1997, FEBS LETT, V414, P537, DOI 10.1016/S0014-5793(97)01065-X; GATELY MK, 1993, CANCER INVEST, V11, P500, DOI 10.3109/07357909309018881; Gibson TB, 2006, CLIN COLORECTAL CANC, V6, P29, DOI 10.3816/CCC.2006.n.01; Gillies SD, 2005, BLOOD, V105, P3972, DOI 10.1182/blood-2004-09-3533; GLENNIE MJ, 1987, J IMMUNOL, V139, P2367; GOLDMACHER VS, 1992, BIOCHEM BIOPH RES CO, V183, P758, DOI 10.1016/0006-291X(92)90548-Y; Graeven U, 2006, BRIT J CANCER, V94, P1293, DOI 10.1038/sj.bjc.6603083; Grana C, 2002, BRIT J CANCER, V86, P207, DOI 10.1038/sj.bjc.6600047; GRIFFIN JD, 1984, LEUKEMIA RES, V8, P521, DOI 10.1016/0145-2126(84)90001-8; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Haagen I A, 1994, Ther Immunol, V1, P279; Hakamori S, 1998, ACTA ANAT, V161, P79; Harari PM, 2004, ENDOCR-RELAT CANCER, V11, P689, DOI 10.1677/erc.1.00600; Harding J, 2005, DRUG TODAY, V41, P107, DOI 10.1358/dot.2005.41.2.882662; Hassan R, 2004, CLIN CANCER RES, V10, P3937, DOI 10.1158/1078-0432.CCR-03-0801; Hassan R, 2002, CLIN CANCER RES, V8, P3520; Hassanizadeh SM, 2002, VADOSE ZONE J, V1, P38, DOI 10.2136/vzj2002.3800; Held G, 2004, EUR J IMMUNOL, V34, P2919, DOI 10.1002/eji.200425297; Hoffmann P, 2005, INT J CANCER, V115, P98, DOI 10.1002/ijc.20908; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Holliger P, 1999, CANCER RES, V59, P2909; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Hoogenboom HR, 1998, IMMUNOTECHNOLOGY, V4, P1, DOI 10.1016/S1380-2933(98)00007-4; Howard OMZ, 2000, BLOOD, V96, P840, DOI 10.1182/blood.V96.3.840.015k32_840_845; Huang SM, 1999, CANCER RES, V59, P1935; Hyland S, 2003, ONCOGENE, V22, P1557, DOI 10.1038/sj.onc.1206299; Irie RF, 2004, CANCER IMMUNOL IMMUN, V53, P110, DOI 10.1007/s00262-003-0436-1; Jager E, 1998, J EXP MED, V187, P265, DOI 10.1084/jem.187.2.265; Jhanwar YS, 2005, J NUCL MED, V46, p141S; Juweid ME, 1999, CANCER, V85, P1828, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1828::AID-CNCR25>3.0.CO;2-H; Kaminski MS, 2001, J CLIN ONCOL, V19, P3918, DOI 10.1200/JCO.2001.19.19.3918; Karashima T, 2002, CLIN CANCER RES, V8, P1253; Katayose Y, 1996, CANCER RES, V56, P4205; KAWAKAMI Y, 1994, J EXP MED, V180, P347, DOI 10.1084/jem.180.1.347; Kawakami Y, 2000, J IMMUNOTHER, V23, P17, DOI 10.1097/00002371-200001000-00004; KERR DE, 1995, CANCER RES, V55, P3558; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kiessling R, 1999, CANCER IMMUNOL IMMUN, V48, P353, DOI 10.1007/s002620050586; Kiewe P, 2006, CLIN CANCER RES, V12, P3085, DOI 10.1158/1078-0432.CCR-05-2436; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; King DM, 2004, J CLIN ONCOL, V22, P4463, DOI 10.1200/JCO.2004.11.035; Kinugasa T, 1998, INT J CANCER, V76, P148, DOI 10.1002/(SICI)1097-0215(19980330)76:1<148::AID-IJC23>3.3.CO;2-J; Kipriyanov Sergey M, 2002, Methods Mol Biol, V178, P317; Kipriyanov SM, 1998, INT J CANCER, V77, P763, DOI 10.1002/(SICI)1097-0215(19980831)77:5<763::AID-IJC16>3.0.CO;2-2; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kollmannsberger C, 2006, ANN ONCOL, V17, P1007, DOI 10.1093/annonc/mdl042; Korn T, 2004, J GENE MED, V6, P642, DOI 10.1002/jgm.555; Kranz D M, 1995, J Hematother, V4, P403, DOI 10.1089/scd.1.1995.4.403; Kreitman RJ, 2005, J CLIN ONCOL, V23, P6719, DOI 10.1200/JCO.2005.11.437; Kushner BH, 2001, J CLIN ONCOL, V19, P4189, DOI 10.1200/JCO.2001.19.22.4189; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leonard JP, 2004, CLIN CANCER RES, V10, P5327, DOI 10.1158/1078-0432.CCR-04-0294; Lewis LD, 2002, CANCER CHEMOTH PHARM, V49, P375, DOI 10.1007/s00280-002-0424-8; Li JL, 2004, HYBRIDOMA HYBRIDOM, V23, P1, DOI 10.1089/153685904322771962; Li JL, 2003, J IMMUNOTHER, V26, P320, DOI 10.1097/00002371-200307000-00004; Loffler A, 2000, BLOOD, V95, P2098, DOI 10.1182/blood.V95.6.2098; Loffler A, 2003, LEUKEMIA, V17, P900, DOI 10.1038/sj.leu.2402890; Maletz K, 2001, INT J CANCER, V93, P409, DOI 10.1002/ijc.1348; Manzke O, 2001, INT J CANCER, V91, P508, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1068>3.0.CO;2-D; Manzke O, 2001, INT J CANCER, V91, P516, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1069>3.0.CO;2-A; Mapara MY, 2004, J CLIN ONCOL, V22, P1136, DOI 10.1200/JCO.2004.10.041; Marasco WA, 1997, GENE THER, V4, P11, DOI 10.1038/sj.gt.3300346; Matthey B, 2004, INT J CANCER, V111, P568, DOI 10.1002/ijc.20278; McKeage K, 2002, DRUGS, V62, P209, DOI 10.2165/00003495-200262010-00008; McNeel DG, 2005, CLIN CANCER RES, V11, P7851, DOI 10.1158/1078-0432.CCR-05-0262; Mehta K, 2004, MOL CANCER THER, V3, P345; MIESCHER S, 1986, J IMMUNOL, V136, P1899; Mocellin S, 2001, J IMMUNOTHER, V24, P392, DOI 10.1097/00002371-200109000-00002; Modjtahedi H, 2003, INT J CANCER, V105, P273, DOI 10.1002/ijc.11055; MULE JJ, 1987, J IMMUNOL, V139, P285; Multani PS, 1998, CLIN CANCER RES, V4, P2599; NAGANE M, 2001, CANC LETT, V162, P17; Napier MP, 2000, CLIN CANCER RES, V6, P765; Offner S, 2006, MOL IMMUNOL, V43, P763, DOI 10.1016/j.molimm.2005.03.007; Ogg GS, 2000, BRIT J CANCER, V82, P1058; Okamoto I, 2003, CANCER SCI, V94, P50, DOI 10.1111/j.1349-7006.2003.tb01351.x; Omidfar K, 2004, TUMOR BIOL, V25, P179, DOI 10.1159/000081100; Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754; Oved K, 2005, CANCER IMMUNOL IMMUN, V54, P867, DOI 10.1007/s00262-005-0666-5; PAGANELLI G, 1991, NUCL MED COMMUN, V12, P211, DOI 10.1097/00006231-199103000-00006; Paganelli G, 2001, CANCER BIOTHER RADIO, V16, P227, DOI 10.1089/10849780152389410; Pascolo S, 2001, CANCER RES, V61, P4072; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; Peumans WJ, 2001, FASEB J, V15, P1493, DOI 10.1096/fj.00-0751rev; Pittet MJ, 1999, J EXP MED, V190, P705, DOI 10.1084/jem.190.5.705; Plaksin D, 1997, J IMMUNOL, V158, P2218; Polito I, 2004, LEUKEMIA, V18, P1215, DOI 10.1038/sj.leu.2403378; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; Rae JM, 2004, BREAST CANCER RES TR, V87, P87, DOI 10.1023/B:BREA.0000041585.26734.f9; REIST CJ, 1995, CANCER RES, V55, P4375; Reiter Y, 1997, P NATL ACAD SCI USA, V94, P4631, DOI 10.1073/pnas.94.9.4631; Repp R, 2003, BRIT J CANCER, V89, P2234, DOI 10.1038/sj.bjc.6601367; Reusch U, 2006, CLIN CANCER RES, V12, P183, DOI 10.1158/1078-0432.CCR-05-1855; Riesenberg R, 2001, J HISTOCHEM CYTOCHEM, V49, P911, DOI 10.1177/002215540104900711; Robert B, 2000, EUR J IMMUNOL, V30, P3165, DOI 10.1002/1521-4141(200011)30:11<3165::AID-IMMU3165>3.0.CO;2-R; Robinson BWS, 1998, J IMMUNOTHER, V21, P211, DOI 10.1097/00002371-199805000-00007; Romero P, 2002, IMMUNOL REV, V188, P81, DOI 10.1034/j.1600-065X.2002.18808.x; Rosenberg SA, 1998, ANN SURG, V228, P307, DOI 10.1097/00000658-199809000-00004; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Rowinsky EK, 2004, J CLIN ONCOL, V22, P3003, DOI 10.1200/JCO.2004.11.061; Sacchi S, 2001, CRIT REV ONCOL HEMAT, V37, P13, DOI 10.1016/S1040-8428(00)00069-X; Saleh MN, 2000, J CLIN ONCOL, V18, P2282, DOI 10.1200/JCO.2000.18.11.2282; Sanderson RJ, 2005, CLIN CANCER RES, V11, P843; Schaed SG, 2002, CLIN CANCER RES, V8, P967; Schlereth B, 2005, CANCER RES, V65, P2882, DOI 10.1158/0008-5472.CAN-04-2637; Schlosser KL, 2006, SOC NATUR RESOUR, V19, P3, DOI 10.1080/08941920500323096; Schnirring L, 2002, PHYSICIAN SPORTSMED, V30, P4, DOI 10.3810/psm.2002.04.243; Schwaab T, 2001, J IMMUNOTHER, V24, P79, DOI 10.1097/00002371-200101000-00009; Seidman AD, 2001, J CLIN ONCOL, V19, P2587, DOI 10.1200/JCO.2001.19.10.2587; Shan DM, 2000, CANCER IMMUNOL IMMUN, V48, P673, DOI 10.1007/s002620050016; Sharkey RM, 2005, J NUCL MED, V46, P620; Sharkey RM, 2005, J NUCL MED, V46, p115S; SHAW DR, 1988, J BIOL RESP MODIF, V7, P204; Smith J, 2005, FASEB J, V19, P331, DOI 10.1096/fj.04-2863rev; Smith-Jones PM, 2004, METHOD ENZYMOL, V386, P262; SOIFFER RJ, 1993, BLOOD, V82, P2790, DOI 10.1182/blood.V82.9.2790.bloodjournal8292790; Sperr WR, 2005, LEUKEMIA LYMPHOMA, V46, P1115, DOI 10.1080/10428190500126075; STEVENSON GT, 1989, ANTI-CANCER DRUG DES, V3, P219; Stocks M, 2005, CURR OPIN CHEM BIOL, V9, P359, DOI 10.1016/j.cbpa.2005.06.003; Strube RW, 2002, J IMMUNOL METHODS, V263, P149, DOI 10.1016/S0022-1759(02)00035-2; Takai N, 2005, CANCER-AM CANCER SOC, V104, P2701, DOI 10.1002/cncr.21533; TAMMINEN WL, 1987, EUR J IMMUNOL, V17, P999, DOI 10.1002/eji.1830170716; TIEBOUT RF, 1987, J IMMUNOL, V139, P3402; Tijink BM, 2006, J NUCL MED, V47, P1127; Tolcher AW, 1999, J CLIN ONCOL, V17, P478, DOI 10.1200/JCO.1999.17.2.478; Torres LA, 2005, NUCL MED COMMUN, V26, P1049, DOI 10.1097/00006231-200512000-00002; Tse E, 2002, J MOL BIOL, V317, P85, DOI 10.1006/jmbi.2002.5403; Tur MK, 2003, CANCER RES, V63, P8414; Verheul HMW, 2004, J PATHOL, V202, P5, DOI 10.1002/path.1473; Visintin M, 2002, J MOL BIOL, V317, P73, DOI 10.1006/jmbi.2002.5392; Visseren MJW, 1997, INT J CANCER, V73, P125, DOI 10.1002/(SICI)1097-0215(19970926)73:1<125::AID-IJC19>3.0.CO;2-F; Viti F, 1999, CANCER RES, V59, P347; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; WALDMANN TA, 1992, ANN INTERN MED, V116, P148, DOI 10.7326/0003-4819-116-2-148; Waldmann TA, 2002, J CLIN IMMUNOL, V22, P51, DOI 10.1023/A:1014416616687; WALLACE PM, 1994, CANCER RES, V54, P2719; Weng WK, 2003, J CLIN ONCOL, V21, P3940, DOI 10.1200/JCO.2003.05.013; Went P, 2006, BRIT J CANCER, V94, P128, DOI 10.1038/sj.bjc.6602924; Went PT, 2004, HUM PATHOL, V35, P122, DOI 10.1016/j.humpath.2003.08.026; Whiteside TL, 1999, CANCER IMMUNOL IMMUN, V48, P346, DOI 10.1007/s002620050585; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Wimberger P, 2003, INT J CANCER, V105, P241, DOI 10.1002/ijc.11056; Witlox MA, 2002, J GENE MED, V4, P510, DOI 10.1002/jgm.308; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Wolf E, 2005, DRUG DISCOV TODAY, V10, P1237, DOI 10.1016/S1359-6446(05)03554-3; WOLFE F, 1994, J MUSCULOSKELET PAIN, V2, P24; Wulff C, 2002, ENDOCRINOLOGY, V143, P2797, DOI 10.1210/en.143.7.2797; WULFING C, 1994, J MOL BIOL, V242, P655, DOI 10.1006/jmbi.1994.1615; WYLIE DE, 1982, J EXP MED, V155, P403, DOI 10.1084/jem.155.2.403; Xiong DS, 2002, CANCER LETT, V177, P29, DOI 10.1016/S0304-3835(01)00758-3; Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349-7006.2004.tb02181.x; Yamano Y, 2004, J EXP MED, V199, P1367, DOI 10.1084/jem.20032042; Yang XD, 2001, CRIT REV ONCOL HEMAT, V38, P17, DOI 10.1016/S1040-8428(00)00134-7; Yang XD, 1999, CANCER RES, V59, P1236; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327; Yu Rui, 2005, Sheng Wu Gong Cheng Xue Bao, V21, P289; Zaki MH, 2002, J INVEST DERMATOL, V118, P366, DOI 10.1046/j.1523-1747.2002.01646.x; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x; ZEIN N, 1988, SCIENCE, V240, P1198, DOI 10.1126/science.3240341; Zhang Wei, 2002, Angiogenesis, V5, P35, DOI 10.1023/A:1021540120521; ZHOU H, 1993, CANCER RES, V53, P3817; Zhu ZP, 1996, BIO-TECHNOL, V14, P192, DOI 10.1038/nbt0296-192	240	60	67	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3714	3733		10.1038/sj.onc.1210372	http://dx.doi.org/10.1038/sj.onc.1210372			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530025				2023-01-03	WOS:000246816100014
J	Wang, L; Maher, TJ; Wurtman, RJ				Wang, Lei; Maher, Timothy J.; Wurtman, Richard J.			Oral L-glutamine increases GABA levels in striatal tissue and extracellular fluid	FASEB JOURNAL			English	Article						microdialysis; glutamate; neurotransmitter precursor; hepatic encephalopathy	GAMMA-AMINOBUTYRIC-ACID; INDUCED HEPATIC-ENCEPHALOPATHY; BLOOD-BRAIN-BARRIER; RAT-BRAIN; IN-VIVO; METABOLIC COMPARTMENTATION; TRYPTOPHAN LEVELS; TRANSPORT; RELEASE; AMMONIA	We explored the possibility that circulating glutamine affects gamma-aminobutyric acid (GABA) levels in rat striatal tissue and GABA concentrations in striatal extracellular fluid (ECF). Striatal microdialysates, each collected over a 20 min interval, were obtained after no treatment, oral L-glutamine (0.5 g/kg), or glutamine followed by NMDA ( administered via the microdialysis probe). GABA concentrations were measured by HPLC using a stable OPA/sulfite precolumn derivatization and an electrochemical detection method. L-Glutamine administration significantly increased ECF GABA concentrations by 30%, and enhanced the response evoked by NMDA alone (70%) to 120% over baseline (all P < 0.05). Striatal GABA levels increased significantly 2.5 h after oral L-glutamine ( e. g., from 1.76 +/- 0.04 mu mol/g in vehicle-treated rats to 2.00 +/- 0.15 mu mol/g in those receiving 2.0 g/kg of glutamine). Striatal glutamine levels also increased significantly, but not those of glutamate. These data suggest that GABA synthesis in, and release from, rat striatum may be regulated in part by circulating glutamine. Hence, glutamine administration may provide a useful adjunct for treating disorders ( e. g., anxiety, seizures) when enhanced GABAergic transmission is desired. Moreover, the elevation in plasma and brain glutamine associated with hepatic failure may, by increasing brain GABA release, produce some of the manifestations of hepatic encephalopathy.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; Masachusetts Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Boston, MA USA	Massachusetts Institute of Technology (MIT)	Wurtman, RJ (corresponding author), MIT, Dept Brain & Cognit Sci, 43 Vassar St,46-5023B, Cambridge, MA 02139 USA.	dick@mit.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH028783] Funding Source: NIH RePORTER; NIMH NIH HHS [2 R01 MH028783-31] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ACWORTH IN, 1988, BRAIN RES BULL, V21, P473, DOI 10.1016/0361-9230(88)90161-X; Anagnostaras SG, 1999, NAT NEUROSCI, V2, P780, DOI 10.1038/12146; Bak LK, 2006, J NEUROCHEM, V98, P641, DOI 10.1111/j.1471-4159.2006.03913.x; Basile AS, 2002, NEUROCHEM INT, V41, P115, DOI 10.1016/S0197-0186(02)00032-3; BATTAGLIOLI G, 1991, NEUROCHEM RES, V16, P151, DOI 10.1007/BF00965703; Battaglioli G, 1996, NEUROSCI LETT, V209, P129, DOI 10.1016/0304-3940(96)12606-9; BENES FM, 1991, ARCH GEN PSYCHIAT, V48, P996; CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025; DECHELOTTE P, 1991, AM J PHYSIOL, V260, pG677, DOI 10.1152/ajpgi.1991.260.5.G677; DEJONG CHC, 1992, J NEUROCHEM, V59, P1071, DOI 10.1111/j.1471-4159.1992.tb08349.x; DONZANTI BA, 1988, LIFE SCI, V43, P913, DOI 10.1016/0024-3205(88)90267-6; Ennis SR, 1998, J NEUROCHEM, V71, P2565; FERNSTROM JD, 1971, SCIENCE, V173, P149, DOI 10.1126/science.173.3992.149; FUNOVICS JM, 1978, J NEURAL TRANSM, P61; GRIPPON P, 1986, HEPATOLOGY, V6, P682, DOI 10.1002/hep.1840060424; HILGIER W, 1994, J NEUROCHEM, V62, P197; Kanamori K, 2005, J NEUROCHEM, V94, P74, DOI 10.1111/j.1471-4159.2005.03170.x; Kanamori K, 2004, J NEUROCHEM, V90, P203, DOI 10.1111/j.1471-4159.2004.02478.x; KEEP RF, 1995, J NEUROCHEM, V65, P2571; Kohling R, 2002, SCIENCE, V298, P1350; Lacey Janet M., 1996, Journal of Parenteral and Enteral Nutrition, V20, P74, DOI 10.1177/014860719602000174; LARSSON OM, 1985, INT J DEV NEUROSCI, V3, P177, DOI 10.1016/0736-5748(85)90008-5; LAVOIE J, 1987, J NEUROCHEM, V49, P692, DOI 10.1111/j.1471-4159.1987.tb00949.x; LIEBSCHUTZ J, 1977, BIOCHEM PHARMACOL, V26, P443, DOI 10.1016/0006-2952(77)90206-4; MARTIN DL, 1993, J NEUROCHEM, V60, P395, DOI 10.1111/j.1471-4159.1993.tb03165.x; MELAMED E, 1980, P NATL ACAD SCI-BIOL, V77, P4305, DOI 10.1073/pnas.77.7.4305; Pardridge WM, 1979, GLUTAMIC ACID ADV BI, P125; Patel AB, 2001, BRAIN RES, V919, P207, DOI 10.1016/S0006-8993(01)03015-3; PATEL AJ, 1974, J NEUROCHEM, V23, P1271; Paxinos G., 2004, RAT BRAIN STEREOTAXI; Rae C, 2003, J NEUROCHEM, V85, P503, DOI 10.1046/j.1471-4159.2003.01713.x; SCHAECHTER JD, 1990, BRAIN RES, V532, P203, DOI 10.1016/0006-8993(90)91761-5; Smismans A, 1997, DIABETOLOGIA, V40, P1411, DOI 10.1007/s001250050843; SMITH QR, 1987, J NEUROCHEM, V49, P1651, DOI 10.1111/j.1471-4159.1987.tb01039.x; SMITH S, 1994, J CHROMATOGR B, V652, P228, DOI 10.1016/0378-4347(93)E0391-3; STORMMATHISEN J, 1983, NATURE, V301, P517, DOI 10.1038/301517a0; VANLEEUWEN PAM, 1991, SURGERY, V110, P169; Vogels BAPM, 1997, J HEPATOL, V26, P387, DOI 10.1016/S0168-8278(97)80057-8; Waagepetersen HS, 1999, J NEUROCHEM, V73, P1335, DOI 10.1046/j.1471-4159.1999.0731335.x; WEISER M, 1978, J NEURAL TRANSM, P95; WHITE HL, 1981, MOL CELL BIOCHEM, V39, P253, DOI 10.1007/BF00232578; WURTMAN RJ, 1980, PHARMACOL REV, V32, P315; WYSMYK U, 1992, NEUROCHEM RES, V17, P1187, DOI 10.1007/BF00968397; ZENEROLI ML, 1982, J NEUROCHEM, V38, P1219, DOI 10.1111/j.1471-4159.1982.tb07893.x	44	41	45	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1227	1232		10.1096/fj.06-7495com	http://dx.doi.org/10.1096/fj.06-7495com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17218538				2023-01-03	WOS:000245650400026
J	Huikeshoven, M; Koster, PHL; de Borgie, CAJM; Beek, JF; van Gemert, MJC; van der Horst, CMAM				Huikeshoven, Menno; Koster, Petra H. L.; de Borgie, Corianne A. J. M.; Beek, Johan F.; van Gemert, Martin J. C.; van der Horst, Chantal M. A. M.			Redarkening of port-wine stains 10 years after pulsed-dye-laser treatment	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EFFICACY	Background: Although pulsed-dye-laser therapy is currently the gold standard for the treatment of port-wine stains, few objective data are available on its long-term efficacy. Using objective color measurements, we performed a 10-year follow-up of a previously conducted prospective clinical study of the treatment of port-wine stains with a pulsed-dye laser. Methods: We invited the patients to undergo repeated color measurements performed by the same procedures as in the previous study. The results at long-term follow-up were compared with color measurements obtained before treatment and after completion of an average of five laser treatments of the complete port-wine stain. A questionnaire was used to investigate patients' satisfaction with the treatment and their perception of long-term changes in the stain. Results: Of the 89 patients from whom color measurements were obtained in the previous study, 51 were included in this study. The patients had received a median of seven additional treatment sessions since the last color measurement, which had been made after an average of five treatments. The median length of follow-up was 9.5 years. On average, the stain when measured at follow-up was significantly darker than it was when measured after the last of the initial five laser treatments (P=0.001), but it was still significantly lighter than it was when measured before treatment (P<0.001). Fifty-nine percent of patients were satisfied with the overall treatment result. Six percent of patients reported that the stain had become lighter since their last treatment, 59% that it was unchanged, and 35% that it had become darker. Conclusions: Using objective color measurements, we observed significant redarkening of port-wine stains at long-term follow-up after pulsed-dye-laser therapy. Patients should be informed about the possibility of redarkening before beginning treatment.	Univ Amsterdam, Acad Med Ctr, Dept Plast Reconstruct & Hand Surg, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Ctr Laser, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Huikeshoven, M (corresponding author), Univ Amsterdam, Acad Med Ctr G4 226, Dept Plast Reconstruct & Hand Surg, Meibergdreeef 9, NL-1105 AZ Amsterdam, Netherlands.	m.huikeshoven@amc.uva.nl		van der Horst, chantal/0000-0002-4937-3786				BARSKY SH, 1980, J INVEST DERMATOL, V74, P154, DOI 10.1111/1523-1747.ep12535052; BRAINARD DH, 1995, HDB OPTICS, V1; Breugem CC, 2005, PLAST RECONSTR SURG, V115, P578, DOI 10.1097/01.PRS.0000150150.69479.70; Hansen K, 2003, DERMATOL SURG, V29, P49, DOI 10.1046/j.1524-4725.2003.29010.x; Heger M, 2005, THROMB HAEMOSTASIS, V93, P242, DOI 10.1160/TH04-05-0291; Ho WS, 2002, LASER SURG MED, V30, P44, DOI 10.1002/lsm.10003; Koster PHL, 1998, PLAST RECONSTR SURG, V102, P1210, DOI 10.1097/00006534-199809040-00047; Michel S, 2000, BRIT J DERMATOL, V143, P1230, DOI 10.1046/j.1365-2133.2000.03893.x; MORK NJ, 1998, J EUR ACAD DERMATOL, V11, pS142; Orten SS, 1996, ARCH OTOLARYNGOL, V122, P1174; Ozluer SM, 2001, CLIN EXP DERMATOL, V26, P37, DOI 10.1046/j.1365-2230.2001.00756.x; ROSEN S, 1987, J AM ACAD DERMATOL, V17, P164, DOI 10.1016/S0190-9622(87)70186-8; TAN OT, 1989, NEW ENGL J MED, V320, P416, DOI 10.1056/NEJM198902163200702; TAN OT, 1992, MANAGEMENT TREATMENT, P83; Troilius A, 2000, DERMATOL SURG, V26, P190, DOI 10.1046/j.1524-4725.2000.09204.x; van der Horst CMAM, 1998, NEW ENGL J MED, V338, P1028, DOI 10.1056/NEJM199804093381504	16	92	98	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2007	356	12					1235	1240		10.1056/NEJMoa064329	http://dx.doi.org/10.1056/NEJMoa064329			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148UP	17377161				2023-01-03	WOS:000245101900008
J	El-Shemy, HA; Aboul-Enein, AM; Aboul-Enein, KM; Fujita, K				El-Shemy, Hany A.; Aboul-Enein, Ahmed M.; Aboul-Enein, Khalid Mostafa; Fujita, Kounosuke			Willow Leaves' Extracts Contain Anti-Tumor Agents Effective against Three Cell Types	PLOS ONE			English	Article								Many higher plants contain novel metabolites with antimicrobial, antifungal and antiviral properties. However, in the developed world almost all clinically used chemotherapeutics have been produced by in vitro chemical synthesis. Exceptions, like taxol and vincristine, were structurally complex metabolites that were difficult to synthesize in vitro. Many non-natural, synthetic drugs cause severe side effects that were not acceptable except as treatments of last resort for terminal diseases such as cancer. The metabolites discovered in medicinal plants may avoid the side effect of synthetic drugs, because they must accumulate within living cells. The aim here was to test an aqueous extract from the young developing leaves of willow (Salix safsaf, Salicaceae) trees for activity against human carcinoma cells in vivo and in vitro. In vivo Ehrlich Ascites Carcinoma Cells (EACC) were injected into the intraperitoneal cavity of mice. The willow extract was fed via stomach tube. The (EACC) derived tumor growth was reduced by the willow extract and death was delayed (for 35 days). In vitro the willow extract could kill the majority (75%-80%) of abnormal cells among primary cells harvested from seven patients with acute lymphoblastic leukemia (ALL) and 13 with AML (acute myeloid leukemia). DNA fragmentation patterns within treated cells inferred targeted cell death by apoptosis had occurred. The metabolites within the willow extract may act as tumor inhibitors that promote apoptosis, cause DNA damage, and affect cell membranes and/or denature proteins.	[El-Shemy, Hany A.; Aboul-Enein, Ahmed M.] Cairo Univ, Fac Agr, Dept Biochem, Giza, Egypt; [Aboul-Enein, Khalid Mostafa] Cairo Univ, Natl Canc Inst, Dept Clin Pathol, Cairo, Egypt; [El-Shemy, Hany A.; Fujita, Kounosuke] Hiroshima Univ, Grad Sch Biosphere Sci, Hiroshima, Japan	Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Cairo University; National Cancer Institute - Egypt; Hiroshima University	El-Shemy, HA (corresponding author), Cairo Univ, Fac Agr, Dept Biochem, Giza, Egypt.	helshemy@hotmail.com	El-Shemy, Hany A./A-6367-2008	Aboul-Enein, Ahmed/0000-0002-3350-3451				ADAMKIEWICZ V, 1961, CAN J BIOCHEM PHYS, V39, P1097, DOI 10.1139/o61-111; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BHATT KKS, 1995, MEDICINAL PLANT INFO; Bravo L, 1998, NUTR REV, V56, P317, DOI 10.1111/j.1753-4887.1998.tb01670.x; Cheng JT, 2000, J CLIN PHARMACOL, V40, P445, DOI 10.1177/00912700022009198; CLAUDIA O, 2003, LANCET ONCOL, V4, P200; Clement MV, 1998, BLOOD, V92, P996; El-Shemy HA, 2003, J BIOCHEM MOL BIOL, V36, P387; Fiehn O, 2000, NAT BIOTECHNOL, V18, P1157, DOI 10.1038/81137; Freeman M, 2002, ANNU REV CELL DEV BI, V18, P515, DOI 10.1146/annurev.cellbio.18.012502.083458; Gao XH, 2002, J NUTR, V132, P2076, DOI 10.1093/jn/132.7.2076; GRONBECK M, 1995, BRIT MED J, V310, P1169; Han SS, 2002, J BIOCHEM MOL BIOL, V35, P337; Hsieh TC, 1999, EXP CELL RES, V249, P109, DOI 10.1006/excr.1999.4471; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; KUPCHAN SM, 1976, SCIENCE, V191, P571, DOI 10.1126/science.1251193; Leven MD, 1979, PLANTA MED, V36, P311; MATSUMOTO Y, 1993, J PHARM SCI, V82, P399, DOI 10.1002/jps.2600820413; METZNER J, 1989, PHARMAZIE, V44, P555; Mungur R, 2005, J BIOMED BIOTECHNOL, V2, P198, DOI DOI 10.1016/J.CHEMOLAB.2010.04.010; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; STEINEGGER E, 1972, PHARM ACTA HELV, V47, P222; WILLETT WC, 1994, SCIENCE, V264, P532, DOI 10.1126/science.8160011; Wood M, 1997, BOOK HERBAL WISDOM U	25	47	52	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2007	2	1							e178	10.1371/journal.pone.0000178	http://dx.doi.org/10.1371/journal.pone.0000178			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DH	17264881	Green Published, Green Submitted, gold			2023-01-03	WOS:000207444200003
J	Kushel, MB; Miaskowski, C				Kushel, Margot B.; Miaskowski, Christine			End-of-life care for homeless patients - "She says she is there to help me in any situation"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEVERE MENTAL-ILLNESS; NEW-YORK-CITY; UNITED-STATES; MEDICAL-CARE; RISK-FACTORS; CONTROLLED SUBSTANCES; SUSTAINING TREATMENT; OPIOID DEPENDENCE; PAIN MANAGEMENT; ADULTS	Homelessness annually affects an estimated 2.3 million to 3.5 million individuals living in the United States. Homeless people face difficulties in meeting their basic needs. Many have substance abuse problems and mental illness, lack social support, and have no medical insurance. These challenges complicate the homeless patient's ability to engage in end-of-life advanced planning, adhere to medications, and find an adequate site to receive terminal care. Employing a multidisciplinary team to care for homeless patients can help address their needs and improve care. For patients who continue to use illicit substances while receiving end-of-life care, experts recommend scheduling frequent clinic visits, using long-acting pain medications, dispensing small quantities of medications at a time, and using a written pain agreement. Homeless people are less likely to have a surrogate decision maker. Clinicians should have frequent, well-documented conversations with these patients about end-of-life wishes. Homeless people can rarely use hospice services because they lack the financial resources for inpatient hospice and have neither the home nor the social support required for home hospice. Developing inpatient palliative care services at hospitals that serve many homeless people could improve the end-of-life care homeless people receive.	Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Div Gen Internal Med, San Francisco, CA USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Kushel, MB (corresponding author), Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, Box 1364, San Francisco, CA 94143 USA.	mkushel@medsfgh.ucsf.edu		Kushel, Margot/0000-0002-1361-6889	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS011415] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA107091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR003923] Funding Source: NIH RePORTER; AHRQ HHS [K08 HS011415] Funding Source: Medline; NCI NIH HHS [CA107091] Funding Source: Medline; NINR NIH HHS [NR03923] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		ASCH DA, 1995, AM J RESP CRIT CARE, V151, P288, DOI 10.1164/ajrccm.151.2.7842181; Ashburn MA, 2003, PRINCIPLES ANALGESIC; Bamberger JD, 2000, AM J PUBLIC HEALTH, V90, P699, DOI 10.2105/AJPH.90.5.699; Barrow SM, 1999, AM J PUBLIC HEALTH, V89, P529, DOI 10.2105/AJPH.89.4.529; Blendon RJ, 1998, JAMA-J AM MED ASSOC, V279, P827, DOI 10.1001/jama.279.11.827; Bonin E., 2004, ADAPTING YOUR PRACTI; Buchanan D, 2006, AM J PUBLIC HEALTH, V96, P1278, DOI 10.2105/AJPH.2005.067850; Burt M. R., 2006, CHARACTERISTICS TRAN; BURT MR, 1999, HOMELESSNESS PROGRAM; Burt MR, 2001, HELPING AM HOMELESS; Caton CLM, 2005, AM J PUBLIC HEALTH, V95, P1753, DOI 10.2105/AJPH.2005.063321; Caton CLM, 2000, AM J PUBLIC HEALTH, V90, P258, DOI 10.2105/AJPH.90.2.258; Cicero TJ, 2005, J PAIN, V6, P662, DOI 10.1016/j.jpain.2005.05.004; Culhane DP, 2002, HOUS POLICY DEBATE, V13, P107, DOI 10.1080/10511482.2002.9521437; Cunningham WE, 1999, MED CARE, V37, P1270, DOI 10.1097/00005650-199912000-00010; Dumais A, 2005, AM J PSYCHIAT, V162, P2116, DOI 10.1176/appi.ajp.162.11.2116; *FED STAT MED BOAR, PAIN POL RES CTR WEB; *FED STAT MED BOAR, 2004, MOD POL US CONTR SUB; Fishman SM, 1999, J PAIN SYMPTOM MANAG, V18, P27, DOI 10.1016/S0885-3924(99)00035-4; Fishman SM, 2002, CLIN J PAIN, V18, pS70, DOI 10.1097/00002508-200207001-00008; Friedmann PD, 2006, MED CARE, V44, P8, DOI 10.1097/01.mlr.0000188913.50489.77; Gelberg L, 1997, AM J PUBLIC HEALTH, V87, P217, DOI 10.2105/AJPH.87.2.217; GELBERG L, 1989, JAMA-J AM MED ASSOC, V262, P1973, DOI 10.1001/jama.262.14.1973; Gilson AM, 2001, J PAIN SYMPTOM MANAG, V21, P227, DOI 10.1016/S0885-3924(00)00263-3; Grant BF, 2005, J CLIN PSYCHIAT, V66, P1205, DOI 10.4088/JCP.v66n1001; Hernandez M, 2005, CURR OPIN ANESTHESIO, V18, P315, DOI 10.1097/01.aco.0000169241.21680.0b; HIBBS JR, 1994, NEW ENGL J MED, V331, P304, DOI 10.1056/NEJM199408043310506; *HLTH CAR HOM CLIN, 2004, HEAL HANDS HCH CLIN; Hwang SW, 2000, CAN MED ASSOC J, V163, P161; Hwang SW, 1997, ANN INTERN MED, V126, P625, DOI 10.7326/0003-4819-126-8-199704150-00007; Hwang SW, 2000, JAMA-J AM MED ASSOC, V283, P2152, DOI 10.1001/jama.283.16.2152; Johnson RE, 2000, NEW ENGL J MED, V343, P1290, DOI 10.1056/NEJM200011023431802; Joranson DE, 2002, J PAIN SYMPTOM MANAG, V23, P138, DOI 10.1016/S0885-3924(01)00403-1; KARP N, 2003, INCAPACITATED HLTH C; Kertesz SG, 2005, MED CARE, V43, P574, DOI 10.1097/01.mlr.0000163652.91463.b4; Kessell ER, 2006, J URBAN HEALTH, V83, P860, DOI 10.1007/s11524-006-9083-0; Kirkpatrick AF, 1998, J CLIN ANESTH, V10, P435, DOI 10.1016/S0952-8180(98)00062-2; Korkeila JA, 2005, COMPR PSYCHIAT, V46, P447, DOI 10.1016/j.comppsych.2005.03.008; Krantz MJ, 2004, ARCH INTERN MED, V164, P277, DOI 10.1001/archinte.164.3.277; Kushel MB, 2001, JAMA-J AM MED ASSOC, V285, P200, DOI 10.1001/jama.285.2.200; Kushel MB, 2002, AM J PUBLIC HEALTH, V92, P778, DOI 10.2105/AJPH.92.5.778; LING W, 1994, J PSYCHOACTIVE DRUGS, V26, P119, DOI 10.1080/02791072.1994.10472259; LINHORST DM, 1991, COMMUNITY MENT HLT J, V27, P135, DOI 10.1007/BF00752816; Lipton FR, 2000, PSYCHIATR SERV, V51, P479, DOI 10.1176/appi.ps.51.4.479; Loas G, 2005, PSYCHIAT RES, V137, P103, DOI 10.1016/j.psychres.2004.06.022; MARTELL JV, 1992, ANN INTERN MED, V116, P299, DOI 10.7326/0003-4819-116-4-299; Merrill J, 2002, J GEN INTERN MED, V17, P327, DOI 10.1046/j.1525-1497.2002.10625.x; MIASKOWSKI C, 2005, CLIN PRACTICE GUIDEL, V3; Morrison RS, 2005, J PALLIAT MED, V8, P1127, DOI 10.1089/jpm.2005.8.1127; Moss AR, 2004, CLIN INFECT DIS, V39, P1190, DOI 10.1086/424008; Norris WM, 2005, CHEST, V127, P2180, DOI 10.1378/chest.127.6.2180; O'Connor PG, 2000, ANN INTERN MED, V133, P40, DOI 10.7326/0003-4819-133-1-200007040-00008; Passik S. D., 2002, PRINCIPLES PRACTICE; Passik SD, 2001, J PAIN SYMPTOM MANAG, V21, P359, DOI 10.1016/S0885-3924(01)00279-2; Passik Steven D, 2002, J Pain Palliat Care Pharmacother, V16, P39; Passik Steven D, 2004, Curr Pain Headache Rep, V8, P289, DOI 10.1007/s11916-004-0010-3; Rosenheck R, 2003, ARCH GEN PSYCHIAT, V60, P940, DOI 10.1001/archpsyc.60.9.940; Rosenheck R, 1998, MED CARE, V36, P1256, DOI 10.1097/00005650-199808000-00013; Salit SA, 1998, NEW ENGL J MED, V338, P1734, DOI 10.1056/NEJM199806113382406; Song J, 2005, J CLIN ETHIC, V16, P251; Tarzian Anita J, 2005, J Palliat Med, V8, P36, DOI 10.1089/jpm.2005.8.36; Tsai M, 2005, J HEALTH CARE POOR U, V16, P297, DOI 10.1353/hpu.2005.0042; Tsemberis S, 2000, PSYCHIATR SERV, V51, P487, DOI 10.1176/appi.ps.51.4.487; Tsemberis S, 2005, PSYCHIAT SERV, V56, P1303; Tulsky JP, 2004, INT J TUBERC LUNG D, V8, P83; *US DEP HOUS URB D, SUPP HOUS PROGR; *US DEP HOUS URB D, HOUS CHOIC VOCH FACT; US Department of Housing and Urban Development, HUDS PUBL HOUS PROGR; WEISSMAN DE, 1989, PAIN, V36, P363, DOI 10.1016/0304-3959(89)90097-3; White DB, 2006, CRIT CARE MED, V34, P2053, DOI 10.1097/01.CCM.0000227654.38708.C1; White KR, 2002, MED CARE, V40, P17, DOI 10.1097/00005650-200201000-00004; Zacny J, 2003, DRUG ALCOHOL DEPEN, V69, P215, DOI 10.1016/S0376-8716(03)00003-6; Zlotnick C, 2003, SUBST USE MISUSE, V38, P577, DOI 10.1081/JA-120017386	73	37	38	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2006	296	24					2959	2966		10.1001/jama.296.24.2959	http://dx.doi.org/10.1001/jama.296.24.2959			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	120FD	17190897				2023-01-03	WOS:000243069000028
J	van Rheenen, PF; Brabin, BJ				van Rheenen, Patrick F.; Brabin, Bernard J.			A practical approach to timing cord clamping in resource poor settings	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; UMBILICAL-CORD; PLACENTAL TRANSFUSION; PRETERM INFANTS; DEVELOPING-COUNTRIES; LEBOYER CHILDBIRTH; IRON-DEFICIENCY; BLOOD-VISCOSITY; TERM INFANTS; FETAL ANEMIA		Univ Groningen, Univ Med Ctr Groningen, Dept Paediat, NL-9700 RB Groningen, Netherlands; Emma Childrens Hosp, Acad Med Ctr, Amsterdam, Netherlands	University of Groningen; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam	van Rheenen, PF (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Paediat, POB 30001, NL-9700 RB Groningen, Netherlands.	p.f.vanrheenen@gmail.com	Brabin, Bernard/AAJ-7389-2020	Brabin, Bernard/0000-0001-6860-2508; /0000-0003-3867-2665				Aladangady N, 2006, PEDIATRICS, V117, P93, DOI 10.1542/peds.2004-1773; [Anonymous], 2004, COCHRANE REV HDB 4 2; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Begley C M, 1990, Midwifery, V6, P3, DOI 10.1016/S0266-6138(05)80091-9; Bhutta ZA, 1999, PEDIATR PULM, V27, P305, DOI 10.1002/(SICI)1099-0496(199905)27:5<305::AID-PPUL2>3.0.CO;2-Q; Brabin B, 2003, T ROY SOC TROP MED H, V97, P36, DOI 10.1016/S0035-9203(03)90014-9; BRABIN B, 1992, ANN TROP PAEDIATR, V12, P303, DOI 10.1080/02724936.1992.11747589; Brabin BJ, 2004, ANN TROP PAEDIATR, V24, P311, DOI 10.1179/027249304225019136; Brabin BJ, 2001, J NUTR, V131, p636S, DOI 10.1093/jn/131.2.636S; Cernadas JMC, 2006, PEDIATRICS, V117, pE779, DOI 10.1542/peds.2005-1156; Chaparro CM, 2006, LANCET, V367, P1997, DOI 10.1016/S0140-6736(06)68889-2; CHOCKALINGAM UM, 1987, J PEDIATR-US, V111, P283, DOI 10.1016/S0022-3476(87)80088-4; COTTER A, 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001808, DOI 10.1002/14651858.CD001808]; Crawley J, 2004, AM J TROP MED HYG, V71, P25, DOI 10.4269/ajtmh.2004.71.25; Emhamed MO, 2004, TROP DOCT, V34, P218, DOI 10.1177/004947550403400410; Geethanath R M, 1997, Indian Pediatr, V34, P103; Grajeda R, 1997, AM J CLIN NUTR, V65, P425, DOI 10.1093/ajcn/65.2.425; Grantham-McGregor S, 2001, J NUTR, V131, p649S, DOI 10.1093/jn/131.2.649S; Gupta Rajesh, 2002, Indian Pediatr, V39, P130; Hay WW., 1999, NEONATOLOGY PATHOPHY, P411; HOFMEYR GJ, 1993, ONLINE J CURR CLIN T, V110, P2002; Kambarami R., 2000, Central African Journal of Medicine, V46, P205; Khan GQ, 1997, AM J OBSTET GYNECOL, V177, P770, DOI 10.1016/S0002-9378(97)70266-7; KINMOND S, 1993, BMJ-BRIT MED J, V306, P172, DOI 10.1136/bmj.306.6871.172; Lalonde A, 2006, INT J GYNECOL OBSTET, V94, P243, DOI 10.1016/j.ijgo.2006.04.016; LANZKOWSKY P, 1960, BRIT MED J, V2, P1777, DOI 10.1136/bmj.2.5215.1777; le Cessie S, 2002, ARCH DIS CHILD-FETAL, V86, P182, DOI 10.1136/fn.86.3.F182; LINDERKAMP O, 1992, ACTA PAEDIATR, V81, P745, DOI 10.1111/j.1651-2227.1992.tb12095.x; LINDERKAMP O, 1982, CLIN PERINATOL, V9, P559, DOI 10.1016/S0095-5108(18)31013-3; McDonnell M, 1997, J PAEDIATR CHILD H, V33, P308, DOI 10.1111/j.1440-1754.1997.tb01606.x; Mercer JS, 2006, PEDIATRICS, V117, P1235, DOI 10.1542/peds.2005-1706; Mercer Judith S, 2003, J Perinatol, V23, P466, DOI 10.1038/sj.jp.7210970; MONDKAR FA, 1993, J POSTGRAD MED, V39, P57; NELLE M, 1995, AM J PERINAT, V12, P212, DOI 10.1055/s-2007-994455; NELLE M, 1993, AM J OBSTET GYNECOL, V169, P189, DOI 10.1016/0002-9378(93)90161-B; Nelle M, 1996, J PERINAT MED, V24, P513, DOI 10.1515/jpme.1996.24.5.513; PAOCHEN W, 1960, CHIN MED J, V80, P351; Perlman JM, 2006, PEDIATRICS, V117, pE978, DOI 10.1542/ped.2006-0350; PRENDIVILLE WJ, 1988, BMJ-BRIT MED J, V297, P1295, DOI 10.1136/bmj.297.6659.1295; PRENDIVILLE WJ, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000007, DOI 10.1002/14651858.CD000007]; Rabe H, 2000, EUR J PEDIATR, V159, P775, DOI 10.1007/PL00008345; Rogers J, 1998, LANCET, V351, P693, DOI 10.1016/S0140-6736(97)09409-9; SAIGAL S, 1972, PEDIATRICS, V49, P406; Schellenberg D, 2003, B WORLD HEALTH ORGAN, V81, P581; van Eijk AM, 2002, AM J TROP MED HYG, V67, P44, DOI 10.4269/ajtmh.2002.67.44; Van Rheenen P, 2004, ANN TROP PAEDIATR, V24, P3, DOI 10.1179/027249304225013286; van Rheenen PF, 2006, ANN TROP PAEDIATR, V26, P157, DOI 10.1179/146532806X120246; VANRHEENEN PF, DELAYED CORD CLAMPIN; WARDROP CAJ, 1995, J PERINAT MED, V23, P139, DOI 10.1515/jpme.1995.23.1-2.139; YAO AC, 1969, LANCET, V2, P505; YAO AC, 1974, AM J DIS CHILD, V127, P128, DOI 10.1001/archpedi.1974.02110200130021; YAO AC, 1974, BIOL NEONATE, V25, P186; YAO AC, 1968, LANCET, V1, P380; YAO AC, 1969, LANCET, V2, P871	54	44	44	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 4	2006	333	7575					954	958B		10.1136/bmj.39002.389236.BE	http://dx.doi.org/10.1136/bmj.39002.389236.BE			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	107GE	17082547	Green Published			2023-01-03	WOS:000242157900022
J	Oxman, AD; Flottorp, S; Havelsrud, K; Fretheim, A; Odgaard-Jensen, J; Austvoll-Dahlgren, A; Carling, C; Pallesen, S; Bjorvatn, B				Oxman, Andrew D.; Flottorp, Signe; Havelsrud, Kari; Fretheim, Atle; Odgaard-Jensen, Jan; Austvoll-Dahlgren, Astrid; Carling, Cheryl; Pallesen, Stale; Bjorvatn, Bjorn			A Televised, Web-Based Randomised Trial of an Herbal Remedy (Valerian) for Insomnia	PLOS ONE			English	Article							DOUBLE-BLIND; SLEEP; DIPHENHYDRAMINE; EXTRACT	Background. This trial was conducted as part of a project that aims to enhance public understanding and use of research in decisions about healthcare by enabling viewers to participate in research and to follow the process, through television reports and on the web. Valerian is an herbal over-the-counter drug that is widely used for insomnia. Systematic reviews have found inconsistent and inconclusive results about its effects. Methods. Participants were recruited through a weekly nationally televised health program in Norway. Enrolment and data collection were over the Internet. 405 participants who were 18 to 75 years old and had insomnia completed a two week diary-keeping run-in period without treatment and were randomised and mailed valerian or placebo tablets for two weeks. All participants and investigators were blind to treatment until after the analysis was completed. Findings. For the primary outcome of a minimally important improvement in self-reported sleep quality (>= 0.5 units on a 7 point scale), the difference between the valerian group (29%) and the placebo group (21%) was not statistically significant (difference 7.5%; 95% CI-0.9 to 15.9; p = 0.08). On the global self-assessment question at the end of the treatment period 5.5% (95% CI 0.2 to 10.8) more participants in the valerian group perceived their sleep as better or much better (p = 0.04). There were similar trends favouring the valerian group for night awakenings (difference = 6.0%, 95% CI-0.5 to 12.5) and sleep duration (difference = 7.5%, 95% CI-1.0 to 16.1). There were no serious adverse events and no important or statistically significant differences in minor adverse events. Interpretation. Based on this and previous studies, valerian appears to be safe, but with modest beneficial effects at most on insomnia compared to placebo. The combined use of television and the Internet in randomised trials offers opportunities to answer questions about the effects of health care interventions and to improve public understanding and use of randomised trials. Trial Registration. Controlled-Trials.com ISRCTN72748991	[Oxman, Andrew D.; Flottorp, Signe; Havelsrud, Kari; Fretheim, Atle; Odgaard-Jensen, Jan; Austvoll-Dahlgren, Astrid; Carling, Cheryl] Norwegian Knowledge Ctr Hlth Serv, Oslo, Norway; [Pallesen, Stale; Bjorvatn, Bjorn] Haukeland Hosp, Norwegian Competence Ctr Sleep Disorders, N-5021 Bergen, Norway; [Pallesen, Stale] Univ Bergen, Dept Psychosocial Sci, Bergen, Norway; [Bjorvatn, Bjorn] Univ Bergen, Sect Gen Practice, Bergen, Norway	Norwegian Knowledge Centre for Health Services; University of Bergen; Haukeland University Hospital; University of Bergen; University of Bergen	Oxman, AD (corresponding author), Norwegian Knowledge Ctr Hlth Serv, Oslo, Norway.	oxman@online.no	Oxman, Andrew/Y-3004-2019	Oxman, Andrew/0000-0002-5608-5061; Fretheim, Atle/0000-0002-6268-7966; Flottorp, Signe/0000-0003-2961-7461	Norwegian Knowledge Centre for the Health Services (NOKC)	Norwegian Knowledge Centre for the Health Services (NOKC)	The trial was funded by the Norwegian Knowledge Centre for the Health Services (NOKC) as part of "ForskningsPuls" (Research Pulse), a collaboration between NOKC and the Norwegian Broadcasting Corporation (NRK). ForskningsPuls aims to enhance public understanding and use of research in decisions about healthcare by enabling viewers to participate in research and to follow the process, both through reports on Puls (Pulse), a weekly television health program, and on the web pages of Puls and NOKC. Seven of the authors are employed by NOKC. Otherwise neither NOKC or NRK had any role in the design or conduct of the study; the collection, analysis or interpretation of the data; or the preparation, review or approval of the manuscript.	American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS; Babkoff H, 1996, J CLIN EPIDEMIOL, V49, P455, DOI 10.1016/0895-4356(95)00529-3; Bent S, 2006, AM J MED, V119, P1005, DOI 10.1016/j.amjmed.2006.02.026; BUSCEMI N, 2005, AHRQ PUBLICATION; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Coxeter PD, 2003, COMPLEMENT THER MED, V11, P215, DOI 10.1016/S0965-2299(03)00122-5; Diaper A, 2004, PHYTOTHER RES, V18, P831, DOI 10.1002/ptr.1574; Glass JR, 2003, J CLIN PSYCHOPHARM, V23, P260, DOI 10.1097/00004714-200306000-00007; Gutierrez S, 2004, PHARMACOL BIOCHEM BE, V78, P57, DOI 10.1016/j.pbb.2004.02.011; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Hallam KT, 2003, HUM PSYCHOPHARM CLIN, V18, P619, DOI 10.1002/hup.542; Herrera-Arellano A, 2001, PLANTA MED, V67, P695, DOI 10.1055/s-2001-18344; Holbrook AM, 2000, CAN MED ASSOC J, V162, P225; Jacobs BP, 2005, MEDICINE, V84, P197, DOI 10.1097/01.md.0000172299.72364.95; Morin CM, 2005, SLEEP, V28, P1465, DOI 10.1093/sleep/28.11.1465; Morris CA, 2003, JAMA-J AM MED ASSOC, V290, P1505, DOI 10.1001/jama.290.11.1505; Moul DE, 2004, SLEEP MED REV, V8, P177, DOI 10.1016/S1087-0792(03)00060-1; MURTAGH DRR, 1995, J CONSULT CLIN PSYCH, V63, P79, DOI 10.1037/0022-006X.63.1.79; Pallesen S, 2001, SLEEP, V24, P771; Pallesen Stale, 2002, Tidsskr Nor Laegeforen, V122, P2857; Poyares DR, 2002, PROG NEURO-PSYCHOPH, V26, P539, DOI 10.1016/S0278-5846(01)00305-0; RICHMAN A, 1999, WHOLE FOODS, V22, P49; Roth T, 2002, SLEEP MED, V3, P99, DOI 10.1016/S1389-9457(01)00131-9; Sackett DL, 2007, INT J EPIDEMIOL, V36, P664, DOI 10.1093/ije/dym088; SANDERS TAB, 1990, LANCET, V336, P918, DOI 10.1016/0140-6736(90)92280-U; Sateia MJ, 2004, LANCET, V364, P1959, DOI 10.1016/S0140-6736(04)17480-1; Sateia MJ, 2000, SLEEP, V23, P243; SCHENK CH, 2003, JAMA-J AM MED ASSOC, V289, P2476; Stevinson C, 2000, SLEEP MED, V1, P91, DOI 10.1016/S1389-9457(99)00015-5; Ziegler G, 2002, EUR J MED RES, V7, P480	30	19	20	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2007	2	10							e1040	10.1371/journal.pone.0001040	http://dx.doi.org/10.1371/journal.pone.0001040			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10HW	17940604	Green Submitted, gold, Green Published, Green Accepted			2023-01-03	WOS:000207456100008
J	Wadman, M				Wadman, Meredith			Copycat consolidation	NATURE			English	News Item																			0	0	0	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 27	2007	449	7161					393	393		10.1038/449393a	http://dx.doi.org/10.1038/449393a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214GQ	17898741	Bronze			2023-01-03	WOS:000249724800014
J	Ali, B; Zafari, AM				Ali, Bakhtiar; Zafari, A. Maziar			Narrative review: Cardiopulmonary resuscitation and emergency cardiovascular care: Review of the current guidelines	ANNALS OF INTERNAL MEDICINE			English	Review							HOSPITAL CARDIAC-ARREST; PUBLIC-ACCESS DEFIBRILLATION; CHEST COMPRESSION DEVICE; BASIC LIFE-SUPPORT; VENTRICULAR-FIBRILLATION; WAVE-FORM; CIRCULATION TIMES; EPINEPHRINE; VASOPRESSIN; SURVIVAL	Sudden cardiac death is a major clinical problem, causing 300 000 to 400000 deaths annually and 63% of all cardiac deaths. Despite the overall decrease in cardiovascular mortality, the proportion of cardiovascular death from sudden cardiac death has remained constant. Survival rates among patients who have out-of-hospital cardiac arrest vary from 5% to 18%, depending on the presenting rhythm. The latest guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care published by the American Heart Association include substantial changes to the algorithms for basic life support and advanced cardiovascular life support. For unwitnessed cardiac arrest, immediate defibrillation of the patient is no longer recommended. Rather, 2 minutes of CPR before defibrillation is now recommended. People in cardiac arrest should no longer receive stacked shocks. The compression-ventilation ratio has been changed from 15:2 to 30:2. This article is a contemporary review of the management of CPR and emergency cardiovascular care. It examines current practice and data supporting use of CPR, along with changes in the management of sudden cardiac death.	Atlanta Vet Affairs Med Ctr, Decatur, GA USA; Emory Univ, Sch Med, Atlanta, GA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Emory University	Zafari, AM (corresponding author), Emory Univ, Div Cardiol, Woodruff Mem Res Bldg, Room 322,1639 Pierce Dr, Atlanta, GA 30332 USA.	azafari@emory.edu	Zafari, Abarmard/GRF-6849-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL079156] Funding Source: NIH RePORTER; NHLBI NIH HHS [1U01HL079156] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abella BS, 2005, CIRCULATION, V111, P428, DOI 10.1161/01.CIR.0000153811.84257.59; *AM HEART ASS, 2003, CURR OPIN CARDIOL, V18, P14; [Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Assar D, 2000, RESUSCITATION, V45, P7, DOI 10.1016/S0300-9572(00)00152-0; AUBLE TE, 1995, ANN EMERG MED, V25, P642, DOI 10.1016/S0196-0644(95)70178-8; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; BARSAN WG, 1981, ANN EMERG MED, V10, P73, DOI 10.1016/S0196-0644(81)80339-3; Berg MD, 2005, RESUSCITATION, V64, P287, DOI 10.1016/j.resuscitation.2004.07.017; Berg RA, 2001, CIRCULATION, V104, P2465, DOI 10.1161/hc4501.098926; BROWN DC, 1979, JACEP-J AM COLL EMER, V8, P448, DOI 10.1016/S0361-1124(79)80058-1; Caffrey SL, 2002, NEW ENGL J MED, V347, P1242, DOI 10.1056/NEJMoa020932; Carpenter J, 2003, RESUSCITATION, V59, P189, DOI 10.1016/S0300-9572(03)00183-7; CHANDRASTROBOS N, 2004, HURSTS HEART, P1030; CHOUX C, 1995, RESUSCITATION, V29, P3, DOI 10.1016/0300-9572(94)00810-3; Chugh SS, 2004, J AM COLL CARDIOL, V44, P1268, DOI 10.1016/j.jacc.2004.06.029; Cobb LA, 1999, JAMA-J AM MED ASSOC, V281, P1182, DOI 10.1001/jama.281.13.1182; Cobb LA, 2002, JAMA-J AM MED ASSOC, V288, P3008, DOI 10.1001/jama.288.23.3008; COON GA, 1981, ANN EMERG MED, V10, P462, DOI 10.1016/S0196-0644(81)80277-6; Crile G, 1906, J EXP MED, V8, P713, DOI 10.1084/jem.8.6.713; CUMMINS RO, 1995, ANN EMERG MED, V25, P833; DELUNA AB, 1989, AM HEART J, V117, P151, DOI 10.1016/0002-8703(89)90670-4; DEVRIES W, 2004, NEW ENGL J MED, V351, P637; DITCHEY RV, 1988, CIRCULATION, V78, P382, DOI 10.1161/01.CIR.78.2.382; Dorian P, 2002, NEW ENGL J MED, V346, P884, DOI 10.1056/NEJMoa013029; Eftestol T, 2002, CIRCULATION, V105, P2270, DOI 10.1161/01.CIR.0000016362.42586.FE; EMERMAN CL, 1988, CRIT CARE MED, V16, P1138, DOI 10.1097/00003246-198811000-00011; *EUR RES COUNC VAS, 2004, NEW ENGL J MED, V350, P105; Gliner BE, 1999, RESUSCITATION, V41, P133, DOI 10.1016/S0300-9572(99)00040-4; Gueugniaud PY, 1998, NEW ENGL J MED, V339, P1595, DOI 10.1056/NEJM199811263392204; Guyette FX, 2004, RESUSCITATION, V63, P277, DOI 10.1016/j.resuscitation.2004.05.007; Hallstrom A, 2006, JAMA-J AM MED ASSOC, V295, P2620, DOI 10.1001/jama.295.22.2620; Heidenreich JW, 2004, RESUSCITATION, V62, P283, DOI 10.1016/j.resuscitation.2004.05.013; Holmberg M, 1998, RESUSCITATION, V36, P29, DOI 10.1016/S0300-9572(97)00089-0; Holmberg M, 2001, EUR HEART J, V22, P511, DOI 10.1053/euhj.2000.2421; HORNCHEN U, 1987, CRIT CARE MED, V15, P1037; Huikuri HV, 2001, NEW ENGL J MED, V345, P1473, DOI 10.1056/NEJMra000650; Jacobs Ian G, 2005, Emerg Med Australas, V17, P39, DOI 10.1111/j.1742-6723.2005.00694.x; KERN KB, 1990, RESUSCITATION, V20, P221, DOI 10.1016/0300-9572(90)90005-Y; Kern KB, 2002, CIRCULATION, V105, P645, DOI 10.1161/hc0502.102963; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; Kudenchuk PJ, 2006, CIRCULATION, V114, P2010, DOI 10.1161/CIRCULATIONAHA.106.636506; Kudenchuk PJ, 1999, NEW ENGL J MED, V341, P871, DOI 10.1056/NEJM199909163411203; KUHN GJ, 1981, ANN EMERG MED, V10, P417, DOI 10.1016/S0196-0644(81)80308-3; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; Lindner KH, 1997, LANCET, V349, P535, DOI 10.1016/S0140-6736(97)80087-6; Martens PR, 2001, RESUSCITATION, V49, P233, DOI 10.1016/S0300-9572(01)00321-5; MICHAEL JR, 1984, CIRCULATION, V69, P822, DOI 10.1161/01.CIR.69.4.822; Myerburg RJ, 1997, AM J CARDIOL, V80, pF10, DOI 10.1016/S0002-9149(97)00477-3; Nichol G, 1998, CIRCULATION, V97, P1315, DOI 10.1161/01.CIR.97.13.1315; Niemann JT, 2002, RESUSCITATION, V53, P153, DOI 10.1016/S0300-9572(02)00004-7; Ong MEH, 2006, JAMA-J AM MED ASSOC, V295, P2629, DOI 10.1001/jama.295.22.2629; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Rea TD, 2004, RESUSCITATION, V63, P17, DOI 10.1016/j.resuscitation.2004.03.025; Schneider T, 2000, CIRCULATION, V102, P1780; Schwarz B, 2003, ANESTHESIOLOGY, V98, P1063, DOI 10.1097/00000542-200305000-00007; *STEER COMM CTR VA, 2005, RESUSCITATION, V66, P149; Stiell IG, 2004, NEW ENGL J MED, V351, P647, DOI 10.1056/NEJMoa040325; Stiell IG, 1999, ANN EMERG MED, V33, P44, DOI 10.1016/S0196-0644(99)70415-4; Stiell IG, 2001, LANCET, V358, P105, DOI 10.1016/S0140-6736(01)05328-4; STUEVEN HA, 1984, ANN EMERG MED, V13, P815, DOI 10.1016/S0196-0644(84)80447-3; TZIVONI D, 1988, CIRCULATION, V77, P392, DOI 10.1161/01.CIR.77.2.392; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; Valenzuela TD, 1997, CIRCULATION, V96, P3308; van Alem AP, 2003, RESUSCITATION, V58, P17, DOI 10.1016/S0300-9572(03)00106-0; VANHOEYWEGHEN RJ, 1993, RESUSCITATION, V26, P47, DOI 10.1016/0300-9572(93)90162-J; Waalewijn RA, 2001, RESUSCITATION, V50, P273, DOI 10.1016/S0300-9572(01)00354-9; WEAVER WD, 1982, NEW ENGL J MED, V307, P1101, DOI 10.1056/NEJM198210283071801; WEAVER WD, 1976, CIRCULATION, V54, P895, DOI 10.1161/01.CIR.54.6.895; WEISFELDT ML, 1995, CIRCULATION, V92, P2763, DOI 10.1161/01.CIR.92.9.2763; Weisfeldt ML, 2002, JAMA-J AM MED ASSOC, V288, P3035, DOI 10.1001/jama.288.23.3035; WEISFELDT ML, 1995, CIRCULATION, V92, P2740, DOI 10.1161/01.CIR.92.9.2740; Wenzel V, 1999, CIRCULATION, V99, P1379, DOI 10.1161/01.CIR.99.10.1379; Wenzel V, 2006, CRIT CARE, V10, DOI 10.1186/cc4846; White RD, 2005, RESUSCITATION, V65, P279, DOI 10.1016/j.resuscitation.2004.10.018; White RD, 2002, RESUSCITATION, V55, P17, DOI 10.1016/S0300-9572(02)00194-6; Wik L, 2003, JAMA-J AM MED ASSOC, V289, P1389, DOI 10.1001/jama.289.11.1389; YAKAITIS RW, 1979, CRIT CARE MED, V7, P293, DOI 10.1097/00003246-197907000-00001; Yu T, 2002, CIRCULATION, V106, P368, DOI 10.1161/01.CIR.0000021429.22005.2E; Zafari AM, 2004, J AM COLL CARDIOL, V44, P846, DOI 10.1016/j.jacc.2004.04.054; Zheng ZJ, 2001, CIRCULATION, V104, P2158, DOI 10.1161/hc4301.098254; Zipes DP, 1998, CIRCULATION, V98, P2334, DOI 10.1161/01.CIR.98.21.2334; 2005, CIRCULATION S, V112, P35; 2004, AM J CARDIOL, V93, P576; 2002, AM J CARDIOL, V90, P853; 2005, CIRCULATION, V122; 2005, CIRCULATION S, V112, P58	87	48	49	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 7	2007	147	3					171	179		10.7326/0003-4819-147-3-200708070-00006	http://dx.doi.org/10.7326/0003-4819-147-3-200708070-00006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196AV	17679705				2023-01-03	WOS:000248454700004
J	Coombes, R				Coombes, Rebecca			Medicine and the media - Having the last laugh at big pharma - How campaigners are creating humorous videos to hit back at the drug industry	BRITISH MEDICAL JOURNAL			English	Editorial Material												rcoombes@bmjgroup.com							0	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 24	2007	334	7590					396	397		10.1136/bmj.39133.480880.59	http://dx.doi.org/10.1136/bmj.39133.480880.59			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	142MQ	17322252	Green Published			2023-01-03	WOS:000244654400025
J	Reddy, KS				Reddy, K. Srinath			The preventive polypill - Much promise, insufficent evidence	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARDIOVASCULAR-DISEASE		Publ Hlth Fdn India, New Delhi, India; All India Inst Med Sci, New Delhi, India	Public Health Foundation of India; All India Institute of Medical Sciences (AIIMS) New Delhi	Reddy, KS (corresponding author), Publ Hlth Fdn India, New Delhi, India.							Gaziano TA, 2006, LANCET, V368, P679, DOI 10.1016/S0140-6736(06)69252-0; Reddy KS, 2004, NEW ENGL J MED, V350, P2438, DOI 10.1056/NEJMp048024; Wald NJ, 2003, BRIT MED J, V327, P586	3	35	40	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2007	356	3					212	212		10.1056/NEJMp068219	http://dx.doi.org/10.1056/NEJMp068219			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126BV	17229947				2023-01-03	WOS:000243488100002
J	Sacco, RL; Chong, JY; Prabhakaran, S; Elkind, MSV				Sacco, Ralph L.; Chong, Ji Y.; Prabhakaran, Shyam; Elkind, Mitchell S. V.			Experimental treatments for acute ischaemic stroke	LANCET			English	Review							TISSUE-PLASMINOGEN ACTIVATOR; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PLACEBO-CONTROLLED TRIAL; ALIAS PILOT TRIAL; DOSE-ESCALATION; DOUBLE-BLIND; INTRAARTERIAL THROMBOLYSIS; INTRAVENOUS THROMBOLYSIS; MECHANICAL THROMBECTOMY; SCIENTIFIC STATEMENT	Treatments for acute ischaemic stroke continue to evolve. Experimental approaches to restore cerebral perfusion include techniques to augment recanalising therapies, including combination of antiplatelet agents with intravenous thrombolysis, bridging therapy of combining intravenous with intra-arterial thrombolysis, and trials of new thrombolytic agents. Trials with MRI selection criteria are underway to expand the window of opportunity for thrombolysis. Sonothrombolysis and novel endovascular mechanical devices to retrieve or dissolve acute cerebral occlusions are being tested. Approaches to improve cerebral perfusion with other devices and induced hypertension are also being considered. Although numerous neuroprotective agents have not shown benefit, trials of hypothermia, magnesium, caffeinol, high doses of statins, and albumin are continuing. The findings of these randomised trials are anticipated to allow improved treatment of patients with acute stroke.	Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA; Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA	Columbia University; Columbia University; Rush University	Sacco, RL (corresponding author), Neurol Inst, 710 W 168th St, New York, NY 10032 USA.	rls1@columbia.edu	Sacco, Ralph/Y-9278-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048134, R01NS050724] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 50724, R01 NS 48134] Funding Source: Medline; PHS HHS [K23 42912] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams H, 2005, STROKE, V36, P916, DOI 10.1161/01.STR.0000163257.66207.2d; Adams HP, 2003, STROKE, V34, P1056, DOI 10.1161/01.STR.0000064841.47697.22; Agarwal P, 2004, CATHETER CARDIO INTE, V62, P396, DOI 10.1002/ccd.20092; Albers GW, 2006, ANN NEUROL, V60, P508, DOI 10.1002/ana.20976; Albers GV, 2001, JAMA-J AM MED ASSOC, V286, P2673, DOI 10.1001/jama.286.21.2673; ALBERS GW, 1995, STROKE, V26, P254, DOI 10.1161/01.STR.26.2.254; Albers GW, 2001, STROKE, V32, P1598, DOI 10.1161/01.STR.32.7.1598; Alexandrov AV, 2004, NEW ENGL J MED, V351, P2170, DOI 10.1056/NEJMoa041175; Alexandrov AV, 2002, NEUROLOGY, V59, P862, DOI 10.1212/WNL.59.6.862; Alexandrov AV, 2001, CIRCULATION, V103, P2897, DOI 10.1161/01.CIR.103.24.2897; Amarenco P, 2004, STROKE, V35, P2902, DOI 10.1161/01.STR.0000147965.52712.fa; Amarenco P, 2006, NEW ENGL J MED, V355, P549; Aronowski J, 2003, STROKE, V34, P1246, DOI 10.1161/01.STR.0000068170.80517.B3; Ballantyne CM, 2003, AM J CARDIOL, V92, p3K, DOI 10.1016/S0002-9149(03)00768-9; Bath PMW, 2000, STROKE, V31, P2257; Belayev L, 2004, BRAIN RES, V1008, P278, DOI 10.1016/j.brainres.2004.02.039; Berlis A, 2004, STROKE, V35, P1112, DOI 10.1161/01.STR.0000124126.17508.d3; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Broderick J, 2004, STROKE, V35, P904, DOI 10.1161/01.STR.0000121641.77121.98; Bruno A, 1999, NEUROLOGY, V52, P280, DOI 10.1212/WNL.52.2.280; Butcher KS, 2005, STROKE, V36, P1153, DOI 10.1161/01.STR.0000166181.86928.8b; Campbell MS, 2004, STROKE, V35, P291; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chopko BW, 2000, NEUROSURGERY, V46, P1529, DOI 10.1097/00006123-200006000-00046; Clark WM, 2001, NEUROLOGY, V57, P1595, DOI 10.1212/WNL.57.9.1595; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; Clark WM, 2000, STROKE, V31, P811, DOI 10.1161/01.STR.31.4.811; *CLINICALTRIALS GO, 2006, MR REC STROK CLOTS U; *CLINICALTRIALS GO, 2006, ICTUS STUD INT CIT T; *CLINICALTRIALS GO, 2006, COMB APPR LYS UT EPT; *CLINICALTRIALS GO, 2005, MICR ULTR STROK TRIA; *CLINICALTRIALS GO, 2006, SAF EFF NEUROFLO TEC; *CLINICALTRIALS GO, 2006, SAF STUD INT BET 1A; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Daffertshofer M, 2005, STROKE, V36, P1441, DOI 10.1161/01.STR.0000170707.86793.1a; Davis SM, 1997, LANCET, V349, P32, DOI 10.1016/S0140-6736(05)62166-6; Demchuk AM, 2001, STROKE, V32, P89, DOI 10.1161/01.STR.32.1.89; Diener HC, 1999, STROKE, V30, P234; Dijkmans P A, 2004, Eur J Echocardiogr, V5, P245, DOI 10.1016/j.euje.2004.02.001; Dippel DWJ, 2003, BMC CARDIOVASC DISOR, V3, DOI 10.1186/1471-2261-3-2; *ENL AC STROK TRIA, 2001, NEUROLOGY, V547, P1428; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Fisher M, 2005, STROKE, V36, P1808, DOI 10.1161/01.STR.0000173403.60553.27; Fisher M, 2003, STROKE, V34, P1539, DOI 10.1161/01.STR.0000072983.64326.53; Fourie P, 2003, AM J NEURORADIOL, V24, P630; FRANCIS CW, 1995, ULTRASOUND MED BIOL, V21, P419, DOI 10.1016/0301-5629(94)00119-X; Furlan AJ, 2006, STROKE, V37, P1227, DOI 10.1161/01.STR.0000217403.66996.6d; GEORGIA MA, 2004, NEUROLOGY, V63, P312; Ginsberg MD, 2006, STROKE, V37, P2100, DOI 10.1161/01.STR.0000231388.72646.05; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gropen TI, 2006, NEUROLOGY, V67, P88, DOI 10.1212/01.wnl.0000223622.13641.6d; Grotta J, 2001, CEREBROVASC DIS, V12, P258, DOI 10.1159/000047713; Hacke W, 2005, STROKE, V36, P66, DOI 10.1161/01.STR.0000149938.08731.2c; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hacke W, 2004, LANCET, V363, P768; Haley EC, 2005, STROKE, V36, P607, DOI 10.1161/01.STR.0000154872.73240.e9; Hennerici MG, 2006, LANCET, V368, P1871, DOI 10.1016/S0140-6736(06)69776-6; Hickenbottom SL, 1998, SEMIN NEUROL, V18, P485, DOI 10.1055/s-2008-1040901; Hillis AE, 2003, CEREBROVASC DIS, V16, P236, DOI 10.1159/000071122; Holzer M, 2002, NEW ENGL J MED, V346, P549; Horn J, 2001, STROKE, V32, P461, DOI 10.1161/01.STR.32.2.461; Kerber CW, 2002, J VASC INTERV RADIOL, V13, P1269, DOI 10.1016/S1051-0443(07)61978-2; Kidwell CS, 2003, STROKE, V34, P2729, DOI 10.1161/01.STR.0000097608.38779.CC; Lee DH, 2002, J VASC INTERV RADIOL, V13, P769; Lees KR, 2006, NEW ENGL J MED, V354, P588, DOI 10.1056/NEJMoa052980; Lees KR, 2004, LANCET, V363, P439, DOI 10.1016/S0140-6736(04)15490-1; Leonardi-Bee J, 2002, STROKE, V33, P1315, DOI 10.1161/01.STR.0000014509.11540.66; Lewandowski CA, 1999, STROKE, V30, P2598, DOI 10.1161/01.STR.30.12.2598; Liu M, 2003, COCHRANE DB SYST REV, V3; Lyden P, 2002, STROKE, V33, P122, DOI 10.1161/hs0102.101478; Mahon BR, 2003, AM J NEURORADIOL, V24, P534; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MOHR JP, 1994, CEREBROVASC DIS, V4, P197, DOI 10.1159/000108482; Molina CA, 2006, STROKE, V37, P425, DOI 10.1161/01.STR.0000199064.94588.39; Montaner J, 2004, STROKE, V35, P293; Nakano S, 2002, STROKE, V33, P2872, DOI 10.1161/01.STR.0000038985.26269.F2; Nesbit Gary M, 2004, J Vasc Interv Radiol, V15, pS103; O'Collins VE, 2006, ANN NEUROL, V59, P467, DOI 10.1002/ana.20741; Ohman EM, 1997, CIRCULATION, V95, P846; Palesch YY, 2006, STROKE, V37, P2107, DOI 10.1161/01.STR.0000231389.34701.b5; Qizilbash N, 2000, COCHRANE DB SYST REV, V2; Reddrop C, 2005, STROKE, V36, P1241, DOI 10.1161/01.STR.0000166050.84056.48; Ribo M, 2006, STROKE, V37, P1000, DOI 10.1161/01.STR.0000206443.96112.d9; Ringer AJ, 2001, NEUROSURGERY, V48, P1282, DOI 10.1097/00006123-200106000-00019; Rordorf G, 2001, NEUROLOGY, V56, P1210, DOI 10.1212/WNL.56.9.1210; Sacco RL, 2001, JAMA-J AM MED ASSOC, V285, P1719, DOI 10.1001/jama.285.13.1719; Saver JL, 2004, STROKE, V35, pE106, DOI 10.1161/01.STR.0000124458.98123.52; Schellinger PD, 2003, STROKE, V34, P575, DOI 10.1161/01.STR.0000051504.10095.9C; Schumacher HC, 2003, CARDIOVASC INTER RAD, V26, P305, DOI 10.1007/s00270-003-2719-5; Scott JF, 1999, STROKE, V30, P793, DOI 10.1161/01.STR.30.4.793; Scott P, 1996, STROKE, V27, P1453; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Sironi L, 2003, ARTERIOSCL THROM VAS, V23, P322, DOI 10.1161/01.ATV.0000044458.23905.3B; Smith WS, 2006, AM J NEURORADIOL, V27, P1177; Smith WS, 2005, STROKE, V36, P1432, DOI 10.1161/01.STR.0000171066.25248.1d; *STROK CTR STROK T, 2006, DESM AC ISCH STROK 2; *STROK CTR STROK T, REP STROK SAF STUD I; *STROK CTR STROK T, 2006, 3 INT STROK TRIAL; *STROK CTR STROK T, 2006, TREATM HYP ISCH STRO; *STROK CTR STROK T, 2005, GLUC REG AC STROK PA; *STROK CTR STROK T, PICL PAT AC ISCH STR; *STROK CTR STROK T, 2006, NAN ENH CLOTBUST TRE; *STROK CTR STROK T, 2005, CONTR HYP HYP IMM PO; *STROK CTR STROK T, 2005, INT MAN STROK STUD; Sugg RM, 2006, ARCH NEUROL-CHICAGO, V63, P1057, DOI 10.1001/archneur.63.8.1057; Thomalla G, 2006, STROKE, V37, P852, DOI 10.1161/01.STR.0000204120.79399.72; Thomas D, 2003, RES AFR LITERATURES, V34, P214, DOI 10.2979/RAL.2003.34.3.214; TSAI FY, 1994, AM J NEURORADIOL, V15, P1823; Ueda T, 1998, STROKE, V29, P2568, DOI 10.1161/01.STR.29.12.2568; Warach S, 2000, ANN NEUROL, V48, P713, DOI 10.1002/1531-8249(200011)48:5<713::AID-ANA4>3.3.CO;2-R; Zhang L, 2005, CIRCULATION, V112, P3486, DOI 10.1161/CIRCULATIONAHA.104.516757	112	89	95	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN-FEB	2007	369	9558					331	341		10.1016/S0140-6736(07)60155-X	http://dx.doi.org/10.1016/S0140-6736(07)60155-X			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131ZR	17258673				2023-01-03	WOS:000243912000037
J	Collier, J				Collier, Joe			Getting new drugs to market: how individuals,could do this without leaving their desks	BRITISH MEDICAL JOURNAL			English	Editorial Material									St George Hosp, Sch Med, Dept Basic Med Sci, London SW17 0RE, England	St Georges University London	Collier, J (corresponding author), St George Hosp, Sch Med, Dept Basic Med Sci, London SW17 0RE, England.	jcollier@sgul.ac.uk						Henry D, 2002, LANCET, V360, P1590, DOI 10.1016/S0140-6736(02)11527-3; JACK A, 2006, FINANCIAL TIMES 0929	2	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 23	2006	333	7582					1315	1317		10.1136/bmj.39055.610764.47	http://dx.doi.org/10.1136/bmj.39055.610764.47			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121MC	17185722	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000243160700020
J	Chou, R; Fu, R; Huffman, LH; Korthuis, PT				Chou, Roger; Fu, Rongwei; Huffman, Laurie Hoyt; Korthuis, P. Todd			Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses	LANCET			English	Article							DOUBLE-BLIND TRIAL; RANDOMIZED CLINICAL-TRIALS; HIV-INFECTED PATIENTS; COMBINATION THERAPY; PLUS ZIDOVUDINE; HIV-1-INFECTED PATIENTS; NAIVE PATIENTS; TRIPLE; LAMIVUDINE; EFFICACY	Background The optimum treatment choice between initial highly-active antiretroviral therapy (HAART) with a protease inhibitor (PI) versus a non-nucleoside reverse transcriptase inhibitor (NNRTI) is uncertain. An indirect analysis reported that PI-based HAART was better than NNRTI-based HAART. However, direct evidence for competing interventions is deemed more reliable than indirect evidence for making treatment decisions. We did a meta-analysis of head-to-head trials and compared the results with those of indirect analyses. Methods 12 trials of at least 24 weeks' duration directly compared NNRTI-based versus PI-based HAART in HIV-infected patients with limited or no previous exposure to antiretrovirals. We also identified six trials of NNRTI-based HAART and eight trials of PI-based HAART, each versus two NRTI regimens. We analysed the outcomes of virological suppression, death or disease progression, and withdrawals due to adverse events. Findings In the direct meta-analysis, NNRTI-based regimens were better than PI-based regimens for virological suppression (OR 1.60, 95% Cl 1.31-1.96). The difference was reduced in higher-quality trials, but still favoured NNRTI-based HAART. There were no differences in death or disease progression (0.87, 0.56-1.35) or withdrawal because of adverse events (0.68, 0.43-1.08). By contrast, in indirect analyses NNRTI-based HAART was worse than PI-based HAART for virological suppression (0.26, 0.07-0.91). There were no significant differences for death or disease progression (1.28, 0.56-2.94) and withdrawals because of adverse events (1.46, 0.66-3.24). When trials of delavirdine were excluded, similar results were produced. Interpretation Results from direct analyses suggested that NNRTI-based HAART was more effective than Pi-based HAART for virological suppression and was similar to PI-based HAART for clinical outcomes. Indirect comparisons could be unreliable for complex and rapidly evolving interventions such as HAART.	Oregon Hlth & Sci Univ, Oregon Evidence Based Practice Ctr, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Med, Portland, OR USA; Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR USA; Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR USA; Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Chou, R (corresponding author), Oregon Hlth & Sci Univ, Oregon Evidence Based Practice Ctr, 3181 SW Sam Jackson Pk Rd,Mailcode BICC, Portland, OR 97239 USA.	chour@ohsu.edu		Chou, Roger/0000-0001-9889-8610; Korthuis, Philip/0000-0001-5556-3597				[Anonymous], 1992, MMWR Recomm Rep, V41, P1; BARTLETT J, 2004, 25 INT AIDS C JUL 11; Bartlett JA, 2001, AIDS, V15, P1369, DOI 10.1097/00002030-200107270-00006; Berlin JA, 1994, ONLINE J CURR CLIN T; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; COOPER D, 2005, 12 C RETR OPP INF FE; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Floridia M, 1999, J ACQ IMMUN DEF SYND, V20, P11, DOI 10.1097/00042560-199901010-00002; Friedland GH, 1999, J ACQ IMMUN DEF SYND, V21, P281, DOI 10.1097/00126334-199908010-00005; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; Garcia F, 1999, AIDS, V13, P2377, DOI 10.1097/00002030-199912030-00009; Garcia F, 2000, J ACQ IMMUN DEF SYND, V25, P26, DOI 10.1097/00126334-200009010-00004; Gartland M, 2000, AIDS, V14, P367, DOI 10.1097/00002030-200003100-00009; Gartland M, 2001, ANTIVIR THER, V6, P127; Glenny AM, 2005, HEALTH TECHNOL ASSES, V9, P1; Goodgame JC, 2000, ANTIVIR THER, V5, P215; GUARDIOLA J, 2000, 40 INT C ANT AG CHEM; Huwiler-Muntener K, 2002, JAMA-J AM MED ASSOC, V287, P2801, DOI 10.1001/jama.287.21.2801; Ioannidis JPA, 1997, CONTROL CLIN TRIALS, V18, P431, DOI 10.1016/S0197-2456(97)00097-4; Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; Maggiolo F, 2003, ANTIVIR THER, V8, P339; Martinez-Picado J, 2003, ANN INTERN MED, V139, P81, DOI 10.7326/0003-4819-139-2-200307150-00007; MIRO JM, 2005, 10 EUR AIDS C NOV 17; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; MONTANER JSG, 2002, 42 INT C ANT AG CHEM; MOYLE G, 1999, 39 INT C ANT AG CHEM; Murphy EL, 2001, ANN INTERN MED, V135, P17, DOI 10.7326/0003-4819-135-1-200107030-00005; Opravil M, 2000, J ACQ IMMUN DEF SYND, V23, P17; *PAN CLIN PRACT TR, 2005, GUID US ANT AG HIV 1; PARA M, 1999, 39 INT C ANT AG CHEM; Phillips A, 2003, AIDS, V17, P619, DOI 10.1097/00002030-200303070-00018; Podzamczer D, 2002, ANTIVIR THER, V7, P81; Raffi F, 2001, HIV Clin Trials, V2, P330; RIDDLER S, 2005, MCT00050895 NIAD; Robbins GK, 2003, NEW ENGL J MED, V349, P2293, DOI 10.1056/NEJMoa030264; Saag MS, 2001, AIDS, V15, P1971, DOI 10.1097/00002030-200110190-00009; SKOWRON G, 1997, 37 INT C ANT AG CHEM; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; Squires K, 2004, JAIDS-J ACQ IMM DEF, V36, P1011, DOI 10.1097/00126334-200408150-00003; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Stellbrink HJ, 2000, CLIN DRUG INVEST, V20, P295, DOI 10.2165/00044011-200020050-00001; Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; Sutton AJ, 2000, BMJ-BRIT MED J, V320, P1574, DOI 10.1136/bmj.320.7249.1574; Toma M, 2006, JAMA-J AM MED ASSOC, V295, P1281, DOI 10.1001/jama.295.11.1281; Torre D, 2001, HIV Clin Trials, V2, P113, DOI 10.1310/4KVA-U5H3-UBXT-84G7; van Leeuwen R, 2003, AIDS, V17, P987, DOI 10.1097/00002030-200305020-00007; Yazdanpanah Y, 2004, BMJ-BRIT MED J, V328, P249, DOI 10.1136/bmj.37995.435787.A6; Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251	54	74	75	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 28	2006	368	9546					1503	1515		10.1016/S0140-6736(06)69638-4	http://dx.doi.org/10.1016/S0140-6736(06)69638-4			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	099GZ	17071284				2023-01-03	WOS:000241582700028
J	Yu, S; Wong, YC; Wang, XH; Ling, MT; Ng, CF; Chen, S; Chan, FL				Yu, S.; Wong, Y. C.; Wang, X. H.; Ling, M. T.; Ng, C. F.; Chen, S.; Chan, F. L.			Orphan nuclear receptor estrogen-related receptor-beta suppresses in vitro and in vivo growth of prostate cancer cells via p21(WAF1/CIP1) induction and as a potential therapeutic target in prostate cancer	ONCOGENE			English	Article						estrogen-related receptor; estrogen receptor-related; receptor; ERR beta; orphan nuclear receptor; tumor suppression; prostate cancer	PROLIFERATOR-ACTIVATED RECEPTOR; ANDROGEN RECEPTOR; GAMMA COACTIVATOR-1-ALPHA; TRANSCRIPTIONAL CONTROL; DNA-REPLICATION; MOUSE EMBRYOS; ERR-ALPHA; EXPRESSION; IDENTIFICATION; PGC-1-ALPHA	Recent studies indicate that estrogen-related receptors (ERRs) are involved in similar estrogen receptor (ER) regulatory pathways and play roles in energy and lipid metabolism. Here, we analysed the functional role of ERR beta in prostate cancer cell growth regulation in an androgen-sensitive and androgen-insensitive prostate cancer cell lines. ERR beta was expressed in normal human prostates, but exhibited a reduced expression in prostate cancer lesions. Stable ERR beta expression suppressed significantly cell proliferation and tumorigenicity of LNCaP and DU145 cells, accompanied by an S-phase suppression and increased p21 expression. Reporter and chromatin immunoprecipitation assays showed that ERRb could directly transactivate p21 gene promoter, which could be further enhanced by peroxisome proliferator-activated receptor-gamma coactivator-1 alpha. Truncation analysis showed that ERR beta-mediated p21 transactivation and prostate cancer cell growth inhibition required intact DNA-binding domain and AF2 domains in ERR beta. Interestingly, ERR beta displayed a cell cycle associated downregulated expression pattern in ERR beta-transduced and non-transduced cells. Finally, we showed that ERR beta-mediated growth inhibition could be potentiated by an ERRb/gamma agonist DY131. Knockdown of ERR beta by RNA interference could reduce the DY131-induced growth inhibition in prostate cancer cells. Taken together, our findings indicate that ERR beta performs a tumor suppressing function in prostate cancer cells, and targeting ERR beta could be a potential therapeutic strategy for prostate cancer.	[Yu, S.; Chan, F. L.] Chinese Univ Hong Kong, Dept Anat, Shatin, Hong Kong, Peoples R China; [Wong, Y. C.; Wang, X. H.; Ling, M. T.] Univ Hong Kong, Dept Anat, Shatin, Hong Kong, Peoples R China; [Ng, C. F.] Chinese Univ Hong Kong, Dept Surg, Shatin, Hong Kong, Peoples R China; [Chen, S.] Beckman Res Inst City Hope, Dept Surg Res, Duarte, CA USA	Chinese University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; City of Hope; Beckman Research Institute of City of Hope	Chan, FL (corresponding author), Chinese Univ Hong Kong, Dept Anat, Basic Med Sci Bldg, Shatin, Hong Kong, Peoples R China.	franky-chan@cuhk.edu.hk	Chan, Franky L./M-1043-2018; Ng, Chi-Fai/E-5134-2011; Chi-fai, NG/AAV-8270-2021	Chan, Franky L./0000-0003-0567-2052; Ng, Chi-Fai/0000-0002-1723-9646; 				Bookout AL, 2006, CELL, V126, P789, DOI 10.1016/j.cell.2006.06.049; Castet A, 2006, MOL ENDOCRINOL, V20, P1035, DOI 10.1210/me.2005-0227; Chan PSF, 1999, PROSTATE, V41, P99; Chen F, 1999, GENE, V228, P101, DOI 10.1016/S0378-1119(98)00619-2; Cheung CP, 2005, J CLIN ENDOCR METAB, V90, P1830, DOI 10.1210/jc.2004-1421; Fujimoto J, 2005, J STEROID BIOCHEM, V94, P67, DOI 10.1016/j.jsbmb.2004.12.030; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Griffiths K, 2000, Prostate, V45, P87, DOI 10.1002/1097-0045(20001001)45:2<87::AID-PROS2>3.0.CO;2-G; Ho E, 2004, ARCH BIOCHEM BIOPHYS, V428, P109, DOI 10.1016/j.abb.2004.01.009; Ho SM, 2004, J CELL BIOCHEM, V91, P491, DOI 10.1002/jcb.10759; Huang CY, 2005, MOL ENDOCRINOL, V19, P2915, DOI 10.1210/me.2005-0097; Huss JM, 2004, MOL CELL BIOL, V24, P9079, DOI 10.1128/MCB.24.20.9079-9091.2004; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Ichida M, 2002, J BIOL CHEM, V277, P50991, DOI 10.1074/jbc.M210262200; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Litvinov IV, 2006, P NATL ACAD SCI USA, V103, P15085, DOI 10.1073/pnas.0603057103; Liu Y, 2006, PROSTATE CANCER P D, V9, P230, DOI 10.1038/sj.pcan.4500879; Lu DS, 2001, CANCER RES, V61, P6755; Lui K, 2006, PROSTATE, V66, P1600, DOI 10.1002/pros.20429; Luo JM, 2003, MOL CELL BIOL, V23, P7947, DOI 10.1128/MCB.23.22.7947-7956.2003; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; Mitsunaga K, 2004, MECH DEVELOP, V121, P237, DOI 10.1016/j.mod.2004.01.006; Pettersson K, 1996, MECH DEVELOP, V54, P211, DOI 10.1016/0925-4773(95)00479-3; Prins GS, 2006, ANN NY ACAD SCI, V1089, P1, DOI 10.1196/annals.1386.009; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Sharma MJ, 2003, EMBO J, V22, P6101, DOI 10.1093/emboj/cdg585; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Soriano FX, 2006, DIABETES, V55, P1783, DOI 10.2337/db05-0509; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Trapp T, 1996, J BIOL CHEM, V271, P9879, DOI 10.1074/jbc.271.17.9879; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Vankoningsloo S, 2005, J LIPID RES, V46, P1133, DOI 10.1194/jlr.M400464-JLR200; Villena JA, 2007, P NATL ACAD SCI USA, V104, P1418, DOI 10.1073/pnas.0607696104; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wende AR, 2005, MOL CELL BIOL, V25, P10684, DOI 10.1128/MCB.25.24.10684-10694.2005; Wright ME, 2003, MOL ENDOCRINOL, V17, P1726, DOI 10.1210/me.2003-0031; Xie W, 1999, MOL ENDOCRINOL, V13, P2151, DOI 10.1210/me.13.12.2151; Yang XY, 2006, CELL, V126, P801, DOI 10.1016/j.cell.2006.06.050; Yu DD, 2005, BIOORG MED CHEM LETT, V15, P1311, DOI 10.1016/j.bmcl.2005.01.025; Yu SA, 2007, CANCER RES, V67, P4904, DOI 10.1158/0008-5472.CAN-06-3855; Zhang WH, 2002, MOL CELL ENDOCRINOL, V193, P1, DOI 10.1016/s0303-7207(02)00089-8; Zhou W, 2006, J CLIN ENDOCR METAB, V91, P569, DOI 10.1210/jc.2004-1957	45	60	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	23					3313	3328		10.1038/sj.onc.1210986	http://dx.doi.org/10.1038/sj.onc.1210986			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18071305				2023-01-03	WOS:000256111400010
J	Johns, A				Johns, Adrian			When authorship met authenticity	NATURE			English	Editorial Material									[Johns, Adrian] Univ Chicago, Chicago, IL 60637 USA	University of Chicago	Johns, A (corresponding author), Univ Chicago, 1126 E 59th St, Chicago, IL 60637 USA.							Green MD, 2006, J POSTGRAD MED, V52, P288	1	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 28	2008	451	7182					1058	1059		10.1038/4511058a	http://dx.doi.org/10.1038/4511058a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	266RB	18305531	Bronze			2023-01-03	WOS:000253453600026
J	Christakis, NA				Christakis, Nicholas A.			What networks can teach us about drug use	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Christakis, Nicholas A.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA; [Christakis, Nicholas A.] Mt Auburn Hosp, Cambridge, England	Harvard University; Harvard University; Mount Auburn Hospital	Christakis, NA (corresponding author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA.	christak@hcp.med.harvard.edu	Christakis, Nicholas A/B-6690-2008; Christakis, Nicholas A/C-3205-2009						0	1	1	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 23	2008	336	7641					420	420		10.1136/bmj.39496.537396.59	http://dx.doi.org/10.1136/bmj.39496.537396.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	269QM	18292167	Green Published			2023-01-03	WOS:000253664000035
J	Graff, MJL; Adang, EMM; Vernooij-Dassen, MJM; Dekker, J; Jonsson, L; Thijssen, M; Hoefnagels, WHL; Rikkert, MGMO				Graff, Maud J. L.; Adang, Eddy M. M.; Vernooij-Dassen, Myrra J. M.; Dekker, Joost; Jonsson, L.; Thijssen, Marjolein; Hoefnagels, Willibrord H. L.; Rikkert, Marcel G. M. Olde			Community occupational therapy for older patients with dementia and their care givers: cost effectiveness study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ALZHEIMERS-DISEASE; CONTROLLED-TRIAL; RATING-SCALE; CAREGIVERS; HOME; DETERMINANTS; INDIVIDUALS; PREVALENCE; ILLNESS; PEOPLE	Objective To assess the cost effectiveness of community based occupational therapy compared with usual care in older patients with dementia and their care givers from a societal viewpoint. Design Cost effectiveness study alongside a single blind randomised controlled trial. Setting Memory clinic, day clinic of a geriatrics department, and participants' homes. Patients 135 patients aged >= 65 with mild to moderate dementia living in the community and their primary care givers. Intervention 10 sessions of occupational therapy over five weeks, including cognitive and behavioural interventions, to train patients in the use of aids to compensate for cognitive decline and caregivers in coping behaviours and supervision. Main outcome measures Incremental cost effectiveness ratio expressed as the difference in mean total care costs per successful treatment (that is, a combined patient and care giver outcome measure of clinically relevant improvement on process, performance, and competence scales) at three months after randomisation. Bootstrap methods used to determine confidence intervals for these measures. Results The intervention cost (euro)1183 (848; pound $1738) (95% confidence interval (euro)1128 (808; pound $1657) to (euro)1239 (888; pound $1820)) per patient and primary care giver unit at three months. Visits to general practitioners and hospital doctors cost the same in both groups but total mean costs were (euro)1748 (1279; pound $2621) lower in the intervention group, with the main cost savings in informal care. There was a significant difference in proportions of successful treatments of 36% at three months. The number needed to treat for successful treatment at three months was 2.8 (2.7 to 2.9). Conclusions Community occupational therapy intervention for patients with dementia and their care givers is successful and cost effective, especially in terms of informal care giving.	[Graff, Maud J. L.; Thijssen, Marjolein] Radboud Univ Nijmegen Med Ctr, Dept Occupat Therapy 897, Alzheimer Ctr Nijmegen, NL-6500 HB Nijmegen, Netherlands; [Adang, Eddy M. M.] Radboud Univ Nijmegen Med Ctr, Dept Epidemiol Biostat & Hlth Technol Assessment, NL-6500 HB Nijmegen, Netherlands; [Graff, Maud J. L.; Vernooij-Dassen, Myrra J. M.; Thijssen, Marjolein] Radboud Univ Nijmegen Med Ctr, Dept Qual Care Res, Alzheimer Ctr Nijmegen, NL-6500 HB Nijmegen, Netherlands; [Dekker, Joost] Free Univ Med Ctr Amsterdam, Dept Rehabil Med, Amsterdam, Netherlands; [Jonsson, L.] Karolinska Inst, Neurotec Dept, Div Geriatr Epidemiol, Stockholm, Sweden; [Hoefnagels, Willibrord H. L.; Rikkert, Marcel G. M. Olde] Radboud Univ Nijmegen Med Ctr, Dept Geriatr 925, Alzheimer Ctr Nijmegen, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Karolinska Institutet; Radboud University Nijmegen	Graff, MJL (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Occupat Therapy 897, Alzheimer Ctr Nijmegen, POB 9101, NL-6500 HB Nijmegen, Netherlands.	m.graff@pmd.umcn.nl	Jönsson, Linus/G-2253-2017; Graff, M.J.L./L-4333-2015; Vernooij-Dassen, M.J.F.J./H-8107-2014; Adang, E.M.M./L-4169-2015; Rikkert, M.G.M. Olde/H-8078-2014; Rikkert, Marcel Olde/D-9773-2012	Jönsson, Linus/0000-0001-5751-6292; Rikkert, M.G.M. Olde/0000-0003-1397-1677; Dekker, Joost/0000-0003-2027-0027				APA, 1994, DIAGN STAT MAN MENT; Brink T. L., 1982, CLIN GERON, V1, P37, DOI DOI 10.1300/J018V01N01_06; Brodaty H, 1991, Int Psychogeriatr, V3, P11, DOI 10.1017/S1041610291000479; Burgener SC, 1998, GERIATR NURS, V19, P121, DOI 10.1016/S0197-4572(98)90055-6; COEN J, 1998, J HLTH GAIN, V2, P5; Drummond M.F., 2015, METHODS EC EVALUATIO, V4; *DUTCH HLTH COUNC, 2002, 200204 DUTCH HLTH CO; *DUTCH OCC THER AS, 2006, RICHTL DECL VERR EER; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Fisher A. G., 2003, ASSESSMENT MOTOR PRO; Gitlin LN, 2005, J GERONTOL A-BIOL, V60, P368, DOI 10.1093/gerona/60.3.368; Gitlin LN, 2001, GERONTOLOGIST, V41, P4, DOI 10.1093/geront/41.1.4; Graff M.J.L., 2006, DEMENTIA, V5, P503, DOI [10.1177/1471301206069918, DOI 10.1177/1471301206069918]; Graff MJL, 2007, J GERONTOL A-BIOL, V62, P1002, DOI 10.1093/gerona/62.9.1002; Graff MJL, 2006, BMJ-BRIT MED J, V333, P1196, DOI 10.1136/bmj.39001.688843.BE; Graff MJ, 2000, NED TIJDSCHR ERGOTHE, V28, P169; Graff MJL, 2003, OTJR-OCCUP PART HEAL, V23, P155, DOI 10.1177/153944920302300403; Hay J, 2002, J AM GERIATR SOC, V50, P1381, DOI 10.1046/j.1532-5415.2002.50359.x; Jepson C, 1999, Image J Nurs Sch, V31, P115, DOI 10.1111/j.1547-5069.1999.tb00444.x; Jonsson L, 2006, INT J GERIATR PSYCH, V21, P449, DOI 10.1002/gps.1489; KARLSSON G, 1998, HLTH EC DEMENTIA; Knapp M, 2006, BRIT J PSYCHIAT, V188, P574, DOI 10.1192/bjp.bp.105.010561; Maynard A, 2007, BMJ-BRIT MED J, V334, P594, DOI 10.1136/bmj.39132.363356.80; Meerding WJ, 1998, BRIT MED J, V317, P111, DOI 10.1136/bmj.317.7151.111; MELIS RJF, IN PRESS GERONTOL A; MELIS RJF, IN PRESS J GERONTO A; MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N; Oostenbrink J, 2004, HANDLEIDING KOSTENON; Polder J J, 2006, KOSTEN ZIEKTEN NEDER; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; REISBERG B, 1983, PSYCHOPHARMACOL BULL, V19, P702; *RIVM, 2006, VOLKSG TOEK VERK 200; Rockwood K., 2006, TRIAL DESIGNS OUTCOM; *RVZ, 2006, ARB ZORGVR ACHT; Siemonsma PC, 1997, CLIN REHABIL, V11, P273, DOI 10.1177/026921559701100402; Steultjens EMJ, 2004, AGE AGEING, V33, P453, DOI 10.1093/ageing/afh174; TERI L, 1992, PSYCHOL AGING, V7, P622, DOI 10.1037/0882-7974.7.4.622; Teunisse S, 1997, Int Psychogeriatr, V9 Suppl 1, P155, DOI 10.1017/S1041610297004845; Teunisse S., 1997, CLINIMETRICS DEMENTI; VernooijDassen MJFJ, 1996, SOC SCI MED, V43, P41, DOI 10.1016/0277-9536(95)00332-0; Wimo A, 2006, DEMENT GERIATR COGN, V21, P175, DOI 10.1159/000090733; Wimo A, 2003, ALZ DIS ASSOC DIS, V17, P63, DOI 10.1097/00002093-200304000-00002; Wimo A, 1998, HLTH EC DEMENTIA	43	170	172	0	37	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 19	2008	336	7636					134	138		10.1136/bmj.39408.481898.BE	http://dx.doi.org/10.1136/bmj.39408.481898.BE			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	257SS	18171718	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000252819400031
J	Grant, GB; Fridkin, S; Chang, DC; Park, BJ				Grant, Gavin B.; Fridkin, Scott; Chang, Douglas C.; Park, Benjamin J.			Postrecall surveillance following a multistate Fusarium keratitis outbreak, 2004 through 2006	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							SINGAPORE		CDCP, Epidem Intelligence Serv, Office Workforce & Career Dev, Atlanta, GA USA; CDCP, Coordinating Ctr Infect Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Div Bacterial Foodborne & Mycot Dis, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Grant, GB (corresponding author), CDCP, Epidem Intelligence Serv, Office Workforce & Career Dev, Atlanta, GA USA.	gbgrant@cdc.gov		Grant, Gavin/0000-0002-3271-5735				Chang DC, 2006, JAMA-J AM MED ASSOC, V296, P953, DOI 10.1001/jama.296.8.953; Donnio A, 2007, AM J OPHTHALMOL, V143, P356, DOI 10.1016/j.ajo.2006.09.021; Khor WB, 2006, JAMA-J AM MED ASSOC, V295, P2867, DOI 10.1001/jama.295.24.2867; Saw SM, 2007, ARCH OPHTHALMOL-CHIC, V125, P611, DOI 10.1001/archopht.125.5.611; Schuchat A, 2001, EMERG INFECT DIS, V7, P92, DOI 10.3201/eid0701.010114	5	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 26	2007	298	24					2867	2868		10.1001/jama.298.24.2867	http://dx.doi.org/10.1001/jama.298.24.2867			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RW	18159055	Bronze			2023-01-03	WOS:000251816000018
J	Amin, AN; Pistoria, MJ				Amin, Alpesh N.; Pistoria, Michael J.			Update in hospital medicine	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PULMONARY-EMBOLISM; HIP FRACTURE; PROBABILITY; PATIENT		Univ Calif Irvine, Dept Med, Orange, CA USA; Lehigh Valley Hosp, Allentown, PA USA	University of California System; University of California Irvine; Lehigh Valley Hospital	Amin, AN (corresponding author), Univ Calif Irvine, Dept Med, 101 City Dr S,Bldg 58,Room 110,ZC-4076H, Orange, CA USA.	anamin@uci.edu						Fitzgibbons JP, 2006, ANN INTERN MED, V144, P920, DOI 10.7326/0003-4819-144-12-200606200-00010; Le Gal G, 2006, ANN INTERN MED, V144, P165, DOI 10.7326/0003-4819-144-3-200602070-00004; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Oosterheert JJ, 2006, BMJ-BRIT MED J, V333, P1193, DOI 10.1136/bmj.38993.560984.BE; Orosz GM, 2004, JAMA-J AM MED ASSOC, V291, P1738, DOI 10.1001/jama.291.14.1738; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Rowe JW, 2006, ANN INTERN MED, V145, P695, DOI 10.7326/0003-4819-145-9-200611070-00013; Roy A, 2006, MAYO CLIN PROC, V81, P28, DOI 10.4065/81.1.28; Schnipper JL, 2006, ARCH INTERN MED, V166, P565, DOI 10.1001/archinte.166.5.565; Wells PS, 2006, JAMA-J AM MED ASSOC, V295, P199, DOI 10.1001/jama.295.2.199; Wells PS, 1997, LANCET, V350, P1795, DOI 10.1016/S0140-6736(97)08140-3; Wicki J, 2001, ARCH INTERN MED, V161, P92, DOI 10.1001/archinte.161.1.92	12	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 6	2007	147	9					628	632		10.7326/0003-4819-147-9-200711060-00007	http://dx.doi.org/10.7326/0003-4819-147-9-200711060-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227QM	17975185				2023-01-03	WOS:000250672900005
J	Simhan, HN; Caritis, SN				Simhan, Hyagriv N.; Caritis, Steve N.			Drug therapy: Prevention of preterm delivery	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PATENT DUCTUS-ARTERIOSUS; MAGNESIUM-SULFATE; DOUBLE-BLIND; CONTROLLED-TRIAL; NITRIC-OXIDE; 17-ALPHA-HYDROXYPROGESTERONE CAPROATE; CYCLOOXYGENASE-2 INHIBITOR; CALCIUM-CONCENTRATION; UTERINE CONTRACTIONS; ANTAGONIST ATOSIBAN		Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Simhan, HN (corresponding author), 300 Halket St, Pittsburgh, PA 15213 USA.	hsimhan@mail.magee.edu		caritis, steve/0000-0002-2169-0712	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR000005] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))		Andrews WW, 2003, OBSTET GYNECOL, V101, P847, DOI 10.1016/S0029-7844(03)00172-8; [Anonymous], 2003, COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD002255; Anotayanonth S, 2004, COCHRANE DB SYST REV, V4; Bailit JL, 2007, AM J OBSTET GYNECOL, V196, P219, DOI 10.1016/j.ajog.2006.12.021; Bao B, 2003, AM J PHYSIOL-ENDOC M, V285, pE1095, DOI 10.1152/ajpendo.00545.2002; Behrman RE, 2007, PRETERM BIRTH CAUSES; Berghella V, 2005, OBSTET GYN CLIN N AM, V32, P383, DOI 10.1016/j.ogc.2005.04.007; Bisits A, 2004, AM J OBSTET GYNECOL, V191, P683, DOI 10.1016/j.ajog.2004.02.019; Carey JC, 2000, NEW ENGL J MED, V342, P534, DOI 10.1056/NEJM200002243420802; CARITIS SN, 1979, AM J OBSTET GYNECOL, V133, P557, DOI 10.1016/0002-9378(79)90292-8; CARITIS SN, 1987, AM J PHYSIOL, V253, pE410, DOI 10.1152/ajpendo.1987.253.4.E410; CARITIS SN, 1991, AM J OBSTET GYNECOL, V164, P1005, DOI 10.1016/0002-9378(91)90574-B; Challis JRG, 2002, REPRODUCTION, V124, P1; Cordero L, 2007, J PERINATOL, V27, P158, DOI 10.1038/sj.jp.7211659; COX SM, 1990, AM J OBSTET GYNECOL, V163, P767, DOI 10.1016/0002-9378(90)91065-K; CREASY RK, 1980, OBSTET GYNECOL, V55, P692; Crowley P, 2007, COCHRANE DB SYST REV, V18, DOI [10.1002/14651858.CD000065, DOI 10.1002/14651858.CD000065, 10.1002/14651858.CD000065.pub2, DOI 10.1002/14651858.CD000065.PUB2]; Crowther CA, 2003, JAMA-J AM MED ASSOC, V290, P2669, DOI 10.1001/jama.290.20.2669; Crowther CA, 2002, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001060; CUNZE T, 1995, INT J GYNECOL OBSTET, V48, P9, DOI 10.1016/0020-7292(94)02217-8; DARBY MJ, 1989, OBSTET GYNECOL, V74, P88; DUDLEY DKL, 1985, AM J OBSTET GYNECOL, V151, P181, DOI 10.1016/0002-9378(85)90008-0; El-Sayed YY, 1999, OBSTET GYNECOL, V93, P79, DOI 10.1016/S0029-7844(98)00337-8; Elder H A, 1967, Antimicrob Agents Chemother (Bethesda), V7, P101; FERGUSON JE, 1989, AM J OBSTET GYNECOL, V161, P788, DOI 10.1016/0002-9378(89)90403-1; Fomin VP, 2006, AM J OBSTET GYNECOL, V194, P1384, DOI 10.1016/j.ajog.2005.11.045; Fonseca EB, 2007, NEW ENGL J MED, V357, P462, DOI 10.1056/NEJMoa067815; FORMAN A, 1986, ACTA PHARMACOL TOX, V58, P183; FOULON W, 1986, OBSTET GYNECOL, V68, P280; Gibler WB, 2005, CIRCULATION, V111, P2699, DOI 10.1161/01.CIR.0000165556.44271.BE; Goldenberg RL, 1996, OBSTET GYNECOL, V87, P643, DOI 10.1016/0029-7844(96)00035-X; Goldenberg RL, 2000, NEW ENGL J MED, V342, P1500, DOI 10.1056/NEJM200005183422007; Goldenberg RL, 2001, AM J OBSTET GYNECOL, V185, P643, DOI 10.1067/mob.2001.116752; Gomez, 2005, AM J OBSTET GYNECOL, V193, P308; Gomez R, 2005, AM J OBSTET GYNECOL, V192, P350, DOI 10.1016/j.ajog.2004.09.034; Gomez R, 1997, INFECT DIS CLIN N AM, V11, P135, DOI 10.1016/S0891-5520(05)70347-0; GOODWIN TM, 1994, AM J OBSTET GYNECOL, V170, P474, DOI 10.1016/S0002-9378(94)70214-4; Goodwin TM, 1996, AM J PERINAT, V13, P143, DOI 10.1055/s-2007-994312; GORDON MC, 1995, CLIN OBSTET GYNECOL, V38, P697, DOI 10.1097/00003081-199538040-00004; Grimes DA, 2006, OBSTET GYNECOL, V108, P986, DOI 10.1097/01.AOG.0000236445.18265.93; Gross G, 2000, AM J PHYSIOL-REG I, V278, pR1415, DOI 10.1152/ajpregu.2000.278.6.R1415; Gyetvai K, 1999, OBSTET GYNECOL, V94, P869, DOI 10.1016/S0029-7844(99)00329-4; Hammerman C, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.5.e56; Hartmann K, 1999, OBSTET GYNECOL, V93, P504, DOI 10.1016/S0029-7844(98)00497-9; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; Honest H, 2002, BMJ-BRIT MED J, V325, P301, DOI 10.1136/bmj.325.7359.301; Hoyert DL, 2006, PEDIATRICS, V117, P2338, DOI 10.1524/peds.2006-1079; Iams JD, 1996, NEW ENGL J MED, V334, P567, DOI 10.1056/NEJM199602293340904; Iams JD, 1998, PRENAT NEONAT MED, V3, P138; KAMINSKI M, 1974, J PERINAT MED, V2, P37, DOI 10.1515/jpme.1974.2.1.37; KEIRSE MJNC, 1990, BRIT J OBSTET GYNAEC, V97, P149, DOI 10.1111/j.1471-0528.1990.tb01740.x; King J, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001992.pub2; KING JF, 1988, BRIT J OBSTET GYNAEC, V95, P211, DOI 10.1111/j.1471-0528.1988.tb06860.x; Klein LL, 2004, AM J OBSTET GYNECOL, V190, P1493, DOI 10.1016/j.ajog.2004.03.014; KUMAR D, 1963, AM J OBSTET GYNECOL, V86, P1036, DOI 10.1016/S0002-9378(16)35290-5; KURTZMAN JL, 1993, AM J PERINAT, V10, P450; Lamont RF, 2000, BRIT J OBSTET GYNAEC, V107, P439, DOI 10.1111/j.1471-0528.2000.tb13259.x; Ledingham MA, 2000, BRIT J OBSTET GYNAEC, V107, P581, DOI 10.1111/j.1471-0528.2000.tb13297.x; Lees CC, 1999, OBSTET GYNECOL, V94, P403, DOI 10.1016/S0029-7844(99)00296-3; Lemancewicz A, 2000, HUM REPROD, V15, P2018, DOI 10.1093/humrep/15.9.2018; LIGGINS GC, 1972, PEDIATRICS, V50, P515; LIGGINS GC, 1969, J ENDOCRINOL, V45, P515, DOI 10.1677/joe.0.0450515; Lockwood CJ, 2005, AM J PATHOL, V167, P1443, DOI 10.1016/S0002-9440(10)61230-8; Lockwood CJ, 1999, J PERINAT MED, V27, P5, DOI 10.1515/JPM.1999.001; Lockwood CJ, 2001, PAEDIATR PERINAT EP, V15, P78, DOI 10.1046/j.1365-3016.2001.00010.x; MAIN DM, 1987, OBSTET GYNECOL, V69, P61; McPheeters ML, 2005, AM J OBSTET GYNECOL, V192, P1325, DOI 10.1016/j.ajog.2004.12.055; Meis PJ, 2003, NEW ENGL J MED, V349, P1087; Meis PJ, 2003, NEW ENGL J MED, V348, P2379, DOI 10.1056/NEJMoa035140; Mittendorf R, 2002, AM J OBSTET GYNECOL, V186, P1111, DOI 10.1067/mob.2002.123544; MIZUKI J, 1993, AM J OBSTET GYNECOL, V169, P134, DOI 10.1016/0002-9378(93)90147-B; MORALES WJ, 1993, AM J OBSTET GYNECOL, V169, P97, DOI 10.1016/0002-9378(93)90138-9; Moutquin JM, 2000, AM J OBSTET GYNECOL, V182, P1191, DOI 10.1067/mob.2000.104950; NIEBYL JR, 1986, AM J OBSTET GYNECOL, V155, P747, DOI 10.1016/S0002-9378(86)80012-6; NIEBYL JR, 1980, AM J OBSTET GYNECOL, V136, P1014, DOI 10.1016/0002-9378(80)90629-8; NORTON ME, 1993, NEW ENGL J MED, V329, P1602, DOI 10.1056/NEJM199311253292202; Papatsonis D, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004452.pub2; Papatsonis DNM, 1997, OBSTET GYNECOL, V90, P230, DOI 10.1016/S0029-7844(97)00182-8; PAPIERNIK E, 1984, CLIN OBSTET GYNAECOL, V11, P315; PAPIERNIK E, 1974, J PERINAT MED, V2, P30, DOI 10.1515/jpme.1974.2.1.30; PERRY KG, 1995, AM J OBSTET GYNECOL, V173, P1273, DOI 10.1016/0002-9378(95)91369-6; Petrini JR, 2005, OBSTET GYNECOL, V105, P267, DOI 10.1097/01.AOG.0000150560.24297.4f; PHANEUF S, 1994, AM J OBSTET GYNECOL, V171, P1627, DOI 10.1016/0002-9378(94)90414-6; ROMERO R, 1994, ANN NY ACAD SCI, V734, P414, DOI 10.1111/j.1749-6632.1994.tb21771.x; Romero R, 2000, AM J OBSTET GYNECOL, V182, P1173, DOI 10.1067/mob.2000.95834; ROMERO R, 1989, AM J OBSTET GYNECOL, V161, P817, DOI 10.1016/0002-9378(89)90409-2; Rosen T, 2002, J Matern Fetal Neonatal Med, V11, P11, DOI 10.1080/713605444; Rouse DJ, 2007, NEW ENGL J MED, V357, P454, DOI 10.1056/NEJMoa070641; Sadovsky Y, 2000, AM J OBSTET GYNECOL, V182, P370, DOI 10.1016/S0002-9378(00)70226-2; Sakai M, 2001, MOL HUM REPROD, V7, P595, DOI 10.1093/molehr/7.6.595; SAWAYA GF, 1992, AM J OBSTET GYNECOL, V167, P512, DOI 10.1016/S0002-9378(11)91443-4; Sawdy R, 1997, LANCET, V350, P265, DOI 10.1016/S0140-6736(05)62229-5; Smith GN, 1999, BRIT J OBSTET GYNAEC, V106, P736, DOI 10.1111/j.1471-0528.1999.tb08376.x; Smith R, 2007, NEW ENGL J MED, V356, P271, DOI 10.1056/NEJMra061360; SNYDER SW, 1989, AM J OBSTET GYNECOL, V161, P35, DOI 10.1016/0002-9378(89)90226-3; Souter D, 1998, AUST NZ J OBSTET GYN, V38, P11, DOI 10.1111/j.1479-828X.1998.tb02949.x; Suarez VR, 2002, AM J OBSTET GYNECOL, V187, P886, DOI 10.1067/mob.2002.127464; THORP JM, 1990, AM J OBSTET GYNECOL, V163, P655, DOI 10.1016/0002-9378(90)91218-2; Watson JE, 1996, J PEDIATR PSYCHOL, V21, P419, DOI 10.1093/jpepsy/21.3.419; WOODS D L, 1986, Pediatric Pathology, V6, P81; Wray S, 2003, J SOC GYNECOL INVEST, V10, P252, DOI 10.1016/S1071-5576(03)00089-3; Yallampalli C, 1998, J SOC GYNECOL INVEST, V5, P58, DOI 10.1016/S1071-5576(97)00106-8; Yousif MH, 1998, J PHARM PHARMACOL, V50, P681, DOI 10.1111/j.2042-7158.1998.tb06905.x; ZUCKERMAN H, 1984, J PERINAT MED, V12, P25, DOI 10.1515/jpme.1984.12.1.25	104	193	209	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 2	2007	357	5					477	487		10.1056/NEJMra050435	http://dx.doi.org/10.1056/NEJMra050435			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195UB	17671256				2023-01-03	WOS:000248436300009
J	Cayley, WE				Cayley, William E.			Preventing deep vein thrombosis in hospital inpatients	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MOLECULAR-WEIGHT HEPARIN; VENOUS THROMBOEMBOLISM; UNFRACTIONATED HEPARIN; METAANALYSIS; PROPHYLAXIS; SURGERY; RISK				Cayley, WE (corresponding author), Univ Wisconsin, Dept Family Med, Augusta Rural Training Site,Eau Claire Family Med, Augusta, WI 54701 USA.	bcayley@yahoo.com						Agnelli G, 2005, BRIT J SURG, V92, P1212, DOI 10.1002/bjs.5154; *AM COLL OBSTET GY, 2000, ACOG PRACT B, V21; AMARAGIRI SV, 2000, COCHRANE DATABASE SY, V0003; [Anonymous], 2007, VEN THROMB RED RISK; Brookenthal KR, 2001, J ARTHROPLASTY, V16, P293, DOI 10.1054/arth.2001.21499; Fitzmaurice DA, 2007, BMJ-BRIT MED J, V334, P1017, DOI 10.1136/bmj.39210.496505.BE; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; Handoll HH., 2002, COCHRANE DB SYST REV, V4, pCD000305, DOI [10.1002/14651858.CD000305, DOI 10.1002/14651858.CD000305]; Hill J, 2007, BMJ-BRIT MED J, V334, P1053, DOI 10.1136/bmj.39174.678032.AD; Hull RD, 1999, ARCH INTERN MED, V159, P137, DOI 10.1001/archinte.159.2.137; *I CLIN SYST IMPR, 2005, VEN THROMB PROPH; Koch A, 2001, THROMB RES, V102, P295, DOI 10.1016/S0049-3848(01)00251-1; Mismetti P, 2000, THROMB HAEMOSTASIS, V83, P14; Mismetti P, 2004, J THROMB HAEMOST, V2, P1058, DOI 10.1111/j.1538-7836.2004.00757.x; Mismetti P, 2001, BRIT J SURG, V88, P913, DOI 10.1046/j.0007-1323.2001.01800.x; O'Brien J, 2000, LANCET, V355, P1295; Oates-Whitehead RM, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003679.pub2; Palmer AJ, 1997, HAEMOSTASIS, V27, P65; Prandoni P, 2004, ANN INTERN MED, V141, P249, DOI 10.7326/0003-4819-141-4-200408170-00004; Rasmussen MS., 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001217, DOI 10.1002/14651858.CD001217]; Roderick P, 2005, HEALTH TECHNOL ASSES, V9, P1; *SCOTT INT GUID NE, 2002, PROPH VEN THROMB NAT; Tooher R, 2005, ANN SURG, V241, P397, DOI 10.1097/01.sla.0000154120.96169.99; Vanek VW, 1998, AM SURGEON, V64, P1050; Westrich GH, 2000, J BONE JOINT SURG BR, V82B, P795, DOI 10.1302/0301-620X.82B6.9869; Zufferey P, 2003, THROMB HAEMOSTASIS, V90, P654, DOI 10.1160/TH03-02-0086	26	26	27	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 21	2007	335	7611					147	151		10.1136/bmj.39247.542477.AE	http://dx.doi.org/10.1136/bmj.39247.542477.AE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195RA	17641348	Green Published			2023-01-03	WOS:000248428100036
J	Feudtner, C; Feinstein, JA; Satchell, M; Zhao, HQ; Kang, TI				Feudtner, Chris; Feinstein, James A.; Satchell, Marlon; Zhao, Huaqing; Kang, Tammy I.			Shifting place of death among children with complex chronic conditions in the United States, 1989-2003	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; MULTIPLE IMPUTATION; ETHNIC-DIFFERENCES; WASHINGTON-STATE; PALLIATIVE CARE; CANCER-PATIENTS; HOME; HOSPICE; TRENDS; SITE	Context The place where children with complex chronic conditions are dying may be shifting toward residential homes due to the evolving epidemiology of life-threatening childhood conditions, advances in home-based medical technology, and changes in attitudes about pediatric palliative care and hospice services. Objectives To determine whether pediatric deaths attributed to complex chronic conditions are increasingly occurring in the home and to assess race and ethnicity disparities in the location of death. Design, Setting, and Participants Retrospective national-level case series drawn from the National Center for Health Statistics' Multiple Cause of Death Files spanning 1989-2003. Participants included all deceased individuals aged 19 years or younger with a complex chronic condition excluding injury and noncomplex chronic conditions ( as classified by International Classification of Diseases, Ninth Revision or International Classification of Diseases, Tenth Revision). Main Outcome Measure Place where death occurred. Results Among the 22.1% of deaths ( 198 160 of 896 509 total deaths) attributed to a complex chronic condition between 1989 and 2003, the percentage of individuals dying at home increased significantly ( P <. 001) over time for infants ( aged < 1 year) (4.9% in 1989 and 7.3% in 2003); 1- to 9-year-olds (17.9% and 30.7%); and for 10- to 19-year-olds (18.4% and 32.2%). Adjusting for decedent characteristics, the odds of dying at home increased significantly each year ( odds ratio, 1.04; 95% confidence interval, 1.03-1.04) and were reduced among both black and Hispanic decedents ( odds ratio, 0.50; 95% confidence interval, 0.48-0.52 and odds ratio, 0.52; 95% confidence interval, 0.50-0.54, respectively) compared with white decedents. Conclusions Children who die with underlying complex chronic conditions increasingly are dying at home. Racial and ethnic disparities regarding place of death may represent important limitations and opportunities for improvement in the current systems of pediatric chronic and palliative care.	Childrens Hosp Philadelphia, Pediat Adv Care Team, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Pediat Generalist Res Grp, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Biostat & Data Management Core, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Div Gen Pediat, Philadelphia, PA 19104 USA; Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Feudtner, C (corresponding author), Childrens Hosp Philadelphia, Pediat Adv Care Team, 3535 Market St,Room 1523,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	feudtner@email.chop.edu	Feudtner, Chris/AAI-1126-2019; Feinstein, James Aaron/I-6373-2013	Feudtner, Chris/0000-0002-5879-0434; Feinstein, James Aaron/0000-0003-3074-8805	AHRQ HHS [K08 HS00002] Funding Source: Medline; NINR NIH HHS [R21-NR008614] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS000002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R21NR008614] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Burge F, 2003, CAN MED ASSOC J, V168, P265; Burge FI, 2005, J RURAL HEALTH, V21, P233, DOI 10.1111/j.1748-0361.2005.tb00088.x; Caveney AF, 2006, PUBLIC HEALTH REP, V121, P275, DOI 10.1177/003335490612100309; *CDCP, 1996, DOC PUBL US MULT CAU; *COMM PALL END OF, 2003, CHILDR DIE IMPR PALL; Davies E, 2006, BRIT J CANCER, V95, P593, DOI 10.1038/sj.bjc.6603305; Enguidanos S, 2005, J AM GERIATR SOC, V53, P1411, DOI 10.1111/j.1532-5415.2005.53410.x; Feudtner C, 2000, PEDIATRICS, V106, P205; Feudtner C, 2002, PEDIATRICS, V109, P656, DOI 10.1542/peds.109.4.656; Feudtner Chris, 2005, BMC Pediatr, V5, P8, DOI 10.1186/1471-2431-5-8; Flory J, 2004, HEALTH AFFAIR, V23, P194, DOI 10.1377/hlthaff.23.3.194; Fox CS, 2005, AM J CARDIOL, V95, P856, DOI 10.1016/j.amjcard.2004.12.011; GOLDMAN A, 1990, ARCH DIS CHILD, V65, P641, DOI 10.1136/adc.65.6.641; Gomes B, 2006, BMJ-BRIT MED J, V332, P515, DOI 10.1136/bmj.38740.614954.55; Guyer B, 2000, PEDIATRICS, V106, P1307, DOI 10.1542/peds.106.6.1307; Himelstein BP, 2004, NEW ENGL J MED, V350, P1752, DOI 10.1056/NEJMra030334; Iwashyna TJ, 2002, J AM GERIATR SOC, V50, P1113, DOI 10.1046/j.1532-5415.2002.50269.x; Johnson KS, 2005, J AM GERIATR SOC, V53, P2209, DOI 10.1111/j.1532-5415.2005.00502.x; KATZ BP, 1979, PUBLIC HEALTH REP, V94, P522; Kreicbergs U, 2005, J CLIN ONCOL, V23, P9162, DOI 10.1200/JCO.2005.08.557; LAUER ME, 1989, CANCER, V63, P988, DOI 10.1002/1097-0142(19890301)63:5<988::AID-CNCR2820630534>3.0.CO;2-Y; Leuthner Steven R, 2004, J Palliat Med, V7, P269, DOI 10.1089/109662104773709396; Lloyd-Jones DM, 1998, ANN INTERN MED, V129, P1020, DOI 10.7326/0003-4819-129-12-199812150-00005; MCCUSKER J, 1983, PUBLIC HEALTH REP, V98, P170; Meier DE, 2007, J PALLIAT MED, V10, P284, DOI 10.1089/jpm.2006.9985; MOINPOUR CM, 1989, AM J PUBLIC HEALTH, V79, P1549, DOI 10.2105/AJPH.79.11.1549; MOR V, 1983, J HEALTH SOC BEHAV, V24, P375, DOI 10.2307/2136403; Mor Vincent, 2005, J Palliat Med, V8, P58, DOI 10.1089/jpm.2005.8.58; MULHERN RK, 1983, PEDIATRICS, V71, P743; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; PALFREY JS, 1994, PUBLIC HEALTH REP, V109, P226; Polissar L, 1987, J Community Health, V12, P40, DOI 10.1007/BF01321396; Royston P, 2005, STATA J, V5, P188, DOI 10.1177/1536867X0500500204; Royston P, 2004, STATA J, V4, P227, DOI 10.1177/1536867X0400400301; Stuart G, 2002, HEART, V88, pI1; Surkan PJ, 2006, PALLIATIVE MED, V20, P161, DOI 10.1191/0269216306pm1139oa; Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care (full printed version), 2003, UN TREATM CONFR RAC; Vincer MJ, 2006, PEDIATRICS, V118, pE1621, DOI 10.1542/peds.2006-1522; Weitzen S, 2003, MED CARE, V41, P323, DOI 10.1097/00005650-200302000-00013; Wolfe J, 2000, JAMA-J AM MED ASSOC, V284, P2469, DOI 10.1001/jama.284.19.2469	40	159	163	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2007	297	24					2725	2732		10.1001/jama.297.24.2725	http://dx.doi.org/10.1001/jama.297.24.2725			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	182UE	17595273	Bronze			2023-01-03	WOS:000247528700022
J	Feng, RT; Ni, HM; Wang, SY; Tourkova, IL; Shurin, MR; Harada, H; Yin, XM				Feng, Rentian; Ni, Hong-Min; Wang, Shiow Y.; Tourkova, Irina L.; Shurin, Michael R.; Harada, Hisashi; Yin, Xiao-Ming			Cyanidin-3-rutinoside, a natural polyphenol antioxidant, selectively kills leukemic cells by induction of oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR PROTEIN-1; HYDROGEN-PEROXIDE; INDUCED APOPTOSIS; PLANT-EXTRACTS; KAPPA-B; ANTHOCYANINS; BIM; PHOSPHORYLATION; DEATH; DIFFERENTIATION	Anthocyanins are a group of naturally occurring phenolic compounds widely available in fruits and vegetables in human diets. They have broad biological activities including anti-mutagenesis and anticarcinogenesis, which are generally attributed to their antioxidant activities. We studied the effects and the mechanisms of the most common type of anthocyanins, cyanidin-3-rutinoside, in several leukemia and lymphoma cell lines. We found that cyanidin-3-rutinoside extracted and purified from the black raspberry cultivar Jewel induced apoptosis in HL-60 cells in a dose-and time-dependent manner. Paradoxically, this compound induced the accumulation of peroxides, which are involved in the induction of apoptosis in HL-60 cells. In addition, cyanidin-3-rutinoside treatment resulted in reactive oxygen species (ROS)-dependent activation of p38 MAPK and JNK, which contributed to cell death by activating the mitochondrial pathway mediated by Bim. Down-regulation of Bim or overexpression of Bcl-2 or Bcl-x(L) considerably blocked apoptosis. Notably, cyanidin-3-rutinoside treatment did not lead to increased ROS accumulation in normal human peripheral blood mononuclear cells and had no cytotoxic effects on these cells. These results indicate that cyanidin-3-rutinoside has the potential to be used in leukemia therapy with the advantages of being widely available and selective against tumors.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; USDA ARS, Beltsville Agr Res Ctr, Fruit Lab, Beltsville, MD 20705 USA; Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23298 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; United States Department of Agriculture (USDA); Virginia Commonwealth University	Yin, XM (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, 3550 Terrace St, Pittsburgh, PA 15261 USA.	xmyin@pitt.edu	Harada, Hisashi/H-2815-2019	Harada, Hisashi/0000-0001-5993-1289; Shurin, Michael/0000-0002-6570-7395	NATIONAL CANCER INSTITUTE [R01CA111456, R01CA083817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045252] Funding Source: NIH RePORTER; NCI NIH HHS [CA83817, CA111456] Funding Source: Medline; NINDS NIH HHS [NS045252] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Cai BB, 2006, J BIOL CHEM, V281, P25215, DOI 10.1074/jbc.M512627200; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Chen D, 2004, P NATL ACAD SCI USA, V101, P1235, DOI 10.1073/pnas.0308050100; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; Ding M, 2006, J BIOL CHEM, V281, P17359, DOI 10.1074/jbc.M600861200; Ding WX, 2004, HEPATOLOGY, V40, P403, DOI 10.1002/hep.20310; Feng R, 2004, NUTR CANCER, V50, P80, DOI 10.1207/s15327914nc5001_11; Feng RT, 2005, J BIOL CHEM, V280, P27888, DOI 10.1074/jbc.M503347200; Fimognari C, 2005, CHEMOTHERAPY, V51, P332, DOI 10.1159/000088956; Galvano F, 2004, J NUTR BIOCHEM, V15, P2, DOI 10.1016/j.jnutbio.2003.07.004; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hagiwara A, 2001, CANCER LETT, V171, P17, DOI 10.1016/S0304-3835(01)00510-9; HERTOG MGL, 1993, NUTR CANCER, V20, P21, DOI 10.1080/01635589309514267; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Kahkonen MP, 1999, J AGR FOOD CHEM, V47, P3954, DOI 10.1021/jf990146l; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Katsuzaki H, 2003, ONCOL REP, V10, P297; Lazze MC, 2004, CARCINOGENESIS, V25, P1427, DOI 10.1093/carcin/bgh138; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Lopez-Lazaro M, 2002, Curr Med Chem Anticancer Agents, V2, P691; Lu JH, 2006, FEBS LETT, V580, P3539, DOI 10.1016/j.febslet.2006.05.031; Malik A, 2005, P NATL ACAD SCI USA, V102, P14813, DOI 10.1073/pnas.0505870102; Matsuzawa A, 2005, ANTIOXID REDOX SIGN, V7, P472, DOI 10.1089/ars.2005.7.472; Mazza G., 1993, ANTHOCYANINS FRUITS; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; PATTERSON BD, 1984, ANAL BIOCHEM, V139, P487, DOI 10.1016/0003-2697(84)90039-3; PICK E, 1980, J IMMUNOL METHODS, V38, P161, DOI 10.1016/0022-1759(80)90340-3; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; RICHMOND R, 1981, ANAL BIOCHEM, V118, P328, DOI 10.1016/0003-2697(81)90590-X; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015; Serafino A, 2004, FASEB J, V18, P1940, DOI 10.1096/fj.04-1925fje; Strasser A, 2000, ANN NY ACAD SCI, V917, P541; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Wang HB, 1999, J NAT PROD, V62, P294, DOI 10.1021/np980501m; Wang SY, 2005, J AGR FOOD CHEM, V53, P3156, DOI 10.1021/jf048379m; Wenzel H, 2000, CANCER RES, V60, P3823; Zheng W, 2003, J AGR FOOD CHEM, V51, P502, DOI 10.1021/jf020728u; Zheng YH, 2003, J AGR FOOD CHEM, V51, P7162, DOI 10.1021/jf030440k	43	160	172	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13468	13476		10.1074/jbc.M610616200	http://dx.doi.org/10.1074/jbc.M610616200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17360708	hybrid			2023-01-03	WOS:000246060300036
J	Davies, AJ				Davies, A. J.			Radioimmunotherapy for B-cell lymphoma: Y-90 ibritumomab tiuxetan and I-131 tositumomab	ONCOGENE			English	Review						radioimmunotherapy; non-Hodgkin's lymphoma; tositumomab; ibritumomab; monoclonal antibodies; CD20	NON-HODGKIN-LYMPHOMA; TERM-FOLLOW-UP; CHEMOTHERAPY PLUS RITUXIMAB; HIGH-DOSE THERAPY; MONOCLONAL-ANTIBODY THERAPY; BONE-MARROW-TRANSPLANTATION; RANDOMIZED CONTROLLED-TRIAL; MULTICENTER PHASE-II; REFRACTORY LOW-GRADE; FOLLICULAR LYMPHOMA	Radioimmunotherapy, targeting the CD20 antigen, in B-cell lymphoma has clearly demonstrated efficacy and tolerability over the preceding 15 years. As a result, two products are available with Food and Drug Administration approval for marketing - Y-90 ibritumomab tiuxetan and I-131 tositumomab, given as the Zevalin and Bexxar therapeutic regimens, respectively. Both demonstrate high-response rates and durability of remission in the relapsed/refractory disease setting. Data are emerging regarding their utility as initial therapy, and furthermore, they are been investigated for use sequentially with chemotherapy, and in the myeloablative setting. As yet however, how to best use these agents in the clinical disease course remains uncertain.	St Bartholomews Hosp, Dept Med Oncol, London EC1A 7BE, England	University of London; Queen Mary University London	Davies, AJ (corresponding author), St Bartholomews Hosp, Dept Med Oncol, 7th Floor Gloucester House, London EC1A 7BE, England.	Andrew.Davies1@Bartsandthelondon.nhs.uk		Davies, Andrew/0000-0002-7517-6938				Andersen NS, 2002, EUR J CANCER, V38, P401, DOI 10.1016/S0959-8049(01)00366-5; ANDERSON KC, 1984, BLOOD, V63, P1424, DOI 10.1182/blood.V63.6.1424.1424; Ansell SM, 2002, J CLIN ONCOL, V20, P3885, DOI 10.1200/JCO.2002.10.143; Apostolidis J, 2000, J CLIN ONCOL, V18, P527, DOI 10.1200/JCO.2000.18.3.527; Ardeshna KM, 2003, LANCET, V362, P516, DOI 10.1016/S0140-6736(03)14110-4; ARMITAGE JO, 1981, CANCER TREAT REP, V65, P413; BARTLETT N, 2002, P AM SOC CLIN ONCOL, V21; Bastion Y, 1997, J CLIN ONCOL, V15, P1587, DOI 10.1200/JCO.1997.15.4.1587; Bennett JM, 2005, BLOOD, V105, P4576, DOI 10.1182/blood-2004-12-4690; BUCHSBAUM DJ, 1992, CANCER RES, V52, P6476; BUCHSBAUM DJ, 1992, CANCER RES, V52, P637; Chan WC, 1997, BLOOD, V89, P3909; CHATAL JF, 2004, P AM SOC CLIN ONCOL, V22; Cheson BD, 2003, BLOOD, V101, P391, DOI 10.1182/blood-2002-06-1793; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Connors JM, 2005, NEW ENGL J MED, V352, P496, DOI 10.1056/NEJMe048291; Conti PS, 2005, J NUCL MED, V46, P1812; Cragg MS, 2004, BLOOD, V103, P2738, DOI 10.1182/blood-2003-06-2031; CULLEN MH, 1979, CANCER, V44, P645, DOI 10.1002/1097-0142(197908)44:2<645::AID-CNCR2820440234>3.0.CO;2-Y; Czuczman M, 2002, BLOOD, V100, p357A; Davies A, 2005, ANN ONCOL, V16, P112; Davies AJ, 2004, J CLIN ONCOL, V22, P1469, DOI 10.1200/JCO.2004.06.055; Davis TA, 2004, CLIN CANCER RES, V10, P7792, DOI 10.1158/1078-0432.CCR-04-0756; Dosik AD, 2006, CANCER-AM CANCER SOC, V106, P616, DOI 10.1002/cncr.21606; Dreicer R, 2007, J CLIN ONCOL, V25; Fisher RI, 2005, J CLIN ONCOL, V23, P7565, DOI 10.1200/JCO.2004.00.9217; FLINN IW, 2004, BLOOD, V104; Forstpointner R, 2006, BLOOD, V108, P4003, DOI 10.1182/blood-2006-04-016725; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Freedman AS, 1999, BLOOD, V94, P3325, DOI 10.1182/blood.V94.10.3325.422k13_3325_3333; FUNG H, 2003, BLOOD, V102; GALLAGHER CJ, 1986, J CLIN ONCOL, V4, P1470, DOI 10.1200/JCO.1986.4.10.1470; Gopal AK, 2006, BIOL BLOOD MARROW TR, V12, P697, DOI 10.1016/j.bbmt.2006.03.014; Gopal AK, 2002, BLOOD, V99, P3158, DOI 10.1182/blood.V99.9.3158; Gopal AK, 2003, BLOOD, V102, P2351, DOI 10.1182/blood-2003-02-0622; Gordon LI, 2004, BLOOD, V103, P4429, DOI 10.1182/blood-2003-11-3883; GORDON LI, 2003, P AN M AM SOC CLIN, V22, P576; Gregory SA, 2003, BLOOD, V102, p409A; GREGORY SA, 2005, P AN M AM SOC CLIN, V23, P585; GREGORY SA, 2004, P AN M AM SOC CLIN, V22, P6732; Hiddemann W, 2005, BLOOD, V106, P3725, DOI 10.1182/blood-2005-01-0016; HORNING SJ, 1993, SEMIN ONCOL, V20, P75; Horning SJ, 2005, J CLIN ONCOL, V23, P712, DOI 10.1200/JCO.2005.07.040; HUBBARD SM, 1982, BLOOD, V59, P258; Hunault-Berger M, 2002, BLOOD, V100, P1141, DOI 10.1182/blood.V100.4.1141.h81602001141_1141_1152; Hussein MA, 2004, BLOOD, V104, p314B, DOI 10.1182/blood.V104.11.4928.4928; Jacobs SA, 2005, CLIN CANCER RES, V11, p7146S, DOI 10.1158/1078-0432.CCR-1004-0003; JOHNSON PWM, 1995, J CLIN ONCOL, V13, P140, DOI 10.1200/JCO.1995.13.1.140; Johnson TA, 2000, INT J CANCER, V85, P104, DOI 10.1002/(SICI)1097-0215(20000101)85:1<104::AID-IJC19>3.0.CO;2-G; Justice TE, 2006, CANCER, V107, P433, DOI 10.1002/cncr.21998; KAMINSKI M, 2001, BLOOD, V98; Kaminski MS, 2007, J CLIN ONCOL, V25; Kaminski MS, 2005, NEW ENGL J MED, V352, P441, DOI 10.1056/NEJMoa041511; Kaminski MS, 2000, BLOOD, V96, P1259, DOI 10.1182/blood.V96.4.1259.h8001259_1259_1266; Kaminski MS, 2005, J CLIN ONCOL, V23, P7985, DOI 10.1200/JCO.2005.01.0892; Kaminski MS, 2001, J CLIN ONCOL, V19, P3918, DOI 10.1200/JCO.2001.19.19.3918; Kaminski MS, 1996, J CLIN ONCOL, V14, P1974, DOI 10.1200/JCO.1996.14.7.1974; KAMINSKI MS, 1993, NEW ENGL J MED, V329, P459, DOI 10.1056/NEJM199308123290703; Knox SJ, 1996, CLIN CANCER RES, V2, P457; Leahy MF, 2006, J CLIN ONCOL, V24, P4418, DOI 10.1200/JCO.2005.05.3470; Leonard JP, 2003, BLOOD, V102, p105A; Leonard JP, 2005, J CLIN ONCOL, V23, P5696, DOI 10.1200/JCO.2005.14.803; Leonard JP, 2001, BLOOD, V98, p133A; Link B, 2004, J CLIN ONCOL, V22, p562S; Liu SY, 1998, J CLIN ONCOL, V16, P3270, DOI 10.1200/JCO.1998.16.10.3270; MacManus MP, 1996, J CLIN ONCOL, V14, P1282, DOI 10.1200/JCO.1996.14.4.1282; Marcus R, 2005, BLOOD, V105, P1417, DOI 10.1182/blood-2004-08-3175; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; MONES J, 2004, P AM SOC CLIN ONCOL, V22; MORSCHHAUSER HD, 2004, BLOOD, V104; Nademanee A, 2005, BLOOD, V106, P2896, DOI 10.1182/blood-2005-03-1310; NADLER LM, 1980, CANCER RES, V40, P3147; OKI Y, 2004, BLOOD, V104; Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7; PHILIP T, 1995, NEW ENGL J MED, V333, P1540, DOI 10.1056/NEJM199512073332305; Press OW, 2006, J CLIN ONCOL, V24, P4143, DOI 10.1200/JCO.2006.05.8198; PRESS OW, 1993, NEW ENGL J MED, V329, P1219, DOI 10.1056/NEJM199310213291702; Press OW, 2000, BLOOD, V96, P2934; Press OW, 2003, BLOOD, V102, P1606, DOI 10.1182/blood-2003-01-0287; PRESS OW, 1995, LANCET, V346, P336, DOI 10.1016/S0140-6736(95)92225-3; Radford JA, 2003, BLOOD, V102, p408A; SCHILDER RJ, 2002, P AN M AM SOC CLIN, V21, P267; Schouten HC, 2003, J CLIN ONCOL, V21, P3918, DOI 10.1200/JCO.2003.10.023; Shah J, 2007, J CLIN ONCOL, V25; SHIPLEY DL, 2005, J CLIN ONCOL, V23; Shipp MA, 1999, J CLIN ONCOL, V17, P423, DOI 10.1200/JCO.1999.17.1.423; Siegel JA, 1998, J NUCL MED, V39, p28S; Siegel JA, 2002, J NUCL MED, V43, P354; STASHENKO P, 1980, J IMMUNOL, V125, P1678; Stern M, 2005, CRIT REV ONCOL HEMAT, V54, P11, DOI 10.1016/j.critrevonc.2004.10.011; Sweetenham JW, 2004, ASH ANN M, V104, P2633; TEDDER TF, 1986, EUR J IMMUNOL, V16, P881, DOI 10.1002/eji.1830160802; VANOERS MH, 2006, BLOOD; Vose JM, 2000, J CLIN ONCOL, V18, P1316, DOI 10.1200/JCO.2000.18.6.1316; Vose JM, 2004, ONCOLOGIST, V9, P160, DOI 10.1634/theoncologist.9-2-160; Vose JM, 2005, J CLIN ONCOL, V23, P461, DOI 10.1200/JCO.2005.05.117; VOSE JM, 1993, J CLIN ONCOL, V11, P1846, DOI 10.1200/JCO.1993.11.10.1846; Wahl RL, 2003, SEMIN ONCOL, V30, P31, DOI 10.1053/sonc.2003.23799; Wahl RL, 1998, J NUCL MED, V39, p21S; Wiseman GA, 2003, J NUCL MED, V44, P465; Wiseman GA, 2002, CANCER, V94, P1349, DOI 10.1002/cncr.10305; Wiseman GA, 2005, CANCER BIOTHER RADIO, V20, P185, DOI 10.1089/cbr.2005.20.185; Wiseman GA, 2002, BLOOD, V99, P4336, DOI 10.1182/blood.V99.12.4336; WITZIG T, 2003, BLOOD, V102; Witzig TE, 2002, J CLIN ONCOL, V20, P3262, DOI 10.1200/JCO.2002.11.017; Witzig TE, 1999, J CLIN ONCOL, V17, P3793, DOI 10.1200/JCO.1999.17.12.3793; Witzig TE, 2003, J CLIN ONCOL, V21, P1263, DOI 10.1200/JCO.2003.08.043; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Zelenetz AD, 2006, J CLIN ONCOL, V24, p436S; Zelenetz AD, 2002, BLOOD, V100, p357A	110	77	80	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3614	3628		10.1038/sj.onc.1210378	http://dx.doi.org/10.1038/sj.onc.1210378			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530015				2023-01-03	WOS:000246816100004
J	Waldmann, TA				Waldmann, T. A.			Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma	ONCOGENE			English	Review						IL-2 receptor; adult T-cell leukemia; anti-Tac; monoclonal antibody	T-CELL LEUKEMIA; ANTI-CD25 MONOCLONAL-ANTIBODY; IN-VIVO BLOCKADE; INTERLEUKIN-2 RECEPTOR; MURINE MODEL; TRANSPLANT RECIPIENTS; MULTIPLE-SCLEROSIS; HUMANIZED ANTIBODY; ACUTE REJECTION; GROWTH-FACTOR	Daclizumab (Zenapax) identifies the alpha subunit of the interleukin-2 (IL-2) receptor and blocks the interaction of this cytokine with its growth factor receptor. The scientific basis for the choice of the IL-2 receptor alpha subunit as a target for monoclonal antibody-mediated therapy of leukemia/lymphoma is that very few normal cells express IL-2R alpha, whereas the abnormal T cells in patients with an array of lymphoid malignancies express this receptor. In 1997, daclizumab was approved by the FDA for use in the prevention of renal allograft rejection. In addition, anti-Tac provided effective therapy for select patients with T-cell malignancies and an array of inflammatory autoimmune disorders. Finally, therapy with this antibody armed with Y-90 has led to clinical responses in the majority of patients with adult T-cell leukemia. These insights concerning the IL-2/IL-2 receptor system facilitated the development of effective daclizumab antibody therapy for select patients with leukemia/lymphoma.	NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Waldmann, TA (corresponding author), NCI, Metab Branch, Ctr Canc Res, NIH, Bldg 10,Room 4N115,10 Ctr Dr 1374, Bethesda, MD 20892 USA.	tawald@helix.nih.gov	Waldmann, Thomas/AAT-5972-2021	Waldmann, Thomas/0000-0003-4500-6660	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIASC004002, Z01SC004002] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beniaminovitz A, 2000, NEW ENGL J MED, V342, P613, DOI 10.1056/NEJM200003023420902; Bielekova B, 2006, P NATL ACAD SCI USA, V103, P5941, DOI 10.1073/pnas.0601335103; Bielekova B, 2004, P NATL ACAD SCI USA, V101, P8705, DOI 10.1073/pnas.0402653101; DEPPER JM, 1984, J IMMUNOL, V133, P3054; Eckhoff DE, 2000, TRANSPLANTATION, V69, P1867, DOI 10.1097/00007890-200005150-00022; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; JUNGHANS RP, 1990, CANCER RES, V50, P1495; Kreitman RJ, 2000, J CLIN ONCOL, V18, P1622, DOI 10.1200/JCO.2000.18.8.1622; Krueger JG, 2000, J AM ACAD DERMATOL, V43, P448, DOI 10.1067/mjd.2000.106515; Lehky TJ, 1998, ANN NEUROL, V44, P942, DOI 10.1002/ana.410440613; LEONARD WJ, 1985, J BIOL CHEM, V260, P1872; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEONARD WJ, 1982, NATURE, V300, P267, DOI 10.1038/300267a0; Li ZQ, 2005, J IMMUNOL, V174, P5187, DOI 10.4049/jimmunol.174.9.5187; Maciejewski JP, 2003, BLOOD, V102, P3584, DOI 10.1182/blood-2003-04-1032; Morris JC, 2000, ANN RHEUM DIS, V59, P109, DOI 10.1136/ard.59.suppl_1.i109; Nashan B, 1999, TRANSPLANTATION, V67, P110, DOI 10.1097/00007890-199901150-00019; Nussenblatt RB, 1999, P NATL ACAD SCI USA, V96, P7462, DOI 10.1073/pnas.96.13.7462; OMAHONEY D, 2006, J NUCL MED, V47, pP98; Phillips KE, 2000, CANCER RES, V60, P6977; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; RUBIN LA, 1990, ANN INTERN MED, V113, P619, DOI 10.7326/0003-4819-113-8-619; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; Sloand EM, 2006, ANN INTERN MED, V144, P181, DOI 10.7326/0003-4819-144-3-200602070-00006; Sugamura K, 1996, ANNU REV IMMUNOL, V14, P179, DOI 10.1146/annurev.immunol.14.1.179; Tan C, 2002, CANCER RES, V62, P1083; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694; UCHIYAMA T, 1981, J IMMUNOL, V126, P1398; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; Vincenti F, 1998, NEW ENGL J MED, V338, P161, DOI 10.1056/NEJM199801153380304; WALDMANN TA, 1993, BLOOD, V82, P1701; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WALDMANN TA, 1995, BLOOD, V86, P4063, DOI 10.1182/blood.V86.11.4063.bloodjournal86114063; WALDMANN TA, 1986, SCIENCE, V232, P727, DOI 10.1126/science.3008337; Waldmann TA, 2003, ANNU REV IMMUNOL, V21, P1, DOI 10.1146/annurev.immunol.21.120601.140933; WALDMANN TA, 1988, BLOOD, V72, P1805; Wiseman LR, 1999, DRUGS, V58, P1029, DOI 10.2165/00003495-199958060-00006; Zhang ML, 2006, CANCER RES, V66, P8227, DOI 10.1158/0008-5472.CAN-06-1189; Zhang ML, 2005, BLOOD, V105, P1231, DOI 10.1182/blood-2004-05-1709; Zhang ML, 2004, CANCER RES, V64, P5825, DOI 10.1158/0008-5472.CAN-04-1088	42	59	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3699	3703		10.1038/sj.onc.1210368	http://dx.doi.org/10.1038/sj.onc.1210368			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530023				2023-01-03	WOS:000246816100012
J	Deer, B				Deer, Brian			What makes an expert?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												bd@briandeer.com						Geier DA, 2005, MED SCI MONITOR, V11, pCR160; GEIER DA, 2006, AUTOIMMUN REV, DOI DOI 10.1016/J.AUTREV.2006.09.014; Geier M.R., 2007, LANCET NEUROL, V6, P212; SIEDEL K, 2006, SIGNIFICANT MISREP 1; SIEDEL K, 2007, SIGNIFICANT MISRE 13; SIEDEL K, 2006, SIGNIFICANT MISREP 8	6	1	1	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 31	2007	334	7595					666	667		10.1136/bmj.39146.498785.BE	http://dx.doi.org/10.1136/bmj.39146.498785.BE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	154ON	17395945	Green Published			2023-01-03	WOS:000245517100029
J	Shann, F				Shann, Frank			Suckling and sugar reduce pain in babies	LANCET			English	Editorial Material							ORALLY-ADMINISTERED GLUCOSE; RANDOMIZED CONTROLLED-TRIAL; SUCROSE ANALGESIA; NEONATAL PAIN; INFANTS; NEWBORNS; YOUNGER; RELIEF; AGE		Royal Childrens Hosp, Intens Care Unit, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne	Shann, F (corresponding author), Royal Childrens Hosp, Intens Care Unit, Flemington Rd, Parkville, Vic 3052, Australia.	frank.shann@rch.org.au	Shann, Frank/C-9510-2011					ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; Bilgen H, 2001, J PAIN, V2, P301, DOI 10.1054/jpai.2001.23140; Bucher HU, 2000, EARLY HUM DEV, V59, P51, DOI 10.1016/S0378-3782(00)00085-2; Carbajal R, 1999, BRIT MED J, V319, P1393, DOI 10.1136/bmj.319.7222.1393; Carbajal R, 2003, BMJ-BRIT MED J, V326, P13, DOI 10.1136/bmj.326.7379.13; Eriksson M, 2004, ACTA PAEDIATR, V93, P246, DOI 10.1080/08035250310008041; Gradin M, 2005, PEDIATRICS, V115, P1004, DOI 10.1542/peds.2004-1189; Gradin M, 2004, EARLY HUM DEV, V77, P57, DOI 10.1016/j.earlhumdev.2004.01.003; Guala A, 2001, Minerva Pediatr, V53, P271; Isik U, 2000, J PAIN, V1, P275, DOI 10.1054/jpai.2000.8919; Johnston CC, 2002, PEDIATRICS, V110, P523, DOI 10.1542/peds.110.3.523; Lewindon PJ, 1998, ARCH DIS CHILD, V78, P453, DOI 10.1136/adc.78.5.453; Lidow MS, 2002, PAIN, V99, P377, DOI 10.1016/S0304-3959(02)00258-0; Rogers AJ, 2006, ACAD EMERG MED, V13, P617, DOI 10.1197/j.aem.2006.01.026; Shah PS, 2006, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD004950.PUB2; STEVENS B, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001069.P1B2; WILLIS DM, 1977, PEDIATRICS, V60, P535	18	9	9	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 3	2007	369	9563					721	723		10.1016/S0140-6736(07)60335-3	http://dx.doi.org/10.1016/S0140-6736(07)60335-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	143MP	17336631				2023-01-03	WOS:000244726700007
J	Hrdy, DB				Hrdy, Daniel B.			Low-carbohydrate diet and coronary heart disease in women	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Citrona Farms, Winters, CA 95694 USA		Hrdy, DB (corresponding author), Citrona Farms, Winters, CA 95694 USA.							Hu FB, 1998, BMJ-BRIT MED J, V317, P1341, DOI 10.1136/bmj.317.7169.1341	1	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 15	2007	356	7					750	750						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135ZV	17310524				2023-01-03	WOS:000244193300031
J	Jacobson, PD; Parmet, WE				Jacobson, Peter D.; Parmet, Wendy E.			A new era of unapproved drugs - The case of Abigail Alliance v Von Eschenbach	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RATES		Univ Michigan, Sch Publ Hlth, Ctr Law Eth & Hlth, Ann Arbor, MI 48109 USA; Northeastern Univ, Sch Law, Boston, MA 02115 USA	University of Michigan System; University of Michigan; Northeastern University	Jacobson, PD (corresponding author), Univ Michigan, Sch Publ Hlth, Ctr Law Eth & Hlth, 109 Observ, Ann Arbor, MI 48109 USA.	pdj@umich.edu						*AB ALL, AB STOR; Costanza ME, 1995, CLIN CANCER RES, V1, P699; DiMasi JA, 2001, CLIN PHARMACOL THER, V69, P297, DOI 10.1067/mcp.2001.115446; Institute of Medicine, 2006, FUT DRUG SAF PROM PR; Kola I, 2004, NAT REV DRUG DISCOV, V3, P711, DOI 10.1038/nrd1470; Mayer M, 2006, CLIN TRIALS, V3, P149, DOI 10.1191/1740774506cn144oa; PILON R, 2006, WALL STREET J   0603, P9; 2005, WALL STREET J   1115, pA22	8	41	41	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	2007	297	2					205	208		10.1001/jama.297.2.205	http://dx.doi.org/10.1001/jama.297.2.205			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124GI	17213404				2023-01-03	WOS:000243355900030
J	Bodenheimer, T				Bodenheimer, Thomas			Coordinating care - A perilous journey through the health care system	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PARTICIPATORY DECISION-MAKING; CONTROLLED-TRIAL; TRANSITIONS INTERVENTION; PHYSICIAN COMMUNICATION; UNITED-STATES; PATIENT-CARE; INFORMATION; TIME; QUALITY; SATISFACTION		[Bodenheimer, Thomas] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Family & Community Med, San Francisco, CA 94143 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Bodenheimer, T (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Family & Community Med, San Francisco, CA 94143 USA.							*AG HEALTHC RES QU, 2005, AHRQ PARTN IMPL PAT; *AM COLL PHYS, 2006, SYST NEED CHANG REST; American Academy of Family Physicians; American Academy of Pediatrics; American College of Physicians; American Osteopathic Association, 2007, JOINT PRINC PAT CTR; Anderson G, 2001, HEALTH AFFAIR, V20, P146, DOI 10.1377/hlthaff.20.6.146; Anthony D., 2005, ADV PATIENT SAFETY R; Bodenheimer T, 2007, BUILDING TEAMS PRIMA; Bodenheimer T, 2007, ANN FAM MED, V5, P457, DOI 10.1370/afm.731; Bodenheimer T, 2006, NEW ENGL J MED, V355, P861, DOI 10.1056/NEJMp068155; Braddock CH, 1999, JAMA-J AM MED ASSOC, V282, P2313, DOI 10.1001/jama.282.24.2313; Casalino LP, 2007, HEALTH AFFAIR, V26, pW405, DOI 10.1377/hlthaff.26.3.w405; Casalino LP, 2003, ARCH INTERN MED, V163, P1958, DOI 10.1001/archinte.163.16.1958; Coleman EA, 2004, J AM GERIATR SOC, V52, P1817, DOI 10.1111/j.1532-5415.2004.52504.x; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Crosson FJ, 2005, HEALTH AFFAIR, V24, P1543, DOI 10.1377/hlthaff.24.6.1543; *CTR STUD HLTH SYS, CTS PHYS SURV; Davis K, 2005, J GEN INTERN MED, V20, P953, DOI 10.1111/j.1525-1497.2005.0178.x; Davis K, 2007, NEW ENGL J MED, V356, P1166, DOI 10.1056/NEJMe078007; Deveugele M, 2004, PATIENT EDUC COUNS, V54, P227, DOI 10.1016/S0738-3991(03)00239-8; Farber J, 2007, ANN INTERN MED, V147, P693, DOI 10.7326/0003-4819-147-10-200711200-00005; Forrest CB, 2000, ARCH PEDIAT ADOL MED, V154, P499, DOI 10.1001/archpedi.154.5.499; Gandhi TK, 2000, J GEN INTERN MED, V15, P626, DOI 10.1046/j.1525-1497.2000.91119.x; Gandhi TK, 2005, ANN INTERN MED, V142, P352, DOI 10.7326/0003-4819-142-5-200503010-00010; Gillies RR, 2006, HEALTH SERV RES, V41, P1181, DOI 10.1111/j.1475-6773.2006.00529.x; Goroll AH, 2007, J GEN INTERN MED, V22, P410, DOI 10.1007/s11606-006-0083-2; Gottschalk A, 2005, ANN FAM MED, V3, P488, DOI 10.1370/afm.404; Grumbach K, 2002, JAMA-J AM MED ASSOC, V288, P889, DOI 10.1001/jama.288.7.889; Haggerty JL, 2003, BRIT MED J, V327, P1219, DOI 10.1136/bmj.327.7425.1219; Halamka J, 2005, HEALTH AFFAIR, V24, P1170, DOI 10.1377/hlthaff.24.5.1170; Heisler M, 2002, J GEN INTERN MED, V17, P243, DOI 10.1046/j.1525-1497.2002.10905.x; Hillestad R, 2005, HEALTH AFFAIR, V24, P1103, DOI 10.1377/hlthaff.24.5.1103; Kaplan SH, 1996, ANN INTERN MED, V124, P497, DOI 10.7326/0003-4819-124-5-199603010-00007; Kilo CM, 2005, HEALTH AFFAIR, V24, P1296, DOI 10.1377/hlthaff.24.5.1296; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Levine C., 1998, ROUGH CROSSINGS FAMI; LIEBHABER A, 2007, 18 CTR STUD HLTH SYS; McDonald CJ, 2005, HEALTH AFFAIR, V24, P1214, DOI 10.1377/hlthaff.24.5.1214; McDonald K, 2007, CLOSING QUALITY GAP, V7; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; *MED PAYM ADV COMM, 2006, INCR VAL MED REP C; Mehrotra A, 2006, ANN INTERN MED, V145, P826, DOI 10.7326/0003-4819-145-11-200612050-00007; Moore C, 2003, J GEN INTERN MED, V18, P646, DOI 10.1046/j.1525-1497.2003.20722.x; Murray Mark, 2002, Fam Pract Manag, V9, P39; Naylor MD, 2004, J AM GERIATR SOC, V52, P675, DOI 10.1111/j.1532-5415.2004.52202.x; Naylor MD, 2004, J AM GERIATR SOC, V52, P1228; Ostbye T, 2005, ANN FAM MED, V3, P209, DOI 10.1370/afm.310; Overhage JM, 2002, ANN EMERG MED, V39, P14, DOI 10.1067/mem.2002.120794; Pham HH, 2007, NEW ENGL J MED, V356, P1130, DOI 10.1056/NEJMsa063979; ROTER DL, 1989, ANNU REV PUBL HEALTH, V10, P163, DOI 10.1146/annurev.pu.10.050189.001115; Schillinger D, 2003, ARCH INTERN MED, V163, P83, DOI 10.1001/archinte.163.1.83; SCHOEN C, 2004, HLTH AFFAIRS W, V4, P487, DOI DOI 10.1377/HLTHAFF.W4.487; Schoen C, 2005, HLTH AFF MILLWOOD S; Yarnall KSH, 2003, AM J PUBLIC HEALTH, V93, P635, DOI 10.2105/AJPH.93.4.635	52	644	650	0	61	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 6	2008	358	10					1064	1071		10.1056/NEJMhpr0706165	http://dx.doi.org/10.1056/NEJMhpr0706165			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	269JG	18322289				2023-01-03	WOS:000253644700012
J	Ladet, S; David, L; Domard, A				Ladet, Sebastien; David, Laurent; Domard, Alain			Multi-membrane hydrogels	NATURE			English	Article							PHYSICAL HYDROGELS; HYDROALCOHOLIC MEDIUM; ACETYLATED CHITOSANS; AQUEOUS-SOLUTION; TRANSITION; GELS	Polysaccharide- based hydrogels are useful for numerous applications, from food(1) and cosmetic processing to drug delivery and tissue engineering(2,3). The formation of hydrogels from polyelectrolyte solutions is complex, involving a variety of molecular interactions. The physical gelation of polysaccharides can be achieved by balancing solvophobic and solvophilic interactions(4). Polymer chain reorganization can be obtained by solvent exchange, one of the processing routes forming a simple hydrogel assembly. Nevertheless, many studies on hydrogel formation are empirical with a limited understanding of the mechanisms involved, delaying the processing of more complex structures. Here we use a multi- step interrupted gelation process in controlled physico- chemical conditions to generate complex hydrogels with multi- membrane 'onion-like' architectures. Our approach greatly simplifies the processing of gels with complex shapes and a multi- membrane organization. In contrast with existing assemblies described in the literature, our method allows the formation of free 'inter-membrane' spaces well suited for cell or drug introduction. These architectures, potentially useful in biomedical applications, open interesting perspectives by taking advantage of tailor- made three- dimensional multimembrane tubular or spherical structures.	[Ladet, Sebastien; David, Laurent; Domard, Alain] Univ Lyon 1, CNRS, Polymer Mat Polymeres & Biomat, UMR 5223, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Institut National des Sciences Appliquees de Lyon - INSA Lyon; Universite Jean Monnet; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	David, L (corresponding author), Univ Lyon 1, CNRS, Polymer Mat Polymeres & Biomat, UMR 5223, 15 Blvd A Latarjet,Batiment ISTIL, F-69622 Villeurbanne, France.	laurent.david@univ-lyon1.fr; alain.domard@univ-lyon1.fr		DAVID, Laurent/0000-0003-3632-8537				Boucard N, 2005, BIOMACROMOLECULES, V6, P3227, DOI 10.1021/bm050653d; Boucard N, 2007, BIOMATERIALS, V28, P3478, DOI 10.1016/j.biomaterials.2007.04.021; Domard A., 2001, POLYM BIOMATER, V9, P187, DOI DOI 10.1201/9780203904671.CH9; Drury JL, 2003, BIOMATERIALS, V24, P4337, DOI 10.1016/S0142-9612(03)00340-5; HIRANO S, 1985, J BIOMED MATER RES, V19, P413, DOI 10.1002/jbm.820190406; ILMAIN F, 1991, NATURE, V349, P400, DOI 10.1038/349400a0; Lamarque G, 2005, BIOMACROMOLECULES, V6, P131, DOI 10.1021/bm0496357; MALETTE WG, 1983, ANN THORAC SURG, V36, P55, DOI 10.1016/S0003-4975(10)60649-2; Montembault A, 2006, BIOCHIMIE, V88, P551, DOI 10.1016/j.biochi.2006.03.002; Montembault A, 2005, BIOMATERIALS, V26, P933, DOI 10.1016/j.biomaterials.2004.03.033; Ostroha J, 2004, BIOMATERIALS, V25, P4345, DOI 10.1016/j.biomaterials.2003.11.019; Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612; PILNIK W, 1985, CARBOHYD RES, V142, P93, DOI 10.1016/S0008-6215(00)90736-5; PORATH J, 1973, NATURE, V245, P465, DOI 10.1038/245465a0; Pu Q, 2004, J PHYS CHEM B, V108, P14124, DOI 10.1021/jp0486200; Schatz C, 2003, BIOMACROMOLECULES, V4, P641, DOI 10.1021/bm025724c; SIEGEL RA, 1988, MACROMOLECULES, V21, P3254, DOI 10.1021/ma00189a021; Sorlier P, 2001, BIOMACROMOLECULES, V2, P765, DOI 10.1021/bm015531+; Strand SP, 2001, BIOMACROMOLECULES, V2, P126, DOI 10.1021/bm005601x; Varum KM, 1997, CARBOHYD RES, V299, P99, DOI 10.1016/S0008-6215(96)00332-1; VASQUEZ B, 1997, BIOMETERIALS, V18, P521; VONHIPPE.PH, 1969, ACCOUNTS CHEM RES, V2, P257, DOI 10.1021/ar50021a001	22	416	430	15	539	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 6	2008	452	7183					76	U6		10.1038/nature06619	http://dx.doi.org/10.1038/nature06619			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	269SZ	18322531				2023-01-03	WOS:000253671900049
J	Lemeshko, VV; Kugler, W				Lemeshko, Victor V.; Kugler, Wilfried			Synergistic inhibition of mitochondrial respiration by anticancer agent erucylphosphohomocholine and cyclosporin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERUCYLPHOSPHOCHOLINE-INDUCED APOPTOSIS; PERMEABILITY TRANSITION PORE; LINES IN-VITRO; CELL-LINES; BENZODIAZEPINE-RECEPTOR; CASPASE ACTIVATION; DOWN-REGULATION; CYTOCHROME-C; GLIOMA-CELLS; INVOLVEMENT	Alkylphosphocholines are a new class of anticancer agents. The mechanisms by which these drugs display their antitumor activities are not known. In this work, we show that erucylphosphohomocholine, a new antineoplastic compound, significantly decreased ATP synthesis in isolated rat liver mitochondria at a concentration of 50 mu M or higher via permeabilization of the inner membrane. At a concentration of 25 mu M, it induced a moderate swelling of mitochondria, a slight decrease of the inner membrane potential, and an increase in state 4 respiration without an essential influence on state 3 respiration or the outer membrane permeability to cytochrome c. We found that cyclosporin A did not prevent mitochondrial swelling induced by 25-100 mu M erucylphosphohomocholine. Moreover, cyclosporin A induced a fast drop of the inner membrane potential in the presence of 25-50 mu M erucylphosphohomocholine that seems to be due to a strong synergistic inhibition of the respiratory activity. The ratio of uncoupled to state 3 respiration rates increased from 1.3 +/- 0.1 with 25 mu M erucylphosphohomocholine and from 1.5 +/- 0.1 with 1 mu M cyclosporin A to 4.5 +/- 0.3 in the presence of both drugs. On the other hand, oligomycin or cyclosporin A protected certain cancer cell lines against erucylphosphohomocholine-induced apoptosis. This protection might be related to a prevention of cellular ATP hydrolysis by permeabilized mitochondria and to the inhibition of the classical permeability transition pore, respectively. Our findings provide new insight into the mechanisms by which these unusual alterations of mitochondria might be involved in anticancer activity of alkylphosphocholines.	Univ Nacl Colombia, Fac Ciencias, Escuela Fis, Medellin 3840, Colombia; [Kugler, Wilfried] Univ Gottingen, ZentrumKinderheilkunde & Jugendmed, D-37075 Gottingen, Germany	Universidad Nacional de Colombia; University of Gottingen	Lemeshko, VV (corresponding author), Univ Nacl Colombia, Fac Ciencias, Escuela Fis, Calle 59A,63-20, Medellin 3840, Colombia.	vvasilie@unal.edu.co						AZZONE GF, 1984, BIOCHEM SOC T, V12, P414, DOI 10.1042/bst0120414; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Di Paola M, 2006, BBA-BIOENERGETICS, V1757, P1330, DOI 10.1016/j.bbabio.2006.03.024; GUNTER TE, 1990, AM J PHYSIOL, V258, P755; Handrick R, 2006, RADIOTHER ONCOL, V80, P199, DOI 10.1016/j.radonc.2006.07.021; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; Held-Kuznetsov V, 2005, REV NEUROSCIENCE, V16, pS30; HILGARD P, 1993, CANCER CHEMOTH PHARM, V32, P90, DOI 10.1007/BF00685608; Jendrossek V, 2002, CANCER CHEMOTH PHARM, V50, P71, DOI 10.1007/s00280-002-0440-8; Jendrossek V, 2001, ANTICANCER RES, V21, P3389; Jendrossek V, 1999, INT J ONCOL, V14, P15; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Konstantinov SM, 1998, INT J CANCER, V77, P778, DOI 10.1002/(SICI)1097-0215(19980831)77:5<778::AID-IJC18>3.0.CO;2-Y; Konstantinov SM, 2002, MOL CANCER THER, V1, P877; Kugler W, 2005, APOPTOSIS, V10, P1163, DOI 10.1007/s10495-005-1190-y; Kugler W, 2002, J NEUROCHEM, V82, P1160, DOI 10.1046/j.1471-4159.2002.01034.x; KUGLER W, 2006, 15 ANN M ISR SOC NEU, P56; KUGLER W, 2006, 7 C EUR ASS NEUR ONC, P293; Lemeshko VV, 2006, ARCH BIOCHEM BIOPHYS, V454, P114, DOI 10.1016/j.abb.2006.08.008; LEMESHKO VV, 1982, BIOCHEMISTRY-MOSCOW+, V47, P465; Lemeshko VV, 2005, J BIOL CHEM, V280, P15579, DOI 10.1074/jbc.M414064200; Lemeshko VV, 2002, J BIOL CHEM, V277, P17751, DOI 10.1074/jbc.M201002200; Lemeshko VV, 2001, ARCH BIOCHEM BIOPHYS, V388, P60, DOI 10.1006/abbi.2000.2214; Levin E, 2005, BIOCHEMISTRY-US, V44, P9924, DOI 10.1021/bi050150s; Rasola A, 2007, APOPTOSIS, V12, P815, DOI 10.1007/s10495-007-0723-y; Rubel A, 2006, RADIAT ONCOL, V1, DOI 10.1186/1748-717X-1-6; SCHNEIDER WC, 1950, J BIOL CHEM, V183, P123; Veenman L, 2000, DRUG DEVELOP RES, V50, P355, DOI 10.1002/1098-2299(200007/08)50:3/4<355::AID-DDR18>3.0.CO;2-W	28	14	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2007	282	52					37303	37307		10.1074/jbc.C700134200	http://dx.doi.org/10.1074/jbc.C700134200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243YQ	17993460	hybrid			2023-01-03	WOS:000251833600004
J	Lindenauer, PK; Rothberg, MB; Pekow, PS; Kenwood, C; Benjamin, EM; Auerbach, AD				Lindenauer, Peter K.; Rothberg, Michael B.; Pekow, Penelope S.; Kenwood, Christopher; Benjamin, Evan M.; Auerbach, Andrew D.			Outcomes of care by hospitalists, general internists, and family physicians	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LENGTH-OF-STAY; HEALTH-CARE; PATIENT SATISFACTION; RESOURCE UTILIZATION; MEDICINE; SERVICE; QUALITY; IMPACT; COST; IMPLEMENTATION	Background: The hospitalist model is rapidly altering the landscape for inpatient care in the United States, yet evidence about the clinical and economic outcomes of care by hospitalists is derived from a small number of single-hospital studies examining the practices of a few physicians. Methods: We conducted a retrospective cohort study of 76,926 patients 18 years of age or older who were hospitalized between September 2002 and June 2005 for pneumonia, heart failure, chest pain, ischemic stroke, urinary tract infection, acute exacerbation of chronic obstructive pulmonary disease, or acute myocardial infarction at 45 hospitals throughout the United States. We used multivariable models to compare the outcomes of care by 284 hospitalists, 993 general internists, and 971 family physicians. Results: As compared with patients cared for by general internists, patients cared for by hospitalists had a modestly shorter hospital stay (adjusted difference, 0.4 day; P<0.001) and lower costs (adjusted difference, $268; P=0.02) but a similar inpatient rate of death (odds ratio, 0.95; 95% confidence interval [CI], 0.85 to 1.05) and 14-day readmission rate (odds ratio, 0.98; 95% CI, 0.91 to 1.05). As compared with patients cared for by family physicians, patients cared for by hospitalists had a shorter length of stay (adjusted difference, 0.4 day; P<0.001), and the costs (adjusted difference, $125; P=0.33), rate of death (odds ratio, 0.95; 95% CI, 0.83 to 1.07), and 14-day readmission rate (odds ratio, 0.95; 95% CI, 0.87 to 1.04) were similar. Conclusions: For common inpatient diagnoses, the hospitalist model is associated with a small reduction in the length of stay without an adverse effect on rates of death or readmission. Hospitalist care appears to be modestly less expensive than that provided by general internists, but it offers no significant savings as compared with the care provided by family physicians.	Baystate Med Ctr, Ctr Qual & Safety Res, Springfield, MA 01199 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Amherst, MA 01003 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA	Baystate Medical Center; Tufts University; University of Massachusetts System; University of Massachusetts Amherst; University of California System; University of California San Francisco	Lindenauer, PK (corresponding author), Baystate Med Ctr, Ctr Qual & Safety Res, 759 Chestnut St,P-5928, Springfield, MA 01199 USA.	peter.lindenauer@bhs.org	Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213; Auerbach, Andrew/0000-0001-8440-0527	AHRQ HHS [K08 HS11416-02] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS011416] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Auerbach AD, 2002, ANN INTERN MED, V137, P859, DOI 10.7326/0003-4819-137-11-200212030-00006; Auerbach AD, 2003, ARCH INTERN MED, V163, P2330, DOI 10.1001/archinte.163.19.2330; Auerbach AD, 2006, J GEN INTERN MED, V21, P1079, DOI 10.1111/j.1525-1497.2006.00558.x; Coffman J, 2005, MED CARE RES REV, V62, P379, DOI 10.1177/1077558705277379; Cornish PL, 2005, ARCH INTERN MED, V165, P424, DOI 10.1001/archinte.165.4.424; Davis KM, 2000, AM J MED, V108, P621, DOI 10.1016/S0002-9343(00)00362-4; Dudas V, 2001, AM J MED, V111, P26, DOI 10.1016/S0002-9343(01)00966-4; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Fernandez A, 2000, ARCH INTERN MED, V160, P2902, DOI 10.1001/archinte.160.19.2902; Forster AJ, 2005, J GEN INTERN MED, V20, P317, DOI 10.1111/j.1525-1497.2005.30390.x; Goldman Lee, 2001, American Journal of Medicine, V111, p36S; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; Halasyamani LK, 2005, AM J MED, V118, P536, DOI 10.1016/j.amjmed.2005.01.027; Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012; Kaboli PJ, 2004, AM J MANAG CARE, V10, P561; Kralovec PD, 2006, J HOSP MED, V1, P75, DOI 10.1002/jhm.82; LANDRY L, 2004, WALL STREET J   0727, pD1; Lindenauer PK, 2002, ARCH INTERN MED, V162, P1251, DOI 10.1001/archinte.162.11.1251; Lindenauer PK, 1999, ANN INTERN MED, V130, P343, DOI 10.7326/0003-4819-130-4-199902161-00003; Lurie JD, 1999, AM J MED, V106, P441, DOI 10.1016/S0002-9343(99)00045-5; Meltzer D, 2002, ANN INTERN MED, V137, P866, DOI 10.7326/0003-4819-137-11-200212030-00007; Myers JS, 2006, ACAD MED, V81, P432, DOI 10.1097/01.ACM.0000222278.28824.bc; Pham HH, 2005, J GEN INTERN MED, V20, P101, DOI 10.1111/j.1525-1497.2005.40184.x; Phy MP, 2005, ARCH INTERN MED, V165, P796, DOI 10.1001/archinte.165.7.796; Rifkin WD, 2004, J GEN INTERN MED, V19, P1127, DOI 10.1111/j.1525-1497.2004.1930415.x; Roy CL, 2005, ANN INTERN MED, V143, P121, DOI 10.7326/0003-4819-143-2-200507190-00011; van Walraven C, 2004, J GEN INTERN MED, V19, P624, DOI 10.1111/j.1525-1497.2004.30082.x; Wachter RM, 2002, JAMA-J AM MED ASSOC, V287, P487, DOI 10.1001/jama.287.4.487; Wachter RM, 1999, ANN INTERN MED, V130, P338, DOI 10.7326/0003-4819-130-4-199902161-00002; Wachter RM, 1998, JAMA-J AM MED ASSOC, V279, P1560, DOI 10.1001/jama.279.19.1560; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713	31	169	169	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 20	2007	357	25					2589	2600		10.1056/NEJMsa067735	http://dx.doi.org/10.1056/NEJMsa067735			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242MJ	18094379	Green Published			2023-01-03	WOS:000251728900009
J	Milne, JC; Lambert, PD; Schenk, S; Carney, DP; Smith, JJ; Gagne, DJ; Jin, L; Boss, O; Perni, RB; Vu, CB; Bemis, JE; Xie, R; Disch, JS; Ng, PY; Nunes, JJ; Lynch, AV; Yang, HY; Galonek, H; Israelian, K; Choy, W; Iffland, A; Lavu, S; Medvedik, O; Sinclair, DA; Olefsky, JM; Jirousek, MR; Elliott, PJ; Westphal, CH				Milne, Jill C.; Lambert, Philip D.; Schenk, Simon; Carney, David P.; Smith, Jesse J.; Gagne, David J.; Jin, Lei; Boss, Olivier; Perni, Robert B.; Vu, Chi B.; Bemis, Jean E.; Xie, Roger; Disch, Jeremy S.; Ng, Pui Yee; Nunes, Joseph J.; Lynch, Amy V.; Yang, Hongying; Galonek, Heidi; Israelian, Kristine; Choy, Wendy; Iffland, Andre; Lavu, Siva; Medvedik, Oliver; Sinclair, David A.; Olefsky, Jerrold M.; Jirousek, Michael R.; Elliott, Peter J.; Westphal, Christoph H.			Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes	NATURE			English	Article							LIFE-SPAN EXTENSION; CALORIE RESTRICTION; SACCHAROMYCES-CEREVISIAE; SIR2-LIKE PROTEINS; INSULIN-RESISTANCE; CELL-SURVIVAL; LONGEVITY; NAD; DEACETYLASE; GLUCOSE	Calorie restriction extends lifespan and produces a metabolic profile desirable for treating diseases of ageing such as type 2 diabetes(1,2). SIRT1, an NAD(+)-dependent deacetylase, is a principal modulator of pathways downstream of calorie restriction that produce beneficial effects on glucose homeostasis and insulin sensitivity(3-9). Resveratrol, a polyphenolic SIRT1 activator, mimics the anti-ageing effects of calorie restriction in lower organisms and in mice fed a high-fat diet ameliorates insulin resistance, increases mitochondrial content, and prolongs survival10-14. Here we describe the identification and characterization of small molecule activators of SIRT1 that are structurally unrelated to, and 1,000-fold more potent than, resveratrol. These compounds bind to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. In diet-induced obese and genetically obese mice, these compounds improve insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. In Zucker fa/fa rats, hyperinsulinaemic-euglycaemic clamp studies demonstrate that SIRT1 activators improve whole-body glucose homeostasis and insulin sensitivity in adipose tissue, skeletal muscle and liver. Thus, SIRT1 activation is a promising new therapeutic approach for treating diseases of ageing such as type 2 diabetes.	Sirtris Pharmaceut Inc, Cambridge, MA 02139 USA; Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Harvard Univ, Sch Med, Dept Pathol, Paul F Glenn Labs Biol Mech Aging, Boston, MA 02115 USA	University of California System; University of California San Diego; Harvard University; Harvard Medical School	Westphal, CH (corresponding author), Sirtris Pharmaceut Inc, 790 Mem Dr, Cambridge, MA 02139 USA.	cwestphal@sirtrispharma.com		Schenk, Simon/0000-0002-8224-3203; Sinclair, David/0000-0002-9936-436X; Disch, Jeremy/0000-0002-0357-1672	NATIONAL INSTITUTE ON AGING [R01AG019719, P01AG027916, R01AG028730] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG027916-030003, R01 AG019719-07, R01 AG028730-02, R01 AG028730, P01 AG027916-040003, R01 AG019719, P01 AG027916, R01 AG028730-03] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; BANKS A, 2007, DIABETES, V56; Barzilai N, 1998, J CLIN INVEST, V101, P1353, DOI 10.1172/JCI485; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; Borra MT, 2004, BIOCHEMISTRY-US, V43, P9877, DOI 10.1021/bi049592e; Brink CB, 2004, BRIT J CLIN PHARMACO, V57, P373, DOI 10.1111/j.1365-2125.2003.02046.x; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Facchini FS, 2001, J CLIN ENDOCR METAB, V86, P3574, DOI 10.1210/jc.86.8.3574; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Heilbronn LK, 2006, JAMA-J AM MED ASSOC, V295, P1539, DOI 10.1001/jama.295.13.1539; Heilbronn LK, 2005, OBES RES, V13, P574, DOI 10.1038/oby.2005.61; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jarolim S, 2004, FEMS YEAST RES, V5, P169, DOI 10.1016/j.femsyr.2004.06.015; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Napper AD, 2005, J MED CHEM, V48, P8045, DOI 10.1021/jm050522v; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Rodgers JT, 2007, P NATL ACAD SCI USA, V104, P12861, DOI 10.1073/pnas.0702509104; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Sarabu R, 2005, CURR OPIN DRUG DISC, V8, P631; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789	28	1350	1433	11	295	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 29	2007	450	7170					712	716		10.1038/nature06261	http://dx.doi.org/10.1038/nature06261			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	235BY	18046409	Green Accepted			2023-01-03	WOS:000251209700052
J	Weber, DM; Chen, C; Niesvizky, R; Wang, M; Belch, A; Stadtmauer, EA; Siegel, D; Borrello, I; Rajkumar, SV; Chanan-Khan, AA; Lonial, S; Yu, ZN; Patin, J; Olesnyckyj, M; Zeldis, JB; Knight, RD				Weber, Donna M.; Chen, Christine; Niesvizky, Ruben; Wang, Michael; Belch, Andrew; Stadtmauer, Edward A.; Siegel, David; Borrello, Ivan; Rajkumar, S. Vincent; Chanan-Khan, Asher Alban; Lonial, Sagar; Yu, Zhinuan; Patin, John; Olesnyckyj, Marta; Zeldis, Jerome B.; Knight, Robert D.		Multiple Myeloma 009 Study	Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMBINATION THERAPY; DRUG-RESISTANCE; THALIDOMIDE; BORTEZOMIB; PHASE-2; CC-5013	Background Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma. Methods Patients in the United States and Canada who had received at least one previous therapy for multiple myeloma but who required additional treatment were randomly assigned to receive either 25 mg of lenalidomide or placebo on days 1 to 21 of a 28-day cycle. Both groups also received 40 mg of oral dexamethasone on days 1 to 4, 9 to 12, and 17 to 20 for the first four cycles. After the fourth cycle, 40 mg of dexamethasone was administered only on days 1 to 4. Safety, clinical response, time to progression, and overall survival were assessed. Results We assigned 177 patients to the lenalidomide group and 176 to the placebo group. Complete, near-complete, or partial responses occurred in 108 patients (61.0%) in the lenalidomide group and in 35 patients (19.9%) in the placebo group (P<0.001); complete responses occurred in 14.1% and 0.6%, respectively (P<0.001). The median time to progression was 11.1 months in the lenalidomide group and 4.7 months in the placebo group (P<0.001). Median overall survival times in the two groups were 29.6 months and 20.2 months, respectively (P<0.001). Grade 3 or 4 adverse events were reported in 85.3% of the lenalidomide group and in 73.1% of the placebo group; these events resulted in study discontinuation in 19.8% and 10.2%, respectively. Grade 3 or 4 neutropenia and venous thromboembolism were more common in the lenalidomide group than in the placebo group (41.2% vs. 4.6% and 14.7% vs. 3.4%, respectively; P<0.001 for both comparisons). Conclusions Lenalidomide plus dexamethasone is superior to placebo plus dexamethasone in patients with relapsed or refractory multiple myeloma. (ClinicalTrials.gov number, NCT00056160.) N Engl J Med 2007;357:2133-42.	Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA; Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada; Weill Cornell Med Coll, New York, NY USA; Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; Hackensack Univ, Med Ctr, Ctr Canc, Hackensack, NJ USA; Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA; Mayo Clin, Ctr Canc, Rochester, MN USA; Roswell Pk Canc Inst, Buffalo, NY 14263 USA; Emory Univ, Atlanta, GA 30322 USA; Celgene, Summit, NJ USA	University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Cornell University; University of Alberta; University of Pennsylvania; Hackensack University Medical Center; Johns Hopkins University; Johns Hopkins Medicine; Mayo Clinic; Roswell Park Cancer Institute; Emory University; Bristol-Myers Squibb; Celgene Corporation	Weber, DM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, 1515 Holcombe Blvd,Box 429, Houston, TX 77030 USA.	dmweber@mdanderson.org	Rajkumar, S. Vincent/AAV-1834-2021	Rajkumar, S. Vincent/0000-0002-5862-1833				American Cancer Society, 2005, CANC FACTS FIG 2005; Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; *NAT CANC I, COMM TOX CRIT V2 0 C; Rajkumar SV, 2007, J CLIN ONCOL, V25; Rajkumar SV, 2005, BLOOD, V106, P4050, DOI 10.1182/blood-2005-07-2817; Rajkumar SV, 2002, J CLIN ONCOL, V20, P4319, DOI 10.1200/JCO.2002.02.116; Richardson PG, 2006, BLOOD, V108, P3458, DOI 10.1182/blood-2006-04-015909; Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Richardson PG, 2002, BLOOD, V100, P3063, DOI 10.1182/blood-2002-03-0996; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Singhal S, 2000, NEW ENGL J MED, V342, P364; Weber D, 2003, J CLIN ONCOL, V21, P16, DOI 10.1200/JCO.2003.03.139; Zangari M, 2001, BLOOD, V98, p775A; Zonder JA, 2006, BLOOD, V108, P403, DOI 10.1182/blood-2006-01-0154	16	985	1032	2	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 22	2007	357	21					2133	2142		10.1056/NEJMoa070596	http://dx.doi.org/10.1056/NEJMoa070596			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	233FT	18032763				2023-01-03	WOS:000251076500005
J	Matsumoto, T; Sasaki, JI; Alsberg, E; Egusa, H; Yatani, H; Sohmura, T				Matsumoto, Takuya; Sasaki, Jun-Ichi; Alsberg, Eben; Egusa, Hiroshi; Yatani, Hirofumi; Sohmura, Taiji			Three-Dimensional Cell and Tissue Patterning in a Strained Fibrin Gel System	PLOS ONE			English	Article							NERVE GROWTH-FACTOR; CONTROLLED-RELEASE; CYCLIC STRAIN; STIFFNESS; ALIGNMENT; DELIVERY; MATRICES	Techniques developed for the in vitro reproduction of three-dimensional (3D) biomimetic tissue will be valuable for investigating changes in cell function in tissues and for fabricating cell/matrix composites for applications in tissue engineering techniques. In this study, we show that the simple application of a continuous strain to a fibrin gel facilitates the development of fibril alignment and bundle-like structures in the fibrin gel in the direction of the applied strain. Myoblasts cultured in this gel also exhibited well-aligned cell patterning in a direction parallel to the direction of the strain. Interestingly, the direction of cell proliferation was identical to that of cell alignment. Finally, the oriented cells formed linear groups that were aligned parallel to the direction of the strain and replicated the native skeletal muscle cell patterning. In addition, vein endothelial cells formed a linear, aligned vessel-like structure in this system. Thus, the system enables the in vitro reproduction of 3D aligned cell sets replicating biological tissue patterns.	[Matsumoto, Takuya; Sasaki, Jun-Ichi; Egusa, Hiroshi; Yatani, Hirofumi; Sohmura, Taiji] Osaka Univ, Dept Oromaxillofacial Regenerat, Suita, Osaka, Japan; [Alsberg, Eben] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA	Osaka University; Case Western Reserve University	Matsumoto, T (corresponding author), Osaka Univ, Dept Oromaxillofacial Regenerat, Suita, Osaka, Japan.	tmatsu@dent.osaka-u.ac.jp	Egusa, Hiroshi/AFT-9694-2022	Egusa, Hiroshi/0000-0002-0200-8132; Alsberg, Eben/0000-0002-3487-4625	JSPS [18680039, 19659503]; COE program	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); COE program(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	Grants-in-Aid 18680039 and 19659503 from JSPS and young investigator grant from COE program.	Alsberg E, 2006, TISSUE ENG, V12, P3247, DOI 10.1089/ten.2006.12.3247; Bhang SH, 2007, J BIOMED MATER RES A, V80A, P998, DOI 10.1002/jbm.a.31050; Boontheekul T, 2007, TISSUE ENG, V13, P1431, DOI 10.1089/ten.2006.0356; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Chen QH, 2003, J VASC SURG, V37, P660, DOI 10.1067/mva.2003.95; Dubey N, 2001, BIOMATERIALS, V22, P1065, DOI 10.1016/S0142-9612(00)00341-0; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Eyrich D, 2007, BIOMATERIALS, V28, P55, DOI 10.1016/j.biomaterials.2006.08.027; FISCHBACH C, 2007, NAT METHODS IN PRESS; Huang YC, 2005, J APPL PHYSIOL, V98, P706, DOI 10.1152/japplphysiol.00273.2004; Jockenhoevel S, 2001, EUR J CARDIO-THORAC, V19, P424, DOI 10.1016/S1010-7940(01)00624-8; Kim BS, 1999, NAT BIOTECHNOL, V17, P979, DOI 10.1038/13671; Kong HJ, 2005, NAT MATER, V4, P460, DOI 10.1038/nmat1392; LEE RC, 1998, Patent No. 5756350; Matsumoto T, 2007, TISSUE ENG, V13, P207, DOI 10.1089/ten.2006.0058; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; Neidlinger-Wilke C, 2001, J ORTHOP RES, V19, P286, DOI 10.1016/S0736-0266(00)00029-2; Peretti GM, 2006, TISSUE ENG, V12, P1151, DOI 10.1089/ten.2006.12.1151; Powell CA, 2002, AM J PHYSIOL-CELL PH, V283, pC1557, DOI 10.1152/ajpcell.00595.2001; Saez A, 2007, P NATL ACAD SCI USA, V104, P8281, DOI 10.1073/pnas.0702259104; Sakiyama-Elbert SE, 2000, J CONTROL RELEASE, V69, P149, DOI 10.1016/S0168-3659(00)00296-0; Tan W, 2005, J BIOMED MATER RES A, V72A, P146, DOI 10.1002/jbm.a.30182; Thomas AC, 2004, J CONTROL RELEASE, V100, P357, DOI 10.1016/j.jconrel.2004.09.004; Tranquillo RT, 1996, BIOMATERIALS, V17, P349, DOI 10.1016/0142-9612(96)85573-6; Webb K, 2006, J BIOMECH, V39, P1136, DOI 10.1016/j.jbiomech.2004.08.026; Xu T, 2005, BIOMATERIALS, V26, P93, DOI 10.1016/j.biomaterials.2004.04.011; Zhu XY, 2005, NAT MATER, V4, P403, DOI 10.1038/nmat1365	27	83	83	3	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2007	2	11							e1211	10.1371/journal.pone.0001211	http://dx.doi.org/10.1371/journal.pone.0001211			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10JB	18030345	Green Published, Green Submitted, gold			2023-01-03	WOS:000207459200024
J	Kennedy, A; Rogers, A; Bower, P				Kennedy, Anne; Rogers, Anne; Bower, Peter			Support for self care for patients with chronic disease	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; COMPLEX INTERVENTIONS; ULCERATIVE-COLITIS; HEALTH-CARE; MANAGEMENT; FRAMEWORK; QUALITY		Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	University of Manchester	Kennedy, A (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.	anne.p.kennedy@manchester.ac.uk	Bower, Peter/A-1508-2011	Bower, Peter/0000-0001-9558-3349				Barlow J, 2002, PATIENT EDUC COUNS, V48, P177, DOI 10.1016/S0738-3991(02)00032-0; Blakeman T, 2006, BRIT J GEN PRACT, V56, P407; BURY M, 2005, RAPID REV CURRENT ST; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Fairhurst K, 2006, ANN FAM MED, V4, P500, DOI 10.1370/afm.565; Ferlie EB, 2001, MILBANK Q, V79, P281, DOI 10.1111/1468-0009.00206; Griffiths C, 2007, BMJ-BRIT MED J, V334, P1254, DOI 10.1136/bmj.39227.698785.47; Howie JGR, 1996, BRIT J GEN PRACT, V46, P479; *IMPR CHRON CAR, SELF MAN SUPP; Kendall E, 2007, DISABIL SOC, V22, P129, DOI 10.1080/09687590601141535; Kennedy A, 2003, HEALTH SOC CARE COMM, V11, P64, DOI 10.1046/j.1365-2524.2003.00399.x; Kennedy AP, 2004, GUT, V53, P1639, DOI 10.1136/gut.2003.034256; May C, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-86; *NAT PRIM CAR RES, WISE APPR SELF MAN; Newbould J, 2006, CHRONIC ILLN, V2, P249, DOI 10.1179/174592006X157508; NORMAN P, 1996, PREDICTING HLTH BEHA, P197; Robinson A, 2006, GUT, V55, P643, DOI 10.1136/gut.2004.062901; Robinson A, 2001, LANCET, V358, P976, DOI 10.1016/S0140-6736(01)06105-0; Rogers A, 2005, QUAL HEALTH RES, V15, P224, DOI 10.1177/1049732304272048; SANDERS C, IN PRESS SOC SCI MED; UK Government, 2021, GP IT FUTURES SYSTEM; Wagner E H, 1998, Eff Clin Pract, V1, P2; Wagner EH, 2002, BMJ-BRIT MED J, V325, P913, DOI 10.1136/bmj.325.7370.913; Wanless, 2002, SECURING OUR FUTURE	24	199	199	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 10	2007	335	7627					968	970		10.1136/bmj.39372.540903.94	http://dx.doi.org/10.1136/bmj.39372.540903.94			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	232AL	17991978	Green Published			2023-01-03	WOS:000250990400035
J	Ferme, C; Eghbali, H; Meerwaldt, JH; Rieux, C; Bosq, J; Berger, F; Girinsky, T; Brice, P; van't Veer, MB; Walewski, JA; Lederlin, P; Tirelli, U; Carde, P; Van den Neste, E; Gyan, E; Monconduit, M; Divine, M; Raemaekers, JMM; Salles, G; Noordijk, EM; Creemers, G; Gabarre, J; Hagenbeek, A; Reman, O; Blanc, M; Thomas, J; Vie, B; Kluin-Nelemans, JC; Viseu, F; Baars, JW; Poortmans, P; Lugtenburg, PJ; Carrie, C; Jaubert, J; Henry-Amar, M				Ferme, Christophe; Eghbali, Houchingue; Meerwaldt, Jacobus H.; Rieux, Chantal; Bosq, Jacques; Berger, Francoise; Girinsky, Theodore; Brice, Pauline; van't Veer, Mars B.; Walewski, Jan A.; Lederlin, Pierre; Tirelli, Umberto; Carde, Patrice; Van den Neste, Eric; Gyan, Emmanuel; Monconduit, Mathieu; Divine, Marine; Raemaekers, John M. M.; Salles, Gilles; Noordijk, Evert M.; Creemers, Geert-Jan; Gabarre, Jean; Hagenbeek, Anton; Reman, Oumedaly; Blanc, Michel; Thomas, Jose; Vie, Brigitte; Kluin-Nelemans, Johanna C.; Viseu, Fernando; Baars, Joke W.; Poortmans, Philip; Lugtenburg, Pieternella J.; Carrie, Christian; Jaubert, Jerome; Henry-Amar, Michel		EORTC-GELA H8 Trial	Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ABVD CHEMOTHERAPY; CLINICAL-TRIALS; RADIOTHERAPY; VINBLASTINE; DOXORUBICIN; LYMPHOMA; THERAPY; CYCLES; BLEOMYCIN	Background Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure. Methods From 1993 to 1999, we identified 1538 patients (age, 15 to 70 years) who had untreated stage I or II supradiaphragmatic Hodgkin's disease with favorable prognostic features (the H8-F trial) or unfavorable features (the H8-U trial). In the H8-F trial, we compared three cycles of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) combined with doxorubicin, bleomycin, and vinblastine (ABV) plus involved-field radiotherapy with subtotal nodal radiotherapy alone (reference group). In the H8-U trial, we compared three regimens: six cycles of MOPP-ABV plus involved-field radiotherapy (reference group), four cycles of MOPP-ABV plus involved-field radiotherapy, and four cycles of MOPP-ABV plus subtotal nodal radiotherapy. Results The median follow-up was 92 months. In the H8-F trial, the estimated 5-year event-free survival rate was significantly higher after three cycles of MOPP-ABV plus involved-field radiotherapy than after subtotal nodal radiotherapy alone (98% vs. 74%, P<0.001). The 10-year overall survival estimates were 97% and 92%, respectively (P=0.001). In the H8-U trial, the estimated 5-year event-free survival rates were similar in the three treatment groups: 84% after six cycles of MOPP-ABV plus involved-field radiotherapy, 88% after four cycles of MOPP-ABV plus involved-field radiotherapy, and 87% after four cycles of MOPP-ABV plus subtotal nodal radiotherapy. The 10-year overall survival estimates were 88%, 85%, and 84%, respectively. Conclusions Chemotherapy plus involved-field radiotherapy should be the standard treatment for Hodgkin's disease with favorable prognostic features. In patients with unfavorable features, four courses of chemotherapy plus invoved-field radiotherapy should be the standard treatment.	Inst Cancerol Gustave Roussy, Dept Med, F-94805 Villejuif, France; Inst Bergonie, Bordeaux, France; Med Spectrum Twente, Enschede, Netherlands; Ctr Francois Baclesse, F-14021 Caen, France; Univ Lyon 1, Hospices Civils Lyon, F-69365 Lyon, France; CHU St Louis, Paris, France; Dr Daniel Denhoed Canc Ctr, Rotterdam, Netherlands; Marie Sklodowska Curie Mem Inst, Ctr Oncol, Warsaw, Poland; CHU Brabois, Nancy, France; Ctr Riferimento Oncol, I-33081 Aviano, Italy; Clin Univ St Luc, B-1200 Brussels, Belgium; CHU Cochin, Paris, France; Ctr Henri Becquerel, F-76038 Rouen, France; CHU Henri Mondor, F-94010 Creteil, France; Radoubd Univ Med Ctr Nijmegen, Nijmegen, Netherlands; Leiden Univ, Med Ctr, Leiden, Netherlands; Catharina Hosp, Eindhoven, Netherlands; CHU Pitie Salpetriere, Paris, France; Univ Med Ctr Utrecht, Utrecht, Netherlands; Ctr Hosp Univ, Caen, France; Ctr Hosp Univ, Chambery, France; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; Inst Portugues Oncol Francisco Gentil, Oporto, Portugal; Netherlands Canc Inst, Amsterdam, Netherlands; St Ignatius Hosp, Breda, Netherlands; Erasmus MC, Rotterdam, Netherlands; Ctr Leon Berard, F-69373 Lyon, France; Ctr Hosp Univ, St Etienne, France	UNICANCER; Gustave Roussy; UNICANCER; Institut Bergonie; Medical Spectrum Twente; UNICANCER; Centre Francois Baclesse; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Maria Sklodowska-Curie National Research Institute of Oncology; CHU de Nancy; IRCCS Aviano (CRO); Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Centre Henri Becquerel; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Radboud University Nijmegen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Catharina Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Utrecht University; Utrecht University Medical Center; CHU de Caen NORMANDIE; KU Leuven; University Hospital Leuven; Portuguese Institute of Oncology; Netherlands Cancer Institute; Erasmus University Rotterdam; Erasmus MC; UNICANCER; Centre Leon Berard; CHU de St Etienne	Ferme, C (corresponding author), Inst Cancerol Gustave Roussy, Dept Med, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	christophe.ferme@igr.fr	AMSELLEM, Sophie/B-3645-2012; Walewski, Jan/ABC-9523-2020; Henry-Amar, Michel/S-9358-2019; Subbiah, Vivek/O-3347-2019; Salles, Gilles/Z-2336-2019; Poortmans, P.M.P./L-4581-2015; Kluin-Nelemans, Johanna C/F-8658-2018	Subbiah, Vivek/0000-0002-6064-6837; Salles, Gilles/0000-0002-9541-8666; Kluin-Nelemans, Johanna C/0000-0003-2617-9427; GYAN, Emmanuel/0000-0002-7651-9189; Walewski, Jan/0000-0003-4247-2674; Henry-Amar, Michel/0000-0002-9357-6476				Anselmo AP, 2004, ANTICANCER RES, V24, P4045; Bonadonna G, 2004, J CLIN ONCOL, V22, P2835, DOI 10.1200/JCO.2004.12.170; *CYT SOFTW, 2004, STATXACT STAT SOFTW; DIEHL V, 2004, BLOOD, V104, P1307; Eghbali H, 2005, EUR J HAEMATOL, V75, P135, DOI 10.1111/j.1600-0609.2005.00467.x; Engert A, 2003, J CLIN ONCOL, V21, P3601, DOI 10.1200/JCO.2003.03.023; Engert A, 2007, J CLIN ONCOL, V25, P3495, DOI 10.1200/JCO.2006.07.0482; HERSON J, 1979, BIOMETRICS, V35, P775, DOI 10.2307/2530109; KLIMO P, 1988, SEMIN HEMATOL, V25, P34; Laskar S, 2004, J CLIN ONCOL, V22, P62, DOI 10.1200/JCO.2004.01.021; LEE CKK, 1980, CANCER-AM CANCER SOC, V46, P2403, DOI 10.1002/1097-0142(19801201)46:11<2403::AID-CNCR2820461116>3.0.CO;2-9; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; Meyer RM, 2005, J CLIN ONCOL, V23, P4634, DOI 10.1200/JCO.2005.09.085; Nachman JB, 2002, J CLIN ONCOL, V20, P3765, DOI 10.1200/JCO.2002.12.007; Ng AK, 2002, BLOOD, V100, P1989, DOI 10.1182/blood-2002-02-0634; Noordijk EM, 2006, J CLIN ONCOL, V24, P3128, DOI 10.1200/JCO.2005.05.2746; Press OW, 2001, J CLIN ONCOL, V19, P4238, DOI 10.1200/JCO.2001.19.22.4238; Rothman KJ., 1982, EPIDEMIOLOGIC ANAL P; *STAT, 2004, STAT STAT SOFTW REL; Straus DJ, 2004, BLOOD, V104, P3483, DOI 10.1182/blood-2004-04-1311; SUTCLIFFE SB, 1990, J CLIN ONCOL, V8, P1598; Yahalom J, 2005, EUR J HAEMATOL, V75, P90, DOI 10.1111/j.1600-0609.2005.00461.x	22	298	307	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 8	2007	357	19					1916	1927		10.1056/NEJMoa064601	http://dx.doi.org/10.1056/NEJMoa064601			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228LX	17989384				2023-01-03	WOS:000250732500006
J	Levin, NW; Fishbane, S; Canedo, FV; Zeig, S; Nassar, GM; Moran, JE; Villa, G; Beyer, U; Guey, D				Levin, Nothan W.; Fishbane, Steven; Valdes Canedo, Francisco; Zeig, Steven; Nassar, George M.; Moran, John E.; Villa, Giuseppe; Beyer, Ulrich; Guey, Deiphine		MAXIMA Study Investigators	Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA)	LANCET			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; RECEPTOR ACTIVATOR CERA; DARBEPOETIN-ALPHA; ANEMIA MANAGEMENT; STABLE HEMOGLOBIN; INTERVALS	Background Conventional treatment with epoetin to manage anaemia in chronic kidney disease needs frequent administrations, changes of dose, and close monitoring of haemoglobin concentrations. We aimed to compare the effectiveness of methoxy polyethylene glycol-epoetin beta, given intravenously at 2-week or 4-week intervals, with epoetin treatment one to three times per week for haemoglobin control in haemodialysis patients. Methods We screened 1115 adult patients from 96 centres who had stable chronic renal anaemia and were on dialysis treatment and intravenous maintenance epoetin. We did an open-label, parallel-group, non-inferiority trial to compare two dosing intervals of methoxy polyethylene glycol-epoetin beta with standard epoetin treatment. We established baseline haemoglobin concentration and eligibility over a 4-week run-in period. 223 patients were randomly assigned to receive methoxy polyethylene glycol-epoetin beta every 2 weeks, 224 to receive it every 4 weeks, and 226 to receive standard epoetin treatment. The initial dose was based on the average epoetin dose given during the week before the switch. The primary endpoint was change in haemoglobin concentration between baseline and the assessment period. We analysed patients both by intention to treat and per protocol. This study is registered with ClinicalTrials. gov, number NCT00077610. Findings We excluded 133 of the 673 randomised patients from the per-protocol analysis because they had inadequate iron status or fewer than five haemoglobin measurements during the assessment period or needed red blood cell transfusions. The mean change from baseline haemoglobin for patients who had switched to intravenous methoxy polyethylene glycol-epoetin beta every 2 weeks (-0.71 g/L, 95% CI -2.20 to 0.77) or every 4 weeks (-0.25 g/L, -1.79 to 1.29) was non-inferior to the mean change for patients who continued treatment with epoetin (-0.75 g/L, -2.26 to 0.75) (p< 0.0001 for both comparisons). Of the 666 patients who received at least one dose of study drug, the incidence of adverse events or serious adverse events did not differ between groups (p=0.30 and p=0.40, respectively). Interpretation This long-acting erythropoiesis-stimulating agent is as safe as conventional epoetin treatment, and can maintain anaemia management in haemodialysis patients when given intravenously at 4-week dosing intervals.	Renal Res Inst, New York, NY 10128 USA; Winthrop Univ Hosp, Mineola, NY 11501 USA; Hosp Juan Canalejo, La Coruna, Spain; Clin Res Inc, Pembroke Pines, FL USA; Renal Res Inst, Houston, TX USA; Satellite Healthcare Inc, Mountain View, CA USA; IRCCS, Fdn S Maugeri, Pavia, Italy; F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland	Renal Research Institute; Winthrop University Hospital; Complejo Hospitalario Universitario A Coruna; Istituti Clinici Scientifici Maugeri IRCCS; University of Pavia; Roche Holding	Levin, NW (corresponding author), Renal Res Inst, 207 E 94th St,Suite 303, New York, NY 10128 USA.	nlevin@rriny.com	Nassar, George/T-2400-2019	Beyer, Ulrich/0000-0001-5601-2201				Besarab A, 2007, CLIN THER, V29, P626, DOI 10.1016/j.clinthera.2007.04.014; Brunkhorst R, 2004, NEPHROL DIAL TRANSPL, V19, P1224, DOI 10.1093/ndt/gfh106; *CTR MED MED SERV, 2004, 2004 ANN REP END STA; Dougherty FC, 2004, J CLIN ONCOL, V22, p605S; Hertel J, 2006, AM J NEPHROL, V26, P149, DOI 10.1159/000092852; Horl WH, 2003, AM J KIDNEY DIS, V41, P49, DOI 10.1053/ajkd.2003.50018; *I MED COMM ID PRE, PREV MED ERR; Jadoul M, 2004, NEPHROL DIAL TRANSPL, V19, P898, DOI 10.1093/ndt/gfh021; *K DOQI, K DOQI CLIN PRACT GU; Locatelli F, 2003, NEPHROL DIAL TRANSPL, V18, P362, DOI 10.1093/ndt/18.2.362; Locatelli F, 2007, CURR MED RES OPIN, V23, P969, DOI 10.1185/030079907X182103; Macdougall IC, 2006, CLIN J AM SOC NEPHRO, V1, P1211, DOI 10.2215/CJN.00730306; Macdougall Iain C, 2005, Curr Hematol Rep, V4, P436; Manley Harold J, 2003, BMC Nephrol, V4, P10, DOI 10.1186/1471-2369-4-10; Nissenson AR, 2002, AM J KIDNEY DIS, V40, P110, DOI 10.1053/ajkd.2002.33919; Pisoni RL, 2004, AM J KIDNEY DIS, V44, P94, DOI 10.1053/j.ajkd.2004.03.023; Provenzano R, 2007, CLIN NEPHROL, V67, P306; Ross SD, 2003, CLIN THER, V25, P1786, DOI 10.1016/S0149-2918(03)80170-4; Sulowicz W, 2007, CLIN J AM SOC NEPHRO, V2, P637, DOI 10.2215/CJN.03631006; Vanrenterghem Y, 2002, KIDNEY INT, V62, P2167, DOI 10.1046/j.1523-1755.2002.00657.x; Xue JL, 2002, AM J KIDNEY DIS, V40, P1153, DOI 10.1053/ajkd.2002.36861	21	118	127	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 20	2007	370	9596					1415	1421		10.1016/S0140-6736(07)61599-2	http://dx.doi.org/10.1016/S0140-6736(07)61599-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223PY	17950856				2023-01-03	WOS:000250386000018
J	Affolder, R; Rizzo, I; Burgess, C; Bchir, A; Lob-Levyt, J				Affolder, Rebecca; Rizzo, Ivone; Burgess, Craig; Bchir, Abdallah; Lob-Levyt, Julian			A prescription for drug delivery	NATURE			English	Editorial Material									GAVI Alliance, Geneva, Switzerland		Affolder, R (corresponding author), GAVI Alliance, Geneva, Switzerland.								0	1	1	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 13	2007	449	7159					170	172		10.1038/449170a	http://dx.doi.org/10.1038/449170a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	209NF	17851513	Bronze			2023-01-03	WOS:000249394500037
J	Tchantchou, F; Xu, YN; Wu, YJ; Christen, Y; Luo, Y				Tchantchou, Flaubert; Xu, Yanan; Wu, Yanjue; Christen, Yves; Luo, Yuan			EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						AD; dementia; neuronal cells; memory	GINKGO-BILOBA EXTRACT; ELEMENT-BINDING PROTEIN; AMYLOID-BETA-PEPTIDE; DENTATE GYRUS; RANDOMIZED-TRIAL; DOUBLE-BLIND; IN-VIVO; SYNAPTIC PLASTICITY; CELLS; MEMORY	Standardized Ginkgo biloba extract EGb 761 exhibits beneficial effects to patients with Alzheimer's disease ( AD). It was previously demonstrated that EGb 761 inhibits amyloid beta ( A beta) oligomerization in vitro, protects neuronal cells against A beta toxicity, and improves cognitive defects in a mouse model of AD ( Tg 2576). In this study, the neurogenic potential of EGb 761 and its effect on cAMP response element binding protein ( CREB) were examined in a double transgenic mouse model ( TgAPP/ PS1). EGb 761 significantly increases cell proliferation in the hippocampus of both young ( 6 months) and old ( 22 months) TgAPP/ PS1 mice, and the total number of neuronal precursor cells in vitro in a dose-dependent manner. Furthermore, A beta oligomers inhibit phosphorylation of CREB and cell proliferation in the hippocampus of TgAPP/ PS1 mice. Administration of EGb 761 reduces A beta oligomers and restores CREB phosphorylation in the hippocampus of these mice. The present findings suggest that 1) enhanced neurogenesis by EGb 761 may be mediated by activation of CREB, 2) stimulation of neurogenesis by EGb 761 may contribute to its beneficial effects in AD patients and improved cognitive functions in the mouse model of AD, and 3) EGb 761 has therapeutic potential for the prevention and improved treatment of AD.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Integrat Med, Baltimore, MD USA; Ipsen, Paris, France	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Luo, Y (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.	yluo@rx.umaryland.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001928] Funding Source: NIH RePORTER; NCCIH NIH HHS [R01AT001928-03A1] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Barker N, 2000, ADV CANCER RES, V77, P1; Bastianetto S, 2000, J NEUROCHEM, V74, P2268, DOI 10.1046/j.1471-4159.2000.0742268.x; Beglopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P33, DOI 10.1016/j.tips.2005.11.010; Bender RA, 2001, EUR J NEUROSCI, V13, P679, DOI 10.1046/j.1460-9568.2001.01432.x; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Brinton Roberta Diaz, 2006, Current Alzheimer Research, V3, P185; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Colciaghi F, 2004, NEUROBIOL DIS, V16, P454, DOI 10.1016/j.nbd.2004.03.011; DeFeudis F. V., 2000, Current Drug Targets, V1, P25, DOI 10.2174/1389450003349380; DeKosky ST, 2006, CONTEMP CLIN TRIALS, V27, P238, DOI 10.1016/j.cct.2006.02.007; Donovan MH, 2006, J COMP NEUROL, V495, P70, DOI 10.1002/cne.20840; Dusek JA, 1997, P NATL ACAD SCI USA, V94, P7109, DOI 10.1073/pnas.94.13.7109; Feng RB, 2001, NEURON, V32, P911, DOI 10.1016/S0896-6273(01)00523-2; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gohil K, 2002, ANN NY ACAD SCI, V957, P70, DOI 10.1111/j.1749-6632.2002.tb02906.x; Gould E, 1999, TRENDS COGN SCI, V3, P186, DOI 10.1016/S1364-6613(99)01310-8; Gross CG, 2000, NAT REV NEUROSCI, V1, P67, DOI 10.1038/35036235; Hattiangady B, 2005, EXP NEUROL, V195, P353, DOI 10.1016/j.expneurol.2005.05.014; Haughey NJ, 2002, J NEUROCHEM, V83, P1509, DOI 10.1046/j.1471-4159.2002.01267.x; Jiang W, 2005, J CLIN INVEST, V115, P3104, DOI 10.1172/JCI25509; Jin KL, 2004, P NATL ACAD SCI USA, V101, P13363, DOI 10.1073/pnas.0403678101; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; Lee SJ, 2004, NEUROSCIENCE, V124, P549, DOI 10.1016/j.neuroscience.2003.11.035; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; Luo Y, 2002, P NATL ACAD SCI USA, V99, P12197, DOI 10.1073/pnas.182425199; MacKenzie SJ, 2000, BIOCHEM J, V347, P571, DOI 10.1042/0264-6021:3470571; Mattson MP, 2006, TRENDS NEUROSCI, V29, P632, DOI 10.1016/j.tins.2006.09.001; Mazza M, 2006, EUR J NEUROL, V13, P981, DOI 10.1111/j.1468-1331.2006.01409.x; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; Mix JA, 2002, HUM PSYCHOPHARM CLIN, V17, P267, DOI 10.1002/hup.412; Nakagawa S, 2002, J NEUROSCI, V22, P3673; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Parent JM, 1997, J NEUROSCI, V17, P3727; PHILLIPS HS, 1991, NEURON, V7, P695, DOI 10.1016/0896-6273(91)90273-3; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Puzzo D, 2005, J NEUROSCI, V25, P6887, DOI 10.1523/JNEUROSCI.5291-04.2005; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Smith JV, 2002, CELL MOL BIOL, V48, P699; Smith JV, 2004, APPL MICROBIOL BIOT, V64, P465, DOI 10.1007/s00253-003-1527-9; Spencer JPE, 2003, J BIOL CHEM, V278, P34783, DOI 10.1074/jbc.M305063200; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Stackman RW, 2003, EXP NEUROL, V184, P510, DOI 10.1016/S0014-4886(03)00399-6; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Vitolo OV, 2002, P NATL ACAD SCI USA, V99, P13217, DOI 10.1073/pnas.172504199; Ward CP, 2002, PHARMACOL BIOCHEM BE, V72, P913, DOI 10.1016/S0091-3057(02)00768-2; Wu YJ, 2006, J NEUROSCI, V26, P13102, DOI 10.1523/JNEUROSCI.3448-06.2006; Yamamoto-Sasaki M, 1999, BRAIN RES, V824, P300, DOI 10.1016/S0006-8993(99)01220-2; Yao ZX, 2001, BRAIN RES, V889, P181, DOI 10.1016/S0006-8993(00)03131-0; Zhu DY, 2004, P NATL ACAD SCI USA, V101, P9453, DOI 10.1073/pnas.0401063101	58	146	158	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2007	21	10					2400	2408		10.1096/fj.06-7649com	http://dx.doi.org/10.1096/fj.06-7649com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	196AS	17356006				2023-01-03	WOS:000248454400015
J	Kumar, P; Wu, HQ; McBride, JL; Jung, KE; Kim, MH; Davidson, BL; Lee, SK; Shankar, P; Manjunath, N				Kumar, Priti; Wu, Haoquan; McBride, Jodi L.; Jung, Kyeong-Eun; Kim, Moon Hee; Davidson, Beverly L.; Lee, Sang Kyung; Shankar, Premlata; Manjunath, N.			Transvascular delivery of small interfering RNA to the central nervous system	NATURE			English	Article							CELL-PENETRATING PEPTIDES; INHIBITS TUMOR-GROWTH; IN-VIVO DELIVERY; INTRACELLULAR DELIVERY; MODIFIED SIRNAS; GENE-THERAPY; BRAIN; VIRUS; RECEPTORS; TRANSPORTERS	A major impediment in the treatment of neurological diseases is the presence of the blood - brain barrier, which precludes the entry of therapeutic molecules from blood to brain. Here we show that a short peptide derived from rabies virus glycoprotein (RVG) enables the transvascular delivery of small interfering RNA ( siRNA) to the brain. This 29-amino-acid peptide specifically binds to the acetylcholine receptor expressed by neuronal cells. To enable siRNA binding, a chimaeric peptide was synthesized by adding nonamer arginine residues at the carboxy terminus of RVG. This RVG-9R peptide was able to bind and transduce siRNA to neuronal cells in vitro, resulting in efficient gene silencing. After intravenous injection into mice, RVG-9R delivered siRNA to the neuronal cells, resulting in specific gene silencing within the brain. Furthermore, intravenous treatment with RVG-9R-bound antiviral siRNA afforded robust protection against fatal viral encephalitis in mice. Repeated administration of RVG-9R-bound siRNA did not induce inflammatory cytokines or anti-peptide antibodies. Thus, RVG-9R provides a safe and noninvasive approach for the delivery of siRNA and potentially other therapeutic molecules across the blood - brain barrier.	Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Univ Iowa, Dept Internal Med, Roy J & Lucille J Carver Coll Med, Iowa City, IA 52242 USA; Samchully Pharm Co Ltd, Res Ctr, Seoul 135735, South Korea; Hanyang Univ, Dept Bioengn, Seoul 133791, South Korea; Hanyang Univ, Hanyang Fus Mat Program, Seoul 133791, South Korea	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; University of Iowa; Hanyang University; Hanyang University	Manjunath, N (corresponding author), Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA.	shankar@cbrinstitute.org; swamy@cbrinstitute.org	Kumar, Priti/C-5699-2009; McBride, Jodi/C-4494-2016	Davidson, Beverly/0000-0002-3715-6290; Wu, Haoquan/0000-0001-9386-3187; McBride, Jodi/0000-0002-4816-7569				Akaneya Y, 2005, J NEUROPHYSIOL, V93, P594, DOI 10.1152/jn.00161.2004; Chen TJ, 2005, CHINESE J PHYSIOL, V48, P129; de Boer AG, 2007, ANNU REV PHARMACOL, V47, P323, DOI 10.1146/annurev.pharmtox.47.120505.105237; Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0; Diamond MS, 2003, J VIROL, V77, P2578, DOI 10.1128/JVI.77.4.2578-2586.2003; Dietz GPH, 2005, BRAIN RES BULL, V68, P103, DOI 10.1016/j.brainresbull.2005.08.015; Dorn G, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh044; Gotti C, 2004, PROG NEUROBIOL, V74, P363, DOI 10.1016/j.pneurobio.2004.09.006; Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007; Henriques ST, 2006, BIOCHEM J, V399, P1, DOI 10.1042/BJ20061100; Hino T, 2006, BIOCHEM BIOPH RES CO, V340, P263, DOI 10.1016/j.bbrc.2005.11.173; Hoyer D, 2006, J RECEPT SIG TRANSD, V26, P527, DOI 10.1080/10799890600929663; Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Juliano RL, 2005, CURR OPIN MOL THER, V7, P132; Kim WL, 2006, MOL THER, V14, P343, DOI 10.1016/j.ymthe.2006.03.022; Kumar P, 2006, PLOS MED, V3, P505, DOI 10.1371/journal.pmed.0030096; Lafon M, 2005, J NEUROVIROL, V11, P82, DOI 10.1080/13550280590900427; Lentz T L, 1990, J Mol Recognit, V3, P82, DOI 10.1002/jmr.300030205; LENTZ TL, 1982, SCIENCE, V215, P182, DOI 10.1126/science.7053569; Leonard S, 2001, Nicotine Tob Res, V3, P203; Mazarakis ND, 2001, HUM MOL GENET, V10, P2109, DOI 10.1093/hmg/10.19.2109; Melikov K, 2005, CELL MOL LIFE SCI, V62, P2739, DOI 10.1007/s00018-005-5293-y; Miller G, 2002, SCIENCE, V297, P1116, DOI 10.1126/science.297.5584.1116; Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122; Neyts J, 1999, Verh K Acad Geneeskd Belg, V61, P661; Noble CO, 2004, EXPERT OPIN THER TAR, V8, P335, DOI 10.1517/14728222.8.4.335; NOTTER MFD, 1985, J CELL PHYSIOL, V125, P476, DOI 10.1002/jcp.1041250317; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Schlachetzki F, 2004, NEUROLOGY, V62, P1275, DOI 10.1212/01.WNL.0000120551.38463.D9; Schutz B, 2005, J NEUROSCI, V25, P7805, DOI 10.1523/JNEUROSCI.2038-05.2005; Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Zhang Y, 2004, CLIN CANCER RES, V10, P3667, DOI 10.1158/1078-0432.CCR-03-0740; Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688	36	927	1061	15	257	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 5	2007	448	7149					39	43		10.1038/nature05901	http://dx.doi.org/10.1038/nature05901			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185OS	17572664				2023-01-03	WOS:000247720900032
J	Rodriguez, RA; Sen, S; Mehta, K; Moody-Ayers, S; Bacchetti, P; O'Hare, AM				Rodriguez, Rudolph A.; Sen, Saunak; Mehta, Kala; Moody-Ayers, Sandra; Bacchetti, Peter; O'Hare, Ann M.			Geography matters: Relationships among urban residential segregation, dialysis facilities, and patient outcomes	ANNALS OF INTERNAL MEDICINE			English	Article							STAGE RENAL-DISEASE; PAY-FOR-PERFORMANCE; HEMODIALYSIS-PATIENTS; REPLACEMENT THERAPY; RACIAL DISPARITIES; SURVIVAL ANALYSIS; HEALTH-CARE; TRANSPLANTATION; MORTALITY; QUALITY	Background: End-stage renal disease disproportionately affects black Americans. However, the impact of residential segregation by race-a prominent feature of many U.S. cities-on outcomes of patients receiving dialysis and on facility performance has not been evaluated. Objective: To examine the relationship among racial composition of ZIP codes in metropolitan areas, outcomes of patients receiving dialysis, and characteristics of dialysis facilities. Design: Retrospective cohort study of patients receiving dialysis and cross-sectional study of dialysis facilities. Setting: U.S. metropolitan ZIP codes with differing percentages of black residents. Patients: Black and non-Hispanic white patients who initiated long-term dialysis between 1 January 1995 and 31 December 2002 (n = 399 424) and dialysis facilities in operation in December 2004 (n = 3244). Measurements: Mortality and time to transplantation among patients receiving dialysis, and performance of dialysis facilities on the basis of quality indicators (anemia management, dialysis adequacy, and facility-level mortality rates). Results: Most black patients (50.3%) but few white patients (5%) lived in the 3% (n = 769) of ZIP codes in which most residents were black. in analyses adjusted for patient and ZIP code characteristics, mortality rates were higher among white patients but not among black patients living in areas with a higher percentage of black residents (adjusted hazard ratio for ZIP codes with 75% black residents vs. < 10% black residents, 1.14 [95% Cl, 1.07 to 1.21] for white patients and 1.02 [Cl, 0.99 to 1.06] for black patients). Time to transplantation was longer among both black and white patients (adjusted hazard ratio for ZIP codes with >= 75% black residents vs. < 10% black residents, 0.84 [Cl, 0.78 to 0.92] and 0.63 [Cl, 0.57 to 0.71] for black patients and white patients, respectively). Dialysis facilities located in areas with a higher percentage of black residents were more likely to have higher-than-expected mortality rates and were less likely to meet performance targets. Limitations: Patient-level analyses were restricted to black and non-Hispanic white patients. Patient-level and facility-level analyses focused only on the percentage of black residents in each ZIP code. Conclusions: The racial composition of urban residential areas is associated with time to transplantation and dialysis facility performance on standard quality measures. Closer scrutiny of care provided to patients receiving dialysis who live in predominantly black residential areas and to dialysis facilities operating in these areas may be warranted.	Univ Calif San Francisco, San Francisco Gen Hosp, Vet Affairs Med Ctr, San Francisco, CA 94110 USA; Vet Affairs San Francisco Res Enhancement Award P, San Francisco, CA USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Rodriguez, RA (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Vet Affairs Med Ctr, Renal Ctr Bldg 100,Room 350,Box 1341, San Francisco, CA 94110 USA.	rrodriguez@medsfgh.ucsf.edu			NIA NIH HHS [K23 AG 028980-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K23AG028980] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adler NE, 2002, HEALTH AFFAIR, V21, P60, DOI 10.1377/hlthaff.21.2.60; Alexander GC, 1998, JAMA-J AM MED ASSOC, V280, P1148, DOI 10.1001/jama.280.13.1148; Alexander GC, 2002, AM J KIDNEY DIS, V40, P824, DOI 10.1053/ajkd.2002.35695; [Anonymous], 2004, DIABETES EDUCATOR, V30, P196, DOI 10.1177/014572170403000209; Bach PB, 2004, NEW ENGL J MED, V351, P575, DOI 10.1056/NEJMsa040609; Bleyer AJ, 1996, AM J KIDNEY DIS, V28, P72, DOI 10.1016/S0272-6386(96)90133-X; BLOEMBERGEN WE, 1994, J AM SOC NEPHROL, V5, P1231; Brown WW, 2003, KIDNEY INT S, V83, pS50; COWIE CC, 1994, DIABETES CARE, V17, P681, DOI 10.2337/diacare.17.7.681; *CTR MED MED SERV, 2003, NEPHROL DIAL TRANSPL, V18, P147; EGGERS PW, 1990, AM J KIDNEY DIS, V15, P414, DOI 10.1016/S0272-6386(12)70359-1; Epstein AM, 2004, NEW ENGL J MED, V350, P406, DOI 10.1056/NEJMsb035374; Epstein AM, 2000, NEW ENGL J MED, V343, P1537, DOI 10.1056/NEJM200011233432106; Epstein AM, 2004, NEW ENGL J MED, V351, P603, DOI 10.1056/NEJMe048181; Fang L, 2003, AM J MED, V115, P448, DOI 10.1016/S0002-9343(03)00446-7; Ford B.L., 1983, INCOMPLETE DATA SAMP, P185; Frankenfield DL, 1999, AM J KIDNEY DIS, V34, P721, DOI 10.1016/S0272-6386(99)70399-9; Frederick PR, 2002, HEALTH CARE FINANC R, V23, P37; Garg PP, 1999, NEW ENGL J MED, V341, P1653, DOI 10.1056/NEJM199911253412205; HELD PJ, 1987, JAMA-J AM MED ASSOC, V257, P645, DOI 10.1001/jama.257.5.645; Himmelfarb J, 2004, J AM SOC NEPHROL, V15, P3263, DOI 10.1097/01.ASN.0000145893.61791.7B; Hirth RA, 1996, JAMA-J AM MED ASSOC, V276, P1303; Isaacs SL, 2004, NEW ENGL J MED, V351, P1137, DOI 10.1056/NEJMsb040329; Leggat JE, 1998, AM J KIDNEY DIS, V32, P139, DOI 10.1053/ajkd.1998.v32.pm9669435; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Longenecker JC, 2000, J AM SOC NEPHROL, V11, P520, DOI 10.1681/ASN.V113520; McGill JB, 2004, DIABETES ED, V30, P200; McGill JB, 2004, DIABETES ED, V30, P206; *MED PAYM ADV COMM, 2006, REP C MED PAYM POL; Milgate K, 2006, HEALTH AFFAIR, V25, P413, DOI 10.1377/hlthaff.25.2.413; *NAT ESRD CPM WORK, 2002, J AM SOC NEPHROL, V13, P2117; O'Riordan E, 2003, QJM-INT J MED, V96, P739, DOI 10.1093/qjmed/hcg127; Owen WF, 1998, JAMA-J AM MED ASSOC, V280, P1764, DOI 10.1001/jama.280.20.1764; Pei YPC, 2000, KIDNEY INT, V58, P1293, DOI 10.1046/j.1523-1755.2000.00285.x; Powe NR, 2003, KIDNEY INT, V64, P763, DOI 10.1046/j.1523-1755.2003.00138.x; PUGH JA, 1994, AM J KIDNEY DIS, V23, P803; Rosenthal MB, 2005, JAMA-J AM MED ASSOC, V294, P1788, DOI 10.1001/jama.294.14.1788; Roux AVD, 2001, NEW ENGL J MED, V345, P99, DOI 10.1056/NEJM200107123450205; Saran R, 2003, KIDNEY INT, V64, P254, DOI 10.1046/j.1523-1755.2003.00064.x; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Sehgal AR, 2000, AM J KIDNEY DIS, V35, pS148, DOI 10.1016/S0272-6386(00)70242-3; Sehgal AR, 2003, JAMA-J AM MED ASSOC, V289, P996, DOI 10.1001/jama.289.8.996; Stack AG, 2002, J AM SOC NEPHROL, V13, P1279, DOI 10.1681/ASN.V1351279; Tanna MM, 2000, AM J KIDNEY DIS, V36, P1175, DOI 10.1053/ajkd.2000.19832; Werner RM, 2005, CIRCULATION, V111, P1257, DOI 10.1161/01.CIR.0000157729.59754.09; WHITEIS DG, 1992, PUBLIC HEALTH REP, V107, P409; Williams DR, 2001, PUBLIC HEALTH REP, V116, P404, DOI 10.1016/S0033-3549(04)50068-7	47	146	151	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 3	2007	146	7					493	501		10.7326/0003-4819-146-7-200704030-00005	http://dx.doi.org/10.7326/0003-4819-146-7-200704030-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	153VB	17404351				2023-01-03	WOS:000245463200003
J	Franck, L; Colquhoun, D				Franck, Linda; Colquhoun, David			Demand for complementary and alternative medicine is high despite limited evidence.	BRITISH MEDICAL JOURNAL			English	Article									UCL, Dept Pharmacol, London WC1E 6BT, England	University of London; University College London	Colquhoun, D (corresponding author), UCL, Dept Pharmacol, Mortimer St, London WC1E 6BT, England.	d.colquhoun@ucl.ac.uk	Colquhoun, David/C-1664-2008	Colquhoun, David/0000-0002-4263-017X					0	12	12	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 10	2007	334	7592					507	507						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148VV	17347234				2023-01-03	WOS:000245106400035
J	Ives, A; Saunders, C; Bulsara, M; Semmens, J				Ives, Angela; Saunders, Christobel; Bulsara, Max; Semmens, James			Pregnancy after breast cancer: population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WESTERN-AUSTRALIA; CARCINOMA; PROGNOSIS; SURVIVAL; OUTCOMES; WOMEN	Objectives To identify women who survived breast cancer and subsequently conceived and to determine the rate of pregnancy (proportion), management, outcome of the cancer, and outcome of the first subsequent pregnancy. Design Population based descriptive study with cases identified from the Western Australian data linkage system and validated by review of medical charts. Supplementary data obtained from hospital and clinician records. Setting Western Australia, 1982-2003. Participants Women aged <45 with a diagnosis of breast cancer who subsequently conceived. Main outcome measures Pregnancy outcome and rate, survival, time from diagnosis to pregnancy. Results Sixty two (54%) women with a diagnosis of breast cancer who subsequently conceived did so less than two years after their diagnosis: 29 of them had an abortion, 27 had a live birth, and six miscarried. Within a proportional hazards regression model subsequent pregnancy was associated with improved overall survival (hazard ratio 0.59, 95% confidence interval 0.37 to 0.95). When the model was stratified by time from diagnosis subsequent pregnancy was associated with improved overall survival in women who waited at least 24 months to conceive (0.48, 0.27 to 0.83) and a non-significant protective effect was seen for women who waited at least six months to become pregnant. Conclusions Our study does not support the current medical advice given to premenopausal women with a diagnosis of breast cancer to wait two years before attempting to conceive. This recommendation may be valid for women who are receiving treatment or have systemic disease at diagnosis, but for women with localised disease early conception, six months after completing treatment, is unlikely to reduce survival.	Univ Western Australia, Sch Surg & Pathol, Crawley, WA, Australia; Univ Western Australia, Sch Populat Hlth, Crawley, WA, Australia; Curtin Univ Technol, Sch Publ Hlth, Bentley, WA 6845, Australia	University of Western Australia; University of Western Australia; Curtin University	Ives, A (corresponding author), Univ Western Australia, Sch Surg & Pathol, M507, Crawley, WA, Australia.	angela.ives@uwa.edu.au	Saunders, Christobel M/H-5779-2014; Ives, Angela D/H-5113-2014; Bulsara, Max/A-5966-2008	Saunders, Christobel M/0000-0003-2281-9829; Bulsara, Max/0000-0002-8033-6123; Ives, Angela Denise/0000-0001-5734-0821				Blakely LJ, 2004, CANCER-AM CANCER SOC, V100, P465, DOI 10.1002/cncr.11929; Clark R M, 1989, Clin Oncol (R Coll Radiol), V1, P11, DOI 10.1016/S0936-6555(89)80004-4; CLARK RM, 1978, INT J RADIAT ONCOL, V4, P693, DOI 10.1016/0360-3016(78)90196-7; GUINEE VF, 1994, LANCET, V343, P1587; Gwyn K, 2001, ONCOLOGY-NY, V15, P39; HARVEY JC, 1981, SURG GYNECOL OBSTET, V153, P723; HOLLEB AI, 1962, SURG GYNECOL OBSTET, V115, P65; Ives Angela, 2002, Aust Fam Physician, V31, P929; Kroman N, 1997, LANCET, V350, P319, DOI 10.1016/S0140-6736(97)03052-3; McEvoy SP, 2004, MED J AUSTRALIA, V181, P305, DOI 10.5694/j.1326-5377.2004.tb06294.x; *NAT CTR CLASS, 2000, INT STAT CLASS DIS R; National Coding Centre, 1995, AUSTR VERS INT CLASS; NUGENT P, 1985, ARCH SURG-CHICAGO, V120, P1221; Peters MV, 1968, PROGNOSTIC FACTORS B, P65; PETREK JA, 1994, CANCER-AM CANCER SOC, V74, P528, DOI 10.1002/cncr.2820741342; Reichman B S, 1994, J Natl Cancer Inst Monogr, P125; RIBEIRO G, 1986, BRIT J SURG, V73, P607, DOI 10.1002/bjs.1800730805; RIBEIRO GG, 1977, BRIT MED J, V2, P1524, DOI 10.1136/bmj.2.6101.1524; SANKILA R, 1994, AM J OBSTET GYNECOL, V170, P818, DOI 10.1016/S0002-9378(94)70290-X; Semmens JB, 1998, AUST NZ J SURG, V68, P397, DOI 10.1111/j.1445-2197.1998.tb04786.x; Singh KL, 2005, HUM REPROD UPDATE, V11, P69, DOI 10.1093/humupd/dmh052; SUTTON R, 1990, CANCER, V65, P847, DOI 10.1002/1097-0142(19900215)65:4<847::AID-CNCR2820650402>3.0.CO;2-A; Velentgas P, 1999, CANCER, V85, P2424, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2424::AID-CNCR17>3.0.CO;2-4	23	165	175	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 27	2007	334	7586					194	196B		10.1136/bmj.39035.667176.55	http://dx.doi.org/10.1136/bmj.39035.667176.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133QN	17158581	Green Published			2023-01-03	WOS:000244027600035
J	Zachariah, R; Harries, AD; Manzi, M; Gomani, P; Teck, R; Phillips, M; Firmenich, P				Zachariah, Rony; Harries, Anthony David; Manzi, Marcel; Gomani, Patrick; Teck, Roger; Phillips, Mit; Firmenich, Peter			Acceptance of Anti-Retroviral Therapy among Patients Infected with HIV and Tuberculosis in Rural Malawi Is Low and Associated with Cost of Transport	PLOS ONE			English	Article								Background. A study was conducted among newly registered HIV-positive tuberculosis ( TB) patients systematically offered anti-retroviral treatment (ART) in a district hospital in rural Malawi in order to a) determine the acceptance of ART b) conduct a geographic mapping of those placed on ART and c) examine the association between "cost of transport'' and ART acceptance. Methodology/Principal Findings. A retrospective cross-sectional analysis was performed on routine program data for the period of February 2003 to July 2004. Standardized registers and patient cards were used to gather data. The place of residence was used to determine road distances to the Thyolo district hospital. Cost of transport from different parts of the district was based on the known cost for public transport to the road-stop closest to the patient's residence. Of 1,290 newly registered TB patients, 1,003(78%) underwent HIV-testing of whom 770 (77%) were HIV-positive. 742 of these individuals (pulmonary TB = 607; extra-pulmonary TB = 135) were considered eligible for ART of whom only 101(13.6%) accepted ART. Cost of transport to the hospital ART site was significantly associated with ART acceptance and there was a linear trend in association between cost and ART acceptance (X(2) for trend = 25.4, P<0.001). Individuals who had to pay 50 Malawi Kwacha (1 United States Dollar = 100 Malawi Kwacha, MW) or less for a one-way trip to the Thyolo hospital were four times more likely to accept ART than those who had to pay over 100 MW (Adjusted Odds ratio = 4.0, 95% confidence interval: 2.0-8.1, P<0.001). Conclusions/Significance. ART acceptance among TB patients in a rural district in Malawi is low and associated with cost of transport to the centralized hospital based ART site. Decentralizing the ART offer from the hospital to health centers that are closer to home communities would be an essential step towards reducing the overall cost and burden of travel.	[Zachariah, Rony; Manzi, Marcel] Brussels Operat Ctr, Med Dept Operat Res, Brussels, Belgium; [Harries, Anthony David] HIV Care & Support, Minist Hlth, Lilongwe, Malawi; [Gomani, Patrick] Thyolo Dist Hlth Serv, Minist Hlth & Populat, Thyolo, Malawi; [Teck, Roger] Medecins Sans Frontieres, Thyolo, Malawi; [Phillips, Mit] Medecins Sans Frontieres, Access Hlth, Brussels, Belgium; [Firmenich, Peter] Brussels Operat Ctr, Operat Dept, Luxembourg, Luxembourg	Doctors Without Borders	Zachariah, R (corresponding author), Brussels Operat Ctr, Med Dept Operat Res, Brussels, Belgium.	zachariah@internet.lu		zachariah, rony/0000-0002-2915-9328	Medecins sans Frontieres-Brussels; Family Health International, USA; Department for International Development (DFID); Norwegian Agency for Technical Cooperation (NORAD); Royal Dutch TB Association (KNCV); USAID; STOP-TB; WHO; CIFF	Medecins sans Frontieres-Brussels; Family Health International, USA; Department for International Development (DFID); Norwegian Agency for Technical Cooperation (NORAD); Royal Dutch TB Association (KNCV); USAID(United States Agency for International Development (USAID)); STOP-TB; WHO(World Health Organization); CIFF	The joint TB-HIV support program, including ART in Thyolo, is supported by Medecins sans Frontieres-Brussels. We are grateful to Family Health International, USA, the Department for International Development (DFID), the Norwegian Agency for Technical Cooperation (NORAD), the Royal Dutch TB Association (KNCV), USAID, STOP-TB, WHO, and CIFF for supporting TB and TB-HIV control country-wide in Malawi.	Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Floyd K, 2003, INT J TUBERC LUNG D, V7, pS29; Harries AD, 2004, T ROY SOC TROP MED H, V98, P695, DOI 10.1016/j.trstmh.2004.05.002; Harries AD, 2000, SCOT MED J, V45, P47, DOI 10.1177/00369330000450S122; KAPULULA PK, 2001, INT J TUBERC LUNG S1, V5, P167; Kwanjana JK, 2001, MALAWI MED J, V13, P7; MANN GH, 2005, 36 WORLD C LUNG HLTH; *MOHP, 2003, GUID US ANT THER MAL; *MOHP, 2003, MAL HLTH FAC SURV RE; *NAC, 2003, NAT EST HIV AIDS MAL; RAVIGLIONE MC, 1997, AIDS, V11, P115; Reid A, 2006, LANCET INFECT DIS, V6, P483, DOI 10.1016/S1473-3099(06)70549-7; SALANIPONI FM, 2003, INT J TUBERC LUNG S1, V7, P167; *UNAIDS WHO, 1997, WKLY EPIDEMIOL REC, V72, P81; Zachariah R, 2001, INT J TUBERC LUNG D, V5, P843; Zachariah R, 2006, T ROY SOC TROP MED H, V100, P167, DOI 10.1016/j.trstmh.2005.07.008; Zachariah R, 2005, INT J TUBERC LUNG D, V9, P238; Zachariah R, 2002, INT J TUBERC LUNG D, V6, P1046	18	88	88	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2006	1	2							e121	10.1371/journal.pone.0000121	http://dx.doi.org/10.1371/journal.pone.0000121			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DC	17205125	Green Accepted, Green Published, gold, Green Submitted			2023-01-03	WOS:000207443700015
J	Graff, MJL; Vernooij-Dassen, MJM; Thijssen, M; Dekker, J; Hoefnagels, WHL; Rikkert, MGMO				Graff, Maud J. L.; Vernooij-Dassen, Myrra J. M.; Thijssen, Marjolein; Dekker, Joost; Hoefnagels, Willibrord H. L.; Rikkert, Marcel G. M. Olde			Community based occupational therapy for patients with dementia and their care givers: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ALZHEIMERS-DISEASE; RATING-SCALE; CAREGIVERS; HOME; INTERVENTION; INDIVIDUALS; PROGRAM	Objective To determine the effectiveness of community based occupational therapy on daily functioning of patients with dementia and the sense of competence of their care givers. Design Single blind randomised controlled trial. Assessors were blinded for treatment allocation. Setting Memory clinic and day clinic of a geriatrics department and participants' homes. Participants 135 patients aged >= 65 with mild to moderate dementia living in the community and their primary care givers. Interventions 10 sessions of occupational therapy over five weeks, including cognitive and behavioural interventions, to train patients in the use of aids to compensate for cognitive decline and care givers in coping behaviours and supervision. Main outcome measures Patients' daily functioning assessed with the assessment of motor and process skills (AMPS) and interview of deterioration in daily activities in dementia (IDDD). Care giver burden assessed with the sense of competence questionnaire (SCQ). Participants were evaluated at baseline, six weeks, and three months. Results Scores improved significantly relative to baseline in patients and care givers in the intervention group compared with the controls (differences were 1.5 (95% confidence interval 1.3 to 1.7) for the process scale; - 11.7 (- 13.6 to - 9.7) for the performance scale; and 0 1.0; 9.2 to 12.8) for the competence scale). This improvement was still significant at three months. The number needed to treat to reach a clinically relevant improvement in motor and process skills score was 1.3 (1.2 to 1.4) at six weeks. Effect sizes were 2.5, 2.3, and 1.2, respectively, at six weeks and 2.7, 2.4, and 0.8, respectively, at 12 weeks. Conclusions Occupational therapy improved patients' daily functioning and reduced the burden on the care giver, despite the patients' limited learning ability. Effects were still present at 12 weeks, which justifies implementation of this intervention.	Radboud Univ Nijmegen Med Ctr, Res Grp Allied Hlth Care, Dept Allied Hlth Care Disciplines, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen Med Ctr, Ctr Qual Care Res, Alzheimer Ctr Nijmegen, NL-6525 JV Nijmegen, Netherlands; Vrije Univ Amsterdam Med Ctr, EMGO Inst, Dept Rehabil Med, NL-1007 MB Amsterdam, Netherlands; Radboud Univ Nijmegen Med Ctr, Dept Geriatr, Alzheimer Ctr Nijmegen, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Radboud University Nijmegen	Graff, MJL (corresponding author), Radboud Univ Nijmegen Med Ctr, Res Grp Allied Hlth Care, Dept Allied Hlth Care Disciplines, POB 9101, NL-6500 HB Nijmegen, Netherlands.	rn.graff@ergo.umcn.nl	Rikkert, Marcel Olde/D-9773-2012; Rikkert, M.G.M. Olde/H-8078-2014; Vernooij-Dassen, M.J.F.J./H-8107-2014; Graff, M.J.L./L-4333-2015	Rikkert, M.G.M. Olde/0000-0003-1397-1677; Dekker, Joost/0000-0003-2027-0027				APA, 1994, DIAGN STAT MAN MENT; Brink T. L., 1982, CLIN GERON, V1, P37, DOI DOI 10.1300/J018V01N01_06; Burgener SC, 1998, GERIATR NURS, V19, P121, DOI 10.1016/S0197-4572(98)90055-6; COEN J, 1998, J HLTH GAIN, V2, P5; CORCORAN MA, 1992, AM J OCCUP THER, V46, P801, DOI 10.5014/ajot.46.9.801; Fisher A. G., 2003, ASSESSMENT MOTOR PRO; FISHER AG, 2003, ASSESSMENT MOTOR POR; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fossey J, 2006, BMJ-BRIT MED J, V332, P756, DOI 10.1136/bmj.38782.575868.7C; Gitlin LN, 2005, J GERONTOL A-BIOL, V60, P368, DOI 10.1093/gerona/60.3.368; Gitlin LN, 2001, GERONTOLOGIST, V41, P4, DOI 10.1093/geront/41.1.4; Graff M.J.L., 2006, DEMENTIA, V5, P503, DOI [10.1177/1471301206069918, DOI 10.1177/1471301206069918]; Graff MJ, 2000, NED TIJDSCHR ERGOTHE, V28, P169; Graff MJL, 2003, OTJR-OCCUP PART HEAL, V23, P155, DOI 10.1177/153944920302300403; HASSELKUS BR, 1990, OCCUPATIONAL THERAPY, V2, P9; Jepson C, 1999, Image J Nurs Sch, V31, P115, DOI 10.1111/j.1547-5069.1999.tb00444.x; JEPSON G, 1999, IMAGE J NURS SCH, V31, P115; LAW M, 1996, CANADIAN OCCUPATIONA; Luijpen MW, 2003, REV NEUROSCIENCE, V14, P343; Miller G. S., 1906, P BIOL SOC WASH, V19, P41; MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; REISBERG B, 1983, PSYCHOPHARMACOL BULL, V19, P702; RIOPELSMITH R, 1998, OCCUPATIONAL PERFORM, V2; Rockwood K., 2006, TRIAL DESIGNS OUTCOM; Siemonsma PC, 1997, CLIN REHABIL, V11, P273, DOI 10.1177/026921559701100402; Steultjens EMJ, 2004, AGE AGEING, V33, P453, DOI 10.1093/ageing/afh174; TERI L, 1992, PSYCHOL AGING, V7, P622, DOI 10.1037/0882-7974.7.4.622; Teunisse S., 1997, CLINIMETRICS DEMENTI; VernooijDassen MJFJ, 1996, SOC SCI MED, V43, P41, DOI 10.1016/0277-9536(95)00332-0; Vernooj-Dassen M, 2000, INT J AGING HUM DEV, V51, P259, DOI 10.2190/P8L1-N8QD-VTJ4-EURT; Walker MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5; Wimo A, 2006, DEMENT GERIATR COGN, V21, P175, DOI 10.1159/000090733; WITLACH CJ, 1991, GERONTOLOGISTS, V31, P9	34	302	305	1	50	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 9	2006	333	7580					1196	1199		10.1136/bmj.39001.688843.BE	http://dx.doi.org/10.1136/bmj.39001.688843.BE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	119JW	17114212	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000243009600015
J	Lewis, BH; Legato, M; Fisch, H				Lewis, Benjamin H.; Legato, Marianne; Fisch, Harry			Medical implications of the male biological clock	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TESTOSTERONE-REPLACEMENT THERAPY; ADVANCING PATERNAL AGE; ERECTILE DYSFUNCTION; SEMEN QUALITY; CONCEPTION; SYMPTOMS; RISK; MEN		Columbia Univ, Med Ctr, New York Presbyterian Hosp, Male Reprod Ctr,Dept Urol, New York, NY 10028 USA; Columbia Univ, Med Ctr, New York Presbyterian Hosp, Dept Med, New York, NY 10028 USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital	Fisch, H (corresponding author), Columbia Univ, Med Ctr, New York Presbyterian Hosp, Male Reprod Ctr,Dept Urol, 944 Park Ave, New York, NY 10028 USA.	hf4@columbia.edu						[Anonymous], 1995, ANN INTERN MED, V122, P561, DOI 10.7326/0003-4819-122-8-199504150-00001; Araujo AB, 1998, PSYCHOSOM MED, V60, P458, DOI 10.1097/00006842-199807000-00011; Bhasin S, 2006, J CLIN ENDOCR METAB, V91, P1995, DOI 10.1210/jc.2005-2847; CARNEY RM, 1988, PSYCHOSOM MED, V50, P627, DOI 10.1097/00006842-198811000-00009; DaSilva FC, 1997, EUR UROL, V31, P272; de La Rochebrochard E, 2002, HUM REPROD, V17, P1649, DOI 10.1093/humrep/17.6.1649; Eskenazi B, 2003, HUM REPROD, V18, P447, DOI 10.1093/humrep/deg107; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; Fisch H, 2003, J UROLOGY, V169, P2275, DOI 10.1097/01.ju.0000067958.36077.d8; Ford WCL, 2000, HUM REPROD, V15, P1703, DOI 10.1093/humrep/15.8.1703; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; Grundy SM, 2006, J AM COLL CARDIOL, V47, P1093, DOI 10.1016/j.jacc.2005.11.046; Kidd SA, 2001, FERTIL STERIL, V75, P237, DOI 10.1016/S0015-0282(00)01679-4; Malaspina D, 2001, ARCH GEN PSYCHIAT, V58, P361, DOI 10.1001/archpsyc.58.4.361; Marks LS, 2006, JAMA-J AM MED ASSOC, V296, P2351, DOI 10.1001/jama.296.19.2351; MATHIEU C, 1995, HUM REPROD, V10, P1090, DOI 10.1093/oxfordjournals.humrep.a136100; Reichenberg A, 2006, ARCH GEN PSYCHIAT, V63, P1026, DOI 10.1001/archpsyc.63.9.1026; Rhoden EL, 2004, NEW ENGL J MED, V350, P482, DOI 10.1056/NEJMra022251; Shores MM, 2006, ARCH INTERN MED, V166, P1660, DOI 10.1001/archinte.166.15.1660; Thompson IM, 2005, JAMA-J AM MED ASSOC, V294, P2996, DOI 10.1001/jama.294.23.2996; WEI M, 1994, AM J EPIDEMIOL, V140, P930, DOI 10.1093/oxfordjournals.aje.a117181	21	17	18	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2006	296	19					2369	2371		10.1001/jama.296.19.2369	http://dx.doi.org/10.1001/jama.296.19.2369			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104ZI	17105801				2023-01-03	WOS:000241998700026
J	Kelly, K; Brader, P; Rein, A; Shah, JP; Wong, RJ; Fong, YM; Gil, Z				Kelly, Kaitlyn; Brader, Peter; Rein, Avigail; Shah, Jatin P.; Wong, Richard J.; Fong, Yuman; Gil, Ziv			Attenuated multimutated herpes simplex virus-1 effectively treats prostate carcinomas with neural invasion while preserving nerve function	FASEB JOURNAL			English	Article						perineural invasion; gene therapy; prostate cancer; oncolytic therapy; erectile dysfunction	PERINEURAL INVASION; PROGNOSTIC-SIGNIFICANCE; RADICAL PROSTATECTOMY; BETA-GALACTOSIDASE; RADIATION-THERAPY; GENE DELIVERY; BRAIN-TUMORS; PHASE-I; CANCER; G207	Many cancers can cause disability and pain by invading nerves. In particular, prostate carcinoma has a high propensity for neural invasion (NI) at an early stage. Attempted surgical treatment of tumors with NI often leads to erectile dysfunction and deteriorated quality of life. Therefore, there is a need for novel modalities that will selectively target cancer cells while preserving neural function. Herpes simplex viruses (HSVs) have a natural trophism for peripheral nerves. We hypothesized that oncolytic therapy using HSV engineered to minimize neurotoxicity would be appropriate for this clinical setting. Attenuated HSV (NV1023) injected to sciatic nerves of nude mice had no toxic effect on nerve function (n = 30). NV1023 had significant oncolytic effect on prostate carcinoma cells (PC3, DU145, and LNCap) in vitro. An in vivo model of NI was established by implanting prostate carcinoma cells in the sciatic nerves of nude mice. Mice were treated with NV1023 or saline 7 days after establishment of tumors. Significant reduction in tumor size and inhibition of NI was found 6 -8 wk after treatment (P< 0.005). All animals treated with saline developed complete paralysis < 5 wk post-treatment, whereas most NV1023-treated animals had preserved nerve function > 12 wk after treatment (P< 0.0001). We conclude that oncolytic therapy effectively treats prostate carcinomas with NI in an in vivo murine model while preserving neural function. These findings may hold significant clinical implications for patients with prostate cancer or other neurotrophic tumors.	[Kelly, Kaitlyn; Rein, Avigail; Shah, Jatin P.; Wong, Richard J.; Fong, Yuman; Gil, Ziv] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA; [Brader, Peter] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Gil, Z (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10065 USA.	gilz@mskcc.org		Shah, Jatin/0000-0002-6444-6592				AMERICAN CANCER SOCIETY, 2007, CANC FACTS FIG; Bennett JJ, 2004, FASEB J, V18, P1001, DOI 10.1096/fj.02-1080fje; Blank SV, 2002, HUM GENE THER, V13, P627, DOI 10.1089/10430340252837224; Bonin SR, 1997, CANCER-AM CANCER SOC, V79, P75, DOI 10.1002/(SICI)1097-0142(19970101)79:1<75::AID-CNCR11>3.0.CO;2-3; Chahlavi Ali, 1999, Neoplasia (New York), V1, P162, DOI 10.1038/sj.neo.7900016; Chang S S, 1999, Curr Opin Urol, V9, P391, DOI 10.1097/00042307-199909000-00004; CHEN XW, 1995, J VIROL, V69, P7899, DOI 10.1128/JVI.69.12.7899-7908.1995; Cinatl J, 2003, CANCER RES, V63, P1508; Conlon KC, 1996, ANN SURG, V223, P273, DOI 10.1097/00000658-199603000-00007; Cooperberg MR, 2005, J CLIN ONCOL, V23, P8146, DOI 10.1200/JCO.2005.02.9751; DOBSON AT, 1990, NEURON, V5, P353, DOI 10.1016/0896-6273(90)90171-B; GELLER AI, 1988, SCIENCE, V241, P1667, DOI 10.1126/science.2843986; Hu D, 1997, ANESTHESIOLOGY, V86, P957, DOI 10.1097/00000542-199704000-00026; Jarnagin WR, 2006, CANCER GENE THER, V13, P326, DOI 10.1038/sj.cgt.7700890; Jeyaretna Deva S, 2007, Neurosurg Focus, V22, pE4; Kemeny N, 2006, HUM GENE THER, V17, P1214, DOI 10.1089/hum.2006.17.1214; Kim SH, 2000, CANCER GENE THER, V7, P1279, DOI 10.1038/sj.cgt.7700231; Kooby DA, 1999, FASEB J, V13, P1325, DOI 10.1096/fasebj.13.11.1325; Kravchick S, 2003, BJU INT, V92, P28, DOI 10.1046/j.1464-410X.2003.04276.x; Maguire-Zeiss KA, 2001, CURR OPIN MOL THER, V3, P482; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; Maru N, 2001, HUM PATHOL, V32, P828, DOI 10.1053/hupa.2001.26456; Mashour GA, 2001, EXP NEUROL, V169, P64, DOI 10.1006/exnr.2001.7641; MEIGNIER B, 1990, J INFECT DIS, V162, P313, DOI 10.1093/infdis/162.2.313; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Parker JN, 2000, P NATL ACAD SCI USA, V97, P2208, DOI 10.1073/pnas.040557897; Penson DF, 2003, J CLIN ONCOL, V21, P1147, DOI 10.1200/JCO.2003.07.139; Perez MCP, 2004, GENE THER, V11, P1023, DOI 10.1038/sj.gt.3302258; Quinn DI, 2003, CANCER-AM CANCER SOC, V97, P1884, DOI 10.1002/cncr.11263; Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354; RAMAKRISHNAN R, 1994, J VIROL, V68, P1864, DOI 10.1128/JVI.68.3.1864-1873.1994; Rigor BM, 2000, J SURG ONCOL, V75, P280, DOI 10.1002/1096-9098(200012)75:4<280::AID-JSO13>3.0.CO;2-Q; Shen Y, 2006, CANCER GENE THER, V13, P975, DOI 10.1038/sj.cgt.7700946; SINGER PA, 1991, J CLIN ONCOL, V9, P328, DOI 10.1200/JCO.1991.9.2.328; TANAKA A, 1994, CANCER-AM CANCER SOC, V73, P550, DOI 10.1002/1097-0142(19940201)73:3<550::AID-CNCR2820730309>3.0.CO;2-0; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; Tobisu Kenichi, 2006, Int J Clin Oncol, V11, P351, DOI 10.1007/s10147-006-0614-1; Toyoizumi T, 1999, HUM GENE THER, V10, P3013, DOI 10.1089/10430349950016410; VANDERWAL JE, 1990, CANCER, V66, P2031, DOI 10.1002/1097-0142(19901101)66:9<2031::AID-CNCR2820660931>3.0.CO;2-7; Wong RJ, 2001, HUM GENE THER, V12, P253, DOI 10.1089/10430340150218396; Yu ZK, 2004, INT J CANCER, V112, P525, DOI 10.1002/ijc.20421	41	14	15	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1839	1848		10.1096/fj.07-097808	http://dx.doi.org/10.1096/fj.07-097808			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18234972				2023-01-03	WOS:000256352700024
J	Lai, LS; Xu, ZH; Zhou, JH; Lee, KD; Amidon, GL				Lai, Longsheng; Xu, Zhaohui; Zhou, Jiahai; Lee, Kyung-Dall; Amidon, Gordon L.			Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-VALYL ESTER; TRICORN PROTEASE; SERINE HYDROLASE; VALACICLOVIR; ACYCLOVIR; PHARMACOKINETICS; VALGANCICLOVIR; IDENTIFICATION; ENZYMES; ACETYLCHOLINESTERASE	Chemical modification to improve biopharmaceutical properties, especially oral absorption and bioavailability, is a common strategy employed by pharmaceutical chemists. The approach often employs a simple structural modification and utilizes ubiquitous endogenous esterases as activation enzymes, although such enzymes are often unidentified. This report describes the crystal structure and specificity of a novel activating enzyme for valacyclovir and valganciclovir. Our structural insights show that human valacyclovirase has a unique binding mode and specificity for amino acid esters. Biochemical data demonstrate that the enzyme hydrolyzes esters of alpha-amino acids exclusively and displays a broad specificity spectrum for the aminoacyl moiety similar to tricorn-interacting aminopeptidase F1. Crystal structures of the enzyme, two mechanistic mutants, and a complex with a product analogue, when combined with biochemical analysis, reveal the key determinants for substrate recognition; that is, a flexible and mostly hydrophobic acyl pocket, a localized negative electrostatic potential, a large open leaving group-accommodating groove, and a pivotal acidic residue, Asp-123, after the nucleophile Ser-122. This is the first time that a residue immediately after the nucleophile has been found to have its side chain directed into the substrate binding pocket and play an essential role in substrate discrimination in serine hydrolases. These results as well as a phylogenetic analysis establish that the enzyme functions as a specific alpha-amino acid ester hydrolase. Valacyclovirase is a valuable target for amino acid ester prodrug-based oral drug delivery enhancement strategies.	[Lai, Longsheng; Lee, Kyung-Dall; Amidon, Gordon L.] Univ Michigan, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA; [Lai, Longsheng; Lee, Kyung-Dall; Amidon, Gordon L.] Univ Michigan, Ctr Mol Drug Targeting, Ann Arbor, MI 48109 USA; [Xu, Zhaohui; Zhou, Jiahai] Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; [Xu, Zhaohui; Zhou, Jiahai] Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Amidon, GL (corresponding author), Univ Michigan, Dept Pharmaceut Sci, 428 Church St, Ann Arbor, MI 48109 USA.	glamidon@umich.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037188] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 37188] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Balimane PV, 1998, BIOCHEM BIOPH RES CO, V250, P246, DOI 10.1006/bbrc.1998.9298; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURNETTE TC, 1995, J BIOL CHEM, V270, P15827, DOI 10.1074/jbc.270.26.15827; CROOKS RJ, 1994, ANTIVIR CHEM CHEMOTH, V5, P31; Curran M, 2001, DRUGS, V61, P1145, DOI 10.2165/00003495-200161080-00013; DEMIRANDA P, 1983, J ANTIMICROB CHEMOTH, V12, P29, DOI 10.1093/jac/12.suppl_B.29; Ettmayer P, 2004, J MED CHEM, V47, P2393, DOI 10.1021/jm0303812; Goettig P, 2002, EMBO J, V21, P5343, DOI 10.1093/emboj/cdf552; Han HK, 1998, PHARMACEUT RES, V15, P1154, DOI 10.1023/A:1011919319810; Harding MM, 2006, ACTA CRYSTALLOGR D, V62, P678, DOI 10.1107/S0907444906014594; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; Hendrickson WA, 1997, METHOD ENZYMOL, V276, P494, DOI 10.1016/S0076-6879(97)76074-9; Hernaez MJ, 2000, J BACTERIOL, V182, P5448, DOI 10.1128/JB.182.19.5448-5453.2000; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Huhtinen K, 2002, J BIOL CHEM, V277, P3424, DOI 10.1074/jbc.M109040200; Imai T, 2006, DRUG METAB PHARMACOK, V21, P173, DOI 10.2133/dmpk.21.173; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jung D, 1999, J CLIN PHARMACOL, V39, P800, DOI 10.1177/00912709922008452; Kim I, 2003, J BIOL CHEM, V278, P25348, DOI 10.1074/jbc.M302055200; Kim I, 2004, MOL PHARMACEUT, V1, P117, DOI 10.1021/mp0499757; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li J, 1996, BIOCHEMISTRY-US, V35, P9967, DOI 10.1021/bi9605292; Liederer BM, 2006, J PHARM SCI-US, V95, P1177, DOI 10.1002/jps.20542; Nandhagopal N, 2001, J MOL BIOL, V309, P1139, DOI 10.1006/jmbi.2001.4737; Nardini M, 1999, CURR OPIN STRUC BIOL, V9, P732, DOI 10.1016/S0959-440X(99)00037-8; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pescovitz MD, 2000, ANTIMICROB AGENTS CH, V44, P2811, DOI 10.1128/AAC.44.10.2811-2815.2000; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Puente XS, 1998, GENOMICS, V51, P459, DOI 10.1006/geno.1998.5351; PUENTE XS, 1995, J BIOL CHEM, V270, P12926, DOI 10.1074/jbc.270.21.12926; RIPOLL DR, 1993, P NATL ACAD SCI USA, V90, P5128, DOI 10.1073/pnas.90.11.5128; Satoh T, 1998, ANNU REV PHARMACOL, V38, P257, DOI 10.1146/annurev.pharmtox.38.1.257; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; SOULLAWTON J, 1995, ANTIMICROB AGENTS CH, V39, P2759, DOI 10.1128/AAC.39.12.2759; Stella V, 2007, PRODRUGS CHALLENGES; Sugawara M, 2000, J PHARM SCI-US, V89, P781, DOI 10.1002/(SICI)1520-6017(200006)89:6<781::AID-JPS10>3.0.CO;2-7; Tamura N, 1998, CELL, V95, P637, DOI 10.1016/S0092-8674(00)81634-7; Tamura T, 1996, FEBS LETT, V398, P101, DOI 10.1016/S0014-5793(96)01163-5; TAN RC, 1993, BIOCHEMISTRY-US, V32, P401, DOI 10.1021/bi00053a003; WELLER S, 1993, CLIN PHARMACOL THER, V54, P595, DOI 10.1038/clpt.1993.196	43	50	54	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2008	283	14					9318	9327		10.1074/jbc.M709530200	http://dx.doi.org/10.1074/jbc.M709530200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280ZO	18256025	Green Published, hybrid			2023-01-03	WOS:000254465800062
J	Jack, A				Jack, Andrew			Bitter pills	BRITISH MEDICAL JOURNAL			English	Article									Financial Times, London, England		Jack, A (corresponding author), Financial Times, London, England.	Andrew.Jack@ft.com		Jack, Andrew/0000-0001-9679-2898				*AEG, BELG EXP; Atemnkeng MA, 2007, TROP MED INT HEALTH, V12, P68, DOI 10.1111/j.1365-3156.2006.01769.x; European Commission Tax And Customs Union, 2006, SUMM COMM CUST ACT C; JACK A, 2007, FINANCIAL TIMES 1122; JACK A, 2007, FINANCIAL TIMES 0514; Organisation for Economic Co-operation and Development, 2007, EC IMP COUNT PIR; *US FDA, FDA COUNT DRUG TASK; *WHO, 2007, IMPACT M; *WHO INT MED PROD, 2007, IMPACT TECHN SUBGR M; World Health Organization (WHO), 2006, COUNT MED	10	18	18	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	DEC 1	2007	335	7630					1120	1121		10.1136/bmj.39412.431655.AD	http://dx.doi.org/10.1136/bmj.39412.431655.AD			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	240OE	18048535	Green Published			2023-01-03	WOS:000251596100027
J	Chand, K; Califano, J				Chand, Kaillash; Califano, Joseph			Should drugs be decriminalised?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Columbia Univ, Natl Ctr Addict & Subst Abuse, New York, NY 10017 USA	Columbia University		Kailash.Chand@gp-P89609.nhs.uk; info@casacolumbia.org							0	5	5	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 10	2007	335	7627					966	967		10.1136/bmj.39360.489132.AD	http://dx.doi.org/10.1136/bmj.39360.489132.AD			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232AL	17991976	Green Published			2023-01-03	WOS:000250990400034
J	Hayes, DF; Thor, AD; Dressler, LG; Weaver, D; Edgerton, S; Cowan, D; Broadwater, G; Goldstein, LJ; Martino, S; Ingle, JN; Henderson, IC; Norton, L; Winer, EP; Hudis, CA; Ellis, MJ; Berry, DA				Hayes, Daniel F.; Thor, Ann D.; Dressler, Lynn G.; Weaver, Donald; Edgerton, Susan; Cowan, David; Broadwater, Gloria; Goldstein, Lori J.; Martino, Silvana; Ingle, James N.; Henderson, I. Craig; Norton, Larry; Winer, Eric P.; Hudis, Clifford A.; Ellis, Matthew J.; Berry, Donald A.		CALGB Investigators	HER2 and response to paclitaxel in node-positive breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADJUVANT CHEMOTHERAPY; C-ERBB-2 EXPRESSION; PREDICT RESPONSE; DOSE INTENSITY; TRASTUZUMAB; THERAPY; HER-2/NEU; AMPLIFICATION; DOXORUBICIN; RESISTANCE	Background The status of human epidermal growth factor receptor type 2 (HER2) in breast-cancer cells predicts clinical outcomes in women who receive adjuvant anthracycline-based chemotherapy. We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both. Methods We randomly selected 1500 women from 3121 women with node-positive breast cancer who had been randomly assigned to receive doxorubicin (60, 75, or 90 mg per square meter of body-surface area) plus cyclophosphamide (600 mg per square meter) for four cycles, followed by four cycles of paclitaxel (175 mg per square meter) or observation. Tissue blocks from 1322 of these 1500 women were available. Immunohistochemical analyses of these tissue specimens for HER2 with the CB11 monoclonal antibody against HER2 or with a polyclonal-antibody assay kit and fluorescence in situ hybridization for HER2 amplification were performed. Results No interaction was observed between HER2 positivity and doxorubicin doses above 60 mg per square meter. HER2 positivity was, however, associated with a significant benefit from paclitaxel. The interaction between HER2 positivity and the addition of paclitaxel to the treatment was associated with a hazard ratio for recurrence of 0.59 (P=0.01). Patients with a HER2-positive breast cancer benefited from paclitaxel, regardless of estrogen-receptor status, but paclitaxel did not benefit patients with HER2-negative, estrogen-receptor-positive cancers. Conclusions The expression or amplification, or both, of HER2 by a breast cancer is associated with a benefit from the addition of paclitaxel after adjuvant treatment with doxorubicin (<60 mg per square meter) plus cyclophosphamide in node-positive breast cancer, regardless of estrogen-receptor status. Patients with HER2-negative, estrogen-receptor-positive, node-positive breast cancer may gain little benefit from the administration of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide.	Univ Michigan, Canc Ctr 6312, Breast Oncol Program, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Colorado, Ctr Comprehens Canc, Aurora, CO USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Vermont, Ctr Canc, Fletcher Allen Hlth Care, Burlington, VT USA; Duke Univ, Ctr Stat, Canc & Leukemia Grp B, Durham, NC USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Angeles Clin & Res Inst, Santa Monica, CA USA; Mayo Clin, Rochester, MN USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA	University of Michigan System; University of Michigan; University of Colorado System; University of Colorado Anschutz Medical Campus; University of North Carolina; University of North Carolina Chapel Hill; University of Vermont; University of Vermont Medical Center; Duke University; Fox Chase Cancer Center; Angeles Clinic & Research Institute; Mayo Clinic; University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center; Harvard University; Dana-Farber Cancer Institute; Siteman Cancer Center; Washington University (WUSTL); University of Texas System; UTMD Anderson Cancer Center	Hayes, DF (corresponding author), Univ Michigan, Canc Ctr 6312, Breast Oncol Program, Ctr Comprehens Canc, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	hayesdf@umich.edu	Hayes, Daniel/ABE-1129-2020; Hudis, Clifford/AAW-9482-2021	Hudis, Clifford/0000-0001-7144-8791; Norton, Larry/0000-0003-3701-9250	NATIONAL CANCER INSTITUTE [U10CA031946, U10CA033601, R01CA092461] Funding Source: NIH RePORTER; NCI NIH HHS [CA33601, CA31946, CA092461] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Abuharbeid S, 2005, N-S ARCH PHARMACOL, V371, P141, DOI 10.1007/s00210-004-1016-4; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Berry DA, 2006, JAMA-J AM MED ASSOC, V295, P1658, DOI 10.1001/jama.295.14.1658; Berry DA, 2006, JAMA-J AM MED ASSOC, V295, P2356; Budman DR, 1998, J NATL CANCER I, V90, P1205, DOI 10.1093/jnci/90.16.1205; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; Di Leo A, 2004, BREAST CANCER RES TR, V86, P197, DOI 10.1023/B:BREA.0000036783.88387.47; Dressler LG, 2005, J CLIN ONCOL, V23, P4287, DOI 10.1200/JCO.2005.11.012; Formenti SC, 2002, INT J RADIAT ONCOL, V52, P397, DOI 10.1016/S0360-3016(01)02655-4; Gonzalez-Angulo AM, 2004, CANCER-AM CANCER SOC, V101, P258, DOI 10.1002/cncr.20348; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; Joensuu H, 2006, NEW ENGL J MED, V354, P809, DOI 10.1056/NEJMoa053028; Konecny GE, 2004, JNCI-J NATL CANCER I, V96, P1141, DOI 10.1093/jnci/djh198; LIPPMAN ME, 1978, NEW ENGL J MED, V298, P1223, DOI 10.1056/NEJM197806012982203; Mass Robert D, 2005, Clin Breast Cancer, V6, P240, DOI 10.3816/CBC.2005.n.026; McShane LM, 2005, J CLIN ONCOL, V23, P9067, DOI 10.1200/JCO.2004.01.0454; MUSS HB, 1994, NEW ENGL J MED, V331, P211; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Paik S, 2002, JNCI-J NATL CANCER I, V94, P852, DOI 10.1093/jnci/94.11.852; Pegram MD, 2000, SEMIN ONCOL, V27, P21; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Pritchard KI, 2006, NEW ENGL J MED, V354, P2103, DOI 10.1056/NEJMoa054504; Regan MM, 2005, BREAST, V14, P582, DOI 10.1016/j.breast.2005.08.021; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Schmidt M, 2003, J CANCER RES CLIN, V129, P295, DOI 10.1007/s00432-003-0430-1; Sezgin C, 2005, J CHEMOTHERAPY, V17, P96, DOI 10.1179/joc.2005.17.1.96; Sjostrom J, 2002, EUR J CANCER, V38, P535, DOI 10.1016/S0959-8049(01)00403-8; SLAMON D, 2005, BREAST CANC RES TREA, V94; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smith IE, 2006, BMJ-BRIT MED J, V332, P34, DOI 10.1136/bmj.332.7532.34; Tanabe K, 2003, INT J ONCOL, V22, P875; Thor AD, 1998, JNCI-J NATL CANCER I, V90, P1346, DOI 10.1093/jnci/90.18.1346; Tulbah AM, 2002, MED ONCOL, V19, P15; Ueno NT, 2000, CLIN CANCER RES, V6, P250; Ueno NT, 1997, ONCOGENE, V15, P953, DOI 10.1038/sj.onc.1201250; Van Poznak C, 2002, J CLIN ONCOL, V20, P2319, DOI 10.1200/JCO.2002.08.125; Witters LM, 2003, AM J CLIN ONCOL-CANC, V26, P50, DOI 10.1097/00000421-200302000-00011; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2; WOOD WC, 1994, NEW ENGL J MED, V331, P139; WOOD WC, 1994, NEW ENGL J MED, V330, P1253, DOI 10.1056/NEJM199405053301801; Yamauchi H, 2001, J CLIN ONCOL, V19, P2334, DOI 10.1200/JCO.2001.19.8.2334; Yu DH, 2001, SEMIN ONCOL, V28, P12	45	442	464	1	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 11	2007	357	15					1496	1506		10.1056/NEJMoa071167	http://dx.doi.org/10.1056/NEJMoa071167			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	218TE	17928597				2023-01-03	WOS:000250037000006
J	Su, LL; Chong, YS; Chan, YH; Chan, YS; Fok, D; Tun, KT; Ng, FSP; Rauff, M				Su, Lin-Lin; Chong, Yap-Seng; Chan, Yiong-Huak; Chan, Yah-Shih; Fok, Doris; Tun, Kay-Thwe; Ng, Faith S. P.; Rauff, Mary			Antenatal education and postnatal support strategies for improving rates of exclusive breast feeding: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LACTATION CONSULTANT INTERVENTION; HEALTH-CARE; INFANT; PROMOTION; MOTHERS; COUNSELORS; DURATION; ILLNESS	Objective To investigate whether antenatal breast feeding education alone or postnatal lactation support alone improves rates of exclusive breast feeding compared with routine hospital care. Design Randomised controlled trial. Setting A tertiary hospital in Singapore. Participants 450 women with uncomplicated pregnancies. Main outcome measures Primary outcomes were rates of exclusive breast feeding at discharge from hospital and two weeks, six weeks, three months, and six months after delivery. Secondary outcomes were rates of any breast feeding. Results Compared with women who received routine care, women in the postnatal support group were more likely to breastfeed exclusively at two weeks (relative risk 1.82, 95% confidence interval 1.14 to 2.90), six weeks (1.85, 1.11 to 3.09), three months (1.87, 1.03 to 3.41), and six months (2.12, 1.03 to 4.37) postnatally. Women receiving antenatal education were more likely to breast feed exclusively at six weeks (1.73, 1.04 to 2.90), three months (1.92, 1.07 to 3.48), and six months (2.16, 1.05 to 4.43) postnatally. The numbers needed to treat to achieve one woman exclusively breast feeding at six months were 11 (6 to 80) for postnatal support and 10 (6 to 60) for antenatal education. Women who received postnatal support were more likely to exclusively or predominantly breast feed two weeks after delivery compared with women who received antenatal education (1.53, 1.01 to 2.31). The rate of any breastfeeding six weeks after delivery was also higher in the postnatal support group compared with women who received routine care (1.16, 1.02 to 1.31). Conclusions Antenatal breast feeding education and postnatal lactation support, as single interventions based in hospital both significantly improve rates of exclusive breast feeding up to six months after delivery. Postnatal support was marginally more effective than antenatal education.	Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Obstet & Gynaecol, Singapore 119074, Singapore; Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117597, Singapore; Clin Trials & Epidemiol Res Unit, Singapore 1699039, Singapore; Natl Univ Singapore Hosp, Dept Obstet & Gynaecol, Singapore 119074, Singapore	National University of Singapore; National University of Singapore; National University of Singapore	Chong, YS (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Obstet & Gynaecol, Singapore 119074, Singapore.	obgcys@nus.edu.sg	CHAN, YAH SHIH/R-7423-2019	Chong, Yap Seng/0000-0002-7232-8473				[Anonymous], 2002, INFANT FEEDING 2000; Ball TM, 1999, PEDIATRICS, V103, P870; Bartington S, 2006, INT J EPIDEMIOL, V35, P1178, DOI 10.1093/ije/dyl155; Bhandari N, 2003, LANCET, V361, P1418, DOI 10.1016/S0140-6736(03)13134-0; Bonuck KA, 2005, PEDIATRICS, V116, P1413, DOI 10.1542/peds.2005-0435; Bonuck KA, 2006, ARCH PEDIAT ADOL MED, V160, P953, DOI 10.1001/archpedi.160.9.953; Cattaneo A, 2006, ACTA PAEDIATR, V95, P540, DOI 10.1080/08035250500447936; Coutinho SB, 2005, LANCET, V366, P1094, DOI 10.1016/S0140-6736(05)67421-1; DANNER S, 1998, NURSING YOUR BABY 1; Dyson L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001688.pub2; Dyson L., 2006, PROMOTION BREASTFEED, P242; Fok D, 1998, Breastfeed Rev, V6, P5; Foo LL, 2005, HEALTH PROMOT INT, V20, P229, DOI 10.1093/heapro/dai002; Graffy J, 2004, BRIT MED J, V328, P26, DOI 10.1136/bmj.328.7430.26; Haider R, 2000, LANCET, V356, P1643, DOI 10.1016/S0140-6736(00)03159-7; HAMLYN B, 2002, INFANT FEEDIGN 2000; Heinig MJ, 2001, PEDIATR CLIN N AM, V48, P105, DOI 10.1016/S0031-3955(05)70288-1; Hoddinott P, 1999, BRIT MED J, V318, P30, DOI 10.1136/bmj.318.7175.30; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; LEE J, 1994, INT J EPIDEMIOL, V23, P201, DOI 10.1093/ije/23.1.201; Mattar CN, 2007, OBSTET GYNECOL, V109, P73, DOI 10.1097/01.AOG.0000249613.15466.26; Memmott MM, 2006, MATERN CHILD NUTR, V2, P40, DOI 10.1111/j.1740-8709.2006.00040.x; Morrow AL, 1999, LANCET, V353, P1226, DOI 10.1016/S0140-6736(98)08037-4; *NAT U HOSP, 2002, BREASTF NAT IS BEST; *NICE, 2006, 37 NICE; Oddy WH, 2003, ARCH DIS CHILD, V88, P224, DOI 10.1136/adc.88.3.224; Radford A, 1998, BRIT MED J, V317, P1385, DOI 10.1136/bmj.317.7169.1385; Raisler J, 1999, AM J PUBLIC HEALTH, V89, P25, DOI 10.2105/AJPH.89.1.25; Section on Breastfeeding, 2012, Pediatrics, V129, pe827, DOI 10.1542/peds.2011-3552; Sikorski J, 2002, COCHRANE DB SYST REV, pCD001141; WEIMER J, 2001, 13120 USDA EC RES SE; WEIMER J, 2001, 13 USDA FOOD RUR EC, P1; World Health Organization, 2001, OPT DUR EXCL BREASTF	33	108	113	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 22	2007	335	7620					596	599		10.1136/bmj.39279.656343.55	http://dx.doi.org/10.1136/bmj.39279.656343.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215TR	17670909	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000249832400033
J	Slotman, B; Faivre-Finn, C; Kramer, G; Rankin, E; Snee, M; Hatton, M; Postmus, P; Collette, L; Musat, E; Senan, S				Slotman, Ben; Faivre-Finn, Corinne; Kramer, Gijs; Rankin, Elaine; Snee, Michael; Hatton, Matthew; Postmus, Pieter; Collette, Laurence; Musat, Elena; Senan, Suresh		EORTC Rad Oncology Grp; Lung Canc Grp	Prophylactic cranial irradiation in extensive small-cell lung cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WHOLE-BRAIN RADIOTHERAPY; PHASE-III; NEUROLOGIC DISORDERS; CONSECUTIVE PATIENTS; METASTASES; ETOPOSIDE; SURVEILLANCE; CHEMOTHERAPY; METAANALYSIS; TENIPOSIDE	Background: We conducted a randomized trial of prophylactic cranial irradiation in patients with extensive small-cell lung cancer who had had a response to chemotherapy. Methods: Patients between the ages of 18 and 75 years with extensive small-cell lung cancer were randomly assigned to undergo prophylactic cranial irradiation (irradiation group) or receive no further therapy (control group). The primary end point was the time to symptomatic brain metastases. Computed tomography or magnetic resonance imaging of the brain was performed when any predefined key symptom suggestive of brain metastases was present. Results: The two groups (each with 143 patients) were well balanced regarding baseline characteristics. Patients in the irradiation group had a lower risk of symptomatic brain metastases (hazard ratio, 0.27; 95% confidence interval [CI], 0.16 to 0.44; P < 0.001). The cumulative risk of brain metastases within 1 year was 14.6% in the irradiation group (95% CI, 8.3 to 20.9) and 40.4% in the control group (95% CI, 32.1 to 48.6). Irradiation was associated with an increase in median disease-free survival from 12.0 weeks to 14.7 weeks and in median overall survival from 5.4 months to 6.7 months after randomization. The 1-year survival rate was 27.1% (95% CI, 19.4 to 35.5) in the irradiation group and 13.3% (95% CI, 8.1 to 19.9) in the control group. Irradiation had side effects but did not have a clinically significant effect on global health status. Conclusions: Prophylactic cranial irradiation reduces the incidence of symptomatic brain metastases and prolongs disease-free and overall survival.	Vrije Univ Amsterdam, Med Ctr, Dept Radiat Oncol, NL-1081 HV Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Pulm Dis, NL-1081 HV Amsterdam, Netherlands; Arnhems Radiotherapeut Inst, Arnhem, Netherlands; Christie Hosp & Holt Radium Inst, Manchester M20 9BX, Lancs, England; Univ Dundee, Ninewells Hosp, Dundee, Scotland; Cookridge Hosp, Leeds LS16 6QB, W Yorkshire, England; Weston Pk Hosp, Sheffield, S Yorkshire, England; European Org Res Treatment Canc, Dept Stat, Brussels, Belgium; European Org Res Treatment Canc, Dept Med Res, Brussels, Belgium	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Christie NHS Foundation Trust; Christie Hospital; University of Dundee; Cookridge Hospital; Weston Park Hospital; European Organisation for Research & Treatment of Cancer; European Organisation for Research & Treatment of Cancer	Slotman, B (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Radiat Oncol, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.	bj.slotman@vumc.nl	Senan, Suresh/P-5790-2019	Senan, Suresh/0000-0003-3995-2204; Collette, Laurence/0000-0003-2518-7281; postmus, pieter/0000-0002-7774-2868; Faivre-Finn, Corinne/0000-0001-5617-9781; Slotman, Ben/0000-0002-9902-4592	NATIONAL CANCER INSTITUTE [U10CA011488] Funding Source: NIH RePORTER; NCI NIH HHS [5U10-CA11488-34, 5U10-CA11488-35, 5U10-CA11488-36, 5U10-CA11488-37, 5U10-CA11488-33, 5U10-CA11488-32, 5U10-CA11488-31, 5U10-CA11488-30, 5U10-CA11488-29] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arriagada R, 1995, EUR J CANCER, V31A, P83; ARRIAGADA R, 1995, JNCI-J NATL CANCER I, V87, P183, DOI 10.1093/jnci/87.3.183; Auperin A, 1999, NEW ENGL J MED, V341, P476, DOI 10.1056/NEJM199908123410703; Chute JP, 1999, J CLIN ONCOL, V17, P1794, DOI 10.1200/JCO.1999.17.6.1794; FELLETTI R, 1985, RADIOTHER ONCOL, V4, P335, DOI 10.1016/S0167-8140(85)80121-3; FREEDMAN LS, 1976, BIOMETRICS, V32, P691, DOI 10.2307/2529759; Glantz MJ, 1997, SEMIN ONCOL, V24, P477; Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Gregor A, 1997, EUR J CANCER, V33, P1752, DOI 10.1016/S0959-8049(97)00135-4; GROEN HJM, 1993, EUR J CANCER, V29A, P1696, DOI 10.1016/0959-8049(93)90107-Q; HARDY J, 1990, BRIT J CANCER, V62, P684, DOI 10.1038/bjc.1990.357; Kalbfleisch J.D., 2002, STAT ANAL FAILURE TI; Kotalik J, 2001, INT J RADIAT ONCOL, V50, P309, DOI 10.1016/S0360-3016(01)01448-1; KRISTENSEN CA, 1992, J CLIN ONCOL, V10, P1498, DOI 10.1200/JCO.1992.10.9.1498; Lee JJ, 2006, J CLIN ONCOL, V24, P3597, DOI 10.1200/JCO.2006.06.0632; Meert AP, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-5; NUGENT JL, 1979, CANCER, V44, P1885, DOI 10.1002/1097-0142(197911)44:5<1885::AID-CNCR2820440550>3.0.CO;2-F; PIGNON JP, 1992, NEW ENGL J MED, V327, P1618, DOI 10.1056/NEJM199212033272302; Postmus PE, 1998, RADIOTHER ONCOL, V46, P29, DOI 10.1016/S0167-8140(97)00149-7; POSTMUS PE, 1995, J CLIN ONCOL, V13, P660, DOI 10.1200/JCO.1995.13.3.660; POSTMUS PE, 1989, BRIT J CANCER, V59, P254, DOI 10.1038/bjc.1989.52; Postmus PE, 2000, J CLIN ONCOL, V18, P3400, DOI 10.1200/JCO.2000.18.19.3400; Schiller JH, 2001, J CLIN ONCOL, V19, P2114, DOI 10.1200/JCO.2001.19.8.2114; Seute T, 2006, J CLIN ONCOL, V24, P2079, DOI 10.1200/JCO.2005.03.2946; Seute T, 2004, CANCER-AM CANCER SOC, V100, P801, DOI 10.1002/cncr.20043; Sundstrom S, 2005, LUNG CANCER, V48, P251, DOI 10.1016/j.lungcan.2004.10.016; Sundstrom S, 2002, J CLIN ONCOL, V20, P4665, DOI 10.1200/JCO.2002.12.111; Suwinski R, 1998, INT J RADIAT ONCOL, V40, P797, DOI 10.1016/S0360-3016(97)00856-0; Thatcher N, 2005, ANN ONCOL, V16, P235, DOI 10.1093/annonc/mdi700; vanOosterhout AGM, 1996, CANCER, V77, P1434, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1434::AID-CNCR3>3.0.CO;2-C	31	749	791	0	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 16	2007	357	7					664	672		10.1056/NEJMoa071780	http://dx.doi.org/10.1056/NEJMoa071780			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200EF	17699816				2023-01-03	WOS:000248746000006
J	Thuy, TT; Shah, NS; Mai, HA; Do, TN; Duong, T; Truong, L; Dinh, NS; Bui, DD; Luu, TMC; Phung, TPM; Wells, CD; Laserson, KF; Varma, JK				Thuy, Trinh Thanh; Shah, N. Sarita; Mai Hoang Anh; Do Trong Nghia; Duong Thom; Truong Linh; Dinh Ngoc Sy; Bui Duc Duong; Luu Thi Minh Chau; Phung Thi Phuong Mai; Wells, Charles D.; Laserson, Kayla F.; Varma, Jay K.			HIV-Associated TB in An Giang Province, Vietnam, 2001-2004: Epidemiology and TB Treatment Outcomes	PLOS ONE			English	Article								Background. Mortality is high in HIV-infected TB patients, but few studies from Southeast Asia have documented the benefits of interventions, such as co-trimoxazole (CTX), in reducing mortality during TB treatment. To help guide policy in Vietnam, we studied the epidemiology of HIV-associated TB in one province and examined factors associated with outcomes, including the impact of CTX use. Methodology/Principal Findings. We retrospectively abstracted data for all HIV-infected persons diagnosed with TB from 2001-2004 in An Giang, a province in southern Vietnam in which TB patients receive HIV counseling and testing. We used standard WHO definitions to classify TB treatment outcomes. We conducted multivariate analysis to identify risk factors for the composite outcome of death, default, or treatment failure during TB treatment. From 2001-2004, 637 HIV-infected TB patients were diagnosed in An Giang. Of these, 501 (79%) were male, 321 (50%) were aged 25-34 years, and the most common self-reported HIV risk factor was sex with a commercial sex worker in 221 (35%). TB was classified as smear-positive in 531 (83%). During TB treatment, 167 (26%) patients died, 9 (1%) defaulted, and 6 (1%) failed treatment. Of 454 patients who took CTX, 116 (26%) had an unsuccessful outcome compared with 33 (70%) of 47 patients who did not take CTX (relative risk, 0.4; 95% confidence interval [CI], 0.3-0.5). Adjusting for male sex, rural residence, TB smear status and disease location, and the occurrence of adverse events during TB treatment in multivariate analysis, the benefit of CTX persisted (adjusted odds ratio for unsuccessful outcome 0.1; CI, 0.1-0.3). Conclusions/Significance. In An Giang, Vietnam, HIV-associated TB was associated with poor TB treatment outcomes. Outcomes were significantly better in those taking CTX. This finding suggests that Vietnam should consider applying WHO recommendations to prescribe CTX to all HIV-infected TB patients.	[Thuy, Trinh Thanh] US Ctr Dis Control & Prevent, Global AIDS Program, Hanoi, Vietnam; [Shah, N. Sarita; Wells, Charles D.; Laserson, Kayla F.; Varma, Jay K.] US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA; [Mai Hoang Anh; Duong Thom; Truong Linh] An Giang Prov Prevent Med Ctr, Long Xuyen City, Vietnam; [Do Trong Nghia; Dinh Ngoc Sy; Bui Duc Duong] Minist Hlth, Vietnam Natl TB Program, Natl Hosp TB & Lung Dis, Hanoi, Vietnam; [Luu Thi Minh Chau; Phung Thi Phuong Mai] Minist Hlth, LIFE GAP Off, Hanoi, Vietnam; [Varma, Jay K.] US Ctr Dis Control Collaborat, Thailand Minist Publ Hlth, Bangkok, Thailand	Centers for Disease Control & Prevention - USA; Ministry of Public Health - Thailand	Varma, JK (corresponding author), US Ctr Dis Control & Prevent, Global AIDS Program, Hanoi, Vietnam.	jvarma@cdc.gov			U.S. Agency for International Development; U.S. Centers for Disease Control and Prevention	U.S. Agency for International Development(United States Agency for International Development (USAID)); U.S. Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	U.S. Agency for International Development and U.S. Centers for Disease Control and Prevention. USAID was not involved in: study design, collection, analysis, interpretation of data; or the decision to submit for publication.	Apers L, 2004, INT J TUBERC LUNG D, V8, P945; Boeree MJ, 2005, TROP MED INT HEALTH, V10, P723, DOI 10.1111/j.1365-3156.2005.01433.x; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Dean GL, 2002, AIDS, V16, P75, DOI 10.1097/00002030-200201040-00010; Dheda K, 2004, J INFECT DIS, V190, P1670, DOI 10.1086/424676; Freudenberg N, 2006, AM J PUBLIC HEALTH, V96, P424, DOI 10.2105/AJPH.2005.063511; Grimwade K, 2005, AIDS, V19, P163, DOI 10.1097/00002030-200501280-00008; GRIMWADE K, 2004, COCHRANE LIB; Hargreaves NJ, 2001, INT J TUBERC LUNG D, V5, P847; *JOINT UN PROGR HI, 2006, REP GLOB AIDS EP 200; Mukadi YD, 2001, AIDS, V15, P143, DOI 10.1097/00002030-200101260-00002; MWAUNGULU FB, 2004, B WORLD HEALTH ORGAN, V82, P854; Quy HT, 2006, INT J TUBERC LUNG D, V10, P45; Tuan NA, 2007, B WORLD HEALTH ORGAN, V85, P35, DOI 10.2471/BLT.05.026153; *WHO, 2006, GLOB TUB CONTR SURV; *WHO, 2004, INT POL COLL TB HIV; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; World Health Organization, 2003, TREATM TUB GUID NAT, DOI DOI 10.1016/S0035-9203(99)90185-2	18	17	17	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2007	2	6							e507	10.1371/journal.pone.0000507	http://dx.doi.org/10.1371/journal.pone.0000507			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GC	17551587	gold, Green Published			2023-01-03	WOS:000207451500016
J	Rivera, SP; Wang, F; Saarikoski, ST; Taylor, RT; Chapman, B; Zhang, RX; Hankinson, O				Rivera, Steven P.; Wang, Feng; Saarikoski, Sirkku T.; Taylor, Robert T.; Chapman, Brett; Zhang, Ruixue; Hankinson, Oliver			A novel promoter element containing multiple overlapping xenobiotic and hypoxia response elements mediates induction of cytochrome P4502S1 by both dioxin and hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; PROTEIN-DNA INTERACTIONS; LIGANDED AH RECEPTOR; ADULT TISSUES; BINDING; MOUSE; EXPRESSION; GENE; ENHANCER; IDENTIFICATION	Cytochrome P4502S1 (CYP2S1) is expressed at high levels in epithelial tissues and is inducible by 2,3,7,8-tetrachlorodibenzop-dioxin (dioxin) via the aryl hydrocarbon receptor (AHR). Transcriptional initiation of mouse Cyp2s1 was found to occur at three regions, similar to 198, 102, and 22 nucleotides from the translational initiation codon. Approximately 400 nucleotides upstream of its translational initiation codon, mouse Cyp2s1 contains three overlapping xenobiotic-responsive element (XRE) sequences, which make a major contribution toward dioxin inducibility. Each XRE sequence in this trimeric XRE can bind the AHR/aryl hydrocarbon receptor nuclear translocator (ARNT) dimer in a dioxin-dependent fashion in vitro and can mediate dioxin-dependent transcription. Cyp2s1 is also markedly inducible by hypoxia. Induction is dependent on hypoxiai-nducible factor-1 (HIF-1) and is mediated in large part by three overlapping hypoxia response elements (HREs) embedded within the trimeric XRE segment. Although each HRE within this segment can bind HIF-1 alpha/ ARNT in vitro, the most 3' HRE contributes the most toward hypoxia inducibility. AHR/ARNT and HIF-1 alpha/ARNT dimers bind to the region containing the trimeric XRE segment of the endogenous Cyp2s1 gene in vivo in a dioxin-dependent fashion and hypoxia-dependent fashion, respectively. These observations identify a novel regulatory cassette that mediates changes in Cyp2s1 expression.	Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Johnsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Mol Toxicol Interdept Doctoral Program, Los Angeles, CA 90095 USA; Finnish Inst Occupat Hlth, Dept Ind Hyg & Toxicol, FI-00250 Helsinki, Finland	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Finnish Institute of Occupational Health	Hankinson, O (corresponding author), Univ Calif Los Angeles, Dept Pathol & Lab Med, 10833 Le Conte Ave,POB 9517332, Los Angeles, CA 90095 USA.	ohank@mednet.ucla.edu			NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015384] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA028868] Funding Source: Medline; NIEHS NIH HHS [R01 ES015384] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arpiainen S, 2005, MOL PHARMACOL, V67, P1325, DOI 10.1124/mol.104.008078; BACSI SG, 1995, MOL PHARMACOL, V47, P432; Chan WK, 1999, J BIOL CHEM, V274, P12115, DOI 10.1074/jbc.274.17.12115; Choudhary D, 2005, ARCH BIOCHEM BIOPHYS, V436, P50, DOI 10.1016/j.abb.2005.02.001; Choudhary D, 2003, ARCH BIOCHEM BIOPHYS, V414, P91, DOI 10.1016/S0003-9861(03)00174-7; Covello KL, 2004, CURR TOP DEV BIOL, V62, P37; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gassmann M, 1997, KIDNEY INT, V51, P567, DOI 10.1038/ki.1997.81; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; Gradin K, 1996, MOL CELL BIOL, V16, P5221; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pa.35.040195.001515; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; Karlgren Maria, 2005, Toxicol Appl Pharmacol, V207, P57, DOI 10.1016/j.taap.2004.12.022; Kinoshita K, 2004, NUCLEIC ACIDS RES, V32, P3169, DOI 10.1093/nar/gkh637; Kress S, 1998, EUR J BIOCHEM, V258, P803, DOI 10.1046/j.1432-1327.1998.2580803.x; Kumarakulasingham M, 2005, CLIN CANCER RES, V11, P3758, DOI 10.1158/1078-0432.CCR-04-1848; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; Lewis DFV, 2003, CURR MED CHEM, V10, P1955, DOI 10.2174/0929867033456855; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Nelson DR, 2004, PHARMACOGENETICS, V14, P1, DOI 10.1097/00008571-200401000-00001; OKEY AB, 1994, TOXICOL LETT, V70, P1, DOI 10.1016/0378-4274(94)90139-2; PROBST MR, 1993, MOL PHARMACOL, V44, P511; Rivera SP, 2002, MOL PHARMACOL, V61, P255, DOI 10.1124/mol.61.2.255; Rylander T, 2001, BIOCHEM BIOPH RES CO, V281, P529, DOI 10.1006/bbrc.2001.4390; Saarikoski Sirkku T, 2005, Toxicol Appl Pharmacol, V207, P62, DOI 10.1016/j.taap.2004.12.027; Saarikoski ST, 2005, J HISTOCHEM CYTOCHEM, V53, P549, DOI 10.1369/jhc.4C6576.2005; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHEN ES, 1992, J BIOL CHEM, V267, P6815; Smith G, 2003, LANCET, V361, P1336, DOI 10.1016/S0140-6736(03)13081-4; Stoilov I, 2001, TRENDS GENET, V17, P629, DOI 10.1016/S0168-9525(01)02444-1; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; WENGER RH, 2005, SCI STKE 2005; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019	35	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10881	10893		10.1074/jbc.M609617200	http://dx.doi.org/10.1074/jbc.M609617200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17277313	hybrid			2023-01-03	WOS:000245941500007
J	Falagas, ME; Fragoulis, KN; Karydis, I				Falagas, Matthew E.; Fragoulis, Konstantinos N.; Karydis, Ioannis			A Comparative Study on the Cost of New Antibiotics and Drugs of Other Therapeutic Categories	PLOS ONE			English	Article								Background. Drug treatment is becoming more expensive due to the increased cost for the introduction of new drugs, and there seems to be an uneven distribution of medication cost for different therapeutic categories. We hypothesized that the cost of new antimicrobial agents may differ from that of other therapeutic categories and this may play a role in the stagnation of development of new antibiotics. Methodology/Principal Findings. We performed a pharmaco-economical comparative analysis of the drug cost of treatment for new agents introduced in the United States drug market in various therapeutic categories. We calculated the drug cost (in US dollars) of a ten-day treatment of all new drugs approved by the FDA during the period between January 1997 and July 2003, according to the 2004 Red Book Pharmacy's Fundamental Reference. New antineoplastic agents were found to be the most expensive drugs in comparison to all other therapeutic categories, with a median ten-day drug-treatment cost of US$848 compared to the median ten-day drug-treatment costs of all other categories ranging from US$29 to US$301. On the other hand, new antimicrobial drugs were found to be much less expensive, with a median ten-day drug-treatment cost of US$137 and $US85 for all anti-microbial agents and for anti-microbial agents excluding anti-HIV medications, respectively. Conclusions/Significance. The drug-treatment cost of new medications varies considerably by different therapeutic categories. This fact may influence industry decisions regarding the development of new drugs and may play a role in the shortage of new antimicrobial agents in the fight against the serious problem of antimicrobial resistance.	[Falagas, Matthew E.; Fragoulis, Konstantinos N.; Karydis, Ioannis] Alfa Inst Biomed Sci, Athens, Greece; [Falagas, Matthew E.; Fragoulis, Konstantinos N.] Henry Dunant Hosp, Dept Med, Athens, Greece; [Falagas, Matthew E.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA	Alfa Institute Of Biomedical Sciences; Henry Dunant Hospital; Tufts University	Falagas, ME (corresponding author), Alfa Inst Biomed Sci, Athens, Greece.	matthew.falagas@tufts.edu						DIMASI JA, 1995, PHARMACOECONOMICS, V7, P152, DOI 10.2165/00019053-199507020-00007; DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; DiMasi JA, 2001, PHARMACOECONOMICS, V19, P753, DOI 10.2165/00019053-200119070-00004; Emanuel EJ, 2003, J CLIN ONCOL, V21, P4145, DOI 10.1200/JCO.2003.08.156; Falagas ME, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-99; Falagas ME, 2006, CLIN INFECT DIS, V43, P630, DOI 10.1086/506443; Kelloff GJ, 2005, EUR J CANCER, V41, P491, DOI 10.1016/j.ejca.2004.12.006; Letizia C, 1995, Qual Assur, V4, P68; Levy C, 2003, B CANCER, V90, P976; Mehl B, 2001, AM J HEALTH-SYST PH, V58, P125, DOI 10.1093/ajhp/58.2.125; Shah PM, 2005, CLIN MICROBIOL INFEC, V11, P36, DOI 10.1111/j.1469-0691.2005.01141.x; Spellberg B, 2004, CLIN INFECT DIS, V38, P1279, DOI 10.1086/420937; TABLOT GH, 2006, CLIN INFECT DIS, V42, P657; 2004, RED BOOK PHARM FUNDA	14	26	26	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2006	1	1							e11	10.1371/journal.pone.0000011	http://dx.doi.org/10.1371/journal.pone.0000011			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DB	17183637	gold, Green Published, Green Submitted			2023-01-03	WOS:000207443600011
J	Buszewicz, M; Rait, G; Griffin, M; Nazareth, I; Patel, A; Atkinson, A; Barlow, J; Haines, A				Buszewicz, Marta; Rait, Greta; Griffin, Mark; Nazareth, Irwin; Patel, Anita; Atkinson, Angela; Barlow, Julie; Haines, Andy			Self management of arthritis in primary care: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OLDER-ADULTS; RELIABILITY; VALIDITY; OUTCOMES; PEOPLE; SF-36	Objective To evaluate clinical effectivcness of a self management programme for arthritis in patients in primary care with osteoarthritis. Design Randomised controlled trial. Setting 74 general practices in the United Kingdom. Participants 812 patients aged 50 and over with osteoarthritis of hips or knees (or both) and pain or disability (or both). Intervention Participants were randomised to six sessions of self management of arthritis and an education booklet (intervention group) or the education booklet alone (control group). Main outcome measures Primary outcome was quality of life, as assessed by the short form health survey (SF-36). Several other physical mid psychosocial secondary outcomes were assessed. Data were collected at baseline, four months, and 12 months. Results Response rates were 80% and 76% at four and 12 months. The two groups showed significant differences at 12 months on die anxiety subscore of the hospital anxiety and depression scale (mean difference - 0.62, 95% confidence interval - 1.08 to. - 0.16). arthritis self efficacy scale for pain (0.98, 0.07 to 1.89), and self efficacy, for other aspects of management (1.58, 0.25 to 2.90). Results were similar for intention to treat and per protocol analyses. No significant difference was seen in number of visits to the general practitioner at 12 months. Conclusions The self management of arthritis programme reduced anxiety and improved participants' perceived self efficacy to manage symptoms, but it had no significant effect on pain, physical functioning, or contact with primary care.	UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London N19 5LW, England; Kings Coll London, Inst Psychiat, Ctr Econ & Mental Hlth, London SE5 8AT, England; Royal Victoria Infirm, Clin Res Facil, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Coventry Univ, Interdisciplinary Res Ctr Hlth, Coventry CV1 5FB, W Midlands, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of London; University College London; UCL Medical School; University of London; King's College London; Newcastle University - UK; Coventry University; University of London; London School of Hygiene & Tropical Medicine	Buszewicz, M (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London N19 5LW, England.	m.buszewicz@pcps.ucl.ac.uk	Patel, Anita/F-9832-2010; Rait, Greta/C-5577-2009; Griffin, Mark/C-1827-2008	Patel, Anita/0000-0003-0769-1732; Rait, Greta/0000-0002-7216-7294; Nazareth, Irwin/0000-0003-2146-9628; Haines, Andy/0000-0002-8053-4605	Medical Research Council [MC_U122797165] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		*ARC, FACTF ARTHR GLANC; Barlow J, 2002, PATIENT EDUC COUNS, V48, P177, DOI 10.1016/S0738-3991(02)00032-0; Barlow JH, 1998, BRIT J RHEUMATOL, V37, P1315; Barlow JH, 1997, BRIT J HEALTH PSYCH, V2, P175, DOI 10.1111/j.2044-8287.1997.tb00533.x; Barlow JH, 1997, PSYCHOL HEALTH MED, V2, P221, DOI DOI 10.1080/13548509708400580; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; DONALDSON L, 2005, COMMUNICATION   0216; JENKINSON C, 1994, QUAL LIFE RES, V3, P7, DOI 10.1007/BF00647843; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; Khaltaev N, 2003, ARTHRITIS RES THE S3, V5, P174; Lin EHB, 2003, JAMA-J AM MED ASSOC, V290, P2428, DOI 10.1001/jama.290.18.2428; Little R. J., 2019, STAT ANAL MISSING DA, V793; LORIG K, 1989, ARTHRITIS RHEUM, V32, P37, DOI 10.1002/anr.1780320107; LORIG K, 1993, HEALTH EDUC QUART, V20, P17, DOI 10.1177/109019819302000104; LORIG K, 2000, ARTHRITIS HELPBOOK T; LORIG KR, 1993, ARTHRITIS RHEUM, V36, P439, DOI 10.1002/art.1780360403; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; SOLOMON D, 2000, J RHEUMATOL, V29, P362; Sun Y, 1997, CLIN RHEUMATOL, V16, P185, DOI 10.1007/BF02247849; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; Warsi A, 2004, ARCH INTERN MED, V164, P1641, DOI 10.1001/archinte.164.15.1641; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	22	136	138	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 28	2006	333	7574					879	882A		10.1136/bmj.38965.375718.80	http://dx.doi.org/10.1136/bmj.38965.375718.80			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101WT	17040926	Bronze, Green Submitted, Green Published, Green Accepted			2023-01-03	WOS:000241772600013
J	Ringel, SP				Ringel, Steven P.			Lessons from the Santa Fe Trail	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												steven.ringel@uchsc.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 5	2008	299	9					998	999		10.1001/jama.299.9.998	http://dx.doi.org/10.1001/jama.299.9.998			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	269JH	18319403				2023-01-03	WOS:000253644800001
J	Philips, M; Zachariah, R; Venis, S				Philips, Mit; Zachariah, Rony; Venis, Sarah			Task shifting for antiretroviral treatment delivery in sub-Saharan Africa: not a panacea	LANCET			English	Editorial Material							HEALTH-WORKERS; DISTRICT		[Philips, Mit] Med Sans Frontieres, Brussels Operat Ctr, Anal & Advocacy Unit, B-1090 Brussels, Belgium; [Zachariah, Rony] Med Sans Frontieres, Brussels Operat Ctr, Med Dept Operat Res, B-1090 Brussels, Belgium; [Venis, Sarah] Med Sans Frontieres, London, England	Doctors Without Borders; Doctors Without Borders; Doctors Without Borders	Philips, M (corresponding author), Med Sans Frontieres, Brussels Operat Ctr, Anal & Advocacy Unit, 94 Dupre St, B-1090 Brussels, Belgium.	mit.philips@brussels.msf.org		zachariah, rony/0000-0002-2915-9328				Bedelu M, 2007, J INFECT DIS, V196, pS464, DOI 10.1086/521114; BERMAN PA, 1987, SOC SCI MED, V25, P443, DOI 10.1016/0277-9536(87)90168-7; BLUESTONE J, 2005, TASK SHIFTING STRATE, P72; Buchan J, 2002, B WORLD HEALTH ORGAN, V80, P575; BUCHAN J, 2000, HUM RES HLTH DEV J, V4, P111; Dambisya YM, 2007, REV NONFINANCIAL INC; Dovlo Delanyo, 2004, Hum Resour Health, V2, P7, DOI 10.1186/1478-4491-2-7; Gimbel-Sherr Sarah O, 2007, Hum Resour Health, V5, P7, DOI 10.1186/1478-4491-5-7; Haines A, 2007, LANCET, V369, P2121, DOI 10.1016/S0140-6736(07)60325-0; *HRH WORK GROUP HI, 2005, WORK TOG TACKL CRIS, P72; KOBER K, 2005, EXPERT PATIENTS AIDS, P72; Lewin SA, 2005, COCHRANE DB SYST REV, V1, P1, DOI DOI 10.1002/14651858.CD004015.PUB2; Medecins sans Frontieres, 2007, HELP WANT CONFR HLTH; Miles K, 2007, B WORLD HEALTH ORGAN, V85, P555, DOI 10.2471/BLT.06.033076; Mullan F, 2007, LANCET, V370, P2158, DOI 10.1016/S0140-6736(07)60785-5; Ooms G, 2007, PLOS MED, V4, P605, DOI 10.1371/journal.pmed.0040128; Rowe SY, 2007, T ROY SOC TROP MED H, V101, P188, DOI 10.1016/j.trstmh.2006.02.023; Serneels P, 2007, HEALTH POLICY PLANN, V22, P128, DOI 10.1093/heapol/czm005; Sibbald Bonnie, 2004, J Health Serv Res Policy, V9 Suppl 1, P28, DOI 10.1258/135581904322724112; Van Damme W, 2006, AIDS, V20, P653, DOI 10.1097/01.aids.0000216364.44409.b1; WALT G, 1992, COMMUNITY HLTH WORKE; *WEM FDN, 2005, BUDG CEIL HLTH KEN C, P72; WHO, 2006, WORK TOG HLTH WORLD; World Health Organization, TASK SHIFT RAT RED T; Zachariah R, 2007, T ROY SOC TROP MED H, V101, P79, DOI 10.1016/j.trstmh.2006.05.010	25	105	105	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 23	2008	371	9613					682	684		10.1016/S0140-6736(08)60307-4	http://dx.doi.org/10.1016/S0140-6736(08)60307-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266LL	18295026				2023-01-03	WOS:000253436700033
J	MacLean, C; Newberry, S; Maglione, M; McMahon, M; Ranganath, V; Suttorp, M; Mojica, W; Timmer, M; Alexander, A; McNamara, M; Desai, SB; Zhou, A; Chen, S; Carter, J; Tringale, C; Valentine, D; Johnsen, B; Grossman, J				MacLean, Catherine; Newberry, Sydne; Maglione, Margaret; McMahon, Maureen; Ranganath, Veena; Suttorp, Marika; Mojica, Walter; Timmer, Martha; Alexander, Alicia; McNamara, Melissa; Desai, Sheetal B.; Zhou, Annie; Chen, Susan; Carter, Jason; Tringale, Carlo; Valentine, Di; Johnsen, Breanne; Grossman, Jennifer			Systematic review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis	ANNALS OF INTERNAL MEDICINE			English	Review							CYCLICAL ETIDRONATE THERAPY; RANDOMIZED CONTROLLED-TRIAL; EARLY POSTMENOPAUSAL WOMEN; CORTICOSTEROID-INDUCED OSTEOPOROSIS; HORMONE REPLACEMENT THERAPY; ESTROGEN PLUS PROGESTIN; ONCE-WEEKLY ALENDRONATE; VITAMIN-D SUPPLEMENTATION; PRIMARY BILIARY-CIRRHOSIS; PLACEBO-CONTROLLED TRIAL	Background: Although several agents are available to treat osteoporosis, the relative efficacy and toxicity of these agents when used to prevent fractures has not been well described. Purpose: To compare the benefits in fracture reduction and the harms from adverse events of various therapies for osteoporosis. Data Sources: MEDLINE (1966 to November 2007) and other selected databases were searched for English-language studies. Study Selection: For the efficacy analysis, investigators selected studies that reported the rate of or risk for fractures. For the adverse event analysis, they selected studies that reported the relationship between an agent and cardiovascular, thromboembolic, or upper gastrointestinal events; malignant conditions; and osteonecrosis. Data Extraction: Using a standardized protocol, investigators abstracted data on fractures and adverse events, agents and comparators, study design, and variables of methodological quality. Data Synthesis: Good evidence suggests that alendronate, etidronate, ibandronate, risedronate, zoledronic acid, estrogen, parathyroid hormone (1-34), and raloxifene prevent vertebral fractures more than placebo; the evidence for calcitonin was fair. Good evidence suggests that alendronate, risedronate, and estrogen prevent hip fractures more than placebo; the evidence for zoledronic acid was fair. The effects of vitamin D varied with dose, analogue, and study population for both vertebral and hip fractures. Raloxifene, estrogen, and estrogen-progestin increased the risk for thromboembolic events, and etidronate increased the risk for esophageal ulcerations and gastrointestinal perforations, ulcerations, and bleeding. Limitation: Few studies have directly compared different agents or classes of agents used to treat osteoporosis. Conclusion: Although good evidence suggests that many agents are effective in preventing osteoporotic fractures, the data are insufficient to determine the relative efficacy or safety of these agents.	[Maglione, Margaret] RAND Corp, MPP, So California Evidence Based Practice Ctr, Santa Monica, CA 90401 USA; Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA; Univ Calif Los Angeles, Greater Los Angeles Vet Adm Healthcare Syst, Los Angeles, CA USA	RAND Corporation; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Maglione, M (corresponding author), RAND Corp, MPP, So California Evidence Based Practice Ctr, 1776 Main St, Santa Monica, CA 90401 USA.	maglione@rand.org			PHS HHS [290-02-003] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603; Adachi JD, 2001, ARTHRITIS RHEUM, V44, P202, DOI 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W; Adami S, 2000, J ENDOCRINOL INVEST, V23, P310, DOI 10.1007/BF03343728; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Aris RM, 2000, AM J RESP CRIT CARE, V162, P941, DOI 10.1164/ajrccm.162.3.2002051; AVENELL A, 2005, COCHRANE DB SYST REV; Bischoff-Ferrari HA, 2004, JAMA-J AM MED ASSOC, V291, P1999, DOI 10.1001/jama.291.16.1999; Bischoff-Ferrari HA, 2005, JAMA-J AM MED ASSOC, V293, P2257, DOI 10.1001/jama.293.18.2257; Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312; Blair MM, 2000, J FAM PRACTICE, V49, P839; Body JJ, 2002, J CLIN ENDOCR METAB, V87, P4528, DOI 10.1210/jc.2002-020334; Bone HG, 2000, J CLIN ENDOCR METAB, V85, P720, DOI 10.1210/jc.85.2.720; Bonnick S, 2006, J CLIN ENDOCR METAB, V91, P2631, DOI 10.1210/jc.2005-2602; Boonen S, 2005, OSTEOPOROSIS INT, V16, P1291, DOI 10.1007/s00198-005-1945-x; Boutsen Y, 1997, CALCIFIED TISSUE INT, V61, P266, DOI 10.1007/s002239900334; Bradburn MJ, 2007, STAT MED, V26, P53, DOI 10.1002/sim.2528; Brumsen C, 2002, J BONE MINER RES, V17, P1057, DOI 10.1359/jbmr.2002.17.6.1057; Campbell IA, 2004, THORAX, V59, P761, DOI 10.1136/thx.2003.013839; Cauley JA, 2003, JAMA-J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729; Cherry N, 2002, LANCET, V360, P2001; Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325; CHRISCHILLES EA, 1991, ARCH INTERN MED, V151, P2026, DOI 10.1001/archinte.151.10.2026; Coco M, 2003, J AM SOC NEPHROL, V14, P2669, DOI 10.1097/01.ASN.0000087092.53894.80; Cohen S, 1999, ARTHRITIS RHEUM, V42, P2309, DOI 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K; Cortet B, 1999, REV RHUM, V66, P214; Cranney A, 2000, Cochrane Database Syst Rev, pCD001983; Cranney A, 2002, ENDOCR REV, V23, P508, DOI 10.1210/er.2001-2002; Cranney A, 2002, ENDOCR REV, V23, P517, DOI 10.1210/er.2001-3002; Cranney A, 2002, ENDOCR REV, V23, P540, DOI 10.1210/er.2001-6002; Cranney A, 2001, COCHRANE DB SYST REV; Cummings SR, 2007, NEW ENGL J MED, V356, P1895, DOI 10.1056/NEJMc076132; Draper MW, 1996, J BONE MINER RES, V11, P835; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fukunaga M, 2002, OSTEOPOROSIS INT, V13, P971, DOI 10.1007/s001980200135; Gallagher JC, 2005, J CLIN ENDOCR METAB, V90, P1583, DOI 10.1210/jc.2004-0826; GarciaDelgado I, 1997, CALCIFIED TISSUE INT, V60, P155, DOI 10.1007/s002239900206; Geusens P, 1998, ANN RHEUM DIS, V57, P724, DOI 10.1136/ard.57.12.724; Geusens P., 1997, Bone (New York), V20, p9S; Grady D, 2004, OBSTET GYNECOL, V104, P837, DOI 10.1097/01.AOG.0000137349.79204.b8; Grant AM, 2005, LANCET, V365, P1621, DOI 10.1016/S0140-6736(05)63013-9; Greenspan SL, 2003, JAMA-J AM MED ASSOC, V289, P2525, DOI 10.1001/jama.289.19.2525; Greenspan SL, 2007, J CLIN ENDOCR METAB, V92, P131, DOI 10.1210/jc.2006-1272; Grotz W, 2001, J AM SOC NEPHROL, V12, P1530, DOI 10.1681/ASN.V1271530; Guanabens N, 2003, AM J GASTROENTEROL, V98, P2268, DOI 10.1016/S0002-9270(03)00550-1; Hay JE, 2001, J HEPATOL, V34, P292, DOI 10.1016/S0168-8278(00)00093-3; Heath DA, 2000, J CLIN DENSITOM, V3, P27, DOI 10.1385/JCD:3:1:027; Herd RJM, 1997, AM J MED, V103, P92, DOI 10.1016/S0002-9343(97)00019-3; Homik JE, 1999, J RHEUMATOL, V26, P1148; Hooper MJ, 2005, CLIMACTERIC, V8, P251, DOI 10.1080/13697130500118126; HORMIK J, 2000, COCHRANE DB SYST REV; Hosking D, 1998, NEW ENGL J MED, V338, P485, DOI 10.1056/NEJM199802193380801; Hosking D, 2003, CURR MED RES OPIN, V19, P383, DOI 10.1185/030079903125002009; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Ishida Y, 2004, AM J MED, V117, P549, DOI 10.1016/j.amjmed.2004.05.019; Iwamoto Jun, 2003, Keio Journal of Medicine, V52, P230; Jackson RD, 2006, NEW ENGL J MED, V354, P669, DOI 10.1056/NEJMoa055218; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jamal SA, 2007, J BONE MINER RES, V22, P503, DOI 10.1359/JBMR.070112; Jenkins EA, 1999, SCAND J RHEUMATOL, V28, P152; JENSEN D, 1998, 2 JOINT M AM SOC BON; Johnell O, 2002, J CLIN ENDOCR METAB, V87, P985, DOI 10.1210/jc.87.3.985; Johnston CC, 2000, ARCH INTERN MED, V160, P3444, DOI 10.1001/archinte.160.22.3444; Jolly EE, 2003, MENOPAUSE, V10, P337, DOI 10.1097/01.GME.0000058772.59606.2A; Kanaji A, 2006, LEPROSY REV, V77, P147; Kananen K, 2005, J CLIN ENDOCR METAB, V90, P3877, DOI 10.1210/jc.2004-2161; Kanis JA, 2007, OSTEOPOROSIS INT, V18, P1033, DOI 10.1007/s00198-007-0343-y; Kanis JA, 1999, QJM-MON J ASSOC PHYS, V92, P143, DOI 10.1093/qjmed/92.3.143; Karpf DB, 1997, JAMA-J AM MED ASSOC, V277, P1159; Kaufman JM, 2005, OSTEOPOROSIS INT, V16, P510, DOI 10.1007/s00198-004-1713-3; Keen Richard W, 2003, Curr Osteoporos Rep, V1, P66, DOI 10.1007/s11914-003-0011-x; Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ; Kim SH, 2004, AM J MED, V116, P524, DOI 10.1016/j.amjmed.2003.12.019; Kung AWC, 2003, J CLIN ENDOCR METAB, V88, P3130, DOI 10.1210/jc.2002-021855; Kushida K, 2004, J BONE MINER METAB, V22, P469, DOI 10.1007/s00774-004-0509-z; Lees B, 1996, OSTEOPOROSIS INT, V6, P480, DOI 10.1007/BF01629581; LINDSAY R, 1992, OSTEOPOROSIS GUIDE D; Luckey M, 2004, MENOPAUSE, V11, P405, DOI 10.1097/01.GME.0000119981.77837.1F; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941; Lyons RA, 2007, OSTEOPOROSIS INT, V18, P811, DOI 10.1007/s00198-006-0309-5; MacLean C, 2007, COMP EFFECTIVENESS R, V12; McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459; McClung MR, 2004, J BONE MINER RES, V19, P11, DOI 10.1359/JBMR.0301202; Meunier PJ, 1999, OSTEOPOROSIS INT, V10, P330, DOI 10.1007/s001980050236; Meunier PJ, 1997, J CLIN ENDOCR METAB, V82, P2784, DOI 10.1210/jc.82.9.2784; Michalska D, 2006, J CLIN ENDOCR METAB, V91, P870, DOI 10.1210/jc.2004-2212; Milgrom C, 2004, BONE, V35, P418, DOI 10.1016/j.bone.2004.04.016; Miller PD, 2005, J BONE MINER RES, V20, P2105, DOI 10.1359/JBMR.050817; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Mosekilde L, 2000, MATURITAS, V36, P181, DOI 10.1016/S0378-5122(00)00158-4; Muscoso E, 2004, Eur Rev Med Pharmacol Sci, V8, P97; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; Nguyen ND, 2006, J BONE MINER RES, V21, P340, DOI 10.1359/JBMR.050903; Ninkovic M, 2002, J HEPATOL, V37, P93, DOI 10.1016/S0168-8278(02)00100-9; Notelovitz M, 2002, MENOPAUSE, V9, P343, DOI 10.1097/00042192-200209000-00007; Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9; Palmer SC, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005015.pub2; Palomba S, 2005, OSTEOPOROSIS INT, V16, P1141, DOI 10.1007/s00198-005-1927-z; Papadimitropoulos E, 2002, ENDOCR REV, V23, P560, DOI 10.1210/er.2001-8002; Papapoulos SE, 2005, OSTEOPOROSIS INT, V16, P468, DOI 10.1007/s00198-004-1725-z; PECK WA, 1993, AM J MED, V94, P646; Pitt P, 1998, THORAX, V53, P351, DOI 10.1136/thx.53.5.351; Porthouse J, 2005, BMJ-BRIT MED J, V330, P1003, DOI 10.1136/bmj.330.7498.1003; Pouilles JM, 1997, OSTEOPOROSIS INT, V7, P213, DOI 10.1007/BF01622291; Prince RL, 2006, ARCH INTERN MED, V166, P869, DOI 10.1001/archinte.166.8.869; Quandt SA, 2005, MAYO CLIN PROC, V80, P343, DOI 10.4065/80.3.343; Ravn P, 1996, BONE, V19, P527, DOI 10.1016/S8756-3282(96)00229-3; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; Recker R, 2004, BONE, V34, P890, DOI 10.1016/j.bone.2004.01.008; Recker RR, 2007, BONE, V40, P843, DOI 10.1016/j.bone.2006.11.001; Recker RR, 1999, ANN INTERN MED, V130, P897, DOI 10.7326/0003-4819-130-11-199906010-00005; Reid DM, 2000, J BONE MINER RES, V15, P1006, DOI 10.1359/jbmr.2000.15.6.1006; Reid IR, 2006, AM J MED, V119, P777, DOI 10.1016/j.amjmed.2006.02.038; Reid IR, 2004, ARCH INTERN MED, V164, P871, DOI 10.1001/archinte.164.8.871; REID IR, 1988, LANCET, V1, P143; Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807; REID IR, 1994, J CLIN ENDOCR METAB, V79, P1595, DOI 10.1210/jc.79.6.1595; Richy F, 2004, OSTEOPOROSIS INT, V15, P301, DOI 10.1007/s00198-003-1570-5; Richy F, 2005, CALCIFIED TISSUE INT, V76, P176, DOI 10.1007/s00223-004-0005-4; Rosen CJ, 2005, J BONE MINER RES, V20, P141, DOI 10.1359/jbmr.2005.20.1.141; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Roux C, 1998, J CLIN ENDOCR METAB, V83, P1128, DOI 10.1210/jc.83.4.1128; Rubin MR, 2003, J CLIN ENDOCR METAB, V88, P1174, DOI 10.1210/jc.2002-020667; Ryan PJ, 2000, OSTEOPOROSIS INT, V11, P171, DOI 10.1007/PL00004179; Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502; Sasser AC, 2005, WOMEN HEALTH ISS, V15, P97, DOI 10.1016/j.whi.2004.11.006; Sato S, 2003, J RHEUMATOL, V30, P2673; Sato Y, 2000, J BONE MINER RES, V15, P2487, DOI 10.1359/jbmr.2000.15.12.2487; Sato Y, 2005, ARCH INTERN MED, V165, P1737, DOI 10.1001/archinte.165.15.1737; Sato Y, 2005, NEUROLOGY, V64, P811, DOI 10.1212/01.WNL.0000152871.65027.76; Sato Y, 2005, CEREBROVASC DIS, V20, P187, DOI 10.1159/000087203; Sato Y, 2005, ARCH INTERN MED, V165, P1743, DOI 10.1001/archinte.165.15.1743; Sato Y, 2004, AM J PHYS MED REHAB, V83, P298, DOI 10.1097/01.PHM.0000122877.28631.23; Sato Y, 2006, BONE, V39, P1080, DOI 10.1016/j.bone.2006.04.025; Sato Y, 2006, MOVEMENT DISORD, V21, P924, DOI 10.1002/mds.20825; Sawka AM, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-39; SCHACHTER HM, 2005, RALOXIFENE PRIMARY 2; Seeman E, 2006, OSTEOPOROSIS INT, V17, P313, DOI 10.1007/s00198-005-2030-1; Shea B, 2002, ENDOCR REV, V23, P552, DOI 10.1210/er.2001-7002; SILBERSTEIN EB, 1992, J NUCL MED, V33, P1; Skingle SJ, 1997, INT J CLIN PRACT, V51, P364; Smith MR, 2004, J CLIN ENDOCR METAB, V89, P3841, DOI 10.1210/jc.2003-032058; Sorensen OH, 2003, BONE, V32, P120, DOI 10.1016/S8756-3282(02)00946-8; Stefanick ML, 2006, JAMA-J AM MED ASSOC, V295, P1647, DOI 10.1001/jama.295.14.1647; Stevenson M, 2005, HEALTH TECHNOL ASSES, V9, P1; Tauchmanova L, 2006, BONE MARROW TRANSPL, V37, P81, DOI 10.1038/sj.bmt.1705196; Torgerson D J, 2001, BMC Musculoskelet Disord, V2, P7, DOI 10.1186/1471-2474-2-7; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; Toth E, 2005, BONE, V36, P47, DOI 10.1016/j.bone.2004.09.003; Trovas GP, 2002, J BONE MINER RES, V17, P521, DOI 10.1359/jbmr.2002.17.3.521; Uchida S, 2005, J BONE MINER METAB, V23, P382, DOI 10.1007/s00774-005-0616-5; Ushiroyama T, 2001, MATURITAS, V40, P229, DOI 10.1016/S0378-5122(01)00243-2; van Staa T, 1997, AM J MED, V103, P462, DOI 10.1016/S0002-9343(97)00242-8; Vogel VG, 2006, JAMA-J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074; Wallach S, 2000, CALCIFIED TISSUE INT, V67, P277, DOI 10.1007/s002230001146; Wells G, 2002, ENDOCR REV, V23, P529, DOI 10.1210/er.2001-5002; Wimalawansa SJ, 1998, AM J MED, V104, P219, DOI 10.1016/S0002-9343(98)00029-1; Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003-4819-144-10-200605160-00009; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; Zein CO, 2005, HEPATOLOGY, V42, P762, DOI 10.1002/hep.20866; Zheng SR, 2003, CHINESE MED J-PEKING, V116, P1127	162	374	420	1	39	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 5	2008	148	3					197	213		10.7326/0003-4819-148-3-200802050-00198	http://dx.doi.org/10.7326/0003-4819-148-3-200802050-00198			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258DX	18087050				2023-01-03	WOS:000252849700004
J	Hawkes, N				Hawkes, Nigel			How do we get the measure of patient care?	BRITISH MEDICAL JOURNAL			English	Editorial Material							QUALITY					nigel.hawkes@thetimes.co.uk						Dimick JB, 2004, JAMA-J AM MED ASSOC, V292, P847, DOI 10.1001/jama.292.7.847; Lilford RJ, 2007, BMJ-BRIT MED J, V335, P648, DOI 10.1136/bmj.39317.641296.AD	2	4	4	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 2	2008	336	7638					249	249		10.1136/bmj.39470.702627.59	http://dx.doi.org/10.1136/bmj.39470.702627.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	261TM	18244995	Green Published			2023-01-03	WOS:000253102900034
J	Farber, J; Siu, A; Bloom, P				Farber, Jeffrey; Siu, Albert; Bloom, Patricia			How much time do physicians spend providing care outside of office visits?	ANNALS OF INTERNAL MEDICINE			English	Article							TELEPHONE	Background: People with chronic illness require care outside of office visits, much of which is not reimbursed under current Medicare guidelines. Objective: To describe the amount of time geriatricians spend and the nature of care they provide outside of office visits. Design: Cross-sectional study on the time spent by physicians in clinical interactions outside of patient visits during 3 randomly sampled, 1-week periods. Setting: An academic geriatric medicine ambulatory practice. Participants: 16 physicians. Measurements: Information on the method, content, outcome, and participants in clinical interactions outside of office visits was collected on a structured form. Results: There were 472 discrete interactions, representing 296 episodes of care for 226 patients. Fifty-four percent of interactions were linked as multistep episodes, whose mean duration (range; 25th, 75th percentiles) was 18.9 minutes (3 to 70 minutes; 9, 21 minutes). Thirty-six percent of episodes involving a new medical symptom resulted in medication use, 27% resulted in an office visit, and 9% resulted in a referral to another physician. Mean time spent per physician per week was 112.2 minutes (range, 36 to 260 minutes), which represents an additional 6.7 minutes (range, 1.7 to 13.8) of care provided outside of office visits for every 30 minutes of time spent scheduled to see ambulatory patients. For a full-time physician scheduled to see 14 patients per day in 30-minute visits over a 5-day workweek, this would represent an extra 7.8 hours of clinical work per week. Limitation: Data were self-reported and were limited to an academic geriatric medicine practice. Conclusion: Physicians spend a considerable amount of time providing care outside of office visits for patients with chronic illness. This study suggests that collecting empirical data on the amount and nature of nonreimbursed care activities is feasible and should be done in more generalizable settings to inform debates about reimbursement reform.	Mt Sinai Sch Med, New York, NY 10029 USA; Bronx Vet Affairs Med Ctr, Bronx, NY USA	Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center	Farber, J (corresponding author), Mt Sinai Sch Med, Box 1070, New York, NY 10029 USA.	jeffrey.farber@mssm.edu						*AM GER SOC ASS DI, 2006, GER MED CLIN IMP AG; Anderson GF, 2005, NEW ENGL J MED, V353, P305, DOI 10.1056/NEJMsb044133; *ASS DIR GER ACAD, 2006, TRAINING PRACTICE UP, V2; *ASS DIR GER ACAD, 2007, STAT GER WORKF STUD; BABBOTT SF, 2006, POLICY MONOGRAPH SOC; Delichatsios H, 1998, J GEN INTERN MED, V13, P579, DOI 10.1046/j.1525-1497.1998.00179.x; Elnicki DM, 2000, J GEN INTERN MED, V15, P337, DOI 10.1046/j.1525-1497.2000.06459.x; HALLAM L, 1989, FAM PRACT, V6, P47, DOI 10.1093/fampra/6.1.47; Loder E, 2002, HEADACHE, V42, P883, DOI 10.1046/j.1526-4610.2002.02207.x	9	67	70	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 20	2007	147	10					693	U119		10.7326/0003-4819-147-10-200711200-00005	http://dx.doi.org/10.7326/0003-4819-147-10-200711200-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235UJ	18025445				2023-01-03	WOS:000251259500003
J	Myburgh, J; Cooper, J; Finfer, S; Bellomo, R; Norton, R; Bishop, N; Lo, SK; Vallance, S				Myburgh, John; Cooper, James; Finfer, Simon; Bellomo, Rinaldo; Norton, Robyn; Bishop, Nicole; Lo, Sing Kai; Vallance, Shirley		SAFE Study Investigators	Saline or albumin for fluid resuscitation in patients with traumatic brain injury	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEVERE HEAD-INJURY; GLASGOW OUTCOME SCALE; INTRACRANIAL-PRESSURE; VOLUME REGULATION; PRINCIPLES; THERAPY; EDEMA; GUIDELINES; SEVERITY; COMA	Background: The Saline versus Albumin Fluid Evaluation study suggested that patients with traumatic brain injury resuscitated with albumin had a higher mortality rate than those resuscitated with saline. We conducted a post hoc follow-up study of patients with traumatic brain injury who were enrolled in the study. Methods: For patients with traumatic brain injury (i.e., a history of trauma, evidence of head trauma on a computed tomographic [CT] scan, and a score of lessthan/equal 13 on the Glasgow Coma Scale [GCS]), we recorded baseline characteristics from case-report forms, clinical records, and CT scans and determined vital status and functional neurologic outcomes 24 months after randomization. Results: We followed 460 patients, of whom 231 (50.2%) received albumin and 229 (49.8%) received saline. The subgroup of patients with GCS scores of 3 to 8 were classified as having severe brain injury (160 [69.3%] in the albumin group and 158 [69.0%] in the saline group). Demographic characteristics and indexes of severity of brain injury were similar at baseline. At 24 months, 71 of 214 patients in the albumin group (33.2%) had died, as compared with 42 of 206 in the saline group (20.4%) (relative risk, 1.63; 95% confidence interval [CI], 1.17 to 2.26; P=0.003). Among patients with severe brain injury, 61 of 146 patients in the albumin group (41.8%) died, as compared with 32 of 144 in the saline group (22.2%) (relative risk, 1.88; 95% CI, 1.31 to 2.70; P<0.001); among patients with GCS scores of 9 to 12, death occurred in 8 of 50 patients in the albumin group (16.0%) and 8 of 37 in the saline group (21.6%) (relative risk, 0.74; 95% CI, 0.31 to 1.79; P=0.50). Conclusions: In this post hoc study of critically ill patients with traumatic brain injury, fluid resuscitation with albumin was associated with higher mortality rates than was resuscitation with saline. (Current Controlled Trials number, ISRCTN76588266.) N Engl J Med 2007;357:874-84.	ANZICS Clin Trials Grp, Carlton, Vic 3053, Australia; Univ Sydney, George Inst Int Hlth, Sydney, NSW 2006, Australia; Alfred Hosp, Melbourne, Vic, Australia; Auckland Hosp, Auckland, New Zealand; Austin & Repatriat Med Ctr, Melbourne, Vic, Australia; Australian Red Cross Blood Serv, Melbourne, Vic, Australia; Freemantle Hosp, Fremantle, Australia; John Hunter Hosp, Newcastle, NSW, Australia; Middlemore Hosp, Auckland 6, New Zealand; Nepean Hosp, Penrith, Australia; Princess Alexandra Hosp, Brisbane, Qld 4102, Australia; Royal Adelaide Hosp, Adelaide, SA 5000, Australia; Royal Darwin Hosp, Darwin, NT, Australia; Royal Hobart Hosp, Hobart, Tas, Australia; Royal Melbourne Hosp, Melbourne, Vic, Australia; Royal N Shore Hosp, Sydney, NSW, Australia; Royal Prince Alfred Hosp, Sydney, NSW, Australia; St George Hosp, Sydney, NSW, Australia; Western Hosp, Melbourne, Vic, Australia	University of Sydney; Florey Institute of Neuroscience & Mental Health; Auckland City Hospital; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Australian Red Cross Blood Service; John Hunter Hospital; Nepean Hospital; Royal Adelaide Hospital; Royal Hobart Hospital; Royal Melbourne Hospital; Royal North Shore Hospital; University of Sydney; University of Sydney; St George Hospital; Western Hospital	Myburgh, J (corresponding author), ANZICS Clin Trials Grp, Level 3,10 Levers Terrace, Carlton, Vic 3053, Australia.	j.myburgh@unsw.edu.au	Cooper, D. James/G-7961-2013; Joyce, Christopher/B-7437-2013	Cooper, D. James/0000-0002-5872-9051; Myburgh, John/0000-0003-4088-7016; Finfer, Simon/0000-0002-2785-5864; Neal, Bruce/0000-0002-0490-7465; Bellomo, Rinaldo/0000-0002-1650-8939; LO, Sing Kai/0000-0001-8401-1759				*ACS COMM TRAUM, 2004, ADV TRAUM LIF SUPP P; *ANZICS CLIN TRIAL, 2003, BMJ; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barzo P, 1997, ACT NEUR S, V70, P119; Belayev L, 2004, BRAIN RES, V998, P243, DOI 10.1016/j.brainres.2003.11.015; BTF Guidelines, 2000, J NEUROTRAUM, V17, P591; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Eker C, 2000, BRAIN INJURY, V14, P605; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Is M, 2005, NEUROL RES, V27, P67, DOI 10.1179/016164105X18296; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2001, J NEUROSURG, V94, P349; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MYBURGH JA, IN PRESS J TRAUMA; Nordstrom CH, 2005, NEUROCRIT CARE, V2, P83, DOI 10.1385/NCC:2:1:083; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Soreide E, 2005, INJURY, V36, P1001, DOI 10.1016/j.injury.2005.01.002; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; The Brain Trauma Foundation, 2000, AGE J NEUROTRAUMA, V17, P573; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P563, DOI [10.1089/neu.2000.17.563, DOI 10.1089/NEU.2000.17.563]; The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care, 2000, J NEUROTRAUM, V17, P471, DOI DOI 10.1089/NEU.2000.17.471; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; ZHUANG J, 1995, CRIT CARE MED, V23, P140, DOI 10.1097/00003246-199501000-00023; Zornow M H, 1995, New Horiz, V3, P488	37	474	492	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 30	2007	357	9					874	884						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204TA	17761591				2023-01-03	WOS:000249065700006
J	Day, M				Day, Michael			Mapping the alternative	BRITISH MEDICAL JOURNAL			English	Article												miday@f2s.com						*DEP HLTH, 2007, TRUST ASS SAF REG HL; *HOUS LORDS SEL CO, 2000, 6 HOUS LORDS SEL COM; VANHERWEGHEM JL, 1993, LANCET, V341, P387, DOI 10.1016/0140-6736(93)92984-2; Vincent C, 2001, BRIT MED J, V323, P467, DOI 10.1136/bmj.323.7311.467	4	4	4	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAY 5	2007	334	7600					929	931		10.1136/bmj.39192.475382.AD	http://dx.doi.org/10.1136/bmj.39192.475382.AD			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	165YN	17478842	Green Published			2023-01-03	WOS:000246343800033
J	Bonavida, B				Bonavida, B.			'Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions'	ONCOGENE			English	Review						rituximab; CD20 signaling; rituximab resistance; rituximab-induced chemoimmunosensitization	NON-HODGKINS-LYMPHOMA; NF-KAPPA-B; TRAIL-MEDIATED APOPTOSIS; MONOCLONAL-ANTIBODY; DOWN-REGULATION; SIGNALING PATHWAY; STAT3 ACTIVITY; UP-REGULATION; NITRIC-OXIDE; PIVOTAL ROLE	Rituximab (chimeric anti-CD20 monoclonal antibody) is the first Food and Drug Administration approved antitumor antibody and is used in the treatment of B-non-Hodgkin's lymphoma (B-NHL). It is used as single monotherapy or in combination with chemotherapy and has improved the treatment outcome of patients with B-NHL. The in vivo mechanisms of rituximab-mediated antitumor effects include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cell cytotoxicity (CDC), growth-inhibition and apoptosis. A subset of patients does not initially respond to rituximab and several responsive patients develop resistance to further rituximab treatment. The mechanism of rituximab unresponsiveness is not known. Besides the above-postulated mechanisms, rituximab has been shown to trigger the cells via CD20. Studies performed with B-NHL cell lines as model systems revealed several novel mechanisms of rituximab-mediated effects that are involved in chemo/immunosensitization and the development of resistance to rituximab. Rituximab has been shown to inhibit the p38 mitogen-activated protein kinase, nuclear factor-kappa B (NF-kappa B), extracellular signal-regulated kinase 1/2 (ERK 1/2) and AKT antiapoptotic survival pathways, all of which result in upregulation of phosphatase and tensin homolog deleted on chromosome ten and Raf kinase inhibitor protein and in the downregulation of antiapoptotic gene products (particularly Bcl-2, Bcl-(xL) and Mcl-1), and resulting in chemo/immunosensitization. Further, rituximab treatment inhibits the overexpressed transcription repressor Yin Yang 1 (YY1), which negatively regulates Fas and DR5 expression and its inhibition leads to sensitization to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Rituximab-resistant clones were generated as model to examine the mechanism of in vivo rituximab unresponsiveness. These clones showed reduced expression of CD20 and hyperactivation of the above antiapoptotic signaling pathways and failure of rituximab to trigger the cells leading to inhibition of ADCC, CDC and chemo/immunosensitization. Interference with the hyperactivated pathways with various pharmacological and proteasome inhibitors reversed resistance. Furthermore, the above findings have identified several gene products that can serve as new prognostic/diagnostic biomarkers as well as targets for therapeutic intervention in B-NHL.	Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bonavida, B (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA.	BBonavida@mednet.ucla.edu						Alas S, 2003, CLIN CANCER RES, V9, P316; Alas S, 2001, CANCER RES, V61, P5137; Alas S, 2001, CLIN CANCER RES, V7, P709; Baritaki S, 2007, MOL CANCER THER, V6, P1387, DOI 10.1158/1535-7163.MCT-06-0521; Bezombes C, 2004, BLOOD, V104, P1166, DOI 10.1182/blood-2004-01-0277; BLAY JY, 1993, EUR J IMMUNOL, V23, P768; Coiffier Bertrand, 2005, Clin Adv Hematol Oncol, V3, P484; Cragg Mark S., 2005, V8, P140; DEANS JP, 1995, J BIOL CHEM, V270, P22632, DOI 10.1074/jbc.270.38.22632; DEANS JP, 1993, J IMMUNOL, V151, P4494; Deans JP, 1998, J BIOL CHEM, V273, P344, DOI 10.1074/jbc.273.1.344; Deans JP, 2002, IMMUNOLOGY, V107, P176, DOI 10.1046/j.1365-2567.2002.01495.x; Demidem A, 1997, CANCER BIOTHER RADIO, V12, P177, DOI 10.1089/cbr.1997.12.177; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FREEDMAN AS, 1991, HEMATOL ONCOL CLIN N, V5, P871, DOI 10.1016/S0889-8588(18)30390-3; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Golay J, 2001, BLOOD, V98, P3383, DOI 10.1182/blood.V98.12.3383; Haidar JH, 2003, EUR J HAEMATOL, V70, P330, DOI 10.1034/j.1600-0609.2003.00007.x; Hainsworth JD, 2004, SEMIN ONCOL, V31, P17, DOI 10.1053/j.seminoncol.2003.12.005; Huerta-Yepez S, 2004, ONCOGENE, V23, P4993, DOI 10.1038/sj.onc.1207655; Janas E, 2005, CLIN EXP IMMUNOL, V139, P439, DOI 10.1111/j.1365-2249.2005.02720.x; Jazirehi AR, 2007, CANCER RES, V67, P1270, DOI 10.1158/0008-5472.CAN-06-2184; Jazirehi AR, 2004, BLOOD, V104, p930A, DOI 10.1182/blood.V104.11.3410.3410; Jazirehi AR, 2005, ONCOGENE, V24, P2121, DOI 10.1038/sj.onc.1208349; Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500; Jazirehi AR, 2003, MOL CANCER THER, V2, P1183; Jazirehi AR, 2005, CANCER RES, V65, P264; JAZIREHI AR, 2006, P AM ASS CANC RES, V47; Kennedy AD, 2003, BLOOD, V101, P1071, DOI 10.1182/blood-2002-03-0876; Kennedy AD, 2004, J IMMUNOL, V172, P3280, DOI 10.4049/jimmunol.172.5.3280; MANSHOURI T, 2003, LEUKEMIA LYMPHOMA, V44, pS15; REFF ME, 1994, BLOOD, V83, P435; Semac I, 2003, CANCER RES, V63, P534; Shan DM, 2000, CANCER IMMUNOL IMMUN, V48, P673, DOI 10.1007/s002620050016; SUZUKI E, 2007, IN PRESS ONCOGENE; Vega MI, 2005, ONCOGENE, V24, P8114, DOI 10.1038/sj.onc.1208954; Vega MI, 2005, J IMMUNOL, V175, P2174, DOI 10.4049/jimmunol.175.4.2174; Vega MI, 2004, ONCOGENE, V23, P3530, DOI 10.1038/sj.onc.1207336; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Xerri L, 1996, BRIT J HAEMATOL, V92, P900, DOI 10.1046/j.1365-2141.1996.423958.x; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001	45	161	166	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3629	3636		10.1038/sj.onc.1210365	http://dx.doi.org/10.1038/sj.onc.1210365			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530016				2023-01-03	WOS:000246816100005
J	Sykes, NP				Sykes, Nigel P.			Morphine kills the pain, not the patient	LANCET			English	Editorial Material							OPIOID USE; LIFE; END; CANCER		St Christophers Hospice, London SE26 6DZ, England		Sykes, NP (corresponding author), St Christophers Hospice, London SE26 6DZ, England.	n.sykes@stchristophers.org.uk						BILLINGS A, 2007, BBC THOUGHT DAY; *INT NARC CONTR BO, 2006, NARC DRUGS EST WORLD, P109; MORGAN J P, 1985, Advances in Alcohol and Substance Abuse, V5, P163; Morita Tatsuya, 2003, J Palliat Med, V6, P557, DOI 10.1089/109662103768253669; Pargeon KL, 1999, J PAIN SYMPTOM MANAG, V18, P358, DOI 10.1016/S0885-3924(99)00097-4; Portenoy RK, 2006, J PAIN SYMPTOM MANAG, V32, P532, DOI 10.1016/j.jpainsymman.2006.08.003; PORTER J, 1980, NEW ENGL J MED, V302, P123; Regnard C, 2003, PALLIATIVE MED, V17, P714, DOI 10.1191/0269216303pm838cr; Seale C, 2006, PALLIATIVE MED, V20, P3, DOI 10.1191/0269216306pm1094oa; Stjernsward J, 2004, OXFORD TXB PALLIATIV, P1199; Sykes N, 2003, LANCET ONCOL, V4, P312, DOI 10.1016/S1470-2045(03)01079-9; Thorns A, 2000, LANCET, V356, P398, DOI 10.1016/S0140-6736(00)02534-4; WALSH TD, 1984, RECENT RESULTS CANC, V89, P115; *WHO, 1987, CANC PAIN REL	14	15	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 21	2007	369	9570					1325	1326		10.1016/S0140-6736(07)60611-4	http://dx.doi.org/10.1016/S0140-6736(07)60611-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	159HL	17448802				2023-01-03	WOS:000245856100007
J	Metzl, JM				Metzl, Jonathan M.			If direct-to-consumer advertisements come to Europe: lessons from the USA	LANCET			English	Article; Proceedings Paper	Meeting on Medicalisation in the 21st Century	JUN, 2005	New York, NY				ANTIDEPRESSANTS		Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; Univ Michigan, Womens Studies Program, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Metzl, JM (corresponding author), Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA.	jmetzl@umich.edu			NICHD NIH HHS [K12HD001438] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD001438] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aikin K. J., 2003, DIRECT TO CONSUMER A; Alexander-Banys Bambi, 2002, J Pediatr Health Care, V16, P49, DOI 10.1016/S0891-5245(02)96294-2; ANGELL M, 2004, TRUTH DRUG CO THEY D, P83; AUTON F, 2004, INT J ADVER, V23, P1; Hollon MF, 2005, JAMA-J AM MED ASSOC, V293, P2030, DOI 10.1001/jama.293.16.2030; HONE F, 2004, PHARM EXEC, V24, P96; Kravitz RL, 2005, JAMA-J AM MED ASSOC, V293, P1995, DOI 10.1001/jama.293.16.1995; Metzl JM, 2004, SOC SCI MED, V58, P577, DOI 10.1016/S0277-9536(03)00369-1; Metzl Jonathan, 2003, PROZAC COUCH PRESCRI; Weissman JS, 2003, HEALTH AFFAIR, V22, pW82, DOI 10.1377/hlthaff.w3.82	10	12	13	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 24	2007	369	9562					704	706		10.1016/S0140-6736(07)60321-3	http://dx.doi.org/10.1016/S0140-6736(07)60321-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	141RO	17321319				2023-01-03	WOS:000244596600035
J	Lamaziere, A; Burlina, F; Wolf, C; Chassaing, G; Trugnan, G; Ayala-Sanmartin, J				Lamaziere, Antonin; Burlina, Fabienne; Wolf, Claude; Chassaing, Gerard; Trugnan, Germain; Ayala-Sanmartin, Jesus			Non-Metabolic Membrane Tubulation and Permeability Induced by Bioactive Peptides	PLOS ONE			English	Article								Background. Basic cell-penetrating peptides are potential vectors for therapeutic molecules and display antimicrobial activity. The peptide-membrane contact is the first step of the sequential processes leading to peptide internalization and cell activity. However, the molecular mechanisms involved in peptide-membrane interaction are not well understood and are frequently controversial. Herein, we compared the membrane activities of six basic peptides with different size, charge density and amphipaticity: Two cell-penetrating peptides (penetratin and R9), three amphipathic peptides and the neuromodulator substance P. Methodology/Principal Findings. Experiments of X ray diffraction, video-microscopy of giant vesicles, fluorescence spectroscopy, turbidimetry and calcein leakage from large vesicles are reported. Permeability and toxicity experiments were performed on cultured cells. The peptides showed differences in bilayer thickness perturbations, vesicles aggregation and local bending properties which form lipidic tubular structures. These structures invade the vesicle lumen in the absence of exogenous energy. Conclusions/Significance. We showed that the degree of membrane permeabilization with amphipathic peptides is dependent on both peptide size and hydrophobic nature of the residues. We propose a model for peptide-induced membrane perturbations that explains the differences in peptide membrane activities and suggests the existence of a facilitated "physical endocytosis,'' which represents a new pathway for peptide cellular internalization.	[Lamaziere, Antonin; Wolf, Claude; Trugnan, Germain; Ayala-Sanmartin, Jesus] CHU St Antoine, INSERM, UMR 538, Paris, France; [Lamaziere, Antonin; Wolf, Claude; Trugnan, Germain; Ayala-Sanmartin, Jesus] Univ Paris 06, CHU St Antoine, Paris, France; [Burlina, Fabienne; Chassaing, Gerard] Univ Paris 06, CNRS, UMR 7613, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Ayala-Sanmartin, J (corresponding author), CHU St Antoine, INSERM, UMR 538, Paris, France.	jayala@chusa.jussieu.fr	Lamaziere, Antonin/AAH-2285-2022; Lamaziere, Antonin/AFM-0000-2022	Burlina, Fabienne/0000-0002-6042-680X	INSERM; ANR-PCV; ACI	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); ANR-PCV(French National Research Agency (ANR)); ACI	This work was supported by INSERM, ANR-PCV and ACI grants.	Ambroggio EE, 2005, BIOPHYS J, V89, P1874, DOI 10.1529/biophysj.105.066589; AYALASANMARTIN J, 2004, ANNEXINS, V1, P19; Balayssac S, 2006, BIOCHEMISTRY-US, V45, P1408, DOI 10.1021/bi0518390; Bellet-Amalric E, 2000, BBA-BIOMEMBRANES, V1467, P131, DOI 10.1016/S0005-2736(00)00218-2; Berlose JP, 1996, EUR J BIOCHEM, V242, P372, DOI 10.1111/j.1432-1033.1996.0372r.x; Binder H, 2004, BIOPHYS J, V87, P332, DOI 10.1529/biophysj.103.034025; Brattwall CEB, 2003, J AM CHEM SOC, V125, P14214, DOI 10.1021/ja0366989; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; Cedric T, 2004, EUR BIOPHYS J BIOPHY, V33, P513, DOI 10.1007/s00249-004-0392-5; Chachaty C, 2005, BIOPHYS J, V88, P4032, DOI 10.1529/biophysj.104.054155; Chen FY, 2003, BIOPHYS J, V84, P3751, DOI 10.1016/S0006-3495(03)75103-0; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005; Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200; Drin G, 2001, BIOCHEMISTRY-US, V40, P1824, DOI 10.1021/bi002019k; DUPLAA H, 1992, BIOCHIM BIOPHYS ACTA, V1107, P12, DOI 10.1016/0005-2736(92)90323-E; FARGE E, 1992, BIOPHYS J, V61, P347, DOI 10.1016/S0006-3495(92)81841-6; Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9; Goncalves E, 2005, BIOCHEMISTRY-US, V44, P2692, DOI 10.1021/bi048046i; Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4; Hitz T, 2006, BIOCHEMISTRY-US, V45, P5817, DOI 10.1021/bi060285d; Huang HW, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.198304; HUANG HW, 2006, BIOCH BIOPHYS ACTA; Khalil IA, 2006, J BIOL CHEM, V281, P3544, DOI 10.1074/jbc.M503202200; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Ladokhin AS, 2000, ANAL BIOCHEM, V285, P235, DOI 10.1006/abio.2000.4773; Lambert O, 2004, J BIOL CHEM, V279, P10872, DOI 10.1074/jbc.M313657200; Lee MT, 2005, BIOPHYS J, V89, P4006, DOI 10.1529/biophysj.105.068080; LI C, 2006, BIOPHYS J; Magzoub M, 2002, BBA-BIOMEMBRANES, V1563, P53, DOI 10.1016/S0005-2736(02)00373-5; Magzoub M, 2001, BBA-BIOMEMBRANES, V1512, P77, DOI 10.1016/S0005-2736(01)00304-2; Magzoub M, 2003, BIOPHYS CHEM, V103, P271, DOI 10.1016/S0301-4622(02)00321-6; Mangavel C, 1998, BBA-BIOMEMBRANES, V1371, P265, DOI 10.1016/S0005-2736(98)00026-1; Matsuzaki K, 1997, BIOPHYS J, V73, P831, DOI 10.1016/S0006-3495(97)78115-3; McIntosh TJ, 1999, BIOPHYS J, V76, P2090, DOI 10.1016/S0006-3495(99)77365-0; Menger FM, 2003, J AM CHEM SOC, V125, P2846, DOI 10.1021/ja021337z; Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Nekhotiaeva N, 2003, FASEB J, V17, P394, DOI 10.1096/fj.03-0449fje; Oehlke J, 2005, J MOL RECOGNIT, V18, P50, DOI 10.1002/jmr.691; Palm C, 2006, PEPTIDES, V27, P1710, DOI 10.1016/j.peptides.2006.01.006; PEREZ F, 1994, MOL ENDOCRINOL, V8, P1278, DOI 10.1210/me.8.9.1278; Persson D, 2004, BIOCHEMISTRY-US, V43, P11045, DOI 10.1021/bi036054d; Persson D, 2001, FEBS LETT, V505, P307, DOI 10.1016/S0014-5793(01)02843-5; Puff N, 2005, CHEM PHYS LIPIDS, V133, P195, DOI 10.1016/j.chemphyslip.2004.10.003; Rauch C, 2000, BIOPHYS J, V78, P3036, DOI 10.1016/S0006-3495(00)76842-1; Siegel DP, 2006, BIOPHYS J, V90, P200, DOI 10.1529/biophysj.105.070466; Terrone D, 2003, BIOCHEMISTRY-US, V42, P13787, DOI 10.1021/bi035293y; Thoren PEG, 2004, BIOCHEMISTRY-US, V43, P3471, DOI 10.1021/bi0360049; Vives E, 2005, J CONTROL RELEASE, V109, P77, DOI 10.1016/j.jconrel.2005.09.032; Yang L, 2000, BIOPHYS J, V79, P2002, DOI 10.1016/S0006-3495(00)76448-4; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	54	72	72	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2007	2	2							e201	10.1371/journal.pone.0000201	http://dx.doi.org/10.1371/journal.pone.0000201			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DJ	17299584	Green Published, Green Submitted, gold			2023-01-03	WOS:000207444400003
J	Bisset, L; Beller, E; Jull, G; Brooks, P; Darnell, R; Vicenzino, B				Bisset, Leanne; Beller, Elaine; Jull, Gwendolen; Brooks, Peter; Darnell, Ross; Vicenzino, Bill			Mobilisation with movement and exercise, corticosteroid injection, or wait and see for tennis elbow: randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LATERAL EPICONDYLITIS; GRIP STRENGTH; UPPER-LIMB; MUSCULOSKELETAL DISORDERS; PRIMARY-CARE; PHYSIOTHERAPY; PREVALENCE; PAIN; INTERVENTIONS; COMPLAINTS	Objective To investigate the efficacy of physiotherapy compared with a wait and see approach or corticosteroid injections over 52 weeks in tennis elbow. Design Single blind randomised controlled trial. Setting Community setting, Brisbane, Australia. Participants 198 participants aged 18 to 65 years with a clinical diagnosis of tennis elbow of a minimum six weeks' duration, who had not received any other active treatment by a health practitioner in the previous six months. Interventions Eight sessions of physiotherapy; corticosteroid injections; or wait and see. Main outcome measures Global improvement, grip force, and assessor's rating of severity measured at baseline, six weeks, and 52 weeks. Results Corticosteroid injection showed significantly better effects at six weeks but with high recurrence rates thereafter (47/65 of successes subsequently regressed) and significantly poorer outcomes in the long term compared with physiotherapy. Physiotherapy was Superior to wait and see in the short term: no difference was seen at 52 weeks, when most participants in both groups reported a successful outcome. Participants who had physiotherapy Sought less additional treatment, such as non-steroidal anti-inflammatory drugs, than did participants who had wait and see or injections. Conclusion Physiotherapy combining elbow manipulation and exercise has a Superior benefit to wait and see in the first six weeks and to corticosteroid injections after six weeks, providing a reasonable alternative to injections in the mid to long term. The significant short term benefits of corticosteroid injection are paradoxically reversed after six weeks, with high recurrence rates, implying that this treatment should be used with caution in die management of tennis elbow.	Univ Queensland, Sch Hlth & Rehabil Sci, St Lucia, Qld 4072, Australia; Univ Queensland, Queensland Clin Trials Ctr, Sch Populat Hlth, St Lucia, Qld 4072, Australia; Univ Queensland, Fac Hlth Sci, St Lucia, Qld 4072, Australia	University of Queensland; University of Queensland; University of Queensland	Vicenzino, B (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, St Lucia, Qld 4072, Australia.	b.vicenzino@uq.edu.au	Bisset, Leanne/AAS-8947-2021; Jull, Gwendolen/F-4233-2010; Beller, Elaine M/E-1615-2013; Vicenzino, Bill/A-8492-2011; Vicenzino, Guglielmo/F-8744-2010; DARNELL, ROSS E/B-3823-2009	Bisset, Leanne/0000-0001-8807-7093; Jull, Gwendolen/0000-0003-2670-1318; Beller, Elaine M/0000-0002-3241-2611; Vicenzino, Bill/0000-0003-0253-5933; DARNELL, ROSS E/0000-0002-7973-6322				ALLANDER E, 1974, SCAND J RHEUMATOL, V3, P145, DOI 10.3109/03009747409097141; Benjamin SJ, 1999, J ORTHOP SPORT PHYS, V29, P668, DOI 10.2519/jospt.1999.29.11.668; Bisset L, 2005, BRIT J SPORT MED, V39, P411, DOI 10.1136/bjsm.2004.016170; Bot SDM, 2005, ANN RHEUM DIS, V64, P1331, DOI 10.1136/ard.2004.030320; CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X; CHIANG HC, 1993, SCAND J WORK ENV HEA, V19, P126, DOI 10.5271/sjweh.1496; Drechsler WI, 1997, J SPORT REHABIL, V6, P226, DOI 10.1123/jsr.6.3.226; Haker E, 1993, CRIT REV PHYS REHABI, V5, P129; Hay EM, 1999, BRIT MED J, V319, P964, DOI 10.1136/bmj.319.7215.964; KURPPA K, 1991, SCAND J WORK ENV HEA, V17, P32, DOI 10.5271/sjweh.1737; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; RANNEY D, 1995, ERGONOMICS, V38, P1408, DOI 10.1080/00140139508925198; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; Smidt N, 2003, ANN MED, V35, P51, DOI 10.1080/07853890310004138; Smidt N, 2002, LANCET, V359, P657, DOI 10.1016/S0140-6736(02)07811-X; Smidt N, 2005, ANN RHEUM DIS, V64, P1406, DOI 10.1136/ard.2004.029363; Smidt N, 2002, ARCH PHYS MED REHAB, V83, P1145, DOI 10.1053/apmr.2002.33728; STRATFORD P, 1987, Physiotherapy Canada, V39, P250; STRATFORD PW, 1989, PHYS THER, V69, P276, DOI 10.1093/ptj/69.4.276; STRATFORD PW, 1994, CLIN J SPORT MED, V4, P88, DOI DOI 10.1097/00042752-199404000-00004; THURTLE OA, 1984, BRIT J RHEUMATOL, V23, P154; Vicenzino B, 2003, MANUAL THER, V8, P66, DOI 10.1016/S1356-689X(02)00157-1; Walker-Bone K, 2004, ARTHRIT RHEUM-ARTHR, V51, P642, DOI 10.1002/art.20535; Yan J., 2002, R NEWS, V2, P12	24	294	299	1	46	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 4	2006	333	7575					939	941		10.1136/bmj.38961.584653.AE	http://dx.doi.org/10.1136/bmj.38961.584653.AE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	107GE	17012266	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000242157900014
J	Poupot, M; Griffe, L; Marchand, P; Maraval, A; Rolland, O; Martinet, L; L'Faqihi-Olive, FE; Turrin, CO; Caminade, AM; Fournie, JJ; Majoral, JP; Poupot, R				Poupot, Mary; Griffe, Laurent; Marchand, Patrice; Maraval, Alexandrine; Rolland, Olivier; Martinet, Ludovic; L'Faqihi-Olive, Fatima-Ezzahra; Turrin, Cedric-Olivier; Caminade, Anne-Marie; Fournie, Jean-Jacques; Majoral, Jean-Pierre; Poupot, Remy			Design of phosphorylated dendritic architectures to promote human monocyte activation	FASEB JOURNAL			English	Article						cellular immunotherapy; targeting; phosphorus dendrimers	CONTAINING DENDRIMERS; MACROPHAGE ACTIVATION; PROTEIN-KINASE; C-FOS; CELLS; RESPONSES	As first defensive line, monocytes are a pivotal cell population of innate immunity. Monocyte activation can be relevant to a range of immune conditions and responses. Here we present new insights into the activation of monocytes by a series of phosphonic acid-terminated, phosphorus-containing dendrimers. Various dendritic or subdendritic structures were synthesized and tested, revealing the basic structural requirements for monocyte activation. We showed that multivalent character and phosphonic acid capping of dendrimers are crucial for monocyte targeting and activation. Confocal videomicroscopy showed that a fluorescein-tagged dendrimer binds to isolated monocytes and gets internalized within a few seconds. We also found that dendrimers follow the phagolysosomial route during internalization by monocytes. Finally, we performed fluorescence resonance energy transfer (FRET) experiments between a specifically designed fluorescent dendrimer and phycoerythrin-coupled antibodies. We showed that the typical innate Toll-like receptor (TLR)-2 is clearly involved, but not alone, in the sensing of dendrimers by monocytes. In conclusion, phosphorus-containing dendrimers appear as precisely tunable nanobiotools able to target and activate human innate immunity and thus prove to be good candidates to develop new drugs for immunotherapies.	Hop Purpan, INSERM, Ctr Physiopathol Toulouse Purpan, U 563, F-31024 Toulouse 03, France; CNRS, Chim Coordinat Lab, F-31077 Toulouse, France; Univ Toulouse 3, F-31400 Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Caminade, AM (corresponding author), Hop Purpan, INSERM, Ctr Physiopathol Toulouse Purpan, U 563, BP3028, F-31024 Toulouse 03, France.	caminade@lcc-toulouse.fr; majoral@lcc-toulouse.fr; remy.poupot@toulouse.inserm.fr	Poupot, Mary/F-8570-2013; Marchand, Patrice/E-7156-2013; turrin, cedric-olivier/GQA-5382-2022; Caminade, Anne-Marie/E-2819-2015; Turrin, cedric-olivier/C-1746-2013; Martinet, ludovic/O-9693-2014; Fournie, Jean-Jacques/J-7805-2013	Marchand, Patrice/0000-0001-5859-5324; turrin, cedric-olivier/0000-0001-7187-8070; Caminade, Anne-Marie/0000-0001-8487-3578; Turrin, cedric-olivier/0000-0001-7187-8070; Martinet, ludovic/0000-0002-0867-7724; Fournie, Jean-Jacques/0000-0001-6542-6908; Poupot, Mary/0000-0002-2688-1091				Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984; Asthana A, 2005, AAPS PHARMSCITECH, V6, DOI 10.1208/pt060367; Borges A. Rosa, 2005, Current Drug Targets - Infectious Disorders, V5, P247, DOI 10.2174/1568005054880127; Caminade AM, 2004, ACCOUNTS CHEM RES, V37, P341, DOI 10.1021/ar020077n; Cloninger MJ, 2002, CURR OPIN CHEM BIOL, V6, P742, DOI 10.1016/S1367-5931(02)00400-3; Crespo L, 2005, CHEM REV, V105, P1663, DOI 10.1021/cr030449l; Dillon S, 2004, J IMMUNOL, V172, P4733, DOI 10.4049/jimmunol.172.8.4733; Galliot C, 1997, SCIENCE, V277, P1981, DOI 10.1126/science.277.5334.1981; Gillies ER, 2005, DRUG DISCOV TODAY, V10, P35, DOI 10.1016/S1359-6446(04)03276-3; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Jotwani R, 2003, EUR J IMMUNOL, V33, P2980, DOI 10.1002/eji.200324392; LAUNAY N, 1994, ANGEW CHEM INT EDIT, V33, P1589, DOI 10.1002/anie.199415891; Launay N, 1997, J ORGANOMET CHEM, V529, P51, DOI 10.1016/S0022-328X(96)06293-6; Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171; Loup C, 1999, CHEM-EUR J, V5, P3644, DOI 10.1002/(SICI)1521-3765(19991203)5:12<3644::AID-CHEM3644>3.0.CO;2-I; Majoral JP, 1999, CHEM REV, V99, P845, DOI 10.1021/cr970414j; Maszewska M, 2003, OLIGONUCLEOTIDES, V13, P193, DOI 10.1089/154545703322460586; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Owais M., 2005, Current Drug Delivery, V2, P311, DOI 10.2174/156720105774370177; Poupot M, 2003, J IMMUNOL, V171, P2517, DOI 10.4049/jimmunol.171.5.2517; Sadler Kristen, 2002, J Biotechnol, V90, P195; Shaunak S, 2004, NAT BIOTECHNOL, V22, P977, DOI 10.1038/nbt995; Soler-Illia GJDA, 2000, ANGEW CHEM INT EDIT, V39, P4250; SOUCAILLE P, 1988, BIOCHIM BIOPHYS ACTA, V939, P289, DOI 10.1016/0005-2736(88)90073-9; Spaggiari GM, 2006, BLOOD, V107, P1484, DOI 10.1182/blood-2005-07-2775; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816	28	121	124	0	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2339	2351		10.1096/fj.06-5742com	http://dx.doi.org/10.1096/fj.06-5742com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17077311				2023-01-03	WOS:000241702600019
J	Brown, DM; Kaiser, PK; Michels, M; Soubrane, G; Heier, JS; Kim, RY; Sy, JP; Schneider, S				Brown, David M.; Kaiser, Peter K.; Michels, Mark; Soubrane, Gisele; Heier, Jeffrey S.; Kim, Robert Y.; Sy, Judy P.; Schneider, Susan		ANCHOR Study Grp	Ranibizumab versus verteporfin for neovascular age-related macular degeneration	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREVALENCE	Background: We compared ranibizumab - a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A - with photodynamic therapy with verteporfin in the treatment of predominantly classic neovascular age-related macular degeneration. Methods: During the first year of this 2-year, multicenter, double-blind study, we randomly assigned patients in a 1:1:1 ratio to receive monthly intravitreal injections of ranibizumab (0.3 mg or 0.5 mg) plus sham verteporfin therapy or monthly sham injections plus active verteporfin therapy. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months. Results: Of the 423 patients enrolled, 94.3% of those given 0.3 mg of ranibizumab and 96.4% of those given 0.5 mg lost fewer than 15 letters, as compared with 64.3% of those in the verteporfin group (P < 0.001 for each comparison). Visual acuity improved by 15 letters or more in 35.7% of the 0.3-mg group and 40.3% of the 0.5-mg group, as compared with 5.6% of the verteporfin group (P < 0.001 for each comparison). Mean visual acuity increased by 8.5 letters in the 0.3-mg group and 11.3 letters in the 0.5-mg group, as compared with a decrease of 9.5 letters in the verteporfin group (P < 0.001 for each comparison). Among 140 patients treated with 0.5 mg of ranibizumab, presumed endophthalmitis occurred in 2 patients (1.4%) and serious uveitis in 1 (0.7%). Conclusions: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events. Treatment improved visual acuity on average at 1 year. (ClinicalTrials.gov number, NCT00061594.)	Methodist Hosp, Vitreoretinal Consultants, Houston, TX 77030 USA; Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA; Retina Care Specialists, Palm Beach Gardens, FL USA; Univ Paris 12, Clin Ophtalmol, Creteil, France; Ophthalm Consultants Boston, Boston, MA USA; Genentech Inc, San Francisco, CA 94080 USA	The Methodist Hospital System; The Methodist Hospital - Houston; Cleveland Clinic Foundation; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Ophthalmic Consultants of Boston; Roche Holding; Genentech	Brown, DM (corresponding author), Methodist Hosp, Vitreoretinal Consultants, 6560 Fannin St,Suite 750, Houston, TX 77030 USA.	dmbmd@houstonretina.com	Zhang, Kang/Y-2740-2019; Wolf, Sebastian/B-8782-2008	Zhang, Kang/0000-0002-4549-1697; Kaiser, Peter/0000-0001-5126-045X; Wolf, Sebastian/0000-0002-7467-7028				Ali F, 2004, ARCH OPHTHALMOL-CHIC, V122, P710, DOI 10.1001/archopht.122.5.710; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 2004, AV; Antiplatelet Trialists' Collaboration, 1994, BMJ, V308, P81; Arnold J, 2001, AM J OPHTHALMOL, V131, P541; Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160; Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198; Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900; Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119; Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488; Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640; Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; HEIER JS, IN PRESS ARCH OPHTHA; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; *NOV PHARM, 2005, VIS; Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016; Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242	22	2637	2787	4	149	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 5	2006	355	14					1432	1444		10.1056/NEJMoa062655	http://dx.doi.org/10.1056/NEJMoa062655			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	090UA	17021319				2023-01-03	WOS:000240976200005
J	Hirakawa, M; Oike, M; Watanabe, M; Karashima, Y; Ito, Y				Hirakawa, Masakazu; Oike, Masahiro; Watanabe, Michi; Karashima, Yuji; Ito, Yushi			Pivotal role of integrin alpha 5 beta 1 in hypotonic stress-induced responses of human endothelium	FASEB JOURNAL			English	Article						ATP release; tyrosine kinase; RhoA; actin cytoskeleton	FOCAL ADHESION KINASE; INDUCED ATP RELEASE; SHEAR-STRESS; CELL-ADHESION; ACTIVATION; FLOW; RHO; REORGANIZATION; MECHANISM	We have previously reported that both hypotonic stress (HTS) and lysophosphatidic acid (LPA) induce ATP release and a transient reorganization of actin through sequential activation of RhoA/Rho-kinase and focal adhesion kinase F-actin (FAK)/paxillin in human umbilical cord vein endothelial cells (HUVECs). LPA is known to induce the activation of RhoA via its specific receptors, but the mechanisms by which HTS initiates these intracellular signals are not known. The present study aimed to identify the molecule(s) that are unique to the sensing and/or transducing the mechanical stress. Reverse transcriptase-polymerase chain reaction revealed the expression of several integrin subunits in HUVECs. Anti-integrin alpha 5 beta 1 antibody (Ab), but not anti-integrin alpha 2, alpha 6, alpha v, or beta 4 antibodies, inhibited HTS-induced RhoA translocation, tyrosine phosphorylation of FAK and paxillin, ATP release, and actin reorganization. However, the LPA-induced ATP release and actin reorganization were not inhibited by any of these anti-integrin antibodies, indicating that integrin alpha 5 beta 1 plays a pivotal role in the HTS-induced but not in the LPA-induced responses. It is therefore reasonable to assume that this particular subtype of integrin is involved in the initiation of the responses induced by mechanical stimuli in HUVECs.	Kyushu Univ, Grad Sch Med Sci, Dept Pharmacol, Fukuoka 8128582, Japan	Kyushu University	Oike, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Pharmacol, Fukuoka 8128582, Japan.	moike@pharmaco.med.kyushu-u.ac.jp	Karashima, Yuji/AGY-5391-2022	Karashima, Yuji/0000-0002-2866-8999				Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; Ashida N, 2003, J BIOL CHEM, V278, P9327, DOI 10.1074/jbc.M212316200; Bodin P, 1998, INFLAMM RES, V47, P351, DOI 10.1007/s000110050341; BODIN P, 1991, BRIT J PHARMACOL, V103, P1203, DOI 10.1111/j.1476-5381.1991.tb12324.x; Buxton ILO, 2001, AM J PHYSIOL-HEART C, V281, pH1657, DOI 10.1152/ajpheart.2001.281.4.H1657; Carlson TR, 2001, J BIOL CHEM, V276, P26516, DOI 10.1074/jbc.M100282200; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046; Florian JA, 2003, CIRC RES, V93, pE136, DOI 10.1161/01.RES.0000101744.47866.D5; Guyot A, 2002, J PHYSIOL-LONDON, V545, P199, DOI 10.1113/jphysiol.2002.030148; HAMASAKI K, 1995, BIOCHEM BIOPH RES CO, V212, P544, DOI 10.1006/bbrc.1995.2004; HASSESSIAN H, 1993, BRIT J PHARMACOL, V109, P466, DOI 10.1111/j.1476-5381.1993.tb13592.x; Hirakawa M, 2004, J PHYSIOL-LONDON, V558, P479, DOI 10.1113/jphysiol.2004.065334; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; Jalali S, 2001, P NATL ACAD SCI USA, V98, P1042, DOI 10.1073/pnas.031562998; Jans D, 2002, J PHYSIOL-LONDON, V545, P543, DOI 10.1113/jphysiol.2002.026641; Kalinowski L, 2003, CIRCULATION, V107, P2747, DOI 10.1161/01.CIR.0000066912.58385.DE; Knight GE, 2002, AM J PHYSIOL-RENAL, V282, pF281, DOI 10.1152/ajprenal.00293.2000; Knudsen HL, 1997, AM J PHYSIOL-HEART C, V273, pH347, DOI 10.1152/ajpheart.1997.273.1.H347; Koyama T, 2001, J PHYSIOL-LONDON, V532, P759, DOI 10.1111/j.1469-7793.2001.0759e.x; Kranenburg O, 1997, J CELL SCI, V110, P2417; Li S, 1999, J CLIN INVEST, V103, P1141, DOI 10.1172/JCI5367; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Malek AM, 1996, J CELL SCI, V109, P713; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; Muller JM, 1997, CIRC RES, V80, P320, DOI 10.1161/01.RES.80.3.320; Oike M, 2000, AM J PHYSIOL-HEART C, V279, pH630, DOI 10.1152/ajpheart.2000.279.2.H630; Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18; Tzima E, 2002, EMBO J, V21, P6791, DOI 10.1093/emboj/cdf688; Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; Urbich C, 2002, ARTERIOSCL THROM VAS, V22, P69, DOI 10.1161/hq0102.101518; Wang YX, 2002, AM J PHYSIOL-CELL PH, V283, pC1540, DOI 10.1152/ajpcell.00222.2002	33	16	16	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2006	20	12					1992	1999		10.1096/fj.05-5580com	http://dx.doi.org/10.1096/fj.05-5580com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	093GS	17012251				2023-01-03	WOS:000241156900007
J	Bisson, GP; Gaolathe, T; Gross, R; Rollins, C; Bellamy, S; Mogorosi, M; Avalos, A; Friedman, H; Dickinson, D; Frank, I; Ndwapi, N				Bisson, Gregory P.; Gaolathe, Tendani; Gross, Robert; Rollins, Caitlin; Bellamy, Scarlett; Mogorosi, Mpho; Avalos, Ava; Friedman, Harvey; Dickinson, Diana; Frank, Ian; Ndwapi, Ndwapi			Overestimates of Survival after HAART: Implications for Global Scale-Up Efforts	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; FOLLOW-UP; MORTALITY; OUTCOMES; EXPERIENCE; PROGRAM; AFRICA	Background: Monitoring the effectiveness of global antiretroviral therapy scale-up efforts in resource-limited settings is a global health priority, but is complicated by high rates of losses to follow-up after treatment initiation. Determining definitive outcomes of these lost patients, and the effects of losses to follow-up on estimates of survival and risk factors for death after HAART, are key to monitoring the effectiveness of global HAART scale-up efforts. Methodology/Principal Findings: A cohort study comparing clinical outcomes and risk factors for death after HAART initiation as reported before and after tracing of patients lost to follow-up was conducted in Botswana's National Antiretroviral Therapy Program. 410 HIV-infected adults consecutively presenting for HAART were evaluated. The main outcome measures were death or loss to follow-up within the first year after HAART initiation. Of 68 patients initially categorized as lost, over half (58.8%) were confirmed dead after tracing. Patient tracing resulted in reporting of significantly lower survival rates when death was used as the outcome and losses to follow-up were censored [1-year Kaplan Meier survival estimate 0.92 (95% confidence interval, 0.88-0.94 before tracing and 0.83 (95% confidence interval, 0.79-0.86) after tracing, log rank P<0.001]. In addition, a significantly increased risk of death after HAART among men [adjusted hazard ratio 1.74 (95% confidence interval, 1.05-2.87)] would have been missed had patients not been traced [adjusted hazard ratio 1.41 (95% confidence interval, 0.65-3.05)]. Conclusions/Significance: Due to high rates of death among patients lost to follow-up after HAART, survival rates may be inaccurate and important risk factors for death may be missed if patients are not actively traced. Patient tracing and uniform reporting of outcomes after HAART are needed to enable accurate monitoring of global HAART scale-up efforts.	[Bisson, Gregory P.; Gross, Robert; Rollins, Caitlin; Bellamy, Scarlett; Friedman, Harvey; Frank, Ian] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Gaolathe, Tendani; Ndwapi, Ndwapi] Botswana Harvard Sch Public Hlth AIDS Initiative, Partnership HIV Res & Ed, Gaborone, Botswana; [Mogorosi, Mpho; Avalos, Ava] Princess Marina Hosp, Infect Dis Care Clin, Gaborone, Botswana; [Dickinson, Diana] Independence Surg, Gaborone, Botswana	University of Pennsylvania	Bisson, GP (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.	gregbisson@mac.com		Bellamy, Scarlett/0000-0002-2906-4046	National Institutes of Health [P30-AI45008]; PENN AIDS Clinical Trials Unit [U01-AI32783]; Career Development Awards [K23AI058881, K08MH01584]; Agency for Healthcare Research and Quality (AHRQ) Centers for Education and Research on Therapeutics [HS10399]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS010399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI045008, K23AI058881, U01AI032783] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH001584] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); PENN AIDS Clinical Trials Unit; Career Development Awards; Agency for Healthcare Research and Quality (AHRQ) Centers for Education and Research on Therapeutics(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We are grateful for the support of the National Institutes of Health which supported this research through the University of Pennsylvania Center for AIDS Research International, Developmental and Clinical Cores (P30-AI45008) the PENN AIDS Clinical Trials Unit (U01-AI32783), Career Development Awards K23AI058881 (GB) and K08MH01584 (RG), and an Agency for Healthcare Research and Quality (AHRQ) Centers for Education and Research on Therapeutics cooperative agreement (HS10399).	Anglaret X, 2004, JAIDS-J ACQ IMM DEF, V35, P320, DOI 10.1097/00126334-200403010-00015; Bossuyt PM, 2003, BRIT MED J, V326, P41, DOI 10.1136/bmj.326.7379.41; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Calmy A, 2006, AIDS, V20, P1163, DOI 10.1097/01.aids.0000226957.79847.d6; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; Djomand G, 2003, AIDS, V17, pS5, DOI 10.1097/00002030-200317003-00002; Etard JF, 2006, AIDS, V20, P1181, DOI 10.1097/01.aids.0000226959.87471.01; Ferradini L, 2006, LANCET, V367, P1335, DOI 10.1016/S0140-6736(06)68580-2; GAMMINO VBG, 2007, NATL TUBERCULOSIS PR; GUIARD S, 2004, TRICAM MEDICOECONOMI; Hosmer DW, 1999, APPL SURVIVAL ANAL; Hosseinipour Mina C, 2006, J Int Assoc Physicians AIDS Care (Chic), V5, P103, DOI 10.1177/1545109706288722; Lanoy E, 2006, J CLIN EPIDEMIOL, V59, P829, DOI 10.1016/j.jclinepi.2005.11.024; Lawn SD, 2005, AIDS, V19, P2141, DOI 10.1097/01.aids.0000194802.89540.e1; Macharia DK, 2003, AIDS, V17, P938, DOI 10.1097/00002030-200304110-00028; Moher D, 2001, BMC Med Res Methodol, V1, P2, DOI 10.1186/1471-2288-1-2; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Rothman KJ., 2008, MODERN EPIDEMIOLOGY; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; UNAIDS, 2006, REP GLOB AIDS EP; Vandenbroucke JP, 2007, ANN INTERN MED, V147, pW163, DOI 10.7326/0003-4819-147-8-200710160-00010-w1; von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; Weiser S, 2003, JAIDS-J ACQ IMM DEF, V34, P281, DOI 10.1097/00126334-200311010-00004; *WHO, 2006, SCAL ANT THER RES LT; Wools-Kaloustian K, 2006, AIDS, V20, P41, DOI 10.1097/01.aids.0000196177.65551.ea; Yu JKL, 2007, B WORLD HEALTH ORGAN, V85, P550, DOI 10.2471/BLT.06.037739	28	96	97	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2008	3	3							e1725	10.1371/journal.pone.0001725	http://dx.doi.org/10.1371/journal.pone.0001725			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	367XT	18320045	Green Submitted, Green Published, gold			2023-01-03	WOS:000260586600021
J	Claseem, A; Snow, V; Shekelle, P; Casey, DE; Cross, JT; Owens, DK				Claseem, Amir; Snow, Vincenza; Shekelle, Paul; Casey, Donald E., Jr.; Cross, J. Thomas, Jr.; Owens, Douglas K.		Clinical Efficacy Assessment Sub	Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: A clinical practice guideline from the American college of physicians	ANNALS OF INTERNAL MEDICINE			English	Article							HOME-BASED INTERVENTION; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; CONGESTIVE-HEART-FAILURE; CANCER-PATIENTS; UNPLANNED READMISSIONS; ETHICS CONSULTATIONS; FAMILY SATISFACTION; CAREGIVER BURDEN; MANAGEMENT	Recommendation 1: in patients with serious illness at the end of life, clinicians should regularly assess patients for pain, dyspnea, and depression. (Grade: strong recommendation, moderate quality of evidence.) Recommendation 2: In patients with serious illness at the end of life, clinicians should use therapies of proven effectiveness to manage pain. For patients with cancer, this includes nonsteroidal anti-inflammatory drugs, opioids, and bisphosphonates. (Grade: strong recommendation, moderate quality of evidence.) Recommendation 3: In patients with serious illness at the end of life, clinicians should use therapies of proven effectiveness to manage dyspnea, which include opioids in patients with unrelieved dyspnea and oxygen for short-term relief of hypoxemia. (Grade: strong recommendation, moderate quality of evidence.) Recommendation 4: In patients with serious illness at the end of life, clinicians should use therapies of proven effectiveness to manage depression. For patients with cancer, this includes tricyclic antidepressants, selective serotonin reuptake inhibitors, or psychosocial intervention. (Grade: strong recommendation, moderate quality of evidence.) Recommendation 5: Clinicians should ensure that advance care planning, including completion of advance directives, occurs for all patients with serious illness. (Grade: strong recommendation, low quality of evidence.).	[Claseem, Amir] American Coll Phys, Philadelphia, PA 19106 USA		Claseem, A (corresponding author), American Coll Phys, 190 N Independence Mail W, Philadelphia, PA 19106 USA.	aqaseem@acponline.org	Casey, Donald/AFM-6658-2022	Casey, Donald/0000-0002-3820-598X				Abernethy AP, 2003, BRIT MED J, V327, P523, DOI 10.1136/bmj.327.7414.523; Acton Gayle J, 2002, Annu Rev Nurs Res, V20, P149; Acton GJ, 2001, RES NURS HEALTH, V24, P349, DOI 10.1002/nur.1036; Adams K., 2003, PRIORITY AREAS NATL; Baker R, 2000, J AM GERIATR SOC, V48, pS61, DOI 10.1111/j.1532-5415.2000.tb03143.x; Bruera E, 2003, PALLIATIVE MED, V17, P659, DOI 10.1191/0269216303pm826oa; Burgio L, 2003, GERONTOLOGIST, V43, P568, DOI 10.1093/geront/43.4.568; Burns R, 2003, GERONTOLOGIST, V43, P547, DOI 10.1093/geront/43.4.547; CARR D, 2002, AHRQ PUBLICATION; Casarett D, 2005, JAMA-J AM MED ASSOC, V294, P211, DOI 10.1001/jama.294.2.211; Detmar SB, 2002, JAMA-J AM MED ASSOC, V288, P3027, DOI 10.1001/jama.288.23.3027; Eisdorfer C, 2003, GERONTOLOGIST, V43, P521, DOI 10.1093/geront/43.4.521; Field MJ, 1997, APPROACHING DEATH IM; Gitlin LN, 2003, PSYCHOL AGING, V18, P361, DOI 10.1037/0882-7974.18.3.361; Gitlin LN, 2003, GERONTOLOGIST, V43, P532, DOI 10.1093/geront/43.4.532; Grande GE, 2000, PALLIATIVE MED, V14, P375, DOI 10.1191/026921600701536200; Grande GE, 1997, PALLIATIVE MED, V11, P202, DOI 10.1177/026921639701100304; GUO B, 2004, ADV DIRECTIVES END O; Gysels M., 2004, IMPROVING SUPPORTIVE; Hanson LC, 1997, ANN INTERN MED, V126, P381, DOI 10.7326/0003-4819-126-5-199703010-00007; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; HIGGINSON IJ, 2000, ROLE PALLIATIVE CARE; Jennings AL, 2002, THORAX, V57, P939, DOI 10.1136/thorax.57.11.939; Jordhoy MS, 2001, J CLIN ONCOL, V19, P3884, DOI 10.1200/JCO.2001.19.18.3884; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Knols R, 2005, J CLIN ONCOL, V23, P3830, DOI 10.1200/JCO.2005.02.148; Latimer EJ, 1998, J PAIN SYMPTOM MANAG, V16, P41, DOI 10.1016/S0885-3924(98)00027-X; Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004; Lorenz K, 2006, AHRQ PUBLICATION, V06-E001; Lorenz KA, 2008, ANN INTERN MED, V148, P147, DOI 10.7326/0003-4819-148-2-200801150-00010; Mahoney DF, 2003, GERONTOLOGIST, V43, P556, DOI 10.1093/geront/43.4.556; McAlister FA, 2004, J AM COLL CARDIOL, V44, P810, DOI 10.1016/j.jacc.2004.05.055; Morrison RS, 2005, J AM GERIATR SOC, V53, P290, DOI 10.1111/j.1532-5415.2005.53116.x; Patrick DL, 2003, ANN INTERN MED, V139, P410, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00006; Rabow MW, 2004, ARCH INTERN MED, V164, P83, DOI 10.1001/archinte.164.1.83; Ram FSF, 2004, BMJ-BRIT MED J, V329, P315, DOI 10.1136/bmj.38159.650347.55; Riegel B, 2002, ARCH INTERN MED, V162, P705, DOI 10.1001/archinte.162.6.705; Ringdal GI, 2004, PALLIATIVE MED, V18, P108, DOI 10.1191/0269216304pm878oa; Ringdal GI, 2002, J PAIN SYMPTOM MANAG, V24, P53, DOI 10.1016/S0885-3924(02)00417-7; Roffe L, 2005, PSYCHO-ONCOLOGY, V14, P607, DOI 10.1002/pon.889; Schneiderman LJ, 2000, CRIT CARE MED, V28, P3920, DOI 10.1097/00003246-200012000-00033; Schneiderman LJ, 2003, JAMA-J AM MED ASSOC, V290, P1166, DOI 10.1001/jama.290.9.1166; SHUKLA V, 2006, 65 CAN COORD OFF HLT; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Sorensen S, 2002, GERONTOLOGIST, V42, P356, DOI 10.1093/geront/42.3.356; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Stewart S, 1999, LANCET, V354, P1077, DOI 10.1016/S0140-6736(99)03428-5; Stewart S, 1999, ARCH INTERN MED, V159, P257, DOI 10.1001/archinte.159.3.257; Stewart S, 1998, ARCH INTERN MED, V158, P1067, DOI 10.1001/archinte.158.10.1067; Teno JM, 2001, J PAIN SYMPTOM MANAG, V22, P752, DOI 10.1016/S0885-3924(01)00331-1; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Wenrich MD, 2003, J PAIN SYMPTOM MANAG, V25, P236, DOI 10.1016/S0885-3924(02)00694-2; WILSON DM, 2004, SYSTEMATIC REV END L; Windham BG, 2003, AM J MANAG CARE, V9, P447	54	133	136	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	2008	148	2					141	146		10.7326/0003-4819-148-2-200801150-00009	http://dx.doi.org/10.7326/0003-4819-148-2-200801150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	254NZ	18195338				2023-01-03	WOS:000252594600007
J	Bodenheimer, T				Bodenheimer, Thomas			A 63-year-old man with multiple cardiovascular risk factors and poor adherence to treatment plans	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARTICIPATORY DECISION-MAKING; DIABETES SELF-MANAGEMENT; PRIMARY-CARE; GENERAL-PRACTICE; PHYSICIAN COMMUNICATION; GLYCEMIC CONTROL; PATIENT; TIME; OUTCOMES; QUALITY	Mr P has long-standing hypertension, obesity, and diabetes mellitus and has experienced life-threatening cardiovascular events. Mr P is receiving evidence-based clinical care but has adhered to his medical regimen poorly and remains at considerable risk of future catastrophic cardiovascular events. Practicing evidence-based medicine should be a 5-step process: research uncovers the evidence, clinicians learn the evidence, clinicians use the evidence at every visit for every patient, clinicians make sure patients understand the evidence, and clinicians help patients incorporate the evidence into their lives. Research demonstrates, however, that clinicians do not use the evidence at every visit, patients may misunderstand what took place in the visit, and clinicians are not always effective in helping patients incorporate the evidence into their lives. These failures reflect the difficulty faced by clinicians attempting to address multiple issues while providing sufficient information and engaging in collaborative decision making during a brief clinical visit.	Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Bodenheimer, T (corresponding author), San Francisco Gen Hosp, Bldg 80-83,1001 Potrero Ave, San Francisco, CA 94110 USA.	tbodenheimer@fcmucsf.edu						Afonso NM, 2006, AM J MANAG CARE, V12, P589; Ammerman AS, 2002, PREV MED, V35, P25, DOI 10.1006/pmed.2002.1028; [Anonymous], 2007, DIABETES CARE, V30, pS4, DOI [10.2337/dc07-S004, DOI 10.2337/DC07-S004]; BEISECKER AE, 1990, MED CARE, V28, P19, DOI 10.1097/00005650-199001000-00004; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Bodenheimer T, 2007, BUILDING TEAMS PRIMA; Braddock CH, 1999, JAMA-J AM MED ASSOC, V282, P2313, DOI 10.1001/jama.282.24.2313; Campbell SM, 2001, BMJ-BRIT MED J, V323, P784, DOI 10.1136/bmj.323.7316.784; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Davidson J, 2005, AM J MED, V118, p27S, DOI 10.1016/j.amjmed.2005.07.054; Davis WA, 2006, DIABETES CARE, V29, P1764, DOI 10.2337/dc06-0268; Deveugele M, 2004, PATIENT EDUC COUNS, V54, P227, DOI 10.1016/S0738-3991(03)00239-8; Dugdale DC, 1999, J GEN INTERN MED, V14, pS34, DOI 10.1046/j.1525-1497.1999.00263.x; Fahey T, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005182; Funnell MM, 2000, JAMA-J AM MED ASSOC, V284, P1709, DOI 10.1001/jama.284.13.1709; Gibson PG, 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001005, DOI 10.1002/14651858.CD001005]; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; Griffin S, 2000, COCHRANE DB SYST REV, V2; Grumbach K, 2002, JAMA-J AM MED ASSOC, V288, P889, DOI 10.1001/jama.288.7.889; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Gwadry-Sridhar FH, 2004, ARCH INTERN MED, V164, P2315, DOI 10.1001/archinte.164.21.2315; Handley M, 2006, J AM BOARD FAM MED, V19, P224, DOI 10.3122/jabfm.19.3.224; Haynes RB., 2002, COCHRANE DB SYST REV, V2, DOI [10.1002/14651858.CD000011, DOI 10.1002/14651858.CD000011]; Heisler M, 2003, DIABETES CARE, V26, P738, DOI 10.2337/diacare.26.3.738; Heisler M, 2002, J GEN INTERN MED, V17, P243, DOI 10.1046/j.1525-1497.2002.10905.x; Hibbard JH, 2007, HEALTH SERV RES, V42, P1443, DOI 10.1111/j.1475-6773.2006.00669.x; Holland R, 2005, HEART, V91, P899, DOI 10.1136/hrt.2004.048389; *I MED, 2004, HLTH LIT PRESCR END; *I MED, 2003, PRIORITY AREAS NATL, P52; KAPLAN SH, 1995, MED CARE, V33, P1176, DOI 10.1097/00005650-199512000-00002; Kaplan SH, 1996, ANN INTERN MED, V124, P497, DOI 10.7326/0003-4819-124-5-199603010-00007; Krein SL, 2005, DIABETES CARE, V28, P65, DOI 10.2337/diacare.28.1.65; Levinson W, 2005, J GEN INTERN MED, V20, P531, DOI 10.1111/j.1525-1497.2005.04101.x; Lin CT, 2001, ARCH INTERN MED, V161, P1437, DOI 10.1001/archinte.161.11.1437; Lutfey KE, 1999, DIABETES CARE, V22, P635, DOI 10.2337/diacare.22.4.635; Marvel MK, 1999, JAMA-J AM MED ASSOC, V281, P283, DOI 10.1001/jama.281.3.283; McDonald HP, 2002, JAMA-J AM MED ASSOC, V288, P2868, DOI 10.1001/jama.288.22.2868; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Mead N, 2002, PATIENT EDUC COUNS, V48, P51, DOI 10.1016/S0738-3991(02)00099-X; Mechanic D, 2001, NEW ENGL J MED, V344, P198, DOI 10.1056/NEJM200101183440307; Morris LA, 1997, MED CARE, V35, P996, DOI 10.1097/00005650-199710000-00002; Norris SL, 2002, DIABETES CARE, V25, P1159, DOI 10.2337/diacare.25.7.1159; Norris SL, 2001, DIABETES CARE, V24, P561, DOI 10.2337/diacare.24.3.561; O'Brien M K, 1992, Med Care Rev, V49, P435, DOI 10.1177/002570879204900403; Ostbye T, 2005, ANN FAM MED, V3, P209, DOI 10.1370/afm.310; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Parchman ML, 2007, ANN FAM MED, V5, P196, DOI 10.1370/afm.679; Piette JD, 2003, J GEN INTERN MED, V18, P624, DOI 10.1046/j.1525-1497.2003.31968.x; ROTER DL, 1989, ANNU REV PUBL HEALTH, V10, P163, DOI 10.1146/annurev.pu.10.050189.001115; Roumie CL, 2006, ANN INTERN MED, V145, P165, DOI 10.7326/0003-4819-145-3-200608010-00004; Russell LB, 2005, J FAM PRACTICE, V54, P52; Saaddine JB, 2006, ANN INTERN MED, V144, P465, DOI 10.7326/0003-4819-144-7-200604040-00005; Saultz JW, 2005, ANN FAM MED, V3, P159, DOI 10.1370/afm.285; Saydah SH, 2004, JAMA-J AM MED ASSOC, V291, P335, DOI 10.1001/jama.291.3.335; Schillinger D, 2003, ARCH INTERN MED, V163, P83, DOI 10.1001/archinte.163.1.83; SCHILLINGER D, 2005, ADV PATIENT SAFETY R, V1; Shilts MK, 2004, AM J HEALTH PROMOT, V19, P81, DOI 10.4278/0890-1171-19.2.81; Stafford RS, 1999, ARCH FAM MED, V8, P26, DOI 10.1001/archfami.8.1.26; Street RL, 2005, MED CARE, V43, P960, DOI 10.1097/01.mlr.0000178172.40344.70; Thom DH, 2004, HEALTH AFFAIR, V23, P124, DOI 10.1377/hlthaff.23.4.124; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; Williams GC, 1998, DIABETES CARE, V21, P1644, DOI 10.2337/diacare.21.10.1644; Wilson A, 2002, BRIT J GEN PRACT, V52, P1012; Yarnall KSH, 2003, AM J PUBLIC HEALTH, V93, P635, DOI 10.2105/AJPH.93.4.635; Zyzanski SJ, 1998, J FAM PRACTICE, V46, P397	67	30	32	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2007	298	17					2048	2055		10.1001/jama.298.17.2048	http://dx.doi.org/10.1001/jama.298.17.2048			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228GP	17986698				2023-01-03	WOS:000250718200025
J	Bolton-Moore, C; Mubiana-Mbewe, M; Cantrell, RA; Chintu, N; Stringer, EM; Chi, BH; Sinkala, M; Kankasa, C; Wilson, CM; Wilfert, CM; Mwango, A; Levy, J; Abrams, EJ; Bulterys, M; Stringer, JSA				Bolton-Moore, Carolyn; Mubiana-Mbewe, Mwangelwa; Cantrell, Ronald A.; Chintu, Namwinga; Stringer, Elizabeth M.; Chi, Benjamin H.; Sinkala, Moses; Kankasa, Chipepo; Wilson, Craig M.; Wilfert, Catherine M.; Mwango, Albert; Levy, Jens; Abrams, Elaine J.; Bulterys, Marc; Stringer, Jeffrey S. A.			Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIV-INFECTED CHILDREN; SCALING-UP; MORTALITY; AFRICA; CHALLENGES; COHORT; ADHERENCE; DIAGNOSIS; SURVIVAL; DISTRICT	Context The Zambian Ministry of Health provides pediatric antiretroviral therapy (ART) at primary care clinics in Lusaka, where, despite scale-up of perinatal prevention efforts, many children are already infected with the human immunodeficiency virus (HIV). Objective To report early clinical and immunologic outcomes of children enrolled in the pediatric treatment program. Design, Setting, and Patients Open cohort assessment using routinely collected clinical and outcome data from an electronic medical record system in use at 18 government primary health facilities in Lusaka, Zambia. Care was provided primarily by nurses and clinical officers ("physician extenders" akin to physician assistants in the United States). Patients were children (< 16 years of age) presenting for HIV care between May 1, 2004, and June 29, 2007. Intervention Three-drug ART (zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz) for children who met national treatment criteria. Main Outcome Measures Survival, weight gain, CD4 cell count, and hemoglobin response. Results After enrollment of 4975 children into HIV care, 2938 (59.1%) started ART. Of those initiating ART, the median age was 81 months (interquartile range, 36-125), 1531 (52.1%) were female, and 2087 (72.4%) with World Health Organization stage information were in stage III or IV. At the time of analysis, 158 children (5.4%) had withdrawn from care and 382 (13.0%) were at least 30 days late for follow-up. Of the remaining 2398 children receiving ART, 198 (8.3%) died over 3018 child-years of follow-up (mortality rate, 6.6 deaths per 100 child-years; 95% confidence interval [CI], 5.7-7.5); of these deaths, 112 (56.6%) occurred within 90 days of therapy initiation (early mortality rate, 17.4/100 child-years; post-90-day mortality rate, 2.9/100 child-years). Mortality was associated with CD4 cell depletion, lower weight-for-age, younger age, and anemia in multivariate analysis. The mean CD4 cell percentage at ART initiation among the 1561 children who had at least 1 repeat measurement was 12.9% (95% CI, 12.5%-13.3%) and increased to 23.7% (95% CI, 23.1%-24.3%) at 6 months, 27.0% (95% CI, 26.3%-27.6%) at 12 months, 28.0% (95% CI, 27.2%-28.8%) at 18 months, and 28.4% (95% CI, 27.4%-29.4%) at 24 months. Conclusions Care provided by clinicians such as nurses and clinical officers can result in good outcomes for HIV-infected children in primary health care settings in sub-Saharan Africa. Mortality during the first 90 days of therapy is high, pointing to a need for earlier intervention.	CIDRZ, Lusaka, Zambia; Univ Alabama Birmingham, Sch Med, Birmingham, AL USA; Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA; Univ Teaching Hosp, Lusaka, Zambia; Zambian Minist Hlth, Lusaka, Zambia; Elizabeth Glaser Pediat AIDS Fdn, Santa Monica, CA USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; US Ctr Dis Control & Prevent, Global AIDS Program, Lusaka, Zambia	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Zambia; Columbia University	Stringer, JSA (corresponding author), CIDRZ, Plot 1275 Lubutu Rd,POB 34681, Lusaka, Zambia.	stringer@cidrz.org	Stringer, Jeffrey S. A./AAU-2342-2021	Bolton Moore, Carolyn/0000-0001-9103-7746; Stringer, Jeffrey/0000-0002-9590-7216; Mubiana-Mbewe, Mwangelwa/0000-0002-7122-842X; Wilson, Craig/0000-0001-6869-1053	FOGARTY INTERNATIONAL CENTER [K01TW006670, K01TW005708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027767, K08AI001411] Funding Source: NIH RePORTER; FIC NIH HHS [K01-TW05708, K01-TW06670] Funding Source: Medline; NIAID NIH HHS [P30-AI027767, K23-AI01411] Funding Source: Medline; PHS HHS [U62/CCU12354] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aledort Julia E, 2006, Nature, V444 Suppl 1, P19, DOI 10.1038/nature05443; Allison P.D., 2010, SURVIVAL ANAL USING; ANABWANI GM, 2006, 16 INT AIDS C AUG 13; BARRY G, 2006, 16 INT AIDS C AUG 13; Berhane R, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.1.e7; Bobat R, 1998, ANN TROP PAEDIATR, V18, P187, DOI 10.1080/02724936.1998.11747946; Bobat R, 2001, ANN TROP PAEDIATR, V21, P203, DOI 10.1080/02724930120077772; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Centers for Disease Control and Prevention, SAS PROGR CDC GROWTH; De Baets AJ, 2007, PEDIATR INFECT DIS J, V26, P163, DOI 10.1097/01.inf.0000253040.82669.22; DUMAS S, 2006, 16 INT AIDS C AUG 13; FUSCO H, 2005, 3 IAS C HIV PATH TRE; George E, 2007, J INFECT DIS, V195, P1411, DOI 10.1086/514823; Ginsburg AS, 2006, PEDIATR INFECT DIS J, V25, P1057, DOI 10.1097/01.inf.0000243157.16405.f0; *GLOB FUND FIGHT A, ZAMB GLOB FUND PORTF; Gross R, 2006, J INFECT DIS, V194, P1108, DOI 10.1086/507680; Hogg RS, 2002, AIDS, V16, P1051, DOI 10.1097/00002030-200205030-00012; KAMINSAKABANJE S, 2006, 16 INT AIDS C AUG 13; KANKASA C, 2007, 14 C RETR OPP INF FE; Kline MW, 2006, PEDIATRICS, V117, P1388, DOI 10.1542/peds.2005-1348; Kober K, 2004, LANCET, V364, P103, DOI 10.1016/S0140-6736(04)16597-5; Kuhn L, 2005, AIDS, V19, P1677, DOI 10.1097/01.aids.0000186817.38112.da; Laufer MK, 2006, PEDIATR INFECT DIS J, V25, P623, DOI 10.1097/01.inf.0000220264.45692.a0; LIN DY, 1993, BIOMETRIKA, V80, P557, DOI 10.2307/2337177; McConnell MS, 2005, JAIDS-J ACQ IMM DEF, V38, P488, DOI 10.1097/01.qai.0000134744.72079.cc; Mwinga A, 2005, LANCET, V365, P97, DOI 10.1016/S0140-6736(05)17713-7; Nachega JB, 2006, JAIDS-J ACQ IMM DEF, V43, P78, DOI 10.1097/01.qai.0000225015.43266.46; Newell ML, 2004, LANCET, V364, P1236, DOI 10.1016/S0140-6736(04)17140-7; OLSON D, 2006, 16 INT AIDS C AUG 13; Rosenblatt HM, 2005, J INFECT DIS, V192, P445, DOI 10.1086/431597; Stringer EM, 2003, AIDS, V17, P1377, DOI 10.1097/00002030-200306130-00012; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; *UN CHILDR FUND, COUNTR PROF ZAMB; UNAIDS, 2006, REP GLOB AIDS EP; *US PRES EM PLAN A, COUNTR PROF ZAMB; VIOLARI A, 2007, 4 IAS C HIV PATH TRE; *WHO, 2005, TAK STOCK HIV CHILDR; WHO, 2006, COTR PROPH HIV REL I; *WHO, 3 5 IN AIDS TREATM C; WHO Multicentre Growth Reference Study Group, 2006, WHO CHILD GROWTH STA; World Health Organisation, 2006, ANT THER HIV INF INF; World Health Organization, 2004, SCAL ANT THER RES LT; World Health Organization, 2005, INT WHO CLIN STAG HI; Zachariah R, 2006, AIDS, V20, P2355, DOI 10.1097/QAD.0b013e32801086b0; *ZAMB NAT AIDS COU, 2004, NAT GUID LIN MAN CAR	45	265	267	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 24	2007	298	16					1888	1899		10.1001/jama.298.16.1888	http://dx.doi.org/10.1001/jama.298.16.1888			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223GC	17954540	Bronze			2023-01-03	WOS:000250356700021
J	Kenyon, S; Ullman, R; Mori, R; Whittle, M				Kenyon, S.; Ullman, R.; Mori, R.; Whittle, M.		Guideline Dev Grp	Care of healthy women and their babies during childbirth: summary of NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Leicester, Dept Canc Studies & Mol Med, Reprod Sci Sect, Leicester LE2 7LX, Leics, England; Royal Coll Obstet & Gynaecologists, Natl Collaborating Ctr Womens & Childrens Hlth, London W1T 2QA, England	University of Leicester	Kenyon, S (corresponding author), Univ Leicester, Dept Canc Studies & Mol Med, Reprod Sci Sect, Leicester LE2 7LX, Leics, England.	oracle@le.ac.uk		Kenyon, Sara/0000-0002-0756-9617; Mori, Rintaro/0000-0001-7656-6156				National Institute for Health and Clinical Excellence, 2007, INTR CAR CAR HLTH WO	1	10	11	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 29	2007	335	7621					667	668		10.1136/bmj.39322.703380.AD	http://dx.doi.org/10.1136/bmj.39322.703380.AD			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	218AY	17901518	Green Published			2023-01-03	WOS:000249989600044
J	Markowitz, AJ; McPhee, SJ				Markowitz, Amy J.; McPhee, Stephen J.			Lateral sclerosis - "Prepare for the worst and hope for the best"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Mitsumoto H, 2007, JAMA-J AM MED ASSOC, V298, P207, DOI 10.1001/jama.298.2.207	1	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 12	2007	298	10					1208	1208		10.1001/jama.298.10.1208	http://dx.doi.org/10.1001/jama.298.10.1208			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	209FK	17848655				2023-01-03	WOS:000249374200026
J	Jones, I; Whitfield, R; Colquhoun, M; Chamberlain, D; Vetter, N; Newcombe, R				Jones, Ian; Whitfield, Richard; Colquhoun, Michael; Chamberlain, Douglas; Vetter, Norman; Newcombe, Robert			At what age can schoolchildren provide effective chest compressions? An observational study from the Heartstart UK schools training programme	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL CARDIAC-ARREST; BASIC LIFE-SUPPORT; CARDIOPULMONARY-RESUSCITATION; RESCUER FATIGUE; QUALITY; PERFORMANCE; RETENTION; KNOWLEDGE; SYSTEM; SKILLS	Objective To determine at what age children can perform effective chest compressions for cardiopulmonary resuscitation. Design Observational study. Setting Four schools in Cardiff. Participants 157 children aged 9-14 years in three school year groups (ages 9-10, 11-12, and 13-14). Interventions Participants were taught basic life support skills in one lesson lasting 20 minutes. Main outcome measure Effectiveness of chest compression during three minutes' continuous chest compression on a manikin. Results No year 5 pupil (age 9-10) was able to compress the manikin's chest to the depth recommended in guidelines (38-51 mm). 19% of pupils in year 7 (age 11-12) and 45% in year 9 (age 13-14) achieved adequate compression depth. Only the 13-14 year olds performed chest compression as well as adults in other reported studies. Compression depth showed a significant relation with children's age, weight, and height (P < 0.001). Multivariate analyses showed that, if the age and weight of the children were both known, the height (which is closely related to both) was no longer significant (P=0.95). No association was found between pupits' age, sex, weight, or height and the average rate of chest compressions over the three minute period. Similarly, no relation was found between year group and ability to place the hands in the correct position. During the three minutes' compression, compression rate increased and depth decreased. Conclusions The children's ability to achieve an adequate depth of chest compression depended on their age and weight. The ability to provide the correct rate and to employ the correct hand position was similar across all the age ranges tested. Young children who are not yet physically able to compress the chest can learn the principles of chest compression as well as older children.	NHS Trust Cardiff Univ, Welsh Ambulance Serv, Prehosp Emergency Res Unit, Wales Sch Med, Cardiff CF11 8PL, Wales; Wales Heart Res Inst, Cardiff CF14 4XN, Wales; Cardiff Univ, Wales coll Med, Dept Epidemiol Stat & Publ Hlth, Cardiff CF14 4XN, Wales	Cardiff University; Cardiff University; Cardiff University	Colquhoun, M (corresponding author), NHS Trust Cardiff Univ, Welsh Ambulance Serv, Prehosp Emergency Res Unit, Wales Sch Med, Cardiff CF11 8PL, Wales.	mcc@mcolquhoun.plus.com	Newcombe, Robert G/B-4897-2009					Ashton A, 2002, RESUSCITATION, V55, P151, DOI 10.1016/S0300-9572(02)00168-5; *BRIT HEART FDN, 2003, HEARTST UK TRAIN PAC; Eisenburger P, 1999, RESUSCITATION, V41, P3, DOI 10.1016/S0300-9572(99)00034-9; European Resuscitation Council, 2000, RESUSCITATION, V46, P3; Handley AJ, 2003, RESUSCITATION, V57, P57, DOI 10.1016/S0300-9572(02)00400-8; HIGHTOWER D, 1995, ANN EMERG MED, V26, P300, DOI 10.1016/S0196-0644(95)70076-5; Lafferty C, 2003, NZ MED J, V116, P582; Lester C, 1996, RESUSCITATION, V31, P33, DOI 10.1016/0300-9572(95)00912-4; LIND B, 1961, Acta Anaesthesiol Scand Suppl, VSuppl 9, P63; *MAT CHILDHLTH BUR, 1999, BAS EM LIF SKILLS BE; MOORE PJ, 1992, RESUSCITATION, V24, P17, DOI 10.1016/0300-9572(92)90170-H; NADER PR, 1993, PEDIATRICS, V91, P158; PLOTNIKOFF R, 1989, MED J AUSTRALIA, V150, P296, DOI 10.5694/j.1326-5377.1989.tb136488.x; VANKERSCHAVER E, 1989, RESUSCITATION, V17, P211, DOI 10.1016/0300-9572(89)90037-3; Wik L, 2001, RESUSCITATION, V50, P167, DOI 10.1016/S0300-9572(01)00331-8; Woollard M, 2003, RESUSCITATION, V59, P123, DOI 10.1016/S0300-9572(03)00174-6	19	95	100	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 9	2007	334	7605					1201	1203		10.1136/bmj.39167.459028.DE	http://dx.doi.org/10.1136/bmj.39167.459028.DE			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	179GF	17468118	Green Published, Bronze			2023-01-03	WOS:000247277000034
J	Coiffier, B				Coiffier, B.			Rituximab therapy in malignant lymphoma	ONCOGENE			English	Review						rituximab; R-CHOP; follicular lymphoma; diffuse large B-cell lymphoma; monoclonal antibodies	B-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; ANTI-CD20 MONOCLONAL-ANTIBODY; CHRONIC LYMPHOCYTIC-LEUKEMIA; PHASE-II TRIAL; CHEMOTHERAPY PLUS RITUXIMAB; SOLID-ORGAN TRANSPLANTATION; FOLLICULAR LYMPHOMA; R-CHOP; MAINTENANCE RITUXIMAB	Rituximab is the first monoclonal antibody to have been registered for the treatment of B-cell lymphomas. Randomized studies haves demonstrated its activity in follicular lymphoma ( FL), mantle cell lymphoma and diffuse large B-cell lymphoma (DLBCL) in untreated or relapsing patients. Non-comparative studies have shown an activity in all other lymphomas. Because of its high activity and low toxicity ratio, rituximab has transformed the outcome of patients with B-cell lymphoma. A combination of rituximab plus chemotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), has the highest efficacy ever described with any chemotherapy in DLBCL and FL. Some patients are refractory to rituximab but the precise mechanisms of this refractoriness are not understood.	CH Lyon Sud, Dept Hematol, F-69495 Pierre Benite, France; Univ Lyon 1, Pierre Benite, France	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Coiffier, B (corresponding author), CH Lyon Sud, Dept Hematol, F-69495 Pierre Benite, France.	bertrand.coiffier@chu-lyon.fr						Alas S, 2000, ANTICANCER RES, V20, P2961; Alas S, 2001, CANCER RES, V61, P5137; Ardeshna KM, 2003, LANCET, V362, P516, DOI 10.1016/S0140-6736(03)14110-4; Belhadj K, 2004, ANN ONCOL, V15, P504, DOI 10.1093/annonc/mdh090; Berinstein NL, 1998, ANN ONCOL, V9, P995, DOI 10.1023/A:1008416911099; Bienvenu J, 2001, Hematol J, V2, P378, DOI 10.1038/sj.thj.6200133; Blaes AH, 2005, CANCER-AM CANCER SOC, V104, P1661, DOI 10.1002/cncr.21391; Boettcher S, 2004, BLOOD, V104, p170A, DOI 10.1182/blood.V104.11.590.590; Bohen SP, 2003, P NATL ACAD SCI USA, V100, P1926, DOI 10.1073/pnas.0437875100; Boue F, 2006, J CLIN ONCOL, V24, P4123, DOI 10.1200/JCO.2005.05.4684; Brugger W, 2004, SEMIN ONCOL, V31, P33, DOI 10.1053/j.seminoncol.2003.12.008; Byrd JC, 2003, BLOOD, V101, P6, DOI 10.1182/blood-2002-04-1258; Byrd JC, 2005, BLOOD, V105, P49, DOI 10.1182/blood-2004-03-0796; Byrd JC, 2001, J CLIN ONCOL, V19, P2153, DOI 10.1200/JCO.2001.19.8.2153; Cartron G, 2004, BLOOD, V104, P2635, DOI 10.1182/blood-2004-03-1110; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Coiffier B, 2005, J CLIN ONCOL, V23, P6387, DOI 10.1200/JCO.2005.05.015; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; COIFFIER B, 2005, ONCOLOGY, V18, P7; COIFFIER B, 2005, IN PRESS CURR OP HEM, V12; Coiffier B, 2006, SEMIN HEMATOL, V43, P213, DOI 10.1053/j.seminhematol.2006.07.004; Coiffier Bertrand, 2005, Clin Adv Hematol Oncol, V3, P484; Colombat P, 2001, BLOOD, V97, P101, DOI 10.1182/blood.V97.1.101; Conconi A, 2003, BLOOD, V102, P2741, DOI 10.1182/blood-2002-11-3496; Czuczman MS, 2004, J CLIN ONCOL, V22, P4711, DOI 10.1200/JCO.2004.04.020; Davis TA, 2000, CLIN CANCER RES, V6, P2644; Davis TA, 2000, J CLIN ONCOL, V18, P3135, DOI 10.1200/JCO.2000.18.17.3135; Demidem A, 1997, CANCER BIOTHER RADIO, V12, P177, DOI 10.1089/cbr.1997.12.177; Eisenbeis CF, 2004, CLIN CANCER RES, V10, P6101, DOI 10.1158/1078-0432.CCR-04-0525; Ekstrand BC, 2003, BLOOD, V101, P4285, DOI 10.1182/blood-2002-08-2644; Farinha P, 2006, BLOOD, V108, p245A; Feugier P, 2005, J CLIN ONCOL, V23, P4117, DOI 10.1200/JCO.2005.09.131; Foran JM, 2000, J CLIN ONCOL, V18, P317, DOI 10.1200/JCO.2000.18.2.317; Forstpointner R, 2004, BLOOD, V104, P3064, DOI 10.1182/blood-2004-04-1323; Forstpointner R, 2006, BLOOD, V108, P4003, DOI 10.1182/blood-2006-04-016725; Foussard C, 2006, J CLIN ONCOL, V24, p424S; Ghetie MA, 2001, BLOOD, V97, P1392, DOI 10.1182/blood.V97.5.1392; Ghetie MA, 2006, J IMMUNOTHER, V29, P536, DOI 10.1097/01.cji.0000211307.05869.6c; Ghielmini M, 2004, BLOOD, V103, P4416, DOI 10.1182/blood-2003-10-3411; Gianni AM, 2003, BLOOD, V102, P749, DOI 10.1182/blood-2002-08-2476; Gordan LN, 2005, J CLIN ONCOL, V23, P1096, DOI 10.1200/JCO.2005.12.171; Grillo-Lopez AJ, 2002, SEMIN ONCOL, V29, P105, DOI 10.1053/sonc.2002.30145; Habermann TM, 2006, J CLIN ONCOL, V24, P3121, DOI 10.1200/JCO.2005.05.1003; Habermann TM, 2003, BLOOD, V102, p6A; HAGBERG H, 2006, ANN ONCOL S4, V17; Hainsworth JD, 2003, J CLIN ONCOL, V21, P1746, DOI 10.1200/JCO.2003.09.027; Hainsworth JD, 2004, SEMIN ONCOL, V31, P17, DOI 10.1053/j.seminoncol.2003.12.005; Hainsworth JD, 2005, J CLIN ONCOL, V23, P1088, DOI 10.1200/JCO.2005.12.191; Hainsworth JD, 2002, J CLIN ONCOL, V20, P4261, DOI 10.1200/JCO.2002.08.674; Herold M, 2004, BLOOD, V104, p169A, DOI 10.1182/blood.V104.11.584.584; Hiddemann W, 2003, BLOOD, V102, p104A; Hiddemann W, 2005, BLOOD, V106, P3725, DOI 10.1182/blood-2005-01-0016; HOCHSTER HS, 2004, P ASCO NEW ORLEANS; Horwitz Steven M, 2004, Curr Hematol Rep, V3, P227; Jain AB, 2005, TRANSPLANTATION, V80, P1692, DOI 10.1097/01.tp.0000185570.41571.df; Janas E, 2005, CLIN EXP IMMUNOL, V139, P439, DOI 10.1111/j.1365-2249.2005.02720.x; Kahl BS, 2006, CLIN LYMPHOMA MYELOM, V6, P423, DOI 10.3816/CLM.2006.n.024; KAPLAN LD, 2004, P AM SOC CLIN ONCOL; Keating MJ, 2005, J CLIN ONCOL, V23, P4079, DOI 10.1200/JCO.2005.12.051; Kennedy AD, 2004, J IMMUNOL, V172, P3280, DOI 10.4049/jimmunol.172.5.3280; Kim DH, 2006, BLOOD, V108, P2720, DOI 10.1182/blood-2006-01-009480; Kimby E, 2005, CANCER TREAT REV, V31, P456, DOI 10.1016/j.ctrv.2005.05.007; Kimby E, 2002, SEMIN ONCOL, V29, P7, DOI 10.1053/sonc.2002.32747; Lemieux B, 2004, HEMATOL J, V5, P467, DOI 10.1038/sj.thj.6200559; Lemieux B, 2004, BONE MARROW TRANSPL, V33, P921, DOI 10.1038/sj.bmt.1704467; Lim SH, 2004, BLOOD, V104, p395A; Lim SH, 2005, BONE MARROW TRANSPL, V35, P207, DOI 10.1038/sj.bmt.1704742; Maloney DG, 1999, SEMIN ONCOL, V26, P74; Marcus R, 2005, BLOOD, V105, P1417, DOI 10.1182/blood-2004-08-3175; MARCUS R, 2006, BLOOD, V108; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; Milpied N, 2000, ANN ONCOL, V11, P113, DOI 10.1023/A:1008372814223; Mounier N, 2006, HAEMATOLOGICA, V91, P715; Neumann F, 2006, ANN HEMATOL, V85, P530, DOI 10.1007/s00277-006-0113-5; O'Brien SM, 2001, J CLIN ONCOL, V19, P2165, DOI 10.1200/JCO.2001.19.8.2165; Paydas S, 2003, LEUKEMIA LYMPHOMA, V44, P2165, DOI 10.1080/1042819031000123555; PFREUNDSCHUH MG, 2004, P ASCO NEW ORLEANS; Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7; Portlock CS, 2006, LEUKEMIA LYMPHOMA, V47, P1260, DOI 10.1080/10428190600565354; Rehwald U, 2003, BLOOD, V101, P420, DOI 10.1182/blood.V101.2.420; Salles GA, 2004, BLOOD, V104, p49A; Sehn LH, 2007, BLOOD, V109, P1857, DOI 10.1182/blood-2006-08-038257; Sehn LH, 2005, J CLIN ONCOL, V23, P5027, DOI 10.1200/JCO.2005.09.137; Smith MR, 2003, ONCOGENE, V22, P7359, DOI 10.1038/sj.onc.1206939; SOLALCELIGNY P, 2004, BLOOD, V104; Thomas DA, 2006, CANCER-AM CANCER SOC, V106, P1569, DOI 10.1002/cncr.21776; Traulle Catherine, 2005, Future Oncol, V1, P297; van der Kolk LE, 2002, LEUKEMIA, V16, P693, DOI 10.1038/sj.leu.2402424; van Oers MHJ, 2006, BLOOD, V108, P3295, DOI 10.1182/blood-2006-05-021113; Vega MI, 2004, ONCOGENE, V23, P3530, DOI 10.1038/sj.onc.1207336; Weng WK, 2001, BLOOD, V98, P1352, DOI 10.1182/blood.V98.5.1352; Weng WK, 2003, J CLIN ONCOL, V21, P3940, DOI 10.1200/JCO.2003.05.013; Wierda W, 2005, J CLIN ONCOL, V23, P4070, DOI 10.1200/JCO.2005.12.516; Winkler U, 1999, BLOOD, V94, P2217, DOI 10.1182/blood.V94.7.2217.419k02_2217_2224; Winter JN, 2006, BLOOD, V107, P4207, DOI 10.1182/blood-2005-10-4222; Younes A, 2003, CANCER, V98, P310, DOI 10.1002/cncr.11511	96	169	188	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3603	3613		10.1038/sj.onc.1210376	http://dx.doi.org/10.1038/sj.onc.1210376			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530014				2023-01-03	WOS:000246816100003
J	Gupta, R; Plantinga, LC; Fink, NE; Melamed, ML; Coresh, J; Fox, CS; Levin, NW; Powe, NR				Gupta, Rajesh; Plantinga, Laura C.; Fink, Nancy E.; Melamed, Michal L.; Coresh, Josef; Fox, Caroline S.; Levin, Nathan W.; Powe, Neil R.			Statin use and hospitalization for sepsis in patients with chronic kidney disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHRONIC-HEMODIALYSIS PATIENTS; PLACEBO-CONTROLLED TRIAL; COA REDUCTASE INHIBITOR; REACTIVE PROTEIN-LEVELS; DIALYSIS PATIENTS; RISK-FACTORS; IMPROVES SURVIVAL; UNITED-STATES; IN-VIVO; MORTALITY	Context Patients with chronic kidney disease are at high risk for sepsis and sepsis-related mortality. Objective To assess whether statin use is associated with a reduction in hospitalizations for sepsis in dialysis patients. Design, Setting, and Patients National prospective cohort study that enrolled 1041 incident dialysis patients at 81 US not-for-profit outpatient dialysis clinics from October 1995 to June 1998, with follow-up to January 2005. Statin use was determined by medical record review. Rates of hospitalization for sepsis between statin users and control patients were compared using multivariate regression models, with adjustment for potential confounders in the overall cohort and in a subcohort in which control patients were matched to statin users according to their likelihood ( propensity) to have been prescribed a statin. Main Outcome Measure Hospitalizations for sepsis were determined through hospital records from the United States Renal Data System ( mean follow-up, 3.4 years). Results There were 303 hospitalizations for sepsis. Rates of sepsis-related hospitalizations were significantly lower in patients receiving statins ( crude incidence rate, 41/ 1000 patient-years) than in those not receiving statins ( crude incidence rate, 110/ 1000 patient-years) ( P <. 001). With adjustment for demographics and dialysis modality, statin users were substantially less likely to be subsequently hospitalized for sepsis ( incidence rate ratio, 0.41; 95% confidence interval [CI], 0.25-0.68). Further adjustment for comorbidities and laboratory values continued to show this protective association ( incidence rate ratio, 0.38; 95% CI, 0.21-0.67). In the propensity-matched subcohort, statin use was even more protective ( incidence rate ratio, 0.24; 95% CI, 0.11-0.49). Conclusions Use of statins was strongly and independently associated with a reduction in the risk of hospitalization for sepsis in patients who had chronic kidney disease and were receiving dialysis. Randomized trials of statins in patients with chronic kidney disease should examine the prevention of sepsis as a potentially important benefit.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Epidemiol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Populat Hlth, Bronx, NY 10467 USA; Blood Inst Framingham Heart Study, Framingham, MA USA; Renal Res Inst, New York, NY USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Framingham Heart Study; Renal Research Institute	Powe, NR (corresponding author), Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2-600, Baltimore, MD 21205 USA.	npowe@jhmi.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008365] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059616, F32DK069017, K24DK002643] Funding Source: NIH RePORTER; AHRQ HHS [R01-HS-08365] Funding Source: Medline; NHLBI NIH HHS [R01-HL 62985] Funding Source: Medline; NIDDK NIH HHS [R01-DK 59616, F32DK069017, K24DK02643] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aikawa M, 2001, CIRCULATION, V103, P276; Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64; Almog Y, 2004, CIRCULATION, V110, P880, DOI 10.1161/01.CIR.0000138932.17956.F1; Ando H, 2000, J PHARMACOL EXP THER, V294, P1043; Astor BC, 2005, J AM SOC NEPHROL, V16, P1449, DOI 10.1681/ASN.2004090748; Athienites NV, 2000, SEMIN DIALYSIS, V13, P320, DOI 10.1046/j.1525-139x.2000.00095.x; Baigent C, 2003, KIDNEY INT, V63, pS207, DOI 10.1046/j.1523-1755.63.s84.4.x; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; BRUNBUISSON C, 1995, JAMA-J AM MED ASSOC, V274, P968, DOI 10.1001/jama.274.12.968; Catron DM, 2004, INFECT IMMUN, V72, P1036, DOI 10.1128/IAI.72.2.1036-1042.2004; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Coresh J, 1998, J Am Soc Nephrol, V9, pS24; del Real G, 2004, J EXP MED, V200, P541, DOI 10.1084/jem.20040061; Endo A, 2004, ATHEROSCLEROSIS SUPP, V5, P125, DOI 10.1016/j.atherosclerosissup.2004.08.033; Endo A, 2004, ATHEROSCLEROSIS SUPP, V5, P67, DOI 10.1016/j.atherosclerosissup.2004.08.026; Equils O, 2006, CLIN EXP IMMUNOL, V143, P58, DOI 10.1111/j.1365-2249.2005.02961.x; Fox CS, 2004, CLIN NEPHROL, V61, P299; Giguere JF, 2004, J VIROL, V78, P12062, DOI 10.1128/JVI.78.21.12062-12065.2004; Giusti-Paiva A, 2004, SHOCK, V21, P271, DOI 10.1097/10.shk.0000115756.74059.ce; Hackam DG, 2006, LANCET, V367, P413, DOI 10.1016/S0140-6736(06)68041-0; Hoen B, 1998, J AM SOC NEPHROL, V9, P869; IKEURA R, 1988, J ANTIBIOT, V41, P1148, DOI 10.7164/antibiotics.41.1148; Iseki K, 2002, KIDNEY INT, V61, P1887, DOI 10.1046/j.1523-1755.2002.00324.x; Kinchen KS, 2002, ANN INTERN MED, V137, P479, DOI 10.7326/0003-4819-137-6-200209170-00007; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; Liappis AP, 2001, CLIN INFECT DIS, V33, P1352, DOI 10.1086/323334; Liu YM, 2004, JAMA-J AM MED ASSOC, V291, P451, DOI 10.1001/jama.291.4.451; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; McCarey DW, 2004, LANCET, V363, P2015, DOI 10.1016/S0140-6736(04)16449-0; Merx MW, 2004, CIRCULATION, V109, P2560, DOI 10.1161/01.CIR.0000129774.09737.5B; Miskulin DC, 2002, AM J KIDNEY DIS, V39, P324, DOI 10.1053/ajkd.2002.30552; Niessner A, 2006, ATHEROSCLEROSIS, V189, P408, DOI 10.1016/j.atherosclerosis.2005.12.022; Ollendorf DA, 2002, VALUE HEALTH, V5, P79, DOI 10.1046/j.1524-4733.2002.52013.x; Parsons L, REDUCING BIAS PROPEN; Plantinga LC, 2004, J AM SOC NEPHROL, V15, P3144, DOI 10.1097/01.ASN.0000146424.91128.2A; Powe NR, 1999, KIDNEY INT, V55, P1081, DOI 10.1046/j.1523-1755.1999.0550031081.x; Ridker PM, 2005, NEW ENGL J MED, V352, P20, DOI 10.1056/NEJMoa042378; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Sarnak MJ, 2000, KIDNEY INT, V58, P1758, DOI 10.1111/j.1523-1755.2000.00337.x; Sola S, 2006, J AM COLL CARDIOL, V47, P332, DOI 10.1016/j.jacc.2005.06.088; Vollmer T, 2004, LANCET, V363, P1607, DOI 10.1016/S0140-6736(04)16205-3; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058	45	92	99	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 4	2007	297	13					1455	1464		10.1001/jama.297.13.1455	http://dx.doi.org/10.1001/jama.297.13.1455			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153AM	17405971				2023-01-03	WOS:000245404100022
J	Kendall, M; Harris, F; Boyd, K; Sheikh, A; Murray, SA; Brown, D; Mallinson, I; Kearney, N; Worth, A				Kendall, Marilyn; Harris, Fiona; Boyd, Kirsty; Sheikh, Aziz; Murray, Scott A.; Brown, Duncan; Mallinson, Ian; Kearney, Nora; Worth, Allison			Key challenges and ways forward in researching the "good death": qualitative in-depth interview and focus group study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARE; CANCER; VIEWS; NEED	Objective To understand key challenges in researching end of life issues and identify ways of overcoming these. Design Qualitative study involving in-depth interviews with researchers and focus groups with people affected by cancer. Participants An international sample of 32 researchers; seven patients with experience of cancer; and four carers in south east Scotland. Results Researchers highlighted the difficulty of defining, the end of life, overprotective gatekeeping by ethics committees and clinical staff, the need to factor in high attrition rates associated with deterioration or death, and managing the emotions of participants and research staff. People affected by cancer and researchers suggested that many people nearing the end of life do want to be offered the chance to participate in research, provided it is conducted sensitively. Although such research can be demanding, most researchers believed it to be no more problematic than many other areas of research and that the challenges identified can be overcome. Conclusions The continuing taboos around death and dying act as barriers to the commissioning and conduct of end of life research. Some people facing death, however, may want to participate in research and should be allowed to do so. Ethics committees and clinical staff must balance understandable concern about non-maleficence with the right of people with advanced illness to participate in research. Despite the inherent difficulties, end of life research can be conducted with ethical and methodological rigour. Adequate psychological support must be provided for participants, researchers, and transcribers.	Univ Edinburgh, Primary Palliat Care Res Grp, Div Community Hlth Sci, Gen Practice Sect, Edinburgh EH8 9DX, Midlothian, Scotland; St Columbas Hosp, Edinburgh EH5 3RW, Midlothian, Scotland; Univ Stirling, Canc Care Res Ctr, Dept Nursing & Midwifery, Stirling FK9 4LA, Scotland	University of Edinburgh; University of Edinburgh; University of Stirling	Kendall, M (corresponding author), Univ Edinburgh, Primary Palliat Care Res Grp, Div Community Hlth Sci, Gen Practice Sect, Edinburgh EH8 9DX, Midlothian, Scotland.	Marilyn.Kendall@ed.ac.uk	Sheikh, Aziz/D-2818-2009; Harris, Fiona/B-5633-2008	Sheikh, Aziz/0000-0001-7022-3056; Harris, Fiona/0000-0003-3258-5624; Boyd, Kirsty/0000-0002-5526-1078				Addington-Hall J, 2002, EUR J CANCER CARE, V11, P220, DOI 10.1046/j.1365-2354.2002.00343.x; *ASS SOC ANTHR, ETH GUID GOOD RES PR; Beaver K., 1999, INT J PALLIAT NURS, V5, P13, DOI [10.12968/ijpn.1999.5.1.9926, DOI 10.12968/IJPN.1999.5.1.9926]; Bowling A, 2000, BRIT MED J, V320, P1205; *BRIT SOC ASS, STAT ETH PRACT; Clark J, 2003, BRIT MED J, V327, P174, DOI 10.1136/bmj.327.7408.174; Cook AM, 2002, PALLIATIVE MED, V16, P163, DOI 10.1191/0269216302pm551xx; Entwistle V, 2002, EUR J CANCER CARE, V11, P232, DOI 10.1046/j.1365-2354.2002.00344.x; Gray RE, 2003, QUAL INQ, V9, P254, DOI 10.1177/1077800402250957; Gray Ross, 2000, Health Expect, V3, P137, DOI 10.1046/j.1369-6513.2000.00071.x; Harris FM, 2005, WHAT ARE BEST WAYS S; Krishnasamy M, 2000, PALLIATIVE MED, V14, P410, DOI 10.1191/026921600701536246; Lawton J, 2001, QUAL HEALTH RES, V11, P693, DOI 10.1177/104973201129119389; Lee RaymondM., 1993, DOING RES SENSITIVE; Riley J, 2005, LANCET, V365, P735; Rose K, 1998, QUAL HEALTH RES, V8, P556, DOI 10.1177/104973239800800409; ROWLING L, 1999, MORTALITY, V14, P167; Seale C, 1998, CONSTRUCTING DEATH S; Seamark DA, 2000, PALLIATIVE MED, V14, P55, DOI 10.1191/026921600674088597; Seymour J, 2002, EUR J CANCER CARE, V11, P215, DOI 10.1046/j.1365-2354.2002.00342.x; Seymour J, 2005, INT J PALLIAT NURS, V11, P240, DOI 10.12968/ijpn.2005.11.5.240; Woods S, 2000, NURS ETHICS, V7, P314, DOI 10.1191/096973300676700359	22	80	80	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 10	2007	334	7592					521	524		10.1136/bmj.39097.582639.55	http://dx.doi.org/10.1136/bmj.39097.582639.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	148VV	17329313	Bronze, Green Published			2023-01-03	WOS:000245106400042
J	Pas, ABT; Lopriore, E; Engbers, MJ; Walther, FJ				Pas, Arjan B. te; Lopriore, Enrico; Engbers, Marissa J.; Walther, Frans J.			Early Respiratory Management of Respiratory Distress Syndrome in Very Preterm Infants and Bronchopulmonary Dysplasia: A Case-Control Study	PLOS ONE			English	Article							POSITIVE AIRWAY PRESSURE; BIRTH-WEIGHT INFANTS; DELIVERY ROOM; EXPIRATORY PRESSURE; MANUAL VENTILATION; LUNG INJURY; CHEST-WALL; SURFACTANT; IMPROVE; TRIAL	Background. In the period immediately after birth, preterm infants are highly susceptible to lung injury. Early nasal continuous positive airway pressure (ENCPAP) is an attempt to avoid intubation and may minimize lung injury. In contrast, ENCPAP can fail, and at that time surfactant rescue can be less effective. Objective. To compare the pulmonary clinical course and outcome of very preterm infants (gestational age 25-32 weeks) with respiratory distress syndrome (RDS) who started with ENCPAP and failed (ECF group), with a control group of infants matched for gestational age, who were directly intubated in the delivery room (DRI group). Primary outcome consisted of death during admission or bronchopulmonary dysplasia (BPD). Results. 25 infants were included in the ECF group and 50 control infants matched for gestational age were included in the DRI group. Mean gestational age and birth weight in the ECF group were 29.7 weeks and 1,393 g and in the DRI group 29.1 weeks and 1,261 g (p = NS). The incidence of BPD was significantly lower in the ECF group than in the DRI group (4% vs. 35%; P < 0.004; OR 12.6 (95% CI 1.6-101)). Neonatal mortality was similar in both groups (4%). The incidence of neonatal morbidities such as severe cerebral injury, patent ductus arteriosus, necrotizing enterocolitis and retinopathy of prematurity, was not significantly different between the two groups. Conclusion. A trial of ENCPAP at birth may reduce the incidence of BPD and does not seem to be detrimental in very preterm infants. Randomized controlled trials are needed to test whether early respiratory management of preterm infants with RDS plays an important role in the development of BPD.	[Pas, Arjan B. te; Lopriore, Enrico; Engbers, Marissa J.; Walther, Frans J.] Leiden Univ, Med Ctr, Div Neonatol, Dept Pediat, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Pas, ABT (corresponding author), Leiden Univ, Med Ctr, Div Neonatol, Dept Pediat, Leiden, Netherlands.	a.b.te_pas@lumc.nl	Lopriore, Enrico/ABE-3576-2021; pas, arjan te/AAA-9019-2020	Lopriore, Enrico/0000-0002-3513-5066; pas, arjan te/0000-0001-7831-8797; Walther, Frans/0000-0003-1931-159X				Aly H, 2005, PEDIATRICS, V115, P1660, DOI 10.1542/peds.2004-2493; Aly H, 2004, PEDIATRICS, V114, P697, DOI 10.1542/peds.2003-0572-L; Ammari A, 2005, J PEDIATR-US, V147, P341, DOI 10.1016/j.jpeds.2005.04.062; AVERY ME, 1987, PEDIATRICS, V79, P26; BEVILACQUA G, 1993, J PERINAT MED, V21, P329, DOI 10.1515/jpme.1993.21.5.329; Bjorklund LJ, 1997, PEDIATR RES, V42, P348; Bjorklund LJ, 2001, ACTA ANAESTH SCAND, V45, P986, DOI 10.1034/j.1399-6576.2001.450811.x; Donn Steven M, 2003, Semin Neonatol, V8, P441, DOI 10.1016/S1084-2756(03)00124-6; Finer NN, 2004, PEDIATRICS, V114, P651, DOI 10.1542/peds.2004-0394; GERHARDT T, 1980, ACTA PAEDIATR SCAND, V69, P359, DOI 10.1111/j.1651-2227.1980.tb07093.x; Gittermann MK, 1997, EUR J PEDIATR, V156, P384, DOI 10.1007/s004310050620; HELDT GP, 1987, J APPL PHYSIOL, V62, P170, DOI 10.1152/jappl.1987.62.1.170; Hussey SG, 2004, ARCH DIS CHILD-FETAL, V89, pF490, DOI 10.1136/adc.2003.047712; Ikegami M, 2000, PEDIATR RES, V47, P398, DOI 10.1203/00006450-200003000-00019; Ingimarsson J, 2004, INTENS CARE MED, V30, P1446, DOI 10.1007/s00134-004-2227-3; Jobe AH, 2005, J PEDIATR-US, V147, P284, DOI 10.1016/j.jpeds.2005.05.003; Jobe AH, 2002, PEDIATR RES, V52, P387, DOI 10.1203/01.PDR.0000025341.25481.42; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; Lindner W, 1999, PEDIATRICS, V103, P961, DOI 10.1542/peds.103.5.961; Morley CJ, 2001, PEDIATRICS, V108, P1383, DOI 10.1542/peds.108.6.1383; ODONNELL CP, 2005, ARCH DIS CHILD FETAL; Perlman JM, 2006, PEDIATRICS, V117, pE978, DOI 10.1542/ped.2006-0350; SOLL RF, 2001, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD000510, 10.1002/14651858.CD000510]; STEVENS TP, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003063; SUBRAMANIAM P, 2000, COCHRANE DB SYST REV; te Pas AB, 2006, CURR PEDIATR REV, V2, P187, DOI 10.2174/157339606778019693; Thomson MA, 2004, AM J RESP CRIT CARE, V169, P1054, DOI 10.1164/rccm.200309-1276OC; Thomson MA, 2002, BIOL NEONATE, V81, P16, DOI 10.1159/000056766; Van Marter LJ, 2000, PEDIATRICS, V105, P1194, DOI 10.1542/peds.105.6.1194; Verder H, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.2.e24; Wada K, 1997, J APPL PHYSIOL, V83, P1054, DOI 10.1152/jappl.1997.83.4.1054; Yost CC, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001456	32	16	17	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2007	2	2							e192	10.1371/journal.pone.0000192	http://dx.doi.org/10.1371/journal.pone.0000192			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DI	17285145	Green Published, gold, Green Submitted			2023-01-03	WOS:000207444300005
J	Phillips, AN; Gazzard, BG; Clumeck, N; Losso, MH; Lundgren, JD				Phillips, Andrew N.; Gazzard, Brian G.; Clumeck, Nathan; Losso, Marcelo H.; Lundgren, Jens D.			When should antiretroviral therapy for HIV be started?	BRITISH MEDICAL JOURNAL			English	Editorial Material							VIROLOGICAL RESPONSE; PROTEASE INHIBITOR; CLINICAL-PRACTICE; INFECTION; RISK; COUNTS; ADULTS; TIME		UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England; Chelsea & Westminster Hosp, London, England; Hosp St Pierre, Dept Infect Dis, Brussels, Belgium; Hosp JM Ramos Mejia, Serv Inmunocomprometidos, Buenos Aires, DF, Argentina; Hvidovre Univ Hosp, Copenhagen HIV Programme, Copenhagen, Denmark	University of London; University College London; UCL Medical School; Imperial College London; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Hospital Ramos Mejia; University of Buenos Aires; University of Copenhagen	Phillips, AN (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England.	a.phillips@pcps.ucl.ac.uk	Lundgren, Jens/AAE-6876-2019; Phillips, Andrew N/B-4427-2008	Phillips, Andrew N/0000-0003-2384-4807; Lundgren, Jens/0000-0001-8901-7850				Bannister WP, 2006, JAIDS-J ACQ IMM DEF, V42, P229, DOI 10.1097/01.qai.0000214815.95786.31; Beral V, 2004, AIDS, V18, P51, DOI [10.1097/00002030-200401020-00006, 10.1097/01.aids.0000096908.73209.5d]; Blackham J, 2005, AIDS, V19, P487; BURMAN W, 2006, 16 INT AIDS C; Burman WJ, 1998, JAMA-J AM MED ASSOC, V280, P93, DOI 10.1001/jama.280.1.93; Carr A, 2000, AIDS, V14, pF25, DOI 10.1097/00002030-200002180-00001; Carr A, 1998, NEW ENGL J MED, V339, P1296, DOI 10.1056/NEJM199810293391806; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; FRIISMOLLER N, 2006, 13 C RETR OPP INF; Gazzard B, 2005, HIV MED, V6, P1, DOI 10.1111/j.1468-1293.2005.0311b.x; GRINSZTEJN B, 2006, 13 C RETR OPP INF DE; Holmberg SD, 2004, CLIN INFECT DIS, V39, P1699, DOI 10.1086/425743; Lampe FC, 2006, ARCH INTERN MED, V166, P521, DOI 10.1001/archinte.166.5.521; Maini MK, 1996, GENITOURIN MED, V72, P27; Moore RD, 2005, JAIDS-J ACQ IMM DEF, V39, P195; Nolan David, 2005, Sex Health, V2, P153, DOI 10.1071/SH04058; *PAN CLIN PRACT TR, 2006, GUID US ANT AG HIV 1; Phillips AN, 2003, AIDS, V17, P1863, DOI 10.1097/00002030-200309050-00004; Podlekareva D, 2006, J INFECT DIS, V194, P633, DOI 10.1086/506366; Walker BD, 1998, JAMA-J AM MED ASSOC, V280, P91, DOI 10.1001/jama.280.1.91; WEBER R, 2005, 12 C RETR OPP INF	24	58	59	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 13	2007	334	7584					76	78		10.1136/bmj.39064.406389.94	http://dx.doi.org/10.1136/bmj.39064.406389.94			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	127DZ	17218713	Green Published			2023-01-03	WOS:000243566800029
J	Havemeyer, A; Bittner, F; Wollers, S; Mendel, R; Kunze, T; Clement, B				Havemeyer, Antje; Bittner, Florian; Wollers, Silke; Mendel, Ralf; Kunze, Thomas; Clement, Bernd			Identification of the missing component in the mitochondrial benzamidoxime prodrug-converting system as a novel molybdenum enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRATE REDUCTASE; RAT-LIVER; OUTER-MEMBRANE; ARABIDOPSIS-THALIANA; ESCHERICHIA-COLI; ALDEHYDE OXIDASE; XANTHINE-OXIDASE; CYTOCHROME B(5); PIG-LIVER; COFACTOR	Amidoximes can be used as prodrugs for amidines and related functional groups to enhance their intestinal absorption. These prodrugs are reduced to their active amidines. Other N-hydroxylated structures are mutagenic or responsible for toxic effects of drugs and are detoxified by reduction. In this study, a N-reductive enzyme system of pig liver mitochondria using benzamidoxime as a model substrate was identified. A protein fraction free from cytochrome b(5) and cytochrome b(5) reductase was purified, enhancing 250-fold the minor benzamidoxime-reductase activity catalyzed by the membrane-bound cytochrome b(5)/NADH cytochrome b(5) reductase system. This fraction contained a 35-kDa protein with homologies to the C-terminal domain of the human molybdenum cofactor sulfurase. Here it was demonstrated that this 35-kDa protein contains molybdenum cofactor and forms the hitherto ill defined third component of the N-reductive complex in the outer mitochondrial membrane. Thus, the 35-kDa protein represents a novel group of molybdenum proteins in eukaryotes as it forms the catalytic part of a three-component enzyme complex consisting of separate proteins. Supporting these findings, recombinant C-terminal domain of the human molybdenum cofactor sulfurase exhibited N-reductive activity in vitro, which was strictly dependent on molybdenum cofactor.	Univ Kiel, Dept Pharmaceut & Med Chem, Inst Pharmaceut, D-24118 Kiel, Germany; Tech Univ Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany	University of Kiel; Braunschweig University of Technology	Clement, B (corresponding author), Univ Kiel, Dept Pharmaceut & Med Chem, Inst Pharmaceut, Gutenbergstr 76, D-24118 Kiel, Germany.	bclement@pharmazie.uni-kiel.de						Altuve A, 2001, BIOCHEMISTRY-US, V40, P9469, DOI 10.1021/bi010636i; Andersson S, 2005, DRUG METAB DISPOS, V33, P570, DOI 10.1124/dmd.104.002972; Bittner F, 2001, J BIOL CHEM, V276, P40381, DOI 10.1074/jbc.C100472200; Campbell WH, 1999, ANNU REV PLANT PHYS, V50, P277, DOI 10.1146/annurev.arplant.50.1.277; Clement B, 1997, J BIOL CHEM, V272, P19615, DOI 10.1074/jbc.272.31.19615; CLEMENT B, 1988, ARCH PHARM, V321, P955, DOI 10.1002/ardp.19883211228; Clement B, 2005, DRUG METAB DISPOS, V33, P1740, DOI 10.1124/dmd.105.005249; CLEMENT B, 1992, BIOCHEM PHARMACOL, V44, P1501, DOI 10.1016/0006-2952(92)90464-T; Clement B, 2005, LIFE SCI, V77, P205, DOI 10.1016/j.lfs.2004.12.028; Clement B, 2002, DRUG METAB REV, V34, P565, DOI 10.1081/DMR-120005643; Clement B, 2003, DRUG METAB DISPOS, V31, P645, DOI 10.1124/dmd.31.5.645; deKroon AIPM, 1997, BBA-BIOMEMBRANES, V1325, P108, DOI 10.1016/S0005-2736(96)00240-4; Estabrook R W, 1978, Methods Enzymol, V52, P212; Ettmayer P, 2004, J MED CHEM, V47, P2393, DOI 10.1021/jm0303812; Frohlich AK, 2005, XENOBIOTICA, V35, P17, DOI 10.1080/00498250400021895; FUKUSHIMA H, 1981, J BIOL CHEM, V256, P4822; GONENNE A, 1978, ANAL BIOCHEM, V87, P28, DOI 10.1016/0003-2697(78)90565-1; HAUPTMANN J, 1988, PHARMAZIE, V43, P559; Heidenreich T, 2005, J BIOL CHEM, V280, P4213, DOI 10.1074/jbc.M411195200; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; Ichida K, 2001, BIOCHEM BIOPH RES CO, V282, P1194, DOI 10.1006/bbrc.2001.4719; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; JOHNSON JL, 1977, J BIOL CHEM, V252, P4994; KADLUBAR FF, 1974, ARCH BIOCHEM BIOPHYS, V162, P83, DOI 10.1016/0003-9861(74)90107-6; Kroneck PMH, 2002, MET IONS BIOL SYST, V39, P369; Kruger P., 1885, BER DTSCH CHEM GES, V18, P1055; Kurian JR, 2004, J PHARMACOL EXP THER, V311, P1171, DOI 10.1124/jpet.104.072389; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mihara K, 1978, Methods Enzymol, V52, P102; NASON A, 1971, P NATL ACAD SCI USA, V68, P3242, DOI 10.1073/pnas.68.12.3242; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; RAMADOSS CS, 1980, Z NATURFORSCH C, V35, P702; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; TATSUMI K, 1987, ARCH BIOCHEM BIOPHYS, V253, P413, DOI 10.1016/0003-9861(87)90194-9; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337	40	129	140	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2006	281	46					34796	34802		10.1074/jbc.M607697200	http://dx.doi.org/10.1074/jbc.M607697200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	104CN	16973608	hybrid			2023-01-03	WOS:000241933700011
J	Salazar, H; Llorente, I; Jara-Oseguera, A; Garcia-Villegas, R; Munari, M; Gordon, SE; Islas, LD; Rosenbaum, T				Salazar, Hector; Llorente, Itzel; Jara-Oseguera, Andres; Garcia-Villegas, Refugio; Munari, Mika; Gordon, Sharona E.; Islas, Leon D.; Rosenbaum, Tamara			A single N-terminal cysteine in TRPV1 determines activation by pungent compounds from onion and garlic	NATURE NEUROSCIENCE			English	Article							ION-CHANNEL; COVALENT MODIFICATION; CAPSAICIN RECEPTOR; VANILLOID RECEPTOR; ANKYRIN REPEATS; S-NITROSYLATION; TRPA1; CHEMISTRY; ALLIUM; PAIN	Some members of the transient receptor potential (TRP) family of cation channels mediate sensory responses to irritant substances. Although it is well known that TRPA1 channels are activated by pungent compounds found in garlic, onion, mustard and cinnamon extracts, activation of TRPV1 by these extracts remains controversial. Here we establish that TRPV1 is activated by pungent extracts from onion and garlic, as well as by allicin, the active compound in these preparations, and participates together with TRPA1 in the pain-related behavior induced by this compound. We found that in TRPV1 these agents act by covalent modification of cysteine residues. In contrast to TRPA1 channels, modification of a single cysteine located in the N-terminal region of TRPV1 was necessary and sufficient for all the effects we observed. Our findings point to a conserved mechanism of activation in TRP channels, which provides new insights into the molecular basis of noxious stimuli detection.	[Salazar, Hector; Llorente, Itzel; Jara-Oseguera, Andres; Rosenbaum, Tamara] Univ Nacl Autonoma Mexico, Dept Biofis, Inst Fisiol Celular, Mexico City 04510, DF, Mexico; [Jara-Oseguera, Andres; Islas, Leon D.] Univ Nacl Autonoma Mexico, Dept Fisiol, Fac Med, Mexico City 04510, DF, Mexico; [Garcia-Villegas, Refugio] Estudios Avanzados Inst Politecn Nacl, Ctr Invest, Dept Fisiol Biofis & Neurosci, Mexico City 07360, DF, Mexico; [Munari, Mika; Gordon, Sharona E.] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; CIO - Centro de Investigaciones en Optica A.C.; University of Washington; University of Washington Seattle	Rosenbaum, T (corresponding author), Univ Nacl Autonoma Mexico, Dept Biofis, Inst Fisiol Celular, Circuito Exterior S-N,Ciudad Univ, Mexico City 04510, DF, Mexico.	trosenba@ifc.unam.mx	Islas, Leon D/AAW-9845-2020	Islas, Leon D/0000-0002-7461-5214; Rosenbaum, Tamara/0000-0002-4791-3195; Jara Oseguera, Andres/0000-0001-5921-9320; Garcia-Villegas, Refugio/0000-0001-8468-6676	NEI NIH HHS [R01 EY017564, R01 EY017564-04] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY017564] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bautista DM, 2005, P NATL ACAD SCI USA, V102, P12248, DOI 10.1073/pnas.0505356102; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; BLOCK E, 1985, SCI AM, V252, P114, DOI 10.1038/scientificamerican0385-114; Block E, 1996, ADV EXP MED BIOL, V401, P155; CALVEY EM, 1994, J CHROMATOGR SCI, V32, P93, DOI 10.1093/chromsci/32.3.93; Calvey EM, 1998, PHYTOCHEMISTRY, V49, P359, DOI 10.1016/S0031-9422(98)00191-5; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Corey DP, 2004, NATURE, V432, P723, DOI 10.1038/nature03066; Cortright DN, 2007, BBA-MOL BASIS DIS, V1772, P978, DOI 10.1016/j.bbadis.2007.03.003; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Hinman A, 2006, P NATL ACAD SCI USA, V103, P19564, DOI 10.1073/pnas.0609598103; Howard J, 2004, CURR BIOL, V14, pR224, DOI 10.1016/j.cub.2004.02.050; JARA A, 2007, BIOPHYS J, V92, P3901; Jin XS, 2006, J BIOL CHEM, V281, P25006, DOI 10.1074/jbc.C600153200; Jones MG, 2004, J EXP BOT, V55, P1903, DOI 10.1093/jxb/erh138; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Kwan KY, 2006, NEURON, V50, P277, DOI 10.1016/j.neuron.2006.03.042; Lishko PV, 2007, NEURON, V54, P905, DOI 10.1016/j.neuron.2007.05.027; Macpherson LJ, 2007, J NEUROSCI, V27, P11412, DOI 10.1523/JNEUROSCI.3600-07.2007; Macpherson LJ, 2007, NATURE, V445, P541, DOI 10.1038/nature05544; Macpherson LJ, 2005, CURR BIOL, V15, P929, DOI 10.1016/j.cub.2005.04.018; Matalon S, 2003, AM J PHYSIOL-LUNG C, V285, pL1184, DOI 10.1152/ajplung.00281.2003; Michels KB, 2002, ANN EPIDEMIOL, V12, P21, DOI 10.1016/S1047-2797(01)00238-1; Nilius B, 2005, J PHYSIOL-LONDON, V567, P35, DOI 10.1113/jphysiol.2005.088377; Rosenbaum T, 2002, NEURON, V33, P703, DOI 10.1016/S0896-6273(02)00599-8; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; Stein AT, 2006, J GEN PHYSIOL, V128, P509, DOI 10.1085/jgp.200609576; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Susankova K, 2006, MOL PHARMACOL, V70, P383, DOI 10.1124/mol.106.023069; Szallasi A, 1999, PHARMACOL REV, V51, P159; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; Vyklicky L, 2002, NEUROSCIENCE, V111, P435, DOI 10.1016/S0306-4522(02)00051-9; Yoshida T, 2006, NAT CHEM BIOL, V2, P596, DOI 10.1038/nchembio821	35	159	165	1	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	MAR	2008	11	3					255	261		10.1038/nn2056	http://dx.doi.org/10.1038/nn2056			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	267ZS	18297068	Green Accepted			2023-01-03	WOS:000253548300007
J	Clarke, M; Coates, AS; Darby, SC; Davies, C; Gelber, RD; Godwin, I; Goldhirsch, A; Gray, R; Peto, R; Pritchard, KI; Wood, WC				Clarke, M.; Coates, A. S.; Darby, S. C.; Davies, C.; Gelber, R. D.; Godwin, I.; Goldhirsch, A.; Gray, R.; Peto, R.; Pritchard, K. I.; Wood, W. C.		EBCTCG	Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials	LANCET			English	Article							CYTOTOXIC CHEMOTHERAPY; ENDOCRINE THERAPY	Background The long-term effects of adjuvant polychemotherapy regimens in oestrogen-receptor-poor (ER-poor) breast cancer, and the extent to which these effects are modified by age or tamoxifen use, can be assessed by an updated meta-analysis of individual patient data from randomised trials. Methods Collaborative meta-analyses of individual patient data for about 6000 women with ER-poor breast cancer in 46 trials of polychemotherapy versus not (non-taxane-based polychemotherapy, typically about six cycles; trial start dates 1975-96, median 1984) and about 14000 women with ER-poor breast cancer in 50 trials of tamoxifen versus not (some trials in the presence and some in the absence of polychemotherapy; trial start dates 1972-93, median 1982). Findings In women with ER-poor breast cancer, polychemotherapy significantly reduced recurrence, breast cancer mortality; and death from any cause, in those younger than 50 years and those aged 50-69 years at entry into trials of polychemotherapy versus not. In those aged younger than 50 years (1907 women, 15% node-positive), the 10-year risks were: recurrence 33% versus 45% (ratio of 10-year risks 0 . 73, 2p<0.00001), breast cancer mortality 24% versus 32% (ratio 0 . 73, 2p=0.0002), and death from any cause 25% versus 33% (ratio 0 . 75, 2p=0. 0003). In women aged 50-69 years (3965 women, 58% node-positive), the 10-year risks were: recurrence 42% versus 52% (ratio 0 . 82, 2p<0 . 00001), breast cancer mortality 36% versus 42% (ratio 0 . 86, 2p=0. 0004), and death from any cause 39% versus 45% (ratio 0 . 87, 2p=0. 0009). Few were aged 70 years or older. Tamoxifen had little effect on recurrence or death in women who were classified in these trials as having ER-poor disease, and did not significantly modify the effects of polychemotherapy. Interpretation In women who had ER-poor breast cancer, and were either younger than 50 years or between 50 and 69 years, these older adjuvant polychemotherapy regimens were safe (ie, had little effect on mortality from causes other than breast cancer) and produced substantial and definite reductions in the 10-year risks of recurrence and death. Current and future chemotherapy regimens could well yield larger proportional reductions in breast cancer mortality.	[Davies, C.] ATLAS Trial Collaborat Study Grp, Oxford, England; [Clarke, M.; Darby, S. C.; Davies, C.; Godwin, I.; Gray, R.; Peto, R.] CTSU, EBCTCG Secretariat, Oxford OX3 7LF, England; [Gray, R.; Wood, W. C.] Eastern Cooperat Oncol Grp, Boston, MA USA; [Coates, A. S.; Gelber, R. D.; Goldhirsch, A.] Int Breast Canc Study Grp Ludwig, Bern, Switzerland; [Pritchard, K. I.] Natl Canc Inst Canada, Clin Trials Grp, Kingston, ON, Canada; [Pritchard, K. I.] Ontario Clin Oncol Grp, Hamilton, ON, Canada; [Goldhirsch, A.] Swiss Grp Clin Canc Res, Bern, Switzerland; [Goldhirsch, A.] OSAKO, St Gallen, Switzerland; [Pritchard, K. I.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada	University of Oxford; University of Oxford; International Breast Cancer Study Group; Queens University - Canada; Canadian Cancer Trials Group; Swiss Group for Clinical Cancer Research (SAKK); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Clarke, M (corresponding author), CTSU, EBCTCG Secretariat, Richard Doll Bldg, Oxford OX3 7LF, England.	bc.overview@ctsu.ox.ac.uk	GORI, Stefania/N-8827-2016; GORI, Stefania/AAB-4802-2022; Pritchard, Kathleen I/I-2184-2014	GORI, Stefania/0000-0001-6320-405X; GORI, Stefania/0000-0001-6320-405X; Pritchard, Kathleen I/0000-0003-0758-9666; Bergh, Jonas/0000-0001-5526-1847; Wang, Xiang/0000-0002-1522-9532; Gray, Richard/0000-0003-4440-574X; Valentini, Miriam/0000-0002-1421-6975	MRC [MC_U137686850] Funding Source: UKRI; Medical Research Council [MC_U137686850] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ABE O, 1992, LANCET, V339, P71; Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Abe O, 1998, LANCET, V352, P930; Anderson WF, 2006, BREAST CANCER RES TR, V100, P121, DOI 10.1007/s10549-006-9231-y; [Anonymous], 1992, Lancet, V339, P1; CHANG JC, 1981, CANCER-AM CANCER SOC, V48, P2503, DOI 10.1002/1097-0142(19811201)48:11<2503::AID-CNCR2820481126>3.0.CO;2-T; Clahsen PC, 1997, J CLIN ONCOL, V15, P2526, DOI 10.1200/JCO.1997.15.7.2526; Coates AS, 1998, LANCET, V352, P1783, DOI 10.1016/S0140-6736(05)79861-5; Colleoni M, 2001, J CLIN ONCOL, V19, P4141, DOI 10.1200/JCO.2001.19.21.4141; *EARL BREAST CANC, 1990, TREATM EARL BREAST C, V1; GOLDHIRSCH A, 1989, NEW ENGL J MED, V320, P491; KIANG DT, 1980, CANCER, V46, P2814, DOI 10.1002/1097-0142(19801215)46:12+<2814::AID-CNCR2820461415>3.0.CO;2-D; KIANG DT, 1978, NEW ENGL J MED, V299, P1330, DOI 10.1056/NEJM197812142992403; LIPPMAN ME, 1978, NEW ENGL J MED, V298, P1223, DOI 10.1056/NEJM197806012982203; OSBORNE CK, 1989, J CLIN ONCOL, V7, P710, DOI 10.1200/JCO.1989.7.6.710; ROSENBAUM C, 1980, CANCER, V46, P2919, DOI 10.1002/1097-0142(19801215)46:12+<2919::AID-CNCR2820461434>3.0.CO;2-X; RUBENS RD, 1980, CANCER, V46, P2922, DOI 10.1002/1097-0142(19801215)46:12+<2922::AID-CNCR2820461435>3.0.CO;2-D; YOUNG PCM, 1980, CANCER-AM CANCER SOC, V46, P2961, DOI 10.1002/1097-0142(19801215)46:12+<2961::AID-CNCR2820461444>3.0.CO;2-E	18	201	208	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 5	2008	371	9606					29	40						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248YH	18177773				2023-01-03	WOS:000252192600028
J	Chen, RR; Silva, EA; Yuen, WW; Brock, AA; Fischbach, C; Lin, AS; Guldberg, RE; Mooney, DJ				Chen, Ruth R.; Silva, Eduardo A.; Yuen, William W.; Brock, Andrea A.; Fischbach, Claudia; Lin, Angela S.; Guldberg, Robert E.; Mooney, David J.			Integrated approach to designing growth factor delivery systems	FASEB JOURNAL			English	Article						tissue engineering; in vitro models; angiogenesis	ANGIOGENESIS; VEGF; MIGRATION; RECEPTORS; VEGF(165); CELLS; ASSAY	Growth factors have been widely used in strategies to regenerate and repair diseased tissues, but current therapies that go directly from bench to bedside have had limited clinical success. We hypothesize that engineering successful therapies with recombinant proteins will often require specific quantitative information of the spatiotemporal role of the factors and the development of sophisticated delivery approaches that provide appropriate tissue exposures. This hypothesis was tested in the context of therapeutic angiogenesis. An in vitro model of angiogenesis was adapted to quantify the role of the concentration/ gradient of vascular endothelial growth factor [VEGF( 165)] on microvascular endothelial cells, and a delivery system was then designed, based on a mathematical model, to provide the desired profile in ischemic mice hindlimbs. This system significantly enhanced blood vessel formation, and perfusion and recovery from severe ischemia. This general approach may be broadly applicable to growth factor therapies.	Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; St Louis Univ, Dept Biochem Med, St Louis, MO 63103 USA; Sch Mech Engn, Georgia Inst Technol, Atlanta, GA 30332 USA	University of Michigan System; University of Michigan; Harvard University; Saint Louis University; University System of Georgia; Georgia Institute of Technology	Mooney, DJ (corresponding author), Harvard Univ, 319 Pierce Hall, Cambridge, MA 02138 USA.	mooneyd@deas.harvard.edu	Fischbach, Claudia/C-8550-2009; Silva, Eduardo A./M-2711-2015	Fischbach, Claudia/0000-0002-9368-0150; Silva, Eduardo A./0000-0003-3173-7622; Mooney, David/0000-0001-6299-1194	NHLBI NIH HHS [R01 HL-069957] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069957] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chen RR, 2003, PHARM RES-DORDR, V20, P1103, DOI 10.1023/A:1025034925152; Chen RR, 2007, MICROCIRCULATION, V14, P77, DOI 10.1080/10739680601131101; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479; Davenport A.P., 2005, RECEPTOR BINDING TEC, V2nd; Dietrich Franziska, 2006, Angiogenesis, V9, P111, DOI 10.1007/s10456-006-9037-x; Eichmann A, 2005, CURR OPIN NEUROBIOL, V15, P108, DOI 10.1016/j.conb.2005.01.008; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Harris LD, 1998, J BIOMED MATER RES, V42, P396, DOI 10.1002/(SICI)1097-4636(19981205)42:3<396::AID-JBM7>3.0.CO;2-E; Hutchings H, 2003, FASEB J, V17, P1520, DOI 10.1096/fj.02-0691fje; Khurana R, 2005, CIRCULATION, V112, P1813, DOI 10.1161/CIRCULATIONAHA.105.535294; Lazarous DF, 1996, CIRCULATION, V94, P1074, DOI 10.1161/01.CIR.94.5.1074; LIMBIRD LE, 1996, CELL SURFACE RECEPTO; Nakatsu MN, 2003, LAB INVEST, V83, P1873, DOI 10.1097/01.LAB.0000107160.81875.33; NEHLS V, 1995, MICROVASC RES, V50, P311, DOI 10.1006/mvre.1995.1061; Peters MC, 2002, J BIOMED MATER RES, V60, P668, DOI 10.1002/jbm.10134; Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029; Rosinberg Audrey, 2004, Expert Rev Cardiovasc Ther, V2, P271, DOI 10.1586/14779072.2.2.271; Ruhrberg C, 2003, BIOESSAYS, V25, P1052, DOI 10.1002/bies.10351; Russ J. C., 2002, IMAGE PROCESSING HDB, V4th, DOI DOI 10.1201/9781420040760; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Sun QH, 2005, PHARM RES-DORDR, V22, P1110, DOI 10.1007/s11095-005-5644-2; VAISMAN N, 1990, J BIOL CHEM, V265, P19461	24	110	128	1	40	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3896	3903		10.1096/fj.06-7873com	http://dx.doi.org/10.1096/fj.06-7873com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17644610	Green Submitted			2023-01-03	WOS:000251283500015
J	Mackillop, LH; Germain, SJ; Neson-Piercy, C				Mackillop, Lucy H.; Germain, Sarah J.; Neson-Piercy, Catherine			Pregnancy plus - Systemic lupus erythematosus	BRITISH MEDICAL JOURNAL			English	Article							ANTIPHOSPHOLIPID SYNDROME; MANAGEMENT		Queen Charlottes & Chelsea Hosp, London W12 0HS, England; St Thomas Hosp, London SE1 7EH, England; St Thomas Hosp, London, England	Imperial College London; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	Mackillop, LH (corresponding author), Queen Charlottes & Chelsea Hosp, London W12 0HS, England.	lucymackillop@hotrnail.com		Mackillop, Lucy/0000-0002-1927-1594				Branch DW, 2003, OBSTET GYNECOL, V101, P1333, DOI 10.1016/S0029-7844(03)00363-6; Clowse MEB, 2005, ARTHRITIS RHEUM-US, V52, P514, DOI 10.1002/art.20864; D'Cruz DP, 2007, LANCET, V369, P587, DOI 10.1016/S0140-6736(07)60279-7; D'Cruz DP, 2006, BMJ-BRIT MED J, V332, P890, DOI 10.1136/bmj.332.7546.890; Derksen RHWM, 2004, ARTHRITIS RHEUM-US, V50, P1028, DOI 10.1002/art.20105; Khamashta MA, 2006, BEST PRACT RES CL RH, V20, P685, DOI 10.1016/j.berh.2006.04.003; Lim W, 2007, BMJ-BRIT MED J, V334, P1318, DOI 10.1136/bmj.39205.484572.55; Moroni G, 2003, J NEPHROL, V16, P161; Ostensen M, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1957; RuizIrastorza G, 1996, BRIT J RHEUMATOL, V35, P133; Stratta P, 2006, J NEPHROL, V19, P135	11	24	24	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	NOV 3	2007	335	7626					933	936		10.1136/bmj.39358.519491.AD	http://dx.doi.org/10.1136/bmj.39358.519491.AD			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230AS	17974690	Green Published			2023-01-03	WOS:000250848300035
J	Gold, PB; Waghorn, G				Gold, Paul B.; Waghorn, Geoff			Supported employment for people with severe mental illness	LANCET			English	Editorial Material							TRIAL; WORK		Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA; Univ Queensland, Sch Populat Hlth, Richlands, Qld 4076, Australia; Queensland Ctr Mental Hlth Res, Pk Ctr Mental Hlth, Richlands, Qld 4076, Australia	Medical University of South Carolina; University of Queensland; Queensland Centre for Mental Health Research	Waghorn, G (corresponding author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA.	geoff_waghorn@qcmhr.uq.edu.au	Waghorn, Geoffrey/B-6257-2013					Bond GR, 2004, PSYCHIATR REHABIL J, V27, P345, DOI 10.2975/27.2004.345.359; Burns T, 2007, LANCET, V370, P1146, DOI 10.1016/S0140-6736(07)61516-5; Cook JA, 2005, ARCH GEN PSYCHIAT, V62, P505, DOI 10.1001/archpsyc.62.5.505; Crowther RE, 2001, BMJ-BRIT MED J, V322, P204, DOI 10.1136/bmj.322.7280.204; Latimer EA, 2006, BRIT J PSYCHIAT, V189, P65, DOI 10.1192/bjp.bp.105.012641; Mowbray CT, 2005, SOC WORK, V50, P7, DOI 10.1093/sw/50.1.7; ORG. FOR ECON. CO-OPERATION AND DEVELOPMENT, 2006, OECD EMPL OUTL 2006; Organization WH, 2001, WORLD HLTH REPORT 20	8	9	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 29	2007	370	9593					1108	1109		10.1016/S0140-6736(07)61491-3	http://dx.doi.org/10.1016/S0140-6736(07)61491-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	221YQ	17905149				2023-01-03	WOS:000250263700007
J	Cyna, AM; Dodd, J				Cyna, Allan M.; Dodd, Jodie			Clinical update: obstetric anaesthesila	LANCET			English	Article							CONSENT; ANESTHESIA		Womens & Childrens Hosp, Dept Womens Anaesthesia, Adelaide, SA 5006, Australia; Univ Adelaide, Discipline Obstet & Gynaecol, Adelaide, SA, Australia	Womens & Childrens Hospital Australia; University of Adelaide	Cyna, AM (corresponding author), Womens & Childrens Hosp, Dept Womens Anaesthesia, Adelaide, SA 5006, Australia.	allan.cyna@cywhs.sa.gov.au	Cyna, Allan/AAN-5201-2021; Dodd, Jodie/Y-6849-2019	Dodd, Jodie/0000-0002-6363-4874; Cyna, Allan/0000-0002-3138-1091				[Anonymous], 2007, ANESTHESIOLOGY, V106, P843; *AUSTR NZ COLL AN, 2005, AC PAIN MAN SCI EV; Bolton TJ, 2003, ANAESTHESIA, V58, P277, DOI 10.1046/j.1365-2044.2003.30435.x; Chan A.S.J., 2006, PREGNANCY OUTCOME S; Clergue F, 1999, ANESTHESIOLOGY, V91, P1509, DOI 10.1097/00000542-199911000-00045; Clyburn PA, 2004, ANAESTHESIA, V59, P1157, DOI 10.1111/j.1365-2044.2004.04060.x; *COCHR COLL, 2007, COCHRANE LIB; Cyna AM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002251.pub2; Douglas MJ, 2005, EVIDENCE-BASED OBSTETRIC ANESTHESIA, P165; Hepner DL, 2006, ANESTHESIOLOGY, V105, P241, DOI 10.1097/00000542-200608000-00005; Jackson A, 2000, CAN J ANAESTH, V47, P1068, DOI 10.1007/BF03027957; Kelly GD, 2004, INT J OBSTET ANESTH, V13, P71, DOI 10.1016/j.ijoa.2003.08.002; Lewis G., 2004, WHY MOTHERS DIE 2000; Murray D, 2007, ANESTHESIOLOGY, V106, P895, DOI 10.1097/01.anes.0000265145.40825.ac; Ng KW, 2004, COCHRANE DB SYST REV, V2; Paech M, 2006, ANAESTH INTENS CARE, V34, P147, DOI 10.1177/0310057X0603400224; Saravanakumar K, 2006, ANAESTHESIA, V61, P36, DOI 10.1111/j.1365-2044.2005.04433.x; Simmons SW, 2007, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD003401.PUB2; Turnbull DK, 2003, BRIT J ANAESTH, V91, P718, DOI 10.1093/bja/aeg231; Waterstone M, 2001, BMJ-BRIT MED J, V322, P1089, DOI 10.1136/bmj.322.7294.1089	20	18	19	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 25	2007	370	9588					640	642		10.1016/S0140-6736(07)61320-8	http://dx.doi.org/10.1016/S0140-6736(07)61320-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205RD	17720001				2023-01-03	WOS:000249131400010
J	Greene, JA				Greene, Jeremy A.			Pharmaceutical marketing research and the prescribing physician	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								Surveillance of physicians' prescribing patterns and the accumulation and sale of these data for pharmaceutical marketing are currently the subjects of legislation in several states and action by state and national medical associations. Contrary to common perception, the growth of the health care information organization industry has not been limited to the past decade but has been building slowly over the past 50 years, beginning in the 1940s when growth in the prescription drug market fueled industry interest in understanding and influencing prescribing patterns. The development of this surveillance system was not simply imposed on the medical profession by the pharmaceutical industry but was developed through the interactions of pharmaceutical salesmen, pharmaceutical marketers, academic researchers, individual physicians, and physician organizations. Examination of the role of physicians and physician organizations in the development of prescriber profiling is directly relevant to the contemporary policy debate surrounding this issue.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Greene, JA (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.							DEHAEN P, 1945, DEV SCHEDULE NEW DRU, P28; Goss JR, 2000, ANN THORAC SURG, V70, P695, DOI 10.1016/S0003-4975(00)01391-6; GOSSELIN R, 1950, THESIS MASSACHUSETTS; Greene LA, 2004, SOC STUD SCI, V34, P271, DOI 10.1177/0306312704043029; HULL RJ, 1959, WORKINGS PHILOS PHAR, P57; KOWALCZYK L, 2003, BOSTON GLOBE    0525, pA1; *LEA ASS INC, 1962, 1 NDTI LEA ASS INC; MACK J, 2006, PHARMA MARKETING NEW, V5, P1; MARKS HM, 1995, AM J PUBLIC HEALTH, V85, P109, DOI 10.2105/AJPH.85.1.109; MCQUILLAN RL, 1963, STORY DRUG DETAIL MA; Mintz Morton, 1965, THERAPEUTIC NIGHTMAR; MUSACCHIO R, 2006, PHARM EXECUTIVE  MAY, P1; PETERSON AF, 1949, PHARM SELLING DETAIL; PIERSOL GM, 1908, COMMUNICATION; ROSS W, 2006, MED MARKET MEDIA, V41, P61; ROSS W, 2002, MED MARKET MEDIA, V37, P34; Saul Stephanie, 2006, N Y Times Web, pC7; Smith ME, 1997, RADAR CONF, P263, DOI 10.1109/NRC.1997.588317; Southern W.A., 1953, DRUG COSMET IND, V73, P328; SOUTHERN WA, 1953, DRUG COSMET IND, V63, P417; Steinbrook R, 2006, NEW ENGL J MED, V354, P2745, DOI 10.1056/NEJMp068125; Stolberg S G, 2000, N Y Times Web, pA15	22	34	34	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	2007	146	10					742	748		10.7326/0003-4819-146-10-200705150-00008	http://dx.doi.org/10.7326/0003-4819-146-10-200705150-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KJ	17502635				2023-01-03	WOS:000246662000007
J	Basner, RC				Basner, Robert C.			Continuous positive airway pressure for obstructive sleep apnea	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMBULATORY BLOOD-PRESSURE; NASAL CPAP; PRACTICE PARAMETERS; CONTROLLED TRIAL; WEIGHT-LOSS; THERAPY; PATHOGENESIS; PLACEBO; HYPOPNEA; POPULATION	During an evaluation by his internist, a 48-year-old man reports that his wife tells him that he snores loudly. Further questioning reveals that he has been falling asleep whenever sedentary. His physical examination is notable for truncal obesity (body-mass index [ the weight in kilograms divided by the square of the height in meters], 32) and hypertension ( blood pressure, 150/96 mm Hg). He is referred to a sleep specialist for nocturnal polysomnography ( sleep study), which reveals evidence of obstructive sleep apnea, with an obstructive apnea - hypopnea index ( defined as the total number of episodes of obstructive apnea and hypopnea per hour of sleep) of 50, a nadir value for arterial oxygen saturation of 65%, and an arterial oxygen saturation below 90% during 19% of sleep time. Treatment with continuous positive airway pressure (CPAP) is recommended.	Columbia Univ Coll Phys & Surg, Div Pulm Allergy & Crit Care, New York, NY 10032 USA	Columbia University	Basner, RC (corresponding author), Columbia Univ Coll Phys & Surg, Div Pulm Allergy & Crit Care, 630 W 168th St,VC-12206, New York, NY 10032 USA.	rcb42@columbia.edu						Ambrosetti M, 2006, J CARDIOVASC MED, V7, P826, DOI 10.2459/01.JCM.0000250873.01649.41; Ayas NT, 2006, ARCH INTERN MED, V166, P977, DOI 10.1001/archinte.166.9.977; Ayas NT, 2004, SLEEP, V27, P249, DOI 10.1093/sleep/27.2.249; BALFORS EM, 1994, AM J RESP CRIT CARE, V150, P1587, DOI 10.1164/ajrccm.150.6.7952619; Barnes M, 2002, AM J RESP CRIT CARE, V165, P773, DOI 10.1164/ajrccm.165.6.2003166; BEARPARK H, 1995, AM J RESP CRIT CARE, V151, P1459, DOI 10.1164/ajrccm.151.5.7735600; Becker HF, 2003, CIRCULATION, V107, P68, DOI 10.1161/01.CIR.0000042706.47107.7A; Bixler EO, 2001, AM J RESP CRIT CARE, V163, P608, DOI 10.1164/ajrccm.163.3.9911064; Bradshaw DA, 2006, CHEST, V130, P1369, DOI 10.1378/chest.130.5.1369; Campos-Rodriguez F, 2005, CHEST, V128, P624, DOI 10.1378/chest.128.2.624; Centers for Medicare & Medicaid Services (CMS) HHS, 2006, Fed Regist, V71, P67959; Chai CL, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005308.pub2; CHARBONNEAU M, 1991, AM REV RESPIR DIS, V144, P461, DOI 10.1164/ajrccm/144.2.461; Chervin RD, 1997, SLEEP, V20, P284, DOI 10.1093/sleep/20.4.284; Dimsdale JE, 2000, HYPERTENSION, V35, P144, DOI 10.1161/01.HYP.35.1.144; Dixon JB, 2005, INT J OBESITY, V29, P1048, DOI 10.1038/sj.ijo.0802960; EDINGER JD, 1993, SLEEP, V16, P678; ENGLEMAN HM, 1994, LANCET, V343, P572, DOI 10.1016/S0140-6736(94)91522-9; Engleman HM, 1996, SLEEP, V19, P378, DOI 10.1093/sleep/19.5.378; Faccenda JF, 2001, AM J RESP CRIT CARE, V163, P344, DOI 10.1164/ajrccm.163.2.2005037; Fleetham John, 2006, Can Respir J, V13, P387; GARPESTAD E, 1992, J APPL PHYSIOL, V73, P1743, DOI 10.1152/jappl.1992.73.5.1743; GARPESTAD E, 1992, J APPL PHYSIOL, V72, P110, DOI 10.1152/jappl.1992.72.1.110; Gay P, 2006, SLEEP, V29, P381, DOI 10.1093/sleep/29.3.381; George CFP, 1999, SLEEP, V22, P790; Giles T. L., 2006, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001103.PUB3; GLEESON K, 1990, AM REV RESPIR DIS, V142, P295, DOI 10.1164/ajrccm/142.2.295; Hayakawa T, 1996, CHEST, V109, P916, DOI 10.1378/chest.109.4.916; HOFFSTEIN V, 1992, AM REV RESPIR DIS, V145, P841, DOI 10.1164/ajrccm/145.4_Pt_1.841; Jenkinson C, 1997, J SLEEP RES, V6, P199, DOI 10.1046/j.1365-2869.1997.00043.x; Kapur V, 1999, SLEEP, V22, P749, DOI 10.1093/sleep/22.6.749; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; Kushida CA, 2006, SLEEP, V29, P375, DOI 10.1093/sleep/29.3.375; Kushida CA, 2006, SLEEP, V29, P240, DOI 10.1093/sleep/29.2.240; Kuzniar TJ, 2005, CHEST, V128, P1882, DOI 10.1378/chest.128.3.1882; Loredo JS, 2006, SLEEP, V29, P564, DOI 10.1093/sleep/29.4.564; Loube DI, 1999, CHEST, V115, P863, DOI 10.1378/chest.115.3.863; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; Marti S, 2002, EUR RESPIR J, V20, P1511, DOI 10.1183/09031936.02.00306502; Nilius G, 2006, CHEST, V130, P1018, DOI 10.1378/chest.130.4.1018; Nussbaumer Y, 2006, CHEST, V129, P638, DOI 10.1378/chest.129.3.638; ONAL E, 1982, AM REV RESPIR DIS, V126, P676; Patel SR, 2003, ARCH INTERN MED, V163, P565, DOI 10.1001/archinte.163.5.565; Pepperell JCT, 2002, LANCET, V359, P204, DOI 10.1016/S0140-6736(02)07445-7; PRESSMAN MR, 1995, AM J RESP CRIT CARE, V151, P1632, DOI 10.1164/ajrccm.151.5.7735625; Prinsell JR, 1999, CHEST, V116, P1519, DOI 10.1378/chest.116.6.1519; Punjabi NM, 2004, AM J EPIDEMIOL, V160, P521, DOI 10.1093/aje/kwh261; Pusalavidyasagar SS, 2006, SLEEP MED, V7, P474, DOI 10.1016/j.sleep.2006.04.005; REDLINE S, 1995, AM J RESP CRIT CARE, V151, P682; REEVESHOCHE MK, 1995, AM J RESP CRIT CARE, V151, P443, DOI 10.1164/ajrccm.151.2.7842204; Ryan CM, 2005, J APPL PHYSIOL, V99, P2440, DOI 10.1152/japplphysiol.00772.2005; SANDERS MH, 1990, CHEST, V98, P317, DOI 10.1378/chest.98.2.317; Sassani A, 2004, SLEEP, V27, P453, DOI 10.1093/sleep/27.3.453; SCHWARTZ AR, 1991, AM REV RESPIR DIS, V144, P494, DOI 10.1164/ajrccm/144.3_Pt_1.494; Shahar E, 2001, AM J RESP CRIT CARE, V163, P19, DOI 10.1164/ajrccm.163.1.2001008; SMITH PL, 1994, AM J RESP CRIT CARE, V150, P1738; STROHL KP, 1986, AM REV RESPIR DIS, V134, P555; SULLIVAN CE, 1981, LANCET, V1, P862; Teran-Santos J, 1999, NEW ENGL J MED, V340, P847, DOI 10.1056/NEJM199903183401104; Thomas RJ, 2005, J APPL PHYSIOL, V98, P2226, DOI 10.1152/japplphysiol.01225.2004; Veasey SC, 2004, SLEEP, V27, P194, DOI 10.1093/sleep/27.2.194; Veasey SC, 2006, SLEEP, V29, P1036, DOI 10.1093/sleep/29.8.1036; White DP, 2005, AM J RESP CRIT CARE, V172, P1363, DOI 10.1164/rccm.200412-1631SO; Woodson BT, 2003, OTOLARYNG HEAD NECK, V128, P848, DOI 10.1016/S0194-5998(03)00461-3; Younes M, 2004, AM J RESP CRIT CARE, V169, P623, DOI 10.1164/rccm.200307-1023OC; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; 1995, AM J RESP CRIT CARE, V151, P578	67	81	87	2	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 26	2007	356	17					1751	1758		10.1056/NEJMct066953	http://dx.doi.org/10.1056/NEJMct066953			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	160LQ	17460229				2023-01-03	WOS:000245942600010
J	Kripalani, S; LeFevre, F; Phillips, CO; Williams, MV; Basaviah, P; Baker, DW				Kripalani, Sunil; LeFevre, Frank; Phillips, Christopher O.; Williams, Mark V.; Basaviah, Preetha; Baker, David W.			Deficits in communication and information transfer between hospital-based and primary care physicians - Implications for patient safety and continuity of care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							FOLLOW-UP SYSTEM; GENERAL-PRACTITIONERS; DISCHARGE SUMMARIES; ELDERLY PATIENTS; HEALTH-CARE; IMPROVING COMMUNICATION; COMMUNITY PHYSICIANS; EMERGENCY-DEPARTMENT; MEDICAL-RECORD; QUALITY	Context Delayed or inaccurate communication between hospital-based and primary care physicians at hospital discharge may negatively affect continuity of care and contribute to adverse events. Objectives To characterize the prevalence of deficits in communication and information transfer at hospital discharge and to identify interventions to improve this process. Data Sources MEDLINE ( through November 2006), Cochrane Database of Systematic Reviews, and hand search of article bibliographies. Study Selection Observational studies investigating communication and information transfer at hospital discharge (n= 55) and controlled studies evaluating the efficacy of interventions to improve information transfer ( n= 18). Data Extraction Data from observational studies were extracted on the availability, timeliness, content, and format of discharge communications, as well as primary care physician satisfaction. Results of interventions were summarized by their effect on timeliness, accuracy, completeness, and overall quality of the information transfer. Data Synthesis Direct communication between hospital physicians and primary care physicians occurred infrequently (3%-20%). The availability of a discharge summary at the first postdischarge visit was low (12%-34%) and remained poor at 4 weeks (51%-77%), affecting the quality of care in approximately 25% of follow-up visits and contributing to primary care physician dissatisfaction. Discharge summaries often lacked important information such as diagnostic test results ( missing from 33%-63%), treatment or hospital course (7%-22%), discharge medications (2%-40%), test results pending at discharge (65%), patient or family counseling (90%-92%), and follow-up plans (2%-43%). Several interventions, including computer-generated discharge summaries and using patients as couriers, shortened the delivery time of discharge communications. Use of standardized formats to highlight the most pertinent information improved the perceived quality of documents. Conclusions Deficits in communication and information transfer at hospital discharge are common and may adversely affect patient care. Interventions such as computer-generated summaries and standardized formats may facilitate more timely transfer of pertinent patient information to primary care physicians and make discharge summaries more consistently available during follow-up care.	Emory Univ, Sch Med, Div Gen Med, Dept Internal Med, Atlanta, GA 30303 USA; Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA; Northwestern Univ, Dept Med, Div Gen Med, Chicago, IL 60611 USA; Blue Cross & Blue Shield Assoc Technol Evaluat Ct, Chicago, IL USA; Cleveland Clin Fdn, Sect Hosp Med, Cleveland, OH 44195 USA; Stanford Univ, Sch Med, Dept Internal Med, Div Gen Med, Stanford, CA 94305 USA	Emory University; Northwestern University; Feinberg School of Medicine; Northwestern University; Cleveland Clinic Foundation; Stanford University	Kripalani, S (corresponding author), Emory Univ, Sch Med, Div Gen Med, Dept Internal Med, 49 Jesse Hill Jr SE, Atlanta, GA 30303 USA.	skripal@emory.edu		Williams, Mark V/0000-0001-6107-0457	NCRR NIH HHS [K12 RR017643] Funding Source: Medline; NHLBI NIH HHS [K23 HL077597] Funding Source: Medline; BHP HRSA HHS [2-T32-PE10025] Funding Source: Medline; DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [T32PE010025] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K12RR017643] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL077597] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); BHP HRSA HHS; DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS DCR, 1993, ANN ROY COLL SURG, V75, P96; Adhiyaman V, 2000, INT J CLIN PRACT, V54, P457; Al-Rashed SA, 2002, BRIT J CLIN PHARMACO, V54, P657, DOI 10.1046/j.1365-2125.2002.01707.x; ALPERS A, 2001, AM J MED, V11, pS5; Archbold RA, 1998, BRIT J GEN PRACT, V48, P1163; Auerbach AD, 2000, AM J MED, V109, P648, DOI 10.1016/S0002-9343(00)00597-0; BADO W, 1984, BRIT MED J, V288, P1813, DOI 10.1136/bmj.288.6433.1813; BALLA JI, 1994, MED J AUSTRALIA, V161, P656, DOI 10.5694/j.1326-5377.1994.tb126911.x; Bartlett R C, 1991, J Am Med Rec Assoc, V62, P32; Bates DW, 2003, NEW ENGL J MED, V348, P2526, DOI 10.1056/NEJMsa020847; Bell CM, 2006, J GEN INTERN MED, V21, P17; Bertrand D, 1998, Int J Health Care Qual Assur Inc Leadersh Health Serv, V11, P90, DOI 10.1108/09526869810213019; Bolch Denise, 2005, Aust J Rural Health, V13, P91, DOI 10.1111/j.1440-1854.2005.00660.x; Bolton P, 1998, J Qual Clin Pract, V18, P241, DOI 10.1046/j.1440-1762.1998.00281.x; BOYLE CM, 1974, LANCET, V2, P466; Branger P J, 1991, Proc Annu Symp Comput Appl Med Care, P58; BRANGER PJ, 1992, BRIT MED J, V305, P1068, DOI 10.1136/bmj.305.6861.1068; CARTWRIGHT A, 1991, FAM PRACT, V8, P350, DOI 10.1093/fampra/8.4.350; CASTLEDEN WM, 1992, MED J AUSTRALIA, V157, P380, DOI 10.5694/j.1326-5377.1992.tb137245.x; Chaudhry B, 2006, ANN INTERN MED, V144, P742, DOI 10.7326/0003-4819-144-10-200605160-00125; CLEMENTS D, 1992, J ROY COLL PHYS LOND, V26, P169; Coleman EA, 2004, HEALTH SERV RES, V39, P1449, DOI 10.1111/j.1475-6773.2004.00298.x; Coleman EA, 2004, ANN INTERN MED, V141, P533, DOI 10.7326/0003-4819-141-7-200410050-00009; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; COLLEDGE N R, 1992, Health Bulletin (Edinburgh), V50, P219; Crosswhite R, 1997, AM J MANAG CARE, V3, P473; CURRAN P, 1992, ULSTER MED J, V61, P56; de Cruppe W, 2002, GEN HOSP PSYCHIAT, V24, P343, DOI 10.1016/S0163-8343(02)00202-5; DEITELZWEIG S, 2005, SOC HOSP MED ANN M A; Delpierre C, 2004, INT J QUAL HEALTH C, V16, P407, DOI 10.1093/intqhc/mzh064; DEMLO LK, 1981, MED CARE, V19, P1030, DOI 10.1097/00005650-198110000-00005; Dover S B, 1984, Health Trends, V16, P48; Dunnion ME, 2005, J CLIN NURS, V14, P776, DOI 10.1111/j.1365-2702.2005.01129.x; FAIR JF, 1989, BRIT J HOSP MED, V42, P59; FLYER B, 1988, J MED EDUC, V63, P407; Foster DS, 2002, SCOT MED J, V47, DOI 10.1177/003693300204700402; GAMMON DA, 1980, MED J AUSTRALIA, V1, P663, DOI 10.5694/j.1326-5377.1980.tb135216.x; Goldman L, 2001, AM J MED, V111, P36, DOI 10.1016/S0002-9343(01)00968-8; Goldman RD, 2005, CLIN PEDIATR, V44, P305, DOI 10.1177/000992280504400404; HAIKIO JP, 1995, SCAND J PRIM HEALTH, V13, P287, DOI 10.3109/02813439508996777; Halasyamani L, 2006, J HOSP MED, V1, P354, DOI 10.1002/jhm.129; HARDING J, 1987, J ROY COLL GEN PRACT, V37, P494; Hersh W, 2004, JAMA-J AM MED ASSOC, V292, P2273, DOI 10.1001/jama.292.18.2273; Holyoake T I, 1990, Health Bull (Edinb), V48, P29; Howard D J, 1986, Health Trends, V18, P12; Isaac DR, 1997, MED J AUSTRALIA, V166, P9, DOI 10.5694/j.1326-5377.1997.tb138694.x; JANIK DS, 1978, J PEDIATR-US, V93, P519, DOI 10.1016/S0022-3476(78)81185-8; Jansen JO, 2003, EMERG MED J, V20, P256, DOI 10.1136/emj.20.3.256; JELOVSEK F, 1977, METHOD INFORM MED, V16, P199; Johnson PH, 1998, RESP MED, V92, P289, DOI 10.1016/S0954-6111(98)90111-1; *JOINT COMM ACCR H, JOINT COMM NAT PAT S; *JOINT COMM ACCR H, 2006, 610 IM JOINT COMM AC, P338; Jones JS, 1997, ACAD EMERG MED, V4, P1147, DOI 10.1111/j.1553-2712.1997.tb03698.x; KENDRICK AR, 1989, BRIT MED J, V298, P362, DOI 10.1136/bmj.298.6670.362-a; KENNY C, 1991, PUBLIC HEALTH, V105, P243, DOI 10.1016/S0033-3506(05)80114-3; King M H, 1991, West Engl Med J, V106, P40; KING MH, 1991, W ENGL MED J, V106, P55; Kljakovic Marjan, 2004, Inform Prim Care, V12, P227; Knight AM, 2003, J GEN INTERN MED, V18, P134; Kramer JM, 2004, J GEN INTERN MED, V19, P233; Kramer JM, 2004, J GEN INTERN MED, V19, P108; Lee RG, 2003, SOC SCI MED, V56, P449, DOI 10.1016/S0277-9536(02)00045-X; Liesenfeld B, 1996, INT J QUAL HEALTH C, V8, P537, DOI 10.1093/intqhc/8.6.537; LIPWORTH BJ, 1993, SCOT MED J, V38, P116, DOI 10.1177/003693309303800408; LISSAUER T, 1991, ARCH DIS CHILD-FETAL, V66, P433, DOI 10.1136/adc.66.4_Spec_No.433; LLEWELYN DEH, 1988, BRIT MED J, V297, P1504, DOI 10.1136/bmj.297.6662.1504; LLOYD BW, 1993, BRIT MED J, V306, P247, DOI 10.1136/bmj.306.6872.247; Lloyd J, 2000, Aust Health Rev, V23, P134; Lockwood E, 1970, Health Bull (Edinb), V28, P75; LONG A, 1974, BRIT MED J, V4, P456, DOI 10.1136/bmj.4.5942.456; MAGEEAN RJ, 1986, BRIT MED J, V293, P1283, DOI 10.1136/bmj.293.6557.1283; Mant A, 2002, MED J AUSTRALIA, V177, P32, DOI 10.5694/j.1326-5377.2002.tb04632.x; Mant A, 2001, MED J AUSTRALIA, V174, P277, DOI 10.5694/j.1326-5377.2001.tb143268.x; Marks MK, 1999, J PAEDIATR CHILD H, V35, P251, DOI 10.1046/j.1440-1754.1999.00350.x; Massy-Westropp Matthew, 2005, Aust Health Rev, V29, P12; Mathur R, 1997, SCOT MED J, V42, P19, DOI 10.1177/003693309704200108; McInnes E, 1999, FAM PRACT, V16, P289, DOI 10.1093/fampra/16.3.289; MEARA JR, 1992, J PUBLIC HEALTH MED, V14, P145; Moore C, 2006, J GEN INTERN MED, V21, P153; Moore C, 2003, J GEN INTERN MED, V18, P646, DOI 10.1046/j.1525-1497.2003.20722.x; Munday A, 1997, BRIT J GEN PRACT, V47, P563; Myers JS, 2005, J GEN INTERN MED, V20, P165; NEWTON J, 1992, BRIT MED J, V304, P821, DOI 10.1136/bmj.304.6830.821; O'Neill KA, 2001, PEDIATR EMERG CARE, V17, P392, DOI 10.1097/00006565-200110000-00018; OETGEN WJ, 1982, MIL MED, V147, P1054, DOI 10.1093/milmed/147.12.1054; Pantilat SZ, 2002, DM-DIS MON, V48, P218, DOI 10.1016/S0011-5029(02)90029-5; Pantilat SZ, 2001, AM J MED, V111, P15, DOI 10.1016/S0002-9343(01)00964-0; Paterson JM, 1999, CAN FAM PHYSICIAN, V45, P2893; PENNEY TM, 1988, BRIT MED J, V297, P28, DOI 10.1136/bmj.297.6640.28-a; Philp I, 1988, Health Bull (Edinb), V46, P291; Pillai Anand, 2004, Inform Prim Care, V12, P67; Poon EG, 2004, ARCH INTERN MED, V164, P2223, DOI 10.1001/archinte.164.20.2223; Qvist P, 2004, INT J QUAL HEALTH C, V16, P141, DOI 10.1093/intqhc/mzh028; Rao P, 2005, AM J MED QUAL, V20, P337, DOI 10.1177/1062860605281078; Raval AN, 2003, CAN J CARDIOL, V19, P365; RAWAL J, 1993, BRIT MED J, V307, P1044, DOI 10.1136/bmj.307.6911.1044; Roy CL, 2005, ANN INTERN MED, V143, P121, DOI 10.7326/0003-4819-143-2-200507190-00011; Rutherford A, 2001, Aust Fam Physician, V30, P1101; SANDLER DA, 1989, BRIT MED J, V298, P870, DOI 10.1136/bmj.298.6677.870; SANDLER DA, 1987, BRIT MED J, V295, P1523, DOI 10.1136/bmj.295.6612.1523; SANDLER DA, 1989, BRIT MED J, V299, P1511, DOI 10.1136/bmj.299.6714.1511; Sexton J, 2000, J CLIN PHARM THER, V25, P385, DOI 10.1046/j.1365-2710.2000.00305.x; SMITH RP, 1989, OBSTET GYNECOL, V73, P803; *SOC HOSP MED, GROWTH HOSP MED NAT; Solis D H, 1982, J Am Med Rec Assoc, V53, P26; SOLOMON JK, 1995, J ROY COLL PHYS LOND, V29, P307; South J, 1972, J R Coll Gen Pract, V22, P28; Stalhammar J, 1998, SCAND J PRIM HEALTH, V16, P154; Sujansky WV, 1998, WESTERN J MED, V169, P176; Taylor DM, 1997, MED J AUSTRALIA, V167, P575, DOI 10.5694/j.1326-5377.1997.tb138902.x; TEMPLE J, 1988, PRACTITIONER, V232, P148; TULLOCH AJ, 1975, BRIT MED J, V4, P443, DOI 10.1136/bmj.4.5994.443; van Walraven C, 2004, J GEN INTERN MED, V19, P624, DOI 10.1111/j.1525-1497.2004.30082.x; van Walraven C, 2002, J GEN INTERN MED, V17, P186, DOI 10.1046/j.1525-1497.2002.10741.x; van Walraven C, 1998, CAN FAM PHYSICIAN, V44, P62; van Walraven C, 2001, J EVAL CLIN PRACT, V7, P289, DOI 10.1046/j.1365-2753.2001.00305.x; van Walraven C, 1999, AM J MED QUAL, V14, P160, DOI 10.1177/106286069901400403; van Walraven C, 2002, CAN FAM PHYSICIAN, V48, P737; van Walraven C, 1999, CAN MED ASSOC J, V160, P319; van Zyl LT, 2003, CAN J PSYCHIAT, V48, P555, DOI 10.1177/070674370304800807; VANDOMBURG RT, 1985, MED INFORM, V10, P259, DOI 10.3109/14639238509080303; VANWALRAVEN C, 1995, CAN MED ASSOC J, V152, P1437; Vinker S, 2004, BMC FAM PRACT, V5, P1; Wachter RM, 2001, AM J MED, V111, P40, DOI 10.1016/S0002-9343(01)00969-X; Wachter RM, 2002, JAMA-J AM MED ASSOC, V287, P487, DOI 10.1001/jama.287.4.487; Wachter RM, 1999, ANN INTERN MED, V130, P338, DOI 10.7326/0003-4819-130-4-199902161-00002; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713; WAGSTAFF R, 1994, BRIT J GEN PRACT, V44, P315; Wass AR, 1996, J ACCID EMERG MED, V13, P406; Weiner M, 2003, ANN INTERN MED, V139, P430, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00010; Weiner SJ, 2005, ANN INTERN MED, V142, P709, DOI 10.7326/0003-4819-142-8-200504190-00039; Wilkin T J, 1978, Health Bull (Edinb), V36, P16; WILLIAMS EI, 1990, BRIT MED J, V300, P159, DOI 10.1136/bmj.300.6718.159; Wilson S, 2001, J Qual Clin Pract, V21, P104, DOI 10.1046/j.1440-1762.2001.00430.x	134	1290	1304	3	140	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 28	2007	297	8					831	841		10.1001/jama.297.8.831	http://dx.doi.org/10.1001/jama.297.8.831			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	140DS	17327525				2023-01-03	WOS:000244485000026
J	Mulgrew, AT; Fox, N; Ayas, NT; Ryan, CF				Mulgrew, Alan T.; Fox, Nurit; Ayas, Najib T.; Ryan, C. Frank			Diagnosis and initial management of obstructive sleep apnea without polysomnography - A randomized validation study	ANNALS OF INTERNAL MEDICINE			English	Article							POSITIVE AIRWAY PRESSURE; HYPOPNEA SYNDROME; HOME OXIMETRY; CPAP THERAPY; RISK; POPULATION; PREDICTION; QUESTIONNAIRE; HYPERTENSION; RECORDINGS	Background: Polysomnography (PSG), despite limited availability and high cost, is currently recommended for diagnosis of obstructive sleep apnea and titration of effective continuous positive airway pressure (CPAP). Objective: To test the utility of a diagnostic algorithm in conjunction with ambulatory CPAP titration in initial management of obstructive sleep apnea. Design: A randomized, controlled, open-label trial that compared standard PSG with ambulatory CPAP titration in high-risk patients identified by a diagnostic algorithm. Setting: A tertiary referral sleep disorders program in Vancouver, British Columbia, Canada. Patients: 68 patients with a high pretest probability of moderate to severe obstructive sleep apnea (apnea-hypopnea index [AHI] > 15 episodes/h) identified by sequential application of the Epworth Sleepiness Scale (ESS) score, Sleep Apnea Clinical Score, and overnight oximetry. Intervention: Patients were randomly assigned to PSG or ambulatory titration by using a combination of auto-CPAP and overnight oximetry. They were observed for 3 months. Measurements: Apnea-hypopnea index on CPAP, ESS score, quality of life, and CPAP adherence. Results: The PSG and ambulatory groups had similar median BMI (38 kg/m(2)), age (55 years), ESS score (14 points), and respiratory disturbance index (31 episodes of respiratory disturbance/h). Each episode is determined by a computer algorithm based on analysis of oxygen saturation measured by pulse oximetry. After 3 months, there were no differences in the primary outcome, AHI on CPAP (median, 3.2 vs. 2.5; difference, 0.8/h [95% CI, -0.9 to 2.3]) (P = 0.31), between the PSG and ambulatory groups, or in the secondary outcomes, ESS score, Sleep Apnea Quality of Life Index, and CPAP. Adherence to CPAP therapy was better in the ambulatory group than in the PSG group (median, 5.4 vs. 6.0; difference, -1.12 h/night [CI, -2.0 to 0.2]) (P = 0.021). Conclusions: In the initial management of patients with a high probability of obstructive sleep apnea, PSG confers no advantage over the ambulatory approach in terms of diagnosis and CPAP titration. The ambulatory approach may improve adherence to treatment. When access to PSG is inadequate, the ambulatory approach can be used to expedite management of patients most in need of treatment.			Ryan, CF (corresponding author), Lung Ctr, 7th Floor,Diamond Hlth Care Ctr,2775 Laurel St, Vancouver, BC V5Z 1M9, Canada.	fryan@interchange.ubc.ca						Al-Alawi A, 2006, J CLIN SLEEP MED, V2, P281; Ayas NT, 2005, SLEEP, V28, P1211, DOI 10.1093/sleep/28.10.1211; Ayas NT, 2004, SLEEP, V27, P249, DOI 10.1093/sleep/27.2.249; Chervin RD, 1999, ANN INTERN MED, V130, P496, DOI 10.7326/0003-4819-130-6-199903160-00006; Chesson AL, 1997, SLEEP, V20, P406; Chiner E, 1999, THORAX, V54, P968, DOI 10.1136/thx.54.11.968; Engleman HM, 1996, CHEST, V109, P1470, DOI 10.1378/chest.109.6.1470; Ficker JH, 1998, THORAX, V53, P643, DOI 10.1136/thx.53.8.643; Ficker JH, 2000, EUR RESPIR J, V16, P914, DOI 10.1183/09031936.00.16591400; Fitzpatrick MF, 2003, AM J RESP CRIT CARE, V167, P716, DOI 10.1164/rccm.200204-360OC; Flemons WW, 2004, AM J RESP CRIT CARE, V169, P668, DOI 10.1164/rccm.200308-1124PP; Flemons WW, 1998, AM J RESP CRIT CARE, V158, P494; Flemons WW, 2002, AM J RESP CRIT CARE, V165, P159, DOI 10.1164/ajrccm.165.2.2010008; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; FLEMONS WW, 1994, AM J RESP CRIT CARE, V150, P1279, DOI 10.1164/ajrccm.150.5.7952553; Gagnadoux F, 1999, SLEEP, V22, P1095, DOI 10.1093/sleep/22.8.1095; Golpe R, 2002, CHEST, V122, P1156, DOI 10.1378/chest.122.4.1156; Gurubhagavatula I, 2001, AM J RESP CRIT CARE, V164, P1904, DOI 10.1164/ajrccm.164.10.2103039; HLA KM, 1994, ANN INTERN MED, V120, P382, DOI 10.7326/0003-4819-120-5-199403010-00005; Kokturk O, 2005, INT HEART J, V46, P801, DOI 10.1536/ihj.46.801; Krieger J, 1998, EUR RESPIR J, V12, P776, DOI 10.1183/09031936.98.12040776; Kushida CA, 1997, ANN INTERN MED, V127, P581, DOI 10.7326/0003-4819-127-8_Part_1-199710150-00001; Lam B, 2005, THORAX, V60, P504, DOI 10.1136/thx.2004.031591; Lewis KE, 2004, SLEEP, V27, P134, DOI 10.1093/sleep/27.1.134; MAISLIN G, 1995, SLEEP, V18, P158, DOI 10.1093/sleep/18.3.158; Masa JF, 2004, AM J RESP CRIT CARE, V170, P1218, DOI 10.1164/rccm.200312-1787OC; Netzer NC, 1999, ANN INTERN MED, V131, P485, DOI 10.7326/0003-4819-131-7-199910050-00002; Pittman SD, 2004, SLEEP, V27, P1394, DOI 10.1093/sleep/27.7.1394; Rowley JA, 2000, SLEEP, V23, P929, DOI 10.1093/sleep/23.7.929; Schafer H, 1997, RESPIRATION, V64, P194; SERIES F, 1993, ANN INTERN MED, V119, P449, DOI 10.7326/0003-4819-119-6-199309150-00001; SMITH PL, 1994, AM J RESP CRIT CARE, V150, P1738; Teschler H, 1996, AM J RESP CRIT CARE, V154, P734, DOI 10.1164/ajrccm.154.3.8810613; Vazquez JC, 2000, THORAX, V55, P302, DOI 10.1136/thorax.55.4.302; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; Weaver TE, 1997, SLEEP, V20, P278, DOI 10.1093/sleep/20.4.278; West SD, 2006, THORAX, V61, P226, DOI 10.1136/thx.2005.046300; Whitelaw WA, 2005, AM J RESP CRIT CARE, V171, P188, DOI 10.1164/rccm.200310-1360OC; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	39	247	260	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 6	2007	146	3					157	166		10.7326/0003-4819-146-3-200702060-00004	http://dx.doi.org/10.7326/0003-4819-146-3-200702060-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	132QN	17283346				2023-01-03	WOS:000243957400001
J	Garly, ML; Bale, C; Martins, CL; Whittle, HC; Nielsen, J; Lisse, IM; Aaby, P				Garly, May-Lill; Bale, Carlitos; Martins, Cesario Lourenco; Whittle, Hilton C.; Nielsen, Jens; Lisse, Ida M.; Aaby, Peter			Prophylactic antibiotics to prevent pneumonia and other complications after measles: community based randomised double blind placebo controlled trial in Guinea-Bissau	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; VACCINATION; EXPERIENCE; EPIDEMIC; AGE	Objective 16 investigate whether prophylactic antibiotics can prevent complications of measles. Design Community based, randomised, double blind, placebo controlled trial. Setting Bandim Health Project stud), area in Bissau, Guinea-Bissau, west Africa. Participants 84 patients with measles during a measles epidemic in Bissau in 1998 (fewer than originally planned owing to interruption by war). Interventions Sulfamethoxazole-trimethoprim (co-trimoxazole) or placebo for seven days. Main outcome measures Pneumonia and admission to hospital. Also weight change during the first month of infection, diarrhoea, severe fever, oral thrush, stomatitis, conjunctivitis, and otitis media. Results The median age of the patients with measles was 5.4 (range 0.49-24.8) years. One of 46 participants who received co-trimoxazole developed pneumonia, in contrast to six of 38 participants who received placebo (odds ratio 0.08 (95% confidence interval 0 to 0.56), adjusted for age group). The number needed to treat was 7 (4 to 48). All three participants admitted to hospital had received placebo (P = 0.09). The weight gain during the first month after inclusion was 15 (2-29) g/day in the placebo group and 32 (23-42) g/day in the co-trimoxazole group (P = 0.04, adjusted for age group, weight for age at inclusion, measles vaccination status, and duration of disease). Significantly less conjunctivitis occurred among recipients of co-trimoxazole than placebo, as well as a non-significant tendency to less diarrhoea, severe fever, oral thrush, and stomatitis. Complications of otitis media were the same in the two groups. Conclusions The group that received prophylactic antibiotics had less pneumonia and conjunctivitis and had significantly higher weight gains in the month after inclusion. The results indicate that prophylactic antibiotics may have an important role in the management of measles infection in low income countries.	Projecto Saude Bandim, Bissau, Guinea Bissau; MRC Labs, Fajara, Gambia	MRC Laboratory Molecular Biology	Garly, ML (corresponding author), Statens Serum Inst, Div Epidemiol, Bandim Hlth Project, Artillerivej 5, DK-2300 Copenhagen S, Denmark.	mlg@ssi.dk		Aaby, Peter/0000-0001-8331-1389				AABY P, 1986, J INFECT DIS, V154, P858, DOI 10.1093/infdis/154.5.858; AABY P, 1997, PROSPECTIVE COMMUNIT, P276; Chalmers I, 2002, PEDIATRICS, V109, P312, DOI 10.1542/peds.109.2.312; Dietz V, 2004, B WORLD HEALTH ORGAN, V82, P852; Garly ML, 1999, INT J EPIDEMIOL, V28, P347, DOI 10.1093/ije/28.2.347; Helfand RF, 1997, J INFECT DIS, V175, P195, DOI 10.1093/infdis/175.1.195; Hutchins SS, 2004, J INFECT DIS, V189, pS153, DOI 10.1086/379652; Klugman KP, 1996, J ANTIMICROB CHEMOTH, V38, P133, DOI 10.1093/jac/38.suppl_A.133; LOENING WEK, 1983, LANCET, V2, P324; Morley DC, 1997, BRIT MED J, V314, P1692, DOI 10.1136/bmj.314.7095.1692; Nur YA, 1999, J CLIN VIROL, V12, P21, DOI 10.1016/S1386-6532(98)00002-X; Perry Robert T., 2004, Journal of Infectious Diseases, V189, pS4, DOI 10.1086/377712; PERRY RT, 2004, J INFECT DIS S1, V18, P4; Qazi SA, 1999, CLIN INFECT DIS, V28, P214, DOI 10.1086/515124; Quiambao BP, 1998, PEDIATR INFECT DIS J, V17, P89, DOI 10.1097/00006454-199802000-00002; SAMB B, 1995, PEDIATR INFECT DIS J, V14, P695, DOI 10.1097/00006454-199508000-00009; SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6; Shann F, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001477.pub2; Shann F, 1997, BRIT MED J, V314, P334, DOI 10.1136/bmj.314.7077.334; Van Den Hof S, 2002, PEDIATR INFECT DIS J, V21, P1146, DOI 10.1097/00006454-200212000-00012; WHITTLE HC, 1988, LANCET, V1, P963; *WHO, 1995, WHOCDR9515; *WHO, 2004, INT MAN CHILDH; 1996, J ANTIMICROB CHEM SA, V38, P133; 2006, WKLY EPIDEMIOL REC, V10, P99; 2002, WKLY EPIDEMIOL REC, V77, P59	26	27	27	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 16	2006	333	7581					1245	1247		10.1136/bmj.38989.684178.AE	http://dx.doi.org/10.1136/bmj.38989.684178.AE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122AB	17060336	Bronze, Green Submitted, Green Published			2023-01-03	WOS:000243197000016
